0001501134-19-000022.txt : 20190228 0001501134-19-000022.hdr.sgml : 20190228 20190228170035 ACCESSION NUMBER: 0001501134-19-000022 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 111 CONFORMED PERIOD OF REPORT: 20181231 FILED AS OF DATE: 20190228 DATE AS OF CHANGE: 20190228 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Invitae Corp CENTRAL INDEX KEY: 0001501134 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 271701898 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36847 FILM NUMBER: 19644481 BUSINESS ADDRESS: STREET 1: 1400 16TH STREET CITY: SAN FRANCISCO STATE: CA ZIP: 94103 BUSINESS PHONE: (415) 374-7782 MAIL ADDRESS: STREET 1: 1400 16TH STREET CITY: SAN FRANCISCO STATE: CA ZIP: 94103 FORMER COMPANY: FORMER CONFORMED NAME: InVitae Corp DATE OF NAME CHANGE: 20121105 FORMER COMPANY: FORMER CONFORMED NAME: Locus Development Inc DATE OF NAME CHANGE: 20100910 10-K 1 nvta-10k.htm 10-K Document
false--12-31FY434652018-12-3110-K000150113476811562YestruetrueAccelerated Filer477800000Invitae CorpfalsefalseNoYesNVTA00P3Y1.000.020800000.00010.000140000000040000000053597000754810005359700075481000monthlyP7YP2YP5Y00000P10Y3498000459900061830000.00010.000120000000200000003459000345900034590003459000P3YP12M0P10YP6Y3MP8Y9M29DP8Y4M28D00.76920.78700.6990.02370.01550.02040.01830.33330.33330.33330.25 0001501134 2018-01-01 2018-12-31 0001501134 nvta:CombiMatrixCorporationMember 2018-01-01 2018-12-31 0001501134 nvta:GoodStartGeneticsIncMember 2018-01-01 2018-12-31 0001501134 nvta:OmmdomIncMember 2018-01-01 2018-12-31 0001501134 nvta:AltaVoiceMember 2018-01-01 2018-12-31 0001501134 2018-06-29 0001501134 2019-02-22 0001501134 2017-12-31 0001501134 2018-12-31 0001501134 2016-01-01 2016-12-31 0001501134 2017-01-01 2017-12-31 0001501134 nvta:CollaborationAndGenomeNetworkMember 2018-01-01 2018-12-31 0001501134 nvta:CollaborationAndGenomeNetworkMember 2016-01-01 2016-12-31 0001501134 nvta:CollaborationAndGenomeNetworkMember 2017-01-01 2017-12-31 0001501134 nvta:DiagnosticTestsMember 2018-01-01 2018-12-31 0001501134 nvta:DiagnosticTestsMember 2016-01-01 2016-12-31 0001501134 nvta:DiagnosticTestsMember 2017-01-01 2017-12-31 0001501134 us-gaap:AdditionalPaidInCapitalMember 2017-01-01 2017-12-31 0001501134 us-gaap:CommonStockMember 2015-12-31 0001501134 2015-12-31 0001501134 us-gaap:PreferredStockMember 2018-12-31 0001501134 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-12-31 0001501134 us-gaap:RetainedEarningsMember 2018-01-01 2018-12-31 0001501134 us-gaap:CommonStockMember 2017-01-01 2017-12-31 0001501134 us-gaap:CommonStockMember 2017-12-31 0001501134 us-gaap:CommonStockMember 2018-12-31 0001501134 us-gaap:CommonStockMember 2018-01-01 2018-12-31 0001501134 us-gaap:RetainedEarningsMember 2017-12-31 0001501134 2016-12-31 0001501134 us-gaap:AdditionalPaidInCapitalMember 2015-12-31 0001501134 us-gaap:CommonStockMember 2016-01-01 2016-12-31 0001501134 us-gaap:PreferredStockMember 2015-12-31 0001501134 us-gaap:RetainedEarningsMember 2018-01-01 0001501134 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001501134 us-gaap:CommonStockMember 2016-12-31 0001501134 us-gaap:AdditionalPaidInCapitalMember 2016-12-31 0001501134 us-gaap:AdditionalPaidInCapitalMember 2016-01-01 2016-12-31 0001501134 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001501134 us-gaap:PreferredStockMember 2017-01-01 2017-12-31 0001501134 us-gaap:RetainedEarningsMember 2015-12-31 0001501134 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-12-31 0001501134 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0001501134 us-gaap:RetainedEarningsMember 2016-01-01 2016-12-31 0001501134 us-gaap:PreferredStockMember 2016-12-31 0001501134 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-12-31 0001501134 us-gaap:PreferredStockMember 2017-12-31 0001501134 us-gaap:RetainedEarningsMember 2017-01-01 2017-12-31 0001501134 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-01-01 2016-12-31 0001501134 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001501134 us-gaap:RetainedEarningsMember 2018-12-31 0001501134 us-gaap:RetainedEarningsMember 2016-12-31 0001501134 2018-01-01 0001501134 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-01-01 2017-12-31 0001501134 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:LeaseholdImprovementsMember 2016-01-01 2016-12-31 0001501134 nvta:CustomerMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-12-31 0001501134 srt:MaximumMember 2018-01-01 2018-12-31 0001501134 nvta:CustomerMember srt:MaximumMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-12-31 0001501134 nvta:CustomerMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2017-01-01 2017-12-31 0001501134 srt:MaximumMember us-gaap:CustomerRelationshipsMember 2018-01-01 2018-12-31 0001501134 nvta:CustomerMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2017-01-01 2017-12-31 0001501134 nvta:CustomerMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2016-01-01 2016-12-31 0001501134 nvta:CustomerMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-12-31 0001501134 us-gaap:FurnitureAndFixturesMember 2018-01-01 2018-12-31 0001501134 us-gaap:EquipmentMember 2018-01-01 2018-12-31 0001501134 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2018-01-01 2018-12-31 0001501134 us-gaap:AutomobilesMember 2018-01-01 2018-12-31 0001501134 us-gaap:ComputerEquipmentMember 2018-01-01 2018-12-31 0001501134 srt:MinimumMember 2018-01-01 2018-12-31 0001501134 srt:MinimumMember us-gaap:CustomerRelationshipsMember 2018-01-01 2018-12-31 0001501134 srt:MaximumMember 2018-01-01 2018-01-01 0001501134 us-gaap:AccountingStandardsUpdate201409Member 2018-01-01 0001501134 nvta:DiagnosticTestsMember nvta:ChangeInEstimateOfRevenueRecognitionMember 2018-01-01 2018-12-31 0001501134 us-gaap:AccountingStandardsUpdate201409Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2018-01-01 2018-12-31 0001501134 us-gaap:AccountingStandardsUpdate201409Member us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-01-01 2018-12-31 0001501134 nvta:DiagnosticTestsMember us-gaap:AccountingStandardsUpdate201409Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2018-01-01 2018-12-31 0001501134 nvta:DiagnosticTestsMember us-gaap:AccountingStandardsUpdate201409Member us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-01-01 2018-12-31 0001501134 nvta:InstitutionsMember nvta:DiagnosticTestsMember 2017-01-01 2017-12-31 0001501134 nvta:PatientInsuranceMember nvta:DiagnosticTestsMember 2017-01-01 2017-12-31 0001501134 nvta:PatientInsuranceMember nvta:DiagnosticTestsMember 2018-01-01 2018-12-31 0001501134 nvta:InstitutionsMember nvta:DiagnosticTestsMember 2018-01-01 2018-12-31 0001501134 nvta:PatientDirectMember nvta:DiagnosticTestsMember 2018-01-01 2018-12-31 0001501134 nvta:PatientDirectMember nvta:DiagnosticTestsMember 2017-01-01 2017-12-31 0001501134 us-gaap:AccountingStandardsUpdate201409Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2018-12-31 0001501134 us-gaap:AccountingStandardsUpdate201409Member us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-12-31 0001501134 nvta:GoodStartGeneticsIncMember us-gaap:CustomerRelationshipsMember 2017-08-04 2017-08-04 0001501134 nvta:GoodStartGeneticsIncMember us-gaap:DevelopedTechnologyRightsMember 2017-08-04 2017-08-04 0001501134 nvta:GoodStartGeneticsIncMember us-gaap:DevelopedTechnologyRightsMember 2017-08-04 0001501134 nvta:GoodStartGeneticsIncMember us-gaap:CustomerRelationshipsMember 2017-08-04 0001501134 nvta:GoodStartGeneticsIncMember us-gaap:TradeNamesMember 2017-08-04 0001501134 nvta:GoodStartGeneticsIncMember 2017-08-04 0001501134 nvta:GoodStartGeneticsIncMember us-gaap:TradeNamesMember 2017-08-04 2017-08-04 0001501134 nvta:AltaVoiceMember 2017-01-06 0001501134 nvta:AltaVoiceMember us-gaap:CustomerRelationshipsMember 2017-01-06 0001501134 nvta:AltaVoiceMember us-gaap:NoncompeteAgreementsMember 2017-01-06 0001501134 nvta:AltaVoiceMember us-gaap:DevelopedTechnologyRightsMember 2017-01-06 0001501134 nvta:OmmdomIncMember 2017-06-11 2017-06-11 0001501134 nvta:CombiMatrixCorporationMember us-gaap:SeriesFPreferredStockMember 2017-07-31 2017-07-31 0001501134 nvta:AltaVoiceMember 2017-01-06 2017-01-06 0001501134 nvta:OmmdomIncMember us-gaap:CommonStockMember 2018-06-01 2018-06-30 0001501134 nvta:AltaVoiceMember us-gaap:GeneralAndAdministrativeExpenseMember 2018-01-01 2018-12-31 0001501134 nvta:CombiMatrixCorporationMember 2018-12-31 0001501134 nvta:CombiMatrixCorporationMember us-gaap:CommonStockMember us-gaap:GeneralAndAdministrativeExpenseMember 2017-07-31 2017-07-31 0001501134 nvta:GoodStartGeneticsIncMember us-gaap:CommonStockMember us-gaap:GeneralAndAdministrativeExpenseMember 2017-08-04 2017-08-04 0001501134 nvta:GoodStartGeneticsIncMember us-gaap:CommonStockMember 2017-08-04 2017-08-04 0001501134 nvta:AltaVoiceMember us-gaap:CommonStockMember 2017-01-06 2017-01-06 0001501134 us-gaap:EmployeeStockOptionMember nvta:CombiMatrixCorporationMember 2017-07-31 2017-07-31 0001501134 nvta:AltaVoiceMember nvta:OtherIncomeExpenseMember 2017-01-01 2017-12-31 0001501134 nvta:CombiMatrixCorporationMember us-gaap:CustomerRelationshipsMember 2018-01-01 2018-12-31 0001501134 nvta:AltaVoiceMember us-gaap:NoncompeteAgreementsMember 2018-01-01 2018-12-31 0001501134 nvta:GoodStartGeneticsIncMember us-gaap:CommonStockMember 2018-12-31 0001501134 nvta:AltaVoiceMember 2018-03-31 0001501134 srt:MaximumMember nvta:AltaVoiceMember nvta:NewContingentMilestoneBasedOnAchievingRevenueTargetDuringTwoThousandSeventeenAndTwoThousandEighteenMember us-gaap:ScenarioForecastMember 2019-03-31 0001501134 us-gaap:RestrictedStockUnitsRSUMember nvta:CombiMatrixCorporationMember us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:CommonStockMember 2017-07-31 2017-07-31 0001501134 nvta:CombiMatrixCorporationMember us-gaap:CommonStockMember 2017-07-31 0001501134 nvta:OmmdomIncMember us-gaap:CommonStockMember 2017-06-11 2017-06-11 0001501134 nvta:AltaVoiceMember us-gaap:CommonStockMember 2018-04-01 2018-04-30 0001501134 nvta:AltaVoiceMember us-gaap:GeneralAndAdministrativeExpenseMember 2017-01-01 2017-12-31 0001501134 nvta:AltaVoiceMember nvta:NewContingentMilestoneBasedOnAchievingRevenueTargetDuringTwoThousandSeventeenAndTwoThousandEighteenMember us-gaap:ScenarioForecastMember 2019-03-31 2019-03-31 0001501134 nvta:CombiMatrixCorporationMember nvta:SeriesFWarrantsMember 2017-07-31 2017-07-31 0001501134 nvta:CombiMatrixCorporationMember 2017-11-14 0001501134 nvta:CombiMatrixCorporationMember us-gaap:CommonStockMember 2017-07-31 2017-07-31 0001501134 us-gaap:RestrictedStockUnitsRSUMember nvta:CombiMatrixCorporationMember 2017-07-31 2017-07-31 0001501134 nvta:GoodStartGeneticsIncMember us-gaap:CustomerRelationshipsMember 2018-01-01 2018-12-31 0001501134 nvta:CombiMatrixCorporationMember 2017-07-31 0001501134 nvta:GoodStartGeneticsIncMember 2017-08-04 2017-08-04 0001501134 nvta:CombiMatrixCorporationMember us-gaap:WarrantMember 2017-07-31 2017-07-31 0001501134 nvta:AltaVoiceMember nvta:MilestoneBasedOnCertainThresholdOfRevenueAchievedDuringTwoThousandSeventeenMember 2018-03-31 0001501134 nvta:OmmdomIncMember 2017-06-11 0001501134 nvta:AltaVoiceMember us-gaap:CommonStockMember 2018-03-31 2018-03-31 0001501134 nvta:AltaVoiceMember nvta:OtherIncomeExpenseMember 2018-01-01 2018-12-31 0001501134 nvta:GoodStartGeneticsIncMember us-gaap:CommonStockMember us-gaap:GeneralAndAdministrativeExpenseMember 2018-09-01 2018-09-30 0001501134 nvta:CombiMatrixCorporationMember nvta:SeriesDWarrantsMember 2017-07-31 2017-07-31 0001501134 nvta:GoodStartGeneticsIncMember us-gaap:CommonStockMember us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:SubsequentEventMember 2019-01-01 2019-01-31 0001501134 nvta:GoodStartGeneticsIncMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2019-01-01 2019-01-31 0001501134 nvta:CombiMatrixCorporationMember 2017-07-31 2017-07-31 0001501134 nvta:GoodStartGeneticsIncMember us-gaap:CommonStockMember 2018-09-01 2018-09-30 0001501134 nvta:AltaVoiceMember us-gaap:CommonStockMember 2018-03-31 0001501134 nvta:OmmdomIncMember us-gaap:TradeNamesMember 2017-06-11 0001501134 nvta:OmmdomIncMember us-gaap:CustomerRelationshipsMember 2017-06-11 2017-06-11 0001501134 nvta:OmmdomIncMember us-gaap:DevelopedTechnologyRightsMember 2017-06-11 2017-06-11 0001501134 nvta:OmmdomIncMember us-gaap:TradeNamesMember 2017-06-11 2017-06-11 0001501134 nvta:OmmdomIncMember us-gaap:DevelopedTechnologyRightsMember 2017-06-11 0001501134 nvta:OmmdomIncMember us-gaap:CustomerRelationshipsMember 2017-06-11 0001501134 nvta:AltaVoiceMember us-gaap:CustomerRelationshipsMember 2017-01-06 2017-01-06 0001501134 nvta:AltaVoiceMember us-gaap:NoncompeteAgreementsMember 2017-01-06 2017-01-06 0001501134 nvta:AltaVoiceMember us-gaap:DevelopedTechnologyRightsMember 2017-01-06 2017-01-06 0001501134 nvta:CombiMatrixCorporationMember us-gaap:TradeNamesMember 2017-11-14 0001501134 nvta:CombiMatrixCorporationMember us-gaap:DevelopedTechnologyRightsMember 2017-11-14 0001501134 nvta:CombiMatrixCorporationMember us-gaap:OffMarketFavorableLeaseMember 2017-11-14 0001501134 nvta:CombiMatrixCorporationMember nvta:PatentLicensingAgreementMember 2017-11-14 0001501134 nvta:CombiMatrixCorporationMember us-gaap:CustomerRelationshipsMember 2017-11-14 0001501134 nvta:CombiMatrixCorporationMember us-gaap:CustomerRelationshipsMember 2017-11-14 2017-11-14 0001501134 nvta:CombiMatrixCorporationMember us-gaap:DevelopedTechnologyRightsMember 2017-11-14 2017-11-14 0001501134 nvta:CombiMatrixCorporationMember us-gaap:TradeNamesMember 2017-11-14 2017-11-14 0001501134 nvta:CombiMatrixCorporationMember us-gaap:OffMarketFavorableLeaseMember 2017-11-14 2017-11-14 0001501134 nvta:CombiMatrixCorporationMember nvta:PatentLicensingAgreementMember 2017-11-14 2017-11-14 0001501134 us-gaap:TradeNamesMember 2018-12-31 0001501134 nvta:FavorableLeasesMember 2018-12-31 0001501134 nvta:FavorableLeasesMember 2018-01-01 2018-12-31 0001501134 us-gaap:DevelopedTechnologyRightsMember 2018-01-01 2018-12-31 0001501134 us-gaap:DevelopedTechnologyRightsMember 2018-12-31 0001501134 nvta:PatentLicensingAgreementMember 2018-12-31 0001501134 us-gaap:CustomerRelationshipsMember 2018-12-31 0001501134 nvta:PatentLicensingAgreementMember 2018-01-01 2018-12-31 0001501134 us-gaap:NoncompeteAgreementsMember 2018-12-31 0001501134 us-gaap:NoncompeteAgreementsMember 2018-01-01 2018-12-31 0001501134 us-gaap:TradeNamesMember 2018-01-01 2018-12-31 0001501134 us-gaap:CustomerRelationshipsMember 2018-01-01 2018-12-31 0001501134 nvta:OmmdomIncMember 2017-12-31 0001501134 nvta:AltaVoiceMember 2018-12-31 0001501134 nvta:OmmdomIncMember 2018-12-31 0001501134 nvta:GoodStartGeneticsIncMember 2017-12-31 0001501134 nvta:CombiMatrixCorporationMember 2017-12-31 0001501134 nvta:AltaVoiceMember 2017-12-31 0001501134 nvta:GoodStartGeneticsIncMember 2018-12-31 0001501134 us-gaap:FurnitureAndFixturesMember 2018-12-31 0001501134 us-gaap:LeaseholdImprovementsMember 2017-12-31 0001501134 us-gaap:AssetsHeldUnderCapitalLeasesMember 2018-12-31 0001501134 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2018-12-31 0001501134 us-gaap:AssetsHeldUnderCapitalLeasesMember 2017-12-31 0001501134 us-gaap:ComputerEquipmentMember 2018-12-31 0001501134 us-gaap:AutomobilesMember 2017-12-31 0001501134 us-gaap:ConstructionInProgressMember 2018-12-31 0001501134 us-gaap:ConstructionInProgressMember 2017-12-31 0001501134 us-gaap:LeaseholdImprovementsMember 2018-12-31 0001501134 us-gaap:ComputerEquipmentMember 2017-12-31 0001501134 us-gaap:EquipmentMember 2017-12-31 0001501134 us-gaap:AutomobilesMember 2018-12-31 0001501134 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2017-12-31 0001501134 us-gaap:FurnitureAndFixturesMember 2017-12-31 0001501134 us-gaap:EquipmentMember 2018-12-31 0001501134 nvta:AltaVoiceMember us-gaap:FairValueInputsLevel3Member us-gaap:GeneralAndAdministrativeExpenseMember 2018-01-01 2018-12-31 0001501134 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember nvta:ContingentConsiderationMember 2017-12-31 0001501134 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember nvta:ContingentConsiderationMember 2018-12-31 0001501134 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0001501134 us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0001501134 us-gaap:FairValueMeasurementsRecurringMember nvta:ContingentConsiderationMember 2017-12-31 0001501134 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0001501134 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0001501134 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-12-31 0001501134 nvta:NonEmployeeStockOptionMember 2018-01-01 2018-12-31 0001501134 nvta:EmployeeStockPurchasePlan2015Member 2018-01-01 2018-12-31 0001501134 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0001501134 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2017-12-31 0001501134 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2017-12-31 0001501134 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2017-12-31 0001501134 us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0001501134 us-gaap:CertificatesOfDepositMember 2017-12-31 0001501134 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2017-12-31 0001501134 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2017-12-31 0001501134 us-gaap:MoneyMarketFundsMember 2017-12-31 0001501134 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2017-12-31 0001501134 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2017-12-31 0001501134 us-gaap:USTreasurySecuritiesMember 2017-12-31 0001501134 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2017-12-31 0001501134 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2017-12-31 0001501134 nvta:ContingentConsiderationMember 2017-12-31 0001501134 nvta:AltaVoiceMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember nvta:ContingentConsiderationMember 2017-01-31 0001501134 nvta:AltaVoiceMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember nvta:ContingentConsiderationMember 2018-01-01 2018-12-31 0001501134 srt:MinimumMember nvta:AltaVoiceMember nvta:NewContingentMilestoneBasedOnAchievingRevenueTargetDuringTwoThousandSeventeenAndTwoThousandEighteenMember us-gaap:ScenarioForecastMember 2019-03-31 0001501134 srt:MaximumMember nvta:AltaVoiceMember us-gaap:CommonStockMember 2018-12-31 0001501134 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001501134 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2018-12-31 0001501134 nvta:ContingentConsiderationMember 2018-12-31 0001501134 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2018-12-31 0001501134 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2018-12-31 0001501134 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001501134 us-gaap:MoneyMarketFundsMember 2018-12-31 0001501134 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2018-12-31 0001501134 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2018-12-31 0001501134 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2018-12-31 0001501134 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2018-12-31 0001501134 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2018-12-31 0001501134 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2018-12-31 0001501134 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2018-12-31 0001501134 us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001501134 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2018-12-31 0001501134 us-gaap:CommercialPaperMember 2018-12-31 0001501134 us-gaap:FairValueMeasurementsRecurringMember nvta:ContingentConsiderationMember 2018-12-31 0001501134 us-gaap:USTreasurySecuritiesMember 2018-12-31 0001501134 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2018-12-31 0001501134 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2018-12-31 0001501134 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001501134 us-gaap:CertificatesOfDepositMember 2018-12-31 0001501134 nvta:KEWIncMember 2018-01-01 2018-12-31 0001501134 nvta:ServiceAgreementsAndLaboratorySuppliesMember 2018-12-31 0001501134 us-gaap:SecuredDebtMember nvta:LoanAndSecurityAgreementMember nvta:SecondTermLoanMember 2017-03-31 0001501134 nvta:LoanAndSecurityAgreementMember nvta:ThirdTermLoanMember 2018-12-31 0001501134 us-gaap:SecuredDebtMember nvta:LoanAndSecurityAgreementMember 2017-03-01 2017-03-31 0001501134 nvta:NotePurchaseAgreementMember us-gaap:CommonStockMember 2018-11-01 2018-11-30 0001501134 nvta:OfficeFacilityInSanFranciscoMember nvta:NewLeasesMember 2015-09-30 0001501134 us-gaap:SecuredDebtMember nvta:LoanAndSecurityAgreementMember nvta:SecondTermLoanMember 2017-03-01 2017-03-31 0001501134 nvta:NotePurchaseAgreementMember us-gaap:DebtInstrumentRedemptionPeriodTwoMember 2018-01-01 2018-12-31 0001501134 us-gaap:SecuredDebtMember nvta:LoanAndSecurityAgreementMember 2018-01-01 2018-12-31 0001501134 nvta:LoanAndSecurityAgreementMember nvta:FirstTermLoanMember 2017-03-01 2017-03-31 0001501134 nvta:CoDevelopmentAgreementMember 2018-12-31 0001501134 nvta:NotePurchaseAgreementMember 2018-01-01 2018-12-31 0001501134 us-gaap:SecuredDebtMember nvta:LoanAndSecurityAgreementMember 2017-03-31 0001501134 nvta:NotePurchaseAgreementMember 2018-12-31 0001501134 nvta:NotePurchaseAgreementMember us-gaap:CommonStockMember 2018-11-30 0001501134 nvta:LoanAndSecurityAgreementMember nvta:SecondTermLoanMember 2017-03-01 2017-03-31 0001501134 us-gaap:SecuredDebtMember nvta:LoanAndSecurityAgreementMember 2016-01-01 2016-12-31 0001501134 us-gaap:SecuredDebtMember nvta:LoanAndSecurityAgreementMember 2018-11-01 2018-11-30 0001501134 nvta:LoanAndSecurityAgreementMember nvta:FirstTermLoanMember 2017-03-31 0001501134 nvta:NotePurchaseAgreementMember us-gaap:DebtInstrumentRedemptionPeriodOneMember 2018-01-01 2018-12-31 0001501134 nvta:CoDevelopmentAgreementMember 2018-01-01 2018-12-31 0001501134 nvta:NotePurchaseAgreementMember 2018-11-30 0001501134 us-gaap:SecuredDebtMember nvta:LoanAndSecurityAgreementMember 2018-12-31 0001501134 nvta:NotePurchaseAgreementMember nvta:TrancheOneMember 2018-11-30 0001501134 nvta:NotePurchaseAgreementMember us-gaap:ScenarioForecastMember 2020-01-01 0001501134 us-gaap:SecuredDebtMember nvta:LoanAndSecurityAgreementMember 2017-01-01 2017-12-31 0001501134 nvta:NotePurchaseAgreementMember nvta:TrancheOneMember 2018-11-01 2018-11-30 0001501134 nvta:LoanAndSecurityAgreementMember nvta:SecondTermLoanMember 2018-03-31 0001501134 us-gaap:SecuredDebtMember nvta:LoanAndSecurityAgreementMember 2018-10-01 2018-12-31 0001501134 srt:MaximumMember us-gaap:SecuredDebtMember nvta:LoanAndSecurityAgreementMember 2017-03-31 0001501134 srt:MinimumMember us-gaap:SecuredDebtMember nvta:LoanAndSecurityAgreementMember 2017-03-31 0001501134 nvta:OfficeFacilityInSanFranciscoMember nvta:NewLeasesMember 2018-12-31 0001501134 nvta:NotePurchaseAgreementMember us-gaap:DebtInstrumentRedemptionPeriodThreeMember 2018-01-01 2018-12-31 0001501134 nvta:NotePurchaseAgreementMember 2018-11-01 2018-11-30 0001501134 srt:MaximumMember nvta:CowenAndCompanyLimitedLiabilityCompanyMember nvta:CommonStockSalesAgreementMember 2018-08-01 2018-08-31 0001501134 nvta:SeriesAConvertiblePreferredStockConvertedtoCommonStockMember us-gaap:SeriesAPreferredStockMember us-gaap:SubsequentEventMember 2019-01-01 2019-02-28 0001501134 us-gaap:PrivatePlacementMember 2017-08-01 2017-08-31 0001501134 us-gaap:SeriesAPreferredStockMember us-gaap:PrivatePlacementMember 2017-08-01 2017-08-31 0001501134 nvta:UnderwrittenPublicOfferingMember 2018-04-01 2018-04-30 0001501134 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2017-08-31 0001501134 nvta:CowenAndCompanyLimitedLiabilityCompanyMember nvta:CommonStockSalesAgreementMember 2018-08-01 2018-08-31 0001501134 nvta:SeriesAConvertiblePreferredStockConvertedtoCommonStockMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2019-02-28 0001501134 us-gaap:SeriesAPreferredStockMember us-gaap:PrivatePlacementMember 2017-08-31 0001501134 nvta:CowenAndCompanyLimitedLiabilityCompanyMember us-gaap:CommonStockMember nvta:CommonStockSalesAgreementMember 2018-01-01 2018-12-31 0001501134 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2017-08-01 2017-08-31 0001501134 us-gaap:PrivatePlacementMember 2017-08-31 0001501134 us-gaap:CommonStockMember nvta:UnderwrittenPublicOfferingMember 2018-04-01 2018-04-30 0001501134 us-gaap:CommonStockMember nvta:UnderwrittenPublicOfferingMember 2018-04-30 0001501134 nvta:WarrantsissuedtolenderunderLoanandSecurityAgreement2018AmendmentsMember us-gaap:CommonStockMember 2018-12-31 0001501134 nvta:CombiMatrixCorporationMember nvta:SeriesFWarrantsMember us-gaap:CommonStockMember 2018-12-31 0001501134 nvta:WarrantsIssuedToLenderUnderLoanAndSecurityAgreementMember us-gaap:CommonStockMember 2018-12-31 0001501134 us-gaap:EmployeeStockOptionMember nvta:StockIncentivePlanMember 2017-12-31 0001501134 us-gaap:RestrictedStockUnitsRSUMember 2018-12-31 0001501134 nvta:EmployeeStockPurchasePlan2015Member 2017-12-31 0001501134 nvta:StockPayableLiabilitiesMember 2017-12-31 0001501134 us-gaap:WarrantMember 2018-12-31 0001501134 us-gaap:WarrantMember 2017-12-31 0001501134 nvta:StockPayableLiabilitiesMember 2018-12-31 0001501134 us-gaap:ContingentConsiderationClassifiedAsEquityMember 2017-12-31 0001501134 us-gaap:EmployeeStockOptionMember nvta:StockIncentivePlanMember 2018-12-31 0001501134 us-gaap:RestrictedStockUnitsRSUMember 2017-12-31 0001501134 us-gaap:ConvertiblePreferredStockMember 2018-12-31 0001501134 us-gaap:ConvertiblePreferredStockMember 2017-12-31 0001501134 nvta:EmployeeStockPurchasePlan2015Member 2018-12-31 0001501134 us-gaap:ContingentConsiderationClassifiedAsEquityMember 2018-12-31 0001501134 us-gaap:PrivatePlacementMember 2018-08-01 2018-08-31 0001501134 us-gaap:EmployeeStockOptionMember nvta:EmployeesAndDirectorsStockOptionsMember 2017-01-01 2017-12-31 0001501134 us-gaap:EmployeeStockOptionMember nvta:EmployeesAndDirectorsStockOptionsMember 2018-01-01 2018-12-31 0001501134 us-gaap:EmployeeStockOptionMember nvta:EmployeesAndDirectorsStockOptionsMember 2016-01-01 2016-12-31 0001501134 us-gaap:EmployeeStockOptionMember nvta:StockIncentivePlanMember 2016-01-01 2016-12-31 0001501134 us-gaap:RestrictedStockUnitsRSUMember 2016-01-01 2016-12-31 0001501134 nvta:PerformanceRestrictedStockUnitsRsusMember nvta:StockIncentivePlan2015Member 2017-01-01 2017-12-31 0001501134 nvta:EmployeeStockPurchasePlan2015Member 2017-01-01 2017-12-31 0001501134 srt:MaximumMember nvta:StockIncentivePlan2010Member 2018-01-01 2018-12-31 0001501134 nvta:EmployeeStockPurchasePlan2015Member 2016-01-01 2016-12-31 0001501134 nvta:EmployeeStockPurchasePlan2015Member 2015-01-01 2015-01-31 0001501134 us-gaap:RestrictedStockUnitsRSUMember 2017-01-01 2017-12-31 0001501134 us-gaap:EmployeeStockOptionMember nvta:StockIncentivePlanMember 2018-01-01 2018-12-31 0001501134 us-gaap:EmployeeStockOptionMember nvta:StockIncentivePlanMember 2017-01-01 2017-12-31 0001501134 us-gaap:RestrictedStockUnitsRSUMember 2018-01-01 2018-12-31 0001501134 srt:MinimumMember nvta:StockIncentivePlan2010Member 2018-01-01 2018-12-31 0001501134 us-gaap:RestrictedStockUnitsRSUMember nvta:StockIncentivePlanMember 2018-01-01 2018-12-31 0001501134 nvta:PerformanceRestrictedStockUnitsRsusMember 2018-12-31 0001501134 nvta:PerformanceRestrictedStockUnitsRsusMember nvta:StockIncentivePlan2015Member 2017-02-01 2017-02-28 0001501134 nvta:StockIncentivePlanMember 2018-01-01 2018-12-31 0001501134 nvta:PerformanceRestrictedStockUnitsRsusMember 2016-01-01 2016-12-31 0001501134 nvta:PerformanceRestrictedStockUnitsRsusMember nvta:StockIncentivePlan2015Member 2016-02-01 2016-02-29 0001501134 nvta:PerformanceRestrictedStockUnitsRsusMember nvta:StockIncentivePlan2015Member 2016-01-01 2016-12-31 0001501134 nvta:PerformanceRestrictedStockUnitsRsusMember 2018-01-01 2018-12-31 0001501134 nvta:CostOfTestRevenueMember 2017-01-01 2017-12-31 0001501134 nvta:CostOfTestRevenueMember 2018-01-01 2018-12-31 0001501134 nvta:CostOfTestRevenueMember 2016-01-01 2016-12-31 0001501134 us-gaap:GeneralAndAdministrativeExpenseMember 2016-01-01 2016-12-31 0001501134 us-gaap:SellingAndMarketingExpenseMember 2018-01-01 2018-12-31 0001501134 us-gaap:GeneralAndAdministrativeExpenseMember 2018-01-01 2018-12-31 0001501134 us-gaap:GeneralAndAdministrativeExpenseMember 2017-01-01 2017-12-31 0001501134 nvta:ResearchAndDevelopmentMember 2016-01-01 2016-12-31 0001501134 nvta:ResearchAndDevelopmentMember 2018-01-01 2018-12-31 0001501134 nvta:ResearchAndDevelopmentMember 2017-01-01 2017-12-31 0001501134 us-gaap:SellingAndMarketingExpenseMember 2016-01-01 2016-12-31 0001501134 us-gaap:SellingAndMarketingExpenseMember 2017-01-01 2017-12-31 0001501134 us-gaap:RestrictedStockUnitsRSUMember nvta:StockIncentivePlanMember nvta:FirstAnniversaryOfGrantDateMember 2018-01-01 2018-12-31 0001501134 nvta:PerformanceRestrictedStockUnitsRsusMember nvta:StockIncentivePlan2015Member 2018-01-01 2018-12-31 0001501134 us-gaap:RestrictedStockUnitsRSUMember nvta:StockIncentivePlanMember nvta:SecondAnniversaryOfGrantDateMember 2018-01-01 2018-12-31 0001501134 us-gaap:RestrictedStockUnitsRSUMember nvta:StockIncentivePlanMember nvta:ThirdAnniversaryOfGrantDateMember 2018-01-01 2018-12-31 0001501134 srt:MaximumMember nvta:NonEmployeeStockOptionMember 2016-01-01 2016-12-31 0001501134 nvta:NonEmployeeStockOptionMember 2016-01-01 2016-12-31 0001501134 srt:MinimumMember nvta:NonEmployeeStockOptionMember 2016-01-01 2016-12-31 0001501134 srt:MinimumMember nvta:NonEmployeeStockOptionMember 2017-01-01 2017-12-31 0001501134 srt:MaximumMember nvta:NonEmployeeStockOptionMember 2018-01-01 2018-12-31 0001501134 srt:MaximumMember nvta:NonEmployeeStockOptionMember 2017-01-01 2017-12-31 0001501134 srt:MinimumMember nvta:NonEmployeeStockOptionMember 2018-01-01 2018-12-31 0001501134 nvta:PerformanceRestrictedStockUnitsRsusMember 2017-01-01 2017-12-31 0001501134 2018-10-01 2018-12-31 0001501134 us-gaap:CaliforniaFranchiseTaxBoardMember 2018-01-01 2018-12-31 0001501134 us-gaap:InternalRevenueServiceIRSMember nvta:ExpirationTaxYearUnknownMember 2018-12-31 0001501134 us-gaap:StateAndLocalJurisdictionMember 2018-12-31 0001501134 us-gaap:InternalRevenueServiceIRSMember 2018-12-31 0001501134 us-gaap:InternalRevenueServiceIRSMember nvta:ExpirationTaxYear2019Member 2018-12-31 0001501134 us-gaap:CaliforniaFranchiseTaxBoardMember us-gaap:ResearchMember 2018-12-31 0001501134 us-gaap:InternalRevenueServiceIRSMember us-gaap:ResearchMember 2018-12-31 0001501134 us-gaap:InternalRevenueServiceIRSMember 2018-01-01 2018-12-31 0001501134 us-gaap:RestrictedStockUnitsRSUMember 2018-01-01 2018-12-31 0001501134 nvta:EmployeeStockPurchasePlan2015Member 2017-01-01 2017-12-31 0001501134 us-gaap:WarrantMember 2018-01-01 2018-12-31 0001501134 nvta:EmployeeStockPurchasePlan2015Member 2018-01-01 2018-12-31 0001501134 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-12-31 0001501134 us-gaap:RestrictedStockUnitsRSUMember 2017-01-01 2017-12-31 0001501134 nvta:PerformanceRestrictedStockUnitsRsusMember 2017-01-01 2017-12-31 0001501134 nvta:SeriesAConvertiblePreferredStockMember 2016-01-01 2016-12-31 0001501134 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-12-31 0001501134 nvta:SeriesAConvertiblePreferredStockMember 2018-01-01 2018-12-31 0001501134 nvta:EmployeeStockPurchasePlan2015Member 2016-01-01 2016-12-31 0001501134 nvta:PerformanceRestrictedStockUnitsRsusMember 2018-01-01 2018-12-31 0001501134 nvta:SeriesAConvertiblePreferredStockMember 2017-01-01 2017-12-31 0001501134 us-gaap:WarrantMember 2017-01-01 2017-12-31 0001501134 nvta:PerformanceRestrictedStockUnitsRsusMember 2016-01-01 2016-12-31 0001501134 us-gaap:EmployeeStockOptionMember 2016-01-01 2016-12-31 0001501134 us-gaap:WarrantMember 2016-01-01 2016-12-31 0001501134 us-gaap:RestrictedStockUnitsRSUMember 2016-01-01 2016-12-31 0001501134 country:CA 2017-01-01 2017-12-31 0001501134 nvta:RestOfWorldMember 2017-01-01 2017-12-31 0001501134 country:US 2018-01-01 2018-12-31 0001501134 country:US 2017-01-01 2017-12-31 0001501134 nvta:RestOfWorldMember 2018-01-01 2018-12-31 0001501134 nvta:RestOfWorldMember 2016-01-01 2016-12-31 0001501134 country:US 2016-01-01 2016-12-31 0001501134 country:CA 2016-01-01 2016-12-31 0001501134 country:CA 2018-01-01 2018-12-31 0001501134 2018-07-01 2018-09-30 0001501134 2018-01-01 2018-03-31 0001501134 2017-07-01 2017-09-30 0001501134 2017-04-01 2017-06-30 0001501134 2017-01-01 2017-03-31 0001501134 2018-04-01 2018-06-30 0001501134 2017-10-01 2017-12-31 iso4217:USD nvta:Segment iso4217:USD xbrli:shares nvta:gene xbrli:shares xbrli:pure nvta:Employee




UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10‑K

x
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2018
o
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from           to          
Commission File No. 001‑36847
invitaelogo.jpg
Invitae Corporation
(Exact name of the registrant as specified in its charter)
Delaware
27‑1701898
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification No.)
1400 16th Street, San Francisco, California 94103
(Address of principal executive offices, Zip Code)
(415) 374‑7782
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class:
 
Name of each exchange on which registered:
Common Stock, par value $0.0001 per share
 
The New York Stock Exchange
Securities registered pursuant to Section 12(g) of the Act: None
Indicate by check mark if the registrant is a well‑known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes x No o
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes o No x
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S‑T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No o
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S‑K (§229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10‑K or any amendment to this Form 10‑K. x





Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non‑accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b‑2 of the Exchange Act.
Large accelerated filer
o
 
Accelerated filer
x
Non-accelerated filer
o
 
Smaller reporting company
o
 
 
 
Emerging growth company
x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  x
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b‑2 of the Act). Yes  o No  x
As of June 29, 2018, the aggregate market value of common stock held by non‑affiliates of the Registrant was approximately $477.8 million, based on the closing price of the common stock as reported on The New York Stock Exchange for that date.

The number of shares of the registrant’s Common Stock outstanding as of February 22, 2019 was 76,811,562.

DOCUMENTS INCORPORATED BY REFERENCE
Items 10 (as to directors and Section 16(a) Beneficial Ownership Reporting Compliance), 11, 12, 13 and 14 of Part III incorporate by reference information from the registrant’s proxy statement to be filed with the Securities and Exchange Commission in connection with the solicitation of proxies for the registrant’s 2019 Annual Meeting of Stockholders.






TABLE OF CONTENTS
 
 
 
Page No.
 
 
 
 
 


i




PART I
ITEM 1.
Business.
This report contains forward‑looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements in this report other than statements of historical fact, including statements identified by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect” and similar expressions, are forward‑looking statements. Forward‑looking statements include, but are not limited to, statements about:
•
our views regarding the future of genetic testing and its role in mainstream medical practice;
•
our mission and strategy for our business, products and technology, including our ability to expand our content and develop new content while maintaining attractive pricing, further enhance our genetic testing service and the related user experience, build interest in and demand for our tests and attract potential partners;
•
the implementation of our business model;
•
the expected benefits, including cost-savings and synergies, from our acquisitions;
•
the rate and degree of market acceptance of our tests and genetic testing generally;
•
our ability to scale our infrastructure and operations in a cost‑effective manner;
•
the timing of and our ability to introduce improvements to our genetic testing platform and to expand our assay to include additional genes;
•
our expectations with respect to future hiring;
•
the timing and results of studies with respect to our tests;
•
developments and projections relating to our competitors and our industry;
•
our competitive strengths;
•
the degree to which individuals will share genetic information generally, as well as share any related potential economic opportunities with us;
•
our commercial plans, including our sales and marketing expectations;
•
our ability to obtain and maintain adequate reimbursement for our tests;
•
regulatory developments in the United States and foreign countries;
•
our ability to attract and retain key scientific or management personnel;
•
our expectations regarding our ability to obtain and maintain intellectual property protection and not infringe on the rights of others;
•
our expectations regarding the time during which we will be an emerging growth company under the JOBS Act;
•
our ability to obtain funding for our operations and the growth of our business, including potential acquisitions;
•
our financial performance;
•
the impact of accounting pronouncements and our critical accounting policies, judgments, estimates and assumptions on our financial results;
•
our expectations regarding our future revenue, cost of revenue, operating expenses and capital expenditures, and our future capital requirements; and
•
the impact of tax laws on our business.

Forward‑looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those expected. These risks and uncertainties include, but are not limited to, those risks discussed in Item 1A of this report. Although we believe that the expectations and assumptions reflected in the forward‑looking statements are reasonable, we cannot guarantee future results, level of activity, performance or achievements. In addition, neither we nor any other person assumes responsibility for the accuracy and completeness of any of these forward‑looking statements. Any forward‑looking statements in this report speak only as of the date of this report. We expressly disclaim any obligation or undertaking to update any forward‑looking statements.

2




This report contains statistical data and estimates that we obtained from industry publications and reports. These publications typically indicate that they have obtained their information from sources they believe to be reliable, but do not guarantee the accuracy and completeness of their information. Some data contained in this report is also based on our internal estimates. Although we have not independently verified the third‑party data, we believe it to be reasonable.
In this report, all references to “Invitae,” “we,” “us,” “our,” or “the company” mean Invitae Corporation.
Invitae and the Invitae logo are trademarks of Invitae Corporation. We also refer to trademarks of other companies and organizations in this report.
Overview
Combining genetic testing services that support patient care throughout life’s journey – from inherited disease diagnosis, to family planning, to proactive health screening – with a unique, rapidly expanding network of patients, healthcare providers, biopharma and advocacy partners, Invitae is capturing the broad potential of genetics and helping to expand its use across the healthcare continuum. Through the custom design and application of automation, robotics and bioinformatics software solutions tailored to the complexity of sample processing and complex variant interpretation, Invitae can apply its world-class clinical expertise to medical interpretation at scale, simplifying the process of obtaining and utilizing affordable, high-quality genetic information to inform critical healthcare decisions.
By pioneering new ways of sharing and understanding genetic information, Invitae is transforming the field of genetics from one-dimensional testing to complex information management.
Mission and strategy
Invitae’s mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. Our goal is to aggregate a majority of the world’s genetic information into a comprehensive network that enables sharing of data among network participants to improve healthcare and clinical outcomes.
We were founded on four core principles:
•
Patients should own and control their own genetic information;
•
Healthcare professionals are fundamental in ordering and interpreting genetic information;
•
Driving down the price of genetic information will increase its clinical and personal utility; and
•
Genetic information is more valuable when shared.
Our strategy for long-term growth centers on five key drivers of our business, which we believe work in conjunction to create a flywheel effect extending our leadership position in the new market we are building:
invitaeflywheel.jpg

•
Expanding our content offering.  We intend to continue steadily adding additional content to the Invitae platform, ultimately leading to affordable access to the personal molecular information relevant

3




in enabling personalized medicine. The breadth and depth of our offering is a core and central contribution to an improved user experience. 

•
Creating a unique user experience.  A state-of-the-art interactive platform will enhance our service offering, leverage the uniquely empowering characteristics of online sharing of genetic information and, we believe, enable a superior economic offering to clients. We intend to continue to expend substantial efforts developing, acquiring and implementing technology-driven enhancements to our customers’ experience. We believe that an enhanced user experience and the resulting benefits to our brand and reputation will help draw customers to us over and above our direct efforts to do so.

•
Driving volume.  We intend to increase our brand equity and visibility through excellent service and a variety of marketing and promotional techniques, including scientific publications and presentations, sales, marketing, public relations, social media and web technology vehicles. We believe that rapidly increasing the volume of customers using our platform helps us to attract partners. 

•
Attracting partners.  As we add more customers to our platform, we believe our business becomes particularly attractive to potential partners that can help the patients in our network further benefit from their genetic information or that provide us access to new customers who may wish to join our network. We believe the cumulative effect of the increased volume brought by all of these strategic components will allow us to lower the cost of our service. 

•
Lowering the cost and price of genetic information.  Our goal is to provide customers with a broad menu of genetic content at a reasonable price and rapid turn-around time in order to grow volume and further achieve economies of scale. As we do so and benefit from further cost savings, we expect that those cost savings will allow us to deliver still more comprehensive information at decreasing prices and further improve the customer experience, allowing us to reap the cumulative benefits from all of the efforts outlined above.
We seek to differentiate our service in the market by establishing an exceptional experience for our customers. To that end, we believe that elevating the needs of the customer over those of our other stakeholders is essential to our success. Thus, in our decision-making processes, we will strive to prioritize, in order:
•The needs of our customers;
•Motivating our employees to serve our customers; and
•Our long-term stockholder value.
We are certain that focusing on customers as our top priority rather than short-term financial goals is the best way to build and operate an organization for maximum long-term value creation.
Business overview
We are focused on making comprehensive, high-quality genetic information more accessible by lowering the cost of genetic testing, by creating a network of partners to increase the utility of genetic information across the healthcare continuum, and ultimately by managing that information on behalf of our customers.
As our market share grows, we expect that our business will grow in three stages:
1)
Genetic testing: making genetic testing more affordable and more accessible with fast turnaround time. We believe that there is a significant market opportunity for high-volume, low-cost genetic testing that allows us to serve a large number of customers. We launched our first commercial offering in November 2013 with an offering of approximately 200 genes, growing the test menu over time to include more than 20,000 genes to help diagnose disease, inform family planning, and serve healthy individuals. In 2018, we accessioned approximately 303,000 samples and generated revenue of $147.7 million reflecting an approximate 102% and 117% increase over 2017 volume and revenue, respectively. In 2018, we achieved a full-year gross profit of $67.6 million, compared to a full-year gross profit of $18.1 million in 2017. In support of our efforts to reduce the cost per test, expand our test menu, and develop a scalable laboratory infrastructure, we incurred research and development expenses of $63.5 million, $46.5 million and $44.6 million in 2018, 2017, and 2016, respectively.
2)
Genome network: sharing genetic information on a global scale to advance science and medicine. We are focusing our efforts on partnering with patients, family members, healthcare professionals, payers, industry professionals, researchers, and clinical trial sponsors to advance the development of our

4




genome network. Our goal is to build a network through which individuals can access, aggregate, and customize information based on their genotype and phenotype and participate in new research, clinical trials, treatment planning, or other related purposes that may benefit the individual and/or their clinician. Individuals can also decide to share information if they feel it will benefit them or will contribute more broadly to furthering knowledge about their conditions.
In addition to investing in informatics solutions and infrastructure to support network development, we have begun partnering with biopharmaceutical companies, including Alnylam Pharmaceuticals, Inc., Ariad Pharmaceuticals, Inc. (a subsidiary of Takeda Pharmaceutical Company Limited), AstraZeneca, BioMarin Pharmaceutical Inc., Blueprint Medicines Corporation, Jazz Pharmaceuticals plc, Merck & Co., Inc., MyoKardia, Inc., Parion Sciences, Inc. and others to support clinical trial recruitment and other research-related initiatives. Our biopharmaceutical industry partnerships are complemented by partnerships with leading health systems, executive health programs and leading research institutions, including the Geisinger Health System, the Mayo Clinic, Memorial Sloan Kettering Cancer Center, MedCan, NorthShore University HealthSystem, and Stanford Health Care, among others.
3)
Genome management: building a secure and trusted genome management infrastructure. By generating and storing large amounts of individualized genetic information for every patient sample, we believe we can create value over the course of disease or lifetime of a customer.
Competition
Our competitors include companies that offer molecular genetic testing services, including specialty and reference laboratories that offer traditional single and multi-gene tests. Principal competitors include companies such as Ambry Genetics, a subsidiary of Konica Minolta Inc.; Athena Diagnostics, a subsidiary of Quest Diagnostics Incorporated; Baylor Genetics; Blueprint Genetics, Inc.; Centogene AG; Color Genomics, Inc.; Connective Tissue Gene Test LLC; Cooper Surgical, Inc.; Eurofins Scientific; GeneDx, a subsidiary of OPKO Health, Inc.; Laboratory Corporation of America Holdings; MNG Laboratories, LLC; Myriad Genetics, Inc.; Natera, Inc.; Perkin Elmer, Inc.; PreventionGenetics, LLC; Progenity, Inc.; Quest Diagnostics Incorporated; and Sema4 Genomics; as well as other commercial and academic labs. In addition, there are a large number of new entrants into the market for genetic information ranging from informatics and analysis pipeline developers to focused, integrated providers of genetic tools and services for health and wellness, including Illumina, Inc. which is also one of our suppliers. In addition to the companies that currently offer traditional genetic testing services and research centers, other established and emerging healthcare, information technology and service companies may commercialize competitive products including informatics, analysis, integrated genetic tools and services for health and wellness.
We believe the principal competitive factors in our market are:
•breadth and depth of content;
•quality;
•reliability;
•accessibility of results;
•turnaround time of testing results;
•price and quality of tests;
•coverage and reimbursement arrangements with third-party payers;
•convenience of testing;
•brand recognition of test provider;
•additional value-added services and informatics tools;
•client service; and
•quality of website content.
We believe that we compare favorably with our competitors on the basis of these factors. However, many of our competitors and potential competitors have longer operating histories, larger customer bases, greater brand recognition and market penetration, substantially greater financial, technological and research and development resources and selling and marketing capabilities, and more experience dealing with third party payers. As a result, they may be able to respond more quickly to changes in customer requirements, devote greater resources to the development, promotion and sale of their tests, or sell their tests at prices designed to win significant levels of market share. We may not be able to compete effectively against these organizations.

5




Regulation
Reimbursement
In September 2014, the American Medical Association, or AMA, published new Current Procedural Terminology, or CPT, codes for genomic sequencing procedures that are effective for dates of service on or after January 1, 2015. These include genomic sequencing procedure codes for panels, including hereditary colon cancer syndromes, targeted genomic sequence analysis panels for solid organ neoplasms, targeted genomic sequence analysis panels for hematolymphoid neoplasm or disorders, whole exome analyses, and whole genome analyses. In a final determination under the Medicare Clinical Laboratory Fee Schedule, or CLFS, published in November 2014, the Centers for Medicare and Medicaid Services, or CMS, set the 2015 payment rate for these codes by the gap‑fill process. Under the gap‑fill process, local Medicare Administrative Contractors, or MACs, establish rates for those codes that each MAC believes meet the criteria for Medicare coverage and considering laboratory charges and discounts to charges, resources, amounts paid by other payers for the tests, and amounts paid by the MAC for similar tests. In 2015, gap-filled payment rates were established for some, but not all, of the above‑referenced codes. For those codes for which local gap‑filled rates were established in 2015, a national limitation amount for Medicare was established for 2016. Codes for which local gap‑filled rates were not established in 2015 were priced by the local MACs in 2016 insofar as an individual MAC determined that such codes should be covered. Where available, the national limitation amount serves as a cap on the Medicare and Medicaid payment rates for a test procedure. If we are required to report our tests under these codes, there can be no guarantees that Medicare (or its contractors) has or will set adequate reimbursement rates for these codes.
The AMA also released several CPT codes effective January 2016 that may be appropriate to report certain of our tests. In a November 2015 final determination, CMS set the calendar year 2016 CLFS payment rate for these new codes by the gap-fill process. CMS and the local MACs went through the gap-fill process in 2016 and announced final gap-filled rates for 2017 on September 30, 2016. The calendar year 2017 national limitation amounts for certain codes were significantly less than the rates at which we have historically offered our tests.
In April 2014, Congress passed the Protecting Access to Medicare Act of 2014, or PAMA, which included substantial changes to the way in which clinical laboratory services are paid under Medicare. Under the regulations implementing PAMA, laboratories that realize at least $12,500 in Medicare CLFS revenues during the six month reporting period and that receive the majority of their Medicare revenue from payments made under the CLFS or the Physician Fee Schedule must report, beginning in 2017, and then every three years thereafter (or annually for “advanced diagnostic laboratory tests”), private payer payment rates and volumes for their tests. We do not believe that our tests meet the current definition of advanced diagnostic laboratory tests, and therefore believe we are required to report private payer rates for our tests on an every three years basis. CMS uses the rates and volumes reported by laboratories to develop Medicare payment rates for the tests equal to the volume‑weighted median of the private payer payment rates for the tests. Laboratories that fail to report the required payment information may be subject to substantial civil money penalties.
As set forth under the regulations implementing PAMA, for tests furnished on or after January 1, 2018, Medicare payments for clinical diagnostic laboratory tests are paid based upon these reported private payer rates. For clinical diagnostic laboratory tests that are assigned a new or substantially revised code, initial payment rates for clinical diagnostic laboratory tests that are not advanced diagnostic laboratory tests will be assigned by the cross‑walk or gap‑fill methodology, as under prior law. Initial payment rates for new advanced diagnostic laboratory tests will be based on the actual list charge for the laboratory test.
The payment rates calculated under PAMA went into effect starting January 1, 2018. Where applicable, reductions to payment rates resulting from the new methodology are limited to 10% per test per year in each of the years 2018 through 2020 and to 15% per test per year in each of 2021 through 2023 (following a second round of private payer rate reporting in 2020 to establish rates for 2021 through 2023).
PAMA codified Medicare coverage rules for laboratory tests by requiring any local coverage determination to be made following the local coverage determination process. PAMA also authorizes CMS to consolidate coverage policies for clinical laboratory tests among one to four laboratory‑specific MACs. These same contractors may also be designated to process claims if CMS determines that such a model is appropriate. It is unclear whether CMS will proceed with contractor consolidation under this authorization.
PAMA also authorized the adoption of new, temporary billing codes and/or unique test identifiers for FDA‑cleared or approved tests as well as advanced diagnostic laboratory tests. The American Medical Association has created a new section of billing codes, Proprietary Laboratory Analyses, to facilitate implementation of this section of PAMA. At this time, it is unclear how these codes would apply to our tests.

6




In March 2018, CMS published a final national coverage determination, or NCD, for next generation sequencing, or NGS, tests for patients with advanced cancer. The final NCD establishes full coverage for FDA-approved or FDA-cleared NGS-based companion diagnostic assays when offered for their FDA-approved or FDA-cleared use(s), ordered by the patient’s treating physician for Medicare beneficiaries with advanced cancer (recurrent, relapsed, refractory, metastatic, or advanced stage III or IV cancer) who have not have previously been tested with the same test for the same primary diagnosis of cancer or are seeking repeat testing for a new primary cancer diagnosis, and have decided to seek further cancer treatment. The final NCD also gives MACs the authority to establish local coverage for NGS-based assays that are not FDA-approved or FDA-cleared companion diagnostics when offered to patients meeting the above-referenced criteria. It is unclear, however, whether MACs retain the authority to establish local coverage for NGS-based tests provided for patients with cancer that do not meet the above-referenced criteria - e.g., patients with earlier stage cancers or patients with a personal history of cancer - or if such tests are nationally non-covered under the NCD. If CMS interprets the final NCD to exclude coverage for patients with earlier stage cancers or patients with a personal history of cancer, MACs will no longer have discretion to cover our current tests when offered to such patients, notwithstanding historical Medicare coverage for such tests. An interpretation of the NCD that results in Medicare non-coverage for our current and future assays would have significant negative impact on our business, financial condition, and results of operations.
Clinical Laboratory Improvement Amendments of 1988, or CLIA
Our clinical reference laboratories in California are required to hold certain federal certificates to conduct our business. Under CLIA, we are required to hold certificates applicable to the type of laboratory examinations we perform and to comply with standards covering personnel, facilities administration, inspections, quality control, quality assurance and proficiency testing. In 2018, we closed our laboratory in Cambridge, Massachusetts and transferred operations from that facility to our laboratory in San Francisco, California.
We have current certifications under CLIA to perform testing at our laboratory locations in San Francisco and Irvine, California. To renew our CLIA certifications, we are subject to survey and inspection every two years to assess compliance with program standards. Moreover, CLIA inspectors may make random inspections of our clinical reference laboratories. The regulatory and compliance standards applicable to the testing we perform may change over time, and any such changes could have a material effect on our business.
If our clinical reference laboratories are out of compliance with CLIA requirements, we may be subject to sanctions such as suspension, limitation or revocation of our CLIA certificates, as well as directed plan of correction, state on‑site monitoring, civil money penalties, civil injunctive suit or criminal penalties. We must maintain CLIA compliance and certifications to be eligible to bill for diagnostic services provided to Medicare and Medicaid beneficiaries. If we were to be found out of compliance with CLIA requirements and subjected to sanction, our business could be harmed.
State laboratory licensure
We are required to maintain in-state licenses to conduct testing in California. California laws establish standards for day‑to‑day operations of our laboratories in San Francisco and Irvine. Such laws mandate proficiency testing, which involves testing of specimens that have been specifically prepared for the laboratories. If our clinical reference laboratories are out of compliance with California standards, the California Department of Health Services, or DHS, may suspend, restrict or revoke our licenses to operate our clinical reference laboratories, assess substantial civil money penalties, or impose specific corrective action plans. Any such actions could materially affect our business. We maintain current licenses in good standing with DHS. However, we cannot provide assurance that DHS will at all times in the future find us to be in compliance with all such laws.
Several states require the licensure of out‑of‑state laboratories that accept specimens from those states and/or receive specimens from laboratories in those states. Our laboratories hold the required out‑of‑state laboratory licenses for Maryland, New York, Pennsylvania, and Rhode Island.
In addition to having laboratory licenses in New York, our clinical reference laboratories in California are also required to obtain approval on a test‑specific basis by the New York State Department of Health, or NYDOH, before specific testing is performed on samples from New York.
Other states may adopt similar licensure requirements in the future, which may require us to modify, delay or stop our operations in such jurisdictions. Complying with licensure requirements in new jurisdictions may be expensive, time‑consuming, and subject us to significant and unanticipated delays. If we identify any other state with such requirements, or if we are contacted by any other state advising us of such requirements, we intend to follow instructions from the state regulators as to how we should comply with such requirements.

7




We may also be subject to regulation in foreign jurisdictions as we seek to expand international utilization of our tests or such jurisdictions adopt new licensure requirements, which may require review of our tests in order to offer them or may have other limitations such as restrictions on the transport of human blood or saliva necessary for us to perform our tests that may limit our ability to make our tests available outside of the United States.
U.S. Food and Drug Administration, or FDA
We provide our tests as laboratory‑developed tests, or LDTs. CMS and certain state agencies regulate the performance of LDTs (as authorized by CLIA and state law, respectively).
Historically, the FDA has exercised enforcement discretion with respect to most LDTs and has not required laboratories that furnish LDTs to comply with the agency’s requirements for medical devices (e.g., establishment registration, device listing, quality systems regulations, premarket clearance or premarket approval, and post‑ market controls). In recent years, however, the FDA has stated it intends to end its policy of general enforcement discretion and regulate certain LDTs as medical devices. To this end, on October 3, 2014, the FDA issued two draft guidance documents, entitled “Framework for Regulatory Oversight of Laboratory Developed Tests (LDTs)” and “FDA Notification and Medical Device Reporting for Laboratory Developed Tests (LDTs),” respectively, that set forth a proposed risk‑based regulatory framework that would apply varying levels of FDA oversight to LDTs. The FDA has indicated that it does not intend to modify its policy of enforcement discretion until the draft guidance documents are finalized. Subsequently, on January 13, 2017, the FDA published a “discussion paper” in which the agency outlined a substantially revised “possible approach” to the oversight of LDTs. The discussion paper explicitly states that it is not a final version of the 2014 draft guidance and that it does not represent the agency’s “formal position;” rather, the discussion paper describes the evolution of the agency’s thinking on LDTs, which the agency posted to “spur further dialogue.” Notably, in the discussion paper, the agency expressed its willingness to consider “grandfathering” currently marketed LDTs from most or all FDA regulatory requirements. It is unclear at this time when, or if, the FDA will finalize its plans to end enforcement discretion, and even then, the new regulatory requirements are expected to be phased‑in over time. Nevertheless, the FDA may decide to regulate certain LDTs on a case‑by‑case basis at any time.
Legislative proposals addressing the FDA’s oversight of LDTs have been introduced in previous Congresses, and we expect that new legislative proposals will be introduced from time‑to‑time. The likelihood that Congress will pass such legislation and the extent to which such legislation may affect the FDA’s plans to regulate certain LDTs as medical devices is difficult to predict at this time.
If the FDA ultimately regulates certain LDTs as medical devices, whether via final guidance, final regulation, or as instructed by Congress, our tests may be subject to certain additional regulatory requirements. Complying with the FDA’s requirements for medical devices can be expensive, time‑consuming, and subject us to significant or unanticipated delays. Insofar as we may be required to obtain premarket clearance or approval to perform or continue performing an LDT, we cannot assure you that we will be able to obtain such authorization. Even if we obtain regulatory clearance or approval where required, such authorization may not be for the intended uses that we believe are commercially attractive or are critical to the commercial success of our tests. As a result, the application of the FDA’s medical device requirements to our tests could materially and adversely affect our business, financial condition, and results of operations.
Notwithstanding the FDA’s current position with respect to oversight of our tests, we may voluntarily decide to pursue FDA pre‑market review for our current tests and/or tests we may offer in the future if we determine that doing so would be appropriate from a strategic perspective – e.g., if CMS indicated that it no longer intended to cover tests offered as LDTs.
Failure to comply with applicable FDA regulatory requirements may trigger a range of enforcement actions by the FDA including warning letters, civil monetary penalties, injunctions, criminal prosecution, recall or seizure, operating restrictions, partial suspension or total shutdown of operations, and denial of or challenges to applications for clearance or approval, as well as significant adverse publicity.
In addition, in November 2013, the FDA issued final guidance regarding the distribution of products labeled for research use only. Certain of the reagents and other products we use in our tests are labeled as research use only products. Certain of our suppliers may cease selling research use only products to us and any failure to obtain an acceptable substitute could significantly and adversely affect our business, financial condition and results of operations.

8




HIPAA and HITECH
Under the administrative simplification provisions of the Health Insurance Portability and Accountability Act of 1996, or HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, the U.S. Department of Health and Human Services issued regulations that establish uniform standards governing the conduct of certain electronic healthcare transactions and requirements for protecting the privacy and security of protected health information used or disclosed by covered entities, including health care providers and their respective business associates, including the business associates’ subcontractors. Four principal regulations with which we are required to comply have been issued in final form under HIPAA and HITECH: privacy regulations, security regulations, the breach notification rule, and standards for electronic transactions, which establish standards for common healthcare transactions.
The privacy regulations cover the use and disclosure of protected health information by covered entities as well as business associates, which are persons or entities that perform certain functions for or on behalf of a covered entity that involve the creation, receipt, maintenance, or transmittal of protected health information. Business associates are defined to include a subcontractor to whom a business associate delegates a function, activity, or service, other than in the capacity of the business associate’s workforce. As a general rule, a covered entity or business associate may not use or disclose protected health information except as permitted under the privacy regulations. The privacy regulations also set forth certain rights that an individual has with respect to his or her protected health information maintained by a covered entity or business associate, including the right to access or amend certain records containing his or her protected health information, or to request restrictions on the use or disclosure of his or her protected health information.
Covered entities and business associates also must comply with the security regulations, which establish requirements for safeguarding the confidentiality, integrity, and availability of protected health information that is electronically transmitted or electronically stored. In addition, HITECH established, among other things, certain breach notification requirements with which covered entities and business associates must comply. In particular, a covered entity must notify any individual whose unsecured protected health information is breached according to the specifications set forth in the breach notification rule. A covered entity must also notify the Secretary of the U.S. Department of Health and Human Services and, under certain circumstances, the media of a breach of unsecured protected health information.
The HIPAA privacy, security, and breach notification regulations establish a uniform federal “floor” and do not supersede state laws that are more stringent or provide individuals with greater rights with respect to the privacy or security of, and access to, their records containing protected health information or insofar as such state laws apply to personal information that is broader in scope than protected health information as defined under HIPAA. Massachusetts, for example, has a state law that protects the privacy and security of personal information of Massachusetts residents. Many states also have laws or regulations that specifically apply to the use or disclosure of genetic information and that are more stringent than the standards under HIPAA.
There are significant civil and criminal penalties that may be imposed on a covered entity or business associate for violating HIPAA. A covered entity or business associate may also be liable for civil money penalties for a violation that is based on an act or omission of any of its agents, including a downstream business associate, as determined according to the federal common law of agency. Additionally, to the extent that we submit electronic healthcare claims and payment transactions that do not comply with the electronic data transmission standards established under HIPAA and HITECH, payments to us may be delayed or denied.
Federal and state consumer protection laws
The Federal Trade Commission, or FTC, is an independent U.S. law enforcement agency charged with protecting consumers and enhancing competition across broad sectors of the economy. The FTC’s primary legal authority comes from Section 5 of the FTC Act, which prohibits unfair or deceptive acts or practices in the marketplace. The FTC has increasingly used this broad authority to police data privacy and security, using its powers to investigate and bring lawsuits. Where appropriate, the FTC can seek a variety of remedies, such as but not limited to the implementation of comprehensive privacy and security programs, biennial assessments by independent experts, monetary redress to consumers, and provision of robust notice and choice mechanisms to consumers. In addition to its enforcement mechanisms, the FTC uses a variety of tools to protect consumers’ privacy and personal information, including pursuing enforcement actions to stop violations of law, conducting studies and issuing reports, hosting public workshops, developing educational materials, and testifying before the U.S. Congress on issues that affect consumer privacy.

9




The vast majority of cases brought by the FTC fall under the “deceptive” prong of Section 5. These cases often involve a failure on the part of a company to adhere to its own privacy and data protection principles set forth in its policies. To avoid Section 5 violations, the FTC encourages companies to build privacy protections and safeguards into relevant portions of the business, and consider privacy and data protection as the company grows and evolves. In addition, privacy notices should clearly and accurately disclose the type(s) of information the company collects, how the company uses and shares the information, and the security measures used by the company to protect the information.
In recent years, the FTC’s enforcement under Section 5 has included alleged violations of the “unfairness” prong. Many of these cases have alleged that companies were unfair to consumers because they failed to take reasonable and necessary measures to protect consumer data. The FTC has not provided bright line rules defining what constitutes “reasonable and necessary measures” for implementing a cybersecurity program, but it has provided guidance, tips and advice for companies. The FTC has also published past complaints and consent orders, which it urges companies use as examples to help avoid an FTC enforcement action, even if a data breach or loss occurs.
In addition to the FTC Act, most U.S. states have unfair and deceptive acts and practices statutes, or UDAP statutes, that substantially mirror the FTC Act and have been applied in the privacy and data security context. These vary in substance and strength from state to state. Many have broad prohibitions against unfair and deceptive acts and practices, while New York’s UDAP statute, for instance, is limited to only deceptive acts and practice. These statutes generally allow for private rights of action and are enforced by the states’ Attorneys General. In addition, every U.S. state has a data breach notification law that requires entities to report certain security incidents to affected consumers and state regulators.
International privacy and data protection laws
There are a growing number of jurisdictions all over the world that have privacy and data protection laws. These laws are typically triggered by a company’s establishment or physical location in the jurisdiction, data processing activities that take place in the jurisdiction, and/or the processing of personal information about individuals located in that jurisdiction. Certain international privacy and data protection laws, such as those in the European Union, can be more restrictive and prescriptive than those in the U.S., while other jurisdictions can have laws less restrictive or prescriptive than those in the U.S. Enforcement of these laws vary from jurisdiction to jurisdiction, with a variety of civil or criminal penalties.
The European Union’s General Data Protection Regulation, or GDPR, took effect in May 2018. The GDPR applies to any business, regardless of its location, that provides goods or services to residents in the European Union. The GDPR imposes strict requirements on controllers and processors of personal data, including special protections for “sensitive information” which includes health and genetic information of data subjects residing in the European Union. The GDPR also grants individuals various rights in relation to their personal data including the right to access, rectification, objection to processing and deletion, and provides an individual with an express right to seek legal remedies if the individual believes his or her rights have been violated. Failure to comply with the requirements of the GDPR and the related national data protection laws of the member states of the European Union, which may deviate slightly from the GDPR, may result in significant fines.
Federal, state and foreign fraud and abuse laws
In the United States, there are various fraud and abuse laws with which we must comply, and we are potentially subject to regulation by various federal, state and local authorities, including CMS, other divisions of the U.S. Department of Health and Human Services (e.g., the Office of Inspector General), the U.S. Department of Justice, and individual U.S. Attorney offices within the Department of Justice, and state and local governments. We also may be subject to foreign fraud and abuse laws.
In the United States, the federal Anti‑Kickback Statute prohibits knowingly and willfully offering, paying, soliciting or receiving remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or in return for the referral of an individual for the furnishing of or arranging for the furnishing of any item or service for which payment may be made in whole or in part by a federal healthcare program, or the purchasing, leasing, ordering or arranging for or recommending purchasing, leasing or ordering of any good, facility, service or item for which payment may be made in whole or in part by a federal healthcare program. Many courts have held that the Anti‑Kickback Statute may be violated if any one purpose of the remuneration is to induce or reward patient referrals or other federal healthcare program business, regardless of whether there are other legitimate purposes for the arrangement. The definition of “remuneration” has been broadly interpreted to include anything of value, including gifts, discounts, credit arrangements, payments of cash, consulting fees, waivers of co‑payments,

10




ownership interests, and providing anything at less than its fair market value. The Anti‑Kickback Statute is broad and may technically prohibit many innocuous or beneficial arrangements within the healthcare industry. The Anti-Kickback Statute includes several statutory exceptions, and the U.S. Department of Health and Human Services has issued a series of regulatory “safe harbors.” These exceptions and safe harbor regulations set forth certain requirements for various types of arrangements, which, if met, will protect the arrangement from potential liability under the Anti‑Kickback Statute. Although full compliance with the statutory exceptions or regulatory safe harbors ensures against liability under the federal Anti‑Kickback Statute, the failure of a transaction or arrangement to fit within a specific statutory exception or regulatory safe harbor does not necessarily mean that the transaction or arrangement is illegal or that prosecution under the federal Anti‑Kickback Statute will be pursued. Penalties for violations of the Anti‑Kickback Statute are severe, and include imprisonment, criminal fines, civil money penalties, and exclusion from participation in federal healthcare programs. Many states also have anti‑kickback statutes, some of which may apply to items or services reimbursed by any third‑party payer, including commercial insurers.
There are also federal laws related to healthcare fraud and false statements, among others, that apply to healthcare matters. The healthcare fraud statute prohibits, among other things, knowingly and willfully executing a scheme to defraud any healthcare benefit program, including private payers. A violation of this statute is a felony and may result in fines, imprisonment, or exclusion from governmental payer programs such as the Medicare and Medicaid programs. The false statements statute prohibits, among other things, knowingly and willfully falsifying, concealing or covering up a material fact, or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items, or services. A violation of this statute is a felony and may result in fines, imprisonment, or exclusion from governmental payer programs.
Another development affecting the healthcare industry is the increased enforcement of the federal False Claims Act and, in particular, actions brought pursuant to the False Claims Act’s “whistleblower” or “qui tam” provisions. The False Claims Act imposes liability on any person or entity that, among other things, knowingly presents, or causes to be presented, a false or fraudulent claim for payment by a federal governmental payer program. The qui tam provisions of the False Claims Act allow a private individual to bring actions on behalf of the federal government alleging that the defendant has defrauded the federal government by presenting or causing to be presented a false claim to the federal government and permit such individuals to share in any amounts paid by the entity to the government in fines or settlement. When an entity is determined to have violated the False Claims Act, it may be required to pay up to three times the actual damages sustained by the government, plus civil penalties for each false claim. For penalties assessed after January 29, 2018, whose associated violations occurred after November 2, 2015, the penalties range from $11,181 to $22,363 for each false claim. The minimum and maximum per claim penalty amounts are subject to annual increases for inflation.
In addition, various states have enacted false claim laws analogous to the federal False Claims Act, and some of these state laws apply where a claim is submitted to any third‑party payer and not only a governmental payer program.
Additionally, the civil monetary penalties statute imposes penalties against any person or entity that, among other things, is determined to have presented or caused to be presented a claim to a federal health program that the person knows or should know is for an item or service that was not provided as claimed or for a claim that is false or fraudulent. This law also prohibits the offering or transfer of remuneration to a Medicare or state healthcare program beneficiary if the person knows or should know it is likely to influence the beneficiary’s selection of a particular provider, practitioner, or supplier for items or services reimbursable by Medicare or a state healthcare program. There are several exceptions to the prohibition on beneficiary inducement.
A recently enacted law, the Eliminating Kickbacks in Recovery Act of 2018 (“EKRA”), prohibits payments for referrals to recovery homes, clinical treatment facilities, and laboratories. EKRA’s reach extends beyond federal health care programs, to include private insurance (i.e., it is an “all payer” statute). For purposes of EKRA, the term “laboratory” is defined broadly and without reference to any connection to substance use disorder treatment. EKRA is a criminal statute and violations can result in fines of up to $200,000, up to 10 years in prison, or both, per violation. The law includes a limited number of exceptions, some of which closely align with corresponding Anti-Kickback Statute exceptions and safe harbors and others that materially differ.
In Europe various countries have adopted anti‑bribery laws providing for severe consequences, in the form of criminal penalties and/or significant fines, for individuals and/or companies committing a bribery offence. Violations of these anti‑bribery laws, or allegations of such violations, could have a negative impact on our business, results of operations and reputation. For instance, in the United Kingdom, under the Bribery Act 2010, which went into effect in July 2011, a bribery occurs when a person offers, gives or promises to give a financial or other advantage to induce or reward another individual to improperly perform certain functions or activities, including any function of a public nature. Bribery of foreign public officials also falls within the scope of the Bribery

11




Act 2010. Under the new regime, an individual found in violation of the Bribery Act 2010, faces imprisonment of up to ten years. In addition, the individual can be subject to an unlimited fine, as can commercial organizations for failure to prevent bribery.
Physician referral prohibitions
A federal law directed at “self‑referrals,” commonly known as the “Stark Law,” prohibits a physician from referring a patient to an entity for certain Medicare-covered designated health services, including laboratory services, if the physician, or an immediate family member, has a financial relationship with the entity, unless an exception applies. The Stark Law also prohibits an entity from billing for services furnished pursuant to a prohibited referral. A physician or entity that engages in a scheme to circumvent the Stark Law’s referral prohibition may be fined up to $100,000 for each such arrangement or scheme. In addition, any person who presents or causes to be presented a claim to the Medicare program in violation of the Stark Law is subject to civil monetary penalties of up to $15,000 per service, an assessment of up to three times the amount claimed and possible exclusion from participation in federal healthcare programs. Bills submitted in violation of the Stark Law may not be paid by Medicare, and any person collecting any amounts with respect to any such prohibited bill is obligated to refund such amounts. Many states have comparable laws that apply to services covered by other third-party payers. The Stark Law also prohibits state receipt of federal Medicaid matching funds for services furnished pursuant to a prohibited referral. This provision of the Stark Law has not been implemented by regulations, but some courts have held that the submission of claims to Medicaid that would be prohibited as self‑referrals under the Stark Law for Medicare could implicate the False Claims Act.
Corporate practice of medicine
Numerous states have enacted laws prohibiting business corporations, such as us, from practicing medicine and employing or engaging clinicians to practice medicine, generally referred to as the prohibition against the corporate practice of medicine. These laws are designed to prevent interference in the medical decision‑making process by anyone who is not a licensed physician. For example, California’s Medical Board has indicated that determining what diagnostic tests are appropriate for a particular condition and taking responsibility for the ultimate overall care of the patient, including providing treatment options available to the patient, would constitute the unlicensed practice of medicine if performed by an unlicensed person. Violation of these corporate practice of medicine laws may result in civil or criminal fines, as well as sanctions imposed against us and/or the professional through licensure proceedings.
Intellectual property
We rely on a combination of intellectual property rights, including trade secrets, copyrights, trademarks, customary contractual protections and, to a lesser extent, patents, to protect our core technology and intellectual property. With respect to patents, we believe that the practice of patenting individual genes, along with patenting tools and methods specific to individual genes, has impeded the progress of the genetic testing industry beyond single gene tests and is antithetical to our core principle that patients should own and control their own genomic information. In recent years the U.S. Supreme Court has issued a series of unanimous (9‑0) decisions setting forth limits on the patentability of natural phenomena, natural laws, abstract ideas and their applications—i.e., Mayo Collaborative v. Prometheus Laboratories (2012), or Mayo, Association for Molecular Pathology v. Myriad Genetics (2013), or Myriad, and Alice Corporation v. CLS Bank (2014), or Alice. As discussed below, we believe the Mayo, Myriad and Alice decisions bring clarity to the limits to which patents may cover specific genes, mutations of such genes, or gene‑specific technology for determining a patient’s genomic information.

12




Patents
U.S. Supreme Court cases have clarified that naturally occurring DNA sequences are natural phenomena, which should not be patentable. On June 13, 2013, the U.S. Supreme Court decided Myriad, a case challenging the validity of patent claims held by Myriad relating to the cancer genes BRCA1 and BRCA2. The Myriad Court held that genomic DNAs that have been isolated from, or have the same sequence as, naturally occurring samples, such as the DNA constituting the BRCA1 and BRCA2 genes or fragments thereof, are not eligible for patent protection. Instead, the Myriad Court held that only those complementary DNAs (cDNAs) which have a sequence that differs from a naturally occurring fragment of genomic DNA may be patent eligible. Because it will be applied by other courts to all gene patents, the holding in Myriad also invalidates patent claims to other genes and gene variants. Prior to Myriad, on August 16, 2012, the U.S. Court of Appeals for the Federal Circuit had held that certain patent claims of Myriad directed to methods of comparing or analyzing BRCA1 and BRCA2 sequences to determine whether or not a person has a variant or mutation are unpatentable abstract processes, and Myriad did not appeal such ruling.
We do not currently have any patents or patent applications directed to the sequences of specific genes or variants of such genes, nor do we rely on any such in‑licensed patent rights of any third party. We believe that correlations between specific gene variants and a person’s susceptibility to certain conditions or diseases are natural laws that are not patentable under the U.S. Supreme Court’s decision in Mayo. The Mayo case involved patent claims directed to optimizing, on a patient‑specific basis, the dosage of a certain drug by measuring its metabolites in a patient. The Mayo Court determined that patent claims directed at detection of natural correlations, such as the correlation between drug metabolite levels in a patient and that drug’s optimal dosage for such patient, are not eligible for patent protection. The Mayo Court held that claims based on this type of comparison between an observed fact and an understanding of that fact’s implications represent attempts to patent a natural law and, moreover, when the processes for making the comparison are not themselves sufficiently inventive, claims to such processes are similarly patent‑ineligible. On June 19, 2014, the U.S. Supreme Court decided Alice, where it amplified its Mayo and Myriad decisions and clarified the analytical framework for distinguishing between patents that claim laws of nature, natural phenomena and abstract ideas and those that claim patent‑eligible applications of such concepts. According to the Alice Court, the analysis depends on whether a patent claim directed to a law of nature, a natural phenomenon or an abstract idea contains additional elements, an “inventive concept,” that “is sufficient to ensure that the patent in practice amounts to significantly more than a patent upon the [ineligible concept] itself;” (citing Mayo).
We believe that Mayo, Myriad and Alice not only render as unpatentable genes, gene fragments and the detection of a person’s sequence for a gene, but also have the same effect on generic applications of conventional technology to specific gene sequences. For example, we believe that generic claims to primers or probes directed to specific gene sequences and uses of such primers and probes in determining a person’s genetic information are not patentable. We do not currently have any patents or patent applications directed to such subject matter nor have we in‑licensed such patents rights of any third party.
Unlike patents directed to specific genes, we do rely upon, in part, patent protection to protect technology that is not gene‑specific and that provides us with a potential competitive advantage as we focus on making comprehensive genetic information less expensive and more broadly available to our customers. In this regard, we have issued U.S. patents, pending U.S. patent applications and corresponding non-U.S. patents and patent applications directed to various aspects of our laboratory, analytic and business practices. We intend to pursue further patent protection where appropriate.

13




Trade secrets
In addition to seeking patent protection for some of our laboratory, analytic and business practices, we also rely on trade secrets, including unpatented know‑how, technology and other proprietary information, to maintain and develop our competitive position. We have developed proprietary procedures for both the laboratory processing of patient samples and the analysis of the resulting data to generate clinical reports. For example, we have automated aspects of our processes for curating information about known variants, identifying variants in an individual’s sequence information, associating those variants with known information about their potential effects on disease, and presenting that information for review by personnel responsible for its interpretation and for the delivery of test reports to clinicians. We try to protect these trade secrets, in part, by taking reasonable steps to keep them confidential. This includes entering into nondisclosure and confidentiality agreements with parties who have access to them, such as our employees and certain third parties. We also enter into invention or patent assignment agreements with our employees and consultants that obligate them to assign to us any inventions developed in the course of their work for us. However, we may not enter into such agreements with all relevant parties, and these parties may not abide by the terms of their agreements. Despite measures taken to protect our intellectual property, unauthorized parties might copy or independently develop and commercially exploit aspects of our technology or obtain and use information that we regard as proprietary.
Trademarks
We work hard to achieve a high level of quality in our operations and to provide our customers with a superior experience when interacting with us. As a consequence, our brand is very important to us, as it is a symbol of our reputation and representative of the goodwill we seek to generate with our customers. As a consequence, we have invested significant resources in protection of our trademarks.
Environmental matters
Our operations require the use of hazardous materials (including biological materials) that subject us to a variety of federal, state and local environmental and safety laws and regulations. Some of these regulations provide for strict liability, holding a party potentially liable without regard to fault or negligence. We could be held liable for damages and fines as a result of our, or others’, business operations should contamination of the environment or individual exposure to hazardous substances occur. We cannot predict how changes in laws or new regulations will affect our business, operations or the cost of compliance.
Raw materials and suppliers
We rely on a limited number of suppliers, or, in some cases, sole suppliers, including Illumina, Inc., Integrated DNA Technologies Incorporated, Qiagen N.V., Roche Holdings Ltd. and Twist Bioscience Corporation for certain laboratory reagents, as well as sequencers and other equipment and materials which we use in our laboratory operations. We rely on Illumina as the sole supplier of next generation sequencers and associated reagents and as the sole provider of maintenance and repair services for these sequencers. Our laboratory operations could be interrupted if we encounter delays or difficulties in securing these reagents, sequencers or other equipment or materials, and if we cannot obtain an acceptable substitute. Any such interruption could significantly affect our business, financial condition, results of operations and reputation. We believe that there are only a few other manufacturers that are currently capable of supplying and servicing the equipment necessary for our laboratory operations, including sequencers and various associated reagents. The use of equipment or materials provided by these replacement suppliers would require us to alter our laboratory operations. Transitioning to a new supplier would be time consuming and expensive, may result in interruptions in our laboratory operations, could affect the performance specifications of our laboratory operations or could require that we revalidate our tests. We cannot assure you that we would be able to secure alternative equipment, reagents and other materials, or bring such equipment, reagents and materials on line and revalidate them without experiencing interruptions in our workflow. If we encounter delays or difficulties in securing, reconfiguring or revalidating the equipment and reagents we require for our tests, our business and reputation could be adversely affected.
Customer concentration
We receive payment for our tests from partners, patients, institutional customers and third-party payers. As of December 31, 2018, substantially all our revenue has been derived from test reports generated from our assays. A single payer accounted for 22%, 13%, and 11% of our revenue for the years ended December 31, 2018, 2017, and 2016, respectively.

14




Employees
We had 788 employees as of December 31, 2018.
General Information
We were incorporated in the State of Delaware on January 13, 2010 under the name Locus Development, Inc. and changed our name to Invitae Corporation in 2012. In February 2015 we completed an initial public offering of our common stock.
Our principal executive offices are located at 1400 16th Street, San Francisco, California 94103, and our telephone number is (415) 374‑7782. Our website address is www.invitae.com. The information contained on, or that can be accessed through, our website is not part of this annual report on Form 10‑K.
We make available free of charge on our website our annual reports on Form 10‑K, quarterly reports on Form 10‑Q, current reports on Form 8‑K and amendments to those reports, as soon as reasonably practicable after we electronically file or furnish such materials to the Securities and Exchange Commission, or SEC. You may obtain a free copy of these reports in the Investor Relations section of our website, www.invitae.com. All reports that we file are also available at www.sec.gov.
ITEM 1A.
Risk Factors.
Risks related to our business and strategy
We expect to continue incurring significant losses, and we may not successfully execute our plan to achieve or sustain profitability.
We have incurred substantial losses since our inception. For the years ended December 31, 2018, 2017 and 2016, our net losses were $129.4 million, $123.4 million and $100.3 million, respectively. At December 31, 2018, our accumulated deficit was $516.7 million. While our revenue has increased over time, we expect to continue to incur significant losses. In addition, these losses may increase as we focus on scaling our business and operations and expanding our testing capabilities, which may increase our operating expenses. In addition, as a result of the integration of acquired businesses, we may be subject to unforeseen or additional expenditures, costs or liabilities. Our prior losses and expected future losses have had and will continue to have an adverse effect on our stockholders’ equity, working capital and stock price. Our failure to achieve and sustain profitability in the future would negatively affect our business, financial condition, results of operations and cash flows, and could cause the market price of our common stock to decline.
We began operations in January 2010 and commercially launched our initial assay in late November 2013; accordingly, we have a relatively limited operating history upon which you can evaluate our business and prospects. Our limited commercial history makes it difficult to evaluate our current business and makes predictions about our future results, prospects or viability subject to significant uncertainty. Our prospects must be considered in light of the risks and difficulties frequently encountered by companies in their early stage of development, particularly companies in new and rapidly evolving markets such as ours. These risks include an evolving and unpredictable business model and the management of growth. To address these risks, we must, among other things, increase our customer base; implement and successfully execute our business and marketing strategy; identify, acquire and successfully integrate companies, assets or technologies in areas that are complementary to our business strategy; successfully enter into other strategic collaborations or relationships; obtain access to capital on acceptable terms and effectively utilize that capital; identify, hire and successfully integrate additional employees; continue to expand, automate and upgrade our laboratory, technology and data systems; obtain, maintain and expand coverage and reimbursement by healthcare payers; provide rapid test turnaround times with accurate results at low prices; provide superior customer service; respond to competitive developments; and attract, retain and motivate qualified personnel. We cannot assure you that we will be successful in addressing these risks, and the failure to do so could have a material adverse effect on our business, prospects, financial condition and results of operations. 
We have acquired and may continue to acquire businesses or assets, form joint ventures or make investments in other companies or technologies that could harm our operating results, dilute our stockholders’ ownership, or cause us to incur debt or significant expense.
As part of our business strategy, we have pursued and may continue to pursue acquisitions of complementary businesses or assets, as well as technology licensing arrangements. We also may pursue strategic alliances that leverage our core technology and industry experience to expand our offerings or distribution, or make investments in other companies. As an organization, we have limited experience with respect to acquisitions as well as the formation of strategic alliances and joint ventures.

15




In 2017, we established a leading position in family health genetic information services through the strategic acquisition of reproductive health testing capabilities, which included our acquisition of Good Start Genetics, Inc., or Good Start, a molecular diagnostics company focused on preimplantation and carrier screening for inherited disorders, and CombiMatrix Corporation, a company specializing in prenatal diagnosis, miscarriage analysis and pediatric developmental disorders. In 2017 we also acquired AltaVoice, formerly PatientCrossroads, a patient-centered data company with a global platform for collecting, curating, coordinating and delivering safeguarded data from patients and clinicians, and Ommdom, Inc. and its product, CancerGene Connect, an end-to-end platform for collecting and managing genetic family histories to deliver personalized genetic risk information.
With respect to our acquired businesses and any acquisitions we may make in the future, we may not be able to integrate these acquisitions successfully into our existing business, and we could assume unknown or contingent liabilities. Any acquisitions by us also could result in significant write-offs or the incurrence of debt and contingent liabilities, any of which could harm our operating results. Furthermore, the loss of customers, payers, partners or suppliers following the completion of any acquisitions by us could harm our business. For example, we experienced a reduction in Good Start’s sales as a result of the termination of a contract by a third-party laboratory that had performed expanded carrier screening for Good Start. Changes in services, sources of revenue, and branding or rebranding initiatives may involve substantial costs and may not be favorably received by customers, resulting in an adverse impact on our financial results, financial condition and stock price. Integration of an acquired company or business also may require management’s time and resources that otherwise would be available for ongoing development of our existing business. For example, we diverted resources from other projects in order to develop an expanded carrier screening test as a result of the termination of the third-party laboratory contract with Good Start. We may also need to divert cash from other uses in order to fund these integration activities. Ultimately, we may not realize the anticipated benefits of any acquisition, technology license, strategic alliance, joint venture or investment, or these benefits may take longer to realize than we expected.
To finance any acquisitions or investments, we may raise additional funds. If we raise funds by issuing equity securities, dilution to our stockholders could result. Any equity securities issued also may provide for rights, preferences or privileges senior to those of holders of our common stock. If we raise funds by issuing debt securities, these debt securities would have rights, preferences and privileges senior to those of holders of our common stock. The terms of debt securities issued or borrowings could impose significant restrictions on our operations. If we raise funds through collaborations and licensing arrangements, we might be required to relinquish significant rights to our technologies or products, or grant licenses on terms that are not favorable to us. If the price of our common stock is low or volatile, we may not be able to acquire other companies for stock. In addition, our stockholders may experience substantial dilution as a result of additional securities we may issue for acquisitions. Open market sales of substantial amounts of our common stock issued to stockholders of companies we acquire could also depress our share price. Alternatively, we may raise additional funds for our acquisition activities through public or private financings. Additional funds may not be available on terms that are favorable to us, or at all. In addition, our 2018 Note Purchase Agreement limits our ability to merge with or acquire other entities, incur debt, incur liens, pay dividends or other distributions to holders of our capital stock and make investments, in each case subject to certain exceptions.
If third-party payers, including managed care organizations, private health insurers and government health plans do not provide adequate reimbursement for our tests or we are unable to comply with their requirements for reimbursement, our commercial success could be negatively affected.
Our ability to increase the number of billable tests and our revenue will depend on our success achieving reimbursement for our tests from third-party payers. Reimbursement by a payer may depend on a number of factors, including a payer’s determination that a test is appropriate, medically necessary, cost-effective and has received prior authorization.
Since each payer makes its own decision as to whether to establish a policy or enter into a contract to cover our tests, as well as the amount it will reimburse for a test, seeking these approvals is a time-consuming and costly process. In addition, the determination by a payer to cover and the amount it will reimburse for our tests will likely be made on an indication by indication basis. To date, we have obtained policy-level reimbursement approval or contractual reimbursement for some indications for our test from most of the large commercial third-party payers in the United States, and the Centers for Medicare and Medicaid Services, or CMS, provides reimbursement for our multi-gene tests for hereditary breast cancer-related disorders as well as colon cancer. We believe that establishing adequate reimbursement from Medicare is an important factor in gaining adoption from healthcare providers. Our claims for reimbursement from third-party payers may be denied upon submission, and we must appeal the claims. The appeals process is time consuming and expensive, and may not result in payment. In cases where there is not

16




a contracted rate for reimbursement, there is typically a greater coinsurance or copayment requirement from the patient, which may result in further delay or decreased likelihood of collection.
In cases where we have established reimbursement rates with third-party payers, we face additional challenges in complying with their procedural requirements for reimbursement. These requirements often vary from payer to payer, and we have needed additional time and resources to comply with them. We have also experienced, and may continue to experience, delays in or denials of coverage if we do not adequately comply with these requirements. Our third-party payers have also requested, and in the future may request, audits of the amounts paid to us. We could be adversely affected if we are required to repay these or other payers for alleged overpayments due to lack of compliance with their reimbursement policies. In addition, we have experienced, and may continue to experience, delays in reimbursement when we transition to being an in-network provider with a payer.
We expect to continue to focus our resources on increasing adoption of, and expanding coverage and reimbursement for, our current tests and any future tests we may develop. If we fail to expand and maintain broad adoption of, and coverage and reimbursement for, our tests, our ability to generate revenue could be harmed and our future prospects and our business could suffer.
Our inability to raise additional capital on acceptable terms in the future may limit our ability to develop and commercialize new tests and expand our operations.
We expect capital expenditures and operating expenses to increase over the next several years as we expand our infrastructure, commercial operations, research and development activities and pursue acquisitions. We believe our existing cash and cash equivalents as of December 31, 2018, revenue from sales of our tests and available debt under our 2018 Note Purchase Agreement will be sufficient to meet our anticipated cash requirements for our currently-planned operations for the 12-month period following the filing date of this report. We may need additional funding to finance operations prior to achieving profitability, or should we make additional acquisitions. We may seek to raise additional capital through equity offerings, debt financings, collaborations or licensing arrangements. Additional funding may not be available to us on acceptable terms, or at all. If we raise funds by issuing equity securities, dilution to our stockholders would result. Any equity securities issued also may provide for rights, preferences or privileges senior to those of holders of our common stock. The terms of debt securities issued or borrowings, if available, could impose significant restrictions on our operations. Our obligations under our 2018 Note Purchase Agreement are subject to covenants, including quarterly covenants to achieve certain revenue levels as well as additional covenants, including limits on our ability to dispose of assets, undergo a change in control, merge with or acquire other entities, incur debt, incur liens, pay dividends or other distributions to holders of our capital stock, repurchase stock and make investments, in each case subject to certain exceptions. Our obligations under our 2018 Note Purchase Agreement are secured by a security interest on substantially all of our and certain of our subsidiaries' assets.
The incurrence of additional indebtedness or the issuance of certain equity securities could result in increased fixed payment obligations and could also result in restrictive covenants, such as limitations on our ability to incur additional debt or issue additional equity, limitations on our ability to acquire or license intellectual property rights, and other operating restrictions that could adversely affect our ability to conduct our business. In addition, the issuance of additional equity securities by us, or the possibility of such issuance, may cause the market price of our common stock to decline. In the event that we enter into collaborations or licensing arrangements to raise capital, we may be required to accept unfavorable terms. These agreements may require that we relinquish or license to a third party on unfavorable terms our rights to tests we otherwise would seek to develop or commercialize ourselves, or reserve certain opportunities for future potential arrangements when we might be able to achieve more favorable terms. If we are not able to secure additional funding when needed, we may have to delay, reduce the scope of or eliminate one or more research and development programs, selling and marketing initiatives, or potential acquisitions. In addition, we may have to work with a partner on one or more aspects of our tests or market development programs, which could lower the economic value of those tests or programs to our company.
We face intense competition, which is likely to intensify further as existing competitors devote additional resources to, and new participants enter, the market. If we cannot compete successfully, we may be unable to increase our revenue or achieve and sustain profitability.
With the development of next generation sequencing, the clinical genetics market is becoming increasingly competitive, and we expect this competition to intensify in the future. We face competition from a variety of sources, including:
•
dozens of relatively specialized competitors focused on inherited clinical genetics and gene sequencing, such as Ambry Genetics, Inc., a subsidiary of Konica Minolta Inc., Athena Diagnostics, a subsidiary of

17




Quest Diagnostics Incorporated, Baylor Genetics, Blueprint Genetics, Inc., Centogene AG, Color Genomics, Inc., Connective Tissue Gene Test LLC, Cooper Surgical, Inc., Eurofins Scientific, GeneDx, a subsidiary of OPKO Health, Inc., MNG Laboratories, LLC, Myriad Genetics, Inc., Natera, Inc., Perkin Elmer, Inc., PreventionGenetics, LLC, Progenity, Inc. and Sema4 Genomics;
•
a few large, established general testing companies with large market share and significant channel power, such as Laboratory Corporation of America Holdings and Quest Diagnostics Incorporated;
•
a large number of clinical laboratories in an academic or healthcare provider setting that perform clinical genetic testing on behalf of their affiliated institutions and often sell and market more broadly; and
•
a large number of new entrants into the market for genetic information ranging from informatics and analysis pipeline developers to focused, integrated providers of genetic tools and services for health and wellness including Illumina, Inc., which is also one of our suppliers.
Hospitals, academic medical centers and eventually physician practice groups and individual clinicians may also seek to perform at their own facilities the type of genetic testing we would otherwise perform for them. In this regard, continued development of equipment, reagents, and other materials as well as databases and interpretation services may enable broader direct participation in genetic testing and analysis.
Participants in closely related markets such as clinical trial or companion diagnostic testing could converge on offerings that are competitive with the type of tests we perform. Instances where potential competitors are aligned with key suppliers or are themselves suppliers could provide such potential competitors with significant advantages.
In addition, the biotechnology and genetic testing fields are intensely competitive both in terms of service and price, and continue to undergo significant consolidation, permitting larger clinical laboratory service providers to increase cost efficiencies and service levels, resulting in more intense competition.
We believe the principal competitive factors in our market are:
•
breadth and depth of content;
•
quality;
•
reliability;
•
accessibility of results;
•
turnaround time of testing results;
•
price and quality of tests;
•
coverage and reimbursement arrangements with third-party payers;
•
convenience of testing;
•
brand recognition of test provider;
•
additional value-added services and informatics tools;
•
client service; and
•
quality of website content.
Many of our competitors and potential competitors have longer operating histories, larger customer bases, greater brand recognition and market penetration, higher margins on their tests, substantially greater financial, technological and research and development resources, selling and marketing capabilities, lobbying efforts, and more experience dealing with third-party payers. As a result, they may be able to respond more quickly to changes in customer requirements, devote greater resources to the development, promotion and sale of their tests than we do, sell their tests at prices designed to win significant levels of market share, or obtain reimbursement from more third-party payers and at higher prices than we do. We may not be able to compete effectively against these organizations. Increased competition and cost-saving initiatives on the part of governmental entities and other third-party payers are likely to result in pricing pressures, which could harm our sales, profitability or ability to gain market share. In addition, competitors may be acquired by, receive investments from or enter into other commercial relationships with larger, well-established and well-financed companies as use of next generation sequencing for clinical diagnosis and preventative care increases. Certain of our competitors may be able to secure key inputs from vendors on more favorable terms, devote greater resources to marketing and promotional campaigns, adopt more aggressive pricing policies and devote substantially more resources to website and systems development than we

18




can. In addition, companies or governments that control access to genetic testing through umbrella contracts or regional preferences could promote our competitors or prevent us from performing certain services. In addition, some of our competitors have obtained approval or clearance for certain of their tests from the U.S. Food and Drug Administration, or FDA. If payers decide to reimburse only for tests that are FDA-approved or FDA-cleared, or if they are more likely to reimburse for such tests, we may not be able to compete effectively unless we obtain similar approval or clearance for our tests. If we are unable to compete successfully against current and future competitors, we may be unable to increase market acceptance and sales of our tests, which could prevent us from increasing our revenue or achieving profitability and could cause our stock price to decline.
We may not be able to manage our future growth effectively, which could make it difficult to execute our business strategy.
Our expected future growth could create a strain on our organizational, administrative and operational infrastructure, including laboratory operations, quality control, customer service, marketing and sales, and management. We may not be able to maintain the quality of or expected turnaround times for our tests, or satisfy customer demand as it grows. We will likely need to continue expanding our sales force to facilitate our growth, and we may have difficulties locating, recruiting, training and retaining sales personnel. Our ability to manage our growth properly will require us to continue to improve our operational, financial and management controls, as well as our reporting systems and procedures. As we grow, any failure of our controls or interruption of our production facilities or systems will have a larger impact on our business and financial operations. We plan to implement new enterprise software systems in a number of areas affecting a broad range of business processes and functional areas. The time and resources required to implement these new systems is uncertain, and failure to complete these activities in a timely and efficient manner could adversely affect our operations. If we are unable to manage our growth effectively, it may be difficult for us to execute our business strategy and our business could be harmed. Future growth in our business could also make it difficult for us to maintain our corporate culture.
Security breaches, loss of data and other disruptions could compromise sensitive information related to our business or prevent us from accessing critical information and expose us to liability, which could adversely affect our business and our reputation.
In the ordinary course of our business, we collect and store sensitive data, including protected health information, personally identifiable information, credit card information, intellectual property and proprietary business information owned or controlled by ourselves or our customers, payers and other parties. We manage and maintain our applications and data utilizing a combination of on-site systems, managed data center systems and cloud-based data center systems. We also communicate sensitive patient data through our Invitae Family History Tool, Patient Insights Network, or PIN, and CancerGene Connect platform. In addition to storing and transmitting sensitive personal information that is subject to myriad legal protections, these applications and data encompass a wide variety of business-critical information including research and development information, commercial information, and business and financial information. We face a number of risks relative to protecting this critical information, including loss of access risk, inappropriate disclosure, inappropriate modification, and the risk of our being unable to adequately monitor and modify our controls over our critical information. Any technical problems that may arise in connection with our data and systems, including those that are hosted by third-party providers, could result in interruptions in our business and operations. These types of problems may be caused by a variety of factors, including infrastructure changes, human or software errors, viruses, security attacks, fraud, spikes in customer usage and denial of service issues. From time to time, large third-party web hosting providers have experienced outages or other problems that have resulted in their systems being offline and inaccessible. Such outages could materially impact our business and operations.
The secure processing, storage, maintenance and transmission of this critical information are vital to our operations and business strategy, and we devote significant resources to protecting such information. Although we take what we believe to be reasonable and appropriate measures to protect sensitive information from unauthorized access or disclosure, our information technology and infrastructure may be vulnerable to attacks by hackers or viruses or breached due to employee error, malfeasance or other disruptions. Any such breach or interruption could compromise our networks and the information stored there could be accessed by unauthorized parties, altered, publicly disclosed, lost or stolen. Any such access, disclosure or other loss of information could result in legal claims or proceedings, liability under federal or state laws that protect the privacy of personal information, such as but not limited to the Health Insurance Portability and Accountability Act of 1996, or HIPAA, the Health Information Technology for Economic and Clinical Heath Act, or HITECH, state data security and data breach notification laws, and related regulatory penalties. Although we have implemented security measures and a formal, dedicated enterprise security program to prevent unauthorized access to patient data, our Invitae Family History Tool, PIN and CancerGene Connect platform are currently accessible through our online portal and/or through our mobile

19




applications, and there is no guarantee we can protect our online portal or our mobile applications from breach. Unauthorized access, loss or dissemination could also disrupt our operations (including our ability to conduct our analyses, provide test results, bill payers or patients, process claims and appeals, provide customer assistance, conduct research and development activities, collect, process and prepare company financial information, provide information about our tests and other patient and physician education and outreach efforts through our website, and manage the administrative aspects of our business) and damage our reputation, any of which could adversely affect our business.
In addition to security risks, we also face privacy risks. While we have policies that govern our privacy practices and procedures that aim to keep our practices consistent with such policies, such procedures are not invulnerable to human error. Should we inadvertently break the privacy promises we make to patients or consumers, we could receive a complaint from an affected individual or interested privacy regulator, such as the FTC or a state Attorney General. This risk is heightened given the sensitivity of the data we collect.
Penalties for failure to comply with a requirement of HIPAA and HITECH vary significantly, and include civil monetary penalties of up to $1.5 million per calendar year for each provision of HIPAA that is violated. A person who knowingly obtains or discloses individually identifiable health information in violation of HIPAA may face a criminal penalty of up to $50,000 and up to one-year imprisonment. The criminal penalties increase if the wrongful conduct involves false pretenses or the intent to sell, transfer or use identifiable health information for commercial advantage, personal gain or malicious harm. Penalties for unfair or deceptive acts or practices under the FTC Act or state Unfair and Deceptive Acts and Practices, or UDAP, statutes may also vary significantly.
There has been unprecedented activity in the development of data protection regulation around the world. As a result, the interpretation and application of consumer, health-related and data protection laws in the United States, Europe and elsewhere are often uncertain, contradictory and in flux. The European Union’s General Data Protection Regulation, or GDPR, took effect in May 2018. The GDPR applies to any business, regardless of its location, that provides goods or services to residents in the European Union. The GDPR imposes strict requirements on controllers and processors of personal data, including special protections for “sensitive information” which includes health and genetic information of data subjects residing in the European Union. The GDPR also grants individuals various rights in relation to their personal data including the right to access, rectification, objection to processing and deletion, and provides an individual with an express right to seek legal remedies if the individual believes his or her rights have been violated. Failure to comply with the requirements of the GDPR and the related national data protection laws of the member states of the European Union, which may deviate slightly from the GDPR, may result in significant fines.
Additionally, the implementation of GDPR has led other jurisdictions to either amend or propose legislation to amend their existing data privacy and cybersecurity laws to resemble the requirements of GDPR. For example, on June 28, 2018, California adopted the California Consumer Privacy Act of 2018, or CCPA and amended the law in September 2018 to exempt all protected health information (PHI) collected by certain parties subject to HIPAA. The effective date of the CCPA is January 1, 2020; however, legislators have stated that they intend to propose amendments to the CCPA before it goes into effect. The CCPA gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing, and receive detailed information about how their personal information is used. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation.
It is possible the GDPR, CCPA and other data protection laws may be interpreted and applied in a manner that is inconsistent with our practices. If so, this could result in government-imposed fines or orders requiring that we change our practices, which could adversely affect our business. In addition, these privacy regulations may differ from country to country and state to state, and may vary based on whether testing is performed in the United States or in the local country. Complying with these various laws and regulations could cause us to incur substantial costs or require us to change our business practices and compliance procedures in a manner adverse to our business. We can provide no assurance that we are or will remain in compliance with diverse privacy and security requirements in all of the jurisdictions in which we do business. Failure to comply with privacy and security requirements could result in civil or criminal penalties, which could have a material adverse effect on our business.
We rely on highly skilled personnel in a broad array of disciplines and, if we are unable to hire, retain or motivate these individuals, or maintain our corporate culture, we may not be able to maintain the quality of our services or grow effectively.
Our performance, including our research and development programs and laboratory operations, largely depend on our continuing ability to identify, hire, develop, motivate and retain highly skilled personnel for all areas of our organization, including software developers, geneticists, biostatisticians, certified laboratory scientists and other

20




scientific and technical personnel to process and interpret our genetic tests. In addition, we expect the need to continue to expand our sales force with qualified and experienced personnel. Competition in our industry for qualified employees is intense, and we may not be able to attract or retain qualified personnel in the future due to the competition for qualified personnel among life science and technology businesses as well as universities and public and private research institutions, particularly in the San Francisco Bay Area. In addition, our compensation arrangements, such as our equity award programs, may not always be successful in attracting new employees and retaining and motivating our existing employees. If we are not able to attract and retain the necessary personnel to accomplish our business objectives, we may experience constraints that could adversely affect our ability to scale our business, support our research and development efforts and our clinical laboratory. We believe that our corporate culture fosters innovation, creativity and teamwork. However, as our organization grows, we may find it increasingly difficult to maintain the beneficial aspects of our corporate culture. This could negatively impact our ability to retain and attract employees and our future success.
We need to scale our infrastructure in advance of demand for our tests, and our failure to generate sufficient demand for our tests would have a negative impact on our business and our ability to attain profitability.
Our success depends in large part on our ability to extend our market position, to provide customers with high quality test reports quickly and at a lower price than our competitors, and to achieve sufficient test volume to realize economies of scale. In order to execute our business model, we intend to continue to invest heavily in order to significantly scale our infrastructure, including our testing capacity and information systems, expand our commercial operations, customer service, billing and systems processes and enhance our internal quality assurance program. We expect that much of this growth will be in advance of demand for our tests. Our current and future expense levels are to a large extent fixed and are largely based on our investment plans and our estimates of future revenue. Because the timing and amount of revenue from our tests is difficult to forecast, when revenue does not meet our expectations, we may not be able to adjust our spending promptly or reduce our spending to levels commensurate with our revenue. Even if we are able to successfully scale our infrastructure and operations, we cannot assure you that demand for our tests will increase at levels consistent with the growth of our infrastructure. If we fail to generate demand commensurate with this growth or if we fail to scale our infrastructure sufficiently in advance of demand to successfully meet such demand, our business, prospects, financial condition and results of operations could be adversely affected.
If we are not able to continue to generate substantial demand of our tests, our commercial success will be negatively affected.
Our business model assumes that we will be able to generate significant test volume, and we may not succeed in continuing to drive clinical adoption of our test to achieve sufficient volumes. Inasmuch as detailed genetic data from broad-based testing panels such as our tests have only recently become available at relatively affordable prices, the continued pace and degree of clinical acceptance of the utility of such testing is uncertain. Specifically, it is uncertain how much genetic data will be accepted as necessary or useful, as well as how detailed that data should be, particularly since medical practitioners may have become accustomed to genetic testing that is specific to one or a few genes. Given the substantial amount of additional information available from a broad-based testing panel such as ours, there may be distrust as to the reliability of such information when compared with more limited and focused genetic tests. To generate further demand for our tests, we will need to continue to make clinicians aware of the benefits of our tests, including the price, the breadth of our testing options, and the benefits of having additional genetic data available from which to make treatment decisions. Because broad-based testing panels are relatively new, it may be more difficult or take more time for us to expand clinical adoption of our assay beyond our current customer base. In addition, clinicians in other areas of medicine may not adopt genetic testing for hereditary disease as readily as it has been adopted in hereditary cancer and our efforts to sell our tests to clinicians outside of oncology may not be successful. A lack of or delay in clinical acceptance of broad-based panels such as our tests would negatively impact sales and market acceptance of our tests and limit our revenue growth and potential profitability. Genetic testing is expensive and many potential customers may be sensitive to pricing. In addition, potential customers may not adopt our tests if adequate reimbursement is not available, or if we are not able to maintain low prices relative to our competitors. Also, we plan to introduce patient-initiated testing in 2019, in which we will facilitate the ordering of our genetic tests through an online network of physicians. Since we have limited experience directly marketing to patients, we may not be successful in increasing demand for our tests through this new channel. Patient-initiated testing may also be perceived negatively by our existing customer base of clinicians and genetic counselors, in which case our core business could be harmed.

21




If we are not able to generate demand for our tests at sufficient volume, or if it takes significantly more time to generate this demand than we anticipate, our business, prospects, financial condition and results of operations could be materially harmed.
Our success will depend on our ability to use rapidly changing genetic data to interpret test results accurately and consistently, and our failure to do so would have an adverse effect on our operating results and business, harm our reputation and could result in substantial liabilities that exceed our resources.
Our success depends on our ability to provide reliable, high-quality tests that incorporate rapidly evolving information about the role of genes and gene variants in disease and clinically relevant outcomes associated with those variants. Errors, such as failure to detect genomic variants with high accuracy, or mistakes, such as failure to identify, or incompletely or incorrectly identifying, gene variants or their significance, could have a significant adverse impact on our business.
Hundreds of genes can be implicated in some disorders, and overlapping networks of genes and symptoms can be implicated in multiple conditions. As a result, a substantial amount of judgment is required in order to interpret testing results for an individual patient and to develop an appropriate patient report. We classify variants in accordance with published guidelines as benign, likely benign, variants of uncertain significance, likely pathogenic or pathogenic, and these guidelines are subject to change. In addition, it is our practice to offer support to clinicians and geneticists ordering our tests regarding which genes or panels to order as well as interpretation of genetic variants. We also rely on clinicians to interpret what we report and to incorporate specific information about an individual patient into the physician’s treatment decision.
The marketing, sale and use of our genetic tests could subject us to liability for errors in, misunderstandings of, or inappropriate reliance on, information we provide to clinicians or geneticists, and lead to claims against us if someone were to allege that a test failed to perform as it was designed, if we failed to correctly interpret the test results, or if the ordering physician were to misinterpret test results or improperly rely on them when making a clinical decision. In addition, our entry into the reproductive health testing market exposes us to increased liability. A product liability or professional liability claim could result in substantial damages and be costly and time-consuming for us to defend. Although we maintain liability insurance, including for errors and omissions, we cannot assure you that such insurance would fully protect us from the financial impact of defending against these types of claims or any judgments, fines or settlement costs arising out of any such claims. Any liability claim, including an errors and omissions liability claim, brought against us, with or without merit, could increase our insurance rates or prevent us from securing insurance coverage in the future. Additionally, any liability lawsuit could cause injury to our reputation or cause us to suspend sales of our tests. The occurrence of any of these events could have an adverse effect on our reputation and results of operations.
Our industry is subject to rapidly changing technology and new and increasing amounts of scientific data related to genes and genetic variants and their role in disease. Our failure to develop tests to keep pace with these changes could make us obsolete.
In recent years, there have been numerous advances in methods used to analyze very large amounts of genomic information and the role of genetics and gene variants in disease and treatment therapies. Our industry has and will continue to be characterized by rapid technological change, increasingly larger amounts of data, frequent new testing service introductions and evolving industry standards, all of which could make our tests obsolete. Our future success will also depend on our ability to keep pace with the evolving needs of our customers on a timely and cost-effective basis and to pursue new market opportunities that develop as a result of technological and scientific advances. Our tests could become obsolete and our business adversely affected unless we continually update our offerings to reflect new scientific knowledge about genes and genetic variations and their role in diseases and treatment therapies.
Our success will depend in part on our ability to generate sales using our internal sales team and through alternative marketing strategies.
We may not be able to market or sell our current tests and any future tests we may develop effectively enough to drive demand sufficient to support our planned growth. We currently sell our tests primarily through our internal sales force. Historically, our sales efforts have been focused primarily on hereditary cancer and more recently, on reproductive health. Our efforts to sell our tests to clinicians outside of oncology may not be successful, or may be difficult to do successfully without significant additional selling and marketing efforts and expense. We significantly increased the size of our sales force in 2017, 2018, and early 2019. Our future sales will also depend in large part on our ability to develop and substantially expand awareness of our company and our tests through alternative strategies including through education of key opinion leaders, through social media-related and online outreach, education and marketing efforts, and through focused channel partner strategies designed to drive

22




demand for our tests. We also plan to increase our consumer advertising in connection with our introduction of patient-initiated testing in 2019, which could be costly. We have limited experience implementing these types of marketing efforts. We may not be able to drive sufficient levels of revenue using these sales and marketing methods and strategies necessary to support our planned growth, and our failure to do so could limit our revenue and potential profitability.
Outside the United States we use a limited number of distributors to assist with sales, logistics, education and customer support. Sales practices utilized by our distributors that are locally acceptable may not comply with sales practices standards required under U.S. laws that apply to us, which could create additional compliance risk. If our sales and marketing efforts are not successful outside the United States, we may not achieve significant market acceptance for our tests outside the United States, which could adversely impact our business.
Impairment in the value of our goodwill or other intangible assets could have a material adverse effect on our operating results and financial condition.
We record goodwill and intangible assets at fair value upon the acquisition of a business. Goodwill represents the excess of amounts paid for acquiring businesses over the fair value of the net assets acquired. Goodwill and indefinite-lived intangible assets are evaluated for impairment annually, or more frequently if conditions warrant, by comparing the carrying value of a reporting unit to its estimated fair value. Intangible assets with definite lives are reviewed for impairment when events or circumstances indicate that their carrying value may not be recoverable. Declines in operating results, divestitures, sustained market declines and other factors that impact the fair value of a reporting unit could result in an impairment of goodwill or intangible assets and, in turn, a charge to net income. Any such charges could have a material adverse effect on our results of operations or financial condition.
We rely on a limited number of suppliers or, in some cases, sole suppliers, for some of our laboratory instruments, materials and services, and we may not be able to find replacements or immediately transition to alternative suppliers.
We rely on a limited number of suppliers, or, in some cases, sole suppliers, including Illumina, Inc., Integrated DNA Technologies Incorporated, Qiagen N.V., Roche Holdings Ltd. and Twist Bioscience Corporation for certain laboratory substances used in the chemical reactions incorporated into our processes, which we refer to as reagents, as well as sequencers and other equipment and materials which we use in our laboratory operations. We do not have short- or long-term agreements with most of our suppliers, and our suppliers could cease supplying these materials and equipment at any time, or fail to provide us with sufficient quantities of materials or materials that meet our specifications. Our laboratory operations could be interrupted if we encounter delays or difficulties in securing these reagents, sequencers or other equipment or materials, and if we cannot obtain an acceptable substitute. Any such interruption could significantly affect our business, financial condition, results of operations and reputation. We rely on Illumina as the sole supplier of next generation sequencers and associated reagents and as the sole provider of maintenance and repair services for these sequencers. Any disruption in Illumina’s operations could impact our supply chain and laboratory operations as well as our ability to conduct our tests, and it could take a substantial amount of time to integrate replacement equipment into our laboratory operations. We also rely on a subsidiary of Illumina, Verinata Health, Inc., to perform non-invasive prenatal screening, or NIPS, testing on our behalf. In the event of any disruption or termination of these services by Verinata, it may be difficult to find a replacement NIPS offering, which could harm our business, financial condition, results of operation and reputation.
We believe that there are only a few other manufacturers that are currently capable of supplying and servicing the equipment necessary for our laboratory operations, including sequencers and various associated reagents. The use of equipment or materials provided by these replacement suppliers would require us to alter our laboratory operations. Transitioning to a new supplier would be time consuming and expensive, may result in interruptions in our laboratory operations, could affect the performance specifications of our laboratory operations or could require that we revalidate our tests. We cannot assure you that we will be able to secure alternative equipment, reagents and other materials, and bring such equipment, reagents and materials on line and revalidate them without experiencing interruptions in our workflow. In the case of an alternative supplier for Illumina, we cannot assure you that replacement sequencers and associated reagents will be available or will meet our quality control and performance requirements for our laboratory operations. If we encounter delays or difficulties in securing, reconfiguring or revalidating the equipment and reagents we require for our tests, our business, financial condition, results of operations and reputation could be adversely affected.

23




If our laboratories in California become inoperable due to disasters or for any other reason, we will be unable to perform our tests and our business will be harmed.
We perform all of our tests at our production facilities in San Francisco and Irvine, California. Our laboratories and the equipment we use to perform our tests would be costly to replace and could require substantial lead time to replace and qualify for use. Our laboratories may be harmed or rendered inoperable by natural or man-made disasters, including earthquakes, flooding, fire and power outages, which may render it difficult or impossible for us to perform our tests for some period of time. This risk is especially high for us since we perform the substantial majority of our tests at our San Francisco laboratory, which is located in an active seismic region, and we do not have a redundant facility to perform the same tests in the event our San Francisco laboratory is inoperable. The inability to perform our tests or the backlog that could develop if our laboratories are inoperable for even a short period of time may result in the loss of customers or harm our reputation. Although we maintain insurance for damage to our property and the disruption of our business, this insurance may not be sufficient to cover all of our potential losses and may not continue to be available to us on acceptable terms, if at all.
The loss of any member or change in structure of our senior management team could adversely affect our business.
Our success depends in large part upon the skills, experience and performance of members of our executive management team and others in key leadership positions. The efforts of these persons will be critical to us as we continue to develop our technologies and test processes and focus on scaling our business. If we were to lose one or more key executives, we may experience difficulties in competing effectively, developing our technologies and implementing our business strategy. All of our executives and employees are at-will, which means that either we or the executive or employee may terminate their employment at any time. We do not carry key man insurance for any of our executives or employees. In addition, we do not have a long-term retention agreement in place with our president and chief executive officer.
Development of new tests is a complex process, and we may be unable to commercialize new tests on a timely basis, or at all.
We cannot assure you that we will be able to develop and commercialize new tests on a timely basis. Before we can commercialize any new tests, we will need to expend significant funds in order to:
•
conduct research and development;
•
further develop and scale our laboratory processes; and
•
further develop and scale our infrastructure to be able to analyze increasingly larger and more diverse amounts of data.
Our testing service development process involves risk, and development efforts may fail for many reasons, including:
•
failure of any test to perform as expected;
•
lack of validation or reference data; or
•
failure to demonstrate utility of a test.

As we develop tests, we will have to make significant investments in development, marketing and selling resources. In addition, competitors may develop and commercialize competing tests faster than we are able to do so.
Changes in financial accounting standards may cause adverse and unexpected revenue fluctuations and affect our reported results of operations.
We prepare our financial statements in accordance with U.S. GAAP. These principles are subject to interpretation by the SEC and various bodies formed to interpret and create appropriate accounting principles. Changes in these accounting standards or practices may have a significant effect on our results of operations. For example, in May 2014, the Financial Accounting Standards Boards, or FASB, issued Accounting Standards Update 2014-09, “Revenue from Contracts from Customers (Topic 606),” which superseded most existing revenue recognition guidance. We implemented Topic 606 effective January 1, 2018. Please see Note 2, “Summary of significant accounting policies” in the Notes to Consolidated Financial Statements for more information.

24




From inception through December 2017, we recognized revenue principally when cash was received. Under Topic 606 we now generally recognize revenue on an accrual basis. Accrual amounts are recognized based on estimates of the consideration that we expect to receive and such estimates will be updated and subsequently recorded until fully settled. Adjustments to these estimates may cause fluctuations in our revenue, and may have a material adverse effect on our revenue and our results of operations.
We depend on our information technology systems, and any failure of these systems could harm our business.
We depend on information technology and telecommunications systems for significant elements of our operations, including our laboratory information management system, our bioinformatics analytical software systems, our database of information relating to genetic variations and their role in disease process and drug metabolism, our clinical report optimization systems, our customer-facing web-based software, our customer reporting, our Invitae Family History Tool, PIN, and CancerGene Connect platform. We have installed, and expect to expand, a number of enterprise software systems that affect a broad range of business processes and functional areas, including for example, systems handling human resources, financial controls and reporting, customer relationship management, regulatory compliance and other infrastructure operations. In addition, we intend to extend the capabilities of both our preventative and detective security controls by augmenting the monitoring and alerting functions, the network design, and the automatic countermeasure operations of our technical systems. These information technology and telecommunications systems support a variety of functions, including laboratory operations, test validation, sample tracking, quality control, customer service support, billing and reimbursement, research and development activities, scientific and medical curation, and general administrative activities, including financial reporting.
Information technology and telecommunications systems are vulnerable to damage from a variety of sources, including telecommunications or network failures, malicious human acts and natural disasters. Moreover, despite network security and back-up measures, some of our servers are potentially vulnerable to physical or electronic break-ins, computer viruses and similar disruptive problems. Despite the precautionary measures we have taken to prevent unanticipated problems that could affect our information technology and telecommunications systems, failures or significant downtime of our information technology or telecommunications systems or those used by our third-party service providers could prevent us from conducting tests, preparing and providing reports to clinicians, billing payers, processing reimbursement appeals, handling physician or patient inquiries, conducting research and development activities, and managing the administrative and financial aspects of our business. Any disruption or loss of information technology or telecommunications systems on which critical aspects of our operations depend could have an adverse effect on our business and results of operations.
Any technical problems that may arise in connection with our data and systems, including those that are hosted by third-party providers, could result in interruptions in our business and operations. These types of problems may be caused by a variety of factors, including infrastructure changes, human or software errors, viruses, security attacks, fraud, spikes in customer usage and denial of service issues. From time to time, large third-party web hosting providers have experienced outages or other problems that have resulted in their systems being offline and inaccessible. Such outages could materially impact our business and operations.
Ethical, legal and social concerns related to the use of genetic information could reduce demand for our tests.
Genetic testing has raised ethical, legal and social issues regarding privacy and the appropriate uses of the resulting information. Governmental authorities could, for social or other purposes, limit or regulate the use of genetic information or genetic testing or prohibit testing for genetic predisposition to certain conditions, particularly for those that have no known cure. Similarly, these concerns may lead patients to refuse to use, or clinicians to be reluctant to order, genomic tests even if permissible. These and other ethical, legal and social concerns may limit market acceptance of our tests or reduce the potential markets for our tests, either of which could have an adverse effect on our business, financial condition or results of operations.
Our international business exposes us to business, regulatory, political, operational, financial and economic risks associated with doing business outside of the United States.
We currently have a limited number of distribution arrangements in several countries outside of the United States. Doing business internationally involves a number of risks, including:
•
multiple, conflicting and changing laws and regulations such as privacy regulations, tax laws, export and import restrictions, employment laws, regulatory requirements, and other governmental approvals, permits and licenses;

25




•
failure by us or our distributors to obtain regulatory approvals for the use of our tests in various countries;
•
complexities and difficulties in obtaining protection and enforcing our intellectual property;
•
difficulties in staffing and managing foreign operations;
•
complexities associated with managing multiple payer reimbursement regimes, government payers or patient self-pay systems;
•
logistics and regulations associated with shipping samples, including infrastructure conditions and transportation delays;
•
limits on our ability to penetrate international markets if we do not to conduct our tests locally;
•
natural disasters, political and economic instability, including wars, terrorism and political unrest, outbreak of disease, boycotts, curtailment of trade and other business restrictions; and
•
regulatory and compliance risks that relate to maintaining accurate information and control over activities that may fall within the purview of the U.S. Foreign Corrupt Practices Act, or FCPA, its books and records provisions, or its anti-bribery provisions.
Any of these factors could significantly harm our international operations and, consequently, our revenue and results of operations.
In addition, applicable export or import laws and regulations such as prohibitions on the export of samples imposed by countries outside of the United States, or international privacy or data restrictions that are different or more stringent than those of the United States, may require that we build additional laboratories or engage in joint ventures or other business partnerships in order to offer our tests internationally in the future. Any such restrictions would impair our ability to offer our tests in such countries and could have an adverse effect on our business, financial condition and results of operations.
Changes in U.S. tax laws could adversely impact us.
On December 22, 2017, President Trump signed The Tax Cuts and Jobs Act, the Tax Act, into law. The Tax Act contains significant changes to U.S. federal corporate income taxation, including reduction of the corporate tax rate from 35% to 21% for U.S. taxable income, resulting in a one-time remeasurement of deferred taxes to reflect their value at a lower tax rate of 21%, limitation of the deduction for net operating losses to 80% of current year taxable income and elimination of net operating loss carrybacks, deemed repatriation, resulting in one-time taxation of offshore earnings at reduced rates, elimination of U.S. tax on foreign earnings (subject to certain exceptions), and immediate deductions for certain new investments instead of deductions for depreciation expense over time. Although the Tax Act was generally effective January 1, 2018, GAAP requires recognition of the tax effects of new legislation during the reporting period that includes the enactment date, which was December 22, 2017. As a result of the lower corporate tax rate enacted as part of the Tax Act, we recorded a provisional estimate to reduce deferred tax assets by $48.8 million. The reduction in deferred tax assets was offset by a corresponding reduction in our valuation allowance resulting in no net impact to tax expense. We have determined that the adjustment to the deferred tax assets and valuation allowance recorded in connection with the remeasurement of certain deferred tax assets and liabilities is a reasonable estimate at December 31, 2017. In the fourth quarter of 2018, we completed our analysis to determine the effect of the Tax Act and no material adjustments were recognized as of December 31, 2018.
Risks related to government regulation
If the FDA regulates our tests as medical devices, we could incur substantial costs and our business, financial condition and results of operations could be adversely affected.
We provide our tests as laboratory-developed tests, or LDTs. CMS and certain state agencies regulate the performance of LDTs (as authorized by the Clinical Laboratory Improvement Amendments of 1988, or CLIA, and state law, respectively).
Historically, the FDA has exercised enforcement discretion with respect to most LDTs and has not required laboratories that furnish LDTs to comply with the agency’s requirements for medical devices (e.g., establishment registration, device listing, quality systems regulations, premarket clearance or premarket approval, and post-market controls). In recent years, however, the FDA has stated it intends to end its policy of general enforcement discretion and regulate certain LDTs as medical devices. To this end, on October 3, 2014, the FDA issued two draft guidance documents, entitled “Framework for Regulatory Oversight of Laboratory Developed Tests (LDTs)” and “FDA Notification and Medical Device Reporting for Laboratory Developed Tests (LDTs)”, respectively, that set forth

26




a proposed risk-based regulatory framework that would apply varying levels of FDA oversight to LDTs. Subsequently, on January 13, 2017, the FDA published a “discussion paper” in which it outlined a substantially revised “possible approach” to the oversight of LDTs. In December 2018, a draft bill titled the “Verifying Accurate Leading-edge IVCT Development Act of 2018”, or VALID Act, was released for discussion. The draft bill proposes a risk-based approach to regulate LDTs and creates a new in vitro clinical test, or IVCT, category of regulated products, which includes LDTs, and a regulatory structure under the FDA. As proposed, the draft bill grandfathers many existing tests from the proposed premarket approval, quality systems, and labeling requirements, respectively, but would require such tests to comply with other regulatory requirements (e.g., registration and notification, adverse event reporting). We cannot predict if this draft bill will be enacted in its current (or any other) form and cannot quantify the effect of this draft bill on our business.
Legislative proposals addressing the FDA’s oversight of LDTs have been introduced in previous Congresses, and we expect that new legislative proposals will be introduced from time-to-time. The likelihood that Congress will pass such legislation and the extent to which such legislation may affect the FDA’s plans to regulate certain LDTs as medical devices is difficult to predict at this time.
If the FDA ultimately regulates certain LDTs (either as medical devices or as part of a new stand-alone regulatory category for IVCTs), whether via individualized enforcement action, or more generally, as outlined in final guidance or final regulation, or as instructed by Congress, our tests may be subject to certain additional regulatory requirements. Complying with the FDA’s requirements can be expensive, time-consuming and subject us to significant or unanticipated delays. Insofar as we may be required to obtain premarket clearance or approval to perform or continue performing an LDT, we cannot assure you that we will be able to obtain such authorization. Even if we obtain regulatory clearance or approval where required, such authorization may not be for the intended uses that we believe are commercially attractive or are critical to the commercial success of our tests. As a result, the application of the FDA’s requirements to our tests could materially and adversely affect our business, financial condition and results of operations.
Failure to comply with applicable FDA regulatory requirements may trigger a range of enforcement actions by the FDA including warning letters, civil monetary penalties, injunctions, criminal prosecution, recall or seizure, operating restrictions, partial suspension or total shutdown of operations, and denial of or challenges to applications for clearance or approval, as well as significant adverse publicity.
In addition, in November 2013, the FDA issued final guidance regarding the distribution of products labeled for research use only. Certain of the reagents and other products we use in our tests are labeled as research use only products. Certain of our suppliers may cease selling research use only products to us and any failure to obtain an acceptable substitute could significantly and adversely affect our business, financial condition and results of operations.
If we fail to comply with federal, state and foreign laboratory licensing requirements, we could lose the ability to perform our tests or experience disruptions to our business.
We are subject to CLIA, a federal law that regulates clinical laboratories that perform testing on specimens derived from humans for the purpose of providing information for the diagnosis, prevention or treatment of disease. CLIA regulations establish specific standards with respect to personnel qualifications, facility administration, proficiency testing, quality control, quality assurance and inspections. CLIA certification is also required in order for us to be eligible to bill state and federal healthcare programs, as well as many private third-party payers, for our tests. We have current CLIA certifications to conduct our tests at our laboratories in San Francisco and Irvine, California. To renew these certifications, we are subject to survey and inspection every two years. Moreover, CLIA inspectors may make random inspections of our clinical reference laboratories.
We are also required to maintain licenses to conduct testing in California. California laws establish standards for day-to-day operation of our clinical reference laboratories in San Francisco and Irvine, including the training and skills required of personnel and quality control. We also maintain out-of-state laboratory licenses to conduct testing on specimens from Maryland, New York, Pennsylvania and Rhode Island.

27




In addition to having laboratory licenses in New York, our clinical reference laboratories are approved on test-specific bases by the New York State Department of Health, or NYDOH. Other states may adopt similar licensure requirements in the future, which may require us to modify, delay or stop our operations in such jurisdictions. We may also be subject to regulation in foreign jurisdictions as we seek to expand international utilization of our tests or such jurisdictions adopt new licensure requirements, which may require review of our tests in order to offer them or may have other limitations such as restrictions on the transport of samples necessary for us to perform our tests that may limit our ability to make our tests available outside of the United States. Complying with licensure requirements in new jurisdictions may be expensive, time-consuming, and subject us to significant and unanticipated delays.
Failure to comply with applicable clinical laboratory licensure requirements may result in a range of enforcement actions, including license suspension, limitation, or revocation, directed plan of action, onsite monitoring, civil monetary penalties, criminal sanctions, and cancellation of the laboratory’s approval to receive Medicare and Medicaid payment for its services, as well as significant adverse publicity. Any sanction imposed under CLIA, its implementing regulations, or state or foreign laws or regulations governing clinical laboratory licensure, or our failure to renew our CLIA certificate, a state or foreign license, or accreditation, could have a material adverse effect on our business, financial condition and results of operations. Even if we were able to bring our laboratory back into compliance, we could incur significant expenses and potentially lose revenue in doing so.
The College of American Pathologists, or CAP, maintains a clinical laboratory accreditation program. CAP asserts that its program is “designed to go well beyond regulatory compliance” and helps laboratories achieve the highest standards of excellence to positively impact patient care. While not required to operate a CLIA-certified laboratory, many private insurers require CAP accreditation as a condition to contracting with clinical laboratories to cover their tests. In addition, some countries outside the United States require CAP accreditation as a condition to permitting clinical laboratories to test samples taken from their citizens. We have CAP accreditations for our laboratories. Failure to maintain CAP accreditation could have a material adverse effect on the sales of our tests and the results of our operations.
Complying with numerous statutes and regulations pertaining to our business is an expensive and time-consuming process, and any failure to comply could result in substantial penalties.
Our operations are subject to other extensive federal, state, local and foreign laws and regulations, all of which are subject to change. These laws and regulations currently include, among others:
•
HIPAA, which established comprehensive federal standards with respect to the privacy and security of protected health information and requirements for the use of certain standardized electronic transactions;
•
amendments to HIPAA under HITECH, which strengthen and expand HIPAA privacy and security compliance requirements, increase penalties for violators and expand vicarious liability, extend enforcement authority to state attorneys general, and impose requirements for breach notification;
•
the federal Anti-Kickback Statute, which prohibits knowingly and willfully offering, paying, soliciting or receiving remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or in return for the referral of an individual, for the furnishing of or arrangement for the furnishing of any item or service for which payment may be made in whole or in part by a federal healthcare program, or the purchasing, leasing, ordering, arranging for, or recommend purchasing, leasing or ordering, any good, facility, item or service for which payment may be made, in whole or in part, under a federal healthcare program;
•
the federal physician self-referral law, known as the Stark Law, which prohibits a physician from making a referral to an entity for certain designated health services covered by the Medicare program, including laboratory and pathology services, if the physician or an immediate family member has a financial relationship with the entity unless an exception applies, and prohibits an entity from billing for designated health services furnished pursuant to a prohibited referral;
•
the federal false claims law, which impose liability on any person or entity that, among other things, knowingly presents, or causes to be presented, a false or fraudulent claim for payment to the federal government;
•
the federal Civil Monetary Penalties Law, which prohibits, among other things, the offering or transfer of remuneration to a Medicare or state healthcare program beneficiary if the person knows or should know it is likely to influence the beneficiary’s selection of a particular provider, practitioner or supplier of services reimbursable by Medicare or a state healthcare program, unless an exception applies;

28




•
the HIPAA fraud and abuse provisions, which created new federal criminal statutes that prohibit, among other things, defrauding health care benefit programs, willfully obstructing a criminal investigation of a healthcare offense and falsifying or concealing a material fact or making any materially false statements in connection with the payment for healthcare benefits, items or services;
•
other federal and state fraud and abuse laws, such as anti-kickback laws, prohibitions on self-referral, fee-splitting restrictions, insurance fraud laws, anti-markup laws, prohibitions on the provision of tests at no or discounted cost to induce physician or patient adoption, and false claims acts, which may extend to services reimbursable by any third-party payer, including private insurers;
•
the prohibition on reassignment of Medicare claims, which, subject to certain exceptions, precludes the reassignment of Medicare claims to any other party;
•
state laws that prohibit other specified practices, such as billing clinicians for testing that they order; waiving coinsurance, copayments, deductibles and other amounts owed by patients; billing a state Medicaid program at a price that is higher than what is charged to one or more other payers; and
•
similar foreign laws and regulations that apply to us in the countries in which we operate or may operate in the future.
We have adopted policies and procedures designed to comply with these laws and regulations. In the ordinary course of our business, we conduct internal reviews of our compliance with these laws. Our compliance may also be subject to governmental review. The growth of our business and our expansion outside of the United States may increase the potential of violating these laws or our internal policies and procedures. The risk of our being found in violation of these or other laws and regulations is further increased by the fact that many have not been fully interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of interpretations. Any action brought against us for violation of these or other laws or regulations, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management’s attention from the operation of our business. If our operations are found to be in violation of any of these laws and regulations, we may be subject to any applicable penalty associated with the violation, including administrative, civil and criminal penalties, damages, fines, individual imprisonment, exclusion from participation in Federal healthcare programs, refunding of payments received by us, and curtailment or cessation of our operations. Any of the foregoing consequences could seriously harm our business and our financial results.
Healthcare policy changes, including legislation reforming the U.S. healthcare system, may have a material adverse effect on our financial condition, results of operations and cash flows.
In March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, collectively referred to as the Affordable Care Act, was enacted in the United States, which made a number of substantial changes in the way healthcare is financed by both governmental and private insurers. Among other things, the Affordable Care Act requires each medical device manufacturer to pay a sales tax equal to 2.3% of the price for which such manufacturer sells its medical devices, and applied to sales of taxable medical devices from January 1, 2013 through December 31, 2015. The medical device tax has been suspended for 2016 through 2019, but is scheduled to return beginning in 2020. It is unclear at this time when, or if, the provision of our LDTs will trigger the medical device tax if the FDA ends its policy of general enforcement discretion and regulates certain LDTs as medical devices. It is possible, however, that this tax will apply to some or all of our tests or tests that are in development.
Many of the Current Procedure Terminology, or CPT, procedure codes that we use to bill our tests were revised by the American Medical Association, effective January 1, 2013. Moreover, effective January 1, 2015, the AMA released several new codes to report genomic sequencing procedures. In a final determination under the Medicare Clinical Laboratory Fee Schedule, or CLFS, published in November 2014, CMS set the 2015 payment rate for these codes by the gap-fill process. Under the gap-fill process, local Medicare Administrative Contractors, or MACs, establish rates for those codes that each MAC believes meet the criteria for Medicare coverage and considering laboratory charges and discounts to charges, resources, amounts paid by other payers for the tests, and amounts paid by the MAC for similar tests. In 2015, gap-filled payment rates were established for some, but not all, of the above-described codes. For those codes for which local gap-filled rate(s) were established in 2015, a national limitation amount for Medicare was established for 2016. Codes for which local gap-filled rates were not established in 2015 were priced by the local MACs in 2016 insofar as an individual MAC determines that such codes should be covered. Where available, the national limitation amount serves as a cap on the Medicare and Medicaid payment rates for a test procedure.

29




The AMA also released several CPT codes effective January 1, 2016 that may be appropriate to report certain of our tests. In a November 2015 final determination, CMS set the calendar year 2016 CLFS payment rate for these new codes by the gap-fill process. CMS and the local MACs went through the gap-fill process in 2016 and announced final gap-filled rates for 2017 on September 30, 2016. The calendar year 2017 national limitation amounts for certain codes were significantly less than the rates at which we have historically offered our tests.
In April 2014, Congress passed the Protecting Access to Medicare Act of 2014, or PAMA, which included substantial changes to the way in which clinical laboratory services are paid under Medicare. Under the final rule that implements PAMA, which was promulgated by CMS in June 2016, clinical laboratories must report to CMS private payer rates beginning in 2017 and every three years thereafter for clinical diagnostic laboratory tests that are not advanced diagnostic laboratory tests and every year for advanced diagnostic laboratory tests.
We do not believe that our tests meet the definition of advanced diagnostic laboratory tests, but in the event that we seek designation for one or more of our tests as an advanced diagnostic laboratory test and the tests are determined by CMS to meet these criteria or new criteria developed by CMS, we would be required to report private payer data for those tests annually. Otherwise, we will be required to report private payer rates for our tests on an every three years basis. Laboratories that fail to timely report the required payment information may be subject to substantial civil money penalties.
As set forth in the PAMA final rule, for tests furnished on or after January 1, 2018, Medicare payments for clinical diagnostic laboratory tests are paid based upon these reported private payer rates. For clinical diagnostic laboratory tests that are assigned a new or substantially revised code, initial payment rates for clinical diagnostic laboratory tests that are not advanced diagnostic laboratory tests will be assigned by the cross-walk or gap-fill methodology, similar to prior law. Initial payment rates for new advanced diagnostic laboratory tests will be based on the actual list charge for the laboratory test. The payment rates calculated under PAMA went into effect starting January 1, 2018. Where applicable, reductions to payment rates resulting from the new methodology are limited to 10% per test per year in each of the years 2018 through 2020 and to 15% per test per year in each of 2021 through 2023 (following a second round of private payer rate reporting in 2020 to establish rates for 2021 through 2023).
PAMA also authorized the adoption of new, temporary billing codes and/or unique test identifiers for FDA-cleared or approved tests as well as advanced diagnostic laboratory tests. The CPT® Editorial Panel approved a proposal to create a new section of billing codes to facilitate implementation of this section of PAMA, but it is unclear how these codes would apply to our tests.
In March 2018, CMS published a final national coverage determination, or NCD, for next generation sequencing, or NGS, tests for patients with advanced cancer. The final NCD establishes full coverage for FDA-approved or FDA-cleared NGS-based companion diagnostic assays when offered for their FDA-approved or FDA-cleared use(s), ordered by the patient’s treating physician for Medicare beneficiaries with advanced cancer (recurrent, relapsed, refractory, metastatic, or advanced stage III or IV cancer) who have not have previously been tested with the same test for the same primary diagnosis of cancer or are seeking repeat testing for a new primary cancer diagnosis, and have decided to seek further cancer treatment. The final NCD also gives MACs the authority to establish local coverage for NGS-based assays that are not FDA-approved or FDA-cleared companion diagnostics when offered to patients meeting the above-referenced criteria. It is unclear, however, whether MACs retain the authority to establish local coverage for NGS-based tests provided for patients with cancer that do not meet the above-referenced criteria - e.g., patients with earlier stage cancers or patients with a personal history of cancer - or if such tests are nationally non-covered under the NCD. If CMS interprets the final NCD to exclude coverage for patients with earlier stage cancers or personal history of cancer, MACs will no longer have discretion to cover our current tests when offered to such patients, notwithstanding historical Medicare coverage for such tests. An interpretation of the NCD that results in Medicare non-coverage for our current and future assays would have significant negative impact on our business, financial condition and results of operations.
We cannot predict whether future healthcare initiatives will be implemented at the federal or state level, or how any future legislation or regulation may affect us. For instance, the payment reductions imposed by the Affordable Care Act and the expansion of the federal and state governments’ role in the U.S. healthcare industry as well as changes to the reimbursement amounts paid by payers for our tests and future tests or our medical procedure volumes may reduce our profits and have a materially adverse effect on our business, financial condition, results of operations and cash flows. Notably, Congress enacted legislation in 2017 that eliminates the Affordable Care Act’s “individual mandate” beginning in 2019, which may significantly impact the number of covered lives participating in exchange plans. Moreover, Congress has proposed on several occasions to impose a 20% coinsurance on patients for clinical laboratory tests reimbursed under the clinical laboratory fee schedule, which would increase our billing and collecting costs and decrease our revenue.

30




If we use hazardous materials in a manner that causes injury, we could be liable for resulting damages.
Our activities currently require the use of hazardous chemicals and biological material. We cannot eliminate the risk of accidental contamination or injury to employees or third parties from the use, storage, handling or disposal of these materials. In the event of contamination or injury, we could be held liable for any resulting damages, and any liability could exceed our resources or any applicable insurance coverage we may have. In 2018, we decommissioned our laboratory in Cambridge, Massachusetts; however, we could be held liable for any damages resulting from our prior use of hazardous chemicals and biological materials at this facility. Additionally, we are subject on an ongoing basis to federal, state and local laws and regulations governing the use, storage, handling and disposal of these materials and specified waste products. The cost of compliance with these laws and regulations may become significant, and our failure to comply may result in substantial fines or other consequences, and either could negatively affect our operating results.
We could be adversely affected by violations of the FCPA and other worldwide anti-bribery laws.
We are subject to the FCPA, which prohibits companies and their intermediaries from making payments in violation of law to non-U.S. government officials for the purpose of obtaining or retaining business or securing any other improper advantage. We use a limited number of independent distributors to sell our tests internationally, which requires a high degree of vigilance in maintaining our policy against participation in corrupt activity, because these distributors could be deemed to be our agents, and we could be held responsible for their actions. Other U.S. companies in the medical device and pharmaceutical fields have faced criminal penalties under the FCPA for allowing their agents to deviate from appropriate practices in doing business with these individuals. We are also subject to similar anti-bribery laws in the jurisdictions in which we operate, including the United Kingdom’s Bribery Act of 2010, which also prohibits commercial bribery and makes it a crime for companies to fail to prevent bribery. These laws are complex and far-reaching in nature, and, as a result, we cannot assure you that we would not be required in the future to alter one or more of our practices to be in compliance with these laws or any changes in these laws or the interpretation thereof. Any violations of these laws, or allegations of such violations, could disrupt our operations, involve significant management distraction, involve significant costs and expenses, including legal fees, and could result in a material adverse effect on our business, prospects, financial condition or results of operations. We could also incur severe penalties, including criminal and civil penalties, disgorgement and other remedial measures.
Risks related to our intellectual property
Litigation or other proceedings or third-party claims of intellectual property infringement or misappropriation may require us to spend significant time and money, and could in the future prevent us from selling our tests or impact our stock price.
Our commercial success will depend in part on our avoiding infringement of patents and proprietary rights of third parties, including for example the intellectual property rights of competitors. As we continue to commercialize our tests in their current or an updated form, launch different and expanded tests, and enter new markets, competitors might claim that our tests infringe or misappropriate their intellectual property rights as part of business strategies designed to impede our successful commercialization and entry into new markets. Our activities may be subject to claims that we infringe or otherwise violate patents or other intellectual property rights owned or controlled by third parties. We cannot assure you that our operations do not, or will not in the future, infringe existing or future patents. We may be unaware of patents that a third party, including for example a competitor in the genetic testing market, might assert are infringed by our business. There may also be patent applications that, if issued as patents, could be asserted against us. Third parties making claims against us for infringement or misappropriation of their intellectual property rights may seek and obtain injunctive or other equitable relief, which could effectively block our ability to perform our tests. Further, if a patent infringement suit were brought against us, we could be forced to stop or delay our development or sales of any tests or other activities that are the subject of such suit. Defense of these claims, regardless of merit, could cause us to incur substantial expenses and be a substantial diversion of our employee resources. Any adverse ruling or perception of an adverse ruling in defending ourselves could have a material adverse impact on our business and stock price. In the event of a successful claim of infringement against us by a third party, we may have to (1) pay substantial damages, possibly including treble damages and attorneys’ fees if we are found to have willfully infringed patents; (2) obtain one or more licenses, which may not be available on commercially reasonable terms (if at all); (3) pay royalties; and/or (4) redesign any infringing tests or other activities, which may be impossible or require substantial time and monetary expenditure, all of which could have a material adverse impact on our cash position and business and financial condition.
If licenses to third-party intellectual property rights are or become required for us to engage in our business, we may be unable to obtain them at a reasonable cost, if at all. Even if such licenses are available, we could incur

31




substantial costs related to royalty payments for licenses obtained from third parties, which could negatively affect our gross margins. Moreover, we could encounter delays in the introduction of tests while we attempt to develop alternatives. Defense of any lawsuit or failure to obtain any of these licenses on favorable terms could prevent us from commercializing tests, which could materially affect our ability to grow and thus adversely affect our business and financial condition.
Developments in patent law could have a negative impact on our business.
Although we view current U.S. Supreme Court precedent to be aligned with our belief that naturally occurring DNA sequences and detection of natural correlations between observed facts (such as patient genetic data) and an understanding of that fact’s implications (such as a patient’s risk of disease associated with certain genetic variations) should not be patentable, it is possible that subsequent determinations by the U.S. Supreme Court or other federal courts could limit, alter or potentially overrule current law. Moreover, from time to time the U.S. Supreme Court, other federal courts, the United States Congress or the U.S. Patent and Trademark Office, or USPTO, may change the standards of patentability, and any such changes could run contrary to, or otherwise be inconsistent with, our belief that naturally occurring DNA sequences and detection of natural correlations between observed facts and an understanding of that fact’s implications should not be patentable, which could result in third parties newly claiming that our business practices infringe patents drawn from categories of patents which we currently view to be invalid as directed to unpatentable subject matter.
Our inability to effectively protect our proprietary technologies, including the confidentiality of our trade secrets, could harm our competitive position.
We currently rely upon trade secret protection and copyright, as well as non-disclosure agreements and invention assignment agreements with our employees, consultants and third-parties, and to a limited extent patent protection, to protect our confidential and proprietary information. Although our competitors have utilized and are expected to continue utilizing similar methods and have aggregated and are expected to continue to aggregate similar databases of genetic testing information, our success will depend upon our ability to develop proprietary methods and databases and to defend any advantages afforded to us by such methods and databases relative to our competitors. If we do not protect our intellectual property adequately, competitors may be able to use our methods and databases and thereby erode any competitive advantages we may have.
We will be able to protect our proprietary rights from unauthorized use by third parties only to the extent that our proprietary technologies are covered by valid and enforceable patents or are effectively maintained as trade secrets. In this regard, we have applied, and we intend to continue applying, for patents covering such aspects of our technologies as we deem appropriate. However, we expect that potential patent coverage we may obtain will not be sufficient to prevent substantial competition. In this regard, we believe it is probable that others will independently develop similar or alternative technologies or design around those technologies for which we may obtain patent protection. In addition, any patent applications we file may be challenged and may not result in issued patents or may be invalidated or narrowed in scope after they are issued. Questions as to inventorship or ownership may also arise. Any finding that our patents or applications are unenforceable could harm our ability to prevent others from practicing the related technology, and a finding that others have inventorship or ownership rights to our patents and applications could require us to obtain certain rights to practice related technologies, which may not be available on favorable terms, if at all. If we initiate lawsuits to protect or enforce our patents, or litigate against third party claims, which would be expensive, and, if we lose, we may lose some of our intellectual property rights. Furthermore, these lawsuits may divert the attention of our management and technical personnel.
We expect to rely primarily upon trade secrets and proprietary know-how protection for our confidential and proprietary information, and we have taken security measures to protect this information. These measures, however, may not provide adequate protection for our trade secrets, know-how or other confidential information. Among other things, we seek to protect our trade secrets and confidential information by entering into confidentiality agreements with employees and consultants. There can be no assurance that any confidentiality agreements that we have with our employees and consultants will provide meaningful protection for our trade secrets and confidential information or will provide adequate remedies in the event of unauthorized use or disclosure of such information. Accordingly, there also can be no assurance that our trade secrets will not otherwise become known or be independently developed by competitors. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret can be difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, trade secrets may be independently developed by others in a manner that could prevent legal recourse by us. If any of our confidential or proprietary information, such as our trade secrets, were to be disclosed or misappropriated, or if any such information was independently developed by a competitor, our competitive position could be harmed. 

32




We may not be able to enforce our intellectual property rights throughout the world.
The laws of some foreign countries do not protect proprietary rights to the same extent as the laws of the United States, and many companies have encountered significant challenges in establishing and enforcing their proprietary rights outside of the United States. These challenges can be caused by the absence of rules and methods for the establishment and enforcement of intellectual property rights outside of the United States. In addition, the legal systems of some countries, particularly developing countries, do not favor the enforcement of patents and other intellectual property protection, especially those relating to healthcare. This could make it difficult for us to stop the infringement of our patents, if obtained, or the misappropriation of our other intellectual property rights. For example, many foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third parties. In addition, many countries limit the enforceability of patents against third parties, including government agencies or government contractors. In these countries, patents may provide limited or no benefit. Patent protection must ultimately be sought on a country-by-country basis, which is an expensive and time-consuming process with uncertain outcomes. Accordingly, we may choose not to seek patent protection in certain countries, and we will not have the benefit of patent protection in such countries. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate. In addition, changes in the law and legal decisions by courts in the United States and foreign countries may affect our ability to obtain adequate protection for our technology and the enforcement of intellectual property.
Third parties may assert that our employees or consultants have wrongfully used or disclosed confidential information or misappropriated trade secrets.
We employ individuals who were previously employed at universities or genetic testing, diagnostic or other healthcare companies, including our competitors or potential competitors. Although we try to ensure that our employees and consultants do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or our employees or consultants have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information, of a former employer or other third parties. Further, we may be subject to ownership disputes in the future arising, for example, from conflicting obligations of consultants or others who are involved in developing our intellectual property. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.
Risks related to being a public company
We incur increased costs and demands on management as a result of compliance with laws and regulations applicable to public companies, which could harm our operating results.
As a public company, we incur significant legal, accounting and other expenses , including costs associated with public company reporting requirements. In addition, the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, as well as rules implemented by the SEC and the New York Stock Exchange, or NYSE, impose a number of requirements on public companies, including with respect to corporate governance practices. The SEC and other regulators have continued to adopt new rules and regulations and make additional changes to existing regulations that require our compliance. In addition, the Dodd-Frank Wall Street Reform and Consumer Protection Act, or the Dodd-Frank Act, enacted in 2010, includes significant corporate governance and executive-compensation-related provisions. Our management and other personnel need to devote a substantial amount of time to these compliance and disclosure obligations. If these requirements divert the attention of our management and personnel from other aspects of our business concerns, they could have a material adverse effect on our business, financial condition and results of operations. Moreover, these rules and regulations applicable to public companies substantially increase our legal, accounting and financial compliance costs, require that we hire additional personnel and make some activities more time-consuming and costly. It may also be more expensive for us to obtain director and officer liability insurance.
If we are unable to maintain effective internal control over financial reporting, investors may lose confidence in the accuracy and completeness of our reported financial information and the market price of our common stock may be negatively affected.
We are required to maintain internal control over financial reporting and to report any material weaknesses in such internal controls. Section 404 of the Sarbanes-Oxley Act requires that we evaluate and determine the effectiveness of our internal control over financial reporting and provide a management report on our internal control over financial reporting. If we have a material weakness in our internal control over financial reporting, we may not

33




detect errors on a timely basis and our financial statements may be materially misstated. We have compiled the system and process documentation necessary to perform the evaluation needed to comply with Section 404 of the Sarbanes-Oxley Act. We need to maintain and enhance these processes and controls as we grow and we have required, and may continue to require, additional personnel and resources to do so.
During the evaluation and testing process, if we identify one or more material weaknesses in our internal controls, our management will be unable to conclude that our internal control over financial reporting is effective. Moreover, when we are no longer an emerging growth company, as described below, our independent registered public accounting firm will be required to issue an attestation report on the effectiveness of our internal control over financial reporting. Even if our management concludes that our internal control over financial reporting is effective, our independent registered public accounting firm may conclude that there are material weaknesses with respect to our internal controls or the level at which our internal controls are documented, designed, implemented or reviewed.
If we are unable to conclude that our internal control over financial reporting is effective, or when we are no longer an emerging growth company, if our auditors were to express an adverse opinion on the effectiveness of our internal control over financial reporting because we had one or more material weaknesses, investors could lose confidence in the accuracy and completeness of our financial disclosures, which could cause the price of our common stock to decline. Internal control deficiencies could also result in the restatement of our financial results in the future.
We are an emerging growth company and have elected to comply with reduced public company reporting requirements applicable to emerging growth companies, which could make our common stock less attractive to investors.
We are an emerging growth company, as defined under the Securities Act. We will remain an emerging growth company until December 31, 2020, although if our revenue exceeds $1.07 billion in any fiscal year before that time, we would cease to be an emerging growth company as of the end of that fiscal year. In addition, if the market value of our common stock that is held by non-affiliates exceeds $700 million as of the last business day of our second fiscal quarter of any fiscal year before the end of that five-year period, we would cease to be an emerging growth company as of December 31 of that year. As an emerging growth company, we have chosen to take advantage of exemptions from various reporting requirements applicable to certain other public companies, including not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced financial statement and financial-related disclosures, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirement of holding a nonbinding advisory vote on executive compensation and obtaining stockholder approval of any golden parachute payments not previously approved by our stockholders. We cannot predict whether investors will find our common stock less attractive because we have chosen to rely on any of these exemptions. If investors find our common stock less attractive as a result of any choices to reduce future disclosure we may make, there may be a less active trading market for our common stock and our stock price may be more volatile.
Risks related to our common stock
Our stock price is volatile, and you may not be able to sell shares of our common stock at or above the price you paid.
The trading price of our common stock is volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control. These factors include:
•
actual or anticipated fluctuations in our operating results;
•
competition from existing tests or new tests that may emerge;
•
announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures, collaborations or capital commitments;
•
failure to meet or exceed financial estimates and projections of the investment community or that we provide to the public;
•
issuance of new or updated research or reports by securities analysts or changed recommendations for our stock;
•
our focus on long-term goals over short-term results;
•
the timing of our investments in the growth of our business;
•
actual or anticipated changes in regulatory oversight of our business;

34




•
additions or departures of key management or other personnel;
•
disputes or other developments related to our intellectual property or other proprietary rights, including litigation;
•
changes in reimbursement by current or potential payers;
•
general economic and market conditions; and
•
issuances of significant amounts of our common stock.
In addition, the stock market in general, and the market for stock of life sciences companies in particular, has experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of those companies. Broad market and industry factors may seriously affect the market price of our common stock, regardless of our actual operating performance. In addition, in the past, following periods of volatility in the overall market and the market price of a particular company’s securities, securities class action litigation has often been instituted against these companies. This litigation, if instituted against us, could result in substantial costs and a diversion of our management’s attention and resources.
If securities or industry analysts issue an adverse opinion regarding our stock or do not publish research or reports about our company, our stock price and trading volume could decline.
The trading market for our common stock will depend in part on the research and reports that equity research analysts publish about us and our business. We do not control these analysts or the content and opinions included in their reports. Securities analysts may elect not to provide research coverage of our company and such lack of research coverage may adversely affect the market price of our common stock. The price of our common stock could also decline if one or more equity research analysts downgrade our common stock, change their price targets, issue other unfavorable commentary or cease publishing reports about us or our business. If one or more equity research analysts cease coverage of our company, we could lose visibility in the market, which in turn could cause our stock price to decline.
Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.
At December 31, 2018, our total gross deferred tax assets were $131.9 million. Due to our lack of earnings history and uncertainties surrounding our ability to generate future taxable income, the net deferred tax assets have been fully offset by a valuation allowance. The deferred tax assets were primarily comprised of federal and state tax net operating losses and tax credit carryforwards. Furthermore, under Section 382 of the Internal Revenue Code of 1986, as amended, or the Internal Revenue Code, if a corporation undergoes an “ownership change,” the corporation’s ability to use its pre-change net operating loss carryforwards, or NOLs, and other pre-change tax attributes (such as research tax credits) to offset its future taxable income may be limited. In general, an “ownership change” occurs if there is a cumulative change in our ownership by “5% shareholders” that exceeds 50 percentage points over a rolling three-year period. Our existing NOLs and tax credit carryovers may be subject to limitations arising from previous ownership changes, and if we undergo one or more ownership changes in connection with completed acquisitions, or other future transactions in our stock, our ability to utilize NOLs and tax credit carryovers could be further limited by Section 382 of the Internal Revenue Code. As a result, if we earn net taxable income, our ability to use our pre-change net operating loss and tax credit carryforwards to offset U.S. federal taxable income may be subject to limitations, which could potentially result in increased future tax liability to us. The annual limitation may result in the expiration of certain net operating loss and tax credit carryforwards before their utilization. In addition, the Tax Act limits the deduction for NOLs to 80% of current year taxable income and eliminates NOL carrybacks. Also, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed.
We have never paid dividends on our capital stock, and we do not anticipate paying dividends in the foreseeable future.
We have never paid dividends on any of our capital stock and currently intend to retain any future earnings to fund the growth of our business. In addition, our 2018 Note Purchase Agreement limits our ability to pay dividends on our common stock. Any determination to pay dividends in the future will be at the discretion of our board of directors and will depend on our financial condition, operating results, capital requirements, general business conditions and other factors that our board of directors may deem relevant. As a result, capital appreciation, if any, of our common stock will be the sole source of gain for the foreseeable future.

35




Anti-takeover provisions in our charter documents and under Delaware law could discourage, delay or prevent a change in control and may affect the trading price of our common stock.
Provisions in our restated certificate of incorporation and our amended and restated bylaws may have the effect of delaying or preventing a change of control or changes in our management. Our restated certificate of incorporation and amended and restated bylaws include provisions that:
•
authorize our board of directors to issue, without further action by the stockholders, up to 20,000,000 shares of undesignated preferred stock;
•
require that any action to be taken by our stockholders be effected at a duly called annual or special meeting and not by written consent;
•
specify that special meetings of our stockholders can be called only by our board of directors, our chairman of the board or our chief executive officer;
•
establish an advance notice procedure for stockholder approvals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election to our board of directors;
•
establish that our board of directors is divided into three classes, Class I, Class II and Class III, with each class serving staggered terms;
•
provide that our directors may be removed only for cause;
•
provide that vacancies on our board of directors may, except as otherwise required by law, be filled only by a majority of directors then in office, even if less than a quorum; and
•
require a super-majority of votes to amend certain of the above-mentioned provisions as well as to amend our bylaws generally.
In addition, we are subject to the provisions of Section 203 of the Delaware General Corporation Law regulating corporate takeovers. Section 203 generally prohibits us from engaging in a business combination with an interested stockholder subject to certain exceptions.
Our certificate of incorporation designates the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or other employees.
Our certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall be the sole and exclusive forum for:
•
any derivative action or proceeding brought on our behalf;
•
any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers, or other employees to us or our stockholders;
•
any action asserting a claim arising pursuant to any provision of the Delaware General Corporation Law; or
•
any action asserting a claim against us governed by the internal affairs doctrine.
Any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock shall be deemed to have notice of and consented to the provisions of our certificate of incorporation described above. This choice of forum provision may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and other employees. Alternatively, if a court were to find these provisions of our certificate of incorporation inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving such matters in other jurisdictions, which could adversely affect our business, financial condition or results of operations.
ITEM 1B.
Unresolved Staff Comments.
None.
ITEM 2.
Properties.

36




Our headquarters and main production facility is located in San Francisco, California, where we currently lease and occupy approximately 103,000 square feet of laboratory and office space. The lease for this facility expires in July 2026 and we may renew the lease for an additional ten years.
Our subsidiary Good Start leases approximately 67,000 square feet of laboratory and office space in Massachusetts, and our subsidiary CombiMatrix leases approximately 12,000 square feet of laboratory and office space in Irvine, California. We also lease additional facilities in Palo Alto and Oakland, California.
We believe that our facilities are adequate for our current needs and that additional space will be available on commercially reasonable terms if required.
ITEM 3.
Legal Proceedings.
We are not a party to any material legal proceedings on the date of this report. We may from time to time become involved in legal proceedings arising in the ordinary course of business, and the resolution of any such claims could be material.
ITEM 4.
Mine Safety Disclosure.
Not applicable.
 
Executive Officers of the Registrant
The names of our executive officers and other corporate officers, and their ages as of February 28, 2019, are as follows:
 
Name
 
Age
 
Position
Executive officers
 
 
 
 
Randal W. Scott, Ph.D.
 
61
 
Executive Chairman and Director
Sean E. George, Ph.D.
 
45
 
President, Chief Executive Officer, Director and Co-Founder
Lee Bendekgey
 
61
 
Chief Operating Officer and Secretary
Thomas R. Brida
 
48
 
General Counsel
Shelly D. Guyer
 
58
 
Chief Financial Officer
Robert L. Nussbaum, M.D.
 
69
 
Chief Medical Officer
Katherine A. Stueland
 
43
 
Chief Commercial Officer
Randal W. Scott, Ph.D. has served as our Executive Chairman since January 2017 and as a director since 2010. From August 2012 through January 2017, Dr. Scott served as our Chief Executive Officer. From 2000 through August 2012, Dr. Scott held a number of positions at Genomic Health, Inc., a publicly held genomic information company which he co-founded in 2000, most recently serving as the Chief Executive Officer of a wholly-owned subsidiary of Genomic Health, and as a director. Dr. Scott also served as Executive Chairman of the Board of Genomic Health from January 2009 until March 2012 and as Chairman of the Board and Chief Executive Officer from August 2000 until December 2008. Dr. Scott was a founder of Incyte Corporation, which at the time was a genomic information company, and served in various roles from 1991 through 2000, including Chairman of the Board, President and Chief Scientific Officer. Dr. Scott holds a B.S. in Chemistry from Emporia State University and a Ph.D. in Biochemistry from the University of Kansas.
Sean E. George, Ph.D. is one of our co-founders and has been our President and Chief Executive Officer since January 2017, a position he also held from January 2010 through August 2012. Dr. George also served as our President since August 2012 and he served as our Chief Operating Officer from August 2012 until January 2017. He has also served as a director since January 2010. Prior to co-founding Invitae, Dr. George served as Chief Operating Officer from 2007 to November 2009 at Navigenics, Inc., a personalized medicine company. Previously, he served as Senior Vice President of Marketing and Senior Vice President, Life Science Business at Affymetrix, Inc., a provider of life science and molecular diagnostic products, as well as Vice President, Labeling and Detection Business at Invitrogen Corporation, a provider of tools to the life sciences industry, during his tenure there from 2002 to 2007. Dr. George holds a B.S. in Microbiology and Molecular Genetics from the University of California Los Angeles, an M.S. in Molecular and Cellular Biology from the University of California Santa Barbara, and a Ph.D. in Molecular Genetics from the University of California Santa Cruz.

37




Lee Bendekgey has served as our Chief Operating Officer since June 2017. Mr. Bendekgey also served as our Chief Financial Officer from November 2013 to June 2017 and as our General Counsel from November 2013 through January 2017. Prior to joining our company, he was the General Counsel of DNAnexus, Inc., a cloud-based genome informatics and data management company, from September 2011 to October 2013. From March 2009 until September 2011, Mr. Bendekgey pursued personal interests. Prior to that, he was Chief Financial Officer and General Counsel for Nuvelo, Inc., a biopharmaceutical company, from July 2004 to March 2009. Mr. Bendekgey also served as General Counsel and Chief Financial Officer for Incyte Corporation from 1998 to 2004. Mr. Bendekgey holds a B.A. in French and Political Science from Kalamazoo College and a J.D. from Stanford Law School.
Thomas R. Brida has served as our General Counsel since January 2017. Mr. Brida also served as our Deputy General Counsel from January 2016 to January 2017. Prior to joining Invitae, he was Associate General Counsel at Bio-Rad Laboratories, a life science research and clinical diagnostics manufacturer, from January 2004 to January 2016. He holds a B.A. from Stanford University and a J.D. from the U.C. Berkeley School of Law.
Shelly D. Guyer has served as our Chief Financial Officer since June 2017. Ms. Guyer served as Chief Financial Officer of Veracyte, Inc., a genomic diagnostics company, from April 2013 to December 2016 and served as Veracyte’s Secretary from April 2013 to March 2014. Previously, she served as Chief Financial Officer and Executive Vice President of Finance and Administration of iRhythm Technologies, Inc., a digital healthcare company, from April 2008 to December 2012. From March 2006 to August 2007, Ms. Guyer served as Vice President of Business Development and Investor Relations of Nuvelo, Inc., a biopharmaceutical company. Prior to joining Nuvelo, Ms. Guyer worked at J.P. Morgan Securities and its predecessor companies for over 17 years, serving in a variety of roles including in healthcare investment banking. Ms. Guyer holds an A.B. in Politics from Princeton University and an M.B.A. from the Haas School of Business at the University of California Berkeley.
Robert L. Nussbaum, M.D. has served as our Chief Medical Officer since August 2015. From April 2006 to August 2015, he was chief of the Division of Genomic Medicine at UCSF Health where he also held leadership roles in the Cancer Genetics and Prevention Program beginning in January 2009 and the Program in Cardiovascular Genetics beginning in July 2007. From April 2006 to August 2015, he served as a member of the UCSF Institute for Human Genetics. Prior to joining UCSF Health, Dr. Nussbaum was chief of the Genetic Disease Research Branch of the National Human Genome Research Institute, one of the National Institutes of Health, from 1994 to 2006. He is a member of the National Academy of Medicine and a fellow at the American Academy of Arts and Sciences. Dr. Nussbaum is a board-certified internist and medical geneticist who holds a B.S. in Applied Mathematics from Harvard College and an M.D. from Harvard Medical School in the Harvard-MIT joint program in Health Sciences and Technology. He completed his residency in internal medicine at Barnes-Jewish Hospital and a fellowship in medical genetics at the Baylor College of Medicine.
Katherine A. Stueland has served as our Chief Commercial Officer since October 2016. From January 2014 to October 2016, she served as our head of communications and investor relations. Prior to joining Invitae, Ms. Stueland was a Principal at Vivo Communications, a healthcare communications company, from January 2013 to December 2013. Previously, she served as Vice President, Communications and Investor Relations at Dendreon Corporation, a biotechnology company. Ms. Stueland holds a B.S in English Literature from Miami University in Ohio.

38




PART II
ITEM 5.
Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.
Our common stock has been publicly traded on the New York Stock Exchange under the symbol “NVTA” since February 12, 2015. Prior to that time, there was no public market for our common stock.
As of February 22, 2019, there were 48 stockholders of record of our common stock. The actual number of stockholders is greater than this number of record holders and includes stockholders who are beneficial owners but whose shares are held in street name by brokers and other nominees.
Dividend policy
We have never declared or paid any cash dividends on our capital stock. We currently intend to retain any future earnings and do not expect to pay any dividends in the foreseeable future. In addition, our 2018 Note Purchase Agreement limits our ability to pay dividends on our common stock. Any determination to pay dividends in the future will be at the discretion of our board of directors and will depend on our financial condition, operating results, capital requirements, general business conditions and other factors that our board of directors may deem relevant.
Stock performance graph
The following information shall not be deemed to be soliciting material or to be filed with the SEC, or subject to Regulations 14A or 14C under the Securities Exchange Act of 1934 (“Exchange Act”) or to the liabilities of Section 18 of the Exchange Act nor shall such information be incorporated by reference into any future filing under the Securities Act or the Exchange Act, except to the extent that we specifically incorporate it by reference into such filing.
nvtastockgraph2018.jpg
_________________________________________________________________
(*)
The above graph shows the cumulative total stockholder return of an investment of $100 in cash from February 12, 2015 (the date our common stock commenced trading on the New York Stock Exchange) through December 31, 2018 for: (i) our common stock; (ii) the S&P 500 Index; and (iii) the S&P 500 Healthcare Index. All values assume reinvestment of the full amount of all dividends. The comparisons in the table are required by the SEC and are not intended to be forecasts or indicative of future stockholder returns.

39




 
2/12/2015
 
12/31/2015
 
12/31/2016
 
12/31/2017
 
12/31/2018
Invitae Corporation
$
100.00

 
$
48.15

 
$
46.57

 
$
53.26

 
$
64.87

S&P 500
$
100.00

 
$
97.87

 
$
107.20

 
$
128.02

 
$
120.03

S&P 500 Healthcare Index
$
100.00

 
$
102.41

 
$
97.94

 
$
117.53

 
$
123.05

ITEM 6.    Selected Financial Data.
The information set forth below should be read together with “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our financial statements and related notes included elsewhere in this report. The selected consolidated balance sheet data at December 31, 2018 and 2017 and the selected consolidated statements of operations data for each of the years ended December 31, 2018, 2017, and 2016 have been derived from our audited consolidated financial statements that are included elsewhere in this report. The selected consolidated balance sheet data at December 31, 2016, 2015 and 2014 and the selected consolidated statement of operations data for the years ended December 31, 2015 and 2014 have been derived from our audited consolidated financial statements not included in this report. Historical results are not necessarily indicative of results to be expected in any future period.
 
Year Ended December 31,
 
2018 (1)
 
2017 (2)
 
2016
 
2015 (3)
 
2014
 
(In thousands except per share data)
Consolidated Statements of Operations Data
 
 
 
 
 
 
 
 
 
Test revenue
$
144,560

 
$
65,169

 
$
24,840

 
$
8,378

 
$
1,604

Other revenue
3,139

 
3,052

 
208

 
—

 
—

Total revenue
147,699

 
68,221

 
25,048

 
8,378

 
1,604

Costs and operating expenses:
 

 
 

 
 

 
 

 
 

Cost of revenue (4)
80,105

 
50,142

 
27,878

 
16,523

 
5,624

Research and development (4)
63,496

 
46,469

 
44,630

 
42,806

 
22,063

Selling and marketing (4)
74,428

 
53,417

 
28,638

 
22,479

 
8,669

General and administrative (4)
52,227

 
39,472

 
24,085

 
16,047

 
12,600

Total costs and operating expenses
270,256

 
189,500

 
125,231

 
97,855

 
48,956

Loss from operations
(122,557
)
 
(121,279
)
 
(100,183
)
 
(89,477
)
 
(47,352
)
Other income (expense), net
(2,568
)
 
(303
)
 
348

 
(94
)
 
(79
)
Interest expense
(7,030
)
 
(3,654
)
 
(421
)
 
(211
)
 
(61
)
Net loss before taxes
(132,155
)
 
(125,236
)
 
(100,256
)
 
(89,782
)
 
(47,492
)
Income tax benefit
(2,800
)
 
(1,856
)
 
—

 
—

 
—

Net loss
$
(129,355
)
 
$
(123,380
)
 
$
(100,256
)
 
$
(89,782
)
 
$
(47,492
)
Net loss per share, basic and diluted (5)
$
(1.94
)
 
$
(2.65
)
 
$
(3.02
)
 
$
(3.18
)
 
$
(56.14
)
Shares used in computing net loss per share, basic and diluted
66,747

 
46,512

 
33,176

 
28,213

 
846



40




 
As of December 31,
 
2018 (1)
 
2017 (2)
 
2016
 
2015 (3)
 
2014
 
(In thousands)
Consolidated Balance Sheet Data:
 

 
 

 
 

 
 

 
 

Cash and cash equivalents
$
112,158

 
$
12,053

 
$
66,825

 
$
73,238

 
$
107,027

Working capital
129,127

 
53,294

 
87,047

 
120,433

 
102,020

Total assets
282,959

 
211,078

 
130,651

 
156,676

 
128,778

Capital lease obligations
3,312

 
5,412

 
1,575

 
3,164

 
3,535

Debt
74,477

 
39,084

 
12,102

 
7,040

 
—

Total liabilities
121,120

 
89,284

 
31,577

 
18,300

 
10,049

Convertible preferred stock
—

 
—

 
—

 
—

 
202,305

Accumulated deficit
(516,712
)
 
(398,598
)
 
(275,218
)
 
(174,962
)
 
(85,180
)
Total stockholders' equity (deficit)
161,839

 
121,794

 
99,074

 
138,376

 
(83,576
)
___________________________________________________________________ 
(1)On January 1, 2018, we adopted ASC Topic 606 using the modified retrospective transition method. Prior period amounts are presented as originally reported based upon the accounting standards in effect for those periods.

(2)In 2017, we completed the acquisition of four businesses which are included in our selected consolidated financial data as of each acquisition date.

(3)Upon the closing of our initial public offering in February 2015, 141,131,524 shares of convertible preferred stock then outstanding converted into 23,521,889 shares of common stock.

(4)Includes employee stock‑based compensation as follows:
 
Year Ended December 31,
 
2018
 
2017
 
2016
 
2015
 
2014
 
(In thousands)
Cost of revenue
$
2,960

 
$
2,093

 
$
1,353

 
$
368

 
$
102

Research and development
7,017

 
6,158

 
4,976

 
1,545

 
382

Selling and marketing
4,887

 
3,956

 
1,709

 
688

 
216

General and administrative
5,986

 
7,014

 
2,661

 
876

 
271

Total stock-based compensation
$
20,850

 
$
19,221

 
$
10,699

 
$
3,477

 
$
971


(5)See Note 2, "Summary of significant accounting policies," and Note 13, "Net loss per share," in our audited consolidated financial statements included elsewhere in this report for an explanation of the calculations of our basic and diluted net loss per share.





41




ITEM 7.
Management’s Discussion and Analysis of Financial Condition and Results of Operations.
The following discussion of our financial condition and results of operations should be read in conjunction with our financial statements and the related notes included in Item 8 of this report. Historic results are not necessarily indicative of future results.
Business overview
We offer high-quality, comprehensive, affordable genetic testing across multiple clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, metabolic conditions and rare diseases. To augment our offering and realize our mission, we have acquired multiple assets. We acquired four businesses in 2017 and in doing so expanded our suite of genome management offerings and completed our entry into prenatal and perinatal genetic testing.
In 2017, we established a leading position in family health genetic information services through the strategic acquisition of reproductive health testing capabilities. In January 2017, we acquired AltaVoice, formerly PatientCrossroads, a patient-centered data company with a global platform for collecting, curating, coordinating and delivering safeguarded data from patients and clinicians. This acquisition was complemented by the acquisition in June 2017 of Ommdom, Inc. and its product, CancerGene Connect, an end-to-end platform for collecting and managing genetic family histories to deliver personalized genetic risk information. In August 2017, we acquired Good Start Genetics, Inc., or Good Start, a molecular diagnostics company focused on preimplantation and carrier screening for inherited disorders. In November 2017, we completed our acquisition of CombiMatrix Corporation (CombiMatrix), a company specializing in prenatal diagnosis, miscarriage analysis and pediatric developmental disorders.
We have experienced rapid growth. For the years ended December 31, 2018, 2017 and 2016, our revenue was $147.7 million, $68.2 million and $25.0 million, respectively and we incurred net losses of $129.4 million, $123.4 million and $100.3 million, respectively. At December 31, 2018, our accumulated deficit was $516.7 million. We increased our number of employees to 788 at December 31, 2018 from 594 on December 31, 2017. Our sales force grew to 128 at December 31, 2018 from 103 at December 31, 2017. We expect headcount will continue to increase in 2019 as we add staff to support anticipated growth.
Sales of our tests have grown significantly. In 2018, 2017 and 2016, we generated approximately 292,000, 145,000 and 57,000 billable tests, respectively. Through December 31, 2018, approximately 29% of the billable tests we performed have been billable to institutions and patients, and the remainder have been billable to third-party payers. Many of the gene tests on our assays are tests for which private insurers reimburse. However, when we do not have reimbursement policies or contracts with private insurers, our claims for reimbursement may be denied upon submission, and we must appeal the claims. The appeals process is time consuming and expensive, and may not result in payment. Even if we are successful in achieving reimbursement, we may be paid at lower rates than if we were under contract with the third-party payer. When there is not a contracted rate for reimbursement, there is typically a greater coinsurance or copayment requirement from the patient which may result in further delay or decreased likelihood of collection.
We expect to incur operating losses for the near-term future and may need to raise additional capital in order to fund our operations. If we are unable to achieve our revenue growth objectives and successfully manage our costs, we may not be able to achieve profitability.
We believe that the keys to our future growth will be to increase billable test volumes, achieve broad reimbursement coverage for our tests from third-party payers, consistently drive down the price for genetic analysis and interpretation, steadily increase the amount of genetic content we offer, consistently improve the client experience, drive physician and patient utilization of our website for ordering and delivery of results and increase the number of strategic partners working with us to add value for our clients.
Factors affecting our performance
Number of billable tests
The growth in our genetic testing business is tied to the number of tests for which we bill third-party payers, institutions, partners or patients, which we refer to as billable tests. We typically bill for our services following delivery of the billable test report derived from testing samples and interpreting the results. We incur the expenses associated with a test in the period in which the test is processed regardless of when payment is received with respect to that test. We believe the number of billable tests in any period is the most important indicator of the growth in our business, and with time, this will translate into the number of customers we add to the platform and the revenue generated per customer.

42




Success obtaining and maintaining reimbursement
Our ability to increase the number of billable tests and our revenue will depend in part on our success achieving broad reimbursement coverage and laboratory service contracts for our tests from third-party payers and agreements with institutions and partners. Reimbursement may depend on a number of factors, including a payer’s determination that a test is appropriate, medically necessary and cost-effective, as well as whether we are in contract, where we get paid more consistently and at higher rates. Because each payer makes its own decision as to whether to establish a policy or enter into a contract to reimburse for our testing services, seeking these approvals is a time-consuming and costly process. In addition, clinicians may decide not to order our tests if the cost of the test is not covered by insurance. Our revenue growth also depends on our ability to successfully promote the adoption of our testing services and expand our base of ordering clinicians. We believe that establishing coverage and obtaining contracts from third-party payers is an important factor in gaining adoption by ordering clinicians. As of December 2018, we have entered in to contracts for laboratory services with payers covering approximately 264 million lives, comprised of Medicare, most national health plans, and Medicaid in 37 states, including California (Medi-Cal), our home state.
In cases where we have established reimbursement rates with third-party payers, we face additional challenges in complying with their procedural requirements for reimbursement. These requirements may vary from payer to payer, and it may be time-consuming and require additional resources to meet these requirements. We may also experience delays in or denials of coverage if we do not adequately comply with these requirements. In addition, we have experienced, and may continue to experience, delays in reimbursement when we transition to being an in-network provider with a payer.
We expect to continue to focus our resources on increasing adoption of, and expanding coverage and reimbursement for, our current tests, tests provided by companies we acquire and any future tests we may develop. However, if we are not able to continue to obtain and maintain adequate reimbursement from third-party payers and institutions for our testing services and expand the base of clinicians ordering our tests, we may not be able to effectively increase the number of billable tests or our revenue.
Ability to lower the costs associated with performing our tests
Reducing the costs associated with performing our genetic tests is both a near-term focus and a strategic objective of ours. Over the long term, we need to continue to reduce the cost of performing tests by improving the output efficiency of our assays and laboratory processes, modifying our platform-agnostic assays and laboratory processes to use materials and technologies that provide equal or greater quality at lower cost, improving how we manage our materials, porting some tests onto next generation sequencing platforms and negotiating favorable terms for our materials purchases. We also intend to continue to design and implement hardware and software tools that will reduce personnel-related costs for both laboratory and clinical operations/medical interpretation by increasing personnel efficiency and thus lowering labor costs per test.
Ability to expand our genetic content
As we reduce our costs, we intend to continue to expand our test menus by steadily releasing additional genetic content for the same or lower prices per test, ultimately leading to affordable whole genome services. The breadth and flexibility of our offering will be a critical factor in our ability to address new markets for genetic testing services. Both of these will be critical to our ability to continue to grow the volume of billable tests we deliver.
Investment in our business and timing of expenses
We plan to continue to invest in our genetic testing and information management business. We deploy state-of-the-art and costly technologies in our genetic testing services, and we intend to continue to scale our infrastructure, including our testing capacity and information systems. We also expect to incur software development costs as we seek to further automate our laboratory processes and our genetic interpretation and report sign-out procedures, scale our customer service capabilities and expand the functionality of our website. We plan to hire additional personnel as necessary to support anticipated growth, including software engineers, sales and marketing personnel, billing personnel, research and development personnel, medical specialists, biostatisticians and geneticists. We will also incur additional costs related to the expansion of our production facility in San Francisco to accommodate growth. In addition, we expect to incur ongoing expenses as a result of operating as a public company. The expenses we incur may vary significantly by quarter, as we focus on building out different aspects of our business.

43




How we recognize revenue
From inception through December 31, 2017, we recognized revenue principally when cash was received. Effective January 1, 2018, we implemented Financial Accounting Standards Board Accounting Standards Codification Topic 2014-09, Revenue from Contracts with Customers ("Topic 606"), using the modified retrospective method. (See Note 3, “Revenue, accounts receivable and deferred revenue” in the Notes to Consolidated Financial Statements included elsewhere in this report.) Prior period amounts are not adjusted and continue to be reported under the accounting standards in effect for those periods. Under Topic 606, we generally recognize revenue on an accrual basis, which is when a customer obtains control of the promised goods or services, typically a test report. Accrual amounts recognized are based on estimates of the consideration that we expect to receive and such estimates will be adjusted and subsequently recorded until fully settled. Changes to such estimates may increase or decrease revenue recognized in future periods. Revenue from our tests may not be equal to billed amounts due to a number of factors, including differences in reimbursement rates, the amounts of patient copayments, the existence of secondary payers and claims denials.
Financial overview
Revenue
We primarily generate revenue from the sale of our tests, which provide the analysis and associated interpretation of the sequencing of parts of the genome. Clients are billed upon delivery of test results to the physician. Our ability to increase our revenue will depend on our ability to increase our market penetration, obtain contracted reimbursement coverage from third-party payers, enter into contracts with institutions and partners, and increase the rate at which we are paid for tests performed.
Cost of revenue
Cost of revenue reflects the aggregate costs incurred in delivering test results to clinicians and includes expenses for materials and supplies, personnel-related costs, equipment and infrastructure expenses associated with testing and allocated overhead including rent, equipment depreciation and utilities. Costs associated with performing our test are recorded as the patient’s sample is processed. We expect cost of revenue to generally increase in line with the increase in the number of tests we perform. However, we expect that the cost per test will decrease over time due to the efficiencies we expect to gain as test volume increases and from automation and other cost reductions, but it could fluctuate quarter-to-quarter.
Operating expenses
Our operating expenses are classified into three categories: research and development, selling and marketing, and general and administrative. For each category, the largest component is personnel-related costs, which include salaries, employee benefit costs, bonuses, commissions, as applicable, and stock-based compensation expense.
Research and development
Research and development expenses represent costs incurred to develop our technology and future tests. These costs are principally for process development associated with our efforts to expand the number of genes we can evaluate in our tests and with our efforts to lower the cost of performing our test. In addition, we incur process development costs to further develop the software we use to operate our laboratory, analyze the data it generates, process customer orders, deliver reports and automate our business processes. These costs consist of personnel-related costs, laboratory supplies and equipment expenses, consulting costs, amortization of acquired intangibles, and allocated overhead including rent, information technology, equipment depreciation and utilities.
We expense all research and development costs in the periods in which they are incurred. We expect our research and development expenses to increase as we continue our efforts to develop additional tests, make investments to reduce testing costs and work on scaling the business.
Selling and marketing
Selling and marketing expenses consist of personnel-related costs, client service expenses, advertising and marketing expenses, educational and promotional expenses, market research and analysis, amortization of acquisition-related intangible assets and allocated overhead including rent, information technology, equipment depreciation and utilities. We expect our selling and marketing expenses to significantly increase as we expand our salesforce and increase our advertising.

44




General and administrative
General and administrative expenses include executive, finance and accounting, billing and collections, legal and human resources functions. These expenses include personnel-related costs, audit and legal expenses, consulting costs, amortization of acquisition-related intangible assets, losses incurred in relation to collaboration agreements and allocated overhead including rent, information technology, equipment depreciation and utilities. We expect our general and administrative expenses to increase at a moderate growth rate as we support continued growth of operations.
Other income (expense), net
Other income (expense), net, primarily consists of interest income, offset by losses on extinguishment of debt, adjustments to fair value of acquisition liabilities, and losses on disposal of assets.
Interest expense
Interest expense is attributable to debt financing and capital leases. See Note 9 “Commitments and contingencies” in the Notes to Consolidated Financial Statements included elsewhere in this report.
Income tax benefit
Income tax benefit primarily consists of tax impacts of our deferred income tax asset assessments resulting from our acquisitions.
Critical accounting policies and estimates
Management’s discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles, or U.S. GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenue generated and expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions and any such differences may be material. We believe that the accounting policies discussed below are critical to understanding our historical and future performance, as these policies relate to the more significant areas involving management’s judgments and estimates.
Revenue recognition
We generate test revenue primarily from delivery of test reports generated from our assays. Other revenue consists primarily of revenue from genome network subscription services which we recognize on a straight-line basis over the subscription term, and from revenue from collaboration agreements.
Effective January 1, 2018, we adopted ASC Topic 606. Under Topic 606 we generally recognize revenue on an accrual basis, that is when a customer obtains control of the promised goods or services which for us is delivery of a test report. Accrual amounts recognized under Topic 606 are based on an estimate of the consideration that we expect to receive, and such estimates will be adjusted and subsequently recorded until fully settled. The estimate of the consideration that we expect to receive requires significant judgment by management and any adjustments may be material. Prior period amounts are not adjusted and continue to be reported under the accounting standards in effect for those periods.
Business Combinations - Purchase Accounting
We apply ASC 805, Business Combinations, or ASC 805, which is the accounting guidance related to business combinations. The standard requires recognition of assets acquired, liabilities assumed, and contingent consideration at their fair value on the acquisition date with subsequent changes recognized in earnings; requires acquisition-related expenses and restructuring costs to be recognized separately from the business combination and expensed as incurred; requires in-process research and development to be capitalized at fair value as an indefinite-lived intangible asset until completion or abandonment; and requires that changes in accounting for deferred tax asset valuation allowances and acquired income tax uncertainties after the measurement period be recognized as a component of provision for taxes.

45




We account for acquisitions of entities that include inputs and processes and have the ability to create outputs as business combinations. The purchase prices of acquisitions are allocated to tangible assets, liabilities and identifiable intangible assets acquired based on their estimated fair values. The excess of purchase prices over those fair values is recorded as goodwill. Acquisition-related expenses are expensed as incurred. While we use our best estimates and assumptions as a part of the process to accurately value assets acquired and liabilities assumed at the business combination date, these estimates and assumptions are inherently uncertain and subject to refinement. Our key assumptions used have included projected revenue, cost of goods sold and operating expenses for the acquired entities, as well as discount rates. As a result, during the measurement period, which may be up to one year from the business combination date, we may record adjustments to the assets acquired and liabilities assumed, with the corresponding offset to goodwill. After the measurement period, we record adjustments to assets acquired or liabilities assumed subsequent to the measurement period in our operating results in the period in which the adjustments were determined.
Goodwill
In accordance with ASC 350, Intangibles - Goodwill and Other, or ASC 350, we do not amortize goodwill or other intangible assets with indefinite lives but rather test them for impairment. ASC 350 requires us to perform an impairment review of our goodwill balance at least annually, which we do in the fourth quarter of each year for our single consolidated reporting unit, and whenever events or changes in circumstances indicate that the carrying amount of these assets may not be recoverable.
Stock-based compensation
Stock-based compensation expense is measured at the date of grant and is based on the estimated fair value of the award. Compensation cost is recognized as expense on a straight-line basis over the vesting period for options and restricted stock unit, or RSU, awards and on an accelerated basis for performance-based restricted stock unit, or PRSU, awards. We recognize stock-based compensation expense associated with PRSU grants when we determine the achievement of performance conditions is probable. In determining the fair value of stock options and Employee Stock Purchase Plan, or ESPP, purchases, we estimate the grant date fair value, and the resulting stock-based compensation expense, using the Black-Scholes option-pricing model. We estimate the grant date fair value of RSU and PRSU awards based on the grant date share price.
We account for stock-based compensation arrangements with non-employees using a fair value approach. The fair value of these options is measured using the Black-Scholes option-pricing model reflecting the same assumptions as applied to employee options in each of the reported periods, other than the expected life, which is assumed to be the remaining contractual life of the option. The compensation expenses of these arrangements are subject to remeasurement over the vesting terms as earned.
For the years ended December 31, 2018, 2017 and 2016, we recorded stock-based compensation expense of $20.9 million, $19.2 million and $10.7 million, respectively. At December 31, 2018, unrecognized compensation expense related to unvested stock options was $4.5 million, which we expect to recognize over a weighted-average period of 1.8 years. Unrecognized compensation expense related to RSUs at December 31, 2018, net of estimated forfeitures, was $22.6 million, which we expect to recognize on a straight-line basis over a weighted-average period of 2.1 years.
The Black-Scholes option-pricing model requires the use of highly subjective assumptions, which determine the fair value of stock-based awards. These assumptions include:
Expected term—The expected term represents the period that stock-based awards are expected to be outstanding. We use the simplified method to determine the expected term, which is based on the mid-point between the vesting date and the end of the contractual term.
Expected volatility—Because we were privately held until our initial public offering in February 2015 and did not have any trading history for our common stock, we have estimated expected volatility using our own stock price volatility when available as well as the average volatility for comparable publicly traded life sciences companies, including molecular diagnostics companies, over a period equal to the expected term of stock option grants and RSUs. When selecting comparable publicly-traded biopharmaceutical companies, including molecular diagnostics companies, we have selected companies with comparable characteristics to us, including enterprise value, risk profiles, position within the industry and with historical share price information sufficient to meet the expected life of the stock-based awards. We have computed historical volatility data using daily closing prices for the selected companies’ shares during the equivalent period of the calculated expected term of the stock-based awards. We will continue to apply this process until a sufficient amount of historical information regarding the volatility of our own

46




stock price becomes available. We estimate expected volatility for ESPP purchases using our own stock price volatility over the expected six-month term of the ESPP purchase period.
Risk-free interest rate—The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of an option.
Dividend yield—We have never paid dividends on our common stock and have no plans to pay dividends on our common stock. Therefore, we used an expected dividend yield of zero.
In addition to the Black-Scholes assumptions, we estimate our forfeiture rate based on an analysis of our actual forfeitures and will continue to evaluate the adequacy of the forfeiture rate based on actual forfeiture experience, analysis of employee turnover behavior and other factors. The impact from any forfeiture rate adjustment would be recognized in full in the period of adjustment and if the actual number of future forfeitures differs from our estimates, we might be required to record adjustments to stock-based compensation in future periods.

47




Results of Operations
Comparison of the Years Ended December 31, 2018 and 2017
 
Year Ended
December 31,
 
Dollar
 
%
 
2018
 
2017
 
Change
 
Change
Revenue:
 

 
 

 
 

 
 

Test revenue
$
144,560

 
$
65,169

 
$
79,391

 
122
%
Other revenue
3,139

 
3,052

 
87

 
3
%
Total revenue
147,699

 
68,221

 
79,478

 
117
%
Operating expenses:
 
 
 
 
 

 
 

Cost of revenue
80,105

 
50,142

 
29,963

 
60
%
Research and development
63,496

 
46,469

 
17,027

 
37
%
Selling and marketing
74,428

 
53,417

 
21,011

 
39
%
General and administrative
52,227

 
39,472

 
12,755

 
32
%
Total operating expenses
270,256

 
189,500

 
80,756

 
43
%
Loss from operations
(122,557
)
 
(121,279
)
 
(1,278
)
 
1
%
Other income (expense), net
(2,568
)
 
(303
)
 
(2,265
)
 
748
%
Interest expense
(7,030
)
 
(3,654
)
 
(3,376
)
 
92
%
Net loss before taxes
(132,155
)
 
(125,236
)
 
(6,919
)
 
6
%
Income tax benefit
(2,800
)
 
(1,856
)
 
(944
)
 
51
%
Net loss
$
(129,355
)
 
$
(123,380
)
 
$
(5,975
)
 
5
%
Revenue
The increase in revenue of $79.5 million for the year ended December 31, 2018 compared to the same period in 2017 was due primarily to increased test volume from growth in our historical business as well as the full year impact from our acquisitions of AltaVoice, Good Start Genetics and CombiMatrix completed in 2017. Billable test volumes increased to approximately 292,000 during the year ended December 31, 2018 compared to 145,000 in the same period in 2017. Average revenue per test increased to $495 per test during the year ended December 31, 2018 compared to $449 in the same period in 2017. Test revenue during the year ended December 31, 2018 included $4.3 million of revenue recognized in 2018 relating to notification from Medicare of approval for payment of certain Current Procedure Terminology (CPT) codes and $2.0 million in cash received from customers which exceeded our estimated collections.
Cost of revenue
The increase in the cost of revenue of $30.0 million for the year ended December 31, 2018 compared to the same period in 2017 was primarily due to costs associated with increased test volume partially offset by the effect of cost efficiencies. For the year ended December 31, 2018, the number of samples accessioned increased to approximately 303,000 from approximately 150,000 for the same period in 2017. Cost per sample accessioned was $264 in 2018 compared to $335 in 2017. The decrease in the cost per sample accessioned was primarily attributable to increased volume which resulted in lower labor costs and to production improvements which resulted in material efficiencies, and to automation and software improvements which reduced the medical interpretation time per report.

48




Research and development
The increase in research and development expense of $17.0 million for the year ended December 31, 2018 compared to the same period in 2017 was due to growth in the business and the effect of business acquisitions in 2017 and principally consisted of the following elements: personnel costs which increased by $19.2 million due primarily to increases in headcount; lab expenses increased by $4.8 million due to increases in development activities; depreciation and amortization expense increased by $1.9 million principally due to amortization of intangible assets associated with business acquisitions; professional fees increased by $1.5 million reflecting increased utilization of outside consultants; information technology costs increased by $1.4 million due to increased spending on networking equipment and software licenses; and stock-based compensation costs increased by $0.9 million and travel-related costs increased by $0.6 million, both due to increases in headcount. These cost increases were partially offset by an increase of $14.4 million in allocations of resources from research and development to cost of revenue, to support the increase in production volumes.
Selling and marketing
The increase in selling and marketing expenses of $21.0 million for the year ended December 31, 2018 compared to the same period in 2017 was due to growth in the business and the effect of business acquisitions in 2017 and principally consisted of the following elements: increases in personnel costs of $11.5 million due to increases in headcount, marketing costs, principally for branding initiatives, increased by $3.2 million, travel expenses increased by $2.3 million due to our growing sales force, amortization expense increased by $1.5 million due to amortization of intangible assets associated with business acquisitions, stock-based compensation increased by $0.9 million due to increases in headcount, and information technology costs increased by $0.8 million.
General and administrative
The increase in general and administrative expenses of $12.8 million for the year ended December 31, 2018 compared to the same period in 2017 was primarily due to the growth of the business and the effect of business acquisitions in 2017 and principally consisted of the following elements: personnel-related costs increased by $6.5 million principally due to increases in headcount, including an internal billings and collections team hired to replace third-party billings and collection contractors; $2.9 million of losses related to our collaboration agreement with KEW, Inc. with no similar expense in 2017; right of first refusal payments relating to the collaboration agreement with KEW and a separate co-development agreement with a different privately held genetics company were $2.6 million with no similar costs in 2017 (see Note 8, "Investment in privately held company," and Note 9, "Commitments and contingencies," in the Notes to Consolidated Financial Statements included elsewhere in this report for further details on these arrangements); professional fees increased by $2.3 million principally due to the utilization of outside consultants to augment existing staff; occupancy costs increased by $2.2 million, due principally to costs related to facilities acquired through business acquisitions; information technology costs increased by $1.5 million due primarily to computer equipment and software purchases to support headcount growth; and travel expenses increased by $0.7 million due to increases in headcount.
These cost increases were offset by increased allocations of technology and facilities-related expenses to other functional areas of $2.9 million, reduction of depreciation and amortization costs of $1.5 million and a decrease in stock-based compensation of $1.0 million.
Other income (expense), net
The increase in other expense, net of $2.3 million for the year ended December 31, 2018 compared to the same period in 2017 was principally due to a loss on extinguishment of debt of $5.3 million recorded in November 2018 compared to $0.7 million in 2017. This charge in November 2018 related to our repayment in full, and prior to the scheduled maturity date, of the balance of our obligations under a Loan and Security Agreement entered into in 2017 ("2017 Loan Agreement"). This was partially offset by a gain on remeasurement of an acquisition-related liability from AltaVoice of $1.6 million in the first quarter of 2018 as well as an increase in interest income of $0.7 million.
Interest expense
The increase in interest expense of $3.4 million for the year ended December 31, 2018 compared to the same period in 2017 was due principally to the impact of borrowings under the 2017 Loan Agreement entered into in March 2017 as well as borrowings under a separate arrangement in November 2018. See Note 9, “Commitments and contingencies” in the Notes to Consolidated Financial Statements included elsewhere in this report.

49




Income tax benefit
The increase in income tax benefit of $0.9 million for the year ended December 31, 2018 compared to the same period in 2017 was due primarily to changes in our deferred income taxes during 2017 resulting from the completion of our analyses associated with the acquisitions of AltaVoice and Ommdom as compared to changes in our deferred income taxes during 2018 resulting from the completion of our analysis of historical net operating losses for CombiMatrix.
Comparison of the Years Ended December 31, 2017 and 2016
 
Year Ended
December 31,
 
Dollar
 
%
 
2017
 
2016
 
Change
 
Change
Revenue:
 

 
 

 
 

 
 

Test revenue
$
65,169

 
$
24,840

 
$
40,329

 
162
 %
Other revenue
3,052

 
208

 
2,844

 
1,367
 %
Total revenue
68,221

 
25,048

 
43,173

 
172
 %
Operating expenses:
 
 
 

 
 

 
 

Cost of revenue
50,142

 
27,878

 
22,264

 
80
 %
Research and development
46,469

 
44,630

 
1,839

 
4
 %
Selling and marketing
53,417

 
28,638

 
24,779

 
87
 %
General and administrative
39,472

 
24,085

 
15,387

 
64
 %
Total operating expenses
189,500

 
125,231

 
64,269

 
51
 %
Loss from operations
(121,279
)
 
(100,183
)
 
(21,096
)
 
21
 %
Other income (expense), net
(303
)
 
348

 
(651
)
 
(187
)%
Interest expense
(3,654
)
 
(421
)
 
(3,233
)
 
768
 %
Net loss before taxes
(125,236
)
 
(100,256
)
 
(24,980
)
 
25
 %
Income tax benefit
(1,856
)
 
—

 
(1,856
)
 
(100
)%
Net loss
$
(123,380
)
 
$
(100,256
)
 
$
(23,124
)
 
23
 %
Revenue
The increase in total revenue of $43.2 million for the year ended December 31, 2017 compared to the same period in 2016 was due primarily to increased test volume from our historical business and test and other revenues from our acquisitions of AltaVoice, Good Start Genetics and CombiMatrix. Revenue recognized on a cash basis was $46.4 million in the year ended December 31, 2017 compared to $21.3 million in the same period in 2016, and this increase was principally attributable to increased test volumes from our historical business. Revenue recognized on an accrual basis was $21.8 million in the year ended December 31, 2017 compared to $3.6 million in the same period in 2016. Of this increase, $7.2 million was attributable to increased test volumes from our historical business, $6.2 million was attributable to revenues relating to our acquisition of Good Start Genetics, $2.8 million was attributable to genome network revenues relating to our acquisition of AltaVoice and $2.0 million was attributable to revenues relating to our acquisition of CombiMatrix.
Cost of revenue
The increase in the cost of revenue of $22.3 million for the year ended December 31, 2017 compared to the same period in 2016 was primarily due to costs associated with increased test volume partially offset by the effect of cost efficiencies. For the year ended December 31, 2017, the number of samples accessioned increased to approximately 150,000 from approximately 59,000 for the same period in 2016. This increase included approximately 13,000 Good Start Genetics samples and 2,000 CombiMatrix samples. Cost per sample accessioned was $335 in 2017 compared to $473 in 2016. The decrease in the cost per sample was primarily attributable to increased volume, which led to higher labor efficiencies, to production improvements which resulted in lower materials costs, and to automation and software improvements which have reduced the medical interpretation time per report.

50




Research and development
The increase in research and development expense of $1.8 million for the year ended December 31, 2017 compared to the same period in 2016 was due primarily to personnel costs which increased by $3.3 million principally reflecting the acquisitions of Good Start Genetics and CombiMatrix. Facilities and information technology costs increased by $2.8 million reflecting costs associated with our new production facility and headquarters, which became fully operational in February 2017. Stock-based compensation costs increased by $1.2 million and depreciation expense increased by $0.7 million. These cost increases were partially offset by an increase of $6.5 million in allocations of resources from research and development to cost of revenue, reflecting increased test volumes.
Selling and marketing
The increase in selling and marketing expenses of $24.8 million for the year ended December 31, 2017 compared to the same period in 2016 was due primarily to increased personnel costs of $16.1 million including increases of $12.4 million in salaries and benefits, $2.8 million in sales commissions and $0.9 million in other payroll related costs. Facilities and information technology costs increased by $4.7 million, reflecting costs associated with our new production facility and headquarters, which became fully operational in February 2017. Stock-based compensation increased by $2.2 million and travel costs increased by $2.1 million reflecting our growing sales force. In addition, marketing costs increased by $1.0 million and professional services costs increased by $0.4 million.
These cost increases were partially offset by an increase of $1.9 million in allocations of resources from sales and marketing to cost of revenue, reflecting increased test volumes and sign-out activity. In addition, depreciation and amortization costs decreased by $0.2 million.
General and administrative
The increase in general and administrative expenses of $15.4 million for the year ended December 31, 2017 compared to the same period in 2016 was primarily due to increased personnel costs of $5.7 million. Headcount increased principally due to hiring an internal billings and collection team to replace third-party billings and collections contractors. Headcount also increased due to the acquisitions of Good Start Genetics and CombiMatrix. Stock-based compensation increased by $4.4 million due principally to acquisition-related stock compensation expense for Good Start Genetics and CombiMatrix. Depreciation and amortization expense increased by $2.3 million, due primarily to intangible asset amortization of $1.6 million in 2017 and increased depreciation expense of $0.7 million principally for leasehold improvements associated with our new production facility and headquarters. Occupancy costs increased by $2.1 million, principally reflecting costs associated with our new production facility and headquarters. Acquisition-related legal and accounting fees increased by $1.8 million, internal billing and collection costs increased by $1.5 million and legal costs increased by $1.2 million. Professional fees increased by $1.4 million, principally due to third-party billings and collection costs reflecting increased sales volumes and costs related to running dual billing systems for a portion of 2017 as we moved from a third-party billing agency to in-house billing. Information technology costs increased by $1.1 million due principally to computer equipment and software purchases to support headcount growth.
These cost increases were offset by increased allocations of technology and facilities-related expenses to other functional areas of $7.5 million, reflecting the allocation of costs associated with our new production facility and headquarters, which became fully operational in February 2017. From February 2016 to January 2017, we recorded rent expense for our new production facility and headquarters as general and administrative expense. Beginning in February 2017, we began allocating this cost across our organization.
Other income (expense), net
The decrease in other income (expense), net of $0.7 million for the year ended December 31, 2017 compared to the same period in 2016 was principally due to a loss on extinguishment of debt of $0.7 million recorded in March 2017. This charge related to our repayment in full, and prior to the scheduled maturity date, of the balance of our obligations under an agreement entered into in July 2015, or the 2015 Loan Agreement.

51




Interest expense
The increase in interest expense of $3.2 million for the year ended December 31, 2017 compared to the same period in 2016 was due principally to borrowings, under the 2017 Loan Agreement. See Note 9, “Commitments and contingencies” in the Notes to Consolidated Financial Statements included elsewhere in this report. We borrowed $40.0 million pursuant to the 2017 Loan Agreement in March 2017.
Income tax benefit
The income tax benefit of $1.9 million recorded in the year ended December 31, 2017 was due to changes in our deferred income tax asset valuation allowances resulting from our acquisitions of AltaVoice in January 2017 and Ommdom in June 2017.
Liquidity and capital resources
Liquidity and capital expenditures
We have incurred net losses since our inception. For the years ended December 31, 2018, 2017 and 2016, our net losses were $129.4 million, $123.4 million and $100.3 million, respectively, and we expect to incur additional losses in the near term. At December 31, 2018, we had an accumulated deficit of $516.7 million. While our revenue has increased over time, we may never achieve revenue sufficient to offset our expenses.
Since inception, our operations have been financed primarily by net proceeds from sales of our capital stock, fees collected from our customers as well as borrowing from debt facilities.
From inception through December 31, 2018, we have entered into various capital lease agreements for an aggregate financing amount of $15.2 million to obtain laboratory equipment. The terms of our capital leases are typically three years and are secured by the underlying equipment.
In November 2018, we entered into a Note Purchase Agreement (the "2018 Note Purchase Agreement") pursuant to which we are eligible to borrow an aggregate principal amount up to $200.0 million over its maturity term of 7 years which includes an initial borrowing of $75.0 million in November 2018 which we used to extinguish our previous debt. The outstanding principal amount under the 2018 Note Purchase Agreement bears interest at a rate of 8.75% annually. In addition, beginning on January 1, 2020 and continuing until the maturity date, we will make quarterly payments of 0.5% of our annual net revenues subject to a maximum annual amount of such payments of $1.6 million which will be recognized as interest expense. Through the fixed interest charges and the quarterly revenue payments, we are required to pay total amounts to generate an 11% internal rate of return to the lender on any outstanding principal balances due in a lump-sum upon the repayment or maturity of any outstanding principal. See more details on the 2018 Note Purchase Agreement in Note 9, “Commitments and contingencies” in the Notes to Consolidated Financial Statements included elsewhere in this report.
The 2018 Note Purchase Agreement contains quarterly covenants to achieve certain revenue levels as well as additional covenants, including limits on our ability to dispose of assets, undergo a change of control, merge with or acquire other entities, incur debt, incur liens, pay dividends or other distributions to holders of our capital stock, repurchase stock and make investments, in each case subject to certain exceptions.
In connection with the 2018 Note Purchase Agreement, in November 2018, we entered into a Securities Purchase Agreement pursuant to which the lender purchased 373,524 shares of our common stock at a price of $13.39 per share for an aggregate amount of $5.0 million. The price paid by the lender was calculated based on the 15-day average closing share price prior to the issuance. The fair value of the common stock purchased by the lender was $5.4 million.
At December 31, 2018 and 2017, we had $131.9 million and $76.0 million, respectively, of cash, cash equivalents, restricted cash and marketable securities.
Our primary uses of cash are to fund our operations as we continue to grow our business and potentially to acquire businesses and technologies. Cash used to fund operating expenses is affected by the timing of when we pay expenses, as reflected in the change in our outstanding accounts payable and accrued expenses. We estimate our capital expenditures for the full year 2019 will be approximately $10.0 million.
We have incurred substantial losses since our inception, and we expect to continue to incur losses in the near term. We believe our existing cash, cash equivalents and marketable securities as of December 31, 2018, revenue from the sale of our tests, and notes available to us pursuant to the 2018 Note Purchase Agreement, will be sufficient to meet our anticipated cash requirements for the foreseeable future.

52




We may need additional funding to finance operations prior to achieving profitability or should we make additional acquisitions. We regularly consider fundraising opportunities and will determine the timing, nature and size of future financings based upon various factors, including market conditions and our operating plans. We may in the future elect to finance operations by selling equity or debt securities or borrowing money. We also may elect to finance future acquisitions. If we issue equity securities, dilution to stockholders may result. Any equity securities issued may also provide for rights, preferences or privileges senior to those of holders of our common stock. If we raise funds by issuing debt securities, these debt securities would have rights, preferences and privileges senior to those of holders of our common stock. In addition, the terms of debt securities or borrowings could impose significant restrictions on our operations. If additional funding is required, there can be no assurance that additional funds will be available to us on acceptable terms on a timely basis, if at all. If we are unable to obtain additional funding when needed, we will need to curtail planned activities to reduce costs. Doing so will likely have an unfavorable effect on our ability to execute on our business plan, and have an adverse effect on our business, results of operations and future prospects.
The following table summarizes our cash flows (in thousands):
 
Year Ended December 31,
 
2018
 
2017
 
2016
Cash used in operating activities
$
(92,220
)
 
$
(97,981
)
 
$
(76,317
)
Cash provided by (used in) investing activities
35,773

 
(36,953
)
 
16,061

Cash provided by financing activities
157,152

 
80,871

 
53,709

Net increase (decrease) in cash, cash equivalents and restricted cash
$
100,705

 
$
(54,063
)
 
$
(6,547
)
Cash flows from operating activities
For the year ended December 31, 2018, cash used in operating activities of $92.2 million principally resulted from our net loss of $129.4 million offset by non-cash charges of $20.9 million for stock-based compensation, $13.5 million for depreciation and amortization, $5.3 million related to debt extinguishment costs, $2.9 million of impairment losses related to our collaboration agreement with KEW, $0.8 million of other non-cash adjustments and $0.4 million for remeasurements of liabilities associated with business combinations, all partially offset by a $2.9 million benefit from income taxes resulting from the completion of our analysis of historical net operating losses for CombiMatrix. The net effect on cash of changes in net operating assets was a use of cash of $3.8 million due principally to the effect of increase in accounts receivable due to timing of collections partially offset by an increase in accrued and other liabilities.
For the year ended December 31, 2017, cash used in operating activities of $98.0 million principally resulted from our net loss of $123.4 million and non-cash income tax benefits offset by non-cash charges of $19.2 million for stock-based compensation, $9.2 million for depreciation and amortization and $1.8 million for remeasurements of liabilities associated with business combinations. The net effect on cash of changes in net operating assets was a use of cash of $3.4 million due principally to the effect of increase in accounts receivable.
For the year ended December 31, 2016, cash used in operating activities of $76.3 million principally resulted from our net loss of $100.3 million offset by non-cash charges of $10.7 million for stock-based compensation, $6.6 million for depreciation and amortization and $1.0 million for asset impairment charges. The net effect on cash of changes in net operating assets was $5.3 million and was due principally to the effect of increases in accrued expenses and other assets.
Cash flows from investing activities
For the year ended December 31, 2018, cash provided by investing activities of $35.8 million resulted primarily from proceeds from maturities and sales of marketable securities exceeding purchases of marketable securities by $42.7 million and purchases of property and equipment of $6.0 million.
For the year ended December 31, 2017, cash used in investing activities of $37.0 million resulted primarily from purchases of marketable securities exceeding proceeds from maturities of marketable securities by $33.1 million and purchases of property and equipment of $6.7 million, partially offset by $2.8 million cash acquired from acquisition of businesses.
For the year ended December 31, 2016, cash provided by investing activities of $16.1 million resulted primarily from proceeds from maturities of marketable securities exceeding purchases of marketable securities by $27.7 million, partially offset by purchases of property and equipment of $11.6 million.

53




Cash flows from financing activities
For the year ended December 31, 2018, cash provided by financing activities of $157.2 million consisted of net proceeds from the public offerings of common stock of $112.4 million, net proceeds of $93.9 million from the second term loan under the Amended 2017 Loan Agreement and from the 2018 Note Purchase Agreement, and cash received from issuances of common stock totaling $17.5 million (which includes $6.5 million received from exercises of warrants issued pursuant to the acquisition of CombiMatrix (see Note 4, “Business combinations,” in the Notes to Consolidated Financial Statements included elsewhere in this report), $5.0 million received pursuant to the Securities Purchase Agreement entered into in connection with our 2018 Note Purchase Agreement, employee stock purchases of $3.2 million, and stock option exercises of $2.7 million). These cash inflows were partially offset by loan payments of $60.0 million to extinguish our 2017 Loan Agreement, payments of $4.6 million related to the extinguishment of our 2017 Loan Agreement and related amendments and capital lease payments of $2.1 million.
For the year ended December 31, 2017, cash provided by financing activities of $80.9 million consisted of net proceeds of $68.9 million from a private placement, net proceeds of $39.7 million from an initial term loan under the 2017 Loan Agreement and cash received from employee stock plan purchases, exercises of stock options and exercises of warrants totaling $5.7 million. These cash inflows were partially offset by a cash payment of $18.4 million to settle loan obligations assumed in the Good Start acquisition, other loan payments of $12.1 million and capital lease obligations payments of $3.0 million.
For the year ended December 31, 2016, cash provided by financing activities of $53.7 million resulted from net proceeds from an underwritten public offering of common stock of $47.1 million, borrowings of $7.5 million under the a loan agreement and cash received from exercises of stock options of $3.1 million, partially offset by loan payments of $2.4 million and capital lease obligations payments of $1.6 million.
Contractual obligations
The following table summarizes our contractual obligations, including interest, as of December 31, 2018 (in thousands):
Contractual obligations:
 
2019
 
2020 and 2021
 
2022 and 2023
 
2024 and beyond
 
Total
Operating leases(1)
 
$
10,774

 
$
21,969

 
$
19,965

 
$
25,715

 
$
78,423

Capital leases
 
2,087

 
1,413

 
—

 
—

 
3,500

Debt
 
6,654

 
16,576

 
16,558

 
89,998

 
129,786

Purchase commitments
 
3,040

 
4,480

 
—

 
—

 
7,520

Total
 
$
22,555

 
$
44,438

 
$
36,523

 
$
115,713

 
$
219,229

_____________________________________ 
(1) Operating lease commitments are net of total sublease payments of $0.2 million.
In September 2015, we entered into a lease agreement for our current production facility and headquarters in San Francisco, California, in which we commenced occupancy and operations in January 2017. This lease expires in July 2026. Leases for other facilities in California and Massachusetts expire at various dates from 2019 through 2026. Aggregate future minimum lease payments for these facilities are included in the table above.
Debt in the table above includes principal and interest payments pertaining our 2018 Note Purchase Agreement.
In the normal course of business, we enter into various purchase commitments primarily related to service agreements, laboratory supplies and a co-development agreement. Our total future payments under noncancelable unconditional purchase commitments having a remaining term of over one year are included above.
See Note 9, "Commitments and contingencies" in the Notes to Consolidated Financial Statements for additional details regarding our leases, debt, and purchase commitments.
Off-balance sheet arrangements
We have not entered into any off-balance sheet arrangements. See Note 8, "Investments in privately held company" in the Notes to Consolidated Financial Statements included elsewhere in this report for a discussion of our holding in a variable interest entity.
Recent accounting pronouncements

54




See “Recent accounting pronouncements” in Note 2, “Summary of significant accounting policies” in the Notes to Consolidated Financial Statements for a discussion of recently adopted accounting pronouncements and accounting pronouncements not yet adopted, and their expected effect on our financial position and results of operations.
ITEM 7A.    Quantitative and Qualitative Disclosures about Market Risk.
We are exposed to market risks in the ordinary course of our business. These risks primarily relate to interest rates. We had loan obligations under our 2018 Note Purchase Agreement of $74.5 million at December 31, 2018. This loan is subject to a fixed interest rate, plus beginning on January 1, 2020 and continuing until the maturity date, quarterly payments of 0.5% of our annual net revenues subject to a maximum annual amount of such payments of $1.6 million. We had capital lease obligations of $3.3 million as of December 31, 2018, which result from various capital lease agreements to obtain laboratory equipment. Our capital lease obligations carry fixed rates of interest. Our cash, cash equivalents, restricted cash and marketable securities totaled $131.9 million at December 31, 2018, and consisted of bank deposits, commercial paper, money market funds, U.S. treasury notes, and U.S. government agency securities. Such interest-bearing instruments carry a degree of risk; however, because our investments are primarily short-term in duration, we have not been exposed to, nor do we anticipate being exposed to, material risks due to changes in interest rates. At December 31, 2018, a hypothetical 1% (100 basis points) increase or decrease in interest rates would not have resulted in a material change in the fair value of our cash equivalents and portfolio of marketable securities. Fluctuations in the value of our cash equivalents and portfolio of marketable securities caused by a change in interest rates (gains or losses on the carrying value) are recorded in other comprehensive gain (loss) and are realized only if we sell the underlying securities prior to maturity or declines in fair value are determined to be other-than-temporary.


55




ITEM 8.
Consolidated Financial Statements and Supplementary Data.

Index to Consolidated Financial Statements


56





Report of Independent Registered Public Accounting Firm
To the Stockholders and Board of Directors of Invitae Corporation
Opinion on the Financial Statements
We have audited the accompanying consolidated balance sheets of Invitae Corporation (the Company) as of December 31, 2018 and 2017, the related consolidated statements of operations, comprehensive loss, convertible preferred stock and stockholders’ equity and cash flows for each of the three years in the period ended December 31, 2018, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2018 and 2017, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2018, in conformity with U.S. generally accepted accounting principles.
Adoption of ASU No. 2014-09
As discussed in Note 2 to the consolidated financial statements, the Company changed its method of accounting for revenue in 2018 due to the adoption of Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers (Topic 606), and the related amendments.
Basis for Opinion
These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.
Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

/s/ Ernst & Young LLP

We have served as the Company’s auditor since 2013.
Redwood City, California
February 28, 2019


57




INVITAE CORPORATION
Consolidated Balance Sheets
(in thousands, except par value data)
 
December 31, 2018
 
December 31, 2017
Assets
 

 
 

Current assets:
 

 
 

Cash and cash equivalents
$
112,158

 
$
12,053

Marketable securities
13,727

 
52,607

Accounts receivable
26,296

 
10,422

Prepaid expenses and other current assets
13,258

 
11,599

Total current assets
165,439

 
86,681

Property and equipment, net
27,886

 
30,341

Restricted cash
6,006

 
5,406

Marketable securities, non-current
—

 
5,983

Intangible assets, net
30,469

 
35,516

Goodwill
50,095

 
46,575

Other assets
3,064

 
576

Total assets
$
282,959

 
$
211,078

Liabilities and stockholders’ equity
 
 
 
Current liabilities:
 
 
 
Accounts payable
$
7,812

 
$
8,606

Accrued liabilities
26,563

 
22,742

Capital lease obligation, current portion
1,937

 
2,039

Total current liabilities
36,312

 
33,387

Capital lease obligation, net of current portion
1,375

 
3,373

Debt
74,477

 
39,084

Other long-term liabilities
8,956

 
13,440

Total liabilities
121,120

 
89,284

Commitments and contingencies (Note 9)


 


Stockholders’ equity:
 
 
 
Preferred stock, $0.0001 par value: 20,000 shares authorized; 3,459 shares issued and outstanding as of December 31, 2018 and 2017
—

 
—

Common stock, $0.0001 par value: 400,000 shares authorized; 75,481 and 53,597 shares issued and outstanding as of December 31, 2018 and 2017, respectively
8

 
5

Accumulated other comprehensive loss
(5
)
 
(171
)
Additional paid-in capital
678,548

 
520,558

Accumulated deficit
(516,712
)
 
(398,598
)
Total stockholders’ equity
161,839

 
121,794

Total liabilities and stockholders’ equity
$
282,959

 
$
211,078

The accompanying notes are an integral part of these financial statements.


58




INVITAE CORPORATION
Consolidated Statements of Operations
(in thousands, except per share data)
 
Year Ended December 31,
 
2018
 
2017
 
2016
Revenue:
 
 
 
 
 
Test revenue
$
144,560

 
$
65,169

 
$
24,840

Other revenue
3,139

 
3,052

 
208

Total revenue
147,699

 
68,221

 
25,048

Costs and operating expenses:
 
 
 
 
 
Cost of revenue
80,105

 
50,142

 
27,878

Research and development
63,496

 
46,469

 
44,630

Selling and marketing
74,428

 
53,417

 
28,638

General and administrative
52,227

 
39,472

 
24,085

Total costs and operating expenses
270,256

 
189,500

 
125,231

Loss from operations
(122,557
)
 
(121,279
)
 
(100,183
)
Other income (expense), net
(2,568
)
 
(303
)
 
348

Interest expense
(7,030
)
 
(3,654
)
 
(421
)
Net loss before taxes
(132,155
)
 
(125,236
)
 
(100,256
)
Income tax benefit
(2,800
)
 
(1,856
)
 
—

Net loss
$
(129,355
)
 
$
(123,380
)
 
$
(100,256
)
Net loss per share, basic and diluted
$
(1.94
)
 
$
(2.65
)
 
$
(3.02
)
Shares used in computing net loss per share, basic and diluted
66,747

 
46,512

 
33,176

The accompanying notes are an integral part of these financial statements.


59




INVITAE CORPORATION
Consolidated Statements of Comprehensive Loss
(in thousands)
 
Year Ended December 31,
 
2018
 
2017
 
2016
 
 
Net loss
$
(129,355
)
 
$
(123,380
)
 
$
(100,256
)
Other comprehensive income (loss):
 
 
 
 
 
Unrealized income (loss) on available-for-sale marketable securities, net of tax
166

 
(171
)
 
15

Comprehensive loss
$
(129,189
)
 
$
(123,551
)
 
$
(100,241
)
The accompanying notes are an integral part of these financial statements.


60




INVITAE CORPORATION
Consolidated Statements of Convertible Preferred Stock and Stockholders’ Equity
(in thousands)
 
 
 
 
 
 
 
 
 
 
 
Accumulated
 
 
 
 
 
Convertible
 
 
 
 
 
Additional
 
Other
 
 
 
Total
 
Preferred Stock
 
Common Stock
 
Paid-In
 
Comprehensive
 
Accumulated
 
Stockholders'
 
Shares
 
Amount
 
Shares
 
Amount
 
Capital
 
Income (Loss)
 
Deficit
 
Equity
Balance as of December 31, 2015
—

 
$
—

 
31,935

 
$
4

 
$
313,349

 
$
(15
)
 
$
(174,962
)
 
$
138,376

Common stock issued on exercise of stock options
—

 
—

 
244

 
—

 
744

 
—

 
—

 
744

Common stock issued pursuant to vesting of restricted stock units
—

 
—

 
157

 
(1
)
 
—

 
—

 
—

 
(1
)
Common stock issued pursuant to employee stock purchase plan
—

 
—

 
370

 
—

 
2,391

 
—

 
—

 
2,391

Common stock issued in connection with underwritten public offering, net of offering costs of $3,498
—

 
—

 
8,433

 
1

 
47,101

 
—

 
—

 
47,102

Vesting of common stock related to early exercise of options
—

 
—

 
5

 
—

 
4

 
—

 
—

 
4

Stock-based compensation expense
—

 
—

 
—

 
—

 
10,699

 
—

 
—

 
10,699

Unrealized income (loss) on available-for-sale marketable securities, net of tax
—

 
—

 
—

 
—

 
—

 
15

 
—

 
15

Net loss
—

 
—

 
—

 
—

 
—

 
—

 
(100,256
)
 
(100,256
)
Balance as of December 31, 2016
—

 
—

 
41,144

 
4

 
374,288

 
—

 
(275,218
)
 
99,074

Common and convertible preferred stock issued in private placement, net of offering costs of $4,599
3,459

 
—

 
5,188

 
1

 
68,896

 
—

 
—

 
68,897

Common stock issued on exercise of stock options, net
—

 
—

 
387

 
—

 
1,706

 
—

 
—

 
1,706

Common stock issued pursuant to vesting of restricted stock units, net
—

 
—

 
925

 
—

 
—

 
—

 
—

 
—

Common stock issued pursuant to acquisition-related transaction bonus
—

 
—

 
4

 
—

 
—

 
—

 
—

 
—

Common stock issued pursuant to exercises of warrants
—

 
—

 
232

 
—

 
1,381

 
—

 
—

 
1,381

Common stock issued pursuant to employee stock purchase plan
—

 
—

 
379

 
—

 
2,635

 
—

 
—

 
2,635

Common stock issued pursuant to business combinations
—

 
—

 
5,176

 
—

 
50,808

 
—

 
—

 
50,808

Common stock issued to settle assumed liabilities
—

 
—

 
162

 
—

 
1,272

 
—

 
—

 
1,272

Warrants issued pursuant to the 2017 Loan Agreement
—

 
—

 
—

 
—

 
740

 
—

 
—

 
740

Stock-based compensation expense
—

 
—

 
—

 
—

 
18,832

 
—

 
—

 
18,832

Unrealized income (loss) on available-for-sale marketable securities, net of tax
—

 
—

 
—

 
—

 
—

 
(171
)
 
—

 
(171
)
Net loss
—

 
—

 
—

 
—

 
—

 
—

 
(123,380
)
 
(123,380
)
Balance as of December 31, 2017
3,459

 
—

 
53,597

 
5

 
520,558

 
(171
)
 
(398,598
)
 
121,794

Cumulative effect of accounting change
—

 
—

 
—

 
—

 
—

 
—

 
11,241

 
11,241

Common stock issued in connection with public offering, net of offering costs of $6,183
—

 
—

 
17,103

 
3

 
112,438

 
—

 
—

 
112,441

Common stock issued on exercise of stock options, net
—

 
—

 
351

 
—

 
2,741

 
—

 
—

 
2,741

Common stock issued pursuant to vesting of restricted stock units, net
—

 
—

 
1,369

 
—

 
—

 
—

 
—

 
—

Common stock issued pursuant to exercises of warrants
—

 
—

 
1,099

 
—

 
6,539

 
—

 
—

 
6,539

Common stock issued pursuant to employee stock purchase plan
—

 
—

 
566

 
—

 
3,231

 
—

 
—

 
3,231

Common stock issued pursuant to business combinations
—

 
—

 
1,022

 
—

 
6,455

 
—

 
—

 
6,455

Warrants issued pursuant to 2017 Loan Agreement
—

 
—

 
—

 
—

 
383

 
—

 
—

 
383

Common stock issued pursuant to Securities Purchase Agreement (see Note 9)
—

 
—

 
374

 
—

 
5,353

 
—

 
—

 
5,353

Stock-based compensation expense
—

 
—

 
—

 
—

 
20,850

 
—

 
—

 
20,850

Unrealized income (loss) on available-for-sale marketable securities, net of tax
—

 
—

 
—

 
—

 
—

 
166

 
—

 
166

Net loss
—

 
—

 
—

 
—

 
—

 
—

 
(129,355
)
 
(129,355
)
Balance as of December 31, 2018
3,459

 
$
—

 
75,481

 
$
8

 
$
678,548

 
$
(5
)
 
$
(516,712
)
 
$
161,839

The accompanying notes are an integral part of these financial statements.

61




INVITAE CORPORATION
Consolidated Statements of Cash Flows
(in thousands)
 
Year Ended December 31,
 
2018
 
2017
 
2016
Cash flows from operating activities:
 
 
 
 
 

Net loss
$
(129,355
)
 
$
(123,380
)
 
$
(100,256
)
Adjustments to reconcile net loss to net cash used in operating activities:
 
 
 
 
 
Depreciation and amortization
13,540

 
9,181

 
6,553

Stock-based compensation
20,850

 
19,221

 
10,699

Impairment losses
2,925

 
—

 
—

Remeasurements of liabilities associated with business combinations
362

 
1,810

 
—

Benefit from income taxes
(2,862
)
 
(1,856
)
 
—

Debt extinguishment costs
5,266

 
—

 
—

Other
806

 
404

 
1,341

Changes in operating assets and liabilities, net of effects of business combination:
 
 
 
 
 
Accounts receivable
(5,291
)
 
(1,963
)
 
(843
)
Prepaid expenses and other current assets
(1,445
)
 
(641
)
 
(1,149
)
Other assets
(163
)
 
(185
)
 
1,465

Accounts payable
(417
)
 
(535
)
 
(111
)
Accrued expenses and other liabilities
3,564

 
(37
)
 
5,984

Net cash used in operating activities
(92,220
)
 
(97,981
)
 
(76,317
)
 
 
 
 
 
 
Cash flows from investing activities:
 
 
 
 
 
Purchases of marketable securities
(9,680
)
 
(101,867
)
 
(90,236
)
Proceeds from sales of marketable securities
19,965

 
—

 
—

Proceeds from maturities of marketable securities
32,458

 
68,768

 
117,922

Acquisition of businesses, acquired cash
—

 
2,821

 
—

Purchases of property and equipment
(5,970
)
 
(6,675
)
 
(11,625
)
Other
(1,000
)
 
—

 
—

Net cash provided by (used in) investing activities
35,773

 
(36,953
)
 
16,061

 
 
 
 
 
 
Cash flows from financing activities:
 
 
 
 
 
Proceeds from public offering of common stock, net of issuance costs
112,441

 
—

 
47,102

Proceeds from issuance of common stock
17,511

 
74,619

 
3,134

Net proceeds from issuance of debt
93,909

 
39,661

 
7,500

Payments for debt extinguishment costs
(4,609
)
 
—

 
—

Loan payments
(60,000
)
 
(30,457
)
 
(2,438
)
Capital lease principal payments
(2,100
)
 
(2,952
)
 
(1,589
)
Net cash provided by financing activities
157,152

 
80,871

 
53,709

 
 
 
 
 
 
Net increase (decrease) in cash, cash equivalents and restricted cash
100,705

 
(54,063
)
 
(6,547
)
Cash, cash equivalents and restricted cash at beginning of period
17,459

 
71,522

 
78,069

Cash, cash equivalents and restricted cash at end of period
$
118,164

 
$
17,459

 
$
71,522

Supplemental cash flow information:
 
 
 
 
 
Interest paid
$
6,231

 
$
2,852

 
$
421

Supplemental cash flow information of non-cash investing and financing activities:
 
 
 
 
Equipment acquired through capital leases
$
—

 
$
6,789

 
$
—

Purchases of property and equipment in accounts payable and accrued liabilities
$
510

 
$
200

 
$
1,644

Amounts related to co-development agreement in other assets and accrued liabilities
$
2,000

 
$
—

 
$
—

Warrants issued pursuant to 2017 Loan Agreement
$
383

 
$
740

 
$
—

Common stock issued for acquisition of businesses
$
6,445

 
$
50,808

 
$
—

Consideration payable for acquisition of businesses
$
—

 
$
13,276

 
$
—

Common stock issued to settle assumed liabilities
$
—

 
$
1,272

 
$
—

The accompanying notes are an integral part of these financial statements.

62




INVITAE CORPORATION
Notes to Consolidated Financial Statements

1. Organization and description of business
Invitae Corporation (the “Company”) was incorporated in the State of Delaware on January 13, 2010, as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. The Company utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process DNA-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients. The Company’s headquarters and main production facility is located in San Francisco, California. The Company currently has more than 20,000 genes in production and provides a variety of diagnostic tests that can be used in multiple indications. The Company’s tests include genes associated with hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders, metabolic disorders and other hereditary conditions. In addition, and as a result of the acquisitions of Good Start Genetics ("Good Start") in August 2017 and CombiMatrix Corporation ("CombiMatrix") in November 2017, the Company’s services also include screening and testing in reproductive health, including preimplantation and carrier screening for inherited disorders, prenatal diagnosis, miscarriage analysis and pediatric developmental disorders. The Company operates in one segment.
2. Summary of significant accounting policies
Principles of consolidation
The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.
Use of estimates
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. The Company bases these estimates on historical and anticipated results, trends and various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to future events. Actual results could differ materially from those estimates and assumptions.
Significant estimates and assumptions made by management include the determination of:
•
revenue recognition (See Note 3, “Revenue, accounts receivable and deferred revenue” for further information);
•
the fair value of assets acquired and liabilities assumed for business combinations;
•
the fair value of goodwill and intangible assets;
•
the recoverability of long-lived assets;
•
stock-based compensation expense and the fair value of awards issued; and
•
income tax uncertainties.
Concentrations of credit risk and other risks and uncertainties
Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents, marketable securities and accounts receivable. The Company’s cash and cash equivalents are held by financial institutions in the United States. Such deposits may exceed federally insured limits.
Significant customers are those that represent 10% or more of the Company’s total revenue for each year presented on the statements of operations. For the significant customer, revenue as a percentage of total revenue were as follows:
 
December 31,
Customers
2018
 
2017
 
2016
Medicare
22
%
 
13
%
 
11
%


63




Medicare represented 21% and 13% of accounts receivable as of December 31, 2018 and 2017.
Cash, cash equivalents, and restricted cash
The Company considers all highly liquid investments with original maturities of three months or less from the date of purchase to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market funds and U.S. government agency securities.
Restricted cash consists of money market funds that serve as collateral for security deposits for the Company’s facility lease and sublease agreements and collateral for a credit card agreement at one of the Company’s financial institutions.
The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the statements of cash flows (in thousands):
 
December 31, 2018
 
December 31, 2017
Cash and cash equivalents
$
112,158

 
$
12,053

Restricted cash
6,006

 
5,406

Total cash, cash equivalents and restricted cash
$
118,164

 
$
17,459


Marketable securities
All marketable securities have been classified as “available-for-sale” and are carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities. Management determines the appropriate classification of its marketable debt securities at the time of purchase and reevaluates such designation at each balance sheet date. Short-term marketable securities have maturities less than 365 days at the balance sheet date. Unrealized gains and losses are excluded from earnings and are reported as a component of other comprehensive loss. Realized gains and losses and declines in fair value judged to be other than temporary, if any, on available-for-sale securities are included in interest and other income (expense), net. The cost of securities sold is based on the specific-identification method. Interest on marketable securities is included in interest and other income (expense), net.
Accounts receivable
The Company receives payment for its tests from partners, patients, institutional customers and third-party payers. See Note 3, "Revenue, accounts receivable and deferred revenue" for further information.
Inventory
The Company maintains test reagents and other consumables primarily used in sample collection kits which are valued at the lower of cost or market value. Cost is determined using actual costs on a first-in, first-out basis. The Company's inventory was $8.3 million and $5.4 million as of December 31, 2018 and 2017, respectively, and was recorded in prepaid expenses and other current assets in the Company's consolidated balance sheets.
Business combinations
The tangible and identifiable intangible assets acquired and liabilities assumed in a business combination are recorded based on their estimated fair values as of the business combination date, including identifiable intangible assets which either arise from a contractual or legal right or are separable from goodwill. The Company bases the estimated fair value of identifiable intangible assets acquired in a business combination on independent valuations that use information and assumptions provided by management, which consider management’s estimates of inputs and assumptions that a market participant would use. Any excess purchase price over the estimated fair value assigned to the net tangible and identifiable intangible assets acquired and liabilities assumed is recorded to goodwill. The use of alternative valuation assumptions, including estimated revenue projections, growth rates, cash flows, discount rates, estimated useful lives and probabilities surrounding the achievement of contingent milestones could result in different purchase price allocations and amortization expense in current and future periods.

64




In circumstances where an acquisition involves a contingent consideration arrangement that meets the definition of a liability under Financial Accounting Standards Board (“FASB") Accounting Standards Codification (“ASC”) Topic 480, Distinguishing Liabilities from Equity, the Company recognizes a liability equal to the fair value of the contingent payments the Company expects to make as of the acquisition date. The Company remeasures this liability each reporting period and records changes in the fair value as a component of operating expenses.
Transaction costs associated with acquisitions are expensed as incurred in general and administrative expenses. Results of operations and cash flows of acquired companies are included in the Company’s operating results from the date of acquisition.
Intangible assets
Amortizable intangible assets include trade names, non-compete agreements, developed technology and customer relationships acquired as part of business combinations. Customer relationships are amortized on an accelerated basis, utilizing free cash flows, over periods ranging from five to 11 years. All other intangible assets subject to amortization are amortized using the straight-line method over their estimated useful lives ranging from two to 15 years. All intangible assets subject to amortization are reviewed for impairment in accordance with ASC 360, Property, Plant and Equipment.
Goodwill
In accordance with ASC 350, Intangibles-Goodwill and Other (“ASC 350”), the Company’s goodwill is not amortized but is tested for impairment on an annual basis or whenever events or changes in circumstances indicate that the carrying amount of these assets may not be recoverable. Under ASC 350, the Company performs annual impairment reviews of its goodwill balance during the fourth fiscal quarter. In testing for impairment, the Company compares the fair value of its reporting unit to its carrying value including the goodwill of that unit. If the carrying value, including goodwill, exceeds the reporting unit’s fair value, the Company will recognize an impairment loss for the amount by which the carrying amount exceeds the reporting unit’s fair value. The loss recognized cannot exceed the total amount of goodwill allocated to that reporting unit. The Company did not incur any goodwill impairment losses in any of the periods presented.
Leases
The Company rents its facilities under operating lease agreements and recognizes related rent expense on a straight-line basis over the term of the applicable lease agreement. Some of the lease agreements contain rent holidays, scheduled rent increases, lease incentives, and renewal options. Rent holidays and scheduled rent increases are included in the determination of rent expense to be recorded over the lease term. Lease incentives are recognized as a reduction of rent expense on a straight-line basis over the term of the lease. Renewals are not assumed in the determination of the lease term unless they are deemed to be reasonably assured at the inception of the lease. The Company recognizes rent expense beginning on the date it obtains the legal right to use and control the leased space.
Property and equipment, net
Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is computed using the straight‑line method over the estimated useful lives of the assets, generally between three and seven years. Leasehold improvements are amortized using the straight‑line method over the shorter of the estimated useful life of the asset or the term of the lease. Amortization expense of assets acquired through capital leases is included in depreciation and amortization expense in the consolidated statements of operations. Maintenance and repairs are charged to expense as incurred, and improvements and betterments are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in the statements of operations in the period realized.

65




The estimated useful lives of property and equipment are as follows:
Furniture and fixtures
7 years
Automobiles
7 years
Laboratory equipment
5 years
Computer equipment
3 years
Software
3 years
Leasehold improvements
Shorter of lease term or estimated useful life

Long‑lived assets
The Company reviews long‑lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. An impairment loss is recognized when the total estimated future undiscounted cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. Impairment, if any, is assessed using discounted cash flows or other appropriate measures of fair value. Other than impairment losses of $1.0 million in 2016 relating to leasehold improvements and to the shutdown of the Company’s Chilean operations, there were no long-lived asset impairment losses recorded for any period presented. All impairment losses were charged to general and administrative expense.
Variable interest entity
The Company had a variable interest in a variable interest entity (“VIE”) through an investment in convertible notes issued by the VIE. The convertible notes do not provide the Company with voting rights in the VIE or with power to direct the activities of the VIE which most significantly affect its economic performance. The Company is not the VIE’s primary beneficiary and it does not consolidate the VIE.
Fair value of financial instruments
The Company’s financial instruments consist principally of cash and cash equivalents, marketable securities, accounts payable, accrued liabilities, capital leases and debt. The carrying amounts of certain of these financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued and other current liabilities approximate their current fair value due to the relatively short-term nature of these accounts. Based on borrowing rates available to the Company, the carrying value of capital leases and debt approximate their fair values.
Revenue recognition
The Company recognizes revenue when control of the promised goods or services is transferred to the customer in an amount that reflects the consideration it expects to be entitled to in exchange for those goods or services. All revenues are generated from contracts with customers.
Test revenue is generated primarily from the sale of tests that provide analysis and associated interpretation of the sequencing of parts of the genome.
Other revenue consists primarily of revenue from genome network subscription services which is recognized on a straight-line basis over the subscription term, and revenue from collaboration agreements.
Cost of revenue
Cost of revenue reflects the aggregate costs incurred in delivering the genetic testing results to clinicians and includes expenses for personnel-related costs including stock-based compensation, materials and supplies, equipment and infrastructure expenses associated with testing and allocated overhead including rent, equipment depreciation and utilities.

66




Income taxes
The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and the tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized.
Stock-based compensation
The Company measures its stock-based payment awards made to employees and directors based on the estimated fair values of the awards and recognizes the compensation expense over the requisite service period. The Company uses the Black-Scholes option-pricing model to estimate the fair value of its stock option awards and employee stock purchase plan (“ESPP”) purchases. The fair value of restricted stock unit (“RSU”) awards with time-based vesting terms is based on the grant date share price. The Company grants performance-based restricted stock unit (“PRSU”) awards to certain employees which vest upon the achievement of certain performance conditions, subject to the employees’ continued service relationship with the Company. The probability of vesting is assessed at each reporting period and compensation cost is adjusted based on this probability assessment. The Company recognizes such compensation expense on an accelerated vesting method.
Stock-based compensation expense for awards without a performance condition is recognized using the straight-line method. Stock-based compensation expense is based on the value of the portion of stock-based payment awards that is ultimately expected to vest. As such, the Company’s stock-based compensation is reduced for estimated forfeitures at the date of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.
The Company accounts for compensation expense related to stock options granted to non-employees based on fair values estimated using the Black-Scholes option-pricing model. Stock options granted to non-employees are re-measured at each reporting date until the award is vested.
The Company accounts for stock issued as compensation in connection with business combinations based on the fair value of the Company’s common stock on the date of issuance.
Advertising
Advertising expenses are expensed as incurred. The Company incurred advertising expenses of $0.6 million, $0.6 million and $0.5 million during the years ended December 31, 2018, 2017 and 2016, respectively.
Comprehensive loss
Comprehensive loss is composed of two components: net loss and other comprehensive income (loss). Other comprehensive income (loss) refers to gains and losses that under U.S. GAAP are recorded as an element of stockholders’ equity, but are excluded from net loss. The Company’s other comprehensive income (loss) consists of unrealized gains or losses on investments in available-for-sale securities.
Net loss per share
Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common share equivalents outstanding for the period determined using the treasury stock method. Potentially dilutive securities, consisting of preferred stock, options to purchase common stock, common stock warrants, RSUs and PRSUs, are considered to be common stock equivalents and were excluded from the calculation of diluted net loss per share because their effect would be antidilutive for all periods presented.
Recent accounting pronouncements
The Company evaluates all Accounting Standards Updates (“ASUs”) issued by the FASB for consideration of their applicability. ASUs not included in the disclosures in this report were assessed and determined to be either not applicable or are not expected to have a material impact on the Company’s consolidated financial statements.

67




Recently issued accounting pronouncements not yet adopted
In November 2018, the FASB issued ASU 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606, which clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under Accounting Standards Codification ("ASC") 606 when the counterparty is a customer. In addition, Topic 808 precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue from contracts with customers if the counterparty is not a customer for that transaction. This guidance will be effective for the Company beginning January 1, 2020. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements.
In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326), which replaces the incurred loss impairment methodology in current U.S. GAAP with a methodology that reflects expected credit losses. The amended guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2019, with early adoption permitted for the fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements.
In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) and in July 2018 issued ASU 2018-10, Codification Improvements to Topic 842, Leases and ASU 2018-11, Leases (Topic 842): Targeted Improvements (the foregoing ASUs collectively referred to as “Topic 842”). Under the new guidance, lessees are required to recognize a lease liability and a right-of-use asset for all leases (with the exception of short-term leases) at the commencement date and also requires expanded disclosures about leasing arrangements. Topic 842 is effective for annual and interim periods beginning on or after December 15, 2018 and early adoption is permitted. Entities may initially apply the new leases standard at the adoption date and recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption.
The Company is evaluating the final effect that Topic 842 and related standards will have on its consolidated financial statements, related disclosures and ongoing financial reporting, but expects implementation of Topic 842 to result in the recognition of material right of use assets and corresponding lease liabilities in its consolidated balance sheets as of the implementation of Topic 842 on January 1, 2019, principally relating to facilities leases. The Company does not have any material embedded leases and the implementation of Topic 842 is primarily focused on the treatment of the Company's previously identified leases. As of December 31, 2018, the Company's total future undiscounted capital lease payments were $3.5 million and future undiscounted non-cancelable minimum operating lease payments, net of subleases were $78.4 million
Recently adopted accounting pronouncements
In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606), designed to enable users of financial statements to better understand the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. On January 1, 2018, the Company adopted the provisions of Topic 606 using the modified retrospective method. From adoption to date, the Company has recognized all its revenue from contracts with customers within the scope of Topic 606. In connection with the adoption, the Company recognized the cumulative effect of initially applying this standard as an adjustment to retained earnings on the date of adoption. Comparative information prior to the date of adoption has not been restated and continues to be reported under the accounting standards in effect for those periods.
In connection with the adoption of Topic 606, the Company amended its revenue recognition policy to provide for the recognition of certain variable consideration related to diagnostic tests that was previously deferred pending cash collection. Under Topic 606, the Company records variable consideration based on an estimate of the consideration to which it will be entitled.
The Company recognizes revenue when control of the promised goods or services is transferred to the customer in an amount that reflects the consideration it expects to be entitled to in exchange for those goods or services. All revenues are generated from contracts with customers.

68




Diagnostic tests
The majority of the Company’s revenue is generated from genetic testing services that provide analysis and associated interpretation of the sequencing of parts of the genome. Test orders are placed under signed requisitions, and the Company often enters into contracts with institutions (e.g., hospitals and clinics) and insurance companies that include pricing provisions under which such tests are billed. Billing terms are generally net thirty days.
While the transaction price of diagnostic tests is originally established either via contract or pursuant to the Company’s standard list price, the Company often provides concessions for tests billed to insurance carriers, and therefore the transaction price for patient insurance-billed tests is considered to be variable and revenue is recognized based on an estimate of the consideration to which the Company will be entitled at an amount for which it is probable that a reversal of cumulative consideration will not occur. Making these estimates requires significant judgments based upon such factors as length of payer relationship, historical payment patterns, changes in contract provisions and insurance reimbursement policies. These judgments are reviewed quarterly and revenue recognized is updated, as necessary, until the Company’s obligations are fully settled.
In connection with some diagnostic test orders, the Company offers limited re-requisition rights (“Re-Requisition Rights”) that are considered distinct at contract inception, and therefore certain diagnostic test orders contain two performance obligations, the performance of the original test and the Re-Requisition Rights. When Re-Requisition Rights are granted, the Company allocates the transaction price to each performance obligation based on the relative estimated standalone selling prices. In order to comply with loss contract rules, the allocations are adjusted, if necessary, to ensure the amount deferred for Re-Requisition Rights is no less than the estimated cost of fulfilling the Company’s related obligations.
The Company looks to transfer of control in assessing timing of recognition of revenue in connection with each performance obligation. In general, revenue in connection with diagnostic tests is recognized upon delivery of the underlying clinical report or when the report is made available on the Company’s web portal. Outstanding performance obligations pertaining to orders received but for which the underlying report has not been issued are generally satisfied within a thirty-day period. Revenue in connection with Re-Requisition Rights is recognized as the rights are exercised or expire unexercised, which is generally within ninety days of initial deferral.
Other contracts
The Company also enters into collaboration and genome network contracts. Collaboration agreements provide customers with diagnostic testing and related data aggregation reporting services that are provided over the contract term. Collaboration revenue is recognized as the testing and reporting services are delivered to the customer. Genome network offerings consist of subscription services related to a proprietary software platform designed to connect patients, clinicians, advocacy organizations, researchers and therapeutic developers to accelerate the understanding, diagnosis and treatment of hereditary disease. Such services are recognized on a straight-line basis over the subscription periods.
Amounts due under collaboration and genome network agreements are typically billable on net thirty-day terms.
3. Revenue, accounts receivable and deferred revenue
As described in Note 2, "Summary of significant accounting policies," the Company adopted Topic 606 effective January 1, 2018. In connection with the adoption the Company utilized the following practical expedients and exemptions:
•
Certain information about remaining performance obligations is not disclosed because the underlying contracts have an original expected duration of one year or less.
•
Costs to obtain or fulfill a contract are expensed when incurred because the amortization period would have been one year or less.
•
No adjustments to promised consideration were made for financing as the Company expects, at contract inception, that the period between the transfer of a promised good or service and when the customer pays for that good or service will be one year or less.
The adoption of Topic 606 resulted in a cumulative-effect adjustment to accounts receivable and accumulated deficit of $11.2 million as of January 1, 2018 primarily related to the recognition of uncollected

69




diagnostic test variable consideration as of the date of adoption. Test revenue without adoption of Topic 606 for the year ended December 31, 2018 includes cash collections related to accounts receivable recorded as of January 1, 2018 in connection with the Topic 606 cumulative-effect adjustment.
The effect of the adoption of Topic 606 on financial statement line items in the Company’s consolidated statement of operations for the year ended December 31, 2018, and the Company’s consolidated balance sheet as of December 31, 2018 was as follows (in thousands, except per share amounts):

 
 
Year Ended December 31, 2018
 
 
 
 
Without
 
Effect of
 
 
 
 
Adoption of
 
Adoption
 
 
As Reported
 
Topic 606
 
Higher/(Lower)
Test revenue
 
$
144,560

 
$
144,222

 
$
338

Net loss
 
$
(129,355
)
 
$
(129,693
)
 
$
338

Net loss per share, basic and diluted
 
$
(1.94
)
 
$
(1.94
)
 
$
—


 
 
As of December 31, 2018
 
 
 
 
Without
 
Effect of
 
 
 
 
Adoption of
 
Adoption
 
 
As Reported
 
Topic 606
 
Higher/(Lower)
Accounts receivable
 
$
26,296

 
$
14,150

 
$
12,146

Accumulated deficit
 
$
(516,712
)
 
$
(528,291
)
 
$
11,579

Stockholders' equity
 
$
161,839

 
$
150,260

 
$
11,579


Disaggregation of revenue
Test revenue is generated from sales of diagnostic tests to three groups of customers: institutions, such as hospitals, clinics and partners; patients who pay directly; and patients’ insurance carriers. Amounts billed and collected, and the timing of collections, vary based on whether the payer is an institution, an insurance carrier or a patient. Other revenue consists principally of revenue recognized under collaboration and genome network agreements.
The following table includes the Company’s revenues as disaggregated by payer category (in thousands):
 
 
Year Ended December 31,
 
 
2018
 
2017 (1)
Test revenue:
 
 
 
 
Institutions
 
$
34,618

 
$
17,238

Patient - direct
 
13,589

 
5,638

Patient - insurance
 
96,353

 
42,293

 Total test revenue
 
144,560

 
65,169

Other revenue
 
3,139

 
3,052

Total revenue
 
$
147,699

 
$
68,221

___________________________________________________________________ 
(1)
As noted above, prior period amounts are presented as originally reported based upon the accounting standards in effect for those periods.
Included in revenue in the Company’s consolidated statements of operations for the year ended December 31, 2018 was $0.3 million that was included in deferred revenue at January 1, 2018.
The Company recognizes revenue related to billings based on estimates of the amount that will ultimately be realized. The estimate of the transaction price of test revenue is based on many factors such as length of payer relationship, historical payment patterns, changes in contract provisions and insurance reimbursement policies. Cash collections for certain tests delivered may differ from rates originally estimated. As a result of new information, the Company updated its estimate of the amounts to be recognized for previously delivered tests which resulted in

70




an additional $4.5 million of test revenue for the year ended December 31, 2018. These changes in estimates decreased the Company’s loss from operations by $4.5 million and decreased basic and diluted net loss per share by approximately $0.07 for the year ended December 31, 2018.
Accounts receivable
The majority of the Company’s accounts receivable represents amounts billed to institutions (e.g., hospitals, clinics) and estimated amounts to be collected from third-party insurance payers for test revenue recognized. Also included is amounts due under the terms of collaboration and genome network agreements for diagnostic testing and data aggregation reporting services provided and proprietary platform access rights transferred.
Deferred revenues
The Company records deferred revenues when cash payments are received or due in advance of its performance related to one or more performance obligations. The amounts deferred to date primarily consist of consideration received pertaining to the estimated exercise of certain Re-Requisition Rights. The Company defers revenue related to Re-Requisition Rights in amounts no less than the estimated cost of fulfilling its related obligations. The Company recognizes revenue related to Re-Requisition Rights as the rights are exercised or expire unexercised, which is generally within 90 days of initial deferral.
4. Business combinations
AltaVoice
On January 6, 2017, the Company acquired AltaVoice (formerly PatientCrossroads, Inc.), a privately-owned patient-centered data company with a global platform for collecting, curating, coordinating and delivering safeguarded data from patients and clinicians. The acquisition, complemented by several other strategic partnerships, expanded the Company's genome network, designed to connect patients, clinicians, advocacy organizations, researchers and therapeutic developers to accelerate the understanding, diagnosis, and treatment of hereditary disease. Pursuant to the terms of the Stock Purchase Agreement, the Company acquired all of the outstanding shares of AltaVoice for total purchase consideration of $12.4 million, payable in the Company’s common stock, as follows:
(a)
payment of $5.5 million through the issuance of 641,126 shares of the Company’s common stock;
(b)
payment of $5.0 million in the Company’s common stock, payable on March 31, 2018, with the common shares deliverable equal to $5.0 million divided by the trailing average share price of the Company’s common stock for the 30 days preceding March 31, 2018. This payment was made in April 2018 through the issuance of 716,332 shares of the Company's common stock;
(c)
payment of $5.0 million in the Company’s common stock, which was contingently payable on March 31, 2018 if a milestone based on a certain threshold of revenue was achieved during 2017, with the shares deliverable equal to $5.0 million divided by the trailing average share price of the Company’s common stock for the 30 days preceding March 31, 2018. As the foregoing milestone was not achieved, there was a new contingent milestone based on achieving a revenue target during 2017 and 2018. Since this new contingent milestone was achieved, on March 31, 2019, a payment of $5.0 million in the Company’s common stock will be payable. The actual payout is dependent upon meeting the 2017 and 2018 revenue targets (capped at $14.0 million) times 75% less $5.5 million. This formula in effect caps the possible payout amount at $5.0 million in the Company’s common shares. The number of shares to be issued will be equal to the payout amount divided by the trailing average share price of the Company’s common stock for the 30 days preceding March 31, 2019.
The first payment of $5.5 million was classified as equity. The second payment was discounted to $4.7 million as of the acquisition date, recorded as a liability, and was accreted to fair value at each reporting date until the extinguishment of the liability in April 2018. The third payment, representing contingent consideration, was determined to have a fair value of $2.2 million as of the acquisition date and was recorded as a liability. In accordance with ASC Topic 805, Business Combinations, the contingent consideration of $2.2 million was remeasured to fair value at each reporting date until the contingency was resolved, with changes in fair value recognized in earnings.
For the second payment, the acquisition-date fair value was $4.7 million, and the Company recorded accretion gains (losses) of $1.6 million and $(0.2) million in other income (expense), net, for the years ended December 31, 2018 and 2017, respectively. The accretion gains in 2018 resulted from an adjustment to the value of

71




the second payment as of March 31, 2018, and principally reflected the difference between the value of the common shares deliverable, based upon the closing price of the Company’s stock on March 29, 2018, and the value per share used to calculate the number of common shares deliverable. The accretion losses in 2017 resulted from adjustments to the discounted value of the second payment, reflecting the passage of time.
For the third payment, the acquisition-date fair value was $2.2 million, and the Company recorded remeasurement losses of $1.2 million and $1.6 million in general and administrative expense for the years ended December 31, 2018 and 2017, respectively. The remeasurement losses in 2018 reflect updated estimations of fair value of the third payment, based upon achieving a revenue target during 2017 and 2018, as the milestone based on a certain threshold of revenue to be achieved during 2017 was not met. The principal inputs affecting those estimations have been updates to the Company’s revenue forecasts and the passage of time.
Assets acquired and liabilities assumed are recorded based on valuations derived from estimated fair value assessments and assumptions used by the Company. While the Company believes that its estimates and assumptions underlying the valuations are reasonable, different estimates and assumptions could result in different valuations assigned to the individual assets acquired and liabilities assumed, and the resulting amount of goodwill. The following table summarizes the fair values of assets acquired and liabilities assumed at the date of acquisition (in thousands):
Cash
$
54

Accounts receivable
274

Prepaid expense and other assets
52

Non-compete agreement
286

Developed technology
570

Customer relationships
3,389

Total identifiable assets acquired
4,625

Accounts payable
(28
)
Deferred revenue
(202
)
Accrued expenses
(21
)
Deferred tax liability
(1,422
)
Total liabilities assumed
(1,673
)
Net identifiable assets acquired
2,952

Goodwill
9,432

Net assets acquired
$
12,384


Acquisition-related intangibles included in the above table are finite-lived. Customer relationships are being amortized on an accelerated basis, utilizing free cash flows, over a period of ten years. All other acquisition-related intangibles are being amortized on a straight-line basis over their estimated lives, which approximates the pattern in which the economic benefits of the intangible assets are expected to be realized, as follows (in thousands):
 
Gross
Purchased
Intangible
Assets
 
Estimated
Useful
Life
(in Years)
Non-compete agreement
$
286

 
5
Developed technology
570

 
6
Customer relationships
3,389

 
10
 
$
4,245

 
 

Goodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired. The acquisition of AltaVoice resulted in $9.4 million of goodwill which the Company believes consists principally of expected synergies to be realized by combining capabilities, technology and data to accelerate the use of genetic information for the diagnosis and treatment of hereditary diseases. In accordance with ASC 350, goodwill will not be amortized but will be tested for impairment at least annually. Goodwill created as a result of the acquisition is not deductible for tax purposes. The Company has finalized its assessment of fair value of the assets and liabilities assumed at the acquisition date.

72




Ommdom
On June 11, 2017, the Company acquired Ommdom, Inc. (“Ommdom”), a privately held company that develops, commercializes and sells hereditary risk assessment and management software, including CancerGene Connect, a cancer genetic counseling platform. The acquisition expanded Invitae’s suite of genome management offerings designed to help patients and clinicians use genetic information as part of mainstream medical care. CancerGene Connect is a platform for collecting and managing genetic family histories.
Pursuant to the terms of a Stock Exchange Agreement, the Company acquired all of the outstanding shares of Ommdom for consideration of $6.1 million, payable entirely in the Company’s common stock. There was no cash consideration nor any contingent payments associated with the acquisition, other than a hold-back amount of $0.6 million. Per the terms of the agreement, the Company was obligated to issue shares of its common stock as follows:
(a)
payment of $5.5 million through the issuance of 600,108 shares of the Company’s common stock on the acquisition date; and
(b)
payment of $0.6 million through the issuance of 66,582 shares of the Company’s common stock, representing a hold-back amount, and payable on the twelve-month anniversary of the acquisition date.
The first payment of $5.5 million was classified as equity. The second payment of $0.6 million was recorded as a stock payable liability on the acquisition date and was reclassified to equity upon the issuance of 66,582 shares of the Company’s common stock in June 2018.
Assets acquired and liabilities assumed are recorded based on valuations derived from estimated fair value assessments and assumptions used by the Company. While the Company believes that its estimates and assumptions underlying the valuations are reasonable, different estimates and assumptions could result in different valuations assigned to the individual assets acquired and liabilities assumed, and the resulting amount of goodwill. The following table summarizes the fair values of assets acquired and liabilities assumed at the date of acquisition (in thousands):
Cash
$
53

Accounts receivable
10

Prepaid expense and other assets
4

Trade name
13

Developed technology
2,335

Customer relationships
147

Total identifiable assets acquired
2,562

Accounts payable
(16
)
Accrued expenses
(17
)
Deferred tax liability
(434
)
Total liabilities assumed
(467
)
Net identifiable assets acquired
2,095

Goodwill
4,045

Net assets acquired
$
6,140


Finite-lived intangibles included in the above table are being amortized on a straight-line basis over their estimated lives, which approximates the pattern in which the economic benefits of the intangible assets are expected to be realized, as follows (in thousands):
 
Gross
Purchased
Intangible
Assets
 
Estimated
Useful
Life
(in Years)
Trade name
$
13

 
5
Developed technology
2,335

 
5
Customer relationships
147

 
5
 
$
2,495

 
 


73




Goodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired. The acquisition of Ommdom resulted in the recognition of $4.0 million of goodwill which the Company believes consists principally of expected synergies to be realized by expanding the Company’s suite of genome management offerings. In accordance with ASC 350, goodwill will not be amortized but rather will be tested for impairment at least annually. Goodwill created as a result of the acquisition is not deductible for tax purposes. The Company has finalized its assessment of fair value of the assets and liabilities assumed at the acquisition date.
Good Start Genetics
On August 4, 2017, the Company acquired 100% of the fully diluted equity of Good Start, a privately held molecular diagnostics company focused on preimplantation and carrier screening for inherited disorders. The acquisition of Good Start was intended to further Invitae’s plan to create a comprehensive genetic information platform providing high-quality, affordable genetic information coupled with world-class clinical expertise to inform healthcare decisions throughout every stage of an individual’s life. The purchase consideration for the Good Start acquisition consisted of the assumption of the net liabilities of Good Start of $24.4 million at the acquisition date.
Immediately subsequent to the acquisition of Good Start, the Company paid $18.4 million in cash to settle outstanding notes payable, accrued interest and related costs. In addition, and immediately subsequent to the acquisition, the Company settled outstanding convertible promissory notes payable through:
(a)
payment of $11.9 million through the issuance of 1,148,283 shares of the Company’s common stock; and
(b)
payment of $3.6 million through the issuance of 343,986 shares of the Company’s common stock, representing a hold-back amount payable on the one-year anniversary of the acquisition date. In September 2018, the Company issued 212,260 shares in partial payment of the hold-back amount payable. The remainder of the hold-back amount payable, approximately $1.3 million as of December 31, 2018, will be settled upon resolution of outstanding claims from Good Start customers, of which $0.6 million was settled in January 2019.
Also in connection with the acquisition of Good Start and immediately subsequent to the acquisition, the Company paid bonuses to certain members of Good Start’s management team through:
(a)
payment of $0.9 million through the issuance of 83,025 shares of the Company’s common stock; and
(b)
payment of $0.4 million through the issuance of 37,406 shares of the Company’s common stock, representing a hold-back amount payable on the one-year anniversary of the acquisition date. In September 2018, the Company issued 27,784 shares in partial payment of the hold-back amount payable to settle bonuses to Good Start's management team. The remainder of the hold-back amount payable, approximately $0.2 million as of December 31, 2018, will be settled upon resolution of outstanding claims from Good Start customers, of which $0.1 million was settled in January 2019.
These bonus payments were recorded as general and administrative expense.
Assets acquired and liabilities assumed are recorded based on valuations derived from estimated fair value assessments and assumptions used by the Company. While the Company believes that its estimates and assumptions underlying the valuations are reasonable, different estimates and assumptions could result in different valuations assigned to the individual assets acquired and liabilities assumed, and the resulting amount of goodwill.
At acquisition date, the Company also recorded $4.8 million as a provisional amount for a deferred tax liability because certain information and analysis related to Good Start’s historical net operating losses that could have affected the Company’s initial valuation was still being obtained or reviewed at that time. This provisional amount for the deferred tax liability was subsequently reversed during the fourth quarter of 2017 based on the results of further analysis of Good Start’s historical net operating losses.

74




The following table summarizes the fair values of assets acquired and liabilities assumed at the date of acquisition (in thousands):
Cash and restricted cash
$
1,381

Accounts receivable
2,246

Prepaid expense and other assets
1,579

Property and equipment
1,320

Trade name
460

Developed technology
5,896

Customer relationships
7,830

Total identifiable assets acquired
20,712

Accounts payable
(5,418
)
Accrued expenses
(6,802
)
Notes payable
(17,904
)
Convertible promissory notes payable
(15,430
)
Other liabilities
(222
)
Total liabilities assumed
(45,776
)
Net identifiable assets acquired
(25,064
)
Goodwill
25,064

Net assets acquired
$
—


During the year ended December 31, 2018, the Company recorded adjustments to its accounting for the amount recorded as accounts receivable at acquisition. Accordingly, the fair value of accounts receivable was decreased by $0.7 million during the year ended December 31, 2018, with corresponding increases to goodwill.

Customer relationships are being amortized on an accelerated basis, utilizing free cash flows, over a period of eight years. All other finite-lived intangibles included in the above table are being amortized on a straight-line basis over their estimated lives, which approximates the pattern in which the economic benefits of the intangible assets are expected to be realized, as follows (in thousands):
 
Gross
Purchased
Intangible
Assets
 
Estimated
Useful
Life
(in Years)
Trade name
$
460

 
3
Developed technology
5,896

 
5
Customer relationships
7,830

 
8
 
$
14,186

 
 

Goodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired. The acquisition of Good Start resulted in the recognition of $25.1 million of goodwill which the Company believes consists principally of expected synergies to be realized by expanding the Company’s suite of genome management offerings. In accordance with ASC 350, goodwill will not be amortized but rather will be tested for impairment at least annually. Goodwill created as a result of the acquisition is not deductible for tax purposes. The Company has finalized its assessment of fair value of the assets and liabilities assumed at the acquisition date.
CombiMatrix
On November 14, 2017, the Company completed its acquisition of CombiMatrix in accordance with the terms of the Agreement and Plan of Merger and Reorganization, dated as of July 31, 2017 (the “Merger Agreement”), by and among the Company, Coronado Merger Sub, Inc., a wholly owned subsidiary of the Company (“Merger Sub”), and CombiMatrix, pursuant to which Merger Sub merged with and into CombiMatrix, with CombiMatrix surviving as a wholly owned subsidiary of the Company (the “Merger”).
At the closing of the Merger, the Company issued shares of its common stock to (i) CombiMatrix’s common stockholders, at an exchange ratio of 0.8692 of a share of the Company’s common stock (the “Merger Exchange

75




Ratio”) for each share of CombiMatrix common stock outstanding immediately prior to the Merger, (ii) CombiMatrix’s Series F preferred stockholders, at the Merger Exchange Ratio for each share of CombiMatrix common stock underlying Series F preferred stock outstanding immediately prior to the Merger, (iii) holders of outstanding and unexercised in-the-money CombiMatrix stock options, which were fully accelerated to the extent of any applicable vesting period and converted into the right to receive the number of shares of the Company’s common stock equal to the Merger Exchange Ratio multiplied by the number of shares of CombiMatrix common stock issuable upon exercise of such option, minus the number of shares of the Company’s common stock determined by dividing the aggregate exercise price for such option by $9.491, and (iv) holders of outstanding and unsettled CombiMatrix restricted stock units, which were fully accelerated to the extent of any applicable vesting period and converted into the right to receive a number of shares of the Company’s common stock determined by multiplying the number of shares of CombiMatrix common stock that were subject to such restricted stock unit by the Merger Exchange Ratio.
In addition, at the closing of the Merger, (a) all outstanding and unexercised out-of-the money CombiMatrix stock options were cancelled and terminated without the right to receive any consideration, (b) all CombiMatrix Series D Warrants and Series F Warrants outstanding and unexercised immediately prior to the closing of the Merger were assumed by the Company and converted into warrants to purchase the number of shares of the Company’s common stock determined by multiplying the number of shares of CombiMatrix common stock subject to such warrants by the Merger Exchange Ratio, and with the exercise price adjusted by dividing the per share exercise price of the CombiMatrix common stock subject to such warrants by the Merger Exchange Ratio, and (c) certain entitlements under CombiMatrix’s executive compensation transaction bonus plan (the “Transaction Bonus Plan”) were paid in shares of the Company’s common stock or RSUs to be settled in shares of the Company’s common stock. All outstanding and unexercised CombiMatrix Series A, Series B, Series C, Series E, and PIPE warrants were repurchased by CombiMatrix prior to closing pursuant to that certain CombiMatrix Common Stock Purchase Warrants Repurchase Agreement dated July 11, 2016.
Pursuant to the Merger Agreement, the Company issued an aggregate of 2,703,389 shares of its common stock as follows:
(a)
payment of $20.5 million through the issuance of 2,611,703 shares of the Company’s common stock to holders of CombiMatrix common stock outstanding;
(b)
payment of $0.7 million through the issuance of 85,219 shares of the Company’s RSUs to holders of outstanding and unsettled CombiMatrix restricted stock units;
(c)
payment of $0.1 million through the issuance of 3,323 shares of the Company’s common stock to holders of outstanding and unexercised in-the-money CombiMatrix stock options; and
(d)
payment of $0.1 million through the issuance of 3,144 shares of the Company’s common stock to holders of CombiMatrix Series F preferred stock.
In addition, and pursuant to the Merger Agreement, the Company issued warrants to purchase an aggregate of 2,077,273 shares of its common stock as follows:
(a)
payment of $7.4 million through the issuance of warrants to purchase a total of 1,739,689 shares of the Company’s common stock in exchange for all outstanding CombiMatrix Series F warrants; and
(b)
payment of $1,000 through the issuance of warrants to purchase a total of 337,584 shares of the Company’s common stock in exchange for all outstanding CombiMatrix Series D warrants.
In connection with the acquisition of CombiMatrix, the Company paid bonuses to certain members of CombiMatrix’s management team through:
(a)
payment of $1.7 million through the issuance of common stock and RSUs totaling 214,976 shares of the Company’s common stock to settle payments pursuant to CombiMatrix’s executive compensation transaction bonus plan (the “Transaction Bonus Plan”), recorded as post-combination compensation expense and included in general and administrative expense; and
(b)
payment of $0.2 million through the issuance of 22,966 shares of the Company’s common stock to settle payments pursuant to the Transaction Bonus Plan, recorded as an assumed liability at the acquisition date.

76




Assets acquired and liabilities assumed are recorded based on valuations derived from estimated fair value assessments and assumptions used by the Company. While the Company believes that its estimates and assumptions underlying the valuations are reasonable, different estimates and assumptions could result in different valuations assigned to the individual assets acquired and liabilities assumed, and the resulting amount of goodwill. The following table summarizes the fair values of assets acquired and liabilities assumed at the date of acquisition (in thousands):
Cash and restricted cash
$
1,333

Accounts receivable
4,118

Prepaid expense and other assets
1,299

Property and equipment
437

Other assets - non current
30

Favorable leases
247

Trade name
103

Patent licensing agreement
496

Developed technology
3,162

Customer relationships
12,397

Total identifiable assets acquired
23,622

 
 
Accounts payable
(276
)
Accrued expenses
(3,925
)
Deferred tax liability
(2,862
)
Other liabilities
(180
)
Total liabilities assumed
(7,243
)
 
 
Net identifiable assets acquired
16,379

Goodwill
11,554

Net assets acquired
$
27,933


During the year ended December 31, 2018, upon the completion of the Company's analysis of CombiMatrix's historical net operating losses, the Company recorded a deferred tax liability of $2.9 million with corresponding increases to goodwill. The $2.9 million net deferred tax liability represents the excess of the financial reporting over tax basis in acquired intangibles over the amount of CombiMatrix’s historical net operating loss carryovers that were determined to be available to offset future income due to change in ownership operating loss carryover limitation rules under Internal Revenue Code section 382.
Customer relationships are being amortized on an accelerated basis, utilizing free cash flows, over a period of eleven years. All other finite-lived intangibles included in the above table are being amortized on a straight-line basis over their estimated lives, which approximates the pattern in which the economic benefits of the intangible assets are expected to be realized, as follows (in thousands):
 
Gross
Purchased
Intangible
Assets
 
Estimated
Useful
Life
(in Years)
Favorable leases
$
247

 
2
Trade name
103

 
1
Patent licensing agreement
496

 
15
Developed technology
3,162

 
4
Customer relationships
12,397

 
11
 
$
16,405

 
 


77




Goodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired. The acquisition of CombiMatrix resulted in the recognition of $11.6 million of goodwill which the Company believes consists principally of expected synergies to be realized by expanding the Company’s suite of genome management offerings. In accordance with ASC 350, goodwill will not be amortized but rather will be tested for impairment at least annually. Goodwill created as a result of the acquisition is not deductible for tax purposes. The Company has finalized its assessment of fair value of the assets and liabilities assumed at the acquisition date.
5. Goodwill and intangible assets
Goodwill
Details of the Company’s goodwill for the year ended December 31, 2018 are as follows (in thousands):
 
AltaVoice
 
Ommdom
 
Good Start
 
CombiMatrix
 
Total
Balance as of December 31, 2017
$
9,432

 
$
4,045

 
$
24,406

 
$
8,692

 
$
46,575

Goodwill adjustment
—

 
—

 
658

 
2,862

 
3,520

Balance as of December 31, 2018
$
9,432

 
$
4,045

 
$
25,064

 
$
11,554

 
$
50,095


The goodwill adjustments were principally due to changes in the fair value of accounts receivable for Good Start as well as the recognition of a $2.9 million deferred tax liability for CombiMatrix resulting from the completion of the Company’s analysis of historical net operating losses.
Intangible assets
The following table presents details of the Company’s finite-lived intangible assets as of December 31, 2018 (in thousands):
 
Cost
 
Accumulated
Amortization
 
Net
 
Weighted Average
Useful Life
(in Years)
 
Weighted Average
Estimated Remaining
Useful Life
(in Years)
Customer relationships
$
23,763

 
$
(2,783
)
 
$
20,980

 
10.0
 
8.6
Developed technology
11,963

 
(3,482
)
 
8,481

 
4.8
 
3.4
Non-compete agreement
286

 
(114
)
 
172

 
5.0
 
3.0
Trade name
576

 
(329
)
 
247

 
2.7
 
1.4
Patent licensing agreement
496

 
(37
)
 
459

 
15.0
 
13.9
Favorable leases
247

 
(117
)
 
130

 
2.2
 
1.1
 
$
37,331

 
$
(6,862
)
 
$
30,469

 
8.2
 
6.8

Acquisition-related intangibles included in the above table are finite-lived. Customer relationships are being amortized on an accelerated basis, in proportion to estimated cash flows, over periods ranging from five to eleven years. All other acquisition-related intangibles are being amortized on a straight-line basis over their estimated lives, which approximates the pattern in which the economic benefits of the intangible assets are realized. Amortization expense was $5.0 million, $1.8 million, and nil for the years ended December 31, 2018, 2017, and 2016, respectively. Intangible assets are carried at cost less accumulated amortization. Amortization expense is recorded to research and development, sales and marketing and general and administrative expense.

78




The following table summarizes the Company’s estimated future amortization expense of intangible assets with finite lives as of December 31, 2018 (in thousands):
 
Amount
2019
$
5,250

2020
5,525

2021
5,829

2022
4,124

2023
3,111

Thereafter
6,630

Total estimated future amortization expense
$
30,469


6. Balance sheet components
Property and equipment, net
Property and equipment consisted of the following (in thousands):
 
December 31, 2018
 
December 31, 2017
Leasehold improvements
$
13,034

 
$
12,623

Laboratory equipment
22,149

 
17,705

Equipment under capital lease
7,129

 
11,446

Computer equipment
4,723

 
4,023

Software
2,594

 
2,520

Furniture and fixtures
784

 
569

Automobiles
20

 
20

Construction-in-progress
1,962

 
965

Total property and equipment, gross
52,395

 
49,871

Accumulated depreciation and amortization
(24,509
)
 
(19,530
)
Total property and equipment, net
$
27,886

 
$
30,341


Depreciation expense was $8.5 million, $7.2 million and $6.6 million for the years ended December 31, 2018, 2017 and 2016, respectively.
Accrued liabilities
Accrued liabilities consisted of the following (in thousands):
 
December 31, 2018
 
December 31, 2017
Accrued compensation and related expenses
$
7,917

 
$
7,406

Deferred revenue
761

 
307

Liabilities associated with business combinations
6,460

 
9,497

Liability associated with co-development agreement
2,000

 
—

Other
9,425

 
5,532

Total accrued liabilities
$
26,563

 
$
22,742



79




Other long-term liabilities
Other long-term liabilities consisted of the following (in thousands):
 
December 31, 2018
 
December 31, 2017
Lease incentive obligation, non-current
$
3,280

 
$
3,831

Deferred rent, non-current
5,495

 
5,153

Liabilities associated with business combinations
—

 
3,779

Other non-current liabilities
181

 
677

Total other long-term liabilities
$
8,956

 
$
13,440


7. Fair value measurements
Financial assets and liabilities are recorded at fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The authoritative guidance establishes a three-level valuation hierarchy that prioritizes the inputs to valuation techniques used to measure fair value based upon whether such inputs are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions made by the reporting entity.
The three-level hierarchy for the inputs to valuation techniques is summarized as follows:
Level 1—Observable inputs such as quoted prices (unadjusted) for identical instruments in active markets.
Level 2—Observable inputs such as quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, or model-derived valuations whose significant inputs are observable.
Level 3—Unobservable inputs that reflect the reporting entity’s own assumptions.

80




The following tables set forth the fair value of the Company’s consolidated financial instruments that were measured at fair value on a recurring basis (in thousands):
 
 
December 31, 2018
 
 
Amortized Cost
 
Gross Unrealized Gains
 
Gross Unrealized Losses
 
Estimated Fair Value
 
Level 1
 
Level 2
 
Level 3
Financial assets:
 
 
 
 
 
 
 
 
 
 

 
 

 
 

Money market funds
 
$
93,934

 
$
—

 
$
—

 
$
93,934

 
$
93,934

 
$
—

 
$
—

Certificates of deposit
 
300

 
—

 
—

 
300

 
—

 
300

 
—

Commercial paper
 
10,908

 
—

 
(1
)
 
10,907

 
—

 
10,907

 
—

U.S. treasury notes
 
9,990

 
—

 
—

 
9,990

 
9,990

 
—

 
—

U.S. government agency securities
 
6,001

 
—

 
(4
)
 
5,997

 
—

 
5,997

 
—

Total financial assets
 
$
121,133

 
$
—

 
$
(5
)
 
$
121,128

 
$
103,924

 
$
17,204

 
$
—

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Financial liabilities:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Contingent consideration
 
 
 
 
 
 
 
$
4,998

 
$
—

 
$
—

 
$
4,998

Total financial liabilities
 
 
 
 
 
 
 
$
4,998

 
$
—

 
$
—

 
$
4,998

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
December 31, 2018
Reported as:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash equivalents
 
 
 
 
 
 
 
 
 
 
 
$
101,395
 
Restricted cash
 
 
 
 
 
 
 
 
 
 
 
6,006
 
Marketable securities
 
 
 
 
 
 
 
 
 
 
 
13,727
 
Total cash equivalents, restricted cash, and marketable securities
 
 
 
$
121,128
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Accrued liabilities
 
 
 
 
 
 
 
 
 
 
 
$
4,998
 

81




 
 
December 31, 2017
 
 
Amortized
Cost
 
Gross
Unrealized
Gains
 
Gross
Unrealized
Losses
 
Estimated
Fair Value
 
Level 1
 
Level 2
 
Level 3
Financial assets:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Money market funds
 
$
5,998

 
$
—

 
$
—

 
$
5,998

 
$
5,998

 
$
—

 
$
—

Certificates of deposit
 
300

 
—

 
—

 
300

 
300

 
—

 
—

U.S. treasury notes
 
12,010

 
—

 
(19
)
 
11,991

 
11,991

 
—

 
—

U.S. government agency securities
 
46,451

 
—

 
(152
)
 
46,299

 
—

 
46,299

 
—

Total financial assets
 
$
64,759

 
$
—

 
$
(171
)
 
$
64,588

 
$
18,289

 
$
46,299

 
$
—

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Financial liabilities:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Contingent consideration
 
 
 
 
 
 
 
$
3,779

 
$
—

 
$
—

 
$
3,779

Total financial liabilities
 
 
 
 
 
 
 
$
3,779

 
$
—

 
$
—

 
$
3,779

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
December 31, 2017
Reported as:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash equivalents
 
 
 
 
 
 
 
 
 
 
 
$
592
 
Restricted cash
 
 
 
 
 
 
 
 
 
 
 
5,406
 
Marketable securities
 
 
 
 
 
 
 
 
 
 
 
58,590
 
Total cash equivalents, restricted cash, and marketable securities
 
 
 
$
64,588
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Accrued liabilities
 
 
 
 
 
 
 
 
 
 
 
$
3,779
 

There were no transfers between Level 1, Level 2 and Level 3 during the periods presented. The total fair value of investments with unrealized losses at December 31, 2018 was $13.4 million. None of the available-for-sale securities held as of December 31, 2018 has been in a material continuous unrealized loss position for more than one year. At December 31, 2018, unrealized losses on available-for-sale investments are not attributed to credit risk and are considered to be temporary. The Company believes it is more likely than not that investments in an unrealized loss position will be held until maturity or the recovery of the cost basis of the investment. To date, the Company has not identified any other-than-temporary declines in market value and thus has not recorded any impairment charges on its financial assets other than on the convertible notes which are described in Note 8, “Investment in privately held company.”
At December 31, 2018, the remaining contractual maturities of available-for-sale securities ranged from less than one to 4 months. For the years ended December 31, 2018, 2017 and 2016, there were no realized gains or losses on available-for-sale securities.
The Company’s certificates of deposit, commercial paper, and debt securities of U.S. government agency entities are classified as Level 2 as they are valued based upon quoted market prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant inputs are observable in the market or can be corroborated by observable market data for substantially the full term of the assets. Where applicable, these models project future cash flows and discount the future amounts to a present value using market-based observable inputs obtained from various third party data providers, including but not limited to benchmark yields, interest rate curves, reported trades, broker/dealer quotes and reference data.

82




The following table presents the Company’s Level 3 financial instruments that are measured at fair value on a recurring basis (in thousands):
 
Level 3
 
Contingent Consideration Liability
Balance as of December 31, 2017
$
3,779

Change in estimate of fair value
1,219

Balance as of December 31, 2018
$
4,998


As of December 31, 2018, the Company had a contingent obligation of up to $5.0 million payable in the Company’s common stock to the former owners of AltaVoice in conjunction with the Company’s acquisition of AltaVoice in January 2017. The contingency was dependent upon future revenues attributable to AltaVoice. If the revenue attributable to AltaVoice for the combined period of 2017 and 2018 was at least $10 million, the Company would make a payment of up to $5.0 million in the Company’s common stock in March 2019. The Company estimated the fair value of the contingent consideration at $2.2 million at the acquisition date in January 2017, based on a Monte Carlo simulation, as well as estimates of the 30-day trailing price of its stock at certain dates, its volatility assumptions and its revenue forecasts, all of which were significant inputs in the Level 3 measurement not supported by market activity. The value of the liability was subsequently remeasured to fair value at each reporting date. Changes in estimated fair value are recorded as general and administrative expense until the contingency is paid or expires. The change in the fair value of the contingent consideration between the acquisition date and December 31, 2018 was an increase of $2.8 million.
The fair value of the Company’s outstanding debt is estimated using the net present value of future debt payments, discounted at an interest rate that is consistent with market interest rates, which is a Level 2 input. The carrying amount of the Company’s outstanding debt at December 31, 2018 approximated its fair value and as of December 31, 2017, the Company's debt carrying amount and fair value were as follows (in thousands):
 
December 31, 2017
 
Carrying Amount
 
Fair Value
Debt
$
39,084

 
$
40,526


8. Investment in privately held company
 
On March 15, 2018, the Company entered into a collaboration agreement with KEW, Inc. (“KEW”), a privately held comprehensive genomic profiling company. The Company determined it had a variable interest in a VIE through its investment in a convertible note issued by KEW. During the year ended December 31, 2018, the Company incurred losses relating to this collaboration agreement with KEW of $2.9 million which were recognized in general and administrative expenses in the Company’s consolidated statements of operations. As of December 31, 2018, the Company fulfilled its obligations with respect to the collaboration agreement and there are no balances recorded in the Company's consolidated balance sheets pertaining to this arrangement.

83




9. Commitments and contingencies
Operating leases
In September 2015, the Company entered into a lease agreement for its headquarters and main production facility in San Francisco, California. This lease expires in July 2026 and the Company may renew the lease for an additional ten years. The Company has determined the lease term to be a ten-year period expiring in 2026. The lease term commenced when the Company took occupancy of the facility in February 2016. In connection with the execution of the lease, the Company provided a security deposit of approximately $4.6 million which is included in restricted cash in the Company’s consolidated balance sheets. Minimum annual rent under the lease is subject to increases based on stated rental adjustment terms. In addition, per the terms of the lease, the Company received a $5.2 million lease incentive in the form of reimbursement from the landlord for a portion of the costs of leasehold improvements the Company has made to the facility. The assets purchased with the lease incentive are included in property and equipment, net, in the Company’s consolidated balance sheets and the lease incentive is recognized as a reduction of rental expense on a straight-line basis over the term of the lease. At December 31, 2018, all of the lease incentive had been utilized by the Company and all related reimbursements had been received from the landlord. Aggregate future minimum lease payments for this facility at December 31, 2018 were approximately $57.8 million.
Future minimum payments under non-cancelable operating leases and future minimum payments to be received from non-cancelable subleases as of December 31, 2018 are as follows (in thousands):
 
Amounts
2019
$
10,948

2020
10,860

2021
11,109

2022
11,067

2023
8,898

Thereafter
25,715

Future non-cancelable minimum operating lease payments
78,597

Less: minimum payments to be received from non-cancelable subleases
(174
)
Total future non-cancelable minimum operating lease payments, net
$
78,423


The following table summarizes rent expense related to non-cancelable operating leases (in thousands):
 
Year Ended December 31,
 
2018
 
2017
 
2016
Rent expense
$
9,720

 
$
8,950

 
$
8,901

Sublease income
227

 
398

 
257

Rent expense, net of sublease income
$
9,493

 
$
8,552

 
$
8,644


Debt financing
In March 2017, the Company entered into a Loan and Security Agreement (the “2017 Loan Agreement”) with a lender pursuant to which the Company borrowed an initial term loan of $40.0 million, and received net proceeds of approximately $39.7 million. Subject to certain conditions, the Company was eligible to borrow a second term loan pursuant to the 2017 Loan Agreement of $20.0 million in the first quarter of 2018 and did so in March 2018, receiving net proceeds of approximately $19.8 million.
In February 2018 and June 2018, the Company entered into amendments to the 2017 Loan Agreement (the “2018 Amendments”) pursuant to which the Company, subject to certain conditions, was eligible to borrow a third term loan of $20.0 million during the period from April 2, 2018 to December 31, 2018. Pursuant to the 2018 Amendments, since the third term loan became available and the Company did not draw upon the third term loan, a fee of 1% was applied to the difference between $20.0 million and the amount drawn, or $0.2 million.

Term loans under the amended 2017 Loan Agreement bore interest at a floating rate equal to an index rate plus 7.73%, where the index rate was the greater of 0.77% or the 30-day U.S. Dollar London Interbank Offered Rate (“LIBOR”) as reported in The Wall Street Journal, with the floating rate resetting monthly subject to a floor of 8.5%.

84




The Company could make monthly interest-only payments until May 1, 2019 (or, subject to certain conditions, May 1, 2020), and thereafter monthly payments of principal and interest were required to fully amortize the borrowed amount by a final maturity date of March 1, 2022. A fee of 5% of each funded draw was due at the earlier of prepayment or loan maturity, a facility fee of 0.5% was due upon funding for each draw, and a prepayment fee of between 1% and 3% of the outstanding balance applied in the event of a prepayment. Concurrent with each term loan, the Company granted to the lender a warrant to acquire shares of the Company’s common stock equal to the quotient of 3% of the funded amount divided by a per share exercise price equal to the lower of the average closing price for the previous ten days of trading (calculated on the day prior to funding) or the closing price on the day prior to funding. In connection with the initial term loan, in 2017, the Company issued the lender warrants to purchase 116,845 shares of common stock at an exercise price of $10.27 per share. The Company classified these warrants as equity with a fair value of $0.7 million. In connection with the second term loan, in 2018, the Company issued the lender warrants to purchase 85,482 shares of common stock at an exercise price of $7.02 per share. The Company classified these warrants as equity with a fair value of $0.4 million. All warrants issued pursuant to the amended 2017 Loan Agreement have a term of ten years from the date of issuance and include a cashless exercise provision.
In November 2018, the Company entered into a Note Purchase Agreement (the "2018 Note Purchase Agreement") pursuant to which the Company was eligible to borrow an aggregate principal amount up to $200.0 million over a seven year maturity term which included an initial borrowing of $75.0 million in November 2018. The Company received net proceeds of $10.3 million after terminating and repaying the balance of its obligations of approximately $64.7 million under the 2017 Loan Agreement and associated amendments with its previous lender. The Company incurred $5.3 million of debt extinguishment costs upon terminating its previous debt facility which the Company recorded as other income (expense), net in its consolidated statements of operations during the year ended December 31, 2018.
At December 31, 2018, obligations under the 2018 Note Purchase Agreement were $75.0 million which are required to be repaid to the lender in a balloon payment no later than 2025. If the Company repays prior to the three year anniversary following the initial borrowing, the amount due will be: 117.5% of the principal amount if payment is made within 12 months after the borrowing; 132.5% of the principal amount if payment is made between 12 and 24 months after the borrowing; and 145.0% of the principal amount if payment is made between 24 and 36 months after the borrowing.
The outstanding principal amount under the 2018 Note Purchase Agreement bears interest at a rate of 8.75% annually. In addition, beginning on January 1, 2020 and continuing until repayment or maturity of any outstanding principal, the Company will make quarterly payments of 0.5% of the Company's annual net revenues subject to a maximum annual amount of such payments of $1.6 million which will be recognized as interest expense. Through the fixed interest charges and the quarterly revenue payments, the Company is required to pay total amounts to generate an 11% internal rate of return to the lender on any outstanding principal balances due in a lump-sum upon the repayment or maturity of any outstanding principal. During the year ended December 31, 2018, the 2018 Note Purchase Agreement bore interest at an average interest rate of 10.6%.
The 2018 Note Purchase Agreement contains quarterly covenants to achieve certain revenue levels as well as additional covenants, including limits on the Company’s ability to dispose of assets, undergo a change of control, merge with or acquire other entities, incur debt, incur liens, pay dividends or other distributions to holders of its capital stock, repurchase stock and make investments, in each case subject to certain exceptions. The Company’s obligations under the 2018 Note Purchase Agreement are secured by a security interest on substantially all of its and certain of its subsidiaries’ assets.
In connection with the 2018 Note Purchase Agreement, in November 2018, the Company entered into a Securities Purchase Agreement with the lender pursuant to which the Company issued 373,524 shares of its common stock at a price of $13.39 per share for an aggregate amount of $5.0 million. The share price paid by the lender was calculated based on the 15-day average closing share price prior to the issuance. The relative fair value method was used to allocate the proceeds between the common stock issued and the note proceeds; the fair value of the common stock issued to the lender was determined to be $5.4 million.

85




Debt discounts, including debt issuance costs, related to the 2018 Note Purchase Agreement of $0.7 million were recorded as a direct deduction from the debt liability and are being amortized to interest expense over the term of the 2018 Note Purchase Agreement. Future estimated payments under the 2018 Note Purchase Agreement as of December 31, 2018 are as follows (in thousands):
 
Amounts
2019
$
6,654

2020
8,297

2021
8,279

2022
8,279

2023
8,279

Thereafter
89,998

Total remaining payments
129,786

Less: amount representing debt discount
(721
)
Less: amount representing interest
(54,588
)
Total non-current debt obligation
$
74,477


Interest expense related to the Company's debt financings was $6.7 million, $3.5 million and $0.3 million for the years ended December 31, 2018, 2017 and 2016, respectively.
Capital leases
The Company has entered into various capital lease agreements to obtain laboratory equipment. The terms of the Company's capital leases are typically three years and are secured by the underlying equipment. The portion of the future payments designated as principal repayment was classified as a capital lease obligation on the consolidated balance sheets.
Future payments under capital leases at December 31, 2018 were as follows (in thousands):
 
Amounts
2019
$
2,087

2020
1,392

2021
21

Total capital lease obligations
3,500

Less: amount representing interest
(188
)
Present value of net minimum capital lease payments
3,312

Less: current portion
(1,937
)
Total non-current capital lease obligations
$
1,375


Interest expense related to capital leases was $0.3 million, $0.2 million and $0.1 million for the years ended December 31, 2018, 2017 and 2016, respectively.
Property and equipment under capital leases was $7.1 million and $11.4 million as of December 31, 2018 and 2017, respectively. Accumulated depreciation, collectively, on these assets was $2.0 million and $3.0 million at December 31, 2018 and 2017, respectively.
Guarantees and indemnifications
As permitted under Delaware law and in accordance with the Company’s bylaws, the Company indemnifies its directors and officers for certain events or occurrences while the officer or director is or was serving in such capacity. The maximum amount of potential future indemnification is unlimited; however, the Company maintains director and officer liability insurance. This insurance allows the transfer of the risk associated with the Company’s exposure and may enable it to recover a portion of any future amounts paid. The Company believes the fair value of these indemnification agreements is minimal. Accordingly, the Company did not record any liabilities associated with these indemnification agreements at December 31, 2018 or December 31, 2017.

86




Other commitments
In the normal course of business, the Company enters into various purchase commitments primarily related to service agreements, laboratory supplies, and a co-development agreement. At December 31, 2018, the Company’s total future payments under noncancelable unconditional purchase commitments having a remaining term of over one year were as follows (in thousands):
 
Amount
2019
$
3,040

2020
3,040

2021
1,440

Total
$
7,520


In addition, in September 2018, the Company entered into a co-development agreement with a privately held genetics testing company. The co-development agreement grants the Company the right of first refusal to enter into an agreement for an acquisition of the entity in return for total fees of $3.0 million over the term of the 12-month agreement, of which $1.0 million has been paid by the Company as of December 31, 2018. The unpaid fees of $2.0 million were paid in January 2019, and as of December 31, 2018, were recorded as an accrued liability in the Company’s consolidated balance sheets.
Contingencies
The Company was not a party to any material legal proceedings at December 31, 2018, or at the date of this report. The Company may from time to time become involved in various legal proceedings arising in the ordinary course of business, and the resolution of any such claims could be material.
10. Stockholders’ Equity
Common stock
As of December 31, 2018 and 2017, the Company had reserved shares of common stock, on an as‑if converted basis, for issuance as follows (in thousands):
 
As of December 31,
 
2018
 
2017
Options issued and outstanding
3,855

 
4,115

RSU awards issued and outstanding
4,031

 
2,387

Shares available for grant under stock option plans
118

 
2,397

Shares reserved for issuance under the 2015 Employee Stock Purchase Plan
278

 
308

Common stock underlying warrants
611

 
1,962

Common stock issuable upon conversion of preferred stock
3,459

 
3,459

Common stock underlying stock payable liabilities
132

 
689

Common stock payable as contingent consideration
452

 
551

Total
12,936

 
15,868


Private placement
In August 2017, in a private placement to certain accredited investors, the Company issued 5.2 million shares of its common stock at a price of $8.50 per share, and 3.5 million shares of its Series A convertible preferred stock at a price of $8.50 per share, for gross proceeds of approximately $73.5 million and net proceeds of $68.9 million. The Series A preferred stock is a non-voting common stock equivalent and conversion of the Series A preferred stock is prohibited if the holder exceeds a specified threshold of voting security ownership. The Series A preferred stock is convertible into common stock on a one-for-one basis, subject to adjustment for events such as stock splits, combinations and the like. The Series A Preferred Stock has the right to receive dividends first or simultaneously with payment of dividends on common stock, in an amount equal to the product of (i) the dividend payable on each share of common stock and (ii) the number of shares of common stock issuable upon conversion

87




of a share of Series A Preferred Stock. The Series A Preferred Stock has no voting rights except as required by law, as modified by the Company’s Amended and Restated Certificate of Incorporation. In the event of any liquidation or dissolution of the Company, the Series A Preferred Stock is entitled to receive $0.001 per share prior to the payment of any amount to any holders of capital stock of the Company ranking junior to the Series A Preferred Stock and thereafter shall participate pari passu with the holders of the Company’s common stock (on an as-if-converted-to-common-stock basis). During January and February 2019, 1.1 million shares of Series A convertible preferred stock were converted to 1.1 million shares of common stock.
Public offering
In April 2018, the Company issued, in an underwritten public offering, an aggregate of 12.8 million shares of its common stock at a price of $4.50 per share, for gross proceeds of $57.5 million and net proceeds of $53.5 million.
2018 Sales Agreement
In August 2018, the Company entered into a Common Stock Sales Agreement (the “2018 Sales Agreement”) with Cowen and Company, LLC (“Cowen”), under which the Company may offer and sell from time to time at its sole discretion shares of its common stock through Cowen as its sales agent, in an aggregate amount not to exceed $75.0 million. Cowen may sell the shares by any method permitted by law deemed to be an “at the market” offering as defined in Rule 415 of the Securities Act, including without limitation sales made directly on The New York Stock Exchange, and also may sell the shares in privately negotiated transactions, subject to the Company’s prior approval. The Company is obligated to pay Cowen a commission equal to 3% of the gross proceeds of the sales price of all shares sold through it as sales agent under the 2018 Sales Agreement. During the year ended December 31, 2018, the Company issued a total of 4.3 million shares of common stock under the 2018 Sales Agreement for aggregate gross proceeds of $61.1 million and net proceeds of $58.9 million.
Common stock warrants
As of December 31, 2018, the Company had outstanding warrants to purchase common stock as follows:
Warrant
 
Issuance Date
 
Expiration Date
 
Exercise
Price
Per Share
 
Number of Shares of Common Stock Underlying Warrants
Warrants issued in exchange for CombiMatrix Series F warrants
 
November 2017
 
March 2021
 
$
5.95

 
408,548

Warrants issued to lender under 2017 Loan Agreement
 
March 2017
 
March 2027
 
$
10.27

 
116,845

Warrants issued to lender under 2017 Loan Agreement - 2018 Amendments
 
March 2018
 
March 2028
 
$
7.02

 
85,482

 
 
 
 
 
 
 
 
610,875


The exercise price of warrants issued in exchange for CombiMatrix Series F warrants was determined pursuant to the terms of the Merger Agreement (See Note 4, "Business Combinations"). The CombiMatrix Series D warrants expired during the year ended December 31, 2018. The exercise price of the warrants issued to the lender under the 2017 Loan Agreement was the closing price of the Company’s common stock on the date of the agreements. During the year ended December 31, 2018, the Company received $6.5 million from exercises 1.0 million shares of common stock under these warrants.
11. Stock incentive plans
Stock incentive plans
In 2010, the Company adopted the 2010 Incentive Plan (the “2010 Plan”). The 2010 Plan provides for the granting of stock-based awards to employees, directors and consultants under terms and provisions established by the Board of Directors. Under the terms of the 2010 Plan, options may be granted at an exercise price not less than fair market value. For employees holding more than 10% of the voting rights of all classes of stock, the exercise prices for incentive and nonstatutory stock options must be at least 110% of fair market of the common stock on the grant date, as determined by the Board of Directors. The terms of options granted under the 2010 Plan may not exceed ten years.

88




In January 2015, the Company adopted the 2015 Stock Incentive Plan (the “2015 Plan”), which became effective upon the closing of the Company’s initial public offering (“IPO”). Shares outstanding under the 2010 Plan were transferred to the 2015 Plan upon effectiveness of the 2015 Plan. The 2015 Plan provides for automatic annual increases in shares available for grant, beginning on January 1, 2016 through January 1, 2025. In addition, shares subject to awards under the 2010 Plan that are forfeited or terminated will be added to the 2015 Plan. The 2015 Plan provides for the grant of incentive stock options, nonstatutory stock options, restricted stock awards, stock units, stock appreciation rights and other forms of equity compensation, all of which may be granted to employees, including officers, non-employee directors and consultants. Additionally, the 2015 Plan provides for the grant of cash-based awards.
Options granted generally vest over a period of four years. Typically, the vesting schedule for options granted to newly hired employees provides that 1/4 of the award vests upon the first anniversary of the employee’s date of hire, with the remainder of the award vesting monthly thereafter at a rate of 1/48 of the total shares subject to the option. All other options typically vest in equal monthly installments over the four-year vesting schedule.
RSUs generally vest over a period of three years. Typically, the vesting schedule for RSUs provides that one third of the award vests upon each anniversary of the grant date.
In February 2016, the Company granted PRSUs under the 2015 Plan, which PRSUs could be earned based on the achievement of specified performance conditions measured over a period of approximately 12 months. In February 2017, upon the Audit Committee’s determination of the level of achievement, 352,045 fully vested stock units were awarded to holders of PRSUs. The Company has not granted any PRSUs since 2016.
Based on its evaluations of the probability of achieving performance conditions, the Company recorded stock-based compensation expense of nil, $0.4 million, and $1.9 million for the years ended December 31, 2018, 2017, and 2016, respectively, related to the PRSUs.
Activity under the 2010 Plan and the 2015 Plan is set forth below (in thousands, except per share amounts and years):
 
Shares
Available
For Grant
 
Stock
Options
Outstanding
 
Weighted-
Average
Exercise
Price
 
Weighted-
Average
Remaining
Contractual
Life (years)
 
Aggregate
Intrinsic
Value
Balance at December 31, 2017
2,397

 
4,115

 
$
8.51

 
7.6
 
$
5,128

Additional shares reserved
754

 
—

 
 
 
 
 
 
Options granted
(260
)
 
260

 
$
8.50

 
 
 
 
Options cancelled
169

 
(169
)
 
$
9.35

 
 
 
 
Options exercised
—

 
(351
)
 
$
7.73

 
 
 
 
RSUs granted
(3,282
)
 
—

 
 
 
 
 
 
RSUs cancelled
340

 
—

 
 
 
 
 
 
Balance at December 31, 2018
118

 
3,855

 
$
8.54

 
6.8
 
$
9,927

Options exercisable at December 31, 2018
 
 
2,737

 
$
8.27

 
6.4
 
$
7,787

Options vested and expected to vest at December 31, 2018
 
 
3,710

 
$
8.52

 
6.8
 
$
9,626


The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying stock options and the fair value of the Company’s common stock for stock options that were in-the-money.
The weighted-average fair value of options to purchase common stock granted was $4.87, $5.82 and $6.18 in the years ended December 31, 2018, 2017 and 2016, respectively. The weighted-average fair value of RSUs granted was $7.46, $10.03 and $9.80 in the years ended December 31, 2018, 2017 and 2016, respectively. No PRSUs were granted in the years ended December 31, 2018 or 2017 and the weighted average fair value of PRSUs granted in the year ended December 31, 2016 was $6.50.
The total grant-date fair value of options to purchase common stock vested was $5.9 million, $6.9 million and $5.6 million in the year ended December 31, 2018, 2017, and 2016, respectively.
The intrinsic value of options to purchase common stock exercised was $1.7 million, $2.1 million and $1.4 million in the years ended December 31, 2018, 2017 and 2016, respectively.

89




The following table summarizes RSU activity for the year ended December 31, 2018 (in thousands, except per share data:
 
Number of Shares
 
Weighted-Average Grant Date Fair Value
Balance at December 31, 2017
2,387

 
$
9.91

RSUs granted
3,282

 
$
7.46

RSUs vested
(1,298
)
 
$
8.84

RSUs cancelled
(340
)
 
$
8.84

Balance at December 31, 2018
4,031

 
$
8.35


2015 employee stock purchase plan
In January 2015, the Company adopted the 2015 Employee Stock Purchase Plan (the “ESPP”), which became effective upon the closing of the IPO. Employees participating in the ESPP may purchase common stock at 85% of the lesser of the fair market value of common stock on the purchase date or last trading day preceding the offering date. At December 31, 2018, cash received from payroll deductions pursuant to the ESPP was $0.6 million.
The ESPP provides for automatic annual increases in shares available for grant, beginning on January 1, 2016 and continuing through January 1, 2025. At December 31, 2018, a total of 277,577 shares of common stock are reserved for issuance under the ESPP.
Stock-based compensation
The Company uses the grant date fair value of its common stock to value both employee and non-employee options when granted. The Company revalues non-employee options each reporting period using the fair market value of the Company’s common stock as of the last day of each reporting period.
In determining the fair value of stock options and ESPP purchases, the Company uses the Black-Scholes option-pricing model and, for stock options, the assumptions discussed below. Each of these inputs is subjective and its determination generally requires significant judgment. The fair value of RSU and PRSU awards is based on the grant date share price. Compensation cost is recognized as expense on a straight-line basis over the vesting period for options and RSUs and on an accelerated basis for PRSUs.
In 2016, the Company modified certain stock options and RSU awards. The terms of the stock option modifications included acceleration of vesting and extensions of post-termination exercise periods. The terms of the RSU award modifications included acceleration of vesting. A total of 14 employees were affected by the stock option and RSU modifications and the total incremental compensation cost relating to these modifications was $0.3 million.
Expected term—The expected term represents the period that the Company’s stock-based awards are expected to be outstanding and is determined using the simplified method (based on the midpoint between the vesting date and the end of the contractual term).
Expected volatility—Because the Company was privately held until its initial public offering in February 2015 and did not have any trading history for its common stock, the Company estimates expected volatility using its own stock price volatility when available as well as the average volatility for comparable publicly traded life sciences companies, including molecular diagnostics companies, over a period equal to the expected term of stock option grants and RSUs. When selecting comparable publicly-traded biopharmaceutical companies, including molecular diagnostics companies, the Company selected companies with comparable characteristics, including enterprise value, risk profiles, position within the industry and with historical share price information sufficient to meet the expected life of the stock-based awards. The Company computed historical volatility data using daily closing prices for the selected companies’ shares during the equivalent period of the calculated expected term of the stock-based awards. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available. The Company estimates expected volatility for ESPP purchases using its own stock price volatility over the expected six-month term ESPP purchase periods.
Risk-free interest rate—The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of the option.

90




Dividend yield—The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company used an expected dividend yield of zero.
The fair value of share-based payments for stock options granted to employees and directors was estimated on the date of grant using the Black-Scholes option-pricing model based on the following assumptions:
 
Year Ended December 31,
 
2018
 
2017
 
2016
Expected term (in years)
6.00
 
6.03
 
6.03
Expected volatility
59.58%
 
72.64%
 
71.42%
Risk-free interest rate
2.80%
 
2.01%
 
1.37%

Stock-based compensation related to stock options granted to non-employees is recognized as the stock options vest. The fair value of the stock options granted is calculated at each reporting date using the Black-Scholes option-pricing model based on the following assumptions:
 
Year Ended December 31,
 
2018
 
2017
 
2016
Expected term (in years)
—
 
8.41 – 8.83
 
6.25 – 10.00
Expected volatility
—
 
69.9 – 78.70%
 
76.92%
Risk-free interest rate
—
 
1.83 – 2.04%
 
1.55 – 2.37%

No stock options granted to non-employees vested during the year ended December 31, 2018.
The fair value of shares purchased pursuant to the ESPP is estimated using the Black‑Scholes option pricing model. For the years ended December 31, 2018, 2017 and 2016, the weighted average grant date fair value per share for the ESPP was $3.26, $2.51 and $2.66, respectively and stock‑based compensation expense for the ESPP was $1.4 million, $1.1 million and $0.9 million, respectively.
The fair value of the shares purchased pursuant to the ESPP was estimated using the following assumptions:
 
Year Ended December 31,
 
2018
 
2017
 
2016
Expected term (in years)
0.5
 
0.5
 
0.5
Expected volatility
71.66%
 
52.50%
 
66.31%
Risk-free interest rate
2.09%
 
1.23%
 
0.50%

The following table summarizes stock-based compensation expense for the years ended December 31, 2018, 2017 and 2016, included in the consolidated statements of operations (in thousands):
 
Year Ended December 31,
 
2018
 
2017
 
2016
Cost of revenue
$
2,960

 
$
2,093

 
$
1,353

Research and development
7,017

 
6,158

 
4,976

Selling and marketing
4,887

 
3,956

 
1,709

General and administrative
5,986

 
7,014

 
2,661

Total stock-based compensation expense
$
20,850

 
$
19,221

 
$
10,699


At December 31, 2018, unrecognized compensation expense related to unvested stock options, net of estimated forfeitures, was $4.5 million, which the Company expects to recognize on a straight-line basis over a weighted-average period of 1.8 years. Unrecognized compensation expense related to RSUs at December 31, 2018, net of estimated forfeitures, was $22.6 million, which the Company expects to recognize on a straight-line basis over a weighted-average period of 2.1 years. At December 31, 2018, there was no unrecognized compensation expense related to PRSUs and no capitalized stock-based employee compensation.

91




12. Income taxes
The Company recorded a benefit for income taxes in the years ended December 31, 2018 and 2017. The Company did not record a provision or benefit for income taxes during the year ended December 31, 2016. The components of net loss before taxes by U.S. and foreign jurisdictions are as follows (in thousands):
 
Year Ended December 31,
 
2018
 
2017
 
2016
United States
$
132,194

 
$
124,108

 
$
99,793

Foreign
(39
)
 
1,128

 
463

Total
$
132,155

 
$
125,236

 
$
100,256


The components of the provision for income taxes are as follows (in thousands):
 
Year Ended December 31,
 
2018
 
2017
 
2016
Current:
 
 
 
 
 
Foreign
62

 
—

 
—

Total current benefit for income taxes
62

 
—

 
—

Deferred:
 
 
 
 
 
Federal
(2,862
)
 
(1,704
)
 
—

State
—

 
(152
)
 
—

Total deferred benefit for income taxes
(2,862
)
 
(1,856
)
 
—

Total income tax benefit
$
(2,800
)
 
$
(1,856
)
 
$
—


The following table presents a reconciliation of the tax expense computed at the statutory federal rate and the Company’s tax expense for the periods presented:
 
Year Ended December 31,
 
2018
 
2017
 
2016
U.S. federal taxes at statutory rate
21.0
 %
 
34.0
 %
 
34.0
 %
State taxes (net of federal benefit)
5.2
 %
 
3.3
 %
 
1.4
 %
Stock-based compensation
(0.7
)%
 
(1.1
)%
 
(1.7
)%
Research and development credits
2.7
 %
 
—
 %
 
—
 %
Non-deductible expenses
(0.6
)%
 
—
 %
 
0.2
 %
Foreign tax differential
—
 %
 
(0.3
)%
 
(0.2
)%
Other
—
 %
 
—
 %
 
1.1
 %
Change in valuation allowance
(25.5
)%
 
(34.4
)%
 
(34.8
)%
Change in deferred—Tax Reform
—
 %
 
(39.0
)%
 
—
 %
Change in valuation allowance—Tax Reform
—
 %
 
39.0
 %
 
—
 %
Total
2.1
 %
 
1.5
 %
 
—
 %


92




The tax effects of temporary differences and carryforwards that give rise to significant portions of the deferred tax assets are as follows (in thousands):
 
As of December 31,
 
2018
 
2017
Deferred tax assets:
 

 
 

Net operating loss carryforwards
$
76,972

 
$
70,825

Tax credits
15

 
15

Revenue recognition differences
47,650

 
29,819

Accruals and other
7,262

 
5,544

Gross deferred tax assets
131,899

 
106,203

Valuation allowance
(121,954
)
 
(95,687
)
Total deferred tax assets
9,945

 
10,516

Deferred tax liabilities:
 
 
 
Property and equipment
(9,945
)
 
(10,516
)
Total deferred tax liabilities
(9,945
)
 
(10,516
)
Net deferred tax assets
$
—

 
$
—


On December 22, 2017, the Tax Cuts and Jobs Act of 2017 (the “Tax Act”) was signed into law making significant changes to the Internal Revenue Code. Changes included among other items, a reduction of the corporate tax rate from a top marginal rate of 35% to a flat rate of 21%. Although the Tax Act was generally effective January 1, 2018, GAAP required recognition of the tax effects of new legislation during the reporting period that includes the enactment date, which was December 22, 2017. As a result of the lower corporate tax rate enacted as part of the Tax Act, during 2017, the Company recorded a provisional estimate to reduce deferred tax assets by $48.8 million offset by a corresponding reduction in the valuation allowance resulting in no net impact to the Company's income tax benefit or expense.
On December 22, 2017, the Securities and Exchange Commission issued Staff Accounting Bulletin No. 118 ("SAB 118") to address the application of U.S. GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the Tax Act. In accordance with SAB 118, during 2017, the Company recorded a provisional estimate which resulted in a $48.8 million reduction in deferred tax assets and in the fourth quarter of 2018, the Company completed its analysis of the impact of the Tax Act and determined that no material adjustments were required to the provisional amounts previously recorded.     
The Company has established a full valuation allowance against its deferred tax assets due to the uncertainty surrounding realization of such assets. The Company's valuation allowance increased by $26.3 million, $2.0 million, and $33.4 million during the years ended December 31, 2018, 2017, and 2016, respectively.
As of December 31, 2018, the Company had net operating loss carryforwards of approximately $318.7 million and $134.3 million available to reduce future taxable income, if any, for Federal and state income tax purposes, respectively. Of the $318.7 million, $277.3 million will begin to expire in 2030 while $41.4 million have no expiration date. The state net operating loss carryforwards will begin to expire in 2030.
As of December 31, 2018, the Company had research and development credit carryforwards of approximately $9.0 million and $7.4 million available to reduce its future tax liability, if any, for Federal and state income tax purposes, respectively. The Federal credit carryforwards begin to expire in 2030. California credit carryforwards have no expiration date.
Internal Revenue Code ("IRC") section 382 places a limitation (the “Section 382 limitation” or “annual limitation”) on the amount of taxable income that can be offset by net operating loss carryforwards after a change in control (generally greater than 50% change in ownership) of a loss corporation. Similar provisions exist for states. In addition, and as a result of the acquisitions of Good Start Genetics and CombiMatrix in 2017, tax loss carryforwards from acquired entities are also subject to the Section 382 limitation due to the change in control in the acquired entities in the current year.
The Company performed a section 382 analysis for Good Start Genetics and CombiMatrix and concluded that a substantial portion of the acquired operating loss and credit carryovers would expire unused as a result of

93




annual limitations under IRC sections 382 and 383 in 2017. As a result, the federal and state operating loss and credit carryforwards acquired in connection with the Good Start Genetics and CombiMatrix acquisitions were reduced by the amount of tax attributes estimated to expire during their respective carryforward periods. In addition, as a result of equity issued in connection with its 2017 acquisitions, the Company also performed a section 382 analysis with respect to its legacy operating loss and credit carryforwards. The Company concluded while an ownership change occurred in 2017 as defined under IRC section 382, none of the Company’s legacy carryforwards would expire unused solely as a result of annual limitations imposed on the use of the carryforwards under IRC sections 382 and 383.
As of December 31, 2018, the Company had unrecognized tax benefits of $16.4 million, which primarily relates to research and development credits, none of which would currently affect the Company’s effective tax rate if recognized due to the Company’s deferred tax assets being fully offset by a valuation allowance. Unrecognized tax benefits are not expected to change in the next 12 months.
A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in thousands):
 
Year ended December 31,
 
2018
 
2017
 
2016
Unrecognized tax benefits, beginning of period
$
10,561

 
$
7,791

 
$
11,429

Gross increases—current period tax positions
5,686

 
2,552

 
782

Gross increases (decreases)—prior period tax positions
128

 
218

 
(4,420
)
Unrecognized tax benefits, end of period
$
16,375

 
$
10,561

 
$
7,791


The Company’s policy is to include penalties and interest expense related to income taxes as a component of tax expense. The Company has not accrued interest and penalties related to the unrecognized tax benefits reflected in the financial statements for the years ended December 31, 2018, 2017 and 2016.
The Company’s major tax jurisdictions are the United States and California. All of the Company’s tax years will remain open for examination by the Federal and state tax authorities for three and four years, respectively, from the date of utilization of the net operating loss or research and development credit. The Company does not have any tax audits pending.
13. Net loss per share
The following table presents the calculation of basic and diluted net loss per share for the years ended December 31, 2018, 2017 and 2016 (in thousands, except per share data):
 
Year ended December 31,
 
2018
 
2017
 
2016
Net loss
$
(129,355
)
 
$
(123,380
)
 
$
(100,256
)
Shares used in computing net loss per share, basic and diluted
66,747

 
46,512

 
33,176

Net loss per share, basic and diluted
$
(1.94
)
 
$
(2.65
)
 
$
(3.02
)


94




The following common stock equivalents have been excluded from diluted net loss per share for the years ended December 31, 2018, 2017 and 2016 because their inclusion would be anti-dilutive (in thousands):
 
Year Ended December 31,
 
2018
 
2017
 
2016
Shares of common stock subject to outstanding options
3,855

 
4,115

 
4,491

Shares of common stock subject to outstanding warrants
611

 
1,962

 
—

Shares of common stock subject to outstanding RSUs
4,031

 
2,387

 
892

Shares of common stock subject to outstanding PRSUs
—

 
—

 
530

Shares of common stock pursuant to ESPP
63

 
59

 
55

Shares of common stock underlying Series A convertible preferred stock
3,459

 
3,459

 
—

Total shares of common stock equivalents
12,019

 
11,982

 
5,968


14. Geographic information
Revenue by country is determined based on the billing address of the customer and is summarized as follows (in thousands):
 
Year Ended December 31,
 
2018
 
2017
 
2016
United States
$
138,239

 
$
62,446

 
$
20,758

Canada
4,206

 
3,226

 
2,526

Rest of world
5,254

 
2,549

 
1,764

Total revenue
$
147,699

 
$
68,221

 
$
25,048


As of December 31, 2018 and 2017, all long-lived assets were located in the United States.
15. Selected quarterly data (unaudited)
The following table summarizes the Company's quarterly financial information for 2018 and 2017 (in thousands, except per share amounts):
 
 
Three Months Ended
 
 
March 31, 2018
 
June 30, 2018
 
September 30, 2018
 
December 31, 2018
Revenue
 
$
27,671

 
$
37,306

 
$
37,366

 
$
45,356

Cost of revenue
 
$
18,076

 
$
20,447

 
$
20,441

 
$
21,141

Loss from operations
 
$
(36,475
)
 
$
(30,068
)
 
$
(30,110
)
 
$
(25,904
)
Net loss(2)
 
$
(36,120
)
 
$
(31,671
)
 
$
(31,723
)
 
$
(29,841
)
Net loss per share, basic and diluted(1)
 
$
(0.66
)
 
$
(0.47
)
 
$
(0.45
)
 
$
(0.40
)
 
 
 
 
 
 
 
 
 
 
 
Three Months Ended
 
 
March 31, 2017
 
June 30, 2017
 
September 30, 2017
 
December 31, 2017
Revenue
 
$
10,338

 
$
14,336

 
$
18,148

 
$
25,399

Cost of revenue
 
$
9,329

 
$
10,490

 
$
13,274

 
$
17,049

Loss from operations
 
$
(27,337
)
 
$
(28,075
)
 
$
(30,976
)
 
$
(34,891
)
Net loss(2)
 
$
(26,928
)
 
$
(28,557
)
 
$
(27,402
)
 
$
(40,493
)
Net loss per share, basic and diluted(1)
 
$
(0.64
)
 
$
(0.66
)
 
$
(0.57
)
 
$
(0.78
)
___________________________________________________________________ 
(1) 
Net loss per share is computed independently for each of the quarters presented. Therefore, the sum of quarterly net loss per share information may not equal annual net loss per share.

95




(2)
Includes $5.3 million of debt extinguishment costs during the three months ended December 31, 2018. See Note 9, "Commitments and contingencies" for further information.
ITEM 9.
Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.
Not applicable.
ITEM 9A.
Controls and Procedures.
Evaluation of disclosure controls and procedures
We maintain “disclosure controls and procedures,” as such term is defined in Rule 13a‑15(e) under the Securities Exchange Act of 1934, or Exchange Act, that are designed to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in Securities and Exchange Commission rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, management recognized that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Our disclosure controls and procedures have been designed to meet reasonable assurance standards. Additionally, in designing disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost‑benefit relationship of possible disclosure controls and procedures. The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.
Based on their evaluation as of the end of the period covered by this Annual Report on Form 10‑K, our Chief Executive Officer (our principal executive officer) and Chief Financial Officer (our principal financial officer) have concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.
Changes in internal controls
There was no change in our internal control over financial reporting (as defined in Rule 13a‑15(f) under the Exchange Act) identified in connection with the evaluation described in Item 9A above that occurred during our last fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
Management’s annual report on internal control over financial reporting
Our management is responsible for establishing and maintaining internal control over our financial reporting. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of the effectiveness of internal control to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with policies or procedures may deteriorate. Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, assessed the effectiveness of our internal control over financial reporting as of December 31, 2018. In making this assessment, our management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission, or COSO, in Internal Control—Integrated Framework (2013 Framework). Based on the assessment using those criteria, our management concluded that, as of December 31, 2018, our internal control over financial reporting was effective.
ITEM 9B.
Other Information.
As of the date of this filing, Patricia E. Dumond has ceased to serve as our Principal Accounting Officer. Shelly D. Guyer, age 58, our Chief Financial Officer since June 2017, has been appointed to serve in the additional position of Principal Accounting Officer. Ms. Guyer served as Chief Financial Officer of Veracyte, Inc., a genomic diagnostics company, from April 2013 to December 2016 and served as Veracyte’s Secretary from April 2013 to March 2014. Ms. Guyer has no family relationships with any of our directors or executive officers, and she has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K. Ms. Dumond will continue as an employee of Invitae working on various matters, including direct offering of product lines into the marketplace.

96




PART III
ITEM 10.
Directors, Executive Officers and Corporate Governance.
The information required by this item with respect to directors is incorporated by reference from the information under the caption “Election of Directors,” contained in our proxy statement to be filed with the Securities and Exchange Commission no later than 120 days from the end of our fiscal year ended December 31, 2018 in connection with the solicitation of proxies for our 2019 Annual Meeting of Stockholders, or the Proxy Statement. Certain information required by this item concerning executive officers is set forth in Part I of this Report under the caption “Executive Officers of the Registrant” and is incorporated herein by reference.
There have been no material changes to the procedures by which stockholders may recommend nominees to our Board of Directors.
Item 405 of Regulation S-K calls for disclosure of any known late filing or failure by an insider to file a report required by Section 16(a) of the Exchange Act. This disclosure is contained in the section entitled “Section 16(a) Beneficial Ownership Reporting Compliance” in the Proxy Statement and is incorporated herein by reference.
Our board of directors has adopted a code of ethics for senior financial officers applicable to our Chief Executive Officer and Chief Financial Officer as well as other key management employees addressing ethical issues. The code of business conduct and the code of ethics are each posted on our website www.invitae.com. The code of business conduct and the code of ethics can only be amended by the approval of a majority of our board of directors. Any waiver to the code of business conduct for an executive officer or director or any waiver of the code of ethics may only be granted by our board of directors or our nominating and corporate governance committee and must be timely disclosed as required by applicable law. We have implemented whistleblower procedures that establish formal protocols for receiving and handling complaints from employees. Any concerns regarding accounting or auditing matters reported under these procedures will be communicated promptly to our audit committee. Stockholders may request a free copy of our code of business conduct and code of ethics by contacting Invitae Corporation, Attention: Chief Financial Officer, 1400 16th Street, San Francisco, California 94103.
To date, there have been no waivers under our code of business conduct or code of ethics. We intend to disclose future amendments to certain provisions of our code of business conduct or code of ethics or waivers of such codes granted to executive officers and directors on our website at http://www.invitae.com within four business days following the date of such amendment or waiver.
Our Board of Directors has appointed an Audit Committee, comprised of Eric Aguiar, Geoffrey S. Crouse and Christine M. Gorjanc. The Board of Directors has determined that each of the members of our Audit Committee qualifies as an Audit Committee Financial Expert under the definition outlined by the Securities and Exchange Commission. In addition, each of the members of the Audit Committee qualifies as an "independent director" under the current rules of the New York Stock Exchange and Securities and Exchange Commission rules and regulations.
ITEM 11.
Executive Compensation.
The information required by this item is incorporated by reference from the information under the captions “Election of Directors-Director Compensation” and “Executive Compensation” contained in the Proxy Statement.
ITEM 12.
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.
The information required by this item is incorporated by reference to the disclosure appearing under the headings “Security Ownership of Certain Beneficial Owners and Management” and “Executive Compensation-Equity Compensation Plan Information” contained in the Proxy Statement.
ITEM 13.
Certain Relationships and Related Transactions, and Director Independence.
The information required by this item is incorporated by reference from the information under the caption “Election of Directors-Certain Relationships and Related Transactions” and “Director Independence” contained in the Proxy Statement.

97




ITEM 14.
Principal Accountant Fees and Services.
The information required by this item is incorporated by reference from the information under the caption “Ratification of the Appointment of Independent Registered Public Accounting Firm” contained in the Proxy Statement.


98




PART IV
ITEM 15.
Exhibits and Financial Statement Schedules.
(a)
Documents filed as part of this report
1.
Financial Statements: Reference is made to the Index to Financial Statements of Invitae Corporation included in Item 8 of Part II hereof.
2.
Financial Statement Schedules: All schedules have been omitted because they are not required, not applicable, or the required information is included in the financial statements or notes thereto.
3.
Exhibits: See Item 15(b) below. Each management contract or compensating plan or arrangement required to be filed has been identified.
(b)
Exhibits
Exhibit
Number
 
Description
 
 
 
2.1&@
 
 
 
 
2.2@
 
 
 
 
2.3@
 
 
 
 
2.4@
 
 
 
 
2.5
 
 
 
 
3.1
 
 
 
 
3.1.1
 
 
 
 
3.2
 
 
 
 
4.1
 
 
 
 
4.2
 
 
 
 
4.3
 
 
 
 
4.4
 
 
 
 
4.5
 
 
 
 
4.6
 

99




Exhibit
Number
 
Description
 
 
 
4.7
 
 
 
 
10.1
 
 
 
 
10.2#
 
 
 
 
10.3#
 
 
 
 
10.4#
 
 
 
 
10.5#
 
 
 
 
10.6#
 
 
 
 
10.7#
 
 
 
 
10.8#
 
 
 
 
10.9#
 
 
 
 
10.10
 
 
 
 
10.11
 
 
 
 
10.12&
 
 
 
 
10.13
 

 
 
 
10.14
 
 
 
 
10.15
 
 
 
 
10.16
 

100




Exhibit
Number
 
Description
 
 
 
10.17#
 
 
 
 
10.18
 
 
 
 
10.19*
 
 
 
 
21.1*
 
 
 
 
23.1*
 
 
 
 
24.1*
 
Power of Attorney (contained on the signature page to this Form 10‑K).
 
 
 
31.1*
 
 
 
 
31.2*
 
 
 
 
32.1+
 
 
 
 
32.2+
 
 
 
 
101.INS
 
XBRL Instance Document
 
 
 
101.SCH
 
XBRL Taxonomy Extension Schema
 
 
 
101.CAL
 
XBRL Taxonomy Extension Calculation Linkbase
 
 
 
101.DEF
 
XBRL Taxonomy Extension Definition Linkbase
 
 
 
101.LAB
 
XBRL Taxonomy Extension label Linkbase
 
 
 
101.PRE
 
XBRL Taxonomy Extension Presentation Linkbase
__________________________________________
#
Indicates management contract or compensatory plan or arrangement.
*
Filed herewith.
@
The schedules and exhibits to this agreement have been omitted pursuant to Item 601(b)(2) of Regulation S-K. A copy of any omitted schedule and/or exhibit will be furnished to the SEC upon request.
+
In accordance with Item 601(b)(32)(ii) of Regulation S‑K and SEC Release No. 34‑47986, the certifications furnished in Exhibits 32.1 and 32.2 hereto are deemed to accompany this Form 10‑K and will not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or deemed to be incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933 except to the extent that the registrant specifically incorporates it by reference.
&
Confidential treatment has been granted with respect to certain portions of this exhibit.
Copies of the above exhibits not contained herein are available to any stockholder, upon payment of a reasonable per page fee, upon written request to: Chief Financial Officer, Invitae Corporation, 1400 16th Street, San Francisco, California 94103.
(c)
Financial Statement Schedules: Reference is made to Item 15(a) 2 above.
ITEM 16.
Form 10-K Summary.
Not applicable.


101




SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
INVITAE CORPORATION
 
By:
/s/ Sean E. George, Ph.D.
 
 
Sean E. George, Ph.D.
President and Chief Executive Officer
Date: February 28, 2019
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Sean E. George and Shelly D. Guyer, and each of them, his true and lawful attorneys‑in‑fact, each with full power of substitution, for him or her in any and all capacities, to sign any amendments to this report on Form 10‑K and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that each of said attorneys‑ in‑fact or their substitute or substitutes may do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons, on behalf of the registrant on the dates and the capacities indicated.
Signature
 
Title
 
Date
 
 
 
 
 
/s/ Sean E. George, Ph.D.
 
President and Chief Executive Officer (Principal Executive Officer) and Director
 
February 28, 2019
Sean E. George, Ph.D.
 
 
 
 
 
 
 
 
/s/ Shelly D. Guyer
 
Chief Financial Officer
(Principal Financial and Accounting Officer)
 
February 28, 2019
Shelly D. Guyer
 
 
 
 
 
 
 
 
/s/ Randal W. Scott, Ph.D.
 
Executive Chairman of the Board of Directors
 
February 28, 2019
Randal W. Scott, Ph.D.
 
 
 
 
 
 
 
 
/s/ Eric Aguiar, M.D.
 
Director
 
February 28, 2019
Eric Aguiar, M.D.
 
 
 
 
 
 
 
 
/s/ Geoffrey S. Crouse
 
Director
 
February 28, 2019
Geoffrey S. Crouse
 
 
 
 
 
 
 
 
/s/ Christine M. Gorjanc
 
Director
 
February 28, 2019
Christine M. Gorjanc
 
 
 
 
 
 
 
 
/s/ Chitra Nayak
 
Director
 
February 28, 2019
Chitra Nayak
 
 
 

102
 EX-10.19 2 nvta-exhibit1019.htm EXHIBIT 10.19 Exhibit

Exhibit 10.19

INVITAE CORPORATION
$75,000,000

COMMON STOCK

SALES AGREEMENT
August 9, 2018

Cowen and Company, LLC
599 Lexington Avenue
New York, NY 10022

Ladies and Gentlemen:

Invitae Corporation, a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
1.  Issuance and Sale of Shares. The Company agrees that, from time to time during the term of this Agreement, on the terms and subject to the conditions set forth herein, it may issue and sell through Cowen, acting as agent and/or principal, shares of the Company’s common stock, $0.0001 par value per share (the “Common Stock”), having an aggregate offering price of up to $75,000,000.00 (the “Placement Shares”). Notwithstanding anything to the contrary contained herein, the parties hereto agree that compliance with the limitation set forth in this Section 1 on the number of shares of Common Stock issued and sold under this Agreement shall be the sole responsibility of the Company, and Cowen shall have no obligation in connection with such compliance. The issuance and sale of Common Stock through Cowen will be effected pursuant to the Registration Statement (as defined below) being filed by the Company and which will be declared effective by the Securities and Exchange Commission (the “Commission”), although nothing in this Agreement shall be construed as requiring the Company to use the Registration Statement (as defined below) to issue the Common Stock.
The Company has filed or will file, in accordance with the provisions of the Securities Act of 1933, as amended, and the rules and regulations thereunder (collectively, the “Securities Act”), with the Commission a registration statement on Form S-3, including a base prospectus, relating to certain securities, including the Common Stock, to be issued from time to time by the Company, and which incorporates by reference documents that the Company has filed or will file in accordance with the provisions of the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder (collectively, the “Exchange Act”). The Company has prepared a prospectus supplement specifically relating to the Placement Shares (the “Prospectus Supplement”) to the base prospectus



included as part of such registration statement. Following the date that such registration statement is declared effective, the Company shall furnish to Cowen, for use by Cowen, copies of the base prospectus included as part of such registration statement, as supplemented by the Prospectus Supplement, relating to the Placement Shares. Except where the context otherwise requires, such registration statement, as amended when it becomes effective, including all documents filed as part thereof or incorporated by reference therein, and including any information contained in a Prospectus (as defined below) subsequently filed with the Commission pursuant to Rule 424(b) under the Securities Act or deemed to be a part of such registration statement pursuant to Rule 430B or 462(b) of the Securities Act, is herein called the “Registration Statement.” The base prospectus, including all documents incorporated therein by reference, included in the Registration Statement, as it may be supplemented by the Prospectus Supplement, in the form in which such base prospectus and/or Prospectus Supplement have most recently been filed by the Company with the Commission pursuant to Rule 424(b) under the Securities Act, together with any “issuer free writing prospectus,” as defined in Rule 433 of the Securities Act regulations (“Rule 433”), relating to the Placement Shares that (i) is required to be filed with the Commission by the Company or (ii) is exempt from filing pursuant to Rule 433(d)(5)(i), in each case in the form filed or required to be filed with the Commission or, if not required to be filed, in the form retained in the Company’s records pursuant to Rule 433(g), is herein called the “Prospectus.” Any reference herein to the Registration Statement, the Prospectus or any amendment or supplement thereto shall be deemed to refer to and include the documents incorporated by reference therein, and any reference herein to the terms “amend,” “amendment” or “supplement” with respect to the Registration Statement or the Prospectus shall be deemed to refer to and include the filing after the execution hereof of any document with the Commission deemed to be incorporated by reference therein. For purposes of this Agreement, all references to the Registration Statement, the Prospectus or to any amendment or supplement thereto shall be deemed to include any copy filed with the Commission pursuant to the Electronic Data Gathering, Analysis, and Retrieval system or any successor thereto (“EDGAR”).
2.      Placements. Each time that the Company wishes to issue and sell any Placement Shares hereunder (each, a “Placement”), it will notify Cowen by email notice (or other method mutually agreed to in writing by the parties) (a “Placement Notice”) containing the parameters in accordance with which it desires the Placement Shares to be sold, which shall at a minimum include the number of Placement Shares to be issued, the time period during which sales are requested to be made, any limitation on the number of Placement Shares that may be sold in any one Trading Day (as defined in Section 3) and any minimum price below which sales may not be made, a form of which containing such minimum sales parameters necessary is attached hereto as Schedule 1. The Placement Notice shall originate from any of the individuals from the Company set forth on Schedule 2 (with a copy to each of the other individuals from the Company listed on such schedule), and shall be addressed to each of the individuals from Cowen set forth on Schedule 2, as such Schedule 2 may be amended from time to time. The Placement Notice shall be effective upon receipt by Cowen unless and until (i) in accordance with the notice requirements set forth in Section 4, Cowen declines to accept the terms contained therein for any reason, in its sole discretion, (ii) the entire amount of the Placement Shares thereunder have been sold, (iii) in accordance with the notice requirements set forth in Section 4, the Company suspends or terminates the Placement Notice, (iv) the Company issues a subsequent Placement Notice with parameters superseding those

2


on the earlier dated Placement Notice, or (v) this Agreement has been terminated under the provisions of Section 11. The amount of any discount, commission or other compensation to be paid by the Company to Cowen in connection with the sale of the Placement Shares shall be calculated in accordance with the terms set forth in Schedule 3. It is expressly acknowledged and agreed that neither the Company nor Cowen will have any obligation whatsoever with respect to a Placement or any Placement Shares unless and until the Company delivers a Placement Notice to Cowen and Cowen does not decline such Placement Notice pursuant to the terms set forth above, and then only upon the terms specified therein and herein. In the event of a conflict between the terms of this Agreement and the terms of a Placement Notice, the terms of the Placement Notice will control.
3.      Sale of Placement Shares by Cowen. Subject to the terms and conditions herein set forth, upon the Company’s delivery of a Placement Notice, and unless the sale of the Placement Shares described therein has been declined, suspended, or otherwise terminated in accordance with the terms of this Agreement, Cowen, for the period specified in the Placement Notice, will use its commercially reasonable efforts consistent with its normal trading and sales practices and applicable state and federal laws, rules and regulations and the rules of the New York Stock Exchange (the “NYSE”) to sell such Placement Shares up to the amount specified in such Placement Notice, and otherwise in accordance with the terms of such Placement Notice. Cowen will provide written confirmation to the Company (including by email correspondence to each of the individuals of the Company set forth on Schedule 2, if receipt of such correspondence is actually acknowledged by any of the individuals to whom the notice is sent, other than via auto-reply) no later than the opening of the Trading Day (as defined below) immediately following the Trading Day on which it has made sales of Placement Shares hereunder setting forth the number of Placement Shares sold on such day, the volume-weighted average price of the Placement Shares sold, and the Net Proceeds (as defined below) payable to the Company. Subject to the terms of a Placement Notice, Cowen may sell Placement Shares by any method permitted by law deemed to be an “at the market offering” as defined in Rule 415(a)(4) of the Securities Act, including without limitation sales made through the NYSE or on any other existing trading market for the Common Stock. Notwithstanding the provisions of Section 6(ddd), Cowen shall not purchase Placement Shares for its own account as principal unless expressly authorized to do so by the Company in a Placement Notice. The Company acknowledges and agrees that (i) there can be no assurance that Cowen will be successful in selling Placement Shares, and (ii) Cowen will incur no liability or obligation to the Company or any other person or entity if it does not sell Placement Shares for any reason other than a failure by Cowen to use its commercially reasonable efforts consistent with its normal trading and sales practices to sell such Placement Shares as required under this Section 3. For the purposes hereof, “Trading Day” means any day on which the Company’s Common Stock is purchased and sold on the principal market on which the Common Stock is listed or quoted.
4.      Suspension of Sales.
(a)    The Company or Cowen may, upon notice to the other party in writing (including by email correspondence to each of the individuals of the other party set forth on Schedule 2, if receipt of such correspondence is actually acknowledged by any of the individuals to whom the notice is sent, other than via auto-reply) or by telephone (confirmed immediately by verifiable

3


facsimile transmission or email correspondence to each of the individuals of the other party set forth on Schedule 2), suspend any sale of Placement Shares; provided, however, that such suspension shall not affect or impair either party’s obligations with respect to any Placement Shares sold hereunder prior to the receipt of such notice. Each of the parties agrees that no such notice under this Section 4 shall be effective against the other unless it is made to one of the individuals named on Schedule 2 hereto, as such schedule may be amended from time to time.
(b)    Notwithstanding any other provision of this Agreement, during any period in which the Company is in possession of material non-public information, the Company and Cowen agree that (i) no sale of Placement Shares will take place, (ii) the Company shall not request the sale of any Placement Shares, and (iii) Cowen shall not be obligated to sell or offer to sell any Placement Shares.

(c)    If either Cowen or the Company has reason to believe that the exemptive provisions set forth in Rule 101(c)(1) of Regulation M under the Exchange Act are not satisfied with respect to the Common Stock, it shall promptly notify the other party, and Cowen may, at its sole discretion, suspend sales of the Placement Shares under this Agreement.

(d)    Notwithstanding any other provision of this Agreement, during any period in which the Registration Statement is no longer effective under the Securities Act, the Company shall promptly notify Cowen, the Company shall not request the sale of any Placement Shares, and Cowen shall not be obligated to sell or offer to sell any Placement Shares.

5.      Settlement.
(a)         Settlement of Placement Shares. Unless otherwise specified in the applicable Placement Notice, settlement for sales of Placement Shares will occur on the second (2nd) Trading Day (or such earlier day as is industry practice for regular-way trading) following the date on which such sales are made (each, a “Settlement Date” and the first such settlement date, the “First Delivery Date”). The amount of proceeds to be delivered to the Company on a Settlement Date against receipt of the Placement Shares sold (the “Net Proceeds”) will be equal to the aggregate sales price received by Cowen at which such Placement Shares were sold, after deduction for (i) Cowen’s commission, discount or other compensation for such sales payable by the Company pursuant to Section 2 hereof, (ii) any other amounts due and payable by the Company to Cowen hereunder pursuant to Section 7(g) (Expenses) hereof, and (iii) any transaction fees imposed by any governmental or self-regulatory organization in respect of such sales.
(b)         Delivery of Placement Shares. On or before each Settlement Date, the Company will, or will cause its transfer agent to, electronically transfer the Placement Shares being sold by crediting Cowen’s or its designee’s account (provided that Cowen shall have given the Company written notice of such designee at least one Trading Day prior to the Settlement Date) at The Depository Trust Company through its Deposit and Withdrawal at Custodian System or by such other means of delivery as may be mutually agreed upon by the parties hereto which in all cases shall be freely tradeable, transferable, registered shares in good deliverable form. On each

4


Settlement Date, Cowen will deliver the related Net Proceeds in same day funds to an account designated by the Company on, or prior to, the Settlement Date. The Company agrees that if the Company, or its transfer agent (if applicable), defaults in its obligation to deliver duly authorized Placement Shares on a Settlement Date, the Company agrees that in addition to and in no way limiting the rights and obligations set forth in Section 9(a) (Indemnification and Contribution) hereto, it will (i) hold Cowen harmless against any loss, claim, damage, or reasonable and documented expense (including reasonable and documented legal fees and expenses), as incurred, arising out of or in connection with such default by the Company and (ii) pay to Cowen (without duplication) any commission, discount, or other compensation to which it would otherwise have been entitled absent such default.
6.      Representations and Warranties of the Company. The Company represents and warrants to, and agrees with, Cowen that, unless such representation and warranty specifies a different time, as of the date of this Agreement, each Representation Date (as defined in Section 7(m)), each date on which a Placement Notice is given, and any date on which Placement Shares are sold hereunder:
(a)     Compliance with Registration Requirements. The Registration Statement and any Rule 462(b) Registration Statement has been or will be declared effective by the Commission under the Securities Act prior to the delivery of any Placement Notice by the Company. The Company has complied to the Commission’s satisfaction with all requests of the Commission for additional or supplemental information in connection therewith. No stop order suspending the effectiveness of the Registration Statement or any Rule 462(b) Registration Statement is in effect and no proceedings for such purpose have been instituted or are pending or, to the knowledge of the Company, threatened by the Commission. The Company meets the requirements for use of Form S‑3 under the Securities Act. The sale of the Placement Shares hereunder meets the requirements of General Instruction I.B.1 of Form S-3.
(b)     No Misstatement or Omission. The Prospectus when filed complied and, as amended or supplemented, if applicable, will comply in all material respects with the Securities Act. Each of the Registration Statement, any Rule 462(b) Registration Statement, the Prospectus and any post-effective amendments or supplements thereto, at the time it became effective or its date, as applicable, complied and as of each of the Settlement Dates, if any, will comply in all material respects with the Securities Act and did not and, as of each Settlement Date, if any, will not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading. The Prospectus, as amended or supplemented, as of its date, did not and, as of each of the Settlement Dates, if any, will not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. The representations and warranties set forth in the two immediately preceding sentences do not apply to statements in or omissions from the Registration Statement, any Rule 462(b) Registration Statement, or any post-effective amendment thereto, or the Prospectus, or any amendments or supplements thereto, made in reliance upon and in conformity with information relating to Cowen furnished to the Company in writing by Cowen expressly for use therein. There are no contracts or other documents required

5


to be described in the Prospectus or to be filed as exhibits to the Registration Statement which have not been described or filed as required.
(c)     Offering Materials Furnished to Cowen. The Company has delivered to Cowen one complete copy of the Registration Statement and a copy of each consent and certificate of experts filed as a part thereof, and conformed copies of the Registration Statement (without exhibits) and the Prospectus, as amended or supplemented, in such quantities and at such places as Cowen has reasonably requested.
(d)     Emerging Growth Company. From the time of initial confidential submission of the registration statement relating to the Company’s initial public offering to the Commission (or, if earlier, the first date on which the Company engaged directly or through any person authorized to act on its behalf in any Testing-the-Waters Communication) through the date hereof, the Company has been and is an “emerging growth company,” as defined in Section 2(a) of the Securities Act (an “Emerging Growth Company”).
(e)     Incorporated Documents. The documents incorporated by reference in the Registration Statement and the Prospectus, when they were filed with the Commission conformed in all material respects to the requirements of the Exchange Act, and none of such documents contained any untrue statement of a material fact or omitted to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading; and any further documents so filed and incorporated by reference in the Registration Statement or the Prospectus, when such documents are filed with the Commission, will conform in all material respects to the requirements of the Exchange Act and will not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading.
(f)     Financial Statements. The financial statements (including the related notes thereto) of the Company and its consolidated subsidiaries and CombiMatrix Corporation included or incorporated by reference in the Registration Statement and the Prospectus comply in all material respects with the applicable requirements of the Securities Act and the Exchange Act, as applicable, and present fairly, in all material respects, the financial position of the Company and its consolidated subsidiaries and CombiMatrix Corporation as of the dates indicated and the results of their operations and the changes in their cash flows for the periods specified; such financial statements have been prepared in conformity with generally accepted accounting principles in the United States (“GAAP”) applied on a consistent basis throughout the periods covered thereby, and any supporting schedules included or incorporated by reference in the Registration Statement present fairly, in all material respects, the information required to be stated therein; and the other financial information included or incorporated by reference in the Registration Statement and the Prospectus has been derived from the accounting records of the Company and its consolidated subsidiaries and CombiMatrix Corporation and presents fairly the information shown thereby.
(g)     No Material Adverse Change. Since the date of the most recent financial statements of the Company included or incorporated by reference in the Registration Statement and the Prospectus, (i) there has not been any change in the capital stock (other than the issuance of shares

6


of Common Stock upon exercise of stock options and warrants described as outstanding in, the grant of options and awards under existing equity incentive plans described in, and the issuance of Common Stock in connection with acquisitions described in, the Registration Statement and the Prospectus), short-term debt or long-term debt of the Company or any of its subsidiaries, or any dividend or distribution of any kind declared, set aside for payment, paid or made by the Company on any class of capital stock, or any material adverse change, or any development that would reasonably be expected to result in a material adverse change, in or affecting the business, properties, management, financial position, stockholders’ equity, results of operations or prospects of the Company and its subsidiaries taken as a whole; (ii) neither the Company nor any of its subsidiaries has entered into any transaction or agreement (whether or not in the ordinary course of business) that is material to the Company and its subsidiaries taken as a whole or incurred any liability or obligation, direct or contingent, that is material to the Company and its subsidiaries taken as a whole; and (iii) neither the Company nor any of its subsidiaries has sustained any loss or interference with its business that is material to the Company and its subsidiaries taken as a whole and that is either from fire, explosion, flood or other calamity, whether or not covered by insurance, or from any labor disturbance or dispute or any action, order or decree of any court or arbitrator or governmental or regulatory authority, except in each case as otherwise disclosed in the Registration Statement and the Prospectus.
(h)     Organization and Good Standing. The Company and each of its subsidiaries have been duly organized and are validly existing and in good standing under the laws of their respective jurisdictions of organization, are duly qualified to do business and are in good standing in each jurisdiction in which their respective ownership or lease of property or the conduct of their respective businesses requires such qualification, and have all power and authority necessary to own or hold their respective properties and to conduct the businesses in which they are engaged, except where the failure to be so qualified or in good standing or have such power or authority would not, individually or in the aggregate, have a material adverse effect on the business, properties, management, financial position, stockholders’ equity, results of operations or prospects of the Company and its subsidiaries taken as a whole or on the performance by the Company of its obligations under this Agreement (a “Material Adverse Effect”). Except as disclosed in the Registration Statement and the Prospectus, the Company does not own or control, directly or indirectly, any corporation, association or other entity other than the subsidiaries listed in Exhibit 21 to the Company’s most recently filed Annual Report on Form 10-K. The subsidiaries listed in Schedule 4 to this Agreement are the only significant subsidiaries of the Company as of the end of the Company’s most recently completed fiscal year.
(i)     Capitalization. The Company has an authorized capitalization as set forth in the Registration Statement and the Prospectus under the heading “Description of Capital Stock”; all the outstanding shares of capital stock of the Company have been duly and validly authorized and issued and are fully paid and non-assessable and are not subject to any pre-emptive or similar rights; except as described in or expressly contemplated by the Prospectus, there are no outstanding rights (including, without limitation, pre-emptive rights), warrants or options to acquire, or instruments convertible into or exchangeable for, any shares of capital stock or other equity interest in the Company or any of its subsidiaries, or any contract, commitment, agreement, understanding or

7


arrangement of any kind relating to the issuance of any capital stock of the Company or any such subsidiary, any such convertible or exchangeable securities or any such rights, warrants or options; the capital stock of the Company conforms in all material respects to the description thereof contained in the Registration Statement and the Prospectus; and all the outstanding shares of capital stock or other equity interests of each subsidiary owned, directly or indirectly, by the Company have been duly and validly authorized and issued, are fully paid and non-assessable (except, in the case of any foreign subsidiary, for directors’ qualifying shares) and are owned directly or indirectly by the Company, free and clear of any lien, charge, encumbrance, security interest, restriction on voting or transfer or any other claim of any third party.
(j)     Stock Options. With respect to the stock options (the “Stock Options”) granted pursuant to the stock-based compensation plans of the Company and its subsidiaries (the “Company Stock Plans”), (i) each Stock Option intended to qualify as an “incentive stock option” under Section 422 of the Internal Revenue Code of 1986, as amended (the “Code”) so qualifies, (ii) each grant of a Stock Option was duly authorized no later than the date on which the grant of such Stock Option was by its terms to be effective by all necessary corporate action, including, as applicable, approval by the board of directors of the Company (or a duly constituted and authorized committee thereof) and any required stockholder approval by the necessary number of votes or written consents, and the award agreement governing such grant (if any) was duly executed and delivered by each party thereto, (iii) each such grant was made in accordance with the terms of the Company Stock Plans and, to the extent applicable, the Exchange Act and the rules of the NYSE, and (iv) each such grant was properly accounted for in accordance with GAAP in the financial statements (including the related notes) of the Company. Each Company Stock Plan is accurately described in all material respects in the Registration Statement and the Prospectus.
(k)     Due Authorization. The Company has full right, power and authority to execute and deliver this Agreement and to perform its obligations hereunder; and all action required to be taken for the due and proper authorization, execution and delivery by it of this Agreement and the consummation by it of the transactions contemplated hereby has been duly and validly taken.
(l)     Sales Agreement. This Agreement has been duly authorized, executed and delivered by the Company.
(m)     The Placement Shares. The Placement Shares to be issued and sold by the Company hereunder have been duly authorized by the Company and, when issued and delivered and paid for as provided herein, will be duly and validly issued, will be fully paid and nonassessable and will conform to the descriptions thereof in the Registration Statement and the Prospectus; and the issuance of the Placement Shares is not subject to any preemptive or similar rights.
(n)     No Violation or Default. Neither the Company nor any of its subsidiaries is (i) in violation of its charter or by-laws or similar organizational documents; (ii) in default, and no event has occurred that, with notice or lapse of time or both, would constitute such a default, in the due performance or observance of any term, covenant or condition contained in any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company or any of its subsidiaries is a party or by which the Company or any of its subsidiaries is bound or to which any

8


of the property or assets of the Company or any of its subsidiaries is subject; or (iii) in violation of any law or statute or any judgment, order, rule or regulation of any court or arbitrator or governmental or regulatory authority, except, in the case of clauses (ii) and (iii) above, for any such default or violation that would not, individually or in the aggregate, have a Material Adverse Effect.
(o)     No Conflicts. The execution, delivery and performance by the Company of this Agreement, the issuance and sale of the Placement Shares and the consummation by the Company of the transactions contemplated by this Agreement will not (i) conflict with or result in a breach or violation of any of the terms or provisions of, or constitute a default under, or result in the creation or imposition of any lien, charge or encumbrance upon any property or assets of the Company or any of its subsidiaries pursuant to, any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company or any of its subsidiaries is a party or by which the Company or any of its subsidiaries is bound or to which any of the property or assets of the Company or any of its subsidiaries is subject, (ii) result in any violation of the provisions of the charter or by-laws or similar organizational documents of the Company or any of its subsidiaries or (iii) result in the violation of any law or statute or any judgment, order, rule or regulation of any court or arbitrator or governmental or regulatory authority, except, in the case of clauses (i) and (iii) above, for any such conflict, breach, violation or default that would not, individually or in the aggregate, have a Material Adverse Effect.
(p)     No Consents Required. No consent, filing, approval, authorization, order, license, registration or qualification of or with any court or arbitrator or governmental or regulatory authority is required for the execution, delivery and performance by the Company of this Agreement, the issuance and sale of the Placement Shares and the consummation of the transactions contemplated by this Agreement, except for the registration of the Placement Shares under the Securities Act and such consents, approvals, authorizations, orders and registrations or qualifications as may be required by the Financial Industry Regulatory Authority, Inc. (“FINRA”), the NYSE and under applicable state securities laws in connection with the purchase and distribution of the Placement Shares by Cowen.
(q)     Legal Proceedings. Except as described in the Registration Statement and the Prospectus: (x) there are no legal, governmental or regulatory investigations, actions, suits or proceedings pending to which the Company or any of its subsidiaries is or may be a party or to which any property of the Company or any of its subsidiaries is or may be the subject that, individually or in the aggregate, if determined adversely to the Company or any of its subsidiaries, could reasonably be expected to have a Material Adverse Effect or have a material adverse effect on the power or ability of the Company to perform its obligations under this Agreement or to consummate the transactions contemplated hereby; (y) to the knowledge of the Company, no such investigations, actions, suits or proceedings are threatened or contemplated by any governmental or regulatory authority or threatened by others; and (z) (i) there are no current or pending legal, governmental or regulatory actions, suits or proceedings that are required under the Securities Act to be described in the Registration Statement or the Prospectus that are not so described in the Registration Statement and the Prospectus and (ii) there are no statutes, regulations or contracts or other documents that are required under the Securities Act to be filed as exhibits to the Registration

9


Statement or described in the Registration Statement or the Prospectus that are not so filed as exhibits to the Registration Statement or described in the Registration Statement and the Prospectus.
(r)     Independent Accountants. Ernst & Young LLP, who has certified certain financial statements of the Company and its subsidiaries, is an independent registered public accounting firm with respect to the Company and its subsidiaries within the applicable rules and regulations adopted by the Commission and the Public Company Accounting Oversight Board (United States) and as required by the Securities Act.
(s)     Title to Real and Personal Property. The Company and its subsidiaries have good and marketable title in fee simple (in the case of real property) to, or have valid and marketable rights to lease or otherwise use, all items of real and personal property and assets that are material to the respective businesses of the Company and its subsidiaries, in each case free and clear of all liens, encumbrances, claims and defects and imperfections of title except those that (i) do not materially interfere with the use made and proposed to be made of such property by the Company and its subsidiaries, (ii) could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect or (iii) result from the lease of such property and assets, to the extent applicable.
(t)     Title to Intellectual Property. Except as described in the Registration Statement and the Prospectus or as could not reasonably be expected to result in a Material Adverse Effect, to the Company’s knowledge (i) the Company and its subsidiaries own, possess, license or can acquire or license on reasonable terms all material patents, patent applications, trademarks, service marks, trade names, trademark registrations, service mark registrations, copyrights, licenses and know-how (including trade secrets and other unpatented and/or unpatentable proprietary or confidential information, systems or procedures) necessary for the conduct of their respective businesses as currently conducted and as proposed to be conducted in the manner described in the Registration Statement and the Prospectus (collectively, “Intellectual Property”), and (ii) the conduct of their respective businesses does not and will not conflict in any material respect with any valid and enforceable Intellectual Property rights of others. Except as described in the Registration Statement and the Prospectus, the Company and its subsidiaries have not received any notice of any claim of infringement, misappropriation or conflict with any intellectual property rights of another in connection with its patents, patent applications, patent rights, licenses, inventions, trademarks, service marks, trade names, copyrights and know-how which could reasonably be expected to result in a Material Adverse Effect, and the Company is unaware of any facts which would form a reasonable basis for any such notice or claim. To the Company’s knowledge, (i) there are no third party rights to any of the Intellectual Property that is disclosed in the Registration Statement and the Prospectus as owned by the Company (the “Company Intellectual Property”); and (ii) there is no material infringement by third parties of any of the Company Intellectual Property. Except as disclosed in the Registration Statement and the Prospectus or as could not reasonably be expected to result in a Material Adverse Effect, there is no pending or, to the Company’s knowledge, threatened action, suit, proceeding or claim by others: (A) challenging the Company’s rights in or to any Intellectual Property, and the Company is unaware of any facts which would form a reasonable basis for any such action, suit, proceeding or claim; (B) challenging the validity, enforceability or

10


scope of any Intellectual Property, and the Company is unaware of any facts which would form a reasonable basis for any such action, suit, proceeding or claim; or (C) asserting that the Company or its subsidiaries infringe, misappropriate, or otherwise violate, or would, upon the commercialization of any product or service described in the Registration Statement and the Prospectus as under development, infringe, misappropriate, or otherwise violate, any intellectual property rights of others, and the Company is unaware of any facts which would form a reasonable basis for any such action, suit, proceeding or claim. To the knowledge of the Company, the Company and its subsidiaries have complied with the terms of each agreement pursuant to which Intellectual Property has been licensed to the Company or its subsidiaries, and all such agreements are in full force and effect. To the Company’s knowledge, and except as is disclosed in the Registration Statement and the Prospectus, there are no material defects in any of the patents or patent applications included in the Company Intellectual Property.
(u)     Trade Secrets. The Company and its subsidiaries have taken reasonable and customary actions to protect their rights in and prevent the unauthorized use and disclosure of material trade secrets and confidential business information (including confidential source code, ideas, research and development information, know-how, formulas, compositions, technical data, designs, drawings, specifications, research records, records of inventions, test information, financial, marketing and business data, customer and supplier lists and information, pricing and cost information, business and marketing plans and proposals) owned by the Company and its subsidiaries, and, to the knowledge of the Company, there has been no material unauthorized use or disclosure.
(v)      IT Assets. Except as could not reasonably be expected to have a Material Adverse Effect, (i) the computers, software, servers, networks, data communications lines, and other information technology systems owned, licensed, leased or otherwise used by the Company or its subsidiaries (excluding any public networks) (collectively, the “IT Assets”) operate and perform as is reasonably necessary for the operation of the business of the Company and its subsidiaries as currently conducted and as proposed to be conducted as described in the Registration Statement and the Prospectus, and (ii) to the Company’s knowledge such IT Assets are not infected by viruses, disabling code or other harmful code.
(w)     Data Privacy and Security Laws. The Company and its subsidiaries are, and at all prior times were, in material compliance with all applicable state and federal data privacy and security laws and regulations, including without limitation the Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) as amended by the Health Information Technology for Economic and Clinical Health Act (the “HITECH Act”) (collectively, the “Privacy Laws”). To ensure compliance with the Privacy Laws, the Company and its subsidiaries have in place, comply with, and take appropriate steps reasonably designed to ensure compliance in all material respects with their policies and procedures relating to data privacy and security and the collection, storage, use, disclosure, handling, and analysis of Personal Data (the “Policies”). “Personal Data” means (i) a natural person’s name, street address, telephone number, e-mail address, photograph, social security number or tax identification number, driver’s license number, passport number, credit card number, bank information, or customer or account number; (ii) any information which would qualify

11


as “personally identifying information” under the Federal Trade Commission Act, as amended; (iii) Protected Health Information as defined by HIPAA; and (iv) any other piece of information that allows the identification of such natural person, or his or her family, or permits the collection or analysis of any data related to an identified person’s health or sexual orientation. The Company and its subsidiaries have at all times made all disclosures to users or customers required by applicable laws and regulatory rules or requirements, and no disclosure made pursuant to any Policy has, to the knowledge of the Company, been inaccurate or in violation of any applicable laws and regulatory rules or requirements in any material respect. The Company further certifies that neither it nor any subsidiary: (i) has received notice of any actual or potential material liability under or relating to, or actual or potential material violation of, any of the Privacy Laws, and has no knowledge of any event or condition that would reasonably be expected to result in any such notice; (ii) is currently conducting or paying for, in whole or in part, any investigation, remediation or other corrective action pursuant to any Privacy Law; or (iii) is a party to any order, decree, or agreement that imposes any obligation or liability under any Privacy Law.
(x)     No Complaints. There is no complaint, audit, proceeding, investigation (formal or informal) or claim currently pending against the Company or its subsidiaries, or to the knowledge of the Company, any of its customers (specific to the customer’s use of the products or services of the Company) by the Federal Trade Commission, the U.S. Department of Health and Human Services and any office contained therein (“HHS”), or any similar authority in any jurisdiction other than the United States or any other governmental entity, or by any person with respect to the collection, use or disclosure of Personal Data by the Company or its subsidiaries, and, to the knowledge of the Company, no such complaint, audit, proceeding, investigation or claim is threatened.
(y)     Clinical Data. The descriptions of the results of any studies and tests conducted by or on behalf of, or sponsored by, the Company or its subsidiaries, or in which the Company has participated, that are described in the Registration Statement and the Prospectus, or the results of which are referred to in the Registration Statement and the Prospectus do not contain any misstatement of material fact or omit to state a material fact necessary to make such statements not misleading. The Company has no knowledge of any studies or tests not described in the Registration Statement and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement or Prospectus.
(z)      Compliance with Health Care Laws. The Company and its subsidiaries are, and at all times have been, in compliance in all material respects with all applicable Health Care Laws. For purposes of this Agreement, “Health Care Laws” means: (i) the Federal Food, Drug, and Cosmetic Act and the regulations promulgated thereunder; (ii) all applicable federal, state, local and foreign health care laws, including, without limitation, the Clinical Laboratory Improvement Amendments of 1988 (42 U.S.C. Section 263a et seq.), the U.S. Anti-Kickback Statute (42 U.S.C. Section 1320a-7b(b)), the Anti-Inducement Law (42 U.S.C. § 1320a-7a(a)(5)), the U.S. Civil False Claims Act (31 U.S.C. Section 3729 et seq.), the criminal False Statements Law (42 U.S.C. Section 1320a-7b(a)), 18 U.S.C. Sections 286 and 287, the health care fraud criminal provisions under HIPAA (42 U.S.C. Section 1320d et seq.), the Stark Law (42 U.S.C. Section 1395nn), the civil

12


monetary penalties law (42 U.S.C. Section 1320a-7a), the exclusion laws, laws governing government funded or sponsored healthcare programs, and the directives and regulations promulgated pursuant to such statutes and any state or non-U.S. counterpart thereof; (iii) HIPAA, as amended by the HITECH Act (42 U.S.C. Section 17921 et seq.); (iv) the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Affordability Reconciliation Act of 2010, the regulations promulgated thereunder; (v) licensure, quality, safety and accreditation requirements under applicable federal, state, local or foreign laws or regulatory bodies; and (vi) all other local, state, federal, national, supranational and foreign laws, relating to the regulation of the Company or its subsidiaries. Neither the Company, any of its subsidiaries, nor to the Company’s knowledge, any of its officers, directors, employees or agents have engaged in activities which are, as applicable, cause for material liability under a Health Care Law. Neither the Company nor any of its subsidiaries has received written notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any court or arbitrator or governmental or regulatory authority or third party alleging a material violation of any Health Care Laws nor, to the Company’s knowledge, is any such claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action threatened. The Company and its subsidiaries have filed, maintained or submitted all material reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by the applicable Health Care Laws, and all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were complete and accurate on the date filed in all material respects (or were corrected or supplemented by a subsequent submission). Neither the Company nor any of its subsidiaries is a party to any corporate integrity agreements, monitoring agreements, consent decrees, settlement orders, or similar agreements with or imposed by any governmental or regulatory authority. Additionally, neither the Company, any of its subsidiaries nor any of their respective employees, officers, directors, or agents has been excluded, suspended or debarred from participation in any U.S. federal health care program or human clinical research or, to the knowledge of the Company, is subject to a governmental inquiry, investigation, proceeding, or other similar action that could reasonably be expected to result in debarment, suspension, or exclusion.
(aa)     Clinical Laboratory Tests. The Company’s clinical laboratory tests are conducted in compliance in all material respects with all applicable Health Care Laws, and, to the extent applicable, the respective counterparts thereof promulgated by governmental authorities in countries outside the United States. The Company has not received notice from the FDA, HHS or other governmental authority alleging or asserting material noncompliance with any applicable Health Care Law. To the Company’s knowledge, neither the FDA nor any other governmental authority is considering such action.
(bb)     No Undisclosed Relationships. No relationship, direct or indirect, exists between or among the Company or any of its subsidiaries, on the one hand, and the directors, officers or stockholders of the Company or, to the knowledge of the Company, the customers or suppliers of the Company or any of its subsidiaries, on the other, that is required by the Securities Act to be described in the Registration Statement and the Prospectus and that is not so described in such documents.

13


(cc)     Investment Company Act. The Company is not and, after giving effect to the offering and sale of the Placement Shares and the application of the proceeds thereof as described in the Registration Statement and the Prospectus, will not be required to register as an “investment company” or an entity “controlled” by an “investment company” within the meaning of the Investment Company Act of 1940, as amended, and the rules and regulations of the Commission thereunder (collectively, the “Investment Company Act”).
(dd)     Taxes. The Company and its subsidiaries have paid all federal, state, local and foreign taxes and filed all tax returns required to be paid or filed through the date hereof; and except as otherwise disclosed in the Registration Statement and the Prospectus, there is no tax deficiency that has been, or could reasonably be expected to be, asserted against the Company or any of its subsidiaries or any of their respective properties or assets.
(ee)     Licenses and Permits. The Company and its subsidiaries possess all licenses, certificates, permits and other authorizations issued by, and have made all declarations and filings with, the appropriate federal, state, local or foreign governmental or regulatory authorities that are necessary for the ownership or lease of their respective properties or the conduct of their respective businesses as described in the Registration Statement and the Prospectus, except where the failure to possess or make the same would not, individually or in the aggregate, have a Material Adverse Effect; and except as described in the Registration Statement and the Prospectus, neither the Company nor any of its subsidiaries has received notice of any revocation or modification of any such license, certificate, permit or authorization or has any reason to believe that any such license, certificate, permit or authorization will not be renewed in the ordinary course. To the Company’s knowledge, no party granting any such licenses, certificates, permits and other authorizations has taken any action to limit, suspend or revoke the same in any material respect. The Company and its subsidiaries have filed, obtained, maintained or submitted all material reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required and that all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were materially complete and correct on the date filed (or were corrected or supplemented by a subsequent submission) as required for maintenance of their licenses, certificates, permits and other authorizations that are necessary for the conduct of their respective businesses.
(ff)     No Labor Disputes. No labor disturbance by or dispute with employees of the Company or any of its subsidiaries exists or, to the knowledge of the Company, is contemplated or threatened, and the Company is not aware of any existing or imminent labor disturbance by, or dispute with, the employees of any of its or its subsidiaries’ principal suppliers, contractors or customers, except as would not have a Material Adverse Effect.
(gg)     Compliance with and Liability under Environmental Laws. (i) The Company and its subsidiaries (a) are, and at all prior times were, in material compliance with any and all applicable federal, state, local and foreign laws, rules, regulations, requirements, decisions, judgments, decrees, orders and the common law relating to pollution or the protection of the environment, natural resources or human health or safety, including those relating to the generation, storage, treatment, use, handling, transportation, Release or threat of Release of Hazardous Materials (collectively,

14


“Environmental Laws”), (b) have received and are in compliance with all permits, licenses, certificates or other authorizations or approvals required of them under applicable Environmental Laws to conduct their respective businesses, (c) have not received notice of any actual or potential liability under or relating to, or actual or potential violation of, any Environmental Laws, including for the investigation or remediation of any Release or threat of Release of Hazardous Materials, and have no knowledge of any event or condition that would reasonably be expected to result in any such notice, (d) are not conducting or paying for, in whole or in part, any investigation, remediation or other corrective action pursuant to any Environmental Law at any location, and (e) are not a party to any order, decree or agreement that imposes any obligation or liability under any Environmental Law, and (ii) there are no costs or liabilities associated with Environmental Laws of or relating to the Company or its subsidiaries, except in the case of each of (i) and (ii) above, for any such matter, as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; and (iii) except as described in the Registration Statement and the Prospectus, (a) there are no proceedings that are pending, or that are known to be contemplated, against the Company or any of its subsidiaries under any Environmental Laws in which a governmental entity is also a party, other than such proceedings regarding which it is reasonably believed no monetary sanctions of $100,000 or more will be imposed, (b) the Company and its subsidiaries are not aware of any facts or issues regarding the Company’s or its subsidiaries’ compliance with Environmental Laws, or liabilities or other obligations under Environmental Laws, including the Release or threat of Release of Hazardous Materials, that could reasonably be expected to have a material effect on the capital expenditures, earnings or competitive position of the Company and its subsidiaries, and (c) none of the Company and its subsidiaries anticipates material capital expenditures relating to any Environmental Laws.
(hh)     Hazardous Materials. There has been no storage, generation, transportation, use, handling, treatment, Release or threat of Release of Hazardous Materials by, relating to or caused by the Company or any of its subsidiaries (or, to the knowledge of the Company and its subsidiaries, any other entity (including any predecessor) for whose acts or omissions the Company or any of its subsidiaries is or could reasonably be expected to be liable) at, on, under or from any property or facility now or previously owned, operated or leased by the Company or any of its subsidiaries, or at, on, under or from any other property or facility, in violation of any Environmental Laws or in a manner or amount or to a location that could reasonably be expected to result in any liability under any Environmental Law, except for any violation or liability which would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. “Hazardous Materials” means any material, chemical, substance ,waste, pollutant, contaminant, compound, mixture, or constituent thereof, in any form or amount, including petroleum (including crude oil or any fraction thereof) and petroleum products, natural gas liquids, asbestos and asbestos containing materials, naturally occurring radioactive materials, brine, and drilling mud, regulated or which can give rise to liability under any Environmental Law. “Release” means any spilling, leaking, seepage, pumping, pouring, emitting, emptying, discharging, injecting, escaping, leaching, dumping, disposing, depositing, dispersing, or migrating in, into or through the environment, or in, into from or through any building or structure.

15


(ii)     Compliance with ERISA. (i) Each employee benefit plan, within the meaning of Section 3(3) of the Employee Retirement Income Security Act of 1974, as amended (“ERISA”), for which the Company or any member of its “Controlled Group” (defined as any organization which is a member of a controlled group of corporations within the meaning of Section 414 of the Code) would have any liability (each, a “Plan”) has been maintained in compliance with its terms and the requirements of any applicable statutes, orders, rules and regulations, including but not limited to ERISA and the Code, except for noncompliance that could not reasonably be expected to result in material liability to the Company or its subsidiaries; (ii) no prohibited transaction, within the meaning of Section 406 of ERISA or Section 4975 of the Code, has occurred with respect to any Plan excluding transactions effected pursuant to a statutory or administrative exemption that could reasonably be expected to result in a material liability to the Company or its subsidiaries; (iii) for each Plan that is subject to the funding rules of Section 412 of the Code or Section 302 of ERISA, the minimum funding standard of Section 412 of the Code or Section 302 of ERISA, as applicable, has been satisfied (without taking into account any waiver thereof or extension of any amortization period) and is reasonably expected to be satisfied in the future (without taking into account any waiver thereof or extension of any amortization period); (iv) the fair market value of the assets of each Plan exceeds the present value of all benefits accrued under such Plan (determined based on those assumptions used to fund such Plan); (v) no “reportable event” (within the meaning of Section 4043(c) of ERISA) has occurred or is reasonably expected to occur that either has resulted, or could reasonably be expected to result, in material liability to the Company or its subsidiaries; (vi) neither the Company nor any member of the Controlled Group has incurred, nor reasonably expects to incur, any liability under Title IV of ERISA (other than contributions to the Plan or premiums to the PBGC, in the ordinary course and without default) in respect of a Plan (including a “multiemployer plan”, within the meaning of Section 4001(a)(3) of ERISA); and (vii) there is no pending audit or investigation by the Internal Revenue Service, the U.S. Department of Labor, the Pension Benefit Guaranty Corporation or any other governmental agency or any foreign regulatory agency with respect to any Plan that could reasonably be expected to result in material liability to the Company or its subsidiaries. None of the following events has occurred or is reasonably likely to occur: (x) a material increase in the aggregate amount of contributions required to be made to all Plans by the Company or its subsidiaries in the current fiscal year of the Company and its subsidiaries compared to the amount of such contributions made in the Company and its subsidiaries’ most recently completed fiscal year; or (y) a material increase in the Company and its subsidiaries’ “accumulated post-retirement benefit obligations” (within the meaning of Statement of Financial Accounting Standards 106) compared to the amount of such obligations in the Company and its subsidiaries’ most recently completed fiscal year.
(jj)     Disclosure Controls. The Company and its subsidiaries maintain a system of disclosure controls and procedures (as defined in Rule 13a-15(e) of the Exchange Act) that are designed to comply with the requirements of the Exchange Act and that has been designed to ensure that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Commission’s rules and forms, including controls and procedures designed to ensure that such information is accumulated and communicated to the Company’s management as appropriate to allow timely decisions regarding required disclosure. The Company and its subsidiaries have

16


carried out evaluations of the effectiveness of their disclosure controls and procedures as required by Rule 13a-15 of the Exchange Act.
(kk)     Accounting Controls. The Company and its subsidiaries maintain a system of internal control over financial reporting (as defined in Rule 13a-15(f) of the Exchange Act) that comply with the requirements of the Exchange Act and have been designed by, or under the supervision of, their respective principal executive and principal financial officers, or persons performing similar functions, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP, including, but not limited to, internal accounting controls sufficient to provide reasonable assurance that (i) transactions are executed in accordance with management’s general or specific authorizations; (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability; (iii) access to assets is permitted only in accordance with management’s general or specific authorization; (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences and (v) interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement fairly presents the information called for in all material respects and is prepared in accordance with the Commission’s rules and guidelines applicable thereto. Except as disclosed in the Registration Statement and the Prospectus, there are no material weaknesses in the Company’s internal controls over financial reporting. The Company’s auditors and the Audit Committee of the Board of Directors of the Company have been advised of: (i) all significant deficiencies and material weaknesses in the design and operation of internal controls over financial reporting which have adversely affected or are reasonably likely to adversely affect the Company’s ability to record, process, summarize and report financial information; and (ii) any fraud, whether or not material, that involves management or other employees who have a significant role in the Company’s internal accounting controls over financial reporting.
(ll)     eXtensible Business Reporting Language. The interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement fairly presents the information called for in all material respects and has been prepared in accordance with the Commission’s rules and guidelines applicable thereto.
(mm)     Insurance. The Company and its subsidiaries have insurance covering their respective properties, operations, personnel and businesses, including business interruption insurance, which insurance is in amounts and insures against such losses and risks the Company reasonably believes as are adequate to protect the Company and its subsidiaries and their respective businesses; and neither the Company nor any of its subsidiaries has (i) received notice from any insurer or agent of such insurer that capital improvements or other expenditures are required or necessary to be made in order to continue such insurance or (ii) any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage at reasonable cost from similar insurers as may be necessary to continue its business.
(nn)     No Unlawful Contributions or Other Payments. Neither the Company nor any of its subsidiaries nor, to the Company’s knowledge, any director, officer, employee, agent, affiliate or other person acting on behalf of the Company or any subsidiary has (i) used any corporate funds

17


for any unlawful contribution, gift, entertainment or other unlawful expense relating to political activity; (ii) made any direct or indirect unlawful payment to any foreign or domestic government officials or employees, political parties or campaigns, political party officials, or candidates for political office from corporate funds; (iii) violated or is in violation of any provision of the U.S. Foreign Corrupt Practices Act of 1977, as amended, or any applicable anti-corruption laws, rules, or regulations of any other jurisdiction in which the Company or any subsidiary conducts business; or (iv) made any other unlawful bribe, rebate, payoff, influence payment, kickback or other unlawful payment to any person.
(oo)     Compliance with Money Laundering Laws. The operations of the Company and its subsidiaries are and have been conducted at all times in compliance with all applicable financial recordkeeping and reporting requirements, including those of the U.S. Bank Secrecy Act, as amended by Title III of the Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act of 2001 (USA PATRIOT Act), and the applicable anti-money laundering statutes of jurisdictions where the Company and its subsidiaries conduct business, the rules and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any governmental agency (collectively, the “Anti-Money Laundering Laws”), and no action, suit or proceeding by or before any court or governmental agency, authority, body or any arbitrator involving the Company or any of its subsidiaries with respect to Anti-Money Laundering Laws is pending, or to the knowledge of the Company, threatened.
(pp)         Compliance with OFAC.
a.
(i) Neither the Company nor any of its subsidiaries, nor to the Company’s knowledge, any director, officer or employee thereof, any agent, affiliate, representative, or other person acting on behalf of the Company or any of its subsidiaries, is an individual or entity (“Person”) that is, or is 50% or more owned, in the aggregate, by one or more Persons that is the subject of any sanctions administered or enforced by the U.S. Department of Treasury’s Office of Foreign Assets Control (“OFAC”), the United Nations Security Council (“UNSC”), the European Union (“EU”), Her Majesty’s Treasury (“HMT”), or other relevant sanctions authority (collectively, “Sanctions”), and (ii) neither the Company nor any of its subsidiaries is located, organized, or resident in a country or territory that is the subject of a U.S. government embargo (currently including, without limitation, Cuba, Iran, North Korea, Syria and the Crimea Region of Ukraine).
(A)
The Company will not, directly or indirectly, use the Net Proceeds, or knowingly lend, contribute or otherwise make available such Net Proceeds to any subsidiary, joint venture partner or other Person: (i) to fund or facilitate any activities or business of or with any Person that, at the time of such funding or facilitation, is the subject of Sanctions, or in any country or territory that, at the time of such funding or facilitation, is the subject of a U.S. government embargo; or (ii) in

18


any other manner, in each case of clause (i) or (ii), that would result in a violation of Sanctions by any Person (including Cowen)

(B)
For the past five (5) years, the Company and its subsidiaries have not knowingly engaged in, are not now knowingly engaged in, any direct or indirect dealings or transactions with any Person that at the time of the dealing or transaction is or was the subject of Sanctions or any country or territory that, at the time of the dealing or transaction is or was the subject of a U.S. government embargo.

(qq)     No Restrictions on Subsidiaries. No subsidiary of the Company is currently prohibited, directly or indirectly, under any agreement or other instrument to which it is a party or is subject, from paying any dividends to the Company, from making any other distribution on such subsidiary’s capital stock, from repaying to the Company any loans or advances to such subsidiary from the Company or from transferring any of such subsidiary’s properties or assets to the Company or any other subsidiary of the Company.
(rr)     No Broker’s Fees. Neither the Company nor any of its subsidiaries is a party to any contract, agreement or understanding with any person (other than this Agreement) that would give rise to a valid claim against the Company or any of its subsidiaries or Cowen for a brokerage commission, finder’s fee or like payment in connection with the offering and sale of the Placement Shares.
(ss)     No Registration Rights. Except as disclosed in the Registration Statement and the Prospectus and as have been duly waived or satisfied, no person has the right to require the Company or any of its subsidiaries to register any securities for sale under the Securities Act by reason of the filing of the Registration Statement with the Commission or the issuance and sale of the Placement Shares.
(tt)     No Stabilization. The Company has not taken, directly or indirectly, any action designed to or that could reasonably be expected to cause or result in any stabilization or manipulation of the price of the Placement Shares.
(uu)     Margin Rules. The application of the proceeds received by the Company from the issuance, sale and delivery of the Placement Shares as described in the Registration Statement, and the Prospectus will not violate Regulation T, U or X of the Board of Governors of the Federal Reserve System or any other regulation of such Board of Governors.
(vv)     Forward-Looking Statements. No forward-looking statement (within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act) contained in the Registration Statement or the Prospectus has been made without a reasonable basis or has been disclosed other than in good faith.
(ww)     Statistical and Market Data. Nothing has come to the attention of the Company that has caused the Company to believe that the statistical and market-related data included or

19


incorporated by reference in the Registration Statement and the Prospectus is not based on or derived from sources that are reliable and accurate in all material respects.
(xx)     Sarbanes-Oxley Act. There is and has been no failure on the part of the Company or, to the knowledge of the Company, any of the Company’s directors or officers, in their capacities as such, to comply with any provision of the Sarbanes-Oxley Act of 2002, as amended, and the rules and regulations promulgated in connection therewith (the “Sarbanes-Oxley Act”) applicable to the Company or any of the Company’s directors or officers, in their capacities as such, including Section 402 related to loans and Sections 302 and 906 related to certifications.
(yy)     Status under the Securities Act. The Company currently is not an “ineligible issuer,” as defined in Rule 405 of the rules and regulation of the Commission. The Company has paid the registration fee for this offering pursuant to Rule 456(b)(1) under the Securities Act or will pay such fee within the time period required by such rule (without giving effect to the proviso therein) and in any event prior to any Settlement Date.
(zz)     No Ratings. There are no debt securities or preferred stock issued or guaranteed by the Company or any of its subsidiaries that are rated by a “nationally recognized statistical rating organization”, as such term is defined in Section 3(a)(62) of the Exchange Act.
([[)     Required Filings. The Company has timely made all filings required to be made by it under the Exchange Act.
(aaa)     No Reliance. The Company has not relied upon Cowen or legal counsel for Cowen for any legal, tax or accounting advice in connection with the offering and sale of the Placement Shares.
(bbb)     Cowen Purchases. The Company acknowledges and agrees that Cowen has informed the Company that Cowen may, to the extent permitted under the Securities Act and the Exchange Act, purchase and sell shares of Common Stock for its own account while this Agreement is in effect.
(ccc)     Listing. The Company is subject to and in compliance in all material respects with the reporting requirements of Section 13 or Section 15(d) of the Exchange Act. The Common Stock is registered pursuant to Section 12(b) or Section 12(g) of the Exchange Act and is listed on the NYSE, and the Company has taken no action designed to, or reasonably likely to have the effect of, terminating the registration of the Common Stock under the Exchange Act or delisting the Common Stock from the NYSE, nor has the Company received any notification that the Commission or NYSE is contemplating terminating such registration or listing.
(ddd)     FINRA Exemption. To enable Cowen to rely on Rule 5110(b)(7)(C)(i) of FINRA, the Company represents that the Company (i) has a non-affiliate, public common equity float of at least $150 million or a non-affiliate, public common equity float of at least $100 million and annual trading volume of at least three million shares and (ii) has been subject to the Exchange Act reporting requirements for a period of at least 36 months.

20


Any certificate signed by an officer of the Company and delivered to Cowen or to counsel for Cowen in connection with this Agreement shall be deemed to be a representation and warranty by the Company to Cowen as to the matters set forth therein.
The Company acknowledges that Cowen and, for purposes of the opinions to be delivered pursuant to Section 7 hereof, counsel to the Company and counsel to Cowen, will rely upon the accuracy and truthfulness of the foregoing representations and hereby consents to such reliance.
7.      Covenants of the Company. The Company covenants and agrees with Cowen that:
(a)         Registration Statement Amendments. After the date of this Agreement and during any period in which a Prospectus relating to any Placement Shares is required to be delivered by Cowen under the Securities Act (including in circumstances where such requirement may be satisfied pursuant to Rule 172 under the Securities Act or similar rule), (i) the Company will notify Cowen promptly of the time when any subsequent amendment to the Registration Statement, other than documents incorporated by reference, has been filed with the Commission and/or has become effective or any subsequent supplement to the Prospectus has been filed and of any request by the Commission for any amendment or supplement to the Registration Statement or Prospectus or for additional information (insofar as such request relates to the transactions contemplated hereby), (ii) the Company will prepare and file with the Commission, promptly upon Cowen’s reasonable request, any amendments or supplements to the Registration Statement or Prospectus that, in Cowen’s reasonable opinion, may be necessary or advisable in connection with the distribution of the Placement Shares by Cowen (provided, however, that the failure of Cowen to make such request shall not relieve the Company of any obligation or liability hereunder, or affect Cowen’s right to rely on the representations and warranties made by the Company in this Agreement; provided, further, that the only remedy Cowen shall have with respect to the failure by the Company to comply with Cowen’s request shall be to cease making sales under this Agreement); (iii) the Company will not file any amendment or supplement to the Registration Statement or Prospectus, other than documents incorporated by reference, relating to the Placement Shares or a security convertible into the Placement Shares unless a copy thereof has been submitted to Cowen within a reasonable period of time before the filing and Cowen has not reasonably objected thereto (provided, however, that (A) the failure of Cowen to make such objection shall not relieve the Company of any obligation or liability hereunder, or affect Cowen’s right to rely on the representations and warranties made by the Company in this Agreement, (B) the Company has no obligation to provide Cowen any advance copy of such filing or to provide Cowen an opportunity to object to such filing if the filing does not name Cowen or does not relate to the transaction herein provided and (C) the only remedy Cowen shall have with respect to the failure by the Company to provide Cowen with such copy or the filing of such amendment or supplement despite Cowen’s objection shall be to cease making sales under this Agreement) and the Company will furnish to Cowen at the time of filing thereof a copy of any document that upon filing is deemed to be incorporated by reference into the Registration Statement or Prospectus, except for those documents available via EDGAR; (iv) the Company will cause each amendment or supplement to the Prospectus, other than documents incorporated by reference, to be filed with the Commission as required pursuant to the applicable paragraph of Rule 424(b) of the Securities Act; and (v) prior to the termination of this Agreement, the Company will

21


notify Cowen if at any time the Registration Statement shall no longer be effective as a result of the passage of time pursuant to Rule 415 under the Securities Act or otherwise.
(b)         Notice of Commission Stop Orders. The Company will advise Cowen, promptly after it receives notice or obtains knowledge thereof, of the issuance or threatened issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement, of the suspension of the qualification of the Placement Shares for offering or sale in any jurisdiction, or of the initiation or threatening of any proceeding for any such purpose; and it will promptly use its commercially reasonable efforts to prevent the issuance of any stop order or to obtain its withdrawal if such a stop order should be issued.
(c)         Delivery of Prospectus; Subsequent Changes. During any period in which a Prospectus relating to the Placement Shares is required to be delivered by Cowen under the Securities Act with respect to a pending sale of the Placement Shares (including in circumstances where such requirement may be satisfied pursuant to Rule 172 under the Securities Act or similar rule), the Company will comply with all the requirements imposed upon it by the Securities Act, as from time to time in force, and to file on or before their respective due dates (taking into account any extensions available under the Exchange Act) all reports and any definitive proxy or information statements required to be filed by the Company with the Commission pursuant to Sections 13(a), 13(c), 14, 15(d) or any other provision of or under the Exchange Act. If during such period any event occurs as a result of which the Prospectus as then amended or supplemented would include an untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances then existing, not misleading, or if during such period it is necessary to amend or supplement the Registration Statement or Prospectus to comply with the Securities Act, the Company will promptly notify Cowen to suspend the offering of Placement Shares during such period and the Company will promptly amend or supplement the Registration Statement or Prospectus (at the expense of the Company) so as to correct such statement or omission or effect such compliance; provided, however, that the Company may delay the filing of any amendment or supplement if, in the reasonable judgment of the Company, it is in the best interest of the Company to do so.
(d)         Listing of Placement Shares. During any period in which the Prospectus relating to the Placement Shares is required to be delivered by Cowen under the Securities Act with respect to a pending sale of the Placement Shares (including in circumstances where such requirement may be satisfied pursuant to Rule 172 under the Securities Act or similar rule), the Company will use its commercially reasonable efforts to cause the Placement Shares to be listed on the NYSE and to qualify the Placement Shares for sale under the securities laws of such jurisdictions as Cowen reasonably designates and to continue such qualifications in effect so long as required for the distribution of the Placement Shares; provided, however, that the Company shall not be required in connection therewith to qualify as a foreign corporation or dealer in securities or file a general consent to service of process in any jurisdiction.
(e)         Delivery of Registration Statement and Prospectus. Following the date that the Registration Statement is declared effective by the Commission, the Company will furnish to Cowen and its counsel (at the expense of the Company) copies of the Registration Statement, the

22


Prospectus (including all documents incorporated by reference therein) and all amendments and supplements to the Registration Statement or Prospectus that are filed with the Commission during any period in which a Prospectus relating to the Placement Shares is required to be delivered under the Securities Act (including all documents filed with the Commission during such period that are deemed to be incorporated by reference therein), in each case as soon as reasonably practicable and in such quantities as Cowen may from time to time reasonably request and, at Cowen’s reasonable request, will also furnish copies of the Prospectus to each exchange or market on which sales of the Placement Shares may be made; provided, however, that the Company shall not be required to furnish any document (other than the Prospectus) to Cowen to the extent such document is available on EDGAR.
(f)         Earnings Statement. The Company will make generally available to its security holders as soon as practicable, but in any event not later than 15 months after the end of the Company’s current fiscal quarter, an earnings statement covering a 12-month period that satisfies the provisions of Section 11(a) and Rule 158 of the Securities Act.
(g)         Expenses. The Company, whether or not the transactions contemplated hereunder are consummated or this Agreement is terminated, in accordance with the provisions of Section 11 hereunder, will pay the following expenses all incident to the performance of its obligations hereunder, including, but not limited to, expenses relating to (i) the preparation, printing and filing of the Registration Statement and each amendment and supplement thereto, and of each Prospectus and of each amendment and supplement thereto, (ii) the preparation, issuance and delivery of the Placement Shares, (iii) the qualification of the Placement Shares under securities laws in accordance with the provisions of Section 7(d) of this Agreement, including filing fees (provided, however, that any fees or disbursements of counsel for Cowen in connection therewith shall be paid by Cowen except as set forth in (vii) below), (iv) the printing and delivery to Cowen of copies of the Prospectus and any amendments or supplements thereto, and of this Agreement, (v) the fees and expenses incurred in connection with the listing or qualification of the Placement Shares for trading on the NYSE, (vi) the filing fees and expenses, if any, of the Commission, (vii) the filing fees and associated legal expenses of Cowen’s outside counsel for filings with the FINRA Corporate Financing Department, such legal expense reimbursement not to exceed $10,000 in the aggregate and (viii) the reasonable fees and disbursements of Cowen’s outside counsel in an amount not to exceed $50,000 in the aggregate.
(h)     Use of Proceeds. The Company will use the Net Proceeds as described in the Prospectus in the section entitled “Use of Proceeds.”
(i)     Notice of Other Sales. During the pendency of any Placement Notice given hereunder, and for three (3) trading days following the termination of any Placement Notice given hereunder, the Company shall provide Cowen notice as promptly as reasonably practicable before it offers to sell, contracts to sell, sells, grants any option to sell or otherwise disposes of any shares of Common Stock (other than Placement Shares offered pursuant to the provisions of this Agreement) or securities convertible into or exchangeable for Common Stock, warrants or any rights to purchase or acquire Common Stock; provided, that such notice shall not be required in connection with (i) the issuance, grant or sale of Common Stock, options to purchase shares of

23


Common Stock or any other equity awards, or Common Stock issuable upon the exercise of options or other equity awards pursuant to any equity incentive plan, stock option, stock bonus, employee stock purchase or other stock plan or arrangement described in the Prospectus, (ii) warrants that may be issued by the Company in connection with that certain Loan and Security Agreement dated as of March 15, 2017 among the Company, Oxford Capital, LLC and PatientCrossroads, Inc., as amended, (iii) the issuance of securities in connection with an acquisition, merger or sale or purchase of assets, (iv) the issuance or sale of Common Stock pursuant to any dividend reinvestment plan that the Company may adopt from time to time provided the implementation of such is disclosed to Cowen in advance, or (v) the issuance of any shares of Common Stock issuable upon the exchange, conversion or redemption of securities or the exercise of warrants, options or other rights in effect or outstanding.
(j)         Change of Circumstances. The Company will, at any time during a fiscal quarter in which the Company intends to tender a Placement Notice or sell Placement Shares, advise Cowen promptly after it shall have received notice or obtained knowledge thereof, of any information or fact that would alter or affect in any material respect any opinion, certificate, letter or other document provided to Cowen pursuant to this Agreement.
(k)         Due Diligence Cooperation. During the term of this Agreement, the Company will cooperate with any reasonable due diligence review conducted by Cowen or its agents in connection with the transactions contemplated hereby, including, without limitation, providing information and making available documents and senior corporate officers, during regular business hours and at the Company’s principal offices, as Cowen may reasonably request.
(l)         Required Filings Relating to Placement of Placement Shares. The Company agrees that on such dates as the Securities Act shall require, the Company will (i) file a prospectus supplement with the Commission under the applicable paragraph of Rule 424(b) under the Securities Act (each and every filing under Rule 424(b), a “Filing Date”), which prospectus supplement will set forth, within the relevant period, the amount of Placement Shares sold through Cowen, the Net Proceeds to the Company and the compensation payable by the Company to Cowen with respect to such Placement Shares, and (ii) deliver such number of copies of each such prospectus supplement to each exchange or market on which such sales were effected as may be required by the rules or regulations of such exchange or market.
(m)         Representation Dates; Certificate. During the term of this Agreement, on or prior to the First Delivery Date and each time the Company (i) files the Prospectus relating to the Placement Shares or amends or supplements the Registration Statement or the Prospectus relating to the Placement Shares (other than a prospectus supplement filed in accordance with Section 7(l) of this Agreement) by means of a post-effective amendment, sticker, or supplement but not by means of incorporation of document(s) by reference to the Registration Statement or the Prospectus relating to the Placement Shares; (ii) files an Annual Report on Form 10-K under the Exchange Act; (iii) files its Quarterly Reports on Form 10-Q under the Exchange Act; or (iv) files a Current Report on Form 8-K containing amended financial information (other than an earnings release) under the Exchange Act (each date of filing of one or more of the documents referred to in clauses (i) through (iv) shall be a “Representation Date”); the Company shall furnish Cowen with a certificate, in the

24


form attached hereto as Exhibit 7(m) within three (3) Trading Days of any Representation Date if requested by Cowen. The requirement to provide a certificate under this Section 7(m) shall be automatically waived for any Representation Date occurring at a time at which no Placement Notice is pending, which waiver shall continue until the earlier to occur of the date the Company delivers a Placement Notice hereunder (which for such calendar quarter shall be considered a Representation Date) and the next occurring Representation Date; provided, however, that such waiver shall not apply for any Representation Date on which the Company files its Annual Report on Form 10-K. Notwithstanding the foregoing, if the Company subsequently decides to sell Placement Shares following a Representation Date when the Company relied on such waiver and did not provide Cowen with a certificate under this Section 7(m), then before the Company delivers the Placement Notice or Cowen sells any Placement Shares, the Company shall provide Cowen with a certificate, in the form attached hereto as Exhibit 7(m), dated the date of the Placement Notice.
(n)         Legal Opinion. On or prior to the First Delivery Date and within three (3) Trading Days of each Representation Date with respect to which the Company is obligated to deliver a certificate in the form attached hereto as Exhibit 7(m) for which no waiver is applicable, the Company shall cause to be furnished to Cowen a written opinion of Pillsbury Winthrop Shaw Pittman LLP (“Company Counsel”), or other counsel satisfactory to Cowen, in form and substance reasonably satisfactory to Cowen and its counsel, dated the date that the opinion is required to be delivered, modified, as necessary, to relate to the Registration Statement and the Prospectus as then amended or supplemented; provided, however, that in lieu of such opinion for subsequent Representation Dates, counsel may furnish Cowen with a letter (a “Reliance Letter”) to the effect that Cowen may rely on a prior opinion delivered under this Section 7(n) to the same extent as if it were dated the date of such letter (except that statements in such prior opinion shall be deemed to relate to the Registration Statement and the Prospectus as amended or supplemented at such Representation Date).
(o)         Comfort Letter. On or prior to the First Delivery Date and within three (3) Trading Days of each Representation Date with respect to which the Company is obligated to deliver a certificate in the form attached hereto as Exhibit 7(m) for which no waiver is applicable, the Company shall cause its independent accountants to furnish Cowen letters (the “Comfort Letters”), dated the date the Comfort Letter is delivered, in form and substance reasonably satisfactory to Cowen, (i) confirming that they are an independent registered public accounting firm within the meaning of the Securities Act and the PCAOB, (ii) stating, as of such date, the conclusions and findings of such firm with respect to the financial information and other matters ordinarily covered by accountants’ “comfort letters” to Cowen in connection with registered public offerings (the first such letter, the “Initial Comfort Letter”) and (iii) updating the Initial Comfort Letter with any information that would have been included in the Initial Comfort Letter had it been given on such date and modified as necessary to relate to the Registration Statement and the Prospectus, as amended and supplemented to the date of such letter.
(p)         Market Activities. The Company will not, directly or indirectly, (i) take any action designed to cause or result in, or that constitutes or might reasonably be expected to constitute, the stabilization or manipulation of the price of any security of the Company to facilitate the sale

25


or resale of the Placement Shares or (ii) sell, bid for, or purchase the Placement Shares to be issued and sold pursuant to this Agreement, or pay anyone any compensation for soliciting purchases of the Placement Shares other than Cowen; provided, however, that the Company may bid for and purchase shares of its Common Stock in accordance with Rule 10b-18 under the Exchange Act.
(q)         Insurance. The Company and its subsidiaries shall maintain, or cause to be maintained, insurance in such amounts and covering such risks as is reasonable and customary for the business for which it is engaged.
(r)         Compliance with Laws. The Company and each of its subsidiaries shall use commercially reasonable efforts to maintain, or cause to be maintained, all material environmental permits, licenses and other authorizations required by federal, state and local law in order to conduct their businesses as described in the Prospectus, and the Company and each of its subsidiaries shall conduct their businesses, or cause their businesses to be conducted, in substantial compliance with such permits, licenses and authorizations and with applicable environmental laws, except where the failure to maintain or be in compliance with such permits, licenses and authorizations could not reasonably be expected to result in a Material Adverse Effect.
(s)         Investment Company Act. The Company will conduct its affairs in such a manner so as to reasonably ensure that neither it nor its subsidiaries will be or become, at any time prior to the termination of this Agreement, an “investment company,” as such term is defined in the Investment Company Act, assuming no change in the Commission’s current interpretation as to entities that are not considered an investment company.
(t)         Securities Act and Exchange Act. The Company will use commercially reasonable efforts to comply with all requirements imposed upon it by the Securities Act and the Exchange Act as from time to time in force, so far as necessary to permit the continuance of sales of, or dealings in, the Placement Shares as contemplated by the provisions hereof and the Prospectus.
(u)         No Offer to Sell. Other than a free writing prospectus (as defined in Rule 405 under the Securities Act) approved in advance by the Company and Cowen in its capacity as principal or agent hereunder, neither Cowen nor the Company (including its agents and representatives, other than Cowen in its capacity as such) will make, use, prepare, authorize, approve or refer to any written communication (as defined in Rule 405 under the Securities Act), required to be filed with the Commission, that constitutes an offer to sell or solicitation of an offer to buy Placement Shares hereunder.
(v)         Sarbanes-Oxley Act. The Company and its subsidiaries will use commercially reasonable efforts to comply with all effective applicable provisions of the Sarbanes-Oxley Act.
(w)      Status under the Securities Act. The Company shall notify Cowen promptly upon the Company becoming an “ineligible issuer,” as defined in Rule 405 of the rules and regulations of the Commission.

26


8.      Conditions to Cowen’s Obligations. The obligations of Cowen hereunder with respect to a Placement will be subject to the continuing accuracy and completeness of the representations and warranties made by the Company herein, to the due performance by the Company of its obligations hereunder, to the completion by Cowen of a due diligence review satisfactory to Cowen in its reasonable judgment, and to the continuing satisfaction (or waiver by Cowen in its sole discretion) of the following additional conditions:
(a)         Registration Statement Effective. The Registration Statement shall be effective and shall be available for (i) all sales of Placement Shares issued pursuant to all prior Placement Notices and (ii) the sale of all Placement Shares contemplated to be issued by any Placement Notice.
(b)         No Material Notices. None of the following events shall have occurred and be continuing: (i) receipt by the Company or any of its subsidiaries of any request for additional information from the Commission or any other federal or state governmental authority during the period of effectiveness of the Registration Statement, the response to which would require any post-effective amendments or supplements to the Registration Statement or the Prospectus; (ii) the issuance by the Commission or any other federal or state governmental authority of any stop order suspending the effectiveness of the Registration Statement or the initiation of any proceedings for that purpose; (iii) receipt by the Company of any notification with respect to the suspension of the qualification or exemption from qualification of any of the Placement Shares for sale in any jurisdiction or the initiation or threatening of any proceeding for such purpose; or (iv) the occurrence of any event that makes any material statement made in the Registration Statement or the Prospectus or any material document incorporated or deemed to be incorporated therein by reference untrue in any material respect or that requires the making of any changes in the Registration Statement, related Prospectus or such documents so that, in the case of the Registration Statement, it will not contain any materially untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein not misleading and, that in the case of the Prospectus, it will not contain any materially untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading.
(c)         No Misstatement or Material Omission. Cowen shall not have advised the Company that the Registration Statement or Prospectus, or any amendment or supplement thereto, contains an untrue statement of fact that in Cowen’s reasonable opinion is material, or omits to state a fact that in Cowen’s reasonable opinion is material and is required to be stated therein or is necessary to make the statements therein not misleading.
(d)         Material Changes. Except as contemplated in the Prospectus, or disclosed in the Company’s reports filed with the Commission, there shall not have been any material adverse change, on a consolidated basis, in the authorized capital stock of the Company or any Material Adverse Effect or any development that could reasonably be expected to result in a Material Adverse Effect, or any downgrading in or withdrawal of the rating assigned to any of the Company’s securities (other than asset backed securities) by any rating organization or a public announcement by any rating organization that it has under surveillance or review its rating of any of the Company’s

27


securities (other than asset backed securities), the effect of which, in the case of any such action by a rating organization described above, in the reasonable judgment of Cowen (without relieving the Company of any obligation or liability it may otherwise have), is so material as to make it impracticable or inadvisable to proceed with the offering of the Placement Shares on the terms and in the manner contemplated in the Prospectus.
(e)         Company Counsel Legal Opinion. Cowen shall have received the opinion of Company Counsel required to be delivered pursuant to Section 7(n) on or before the date on which such delivery of such opinion is required pursuant to Section 7(n).
(f)         Cowen Counsel Legal Opinion. Cowen shall have received from Cooley LLP, counsel for Cowen, such opinion or opinions, on or before the date on which the delivery of the Company Counsel legal opinion is required pursuant to Section 7(n), with respect to such matters as Cowen may reasonably require, and the Company shall have furnished to such counsel such documents as they request for enabling them to pass upon such matters.
(g)         Comfort Letter. Cowen shall have received the Comfort Letter required to be delivered pursuant to Section 7(o) on or before the date on which such delivery of such Comfort Letter is required pursuant to Section 7(o).
(h)         Representation Certificate. Cowen shall have received the certificate required to be delivered pursuant to Section 7(m) on or before the date on which delivery of such certificate is required pursuant to Section 7(m).
(i)         Secretary’s Certificate. On or prior to the First Delivery Date, Cowen shall have received a certificate, signed on behalf of the Company by its corporate Secretary, in form and substance satisfactory to Cowen and its counsel.
(j)         No Suspension. Trading in the Common Stock shall not have been suspended on the NYSE.
(k)         Other Materials. On each date on which the Company is required to deliver a certificate pursuant to Section 7(m), the Company shall have furnished to Cowen such appropriate further information, certificates and documents as Cowen may have reasonably requested. All such opinions, certificates, letters and other documents shall have been in compliance with the provisions hereof. The Company will furnish Cowen with such conformed copies of such opinions, certificates, letters and other documents as Cowen shall have reasonably requested.
(l)         Securities Act Filings Made. All filings with the Commission required by Rule 424 under the Securities Act to have been filed prior to the issuance of any Placement Notice hereunder shall have been made within the applicable time period prescribed for such filing by Rule 424.
(m)         Approval for Listing. The Placement Shares shall have been approved for listing on the NYSE, subject only to notice of issuance.

28


(n)         No Termination Event. There shall not have occurred any event that would permit Cowen to terminate this Agreement pursuant to Section 11(a).
9.      Indemnification and Contribution.
(a)         Company Indemnification. The Company agrees to indemnify and hold harmless Cowen, the directors, officers, partners, employees and agents of Cowen and each person, if any, who (i) controls Cowen within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act, or (ii) is controlled by or is under common control with Cowen from and against any and all losses, claims, liabilities, expenses and damages (including, but not limited to, any and all reasonable investigative, legal and other expenses incurred in connection with, and any and all amounts paid in settlement (in accordance with Section 9(c)) of, any action, suit or proceeding between any of the indemnified parties and any indemnifying parties or between any indemnified party and any third party, or otherwise, or any claim asserted), as and when incurred, to which Cowen, or any such person, may become subject under the Securities Act, the Exchange Act or other federal or state statutory law or regulation, at common law or otherwise, insofar as such losses, claims, liabilities, expenses or damages arise out of or are based, directly or indirectly, on (x) any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement or the Prospectus or any amendment or supplement to the Registration Statement or the Prospectus or in any free writing prospectus or in any application or other document executed by or on behalf of the Company or based on written information furnished by or on behalf of the Company filed in any jurisdiction in order to qualify the Placement Shares under the securities laws thereof or filed with the Commission or (y) the omission or alleged omission to state in any such document a material fact required to be stated in it or necessary to make the statements in it not misleading; provided, however, that this indemnity agreement shall not apply to the extent that such loss, claim, liability, expense or damage arises from the sale of the Placement Shares pursuant to this Agreement and is caused directly or indirectly by an untrue statement or omission made in reliance upon and in conformity with the Agent’s Information. This indemnity agreement will be in addition to any liability that the Company might otherwise have.
(b)         Cowen Indemnification. Cowen agrees to indemnify and hold harmless the Company and its directors and each officer of the Company that signed the Registration Statement, and each person, if any, who controls the Company within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act against any and all loss, liability, claim, damage and expense described in the indemnity contained in Section 9(a), as incurred, but only with respect to untrue statements or omissions, or alleged untrue statements or omissions, made in the Registration Statement (or any amendments thereto) or the Prospectus (or any amendment or supplement thereto) in reliance upon and in conformity with the Agent’s Information.
(c)         Procedure. Any party that proposes to assert the right to be indemnified under this Section 9 will, promptly after receipt of notice of commencement of any action against such party in respect of which a claim is to be made against an indemnifying party or parties under this Section 9, notify each such indemnifying party of the commencement of such action, enclosing a copy of all papers served, but the omission so to notify such indemnifying party will not relieve the indemnifying party from (i) any liability that it might have to any indemnified party otherwise

29


than under this Section 9 and (ii) any liability that it may have to any indemnified party under the foregoing provision of this Section 9 unless, and only to the extent that, such omission results in the forfeiture of substantive rights or defenses by the indemnifying party. If any such action is brought against any indemnified party and it notifies the indemnifying party of its commencement, the indemnifying party will be entitled to participate in and, to the extent that it elects by delivering written notice to the indemnified party promptly after receiving notice of the commencement of the action from the indemnified party, jointly with any other indemnifying party similarly notified, to assume the defense of the action, with counsel reasonably satisfactory to the indemnified party, and after notice from the indemnifying party to the indemnified party of its election to assume the defense, the indemnifying party will not be liable to the indemnified party for any legal or other expenses except as provided below and except for the reasonable costs of investigation subsequently incurred by the indemnified party in connection with the defense. The indemnified party will have the right to employ its own counsel in any such action, but the fees, expenses and other charges of such counsel will be at the expense of such indemnified party unless (1) the employment of counsel by the indemnified party has been authorized in writing by the indemnifying party, (2) the indemnified party has reasonably concluded (based on advice of counsel) that there may be legal defenses available to it or other indemnified parties that are different from or in addition to those available to the indemnifying party, (3) a conflict or potential conflict exists (based on advice of counsel to the indemnified party) between the indemnified party and the indemnifying party (in which case the indemnifying party will not have the right to direct the defense of such action on behalf of the indemnified party) or (4) the indemnifying party has not in fact employed counsel to assume the defense of such action within a reasonable time after receiving notice of the commencement of the action, in each of which cases the reasonable fees, disbursements and other charges of counsel will be at the expense of the indemnifying party or parties. It is understood that the indemnifying party or parties shall not, in connection with any proceeding or related proceedings in the same jurisdiction, be liable for the reasonable fees, disbursements and other charges of more than one separate firm admitted to practice in such jurisdiction at any one time for all such indemnified party or parties. All such fees, disbursements and other charges will be reimbursed by the indemnifying party promptly as they are incurred. An indemnifying party will not, in any event, be liable for any settlement of any action or claim effected without its written consent. No indemnifying party shall, without the prior written consent of each indemnified party, settle or compromise or consent to the entry of any judgment in any pending or threatened claim, action or proceeding relating to the matters contemplated by this Section 9 (whether or not any indemnified party is a party thereto), unless such settlement, compromise or consent includes an unconditional release of each indemnified party from all liability arising or that may arise out of such claim, action or proceeding.
(d)         Contribution. In order to provide for just and equitable contribution in circumstances in which the indemnification provided for in the foregoing paragraphs of this Section 9 is applicable in accordance with its terms but for any reason is held to be unavailable from the Company or Cowen, the Company and Cowen will contribute to the total losses, claims, liabilities, expenses and damages (including any investigative, legal and other expenses reasonably incurred in connection with, and any amount paid in settlement of, any action, suit or proceeding or any claim asserted, but after deducting any contribution received by the Company from persons other

30


than Cowen, such as persons who control the Company within the meaning of the Securities Act, officers of the Company who signed the Registration Statement and directors of the Company, who also may be liable for contribution) to which the Company and Cowen may be subject in such proportion as shall be appropriate to reflect the relative benefits received by the Company on the one hand and Cowen on the other. The relative benefits received by the Company on the one hand and Cowen on the other hand shall be deemed to be in the same proportion as the total Net Proceeds from the sale of the Placement Shares (before deducting expenses) received by the Company bear to the total compensation received by Cowen from the sale of Placement Shares on behalf of the Company. If, but only if, the allocation provided by the foregoing sentence is not permitted by applicable law, the allocation of contribution shall be made in such proportion as is appropriate to reflect not only the relative benefits referred to in the foregoing sentence but also the relative fault of the Company, on the one hand, and Cowen, on the other, with respect to the statements or omission that resulted in such loss, claim, liability, expense or damage, or action in respect thereof, as well as any other relevant equitable considerations with respect to such offering. Such relative fault shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material fact relates to information supplied by the Company or Cowen, the intent of the parties and their relative knowledge, access to information and opportunity to correct or prevent such statement or omission. The Company and Cowen agree that it would not be just and equitable if contributions pursuant to this Section 9(d) were to be determined by pro rata allocation or by any other method of allocation that does not take into account the equitable considerations referred to herein. The amount paid or payable by an indemnified party as a result of the loss, claim, liability, expense, or damage, or action in respect thereof, referred to above in this Section 9(d) shall be deemed to include, for the purpose of this Section 9(d), any legal or other expenses reasonably incurred by such indemnified party in connection with investigating or defending any such action or claim to the extent consistent with Section 9(c) hereof. Notwithstanding the foregoing provisions of this Section 9(d), Cowen shall not be required to contribute any amount in excess of the commissions received by it under this Agreement and no person found guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) will be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. For purposes of this Section 9(d), any person who controls a party to this Agreement within the meaning of the Securities Act, and any officers, directors, partners, employees or agents of Cowen, will have the same rights to contribution as that party, and each director of the Company and each officer of the Company who signed the Registration Statement will have the same rights to contribution as the Company, subject in each case to the provisions hereof. Any party entitled to contribution, promptly after receipt of notice of commencement of any action against such party in respect of which a claim for contribution may be made under this Section 9(d), will notify any such party or parties from whom contribution may be sought, but the omission to so notify will not relieve that party or parties from whom contribution may be sought from any other obligation it or they may have under this Section 9(d) except to the extent that the failure to so notify such other party materially prejudiced the substantive rights or defenses of the party from whom contribution is sought. Except for a settlement entered into pursuant to the last sentence of Section 9(c) hereof, no party will be liable for contribution with respect to any action or claim settled without its written consent if such consent is required pursuant to Section 9(c) hereof.

31


10.      Representations and Agreements to Survive Delivery. The indemnity and contribution agreements contained in Section 9 of this Agreement and all representations and warranties of the Company herein or in certificates delivered pursuant hereto shall survive, as of their respective dates, regardless of (i) any investigation made by or on behalf of Cowen, any controlling persons, or the Company (or any of their respective officers, directors or controlling persons), (ii) delivery and acceptance of the Placement Shares and payment therefor or (iii) any termination of this Agreement.
11.      Termination.
(a)         Cowen shall have the right by giving written notice as hereinafter specified at any time to terminate this Agreement if (i) any Material Adverse Effect, or any development that could reasonably be expected to result in a Material Adverse Effect has occurred that, in the reasonable judgment of Cowen, may materially impair the ability of Cowen to sell the Placement Shares hereunder, (ii) the Company shall have failed, refused or been unable to perform any agreement on its part to be performed hereunder; provided, however, in the case of any failure of the Company to deliver (or cause another person to deliver) any certification, opinion, or letter required under Sections 7(m), 7(n), or 7(o), Cowen’s right to terminate shall not arise unless such failure to deliver (or cause to be delivered) continues for more than thirty (30) days from the date such delivery was required, (iii) any other condition of Cowen’s obligations hereunder is not fulfilled or (iv), any suspension or limitation of trading in the Placement Shares or in securities generally on the NYSE shall have occurred. Any such termination shall be without liability of any party to any other party except that the provisions of Section 7(g) (Expenses), Section 9 (Indemnification and Contribution), Section 10 (Representations and Agreements to Survive Delivery), Section 16 (Applicable Law; Consent to Jurisdiction) and Section 17 (Waiver of Jury Trial) hereof shall remain in full force and effect notwithstanding such termination. If Cowen elects to terminate this Agreement as provided in this Section 11(a), Cowen shall provide the required notice as specified in Section 12 (Notices).
(b)         The Company shall have the right, by giving five (5) days’ notice as hereinafter specified to terminate this Agreement in its sole discretion at any time after the date of this Agreement. Any such termination shall be without liability of any party to any other party except that the provisions of Section 7(g), Section 9, Section 10, Section 16 and Section 17 hereof shall remain in full force and effect notwithstanding such termination.
(c)         Cowen shall have the right, by giving five (5) days’ notice as hereinafter specified to terminate this Agreement in its sole discretion at any time after the date of this Agreement. Any such termination shall be without liability of any party to any other party except that the provisions of Section 7(g), Section 9, Section 10, Section 16 and Section 17 hereof shall remain in full force and effect notwithstanding such termination.
(d)         Unless earlier terminated pursuant to this Section 11, this Agreement shall automatically terminate upon the issuance and sale of all of the Placement Shares through Cowen on the terms and subject to the conditions set forth herein; provided that the provisions of Section

32


7(g), Section 9, Section 10, Section 16 and Section 17 hereof shall remain in full force and effect notwithstanding such termination.
(e)         This Agreement shall remain in full force and effect unless terminated pursuant to Sections 11(a), (b), (c), or (d) above or otherwise by mutual agreement of the parties; provided, however, that any such termination by mutual agreement shall in all cases be deemed to provide that Section 7(g), Section 9, Section 10, Section 16 and Section 17 shall remain in full force and effect.
(f)         Any termination of this Agreement shall be effective on the date specified in such notice of termination; provided, however, that such termination shall not be effective until the close of business on the date of receipt of such notice by Cowen or the Company, as the case may be. If such termination shall occur prior to the Settlement Date for any sale of Placement Shares, such Placement Shares shall settle in accordance with the provisions of this Agreement.
12.      Notices. All notices or other communications required or permitted to be given by any party to any other party pursuant to the terms of this Agreement shall be in writing, unless otherwise specified in this Agreement, and if sent to Cowen, shall be delivered to Cowen at Cowen and Company, LLC, 599 Lexington Avenue, New York, NY 10022, fax no. 646-562-1124, Attention: General Counsel, with a copy to Cooley LLP, 1114 Avenue of the Americas, New York, NY 10036, fax no. (212) 479-6275, Attention: Daniel I. Goldberg; or if sent to the Company, shall be delivered to Invitae Corporation, 1400 16th Street, San Francisco, California 94103, fax no. (415) 276-4164, Attention: General Counsel, with a copy to Pillsbury Winthrop Shaw Pittman LLP, 2550 Hanover Street, Palo Alto, CA 94304, fax no. (650) 233-4545, Attention: Gabriella A. Lombardi. Each party to this Agreement may change such address for notices by sending to the parties to this Agreement written notice of a new address for such purpose. Each such notice or other communication shall be deemed given (i) when delivered personally or by verifiable facsimile transmission (with an original to follow) on or before 4:30 p.m., New York City time, on a Business Day (as defined below), or, if such day is not a Business Day on the next succeeding Business Day, (ii) on the next Business Day after timely delivery to a nationally-recognized overnight courier, (iii) on the Business Day actually received if deposited in the U.S. mail (certified or registered mail, return receipt requested, postage prepaid), and (iv) when delivered by electronic communication (“Electronic Notice”), at the time the party sending Electronic Notice receives verification of receipt by the receiving party, other than via auto reply. For purposes of this Agreement, “Business Day” shall mean any day on which the NYSE and commercial banks in the City of New York are open for business.
13.      Successors and Assigns. This Agreement shall inure to the benefit of and be binding upon the Company and Cowen and their respective successors and the affiliates, controlling persons, officers and directors referred to in Section 9 hereof. References to any of the parties contained in this Agreement shall be deemed to include the successors and permitted assigns of such party. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and permitted assigns any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement. Neither party may assign its rights or obligations under this Agreement without the prior written

33


consent of the other party; provided, however, that Cowen may assign its rights and obligations hereunder to an affiliate of Cowen without obtaining the Company’s consent.
14.      Adjustments for Share Splits. The parties acknowledge and agree that all share-related numbers contained in this Agreement shall be adjusted to take into account any share split, share dividend or similar event effected with respect to the Common Stock.
15.      Entire Agreement; Amendment; Severability. This Agreement (including all schedules and exhibits attached hereto and Placement Notices issued pursuant hereto) constitutes the entire agreement and supersedes all other prior and contemporaneous agreements and undertakings, both written and oral, among the parties hereto with regard to the subject matter hereof. Neither this Agreement nor any term hereof may be amended except pursuant to a written instrument executed by the Company and Cowen. In the event that any one or more of the provisions contained herein, or the application thereof in any circumstance, is held invalid, illegal or unenforceable as written by a court of competent jurisdiction, then such provision shall be given full force and effect to the fullest possible extent that it is valid, legal and enforceable, and the remainder of the terms and provisions herein shall be construed as if such invalid, illegal or unenforceable term or provision was not contained herein, but only to the extent that giving effect to such provision and the remainder of the terms and provisions hereof shall be in accordance with the intent of the parties as reflected in this Agreement.
16.      Applicable Law; Consent to Jurisdiction. This Agreement shall be governed by, and construed in accordance with, the internal laws of the State of New York without regard to the principles of conflicts of laws. Each party hereby irrevocably submits to the non-exclusive jurisdiction of the state and federal courts sitting in the City of New York, borough of Manhattan, for the adjudication of any dispute hereunder or in connection with any transaction contemplated hereby, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof (certified or registered mail, return receipt requested) to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law.
17.      Waiver of Jury Trial. The Company and Cowen each hereby irrevocably waives any right it may have to a trial by jury in respect of any claim based upon or arising out of this Agreement or any transaction contemplated hereby.
18.      Absence of Fiduciary Relationship. The Company acknowledges and agrees that:
(a)         Cowen has been retained solely to act as sales agent in connection with the sale of the Placement Shares and that no fiduciary, advisory or agency relationship between the

34


Company and Cowen has been created in respect of any of the transactions contemplated by this Agreement, irrespective of whether Cowen has advised or is advising the Company on other matters;
(b)         the Company is capable of evaluating and understanding and understands and accepts the terms, risks and conditions of the transactions contemplated by this Agreement;
(c)         the Company has been advised that Cowen and its affiliates are engaged in a broad range of transactions which may involve interests that differ from those of the Company and that Cowen has no obligation to disclose such interests and transactions to the Company by virtue of any fiduciary, advisory or agency relationship; and
(d)         the Company waives, to the fullest extent permitted by law, any claims it may have against Cowen, for breach of fiduciary duty or alleged breach of fiduciary duty in connection with the sale of the Placement Shares under this Agreement and agrees that Cowen shall have no liability (whether direct or indirect) to the Company in respect of such a fiduciary claim or to any person asserting a fiduciary duty claim on behalf of or in right of the Company, including stockholders, partners, employees or creditors of the Company.
19.      Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Delivery of an executed Agreement by one party to the other may be made by Electronic Notice or facsimile transmission.
20.      Definitions. As used in this Agreement, the following term has the meaning set forth below:
(a)         “Applicable Time” means the date of this Agreement, each Representation Date, the date on which a Placement Notice is given, and any date on which Placement Shares are sold hereunder.
(b)         “Agent’s Information” means, solely the following information in the Prospectus: the third sentence of the eighth paragraph under the caption “Plan of Distribution” in the Prospectus.
[Remainder of Page Intentionally Blank]



35



If the foregoing correctly sets forth the understanding between the Company and Cowen, please so indicate in the space provided below for that purpose, whereupon this letter shall constitute a binding agreement between the Company and Cowen.
Very truly yours,

COWEN AND COMPANY, LLC


By:  /s/ E. James Streator, III __________________
Name: E. James Streator, III
Title: Managing Director



ACCEPTED as of the date
first-above written:

INVITAE CORPORATION


By: _ /s/ Shelly D. Guyer _______________________
Name: Shelly D. Guyer
Title: CFO










[Signature Page to Invitae Corporation Sales Agreement]

36



SCHEDULE 1
FORM OF PLACEMENT NOTICE

From:    [Ÿ]
Cc:    [Ÿ]
To:     [Ÿ]
Date:

Subject:     Cowen and Company, LLC – At the Market Offering – Placement Notice
Ladies and Gentlemen:
Pursuant to the terms and subject to the conditions contained in the Sales Agreement between Invitae Corporation (the “Company”), and Cowen and Company, LLC (“Cowen”) dated August 9, 2018 (the “Agreement”), I hereby request on behalf of the Company that Cowen sell up to [Ÿ] shares of the Company’s common stock, $0.0001 par value per share, at a minimum market price of $[Ÿ] per share. Sales should begin on the date of this Notice and shall continue until [DATE] [all shares are sold].


SCHEDULE 2
Placement Notice Individuals
The Company
Sean E. George
Shelly D. Guyer
Patty Dumond

Cowen and Company, LLC
Michael Murphy, Director





SCHEDULE 3
Compensation
Cowen shall be paid compensation equal to 3.0% of the gross proceeds from the sales of Common Stock pursuant to the terms of this Agreement.



SCHEDULE 4
Schedule of Subsidiaries
CombiMatrix Corporation, a Delaware corporation

Exhibit 7(m)



OFFICER CERTIFICATE


The undersigned, the duly qualified and elected President and Chief Executive Officer of Invitae Corporation, a Delaware corporation (the “Company”), does hereby certify in such capacity and on behalf of the Company, pursuant to Section 7(m) of the Sales Agreement dated August 9, 2018 (the “Sales Agreement”) between the Company and Cowen and Company, LLC, that to the best of the knowledge of the undersigned:

(i)    The representations and warranties of the Company in Section 6 of the Sales Agreement (A) to the extent such representations and warranties are subject to qualifications and exceptions contained therein relating to materiality or Material Adverse Effect, are true and correct on and as of the date hereof with the same force and effect as if expressly made on and as of the date hereof, except for those representations and warranties that speak solely as of a specific date and which were true and correct as of such date, and (B) to the extent such representations and warranties are not subject to any qualifications or exceptions, are true and correct in all material respects as of the date hereof as if made on and as of the date hereof with the same force and effect as if expressly made on and as of the date hereof except for those representations and warranties that speak solely as of a specific date and which were true and correct as of such date; and
(ii)    The Company has complied with all agreements and satisfied all conditions on its part to be performed or satisfied pursuant to the Sales Agreement at or prior to the date hereof.
Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Sales Agreement.




By:                        
Name:
Title:


Date:                





 EX-21.1 3 nvta-exhibit211.htm EXHIBIT 21.1 Exhibit


Exhibit 21.1
 
LIST OF SUBSIDIARIES OF INVITAE CORPORATION
 
Subsidiary
 
Jurisdiction
Good Start Genetics, Inc.
 
Delaware
CombiMatrix Corporation
 
Delaware
CombiMatrix Molecular Diagnostics, Inc.
 
California
PatientCrossroads, Inc.
 
California
Ommdom Inc.
 
Delaware
Invitae Canada Inc.
 
British Colombia, Canada



 EX-23.1 4 nvta-exhibit231.htm EXHIBIT 23.1 Exhibit


Exhibit 23.1



CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the incorporation by reference in the following Registration Statements:
(1)
Registration Statements on Form S-3 (Nos. 333-220053, 333-220054 and 333-226756) of Invitae Corporation and the related prospectuses
(2)
Registration Statement on Form S-4 (No. 333-220447) of Invitae Corporation, including any post-effective amendments thereto on Form S-3 or Form S-8
(3)
Registration Statement on Form S-8 (No. 333-202066) pertaining to the 2015 Stock Incentive Plan, the Employee Stock Purchase Plan, and the 2010 Stock Incentive Plan of Invitae Corporation
(4)
Registration Statements on Form S-8 (Nos. 333-216761 and 333-223455) pertaining to the 2015 Stock Incentive Plan and the Employee Stock Purchase Plan of Invitae Corporation

of our report dated February 28, 2019, with respect to the consolidated financial statements of Invitae Corporation included in this Annual Report (Form 10-K) for the year ended December 31, 2018.


/s/ Ernst & Young LLP

Redwood City, California
February 28, 2019




 EX-31.1 5 nvta-exhibit311.htm EXHIBIT 31.1 Exhibit


Exhibit 31.1
PRINCIPAL EXECUTIVE OFFICER’S CERTIFICATION PURSUANT TO
SECTION 302 OF THE SARBANES‑OXLEY ACT OF 2002
I, Sean E. George, certify that:
1. I have reviewed this annual report on Form 10‑K of Invitae Corporation;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a‑15(e) and 15d‑15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
Date: February 28, 2019
 
 
 
 
/s/ Sean E. George, Ph.D.
 
Sean E. George, Ph.D.
 
Chief Executive Officer (Principal Executive Officer) and Director


 EX-31.2 6 nvta-exhibit312.htm EXHIBIT 31.2 Exhibit


Exhibit 31.2
PRINCIPAL FINANCIAL OFFICER’S CERTIFICATION PURSUANT TO
SECTION 302 OF THE SARBANES‑OXLEY ACT OF 2002
I, Shelly D. Guyer, certify that:
1. I have reviewed this annual report on Form 10‑K of Invitae Corporation;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a‑15(e) and 15d‑15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
Date: February 28, 2019
 
 
 
 
/s/ Shelly D. Guyer
 
Shelly D. Guyer
 
Chief Financial Officer (Principal Financial and Accounting Officer)


 EX-32.1 7 nvta-exhibit321.htm EXHIBIT 32.1 Exhibit


Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES‑OXLEY ACT OF 2002
In connection with the annual report of Invitae Corporation (the “Company”) on Form 10‑K for the year ended December 31, 2018, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned officer of the Company certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes‑Oxley Act of 2002, that, to such officer’s knowledge:

(1)
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: February 28, 2019
 
 
/s/ Sean E. George, Ph.D.
 
Sean E. George, Ph.D.
Chief Executive Officer (Principal Executive Officer) and Director



 EX-32.2 8 nvta-exhibit322.htm EXHIBIT 32.2 Exhibit


Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES‑OXLEY ACT OF 2002
In connection with the annual report of Invitae Corporation (the “Company”) on Form 10‑K for the year ended December 31, 2018, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned officer of the Company certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes‑Oxley Act of 2002, that, to such officer’s knowledge:

(1)
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: February 28, 2019
 
 
/s/ Shelly D. Guyer
 
Shelly D. Guyer
Chief Financial Officer (Principal Financial and Accounting Officer)



 EX-101.SCH 9 nvta-20181231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2106100 - Disclosure - Balance sheet components link:presentationLink link:calculationLink link:definitionLink 2406403 - Disclosure - Balance sheet components - Accrued liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2406404 - Disclosure - Balance sheet components - Other long-term liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Balance sheet components - Property and equipment (Details) link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - Balance sheet components (Tables) link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - Business combinations link:presentationLink link:calculationLink link:definitionLink 2404402 - Disclosure - Business combinations - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2404404 - Disclosure - Business combinations - Schedule of economic benefits of intangible assets expected to be realized (Details) link:presentationLink link:calculationLink link:definitionLink 2404403 - Disclosure - Business combinations - Summary of fair values of assets acquired and liabilities assumed (Details) link:presentationLink link:calculationLink link:definitionLink 2304301 - Disclosure - Business combinations (Tables) link:presentationLink link:calculationLink link:definitionLink 2109100 - Disclosure - Commitments and contingencies link:presentationLink link:calculationLink link:definitionLink 2409407 - Disclosure - Commitments and contingencies - Capital leases narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2409405 - Disclosure - Commitments and contingencies - Debt financing narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2409402 - Disclosure - Commitments and contingencies - Operating leases narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2409410 - Disclosure - Commitments and contingencies - Other commitments narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2409408 - Disclosure - Commitments and contingencies - Schedule of future minimum lease payments under capital leases (Details) link:presentationLink link:calculationLink link:definitionLink 2409408 - Disclosure - Commitments and contingencies - Schedule of future minimum lease payments under capital leases (Details) link:presentationLink link:calculationLink link:definitionLink 2409403 - Disclosure - Commitments and contingencies - Schedule of future minimum payments under operating leases (Details) link:presentationLink link:calculationLink link:definitionLink 2409406 - Disclosure - Commitments and contingencies - Schedule of future payments under loan and security agreement (Details) link:presentationLink link:calculationLink link:definitionLink 2409406 - Disclosure - Commitments and contingencies - Schedule of future payments under loan and security agreement (Details) link:presentationLink link:calculationLink link:definitionLink 2409409 - Disclosure - Commitments and contingencies - Schedule of future payments under noncancelable unconditional purchase commitments (Details) link:presentationLink link:calculationLink link:definitionLink 2409404 - Disclosure - Commitments and contingencies - Schedule of rent expense related to non-cancelable operating leases (Details) link:presentationLink link:calculationLink link:definitionLink 2309301 - Disclosure - Commitments and contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1001501 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1006000 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - Consolidated Statements of Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 1004501 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 0002000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - Fair value measurements link:presentationLink link:calculationLink link:definitionLink 2407405 - Disclosure - Fair value measurements - Carrying amount and the estimated fair value of the Company's outstanding debt (Details) link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - Fair value measurements - Financial instruments at fair value on a recurring basis (Details) link:presentationLink link:calculationLink link:definitionLink 2407404 - Disclosure - Fair value measurements - Level 3 financial instruments measured at fair value on a recurring basis (Details) link:presentationLink link:calculationLink link:definitionLink 2407403 - Disclosure - Fair value measurements - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2307301 - Disclosure - Fair value measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 2114100 - Disclosure - Geographic information link:presentationLink link:calculationLink link:definitionLink 2414402 - Disclosure - Geographic information - Schedule of revenue by country (Details) link:presentationLink link:calculationLink link:definitionLink 2314301 - Disclosure - Geographic information (Tables) link:presentationLink link:calculationLink link:definitionLink 2105100 - Disclosure - Goodwill and intangible assets link:presentationLink link:calculationLink link:definitionLink 2405403 - Disclosure - Goodwill and intangible assets - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2405404 - Disclosure - Goodwill and intangible assets - Schedule of finite-lived intangible assets (Details) link:presentationLink link:calculationLink link:definitionLink 2405405 - Disclosure - Goodwill and intangible assets - Summary of estimated future amortization expense of intangible assets with finite lives (Details) link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - Goodwill and intangible assets - Summary of goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - Goodwill and intangible assets (Tables) link:presentationLink link:calculationLink link:definitionLink 2112100 - Disclosure - Income taxes link:presentationLink link:calculationLink link:definitionLink 2412402 - Disclosure - Income Taxes - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2412403 - Disclosure - Income Taxes - Schedule of components of loss before income taxes by U.S. and foreign jurisdictions (Details) link:presentationLink link:calculationLink link:definitionLink 2412404 - Disclosure - Income Taxes - Schedule of components of the provision for income taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2412406 - Disclosure - Income Taxes - Schedule of net deferred tax assets (Details) link:presentationLink link:calculationLink link:definitionLink 2412405 - Disclosure - Income Taxes - Schedule of reconciliation of the tax expense computed at the statutory federal rate and Company's tax expense (Details) link:presentationLink link:calculationLink link:definitionLink 2412407 - Disclosure - Income Taxes - Schedule of reconciliation of unrecognized tax benefits (Details) link:presentationLink link:calculationLink link:definitionLink 2312301 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 2408401 - Disclosure - Investment in privately held company (Details) link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - Investment in privately held company Investment in privately held company link:presentationLink link:calculationLink link:definitionLink 2113100 - Disclosure - Net loss per common share link:presentationLink link:calculationLink link:definitionLink 2413403 - Disclosure - Net loss per common share - Schedule of antidilutive securities excluded from computation of earnings per share (Details) link:presentationLink link:calculationLink link:definitionLink 2413402 - Disclosure - Net loss per common share - Schedule of earnings per share, basic and diluted (Details) link:presentationLink link:calculationLink link:definitionLink 2313301 - Disclosure - Net loss per common share (Tables) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - Organization and description of business link:presentationLink link:calculationLink link:definitionLink 2401401 - Disclosure - Organization and description of business - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2103100 - Disclosure - Revenue, accounts receivable and deferred revenue link:presentationLink link:calculationLink link:definitionLink 2403402 - Disclosure - Revenue, accounts receivable and deferred revenue - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2403404 - Disclosure - Revenue, accounts receivable and deferred revenue - Schedule of disaggregated revenue by payer category (Details) link:presentationLink link:calculationLink link:definitionLink 2403403 - Disclosure - Revenue, accounts receivable and deferred revenue - Schedule of impact of adoption of topic 606 on condensed statement of operations and balance sheet (Details) link:presentationLink link:calculationLink link:definitionLink 2303301 - Disclosure - Revenue, accounts receivable and deferred revenue (Tables) link:presentationLink link:calculationLink link:definitionLink 2115100 - Disclosure - Selected quarterly data (unaudited) link:presentationLink link:calculationLink link:definitionLink 2415402 - Disclosure - Selected Quarterly Data (Unaudited) (Details) link:presentationLink link:calculationLink link:definitionLink 2315301 - Disclosure - Selected Quarterly Data (Unaudited) (Tables) link:presentationLink link:calculationLink link:definitionLink 2111100 - Disclosure - Stock incentive plans link:presentationLink link:calculationLink link:definitionLink 2411402 - Disclosure - Stock incentive plans - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2411403 - Disclosure - Stock incentive plans - Schedule of activity under stock incentive plans (Details) link:presentationLink link:calculationLink link:definitionLink 2411405 - Disclosure - Stock incentive plans - Schedule of assumptions used in determination of fair value of options (Details) link:presentationLink link:calculationLink link:definitionLink 2411406 - Disclosure - Stock incentive plans - Stock-based compensation expense (Details) link:presentationLink link:calculationLink link:definitionLink 2411404 - Disclosure - Stock incentive plans - Summary of RSU activity (Details) link:presentationLink link:calculationLink link:definitionLink 2311301 - Disclosure - Stock incentive plans (Tables) link:presentationLink link:calculationLink link:definitionLink 2110100 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 2410403 - Disclosure - Stockholders' Equity - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2410404 - Disclosure - Stockholders' Equity - Schedule of outstanding warrants to purchase common stock (Details) link:presentationLink link:calculationLink link:definitionLink 2410402 - Disclosure - Stockholders' Equity - Schedule of shares of common stock reserved for future issuance (Details) link:presentationLink link:calculationLink link:definitionLink 2310301 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - Summary of significant accounting policies link:presentationLink link:calculationLink link:definitionLink 2402403 - Disclosure - Summary of significant accounting policies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2202201 - Disclosure - Summary of significant accounting policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2402405 - Disclosure - Summary of significant accounting policies - Schedule of cash, cash equivalents and restricted cash (Details) link:presentationLink link:calculationLink link:definitionLink 2402404 - Disclosure - Summary of significant accounting policies - Schedule of significant customers, revenue as a percentage (Details) link:presentationLink link:calculationLink link:definitionLink 2402406 - Disclosure - Summary of significant accounting policies - Schedule of useful lives of property and equipment (Details) link:presentationLink link:calculationLink link:definitionLink 2302302 - Disclosure - Summary of significant accounting policies (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 10 nvta-20181231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 11 nvta-20181231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 12 nvta-20181231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Income Statement Location Income Statement Location [Axis] Income Statement Location Income Statement Location [Domain] Cost of revenue Cost Of Test Revenue [Member] Cost of test revenue. Research and development Research And Development [Member] Represents the information pertaining to research and development expenses included in the income statement. Selling and marketing Selling and Marketing Expense [Member] General and administrative General and Administrative Expense [Member] Award Type Award Type [Axis] Equity Award Equity Award [Domain] Stock-based compensation Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Total stock-based compensation expense Allocated Share-based Compensation Expense Balance Sheet Related Disclosures [Abstract] Accrued compensation and related expenses Employee-related Liabilities, Current Deferred revenue Contract with Customer, Liability, Current Liabilities associated with business combinations Business Combination Accrued Liabilities Current Business combination accrued liabilities current. Liability associated with co-development agreement Due to Affiliate, Current Other Other Accrued Liabilities, Current Total accrued liabilities Accrued Liabilities, Current Quarterly Financial Information Disclosure [Abstract] Schedule of selected quarterly data Quarterly Financial Information [Table Text Block] Plan Name Plan Name [Axis] Plan Name Plan Name [Domain] 2015 Employee Stock Purchase Plan Employee Stock Purchase Plan2015 [Member] Represents the information pertaining to the 2015 employee stock purchase plan. Title of Individual Title of Individual [Axis] Relationship to Entity Relationship to Entity [Domain] Employees and directors stock options Employees And Directors Stock Options [Member] Employees and Directors Stock Options [Member]. Employee Stock Option Employee Stock Option [Member] Non-Employee Options Non Employee Stock Option [Member] An arrangement whereby a non-employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Range Range [Axis] Range Range [Domain] Minimum Minimum [Member] Maximum Maximum [Member] Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Expected term (in years) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Expected volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Risk-free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Expected term (in years) Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Term Expected volatility Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Volatility Rate Risk-free interest rate Share-based Goods and Nonemployee Services Transaction, Valuation Method, Risk Free Interest Rate Goodwill and Intangible Assets Disclosure [Abstract] Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Finite-Lived Intangible Assets by Major Class Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name Finite-Lived Intangible Assets, Major Class Name [Domain] Customer relationships Customer Relationships [Member] Developed technology Developed Technology Rights [Member] Non-compete agreement Noncompete Agreements [Member] Trade name Trade Names [Member] Patent licensing agreement Patent Licensing Agreement [Member] Patent licensing agreement. Favorable leases Favorable Leases [Member] Favorable leases. Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Cost Finite-Lived Intangible Assets, Gross Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Net Finite-Lived Intangible Assets, Net Weighted Average Useful Life (in Years) Finite-Lived Intangible Asset, Useful Life Weighted Average Estimated Remaining Useful Life (in Years) Finite-Lived Intangible Assets, Remaining Amortization Period Statement of Stockholders' Equity [Abstract] Statement [Table] Statement [Table] Equity Components Equity Components [Axis] Equity Component Equity Component [Domain] Preferred Stock Preferred Stock [Member] Common Stock Common Stock [Member] Additional Paid-In Capital Additional Paid-in Capital [Member] Accumulated Other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] Accumulated Deficit Retained Earnings [Member] Statement [Line Items] Statement [Line Items] Increase (Decrease) in Stockholders' Deficit Increase (Decrease) in Stockholders' Equity [Roll Forward] Balance at the beginning of the period Stockholders' Equity Attributable to Parent Balance at the beginning of the period (in shares) Shares, Outstanding Common stock issued on exercise of stock options Stock Issued During Period, Value, Stock Options Exercised Options exercised (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Common stock issued pursuant to vesting of restricted stock units Stock Issued During Period, Value, Restricted Stock Award, Gross Common stock issued pursuant to vesting of restricted stock units (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Gross Common stock issued pursuant to employee stock purchase plan Stock Issued During Period, Value, Employee Stock Purchase Plan Common stock issued pursuant to employee stock purchase plan (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Common stock issued in connection with initial public offering, net of offering costs Stock Issued During Period, Value, New Issues Common stock issued in connection with initial public offering, net of offering costs (in shares) Stock Issued During Period, Shares, New Issues Vesting of common stock related to early exercise of options Stock Issued During Period Value Vesting Of Common Stock Related To Early Exercise Of Options Value of stock issued as a result of the vesting of common stock related to early exercise of stock options. Vesting of common stock related to early exercise of options (in shares) Stock Issued During Period Shares Vesting Of Common Stock Related To Early Exercise Of Options Number of share options exercised during the current period due to vesting of common stock related to early exercise of options. Stock-based compensation expense Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Unrealized income (loss) on available-for-sale marketable securities, net of tax Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, before Tax Net loss Net Income (Loss) Attributable to Parent Common and convertible preferred stock issued in private placement, net of offering costs Stock Issued During Period Value In Connection With Private Placement Net Of Offering Costs Stock issued during period value in connection with private placement, net of offering costs. Common and convertible preferred stock issued in private placement, net of offering costs (in shares) Stock Issued During Period Shares In Connection With Private Placement Net Of Offering Costs Stock issued during period shares in connection with private placement, net of offering costs. Common stock issued on exercise of stock options, net Stock Issued, Value, Stock Options Exercised, Net of Tax Benefit (Expense) Common stock issued pursuant to acquisition-related transaction bonus (in shares) Stock Issued During Period Shares Acquisition Related Transaction Bonus Stock issued during period, shares, acquisition-related transaction bonus. Common stock issued pursuant to exercises of warrants Stock Issued During Period Value Warrants Exercised Stock issued during period value warrants exercised. Common stock issued pursuant to exercises of warrants (in shares) Stock Issued During Period Shares Warrants Exercised Stock issued during period shares warrants exercised. Common stock issued pursuant to business combinations Stock Issued During Period, Value, Acquisitions Common stock issued pursuant to business combinations (in shares) Stock Issued During Period, Shares, Acquisitions Common stock issued to settle assumed liabilities Stock Issued During Period, Value, Purchase of Assets Common stock issued to settle assumed liabilities (in shares) Stock Issued During Period, Shares, Purchase of Assets Warrants issued pursuant to the 2017 Loan Agreement Adjustments to Additional Paid in Capital, Stock Issued, Own-share Lending Arrangement, Issuance Costs Cumulative effect of accounting change Cumulative Effect of New Accounting Principle in Period of Adoption Common stock issued pursuant to Securities Purchase Agreement (see Note 9) Stock Issued During Period, Value, Conversion of Convertible Securities Common stock issued pursuant to debt financing (in shares) Stock Issued During Period, Shares, Conversion of Convertible Securities Balance at the end of the period Balance at the end of the period (in shares) Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization and description of business Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] Commitments and Contingencies Disclosure [Abstract] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Common stock Debt Instrument Debt Instrument [Axis] Debt Instrument, Name Debt Instrument, Name [Domain] Loan and Security Agreement Loan And Security Agreement [Member] Represents information pertaining to loan and security agreement. Initial sale of notes Tranche One [Member] Tranche one. Credit Facility Credit Facility [Axis] Credit Facility Credit Facility [Domain] Secured Debt Secured Debt [Member] Note Purchase Agreement Note Purchase Agreement [Member] Note purchase agreement. Long-term Debt, Type Long-term Debt, Type [Axis] Long-term Debt, Type Long-term Debt, Type [Domain] Initial term loan First Term Loan [Member] First term loan. Second Term Loan Second Term Loan [Member] Second term loan. Third Term Loan Third Term Loan [Member] Third term loan. Scenario Scenario [Axis] Scenario, Unspecified Scenario, Unspecified [Domain] Scenario, forecast Scenario, Forecast [Member] Debt Instrument, Redemption, Period [Axis] Debt Instrument, Redemption, Period [Axis] Debt Instrument, Redemption, Period [Domain] Debt Instrument, Redemption, Period [Domain] Payment made within 12 months after closing date Debt Instrument, Redemption, Period One [Member] Payment made within 24 months after closing date Debt Instrument, Redemption, Period Two [Member] Payment made within 36 months after closing date Debt Instrument, Redemption, Period Three [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Term loan, borrowing amount Long-term Debt, Gross Net proceeds from term loan Proceeds from Debt, Net of Issuance Costs Term loan, line fee percentage on unused commitment amount Debt Instrument Commitment Fee Percentage On Unused Borrowing Capacity Debt instrument commitment fee percentage on unused borrowing capacity. Term loan, line fee on unused commitment amount Line of Credit Facility, Remaining Borrowing Capacity Term loans, variable interest rate Debt Instrument, Basis Spread on Variable Rate Term loans, index interest rate, minimum Debt Instrument Index Interest Rate Minimum Debt instrument index interest rate minimum. Term loans, frequency of periodic payment Debt Instrument, Frequency of Periodic Payment Term loans, floor interest rate Debt Instrument Floor Interest Rate Debt instrument floor interest rate. Term loans, fee percentage of funded draw Debt Instrument, Redemption Price, Percentage Term loans, facility fee percentage Debt Instrument Facility Fee Percentage Debt instrument facility fee percentage. Term loans, prepayment fee percentage of outstanding balance Prepayment Fee Percentage Of Outstanding Balance Prepayment fee percentage of outstanding balance. Warrants issued to acquire shares, percentage of funded amount Warrants Issued To Acquire Shares Percentage Of Funded Amount Warrants issued to acquire shares percentage of funded amount. Warrants issued to purchase shares of common stock (in shares) Warrants Issued To Purchase Common Stock Warrants issued to purchase common stock. Warrants issued to purchase common stock exercise price (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Fair value of warrant Warrants Not Settleable in Cash, Fair Value Disclosure Warrants term Warrants Term Warrants term. Maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Debt instrument, term Debt Instrument, Term Proceeds from Notes Payable Proceeds from Notes Payable Repayments of Long-term Debt Repayments of Long-term Debt Debt extinguishment costs Payment for Debt Extinguishment or Debt Prepayment Cost Debt instrument, interest rate, stated percentage Debt Instrument, Interest Rate, Stated Percentage Percentage of net annual revenue receivable by purchasers in addition to interest, beginning on January 1, 2020 Percentage Of Net Annual Revenue Receivable By Lender In Addition To Interest Percentage of Net annual revenue receivable by lender in addition to interest. Maximum net annual revenue receivable by purchasers in addition to interest, beginning on January 1, 2020 Maximum Net Annual Revenue Receivable By Lender In Addition To Interest Maximum net annual revenue receivable by lender in addition to interest. Internal rate of return percentage Internal Rate Of Return Percentage Internal rate of return percentage. Debt instrument, average effective interest rate Debt Instrument, Interest Rate During Period Common stock issued during period (in shares) Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Shares issued price per share (in dollars per share) Shares Issued, Price Per Share Fair value of common stock Equity, Fair Value Disclosure Debt issuance cost Debt Related Commitment Fees and Debt Issuance Costs Interest expense Interest Expense, Debt Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] 2010 Plan Stock Incentive Plan2010 [Member] Represents the information pertaining to the 2010 stock incentive plan, which provides for the granting of stock based awards to employees, directors, and consultants under terms and provisions established by the board of directors. 2015 Plan Stock Incentive Plan2015 [Member] Represents the information pertaining to the 2015 stock incentive plan. Stock incentive plans Stock Incentive Plan [Member] Represents the stock incentive plans of the entity, which includes the 2010 plan, the 2015 plan, employee stock purchase plan. Vesting Vesting [Axis] Vesting Vesting [Domain] First anniversary First Anniversary Of Grant Date [Member] Represents the information pertaining to first anniversary of grant date. Second anniversary Second Anniversary Of Grant Date [Member] Represents the information pertaining to second anniversary of grant date. Third anniversary Third Anniversary Of Grant Date [Member] Represents the information pertaining to third anniversary of grant date. Shares of common stock subject to outstanding RSUs Restricted Stock Units (RSUs) [Member] Shares of common stock subject to outstanding PRSUs Performance Restricted Stock Units Rsus [Member] Share instrument which is convertible to stock or an equivalent amount of cash, when specified performance conditions are met. Shares of common stock subject to outstanding options Stock incentive plan Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Employees holding voting rights of all classes of stock (as a percent) Share Based Compensation Arrangement By Share Based Payment Award Voting Rights Of Common Stock Holding Percentage Represents the percentage of voting rights of all classes of stock held by the employees. Exercise price of options on common stock (as a percent) Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent Term of options granted Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period Vesting period Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Share-based compensation arrangement by share-based payment award, award vesting rights, percentage Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Share-based compensation arrangement by share-based payment award, vesting rights, equal monthly vesting percentage Share Based Compensation Arrangement By Share Based Payment Award Vesting Rights Equal Monthly Vesting Percentage Represents the monthly percentage of vesting of share-based compensation awards. Vested stock units awarded (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares Weighted-average grant date fair value (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Stock-based compensation Share-based Compensation Share-based compensation arrangement by share-based payment award equity instruments other than options granted in period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Total grant date fair value of options to purchase common stock vested Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value Exercised, aggregate intrinsic value Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value Purchase price of common stock of the lesser of fair market value on the purchase date or the last trading day preceding the offering date (as a percent) Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Purchase Date Proceeds from stock plans Proceeds from Stock Plans Additional shares reserved (in shares) Common Stock, Capital Shares Reserved for Future Issuance Number of employees affected by the stock option and RSU modifications Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Number of Employees Affected Incremental compensation cost relating to stock option and RSU modifications Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Incremental Compensation Cost Unrecognized stock-based compensation Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options Expected period to recognize on a straight-line basis Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Capitalized stock-based employee compensation Stock Based Employee Compensation Capitalized Represents the information pertaining to capitalized stock based employee compensation. Schedule of Operating Leased Assets [Table] Schedule of Operating Leased Assets [Table] Property, Plant and Equipment, Type Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Domain] Property, Plant and Equipment, Type [Domain] Office Facility In San Francisco Office Facility In San Francisco [Member] Represents the information pertaining to office facility in San Francisco. Type of Arrangement and Non-arrangement Transactions Type of Arrangement and Non-arrangement Transactions [Axis] Arrangements and Non-arrangement Transactions Arrangements and Non-arrangement Transactions [Domain] New leases New Leases [Member] Information pertaining to new lease arrangements. Operating Leased Assets [Line Items] Operating Leased Assets [Line Items] Additional term of lease Lessee, Operating Lease, Renewal Term Lease term Lessee, Operating Lease, Term of Contract Security deposit Security Deposit Lease incentive in form of lease improvements Lease Incentive Receivable Total minimum lease payments Operating Leases, Future Minimum Payments Due Fair Value Disclosures [Abstract] Schedule of Financial instruments at fair value on a recurring basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Schedule of Level 3 financial instruments measured at fair value on a recurring basis Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Schedule of Carrying amount and the estimated fair value of the Company's outstanding debt Fair Value, Liabilities Measured on Recurring Basis [Table Text Block] Stock incentive plans Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Income Tax Disclosure [Abstract] Reconciliation of the tax expense computed at the statutory federal rate and Company's tax expense Effective Income Tax Rate Reconciliation, Percent [Abstract] U.S. federal taxes at statutory rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent State taxes (net of federal benefit) Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent Stock-based compensation Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Compensation Cost, Percent Research and development credits Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent Non-deductible expenses Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent Foreign tax differential Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent Other Effective Income Tax Rate Reconciliation, Other Adjustments, Percent Change in valuation allowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent Change in deferred—Tax Reform Tax Cuts And Jobs Act Of2017 Change In Deferred Tax Percentage Tax cuts and jobs act of 2017, change in deferred tax percentage. Change in valuation allowance—Tax Reform Tax Cuts And Jobs Act Of2017 Change In Valuation Allowance Tax cuts and jobs act of 2017, change in valuation allowance. Total Effective Income Tax Rate Reconciliation, Percent Balance sheet components Supplemental Balance Sheet Disclosures [Text Block] Investment in privately held company Collaborative Arrangement Disclosure [Text Block] Segments, Geographical Areas [Abstract] Schedule of revenue by country Revenue from External Customers by Geographic Areas [Table Text Block] Goodwill and intangible assets Goodwill and Intangible Assets Disclosure [Text Block] Geographic information Segment Reporting Disclosure [Text Block] Schedule of activity under stock incentive plans Share-based Compensation, Activity [Table Text Block] Summary of RSU activity Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block] Schedule of assumptions used in determination of fair value of options Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Summary of stock based compensation expense related to stock options included in consolidated statements of operations Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block] Statement of Financial Position [Abstract] Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Preferred stock, authorized (in shares) Preferred Stock, Shares Authorized Preferred stock, issued (in shares) Preferred Stock, Shares Issued Preferred stock, outstanding (in shares) Preferred Stock, Shares Outstanding Common stock, authorized (in shares) Common Stock, Shares Authorized Common stock, issued (in shares) Common Stock, Shares, Issued Common stock, outstanding (in shares) Common Stock, Shares, Outstanding Number of genes Number Of Genes Number of genes. Number of operating segments Number of Operating Segments Schedule of components of loss before income taxes by U.S. and foreign jurisdictions Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] Schedule of components of the provision for income taxes Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Schedule of reconciliation of the tax expense computed at the statutory federal rate and Company's tax expense Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Schedule of net deferred tax assets Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Schedule of reconciliation of gross unrecognized tax benefits Summary of Income Tax Contingencies [Table Text Block] Document And Entity Information [Abstract] Document and Entity Information Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Amendment Flag Amendment Flag Current Fiscal Year End Date Current Fiscal Year End Date Entity Current Reporting Status Entity Current Reporting Status Entity Filer Category Entity Filer Category Entity Small Business Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period Entity Shell Company Entity Shell Company Trading Symbol Trading Symbol Entity Voluntary Filers Entity Voluntary Filers Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity Public Float Entity Public Float Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Earnings Per Share [Abstract] Shares used in computing net loss per share, basic and diluted (in shares) Weighted Average Number of Shares Outstanding, Basic and Diluted Net loss per share, basic and diluted (in dollars per share) Earnings Per Share, Basic and Diluted Schedule of Goodwill [Table] Schedule of Goodwill [Table] Business Acquisition Business Acquisition [Axis] Business Acquisition, Acquiree Business Acquisition, Acquiree [Domain] CombiMatrix Combi Matrix Corporation [Member] CombiMatrix Corporation. Goodwill [Line Items] Goodwill [Line Items] Goodwill adjustment Goodwill, Purchase Accounting Adjustments Intangible assets estimated useful lives Amortization expense Amortization of Intangible Assets Schedule of earnings per share, basic and diluted Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of antidilutive securities excluded from computation of earnings per share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Accounting Policies [Abstract] Summary Of Significant Accounting Policies [Table] Summary Of Significant Accounting Policies [Table] Summary of significant accounting policies. Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Revenue Sales Revenue, Net [Member] Accounts receivable Accounts Receivable [Member] Concentration Risk Type Concentration Risk Type [Axis] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Customer concentration risk Customer Concentration Risk [Member] Customer Customer [Axis] Customer [Domain] Customer [Domain] Medicare Customer [Member] Represents the information pertaining to Customer A. Leasehold improvements Leasehold Improvements [Member] Summary Of Significant Accounting Policies [Line Items] Summary Of Significant Accounting Policies [Line Items] Summary of significant accounting policies. Concentration risk (as a percent) Concentration Risk, Percentage Inventory Inventory, Net Goodwill impairment loss Goodwill, Impairment Loss Property and equipment, estimated useful lives Property, Plant and Equipment, Useful Life Impairment losses Asset Impairment Charges Long-lived asset impairment losses Impairment of Long-Lived Assets to be Disposed of Advertising expense Advertising Expense Future undiscounted capital lease payments Capital Leases, Future Minimum Payments Due Future undiscounted non-cancelable minimum operating lease payments Operating Leases Future Minimum Payments Due, Net Operating Leases Future Minimum Payments Due, Net Revenue from Contract with Customer [Abstract] Revenue, accounts receivable and deferred revenue Revenue from Contract with Customer [Text Block] Business Combinations [Abstract] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] AltaVoice Alta Voice [Member] Alta Voice. Ommdom, Inc. Ommdom Inc [Member] Ommdom Inc. Good Start Genetics Good Start Genetics Inc [Member] Good Start Genetics, Inc. Business Acquisition [Line Items] Business Acquisition [Line Items] Summary of fair values of assets acquired and liabilities assumed Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Schedule of economic benefits of intangible assets expected to be realized Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block] Lease incentive obligation, non-current Lease Incentive Payable Non Current This item represents an incentive or inducement contractually stipulated between parties to a lease whereby the lessor has committed to provide the entity (lessee) with a cash payment as inducement to enter the lease. Used to reflect the current portion of the liabilities (due beyond one year or beyond the normal operating cycle if longer). Deferred rent, non-current Deferred Rent Credit, Noncurrent Liabilities associated with business combinations Business Combination Accrued Liabilities Noncurrent Business combination accrued liabilities noncurrent. Other non-current liabilities Other Accrued Liabilities, Noncurrent Total other long-term liabilities Other Liabilities, Noncurrent Rent expense Operating Leases, Rent Expense, Minimum Rentals Sublease income Operating Leases, Rent Expense, Sublease Rentals Rent expense, net of sublease income Operating Leases, Rent Expense, Net Income Statement [Abstract] Product and Service [Axis] Product and Service [Axis] Product and Service [Domain] Product and Service [Domain] Test revenue Diagnostic Tests [Member] Diagnostic tests. Other revenue Collaboration And Genome Network [Member] Collaboration and genome network. Revenue: Revenues [Abstract] Total revenue Revenue from Contract with Customer, Excluding Assessed Tax Costs and operating expenses: Operating Costs and Expenses [Abstract] Cost of revenue Cost of Revenue Research and development Research and Development Expense Selling and marketing Selling and Marketing Expense General and administrative General and Administrative Expense Total costs and operating expenses Costs and Expenses Loss from operations Operating Income (Loss) Other income (expense), net Other Nonoperating Income (Expense) Interest expense Interest Expense Net loss before taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Income tax benefit Income Tax Expense (Benefit) Net loss Net loss per share, basic and diluted (in dollars per share) Income (Loss) from Continuing Operations, Per Basic and Diluted Share Stockholders' Equity Note [Abstract] Schedule of shares of common stock reserved for future issuance Schedule Of Common Stock Reserved For Future Issuance Table [Text Block] Tabular disclosure of Common stock reserved for future issuance. Schedule of outstanding warrants to purchase common stock Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Principles of consolidation Consolidation, Policy [Policy Text Block] Use of estimates Use of Estimates, Policy [Policy Text Block] Concentrations of credit risk and other risks and uncertainties Concentration Risk, Credit Risk, Policy [Policy Text Block] Cash, cash equivalents, and restricted cash Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Marketable securities Marketable Securities, Policy [Policy Text Block] Accounts receivable Receivables, Policy [Policy Text Block] Inventory Inventory, Policy [Policy Text Block] Business combinations Business Combinations Policy [Policy Text Block] Intangible assets Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block] Goodwill Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] Leases Lessee, Leases [Policy Text Block] Property and equipment, net Property, Plant and Equipment, Policy [Policy Text Block] Long-lived assets Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Variable interest entity Consolidation, Variable Interest Entity, Policy [Policy Text Block] Fair value of financial instruments Fair Value of Financial Instruments, Policy [Policy Text Block] Revenue recognition and cost of revenue Revenue from Contract with Customer [Policy Text Block] Income taxes Income Tax, Policy [Policy Text Block] Stock-based compensation Compensation Related Costs, Policy [Policy Text Block] Advertising Advertising Costs, Policy [Policy Text Block] Comprehensive loss Comprehensive Income, Policy [Policy Text Block] Net loss per share Earnings Per Share, Policy [Policy Text Block] Recent accounting pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Offering costs Payments of Stock Issuance Costs Class of Warrant or Right [Table] Class of Warrant or Right [Table] Class of Warrant or Right Class of Warrant or Right [Axis] Class of Warrant or Right Class of Warrant or Right [Domain] Warrants issued to lender under Loan and Security Agreement Warrants Issued To Lender Under Loan And Security Agreement [Member] Warrants issued to lender under loan and security agreement. Warrants issued to lender under Loan and Security Agreement - 2018 Amendments Warrants issued to lender under Loan and Security Agreement - 2018 Amendments [Member] Warrants issued to lender under Loan and Security Agreement - 2018 Amendments [Member] Class of Stock Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Series F Warrants Series F Warrants [Member] Series F warrants. Class of Warrant or Right [Line Items] Class of Warrant or Right [Line Items] Exercise price per share (in dollars per share) Number of shares of common stock underlying warrants (in shares) Class of Warrant or Right, Outstanding Loss from operations Statement of Comprehensive Income [Abstract] Other comprehensive income (loss): Other Comprehensive Income (Loss), Net of Tax [Abstract] Unrealized income (loss) on available-for-sale marketable securities, net of tax Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent 2019 Operating Leases, Future Minimum Payments Due, Next Twelve Months 2020 Operating Leases, Future Minimum Payments, Due in Two Years 2021 Operating Leases, Future Minimum Payments, Due in Three Years 2022 Operating Leases, Future Minimum Payments, Due in Four Years 2023 Operating Leases, Future Minimum Payments, Due in Five Years Thereafter Operating Leases, Future Minimum Payments, Due Thereafter Future non-cancelable minimum operating lease payments Less: minimum payments to be received from non-cancelable subleases Operating Leases, Future Minimum Payments Due, Future Minimum Sublease Rentals Total future non-cancelable minimum operating lease payments, net Ommdom Good Start Goodwill [Roll Forward] Goodwill [Roll Forward] December 31, 2017 Goodwill December 31, 2018 Net loss per common share Earnings Per Share [Text Block] Summary of significant accounting policies Significant Accounting Policies [Text Block] Earnings Per Share [Table] Earnings Per Share [Table] Earnings per share. Antidilutive Securities Antidilutive Securities [Axis] Antidilutive Securities, Name Antidilutive Securities, Name [Domain] Shares of common stock subject to outstanding warrants Warrant [Member] Shares of common stock pursuant to ESPP Shares of common stock underlying Series A convertible preferred stock Series A Convertible Preferred Stock [Member] Series A convertible preferred stock. Earnings Per Share [Line Items] Earnings Per Share [Line Items] Earnings per share. Antidilutive securities excluded from computation of earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Restricted cash Restricted Cash and Cash Equivalents Total cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Schedule of Revenues from External Customers and Long-Lived Assets [Table] Schedule of Revenues from External Customers and Long-Lived Assets [Table] Geographical Geographical [Axis] Geographical Geographical [Domain] United States UNITED STATES Canada CANADA Rest of world Rest Of World [Member] Represents the information pertaining to rest of the world. Geographic information Revenues from External Customers and Long-Lived Assets [Line Items] Favorable leases Off-Market Favorable Lease [Member] Gross Purchased Intangible Assets Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Shareholders' Equity Class Shareholders' Equity Class [Axis] Fair Value by Shareholders' Equity Class Fair Value by Shareholders' Equity Class [Domain] Stock Payable Liabilities Stock Payable Liabilities [Member] Stock payable liabilities. Payable as Contingent Consideration Contingent Consideration Classified as Equity [Member] Convertible Preferred Stock Convertible Preferred Stock [Member] Class of Stock Class of Stock [Line Items] Options issued and outstanding (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number RSU awards issued and outstanding (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Shares available for grant under stock options plans (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Common stock reserved for future issuance (in shares) Selected quarterly data (unaudited) Quarterly Financial Information [Text Block] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Laboratory equipment Equipment [Member] Equipment under capital lease Assets Held under Capital Leases [Member] Computer equipment Computer Equipment [Member] Software Software and Software Development Costs [Member] Furniture and fixtures Furniture and Fixtures [Member] Automobiles Automobiles [Member] Construction-in-progress Construction in Progress [Member] Property and equipment Property, Plant and Equipment [Line Items] Total property and equipment, gross Property, Plant and Equipment, Gross Accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Total property and equipment, net Property, Plant and Equipment, Net Depreciation Depreciation Schedule of Product Information [Table] Schedule of Product Information [Table] Product Information [Line Items] Product Information [Line Items] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value Measurements, Recurring and Nonrecurring [Table] Financial Instrument [Axis] Financial Instrument [Axis] Financial Instruments [Domain] Financial Instruments [Domain] Money market funds Money Market Funds [Member] Certificates of deposit Certificates of Deposit [Member] Commercial paper Commercial Paper [Member] U.S. treasury notes US Treasury Securities [Member] U.S. government agency securities US Government Agencies Debt Securities [Member] Contingent consideration Contingent Consideration [Member] Contingent consideration. Measurement Frequency Measurement Frequency [Axis] Fair Value, Measurement Frequency Fair Value, Measurement Frequency [Domain] Recurring basis Fair Value, Measurements, Recurring [Member] Fair Value, Hierarchy Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy Fair Value Hierarchy and NAV [Domain] Level 1 Fair Value, Inputs, Level 1 [Member] Level 2 Fair Value, Inputs, Level 2 [Member] Level 3 Fair Value, Inputs, Level 3 [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Cash equivalents, restricted cash and marketable securities, amortized cost Cash Equivalents Restricted Cash And Marketable Securities Amortized Cost Cash equivalents restricted cash and marketable securities amortized cost. Cash equivalents, restricted cash and marketable securities, gross unrealized loss before tax Cash Equivalents Restricted Cash And Marketable Securities Amortized Cost Gross Unrealized Loss Before Tax Cash equivalents restricted cash and marketable securities amortized cost gross unrealized loss before tax. Cash equivalents, restricted cash and marketable securities, estimated fair value Cash Equivalents Restricted Cash And Marketable Securities Fair Value Cash equivalents restricted cash and marketable securities fair value. Total financial assets Assets, Fair Value Disclosure Total financial liabilities Financial and Nonfinancial Liabilities, Fair Value Disclosure Cash equivalents Cash Equivalents, at Carrying Value Restricted cash Restricted Cash Marketable securities Debt Securities, Available-for-sale Accrued liabilities Stockholders’ Equity Stockholders' Equity Note Disclosure [Text Block] Schedule of Capital Leased Assets [Table] Schedule of Capital Leased Assets [Table] Capital Leased Assets [Line Items] Capital Leased Assets [Line Items] Lease term Capital Leases Term Of Contract Term of the lessor's leasing arrangement in a capital leasing arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Interest expense Capital Leases, Income Statement, Interest Expense Accumulated depreciation and amortization Capital Leases, Lessee Balance Sheet, Assets by Major Class, Accumulated Depreciation Schedule of impact of adoption of topic 606 on condensed consolidated statement of operations and balance sheet Schedule of Prospective Adoption of New Accounting Pronouncements [Table Text Block] Schedule of disaggregated revenue by payer category Disaggregation of Revenue [Table Text Block] Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table] Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table] Related Party [Axis] Related Party [Axis] Related Party [Domain] Related Party [Domain] KEW K E W Inc [Member] KEW, Inc. Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Loss on license agreement Gain Loss On License Agreement Gain (loss) on license agreement. Measurement Basis Measurement Basis [Axis] Fair Value Measurement Fair Value Measurement [Domain] Portion at Fair Value Measurement [Member] Portion at Fair Value Measurement [Member] Carrying Amount Reported Value Measurement [Member] Fair Value Estimate of Fair Value Measurement [Member] Debt Long-term Debt 2019 Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months 2020 Finite-Lived Intangible Assets, Amortization Expense, Year Two 2021 Finite-Lived Intangible Assets, Amortization Expense, Year Three 2022 Finite-Lived Intangible Assets, Amortization Expense, Year Four 2023 Finite-Lived Intangible Assets, Amortization Expense, Year Five Thereafter Finite-Lived Intangible Assets, Amortization Expense, after Year Five Revenue, Initial Application Period Cumulative Effect Transition [Table] Revenue, Initial Application Period Cumulative Effect Transition [Table] Initial Application Period Cumulative Effect Transition [Axis] Initial Application Period Cumulative Effect Transition [Axis] Initial Application Period Cumulative Effect Transition [Domain] Initial Application Period Cumulative Effect Transition [Domain] Without adoption of topic 606 Calculated under Revenue Guidance in Effect before Topic 606 [Member] Effect of adoption higher/lower Difference between Revenue Guidance in Effect before and after Topic 606 [Member] Adjustments for New Accounting Pronouncements [Axis] Adjustments for New Accounting Pronouncements [Axis] Type of Adoption [Domain] Type of Adoption [Domain] Topic 606 Accounting Standards Update 2014-09 [Member] Revenue, Initial Application Period Cumulative Effect Transition [Line Items] Revenue, Initial Application Period Cumulative Effect Transition [Line Items] Accounts receivable Accounts Receivable, Net, Current Accumulated deficit Retained Earnings (Accumulated Deficit) Stockholders' equity Fair value measurements Fair Value Disclosures [Text Block] Fair Value Option, Disclosures [Table] Fair Value Option, Disclosures [Table] Contingent Consideration by Type Contingent Consideration by Type [Axis] Contingent Consideration Type Contingent Consideration Type [Domain] New Contingent Milestone Based On Achieving Revenue Target During 2017 And 2018 New Contingent Milestone Based On Achieving Revenue Target During Two Thousand Seventeen And Two Thousand Eighteen [Member] New contingent milestone based on achieving revenue target during two thousand seventeen and two thousand eighteen. Equity Interest Type Equity Interest Type [Axis] Equity Interest Issued or Issuable, Type Equity Interest Issued or Issuable, Type [Domain] Fair Value, Option, Quantitative Disclosures [Line Items] Fair Value, Option, Quantitative Disclosures [Line Items] Transfers of assets and liabilities between Level 1, Level 2 and Level 3 Fair Value Assets And Liabilities Level1 Level2 And Level3 Transfers Amount Fair value assets and liabilities level1 level2 and level3 transfers’ amount. Total fair value of investments with unrealized losses Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value Available-for-sale securities gross realized gain (loss) Available-for-sale Securities, Gross Realized Gain (Loss) Contingently payable amount Business Combination, Contingent Consideration, Liability Contingent revenue threshold Business Combination Contingent Consideration Liability Revenue Threshold Business combination contingent consideration liability revenue threshold. Common stock issued, value Business Acquisition, Equity Interest Issued or Issuable, Value Assigned Estimated fair value for contingent consideration Estimated Fair Value For Contingent Consideration Estimated fair value for contingent consideration. Increase in fair value of contingent consideration Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Unrecognized tax benefits, beginning of period Unrecognized Tax Benefits Gross increases—current period tax positions Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Gross increases (decreases)—prior period tax positions Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions Unrecognized tax benefits increases decreases resulting from prior period tax positions. Unrecognized tax benefits, end of period Subsequent Event Type [Axis] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Subsequent event Subsequent Event [Member] Transaction Type [Axis] Transaction Type [Axis] Transaction [Domain] Transaction [Domain] 2018 Sales Agreement Common Stock Sales Agreement [Member] Common stock sales agreement. Cowen and Company, LLC Cowen And Company Limited Liability Company [Member] Cowen and company limited liability company. Sale of Stock Sale of Stock [Axis] Sale of Stock Sale of Stock [Domain] Private placement Private Placement [Member] Underwritten public offering Underwritten Public Offering [Member] Underwritten public offering. Series A Convertible Preferred Stock Series A Preferred Stock [Member] Stock Conversion Description [Axis] Stock Conversion Description [Axis] Conversion of Stock, Name [Domain] Conversion of Stock, Name [Domain] Series A convertible preferred stock converted to common stock Series A Convertible Preferred Stock Converted to Common Stock [Member] Series A Convertible Preferred Stock Converted to Common Stock [Member] Class of Stock [Line Items] Number of shares sold in private placement (in shares) Sale of Stock, Number of Shares Issued in Transaction Gross proceeds from private placement Proceeds from Issuance of Private Placement Net proceeds from private placement Net Proceeds From Issuance Of Private Placement Net proceeds from issuance of private placement. Preferred stock to common stock conversion ratio Preferred Stock To Common Stock Conversion Ratio Preferred stock to common stock conversion ratio. Preferred stock liquidation preference per share (in dollars per share) Preferred Stock, Liquidation Preference Per Share Shares converted (in shares) Conversion of Stock, Shares Converted Shares issued upon conversion (in shares) Convertible Preferred Stock, Shares Issued upon Conversion Shares issued price per share (in dollars per share) Sale of Stock, Price Per Share Proceeds from issuance of common stock Proceeds from Issuance of Common Stock Net proceeds from issuance of common stock Net Proceeds From Issuance Of Common Stock Net proceeds from issuance of common stock. Percentage of commission payable on gross proceeds Percentage Of Commission Payable On Gross Proceeds Percentage of commission payable on gross proceeds. Proceeds from warrant exercises Proceeds from Warrant Exercises Common stock issued pursuant to exercise of warrants (in shares) Income taxes Income Tax Disclosure [Text Block] Future payments under the Loan Agreement Long-term Debt, Fiscal Year Maturity [Abstract] 2019 Long Term Debt Maturities Repayments Next Twelve Months Long term debt maturities repayments next twelve months. 2020 Long Term Debt Maturities Repayments In Year Two Interest and principal amount of long-term debt, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. 2021 Long Term Debt Maturities Repayments In Year Three Interest and principal amount of long-term debt, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. 2022 Long Term Debt Maturities Repayments In Year Four Interest and principal amount of long-term debt, Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. 2023 Long Term Debt Maturities Repayments In Year Fifth Interest and principal amount of long-term debt, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. Thereafter Long Term Debt Maturities Repayments Thereafter Interest and principal amount of long-term debt, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing after fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. Total remaining payments Long Term Debt Minimum Payments Due Amount of minimum payments owed for long-term debt, including principal and interest. Less: amount representing debt discount Debt Instrument, Unamortized Discount Less: amount representing interest Interest Payable Total non-current debt obligation Long-term Debt, Excluding Current Maturities Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Adjustments for Change in Accounting Principle [Axis] Adjustments for Change in Accounting Principle [Axis] Adjustments for Change in Accounting Principle [Domain] Adjustments for Change in Accounting Principle [Domain] Change in estimate of revenue recognition Change In Estimate Of Revenue Recognition [Member] Change in estimate of revenue recognition. Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Performance obligations underlying contracts period Revenue Performance Obligation Satisfied At Point In Time Period Revenue performance obligation satisfied at point in time period. Sales commissions amortization period Sales Commissions Amortization Period Sales commissions amortization period. Period of payments to be received for goods or service Period Of Payments To Be Received For Goods Or Service Period of payments to be received for goods or service. Revenue recognized Contract with Customer, Liability, Revenue Recognized Long-term Purchase Commitment [Table] Long-term Purchase Commitment [Table] Recorded Unconditional Purchase Obligation by Category of Item Purchased [Axis] Recorded Unconditional Purchase Obligation by Category of Item Purchased [Axis] Unconditional Purchase Obligation, Category of Goods or Services Acquired [Domain] Unconditional Purchase Obligation, Category of Goods or Services Acquired [Domain] Service agreements and laboratory supplies Service Agreements And Laboratory Supplies [Member] Service agreements and laboratory supplies. Long-term Purchase Commitment [Line Items] Long-term Purchase Commitment [Line Items] 2019 Recorded Unconditional Purchase Obligation Due in Next Twelve Months 2020 Recorded Unconditional Purchase Obligation Due in Second Year 2021 Recorded Unconditional Purchase Obligation Due in Third Year Total Recorded Unconditional Purchase Obligation Deferred tax assets: Deferred Tax Assets, Net of Valuation Allowance [Abstract] Net operating loss carryforwards Deferred Tax Assets, Operating Loss Carryforwards Tax credits Deferred Tax Assets, Tax Credit Carryforwards Revenue recognition differences Deferred Tax Assets Revenue Recognition Reserves Deferred tax assets revenue recognition reserves. Accruals and other Deferred Tax Assets Tax Accrued Liabilities And Other Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accruals and not separately disclosed. Gross deferred tax assets Deferred Tax Assets, Gross Valuation allowance Deferred Tax Assets, Valuation Allowance Total deferred tax assets Deferred Tax Assets, Net of Valuation Allowance Deferred tax liabilities: Deferred Tax Liabilities, Gross [Abstract] Property and equipment Deferred Tax Liabilities, Property, Plant and Equipment Total deferred tax liabilities Deferred Tax Liabilities, Gross Net deferred tax assets Deferred Tax Assets, Net Number of Shares Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Balance at the beginning of the period (in shares) Granted (in shares) Vested (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Cancelled (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Balance at the end of the period (in shares) Weighted-Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Balance at the beginning of the period (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Granted (in dollars per share) Vested (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Canceled (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Balance at the end of the period (in dollars per share) United States Income (Loss) from Continuing Operations before Income Taxes, Domestic Foreign Income (Loss) from Continuing Operations before Income Taxes, Foreign Total Other Commitments [Table] Other Commitments [Table] Co Development Agreement Co Development Agreement [Member] Co-development agreement. Other Commitments [Axis] Other Commitments [Axis] Other Commitments [Domain] Other Commitments [Domain] Other Commitments [Line Items] Other Commitments [Line Items] Right of refusal fees related to acquisition agreement Business Acquisition, Transaction Costs Registration payment arrangement term Registration Payment Arrangement, Term Payment of refusal fees related to the acquisition agreement Payment Of Transaction Costs Relating To Acquisition Refusal Payment of transaction costs relating to acquisition refusal. Schedule of future minimum payments under operating leases Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] Schedule of rent expense related to non-cancelable operating leases Schedule of Rent Expense [Table Text Block] Schedule of future payments under loan and security agreement Schedule Of Future Payments And Components Of Long Term Debt Table [Text Block] Tabular disclosure of future payments of long-term debt, components of long-term debt and long-term debt less current maturities. Schedule of future minimum lease payments under capital leases Schedule of Future Minimum Lease Payments for Capital Leases [Table Text Block] Schedule of future payments under noncancelable unconditional purchase commitments Recorded Unconditional Purchase Obligations [Table Text Block] Future payments under the capital lease Capital Leases, Future Minimum Payments, Present Value of Net Minimum Payments, Fiscal Year Maturity [Abstract] 2019 Capital Leases, Future Minimum Payments Due, Next Twelve Months 2020 Capital Leases, Future Minimum Payments Due in Two Years 2021 Capital Leases, Future Minimum Payments Due in Three Years Total capital lease obligations Less: amount representing interest Capital Leases, Future Minimum Payments, Interest Included in Payments Present value of net minimum capital lease payments Capital Leases, Future Minimum Payments, Present Value of Net Minimum Payments Less: current portion Capital Lease Obligations, Current Total non-current capital lease obligations Capital Lease Obligations, Noncurrent Schedule significant customer, revenue as a percentage Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block] Schedule of restrictions on cash and cash equivalents Restrictions on Cash and Cash Equivalents [Table Text Block] Schedule of cash, cash equivalents and restricted cash Schedule of Cash and Cash Equivalents [Table Text Block] Schedule of useful lives of property and equipment Property Plant And Equipment Useful Lives [Table Text Block] Represents the tabular disclosure of useful lives of the property, plant and equipment. Schedule of property and equipment, net Property, Plant and Equipment [Table Text Block] Schedule of accrued liabilities Schedule of Accrued Liabilities [Table Text Block] Schedule of other long-term liabilities Other Noncurrent Liabilities [Table Text Block] Current: Current Income Tax Expense (Benefit), Continuing Operations [Abstract] Foreign Current Foreign Tax Expense (Benefit) Total current benefit for income taxes Current Income Tax Expense (Benefit) Deferred Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract] Federal Deferred Federal Income Tax Expense (Benefit) State Deferred State and Local Income Tax Expense (Benefit) Total deferred benefit for income taxes Deferred Income Tax Expense (Benefit) Total income tax benefit Summary of goodwill Schedule of Goodwill [Table Text Block] Schedule of finite-lived intangible assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Summary of estimated future amortization expense of intangible assets with finite lives Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Useful lives Cash Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Cash and restricted cash Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents And Restricted Cash Business combination recognized identifiable assets acquired and liabilities assumed cash and equivalents and restricted cash. Accounts receivable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables Prepaid expense and other assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets Property and equipment Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment Other assets - non current Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets Intangible Assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Total identifiable assets acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Accounts payable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable Deferred revenue Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue Accrued expenses Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accrued Expenses Business combination recognized identifiable assets acquired and liabilities assumed current liabilities accrued expenses. Deferred tax liability Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Notes payable Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Notes Payable Business combination recognized identifiable assets acquired and liabilities assumed notes payable. Convertible promissory notes payable Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Convertible Promissory Notes Payable Business combination recognized identifiable assets acquired and liabilities assumed convertible promissory notes payable. Other liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other Total liabilities assumed Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities Net identifiable assets acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Goodwill Net assets acquired Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Income Tax Contingency [Table] Income Tax Contingency [Table] Tax Period [Axis] Tax Period [Axis] Tax Period [Domain] Tax Period [Domain] Begins to expire 2030 Expiration, Tax Year 2019 [Member] Expiration, Tax Year 2019 [Member] No expiration date Expiration, Tax Year Unknown [Member] Expiration, Tax Year Unknown [Member] Income Tax Authority [Axis] Income Tax Authority [Axis] Income Tax Authority [Domain] Income Tax Authority [Domain] State State and Local Jurisdiction [Member] Tax Credit Carryforward Tax Credit Carryforward [Axis] Tax Credit Carryforward, Name Tax Credit Carryforward, Name [Domain] Research and development Research Tax Credit Carryforward [Member] Income Tax Authority, Name Income Tax Authority, Name [Axis] Income Tax Authority, Name [Domain] Income Tax Authority, Name [Domain] Federal Internal Revenue Service (IRS) [Member] California California Franchise Tax Board [Member] Income Tax Contingency [Line Items] Income Tax Contingency [Line Items] Corporate tax rate Provisional amount related to the remeasurement of certain deferred tax assets and liabilities Tax Cuts And Jobs Act Of2017 Incomplete Accounting Change In Tax Rate Provisional Income Tax Expense Benefit Tax cuts and jobs act of 2017, incomplete accounting, change in tax rate, provisional income tax expense (benefit). Increase in valuation allowance Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Net operating loss carryforwards Operating Loss Carryforwards Tax credit carryforwards Tax Credit Carryforward, Amount Net operating loss carryforwards change in ownership percentage minimum Net Operating Loss Carryforwards Change In Ownership Percentage Minimum Net operating loss carryforwards change in ownership percentage minimum. Unrecognized tax benefits Number of tax years open for examination Income Tax Examination Number Of Period Under Examination Income tax examination number of period under examination. Milestone Based on Certain Threshold of Revenue Achieved During 2017 [Member] Milestone Based On Certain Threshold Of Revenue Achieved During Two Thousand Seventeen [Member] Milestone based on certain threshold of revenue achieved during two thousand seventeen. Other (income) expense Other Income Expense [Member] Other income expense. Restricted Stock Units (RSUs) Series F Preferred Stock Series F Preferred Stock [Member] Series D Warrants Series D Warrants [Member] Series D warrants. Total purchase consideration Business Combination, Consideration Transferred Payment through issuance of shares company's common stock Business Combination, Consideration Transferred, Equity Interests Issued and Issuable Common stock issued (in shares) Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Contingent consideration, revenue target for payout Business Combination Contingent Consideration Actual Revenue Target For Payout Business combination, contingent consideration, actual revenue target for payout. Contingent consideration, revenue target (as a percent) Business Combination Contingent Consideration Percentage Of Actual Revenue Target Business combination, contingent consideration, percentage of actual revenue target. Contingent consideration, amount deducted on revenue target Business Combination Contingent Consideration Amount Deducted On Actual Revenue Target Business combination, contingent consideration, amount deducted on actual revenue target Business combination possible payout amount Business Combination Contingent Consideration Possible Payout Amount Business combination contingent consideration possible payout amount. Purchase consideration, second payment discounted and recorded as liability Business Combination, Consideration Transferred, Liabilities Incurred Change in fair value of contingent consideration Accretion gains (losses) Business Combination, Step Acquisition, Equity Interest in Acquiree, Accretion Gain (Loss), Net Business Combination, Step Acquisition, Equity Interest in Acquiree, Accretion Gain (Loss), Net Change in estimate of fair value Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Loss Goodwill acquired Goodwill, Acquired During Period Hold-back consideration amount Business Combination Hold Back Consideration Business combination hold back consideration. Common stock issued, related to hold back (in shares) Business Acquisition Equity Interests Issued Or Issuable Number Of Shares Issued Related To Hold Back Business acquisition equity interests issued or issuable number of shares issued related to hold back. Percentage of diluted interest acquired Business Acquisition, Percentage of Voting Interests Acquired Cash consideration Payments to Acquire Businesses, Gross Equity interests issued for settlement of convertible debt Business Combination Consideration Transferred Equity Interests Issued And Issuable For Settlement Of Convertible Debt Business combination consideration transferred equity interests issued and issuable for settlement of convertible debt. Equity interests issued for settlement of convertible debt (in shares) Business Acquisition Equity Interests Issued Or Issuable Number Of Shares For Settlement Of Convertible Debt Business acquisition equity interests issued or issuable number of shares for settlement of convertible debt. Payment by issuance of common stock to settle bonuses Business Combination Sale Of Hold Back Stock For Payment Of Bonus Business combination sale of hold back stock for payment of bonus. Issuance of common stock to settle bonuses (in shares) Business Acquisition Number Of Hold Back Shares Issued Or Issuable For Payment Of Bonus Business acquisition number of hold back shares Issued or Issuable for payment of bonus. Remaining hold-back amount payable to settle outstanding claims Business Combination Remaining Hold Back Amount Payable Upon Settlement Of Outstanding Claims Business combination remaining hold back amount payable upon settlement of outstanding claims. Remaining hold back amount payable to settle bonuses Business Combination Remaining Hold Back Amount Payable to Settle Bonuses Business Combination Remaining Hold Back Amount Payable to Settle Bonuses Provisional deferred tax liability Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Provisional Deferred Tax Liabilities Business combination recognized identifiable assets acquired and liabilities assumed provisional deferred tax liabilities. Decrease in accounts receivable Increase (Decrease) in Accounts Receivable Business combination common stock conversion ratio Business Combination Common Stock Conversion Ratio Business combination common stock conversion ratio. Trailing average share value (in dollars per share) Trailing Average Share Value Trailing average share value. Deferred tax liability December 31, 2017 Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value December 31, 2018 Institutions Institutions [Member] Institutions Patient - direct Patient Direct [Member] Patient direct. Patient - insurance Patient Insurance [Member] Patient insurance. Business combinations Business Combination Disclosure [Text Block] Assets Assets [Abstract] Current assets: Assets, Current [Abstract] Marketable securities Debt Securities, Available-for-sale, Current Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Total current assets Assets, Current Property and equipment, net Marketable securities, non-current Debt Securities, Available-for-sale, Noncurrent Intangible assets, net Other assets Other Assets, Noncurrent Total assets Assets Liabilities and stockholders’ equity Liabilities and Equity [Abstract] Current liabilities: Liabilities, Current [Abstract] Accounts payable Accounts Payable, Current Capital lease obligation, current portion Total current liabilities Liabilities, Current Capital lease obligation, net of current portion Debt Other long-term liabilities Total liabilities Liabilities Commitments and contingencies (Note 9) Commitments and Contingencies Stockholders’ equity: Stockholders' Equity Attributable to Parent [Abstract] Preferred stock, $0.0001 par value: 20,000 shares authorized; 3,459 shares issued and outstanding as of December 31, 2018 and 2017 Preferred Stock, Value, Issued Common stock, $0.0001 par value: 400,000 shares authorized; 75,481 and 53,597 shares issued and outstanding as of December 31, 2018 and 2017, respectively Common Stock, Value, Issued Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Additional paid-in capital Additional Paid in Capital Total stockholders’ equity Total liabilities and stockholders’ equity Liabilities and Equity Commitments and contingencies Commitments and Contingencies Disclosure [Text Block] Statement of Cash Flows [Abstract] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Depreciation and amortization Depreciation, Depletion and Amortization Remeasurements of liabilities associated with business combinations Business Combination Remeasurement Of Liabilities Business combination remeasurement of liabilities. Benefit from income taxes Debt extinguishment costs Gain (Loss) on Extinguishment of Debt Other Other Operating Activities, Cash Flow Statement Changes in operating assets and liabilities, net of effects of business combination: Increase (Decrease) in Operating Capital [Abstract] Accounts receivable Prepaid expenses and other current assets Increase Decrease In Prepaid Expense And Other Current Assets The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods and also includes other current operating assets not separately disclosed in the statement of cash flows. Other assets Increase (Decrease) in Other Operating Assets Accounts payable Increase (Decrease) in Accounts Payable Accrued expenses and other liabilities Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Purchases of marketable securities Payments to Acquire Available-for-sale Securities Proceeds from sales of marketable securities Proceeds from Sale of Debt Securities, Available-for-sale Proceeds from maturities of marketable securities Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale Acquisition of businesses, acquired cash Cash Acquired from Acquisition Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Other Payments for (Proceeds from) Other Investing Activities Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Proceeds from public offering of common stock, net of issuance costs Proceeds From Issuance Of Public Offerings Of Common Stock Net Of Issuance Costs Proceeds from issuance of public offerings of common stock net of issuance costs. Net proceeds from issuance of debt Proceeds from Loan Originations Payments for debt extinguishment costs Loan payments Payments of Loan Costs Capital lease principal payments Repayments of Long-term Capital Lease Obligations Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Net increase (decrease) in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, cash equivalents and restricted cash at beginning of period Cash, cash equivalents and restricted cash at end of period Supplemental cash flow information: Supplemental Cash Flow Information [Abstract] Interest paid Interest Paid, Excluding Capitalized Interest, Operating Activities Supplemental cash flow information of non-cash investing and financing activities: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Equipment acquired through capital leases Capital Lease Obligations Incurred Purchases of property and equipment in accounts payable and accrued liabilities Capital Expenditures And Adjustments Incurred But Not Yet Paid Future cash outflow (inflow) associated with purchases of fixed assets that have occurred, including adjustments to the amount payable. Amounts related to co-development agreement in other assets and accrued liabilities Noncash or part noncash amounts related to co-development agreement in other assets and accrued liabilities Noncash or part noncash amounts related to co-development agreement in other assets and accrued liabilities Warrants issued pursuant to 2017 Loan Agreement Debt Conversion, Converted Instrument, Amount Common stock issued for acquisition of businesses Stock Issued Consideration payable for acquisition of businesses Noncash or Part Noncash Acquisition, Payables Assumed Common stock issued to settle assumed liabilities Liabilities Assumed Activity under the plan Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Shares available for grant, beginning balance (in shares) Stock options outstanding, beginning balance (in shares) Additional shares reserved (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized Options granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Option cancelled (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Options exercised (in shares) Units granted (in shares) Units cancelled (in shares) Shares available for grant, ending balance (in shares) Stock options outstanding, ending balance (in shares) Weighted- Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Balance at the beginning of the period (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Options granted (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Options cancelled (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Options exercised (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Balance at the end of the period (in dollars per share) Additional information Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Exercisable (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Exercisable, weighted-average exercise price (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Weighted-average remaining contractual life Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Exercisable, weighted-average remaining contractual life Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Aggregate intrinsic value Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Exercisable, aggregate intrinsic value Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Vested and expected to vest Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest [Abstract] Number of options (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Weighted-average exercise price (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Weighted-average remaining contractual life Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Aggregate intrinsic value Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value EX-101.PRE 13 nvta-20181231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 14 invitaeflywheel.jpg begin 644 invitaeflywheel.jpg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�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�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end GRAPHIC 15 invitaelogo.jpg begin 644 invitaelogo.jpg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nvtastockgraph2018.jpg begin 644 nvtastockgraph2018.jpg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end XML 17 nvta-10k_htm.xml IDEA: XBRL DOCUMENT 0001501134 2018-01-01 2018-12-31 0001501134 2016-01-01 2016-12-31 0001501134 nvta:AltaVoiceMember us-gaap:GeneralAndAdministrativeExpenseMember 2018-01-01 2018-12-31 0001501134 nvta:CombiMatrixCorporationMember 2018-12-31 0001501134 nvta:CombiMatrixCorporationMember us-gaap:CommonStockMember us-gaap:GeneralAndAdministrativeExpenseMember 2017-07-31 2017-07-31 0001501134 nvta:GoodStartGeneticsIncMember us-gaap:CommonStockMember us-gaap:GeneralAndAdministrativeExpenseMember 2017-08-04 2017-08-04 0001501134 nvta:GoodStartGeneticsIncMember us-gaap:CommonStockMember 2017-08-04 2017-08-04 0001501134 nvta:AltaVoiceMember us-gaap:CommonStockMember 2017-01-06 2017-01-06 0001501134 us-gaap:EmployeeStockOptionMember nvta:CombiMatrixCorporationMember 2017-07-31 2017-07-31 0001501134 nvta:AltaVoiceMember nvta:OtherIncomeExpenseMember 2017-01-01 2017-12-31 0001501134 nvta:CombiMatrixCorporationMember us-gaap:CustomerRelationshipsMember 2018-01-01 2018-12-31 0001501134 nvta:AltaVoiceMember us-gaap:NoncompeteAgreementsMember 2018-01-01 2018-12-31 0001501134 2017-01-01 2017-12-31 0001501134 nvta:GoodStartGeneticsIncMember us-gaap:CommonStockMember 2018-12-31 0001501134 nvta:AltaVoiceMember 2018-03-31 0001501134 srt:MaximumMember nvta:AltaVoiceMember nvta:NewContingentMilestoneBasedOnAchievingRevenueTargetDuringTwoThousandSeventeenAndTwoThousandEighteenMember us-gaap:ScenarioForecastMember 2019-03-31 0001501134 us-gaap:RestrictedStockUnitsRSUMember nvta:CombiMatrixCorporationMember us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:CommonStockMember 2017-07-31 2017-07-31 0001501134 nvta:CombiMatrixCorporationMember us-gaap:CommonStockMember 2017-07-31 0001501134 nvta:OmmdomIncMember us-gaap:CommonStockMember 2017-06-11 2017-06-11 0001501134 nvta:AltaVoiceMember us-gaap:CommonStockMember 2018-04-01 2018-04-30 0001501134 nvta:AltaVoiceMember us-gaap:GeneralAndAdministrativeExpenseMember 2017-01-01 2017-12-31 0001501134 nvta:AltaVoiceMember nvta:NewContingentMilestoneBasedOnAchievingRevenueTargetDuringTwoThousandSeventeenAndTwoThousandEighteenMember us-gaap:ScenarioForecastMember 2019-03-31 2019-03-31 0001501134 nvta:CombiMatrixCorporationMember nvta:SeriesFWarrantsMember 2017-07-31 2017-07-31 0001501134 nvta:CollaborationAndGenomeNetworkMember 2018-01-01 2018-12-31 0001501134 nvta:CombiMatrixCorporationMember 2017-11-14 0001501134 nvta:CombiMatrixCorporationMember us-gaap:CommonStockMember 2017-07-31 2017-07-31 0001501134 us-gaap:RestrictedStockUnitsRSUMember nvta:CombiMatrixCorporationMember 2017-07-31 2017-07-31 0001501134 nvta:GoodStartGeneticsIncMember us-gaap:CustomerRelationshipsMember 2018-01-01 2018-12-31 0001501134 nvta:CombiMatrixCorporationMember 2017-07-31 0001501134 nvta:GoodStartGeneticsIncMember 2017-08-04 2017-08-04 0001501134 nvta:CombiMatrixCorporationMember us-gaap:WarrantMember 2017-07-31 2017-07-31 0001501134 nvta:AltaVoiceMember nvta:MilestoneBasedOnCertainThresholdOfRevenueAchievedDuringTwoThousandSeventeenMember 2018-03-31 0001501134 nvta:OmmdomIncMember 2017-06-11 0001501134 nvta:AltaVoiceMember us-gaap:CommonStockMember 2018-03-31 2018-03-31 0001501134 nvta:CollaborationAndGenomeNetworkMember 2016-01-01 2016-12-31 0001501134 nvta:AltaVoiceMember nvta:OtherIncomeExpenseMember 2018-01-01 2018-12-31 0001501134 nvta:GoodStartGeneticsIncMember us-gaap:CommonStockMember us-gaap:GeneralAndAdministrativeExpenseMember 2018-09-01 2018-09-30 0001501134 nvta:CombiMatrixCorporationMember nvta:SeriesDWarrantsMember 2017-07-31 2017-07-31 0001501134 nvta:GoodStartGeneticsIncMember us-gaap:CommonStockMember us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:SubsequentEventMember 2019-01-01 2019-01-31 0001501134 nvta:GoodStartGeneticsIncMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2019-01-01 2019-01-31 0001501134 nvta:CombiMatrixCorporationMember 2017-07-31 2017-07-31 0001501134 nvta:GoodStartGeneticsIncMember us-gaap:CommonStockMember 2018-09-01 2018-09-30 0001501134 nvta:AltaVoiceMember us-gaap:CommonStockMember 2018-03-31 0001501134 nvta:OmmdomIncMember us-gaap:TradeNamesMember 2017-06-11 0001501134 nvta:OmmdomIncMember us-gaap:CustomerRelationshipsMember 2017-06-11 2017-06-11 0001501134 nvta:CollaborationAndGenomeNetworkMember 2017-01-01 2017-12-31 0001501134 nvta:OmmdomIncMember us-gaap:DevelopedTechnologyRightsMember 2017-06-11 2017-06-11 0001501134 nvta:OmmdomIncMember us-gaap:TradeNamesMember 2017-06-11 2017-06-11 0001501134 nvta:OmmdomIncMember us-gaap:DevelopedTechnologyRightsMember 2017-06-11 0001501134 nvta:OmmdomIncMember us-gaap:CustomerRelationshipsMember 2017-06-11 0001501134 nvta:AltaVoiceMember us-gaap:CustomerRelationshipsMember 2017-01-06 2017-01-06 0001501134 nvta:AltaVoiceMember us-gaap:NoncompeteAgreementsMember 2017-01-06 2017-01-06 0001501134 nvta:AltaVoiceMember us-gaap:DevelopedTechnologyRightsMember 2017-01-06 2017-01-06 0001501134 nvta:CombiMatrixCorporationMember us-gaap:TradeNamesMember 2017-11-14 0001501134 nvta:CombiMatrixCorporationMember us-gaap:DevelopedTechnologyRightsMember 2017-11-14 0001501134 nvta:CombiMatrixCorporationMember us-gaap:OffMarketFavorableLeaseMember 2017-11-14 0001501134 nvta:DiagnosticTestsMember 2018-01-01 2018-12-31 0001501134 nvta:CombiMatrixCorporationMember nvta:PatentLicensingAgreementMember 2017-11-14 0001501134 nvta:CombiMatrixCorporationMember us-gaap:CustomerRelationshipsMember 2017-11-14 0001501134 nvta:CombiMatrixCorporationMember us-gaap:CustomerRelationshipsMember 2017-11-14 2017-11-14 0001501134 nvta:CombiMatrixCorporationMember us-gaap:DevelopedTechnologyRightsMember 2017-11-14 2017-11-14 0001501134 nvta:CombiMatrixCorporationMember us-gaap:TradeNamesMember 2017-11-14 2017-11-14 0001501134 nvta:CombiMatrixCorporationMember us-gaap:OffMarketFavorableLeaseMember 2017-11-14 2017-11-14 0001501134 nvta:CombiMatrixCorporationMember nvta:PatentLicensingAgreementMember 2017-11-14 2017-11-14 0001501134 us-gaap:TradeNamesMember 2018-12-31 0001501134 nvta:FavorableLeasesMember 2018-12-31 0001501134 nvta:FavorableLeasesMember 2018-01-01 2018-12-31 0001501134 nvta:DiagnosticTestsMember 2016-01-01 2016-12-31 0001501134 us-gaap:DevelopedTechnologyRightsMember 2018-01-01 2018-12-31 0001501134 us-gaap:DevelopedTechnologyRightsMember 2018-12-31 0001501134 nvta:PatentLicensingAgreementMember 2018-12-31 0001501134 us-gaap:CustomerRelationshipsMember 2018-12-31 0001501134 nvta:PatentLicensingAgreementMember 2018-01-01 2018-12-31 0001501134 us-gaap:NoncompeteAgreementsMember 2018-12-31 0001501134 us-gaap:NoncompeteAgreementsMember 2018-01-01 2018-12-31 0001501134 us-gaap:TradeNamesMember 2018-01-01 2018-12-31 0001501134 us-gaap:CustomerRelationshipsMember 2018-01-01 2018-12-31 0001501134 nvta:OmmdomIncMember 2017-12-31 0001501134 nvta:DiagnosticTestsMember 2017-01-01 2017-12-31 0001501134 nvta:AltaVoiceMember 2018-12-31 0001501134 nvta:OmmdomIncMember 2018-12-31 0001501134 nvta:GoodStartGeneticsIncMember 2017-12-31 0001501134 nvta:CombiMatrixCorporationMember 2017-12-31 0001501134 nvta:AltaVoiceMember 2017-12-31 0001501134 nvta:GoodStartGeneticsIncMember 2018-12-31 0001501134 us-gaap:FurnitureAndFixturesMember 2018-12-31 0001501134 us-gaap:LeaseholdImprovementsMember 2017-12-31 0001501134 us-gaap:AssetsHeldUnderCapitalLeasesMember 2018-12-31 0001501134 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2018-12-31 0001501134 us-gaap:AdditionalPaidInCapitalMember 2017-01-01 2017-12-31 0001501134 us-gaap:AssetsHeldUnderCapitalLeasesMember 2017-12-31 0001501134 us-gaap:ComputerEquipmentMember 2018-12-31 0001501134 us-gaap:AutomobilesMember 2017-12-31 0001501134 us-gaap:ConstructionInProgressMember 2018-12-31 0001501134 us-gaap:ConstructionInProgressMember 2017-12-31 0001501134 us-gaap:LeaseholdImprovementsMember 2018-12-31 0001501134 us-gaap:ComputerEquipmentMember 2017-12-31 0001501134 us-gaap:EquipmentMember 2017-12-31 0001501134 us-gaap:AutomobilesMember 2018-12-31 0001501134 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2017-12-31 0001501134 us-gaap:CommonStockMember 2015-12-31 0001501134 us-gaap:FurnitureAndFixturesMember 2017-12-31 0001501134 us-gaap:EquipmentMember 2018-12-31 0001501134 nvta:AltaVoiceMember us-gaap:FairValueInputsLevel3Member us-gaap:GeneralAndAdministrativeExpenseMember 2018-01-01 2018-12-31 0001501134 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember nvta:ContingentConsiderationMember 2017-12-31 0001501134 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember nvta:ContingentConsiderationMember 2018-12-31 0001501134 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0001501134 us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0001501134 us-gaap:FairValueMeasurementsRecurringMember nvta:ContingentConsiderationMember 2017-12-31 0001501134 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0001501134 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0001501134 nvta:CombiMatrixCorporationMember 2018-01-01 2018-12-31 0001501134 2015-12-31 0001501134 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-12-31 0001501134 nvta:NonEmployeeStockOptionMember 2018-01-01 2018-12-31 0001501134 nvta:EmployeeStockPurchasePlan2015Member 2018-01-01 2018-12-31 0001501134 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0001501134 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2017-12-31 0001501134 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2017-12-31 0001501134 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2017-12-31 0001501134 us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0001501134 us-gaap:CertificatesOfDepositMember 2017-12-31 0001501134 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2017-12-31 0001501134 us-gaap:PreferredStockMember 2018-12-31 0001501134 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2017-12-31 0001501134 us-gaap:MoneyMarketFundsMember 2017-12-31 0001501134 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2017-12-31 0001501134 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2017-12-31 0001501134 us-gaap:USTreasurySecuritiesMember 2017-12-31 0001501134 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2017-12-31 0001501134 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2017-12-31 0001501134 nvta:ContingentConsiderationMember 2017-12-31 0001501134 nvta:AltaVoiceMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember nvta:ContingentConsiderationMember 2017-01-31 0001501134 nvta:AltaVoiceMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember nvta:ContingentConsiderationMember 2018-01-01 2018-12-31 0001501134 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-12-31 0001501134 srt:MinimumMember nvta:AltaVoiceMember nvta:NewContingentMilestoneBasedOnAchievingRevenueTargetDuringTwoThousandSeventeenAndTwoThousandEighteenMember us-gaap:ScenarioForecastMember 2019-03-31 0001501134 srt:MaximumMember nvta:AltaVoiceMember us-gaap:CommonStockMember 2018-12-31 0001501134 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001501134 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2018-12-31 0001501134 nvta:ContingentConsiderationMember 2018-12-31 0001501134 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2018-12-31 0001501134 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2018-12-31 0001501134 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001501134 us-gaap:MoneyMarketFundsMember 2018-12-31 0001501134 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2018-12-31 0001501134 us-gaap:RetainedEarningsMember 2018-01-01 2018-12-31 0001501134 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2018-12-31 0001501134 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2018-12-31 0001501134 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2018-12-31 0001501134 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2018-12-31 0001501134 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2018-12-31 0001501134 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2018-12-31 0001501134 us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001501134 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2018-12-31 0001501134 us-gaap:CommercialPaperMember 2018-12-31 0001501134 us-gaap:FairValueMeasurementsRecurringMember nvta:ContingentConsiderationMember 2018-12-31 0001501134 us-gaap:CommonStockMember 2017-01-01 2017-12-31 0001501134 us-gaap:USTreasurySecuritiesMember 2018-12-31 0001501134 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2018-12-31 0001501134 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2018-12-31 0001501134 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001501134 us-gaap:CertificatesOfDepositMember 2018-12-31 0001501134 nvta:KEWIncMember 2018-01-01 2018-12-31 0001501134 nvta:ServiceAgreementsAndLaboratorySuppliesMember 2018-12-31 0001501134 us-gaap:SecuredDebtMember nvta:LoanAndSecurityAgreementMember nvta:SecondTermLoanMember 2017-03-31 0001501134 nvta:LoanAndSecurityAgreementMember nvta:ThirdTermLoanMember 2018-12-31 0001501134 us-gaap:SecuredDebtMember nvta:LoanAndSecurityAgreementMember 2017-03-01 2017-03-31 0001501134 us-gaap:CommonStockMember 2017-12-31 0001501134 nvta:NotePurchaseAgreementMember us-gaap:CommonStockMember 2018-11-01 2018-11-30 0001501134 nvta:OfficeFacilityInSanFranciscoMember nvta:NewLeasesMember 2015-09-30 0001501134 us-gaap:SecuredDebtMember nvta:LoanAndSecurityAgreementMember nvta:SecondTermLoanMember 2017-03-01 2017-03-31 0001501134 nvta:NotePurchaseAgreementMember us-gaap:DebtInstrumentRedemptionPeriodTwoMember 2018-01-01 2018-12-31 0001501134 us-gaap:SecuredDebtMember nvta:LoanAndSecurityAgreementMember 2018-01-01 2018-12-31 0001501134 nvta:LoanAndSecurityAgreementMember nvta:FirstTermLoanMember 2017-03-01 2017-03-31 0001501134 nvta:CoDevelopmentAgreementMember 2018-12-31 0001501134 nvta:NotePurchaseAgreementMember 2018-01-01 2018-12-31 0001501134 us-gaap:SecuredDebtMember nvta:LoanAndSecurityAgreementMember 2017-03-31 0001501134 nvta:NotePurchaseAgreementMember 2018-12-31 0001501134 us-gaap:CommonStockMember 2018-12-31 0001501134 nvta:NotePurchaseAgreementMember us-gaap:CommonStockMember 2018-11-30 0001501134 nvta:LoanAndSecurityAgreementMember nvta:SecondTermLoanMember 2017-03-01 2017-03-31 0001501134 us-gaap:SecuredDebtMember nvta:LoanAndSecurityAgreementMember 2016-01-01 2016-12-31 0001501134 us-gaap:SecuredDebtMember nvta:LoanAndSecurityAgreementMember 2018-11-01 2018-11-30 0001501134 nvta:LoanAndSecurityAgreementMember nvta:FirstTermLoanMember 2017-03-31 0001501134 nvta:NotePurchaseAgreementMember us-gaap:DebtInstrumentRedemptionPeriodOneMember 2018-01-01 2018-12-31 0001501134 nvta:CoDevelopmentAgreementMember 2018-01-01 2018-12-31 0001501134 nvta:NotePurchaseAgreementMember 2018-11-30 0001501134 us-gaap:SecuredDebtMember nvta:LoanAndSecurityAgreementMember 2018-12-31 0001501134 nvta:NotePurchaseAgreementMember nvta:TrancheOneMember 2018-11-30 0001501134 us-gaap:CommonStockMember 2018-01-01 2018-12-31 0001501134 nvta:NotePurchaseAgreementMember us-gaap:ScenarioForecastMember 2020-01-01 0001501134 us-gaap:SecuredDebtMember nvta:LoanAndSecurityAgreementMember 2017-01-01 2017-12-31 0001501134 nvta:NotePurchaseAgreementMember nvta:TrancheOneMember 2018-11-01 2018-11-30 0001501134 nvta:LoanAndSecurityAgreementMember nvta:SecondTermLoanMember 2018-03-31 0001501134 us-gaap:SecuredDebtMember nvta:LoanAndSecurityAgreementMember 2018-10-01 2018-12-31 0001501134 srt:MaximumMember us-gaap:SecuredDebtMember nvta:LoanAndSecurityAgreementMember 2017-03-31 0001501134 srt:MinimumMember us-gaap:SecuredDebtMember nvta:LoanAndSecurityAgreementMember 2017-03-31 0001501134 nvta:OfficeFacilityInSanFranciscoMember nvta:NewLeasesMember 2018-12-31 0001501134 nvta:NotePurchaseAgreementMember us-gaap:DebtInstrumentRedemptionPeriodThreeMember 2018-01-01 2018-12-31 0001501134 nvta:NotePurchaseAgreementMember 2018-11-01 2018-11-30 0001501134 us-gaap:RetainedEarningsMember 2017-12-31 0001501134 srt:MaximumMember nvta:CowenAndCompanyLimitedLiabilityCompanyMember nvta:CommonStockSalesAgreementMember 2018-08-01 2018-08-31 0001501134 nvta:SeriesAConvertiblePreferredStockConvertedtoCommonStockMember us-gaap:SeriesAPreferredStockMember us-gaap:SubsequentEventMember 2019-01-01 2019-02-28 0001501134 us-gaap:PrivatePlacementMember 2017-08-01 2017-08-31 0001501134 us-gaap:SeriesAPreferredStockMember us-gaap:PrivatePlacementMember 2017-08-01 2017-08-31 0001501134 nvta:UnderwrittenPublicOfferingMember 2018-04-01 2018-04-30 0001501134 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2017-08-31 0001501134 nvta:CowenAndCompanyLimitedLiabilityCompanyMember nvta:CommonStockSalesAgreementMember 2018-08-01 2018-08-31 0001501134 nvta:SeriesAConvertiblePreferredStockConvertedtoCommonStockMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2019-02-28 0001501134 us-gaap:SeriesAPreferredStockMember us-gaap:PrivatePlacementMember 2017-08-31 0001501134 nvta:CowenAndCompanyLimitedLiabilityCompanyMember us-gaap:CommonStockMember nvta:CommonStockSalesAgreementMember 2018-01-01 2018-12-31 0001501134 2016-12-31 0001501134 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2017-08-01 2017-08-31 0001501134 us-gaap:PrivatePlacementMember 2017-08-31 0001501134 us-gaap:CommonStockMember nvta:UnderwrittenPublicOfferingMember 2018-04-01 2018-04-30 0001501134 us-gaap:CommonStockMember nvta:UnderwrittenPublicOfferingMember 2018-04-30 0001501134 nvta:WarrantsissuedtolenderunderLoanandSecurityAgreement2018AmendmentsMember us-gaap:CommonStockMember 2018-12-31 0001501134 nvta:CombiMatrixCorporationMember nvta:SeriesFWarrantsMember us-gaap:CommonStockMember 2018-12-31 0001501134 nvta:WarrantsIssuedToLenderUnderLoanAndSecurityAgreementMember us-gaap:CommonStockMember 2018-12-31 0001501134 us-gaap:EmployeeStockOptionMember nvta:StockIncentivePlanMember 2017-12-31 0001501134 us-gaap:RestrictedStockUnitsRSUMember 2018-12-31 0001501134 nvta:EmployeeStockPurchasePlan2015Member 2017-12-31 0001501134 nvta:GoodStartGeneticsIncMember 2018-01-01 2018-12-31 0001501134 us-gaap:AdditionalPaidInCapitalMember 2015-12-31 0001501134 nvta:StockPayableLiabilitiesMember 2017-12-31 0001501134 us-gaap:WarrantMember 2018-12-31 0001501134 us-gaap:WarrantMember 2017-12-31 0001501134 nvta:StockPayableLiabilitiesMember 2018-12-31 0001501134 us-gaap:ContingentConsiderationClassifiedAsEquityMember 2017-12-31 0001501134 us-gaap:EmployeeStockOptionMember nvta:StockIncentivePlanMember 2018-12-31 0001501134 us-gaap:RestrictedStockUnitsRSUMember 2017-12-31 0001501134 us-gaap:ConvertiblePreferredStockMember 2018-12-31 0001501134 us-gaap:ConvertiblePreferredStockMember 2017-12-31 0001501134 nvta:EmployeeStockPurchasePlan2015Member 2018-12-31 0001501134 us-gaap:CommonStockMember 2016-01-01 2016-12-31 0001501134 us-gaap:ContingentConsiderationClassifiedAsEquityMember 2018-12-31 0001501134 us-gaap:PrivatePlacementMember 2018-08-01 2018-08-31 0001501134 us-gaap:EmployeeStockOptionMember nvta:EmployeesAndDirectorsStockOptionsMember 2017-01-01 2017-12-31 0001501134 us-gaap:EmployeeStockOptionMember nvta:EmployeesAndDirectorsStockOptionsMember 2018-01-01 2018-12-31 0001501134 us-gaap:EmployeeStockOptionMember nvta:EmployeesAndDirectorsStockOptionsMember 2016-01-01 2016-12-31 0001501134 us-gaap:EmployeeStockOptionMember nvta:StockIncentivePlanMember 2016-01-01 2016-12-31 0001501134 us-gaap:RestrictedStockUnitsRSUMember 2016-01-01 2016-12-31 0001501134 nvta:PerformanceRestrictedStockUnitsRsusMember nvta:StockIncentivePlan2015Member 2017-01-01 2017-12-31 0001501134 nvta:EmployeeStockPurchasePlan2015Member 2017-01-01 2017-12-31 0001501134 srt:MaximumMember nvta:StockIncentivePlan2010Member 2018-01-01 2018-12-31 0001501134 us-gaap:PreferredStockMember 2015-12-31 0001501134 nvta:EmployeeStockPurchasePlan2015Member 2016-01-01 2016-12-31 0001501134 nvta:EmployeeStockPurchasePlan2015Member 2015-01-01 2015-01-31 0001501134 us-gaap:RestrictedStockUnitsRSUMember 2017-01-01 2017-12-31 0001501134 us-gaap:EmployeeStockOptionMember nvta:StockIncentivePlanMember 2018-01-01 2018-12-31 0001501134 us-gaap:EmployeeStockOptionMember nvta:StockIncentivePlanMember 2017-01-01 2017-12-31 0001501134 us-gaap:RestrictedStockUnitsRSUMember 2018-01-01 2018-12-31 0001501134 srt:MinimumMember nvta:StockIncentivePlan2010Member 2018-01-01 2018-12-31 0001501134 us-gaap:RestrictedStockUnitsRSUMember nvta:StockIncentivePlanMember 2018-01-01 2018-12-31 0001501134 nvta:PerformanceRestrictedStockUnitsRsusMember 2018-12-31 0001501134 nvta:PerformanceRestrictedStockUnitsRsusMember nvta:StockIncentivePlan2015Member 2017-02-01 2017-02-28 0001501134 us-gaap:RetainedEarningsMember 2018-01-01 0001501134 nvta:StockIncentivePlanMember 2018-01-01 2018-12-31 0001501134 nvta:PerformanceRestrictedStockUnitsRsusMember 2016-01-01 2016-12-31 0001501134 nvta:PerformanceRestrictedStockUnitsRsusMember nvta:StockIncentivePlan2015Member 2016-02-01 2016-02-29 0001501134 nvta:PerformanceRestrictedStockUnitsRsusMember nvta:StockIncentivePlan2015Member 2016-01-01 2016-12-31 0001501134 nvta:PerformanceRestrictedStockUnitsRsusMember 2018-01-01 2018-12-31 0001501134 nvta:CostOfTestRevenueMember 2017-01-01 2017-12-31 0001501134 nvta:CostOfTestRevenueMember 2018-01-01 2018-12-31 0001501134 nvta:CostOfTestRevenueMember 2016-01-01 2016-12-31 0001501134 us-gaap:GeneralAndAdministrativeExpenseMember 2016-01-01 2016-12-31 0001501134 us-gaap:SellingAndMarketingExpenseMember 2018-01-01 2018-12-31 0001501134 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001501134 us-gaap:GeneralAndAdministrativeExpenseMember 2018-01-01 2018-12-31 0001501134 us-gaap:GeneralAndAdministrativeExpenseMember 2017-01-01 2017-12-31 0001501134 nvta:ResearchAndDevelopmentMember 2016-01-01 2016-12-31 0001501134 nvta:ResearchAndDevelopmentMember 2018-01-01 2018-12-31 0001501134 nvta:ResearchAndDevelopmentMember 2017-01-01 2017-12-31 0001501134 us-gaap:SellingAndMarketingExpenseMember 2016-01-01 2016-12-31 0001501134 us-gaap:SellingAndMarketingExpenseMember 2017-01-01 2017-12-31 0001501134 us-gaap:RestrictedStockUnitsRSUMember nvta:StockIncentivePlanMember nvta:FirstAnniversaryOfGrantDateMember 2018-01-01 2018-12-31 0001501134 nvta:PerformanceRestrictedStockUnitsRsusMember nvta:StockIncentivePlan2015Member 2018-01-01 2018-12-31 0001501134 us-gaap:RestrictedStockUnitsRSUMember nvta:StockIncentivePlanMember nvta:SecondAnniversaryOfGrantDateMember 2018-01-01 2018-12-31 0001501134 us-gaap:CommonStockMember 2016-12-31 0001501134 us-gaap:RestrictedStockUnitsRSUMember nvta:StockIncentivePlanMember nvta:ThirdAnniversaryOfGrantDateMember 2018-01-01 2018-12-31 0001501134 srt:MaximumMember nvta:NonEmployeeStockOptionMember 2016-01-01 2016-12-31 0001501134 nvta:NonEmployeeStockOptionMember 2016-01-01 2016-12-31 0001501134 srt:MinimumMember nvta:NonEmployeeStockOptionMember 2016-01-01 2016-12-31 0001501134 srt:MinimumMember nvta:NonEmployeeStockOptionMember 2017-01-01 2017-12-31 0001501134 srt:MaximumMember nvta:NonEmployeeStockOptionMember 2018-01-01 2018-12-31 0001501134 srt:MaximumMember nvta:NonEmployeeStockOptionMember 2017-01-01 2017-12-31 0001501134 srt:MinimumMember nvta:NonEmployeeStockOptionMember 2018-01-01 2018-12-31 0001501134 nvta:PerformanceRestrictedStockUnitsRsusMember 2017-01-01 2017-12-31 0001501134 2018-10-01 2018-12-31 0001501134 us-gaap:AdditionalPaidInCapitalMember 2016-12-31 0001501134 us-gaap:CaliforniaFranchiseTaxBoardMember 2018-01-01 2018-12-31 0001501134 us-gaap:InternalRevenueServiceIRSMember nvta:ExpirationTaxYearUnknownMember 2018-12-31 0001501134 us-gaap:StateAndLocalJurisdictionMember 2018-12-31 0001501134 us-gaap:InternalRevenueServiceIRSMember 2018-12-31 0001501134 us-gaap:InternalRevenueServiceIRSMember nvta:ExpirationTaxYear2019Member 2018-12-31 0001501134 us-gaap:CaliforniaFranchiseTaxBoardMember us-gaap:ResearchMember 2018-12-31 0001501134 us-gaap:InternalRevenueServiceIRSMember us-gaap:ResearchMember 2018-12-31 0001501134 us-gaap:InternalRevenueServiceIRSMember 2018-01-01 2018-12-31 0001501134 us-gaap:RestrictedStockUnitsRSUMember 2018-01-01 2018-12-31 0001501134 nvta:EmployeeStockPurchasePlan2015Member 2017-01-01 2017-12-31 0001501134 us-gaap:AdditionalPaidInCapitalMember 2016-01-01 2016-12-31 0001501134 us-gaap:WarrantMember 2018-01-01 2018-12-31 0001501134 nvta:EmployeeStockPurchasePlan2015Member 2018-01-01 2018-12-31 0001501134 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-12-31 0001501134 us-gaap:RestrictedStockUnitsRSUMember 2017-01-01 2017-12-31 0001501134 nvta:PerformanceRestrictedStockUnitsRsusMember 2017-01-01 2017-12-31 0001501134 nvta:SeriesAConvertiblePreferredStockMember 2016-01-01 2016-12-31 0001501134 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-12-31 0001501134 nvta:SeriesAConvertiblePreferredStockMember 2018-01-01 2018-12-31 0001501134 nvta:EmployeeStockPurchasePlan2015Member 2016-01-01 2016-12-31 0001501134 nvta:PerformanceRestrictedStockUnitsRsusMember 2018-01-01 2018-12-31 0001501134 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001501134 nvta:SeriesAConvertiblePreferredStockMember 2017-01-01 2017-12-31 0001501134 us-gaap:WarrantMember 2017-01-01 2017-12-31 0001501134 nvta:PerformanceRestrictedStockUnitsRsusMember 2016-01-01 2016-12-31 0001501134 us-gaap:EmployeeStockOptionMember 2016-01-01 2016-12-31 0001501134 us-gaap:WarrantMember 2016-01-01 2016-12-31 0001501134 us-gaap:RestrictedStockUnitsRSUMember 2016-01-01 2016-12-31 0001501134 country:CA 2017-01-01 2017-12-31 0001501134 nvta:RestOfWorldMember 2017-01-01 2017-12-31 0001501134 country:US 2018-01-01 2018-12-31 0001501134 country:US 2017-01-01 2017-12-31 0001501134 us-gaap:PreferredStockMember 2017-01-01 2017-12-31 0001501134 nvta:RestOfWorldMember 2018-01-01 2018-12-31 0001501134 nvta:RestOfWorldMember 2016-01-01 2016-12-31 0001501134 country:US 2016-01-01 2016-12-31 0001501134 country:CA 2016-01-01 2016-12-31 0001501134 country:CA 2018-01-01 2018-12-31 0001501134 2018-07-01 2018-09-30 0001501134 2018-01-01 2018-03-31 0001501134 2017-07-01 2017-09-30 0001501134 2017-04-01 2017-06-30 0001501134 2017-01-01 2017-03-31 0001501134 nvta:OmmdomIncMember 2018-01-01 2018-12-31 0001501134 us-gaap:RetainedEarningsMember 2015-12-31 0001501134 2018-04-01 2018-06-30 0001501134 2017-10-01 2017-12-31 0001501134 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-12-31 0001501134 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0001501134 us-gaap:RetainedEarningsMember 2016-01-01 2016-12-31 0001501134 us-gaap:PreferredStockMember 2016-12-31 0001501134 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-12-31 0001501134 us-gaap:PreferredStockMember 2017-12-31 0001501134 us-gaap:RetainedEarningsMember 2017-01-01 2017-12-31 0001501134 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-01-01 2016-12-31 0001501134 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001501134 nvta:AltaVoiceMember 2018-01-01 2018-12-31 0001501134 us-gaap:RetainedEarningsMember 2018-12-31 0001501134 us-gaap:RetainedEarningsMember 2016-12-31 0001501134 2018-01-01 0001501134 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-01-01 2017-12-31 0001501134 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:LeaseholdImprovementsMember 2016-01-01 2016-12-31 0001501134 nvta:CustomerMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-12-31 0001501134 srt:MaximumMember 2018-01-01 2018-12-31 0001501134 nvta:CustomerMember srt:MaximumMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-12-31 0001501134 nvta:CustomerMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2017-01-01 2017-12-31 0001501134 srt:MaximumMember us-gaap:CustomerRelationshipsMember 2018-01-01 2018-12-31 0001501134 2018-06-29 0001501134 nvta:CustomerMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2017-01-01 2017-12-31 0001501134 nvta:CustomerMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2016-01-01 2016-12-31 0001501134 nvta:CustomerMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-12-31 0001501134 us-gaap:FurnitureAndFixturesMember 2018-01-01 2018-12-31 0001501134 us-gaap:EquipmentMember 2018-01-01 2018-12-31 0001501134 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2018-01-01 2018-12-31 0001501134 us-gaap:AutomobilesMember 2018-01-01 2018-12-31 0001501134 us-gaap:ComputerEquipmentMember 2018-01-01 2018-12-31 0001501134 srt:MinimumMember 2018-01-01 2018-12-31 0001501134 srt:MinimumMember us-gaap:CustomerRelationshipsMember 2018-01-01 2018-12-31 0001501134 2019-02-22 0001501134 srt:MaximumMember 2018-01-01 2018-01-01 0001501134 us-gaap:AccountingStandardsUpdate201409Member 2018-01-01 0001501134 nvta:DiagnosticTestsMember nvta:ChangeInEstimateOfRevenueRecognitionMember 2018-01-01 2018-12-31 0001501134 us-gaap:AccountingStandardsUpdate201409Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2018-01-01 2018-12-31 0001501134 us-gaap:AccountingStandardsUpdate201409Member us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-01-01 2018-12-31 0001501134 nvta:DiagnosticTestsMember us-gaap:AccountingStandardsUpdate201409Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2018-01-01 2018-12-31 0001501134 nvta:DiagnosticTestsMember us-gaap:AccountingStandardsUpdate201409Member us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-01-01 2018-12-31 0001501134 nvta:InstitutionsMember nvta:DiagnosticTestsMember 2017-01-01 2017-12-31 0001501134 nvta:PatientInsuranceMember nvta:DiagnosticTestsMember 2017-01-01 2017-12-31 0001501134 nvta:PatientInsuranceMember nvta:DiagnosticTestsMember 2018-01-01 2018-12-31 0001501134 2017-12-31 0001501134 nvta:InstitutionsMember nvta:DiagnosticTestsMember 2018-01-01 2018-12-31 0001501134 nvta:PatientDirectMember nvta:DiagnosticTestsMember 2018-01-01 2018-12-31 0001501134 nvta:PatientDirectMember nvta:DiagnosticTestsMember 2017-01-01 2017-12-31 0001501134 us-gaap:AccountingStandardsUpdate201409Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2018-12-31 0001501134 us-gaap:AccountingStandardsUpdate201409Member us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-12-31 0001501134 nvta:GoodStartGeneticsIncMember us-gaap:CustomerRelationshipsMember 2017-08-04 2017-08-04 0001501134 nvta:GoodStartGeneticsIncMember us-gaap:DevelopedTechnologyRightsMember 2017-08-04 2017-08-04 0001501134 nvta:GoodStartGeneticsIncMember us-gaap:DevelopedTechnologyRightsMember 2017-08-04 0001501134 nvta:GoodStartGeneticsIncMember us-gaap:CustomerRelationshipsMember 2017-08-04 0001501134 nvta:GoodStartGeneticsIncMember us-gaap:TradeNamesMember 2017-08-04 0001501134 2018-12-31 0001501134 nvta:GoodStartGeneticsIncMember 2017-08-04 0001501134 nvta:GoodStartGeneticsIncMember us-gaap:TradeNamesMember 2017-08-04 2017-08-04 0001501134 nvta:AltaVoiceMember 2017-01-06 0001501134 nvta:AltaVoiceMember us-gaap:CustomerRelationshipsMember 2017-01-06 0001501134 nvta:AltaVoiceMember us-gaap:NoncompeteAgreementsMember 2017-01-06 0001501134 nvta:AltaVoiceMember us-gaap:DevelopedTechnologyRightsMember 2017-01-06 0001501134 nvta:OmmdomIncMember 2017-06-11 2017-06-11 0001501134 nvta:CombiMatrixCorporationMember us-gaap:SeriesFPreferredStockMember 2017-07-31 2017-07-31 0001501134 nvta:AltaVoiceMember 2017-01-06 2017-01-06 0001501134 nvta:OmmdomIncMember us-gaap:CommonStockMember 2018-06-01 2018-06-30 iso4217:USD nvta:Segment iso4217:USD shares nvta:gene shares pure nvta:Employee false --12-31 FY 43465 2018-12-31 10-K 0001501134 76811562 Yes true true Accelerated Filer 477800000 Invitae Corp false false No Yes NVTA 0 0 P3Y 1.00 0.0208 0 0 0 0 0.0001 0.0001 400000000 400000000 53597000 75481000 53597000 75481000 monthly P7Y P2Y P5Y 0 0 0 0 0 P10Y 3498000 4599000 6183000 0.0001 0.0001 20000000 20000000 3459000 3459000 3459000 3459000 P3Y P12M 0 P10Y P6Y3M P8Y9M29D P8Y4M28D 0 0.7692 0.7870 0.699 0.0237 0.0155 0.0204 0.0183 0.3333 0.3333 0.3333 0.25 112158000 12053000 13727000 52607000 26296000 10422000 13258000 11599000 165439000 86681000 27886000 30341000 6006000 5406000 0 5983000 30469000 35516000 50095000 46575000 3064000 576000 282959000 211078000 7812000 8606000 26563000 22742000 1937000 2039000 36312000 33387000 1375000 3373000 74477000 39084000 8956000 13440000 121120000 89284000 0 0 8000 5000 -5000 -171000 678548000 520558000 -516712000 -398598000 161839000 121794000 282959000 211078000 144560000 65169000 24840000 3139000 3052000 208000 147699000 68221000 25048000 80105000 50142000 27878000 63496000 46469000 44630000 74428000 53417000 28638000 52227000 39472000 24085000 270256000 189500000 125231000 -122557000 -121279000 -100183000 -2568000 -303000 348000 7030000 3654000 421000 -132155000 -125236000 -100256000 -2800000 -1856000 0 -129355000 -123380000 -100256000 -1.94 -2.65 -3.02 66747000 46512000 33176000 -129355000 -123380000 -100256000 166000 -171000 15000 -129189000 -123551000 -100241000 0 31935000 4000 313349000 -15000 -174962000 138376000 244000 744000 744000 157000 -1000 -1000 370000 2391000 2391000 8433000 1000 47101000 47102000 5000 4000 4000 10699000 10699000 15000 15000 -100256000 -100256000 0 41144000 4000 374288000 -275218000 99074000 3459000 5188000 1000 68896000 68897000 387000 1706000 1706000 925000 4000 232000 1381000 1381000 379000 2635000 2635000 5176000 50808000 50808000 162000 1272000 1272000 740000 740000 18832000 18832000 -171000 -171000 -123380000 -123380000 3459000 53597000 5000 520558000 -171000 -398598000 121794000 11241000 11241000 17103000 3000 112438000 112441000 351000 2741000 2741000 1369000 1099000 6539000 6539000 566000 3231000 3231000 1022000 6455000 6455000 383000 383000 374000 5353000 5353000 20850000 20850000 166000 166000 -129355000 -129355000 3459000 75481000 8000 678548000 -5000 -516712000 161839000 -129355000 -123380000 -100256000 13540000 9181000 6553000 20850000 19221000 10699000 2925000 0 0 362000 1810000 0 -2862000 -1856000 0 -5266000 0 0 806000 404000 1341000 5291000 1963000 843000 1445000 641000 1149000 163000 185000 -1465000 -417000 -535000 -111000 3564000 -37000 5984000 -92220000 -97981000 -76317000 9680000 101867000 90236000 19965000 0 0 32458000 68768000 117922000 0 2821000 0 5970000 6675000 11625000 1000000 0 0 35773000 -36953000 16061000 112441000 0 47102000 17511000 74619000 3134000 93909000 39661000 7500000 4609000 0 0 60000000 30457000 2438000 2100000 2952000 1589000 157152000 80871000 53709000 100705000 -54063000 -6547000 17459000 71522000 78069000 118164000 17459000 71522000 6231000 2852000 421000 0 6789000 0 510000 200000 1644000 2000000 0 0 383000 740000 0 6445000 50808000 0 0 13276000 0 0 1272000 0 Organization and description of business<span style="font-family:Arial;font-size:10pt;">Invitae Corporation (the “Company”) was incorporated in the State of Delaware on January 13, 2010, as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. The Company utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process DNA-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients. The Company’s headquarters and main production facility is located in San Francisco, California. The Company currently has more than </span><span style="font-family:Arial;font-size:10pt;"><span>20,000</span></span><span style="font-family:Arial;font-size:10pt;"> genes in production and provides a variety of diagnostic tests that can be used in multiple indications. The Company’s tests include genes associated with hereditary cancer, neurological disorders, cardiovascular disord</span><span style="font-family:Arial;font-size:10pt;">ers, pediatric disorders, metabolic disorders and other hereditary conditions. In addition, and as a result of the acquisitions of Good Start Genetics ("Good Start") in August 2017 and CombiMatrix Corporation ("CombiMatrix") in November 2017, the C</span><span style="font-family:Arial;font-size:10pt;">ompany’s services also include screening and testing in reproductive health, including preimplantation and carrier screening for inherited disorders, prenatal diagnosis, miscarriage analysis and pediatric developmental disorders. The Company operates in </span><span style="font-family:Arial;font-size:10pt;"><span>one</span></span> segment. 20000 1 Summary of significant accounting policies<div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Principles of consolidation</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Use of estimates</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. The Company bases these estimates on historical and anticipated results, trends and various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to future events. Actual results could differ materially from those estimates and assumptions.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Significant estimates and assumptions made by management include the determination of:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;padding-left:30px;"><div style="line-height:120%;font-size:10pt;text-indent:-30px;"><span style="font-family:Arial;font-size:10pt;">revenue recognition (See Note 3, “Revenue, accounts receivable and deferred revenue” for further information); </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">the fair value of assets acquired and liabilities assumed for business combinations; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">the fair value of goodwill and intangible assets; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">the recoverability of long-lived assets; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">stock-based compensation expense and the fair value of awards issued; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">income tax uncertainties. </span></div></td></tr></table><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Concentrations of credit risk and other risks and uncertainties</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents, marketable securities and accounts receivable. The Company’s cash and cash equivalents are held by financial institutions in the United States. Such deposits may exceed federally insured limits.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Significant customers are those that represent </span><span style="font-family:Arial;font-size:10pt;"><span>10%</span></span><span style="font-family:Arial;font-size:10pt;"> or more of the Company’s total revenue for each year presented on the statements of operations. For the significant customer, revenue as a percentage of total revenue were as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:59%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">Customers</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Medicare</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Medicare represented </span><span style="font-family:Arial;font-size:10pt;"><span>21%</span></span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>13%</span></span><span style="font-family:Arial;font-size:10pt;"> of accounts receivable as of </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">2017</span><span style="font-family:Arial;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Cash, cash equivalents, and restricted cash</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The Company considers all highly liquid investments with original maturities of three months or less from the date of purchase to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market funds and U.S. government agency securities.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Restricted cash consists of money market funds that serve as collateral for security deposits for the Company’s facility lease and sublease agreements and collateral for a credit card agreement at one of the Company’s financial institutions.</span></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the statements of cash flows (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">December 31, 2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>112,158</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>12,053</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Restricted cash</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>6,006</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5,406</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total cash, cash equivalents and restricted cash</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>118,164</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>17,459</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Marketable securities</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">All marketable securities have been classified as “available-for-sale” and are carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities. Management determines the appropriate classification of its marketable debt securities at the time of purchase and reevaluates such designation at each balance sheet date. Short-term marketable securities have maturities less than 365 days at the balance sheet date. Unrealized gains and losses are excluded from earnings and are reported as a component of other comprehensive loss. Realized gains and losses and declines in fair value judged to be other than temporary, if any, on available-for-sale securities are included in interest and other income (expense), net. The cost of securities sold is based on the specific-identification method. Interest on marketable securities is included in interest and other income (expense), net.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Accounts receivable</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The Company receives payment for its tests from partners, patients, institutional customers and third-party payers. See Note 3, "Revenue, accounts receivable and deferred revenue" for further information.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Inventory</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The Company maintains test reagents and other consumables primarily used in sample collection kits which are valued at the lower of cost or market value. Cost is determined using actual costs on a first-in, first-out basis. The Company's inventory was </span><span style="font-family:Arial;font-size:10pt;"><span>$8.3 million</span></span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>$5.4 million</span></span><span style="font-family:Arial;font-size:10pt;"> as of </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">2017</span><span style="font-family:Arial;font-size:10pt;">, respectively, and was recorded in prepaid expenses and other current assets in the Company's consolidated balance sheets.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Business combinations</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The tangible and identifiable intangible assets acquired and liabilities assumed in a business combination are recorded based on their estimated fair values as of the business combination date, including identifiable intangible assets which either arise from a contractual or legal right or are separable from goodwill. The Company bases the estimated fair value of identifiable intangible assets acquired in a business combination on independent valuations that use information and assumptions provided by management, which consider management’s estimates of inputs and assumptions that a market participant would use. Any excess purchase price over the estimated fair value assigned to the net tangible and identifiable intangible assets acquired and liabilities assumed is recorded to goodwill. The use of alternative valuation assumptions, including estimated revenue projections, growth rates, cash flows, discount rates, estimated useful lives and probabilities surrounding the achievement of contingent milestones could result in different purchase price allocations and amortization expense in current and future periods. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In circumstances where an acquisition involves a contingent consideration arrangement that meets the definition of a liability under Financial Accounting Standards Board (“FASB") Accounting Standards Codification (“ASC”) Topic 480, </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Distinguishing Liabilities from Equity</span><span style="font-family:Arial;font-size:10pt;">, the Company recognizes a liability equal to the fair value of the contingent payments the Company expects to make as of the acquisition date. The Company remeasures this liability each reporting period and records changes in the fair value as a component of operating expenses. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Transaction costs associated with acquisitions are expensed as incurred in general and administrative expenses. Results of operations and cash flows of acquired companies are included in the Company’s operating results from the date of acquisition.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Intangible assets</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Amortizable intangible assets include trade names, non-compete agreements, developed technology and customer relationships acquired as part of business combinations. Customer relationships are amortized on an accelerated basis, utilizing free cash flows, over periods ranging from </span><span style="font-family:Arial;font-size:10pt;">five</span><span style="font-family:Arial;font-size:10pt;"> to </span><span style="font-family:Arial;font-size:10pt;"><span>11 years</span></span><span style="font-family:Arial;font-size:10pt;">. All other intangible assets subject to amortization are amortized using the straight-line method over their estimated useful lives ranging from </span><span style="font-family:Arial;font-size:10pt;">two</span><span style="font-family:Arial;font-size:10pt;"> to </span><span style="font-family:Arial;font-size:10pt;"><span>15 years</span></span><span style="font-family:Arial;font-size:10pt;">. All intangible assets subject to amortization are reviewed for impairment in accordance with ASC 360, </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Property, Plant and Equipment.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Goodwill</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In accordance with ASC 350, </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Intangibles-Goodwill and Other</span><span style="font-family:Arial;font-size:10pt;"> (“ASC 350”), the Company’s goodwill is not amortized but is tested for impairment on an annual basis or whenever events or changes in circumstances indicate that the carrying amount of these assets may not be recoverable. Under ASC 350, the Company performs annual impairment reviews of its goodwill balance during the fourth fiscal quarter. In testing for impairment, the Company compares the fair value of its reporting unit to its carrying value including the goodwill of that unit. If the carrying value, including goodwill, exceeds the reporting unit’s fair value, the Company will recognize an impairment loss for the amount by which the carrying amount exceeds the reporting unit’s fair value. The loss recognized cannot exceed the total amount of goodwill allocated to that reporting unit. The Company did not incur any goodwill impairment losses in any of the periods presented.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Leases</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The Company rents its facilities under operating lease agreements and recognizes related rent expense on a straight-line basis over the term of the applicable lease agreement. Some of the lease agreements contain rent holidays, scheduled rent increases, lease incentives, and renewal options. Rent holidays and scheduled rent increases are included in the determination of rent expense to be recorded over the lease term. Lease incentives are recognized as a reduction of rent expense on a straight-line basis over the term of the lease. Renewals are not assumed in the determination of the lease term unless they are deemed to be reasonably assured at the inception of the lease. The Company recognizes rent expense beginning on the date it obtains the legal right to use and control the leased space.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Property and equipment, net</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is computed using the straight‑line method over the estimated useful lives of the assets, generally between </span><span style="font-family:Arial;font-size:10pt;">three</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>seven years</span></span><span style="font-family:Arial;font-size:10pt;">. Leasehold improvements are amortized using the straight‑line method over the shorter of the estimated useful life of the asset or the term of the lease. Amortization expense of assets acquired through capital leases is included in depreciation and amortization expense in the consolidated statements of operations. Maintenance and repairs are charged to expense as incurred, and improvements and betterments are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in the statements of operations in the period realized.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The estimated useful lives of property and equipment are as follows:</span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"/></tr><tr><td style="width:52%;"/><td style="width:48%;"/></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Furniture and fixtures</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>7 years</span></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Automobiles</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>7 years</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Laboratory equipment</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5 years</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Computer equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3 years</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Software</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3 years</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Leasehold improvements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Shorter of lease term or estimated useful life</span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:10px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Long‑lived assets</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The Company reviews long‑lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. An impairment loss is recognized when the total estimated future undiscounted cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. Impairment, if any, is assessed using discounted cash flows or other appropriate measures of fair value. Other than impairment losses of </span><span style="font-family:Arial;font-size:10pt;"><span>$1.0 million</span></span><span style="font-family:Arial;font-size:10pt;"> in 2016 relating to leasehold improvements and to the shutdown of the Company’s Chilean operations, there were </span><span style="font-family:Arial;font-size:10pt;"><span>no</span></span><span style="font-family:Arial;font-size:10pt;"> long-lived asset impairment losses recorded for any period presented. All impairment losses were charged to general and administrative expense.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Variable interest entity</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The Company had a variable interest in a variable interest entity (“VIE”) through an investment in convertible notes issued by the VIE. The convertible notes do not provide the Company with voting rights in the VIE or with power to direct the activities of the VIE which most significantly affect its economic performance. The Company is not the VIE’s primary beneficiary and it does not consolidate the VIE.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Fair value of financial instruments</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The Company’s financial instruments consist principally of cash and cash equivalents, marketable securities, accounts payable, accrued liabilities, capital leases and debt. The carrying amounts of certain of these financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued and other current liabilities approximate their current fair value due to the relatively short-term nature of these accounts. Based on borrowing rates available to the Company, the carrying value of capital leases and debt approximate their fair values. </span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Revenue recognition</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The Company recognizes revenue when control of the promised goods or services is transferred to the customer in an amount that reflects the consideration it expects to be entitled to in exchange for those goods or services. All revenues are generated from contracts with customers.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Test revenue is generated primarily from the sale of tests that provide analysis and associated interpretation of the sequencing of parts of the genome.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other revenue consists primarily of revenue from genome network subscription services which is recognized on a straight-line basis over the subscription term, and revenue from collaboration agreements.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Cost of revenue</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Cost of revenue reflects the aggregate costs incurred in delivering the genetic testing results to clinicians and includes expenses for personnel-related costs including stock-based compensation, materials and supplies, equipment and infrastructure expenses associated with testing and allocated overhead including rent, equipment depreciation and utilities.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Income taxes</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and the tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Stock-based compensation</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The Company measures its stock-based payment awards made to employees and directors based on the estimated fair values of the awards and recognizes the compensation expense over the requisite service period. The Company uses the Black-Scholes option-pricing model to estimate the fair value of its stock option awards and employee stock purchase plan (“ESPP”) purchases. The fair value of restricted stock unit (“RSU”) awards with time-based vesting terms is based on the grant date share price. The Company grants performance-based restricted stock unit (“PRSU”) awards to certain employees which vest upon the achievement of certain performance conditions, subject to the employees’ continued service relationship with the Company. The probability of vesting is assessed at each reporting period and compensation cost is adjusted based on this probability assessment. The Company recognizes such compensation expense on an accelerated vesting method.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Stock-based compensation expense for awards without a performance condition is recognized using the straight-line method. Stock-based compensation expense is based on the value of the portion of stock-based payment awards that is ultimately expected to vest. As such, the Company’s stock-based compensation is reduced for estimated forfeitures at the date of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The Company accounts for compensation expense related to stock options granted to non-employees based on fair values estimated using the Black-Scholes option-pricing model. Stock options granted to non-employees are re-measured at each reporting date until the award is vested.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The Company accounts for stock issued as compensation in connection with business combinations based on the fair value of the Company’s common stock on the date of issuance.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Advertising</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Advertising expenses are expensed as incurred. The Company incurred advertising expenses of </span><span style="font-family:Arial;font-size:10pt;"><span>$0.6 million</span></span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;"><span>$0.6 million</span></span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>$0.5 million</span></span><span style="font-family:Arial;font-size:10pt;"> during the years ended </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;">2017</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">2016</span><span style="font-family:Arial;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Comprehensive loss</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Comprehensive loss is composed of two components: net loss and other comprehensive income (loss). Other comprehensive income (loss) refers to gains and losses that under U.S. GAAP are recorded as an element of stockholders’ equity, but are excluded from net loss. The Company’s other comprehensive income (loss) consists of unrealized gains or losses on investments in available-for-sale securities.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Net loss per share</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common share equivalents outstanding for the period determined using the treasury stock method. Potentially dilutive securities, consisting of preferred stock, options to purchase common stock, common stock warrants, RSUs and PRSUs, are considered to be common stock equivalents and were excluded from the calculation of diluted net loss per share because their effect would be antidilutive for all periods presented. </span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Recent accounting pronouncements</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The Company evaluates all Accounting Standards Updates (“ASUs”) issued by the FASB for consideration of their applicability. ASUs not included in the disclosures in this report were assessed and determined to be either not applicable or are not expected to have a material impact on the Company’s consolidated financial statements.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Recently issued accounting pronouncements not yet adopted</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In November 2018, the FASB issued ASU 2018-18, </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</span><span style="font-family:Arial;font-size:10pt;">, which clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under Accounting Standards Codification ("ASC") 606 when the counterparty is a customer. In addition, Topic 808 precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue from contracts with customers if the counterparty is not a customer for that transaction. This guidance will be effective for the Company beginning January 1, 2020. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In June 2016, the FASB issued ASU No. 2016-13,</span><span style="font-family:Arial;font-size:10pt;font-style:italic;"> Financial Instruments - Credit Losses (Topic 326)</span><span style="font-family:Arial;font-size:10pt;">, which replaces the incurred loss impairment methodology in current U.S. GAAP with a methodology that reflects expected credit losses. The amended guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2019, with early adoption permitted for the fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In February 2016, the FASB issued ASU 2016-02,</span><span style="font-family:Arial;font-size:10pt;font-style:italic;"> Leases (Topic 842) </span><span style="font-family:Arial;font-size:10pt;">and in July 2018 issued ASU 2018-10</span><span style="font-family:Arial;font-size:10pt;font-style:italic;">, Codification Improvements to Topic 842, Leases </span><span style="font-family:Arial;font-size:10pt;">and ASU 2018-11</span><span style="font-family:Arial;font-size:10pt;font-style:italic;">, Leases (Topic 842): Targeted Improvements </span><span style="font-family:Arial;font-size:10pt;">(the foregoing ASUs collectively referred to as “Topic 842”). Under the new guidance, lessees are required to recognize a lease liability and a right-of-use asset for all leases (with the exception of short-term leases) at the commencement date and also requires expanded disclosures about leasing arrangements. Topic 842 is effective for annual and interim periods beginning on or after December 15, 2018 and early adoption is permitted. Entities may initially apply the new leases standard at the adoption date and recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The Company is evaluating the final effect that Topic 842 and related standards will have on its consolidated financial statements, related disclosures and ongoing financial reporting, but expects implementation of Topic 842 to result in the recognition of material right of use assets and corresponding lease liabilities in its consolidated balance sheets as of the implementation of Topic 842 on January 1, 2019, principally relating to facilities leases. The Company does not have any material embedded leases and the implementation of Topic 842 is primarily focused on the treatment of the Company's previously identified leases. As of December 31, 2018, the Company's total future undiscounted capital lease payments were </span><span style="font-family:Arial;font-size:10pt;"><span>$3.5 million</span></span><span style="font-family:Arial;font-size:10pt;"> and future undiscounted non-cancelable minimum operating lease payments, net of subleases were </span><span style="font-family:Arial;font-size:10pt;"><span>$78.4 million</span></span><span style="font-family:Arial;font-size:10pt;"> </span></div><div style="line-height:120%;padding-top:16px;text-indent:30px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Recently adopted accounting pronouncements</span></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In May 2014, the FASB issued ASU 2014-09, </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606),</span><span style="font-family:Arial;font-size:10pt;"> designed to enable users of financial statements to better understand the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. On January 1, 2018, the Company adopted the provisions of Topic 606 using the modified retrospective method. From adoption to date, the Company has recognized all its revenue from contracts with customers within the scope of Topic 606. In connection with the adoption, the Company recognized the cumulative effect of initially applying this standard as an adjustment to retained earnings on the date of adoption. Comparative information prior to the date of adoption has not been restated and continues to be reported under the accounting standards in effect for those periods. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In connection with the adoption of Topic 606, the Company amended its revenue recognition policy to provide for the recognition of certain variable consideration related to diagnostic tests that was previously deferred pending cash collection. Under Topic 606, the Company records variable consideration based on an estimate of the consideration to which it will be entitled.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The Company recognizes revenue when control of the promised goods or services is transferred to the customer in an amount that reflects the consideration it expects to be entitled to in exchange for those goods or services. All revenues are generated from contracts with customers.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Diagnostic tests</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The majority of the Company’s revenue is generated from genetic testing services that provide analysis and associated interpretation of the sequencing of parts of the genome. Test orders are placed under signed requisitions, and the Company often enters into contracts with institutions (e.g., hospitals and clinics) and insurance companies that include pricing provisions under which such tests are billed. Billing terms are generally net thirty days. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">While the transaction price of diagnostic tests is originally established either via contract or pursuant to the Company’s standard list price, the Company often provides concessions for tests billed to insurance carriers, and therefore the transaction price for patient insurance-billed tests is considered to be variable and revenue is recognized based on an estimate of the consideration to which the Company will be entitled at an amount for which it is probable that a reversal of cumulative consideration will not occur. Making these estimates requires significant judgments based upon such factors as length of payer relationship, historical payment patterns, changes in contract provisions and insurance reimbursement policies. These judgments are reviewed quarterly and revenue recognized is updated, as necessary, until the Company’s obligations are fully settled. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In connection with some diagnostic test orders, the Company offers limited re-requisition rights (“Re-Requisition Rights”) that are considered distinct at contract inception, and therefore certain diagnostic test orders contain two performance obligations, the performance of the original test and the Re-Requisition Rights. When Re-Requisition Rights are granted, the Company allocates the transaction price to each performance obligation based on the relative estimated standalone selling prices. In order to comply with loss contract rules, the allocations are adjusted, if necessary, to ensure the amount deferred for Re-Requisition Rights is no less than the estimated cost of fulfilling the Company’s related obligations. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The Company looks to transfer of control in assessing timing of recognition of revenue in connection with each performance obligation. In general, revenue in connection with diagnostic tests is recognized upon delivery of the underlying clinical report or when the report is made available on the Company’s web portal. Outstanding performance obligations pertaining to orders received but for which the underlying report has not been issued are generally satisfied within a thirty-day period. Revenue in connection with Re-Requisition Rights is recognized as the rights are exercised or expire unexercised, which is generally within ninety days of initial deferral. </span></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Other contracts</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The Company also enters into collaboration and genome network contracts. Collaboration agreements provide customers with diagnostic testing and related data aggregation reporting services that are provided over the contract term. Collaboration revenue is recognized as the testing and reporting services are delivered to the customer. Genome network offerings consist of subscription services related to a proprietary software platform designed to connect patients, clinicians, advocacy organizations, researchers and therapeutic developers to accelerate the understanding, diagnosis and treatment of hereditary disease. Such services are recognized on a straight-line basis over the subscription periods. </span></div>Amounts due under collaboration and genome network agreements are typically billable on net thirty-day terms. Principles of consolidationThe consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. Use of estimates<div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. The Company bases these estimates on historical and anticipated results, trends and various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to future events. Actual results could differ materially from those estimates and assumptions.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Significant estimates and assumptions made by management include the determination of:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;padding-left:30px;"><div style="line-height:120%;font-size:10pt;text-indent:-30px;"><span style="font-family:Arial;font-size:10pt;">revenue recognition (See Note 3, “Revenue, accounts receivable and deferred revenue” for further information); </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">the fair value of assets acquired and liabilities assumed for business combinations; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">the fair value of goodwill and intangible assets; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">the recoverability of long-lived assets; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">stock-based compensation expense and the fair value of awards issued; and</span></div></td></tr></table><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Arial;font-size:10pt;">•</span></div>income tax uncertainties. Concentrations of credit risk and other risks and uncertainties<div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents, marketable securities and accounts receivable. The Company’s cash and cash equivalents are held by financial institutions in the United States. Such deposits may exceed federally insured limits.</span></div><span style="font-family:Arial;font-size:10pt;">Significant customers are those that represent </span><span style="font-family:Arial;font-size:10pt;"><span>10%</span></span> or more of the Company’s total revenue for each year presented on the statements of operations. 0.10 For the significant customer, revenue as a percentage of total revenue were as follows:<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:59%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">Customers</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Medicare</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">%</span></div></td></tr></table></div> 0.22 0.13 0.11 0.21 0.13 Cash, cash equivalents, and restricted cash<div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The Company considers all highly liquid investments with original maturities of three months or less from the date of purchase to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market funds and U.S. government agency securities.</span></div>Restricted cash consists of money market funds that serve as collateral for security deposits for the Company’s facility lease and sublease agreements and collateral for a credit card agreement at one of the Company’s financial institutions. The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the statements of cash flows (in thousands):<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">December 31, 2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>112,158</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>12,053</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Restricted cash</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>6,006</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5,406</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total cash, cash equivalents and restricted cash</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>118,164</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>17,459</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the statements of cash flows (in thousands):<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">December 31, 2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>112,158</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>12,053</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Restricted cash</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>6,006</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5,406</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total cash, cash equivalents and restricted cash</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>118,164</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>17,459</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 112158000 12053000 6006000 5406000 118164000 17459000 Marketable securitiesAll marketable securities have been classified as “available-for-sale” and are carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities. Management determines the appropriate classification of its marketable debt securities at the time of purchase and reevaluates such designation at each balance sheet date. Short-term marketable securities have maturities less than 365 days at the balance sheet date. Unrealized gains and losses are excluded from earnings and are reported as a component of other comprehensive loss. Realized gains and losses and declines in fair value judged to be other than temporary, if any, on available-for-sale securities are included in interest and other income (expense), net. The cost of securities sold is based on the specific-identification method. Interest on marketable securities is included in interest and other income (expense), net. Accounts receivableThe Company receives payment for its tests from partners, patients, institutional customers and third-party payers. InventoryThe Company maintains test reagents and other consumables primarily used in sample collection kits which are valued at the lower of cost or market value. Cost is determined using actual costs on a first-in, first-out basis. 8300000 5400000 Business combinations<div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The tangible and identifiable intangible assets acquired and liabilities assumed in a business combination are recorded based on their estimated fair values as of the business combination date, including identifiable intangible assets which either arise from a contractual or legal right or are separable from goodwill. The Company bases the estimated fair value of identifiable intangible assets acquired in a business combination on independent valuations that use information and assumptions provided by management, which consider management’s estimates of inputs and assumptions that a market participant would use. Any excess purchase price over the estimated fair value assigned to the net tangible and identifiable intangible assets acquired and liabilities assumed is recorded to goodwill. The use of alternative valuation assumptions, including estimated revenue projections, growth rates, cash flows, discount rates, estimated useful lives and probabilities surrounding the achievement of contingent milestones could result in different purchase price allocations and amortization expense in current and future periods. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In circumstances where an acquisition involves a contingent consideration arrangement that meets the definition of a liability under Financial Accounting Standards Board (“FASB") Accounting Standards Codification (“ASC”) Topic 480, </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Distinguishing Liabilities from Equity</span><span style="font-family:Arial;font-size:10pt;">, the Company recognizes a liability equal to the fair value of the contingent payments the Company expects to make as of the acquisition date. The Company remeasures this liability each reporting period and records changes in the fair value as a component of operating expenses. </span></div>Transaction costs associated with acquisitions are expensed as incurred in general and administrative expenses. Results of operations and cash flows of acquired companies are included in the Company’s operating results from the date of acquisition. Intangible assets<span style="font-family:Arial;font-size:10pt;">Amortizable intangible assets include trade names, non-compete agreements, developed technology and customer relationships acquired as part of business combinations. Customer relationships are amortized on an accelerated basis, utilizing free cash flows, over periods ranging from </span><span style="font-family:Arial;font-size:10pt;">five</span><span style="font-family:Arial;font-size:10pt;"> to </span><span style="font-family:Arial;font-size:10pt;"><span>11 years</span></span><span style="font-family:Arial;font-size:10pt;">. All other intangible assets subject to amortization are amortized using the straight-line method over their estimated useful lives ranging from </span><span style="font-family:Arial;font-size:10pt;">two</span><span style="font-family:Arial;font-size:10pt;"> to </span><span style="font-family:Arial;font-size:10pt;"><span>15 years</span></span><span style="font-family:Arial;font-size:10pt;">. All intangible assets subject to amortization are reviewed for impairment in accordance with ASC 360, </span>Property, Plant and Equipment. P11Y P15Y Goodwill<span style="font-family:Arial;font-size:10pt;">In accordance with ASC 350, </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Intangibles-Goodwill and Other</span> (“ASC 350”), the Company’s goodwill is not amortized but is tested for impairment on an annual basis or whenever events or changes in circumstances indicate that the carrying amount of these assets may not be recoverable. Under ASC 350, the Company performs annual impairment reviews of its goodwill balance during the fourth fiscal quarter. In testing for impairment, the Company compares the fair value of its reporting unit to its carrying value including the goodwill of that unit. If the carrying value, including goodwill, exceeds the reporting unit’s fair value, the Company will recognize an impairment loss for the amount by which the carrying amount exceeds the reporting unit’s fair value. The loss recognized cannot exceed the total amount of goodwill allocated to that reporting unit. The Company did not incur any goodwill impairment losses in any of the periods presented. LeasesThe Company rents its facilities under operating lease agreements and recognizes related rent expense on a straight-line basis over the term of the applicable lease agreement. Some of the lease agreements contain rent holidays, scheduled rent increases, lease incentives, and renewal options. Rent holidays and scheduled rent increases are included in the determination of rent expense to be recorded over the lease term. Lease incentives are recognized as a reduction of rent expense on a straight-line basis over the term of the lease. Renewals are not assumed in the determination of the lease term unless they are deemed to be reasonably assured at the inception of the lease. The Company recognizes rent expense beginning on the date it obtains the legal right to use and control the leased space. Property and equipment, net<div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is computed using the straight‑line method over the estimated useful lives of the assets, generally between </span><span style="font-family:Arial;font-size:10pt;">three</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>seven years</span></span><span style="font-family:Arial;font-size:10pt;">. Leasehold improvements are amortized using the straight‑line method over the shorter of the estimated useful life of the asset or the term of the lease. Amortization expense of assets acquired through capital leases is included in depreciation and amortization expense in the consolidated statements of operations. Maintenance and repairs are charged to expense as incurred, and improvements and betterments are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in the statements of operations in the period realized.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The estimated useful lives of property and equipment are as follows:</span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"/></tr><tr><td style="width:52%;"/><td style="width:48%;"/></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Furniture and fixtures</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>7 years</span></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Automobiles</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>7 years</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Laboratory equipment</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5 years</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Computer equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3 years</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Software</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3 years</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Leasehold improvements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Shorter of lease term or estimated useful life</span></div></td></tr></table></div> P7Y The estimated useful lives of property and equipment are as follows:<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"/></tr><tr><td style="width:52%;"/><td style="width:48%;"/></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Furniture and fixtures</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>7 years</span></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Automobiles</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>7 years</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Laboratory equipment</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5 years</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Computer equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3 years</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Software</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3 years</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Leasehold improvements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Shorter of lease term or estimated useful life</span></div></td></tr></table></div> P7Y P7Y P5Y P3Y P3Y Long‑lived assetsThe Company reviews long‑lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. An impairment loss is recognized when the total estimated future undiscounted cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. Impairment, if any, is assessed using discounted cash flows or other appropriate measures of fair value. 1000000.0 0 Variable interest entityThe Company had a variable interest in a variable interest entity (“VIE”) through an investment in convertible notes issued by the VIE. The convertible notes do not provide the Company with voting rights in the VIE or with power to direct the activities of the VIE which most significantly affect its economic performance. The Company is not the VIE’s primary beneficiary and it does not consolidate the VIE. Fair value of financial instrumentsThe Company’s financial instruments consist principally of cash and cash equivalents, marketable securities, accounts payable, accrued liabilities, capital leases and debt. The carrying amounts of certain of these financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued and other current liabilities approximate their current fair value due to the relatively short-term nature of these accounts. Based on borrowing rates available to the Company, the carrying value of capital leases and debt approximate their fair values. Revenue recognition<div style="line-height:120%;padding-top:8px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The Company recognizes revenue when control of the promised goods or services is transferred to the customer in an amount that reflects the consideration it expects to be entitled to in exchange for those goods or services. All revenues are generated from contracts with customers.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Test revenue is generated primarily from the sale of tests that provide analysis and associated interpretation of the sequencing of parts of the genome.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other revenue consists primarily of revenue from genome network subscription services which is recognized on a straight-line basis over the subscription term, and revenue from collaboration agreements.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Cost of revenue</span></div>Cost of revenue reflects the aggregate costs incurred in delivering the genetic testing results to clinicians and includes expenses for personnel-related costs including stock-based compensation, materials and supplies, equipment and infrastructure expenses associated with testing and allocated overhead including rent, equipment depreciation and utilities. Income taxesThe Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and the tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. Stock-based compensation<div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The Company measures its stock-based payment awards made to employees and directors based on the estimated fair values of the awards and recognizes the compensation expense over the requisite service period. The Company uses the Black-Scholes option-pricing model to estimate the fair value of its stock option awards and employee stock purchase plan (“ESPP”) purchases. The fair value of restricted stock unit (“RSU”) awards with time-based vesting terms is based on the grant date share price. The Company grants performance-based restricted stock unit (“PRSU”) awards to certain employees which vest upon the achievement of certain performance conditions, subject to the employees’ continued service relationship with the Company. The probability of vesting is assessed at each reporting period and compensation cost is adjusted based on this probability assessment. The Company recognizes such compensation expense on an accelerated vesting method.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Stock-based compensation expense for awards without a performance condition is recognized using the straight-line method. Stock-based compensation expense is based on the value of the portion of stock-based payment awards that is ultimately expected to vest. As such, the Company’s stock-based compensation is reduced for estimated forfeitures at the date of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The Company accounts for compensation expense related to stock options granted to non-employees based on fair values estimated using the Black-Scholes option-pricing model. Stock options granted to non-employees are re-measured at each reporting date until the award is vested.</span></div>The Company accounts for stock issued as compensation in connection with business combinations based on the fair value of the Company’s common stock on the date of issuance. AdvertisingAdvertising expenses are expensed as incurred. 600000 600000 500000 Comprehensive lossComprehensive loss is composed of two components: net loss and other comprehensive income (loss). Other comprehensive income (loss) refers to gains and losses that under U.S. GAAP are recorded as an element of stockholders’ equity, but are excluded from net loss. The Company’s other comprehensive income (loss) consists of unrealized gains or losses on investments in available-for-sale securities. Net loss per shareBasic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common share equivalents outstanding for the period determined using the treasury stock method. Potentially dilutive securities, consisting of preferred stock, options to purchase common stock, common stock warrants, RSUs and PRSUs, are considered to be common stock equivalents and were excluded from the calculation of diluted net loss per share because their effect would be antidilutive for all periods presented. Recent accounting pronouncements<div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The Company evaluates all Accounting Standards Updates (“ASUs”) issued by the FASB for consideration of their applicability. ASUs not included in the disclosures in this report were assessed and determined to be either not applicable or are not expected to have a material impact on the Company’s consolidated financial statements.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Recently issued accounting pronouncements not yet adopted</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In November 2018, the FASB issued ASU 2018-18, </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</span><span style="font-family:Arial;font-size:10pt;">, which clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under Accounting Standards Codification ("ASC") 606 when the counterparty is a customer. In addition, Topic 808 precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue from contracts with customers if the counterparty is not a customer for that transaction. This guidance will be effective for the Company beginning January 1, 2020. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In June 2016, the FASB issued ASU No. 2016-13,</span><span style="font-family:Arial;font-size:10pt;font-style:italic;"> Financial Instruments - Credit Losses (Topic 326)</span><span style="font-family:Arial;font-size:10pt;">, which replaces the incurred loss impairment methodology in current U.S. GAAP with a methodology that reflects expected credit losses. The amended guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2019, with early adoption permitted for the fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In February 2016, the FASB issued ASU 2016-02,</span><span style="font-family:Arial;font-size:10pt;font-style:italic;"> Leases (Topic 842) </span><span style="font-family:Arial;font-size:10pt;">and in July 2018 issued ASU 2018-10</span><span style="font-family:Arial;font-size:10pt;font-style:italic;">, Codification Improvements to Topic 842, Leases </span><span style="font-family:Arial;font-size:10pt;">and ASU 2018-11</span><span style="font-family:Arial;font-size:10pt;font-style:italic;">, Leases (Topic 842): Targeted Improvements </span><span style="font-family:Arial;font-size:10pt;">(the foregoing ASUs collectively referred to as “Topic 842”). Under the new guidance, lessees are required to recognize a lease liability and a right-of-use asset for all leases (with the exception of short-term leases) at the commencement date and also requires expanded disclosures about leasing arrangements. Topic 842 is effective for annual and interim periods beginning on or after December 15, 2018 and early adoption is permitted. Entities may initially apply the new leases standard at the adoption date and recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The Company is evaluating the final effect that Topic 842 and related standards will have on its consolidated financial statements, related disclosures and ongoing financial reporting, but expects implementation of Topic 842 to result in the recognition of material right of use assets and corresponding lease liabilities in its consolidated balance sheets as of the implementation of Topic 842 on January 1, 2019, principally relating to facilities leases. The Company does not have any material embedded leases and the implementation of Topic 842 is primarily focused on the treatment of the Company's previously identified leases. As of December 31, 2018, the Company's total future undiscounted capital lease payments were </span><span style="font-family:Arial;font-size:10pt;"><span>$3.5 million</span></span><span style="font-family:Arial;font-size:10pt;"> and future undiscounted non-cancelable minimum operating lease payments, net of subleases were </span><span style="font-family:Arial;font-size:10pt;"><span>$78.4 million</span></span><span style="font-family:Arial;font-size:10pt;"> </span></div><div style="line-height:120%;padding-top:16px;text-indent:30px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Recently adopted accounting pronouncements</span></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In May 2014, the FASB issued ASU 2014-09, </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606),</span><span style="font-family:Arial;font-size:10pt;"> designed to enable users of financial statements to better understand the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. On January 1, 2018, the Company adopted the provisions of Topic 606 using the modified retrospective method. From adoption to date, the Company has recognized all its revenue from contracts with customers within the scope of Topic 606. In connection with the adoption, the Company recognized the cumulative effect of initially applying this standard as an adjustment to retained earnings on the date of adoption. Comparative information prior to the date of adoption has not been restated and continues to be reported under the accounting standards in effect for those periods. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In connection with the adoption of Topic 606, the Company amended its revenue recognition policy to provide for the recognition of certain variable consideration related to diagnostic tests that was previously deferred pending cash collection. Under Topic 606, the Company records variable consideration based on an estimate of the consideration to which it will be entitled.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The Company recognizes revenue when control of the promised goods or services is transferred to the customer in an amount that reflects the consideration it expects to be entitled to in exchange for those goods or services. All revenues are generated from contracts with customers.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Diagnostic tests</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The majority of the Company’s revenue is generated from genetic testing services that provide analysis and associated interpretation of the sequencing of parts of the genome. Test orders are placed under signed requisitions, and the Company often enters into contracts with institutions (e.g., hospitals and clinics) and insurance companies that include pricing provisions under which such tests are billed. Billing terms are generally net thirty days. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">While the transaction price of diagnostic tests is originally established either via contract or pursuant to the Company’s standard list price, the Company often provides concessions for tests billed to insurance carriers, and therefore the transaction price for patient insurance-billed tests is considered to be variable and revenue is recognized based on an estimate of the consideration to which the Company will be entitled at an amount for which it is probable that a reversal of cumulative consideration will not occur. Making these estimates requires significant judgments based upon such factors as length of payer relationship, historical payment patterns, changes in contract provisions and insurance reimbursement policies. These judgments are reviewed quarterly and revenue recognized is updated, as necessary, until the Company’s obligations are fully settled. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In connection with some diagnostic test orders, the Company offers limited re-requisition rights (“Re-Requisition Rights”) that are considered distinct at contract inception, and therefore certain diagnostic test orders contain two performance obligations, the performance of the original test and the Re-Requisition Rights. When Re-Requisition Rights are granted, the Company allocates the transaction price to each performance obligation based on the relative estimated standalone selling prices. In order to comply with loss contract rules, the allocations are adjusted, if necessary, to ensure the amount deferred for Re-Requisition Rights is no less than the estimated cost of fulfilling the Company’s related obligations. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The Company looks to transfer of control in assessing timing of recognition of revenue in connection with each performance obligation. In general, revenue in connection with diagnostic tests is recognized upon delivery of the underlying clinical report or when the report is made available on the Company’s web portal. Outstanding performance obligations pertaining to orders received but for which the underlying report has not been issued are generally satisfied within a thirty-day period. Revenue in connection with Re-Requisition Rights is recognized as the rights are exercised or expire unexercised, which is generally within ninety days of initial deferral. </span></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Other contracts</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The Company also enters into collaboration and genome network contracts. Collaboration agreements provide customers with diagnostic testing and related data aggregation reporting services that are provided over the contract term. Collaboration revenue is recognized as the testing and reporting services are delivered to the customer. Genome network offerings consist of subscription services related to a proprietary software platform designed to connect patients, clinicians, advocacy organizations, researchers and therapeutic developers to accelerate the understanding, diagnosis and treatment of hereditary disease. Such services are recognized on a straight-line basis over the subscription periods. </span></div>Amounts due under collaboration and genome network agreements are typically billable on net thirty-day terms. 3500000 78400000 Revenue, accounts receivable and deferred revenue <div style="line-height:120%;padding-top:8px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">As described in Note 2, "Summary of significant accounting policies," the Company adopted Topic 606 effective January 1, 2018. In connection with the adoption the Company utilized the following practical expedients and exemptions:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:66px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Certain information about remaining performance obligations is not disclosed because the underlying contracts have an original expected duration of </span><span style="font-family:Arial;font-size:10pt;"><span>one year</span></span><span style="font-family:Arial;font-size:10pt;"> or less.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:66px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Costs to obtain or fulfill a contract are expensed when incurred because the amortization period would have been </span><span style="font-family:Arial;font-size:10pt;"><span>one year</span></span><span style="font-family:Arial;font-size:10pt;"> or less. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:66px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">No adjustments to promised consideration were made for financing as the Company expects, at contract inception, that the period between the transfer of a promised good or service and when the customer pays for that good or service will be </span><span style="font-family:Arial;font-size:10pt;"><span>one year</span></span><span style="font-family:Arial;font-size:10pt;"> or less.</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The adoption of Topic 606 resulted in a cumulative-effect adjustment to accounts receivable and accumulated deficit of </span><span style="font-family:Arial;font-size:10pt;"><span>$11.2 million</span></span><span style="font-family:Arial;font-size:10pt;"> as of January 1, 2018 primarily related to the recognition of uncollected </span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">diagnostic test variable consideration as of the date of adoption. Test revenue without adoption of Topic 606 for the year ended December 31, 2018 includes cash collections related to accounts receivable recorded as of January 1, 2018 in connection with the Topic 606 cumulative-effect adjustment. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The effect of the adoption of Topic 606 on financial statement line items in the Company’s consolidated statement of operations for the year ended </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, and the Company’s consolidated balance sheet as of </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;"> was as follows (in thousands, except per share amounts):</span></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:58%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:Arial;font-size:11pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Year Ended December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:Arial;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:Arial;font-size:11pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Without</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Effect of</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:Arial;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:Arial;font-size:11pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Adoption of</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Adoption</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">As Reported</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Topic 606</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Higher/(Lower)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Test revenue</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>144,560</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>144,222</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>338</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(129,355</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(129,693</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>338</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Net loss per share, basic and diluted</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(1.94</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(1.94</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:58%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">As of December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:Arial;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:Arial;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Without</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Effect of</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:Arial;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:Arial;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Adoption of</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Adoption</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">As Reported</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Topic 606</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Higher/(Lower)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Accounts receivable</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>26,296</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>14,150</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>12,146</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Accumulated deficit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(516,712</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(528,291</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>11,579</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Stockholders' equity</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>161,839</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>150,260</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>11,579</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Disaggregation of revenue</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Test revenue is generated from sales of diagnostic tests to three groups of customers: institutions, such as hospitals, clinics and partners; patients who pay directly; and patients’ insurance carriers. Amounts billed and collected, and the timing of collections, vary based on whether the payer is an institution, an insurance carrier or a patient. Other revenue consists principally of revenue recognized under collaboration and genome network agreements.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following table includes the Company’s revenues as disaggregated by payer category (in thousands):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:70%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017 </span><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Test revenue:</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Institutions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>34,618</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>17,238</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Patient - direct</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>13,589</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5,638</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Patient - insurance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>96,353</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>42,293</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> Total test revenue</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>144,560</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>65,169</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,139</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,052</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total revenue</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>147,699</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>68,221</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;">___________________________________________________________________ </span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:6px;"><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span><span style="font-family:Arial;font-size:9pt;"> </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">As noted above, prior period amounts are presented as originally reported based upon the accounting standards in effect for those periods.</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Included in revenue in the Company’s consolidated statements of operations for the year ended </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;"> was </span><span style="font-family:Arial;font-size:10pt;"><span>$0.3 million</span></span><span style="font-family:Arial;font-size:10pt;"> that was included in deferred revenue at January 1, 2018.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The Company recognizes revenue related to billings based on estimates of the amount that will ultimately be realized. The estimate of the transaction price of test revenue is based on many factors such as length of payer relationship, historical payment patterns, changes in contract provisions and insurance reimbursement policies. Cash collections for certain tests delivered may differ from rates originally estimated. As a result of new information, the Company updated its estimate of the amounts to be recognized for previously delivered tests which resulted in </span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">an additional </span><span style="font-family:Arial;font-size:10pt;"><span>$4.5 million</span></span><span style="font-family:Arial;font-size:10pt;"> of test revenue for the year ended </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">. These changes in estimates decreased the Company’s loss from operations by </span><span style="font-family:Arial;font-size:10pt;"><span>$4.5 million</span></span><span style="font-family:Arial;font-size:10pt;"> and decreased basic and diluted net loss per share by approximately </span><span style="font-family:Arial;font-size:10pt;"><span>$0.07</span></span><span style="font-family:Arial;font-size:10pt;"> for the year ended </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Accounts receivable</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The majority of the Company’s accounts receivable represents amounts billed to institutions (e.g., hospitals, clinics) and estimated amounts to be collected from third-party insurance payers for test revenue recognized. Also included is amounts due under the terms of collaboration and genome network agreements for diagnostic testing and data aggregation reporting services provided and proprietary platform access rights transferred.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Deferred revenues</span></div>The Company records deferred revenues when cash payments are received or due in advance of its performance related to one or more performance obligations. The amounts deferred to date primarily consist of consideration received pertaining to the estimated exercise of certain Re-Requisition Rights. The Company defers revenue related to Re-Requisition Rights in amounts no less than the estimated cost of fulfilling its related obligations. The Company recognizes revenue related to Re-Requisition Rights as the rights are exercised or expire unexercised, which is generally within 90 days of initial deferral. P1Y P1Y P1Y 11200000 The effect of the adoption of Topic 606 on financial statement line items in the Company’s consolidated statement of operations for the year ended <span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, and the Company’s consolidated balance sheet as of </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;"> was as follows (in thousands, except per share amounts):</span><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:58%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:Arial;font-size:11pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Year Ended December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:Arial;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:Arial;font-size:11pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Without</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Effect of</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:Arial;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:Arial;font-size:11pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Adoption of</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Adoption</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">As Reported</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Topic 606</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Higher/(Lower)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Test revenue</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>144,560</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>144,222</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>338</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(129,355</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(129,693</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>338</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Net loss per share, basic and diluted</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(1.94</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(1.94</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:58%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">As of December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:Arial;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:Arial;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Without</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Effect of</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:Arial;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:Arial;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Adoption of</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Adoption</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">As Reported</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Topic 606</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Higher/(Lower)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Accounts receivable</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>26,296</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>14,150</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>12,146</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Accumulated deficit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(516,712</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(528,291</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>11,579</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Stockholders' equity</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>161,839</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>150,260</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>11,579</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 144560000 144222000 338000 -129355000 -129693000 338000 -1.94 -1.94 0 26296000 14150000 12146000 -516712000 -528291000 11579000 161839000 150260000 11579000 The following table includes the Company’s revenues as disaggregated by payer category (in thousands):<div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:70%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017 </span><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Test revenue:</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Institutions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>34,618</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>17,238</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Patient - direct</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>13,589</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5,638</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Patient - insurance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>96,353</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>42,293</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> Total test revenue</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>144,560</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>65,169</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,139</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,052</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total revenue</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>147,699</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>68,221</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;">___________________________________________________________________ </span></div><div style="line-height:120%;font-size:9pt;padding-left:6px;"><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span><span style="font-family:Arial;font-size:9pt;"> </span></div>As noted above, prior period amounts are presented as originally reported based upon the accounting standards in effect for those periods. 34618000 17238000 13589000 5638000 96353000 42293000 144560000 65169000 3139000 3052000 147699000 68221000 300000 4500000 4500000 0.07 Business combinations<div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">AltaVoice</span></div><div style="line-height:120%;padding-bottom:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">On January 6, 2017, the Company acquired AltaVoice (formerly PatientCrossroads, Inc.), a privately-owned patient-centered data company with a global platform for collecting, curating, coordinating and delivering safeguarded data from patients and clinicians. The acquisition, complemented by several other strategic partnerships, expanded the Company's genome network, designed to connect patients, clinicians, advocacy organizations, researchers and therapeutic developers to accelerate the understanding, diagnosis, and treatment of hereditary disease. Pursuant to the terms of the Stock Purchase Agreement, the Company acquired all of the outstanding shares of AltaVoice for total purchase consideration of </span><span style="font-family:Arial;font-size:10pt;"><span>$12.4 million</span></span><span style="font-family:Arial;font-size:10pt;">, payable in the Company’s common stock, as follows:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:Arial;font-size:10pt;">(a)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">payment of </span><span style="font-family:Arial;font-size:10pt;"><span>$5.5 million</span></span><span style="font-family:Arial;font-size:10pt;"> through the issuance of </span><span style="font-family:Arial;font-size:10pt;"><span>641,126</span></span><span style="font-family:Arial;font-size:10pt;"> shares of the Company’s common stock;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:Arial;font-size:10pt;">(b)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">payment of </span><span style="font-family:Arial;font-size:10pt;"><span>$5.0 million</span></span><span style="font-family:Arial;font-size:10pt;"> in the Company’s common stock, payable on March 31, 2018, with the common shares deliverable equal to </span><span style="font-family:Arial;font-size:10pt;"><span>$5.0 million</span></span><span style="font-family:Arial;font-size:10pt;"> divided by the trailing average share price of the Company’s common stock for the 30 days preceding March 31, 2018. This payment was made in April 2018 through the issuance of </span><span style="font-family:Arial;font-size:10pt;"><span>716,332</span></span><span style="font-family:Arial;font-size:10pt;"> shares of the Company's common stock;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:Arial;font-size:10pt;">(c)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">payment of </span><span style="font-family:Arial;font-size:10pt;"><span>$5.0 million</span></span><span style="font-family:Arial;font-size:10pt;"> in the Company’s common stock, which was contingently payable on March 31, 2018 if a milestone based on a certain threshold of revenue was achieved during 2017, with the shares deliverable equal to </span><span style="font-family:Arial;font-size:10pt;"><span>$5.0 million</span></span><span style="font-family:Arial;font-size:10pt;"> divided by the trailing average share price of the Company’s common stock for the 30 days preceding March 31, 2018. As the foregoing milestone was not achieved, there was a new contingent milestone based on achieving a revenue target during 2017 and 2018. Since this new contingent milestone was achieved, on March 31, 2019, a payment of </span><span style="font-family:Arial;font-size:10pt;"><span>$5.0 million</span></span><span style="font-family:Arial;font-size:10pt;"> in the Company’s common stock will be payable. The actual payout is dependent upon meeting the 2017 and 2018 revenue targets (capped at </span><span style="font-family:Arial;font-size:10pt;"><span>$14.0 million</span></span><span style="font-family:Arial;font-size:10pt;">) times </span><span style="font-family:Arial;font-size:10pt;"><span>75%</span></span><span style="font-family:Arial;font-size:10pt;"> less </span><span style="font-family:Arial;font-size:10pt;"><span>$5.5 million</span></span><span style="font-family:Arial;font-size:10pt;">. This formula in effect caps the possible payout amount at </span><span style="font-family:Arial;font-size:10pt;"><span>$5.0 million</span></span><span style="font-family:Arial;font-size:10pt;"> in the Company’s common shares. The number of shares to be issued will be equal to the payout amount divided by the trailing average share price of the Company’s common stock for the 30 days preceding March 31, 2019.</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The first payment of </span><span style="font-family:Arial;font-size:10pt;"><span>$5.5 million</span></span><span style="font-family:Arial;font-size:10pt;"> was classified as equity. The second payment was discounted to </span><span style="font-family:Arial;font-size:10pt;"><span>$4.7 million</span></span><span style="font-family:Arial;font-size:10pt;"> as of the acquisition date, recorded as a liability, and was accreted to fair value at each reporting date until the extinguishment of the liability in April 2018. The third payment, representing contingent consideration, was determined to have a fair value of </span><span style="font-family:Arial;font-size:10pt;"><span>$2.2 million</span></span><span style="font-family:Arial;font-size:10pt;"> as of the acquisition date and was recorded as a liability. In accordance with ASC Topic 805, </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Business Combinations,</span><span style="font-family:Arial;font-size:10pt;"> the contingent consideration of </span><span style="font-family:Arial;font-size:10pt;"><span>$2.2 million</span></span><span style="font-family:Arial;font-size:10pt;"> was remeasured to fair value at each reporting date until the contingency was resolved, with changes in fair value recognized in earnings.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">For the second payment, the acquisition-date fair value was </span><span style="font-family:Arial;font-size:10pt;"><span>$4.7 million</span></span><span style="font-family:Arial;font-size:10pt;">, and the Company recorded accretion gains (losses) of </span><span style="font-family:Arial;font-size:10pt;"><span>$1.6 million</span></span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>$(0.2) million</span></span><span style="font-family:Arial;font-size:10pt;"> in other income (expense), net, for the years ended </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">2017</span><span style="font-family:Arial;font-size:10pt;">, respectively. The accretion gains in 2018 resulted from an adjustment to the value of </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">the second payment as of March 31, 2018, and principally reflected the difference between the value of the common shares deliverable, based upon the closing price of the Company’s stock on March 29, 2018, and the value per share used to calculate the number of common shares deliverable. The accretion losses in 2017 resulted from adjustments to the discounted value of the second payment, reflecting the passage of time. </span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">For the third payment, the acquisition-date fair value was </span><span style="font-family:Arial;font-size:10pt;"><span>$2.2 million</span></span><span style="font-family:Arial;font-size:10pt;">, and the Company recorded remeasurement losses of </span><span style="font-family:Arial;font-size:10pt;"><span>$1.2 million</span></span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>$1.6 million</span></span><span style="font-family:Arial;font-size:10pt;"> in general and administrative expense for the years ended </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">2017</span><span style="font-family:Arial;font-size:10pt;">, respectively. The remeasurement losses in 2018 reflect updated estimations of fair value of the third payment, based upon achieving a revenue target during 2017 and 2018, as the milestone based on a certain threshold of revenue to be achieved during 2017 was not met. The principal inputs affecting those estimations have been updates to the Company’s revenue forecasts and the passage of time.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Assets acquired and liabilities assumed are recorded based on valuations derived from estimated fair value assessments and assumptions used by the Company. While the Company believes that its estimates and assumptions underlying the valuations are reasonable, different estimates and assumptions could result in different valuations assigned to the individual assets acquired and liabilities assumed, and the resulting amount of goodwill. The following table summarizes the fair values of assets acquired and liabilities assumed at the date of acquisition (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:85%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Cash</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>54</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Accounts receivable</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>274</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Prepaid expense and other assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>52</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Non-compete agreement</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>286</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Developed technology</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>570</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Customer relationships</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,389</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total identifiable assets acquired</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,625</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Accounts payable</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(28</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Deferred revenue</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(202</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Accrued expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(21</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Deferred tax liability</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(1,422</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total liabilities assumed</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(1,673</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Net identifiable assets acquired</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,952</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>9,432</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Net assets acquired</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>12,384</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Acquisition-related intangibles included in the above table are finite-lived. Customer relationships are being amortized on an accelerated basis, utilizing free cash flows, over a period of </span><span style="font-family:Arial;font-size:10pt;"><span>ten years</span></span><span style="font-family:Arial;font-size:10pt;">. All other acquisition-related intangibles are being amortized on a straight-line basis over their estimated lives, which approximates the pattern in which the economic benefits of the intangible assets are expected to be realized, as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:69%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Purchased</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Intangible</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Estimated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Useful</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Life</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(in Years)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Non-compete agreement</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>286</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Developed technology</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>570</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>6</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Customer relationships</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,389</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>10</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,245</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Goodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired. The acquisition of AltaVoice resulted in </span><span style="font-family:Arial;font-size:10pt;"><span>$9.4 million</span></span><span style="font-family:Arial;font-size:10pt;"> of goodwill which the Company believes consists principally of expected synergies to be realized by combining capabilities, technology and data to accelerate the use of genetic information for the diagnosis and treatment of hereditary diseases. In accordance with ASC 350, goodwill will not be amortized but will be tested for impairment at least annually. Goodwill created as a result of the acquisition is not deductible for tax purposes. The Company has finalized its assessment of fair value of the assets and liabilities assumed at the acquisition date.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Ommdom</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">On June 11, 2017, the Company acquired Ommdom, Inc. (“Ommdom”), a privately held company that develops, commercializes and sells hereditary risk assessment and management software, including CancerGene Connect, a cancer genetic counseling platform. The acquisition expanded Invitae’s suite of genome management offerings designed to help patients and clinicians use genetic information as part of mainstream medical care. CancerGene Connect is a platform for collecting and managing genetic family histories. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Pursuant to the terms of a Stock Exchange Agreement, the Company acquired all of the outstanding shares of Ommdom for consideration of </span><span style="font-family:Arial;font-size:10pt;"><span>$6.1 million</span></span><span style="font-family:Arial;font-size:10pt;">, payable entirely in the Company’s common stock. There was no cash consideration nor any contingent payments associated with the acquisition, other than a hold-back amount of </span><span style="font-family:Arial;font-size:10pt;"><span>$0.6 million</span></span><span style="font-family:Arial;font-size:10pt;">. Per the terms of the agreement, the Company was obligated to issue shares of its common stock as follows:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:Arial;font-size:10pt;">(a)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">payment of </span><span style="font-family:Arial;font-size:10pt;"><span>$5.5 million</span></span><span style="font-family:Arial;font-size:10pt;"> through the issuance of </span><span style="font-family:Arial;font-size:10pt;"><span>600,108</span></span><span style="font-family:Arial;font-size:10pt;"> shares of the Company’s common stock on the acquisition date; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:Arial;font-size:10pt;">(b)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">payment of </span><span style="font-family:Arial;font-size:10pt;"><span>$0.6 million</span></span><span style="font-family:Arial;font-size:10pt;"> through the issuance of </span><span style="font-family:Arial;font-size:10pt;"><span>66,582</span></span><span style="font-family:Arial;font-size:10pt;"> shares of the Company’s common stock, representing a hold-back amount, and payable on the twelve-month anniversary of the acquisition date.</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The first payment of </span><span style="font-family:Arial;font-size:10pt;"><span>$5.5 million</span></span><span style="font-family:Arial;font-size:10pt;"> was classified as equity. The second payment of </span><span style="font-family:Arial;font-size:10pt;"><span>$0.6 million</span></span><span style="font-family:Arial;font-size:10pt;"> was recorded as a stock payable liability on the acquisition date and was reclassified to equity upon the issuance of </span><span style="font-family:Arial;font-size:10pt;"><span>66,582</span></span><span style="font-family:Arial;font-size:10pt;"> shares of the Company’s common stock in June 2018.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Assets acquired and liabilities assumed are recorded based on valuations derived from estimated fair value assessments and assumptions used by the Company. While the Company believes that its estimates and assumptions underlying the valuations are reasonable, different estimates and assumptions could result in different valuations assigned to the individual assets acquired and liabilities assumed, and the resulting amount of goodwill. The following table summarizes the fair values of assets acquired and liabilities assumed at the date of acquisition (in thousands):</span></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:85%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Cash</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>53</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Accounts receivable</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Prepaid expense and other assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Trade name</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Developed technology</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,335</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Customer relationships</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>147</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total identifiable assets acquired</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,562</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Accounts payable</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(16</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Accrued expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(17</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Deferred tax liability</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(434</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total liabilities assumed</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(467</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Net identifiable assets acquired</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,095</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,045</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Net assets acquired</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>6,140</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Finite-lived intangibles included in the above table are being amortized on a straight-line basis over their estimated lives, which approximates the pattern in which the economic benefits of the intangible assets are expected to be realized, as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:69%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Purchased</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Intangible</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Estimated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Useful</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Life</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(in Years)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Trade name</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Developed technology</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,335</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Customer relationships</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>147</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,495</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Goodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired. The acquisition of Ommdom resulted in the recognition of </span><span style="font-family:Arial;font-size:10pt;"><span>$4.0 million</span></span><span style="font-family:Arial;font-size:10pt;"> of goodwill which the Company believes consists principally of expected synergies to be realized by expanding the Company’s suite of genome management offerings. In accordance with ASC 350, goodwill will not be amortized but rather will be tested for impairment at least annually. Goodwill created as a result of the acquisition is not deductible for tax purposes. The Company has finalized its assessment of fair value of the assets and liabilities assumed at the acquisition date.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Good Start Genetics</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">On August 4, 2017, the Company acquired </span><span style="font-family:Arial;font-size:10pt;"><span>100%</span></span><span style="font-family:Arial;font-size:10pt;"> of the fully diluted equity of Good Start, a privately held molecular diagnostics company focused on preimplantation and carrier screening for inherited disorders. The acquisition of Good Start was intended to further Invitae’s plan to create a comprehensive genetic information platform providing high-quality, affordable genetic information coupled with world-class clinical expertise to inform healthcare decisions throughout every stage of an individual’s life. The purchase consideration for the Good Start acquisition consisted of the assumption of the net liabilities of Good Start of </span><span style="font-family:Arial;font-size:10pt;"><span>$24.4 million</span></span><span style="font-family:Arial;font-size:10pt;"> at the acquisition date.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Immediately subsequent to the acquisition of Good Start, the Company paid </span><span style="font-family:Arial;font-size:10pt;"><span>$18.4 million</span></span><span style="font-family:Arial;font-size:10pt;"> in cash to settle outstanding notes payable, accrued interest and related costs. In addition, and immediately subsequent to the acquisition, the Company settled outstanding convertible promissory notes payable through:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:Arial;font-size:10pt;">(a)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">payment of </span><span style="font-family:Arial;font-size:10pt;"><span>$11.9 million</span></span><span style="font-family:Arial;font-size:10pt;"> through the issuance of </span><span style="font-family:Arial;font-size:10pt;"><span>1,148,283</span></span><span style="font-family:Arial;font-size:10pt;"> shares of the Company’s common stock; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:Arial;font-size:10pt;">(b)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">payment of </span><span style="font-family:Arial;font-size:10pt;"><span>$3.6 million</span></span><span style="font-family:Arial;font-size:10pt;"> through the issuance of </span><span style="font-family:Arial;font-size:10pt;"><span>343,986</span></span><span style="font-family:Arial;font-size:10pt;"> shares of the Company’s common stock, representing a hold-back amount payable on the one-year anniversary of the acquisition date. In September 2018, the Company issued </span><span style="font-family:Arial;font-size:10pt;"><span>212,260</span></span><span style="font-family:Arial;font-size:10pt;"> shares in partial payment of the hold-back amount payable. The remainder of the hold-back amount payable, approximately </span><span style="font-family:Arial;font-size:10pt;"><span>$1.3 million</span></span><span style="font-family:Arial;font-size:10pt;"> as of December 31, 2018, will be settled upon resolution of outstanding claims from Good Start customers, of which </span><span style="font-family:Arial;font-size:10pt;"><span>$0.6 million</span></span><span style="font-family:Arial;font-size:10pt;"> was settled in January 2019. </span></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Also in connection with the acquisition of Good Start and immediately subsequent to the acquisition, the Company paid bonuses to certain members of Good Start’s management team through:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:Arial;font-size:10pt;">(a)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">payment of </span><span style="font-family:Arial;font-size:10pt;"><span>$0.9 million</span></span><span style="font-family:Arial;font-size:10pt;"> through the issuance of </span><span style="font-family:Arial;font-size:10pt;"><span>83,025</span></span><span style="font-family:Arial;font-size:10pt;"> shares of the Company’s common stock; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:Arial;font-size:10pt;">(b)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">payment of </span><span style="font-family:Arial;font-size:10pt;"><span>$0.4 million</span></span><span style="font-family:Arial;font-size:10pt;"> through the issuance of </span><span style="font-family:Arial;font-size:10pt;"><span>37,406</span></span><span style="font-family:Arial;font-size:10pt;"> shares of the Company’s common stock, representing a hold-back amount payable on the one-year anniversary of the acquisition date. In September 2018, the Company issued </span><span style="font-family:Arial;font-size:10pt;"><span>27,784</span></span><span style="font-family:Arial;font-size:10pt;"> shares in partial payment of the hold-back amount payable to settle bonuses to Good Start's management team. The remainder of the hold-back amount payable, approximately </span><span style="font-family:Arial;font-size:10pt;"><span>$0.2 million</span></span><span style="font-family:Arial;font-size:10pt;"> as of December 31, 2018, will be settled upon resolution of outstanding claims from Good Start customers, of which </span><span style="font-family:Arial;font-size:10pt;"><span>$0.1 million</span></span><span style="font-family:Arial;font-size:10pt;"> was settled in January 2019.</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">These bonus payments were recorded as general and administrative expense.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Assets acquired and liabilities assumed are recorded based on valuations derived from estimated fair value assessments and assumptions used by the Company. While the Company believes that its estimates and assumptions underlying the valuations are reasonable, different estimates and assumptions could result in different valuations assigned to the individual assets acquired and liabilities assumed, and the resulting amount of goodwill.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">At acquisition date, the Company also recorded </span><span style="font-family:Arial;font-size:10pt;"><span>$4.8 million</span></span><span style="font-family:Arial;font-size:10pt;"> as a provisional amount for a deferred tax liability because certain information and analysis related to Good Start’s historical net operating losses that could have affected the Company’s initial valuation was still being obtained or reviewed at that time. This provisional amount for the deferred tax liability was subsequently reversed during the fourth quarter of 2017 based on the results of further analysis of Good Start’s historical net operating losses.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following table summarizes the fair values of assets acquired and liabilities assumed at the date of acquisition (in thousands):</span></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:85%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Cash and restricted cash</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,381</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Accounts receivable</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,246</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Prepaid expense and other assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,579</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Property and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,320</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Trade name</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>460</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Developed technology</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5,896</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Customer relationships</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>7,830</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total identifiable assets acquired</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>20,712</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Accounts payable</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(5,418</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Accrued expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(6,802</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Notes payable</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(17,904</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Convertible promissory notes payable</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(15,430</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(222</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total liabilities assumed</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(45,776</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Net identifiable assets acquired</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(25,064</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>25,064</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Net assets acquired</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">During the year ended December 31, 2018, the Company recorded adjustments to its accounting for the amount recorded as accounts receivable at acquisition. Accordingly, the fair value of accounts receivable was decreased by </span><span style="font-family:Arial;font-size:10pt;"><span>$0.7 million</span></span><span style="font-family:Arial;font-size:10pt;"> during the year ended December 31, 2018, with corresponding increases to goodwill. </span></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Customer relationships are being amortized on an accelerated basis, utilizing free cash flows, over a period of </span><span style="font-family:Arial;font-size:10pt;"><span>eight years</span></span><span style="font-family:Arial;font-size:10pt;">. All other finite-lived intangibles included in the above table are being amortized on a straight-line basis over their estimated lives, which approximates the pattern in which the economic benefits of the intangible assets are expected to be realized, as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:67%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Purchased</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Intangible</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Estimated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Useful</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Life</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(in Years)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Trade name</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>460</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Developed technology</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5,896</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Customer relationships</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>7,830</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>8</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>14,186</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Goodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired. The acquisition of Good Start resulted in the recognition of </span><span style="font-family:Arial;font-size:10pt;"><span>$25.1 million</span></span><span style="font-family:Arial;font-size:10pt;"> of goodwill which the Company believes consists principally of expected synergies to be realized by expanding the Company’s suite of genome management offerings. In accordance with ASC 350, goodwill will not be amortized but rather will be tested for impairment at least annually. Goodwill created as a result of the acquisition is not deductible for tax purposes. The Company has finalized its assessment of fair value of the assets and liabilities assumed at the acquisition date.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">CombiMatrix</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">On November 14, 2017, the Company completed its acquisition of CombiMatrix in accordance with the terms of the Agreement and Plan of Merger and Reorganization, dated as of </span><span style="font-family:Arial;font-size:10pt;">July 31, 2017</span><span style="font-family:Arial;font-size:10pt;"> (the “Merger Agreement”), by and among the Company, Coronado Merger Sub, Inc., a wholly owned subsidiary of the Company (“Merger Sub”), and CombiMatrix, pursuant to which Merger Sub merged with and into CombiMatrix, with CombiMatrix surviving as a wholly owned subsidiary of the Company (the “Merger”).</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">At the closing of the Merger, the Company issued shares of its common stock to (i) CombiMatrix’s common stockholders, at an exchange ratio of </span><span style="font-family:Arial;font-size:10pt;"><span>0.8692</span></span><span style="font-family:Arial;font-size:10pt;"> of a share of the Company’s common stock (the “Merger Exchange </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Ratio”) for each share of CombiMatrix common stock outstanding immediately prior to the Merger, (ii) CombiMatrix’s Series F preferred stockholders, at the Merger Exchange Ratio for each share of CombiMatrix common stock underlying Series F preferred stock outstanding immediately prior to the Merger, (iii) holders of outstanding and unexercised in-the-money CombiMatrix stock options, which were fully accelerated to the extent of any applicable vesting period and converted into the right to receive the number of shares of the Company’s common stock equal to the Merger Exchange Ratio multiplied by the number of shares of CombiMatrix common stock issuable upon exercise of such option, minus the number of shares of the Company’s common stock determined by dividing the aggregate exercise price for such option by </span><span style="font-family:Arial;font-size:10pt;"><span>$9.491</span></span><span style="font-family:Arial;font-size:10pt;">, and (iv) holders of outstanding and unsettled CombiMatrix restricted stock units, which were fully accelerated to the extent of any applicable vesting period and converted into the right to receive a number of shares of the Company’s common stock determined by multiplying the number of shares of CombiMatrix common stock that were subject to such restricted stock unit by the Merger Exchange Ratio.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In addition, at the closing of the Merger, (a) all outstanding and unexercised out-of-the money CombiMatrix stock options were cancelled and terminated without the right to receive any consideration, (b) all CombiMatrix Series D Warrants and Series F Warrants outstanding and unexercised immediately prior to the closing of the Merger were assumed by the Company and converted into warrants to purchase the number of shares of the Company’s common stock determined by multiplying the number of shares of CombiMatrix common stock subject to such warrants by the Merger Exchange Ratio, and with the exercise price adjusted by dividing the per share exercise price of the CombiMatrix common stock subject to such warrants by the Merger Exchange Ratio, and (c) certain entitlements under CombiMatrix’s executive compensation transaction bonus plan (the “Transaction Bonus Plan”) were paid in shares of the Company’s common stock or RSUs to be settled in shares of the Company’s common stock. All outstanding and unexercised CombiMatrix Series A, Series B, Series C, Series E, and PIPE warrants were repurchased by CombiMatrix prior to closing pursuant to that certain CombiMatrix Common Stock Purchase Warrants Repurchase Agreement dated July 11, 2016.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Pursuant to the Merger Agreement, the Company issued an aggregate of </span><span style="font-family:Arial;font-size:10pt;"><span>2,703,389</span></span><span style="font-family:Arial;font-size:10pt;"> shares of its common stock as follows:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:Arial;font-size:10pt;">(a)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">payment of </span><span style="font-family:Arial;font-size:10pt;"><span>$20.5 million</span></span><span style="font-family:Arial;font-size:10pt;"> through the issuance of </span><span style="font-family:Arial;font-size:10pt;"><span>2,611,703</span></span><span style="font-family:Arial;font-size:10pt;"> shares of the Company’s common stock to holders of CombiMatrix common stock outstanding;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:Arial;font-size:10pt;">(b)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">payment of </span><span style="font-family:Arial;font-size:10pt;"><span>$0.7 million</span></span><span style="font-family:Arial;font-size:10pt;"> through the issuance of </span><span style="font-family:Arial;font-size:10pt;"><span>85,219</span></span><span style="font-family:Arial;font-size:10pt;"> shares of the Company’s RSUs to holders of outstanding and unsettled CombiMatrix restricted stock units;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:Arial;font-size:10pt;">(c)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">payment of </span><span style="font-family:Arial;font-size:10pt;"><span>$0.1 million</span></span><span style="font-family:Arial;font-size:10pt;"> through the issuance of </span><span style="font-family:Arial;font-size:10pt;"><span>3,323</span></span><span style="font-family:Arial;font-size:10pt;"> shares of the Company’s common stock to holders of outstanding and unexercised in-the-money CombiMatrix stock options; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:Arial;font-size:10pt;">(d)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">payment of </span><span style="font-family:Arial;font-size:10pt;"><span>$0.1 million</span></span><span style="font-family:Arial;font-size:10pt;"> through the issuance of </span><span style="font-family:Arial;font-size:10pt;"><span>3,144</span></span><span style="font-family:Arial;font-size:10pt;"> shares of the Company’s common stock to holders of CombiMatrix Series F preferred stock.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In addition, and pursuant to the Merger Agreement, the Company issued warrants to purchase an aggregate of </span><span style="font-family:Arial;font-size:10pt;"><span>2,077,273</span></span><span style="font-family:Arial;font-size:10pt;"> shares of its common stock as follows:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:Arial;font-size:10pt;">(a)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">payment of </span><span style="font-family:Arial;font-size:10pt;"><span>$7.4 million</span></span><span style="font-family:Arial;font-size:10pt;"> through the issuance of warrants to purchase a total of </span><span style="font-family:Arial;font-size:10pt;"><span>1,739,689</span></span><span style="font-family:Arial;font-size:10pt;"> shares of the Company’s common stock in exchange for all outstanding CombiMatrix Series F warrants; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:Arial;font-size:10pt;">(b)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">payment of </span><span style="font-family:Arial;font-size:10pt;"><span>$1,000</span></span><span style="font-family:Arial;font-size:10pt;"> through the issuance of warrants to purchase a total of </span><span style="font-family:Arial;font-size:10pt;"><span>337,584</span></span><span style="font-family:Arial;font-size:10pt;"> shares of the Company’s common stock in exchange for all outstanding CombiMatrix Series D warrants.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In connection with the acquisition of CombiMatrix, the Company paid bonuses to certain members of CombiMatrix’s management team through:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:Arial;font-size:10pt;">(a)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">payment of </span><span style="font-family:Arial;font-size:10pt;"><span>$1.7 million</span></span><span style="font-family:Arial;font-size:10pt;"> through the issuance of common stock and RSUs totaling </span><span style="font-family:Arial;font-size:10pt;"><span>214,976</span></span><span style="font-family:Arial;font-size:10pt;"> shares of the Company’s common stock to settle payments pursuant to CombiMatrix’s executive compensation transaction bonus plan (the “Transaction Bonus Plan”), recorded as post-combination compensation expense and included in general and administrative expense; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:Arial;font-size:10pt;">(b)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">payment of </span><span style="font-family:Arial;font-size:10pt;"><span>$0.2 million</span></span><span style="font-family:Arial;font-size:10pt;"> through the issuance of </span><span style="font-family:Arial;font-size:10pt;"><span>22,966</span></span><span style="font-family:Arial;font-size:10pt;"> shares of the Company’s common stock to settle payments pursuant to the Transaction Bonus Plan, recorded as an assumed liability at the acquisition date.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Assets acquired and liabilities assumed are recorded based on valuations derived from estimated fair value assessments and assumptions used by the Company. While the Company believes that its estimates and assumptions underlying the valuations are reasonable, different estimates and assumptions could result in different valuations assigned to the individual assets acquired and liabilities assumed, and the resulting amount of goodwill. The following table summarizes the fair values of assets acquired and liabilities assumed at the date of acquisition (in thousands):</span></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:85%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Cash and restricted cash</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,333</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Accounts receivable</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,118</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Prepaid expense and other assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,299</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Property and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>437</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other assets - non current</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>30</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Favorable leases</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>247</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Trade name</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>103</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Patent licensing agreement</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>496</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Developed technology</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,162</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Customer relationships</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>12,397</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total identifiable assets acquired</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>23,622</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Accounts payable</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(276</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Accrued expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(3,925</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Deferred tax liability</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(2,862</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(180</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total liabilities assumed</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(7,243</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Net identifiable assets acquired</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>16,379</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>11,554</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Net assets acquired</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>27,933</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">During the year ended December 31, 2018, upon the completion of the Company's analysis of CombiMatrix's historical net operating losses, the Company recorded a deferred tax liability of </span><span style="font-family:Arial;font-size:10pt;"><span>$2.9 million</span></span><span style="font-family:Arial;font-size:10pt;"> with corresponding increases to goodwill. The </span><span style="font-family:Arial;font-size:10pt;color:#000000;"><span>$2.9 million</span></span><span style="font-family:Arial;font-size:10pt;"> net deferred tax liability represents the excess of the financial reporting over tax basis in acquired intangibles over the amount of CombiMatrix’s historical net operating loss carryovers that were determined to be available to offset future income due to change in ownership operating loss carryover limitation rules under Internal Revenue Code section 382. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Customer relationships are being amortized on an accelerated basis, utilizing free cash flows, over a period of </span><span style="font-family:Arial;font-size:10pt;"><span>eleven years</span></span><span style="font-family:Arial;font-size:10pt;">. All other finite-lived intangibles included in the above table are being amortized on a straight-line basis over their estimated lives, which approximates the pattern in which the economic benefits of the intangible assets are expected to be realized, as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:69%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Purchased</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Intangible</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Estimated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Useful</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Life</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(in Years)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Favorable leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>247</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Trade name</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>103</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Patent licensing agreement</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>496</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>15</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Developed technology</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,162</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Customer relationships</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>12,397</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>11</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>16,405</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><span style="font-family:Arial;font-size:10pt;">Goodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired. The acquisition of CombiMatrix resulted in the recognition of </span><span style="font-family:Arial;font-size:10pt;"><span>$11.6 million</span></span> of goodwill which the Company believes consists principally of expected synergies to be realized by expanding the Company’s suite of genome management offerings. In accordance with ASC 350, goodwill will not be amortized but rather will be tested for impairment at least annually. Goodwill created as a result of the acquisition is not deductible for tax purposes. The Company has finalized its assessment of fair value of the assets and liabilities assumed at the acquisition date. 12400000 5500000 641126 5000000.0 5000000.0 716332 5000000.0 5000000.0 5000000.0 14000000.0 0.75 5500000 5000000.0 5500000 4700000 2200000 2200000 4700000 1600000 -200000 2200000 1200000 1600000 The following table summarizes the fair values of assets acquired and liabilities assumed at the date of acquisition (in thousands):<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:85%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Cash</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>54</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Accounts receivable</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>274</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Prepaid expense and other assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>52</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Non-compete agreement</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>286</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Developed technology</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>570</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Customer relationships</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,389</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total identifiable assets acquired</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,625</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Accounts payable</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(28</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Deferred revenue</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(202</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Accrued expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(21</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Deferred tax liability</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(1,422</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total liabilities assumed</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(1,673</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Net identifiable assets acquired</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,952</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>9,432</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Net assets acquired</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>12,384</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 54000 274000 52000 286000 570000 3389000 4625000 28000 202000 21000 1422000 1673000 2952000 9432000 12384000 Acquisition-related intangibles included in the above table are finite-lived. Customer relationships are being amortized on an accelerated basis, utilizing free cash flows, over a period of <span style="font-family:Arial;font-size:10pt;"><span>ten years</span></span><span style="font-family:Arial;font-size:10pt;">. All other acquisition-related intangibles are being amortized on a straight-line basis over their estimated lives, which approximates the pattern in which the economic benefits of the intangible assets are expected to be realized, as follows (in thousands):</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:69%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Purchased</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Intangible</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Estimated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Useful</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Life</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(in Years)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Non-compete agreement</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>286</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Developed technology</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>570</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>6</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Customer relationships</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,389</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>10</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,245</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div> P10Y 286000 P5Y 570000 P6Y 3389000 P10Y 4245000 9400000 6100000 600000 5500000 600108 600000 66582 5500000 600000 66582 The following table summarizes the fair values of assets acquired and liabilities assumed at the date of acquisition (in thousands):<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:85%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Cash</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>53</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Accounts receivable</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Prepaid expense and other assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Trade name</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Developed technology</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,335</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Customer relationships</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>147</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total identifiable assets acquired</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,562</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Accounts payable</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(16</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Accrued expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(17</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Deferred tax liability</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(434</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total liabilities assumed</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(467</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Net identifiable assets acquired</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,095</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,045</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Net assets acquired</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>6,140</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 53000 10000 4000 13000 2335000 147000 2562000 16000 17000 434000 467000 2095000 4045000 6140000 Finite-lived intangibles included in the above table are being amortized on a straight-line basis over their estimated lives, which approximates the pattern in which the economic benefits of the intangible assets are expected to be realized, as follows (in thousands):<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:69%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Purchased</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Intangible</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Estimated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Useful</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Life</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(in Years)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Trade name</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Developed technology</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,335</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Customer relationships</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>147</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,495</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div> 13000 P5Y 2335000 P5Y 147000 P5Y 2495000 4000000.0 1 24400000 18400000 11900000 1148283 3600000 343986 212260 1300000 600000 900000 83025 400000 37406 27784 200000 100000 4800000 The following table summarizes the fair values of assets acquired and liabilities assumed at the date of acquisition (in thousands):<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:85%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Cash and restricted cash</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,381</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Accounts receivable</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,246</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Prepaid expense and other assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,579</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Property and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,320</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Trade name</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>460</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Developed technology</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5,896</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Customer relationships</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>7,830</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total identifiable assets acquired</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>20,712</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Accounts payable</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(5,418</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Accrued expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(6,802</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Notes payable</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(17,904</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Convertible promissory notes payable</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(15,430</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(222</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total liabilities assumed</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(45,776</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Net identifiable assets acquired</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(25,064</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>25,064</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Net assets acquired</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 1381000 2246000 1579000 1320000 460000 5896000 7830000 20712000 5418000 6802000 17904000 15430000 222000 45776000 -25064000 25064000 0 -700000 Customer relationships are being amortized on an accelerated basis, utilizing free cash flows, over a period of <span style="font-family:Arial;font-size:10pt;"><span>eight years</span></span><span style="font-family:Arial;font-size:10pt;">. All other finite-lived intangibles included in the above table are being amortized on a straight-line basis over their estimated lives, which approximates the pattern in which the economic benefits of the intangible assets are expected to be realized, as follows (in thousands):</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:67%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Purchased</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Intangible</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Estimated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Useful</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Life</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(in Years)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Trade name</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>460</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Developed technology</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5,896</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Customer relationships</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>7,830</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>8</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>14,186</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div> P8Y 460000 P3Y 5896000 P5Y 7830000 P8Y 14186000 25100000 0.8692 9.491 2703389 20500000 2611703 700000 85219 100000 3323 100000 3144 2077273 7400000 1739689 1000 337584 1700000 214976 200000 22966 The following table summarizes the fair values of assets acquired and liabilities assumed at the date of acquisition (in thousands):<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:85%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Cash and restricted cash</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,333</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Accounts receivable</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,118</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Prepaid expense and other assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,299</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Property and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>437</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other assets - non current</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>30</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Favorable leases</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>247</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Trade name</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>103</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Patent licensing agreement</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>496</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Developed technology</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,162</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Customer relationships</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>12,397</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total identifiable assets acquired</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>23,622</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Accounts payable</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(276</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Accrued expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(3,925</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Deferred tax liability</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(2,862</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(180</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total liabilities assumed</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(7,243</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Net identifiable assets acquired</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>16,379</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>11,554</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Net assets acquired</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>27,933</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 1333000 4118000 1299000 437000 30000 247000 103000 496000 3162000 12397000 23622000 276000 3925000 2862000 180000 7243000 16379000 11554000 27933000 2900000 2900000 Customer relationships are being amortized on an accelerated basis, utilizing free cash flows, over a period of <span style="font-family:Arial;font-size:10pt;"><span>eleven years</span></span><span style="font-family:Arial;font-size:10pt;">. All other finite-lived intangibles included in the above table are being amortized on a straight-line basis over their estimated lives, which approximates the pattern in which the economic benefits of the intangible assets are expected to be realized, as follows (in thousands):</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:69%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Purchased</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Intangible</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Estimated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Useful</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Life</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(in Years)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Favorable leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>247</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Trade name</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>103</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Patent licensing agreement</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>496</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>15</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Developed technology</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,162</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Customer relationships</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>12,397</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>11</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>16,405</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div> P11Y 247000 P2Y 103000 P1Y 496000 P15Y 3162000 P4Y 12397000 P11Y 16405000 11600000 Goodwill and intangible assets<div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Goodwill</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Details of the Company’s goodwill for the year ended </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;"> are as follows (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:35%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">AltaVoice</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Ommdom</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Good Start</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">CombiMatrix</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Balance as of December 31, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>9,432</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,045</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>24,406</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>8,692</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>46,575</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Goodwill adjustment</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>658</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,862</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,520</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Balance as of December 31, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>9,432</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,045</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>25,064</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>11,554</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>50,095</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The goodwill adjustments were principally due to changes in the fair value of accounts receivable for Good Start as well as the recognition of a </span><span style="font-family:Arial;font-size:10pt;"><span>$2.9 million</span></span><span style="font-family:Arial;font-size:10pt;"> deferred tax liability for CombiMatrix resulting from the completion of the Company’s analysis of historical net operating losses.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Intangible assets</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following table presents details of the Company’s finite-lived intangible assets as of </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;"> (in thousands):</span></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:35%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:12%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Weighted Average</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Useful Life</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(in Years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Weighted Average</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Estimated Remaining</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Useful Life</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(in Years)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Customer relationships</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>23,763</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(2,783</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>20,980</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>10.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>8.6</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Developed technology</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>11,963</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(3,482</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>8,481</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4.8</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3.4</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Non-compete agreement</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>286</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(114</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>172</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3.0</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Trade name</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>576</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(329</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>247</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2.7</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1.4</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Patent licensing agreement</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>496</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(37</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>459</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>15.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>13.9</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Favorable leases</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>247</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(117</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>130</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2.2</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1.1</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>37,331</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(6,862</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>30,469</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>8.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>6.8</span></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Acquisition-related intangibles included in the above table are finite-lived. Customer relationships are being amortized on an accelerated basis, in proportion to estimated cash flows, over periods ranging from </span><span style="font-family:Arial;font-size:10pt;">five</span><span style="font-family:Arial;font-size:10pt;"> to </span><span style="font-family:Arial;font-size:10pt;"><span>eleven years</span></span><span style="font-family:Arial;font-size:10pt;">. All other acquisition-related intangibles are being amortized on a straight-line basis over their estimated lives, which approximates the pattern in which the economic benefits of the intangible assets are realized. Amortization expense was </span><span style="font-family:Arial;font-size:10pt;"><span>$5.0 million</span></span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;"><span>$1.8 million</span></span><span style="font-family:Arial;font-size:10pt;">, and </span><span style="font-family:Arial;font-size:10pt;">nil</span><span style="font-family:Arial;font-size:10pt;"> for the years ended </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;">2017</span><span style="font-family:Arial;font-size:10pt;">, and </span><span style="font-family:Arial;font-size:10pt;">2016</span><span style="font-family:Arial;font-size:10pt;">, respectively. Intangible assets are carried at cost less accumulated amortization. Amortization expense is recorded to research and development, sales and marketing and general and administrative expense.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following table summarizes the Company’s estimated future amortization expense of intangible assets with finite lives as of </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;"> (in thousands):</span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:85%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Amount</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5,250</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5,525</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5,829</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,124</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,111</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>6,630</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total estimated future amortization expense</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>30,469</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> Details of the Company’s goodwill for the year ended <span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;"> are as follows (in thousands):</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:35%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">AltaVoice</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Ommdom</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Good Start</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">CombiMatrix</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Balance as of December 31, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>9,432</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,045</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>24,406</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>8,692</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>46,575</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Goodwill adjustment</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>658</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,862</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,520</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Balance as of December 31, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>9,432</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,045</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>25,064</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>11,554</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>50,095</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 9432000 4045000 24406000 8692000 46575000 0 0 658000 2862000 3520000 9432000 4045000 25064000 11554000 50095000 2900000 The following table presents details of the Company’s finite-lived intangible assets as of <span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;"> (in thousands):</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:35%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:12%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Weighted Average</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Useful Life</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(in Years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Weighted Average</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Estimated Remaining</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Useful Life</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(in Years)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Customer relationships</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>23,763</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(2,783</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>20,980</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>10.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>8.6</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Developed technology</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>11,963</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(3,482</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>8,481</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4.8</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3.4</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Non-compete agreement</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>286</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(114</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>172</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3.0</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Trade name</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>576</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(329</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>247</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2.7</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1.4</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Patent licensing agreement</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>496</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(37</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>459</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>15.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>13.9</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Favorable leases</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>247</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(117</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>130</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2.2</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1.1</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>37,331</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(6,862</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>30,469</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>8.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>6.8</span></span></div></td></tr></table></div> 23763000 2783000 20980000 P10Y P8Y7M6D 11963000 3482000 8481000 P4Y9M18D P3Y4M24D 286000 114000 172000 P5Y P3Y 576000 329000 247000 P2Y8M12D P1Y4M24D 496000 37000 459000 P15Y P13Y10M24D 247000 117000 130000 P2Y2M12D P1Y1M6D 37331000 6862000 30469000 P8Y2M12D P6Y9M18D P11Y 5000000.0 1800000 The following table summarizes the Company’s estimated future amortization expense of intangible assets with finite lives as of <span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;"> (in thousands):</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:85%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Amount</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5,250</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5,525</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5,829</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,124</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,111</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>6,630</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total estimated future amortization expense</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>30,469</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 5250000 5525000 5829000 4124000 3111000 6630000 30469000 Balance sheet components<div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Property and equipment, net</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Property and equipment consisted of the following (in thousands):</span></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:69%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">December 31, 2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Leasehold improvements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>13,034</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>12,623</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Laboratory equipment</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>22,149</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>17,705</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Equipment under capital lease</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>7,129</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>11,446</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Computer equipment</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,723</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,023</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Software</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,594</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,520</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Furniture and fixtures</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>784</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>569</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Automobiles</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>20</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>20</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Construction-in-progress</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,962</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>965</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total property and equipment, gross</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>52,395</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>49,871</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Accumulated depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(24,509</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(19,530</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total property and equipment, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>27,886</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>30,341</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Depreciation expense was </span><span style="font-family:Arial;font-size:10pt;"><span>$8.5 million</span></span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;"><span>$7.2 million</span></span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>$6.6 million</span></span><span style="font-family:Arial;font-size:10pt;"> for the years ended </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;">2017</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">2016</span><span style="font-family:Arial;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Accrued liabilities</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Accrued liabilities consisted of the following (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:69%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">December 31, 2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Accrued compensation and related expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>7,917</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>7,406</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Deferred revenue</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>761</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>307</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Liabilities associated with business combinations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>6,460</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>9,497</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Liability associated with co-development agreement</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>9,425</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5,532</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total accrued liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>26,563</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>22,742</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Other long-term liabilities</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other long-term liabilities consisted of the following (in thousands):</span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:69%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">December 31, 2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Lease incentive obligation, non-current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,280</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,831</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Deferred rent, non-current</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5,495</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5,153</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Liabilities associated with business combinations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,779</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other non-current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>181</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>677</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total other long-term liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>8,956</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>13,440</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> Property and equipment consisted of the following (in thousands):<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:69%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">December 31, 2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Leasehold improvements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>13,034</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>12,623</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Laboratory equipment</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>22,149</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>17,705</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Equipment under capital lease</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>7,129</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>11,446</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Computer equipment</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,723</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,023</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Software</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,594</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,520</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Furniture and fixtures</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>784</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>569</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Automobiles</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>20</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>20</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Construction-in-progress</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,962</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>965</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total property and equipment, gross</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>52,395</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>49,871</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Accumulated depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(24,509</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(19,530</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total property and equipment, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>27,886</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>30,341</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 13034000 12623000 22149000 17705000 7129000 11446000 4723000 4023000 2594000 2520000 784000 569000 20000 20000 1962000 965000 52395000 49871000 24509000 19530000 27886000 30341000 8500000 7200000 6600000 Accrued liabilities consisted of the following (in thousands):<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:69%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">December 31, 2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Accrued compensation and related expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>7,917</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>7,406</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Deferred revenue</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>761</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>307</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Liabilities associated with business combinations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>6,460</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>9,497</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Liability associated with co-development agreement</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>9,425</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5,532</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total accrued liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>26,563</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>22,742</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 7917000 7406000 761000 307000 6460000 9497000 2000000 0 9425000 5532000 26563000 22742000 Other long-term liabilities consisted of the following (in thousands):<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:69%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">December 31, 2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Lease incentive obligation, non-current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,280</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,831</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Deferred rent, non-current</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5,495</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5,153</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Liabilities associated with business combinations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,779</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other non-current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>181</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>677</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total other long-term liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>8,956</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>13,440</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 3280000 3831000 5495000 5153000 0 3779000 181000 677000 8956000 13440000 Fair value measurements<div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Financial assets and liabilities are recorded at fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The authoritative guidance establishes a three-level valuation hierarchy that prioritizes the inputs to valuation techniques used to measure fair value based upon whether such inputs are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions made by the reporting entity.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The three-level hierarchy for the inputs to valuation techniques is summarized as follows:</span></div><div style="line-height:120%;padding-top:8px;padding-left:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Level 1—Observable inputs such as quoted prices (unadjusted) for identical instruments in active markets.</span></div><div style="line-height:120%;padding-top:8px;padding-left:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Level 2—Observable inputs such as quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, or model-derived valuations whose significant inputs are observable.</span></div><div style="line-height:120%;padding-top:8px;padding-left:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Level 3—Unobservable inputs that reflect the reporting entity’s own assumptions.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following tables set forth the fair value of the Company’s consolidated financial instruments that were measured at fair value on a recurring basis (in thousands):</span></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="29"/></tr><tr><td style="width:28%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="27" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Amortized Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Gross Unrealized Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Gross Unrealized Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Estimated Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Level 3</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Financial assets:</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>93,934</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>93,934</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>93,934</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Certificates of deposit</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>300</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>300</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>300</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>10,908</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>10,907</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>10,907</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">U.S. treasury notes</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>9,990</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>9,990</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>9,990</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">U.S. government agency securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>6,001</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5,997</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5,997</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total financial assets</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>121,133</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>121,128</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>103,924</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>17,204</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Financial liabilities:</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Contingent consideration</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,998</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,998</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total financial liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,998</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,998</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Reported as:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Cash equivalents</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td colspan="5" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>101,395</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Restricted cash</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>6,006</span></span></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Marketable securities</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>13,727</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td colspan="17" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total cash equivalents, restricted cash, and marketable securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>121,128</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Accrued liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,998</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="29"/></tr><tr><td style="width:28%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="27" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">December 31, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Amortized<br/>Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Gross<br/>Unrealized<br/>Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Gross<br/>Unrealized<br/>Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Estimated<br/>Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Level 3</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Financial assets:</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5,998</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5,998</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5,998</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Certificates of deposit</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>300</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>300</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>300</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">U.S. treasury notes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>12,010</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(19</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>11,991</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>11,991</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">U.S. government agency securities</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>46,451</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(152</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>46,299</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>46,299</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total financial assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>64,759</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(171</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>64,588</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>18,289</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>46,299</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Financial liabilities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Contingent consideration</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,779</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,779</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total financial liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,779</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,779</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">December 31, 2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Reported as:</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>592</span></span></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Restricted cash</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5,406</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Marketable securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>58,590</span></span></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td colspan="17" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total cash equivalents, restricted cash, and marketable securities</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>64,588</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Accrued liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,779</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">There were no transfers between Level 1, Level 2 and Level 3 during the periods presented. The total fair value of investments with unrealized losses at </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;"> was </span><span style="font-family:Arial;font-size:10pt;"><span>$13.4 million</span></span><span style="font-family:Arial;font-size:10pt;">. None of the available-for-sale securities held as of </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;"> has been in a material continuous unrealized loss position for more than one year. At </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, unrealized losses on available-for-sale investments are not attributed to credit risk and are considered to be temporary. The Company believes it is more likely than not that investments in an unrealized loss position will be held until maturity or the recovery of the cost basis of the investment. To date, the Company has not identified any other-than-temporary declines in market value and thus has not recorded any impairment charges on its financial assets other than on the convertible notes which are described in Note 8, “Investment in privately held company.” </span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">At </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, the remaining contractual maturities of available-for-sale securities ranged from less than </span><span style="font-family:Arial;font-size:10pt;">one</span><span style="font-family:Arial;font-size:10pt;"> to </span><span style="font-family:Arial;font-size:10pt;">4</span><span style="font-family:Arial;font-size:10pt;"> months. For the years ended </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;">2017</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">2016</span><span style="font-family:Arial;font-size:10pt;">, there were </span><span style="font-family:Arial;font-size:10pt;">no</span><span style="font-family:Arial;font-size:10pt;"> realized gains or losses on available-for-sale securities.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The Company’s certificates of deposit, commercial paper, and debt securities of U.S. government agency entities are classified as Level 2 as they are valued based upon quoted market prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant inputs are observable in the market or can be corroborated by observable market data for substantially the full term of the assets. Where applicable, these models project future cash flows and discount the future amounts to a present value using market-based observable inputs obtained from various third party data providers, including but not limited to benchmark yields, interest rate curves, reported trades, broker/dealer quotes and reference data.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following table presents the Company’s Level 3 financial instruments that are measured at fair value on a recurring basis (in thousands):</span></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:72%;"/><td style="width:1%;"/><td style="width:26%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Level 3</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Contingent Consideration Liability</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Balance as of December 31, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,779</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Change in estimate of fair value</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,219</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Balance as of December 31, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,998</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">As of </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, the Company had a contingent obligation of up to </span><span style="font-family:Arial;font-size:10pt;"><span>$5.0 million</span></span><span style="font-family:Arial;font-size:10pt;"> payable in the Company’s common stock to the former owners of AltaVoice in conjunction with the Company’s acquisition of AltaVoice in January 2017. The contingency was dependent upon future revenues attributable to AltaVoice. If the revenue attributable to AltaVoice for the combined period of 2017 and 2018 was at least </span><span style="font-family:Arial;font-size:10pt;"><span>$10 million</span></span><span style="font-family:Arial;font-size:10pt;">, the Company would make a payment of up to </span><span style="font-family:Arial;font-size:10pt;"><span>$5.0 million</span></span><span style="font-family:Arial;font-size:10pt;"> in the Company’s common stock in March 2019. The Company estimated the fair value of the contingent consideration at </span><span style="font-family:Arial;font-size:10pt;"><span>$2.2 million</span></span><span style="font-family:Arial;font-size:10pt;"> at the acquisition date in January 2017, based on a Monte Carlo simulation, as well as estimates of the 30-day trailing price of its stock at certain dates, its volatility assumptions and its revenue forecasts, all of which were significant inputs in the Level 3 measurement not supported by market activity. The value of the liability was subsequently remeasured to fair value at each reporting date. Changes in estimated fair value are recorded as general and administrative expense until the contingency is paid or expires. The change in the fair value of the contingent consideration between the acquisition date and </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;"> was an increase of </span><span style="font-family:Arial;font-size:10pt;"><span>$2.8 million</span></span><span style="font-family:Arial;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The fair value of the Company’s outstanding debt is estimated using the net present value of future debt payments, discounted at an interest rate that is consistent with market interest rates, which is a Level 2 input. The carrying amount of the Company’s outstanding debt at </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;"> approximated its fair value and as of </span><span style="font-family:Arial;font-size:10pt;">December 31, 2017</span><span style="font-family:Arial;font-size:10pt;">, the Company's debt carrying amount and fair value were as follows (in thousands):</span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:69%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">December 31, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Carrying Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>39,084</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>40,526</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> The following tables set forth the fair value of the Company’s consolidated financial instruments that were measured at fair value on a recurring basis (in thousands):<div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="29"/></tr><tr><td style="width:28%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="27" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Amortized Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Gross Unrealized Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Gross Unrealized Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Estimated Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Level 3</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Financial assets:</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>93,934</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>93,934</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>93,934</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Certificates of deposit</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>300</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>300</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>300</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>10,908</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>10,907</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>10,907</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">U.S. treasury notes</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>9,990</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>9,990</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>9,990</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">U.S. government agency securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>6,001</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5,997</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5,997</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total financial assets</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>121,133</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>121,128</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>103,924</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>17,204</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Financial liabilities:</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Contingent consideration</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,998</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,998</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total financial liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,998</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,998</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Reported as:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Cash equivalents</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td colspan="5" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>101,395</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Restricted cash</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>6,006</span></span></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Marketable securities</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>13,727</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td colspan="17" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total cash equivalents, restricted cash, and marketable securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>121,128</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Accrued liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,998</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="29"/></tr><tr><td style="width:28%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="27" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">December 31, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Amortized<br/>Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Gross<br/>Unrealized<br/>Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Gross<br/>Unrealized<br/>Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Estimated<br/>Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Level 3</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Financial assets:</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5,998</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5,998</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5,998</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Certificates of deposit</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>300</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>300</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>300</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">U.S. treasury notes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>12,010</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(19</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>11,991</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>11,991</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">U.S. government agency securities</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>46,451</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(152</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>46,299</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>46,299</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total financial assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>64,759</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(171</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>64,588</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>18,289</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>46,299</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Financial liabilities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Contingent consideration</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,779</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,779</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total financial liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,779</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,779</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">December 31, 2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Reported as:</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>592</span></span></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Restricted cash</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5,406</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Marketable securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>58,590</span></span></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td colspan="17" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total cash equivalents, restricted cash, and marketable securities</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>64,588</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Accrued liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,779</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div> 93934000 93934000 93934000 300000 300000 0 300000 10908000 1000 10907000 0 10907000 9990000 9990000 9990000 6001000 4000 5997000 5997000 121133000 5000 121128000 103924000 17204000 4998000 4998000 4998000 4998000 101395000 6006000 13727000 121128000 4998000 5998000 5998000 5998000 300000 300000 300000 12010000 19000 11991000 11991000 46451000 152000 46299000 46299000 64759000 171000 64588000 18289000 46299000 3779000 3779000 3779000 3779000 592000 5406000 58590000 64588000 3779000 13400000 The following table presents the Company’s Level 3 financial instruments that are measured at fair value on a recurring basis (in thousands):<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:72%;"/><td style="width:1%;"/><td style="width:26%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Level 3</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Contingent Consideration Liability</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Balance as of December 31, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,779</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Change in estimate of fair value</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,219</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Balance as of December 31, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,998</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 3779000 1219000 4998000 5000000.0 10000000 5000000.0 2200000 2800000 The carrying amount of the Company’s outstanding debt at <span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;"> approximated its fair value and as of </span><span style="font-family:Arial;font-size:10pt;">December 31, 2017</span><span style="font-family:Arial;font-size:10pt;">, the Company's debt carrying amount and fair value were as follows (in thousands):</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:69%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">December 31, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Carrying Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>39,084</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>40,526</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 39084000 40526000 Investment in privately held company<div style="line-height:120%;text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;"> </span></div><span style="font-family:Arial;font-size:10pt;">On March 15, 2018, the Company entered into a collaboration agreement with KEW, Inc. (“KEW”), a privately held comprehensive genomic profiling company</span><span style="font-family:Arial;font-size:10pt;color:#373737;">.</span><span style="font-family:Arial;font-size:10pt;"> The Company determined it had a variable interest in a VIE through its investment in a convertible note issued by KEW</span><span style="font-family:Arial;font-size:10pt;color:#373737;">. </span><span style="font-family:Arial;font-size:10pt;">During the year ended </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, the Company incurred losses relating to this collaboration agreement with KEW of </span><span style="font-family:Arial;font-size:10pt;"><span>$2.9 million</span></span><span style="font-family:Arial;font-size:10pt;"> which were recognized in general and administrative expenses in the Company’s consolidated statements of operations. As of </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span>, the Company fulfilled its obligations with respect to the collaboration agreement and there are no balances recorded in the Company's consolidated balance sheets pertaining to this arrangement. 2900000 Commitments and contingencies<div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Operating leases</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In September 2015, the Company entered into a lease agreement for its headquarters and main production facility in San Francisco, California. This lease expires in July 2026 and the Company may renew the lease for an additional </span><span style="font-family:Arial;font-size:10pt;"><span>ten years</span></span><span style="font-family:Arial;font-size:10pt;">. The Company has determined the lease term to be a ten-year period expiring in 2026. The lease term commenced when the Company took occupancy of the facility in February 2016. In connection with the execution of the lease, the Company provided a security deposit of approximately </span><span style="font-family:Arial;font-size:10pt;"><span>$4.6 million</span></span><span style="font-family:Arial;font-size:10pt;"> which is included in restricted cash in the Company’s consolidated balance sheets. Minimum annual rent under the lease is subject to increases based on stated rental adjustment terms. In addition, per the terms of the lease, the Company received a </span><span style="font-family:Arial;font-size:10pt;"><span>$5.2 million</span></span><span style="font-family:Arial;font-size:10pt;"> lease incentive in the form of reimbursement from the landlord for a portion of the costs of leasehold improvements the Company has made to the facility. The assets purchased with the lease incentive are included in property and equipment, net, in the Company’s consolidated balance sheets and the lease incentive is recognized as a reduction of rental expense on a straight-line basis over the term of the lease. At </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, all of the lease incentive had been utilized by the Company and all related reimbursements had been received from the landlord. Aggregate future minimum lease payments for this facility at </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;"> were approximately </span><span style="font-family:Arial;font-size:10pt;"><span>$57.8 million</span></span><span style="font-family:Arial;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Future minimum payments under non-cancelable operating leases and future minimum payments to be received from non-cancelable subleases as of </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;"> are as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:82%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Amounts</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>10,948</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>10,860</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>11,109</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>11,067</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>8,898</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>25,715</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Future non-cancelable minimum operating lease payments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>78,597</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Less: minimum payments to be received from non-cancelable subleases</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(174</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total future non-cancelable minimum operating lease payments, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>78,423</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following table summarizes rent expense related to non-cancelable operating leases (in thousands):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Rent expense</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>9,720</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>8,950</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>8,901</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Sublease income</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>227</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>398</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>257</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Rent expense, net of sublease income</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>9,493</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>8,552</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>8,644</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Debt financing</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In March 2017, the Company entered into a Loan and Security Agreement (the “2017 Loan Agreement”) with a lender pursuant to which the Company borrowed an initial term loan of </span><span style="font-family:Arial;font-size:10pt;"><span>$40.0 million</span></span><span style="font-family:Arial;font-size:10pt;">, and received net proceeds of approximately </span><span style="font-family:Arial;font-size:10pt;"><span>$39.7 million</span></span><span style="font-family:Arial;font-size:10pt;">. Subject to certain conditions, the Company was eligible to borrow a second term loan pursuant to the 2017 Loan Agreement of </span><span style="font-family:Arial;font-size:10pt;"><span>$20.0 million</span></span><span style="font-family:Arial;font-size:10pt;"> in the first quarter of 2018 and did so in March 2018, receiving net proceeds of approximately </span><span style="font-family:Arial;font-size:10pt;"><span>$19.8 million</span></span><span style="font-family:Arial;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In February 2018 and June 2018, the Company entered into amendments to the 2017 Loan Agreement (the “2018 Amendments”) pursuant to which the Company, subject to certain conditions, was eligible to borrow a third term loan of </span><span style="font-family:Arial;font-size:10pt;"><span>$20.0 million</span></span><span style="font-family:Arial;font-size:10pt;"> during the period from April 2, 2018 to December 31, 2018. Pursuant to the 2018 Amendments, since the third term loan became available and the Company did not draw upon the third term loan, a fee of </span><span style="font-family:Arial;font-size:10pt;"><span>1%</span></span><span style="font-family:Arial;font-size:10pt;"> was applied to the difference between </span><span style="font-family:Arial;font-size:10pt;"><span>$20.0 million</span></span><span style="font-family:Arial;font-size:10pt;"> and the amount drawn, or </span><span style="font-family:Arial;font-size:10pt;"><span>$0.2 million</span></span><span style="font-family:Arial;font-size:10pt;">.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Term loans under the amended 2017 Loan Agreement bore interest at a floating rate equal to an index rate plus </span><span style="font-family:Arial;font-size:10pt;"><span>7.73%</span></span><span style="font-family:Arial;font-size:10pt;">, where the index rate was the greater of </span><span style="font-family:Arial;font-size:10pt;"><span>0.77%</span></span><span style="font-family:Arial;font-size:10pt;"> or the </span><span style="font-family:Arial;font-size:10pt;">30</span><span style="font-family:Arial;font-size:10pt;">-day U.S. Dollar London Interbank Offered Rate (“LIBOR”) as reported in </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">The Wall Street Journal</span><span style="font-family:Arial;font-size:10pt;">, with the floating rate resetting </span><span style="font-family:Arial;">monthly</span><span style="font-family:Arial;font-size:10pt;"> subject to a floor of </span><span style="font-family:Arial;font-size:10pt;"><span>8.5%</span></span><span style="font-family:Arial;font-size:10pt;">. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The Company could make monthly interest-only payments until May 1, 2019 (or, subject to certain conditions, May 1, 2020), and thereafter monthly payments of principal and interest were required to fully amortize the borrowed amount by a final maturity date of </span><span style="font-family:Arial;font-size:10pt;">March 1, 2022</span><span style="font-family:Arial;font-size:10pt;">. A fee of </span><span style="font-family:Arial;font-size:10pt;"><span>5%</span></span><span style="font-family:Arial;font-size:10pt;"> of each funded draw was due at the earlier of prepayment or loan maturity, a facility fee of </span><span style="font-family:Arial;font-size:10pt;"><span>0.5%</span></span><span style="font-family:Arial;font-size:10pt;"> was due upon funding for each draw, and a prepayment fee of between </span><span style="font-family:Arial;font-size:10pt;"><span>1%</span></span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>3%</span></span><span style="font-family:Arial;font-size:10pt;"> of the outstanding balance applied in the event of a prepayment. Concurrent with each term loan, the Company granted to the lender a warrant to acquire shares of the Company’s common stock equal to the quotient of </span><span style="font-family:Arial;font-size:10pt;"><span>3%</span></span><span style="font-family:Arial;font-size:10pt;"> of the funded amount divided by a per share exercise price equal to the lower of the average closing price for the previous ten days of trading (calculated on the day prior to funding) or the closing price on the day prior to funding. In connection with the initial term loan, in 2017, the Company issued the lender warrants to purchase </span><span style="font-family:Arial;font-size:10pt;"><span>116,845</span></span><span style="font-family:Arial;font-size:10pt;"> shares of common stock at an exercise price of </span><span style="font-family:Arial;font-size:10pt;"><span>$10.27</span></span><span style="font-family:Arial;font-size:10pt;"> per share. The Company classified these warrants as equity with a fair value of </span><span style="font-family:Arial;font-size:10pt;"><span>$0.7 million</span></span><span style="font-family:Arial;font-size:10pt;">. In connection with the second term loan, in 2018, the Company issued the lender warrants to purchase </span><span style="font-family:Arial;font-size:10pt;"><span>85,482</span></span><span style="font-family:Arial;font-size:10pt;"> shares of common stock at an exercise price of </span><span style="font-family:Arial;font-size:10pt;"><span>$7.02</span></span><span style="font-family:Arial;font-size:10pt;"> per share. The Company classified these warrants as equity with a fair value of </span><span style="font-family:Arial;font-size:10pt;"><span>$0.4 million</span></span><span style="font-family:Arial;font-size:10pt;">. All warrants issued pursuant to the amended 2017 Loan Agreement have a term of </span><span style="font-family:Arial;font-size:10pt;"><span>ten years</span></span><span style="font-family:Arial;font-size:10pt;"> from the date of issuance and include a cashless exercise provision. </span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In November 2018, the Company entered into a Note Purchase Agreement (the "2018 Note Purchase Agreement") pursuant to which the Company was eligible to borrow an aggregate principal amount up to </span><span style="font-family:Arial;font-size:10pt;"><span>$200.0 million</span></span><span style="font-family:Arial;font-size:10pt;"> over a </span><span style="font-family:Arial;font-size:10pt;">seven</span><span style="font-family:Arial;font-size:10pt;"> year maturity term which included an initial borrowing of </span><span style="font-family:Arial;font-size:10pt;"><span>$75.0 million</span></span><span style="font-family:Arial;font-size:10pt;"> in November 2018. The Company received net proceeds of </span><span style="font-family:Arial;font-size:10pt;"><span>$10.3 million</span></span><span style="font-family:Arial;font-size:10pt;"> after terminating and repaying the balance of its obligations of approximately </span><span style="font-family:Arial;font-size:10pt;"><span>$64.7 million</span></span><span style="font-family:Arial;font-size:10pt;"> under the 2017 Loan Agreement and associated amendments with its previous lender. The Company incurred </span><span style="font-family:Arial;font-size:10pt;"><span>$5.3 million</span></span><span style="font-family:Arial;font-size:10pt;"> of debt extinguishment costs upon terminating its previous debt facility which the Company recorded as other income (expense), net in its consolidated statements of operations during the year ended December 31, 2018.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">At </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, obligations under the 2018 Note Purchase Agreement were </span><span style="font-family:Arial;font-size:10pt;"><span>$75.0 million</span></span><span style="font-family:Arial;font-size:10pt;"> which are required to be repaid to the lender in a balloon payment no later than 2025. If the Company repays prior to the three year anniversary following the initial borrowing, the amount due will be: </span><span style="font-family:Arial;font-size:10pt;"><span>117.5%</span></span><span style="font-family:Arial;font-size:10pt;"> of the principal amount if payment is made within 12 months after the borrowing; </span><span style="font-family:Arial;font-size:10pt;"><span>132.5%</span></span><span style="font-family:Arial;font-size:10pt;"> of the principal amount if payment is made between 12 and 24 months after the borrowing; and </span><span style="font-family:Arial;font-size:10pt;"><span>145.0%</span></span><span style="font-family:Arial;font-size:10pt;"> of the principal amount if payment is made between 24 and 36 months after the borrowing.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:40px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The outstanding principal amount under the 2018 Note Purchase Agreement bears interest at a rate of </span><span style="font-family:Arial;font-size:10pt;"><span>8.75%</span></span><span style="font-family:Arial;font-size:10pt;"> annually. In addition, beginning on January 1, 2020 and continuing until repayment or maturity of any outstanding principal, the Company will make quarterly payments of </span><span style="font-family:Arial;font-size:10pt;"><span>0.5%</span></span><span style="font-family:Arial;font-size:10pt;"> of the Company's annual net revenues subject to a maximum annual amount of such payments of </span><span style="font-family:Arial;font-size:10pt;"><span>$1.6 million</span></span><span style="font-family:Arial;font-size:10pt;"> which will be recognized as interest expense. Through the fixed interest charges and the quarterly revenue payments, the Company is required to pay total amounts to generate an </span><span style="font-family:Arial;font-size:10pt;"><span>11%</span></span><span style="font-family:Arial;font-size:10pt;"> internal rate of return to the lender on any outstanding principal balances due in a lump-sum upon the repayment or maturity of any outstanding principal. During the year ended </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, the 2018 Note Purchase Agreement bore interest at an average interest rate of </span><span style="font-family:Arial;font-size:10pt;"><span>10.6%</span></span><span style="font-family:Arial;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:40px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The 2018 Note Purchase Agreement contains quarterly covenants to achieve certain revenue levels as well as additional covenants, including limits on the Company’s ability to dispose of assets, undergo a change of control, merge with or acquire other entities, incur debt, incur liens, pay dividends or other distributions to holders of its capital stock, repurchase stock and make investments, in each case subject to certain exceptions. The Company’s obligations under the 2018 Note Purchase Agreement are secured by a security interest on substantially all of its and certain of its subsidiaries’ assets.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:40px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In connection with the 2018 Note Purchase Agreement, in November 2018, the Company entered into a Securities Purchase Agreement with the lender pursuant to which the Company issued </span><span style="font-family:Arial;font-size:10pt;"><span>373,524</span></span><span style="font-family:Arial;font-size:10pt;"> shares of its common stock at a price of </span><span style="font-family:Arial;font-size:10pt;"><span>$13.39</span></span><span style="font-family:Arial;font-size:10pt;"> per share for an aggregate amount of </span><span style="font-family:Arial;font-size:10pt;"><span>$5.0 million</span></span><span style="font-family:Arial;font-size:10pt;">. The share price paid by the lender was calculated based on the 15-day average closing share price prior to the issuance. The relative fair value method was used to allocate the proceeds between the common stock issued and the note proceeds; the fair value of the common stock issued to the lender was determined to be </span><span style="font-family:Arial;font-size:10pt;"><span>$5.4 million</span></span><span style="font-family:Arial;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Debt discounts, including debt issuance costs, related to the 2018 Note Purchase Agreement of </span><span style="font-family:Arial;font-size:10pt;"><span>$0.7 million</span></span><span style="font-family:Arial;font-size:10pt;"> were recorded as a direct deduction from the debt liability and are being amortized to interest expense over the term of the 2018 Note Purchase Agreement. Future estimated payments under the 2018 Note Purchase Agreement as of </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;"> are as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:82%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Amounts</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>6,654</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>8,297</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>8,279</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>8,279</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>8,279</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>89,998</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total remaining payments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>129,786</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Less: amount representing debt discount</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(721</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Less: amount representing interest</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(54,588</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total non-current debt obligation</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>74,477</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Interest expense related to the Company's debt financings was </span><span style="font-family:Arial;font-size:10pt;"><span>$6.7 million</span></span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;"><span>$3.5 million</span></span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>$0.3 million</span></span><span style="font-family:Arial;font-size:10pt;"> for the years ended </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;">2017</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">2016</span><span style="font-family:Arial;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Capital leases</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The Company has entered into various capital lease agreements to obtain laboratory equipment. The terms of the Company's capital leases are typically </span><span style="font-family:Arial;font-size:10pt;"><span>three years</span></span><span style="font-family:Arial;font-size:10pt;"> and are secured by the underlying equipment. The portion of the future payments designated as principal repayment was classified as a capital lease obligation on the consolidated balance sheets.</span></div><div style="line-height:120%;padding-bottom:4px;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Future payments under capital leases at </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;"> were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:82%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Amounts</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,087</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,392</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>21</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total capital lease obligations</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,500</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Less: amount representing interest</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(188</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Present value of net minimum capital lease payments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,312</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Less: current portion</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(1,937</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total non-current capital lease obligations</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,375</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Interest expense related to capital leases was </span><span style="font-family:Arial;font-size:10pt;"><span>$0.3 million</span></span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;"><span>$0.2 million</span></span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>$0.1 million</span></span><span style="font-family:Arial;font-size:10pt;"> for the years ended </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;">2017</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">2016</span><span style="font-family:Arial;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Property and equipment under capital leases was </span><span style="font-family:Arial;font-size:10pt;"><span>$7.1 million</span></span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>$11.4 million</span></span><span style="font-family:Arial;font-size:10pt;"> as of </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">2017</span><span style="font-family:Arial;font-size:10pt;">, respectively. Accumulated depreciation, collectively, on these assets was </span><span style="font-family:Arial;font-size:10pt;"><span>$2.0 million</span></span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>$3.0 million</span></span><span style="font-family:Arial;font-size:10pt;"> at </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">2017</span><span style="font-family:Arial;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Guarantees and indemnifications</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">As permitted under Delaware law and in accordance with the Company’s bylaws, the Company indemnifies its directors and officers for certain events or occurrences while the officer or director is or was serving in such capacity. The maximum amount of potential future indemnification is unlimited; however, the Company maintains director and officer liability insurance. This insurance allows the transfer of the risk associated with the Company’s exposure and may enable it to recover a portion of any future amounts paid. The Company believes the fair value of these indemnification agreements is minimal. Accordingly, the Company did not record any liabilities associated with these indemnification agreements at </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;"> or </span><span style="font-family:Arial;font-size:10pt;">December 31, 2017</span><span style="font-family:Arial;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Other commitments</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In the normal course of business, the Company enters into various purchase commitments primarily related to service agreements, laboratory supplies, and a co-development agreement. At </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, the Company’s total future payments under noncancelable unconditional purchase commitments having a remaining term of over one year were as follows (in thousands):</span></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:82%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Amount</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,040</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,040</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,440</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>7,520</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In addition, in September 2018, the Company entered into a co-development agreement with a privately held genetics testing company. The co-development agreement grants the Company the right of first refusal to enter into an agreement for an acquisition of the entity in return for total fees of </span><span style="font-family:Arial;font-size:10pt;"><span>$3.0 million</span></span><span style="font-family:Arial;font-size:10pt;"> over the term of the 12-month agreement, of which </span><span style="font-family:Arial;font-size:10pt;"><span>$1.0 million</span></span><span style="font-family:Arial;font-size:10pt;"> has been paid by the Company as of </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">. The unpaid fees of </span><span style="font-family:Arial;font-size:10pt;"><span>$2.0 million</span></span><span style="font-family:Arial;font-size:10pt;"> were paid in January 2019, and as of </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, were recorded as an accrued liability in the Company’s consolidated balance sheets.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Contingencies</span></div><span style="font-family:Arial;font-size:10pt;">The Company was not a party to any material legal proceedings at </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span>, or at the date of this report. The Company may from time to time become involved in various legal proceedings arising in the ordinary course of business, and the resolution of any such claims could be material. P10Y 4600000 5200000 57800000 Future minimum payments under non-cancelable operating leases and future minimum payments to be received from non-cancelable subleases as of <span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;"> are as follows (in thousands):</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:82%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Amounts</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>10,948</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>10,860</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>11,109</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>11,067</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>8,898</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>25,715</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Future non-cancelable minimum operating lease payments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>78,597</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Less: minimum payments to be received from non-cancelable subleases</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(174</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total future non-cancelable minimum operating lease payments, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>78,423</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 10948000 10860000 11109000 11067000 8898000 25715000 78597000 174000 78423000 The following table summarizes rent expense related to non-cancelable operating leases (in thousands):<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Rent expense</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>9,720</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>8,950</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>8,901</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Sublease income</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>227</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>398</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>257</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Rent expense, net of sublease income</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>9,493</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>8,552</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>8,644</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 9720000 8950000 8901000 227000 398000 257000 9493000 8552000 8644000 40000000.0 39700000 20000000.0 19800000 20000000.0 0.01 20000000.0 200000 0.0773 0.0077 0.085 0.05 0.005 0.01 0.03 0.03 116845 10.27 700000 85482 7.02 400000 P10Y 200000000.0 75000000.0 10300000 64700000 5300000 75000000.0 1.175 1.325 1.450 0.0875 0.005 1600000 0.11 0.106 373524 13.39 5000000.0 5400000 700000 Future estimated payments under the 2018 Note Purchase Agreement as of <span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;"> are as follows (in thousands):</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:82%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Amounts</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>6,654</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>8,297</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>8,279</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>8,279</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>8,279</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>89,998</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total remaining payments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>129,786</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Less: amount representing debt discount</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(721</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Less: amount representing interest</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(54,588</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total non-current debt obligation</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>74,477</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 6654000 8297000 8279000 8279000 8279000 89998000 129786000 721000 54588000 74477000 6700000 3500000 300000 P3Y Future payments under capital leases at <span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;"> were as follows (in thousands):</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:82%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Amounts</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,087</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,392</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>21</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total capital lease obligations</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,500</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Less: amount representing interest</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(188</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Present value of net minimum capital lease payments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,312</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Less: current portion</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(1,937</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total non-current capital lease obligations</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,375</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 2087000 1392000 21000 3500000 188000 3312000 1937000 1375000 300000 200000 100000 7100000 11400000 2000000.0 3000000.0 At <span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, the Company’s total future payments under noncancelable unconditional purchase commitments having a remaining term of over one year were as follows (in thousands):</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:82%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Amount</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,040</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,040</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,440</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>7,520</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 3040000 3040000 1440000 7520000 3000000.0 1000000.0 2000000.0 Stockholders’ Equity<div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Common stock</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">As of </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">2017</span><span style="font-family:Arial;font-size:10pt;">, the Company had reserved shares of common stock, on an as‑if converted basis, for issuance as follows (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:69%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Options issued and outstanding</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,855</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,115</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">RSU awards issued and outstanding</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,031</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,387</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Shares available for grant under stock option plans</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>118</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,397</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Shares reserved for issuance under the 2015 Employee Stock Purchase Plan</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>278</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>308</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Common stock underlying warrants</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>611</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,962</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Common stock issuable upon conversion of preferred stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,459</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,459</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Common stock underlying stock payable liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>132</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>689</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Common stock payable as contingent consideration</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>452</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>551</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>12,936</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>15,868</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Private placement</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In August 2017, in a private placement to certain accredited investors, the Company issued </span><span style="font-family:Arial;font-size:10pt;"><span>5.2 million</span></span><span style="font-family:Arial;font-size:10pt;"> shares of its common stock at a price of </span><span style="font-family:Arial;font-size:10pt;"><span>$8.50</span></span><span style="font-family:Arial;font-size:10pt;"> per share, and </span><span style="font-family:Arial;font-size:10pt;"><span>3.5 million</span></span><span style="font-family:Arial;font-size:10pt;"> shares of its Series A convertible preferred stock at a price of </span><span style="font-family:Arial;font-size:10pt;"><span>$8.50</span></span><span style="font-family:Arial;font-size:10pt;"> per share, for gross proceeds of approximately </span><span style="font-family:Arial;font-size:10pt;"><span>$73.5 million</span></span><span style="font-family:Arial;font-size:10pt;"> and net proceeds of </span><span style="font-family:Arial;font-size:10pt;"><span>$68.9 million</span></span><span style="font-family:Arial;font-size:10pt;">. The Series A preferred stock is a non-voting common stock equivalent and conversion of the Series A preferred stock is prohibited if the holder exceeds a specified threshold of voting security ownership. </span><span style="font-family:Arial;">The Series A preferred stock is convertible into common stock on a one-for-one basis</span><span style="font-family:Arial;font-size:10pt;">, subject to adjustment for events such as stock splits, combinations and the like. The Series A Preferred Stock has the right to receive dividends first or simultaneously with payment of dividends on common stock, in an amount equal to the product of (i) the dividend payable on each share of common stock and (ii) the number of shares of common stock issuable upon conversion </span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">of a share of Series A Preferred Stock. </span><span style="font-family:Arial;">The Series A Preferred Stock has no voting rights except as required by law, as modified by the Company’s Amended and Restated Certificate of Incorporation.</span><span style="font-family:Arial;font-size:10pt;"> In the event of any liquidation or dissolution of the Company, the Series A Preferred Stock is entitled to receive </span><span style="font-family:Arial;font-size:10pt;"><span>$0.001</span></span><span style="font-family:Arial;font-size:10pt;"> per share prior to the payment of any amount to any holders of capital stock of the Company ranking junior to the Series A Preferred Stock and thereafter shall participate pari passu with the holders of the Company’s common stock (on an as-if-converted-to-common-stock basis). During January and February 2019, </span><span style="font-family:Arial;font-size:10pt;color:#000000;"><span>1.1 million</span></span><span style="font-family:Arial;font-size:10pt;"> shares of Series A convertible preferred stock were converted to </span><span style="font-family:Arial;font-size:10pt;color:#000000;"><span>1.1 million</span></span><span style="font-family:Arial;font-size:10pt;"> shares of common stock.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Public offering</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In April 2018, the Company issued, in an underwritten public offering, an aggregate of </span><span style="font-family:Arial;font-size:10pt;"><span>12.8 million</span></span><span style="font-family:Arial;font-size:10pt;"> shares of its common stock at a price of </span><span style="font-family:Arial;font-size:10pt;"><span>$4.50</span></span><span style="font-family:Arial;font-size:10pt;"> per share, for gross proceeds of </span><span style="font-family:Arial;font-size:10pt;"><span>$57.5 million</span></span><span style="font-family:Arial;font-size:10pt;"> and net proceeds of </span><span style="font-family:Arial;font-size:10pt;"><span>$53.5 million</span></span><span style="font-family:Arial;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">2018 Sales Agreement</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In August 2018, the Company entered into a Common Stock Sales Agreement (the “2018 Sales Agreement”) with Cowen and Company, LLC (“Cowen”), under which the Company may offer and sell from time to time at its sole discretion shares of its common stock through Cowen as its sales agent, in an aggregate amount not to exceed </span><span style="font-family:Arial;font-size:10pt;"><span>$75.0 million</span></span><span style="font-family:Arial;font-size:10pt;">. Cowen may sell the shares by any method permitted by law deemed to be an “at the market” offering as defined in Rule 415 of the Securities Act, including without limitation sales made directly on The New York Stock Exchange, and also may sell the shares in privately negotiated transactions, subject to the Company’s prior approval. The Company is obligated to pay Cowen a commission equal to </span><span style="font-family:Arial;font-size:10pt;"><span>3%</span></span><span style="font-family:Arial;font-size:10pt;"> of the gross proceeds of the sales price of all shares sold through it as sales agent under the 2018 Sales Agreement. During the year ended December 31, 2018, the Company issued a total of </span><span style="font-family:Arial;font-size:10pt;"><span>4.3 million</span></span><span style="font-family:Arial;font-size:10pt;"> shares of common stock under the 2018 Sales Agreement for aggregate gross proceeds of </span><span style="font-family:Arial;font-size:10pt;"><span>$61.1 million</span></span><span style="font-family:Arial;font-size:10pt;"> and net proceeds of </span><span style="font-family:Arial;font-size:10pt;"><span>$58.9 million</span></span><span style="font-family:Arial;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Common stock warrants</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">As of </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, the Company had outstanding warrants to purchase common stock as follows:</span></div><div style="line-height:120%;padding-bottom:8px;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:33%;"/><td style="width:1%;"/><td style="width:22%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Warrant</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Issuance Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Expiration Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Exercise</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Price</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Per Share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Number of Shares of Common Stock Underlying Warrants</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Warrants issued in exchange for CombiMatrix Series F warrants</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">November 2017</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">March 2021</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5.95</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>408,548</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Warrants issued to lender under 2017 Loan Agreement</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">March 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">March 2027</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>10.27</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>116,845</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Warrants issued to lender under 2017 Loan Agreement - 2018 Amendments</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">March 2018</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">March 2028</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>7.02</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>85,482</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:Arial;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>610,875</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><span style="font-family:Arial;font-size:10pt;">The exercise price of warrants issued in exchange for CombiMatrix Series F warrants was determined pursuant to the terms of the Merger Agreement (See Note 4, "Business Combinations"). The CombiMatrix Series D warrants expired during the year ended December 31, 2018. The exercise price of the warrants issued to the lender under the 2017 Loan Agreement was the closing price of the Company’s common stock on the date of the agreements. During the year ended </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, the Company received </span><span style="font-family:Arial;font-size:10pt;"><span>$6.5 million</span></span><span style="font-family:Arial;font-size:10pt;"> from exercises </span><span style="font-family:Arial;font-size:10pt;"><span>1.0 million</span></span> shares of common stock under these warrants. As of <span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">2017</span><span style="font-family:Arial;font-size:10pt;">, the Company had reserved shares of common stock, on an as‑if converted basis, for issuance as follows (in thousands):</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:69%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Options issued and outstanding</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,855</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,115</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">RSU awards issued and outstanding</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,031</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,387</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Shares available for grant under stock option plans</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>118</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,397</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Shares reserved for issuance under the 2015 Employee Stock Purchase Plan</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>278</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>308</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Common stock underlying warrants</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>611</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,962</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Common stock issuable upon conversion of preferred stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,459</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,459</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Common stock underlying stock payable liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>132</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>689</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Common stock payable as contingent consideration</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>452</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>551</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>12,936</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>15,868</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 3855000 4115000 4031000 2387000 118000 2397000 278000 308000 611000 1962000 3459000 3459000 132000 689000 452000 551000 12936000 15868000 5200000 8.50 3500000 8.50 73500000 68900000 0.001 1100000 1100000 12800000 4.50 57500000 53500000 75000000.0 0.03 4300000 61100000 58900000 As of <span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, the Company had outstanding warrants to purchase common stock as follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:33%;"/><td style="width:1%;"/><td style="width:22%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Warrant</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Issuance Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Expiration Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Exercise</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Price</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Per Share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Number of Shares of Common Stock Underlying Warrants</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Warrants issued in exchange for CombiMatrix Series F warrants</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">November 2017</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">March 2021</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5.95</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>408,548</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Warrants issued to lender under 2017 Loan Agreement</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">March 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">March 2027</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>10.27</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>116,845</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Warrants issued to lender under 2017 Loan Agreement - 2018 Amendments</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">March 2018</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">March 2028</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>7.02</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>85,482</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:Arial;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>610,875</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 5.95 408548 10.27 116845 7.02 85482 610875 6500000 1000000.0 Stock incentive plans<div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Stock incentive plans</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In 2010, the Company adopted the 2010 Incentive Plan (the “2010 Plan”). The 2010 Plan provides for the granting of stock-based awards to employees, directors and consultants under terms and provisions established by the Board of Directors. Under the terms of the 2010 Plan, options may be granted at an exercise price not less than fair market value. For employees holding more than </span><span style="font-family:Arial;font-size:10pt;"><span>10%</span></span><span style="font-family:Arial;font-size:10pt;"> of the voting rights of all classes of stock, the exercise prices for incentive and nonstatutory stock options must be at least </span><span style="font-family:Arial;font-size:10pt;"><span>110%</span></span><span style="font-family:Arial;font-size:10pt;"> of fair market of the common stock on the grant date, as determined by the Board of Directors. The terms of options granted under the 2010 Plan may not exceed </span><span style="font-family:Arial;font-size:10pt;"><span>ten years</span></span><span style="font-family:Arial;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In January 2015, the Company adopted the 2015 Stock Incentive Plan (the “2015 Plan”), which became effective upon the closing of the Company’s initial public offering (“IPO”). Shares outstanding under the 2010 Plan were transferred to the 2015 Plan upon effectiveness of the 2015 Plan. The 2015 Plan provides for automatic annual increases in shares available for grant, beginning on January 1, 2016 through January 1, 2025. In addition, shares subject to awards under the 2010 Plan that are forfeited or terminated will be added to the 2015 Plan. The 2015 Plan provides for the grant of incentive stock options, nonstatutory stock options, restricted stock awards, stock units, stock appreciation rights and other forms of equity compensation, all of which may be granted to employees, including officers, non-employee directors and consultants. Additionally, the 2015 Plan provides for the grant of cash-based awards.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Options granted generally vest over a period of </span><span style="font-family:Arial;font-size:10pt;"><span>four years</span></span><span style="font-family:Arial;font-size:10pt;">. Typically, the vesting schedule for options granted to newly hired employees provides that 1/4 of the award vests upon the first anniversary of the employee’s date of hire, with the remainder of the award vesting monthly thereafter at a rate of 1/48 of the total shares subject to the option. All other options typically vest in equal monthly installments over the </span><span style="font-family:Arial;font-size:10pt;">four</span><span style="font-family:Arial;font-size:10pt;">-year vesting schedule.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">RSUs generally vest over a period of </span><span style="font-family:Arial;font-size:10pt;"><span>three years</span></span><span style="font-family:Arial;font-size:10pt;">. Typically, the vesting schedule for RSUs provides that one third of the award vests upon each anniversary of the grant date.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In February 2016, the Company granted PRSUs under the 2015 Plan, which PRSUs could be earned based on the achievement of specified performance conditions measured over a period of approximately </span><span style="font-family:Arial;font-size:10pt;"><span>12 months</span></span><span style="font-family:Arial;font-size:10pt;">. In February 2017, upon the Audit Committee’s determination of the level of achievement, </span><span style="font-family:Arial;font-size:10pt;"><span>352,045</span></span><span style="font-family:Arial;font-size:10pt;"> fully vested stock units were awarded to holders of PRSUs. The Company has not granted any PRSUs since 2016.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Based on its evaluations of the probability of achieving performance conditions, the Company recorded stock-based compensation expense of </span><span style="font-family:Arial;font-size:10pt;">nil</span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;"><span>$0.4 million</span></span><span style="font-family:Arial;font-size:10pt;">, and </span><span style="font-family:Arial;font-size:10pt;"><span>$1.9 million</span></span><span style="font-family:Arial;font-size:10pt;"> for the years ended </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;">2017</span><span style="font-family:Arial;font-size:10pt;">, and </span><span style="font-family:Arial;font-size:10pt;">2016</span><span style="font-family:Arial;font-size:10pt;">, respectively, related to the PRSUs.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Activity under the 2010 Plan and the 2015 Plan is set forth below (in thousands, except per share amounts and years):</span></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:41%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Shares</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Available</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">For Grant</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Stock</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Options</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Outstanding</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Weighted-</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Exercise</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Price</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Weighted-</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Remaining</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Contractual</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Life (years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Aggregate</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Intrinsic</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Balance at December 31, 2017</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,397</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,115</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>8.51</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>7.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5,128</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Additional shares reserved</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>754</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Options granted</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(260</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>260</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>8.50</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Options cancelled</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>169</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(169</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>9.35</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Options exercised</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(351</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>7.73</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">RSUs granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(3,282</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">RSUs cancelled</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>340</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Balance at December 31, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>118</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,855</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>8.54</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>6.8</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>9,927</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Options exercisable at December 31, 2018</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,737</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>8.27</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>6.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>7,787</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Options vested and expected to vest at December 31, 2018</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,710</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>8.52</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>6.8</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>9,626</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying stock options and the fair value of the Company’s common stock for stock options that were in-the-money.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The weighted-average fair value of options to purchase common stock granted was </span><span style="font-family:Arial;font-size:10pt;"><span>$4.87</span></span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;"><span>$5.82</span></span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>$6.18</span></span><span style="font-family:Arial;font-size:10pt;"> in the years ended </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;">2017</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">2016</span><span style="font-family:Arial;font-size:10pt;">, respectively. The weighted-average fair value of RSUs granted was </span><span style="font-family:Arial;font-size:10pt;"><span>$7.46</span></span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;"><span>$10.03</span></span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>$9.80</span></span><span style="font-family:Arial;font-size:10pt;"> in the years ended </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;">2017</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">2016</span><span style="font-family:Arial;font-size:10pt;">, respectively. </span><span style="font-family:Arial;font-size:10pt;"><span>No</span></span><span style="font-family:Arial;font-size:10pt;"> PRSUs were granted in the years ended </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;"> or </span><span style="font-family:Arial;font-size:10pt;">2017</span><span style="font-family:Arial;font-size:10pt;"> and the weighted average fair value of PRSUs granted in the year ended </span><span style="font-family:Arial;font-size:10pt;">December 31, 2016</span><span style="font-family:Arial;font-size:10pt;"> was </span><span style="font-family:Arial;font-size:10pt;"><span>$6.50</span></span><span style="font-family:Arial;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The total grant-date fair value of options to purchase common stock vested was </span><span style="font-family:Arial;font-size:10pt;"><span>$5.9 million</span></span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;"><span>$6.9 million</span></span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>$5.6 million</span></span><span style="font-family:Arial;font-size:10pt;"> in the year ended </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;">2017</span><span style="font-family:Arial;font-size:10pt;">, and </span><span style="font-family:Arial;font-size:10pt;">2016</span><span style="font-family:Arial;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The intrinsic value of options to purchase common stock exercised was </span><span style="font-family:Arial;font-size:10pt;"><span>$1.7 million</span></span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;"><span>$2.1 million</span></span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>$1.4 million</span></span><span style="font-family:Arial;font-size:10pt;"> in the years ended </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;">2017</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">2016</span><span style="font-family:Arial;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following table summarizes RSU activity for the year ended </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;"> (in thousands, except per share data:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:69%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Number of Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Weighted-Average Grant Date Fair Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Balance at December 31, 2017</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,387</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>9.91</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">RSUs granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,282</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>7.46</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">RSUs vested</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(1,298</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>8.84</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">RSUs cancelled</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(340</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>8.84</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Balance at December 31, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,031</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>8.35</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">2015 employee stock purchase plan</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In January 2015, the Company adopted the 2015 Employee Stock Purchase Plan (the “ESPP”), which became effective upon the closing of the IPO. Employees participating in the ESPP may purchase common stock at </span><span style="font-family:Arial;font-size:10pt;"><span>85%</span></span><span style="font-family:Arial;font-size:10pt;"> of the lesser of the fair market value of common stock on the purchase date or last trading day preceding the offering date. At </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, cash received from payroll deductions pursuant to the ESPP was </span><span style="font-family:Arial;font-size:10pt;"><span>$0.6 million</span></span><span style="font-family:Arial;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The ESPP provides for automatic annual increases in shares available for grant, beginning on January 1, 2016 and continuing through January 1, 2025. At </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, a total of </span><span style="font-family:Arial;font-size:10pt;"><span>277,577</span></span><span style="font-family:Arial;font-size:10pt;"> shares of common stock are reserved for issuance under the ESPP.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Stock-based compensation</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The Company uses the grant date fair value of its common stock to value both employee and non-employee options when granted. The Company revalues non-employee options each reporting period using the fair market value of the Company’s common stock as of the last day of each reporting period.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In determining the fair value of stock options and ESPP purchases, the Company uses the Black-Scholes option-pricing model and, for stock options, the assumptions discussed below. Each of these inputs is subjective and its determination generally requires significant judgment. The fair value of RSU and PRSU awards is based on the grant date share price. Compensation cost is recognized as expense on a straight-line basis over the vesting period for options and RSUs and on an accelerated basis for PRSUs.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In 2016, the Company modified certain stock options and RSU awards. The terms of the stock option modifications included acceleration of vesting and extensions of post-termination exercise periods. The terms of the RSU award modifications included acceleration of vesting. A total of </span><span style="font-family:Arial;font-size:10pt;"><span>14</span></span><span style="font-family:Arial;font-size:10pt;"> employees were affected by the stock option and RSU modifications and the total incremental compensation cost relating to these modifications was </span><span style="font-family:Arial;font-size:10pt;"><span>$0.3 million</span></span><span style="font-family:Arial;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Expected term</span><span style="font-family:Arial;font-size:10pt;">—The expected term represents the period that the Company’s stock-based awards are expected to be outstanding and is determined using the simplified method (based on the midpoint between the vesting date and the end of the contractual term).</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Expected volatility</span><span style="font-family:Arial;font-size:10pt;">—Because the Company was privately held until its initial public offering in February 2015 and did not have any trading history for its common stock, the Company estimates expected volatility using its own stock price volatility when available as well as the average volatility for comparable publicly traded life sciences companies, including molecular diagnostics companies, over a period equal to the expected term of stock option grants and RSUs. When selecting comparable publicly-traded biopharmaceutical companies, including molecular diagnostics companies, the Company selected companies with comparable characteristics, including enterprise value, risk profiles, position within the industry and with historical share price information sufficient to meet the expected life of the stock-based awards. The Company computed historical volatility data using daily closing prices for the selected companies’ shares during the equivalent period of the calculated expected term of the stock-based awards. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available. The Company estimates expected volatility for ESPP purchases using its own stock price volatility over the expected </span><span style="font-family:Arial;font-size:10pt;">six</span><span style="font-family:Arial;font-size:10pt;">-month term ESPP purchase periods.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Risk-free interest rate</span><span style="font-family:Arial;font-size:10pt;">—The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of the option.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Dividend yield</span><span style="font-family:Arial;font-size:10pt;">—The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company used an expected dividend yield of zero.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The fair value of share-based payments for stock options granted to employees and directors was estimated on the date of grant using the Black-Scholes option-pricing model based on the following assumptions:</span></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:53%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:15%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Expected term (in years)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>6.00</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>6.03</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>6.03</span></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Expected volatility</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>59.58%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>72.64%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>71.42%</span></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Risk-free interest rate</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2.80%</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2.01%</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1.37%</span></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Stock-based compensation related to stock options granted to non-employees is recognized as the stock options vest. The fair value of the stock options granted is calculated at each reporting date using the Black-Scholes option-pricing model based on the following assumptions:</span></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:53%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:15%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Expected term (in years)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">8.41 – 8.83</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">6.25 – 10.00</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Expected volatility</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">69.9 – 78.70%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">76.92%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Risk-free interest rate</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">1.83 – 2.04%</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">1.55 – 2.37%</span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>No</span></span><span style="font-family:Arial;font-size:10pt;"> stock options granted to non-employees vested during the year ended December 31, 2018.</span></div><div style="line-height:120%;padding-bottom:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The fair value of shares purchased pursuant to the ESPP is estimated using the Black‑Scholes option pricing model. For the years ended </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;">2017</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">2016</span><span style="font-family:Arial;font-size:10pt;">, the weighted average grant date fair value per share for the ESPP was </span><span style="font-family:Arial;font-size:10pt;"><span>$3.26</span></span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;"><span>$2.51</span></span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>$2.66</span></span><span style="font-family:Arial;font-size:10pt;">, respectively and stock‑based compensation expense for the ESPP was </span><span style="font-family:Arial;font-size:10pt;"><span>$1.4 million</span></span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;"><span>$1.1 million</span></span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>$0.9 million</span></span><span style="font-family:Arial;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-bottom:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The fair value of the shares purchased pursuant to the ESPP was estimated using the following assumptions:</span></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:53%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:15%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Expected term (in years)</span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>0.5</span></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Expected volatility</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>71.66%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>52.50%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>66.31%</span></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Risk-free interest rate</span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2.09%</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1.23%</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>0.50%</span></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following table summarizes stock-based compensation expense for the years ended </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;">2017</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">2016</span><span style="font-family:Arial;font-size:10pt;">, included in the consolidated statements of operations (in thousands):</span></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Cost of revenue</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,960</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,093</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,353</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Research and development</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>7,017</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>6,158</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,976</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Selling and marketing</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,887</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,956</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,709</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">General and administrative</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5,986</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>7,014</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,661</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total stock-based compensation expense</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>20,850</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>19,221</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>10,699</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><span style="font-family:Arial;font-size:10pt;">At </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, unrecognized compensation expense related to unvested stock options, net of estimated forfeitures, was </span><span style="font-family:Arial;font-size:10pt;"><span>$4.5 million</span></span><span style="font-family:Arial;font-size:10pt;">, which the Company expects to recognize on a straight-line basis over a weighted-average period of </span><span style="font-family:Arial;font-size:10pt;"><span>1.8 years</span></span><span style="font-family:Arial;font-size:10pt;">. Unrecognized compensation expense related to RSUs at </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, net of estimated forfeitures, was </span><span style="font-family:Arial;font-size:10pt;"><span>$22.6 million</span></span><span style="font-family:Arial;font-size:10pt;">, which the Company expects to recognize on a straight-line basis over a weighted-average period of </span><span style="font-family:Arial;font-size:10pt;"><span>2.1 years</span></span><span style="font-family:Arial;font-size:10pt;">. At </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, there was </span><span style="font-family:Arial;font-size:10pt;"><span>no</span></span><span style="font-family:Arial;font-size:10pt;"> unrecognized compensation expense related to PRSUs and </span><span style="font-family:Arial;font-size:10pt;"><span>no</span></span> capitalized stock-based employee compensation. 0.10 1.10 P10Y P4Y P3Y P12M 352045 400000 1900000 Activity under the 2010 Plan and the 2015 Plan is set forth below (in thousands, except per share amounts and years):<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:41%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Shares</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Available</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">For Grant</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Stock</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Options</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Outstanding</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Weighted-</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Exercise</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Price</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Weighted-</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Remaining</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Contractual</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Life (years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Aggregate</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Intrinsic</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Balance at December 31, 2017</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,397</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,115</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>8.51</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>7.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5,128</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Additional shares reserved</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>754</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Options granted</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(260</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>260</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>8.50</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Options cancelled</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>169</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(169</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>9.35</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Options exercised</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(351</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>7.73</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">RSUs granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(3,282</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">RSUs cancelled</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>340</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Balance at December 31, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>118</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,855</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>8.54</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>6.8</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>9,927</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Options exercisable at December 31, 2018</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,737</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>8.27</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>6.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>7,787</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Options vested and expected to vest at December 31, 2018</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,710</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>8.52</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>6.8</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>9,626</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 2397000 4115000 8.51 P7Y7M6D 5128000 754000 260000 260000 8.50 169000 169000 9.35 351000 7.73 3282000 340000 118000 3855000 8.54 P6Y9M18D 9927000 2737000 8.27 P6Y4M24D 7787000 3710000 8.52 P6Y9M18D 9626000 4.87 5.82 6.18 7.46 10.03 9.80 0 6.50 5900000 6900000 5600000 1700000 2100000 1400000 The following table summarizes RSU activity for the year ended <span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;"> (in thousands, except per share data:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:69%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Number of Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Weighted-Average Grant Date Fair Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Balance at December 31, 2017</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,387</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>9.91</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">RSUs granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,282</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>7.46</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">RSUs vested</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(1,298</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>8.84</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">RSUs cancelled</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(340</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>8.84</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Balance at December 31, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,031</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>8.35</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 2387000 9.91 3282000 7.46 1298000 8.84 340000 8.84 4031000 8.35 0.85 600000 277577 14 300000 The fair value of share-based payments for stock options granted to employees and directors was estimated on the date of grant using the Black-Scholes option-pricing model based on the following assumptions:<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:53%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:15%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Expected term (in years)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>6.00</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>6.03</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>6.03</span></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Expected volatility</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>59.58%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>72.64%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>71.42%</span></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Risk-free interest rate</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2.80%</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2.01%</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1.37%</span></span></div></td></tr></table></div> P6Y P6Y10D P6Y10D 0.5958 0.7264 0.7142 0.0280 0.0201 0.0137 The fair value of the stock options granted is calculated at each reporting date using the Black-Scholes option-pricing model based on the following assumptions:<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:53%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:15%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Expected term (in years)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">8.41 – 8.83</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">6.25 – 10.00</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Expected volatility</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">69.9 – 78.70%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">76.92%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Risk-free interest rate</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">1.83 – 2.04%</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">1.55 – 2.37%</span></div></td></tr></table></div> 0 3.26 2.51 2.66 1400000 1100000 900000 The fair value of the shares purchased pursuant to the ESPP was estimated using the following assumptions:<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:53%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:15%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Expected term (in years)</span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>0.5</span></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Expected volatility</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>71.66%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>52.50%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>66.31%</span></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Risk-free interest rate</span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2.09%</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1.23%</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>0.50%</span></span></div></td></tr></table></div> P0M15D P0M15D P0M15D 0.7166 0.5250 0.6631 0.0209 0.0123 0.0050 The following table summarizes stock-based compensation expense for the years ended <span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;">2017</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">2016</span><span style="font-family:Arial;font-size:10pt;">, included in the consolidated statements of operations (in thousands):</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Cost of revenue</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,960</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,093</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,353</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Research and development</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>7,017</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>6,158</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,976</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Selling and marketing</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,887</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,956</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,709</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">General and administrative</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5,986</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>7,014</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,661</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total stock-based compensation expense</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>20,850</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>19,221</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>10,699</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 2960000 2093000 1353000 7017000 6158000 4976000 4887000 3956000 1709000 5986000 7014000 2661000 20850000 19221000 10699000 4500000 P1Y9M18D 22600000 P2Y1M6D 0 0 Income taxes<div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The Company recorded a benefit for income taxes in the years ended </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">2017</span><span style="font-family:Arial;font-size:10pt;">. The Company did not record a provision or benefit for income taxes during the year ended </span><span style="font-family:Arial;font-size:10pt;">December 31, 2016</span><span style="font-family:Arial;font-size:10pt;">. The components of net loss before taxes by U.S. and foreign jurisdictions are as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cff0fc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>132,194</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>124,108</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>99,793</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Foreign</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(39</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,128</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>463</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cff0fc;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>132,155</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>125,236</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>100,256</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The components of the provision for income taxes are as follows (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Current:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Foreign</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>62</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total current benefit for income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>62</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Deferred:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Federal</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(2,862</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(1,704</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">State</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(152</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total deferred benefit for income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(2,862</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(1,856</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total income tax benefit</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(2,800</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(1,856</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following table presents a reconciliation of the tax expense computed at the statutory federal rate and the Company’s tax expense for the periods presented:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:53%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">U.S. federal taxes at statutory rate</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>21.0</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>34.0</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>34.0</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> %</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">State taxes (net of federal benefit)</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5.2</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3.3</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1.4</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> %</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Stock-based compensation</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(0.7</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(1.1</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(1.7</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Research and development credits</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2.7</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> %</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Non-deductible expenses</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(0.6</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> %</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Foreign tax differential</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(0.3</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(0.2</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1.1</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> %</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Change in valuation allowance</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(25.5</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(34.4</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(34.8</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Change in deferred—Tax Reform</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(39.0</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> %</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Change in valuation allowance—Tax Reform</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>39.0</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> %</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2.1</span></span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1.5</span></span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> %</span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The tax effects of temporary differences and carryforwards that give rise to significant portions of the deferred tax assets are as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:69%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Deferred tax assets:</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Net operating loss carryforwards</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>76,972</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>70,825</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cff0fc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Tax credits</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Revenue recognition differences</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>47,650</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>29,819</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cff0fc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Accruals and other</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>7,262</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5,544</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Gross deferred tax assets</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>131,899</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>106,203</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cff0fc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Valuation allowance</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(121,954</span></span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(95,687</span></span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total deferred tax assets</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>9,945</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>10,516</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Deferred tax liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Property and equipment</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(9,945</span></span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(10,516</span></span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cff0fc;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total deferred tax liabilities</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(9,945</span></span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(10,516</span></span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Net deferred tax assets</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">On December 22, 2017, the Tax Cuts and Jobs Act of 2017 (the “Tax Act”) was signed into law making significant changes to the Internal Revenue Code. Changes included among other items, a reduction of the corporate tax rate from a top marginal rate of 35% to a flat rate of </span><span style="font-family:Arial;font-size:10pt;"><span>21%</span></span><span style="font-family:Arial;font-size:10pt;">. Although the Tax Act was generally effective January 1, 2018, GAAP required recognition of the tax effects of new legislation during the reporting period that includes the enactment date, which was December 22, 2017. As a result of the lower corporate tax rate enacted as part of the Tax Act, during 2017, the Company recorded a provisional estimate to reduce deferred tax assets by $</span><span style="font-family:Arial;font-size:10pt;"><span>48.8 million</span></span><span style="font-family:Arial;font-size:10pt;"> offset by a corresponding reduction in the valuation allowance resulting in no net impact to the Company's income tax benefit or expense.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">On December 22, 2017, the Securities and Exchange Commission issued Staff Accounting Bulletin No. 118 ("SAB 118") to address the application of U.S. GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the Tax Act. In accordance with SAB 118, during 2017, the Company recorded a provisional estimate which resulted in a </span><span style="font-family:Arial;font-size:10pt;"><span>$48.8 million</span></span><span style="font-family:Arial;font-size:10pt;"> reduction in deferred tax assets and in the fourth quarter of 2018, the Company completed its analysis of the impact of the Tax Act and determined that no material adjustments were required to the provisional amounts previously recorded.     </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The Company has established a full valuation allowance against its deferred tax assets due to the uncertainty surrounding realization of such assets. The Company's valuation allowance increased by </span><span style="font-family:Arial;font-size:10pt;"><span>$26.3 million</span></span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;"><span>$2.0 million</span></span><span style="font-family:Arial;font-size:10pt;">, and </span><span style="font-family:Arial;font-size:10pt;"><span>$33.4 million</span></span><span style="font-family:Arial;font-size:10pt;"> during the years ended </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;">2017</span><span style="font-family:Arial;font-size:10pt;">, and </span><span style="font-family:Arial;font-size:10pt;">2016</span><span style="font-family:Arial;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">As of </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, the Company had net operating loss carryforwards of approximately </span><span style="font-family:Arial;font-size:10pt;"><span>$318.7 million</span></span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>$134.3 million</span></span><span style="font-family:Arial;font-size:10pt;"> available to reduce future taxable income, if any, for Federal and state income tax purposes, respectively. Of the </span><span style="font-family:Arial;font-size:10pt;"><span>$318.7 million</span></span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;"><span>$277.3 million</span></span><span style="font-family:Arial;font-size:10pt;"> will begin to expire in 2030 while </span><span style="font-family:Arial;font-size:10pt;"><span>$41.4 million</span></span><span style="font-family:Arial;font-size:10pt;"> have no expiration date. The state net operating loss carryforwards will begin to expire in 2030.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">As of </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, the Company had research and development credit carryforwards of approximately </span><span style="font-family:Arial;font-size:10pt;"><span>$9.0 million</span></span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>$7.4 million</span></span><span style="font-family:Arial;font-size:10pt;"> available to reduce its future tax liability, if any, for Federal and state income tax purposes, respectively. The Federal credit carryforwards begin to expire in 2030. California credit carryforwards have no expiration date.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Internal Revenue Code ("IRC") section 382 places a limitation (the “Section 382 limitation” or “annual limitation”) on the amount of taxable income that can be offset by net operating loss carryforwards after a change in control (generally greater than </span><span style="font-family:Arial;font-size:10pt;"><span>50%</span></span><span style="font-family:Arial;font-size:10pt;"> change in ownership) of a loss corporation. Similar provisions exist for states. In addition, and as a result of the acquisitions of Good Start Genetics and CombiMatrix in 2017, tax loss carryforwards from acquired entities are also subject to the Section 382 limitation due to the change in control in the acquired entities in the current year.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The Company performed a section 382 analysis for Good Start Genetics and CombiMatrix and concluded that a substantial portion of the acquired operating loss and credit carryovers would expire unused as a result of </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">annual limitations under IRC sections 382 and 383 in 2017. As a result, the federal and state operating loss and credit carryforwards acquired in connection with the Good Start Genetics and CombiMatrix acquisitions were reduced by the amount of tax attributes estimated to expire during their respective carryforward periods. In addition, as a result of equity issued in connection with its 2017 acquisitions, the Company also performed a section 382 analysis with respect to its legacy operating loss and credit carryforwards. The Company concluded while an ownership change occurred in 2017 as defined under IRC section 382, none of the Company’s legacy carryforwards would expire unused solely as a result of annual limitations imposed on the use of the carryforwards under IRC sections 382 and 383.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">As of </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, the Company had unrecognized tax benefits of </span><span style="font-family:Arial;font-size:10pt;"><span>$16.4 million</span></span><span style="font-family:Arial;font-size:10pt;">, which primarily relates to research and development credits, none of which would currently affect the Company’s effective tax rate if recognized due to the Company’s deferred tax assets being fully offset by a valuation allowance. Unrecognized tax benefits are not expected to change in the next 12 months.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Year ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cff0fc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Unrecognized tax benefits, beginning of period</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>10,561</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>7,791</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>11,429</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Gross increases—current period tax positions</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5,686</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,552</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>782</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cff0fc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Gross increases (decreases)—prior period tax positions</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>128</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>218</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(4,420</span></span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Unrecognized tax benefits, end of period</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>16,375</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>10,561</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>7,791</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The Company’s policy is to include penalties and interest expense related to income taxes as a component of tax expense. The Company has not accrued interest and penalties related to the unrecognized tax benefits reflected in the financial statements for the years ended </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;">2017</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">2016</span><span style="font-family:Arial;font-size:10pt;">.</span></div><span style="font-family:Arial;font-size:10pt;">The Company’s major tax jurisdictions are the United States and California. All of the Company’s tax years will remain open for examination by the Federal and state tax authorities for </span><span style="font-family:Arial;font-size:10pt;">three</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>four years</span></span>, respectively, from the date of utilization of the net operating loss or research and development credit. The Company does not have any tax audits pending. The components of net loss before taxes by U.S. and foreign jurisdictions are as follows (in thousands):<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cff0fc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>132,194</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>124,108</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>99,793</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Foreign</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(39</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,128</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>463</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cff0fc;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>132,155</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>125,236</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>100,256</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> -132194000 -124108000 -99793000 39000 -1128000 -463000 -132155000 -125236000 -100256000 The components of the provision for income taxes are as follows (in thousands):<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Current:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Foreign</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>62</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total current benefit for income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>62</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Deferred:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Federal</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(2,862</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(1,704</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">State</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(152</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total deferred benefit for income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(2,862</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(1,856</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total income tax benefit</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(2,800</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(1,856</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 62000 0 0 62000 0 0 -2862000 -1704000 0 0 -152000 0 -2862000 -1856000 0 -2800000 -1856000 0 The following table presents a reconciliation of the tax expense computed at the statutory federal rate and the Company’s tax expense for the periods presented:<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:53%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">U.S. federal taxes at statutory rate</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>21.0</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>34.0</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>34.0</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> %</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">State taxes (net of federal benefit)</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5.2</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3.3</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1.4</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> %</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Stock-based compensation</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(0.7</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(1.1</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(1.7</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Research and development credits</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2.7</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> %</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Non-deductible expenses</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(0.6</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> %</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Foreign tax differential</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(0.3</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(0.2</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1.1</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> %</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Change in valuation allowance</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(25.5</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(34.4</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(34.8</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Change in deferred—Tax Reform</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(39.0</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> %</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Change in valuation allowance—Tax Reform</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>39.0</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> %</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2.1</span></span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1.5</span></span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> %</span></div></td></tr></table></div> 0.210 0.340 0.340 0.052 0.033 0.014 -0.007 -0.011 -0.017 -0.027 0 0 -0.006 0 0.002 0 -0.003 -0.002 0 0 0.011 -0.255 -0.344 -0.348 0 -0.390 0 0 0.390 0 0.021 0.015 0 The tax effects of temporary differences and carryforwards that give rise to significant portions of the deferred tax assets are as follows (in thousands):<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:69%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Deferred tax assets:</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Net operating loss carryforwards</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>76,972</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>70,825</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cff0fc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Tax credits</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Revenue recognition differences</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>47,650</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>29,819</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cff0fc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Accruals and other</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>7,262</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5,544</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Gross deferred tax assets</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>131,899</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>106,203</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cff0fc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Valuation allowance</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(121,954</span></span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(95,687</span></span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total deferred tax assets</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>9,945</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>10,516</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Deferred tax liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Property and equipment</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(9,945</span></span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(10,516</span></span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cff0fc;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total deferred tax liabilities</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(9,945</span></span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(10,516</span></span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Net deferred tax assets</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 76972000 70825000 15000 15000 47650000 29819000 7262000 5544000 131899000 106203000 121954000 95687000 9945000 10516000 9945000 10516000 9945000 10516000 0 0 0.21 48800000 48800000 26300000 2000000.0 33400000 318700000 134300000 318700000 277300000 41400000 9000000.0 7400000 0.50 16400000 A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in thousands):<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Year ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cff0fc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Unrecognized tax benefits, beginning of period</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>10,561</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>7,791</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>11,429</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Gross increases—current period tax positions</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5,686</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,552</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>782</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cff0fc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Gross increases (decreases)—prior period tax positions</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>128</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>218</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(4,420</span></span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Unrecognized tax benefits, end of period</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>16,375</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>10,561</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>7,791</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 10561000 7791000 11429000 5686000 2552000 782000 128000 218000 -4420000 16375000 10561000 7791000 P4Y Net loss per share<div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following table presents the calculation of basic and diluted net loss per share for the years ended </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;">2017</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">2016</span><span style="font-family:Arial;font-size:10pt;"> (in thousands, except per share data):</span></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Year ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(129,355</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(123,380</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(100,256</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Shares used in computing net loss per share, basic and diluted</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>66,747</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>46,512</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>33,176</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Net loss per share, basic and diluted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(1.94</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(2.65</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(3.02</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following common stock equivalents have been excluded from diluted net loss per share for the years ended </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;">2017</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">2016</span><span style="font-family:Arial;font-size:10pt;"> because their inclusion would be anti-dilutive (in thousands):</span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:59%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Shares of common stock subject to outstanding options</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,855</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,115</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,491</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Shares of common stock subject to outstanding warrants</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>611</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,962</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Shares of common stock subject to outstanding RSUs</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,031</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,387</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>892</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Shares of common stock subject to outstanding PRSUs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>530</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Shares of common stock pursuant to ESPP</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>63</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>59</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>55</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Shares of common stock underlying Series A convertible preferred stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,459</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,459</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total shares of common stock equivalents</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>12,019</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>11,982</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5,968</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> The following table presents the calculation of basic and diluted net loss per share for the years ended <span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;">2017</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">2016</span><span style="font-family:Arial;font-size:10pt;"> (in thousands, except per share data):</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Year ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(129,355</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(123,380</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(100,256</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Shares used in computing net loss per share, basic and diluted</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>66,747</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>46,512</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>33,176</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Net loss per share, basic and diluted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(1.94</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(2.65</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(3.02</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr></table></div> -129355000 -123380000 -100256000 66747000 46512000 33176000 -1.94 -2.65 -3.02 The following common stock equivalents have been excluded from diluted net loss per share for the years ended <span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;">2017</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">2016</span><span style="font-family:Arial;font-size:10pt;"> because their inclusion would be anti-dilutive (in thousands):</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:59%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Shares of common stock subject to outstanding options</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,855</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,115</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,491</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Shares of common stock subject to outstanding warrants</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>611</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,962</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Shares of common stock subject to outstanding RSUs</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,031</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,387</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>892</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Shares of common stock subject to outstanding PRSUs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>530</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Shares of common stock pursuant to ESPP</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>63</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>59</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>55</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Shares of common stock underlying Series A convertible preferred stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,459</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,459</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total shares of common stock equivalents</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>12,019</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>11,982</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5,968</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 3855000 4115000 4491000 611000 1962000 0 4031000 2387000 892000 0 0 530000 63000 59000 55000 3459000 3459000 0 12019000 11982000 5968000 Geographic information<div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Revenue by country is determined based on the billing address of the customer and is summarized as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:60%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"> </span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>138,239</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>62,446</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>20,758</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Canada</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,206</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,226</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,526</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Rest of world</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5,254</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,549</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,764</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total revenue</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>147,699</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>68,221</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>25,048</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><span style="font-family:Arial;font-size:10pt;">As of </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">2017</span>, all long-lived assets were located in the United States. Revenue by country is determined based on the billing address of the customer and is summarized as follows (in thousands):<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:60%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"> </span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>138,239</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>62,446</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>20,758</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Canada</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,206</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,226</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,526</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Rest of world</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5,254</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,549</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,764</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total revenue</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>147,699</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>68,221</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>25,048</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 138239000 62446000 20758000 4206000 3226000 2526000 5254000 2549000 1764000 147699000 68221000 25048000 Selected quarterly data (unaudited)<div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following table summarizes the Company's quarterly financial information for </span><span style="font-family:Arial;font-size:10pt;">2018</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">2017</span><span style="font-family:Arial;font-size:10pt;"> (in thousands, except per share amounts):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:36%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">March 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">June 30, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">September 30, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Revenue</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>27,671</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>37,306</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>37,366</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>45,356</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Cost of revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>18,076</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>20,447</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>20,441</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>21,141</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Loss from operations</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(36,475</span></span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(30,068</span></span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(30,110</span></span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(25,904</span></span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Net loss</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(36,120</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(31,671</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(31,723</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(29,841</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Net loss per share, basic and diluted</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(0.66</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(0.47</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(0.45</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(0.40</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">March 31, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">June 30, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">September 30, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">December 31, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Revenue</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>10,338</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>14,336</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>18,148</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>25,399</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Cost of revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9,329</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>10,490</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>13,274</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>17,049</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Loss from operations</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(27,337</span></span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(28,075</span></span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(30,976</span></span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(34,891</span></span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Net loss</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(26,928</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(28,557</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(27,402</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(40,493</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Net loss per share, basic and diluted</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(0.64</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(0.66</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(0.57</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(0.78</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;">___________________________________________________________________ </span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup> </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Net loss per share is computed independently for each of the quarters presented. Therefore, the sum of quarterly net loss per share information may not equal annual net loss per share.</span></div></td></tr></table><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></span><span style="font-family:Arial;font-size:9pt;"> </span></div><span style="font-family:Arial;font-size:9pt;">Includes </span><span style="font-family:Arial;font-size:9pt;"><span>$5.3 million</span></span> of debt extinguishment costs during the three months ended December 31, 2018. See Note 9, "Commitments and contingencies" for further information. The following table summarizes the Company's quarterly financial information for <span style="font-family:Arial;font-size:10pt;">2018</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">2017</span><span style="font-family:Arial;font-size:10pt;"> (in thousands, except per share amounts):</span><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:36%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">March 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">June 30, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">September 30, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Revenue</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>27,671</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>37,306</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>37,366</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>45,356</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Cost of revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>18,076</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>20,447</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>20,441</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>21,141</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Loss from operations</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(36,475</span></span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(30,068</span></span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(30,110</span></span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(25,904</span></span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Net loss</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(36,120</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(31,671</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(31,723</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(29,841</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Net loss per share, basic and diluted</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(0.66</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(0.47</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(0.45</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(0.40</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">March 31, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">June 30, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">September 30, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">December 31, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Revenue</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>10,338</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>14,336</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>18,148</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>25,399</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Cost of revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9,329</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>10,490</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>13,274</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>17,049</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Loss from operations</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(27,337</span></span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(28,075</span></span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(30,976</span></span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(34,891</span></span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Net loss</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(26,928</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(28,557</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(27,402</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(40,493</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Net loss per share, basic and diluted</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(0.64</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(0.66</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(0.57</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(0.78</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;">___________________________________________________________________ </span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup> </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Net loss per share is computed independently for each of the quarters presented. Therefore, the sum of quarterly net loss per share information may not equal annual net loss per share.</span></div></td></tr></table><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></span><span style="font-family:Arial;font-size:9pt;"> </span></div><span style="font-family:Arial;font-size:9pt;">Includes </span><span style="font-family:Arial;font-size:9pt;"><span>$5.3 million</span></span> of debt extinguishment costs during the three months ended December 31, 2018. See Note 9, "Commitments and contingencies" for further information. 27671000 37306000 37366000 45356000 18076000 20447000 20441000 21141000 -36475000 -30068000 -30110000 -25904000 -36120000 -31671000 -31723000 -29841000 -0.66 -0.47 -0.45 -0.40 10338000 14336000 18148000 25399000 9329000 10490000 13274000 17049000 -27337000 -28075000 -30976000 -34891000 -26928000 -28557000 -27402000 -40493000 -0.64 -0.66 -0.57 -0.78 5300000 XML 18 R1.htm IDEA: XBRL DOCUMENT v3.10.0.1
Document and Entity Information - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2018
Feb. 22, 2019
Jun. 29, 2018
Document And Entity Information [Abstract]      
Entity Registrant Name Invitae Corp    
Entity Central Index Key 0001501134    
Document Type 10-K    
Document Period End Date Dec. 31, 2018    
Amendment Flag false    
Current Fiscal Year End Date --12-31    
Entity Current Reporting Status Yes    
Entity Filer Category Accelerated Filer    
Entity Small Business false    
Entity Emerging Growth Company true    
Entity Ex Transition Period true    
Entity Shell Company false    
Trading Symbol NVTA    
Entity Voluntary Filers No    
Entity Well-known Seasoned Issuer Yes    
Entity Common Stock, Shares Outstanding   76,811,562  
Entity Public Float     $ 477.8
Document Fiscal Year Focus 43465    
Document Fiscal Period Focus FY    

XML 19 R2.htm IDEA: XBRL DOCUMENT v3.10.0.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2018
Dec. 31, 2017
Current assets:    
Cash and cash equivalents $ 112,158 $ 12,053
Marketable securities 13,727 52,607
Accounts receivable 26,296 10,422
Prepaid expenses and other current assets 13,258 11,599
Total current assets 165,439 86,681
Property and equipment, net 27,886 30,341
Restricted cash 6,006 5,406
Marketable securities, non-current 0 5,983
Intangible assets, net 30,469 35,516
Goodwill 50,095 46,575
Other assets 3,064 576
Total assets 282,959 211,078
Current liabilities:    
Accounts payable 7,812 8,606
Accrued liabilities 26,563 22,742
Capital lease obligation, current portion 1,937 2,039
Total current liabilities 36,312 33,387
Capital lease obligation, net of current portion 1,375 3,373
Debt 74,477 39,084
Other long-term liabilities 8,956 13,440
Total liabilities 121,120 89,284
Commitments and contingencies (Note 9)
Stockholders’ equity:    
Preferred stock, $0.0001 par value: 20,000 shares authorized; 3,459 shares issued and outstanding as of December 31, 2018 and 2017 0 0
Common stock, $0.0001 par value: 400,000 shares authorized; 75,481 and 53,597 shares issued and outstanding as of December 31, 2018 and 2017, respectively 8 5
Accumulated other comprehensive loss (5) (171)
Additional paid-in capital 678,548 520,558
Accumulated deficit (516,712) (398,598)
Total stockholders’ equity 161,839 121,794
Total liabilities and stockholders’ equity $ 282,959 $ 211,078
XML 20 R3.htm IDEA: XBRL DOCUMENT v3.10.0.1
Consolidated Balance Sheets (Parenthetical) - $ / shares
Dec. 31, 2018
Dec. 31, 2017
Statement of Financial Position [Abstract]    
Preferred stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Preferred stock, authorized (in shares) 20,000,000 20,000,000
Preferred stock, issued (in shares) 3,459,000 3,459,000
Preferred stock, outstanding (in shares) 3,459,000 3,459,000
Common stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Common stock, authorized (in shares) 400,000,000 400,000,000
Common stock, issued (in shares) 75,481,000 53,597,000
Common stock, outstanding (in shares) 75,481,000 53,597,000
XML 21 R4.htm IDEA: XBRL DOCUMENT v3.10.0.1
Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Revenue:      
Total revenue $ 147,699 $ 68,221 $ 25,048
Costs and operating expenses:      
Cost of revenue 80,105 50,142 27,878
Research and development 63,496 46,469 44,630
Selling and marketing 74,428 53,417 28,638
General and administrative 52,227 39,472 24,085
Total costs and operating expenses 270,256 189,500 125,231
Loss from operations (122,557) (121,279) (100,183)
Other income (expense), net (2,568) (303) 348
Interest expense (7,030) (3,654) (421)
Net loss before taxes (132,155) (125,236) (100,256)
Income tax benefit (2,800) (1,856) 0
Net loss $ (129,355) $ (123,380) $ (100,256)
Net loss per share, basic and diluted (in dollars per share) $ (1.94) $ (2.65) $ (3.02)
Shares used in computing net loss per share, basic and diluted (in shares) 66,747 46,512 33,176
Test revenue      
Revenue:      
Total revenue $ 144,560 $ 65,169 $ 24,840
Other revenue      
Revenue:      
Total revenue $ 3,139 $ 3,052 $ 208
XML 22 R5.htm IDEA: XBRL DOCUMENT v3.10.0.1
Consolidated Statements of Comprehensive Loss - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Statement of Comprehensive Income [Abstract]      
Net loss $ (129,355) $ (123,380) $ (100,256)
Other comprehensive income (loss):      
Unrealized income (loss) on available-for-sale marketable securities, net of tax 166 (171) 15
Comprehensive loss $ (129,189) $ (123,551) $ (100,241)
XML 23 R6.htm IDEA: XBRL DOCUMENT v3.10.0.1
Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity - USD ($)
shares in Thousands, $ in Thousands
Total
Preferred Stock
Common Stock
Additional Paid-In Capital
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Balance at the beginning of the period at Dec. 31, 2015 $ 138,376   $ 4 $ 313,349 $ (15) $ (174,962)
Balance at the beginning of the period (in shares) at Dec. 31, 2015   0 31,935      
Increase (Decrease) in Stockholders' Deficit            
Common stock issued on exercise of stock options 744     744    
Options exercised (in shares)     244      
Common stock issued pursuant to vesting of restricted stock units (1)   $ (1)      
Common stock issued pursuant to vesting of restricted stock units (in shares)     157      
Common stock issued pursuant to employee stock purchase plan 2,391     2,391    
Common stock issued pursuant to employee stock purchase plan (in shares)     370      
Common stock issued in connection with initial public offering, net of offering costs 47,102   $ 1 47,101    
Common stock issued in connection with initial public offering, net of offering costs (in shares)     8,433      
Vesting of common stock related to early exercise of options 4     4    
Vesting of common stock related to early exercise of options (in shares)     5      
Stock-based compensation expense 10,699     10,699    
Unrealized income (loss) on available-for-sale marketable securities, net of tax 15       15  
Net loss (100,256)         (100,256)
Balance at the end of the period at Dec. 31, 2016 99,074   $ 4 374,288   (275,218)
Balance at the end of the period (in shares) at Dec. 31, 2016   0 41,144      
Increase (Decrease) in Stockholders' Deficit            
Options exercised (in shares)     387      
Common stock issued pursuant to vesting of restricted stock units (in shares)     925      
Common stock issued pursuant to employee stock purchase plan 2,635     2,635    
Common stock issued pursuant to employee stock purchase plan (in shares)     379      
Stock-based compensation expense 18,832     18,832    
Unrealized income (loss) on available-for-sale marketable securities, net of tax (171)       (171)  
Net loss (123,380)         (123,380)
Common and convertible preferred stock issued in private placement, net of offering costs 68,897   $ 1 68,896    
Common and convertible preferred stock issued in private placement, net of offering costs (in shares)   3,459 5,188      
Common stock issued on exercise of stock options, net 1,706     1,706    
Common stock issued pursuant to acquisition-related transaction bonus (in shares)     4      
Common stock issued pursuant to exercises of warrants 1,381     1,381    
Common stock issued pursuant to exercises of warrants (in shares)     232      
Common stock issued pursuant to business combinations 50,808     50,808    
Common stock issued pursuant to business combinations (in shares)     5,176      
Common stock issued to settle assumed liabilities 1,272     1,272    
Common stock issued to settle assumed liabilities (in shares)     162      
Warrants issued pursuant to the 2017 Loan Agreement 740     740    
Balance at the end of the period at Dec. 31, 2017 121,794   $ 5 520,558 (171) (398,598)
Balance at the end of the period (in shares) at Dec. 31, 2017   3,459 53,597      
Increase (Decrease) in Stockholders' Deficit            
Options exercised (in shares)     351      
Common stock issued pursuant to vesting of restricted stock units (in shares)     1,369      
Common stock issued pursuant to employee stock purchase plan 3,231     3,231    
Common stock issued pursuant to employee stock purchase plan (in shares)     566      
Common stock issued in connection with initial public offering, net of offering costs 112,441   $ 3 112,438    
Common stock issued in connection with initial public offering, net of offering costs (in shares)     17,103      
Stock-based compensation expense 20,850     20,850    
Unrealized income (loss) on available-for-sale marketable securities, net of tax 166       166  
Net loss (129,355)         (129,355)
Common stock issued on exercise of stock options, net 2,741     2,741    
Common stock issued pursuant to exercises of warrants 6,539     6,539    
Common stock issued pursuant to exercises of warrants (in shares)     1,099      
Common stock issued pursuant to business combinations 6,455     6,455    
Common stock issued pursuant to business combinations (in shares)     1,022      
Warrants issued pursuant to the 2017 Loan Agreement 383     383    
Common stock issued pursuant to Securities Purchase Agreement (see Note 9) 5,353     5,353    
Common stock issued pursuant to debt financing (in shares)     374      
Balance at the end of the period at Dec. 31, 2018 $ 161,839   $ 8 $ 678,548 $ (5) $ (516,712)
Balance at the end of the period (in shares) at Dec. 31, 2018   3,459 75,481      
XML 24 R7.htm IDEA: XBRL DOCUMENT v3.10.0.1
Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Parenthetical) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Statement of Stockholders' Equity [Abstract]      
Offering costs $ 6,183 $ 4,599 $ 3,498
XML 25 R8.htm IDEA: XBRL DOCUMENT v3.10.0.1
Consolidated Statements of Cash Flows - USD ($)
 12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Cash flows from operating activities:      
Net loss $ (129,355,000) $ (123,380,000) $ (100,256,000)
Adjustments to reconcile net loss to net cash used in operating activities:      
Depreciation and amortization 13,540,000 9,181,000 6,553,000
Stock-based compensation 20,850,000 19,221,000 10,699,000
Impairment losses 2,925,000 0 0
Remeasurements of liabilities associated with business combinations 362,000 1,810,000 0
Benefit from income taxes (2,862,000) (1,856,000) 0
Debt extinguishment costs (5,266,000) 0 0
Other 806,000 404,000 1,341,000
Changes in operating assets and liabilities, net of effects of business combination:      
Accounts receivable (5,291,000) (1,963,000) (843,000)
Prepaid expenses and other current assets (1,445,000) (641,000) (1,149,000)
Other assets (163,000) (185,000) 1,465,000
Accounts payable (417,000) (535,000) (111,000)
Accrued expenses and other liabilities 3,564,000 (37,000) 5,984,000
Net cash used in operating activities (92,220,000) (97,981,000) (76,317,000)
Cash flows from investing activities:      
Purchases of marketable securities (9,680,000) (101,867,000) (90,236,000)
Proceeds from sales of marketable securities 19,965,000 0 0
Proceeds from maturities of marketable securities 32,458,000 68,768,000 117,922,000
Acquisition of businesses, acquired cash 0 2,821,000 0
Purchases of property and equipment (5,970,000) (6,675,000) (11,625,000)
Other (1,000,000) 0 0
Net cash provided by (used in) investing activities 35,773,000 (36,953,000) 16,061,000
Cash flows from financing activities:      
Proceeds from public offering of common stock, net of issuance costs 112,441,000 0 47,102,000
Proceeds from issuance of common stock 17,511,000 74,619,000 3,134,000
Net proceeds from issuance of debt 93,909,000 39,661,000 7,500,000
Payments for debt extinguishment costs (4,609,000) 0 0
Loan payments (60,000,000) (30,457,000) (2,438,000)
Capital lease principal payments (2,100,000) (2,952,000) (1,589,000)
Net cash provided by financing activities 157,152,000 80,871,000 53,709,000
Net increase (decrease) in cash, cash equivalents and restricted cash 100,705,000 (54,063,000) (6,547,000)
Cash, cash equivalents and restricted cash at beginning of period 17,459,000 71,522,000 78,069,000
Cash, cash equivalents and restricted cash at end of period 118,164,000 17,459,000 71,522,000
Supplemental cash flow information:      
Interest paid 6,231,000 2,852,000 421,000
Supplemental cash flow information of non-cash investing and financing activities:      
Equipment acquired through capital leases 0 6,789,000 0
Purchases of property and equipment in accounts payable and accrued liabilities 510,000 200,000 1,644,000
Amounts related to co-development agreement in other assets and accrued liabilities 2,000,000 0 0
Warrants issued pursuant to 2017 Loan Agreement 383,000 740,000 0
Common stock issued for acquisition of businesses 6,445,000 50,808,000 0
Consideration payable for acquisition of businesses 0 13,276,000 0
Common stock issued to settle assumed liabilities $ 0 $ 1,272,000 $ 0
XML 26 R9.htm IDEA: XBRL DOCUMENT v3.10.0.1
Organization and description of business
 12 Months Ended
Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Organization and description of business Organization and description of businessInvitae Corporation (the “Company”) was incorporated in the State of Delaware on January 13, 2010, as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. The Company utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process DNA-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients. The Company’s headquarters and main production facility is located in San Francisco, California. The Company currently has more than 20,000 genes in production and provides a variety of diagnostic tests that can be used in multiple indications. The Company’s tests include genes associated with hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders, metabolic disorders and other hereditary conditions. In addition, and as a result of the acquisitions of Good Start Genetics ("Good Start") in August 2017 and CombiMatrix Corporation ("CombiMatrix") in November 2017, the Company’s services also include screening and testing in reproductive health, including preimplantation and carrier screening for inherited disorders, prenatal diagnosis, miscarriage analysis and pediatric developmental disorders. The Company operates in one segment.
XML 27 R10.htm IDEA: XBRL DOCUMENT v3.10.0.1
Summary of significant accounting policies
 12 Months Ended
Dec. 31, 2018
Accounting Policies [Abstract]  
Summary of significant accounting policies Summary of significant accounting policies
Principles of consolidation
The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.
Use of estimates
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. The Company bases these estimates on historical and anticipated results, trends and various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to future events. Actual results could differ materially from those estimates and assumptions.
Significant estimates and assumptions made by management include the determination of:
•
revenue recognition (See Note 3, “Revenue, accounts receivable and deferred revenue” for further information);
•
the fair value of assets acquired and liabilities assumed for business combinations;
•
the fair value of goodwill and intangible assets;
•
the recoverability of long-lived assets;
•
stock-based compensation expense and the fair value of awards issued; and
•
income tax uncertainties.
Concentrations of credit risk and other risks and uncertainties
Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents, marketable securities and accounts receivable. The Company’s cash and cash equivalents are held by financial institutions in the United States. Such deposits may exceed federally insured limits.
Significant customers are those that represent 10% or more of the Company’s total revenue for each year presented on the statements of operations. For the significant customer, revenue as a percentage of total revenue were as follows:
 
December 31,
Customers
2018
 
2017
 
2016
Medicare
22
%
 
13
%
 
11
%

Medicare represented 21% and 13% of accounts receivable as of December 31, 2018 and 2017.
Cash, cash equivalents, and restricted cash
The Company considers all highly liquid investments with original maturities of three months or less from the date of purchase to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market funds and U.S. government agency securities.
Restricted cash consists of money market funds that serve as collateral for security deposits for the Company’s facility lease and sublease agreements and collateral for a credit card agreement at one of the Company’s financial institutions.
The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the statements of cash flows (in thousands):
 
December 31, 2018
 
December 31, 2017
Cash and cash equivalents
$
112,158

 
$
12,053

Restricted cash
6,006

 
5,406

Total cash, cash equivalents and restricted cash
$
118,164

 
$
17,459


Marketable securities
All marketable securities have been classified as “available-for-sale” and are carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities. Management determines the appropriate classification of its marketable debt securities at the time of purchase and reevaluates such designation at each balance sheet date. Short-term marketable securities have maturities less than 365 days at the balance sheet date. Unrealized gains and losses are excluded from earnings and are reported as a component of other comprehensive loss. Realized gains and losses and declines in fair value judged to be other than temporary, if any, on available-for-sale securities are included in interest and other income (expense), net. The cost of securities sold is based on the specific-identification method. Interest on marketable securities is included in interest and other income (expense), net.
Accounts receivable
The Company receives payment for its tests from partners, patients, institutional customers and third-party payers. See Note 3, "Revenue, accounts receivable and deferred revenue" for further information.
Inventory
The Company maintains test reagents and other consumables primarily used in sample collection kits which are valued at the lower of cost or market value. Cost is determined using actual costs on a first-in, first-out basis. The Company's inventory was $8.3 million and $5.4 million as of December 31, 2018 and 2017, respectively, and was recorded in prepaid expenses and other current assets in the Company's consolidated balance sheets.
Business combinations
The tangible and identifiable intangible assets acquired and liabilities assumed in a business combination are recorded based on their estimated fair values as of the business combination date, including identifiable intangible assets which either arise from a contractual or legal right or are separable from goodwill. The Company bases the estimated fair value of identifiable intangible assets acquired in a business combination on independent valuations that use information and assumptions provided by management, which consider management’s estimates of inputs and assumptions that a market participant would use. Any excess purchase price over the estimated fair value assigned to the net tangible and identifiable intangible assets acquired and liabilities assumed is recorded to goodwill. The use of alternative valuation assumptions, including estimated revenue projections, growth rates, cash flows, discount rates, estimated useful lives and probabilities surrounding the achievement of contingent milestones could result in different purchase price allocations and amortization expense in current and future periods.
In circumstances where an acquisition involves a contingent consideration arrangement that meets the definition of a liability under Financial Accounting Standards Board (“FASB") Accounting Standards Codification (“ASC”) Topic 480, Distinguishing Liabilities from Equity, the Company recognizes a liability equal to the fair value of the contingent payments the Company expects to make as of the acquisition date. The Company remeasures this liability each reporting period and records changes in the fair value as a component of operating expenses.
Transaction costs associated with acquisitions are expensed as incurred in general and administrative expenses. Results of operations and cash flows of acquired companies are included in the Company’s operating results from the date of acquisition.
Intangible assets
Amortizable intangible assets include trade names, non-compete agreements, developed technology and customer relationships acquired as part of business combinations. Customer relationships are amortized on an accelerated basis, utilizing free cash flows, over periods ranging from five to 11 years. All other intangible assets subject to amortization are amortized using the straight-line method over their estimated useful lives ranging from two to 15 years. All intangible assets subject to amortization are reviewed for impairment in accordance with ASC 360, Property, Plant and Equipment.
Goodwill
In accordance with ASC 350, Intangibles-Goodwill and Other (“ASC 350”), the Company’s goodwill is not amortized but is tested for impairment on an annual basis or whenever events or changes in circumstances indicate that the carrying amount of these assets may not be recoverable. Under ASC 350, the Company performs annual impairment reviews of its goodwill balance during the fourth fiscal quarter. In testing for impairment, the Company compares the fair value of its reporting unit to its carrying value including the goodwill of that unit. If the carrying value, including goodwill, exceeds the reporting unit’s fair value, the Company will recognize an impairment loss for the amount by which the carrying amount exceeds the reporting unit’s fair value. The loss recognized cannot exceed the total amount of goodwill allocated to that reporting unit. The Company did not incur any goodwill impairment losses in any of the periods presented.
Leases
The Company rents its facilities under operating lease agreements and recognizes related rent expense on a straight-line basis over the term of the applicable lease agreement. Some of the lease agreements contain rent holidays, scheduled rent increases, lease incentives, and renewal options. Rent holidays and scheduled rent increases are included in the determination of rent expense to be recorded over the lease term. Lease incentives are recognized as a reduction of rent expense on a straight-line basis over the term of the lease. Renewals are not assumed in the determination of the lease term unless they are deemed to be reasonably assured at the inception of the lease. The Company recognizes rent expense beginning on the date it obtains the legal right to use and control the leased space.
Property and equipment, net
Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is computed using the straight‑line method over the estimated useful lives of the assets, generally between three and seven years. Leasehold improvements are amortized using the straight‑line method over the shorter of the estimated useful life of the asset or the term of the lease. Amortization expense of assets acquired through capital leases is included in depreciation and amortization expense in the consolidated statements of operations. Maintenance and repairs are charged to expense as incurred, and improvements and betterments are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in the statements of operations in the period realized.
The estimated useful lives of property and equipment are as follows:
Furniture and fixtures
7 years
Automobiles
7 years
Laboratory equipment
5 years
Computer equipment
3 years
Software
3 years
Leasehold improvements
Shorter of lease term or estimated useful life

Long‑lived assets
The Company reviews long‑lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. An impairment loss is recognized when the total estimated future undiscounted cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. Impairment, if any, is assessed using discounted cash flows or other appropriate measures of fair value. Other than impairment losses of $1.0 million in 2016 relating to leasehold improvements and to the shutdown of the Company’s Chilean operations, there were no long-lived asset impairment losses recorded for any period presented. All impairment losses were charged to general and administrative expense.
Variable interest entity
The Company had a variable interest in a variable interest entity (“VIE”) through an investment in convertible notes issued by the VIE. The convertible notes do not provide the Company with voting rights in the VIE or with power to direct the activities of the VIE which most significantly affect its economic performance. The Company is not the VIE’s primary beneficiary and it does not consolidate the VIE.
Fair value of financial instruments
The Company’s financial instruments consist principally of cash and cash equivalents, marketable securities, accounts payable, accrued liabilities, capital leases and debt. The carrying amounts of certain of these financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued and other current liabilities approximate their current fair value due to the relatively short-term nature of these accounts. Based on borrowing rates available to the Company, the carrying value of capital leases and debt approximate their fair values.
Revenue recognition
The Company recognizes revenue when control of the promised goods or services is transferred to the customer in an amount that reflects the consideration it expects to be entitled to in exchange for those goods or services. All revenues are generated from contracts with customers.
Test revenue is generated primarily from the sale of tests that provide analysis and associated interpretation of the sequencing of parts of the genome.
Other revenue consists primarily of revenue from genome network subscription services which is recognized on a straight-line basis over the subscription term, and revenue from collaboration agreements.
Cost of revenue
Cost of revenue reflects the aggregate costs incurred in delivering the genetic testing results to clinicians and includes expenses for personnel-related costs including stock-based compensation, materials and supplies, equipment and infrastructure expenses associated with testing and allocated overhead including rent, equipment depreciation and utilities.
Income taxes
The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and the tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized.
Stock-based compensation
The Company measures its stock-based payment awards made to employees and directors based on the estimated fair values of the awards and recognizes the compensation expense over the requisite service period. The Company uses the Black-Scholes option-pricing model to estimate the fair value of its stock option awards and employee stock purchase plan (“ESPP”) purchases. The fair value of restricted stock unit (“RSU”) awards with time-based vesting terms is based on the grant date share price. The Company grants performance-based restricted stock unit (“PRSU”) awards to certain employees which vest upon the achievement of certain performance conditions, subject to the employees’ continued service relationship with the Company. The probability of vesting is assessed at each reporting period and compensation cost is adjusted based on this probability assessment. The Company recognizes such compensation expense on an accelerated vesting method.
Stock-based compensation expense for awards without a performance condition is recognized using the straight-line method. Stock-based compensation expense is based on the value of the portion of stock-based payment awards that is ultimately expected to vest. As such, the Company’s stock-based compensation is reduced for estimated forfeitures at the date of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.
The Company accounts for compensation expense related to stock options granted to non-employees based on fair values estimated using the Black-Scholes option-pricing model. Stock options granted to non-employees are re-measured at each reporting date until the award is vested.
The Company accounts for stock issued as compensation in connection with business combinations based on the fair value of the Company’s common stock on the date of issuance.
Advertising
Advertising expenses are expensed as incurred. The Company incurred advertising expenses of $0.6 million, $0.6 million and $0.5 million during the years ended December 31, 2018, 2017 and 2016, respectively.
Comprehensive loss
Comprehensive loss is composed of two components: net loss and other comprehensive income (loss). Other comprehensive income (loss) refers to gains and losses that under U.S. GAAP are recorded as an element of stockholders’ equity, but are excluded from net loss. The Company’s other comprehensive income (loss) consists of unrealized gains or losses on investments in available-for-sale securities.
Net loss per share
Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common share equivalents outstanding for the period determined using the treasury stock method. Potentially dilutive securities, consisting of preferred stock, options to purchase common stock, common stock warrants, RSUs and PRSUs, are considered to be common stock equivalents and were excluded from the calculation of diluted net loss per share because their effect would be antidilutive for all periods presented.
Recent accounting pronouncements
The Company evaluates all Accounting Standards Updates (“ASUs”) issued by the FASB for consideration of their applicability. ASUs not included in the disclosures in this report were assessed and determined to be either not applicable or are not expected to have a material impact on the Company’s consolidated financial statements.
Recently issued accounting pronouncements not yet adopted
In November 2018, the FASB issued ASU 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606, which clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under Accounting Standards Codification ("ASC") 606 when the counterparty is a customer. In addition, Topic 808 precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue from contracts with customers if the counterparty is not a customer for that transaction. This guidance will be effective for the Company beginning January 1, 2020. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements.
In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326), which replaces the incurred loss impairment methodology in current U.S. GAAP with a methodology that reflects expected credit losses. The amended guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2019, with early adoption permitted for the fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements.
In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) and in July 2018 issued ASU 2018-10, Codification Improvements to Topic 842, Leases and ASU 2018-11, Leases (Topic 842): Targeted Improvements (the foregoing ASUs collectively referred to as “Topic 842”). Under the new guidance, lessees are required to recognize a lease liability and a right-of-use asset for all leases (with the exception of short-term leases) at the commencement date and also requires expanded disclosures about leasing arrangements. Topic 842 is effective for annual and interim periods beginning on or after December 15, 2018 and early adoption is permitted. Entities may initially apply the new leases standard at the adoption date and recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption.
The Company is evaluating the final effect that Topic 842 and related standards will have on its consolidated financial statements, related disclosures and ongoing financial reporting, but expects implementation of Topic 842 to result in the recognition of material right of use assets and corresponding lease liabilities in its consolidated balance sheets as of the implementation of Topic 842 on January 1, 2019, principally relating to facilities leases. The Company does not have any material embedded leases and the implementation of Topic 842 is primarily focused on the treatment of the Company's previously identified leases. As of December 31, 2018, the Company's total future undiscounted capital lease payments were $3.5 million and future undiscounted non-cancelable minimum operating lease payments, net of subleases were $78.4 million
Recently adopted accounting pronouncements
In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606), designed to enable users of financial statements to better understand the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. On January 1, 2018, the Company adopted the provisions of Topic 606 using the modified retrospective method. From adoption to date, the Company has recognized all its revenue from contracts with customers within the scope of Topic 606. In connection with the adoption, the Company recognized the cumulative effect of initially applying this standard as an adjustment to retained earnings on the date of adoption. Comparative information prior to the date of adoption has not been restated and continues to be reported under the accounting standards in effect for those periods.
In connection with the adoption of Topic 606, the Company amended its revenue recognition policy to provide for the recognition of certain variable consideration related to diagnostic tests that was previously deferred pending cash collection. Under Topic 606, the Company records variable consideration based on an estimate of the consideration to which it will be entitled.
The Company recognizes revenue when control of the promised goods or services is transferred to the customer in an amount that reflects the consideration it expects to be entitled to in exchange for those goods or services. All revenues are generated from contracts with customers.
Diagnostic tests
The majority of the Company’s revenue is generated from genetic testing services that provide analysis and associated interpretation of the sequencing of parts of the genome. Test orders are placed under signed requisitions, and the Company often enters into contracts with institutions (e.g., hospitals and clinics) and insurance companies that include pricing provisions under which such tests are billed. Billing terms are generally net thirty days.
While the transaction price of diagnostic tests is originally established either via contract or pursuant to the Company’s standard list price, the Company often provides concessions for tests billed to insurance carriers, and therefore the transaction price for patient insurance-billed tests is considered to be variable and revenue is recognized based on an estimate of the consideration to which the Company will be entitled at an amount for which it is probable that a reversal of cumulative consideration will not occur. Making these estimates requires significant judgments based upon such factors as length of payer relationship, historical payment patterns, changes in contract provisions and insurance reimbursement policies. These judgments are reviewed quarterly and revenue recognized is updated, as necessary, until the Company’s obligations are fully settled.
In connection with some diagnostic test orders, the Company offers limited re-requisition rights (“Re-Requisition Rights”) that are considered distinct at contract inception, and therefore certain diagnostic test orders contain two performance obligations, the performance of the original test and the Re-Requisition Rights. When Re-Requisition Rights are granted, the Company allocates the transaction price to each performance obligation based on the relative estimated standalone selling prices. In order to comply with loss contract rules, the allocations are adjusted, if necessary, to ensure the amount deferred for Re-Requisition Rights is no less than the estimated cost of fulfilling the Company’s related obligations.
The Company looks to transfer of control in assessing timing of recognition of revenue in connection with each performance obligation. In general, revenue in connection with diagnostic tests is recognized upon delivery of the underlying clinical report or when the report is made available on the Company’s web portal. Outstanding performance obligations pertaining to orders received but for which the underlying report has not been issued are generally satisfied within a thirty-day period. Revenue in connection with Re-Requisition Rights is recognized as the rights are exercised or expire unexercised, which is generally within ninety days of initial deferral.
Other contracts
The Company also enters into collaboration and genome network contracts. Collaboration agreements provide customers with diagnostic testing and related data aggregation reporting services that are provided over the contract term. Collaboration revenue is recognized as the testing and reporting services are delivered to the customer. Genome network offerings consist of subscription services related to a proprietary software platform designed to connect patients, clinicians, advocacy organizations, researchers and therapeutic developers to accelerate the understanding, diagnosis and treatment of hereditary disease. Such services are recognized on a straight-line basis over the subscription periods.
Amounts due under collaboration and genome network agreements are typically billable on net thirty-day terms.
XML 28 R11.htm IDEA: XBRL DOCUMENT v3.10.0.1
Revenue, accounts receivable and deferred revenue
 12 Months Ended
Dec. 31, 2018
Revenue from Contract with Customer [Abstract]  
Revenue, accounts receivable and deferred revenue Revenue, accounts receivable and deferred revenue
As described in Note 2, "Summary of significant accounting policies," the Company adopted Topic 606 effective January 1, 2018. In connection with the adoption the Company utilized the following practical expedients and exemptions:
•
Certain information about remaining performance obligations is not disclosed because the underlying contracts have an original expected duration of one year or less.
•
Costs to obtain or fulfill a contract are expensed when incurred because the amortization period would have been one year or less.
•
No adjustments to promised consideration were made for financing as the Company expects, at contract inception, that the period between the transfer of a promised good or service and when the customer pays for that good or service will be one year or less.
The adoption of Topic 606 resulted in a cumulative-effect adjustment to accounts receivable and accumulated deficit of $11.2 million as of January 1, 2018 primarily related to the recognition of uncollected
diagnostic test variable consideration as of the date of adoption. Test revenue without adoption of Topic 606 for the year ended December 31, 2018 includes cash collections related to accounts receivable recorded as of January 1, 2018 in connection with the Topic 606 cumulative-effect adjustment.
The effect of the adoption of Topic 606 on financial statement line items in the Company’s consolidated statement of operations for the year ended December 31, 2018, and the Company’s consolidated balance sheet as of December 31, 2018 was as follows (in thousands, except per share amounts):

 
 
Year Ended December 31, 2018
 
 
 
 
Without
 
Effect of
 
 
 
 
Adoption of
 
Adoption
 
 
As Reported
 
Topic 606
 
Higher/(Lower)
Test revenue
 
$
144,560

 
$
144,222

 
$
338

Net loss
 
$
(129,355
)
 
$
(129,693
)
 
$
338

Net loss per share, basic and diluted
 
$
(1.94
)
 
$
(1.94
)
 
$
—


 
 
As of December 31, 2018
 
 
 
 
Without
 
Effect of
 
 
 
 
Adoption of
 
Adoption
 
 
As Reported
 
Topic 606
 
Higher/(Lower)
Accounts receivable
 
$
26,296

 
$
14,150

 
$
12,146

Accumulated deficit
 
$
(516,712
)
 
$
(528,291
)
 
$
11,579

Stockholders' equity
 
$
161,839

 
$
150,260

 
$
11,579


Disaggregation of revenue
Test revenue is generated from sales of diagnostic tests to three groups of customers: institutions, such as hospitals, clinics and partners; patients who pay directly; and patients’ insurance carriers. Amounts billed and collected, and the timing of collections, vary based on whether the payer is an institution, an insurance carrier or a patient. Other revenue consists principally of revenue recognized under collaboration and genome network agreements.
The following table includes the Company’s revenues as disaggregated by payer category (in thousands):
 
 
Year Ended December 31,
 
 
2018
 
2017 (1)
Test revenue:
 
 
 
 
Institutions
 
$
34,618

 
$
17,238

Patient - direct
 
13,589

 
5,638

Patient - insurance
 
96,353

 
42,293

 Total test revenue
 
144,560

 
65,169

Other revenue
 
3,139

 
3,052

Total revenue
 
$
147,699

 
$
68,221

___________________________________________________________________ 
(1)
As noted above, prior period amounts are presented as originally reported based upon the accounting standards in effect for those periods.
Included in revenue in the Company’s consolidated statements of operations for the year ended December 31, 2018 was $0.3 million that was included in deferred revenue at January 1, 2018.
The Company recognizes revenue related to billings based on estimates of the amount that will ultimately be realized. The estimate of the transaction price of test revenue is based on many factors such as length of payer relationship, historical payment patterns, changes in contract provisions and insurance reimbursement policies. Cash collections for certain tests delivered may differ from rates originally estimated. As a result of new information, the Company updated its estimate of the amounts to be recognized for previously delivered tests which resulted in
an additional $4.5 million of test revenue for the year ended December 31, 2018. These changes in estimates decreased the Company’s loss from operations by $4.5 million and decreased basic and diluted net loss per share by approximately $0.07 for the year ended December 31, 2018.
Accounts receivable
The majority of the Company’s accounts receivable represents amounts billed to institutions (e.g., hospitals, clinics) and estimated amounts to be collected from third-party insurance payers for test revenue recognized. Also included is amounts due under the terms of collaboration and genome network agreements for diagnostic testing and data aggregation reporting services provided and proprietary platform access rights transferred.
Deferred revenues
The Company records deferred revenues when cash payments are received or due in advance of its performance related to one or more performance obligations. The amounts deferred to date primarily consist of consideration received pertaining to the estimated exercise of certain Re-Requisition Rights. The Company defers revenue related to Re-Requisition Rights in amounts no less than the estimated cost of fulfilling its related obligations. The Company recognizes revenue related to Re-Requisition Rights as the rights are exercised or expire unexercised, which is generally within 90 days of initial deferral.
XML 29 R12.htm IDEA: XBRL DOCUMENT v3.10.0.1
Business combinations
 12 Months Ended
Dec. 31, 2018
Business Combinations [Abstract]  
Business combinations Business combinations
AltaVoice
On January 6, 2017, the Company acquired AltaVoice (formerly PatientCrossroads, Inc.), a privately-owned patient-centered data company with a global platform for collecting, curating, coordinating and delivering safeguarded data from patients and clinicians. The acquisition, complemented by several other strategic partnerships, expanded the Company's genome network, designed to connect patients, clinicians, advocacy organizations, researchers and therapeutic developers to accelerate the understanding, diagnosis, and treatment of hereditary disease. Pursuant to the terms of the Stock Purchase Agreement, the Company acquired all of the outstanding shares of AltaVoice for total purchase consideration of $12.4 million, payable in the Company’s common stock, as follows:
(a)
payment of $5.5 million through the issuance of 641,126 shares of the Company’s common stock;
(b)
payment of $5.0 million in the Company’s common stock, payable on March 31, 2018, with the common shares deliverable equal to $5.0 million divided by the trailing average share price of the Company’s common stock for the 30 days preceding March 31, 2018. This payment was made in April 2018 through the issuance of 716,332 shares of the Company's common stock;
(c)
payment of $5.0 million in the Company’s common stock, which was contingently payable on March 31, 2018 if a milestone based on a certain threshold of revenue was achieved during 2017, with the shares deliverable equal to $5.0 million divided by the trailing average share price of the Company’s common stock for the 30 days preceding March 31, 2018. As the foregoing milestone was not achieved, there was a new contingent milestone based on achieving a revenue target during 2017 and 2018. Since this new contingent milestone was achieved, on March 31, 2019, a payment of $5.0 million in the Company’s common stock will be payable. The actual payout is dependent upon meeting the 2017 and 2018 revenue targets (capped at $14.0 million) times 75% less $5.5 million. This formula in effect caps the possible payout amount at $5.0 million in the Company’s common shares. The number of shares to be issued will be equal to the payout amount divided by the trailing average share price of the Company’s common stock for the 30 days preceding March 31, 2019.
The first payment of $5.5 million was classified as equity. The second payment was discounted to $4.7 million as of the acquisition date, recorded as a liability, and was accreted to fair value at each reporting date until the extinguishment of the liability in April 2018. The third payment, representing contingent consideration, was determined to have a fair value of $2.2 million as of the acquisition date and was recorded as a liability. In accordance with ASC Topic 805, Business Combinations, the contingent consideration of $2.2 million was remeasured to fair value at each reporting date until the contingency was resolved, with changes in fair value recognized in earnings.
For the second payment, the acquisition-date fair value was $4.7 million, and the Company recorded accretion gains (losses) of $1.6 million and $(0.2) million in other income (expense), net, for the years ended December 31, 2018 and 2017, respectively. The accretion gains in 2018 resulted from an adjustment to the value of
the second payment as of March 31, 2018, and principally reflected the difference between the value of the common shares deliverable, based upon the closing price of the Company’s stock on March 29, 2018, and the value per share used to calculate the number of common shares deliverable. The accretion losses in 2017 resulted from adjustments to the discounted value of the second payment, reflecting the passage of time.
For the third payment, the acquisition-date fair value was $2.2 million, and the Company recorded remeasurement losses of $1.2 million and $1.6 million in general and administrative expense for the years ended December 31, 2018 and 2017, respectively. The remeasurement losses in 2018 reflect updated estimations of fair value of the third payment, based upon achieving a revenue target during 2017 and 2018, as the milestone based on a certain threshold of revenue to be achieved during 2017 was not met. The principal inputs affecting those estimations have been updates to the Company’s revenue forecasts and the passage of time.
Assets acquired and liabilities assumed are recorded based on valuations derived from estimated fair value assessments and assumptions used by the Company. While the Company believes that its estimates and assumptions underlying the valuations are reasonable, different estimates and assumptions could result in different valuations assigned to the individual assets acquired and liabilities assumed, and the resulting amount of goodwill. The following table summarizes the fair values of assets acquired and liabilities assumed at the date of acquisition (in thousands):
Cash
$
54

Accounts receivable
274

Prepaid expense and other assets
52

Non-compete agreement
286

Developed technology
570

Customer relationships
3,389

Total identifiable assets acquired
4,625

Accounts payable
(28
)
Deferred revenue
(202
)
Accrued expenses
(21
)
Deferred tax liability
(1,422
)
Total liabilities assumed
(1,673
)
Net identifiable assets acquired
2,952

Goodwill
9,432

Net assets acquired
$
12,384


Acquisition-related intangibles included in the above table are finite-lived. Customer relationships are being amortized on an accelerated basis, utilizing free cash flows, over a period of ten years. All other acquisition-related intangibles are being amortized on a straight-line basis over their estimated lives, which approximates the pattern in which the economic benefits of the intangible assets are expected to be realized, as follows (in thousands):
 
Gross
Purchased
Intangible
Assets
 
Estimated
Useful
Life
(in Years)
Non-compete agreement
$
286

 
5
Developed technology
570

 
6
Customer relationships
3,389

 
10
 
$
4,245

 
 

Goodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired. The acquisition of AltaVoice resulted in $9.4 million of goodwill which the Company believes consists principally of expected synergies to be realized by combining capabilities, technology and data to accelerate the use of genetic information for the diagnosis and treatment of hereditary diseases. In accordance with ASC 350, goodwill will not be amortized but will be tested for impairment at least annually. Goodwill created as a result of the acquisition is not deductible for tax purposes. The Company has finalized its assessment of fair value of the assets and liabilities assumed at the acquisition date.
Ommdom
On June 11, 2017, the Company acquired Ommdom, Inc. (“Ommdom”), a privately held company that develops, commercializes and sells hereditary risk assessment and management software, including CancerGene Connect, a cancer genetic counseling platform. The acquisition expanded Invitae’s suite of genome management offerings designed to help patients and clinicians use genetic information as part of mainstream medical care. CancerGene Connect is a platform for collecting and managing genetic family histories.
Pursuant to the terms of a Stock Exchange Agreement, the Company acquired all of the outstanding shares of Ommdom for consideration of $6.1 million, payable entirely in the Company’s common stock. There was no cash consideration nor any contingent payments associated with the acquisition, other than a hold-back amount of $0.6 million. Per the terms of the agreement, the Company was obligated to issue shares of its common stock as follows:
(a)
payment of $5.5 million through the issuance of 600,108 shares of the Company’s common stock on the acquisition date; and
(b)
payment of $0.6 million through the issuance of 66,582 shares of the Company’s common stock, representing a hold-back amount, and payable on the twelve-month anniversary of the acquisition date.
The first payment of $5.5 million was classified as equity. The second payment of $0.6 million was recorded as a stock payable liability on the acquisition date and was reclassified to equity upon the issuance of 66,582 shares of the Company’s common stock in June 2018.
Assets acquired and liabilities assumed are recorded based on valuations derived from estimated fair value assessments and assumptions used by the Company. While the Company believes that its estimates and assumptions underlying the valuations are reasonable, different estimates and assumptions could result in different valuations assigned to the individual assets acquired and liabilities assumed, and the resulting amount of goodwill. The following table summarizes the fair values of assets acquired and liabilities assumed at the date of acquisition (in thousands):
Cash
$
53

Accounts receivable
10

Prepaid expense and other assets
4

Trade name
13

Developed technology
2,335

Customer relationships
147

Total identifiable assets acquired
2,562

Accounts payable
(16
)
Accrued expenses
(17
)
Deferred tax liability
(434
)
Total liabilities assumed
(467
)
Net identifiable assets acquired
2,095

Goodwill
4,045

Net assets acquired
$
6,140


Finite-lived intangibles included in the above table are being amortized on a straight-line basis over their estimated lives, which approximates the pattern in which the economic benefits of the intangible assets are expected to be realized, as follows (in thousands):
 
Gross
Purchased
Intangible
Assets
 
Estimated
Useful
Life
(in Years)
Trade name
$
13

 
5
Developed technology
2,335

 
5
Customer relationships
147

 
5
 
$
2,495

 
 

Goodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired. The acquisition of Ommdom resulted in the recognition of $4.0 million of goodwill which the Company believes consists principally of expected synergies to be realized by expanding the Company’s suite of genome management offerings. In accordance with ASC 350, goodwill will not be amortized but rather will be tested for impairment at least annually. Goodwill created as a result of the acquisition is not deductible for tax purposes. The Company has finalized its assessment of fair value of the assets and liabilities assumed at the acquisition date.
Good Start Genetics
On August 4, 2017, the Company acquired 100% of the fully diluted equity of Good Start, a privately held molecular diagnostics company focused on preimplantation and carrier screening for inherited disorders. The acquisition of Good Start was intended to further Invitae’s plan to create a comprehensive genetic information platform providing high-quality, affordable genetic information coupled with world-class clinical expertise to inform healthcare decisions throughout every stage of an individual’s life. The purchase consideration for the Good Start acquisition consisted of the assumption of the net liabilities of Good Start of $24.4 million at the acquisition date.
Immediately subsequent to the acquisition of Good Start, the Company paid $18.4 million in cash to settle outstanding notes payable, accrued interest and related costs. In addition, and immediately subsequent to the acquisition, the Company settled outstanding convertible promissory notes payable through:
(a)
payment of $11.9 million through the issuance of 1,148,283 shares of the Company’s common stock; and
(b)
payment of $3.6 million through the issuance of 343,986 shares of the Company’s common stock, representing a hold-back amount payable on the one-year anniversary of the acquisition date. In September 2018, the Company issued 212,260 shares in partial payment of the hold-back amount payable. The remainder of the hold-back amount payable, approximately $1.3 million as of December 31, 2018, will be settled upon resolution of outstanding claims from Good Start customers, of which $0.6 million was settled in January 2019.
Also in connection with the acquisition of Good Start and immediately subsequent to the acquisition, the Company paid bonuses to certain members of Good Start’s management team through:
(a)
payment of $0.9 million through the issuance of 83,025 shares of the Company’s common stock; and
(b)
payment of $0.4 million through the issuance of 37,406 shares of the Company’s common stock, representing a hold-back amount payable on the one-year anniversary of the acquisition date. In September 2018, the Company issued 27,784 shares in partial payment of the hold-back amount payable to settle bonuses to Good Start's management team. The remainder of the hold-back amount payable, approximately $0.2 million as of December 31, 2018, will be settled upon resolution of outstanding claims from Good Start customers, of which $0.1 million was settled in January 2019.
These bonus payments were recorded as general and administrative expense.
Assets acquired and liabilities assumed are recorded based on valuations derived from estimated fair value assessments and assumptions used by the Company. While the Company believes that its estimates and assumptions underlying the valuations are reasonable, different estimates and assumptions could result in different valuations assigned to the individual assets acquired and liabilities assumed, and the resulting amount of goodwill.
At acquisition date, the Company also recorded $4.8 million as a provisional amount for a deferred tax liability because certain information and analysis related to Good Start’s historical net operating losses that could have affected the Company’s initial valuation was still being obtained or reviewed at that time. This provisional amount for the deferred tax liability was subsequently reversed during the fourth quarter of 2017 based on the results of further analysis of Good Start’s historical net operating losses.
The following table summarizes the fair values of assets acquired and liabilities assumed at the date of acquisition (in thousands):
Cash and restricted cash
$
1,381

Accounts receivable
2,246

Prepaid expense and other assets
1,579

Property and equipment
1,320

Trade name
460

Developed technology
5,896

Customer relationships
7,830

Total identifiable assets acquired
20,712

Accounts payable
(5,418
)
Accrued expenses
(6,802
)
Notes payable
(17,904
)
Convertible promissory notes payable
(15,430
)
Other liabilities
(222
)
Total liabilities assumed
(45,776
)
Net identifiable assets acquired
(25,064
)
Goodwill
25,064

Net assets acquired
$
—


During the year ended December 31, 2018, the Company recorded adjustments to its accounting for the amount recorded as accounts receivable at acquisition. Accordingly, the fair value of accounts receivable was decreased by $0.7 million during the year ended December 31, 2018, with corresponding increases to goodwill.

Customer relationships are being amortized on an accelerated basis, utilizing free cash flows, over a period of eight years. All other finite-lived intangibles included in the above table are being amortized on a straight-line basis over their estimated lives, which approximates the pattern in which the economic benefits of the intangible assets are expected to be realized, as follows (in thousands):
 
Gross
Purchased
Intangible
Assets
 
Estimated
Useful
Life
(in Years)
Trade name
$
460

 
3
Developed technology
5,896

 
5
Customer relationships
7,830

 
8
 
$
14,186

 
 

Goodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired. The acquisition of Good Start resulted in the recognition of $25.1 million of goodwill which the Company believes consists principally of expected synergies to be realized by expanding the Company’s suite of genome management offerings. In accordance with ASC 350, goodwill will not be amortized but rather will be tested for impairment at least annually. Goodwill created as a result of the acquisition is not deductible for tax purposes. The Company has finalized its assessment of fair value of the assets and liabilities assumed at the acquisition date.
CombiMatrix
On November 14, 2017, the Company completed its acquisition of CombiMatrix in accordance with the terms of the Agreement and Plan of Merger and Reorganization, dated as of July 31, 2017 (the “Merger Agreement”), by and among the Company, Coronado Merger Sub, Inc., a wholly owned subsidiary of the Company (“Merger Sub”), and CombiMatrix, pursuant to which Merger Sub merged with and into CombiMatrix, with CombiMatrix surviving as a wholly owned subsidiary of the Company (the “Merger”).
At the closing of the Merger, the Company issued shares of its common stock to (i) CombiMatrix’s common stockholders, at an exchange ratio of 0.8692 of a share of the Company’s common stock (the “Merger Exchange
Ratio”) for each share of CombiMatrix common stock outstanding immediately prior to the Merger, (ii) CombiMatrix’s Series F preferred stockholders, at the Merger Exchange Ratio for each share of CombiMatrix common stock underlying Series F preferred stock outstanding immediately prior to the Merger, (iii) holders of outstanding and unexercised in-the-money CombiMatrix stock options, which were fully accelerated to the extent of any applicable vesting period and converted into the right to receive the number of shares of the Company’s common stock equal to the Merger Exchange Ratio multiplied by the number of shares of CombiMatrix common stock issuable upon exercise of such option, minus the number of shares of the Company’s common stock determined by dividing the aggregate exercise price for such option by $9.491, and (iv) holders of outstanding and unsettled CombiMatrix restricted stock units, which were fully accelerated to the extent of any applicable vesting period and converted into the right to receive a number of shares of the Company’s common stock determined by multiplying the number of shares of CombiMatrix common stock that were subject to such restricted stock unit by the Merger Exchange Ratio.
In addition, at the closing of the Merger, (a) all outstanding and unexercised out-of-the money CombiMatrix stock options were cancelled and terminated without the right to receive any consideration, (b) all CombiMatrix Series D Warrants and Series F Warrants outstanding and unexercised immediately prior to the closing of the Merger were assumed by the Company and converted into warrants to purchase the number of shares of the Company’s common stock determined by multiplying the number of shares of CombiMatrix common stock subject to such warrants by the Merger Exchange Ratio, and with the exercise price adjusted by dividing the per share exercise price of the CombiMatrix common stock subject to such warrants by the Merger Exchange Ratio, and (c) certain entitlements under CombiMatrix’s executive compensation transaction bonus plan (the “Transaction Bonus Plan”) were paid in shares of the Company’s common stock or RSUs to be settled in shares of the Company’s common stock. All outstanding and unexercised CombiMatrix Series A, Series B, Series C, Series E, and PIPE warrants were repurchased by CombiMatrix prior to closing pursuant to that certain CombiMatrix Common Stock Purchase Warrants Repurchase Agreement dated July 11, 2016.
Pursuant to the Merger Agreement, the Company issued an aggregate of 2,703,389 shares of its common stock as follows:
(a)
payment of $20.5 million through the issuance of 2,611,703 shares of the Company’s common stock to holders of CombiMatrix common stock outstanding;
(b)
payment of $0.7 million through the issuance of 85,219 shares of the Company’s RSUs to holders of outstanding and unsettled CombiMatrix restricted stock units;
(c)
payment of $0.1 million through the issuance of 3,323 shares of the Company’s common stock to holders of outstanding and unexercised in-the-money CombiMatrix stock options; and
(d)
payment of $0.1 million through the issuance of 3,144 shares of the Company’s common stock to holders of CombiMatrix Series F preferred stock.
In addition, and pursuant to the Merger Agreement, the Company issued warrants to purchase an aggregate of 2,077,273 shares of its common stock as follows:
(a)
payment of $7.4 million through the issuance of warrants to purchase a total of 1,739,689 shares of the Company’s common stock in exchange for all outstanding CombiMatrix Series F warrants; and
(b)
payment of $1,000 through the issuance of warrants to purchase a total of 337,584 shares of the Company’s common stock in exchange for all outstanding CombiMatrix Series D warrants.
In connection with the acquisition of CombiMatrix, the Company paid bonuses to certain members of CombiMatrix’s management team through:
(a)
payment of $1.7 million through the issuance of common stock and RSUs totaling 214,976 shares of the Company’s common stock to settle payments pursuant to CombiMatrix’s executive compensation transaction bonus plan (the “Transaction Bonus Plan”), recorded as post-combination compensation expense and included in general and administrative expense; and
(b)
payment of $0.2 million through the issuance of 22,966 shares of the Company’s common stock to settle payments pursuant to the Transaction Bonus Plan, recorded as an assumed liability at the acquisition date.
Assets acquired and liabilities assumed are recorded based on valuations derived from estimated fair value assessments and assumptions used by the Company. While the Company believes that its estimates and assumptions underlying the valuations are reasonable, different estimates and assumptions could result in different valuations assigned to the individual assets acquired and liabilities assumed, and the resulting amount of goodwill. The following table summarizes the fair values of assets acquired and liabilities assumed at the date of acquisition (in thousands):
Cash and restricted cash
$
1,333

Accounts receivable
4,118

Prepaid expense and other assets
1,299

Property and equipment
437

Other assets - non current
30

Favorable leases
247

Trade name
103

Patent licensing agreement
496

Developed technology
3,162

Customer relationships
12,397

Total identifiable assets acquired
23,622

 
 
Accounts payable
(276
)
Accrued expenses
(3,925
)
Deferred tax liability
(2,862
)
Other liabilities
(180
)
Total liabilities assumed
(7,243
)
 
 
Net identifiable assets acquired
16,379

Goodwill
11,554

Net assets acquired
$
27,933


During the year ended December 31, 2018, upon the completion of the Company's analysis of CombiMatrix's historical net operating losses, the Company recorded a deferred tax liability of $2.9 million with corresponding increases to goodwill. The $2.9 million net deferred tax liability represents the excess of the financial reporting over tax basis in acquired intangibles over the amount of CombiMatrix’s historical net operating loss carryovers that were determined to be available to offset future income due to change in ownership operating loss carryover limitation rules under Internal Revenue Code section 382.
Customer relationships are being amortized on an accelerated basis, utilizing free cash flows, over a period of eleven years. All other finite-lived intangibles included in the above table are being amortized on a straight-line basis over their estimated lives, which approximates the pattern in which the economic benefits of the intangible assets are expected to be realized, as follows (in thousands):
 
Gross
Purchased
Intangible
Assets
 
Estimated
Useful
Life
(in Years)
Favorable leases
$
247

 
2
Trade name
103

 
1
Patent licensing agreement
496

 
15
Developed technology
3,162

 
4
Customer relationships
12,397

 
11
 
$
16,405

 
 

Goodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired. The acquisition of CombiMatrix resulted in the recognition of $11.6 million of goodwill which the Company believes consists principally of expected synergies to be realized by expanding the Company’s suite of genome management offerings. In accordance with ASC 350, goodwill will not be amortized but rather will be tested for impairment at least annually. Goodwill created as a result of the acquisition is not deductible for tax purposes. The Company has finalized its assessment of fair value of the assets and liabilities assumed at the acquisition date.
XML 30 R13.htm IDEA: XBRL DOCUMENT v3.10.0.1
Goodwill and intangible assets
 12 Months Ended
Dec. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and intangible assets Goodwill and intangible assets
Goodwill
Details of the Company’s goodwill for the year ended December 31, 2018 are as follows (in thousands):
 
AltaVoice
 
Ommdom
 
Good Start
 
CombiMatrix
 
Total
Balance as of December 31, 2017
$
9,432

 
$
4,045

 
$
24,406

 
$
8,692

 
$
46,575

Goodwill adjustment
—

 
—

 
658

 
2,862

 
3,520

Balance as of December 31, 2018
$
9,432

 
$
4,045

 
$
25,064

 
$
11,554

 
$
50,095


The goodwill adjustments were principally due to changes in the fair value of accounts receivable for Good Start as well as the recognition of a $2.9 million deferred tax liability for CombiMatrix resulting from the completion of the Company’s analysis of historical net operating losses.
Intangible assets
The following table presents details of the Company’s finite-lived intangible assets as of December 31, 2018 (in thousands):
 
Cost
 
Accumulated
Amortization
 
Net
 
Weighted Average
Useful Life
(in Years)
 
Weighted Average
Estimated Remaining
Useful Life
(in Years)
Customer relationships
$
23,763

 
$
(2,783
)
 
$
20,980

 
10.0
 
8.6
Developed technology
11,963

 
(3,482
)
 
8,481

 
4.8
 
3.4
Non-compete agreement
286

 
(114
)
 
172

 
5.0
 
3.0
Trade name
576

 
(329
)
 
247

 
2.7
 
1.4
Patent licensing agreement
496

 
(37
)
 
459

 
15.0
 
13.9
Favorable leases
247

 
(117
)
 
130

 
2.2
 
1.1
 
$
37,331

 
$
(6,862
)
 
$
30,469

 
8.2
 
6.8

Acquisition-related intangibles included in the above table are finite-lived. Customer relationships are being amortized on an accelerated basis, in proportion to estimated cash flows, over periods ranging from five to eleven years. All other acquisition-related intangibles are being amortized on a straight-line basis over their estimated lives, which approximates the pattern in which the economic benefits of the intangible assets are realized. Amortization expense was $5.0 million, $1.8 million, and nil for the years ended December 31, 2018, 2017, and 2016, respectively. Intangible assets are carried at cost less accumulated amortization. Amortization expense is recorded to research and development, sales and marketing and general and administrative expense.
The following table summarizes the Company’s estimated future amortization expense of intangible assets with finite lives as of December 31, 2018 (in thousands):
 
Amount
2019
$
5,250

2020
5,525

2021
5,829

2022
4,124

2023
3,111

Thereafter
6,630

Total estimated future amortization expense
$
30,469
XML 31 R14.htm IDEA: XBRL DOCUMENT v3.10.0.1
Balance sheet components
 12 Months Ended
Dec. 31, 2018
Balance Sheet Related Disclosures [Abstract]  
Balance sheet components Balance sheet components
Property and equipment, net
Property and equipment consisted of the following (in thousands):
 
December 31, 2018
 
December 31, 2017
Leasehold improvements
$
13,034

 
$
12,623

Laboratory equipment
22,149

 
17,705

Equipment under capital lease
7,129

 
11,446

Computer equipment
4,723

 
4,023

Software
2,594

 
2,520

Furniture and fixtures
784

 
569

Automobiles
20

 
20

Construction-in-progress
1,962

 
965

Total property and equipment, gross
52,395

 
49,871

Accumulated depreciation and amortization
(24,509
)
 
(19,530
)
Total property and equipment, net
$
27,886

 
$
30,341


Depreciation expense was $8.5 million, $7.2 million and $6.6 million for the years ended December 31, 2018, 2017 and 2016, respectively.
Accrued liabilities
Accrued liabilities consisted of the following (in thousands):
 
December 31, 2018
 
December 31, 2017
Accrued compensation and related expenses
$
7,917

 
$
7,406

Deferred revenue
761

 
307

Liabilities associated with business combinations
6,460

 
9,497

Liability associated with co-development agreement
2,000

 
—

Other
9,425

 
5,532

Total accrued liabilities
$
26,563

 
$
22,742


Other long-term liabilities
Other long-term liabilities consisted of the following (in thousands):
 
December 31, 2018
 
December 31, 2017
Lease incentive obligation, non-current
$
3,280

 
$
3,831

Deferred rent, non-current
5,495

 
5,153

Liabilities associated with business combinations
—

 
3,779

Other non-current liabilities
181

 
677

Total other long-term liabilities
$
8,956

 
$
13,440
XML 32 R15.htm IDEA: XBRL DOCUMENT v3.10.0.1
Fair value measurements
 12 Months Ended
Dec. 31, 2018
Fair Value Disclosures [Abstract]  
Fair value measurements Fair value measurements
Financial assets and liabilities are recorded at fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The authoritative guidance establishes a three-level valuation hierarchy that prioritizes the inputs to valuation techniques used to measure fair value based upon whether such inputs are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions made by the reporting entity.
The three-level hierarchy for the inputs to valuation techniques is summarized as follows:
Level 1—Observable inputs such as quoted prices (unadjusted) for identical instruments in active markets.
Level 2—Observable inputs such as quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, or model-derived valuations whose significant inputs are observable.
Level 3—Unobservable inputs that reflect the reporting entity’s own assumptions.
The following tables set forth the fair value of the Company’s consolidated financial instruments that were measured at fair value on a recurring basis (in thousands):
 
 
December 31, 2018
 
 
Amortized Cost
 
Gross Unrealized Gains
 
Gross Unrealized Losses
 
Estimated Fair Value
 
Level 1
 
Level 2
 
Level 3
Financial assets:
 
 
 
 
 
 
 
 
 
 

 
 

 
 

Money market funds
 
$
93,934

 
$
—

 
$
—

 
$
93,934

 
$
93,934

 
$
—

 
$
—

Certificates of deposit
 
300

 
—

 
—

 
300

 
—

 
300

 
—

Commercial paper
 
10,908

 
—

 
(1
)
 
10,907

 
—

 
10,907

 
—

U.S. treasury notes
 
9,990

 
—

 
—

 
9,990

 
9,990

 
—

 
—

U.S. government agency securities
 
6,001

 
—

 
(4
)
 
5,997

 
—

 
5,997

 
—

Total financial assets
 
$
121,133

 
$
—

 
$
(5
)
 
$
121,128

 
$
103,924

 
$
17,204

 
$
—

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Financial liabilities:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Contingent consideration
 
 
 
 
 
 
 
$
4,998

 
$
—

 
$
—

 
$
4,998

Total financial liabilities
 
 
 
 
 
 
 
$
4,998

 
$
—

 
$
—

 
$
4,998

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
December 31, 2018
Reported as:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash equivalents
 
 
 
 
 
 
 
 
 
 
 
$
101,395
 
Restricted cash
 
 
 
 
 
 
 
 
 
 
 
6,006
 
Marketable securities
 
 
 
 
 
 
 
 
 
 
 
13,727
 
Total cash equivalents, restricted cash, and marketable securities
 
 
 
$
121,128
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Accrued liabilities
 
 
 
 
 
 
 
 
 
 
 
$
4,998
 
 
 
December 31, 2017
 
 
Amortized
Cost
 
Gross
Unrealized
Gains
 
Gross
Unrealized
Losses
 
Estimated
Fair Value
 
Level 1
 
Level 2
 
Level 3
Financial assets:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Money market funds
 
$
5,998

 
$
—

 
$
—

 
$
5,998

 
$
5,998

 
$
—

 
$
—

Certificates of deposit
 
300

 
—

 
—

 
300

 
300

 
—

 
—

U.S. treasury notes
 
12,010

 
—

 
(19
)
 
11,991

 
11,991

 
—

 
—

U.S. government agency securities
 
46,451

 
—

 
(152
)
 
46,299

 
—

 
46,299

 
—

Total financial assets
 
$
64,759

 
$
—

 
$
(171
)
 
$
64,588

 
$
18,289

 
$
46,299

 
$
—

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Financial liabilities:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Contingent consideration
 
 
 
 
 
 
 
$
3,779

 
$
—

 
$
—

 
$
3,779

Total financial liabilities
 
 
 
 
 
 
 
$
3,779

 
$
—

 
$
—

 
$
3,779

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
December 31, 2017
Reported as:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash equivalents
 
 
 
 
 
 
 
 
 
 
 
$
592
 
Restricted cash
 
 
 
 
 
 
 
 
 
 
 
5,406
 
Marketable securities
 
 
 
 
 
 
 
 
 
 
 
58,590
 
Total cash equivalents, restricted cash, and marketable securities
 
 
 
$
64,588
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Accrued liabilities
 
 
 
 
 
 
 
 
 
 
 
$
3,779
 

There were no transfers between Level 1, Level 2 and Level 3 during the periods presented. The total fair value of investments with unrealized losses at December 31, 2018 was $13.4 million. None of the available-for-sale securities held as of December 31, 2018 has been in a material continuous unrealized loss position for more than one year. At December 31, 2018, unrealized losses on available-for-sale investments are not attributed to credit risk and are considered to be temporary. The Company believes it is more likely than not that investments in an unrealized loss position will be held until maturity or the recovery of the cost basis of the investment. To date, the Company has not identified any other-than-temporary declines in market value and thus has not recorded any impairment charges on its financial assets other than on the convertible notes which are described in Note 8, “Investment in privately held company.”
At December 31, 2018, the remaining contractual maturities of available-for-sale securities ranged from less than one to 4 months. For the years ended December 31, 2018, 2017 and 2016, there were no realized gains or losses on available-for-sale securities.
The Company’s certificates of deposit, commercial paper, and debt securities of U.S. government agency entities are classified as Level 2 as they are valued based upon quoted market prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant inputs are observable in the market or can be corroborated by observable market data for substantially the full term of the assets. Where applicable, these models project future cash flows and discount the future amounts to a present value using market-based observable inputs obtained from various third party data providers, including but not limited to benchmark yields, interest rate curves, reported trades, broker/dealer quotes and reference data.
The following table presents the Company’s Level 3 financial instruments that are measured at fair value on a recurring basis (in thousands):
 
Level 3
 
Contingent Consideration Liability
Balance as of December 31, 2017
$
3,779

Change in estimate of fair value
1,219

Balance as of December 31, 2018
$
4,998


As of December 31, 2018, the Company had a contingent obligation of up to $5.0 million payable in the Company’s common stock to the former owners of AltaVoice in conjunction with the Company’s acquisition of AltaVoice in January 2017. The contingency was dependent upon future revenues attributable to AltaVoice. If the revenue attributable to AltaVoice for the combined period of 2017 and 2018 was at least $10 million, the Company would make a payment of up to $5.0 million in the Company’s common stock in March 2019. The Company estimated the fair value of the contingent consideration at $2.2 million at the acquisition date in January 2017, based on a Monte Carlo simulation, as well as estimates of the 30-day trailing price of its stock at certain dates, its volatility assumptions and its revenue forecasts, all of which were significant inputs in the Level 3 measurement not supported by market activity. The value of the liability was subsequently remeasured to fair value at each reporting date. Changes in estimated fair value are recorded as general and administrative expense until the contingency is paid or expires. The change in the fair value of the contingent consideration between the acquisition date and December 31, 2018 was an increase of $2.8 million.
The fair value of the Company’s outstanding debt is estimated using the net present value of future debt payments, discounted at an interest rate that is consistent with market interest rates, which is a Level 2 input. The carrying amount of the Company’s outstanding debt at December 31, 2018 approximated its fair value and as of December 31, 2017, the Company's debt carrying amount and fair value were as follows (in thousands):
 
December 31, 2017
 
Carrying Amount
 
Fair Value
Debt
$
39,084

 
$
40,526
XML 33 R16.htm IDEA: XBRL DOCUMENT v3.10.0.1
Investment in privately held company Investment in privately held company
 12 Months Ended
Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Investment in privately held company Investment in privately held company
 
On March 15, 2018, the Company entered into a collaboration agreement with KEW, Inc. (“KEW”), a privately held comprehensive genomic profiling company. The Company determined it had a variable interest in a VIE through its investment in a convertible note issued by KEW. During the year ended December 31, 2018, the Company incurred losses relating to this collaboration agreement with KEW of $2.9 million which were recognized in general and administrative expenses in the Company’s consolidated statements of operations. As of December 31, 2018, the Company fulfilled its obligations with respect to the collaboration agreement and there are no balances recorded in the Company's consolidated balance sheets pertaining to this arrangement.
XML 34 R17.htm IDEA: XBRL DOCUMENT v3.10.0.1
Commitments and contingencies
 12 Months Ended
Dec. 31, 2018
Commitments and Contingencies Disclosure [Abstract]  
Commitments and contingencies Commitments and contingencies
Operating leases
In September 2015, the Company entered into a lease agreement for its headquarters and main production facility in San Francisco, California. This lease expires in July 2026 and the Company may renew the lease for an additional ten years. The Company has determined the lease term to be a ten-year period expiring in 2026. The lease term commenced when the Company took occupancy of the facility in February 2016. In connection with the execution of the lease, the Company provided a security deposit of approximately $4.6 million which is included in restricted cash in the Company’s consolidated balance sheets. Minimum annual rent under the lease is subject to increases based on stated rental adjustment terms. In addition, per the terms of the lease, the Company received a $5.2 million lease incentive in the form of reimbursement from the landlord for a portion of the costs of leasehold improvements the Company has made to the facility. The assets purchased with the lease incentive are included in property and equipment, net, in the Company’s consolidated balance sheets and the lease incentive is recognized as a reduction of rental expense on a straight-line basis over the term of the lease. At December 31, 2018, all of the lease incentive had been utilized by the Company and all related reimbursements had been received from the landlord. Aggregate future minimum lease payments for this facility at December 31, 2018 were approximately $57.8 million.
Future minimum payments under non-cancelable operating leases and future minimum payments to be received from non-cancelable subleases as of December 31, 2018 are as follows (in thousands):
 
Amounts
2019
$
10,948

2020
10,860

2021
11,109

2022
11,067

2023
8,898

Thereafter
25,715

Future non-cancelable minimum operating lease payments
78,597

Less: minimum payments to be received from non-cancelable subleases
(174
)
Total future non-cancelable minimum operating lease payments, net
$
78,423


The following table summarizes rent expense related to non-cancelable operating leases (in thousands):
 
Year Ended December 31,
 
2018
 
2017
 
2016
Rent expense
$
9,720

 
$
8,950

 
$
8,901

Sublease income
227

 
398

 
257

Rent expense, net of sublease income
$
9,493

 
$
8,552

 
$
8,644


Debt financing
In March 2017, the Company entered into a Loan and Security Agreement (the “2017 Loan Agreement”) with a lender pursuant to which the Company borrowed an initial term loan of $40.0 million, and received net proceeds of approximately $39.7 million. Subject to certain conditions, the Company was eligible to borrow a second term loan pursuant to the 2017 Loan Agreement of $20.0 million in the first quarter of 2018 and did so in March 2018, receiving net proceeds of approximately $19.8 million.
In February 2018 and June 2018, the Company entered into amendments to the 2017 Loan Agreement (the “2018 Amendments”) pursuant to which the Company, subject to certain conditions, was eligible to borrow a third term loan of $20.0 million during the period from April 2, 2018 to December 31, 2018. Pursuant to the 2018 Amendments, since the third term loan became available and the Company did not draw upon the third term loan, a fee of 1% was applied to the difference between $20.0 million and the amount drawn, or $0.2 million.

Term loans under the amended 2017 Loan Agreement bore interest at a floating rate equal to an index rate plus 7.73%, where the index rate was the greater of 0.77% or the 30-day U.S. Dollar London Interbank Offered Rate (“LIBOR”) as reported in The Wall Street Journal, with the floating rate resetting monthly subject to a floor of 8.5%.
The Company could make monthly interest-only payments until May 1, 2019 (or, subject to certain conditions, May 1, 2020), and thereafter monthly payments of principal and interest were required to fully amortize the borrowed amount by a final maturity date of March 1, 2022. A fee of 5% of each funded draw was due at the earlier of prepayment or loan maturity, a facility fee of 0.5% was due upon funding for each draw, and a prepayment fee of between 1% and 3% of the outstanding balance applied in the event of a prepayment. Concurrent with each term loan, the Company granted to the lender a warrant to acquire shares of the Company’s common stock equal to the quotient of 3% of the funded amount divided by a per share exercise price equal to the lower of the average closing price for the previous ten days of trading (calculated on the day prior to funding) or the closing price on the day prior to funding. In connection with the initial term loan, in 2017, the Company issued the lender warrants to purchase 116,845 shares of common stock at an exercise price of $10.27 per share. The Company classified these warrants as equity with a fair value of $0.7 million. In connection with the second term loan, in 2018, the Company issued the lender warrants to purchase 85,482 shares of common stock at an exercise price of $7.02 per share. The Company classified these warrants as equity with a fair value of $0.4 million. All warrants issued pursuant to the amended 2017 Loan Agreement have a term of ten years from the date of issuance and include a cashless exercise provision.
In November 2018, the Company entered into a Note Purchase Agreement (the "2018 Note Purchase Agreement") pursuant to which the Company was eligible to borrow an aggregate principal amount up to $200.0 million over a seven year maturity term which included an initial borrowing of $75.0 million in November 2018. The Company received net proceeds of $10.3 million after terminating and repaying the balance of its obligations of approximately $64.7 million under the 2017 Loan Agreement and associated amendments with its previous lender. The Company incurred $5.3 million of debt extinguishment costs upon terminating its previous debt facility which the Company recorded as other income (expense), net in its consolidated statements of operations during the year ended December 31, 2018.
At December 31, 2018, obligations under the 2018 Note Purchase Agreement were $75.0 million which are required to be repaid to the lender in a balloon payment no later than 2025. If the Company repays prior to the three year anniversary following the initial borrowing, the amount due will be: 117.5% of the principal amount if payment is made within 12 months after the borrowing; 132.5% of the principal amount if payment is made between 12 and 24 months after the borrowing; and 145.0% of the principal amount if payment is made between 24 and 36 months after the borrowing.
The outstanding principal amount under the 2018 Note Purchase Agreement bears interest at a rate of 8.75% annually. In addition, beginning on January 1, 2020 and continuing until repayment or maturity of any outstanding principal, the Company will make quarterly payments of 0.5% of the Company's annual net revenues subject to a maximum annual amount of such payments of $1.6 million which will be recognized as interest expense. Through the fixed interest charges and the quarterly revenue payments, the Company is required to pay total amounts to generate an 11% internal rate of return to the lender on any outstanding principal balances due in a lump-sum upon the repayment or maturity of any outstanding principal. During the year ended December 31, 2018, the 2018 Note Purchase Agreement bore interest at an average interest rate of 10.6%.
The 2018 Note Purchase Agreement contains quarterly covenants to achieve certain revenue levels as well as additional covenants, including limits on the Company’s ability to dispose of assets, undergo a change of control, merge with or acquire other entities, incur debt, incur liens, pay dividends or other distributions to holders of its capital stock, repurchase stock and make investments, in each case subject to certain exceptions. The Company’s obligations under the 2018 Note Purchase Agreement are secured by a security interest on substantially all of its and certain of its subsidiaries’ assets.
In connection with the 2018 Note Purchase Agreement, in November 2018, the Company entered into a Securities Purchase Agreement with the lender pursuant to which the Company issued 373,524 shares of its common stock at a price of $13.39 per share for an aggregate amount of $5.0 million. The share price paid by the lender was calculated based on the 15-day average closing share price prior to the issuance. The relative fair value method was used to allocate the proceeds between the common stock issued and the note proceeds; the fair value of the common stock issued to the lender was determined to be $5.4 million.
Debt discounts, including debt issuance costs, related to the 2018 Note Purchase Agreement of $0.7 million were recorded as a direct deduction from the debt liability and are being amortized to interest expense over the term of the 2018 Note Purchase Agreement. Future estimated payments under the 2018 Note Purchase Agreement as of December 31, 2018 are as follows (in thousands):
 
Amounts
2019
$
6,654

2020
8,297

2021
8,279

2022
8,279

2023
8,279

Thereafter
89,998

Total remaining payments
129,786

Less: amount representing debt discount
(721
)
Less: amount representing interest
(54,588
)
Total non-current debt obligation
$
74,477


Interest expense related to the Company's debt financings was $6.7 million, $3.5 million and $0.3 million for the years ended December 31, 2018, 2017 and 2016, respectively.
Capital leases
The Company has entered into various capital lease agreements to obtain laboratory equipment. The terms of the Company's capital leases are typically three years and are secured by the underlying equipment. The portion of the future payments designated as principal repayment was classified as a capital lease obligation on the consolidated balance sheets.
Future payments under capital leases at December 31, 2018 were as follows (in thousands):
 
Amounts
2019
$
2,087

2020
1,392

2021
21

Total capital lease obligations
3,500

Less: amount representing interest
(188
)
Present value of net minimum capital lease payments
3,312

Less: current portion
(1,937
)
Total non-current capital lease obligations
$
1,375


Interest expense related to capital leases was $0.3 million, $0.2 million and $0.1 million for the years ended December 31, 2018, 2017 and 2016, respectively.
Property and equipment under capital leases was $7.1 million and $11.4 million as of December 31, 2018 and 2017, respectively. Accumulated depreciation, collectively, on these assets was $2.0 million and $3.0 million at December 31, 2018 and 2017, respectively.
Guarantees and indemnifications
As permitted under Delaware law and in accordance with the Company’s bylaws, the Company indemnifies its directors and officers for certain events or occurrences while the officer or director is or was serving in such capacity. The maximum amount of potential future indemnification is unlimited; however, the Company maintains director and officer liability insurance. This insurance allows the transfer of the risk associated with the Company’s exposure and may enable it to recover a portion of any future amounts paid. The Company believes the fair value of these indemnification agreements is minimal. Accordingly, the Company did not record any liabilities associated with these indemnification agreements at December 31, 2018 or December 31, 2017.
Other commitments
In the normal course of business, the Company enters into various purchase commitments primarily related to service agreements, laboratory supplies, and a co-development agreement. At December 31, 2018, the Company’s total future payments under noncancelable unconditional purchase commitments having a remaining term of over one year were as follows (in thousands):
 
Amount
2019
$
3,040

2020
3,040

2021
1,440

Total
$
7,520


In addition, in September 2018, the Company entered into a co-development agreement with a privately held genetics testing company. The co-development agreement grants the Company the right of first refusal to enter into an agreement for an acquisition of the entity in return for total fees of $3.0 million over the term of the 12-month agreement, of which $1.0 million has been paid by the Company as of December 31, 2018. The unpaid fees of $2.0 million were paid in January 2019, and as of December 31, 2018, were recorded as an accrued liability in the Company’s consolidated balance sheets.
Contingencies
The Company was not a party to any material legal proceedings at December 31, 2018, or at the date of this report. The Company may from time to time become involved in various legal proceedings arising in the ordinary course of business, and the resolution of any such claims could be material.
XML 35 R18.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stockholders' Equity
 12 Months Ended
Dec. 31, 2018
Stockholders' Equity Note [Abstract]  
Stockholders’ Equity Stockholders’ Equity
Common stock
As of December 31, 2018 and 2017, the Company had reserved shares of common stock, on an as‑if converted basis, for issuance as follows (in thousands):
 
As of December 31,
 
2018
 
2017
Options issued and outstanding
3,855

 
4,115

RSU awards issued and outstanding
4,031

 
2,387

Shares available for grant under stock option plans
118

 
2,397

Shares reserved for issuance under the 2015 Employee Stock Purchase Plan
278

 
308

Common stock underlying warrants
611

 
1,962

Common stock issuable upon conversion of preferred stock
3,459

 
3,459

Common stock underlying stock payable liabilities
132

 
689

Common stock payable as contingent consideration
452

 
551

Total
12,936

 
15,868


Private placement
In August 2017, in a private placement to certain accredited investors, the Company issued 5.2 million shares of its common stock at a price of $8.50 per share, and 3.5 million shares of its Series A convertible preferred stock at a price of $8.50 per share, for gross proceeds of approximately $73.5 million and net proceeds of $68.9 million. The Series A preferred stock is a non-voting common stock equivalent and conversion of the Series A preferred stock is prohibited if the holder exceeds a specified threshold of voting security ownership. The Series A preferred stock is convertible into common stock on a one-for-one basis, subject to adjustment for events such as stock splits, combinations and the like. The Series A Preferred Stock has the right to receive dividends first or simultaneously with payment of dividends on common stock, in an amount equal to the product of (i) the dividend payable on each share of common stock and (ii) the number of shares of common stock issuable upon conversion
of a share of Series A Preferred Stock. The Series A Preferred Stock has no voting rights except as required by law, as modified by the Company’s Amended and Restated Certificate of Incorporation. In the event of any liquidation or dissolution of the Company, the Series A Preferred Stock is entitled to receive $0.001 per share prior to the payment of any amount to any holders of capital stock of the Company ranking junior to the Series A Preferred Stock and thereafter shall participate pari passu with the holders of the Company’s common stock (on an as-if-converted-to-common-stock basis). During January and February 2019, 1.1 million shares of Series A convertible preferred stock were converted to 1.1 million shares of common stock.
Public offering
In April 2018, the Company issued, in an underwritten public offering, an aggregate of 12.8 million shares of its common stock at a price of $4.50 per share, for gross proceeds of $57.5 million and net proceeds of $53.5 million.
2018 Sales Agreement
In August 2018, the Company entered into a Common Stock Sales Agreement (the “2018 Sales Agreement”) with Cowen and Company, LLC (“Cowen”), under which the Company may offer and sell from time to time at its sole discretion shares of its common stock through Cowen as its sales agent, in an aggregate amount not to exceed $75.0 million. Cowen may sell the shares by any method permitted by law deemed to be an “at the market” offering as defined in Rule 415 of the Securities Act, including without limitation sales made directly on The New York Stock Exchange, and also may sell the shares in privately negotiated transactions, subject to the Company’s prior approval. The Company is obligated to pay Cowen a commission equal to 3% of the gross proceeds of the sales price of all shares sold through it as sales agent under the 2018 Sales Agreement. During the year ended December 31, 2018, the Company issued a total of 4.3 million shares of common stock under the 2018 Sales Agreement for aggregate gross proceeds of $61.1 million and net proceeds of $58.9 million.
Common stock warrants
As of December 31, 2018, the Company had outstanding warrants to purchase common stock as follows:
Warrant
 
Issuance Date
 
Expiration Date
 
Exercise
Price
Per Share
 
Number of Shares of Common Stock Underlying Warrants
Warrants issued in exchange for CombiMatrix Series F warrants
 
November 2017
 
March 2021
 
$
5.95

 
408,548

Warrants issued to lender under 2017 Loan Agreement
 
March 2017
 
March 2027
 
$
10.27

 
116,845

Warrants issued to lender under 2017 Loan Agreement - 2018 Amendments
 
March 2018
 
March 2028
 
$
7.02

 
85,482

 
 
 
 
 
 
 
 
610,875


The exercise price of warrants issued in exchange for CombiMatrix Series F warrants was determined pursuant to the terms of the Merger Agreement (See Note 4, "Business Combinations"). The CombiMatrix Series D warrants expired during the year ended December 31, 2018. The exercise price of the warrants issued to the lender under the 2017 Loan Agreement was the closing price of the Company’s common stock on the date of the agreements. During the year ended December 31, 2018, the Company received $6.5 million from exercises 1.0 million shares of common stock under these warrants.
XML 36 R19.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stock incentive plans
 12 Months Ended
Dec. 31, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Stock incentive plans Stock incentive plans
Stock incentive plans
In 2010, the Company adopted the 2010 Incentive Plan (the “2010 Plan”). The 2010 Plan provides for the granting of stock-based awards to employees, directors and consultants under terms and provisions established by the Board of Directors. Under the terms of the 2010 Plan, options may be granted at an exercise price not less than fair market value. For employees holding more than 10% of the voting rights of all classes of stock, the exercise prices for incentive and nonstatutory stock options must be at least 110% of fair market of the common stock on the grant date, as determined by the Board of Directors. The terms of options granted under the 2010 Plan may not exceed ten years.
In January 2015, the Company adopted the 2015 Stock Incentive Plan (the “2015 Plan”), which became effective upon the closing of the Company’s initial public offering (“IPO”). Shares outstanding under the 2010 Plan were transferred to the 2015 Plan upon effectiveness of the 2015 Plan. The 2015 Plan provides for automatic annual increases in shares available for grant, beginning on January 1, 2016 through January 1, 2025. In addition, shares subject to awards under the 2010 Plan that are forfeited or terminated will be added to the 2015 Plan. The 2015 Plan provides for the grant of incentive stock options, nonstatutory stock options, restricted stock awards, stock units, stock appreciation rights and other forms of equity compensation, all of which may be granted to employees, including officers, non-employee directors and consultants. Additionally, the 2015 Plan provides for the grant of cash-based awards.
Options granted generally vest over a period of four years. Typically, the vesting schedule for options granted to newly hired employees provides that 1/4 of the award vests upon the first anniversary of the employee’s date of hire, with the remainder of the award vesting monthly thereafter at a rate of 1/48 of the total shares subject to the option. All other options typically vest in equal monthly installments over the four-year vesting schedule.
RSUs generally vest over a period of three years. Typically, the vesting schedule for RSUs provides that one third of the award vests upon each anniversary of the grant date.
In February 2016, the Company granted PRSUs under the 2015 Plan, which PRSUs could be earned based on the achievement of specified performance conditions measured over a period of approximately 12 months. In February 2017, upon the Audit Committee’s determination of the level of achievement, 352,045 fully vested stock units were awarded to holders of PRSUs. The Company has not granted any PRSUs since 2016.
Based on its evaluations of the probability of achieving performance conditions, the Company recorded stock-based compensation expense of nil, $0.4 million, and $1.9 million for the years ended December 31, 2018, 2017, and 2016, respectively, related to the PRSUs.
Activity under the 2010 Plan and the 2015 Plan is set forth below (in thousands, except per share amounts and years):
 
Shares
Available
For Grant
 
Stock
Options
Outstanding
 
Weighted-
Average
Exercise
Price
 
Weighted-
Average
Remaining
Contractual
Life (years)
 
Aggregate
Intrinsic
Value
Balance at December 31, 2017
2,397

 
4,115

 
$
8.51

 
7.6
 
$
5,128

Additional shares reserved
754

 
—

 
 
 
 
 
 
Options granted
(260
)
 
260

 
$
8.50

 
 
 
 
Options cancelled
169

 
(169
)
 
$
9.35

 
 
 
 
Options exercised
—

 
(351
)
 
$
7.73

 
 
 
 
RSUs granted
(3,282
)
 
—

 
 
 
 
 
 
RSUs cancelled
340

 
—

 
 
 
 
 
 
Balance at December 31, 2018
118

 
3,855

 
$
8.54

 
6.8
 
$
9,927

Options exercisable at December 31, 2018
 
 
2,737

 
$
8.27

 
6.4
 
$
7,787

Options vested and expected to vest at December 31, 2018
 
 
3,710

 
$
8.52

 
6.8
 
$
9,626


The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying stock options and the fair value of the Company’s common stock for stock options that were in-the-money.
The weighted-average fair value of options to purchase common stock granted was $4.87, $5.82 and $6.18 in the years ended December 31, 2018, 2017 and 2016, respectively. The weighted-average fair value of RSUs granted was $7.46, $10.03 and $9.80 in the years ended December 31, 2018, 2017 and 2016, respectively. No PRSUs were granted in the years ended December 31, 2018 or 2017 and the weighted average fair value of PRSUs granted in the year ended December 31, 2016 was $6.50.
The total grant-date fair value of options to purchase common stock vested was $5.9 million, $6.9 million and $5.6 million in the year ended December 31, 2018, 2017, and 2016, respectively.
The intrinsic value of options to purchase common stock exercised was $1.7 million, $2.1 million and $1.4 million in the years ended December 31, 2018, 2017 and 2016, respectively.
The following table summarizes RSU activity for the year ended December 31, 2018 (in thousands, except per share data:
 
Number of Shares
 
Weighted-Average Grant Date Fair Value
Balance at December 31, 2017
2,387

 
$
9.91

RSUs granted
3,282

 
$
7.46

RSUs vested
(1,298
)
 
$
8.84

RSUs cancelled
(340
)
 
$
8.84

Balance at December 31, 2018
4,031

 
$
8.35


2015 employee stock purchase plan
In January 2015, the Company adopted the 2015 Employee Stock Purchase Plan (the “ESPP”), which became effective upon the closing of the IPO. Employees participating in the ESPP may purchase common stock at 85% of the lesser of the fair market value of common stock on the purchase date or last trading day preceding the offering date. At December 31, 2018, cash received from payroll deductions pursuant to the ESPP was $0.6 million.
The ESPP provides for automatic annual increases in shares available for grant, beginning on January 1, 2016 and continuing through January 1, 2025. At December 31, 2018, a total of 277,577 shares of common stock are reserved for issuance under the ESPP.
Stock-based compensation
The Company uses the grant date fair value of its common stock to value both employee and non-employee options when granted. The Company revalues non-employee options each reporting period using the fair market value of the Company’s common stock as of the last day of each reporting period.
In determining the fair value of stock options and ESPP purchases, the Company uses the Black-Scholes option-pricing model and, for stock options, the assumptions discussed below. Each of these inputs is subjective and its determination generally requires significant judgment. The fair value of RSU and PRSU awards is based on the grant date share price. Compensation cost is recognized as expense on a straight-line basis over the vesting period for options and RSUs and on an accelerated basis for PRSUs.
In 2016, the Company modified certain stock options and RSU awards. The terms of the stock option modifications included acceleration of vesting and extensions of post-termination exercise periods. The terms of the RSU award modifications included acceleration of vesting. A total of 14 employees were affected by the stock option and RSU modifications and the total incremental compensation cost relating to these modifications was $0.3 million.
Expected term—The expected term represents the period that the Company’s stock-based awards are expected to be outstanding and is determined using the simplified method (based on the midpoint between the vesting date and the end of the contractual term).
Expected volatility—Because the Company was privately held until its initial public offering in February 2015 and did not have any trading history for its common stock, the Company estimates expected volatility using its own stock price volatility when available as well as the average volatility for comparable publicly traded life sciences companies, including molecular diagnostics companies, over a period equal to the expected term of stock option grants and RSUs. When selecting comparable publicly-traded biopharmaceutical companies, including molecular diagnostics companies, the Company selected companies with comparable characteristics, including enterprise value, risk profiles, position within the industry and with historical share price information sufficient to meet the expected life of the stock-based awards. The Company computed historical volatility data using daily closing prices for the selected companies’ shares during the equivalent period of the calculated expected term of the stock-based awards. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available. The Company estimates expected volatility for ESPP purchases using its own stock price volatility over the expected six-month term ESPP purchase periods.
Risk-free interest rate—The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of the option.
Dividend yield—The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company used an expected dividend yield of zero.
The fair value of share-based payments for stock options granted to employees and directors was estimated on the date of grant using the Black-Scholes option-pricing model based on the following assumptions:
 
Year Ended December 31,
 
2018
 
2017
 
2016
Expected term (in years)
6.00
 
6.03
 
6.03
Expected volatility
59.58%
 
72.64%
 
71.42%
Risk-free interest rate
2.80%
 
2.01%
 
1.37%

Stock-based compensation related to stock options granted to non-employees is recognized as the stock options vest. The fair value of the stock options granted is calculated at each reporting date using the Black-Scholes option-pricing model based on the following assumptions:
 
Year Ended December 31,
 
2018
 
2017
 
2016
Expected term (in years)
—
 
8.41 – 8.83
 
6.25 – 10.00
Expected volatility
—
 
69.9 – 78.70%
 
76.92%
Risk-free interest rate
—
 
1.83 – 2.04%
 
1.55 – 2.37%

No stock options granted to non-employees vested during the year ended December 31, 2018.
The fair value of shares purchased pursuant to the ESPP is estimated using the Black‑Scholes option pricing model. For the years ended December 31, 2018, 2017 and 2016, the weighted average grant date fair value per share for the ESPP was $3.26, $2.51 and $2.66, respectively and stock‑based compensation expense for the ESPP was $1.4 million, $1.1 million and $0.9 million, respectively.
The fair value of the shares purchased pursuant to the ESPP was estimated using the following assumptions:
 
Year Ended December 31,
 
2018
 
2017
 
2016
Expected term (in years)
0.5
 
0.5
 
0.5
Expected volatility
71.66%
 
52.50%
 
66.31%
Risk-free interest rate
2.09%
 
1.23%
 
0.50%

The following table summarizes stock-based compensation expense for the years ended December 31, 2018, 2017 and 2016, included in the consolidated statements of operations (in thousands):
 
Year Ended December 31,
 
2018
 
2017
 
2016
Cost of revenue
$
2,960

 
$
2,093

 
$
1,353

Research and development
7,017

 
6,158

 
4,976

Selling and marketing
4,887

 
3,956

 
1,709

General and administrative
5,986

 
7,014

 
2,661

Total stock-based compensation expense
$
20,850

 
$
19,221

 
$
10,699


At December 31, 2018, unrecognized compensation expense related to unvested stock options, net of estimated forfeitures, was $4.5 million, which the Company expects to recognize on a straight-line basis over a weighted-average period of 1.8 years. Unrecognized compensation expense related to RSUs at December 31, 2018, net of estimated forfeitures, was $22.6 million, which the Company expects to recognize on a straight-line basis over a weighted-average period of 2.1 years. At December 31, 2018, there was no unrecognized compensation expense related to PRSUs and no capitalized stock-based employee compensation.
XML 37 R20.htm IDEA: XBRL DOCUMENT v3.10.0.1
Income taxes
 12 Months Ended
Dec. 31, 2018
Income Tax Disclosure [Abstract]  
Income taxes Income taxes
The Company recorded a benefit for income taxes in the years ended December 31, 2018 and 2017. The Company did not record a provision or benefit for income taxes during the year ended December 31, 2016. The components of net loss before taxes by U.S. and foreign jurisdictions are as follows (in thousands):
 
Year Ended December 31,
 
2018
 
2017
 
2016
United States
$
132,194

 
$
124,108

 
$
99,793

Foreign
(39
)
 
1,128

 
463

Total
$
132,155

 
$
125,236

 
$
100,256


The components of the provision for income taxes are as follows (in thousands):
 
Year Ended December 31,
 
2018
 
2017
 
2016
Current:
 
 
 
 
 
Foreign
62

 
—

 
—

Total current benefit for income taxes
62

 
—

 
—

Deferred:
 
 
 
 
 
Federal
(2,862
)
 
(1,704
)
 
—

State
—

 
(152
)
 
—

Total deferred benefit for income taxes
(2,862
)
 
(1,856
)
 
—

Total income tax benefit
$
(2,800
)
 
$
(1,856
)
 
$
—


The following table presents a reconciliation of the tax expense computed at the statutory federal rate and the Company’s tax expense for the periods presented:
 
Year Ended December 31,
 
2018
 
2017
 
2016
U.S. federal taxes at statutory rate
21.0
 %
 
34.0
 %
 
34.0
 %
State taxes (net of federal benefit)
5.2
 %
 
3.3
 %
 
1.4
 %
Stock-based compensation
(0.7
)%
 
(1.1
)%
 
(1.7
)%
Research and development credits
2.7
 %
 
—
 %
 
—
 %
Non-deductible expenses
(0.6
)%
 
—
 %
 
0.2
 %
Foreign tax differential
—
 %
 
(0.3
)%
 
(0.2
)%
Other
—
 %
 
—
 %
 
1.1
 %
Change in valuation allowance
(25.5
)%
 
(34.4
)%
 
(34.8
)%
Change in deferred—Tax Reform
—
 %
 
(39.0
)%
 
—
 %
Change in valuation allowance—Tax Reform
—
 %
 
39.0
 %
 
—
 %
Total
2.1
 %
 
1.5
 %
 
—
 %

The tax effects of temporary differences and carryforwards that give rise to significant portions of the deferred tax assets are as follows (in thousands):
 
As of December 31,
 
2018
 
2017
Deferred tax assets:
 

 
 

Net operating loss carryforwards
$
76,972

 
$
70,825

Tax credits
15

 
15

Revenue recognition differences
47,650

 
29,819

Accruals and other
7,262

 
5,544

Gross deferred tax assets
131,899

 
106,203

Valuation allowance
(121,954
)
 
(95,687
)
Total deferred tax assets
9,945

 
10,516

Deferred tax liabilities:
 
 
 
Property and equipment
(9,945
)
 
(10,516
)
Total deferred tax liabilities
(9,945
)
 
(10,516
)
Net deferred tax assets
$
—

 
$
—


On December 22, 2017, the Tax Cuts and Jobs Act of 2017 (the “Tax Act”) was signed into law making significant changes to the Internal Revenue Code. Changes included among other items, a reduction of the corporate tax rate from a top marginal rate of 35% to a flat rate of 21%. Although the Tax Act was generally effective January 1, 2018, GAAP required recognition of the tax effects of new legislation during the reporting period that includes the enactment date, which was December 22, 2017. As a result of the lower corporate tax rate enacted as part of the Tax Act, during 2017, the Company recorded a provisional estimate to reduce deferred tax assets by $48.8 million offset by a corresponding reduction in the valuation allowance resulting in no net impact to the Company's income tax benefit or expense.
On December 22, 2017, the Securities and Exchange Commission issued Staff Accounting Bulletin No. 118 ("SAB 118") to address the application of U.S. GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the Tax Act. In accordance with SAB 118, during 2017, the Company recorded a provisional estimate which resulted in a $48.8 million reduction in deferred tax assets and in the fourth quarter of 2018, the Company completed its analysis of the impact of the Tax Act and determined that no material adjustments were required to the provisional amounts previously recorded.     
The Company has established a full valuation allowance against its deferred tax assets due to the uncertainty surrounding realization of such assets. The Company's valuation allowance increased by $26.3 million, $2.0 million, and $33.4 million during the years ended December 31, 2018, 2017, and 2016, respectively.
As of December 31, 2018, the Company had net operating loss carryforwards of approximately $318.7 million and $134.3 million available to reduce future taxable income, if any, for Federal and state income tax purposes, respectively. Of the $318.7 million, $277.3 million will begin to expire in 2030 while $41.4 million have no expiration date. The state net operating loss carryforwards will begin to expire in 2030.
As of December 31, 2018, the Company had research and development credit carryforwards of approximately $9.0 million and $7.4 million available to reduce its future tax liability, if any, for Federal and state income tax purposes, respectively. The Federal credit carryforwards begin to expire in 2030. California credit carryforwards have no expiration date.
Internal Revenue Code ("IRC") section 382 places a limitation (the “Section 382 limitation” or “annual limitation”) on the amount of taxable income that can be offset by net operating loss carryforwards after a change in control (generally greater than 50% change in ownership) of a loss corporation. Similar provisions exist for states. In addition, and as a result of the acquisitions of Good Start Genetics and CombiMatrix in 2017, tax loss carryforwards from acquired entities are also subject to the Section 382 limitation due to the change in control in the acquired entities in the current year.
The Company performed a section 382 analysis for Good Start Genetics and CombiMatrix and concluded that a substantial portion of the acquired operating loss and credit carryovers would expire unused as a result of
annual limitations under IRC sections 382 and 383 in 2017. As a result, the federal and state operating loss and credit carryforwards acquired in connection with the Good Start Genetics and CombiMatrix acquisitions were reduced by the amount of tax attributes estimated to expire during their respective carryforward periods. In addition, as a result of equity issued in connection with its 2017 acquisitions, the Company also performed a section 382 analysis with respect to its legacy operating loss and credit carryforwards. The Company concluded while an ownership change occurred in 2017 as defined under IRC section 382, none of the Company’s legacy carryforwards would expire unused solely as a result of annual limitations imposed on the use of the carryforwards under IRC sections 382 and 383.
As of December 31, 2018, the Company had unrecognized tax benefits of $16.4 million, which primarily relates to research and development credits, none of which would currently affect the Company’s effective tax rate if recognized due to the Company’s deferred tax assets being fully offset by a valuation allowance. Unrecognized tax benefits are not expected to change in the next 12 months.
A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in thousands):
 
Year ended December 31,
 
2018
 
2017
 
2016
Unrecognized tax benefits, beginning of period
$
10,561

 
$
7,791

 
$
11,429

Gross increases—current period tax positions
5,686

 
2,552

 
782

Gross increases (decreases)—prior period tax positions
128

 
218

 
(4,420
)
Unrecognized tax benefits, end of period
$
16,375

 
$
10,561

 
$
7,791


The Company’s policy is to include penalties and interest expense related to income taxes as a component of tax expense. The Company has not accrued interest and penalties related to the unrecognized tax benefits reflected in the financial statements for the years ended December 31, 2018, 2017 and 2016.
The Company’s major tax jurisdictions are the United States and California. All of the Company’s tax years will remain open for examination by the Federal and state tax authorities for three and four years, respectively, from the date of utilization of the net operating loss or research and development credit. The Company does not have any tax audits pending.
XML 38 R21.htm IDEA: XBRL DOCUMENT v3.10.0.1
Net loss per common share
 12 Months Ended
Dec. 31, 2018
Earnings Per Share [Abstract]  
Net loss per common share Net loss per share
The following table presents the calculation of basic and diluted net loss per share for the years ended December 31, 2018, 2017 and 2016 (in thousands, except per share data):
 
Year ended December 31,
 
2018
 
2017
 
2016
Net loss
$
(129,355
)
 
$
(123,380
)
 
$
(100,256
)
Shares used in computing net loss per share, basic and diluted
66,747

 
46,512

 
33,176

Net loss per share, basic and diluted
$
(1.94
)
 
$
(2.65
)
 
$
(3.02
)

The following common stock equivalents have been excluded from diluted net loss per share for the years ended December 31, 2018, 2017 and 2016 because their inclusion would be anti-dilutive (in thousands):
 
Year Ended December 31,
 
2018
 
2017
 
2016
Shares of common stock subject to outstanding options
3,855

 
4,115

 
4,491

Shares of common stock subject to outstanding warrants
611

 
1,962

 
—

Shares of common stock subject to outstanding RSUs
4,031

 
2,387

 
892

Shares of common stock subject to outstanding PRSUs
—

 
—

 
530

Shares of common stock pursuant to ESPP
63

 
59

 
55

Shares of common stock underlying Series A convertible preferred stock
3,459

 
3,459

 
—

Total shares of common stock equivalents
12,019

 
11,982

 
5,968
XML 39 R22.htm IDEA: XBRL DOCUMENT v3.10.0.1
Geographic information
 12 Months Ended
Dec. 31, 2018
Segments, Geographical Areas [Abstract]  
Geographic information Geographic information
Revenue by country is determined based on the billing address of the customer and is summarized as follows (in thousands):
 
Year Ended December 31,
 
2018
 
2017
 
2016
United States
$
138,239

 
$
62,446

 
$
20,758

Canada
4,206

 
3,226

 
2,526

Rest of world
5,254

 
2,549

 
1,764

Total revenue
$
147,699

 
$
68,221

 
$
25,048


As of December 31, 2018 and 2017, all long-lived assets were located in the United States.
XML 40 R23.htm IDEA: XBRL DOCUMENT v3.10.0.1
Selected quarterly data (unaudited)
 12 Months Ended
Dec. 31, 2018
Quarterly Financial Information Disclosure [Abstract]  
Selected quarterly data (unaudited) Selected quarterly data (unaudited)
The following table summarizes the Company's quarterly financial information for 2018 and 2017 (in thousands, except per share amounts):
 
 
Three Months Ended
 
 
March 31, 2018
 
June 30, 2018
 
September 30, 2018
 
December 31, 2018
Revenue
 
$
27,671

 
$
37,306

 
$
37,366

 
$
45,356

Cost of revenue
 
$
18,076

 
$
20,447

 
$
20,441

 
$
21,141

Loss from operations
 
$
(36,475
)
 
$
(30,068
)
 
$
(30,110
)
 
$
(25,904
)
Net loss(2)
 
$
(36,120
)
 
$
(31,671
)
 
$
(31,723
)
 
$
(29,841
)
Net loss per share, basic and diluted(1)
 
$
(0.66
)
 
$
(0.47
)
 
$
(0.45
)
 
$
(0.40
)
 
 
 
 
 
 
 
 
 
 
 
Three Months Ended
 
 
March 31, 2017
 
June 30, 2017
 
September 30, 2017
 
December 31, 2017
Revenue
 
$
10,338

 
$
14,336

 
$
18,148

 
$
25,399

Cost of revenue
 
$
9,329

 
$
10,490

 
$
13,274

 
$
17,049

Loss from operations
 
$
(27,337
)
 
$
(28,075
)
 
$
(30,976
)
 
$
(34,891
)
Net loss(2)
 
$
(26,928
)
 
$
(28,557
)
 
$
(27,402
)
 
$
(40,493
)
Net loss per share, basic and diluted(1)
 
$
(0.64
)
 
$
(0.66
)
 
$
(0.57
)
 
$
(0.78
)
___________________________________________________________________ 
(1) 
Net loss per share is computed independently for each of the quarters presented. Therefore, the sum of quarterly net loss per share information may not equal annual net loss per share.
(2)
Includes $5.3 million of debt extinguishment costs during the three months ended December 31, 2018. See Note 9, "Commitments and contingencies" for further information.
XML 41 R24.htm IDEA: XBRL DOCUMENT v3.10.0.1
Summary of significant accounting policies (Policies)
 12 Months Ended
Dec. 31, 2018
Accounting Policies [Abstract]  
Principles of consolidation Principles of consolidationThe consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.
Use of estimates Use of estimates
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. The Company bases these estimates on historical and anticipated results, trends and various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to future events. Actual results could differ materially from those estimates and assumptions.
Significant estimates and assumptions made by management include the determination of:
•
revenue recognition (See Note 3, “Revenue, accounts receivable and deferred revenue” for further information);
•
the fair value of assets acquired and liabilities assumed for business combinations;
•
the fair value of goodwill and intangible assets;
•
the recoverability of long-lived assets;
•
stock-based compensation expense and the fair value of awards issued; and
•
income tax uncertainties.
Concentrations of credit risk and other risks and uncertainties Concentrations of credit risk and other risks and uncertainties
Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents, marketable securities and accounts receivable. The Company’s cash and cash equivalents are held by financial institutions in the United States. Such deposits may exceed federally insured limits.
Significant customers are those that represent 10% or more of the Company’s total revenue for each year presented on the statements of operations.
Cash, cash equivalents, and restricted cash Cash, cash equivalents, and restricted cash
The Company considers all highly liquid investments with original maturities of three months or less from the date of purchase to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market funds and U.S. government agency securities.
Restricted cash consists of money market funds that serve as collateral for security deposits for the Company’s facility lease and sublease agreements and collateral for a credit card agreement at one of the Company’s financial institutions.
Marketable securities Marketable securitiesAll marketable securities have been classified as “available-for-sale” and are carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities. Management determines the appropriate classification of its marketable debt securities at the time of purchase and reevaluates such designation at each balance sheet date. Short-term marketable securities have maturities less than 365 days at the balance sheet date. Unrealized gains and losses are excluded from earnings and are reported as a component of other comprehensive loss. Realized gains and losses and declines in fair value judged to be other than temporary, if any, on available-for-sale securities are included in interest and other income (expense), net. The cost of securities sold is based on the specific-identification method. Interest on marketable securities is included in interest and other income (expense), net.
Accounts receivable Accounts receivableThe Company receives payment for its tests from partners, patients, institutional customers and third-party payers.
Inventory InventoryThe Company maintains test reagents and other consumables primarily used in sample collection kits which are valued at the lower of cost or market value. Cost is determined using actual costs on a first-in, first-out basis.
Business combinations Business combinations
The tangible and identifiable intangible assets acquired and liabilities assumed in a business combination are recorded based on their estimated fair values as of the business combination date, including identifiable intangible assets which either arise from a contractual or legal right or are separable from goodwill. The Company bases the estimated fair value of identifiable intangible assets acquired in a business combination on independent valuations that use information and assumptions provided by management, which consider management’s estimates of inputs and assumptions that a market participant would use. Any excess purchase price over the estimated fair value assigned to the net tangible and identifiable intangible assets acquired and liabilities assumed is recorded to goodwill. The use of alternative valuation assumptions, including estimated revenue projections, growth rates, cash flows, discount rates, estimated useful lives and probabilities surrounding the achievement of contingent milestones could result in different purchase price allocations and amortization expense in current and future periods.
In circumstances where an acquisition involves a contingent consideration arrangement that meets the definition of a liability under Financial Accounting Standards Board (“FASB") Accounting Standards Codification (“ASC”) Topic 480, Distinguishing Liabilities from Equity, the Company recognizes a liability equal to the fair value of the contingent payments the Company expects to make as of the acquisition date. The Company remeasures this liability each reporting period and records changes in the fair value as a component of operating expenses.
Transaction costs associated with acquisitions are expensed as incurred in general and administrative expenses. Results of operations and cash flows of acquired companies are included in the Company’s operating results from the date of acquisition.
Intangible assets Intangible assetsAmortizable intangible assets include trade names, non-compete agreements, developed technology and customer relationships acquired as part of business combinations. Customer relationships are amortized on an accelerated basis, utilizing free cash flows, over periods ranging from five to 11 years. All other intangible assets subject to amortization are amortized using the straight-line method over their estimated useful lives ranging from two to 15 years. All intangible assets subject to amortization are reviewed for impairment in accordance with ASC 360, Property, Plant and Equipment.
Goodwill GoodwillIn accordance with ASC 350, Intangibles-Goodwill and Other (“ASC 350”), the Company’s goodwill is not amortized but is tested for impairment on an annual basis or whenever events or changes in circumstances indicate that the carrying amount of these assets may not be recoverable. Under ASC 350, the Company performs annual impairment reviews of its goodwill balance during the fourth fiscal quarter. In testing for impairment, the Company compares the fair value of its reporting unit to its carrying value including the goodwill of that unit. If the carrying value, including goodwill, exceeds the reporting unit’s fair value, the Company will recognize an impairment loss for the amount by which the carrying amount exceeds the reporting unit’s fair value. The loss recognized cannot exceed the total amount of goodwill allocated to that reporting unit. The Company did not incur any goodwill impairment losses in any of the periods presented.
Leases LeasesThe Company rents its facilities under operating lease agreements and recognizes related rent expense on a straight-line basis over the term of the applicable lease agreement. Some of the lease agreements contain rent holidays, scheduled rent increases, lease incentives, and renewal options. Rent holidays and scheduled rent increases are included in the determination of rent expense to be recorded over the lease term. Lease incentives are recognized as a reduction of rent expense on a straight-line basis over the term of the lease. Renewals are not assumed in the determination of the lease term unless they are deemed to be reasonably assured at the inception of the lease. The Company recognizes rent expense beginning on the date it obtains the legal right to use and control the leased space.
Property and equipment, net Property and equipment, net
Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is computed using the straight‑line method over the estimated useful lives of the assets, generally between three and seven years. Leasehold improvements are amortized using the straight‑line method over the shorter of the estimated useful life of the asset or the term of the lease. Amortization expense of assets acquired through capital leases is included in depreciation and amortization expense in the consolidated statements of operations. Maintenance and repairs are charged to expense as incurred, and improvements and betterments are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in the statements of operations in the period realized.
The estimated useful lives of property and equipment are as follows:
Furniture and fixtures
7 years
Automobiles
7 years
Laboratory equipment
5 years
Computer equipment
3 years
Software
3 years
Leasehold improvements
Shorter of lease term or estimated useful life
Long-lived assets Long‑lived assetsThe Company reviews long‑lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. An impairment loss is recognized when the total estimated future undiscounted cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. Impairment, if any, is assessed using discounted cash flows or other appropriate measures of fair value.
Variable interest entity Variable interest entityThe Company had a variable interest in a variable interest entity (“VIE”) through an investment in convertible notes issued by the VIE. The convertible notes do not provide the Company with voting rights in the VIE or with power to direct the activities of the VIE which most significantly affect its economic performance. The Company is not the VIE’s primary beneficiary and it does not consolidate the VIE.
Fair value of financial instruments Fair value of financial instrumentsThe Company’s financial instruments consist principally of cash and cash equivalents, marketable securities, accounts payable, accrued liabilities, capital leases and debt. The carrying amounts of certain of these financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued and other current liabilities approximate their current fair value due to the relatively short-term nature of these accounts. Based on borrowing rates available to the Company, the carrying value of capital leases and debt approximate their fair values.
Revenue recognition and cost of revenue Revenue recognition
The Company recognizes revenue when control of the promised goods or services is transferred to the customer in an amount that reflects the consideration it expects to be entitled to in exchange for those goods or services. All revenues are generated from contracts with customers.
Test revenue is generated primarily from the sale of tests that provide analysis and associated interpretation of the sequencing of parts of the genome.
Other revenue consists primarily of revenue from genome network subscription services which is recognized on a straight-line basis over the subscription term, and revenue from collaboration agreements.
Cost of revenue
Cost of revenue reflects the aggregate costs incurred in delivering the genetic testing results to clinicians and includes expenses for personnel-related costs including stock-based compensation, materials and supplies, equipment and infrastructure expenses associated with testing and allocated overhead including rent, equipment depreciation and utilities.
Income taxes Income taxesThe Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and the tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized.
Stock-based compensation Stock-based compensation
The Company measures its stock-based payment awards made to employees and directors based on the estimated fair values of the awards and recognizes the compensation expense over the requisite service period. The Company uses the Black-Scholes option-pricing model to estimate the fair value of its stock option awards and employee stock purchase plan (“ESPP”) purchases. The fair value of restricted stock unit (“RSU”) awards with time-based vesting terms is based on the grant date share price. The Company grants performance-based restricted stock unit (“PRSU”) awards to certain employees which vest upon the achievement of certain performance conditions, subject to the employees’ continued service relationship with the Company. The probability of vesting is assessed at each reporting period and compensation cost is adjusted based on this probability assessment. The Company recognizes such compensation expense on an accelerated vesting method.
Stock-based compensation expense for awards without a performance condition is recognized using the straight-line method. Stock-based compensation expense is based on the value of the portion of stock-based payment awards that is ultimately expected to vest. As such, the Company’s stock-based compensation is reduced for estimated forfeitures at the date of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.
The Company accounts for compensation expense related to stock options granted to non-employees based on fair values estimated using the Black-Scholes option-pricing model. Stock options granted to non-employees are re-measured at each reporting date until the award is vested.
The Company accounts for stock issued as compensation in connection with business combinations based on the fair value of the Company’s common stock on the date of issuance.
Advertising AdvertisingAdvertising expenses are expensed as incurred.
Comprehensive loss Comprehensive lossComprehensive loss is composed of two components: net loss and other comprehensive income (loss). Other comprehensive income (loss) refers to gains and losses that under U.S. GAAP are recorded as an element of stockholders’ equity, but are excluded from net loss. The Company’s other comprehensive income (loss) consists of unrealized gains or losses on investments in available-for-sale securities.
Net loss per share Net loss per shareBasic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common share equivalents outstanding for the period determined using the treasury stock method. Potentially dilutive securities, consisting of preferred stock, options to purchase common stock, common stock warrants, RSUs and PRSUs, are considered to be common stock equivalents and were excluded from the calculation of diluted net loss per share because their effect would be antidilutive for all periods presented.
Recent accounting pronouncements Recent accounting pronouncements
The Company evaluates all Accounting Standards Updates (“ASUs”) issued by the FASB for consideration of their applicability. ASUs not included in the disclosures in this report were assessed and determined to be either not applicable or are not expected to have a material impact on the Company’s consolidated financial statements.
Recently issued accounting pronouncements not yet adopted
In November 2018, the FASB issued ASU 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606, which clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under Accounting Standards Codification ("ASC") 606 when the counterparty is a customer. In addition, Topic 808 precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue from contracts with customers if the counterparty is not a customer for that transaction. This guidance will be effective for the Company beginning January 1, 2020. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements.
In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326), which replaces the incurred loss impairment methodology in current U.S. GAAP with a methodology that reflects expected credit losses. The amended guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2019, with early adoption permitted for the fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements.
In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) and in July 2018 issued ASU 2018-10, Codification Improvements to Topic 842, Leases and ASU 2018-11, Leases (Topic 842): Targeted Improvements (the foregoing ASUs collectively referred to as “Topic 842”). Under the new guidance, lessees are required to recognize a lease liability and a right-of-use asset for all leases (with the exception of short-term leases) at the commencement date and also requires expanded disclosures about leasing arrangements. Topic 842 is effective for annual and interim periods beginning on or after December 15, 2018 and early adoption is permitted. Entities may initially apply the new leases standard at the adoption date and recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption.
The Company is evaluating the final effect that Topic 842 and related standards will have on its consolidated financial statements, related disclosures and ongoing financial reporting, but expects implementation of Topic 842 to result in the recognition of material right of use assets and corresponding lease liabilities in its consolidated balance sheets as of the implementation of Topic 842 on January 1, 2019, principally relating to facilities leases. The Company does not have any material embedded leases and the implementation of Topic 842 is primarily focused on the treatment of the Company's previously identified leases. As of December 31, 2018, the Company's total future undiscounted capital lease payments were $3.5 million and future undiscounted non-cancelable minimum operating lease payments, net of subleases were $78.4 million
Recently adopted accounting pronouncements
In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606), designed to enable users of financial statements to better understand the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. On January 1, 2018, the Company adopted the provisions of Topic 606 using the modified retrospective method. From adoption to date, the Company has recognized all its revenue from contracts with customers within the scope of Topic 606. In connection with the adoption, the Company recognized the cumulative effect of initially applying this standard as an adjustment to retained earnings on the date of adoption. Comparative information prior to the date of adoption has not been restated and continues to be reported under the accounting standards in effect for those periods.
In connection with the adoption of Topic 606, the Company amended its revenue recognition policy to provide for the recognition of certain variable consideration related to diagnostic tests that was previously deferred pending cash collection. Under Topic 606, the Company records variable consideration based on an estimate of the consideration to which it will be entitled.
The Company recognizes revenue when control of the promised goods or services is transferred to the customer in an amount that reflects the consideration it expects to be entitled to in exchange for those goods or services. All revenues are generated from contracts with customers.
Diagnostic tests
The majority of the Company’s revenue is generated from genetic testing services that provide analysis and associated interpretation of the sequencing of parts of the genome. Test orders are placed under signed requisitions, and the Company often enters into contracts with institutions (e.g., hospitals and clinics) and insurance companies that include pricing provisions under which such tests are billed. Billing terms are generally net thirty days.
While the transaction price of diagnostic tests is originally established either via contract or pursuant to the Company’s standard list price, the Company often provides concessions for tests billed to insurance carriers, and therefore the transaction price for patient insurance-billed tests is considered to be variable and revenue is recognized based on an estimate of the consideration to which the Company will be entitled at an amount for which it is probable that a reversal of cumulative consideration will not occur. Making these estimates requires significant judgments based upon such factors as length of payer relationship, historical payment patterns, changes in contract provisions and insurance reimbursement policies. These judgments are reviewed quarterly and revenue recognized is updated, as necessary, until the Company’s obligations are fully settled.
In connection with some diagnostic test orders, the Company offers limited re-requisition rights (“Re-Requisition Rights”) that are considered distinct at contract inception, and therefore certain diagnostic test orders contain two performance obligations, the performance of the original test and the Re-Requisition Rights. When Re-Requisition Rights are granted, the Company allocates the transaction price to each performance obligation based on the relative estimated standalone selling prices. In order to comply with loss contract rules, the allocations are adjusted, if necessary, to ensure the amount deferred for Re-Requisition Rights is no less than the estimated cost of fulfilling the Company’s related obligations.
The Company looks to transfer of control in assessing timing of recognition of revenue in connection with each performance obligation. In general, revenue in connection with diagnostic tests is recognized upon delivery of the underlying clinical report or when the report is made available on the Company’s web portal. Outstanding performance obligations pertaining to orders received but for which the underlying report has not been issued are generally satisfied within a thirty-day period. Revenue in connection with Re-Requisition Rights is recognized as the rights are exercised or expire unexercised, which is generally within ninety days of initial deferral.
Other contracts
The Company also enters into collaboration and genome network contracts. Collaboration agreements provide customers with diagnostic testing and related data aggregation reporting services that are provided over the contract term. Collaboration revenue is recognized as the testing and reporting services are delivered to the customer. Genome network offerings consist of subscription services related to a proprietary software platform designed to connect patients, clinicians, advocacy organizations, researchers and therapeutic developers to accelerate the understanding, diagnosis and treatment of hereditary disease. Such services are recognized on a straight-line basis over the subscription periods.
Amounts due under collaboration and genome network agreements are typically billable on net thirty-day terms.
XML 42 R25.htm IDEA: XBRL DOCUMENT v3.10.0.1
Summary of significant accounting policies (Tables)
 12 Months Ended
Dec. 31, 2018
Accounting Policies [Abstract]  
Schedule significant customer, revenue as a percentage For the significant customer, revenue as a percentage of total revenue were as follows:
 
December 31,
Customers
2018
 
2017
 
2016
Medicare
22
%
 
13
%
 
11
%
Schedule of restrictions on cash and cash equivalents The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the statements of cash flows (in thousands):
 
December 31, 2018
 
December 31, 2017
Cash and cash equivalents
$
112,158

 
$
12,053

Restricted cash
6,006

 
5,406

Total cash, cash equivalents and restricted cash
$
118,164

 
$
17,459
Schedule of cash, cash equivalents and restricted cash The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the statements of cash flows (in thousands):
 
December 31, 2018
 
December 31, 2017
Cash and cash equivalents
$
112,158

 
$
12,053

Restricted cash
6,006

 
5,406

Total cash, cash equivalents and restricted cash
$
118,164

 
$
17,459
Schedule of useful lives of property and equipment The estimated useful lives of property and equipment are as follows:
Furniture and fixtures
7 years
Automobiles
7 years
Laboratory equipment
5 years
Computer equipment
3 years
Software
3 years
Leasehold improvements
Shorter of lease term or estimated useful life
XML 43 R26.htm IDEA: XBRL DOCUMENT v3.10.0.1
Revenue, accounts receivable and deferred revenue (Tables)
 12 Months Ended
Dec. 31, 2018
Revenue from Contract with Customer [Abstract]  
Schedule of impact of adoption of topic 606 on condensed consolidated statement of operations and balance sheet The effect of the adoption of Topic 606 on financial statement line items in the Company’s consolidated statement of operations for the year ended December 31, 2018, and the Company’s consolidated balance sheet as of December 31, 2018 was as follows (in thousands, except per share amounts):

 
 
Year Ended December 31, 2018
 
 
 
 
Without
 
Effect of
 
 
 
 
Adoption of
 
Adoption
 
 
As Reported
 
Topic 606
 
Higher/(Lower)
Test revenue
 
$
144,560

 
$
144,222

 
$
338

Net loss
 
$
(129,355
)
 
$
(129,693
)
 
$
338

Net loss per share, basic and diluted
 
$
(1.94
)
 
$
(1.94
)
 
$
—


 
 
As of December 31, 2018
 
 
 
 
Without
 
Effect of
 
 
 
 
Adoption of
 
Adoption
 
 
As Reported
 
Topic 606
 
Higher/(Lower)
Accounts receivable
 
$
26,296

 
$
14,150

 
$
12,146

Accumulated deficit
 
$
(516,712
)
 
$
(528,291
)
 
$
11,579

Stockholders' equity
 
$
161,839

 
$
150,260

 
$
11,579
Schedule of disaggregated revenue by payer category The following table includes the Company’s revenues as disaggregated by payer category (in thousands):
 
 
Year Ended December 31,
 
 
2018
 
2017 (1)
Test revenue:
 
 
 
 
Institutions
 
$
34,618

 
$
17,238

Patient - direct
 
13,589

 
5,638

Patient - insurance
 
96,353

 
42,293

 Total test revenue
 
144,560

 
65,169

Other revenue
 
3,139

 
3,052

Total revenue
 
$
147,699

 
$
68,221

___________________________________________________________________ 
(1)
As noted above, prior period amounts are presented as originally reported based upon the accounting standards in effect for those periods.
XML 44 R27.htm IDEA: XBRL DOCUMENT v3.10.0.1
Business combinations (Tables)
 12 Months Ended
Dec. 31, 2018
AltaVoice  
Business Acquisition [Line Items]  
Summary of fair values of assets acquired and liabilities assumed The following table summarizes the fair values of assets acquired and liabilities assumed at the date of acquisition (in thousands):
Cash
$
54

Accounts receivable
274

Prepaid expense and other assets
52

Non-compete agreement
286

Developed technology
570

Customer relationships
3,389

Total identifiable assets acquired
4,625

Accounts payable
(28
)
Deferred revenue
(202
)
Accrued expenses
(21
)
Deferred tax liability
(1,422
)
Total liabilities assumed
(1,673
)
Net identifiable assets acquired
2,952

Goodwill
9,432

Net assets acquired
$
12,384
Schedule of economic benefits of intangible assets expected to be realized Acquisition-related intangibles included in the above table are finite-lived. Customer relationships are being amortized on an accelerated basis, utilizing free cash flows, over a period of ten years. All other acquisition-related intangibles are being amortized on a straight-line basis over their estimated lives, which approximates the pattern in which the economic benefits of the intangible assets are expected to be realized, as follows (in thousands):
 
Gross
Purchased
Intangible
Assets
 
Estimated
Useful
Life
(in Years)
Non-compete agreement
$
286

 
5
Developed technology
570

 
6
Customer relationships
3,389

 
10
 
$
4,245

 
 
Ommdom, Inc.  
Business Acquisition [Line Items]  
Summary of fair values of assets acquired and liabilities assumed The following table summarizes the fair values of assets acquired and liabilities assumed at the date of acquisition (in thousands):
Cash
$
53

Accounts receivable
10

Prepaid expense and other assets
4

Trade name
13

Developed technology
2,335

Customer relationships
147

Total identifiable assets acquired
2,562

Accounts payable
(16
)
Accrued expenses
(17
)
Deferred tax liability
(434
)
Total liabilities assumed
(467
)
Net identifiable assets acquired
2,095

Goodwill
4,045

Net assets acquired
$
6,140
Schedule of economic benefits of intangible assets expected to be realized Finite-lived intangibles included in the above table are being amortized on a straight-line basis over their estimated lives, which approximates the pattern in which the economic benefits of the intangible assets are expected to be realized, as follows (in thousands):
 
Gross
Purchased
Intangible
Assets
 
Estimated
Useful
Life
(in Years)
Trade name
$
13

 
5
Developed technology
2,335

 
5
Customer relationships
147

 
5
 
$
2,495

 
 
Good Start Genetics  
Business Acquisition [Line Items]  
Summary of fair values of assets acquired and liabilities assumed The following table summarizes the fair values of assets acquired and liabilities assumed at the date of acquisition (in thousands):
Cash and restricted cash
$
1,381

Accounts receivable
2,246

Prepaid expense and other assets
1,579

Property and equipment
1,320

Trade name
460

Developed technology
5,896

Customer relationships
7,830

Total identifiable assets acquired
20,712

Accounts payable
(5,418
)
Accrued expenses
(6,802
)
Notes payable
(17,904
)
Convertible promissory notes payable
(15,430
)
Other liabilities
(222
)
Total liabilities assumed
(45,776
)
Net identifiable assets acquired
(25,064
)
Goodwill
25,064

Net assets acquired
$
—
Schedule of economic benefits of intangible assets expected to be realized Customer relationships are being amortized on an accelerated basis, utilizing free cash flows, over a period of eight years. All other finite-lived intangibles included in the above table are being amortized on a straight-line basis over their estimated lives, which approximates the pattern in which the economic benefits of the intangible assets are expected to be realized, as follows (in thousands):
 
Gross
Purchased
Intangible
Assets
 
Estimated
Useful
Life
(in Years)
Trade name
$
460

 
3
Developed technology
5,896

 
5
Customer relationships
7,830

 
8
 
$
14,186

 
 
CombiMatrix  
Business Acquisition [Line Items]  
Summary of fair values of assets acquired and liabilities assumed The following table summarizes the fair values of assets acquired and liabilities assumed at the date of acquisition (in thousands):
Cash and restricted cash
$
1,333

Accounts receivable
4,118

Prepaid expense and other assets
1,299

Property and equipment
437

Other assets - non current
30

Favorable leases
247

Trade name
103

Patent licensing agreement
496

Developed technology
3,162

Customer relationships
12,397

Total identifiable assets acquired
23,622

 
 
Accounts payable
(276
)
Accrued expenses
(3,925
)
Deferred tax liability
(2,862
)
Other liabilities
(180
)
Total liabilities assumed
(7,243
)
 
 
Net identifiable assets acquired
16,379

Goodwill
11,554

Net assets acquired
$
27,933
Schedule of economic benefits of intangible assets expected to be realized Customer relationships are being amortized on an accelerated basis, utilizing free cash flows, over a period of eleven years. All other finite-lived intangibles included in the above table are being amortized on a straight-line basis over their estimated lives, which approximates the pattern in which the economic benefits of the intangible assets are expected to be realized, as follows (in thousands):
 
Gross
Purchased
Intangible
Assets
 
Estimated
Useful
Life
(in Years)
Favorable leases
$
247

 
2
Trade name
103

 
1
Patent licensing agreement
496

 
15
Developed technology
3,162

 
4
Customer relationships
12,397

 
11
 
$
16,405

 
 
XML 45 R28.htm IDEA: XBRL DOCUMENT v3.10.0.1
Goodwill and intangible assets (Tables)
 12 Months Ended
Dec. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]  
Summary of goodwill Details of the Company’s goodwill for the year ended December 31, 2018 are as follows (in thousands):
 
AltaVoice
 
Ommdom
 
Good Start
 
CombiMatrix
 
Total
Balance as of December 31, 2017
$
9,432

 
$
4,045

 
$
24,406

 
$
8,692

 
$
46,575

Goodwill adjustment
—

 
—

 
658

 
2,862

 
3,520

Balance as of December 31, 2018
$
9,432

 
$
4,045

 
$
25,064

 
$
11,554

 
$
50,095
Schedule of finite-lived intangible assets The following table presents details of the Company’s finite-lived intangible assets as of December 31, 2018 (in thousands):
 
Cost
 
Accumulated
Amortization
 
Net
 
Weighted Average
Useful Life
(in Years)
 
Weighted Average
Estimated Remaining
Useful Life
(in Years)
Customer relationships
$
23,763

 
$
(2,783
)
 
$
20,980

 
10.0
 
8.6
Developed technology
11,963

 
(3,482
)
 
8,481

 
4.8
 
3.4
Non-compete agreement
286

 
(114
)
 
172

 
5.0
 
3.0
Trade name
576

 
(329
)
 
247

 
2.7
 
1.4
Patent licensing agreement
496

 
(37
)
 
459

 
15.0
 
13.9
Favorable leases
247

 
(117
)
 
130

 
2.2
 
1.1
 
$
37,331

 
$
(6,862
)
 
$
30,469

 
8.2
 
6.8
Summary of estimated future amortization expense of intangible assets with finite lives The following table summarizes the Company’s estimated future amortization expense of intangible assets with finite lives as of December 31, 2018 (in thousands):
 
Amount
2019
$
5,250

2020
5,525

2021
5,829

2022
4,124

2023
3,111

Thereafter
6,630

Total estimated future amortization expense
$
30,469
XML 46 R29.htm IDEA: XBRL DOCUMENT v3.10.0.1
Balance sheet components (Tables)
 12 Months Ended
Dec. 31, 2018
Balance Sheet Related Disclosures [Abstract]  
Schedule of property and equipment, net Property and equipment consisted of the following (in thousands):
 
December 31, 2018
 
December 31, 2017
Leasehold improvements
$
13,034

 
$
12,623

Laboratory equipment
22,149

 
17,705

Equipment under capital lease
7,129

 
11,446

Computer equipment
4,723

 
4,023

Software
2,594

 
2,520

Furniture and fixtures
784

 
569

Automobiles
20

 
20

Construction-in-progress
1,962

 
965

Total property and equipment, gross
52,395

 
49,871

Accumulated depreciation and amortization
(24,509
)
 
(19,530
)
Total property and equipment, net
$
27,886

 
$
30,341
Schedule of accrued liabilities Accrued liabilities consisted of the following (in thousands):
 
December 31, 2018
 
December 31, 2017
Accrued compensation and related expenses
$
7,917

 
$
7,406

Deferred revenue
761

 
307

Liabilities associated with business combinations
6,460

 
9,497

Liability associated with co-development agreement
2,000

 
—

Other
9,425

 
5,532

Total accrued liabilities
$
26,563

 
$
22,742
Schedule of other long-term liabilities Other long-term liabilities consisted of the following (in thousands):
 
December 31, 2018
 
December 31, 2017
Lease incentive obligation, non-current
$
3,280

 
$
3,831

Deferred rent, non-current
5,495

 
5,153

Liabilities associated with business combinations
—

 
3,779

Other non-current liabilities
181

 
677

Total other long-term liabilities
$
8,956

 
$
13,440
XML 47 R30.htm IDEA: XBRL DOCUMENT v3.10.0.1
Fair value measurements (Tables)
 12 Months Ended
Dec. 31, 2018
Fair Value Disclosures [Abstract]  
Schedule of Financial instruments at fair value on a recurring basis The following tables set forth the fair value of the Company’s consolidated financial instruments that were measured at fair value on a recurring basis (in thousands):
 
 
December 31, 2018
 
 
Amortized Cost
 
Gross Unrealized Gains
 
Gross Unrealized Losses
 
Estimated Fair Value
 
Level 1
 
Level 2
 
Level 3
Financial assets:
 
 
 
 
 
 
 
 
 
 

 
 

 
 

Money market funds
 
$
93,934

 
$
—

 
$
—

 
$
93,934

 
$
93,934

 
$
—

 
$
—

Certificates of deposit
 
300

 
—

 
—

 
300

 
—

 
300

 
—

Commercial paper
 
10,908

 
—

 
(1
)
 
10,907

 
—

 
10,907

 
—

U.S. treasury notes
 
9,990

 
—

 
—

 
9,990

 
9,990

 
—

 
—

U.S. government agency securities
 
6,001

 
—

 
(4
)
 
5,997

 
—

 
5,997

 
—

Total financial assets
 
$
121,133

 
$
—

 
$
(5
)
 
$
121,128

 
$
103,924

 
$
17,204

 
$
—

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Financial liabilities:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Contingent consideration
 
 
 
 
 
 
 
$
4,998

 
$
—

 
$
—

 
$
4,998

Total financial liabilities
 
 
 
 
 
 
 
$
4,998

 
$
—

 
$
—

 
$
4,998

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
December 31, 2018
Reported as:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash equivalents
 
 
 
 
 
 
 
 
 
 
 
$
101,395
 
Restricted cash
 
 
 
 
 
 
 
 
 
 
 
6,006
 
Marketable securities
 
 
 
 
 
 
 
 
 
 
 
13,727
 
Total cash equivalents, restricted cash, and marketable securities
 
 
 
$
121,128
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Accrued liabilities
 
 
 
 
 
 
 
 
 
 
 
$
4,998
 
 
 
December 31, 2017
 
 
Amortized
Cost
 
Gross
Unrealized
Gains
 
Gross
Unrealized
Losses
 
Estimated
Fair Value
 
Level 1
 
Level 2
 
Level 3
Financial assets:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Money market funds
 
$
5,998

 
$
—

 
$
—

 
$
5,998

 
$
5,998

 
$
—

 
$
—

Certificates of deposit
 
300

 
—

 
—

 
300

 
300

 
—

 
—

U.S. treasury notes
 
12,010

 
—

 
(19
)
 
11,991

 
11,991

 
—

 
—

U.S. government agency securities
 
46,451

 
—

 
(152
)
 
46,299

 
—

 
46,299

 
—

Total financial assets
 
$
64,759

 
$
—

 
$
(171
)
 
$
64,588

 
$
18,289

 
$
46,299

 
$
—

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Financial liabilities:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Contingent consideration
 
 
 
 
 
 
 
$
3,779

 
$
—

 
$
—

 
$
3,779

Total financial liabilities
 
 
 
 
 
 
 
$
3,779

 
$
—

 
$
—

 
$
3,779

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
December 31, 2017
Reported as:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash equivalents
 
 
 
 
 
 
 
 
 
 
 
$
592
 
Restricted cash
 
 
 
 
 
 
 
 
 
 
 
5,406
 
Marketable securities
 
 
 
 
 
 
 
 
 
 
 
58,590
 
Total cash equivalents, restricted cash, and marketable securities
 
 
 
$
64,588
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Accrued liabilities
 
 
 
 
 
 
 
 
 
 
 
$
3,779
 
Schedule of Level 3 financial instruments measured at fair value on a recurring basis The following table presents the Company’s Level 3 financial instruments that are measured at fair value on a recurring basis (in thousands):
 
Level 3
 
Contingent Consideration Liability
Balance as of December 31, 2017
$
3,779

Change in estimate of fair value
1,219

Balance as of December 31, 2018
$
4,998
Schedule of Carrying amount and the estimated fair value of the Company's outstanding debt The carrying amount of the Company’s outstanding debt at December 31, 2018 approximated its fair value and as of December 31, 2017, the Company's debt carrying amount and fair value were as follows (in thousands):
 
December 31, 2017
 
Carrying Amount
 
Fair Value
Debt
$
39,084

 
$
40,526
XML 48 R31.htm IDEA: XBRL DOCUMENT v3.10.0.1
Commitments and contingencies (Tables)
 12 Months Ended
Dec. 31, 2018
Commitments and Contingencies Disclosure [Abstract]  
Schedule of future minimum payments under operating leases Future minimum payments under non-cancelable operating leases and future minimum payments to be received from non-cancelable subleases as of December 31, 2018 are as follows (in thousands):
 
Amounts
2019
$
10,948

2020
10,860

2021
11,109

2022
11,067

2023
8,898

Thereafter
25,715

Future non-cancelable minimum operating lease payments
78,597

Less: minimum payments to be received from non-cancelable subleases
(174
)
Total future non-cancelable minimum operating lease payments, net
$
78,423
Schedule of rent expense related to non-cancelable operating leases The following table summarizes rent expense related to non-cancelable operating leases (in thousands):
 
Year Ended December 31,
 
2018
 
2017
 
2016
Rent expense
$
9,720

 
$
8,950

 
$
8,901

Sublease income
227

 
398

 
257

Rent expense, net of sublease income
$
9,493

 
$
8,552

 
$
8,644
Schedule of future payments under loan and security agreement Future estimated payments under the 2018 Note Purchase Agreement as of December 31, 2018 are as follows (in thousands):
 
Amounts
2019
$
6,654

2020
8,297

2021
8,279

2022
8,279

2023
8,279

Thereafter
89,998

Total remaining payments
129,786

Less: amount representing debt discount
(721
)
Less: amount representing interest
(54,588
)
Total non-current debt obligation
$
74,477
Schedule of future minimum lease payments under capital leases Future payments under capital leases at December 31, 2018 were as follows (in thousands):
 
Amounts
2019
$
2,087

2020
1,392

2021
21

Total capital lease obligations
3,500

Less: amount representing interest
(188
)
Present value of net minimum capital lease payments
3,312

Less: current portion
(1,937
)
Total non-current capital lease obligations
$
1,375
Schedule of future payments under noncancelable unconditional purchase commitments At December 31, 2018, the Company’s total future payments under noncancelable unconditional purchase commitments having a remaining term of over one year were as follows (in thousands):
 
Amount
2019
$
3,040

2020
3,040

2021
1,440

Total
$
7,520
XML 49 R32.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stockholders' Equity (Tables)
 12 Months Ended
Dec. 31, 2018
Stockholders' Equity Note [Abstract]  
Schedule of shares of common stock reserved for future issuance As of December 31, 2018 and 2017, the Company had reserved shares of common stock, on an as‑if converted basis, for issuance as follows (in thousands):
 
As of December 31,
 
2018
 
2017
Options issued and outstanding
3,855

 
4,115

RSU awards issued and outstanding
4,031

 
2,387

Shares available for grant under stock option plans
118

 
2,397

Shares reserved for issuance under the 2015 Employee Stock Purchase Plan
278

 
308

Common stock underlying warrants
611

 
1,962

Common stock issuable upon conversion of preferred stock
3,459

 
3,459

Common stock underlying stock payable liabilities
132

 
689

Common stock payable as contingent consideration
452

 
551

Total
12,936

 
15,868
Schedule of outstanding warrants to purchase common stock As of December 31, 2018, the Company had outstanding warrants to purchase common stock as follows:
Warrant
 
Issuance Date
 
Expiration Date
 
Exercise
Price
Per Share
 
Number of Shares of Common Stock Underlying Warrants
Warrants issued in exchange for CombiMatrix Series F warrants
 
November 2017
 
March 2021
 
$
5.95

 
408,548

Warrants issued to lender under 2017 Loan Agreement
 
March 2017
 
March 2027
 
$
10.27

 
116,845

Warrants issued to lender under 2017 Loan Agreement - 2018 Amendments
 
March 2018
 
March 2028
 
$
7.02

 
85,482

 
 
 
 
 
 
 
 
610,875
XML 50 R33.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stock incentive plans (Tables)
 12 Months Ended
Dec. 31, 2018
Stock incentive plan  
Schedule of activity under stock incentive plans Activity under the 2010 Plan and the 2015 Plan is set forth below (in thousands, except per share amounts and years):
 
Shares
Available
For Grant
 
Stock
Options
Outstanding
 
Weighted-
Average
Exercise
Price
 
Weighted-
Average
Remaining
Contractual
Life (years)
 
Aggregate
Intrinsic
Value
Balance at December 31, 2017
2,397

 
4,115

 
$
8.51

 
7.6
 
$
5,128

Additional shares reserved
754

 
—

 
 
 
 
 
 
Options granted
(260
)
 
260

 
$
8.50

 
 
 
 
Options cancelled
169

 
(169
)
 
$
9.35

 
 
 
 
Options exercised
—

 
(351
)
 
$
7.73

 
 
 
 
RSUs granted
(3,282
)
 
—

 
 
 
 
 
 
RSUs cancelled
340

 
—

 
 
 
 
 
 
Balance at December 31, 2018
118

 
3,855

 
$
8.54

 
6.8
 
$
9,927

Options exercisable at December 31, 2018
 
 
2,737

 
$
8.27

 
6.4
 
$
7,787

Options vested and expected to vest at December 31, 2018
 
 
3,710

 
$
8.52

 
6.8
 
$
9,626
Summary of RSU activity The following table summarizes RSU activity for the year ended December 31, 2018 (in thousands, except per share data:
 
Number of Shares
 
Weighted-Average Grant Date Fair Value
Balance at December 31, 2017
2,387

 
$
9.91

RSUs granted
3,282

 
$
7.46

RSUs vested
(1,298
)
 
$
8.84

RSUs cancelled
(340
)
 
$
8.84

Balance at December 31, 2018
4,031

 
$
8.35
Summary of stock based compensation expense related to stock options included in consolidated statements of operations The following table summarizes stock-based compensation expense for the years ended December 31, 2018, 2017 and 2016, included in the consolidated statements of operations (in thousands):
 
Year Ended December 31,
 
2018
 
2017
 
2016
Cost of revenue
$
2,960

 
$
2,093

 
$
1,353

Research and development
7,017

 
6,158

 
4,976

Selling and marketing
4,887

 
3,956

 
1,709

General and administrative
5,986

 
7,014

 
2,661

Total stock-based compensation expense
$
20,850

 
$
19,221

 
$
10,699
Employee Stock Option  
Stock incentive plan  
Schedule of assumptions used in determination of fair value of options The fair value of share-based payments for stock options granted to employees and directors was estimated on the date of grant using the Black-Scholes option-pricing model based on the following assumptions:
 
Year Ended December 31,
 
2018
 
2017
 
2016
Expected term (in years)
6.00
 
6.03
 
6.03
Expected volatility
59.58%
 
72.64%
 
71.42%
Risk-free interest rate
2.80%
 
2.01%
 
1.37%
Non-Employee Options  
Stock incentive plan  
Schedule of assumptions used in determination of fair value of options The fair value of the stock options granted is calculated at each reporting date using the Black-Scholes option-pricing model based on the following assumptions:
 
Year Ended December 31,
 
2018
 
2017
 
2016
Expected term (in years)
—
 
8.41 – 8.83
 
6.25 – 10.00
Expected volatility
—
 
69.9 – 78.70%
 
76.92%
Risk-free interest rate
—
 
1.83 – 2.04%
 
1.55 – 2.37%
2015 Employee Stock Purchase Plan  
Stock incentive plan  
Schedule of assumptions used in determination of fair value of options The fair value of the shares purchased pursuant to the ESPP was estimated using the following assumptions:
 
Year Ended December 31,
 
2018
 
2017
 
2016
Expected term (in years)
0.5
 
0.5
 
0.5
Expected volatility
71.66%
 
52.50%
 
66.31%
Risk-free interest rate
2.09%
 
1.23%
 
0.50%
XML 51 R34.htm IDEA: XBRL DOCUMENT v3.10.0.1
Income Taxes (Tables)
 12 Months Ended
Dec. 31, 2018
Income Tax Disclosure [Abstract]  
Schedule of components of loss before income taxes by U.S. and foreign jurisdictions The components of net loss before taxes by U.S. and foreign jurisdictions are as follows (in thousands):
 
Year Ended December 31,
 
2018
 
2017
 
2016
United States
$
132,194

 
$
124,108

 
$
99,793

Foreign
(39
)
 
1,128

 
463

Total
$
132,155

 
$
125,236

 
$
100,256
Schedule of components of the provision for income taxes The components of the provision for income taxes are as follows (in thousands):
 
Year Ended December 31,
 
2018
 
2017
 
2016
Current:
 
 
 
 
 
Foreign
62

 
—

 
—

Total current benefit for income taxes
62

 
—

 
—

Deferred:
 
 
 
 
 
Federal
(2,862
)
 
(1,704
)
 
—

State
—

 
(152
)
 
—

Total deferred benefit for income taxes
(2,862
)
 
(1,856
)
 
—

Total income tax benefit
$
(2,800
)
 
$
(1,856
)
 
$
—
Schedule of reconciliation of the tax expense computed at the statutory federal rate and Company's tax expense The following table presents a reconciliation of the tax expense computed at the statutory federal rate and the Company’s tax expense for the periods presented:
 
Year Ended December 31,
 
2018
 
2017
 
2016
U.S. federal taxes at statutory rate
21.0
 %
 
34.0
 %
 
34.0
 %
State taxes (net of federal benefit)
5.2
 %
 
3.3
 %
 
1.4
 %
Stock-based compensation
(0.7
)%
 
(1.1
)%
 
(1.7
)%
Research and development credits
2.7
 %
 
—
 %
 
—
 %
Non-deductible expenses
(0.6
)%
 
—
 %
 
0.2
 %
Foreign tax differential
—
 %
 
(0.3
)%
 
(0.2
)%
Other
—
 %
 
—
 %
 
1.1
 %
Change in valuation allowance
(25.5
)%
 
(34.4
)%
 
(34.8
)%
Change in deferred—Tax Reform
—
 %
 
(39.0
)%
 
—
 %
Change in valuation allowance—Tax Reform
—
 %
 
39.0
 %
 
—
 %
Total
2.1
 %
 
1.5
 %
 
—
 %
Schedule of net deferred tax assets The tax effects of temporary differences and carryforwards that give rise to significant portions of the deferred tax assets are as follows (in thousands):
 
As of December 31,
 
2018
 
2017
Deferred tax assets:
 

 
 

Net operating loss carryforwards
$
76,972

 
$
70,825

Tax credits
15

 
15

Revenue recognition differences
47,650

 
29,819

Accruals and other
7,262

 
5,544

Gross deferred tax assets
131,899

 
106,203

Valuation allowance
(121,954
)
 
(95,687
)
Total deferred tax assets
9,945

 
10,516

Deferred tax liabilities:
 
 
 
Property and equipment
(9,945
)
 
(10,516
)
Total deferred tax liabilities
(9,945
)
 
(10,516
)
Net deferred tax assets
$
—

 
$
—
Schedule of reconciliation of gross unrecognized tax benefits A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in thousands):
 
Year ended December 31,
 
2018
 
2017
 
2016
Unrecognized tax benefits, beginning of period
$
10,561

 
$
7,791

 
$
11,429

Gross increases—current period tax positions
5,686

 
2,552

 
782

Gross increases (decreases)—prior period tax positions
128

 
218

 
(4,420
)
Unrecognized tax benefits, end of period
$
16,375

 
$
10,561

 
$
7,791
XML 52 R35.htm IDEA: XBRL DOCUMENT v3.10.0.1
Net loss per common share (Tables)
 12 Months Ended
Dec. 31, 2018
Earnings Per Share [Abstract]  
Schedule of earnings per share, basic and diluted The following table presents the calculation of basic and diluted net loss per share for the years ended December 31, 2018, 2017 and 2016 (in thousands, except per share data):
 
Year ended December 31,
 
2018
 
2017
 
2016
Net loss
$
(129,355
)
 
$
(123,380
)
 
$
(100,256
)
Shares used in computing net loss per share, basic and diluted
66,747

 
46,512

 
33,176

Net loss per share, basic and diluted
$
(1.94
)
 
$
(2.65
)
 
$
(3.02
)
Schedule of antidilutive securities excluded from computation of earnings per share The following common stock equivalents have been excluded from diluted net loss per share for the years ended December 31, 2018, 2017 and 2016 because their inclusion would be anti-dilutive (in thousands):
 
Year Ended December 31,
 
2018
 
2017
 
2016
Shares of common stock subject to outstanding options
3,855

 
4,115

 
4,491

Shares of common stock subject to outstanding warrants
611

 
1,962

 
—

Shares of common stock subject to outstanding RSUs
4,031

 
2,387

 
892

Shares of common stock subject to outstanding PRSUs
—

 
—

 
530

Shares of common stock pursuant to ESPP
63

 
59

 
55

Shares of common stock underlying Series A convertible preferred stock
3,459

 
3,459

 
—

Total shares of common stock equivalents
12,019

 
11,982

 
5,968
XML 53 R36.htm IDEA: XBRL DOCUMENT v3.10.0.1
Geographic information (Tables)
 12 Months Ended
Dec. 31, 2018
Segments, Geographical Areas [Abstract]  
Schedule of revenue by country Revenue by country is determined based on the billing address of the customer and is summarized as follows (in thousands):
 
Year Ended December 31,
 
2018
 
2017
 
2016
United States
$
138,239

 
$
62,446

 
$
20,758

Canada
4,206

 
3,226

 
2,526

Rest of world
5,254

 
2,549

 
1,764

Total revenue
$
147,699

 
$
68,221

 
$
25,048
XML 54 R37.htm IDEA: XBRL DOCUMENT v3.10.0.1
Selected Quarterly Data (Unaudited) (Tables)
 12 Months Ended
Dec. 31, 2018
Quarterly Financial Information Disclosure [Abstract]  
Schedule of selected quarterly data The following table summarizes the Company's quarterly financial information for 2018 and 2017 (in thousands, except per share amounts):
 
 
Three Months Ended
 
 
March 31, 2018
 
June 30, 2018
 
September 30, 2018
 
December 31, 2018
Revenue
 
$
27,671

 
$
37,306

 
$
37,366

 
$
45,356

Cost of revenue
 
$
18,076

 
$
20,447

 
$
20,441

 
$
21,141

Loss from operations
 
$
(36,475
)
 
$
(30,068
)
 
$
(30,110
)
 
$
(25,904
)
Net loss(2)
 
$
(36,120
)
 
$
(31,671
)
 
$
(31,723
)
 
$
(29,841
)
Net loss per share, basic and diluted(1)
 
$
(0.66
)
 
$
(0.47
)
 
$
(0.45
)
 
$
(0.40
)
 
 
 
 
 
 
 
 
 
 
 
Three Months Ended
 
 
March 31, 2017
 
June 30, 2017
 
September 30, 2017
 
December 31, 2017
Revenue
 
$
10,338

 
$
14,336

 
$
18,148

 
$
25,399

Cost of revenue
 
$
9,329

 
$
10,490

 
$
13,274

 
$
17,049

Loss from operations
 
$
(27,337
)
 
$
(28,075
)
 
$
(30,976
)
 
$
(34,891
)
Net loss(2)
 
$
(26,928
)
 
$
(28,557
)
 
$
(27,402
)
 
$
(40,493
)
Net loss per share, basic and diluted(1)
 
$
(0.64
)
 
$
(0.66
)
 
$
(0.57
)
 
$
(0.78
)
___________________________________________________________________ 
(1) 
Net loss per share is computed independently for each of the quarters presented. Therefore, the sum of quarterly net loss per share information may not equal annual net loss per share.
(2)
Includes $5.3 million of debt extinguishment costs during the three months ended December 31, 2018. See Note 9, "Commitments and contingencies" for further information.
XML 55 R38.htm IDEA: XBRL DOCUMENT v3.10.0.1
Organization and description of business - Narrative (Details)
gene in Thousands
 12 Months Ended
Dec. 31, 2018
Segment
gene
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Number of genes | gene 20
Number of operating segments | Segment 1
XML 56 R39.htm IDEA: XBRL DOCUMENT v3.10.0.1
Summary of significant accounting policies - Narrative (Details) - USD ($)
 12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Summary Of Significant Accounting Policies [Line Items]      
Inventory $ 8,300,000 $ 5,400,000  
Intangible assets estimated useful lives 8 years 2 months 12 days    
Goodwill impairment loss $ 0 0 $ 0
Impairment losses 2,925,000 0 0
Long-lived asset impairment losses 0 0 0
Advertising expense 600,000 $ 600,000 500,000
Future undiscounted capital lease payments 3,500,000    
Future undiscounted non-cancelable minimum operating lease payments $ 78,423,000    
Leasehold improvements | General and administrative      
Summary Of Significant Accounting Policies [Line Items]      
Impairment losses     $ 1,000,000.0
Customer relationships      
Summary Of Significant Accounting Policies [Line Items]      
Intangible assets estimated useful lives 10 years    
Minimum      
Summary Of Significant Accounting Policies [Line Items]      
Intangible assets estimated useful lives 2 years    
Property and equipment, estimated useful lives 3 years    
Minimum | Customer relationships      
Summary Of Significant Accounting Policies [Line Items]      
Intangible assets estimated useful lives 5 years    
Maximum      
Summary Of Significant Accounting Policies [Line Items]      
Intangible assets estimated useful lives 15 years    
Property and equipment, estimated useful lives 7 years    
Maximum | Customer relationships      
Summary Of Significant Accounting Policies [Line Items]      
Intangible assets estimated useful lives 11 years    
Revenue | Customer concentration risk | Medicare      
Summary Of Significant Accounting Policies [Line Items]      
Concentration risk (as a percent) 22.00% 13.00% 11.00%
Revenue | Customer concentration risk | Medicare | Maximum      
Summary Of Significant Accounting Policies [Line Items]      
Concentration risk (as a percent) 10.00%    
Accounts receivable | Customer concentration risk | Medicare      
Summary Of Significant Accounting Policies [Line Items]      
Concentration risk (as a percent) 21.00% 13.00%  
XML 57 R40.htm IDEA: XBRL DOCUMENT v3.10.0.1
Summary of significant accounting policies - Schedule of significant customers, revenue as a percentage (Details)
 12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Customer concentration risk | Revenue | Medicare      
Product Information [Line Items]      
Concentration risk (as a percent) 22.00% 13.00% 11.00%
XML 58 R41.htm IDEA: XBRL DOCUMENT v3.10.0.1
Summary of significant accounting policies - Schedule of cash, cash equivalents and restricted cash (Details) - USD ($)
$ in Thousands
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Accounting Policies [Abstract]        
Cash and cash equivalents $ 112,158 $ 12,053    
Restricted cash 6,006 5,406    
Total cash, cash equivalents and restricted cash $ 118,164 $ 17,459 $ 71,522 $ 78,069
XML 59 R42.htm IDEA: XBRL DOCUMENT v3.10.0.1
Summary of significant accounting policies - Schedule of useful lives of property and equipment (Details)
 12 Months Ended
Dec. 31, 2018
Furniture and fixtures  
Property and equipment  
Useful lives 7 years
Automobiles  
Property and equipment  
Useful lives 7 years
Laboratory equipment  
Property and equipment  
Useful lives 5 years
Computer equipment  
Property and equipment  
Useful lives 3 years
Software  
Property and equipment  
Useful lives 3 years
XML 60 R43.htm IDEA: XBRL DOCUMENT v3.10.0.1
Revenue, accounts receivable and deferred revenue - Narrative (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 12 Months Ended
Jan. 01, 2018
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Dec. 31, 2017
Sep. 30, 2017
Jun. 30, 2017
Mar. 31, 2017
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Disaggregation of Revenue [Line Items]                        
Cumulative effect of accounting change $ 11,241                      
Revenue recognized                   $ 300    
Total revenue   $ 45,356 $ 37,366 $ 37,306 $ 27,671 $ 25,399 $ 18,148 $ 14,336 $ 10,338 147,699 $ 68,221 $ 25,048
Loss from operations   $ (25,904) $ (30,110) $ (30,068) $ (36,475) $ (34,891) $ (30,976) $ (28,075) $ (27,337) $ (122,557) $ (121,279) $ (100,183)
Net loss per share, basic and diluted (in dollars per share)   $ (0.40) $ (0.45) $ (0.47) $ (0.66) $ (0.78) $ (0.57) $ (0.66) $ (0.64) $ (1.94) $ (2.65) $ (3.02)
Topic 606                        
Disaggregation of Revenue [Line Items]                        
Cumulative effect of accounting change $ 11,200                      
Test revenue                        
Disaggregation of Revenue [Line Items]                        
Total revenue                   $ 144,560 $ 65,169 $ 24,840
Test revenue | Change in estimate of revenue recognition                        
Disaggregation of Revenue [Line Items]                        
Total revenue                   4,500    
Loss from operations                   $ 4,500    
Net loss per share, basic and diluted (in dollars per share)                   $ 0.07    
Maximum                        
Disaggregation of Revenue [Line Items]                        
Performance obligations underlying contracts period 1 year                      
Sales commissions amortization period 1 year                      
Period of payments to be received for goods or service 1 year                      
XML 61 R44.htm IDEA: XBRL DOCUMENT v3.10.0.1
Revenue, accounts receivable and deferred revenue - Schedule of impact of adoption of topic 606 on condensed statement of operations and balance sheet (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Dec. 31, 2017
Sep. 30, 2017
Jun. 30, 2017
Mar. 31, 2017
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]                        
Total revenue $ 45,356 $ 37,366 $ 37,306 $ 27,671 $ 25,399 $ 18,148 $ 14,336 $ 10,338 $ 147,699 $ 68,221 $ 25,048  
Net loss $ (29,841) $ (31,723) $ (31,671) $ (36,120) $ (40,493) $ (27,402) $ (28,557) $ (26,928) $ (129,355) $ (123,380) $ (100,256)  
Net loss per share, basic and diluted (in dollars per share) $ (0.40) $ (0.45) $ (0.47) $ (0.66) $ (0.78) $ (0.57) $ (0.66) $ (0.64) $ (1.94) $ (2.65) $ (3.02)  
Accounts receivable $ 26,296       $ 10,422       $ 26,296 $ 10,422    
Accumulated deficit (516,712)       (398,598)       (516,712) (398,598)    
Stockholders' equity 161,839       $ 121,794       161,839 121,794 $ 99,074 $ 138,376
Without adoption of topic 606 | Topic 606                        
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]                        
Net loss                 $ (129,693)      
Net loss per share, basic and diluted (in dollars per share)                 $ (1.94)      
Accounts receivable 14,150               $ 14,150      
Accumulated deficit (528,291)               (528,291)      
Stockholders' equity 150,260               150,260      
Effect of adoption higher/lower | Topic 606                        
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]                        
Net loss                 $ 338      
Net loss per share, basic and diluted (in dollars per share)                 $ 0      
Accounts receivable 12,146               $ 12,146      
Accumulated deficit 11,579               11,579      
Stockholders' equity $ 11,579               11,579      
Test revenue                        
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]                        
Total revenue                 144,560 $ 65,169 $ 24,840  
Test revenue | Without adoption of topic 606 | Topic 606                        
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]                        
Total revenue                 144,222      
Test revenue | Effect of adoption higher/lower | Topic 606                        
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]                        
Total revenue                 $ 338      
XML 62 R45.htm IDEA: XBRL DOCUMENT v3.10.0.1
Revenue, accounts receivable and deferred revenue - Schedule of disaggregated revenue by payer category (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Dec. 31, 2017
Sep. 30, 2017
Jun. 30, 2017
Mar. 31, 2017
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Disaggregation of Revenue [Line Items]                      
Total revenue $ 45,356 $ 37,366 $ 37,306 $ 27,671 $ 25,399 $ 18,148 $ 14,336 $ 10,338 $ 147,699 $ 68,221 $ 25,048
Test revenue                      
Disaggregation of Revenue [Line Items]                      
Total revenue                 144,560 65,169 24,840
Test revenue | Institutions                      
Disaggregation of Revenue [Line Items]                      
Total revenue                 34,618 17,238  
Test revenue | Patient - direct                      
Disaggregation of Revenue [Line Items]                      
Total revenue                 13,589 5,638  
Test revenue | Patient - insurance                      
Disaggregation of Revenue [Line Items]                      
Total revenue                 96,353 42,293  
Other revenue                      
Disaggregation of Revenue [Line Items]                      
Total revenue                 $ 3,139 $ 3,052 $ 208
XML 63 R46.htm IDEA: XBRL DOCUMENT v3.10.0.1
Business combinations - Narrative (Details) - USD ($)
 1 Months Ended 12 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Nov. 14, 2017
Aug. 04, 2017
Jul. 31, 2017
Jun. 11, 2017
Jan. 06, 2017
Jan. 31, 2019
Sep. 30, 2018
Jun. 30, 2018
Apr. 30, 2018
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Business Acquisition [Line Items]                            
Intangible assets estimated useful lives                       8 years 2 months 12 days    
Goodwill                       $ 50,095,000 $ 46,575,000  
Decrease in accounts receivable                       (5,291,000) (1,963,000) $ (843,000)
Goodwill adjustment                       $ 3,520,000    
Non-compete agreement                            
Business Acquisition [Line Items]                            
Intangible assets estimated useful lives                       5 years    
Customer relationships                            
Business Acquisition [Line Items]                            
Intangible assets estimated useful lives                       10 years    
Maximum                            
Business Acquisition [Line Items]                            
Intangible assets estimated useful lives                       15 years    
Maximum | Customer relationships                            
Business Acquisition [Line Items]                            
Intangible assets estimated useful lives                       11 years    
AltaVoice                            
Business Acquisition [Line Items]                            
Total purchase consideration             $ 12,400,000              
Payment through issuance of shares company's common stock             5,500,000              
Contingently payable amount   $ 5,000,000.0                        
Purchase consideration, second payment discounted and recorded as liability             4,700,000              
Change in fair value of contingent consideration             2,200,000              
Goodwill acquired                       $ 9,400,000    
Goodwill             9,432,000         9,432,000 9,432,000  
Goodwill adjustment                       $ 0    
Deferred tax liability             $ 1,422,000              
AltaVoice | Non-compete agreement                            
Business Acquisition [Line Items]                            
Intangible assets estimated useful lives             5 years         10 years    
AltaVoice | Customer relationships                            
Business Acquisition [Line Items]                            
Intangible assets estimated useful lives             10 years              
AltaVoice | Other (income) expense                            
Business Acquisition [Line Items]                            
Accretion gains (losses)                       $ 1,600,000 (200,000)  
AltaVoice | General and administrative                            
Business Acquisition [Line Items]                            
Change in estimate of fair value                       1,200,000 1,600,000  
AltaVoice | Milestone Based on Certain Threshold of Revenue Achieved During 2017 [Member]                            
Business Acquisition [Line Items]                            
Common stock issued, value   5,000,000.0                        
AltaVoice | Scenario, forecast | New Contingent Milestone Based On Achieving Revenue Target During 2017 And 2018                            
Business Acquisition [Line Items]                            
Contingent consideration, revenue target for payout $ 14,000,000.0                          
Contingent consideration, revenue target (as a percent) 75.00%                          
Contingent consideration, amount deducted on revenue target $ 5,500,000                          
Business combination possible payout amount 5,000,000.0                          
AltaVoice | Scenario, forecast | New Contingent Milestone Based On Achieving Revenue Target During 2017 And 2018 | Maximum                            
Business Acquisition [Line Items]                            
Common stock issued, value $ 5,000,000.0                          
AltaVoice | Common stock                            
Business Acquisition [Line Items]                            
Payment through issuance of shares company's common stock   5,000,000.0         $ 5,500,000              
Common stock issued (in shares)             641,126       716,332      
Common stock issued, value   $ 5,000,000.0                        
AltaVoice | Common stock | Maximum                            
Business Acquisition [Line Items]                            
Contingently payable amount                       5,000,000.0    
Ommdom, Inc.                            
Business Acquisition [Line Items]                            
Total purchase consideration           $ 6,100,000                
Payment through issuance of shares company's common stock           5,500,000                
Purchase consideration, second payment discounted and recorded as liability           600,000                
Hold-back consideration amount           600,000                
Goodwill           4,045,000           4,045,000 4,045,000  
Goodwill adjustment                       0    
Deferred tax liability           $ 434,000                
Ommdom, Inc. | Customer relationships                            
Business Acquisition [Line Items]                            
Intangible assets estimated useful lives           5 years                
Ommdom, Inc. | Common stock                            
Business Acquisition [Line Items]                            
Payment through issuance of shares company's common stock           $ 5,500,000                
Common stock issued (in shares)           600,108                
Hold-back consideration amount           $ 600,000                
Common stock issued, related to hold back (in shares)           66,582       66,582        
Good Start Genetics                            
Business Acquisition [Line Items]                            
Total purchase consideration       $ 24,400,000                    
Percentage of diluted interest acquired       100.00%                    
Goodwill       $ 25,064,000               25,064,000 24,406,000  
Cash consideration       18,400,000                    
Provisional deferred tax liability       $ 4,800,000                    
Decrease in accounts receivable                       700,000    
Goodwill adjustment                       $ 658,000    
Good Start Genetics | Customer relationships                            
Business Acquisition [Line Items]                            
Intangible assets estimated useful lives       8 years               8 years    
Good Start Genetics | Common stock                            
Business Acquisition [Line Items]                            
Hold-back consideration amount       $ 3,600,000                    
Common stock issued, related to hold back (in shares)       343,986         212,260          
Equity interests issued for settlement of convertible debt       $ 11,900,000                    
Equity interests issued for settlement of convertible debt (in shares)       1,148,283                    
Remaining hold-back amount payable to settle outstanding claims                       $ 1,300,000    
Remaining hold back amount payable to settle bonuses                       200,000    
Good Start Genetics | Common stock | General and administrative                            
Business Acquisition [Line Items]                            
Payment through issuance of shares company's common stock       $ 900,000                    
Common stock issued (in shares)       83,025                    
Payment by issuance of common stock to settle bonuses       $ 400,000                    
Issuance of common stock to settle bonuses (in shares)       37,406         27,784          
CombiMatrix                            
Business Acquisition [Line Items]                            
Common stock issued (in shares)         2,703,389                  
Goodwill     $ 11,554,000                 11,554,000 $ 8,692,000  
Goodwill adjustment                       2,862,000    
Trailing average share value (in dollars per share)         $ 9.491                  
Deferred tax liability     $ 2,862,000                 $ 2,900,000    
CombiMatrix | Series F Preferred Stock                            
Business Acquisition [Line Items]                            
Payment through issuance of shares company's common stock         $ 100,000                  
Common stock issued (in shares)         3,144                  
CombiMatrix | Series F Warrants                            
Business Acquisition [Line Items]                            
Payment through issuance of shares company's common stock         $ 7,400,000                  
Common stock issued (in shares)         1,739,689                  
CombiMatrix | Series D Warrants                            
Business Acquisition [Line Items]                            
Payment through issuance of shares company's common stock         $ 1,000                  
Common stock issued (in shares)         337,584                  
CombiMatrix | Restricted Stock Units (RSUs)                            
Business Acquisition [Line Items]                            
Payment through issuance of shares company's common stock         $ 700,000                  
Common stock issued (in shares)         85,219                  
CombiMatrix | Shares of common stock subject to outstanding options                            
Business Acquisition [Line Items]                            
Payment through issuance of shares company's common stock         $ 100,000                  
Common stock issued (in shares)         3,323                  
CombiMatrix | Common stock                            
Business Acquisition [Line Items]                            
Business combination common stock conversion ratio         86.92%                  
CombiMatrix | Shares of common stock subject to outstanding warrants                            
Business Acquisition [Line Items]                            
Common stock issued (in shares)         2,077,273                  
CombiMatrix | Customer relationships                            
Business Acquisition [Line Items]                            
Intangible assets estimated useful lives     11 years                 11 years    
CombiMatrix | General and administrative | Common stock | Restricted Stock Units (RSUs)                            
Business Acquisition [Line Items]                            
Payment through issuance of shares company's common stock         $ 1,700,000                  
Common stock issued (in shares)         214,976                  
CombiMatrix | Common stock                            
Business Acquisition [Line Items]                            
Payment through issuance of shares company's common stock         $ 20,500,000                  
Common stock issued (in shares)         2,611,703                  
CombiMatrix | Common stock | General and administrative                            
Business Acquisition [Line Items]                            
Payment through issuance of shares company's common stock         $ 200,000                  
Common stock issued (in shares)         22,966                  
Subsequent event | Good Start Genetics | Common stock                            
Business Acquisition [Line Items]                            
Hold-back consideration amount               $ 600,000            
Subsequent event | Good Start Genetics | Common stock | General and administrative                            
Business Acquisition [Line Items]                            
Payment by issuance of common stock to settle bonuses               $ 100,000            
XML 64 R47.htm IDEA: XBRL DOCUMENT v3.10.0.1
Business combinations - Summary of fair values of assets acquired and liabilities assumed (Details) - USD ($)
$ in Thousands
Dec. 31, 2018
Dec. 31, 2017
Nov. 14, 2017
Aug. 04, 2017
Jun. 11, 2017
Jan. 06, 2017
Business Acquisition [Line Items]            
Goodwill $ 50,095 $ 46,575        
AltaVoice            
Business Acquisition [Line Items]            
Cash           $ 54
Accounts receivable           274
Prepaid expense and other assets           52
Total identifiable assets acquired           4,625
Accounts payable           (28)
Deferred revenue           (202)
Accrued expenses           (21)
Deferred tax liability           (1,422)
Total liabilities assumed           (1,673)
Net identifiable assets acquired           2,952
Goodwill 9,432 9,432       9,432
Net assets acquired           12,384
AltaVoice | Non-compete agreement            
Business Acquisition [Line Items]            
Intangible Assets           286
AltaVoice | Developed technology            
Business Acquisition [Line Items]            
Intangible Assets           570
AltaVoice | Customer relationships            
Business Acquisition [Line Items]            
Intangible Assets           $ 3,389
Ommdom, Inc.            
Business Acquisition [Line Items]            
Cash         $ 53  
Accounts receivable         10  
Prepaid expense and other assets         4  
Total identifiable assets acquired         2,562  
Accounts payable         (16)  
Accrued expenses         (17)  
Deferred tax liability         (434)  
Total liabilities assumed         (467)  
Net identifiable assets acquired         2,095  
Goodwill 4,045 4,045     4,045  
Net assets acquired         6,140  
Ommdom, Inc. | Trade name            
Business Acquisition [Line Items]            
Intangible Assets         13  
Ommdom, Inc. | Developed technology            
Business Acquisition [Line Items]            
Intangible Assets         2,335  
Ommdom, Inc. | Customer relationships            
Business Acquisition [Line Items]            
Intangible Assets         $ 147  
Good Start Genetics            
Business Acquisition [Line Items]            
Cash and restricted cash       $ 1,381    
Accounts receivable       2,246    
Prepaid expense and other assets       1,579    
Property and equipment       1,320    
Total identifiable assets acquired       20,712    
Accounts payable       (5,418)    
Accrued expenses       (6,802)    
Notes payable       (17,904)    
Convertible promissory notes payable       (15,430)    
Other liabilities       (222)    
Total liabilities assumed       (45,776)    
Net identifiable assets acquired       (25,064)    
Goodwill 25,064 24,406   25,064    
Net assets acquired       0    
Good Start Genetics | Trade name            
Business Acquisition [Line Items]            
Intangible Assets       460    
Good Start Genetics | Developed technology            
Business Acquisition [Line Items]            
Intangible Assets       5,896    
Good Start Genetics | Customer relationships            
Business Acquisition [Line Items]            
Intangible Assets       $ 7,830    
CombiMatrix            
Business Acquisition [Line Items]            
Cash and restricted cash     $ 1,333      
Accounts receivable     4,118      
Prepaid expense and other assets     1,299      
Property and equipment     437      
Other assets - non current     30      
Total identifiable assets acquired     23,622      
Accounts payable     (276)      
Accrued expenses     (3,925)      
Deferred tax liability (2,900)   (2,862)      
Other liabilities     (180)      
Total liabilities assumed     (7,243)      
Net identifiable assets acquired     16,379      
Goodwill $ 11,554 $ 8,692 11,554      
Net assets acquired     27,933      
CombiMatrix | Favorable leases            
Business Acquisition [Line Items]            
Intangible Assets     247      
CombiMatrix | Trade name            
Business Acquisition [Line Items]            
Intangible Assets     103      
CombiMatrix | Patent licensing agreement            
Business Acquisition [Line Items]            
Intangible Assets     496      
CombiMatrix | Developed technology            
Business Acquisition [Line Items]            
Intangible Assets     3,162      
CombiMatrix | Customer relationships            
Business Acquisition [Line Items]            
Intangible Assets     $ 12,397      
XML 65 R48.htm IDEA: XBRL DOCUMENT v3.10.0.1
Business combinations - Schedule of economic benefits of intangible assets expected to be realized (Details) - USD ($)
$ in Thousands
 12 Months Ended
Nov. 14, 2017
Aug. 04, 2017
Jun. 11, 2017
Jan. 06, 2017
Dec. 31, 2018
Business Acquisition [Line Items]          
Gross Purchased Intangible Assets         $ 37,331
Intangible assets estimated useful lives         8 years 2 months 12 days
Non-compete agreement          
Business Acquisition [Line Items]          
Gross Purchased Intangible Assets         $ 286
Intangible assets estimated useful lives         5 years
Trade name          
Business Acquisition [Line Items]          
Gross Purchased Intangible Assets         $ 576
Intangible assets estimated useful lives         2 years 8 months 12 days
Patent licensing agreement          
Business Acquisition [Line Items]          
Gross Purchased Intangible Assets         $ 496
Intangible assets estimated useful lives         15 years
Developed technology          
Business Acquisition [Line Items]          
Gross Purchased Intangible Assets         $ 11,963
Intangible assets estimated useful lives         4 years 9 months 18 days
Customer relationships          
Business Acquisition [Line Items]          
Gross Purchased Intangible Assets         $ 23,763
Intangible assets estimated useful lives         10 years
AltaVoice          
Business Acquisition [Line Items]          
Gross Purchased Intangible Assets       $ 4,245  
AltaVoice | Non-compete agreement          
Business Acquisition [Line Items]          
Gross Purchased Intangible Assets       $ 286  
Intangible assets estimated useful lives       5 years 10 years
AltaVoice | Developed technology          
Business Acquisition [Line Items]          
Gross Purchased Intangible Assets       $ 570  
Intangible assets estimated useful lives       6 years  
AltaVoice | Customer relationships          
Business Acquisition [Line Items]          
Gross Purchased Intangible Assets       $ 3,389  
Intangible assets estimated useful lives       10 years  
Ommdom, Inc.          
Business Acquisition [Line Items]          
Gross Purchased Intangible Assets     $ 2,495    
Ommdom, Inc. | Trade name          
Business Acquisition [Line Items]          
Gross Purchased Intangible Assets     $ 13    
Intangible assets estimated useful lives     5 years    
Ommdom, Inc. | Developed technology          
Business Acquisition [Line Items]          
Gross Purchased Intangible Assets     $ 2,335    
Intangible assets estimated useful lives     5 years    
Ommdom, Inc. | Customer relationships          
Business Acquisition [Line Items]          
Gross Purchased Intangible Assets     $ 147    
Intangible assets estimated useful lives     5 years    
Good Start Genetics          
Business Acquisition [Line Items]          
Gross Purchased Intangible Assets   $ 14,186      
Good Start Genetics | Trade name          
Business Acquisition [Line Items]          
Gross Purchased Intangible Assets   $ 460      
Intangible assets estimated useful lives   3 years      
Good Start Genetics | Developed technology          
Business Acquisition [Line Items]          
Gross Purchased Intangible Assets   $ 5,896      
Intangible assets estimated useful lives   5 years      
Good Start Genetics | Customer relationships          
Business Acquisition [Line Items]          
Gross Purchased Intangible Assets   $ 7,830      
Intangible assets estimated useful lives   8 years     8 years
CombiMatrix          
Business Acquisition [Line Items]          
Gross Purchased Intangible Assets $ 16,405        
CombiMatrix | Favorable leases          
Business Acquisition [Line Items]          
Gross Purchased Intangible Assets $ 247        
Intangible assets estimated useful lives 2 years        
CombiMatrix | Trade name          
Business Acquisition [Line Items]          
Gross Purchased Intangible Assets $ 103        
Intangible assets estimated useful lives 1 year        
CombiMatrix | Patent licensing agreement          
Business Acquisition [Line Items]          
Gross Purchased Intangible Assets $ 496        
Intangible assets estimated useful lives 15 years        
CombiMatrix | Developed technology          
Business Acquisition [Line Items]          
Gross Purchased Intangible Assets $ 3,162        
Intangible assets estimated useful lives 4 years        
CombiMatrix | Customer relationships          
Business Acquisition [Line Items]          
Gross Purchased Intangible Assets $ 12,397        
Intangible assets estimated useful lives 11 years       11 years
XML 66 R49.htm IDEA: XBRL DOCUMENT v3.10.0.1
Goodwill and intangible assets - Summary of goodwill (Details)
$ in Thousands
 12 Months Ended
Dec. 31, 2018
USD ($)
Goodwill [Roll Forward]  
December 31, 2017 $ 46,575
Goodwill adjustment 3,520
December 31, 2018 50,095
AltaVoice  
Goodwill [Roll Forward]  
December 31, 2017 9,432
Goodwill adjustment 0
December 31, 2018 9,432
Ommdom  
Goodwill [Roll Forward]  
December 31, 2017 4,045
Goodwill adjustment 0
December 31, 2018 4,045
Good Start  
Goodwill [Roll Forward]  
December 31, 2017 24,406
Goodwill adjustment 658
December 31, 2018 25,064
CombiMatrix  
Goodwill [Roll Forward]  
December 31, 2017 8,692
Goodwill adjustment 2,862
December 31, 2018 $ 11,554
XML 67 R50.htm IDEA: XBRL DOCUMENT v3.10.0.1
Goodwill and intangible assets - Narrative (Details) - USD ($)
$ in Thousands
 12 Months Ended
Nov. 14, 2017
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Goodwill [Line Items]        
Goodwill adjustment   $ 3,520    
Intangible assets estimated useful lives   8 years 2 months 12 days    
Amortization expense   $ 5,000 $ 1,800
Minimum        
Goodwill [Line Items]        
Intangible assets estimated useful lives   2 years    
Maximum        
Goodwill [Line Items]        
Intangible assets estimated useful lives   15 years    
Customer relationships        
Goodwill [Line Items]        
Intangible assets estimated useful lives   10 years    
Customer relationships | Minimum        
Goodwill [Line Items]        
Intangible assets estimated useful lives   5 years    
Customer relationships | Maximum        
Goodwill [Line Items]        
Intangible assets estimated useful lives   11 years    
CombiMatrix        
Goodwill [Line Items]        
Goodwill adjustment   $ 2,862    
CombiMatrix | Customer relationships        
Goodwill [Line Items]        
Intangible assets estimated useful lives 11 years 11 years    
XML 68 R51.htm IDEA: XBRL DOCUMENT v3.10.0.1
Goodwill and intangible assets - Schedule of finite-lived intangible assets (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Finite-Lived Intangible Assets [Line Items]    
Cost $ 37,331  
Accumulated Amortization (6,862)  
Net $ 30,469 $ 35,516
Weighted Average Useful Life (in Years) 8 years 2 months 12 days  
Weighted Average Estimated Remaining Useful Life (in Years) 6 years 9 months 18 days  
Customer relationships    
Finite-Lived Intangible Assets [Line Items]    
Cost $ 23,763  
Accumulated Amortization (2,783)  
Net $ 20,980  
Weighted Average Useful Life (in Years) 10 years  
Weighted Average Estimated Remaining Useful Life (in Years) 8 years 7 months 6 days  
Developed technology    
Finite-Lived Intangible Assets [Line Items]    
Cost $ 11,963  
Accumulated Amortization (3,482)  
Net $ 8,481  
Weighted Average Useful Life (in Years) 4 years 9 months 18 days  
Weighted Average Estimated Remaining Useful Life (in Years) 3 years 4 months 24 days  
Non-compete agreement    
Finite-Lived Intangible Assets [Line Items]    
Cost $ 286  
Accumulated Amortization (114)  
Net $ 172  
Weighted Average Useful Life (in Years) 5 years  
Weighted Average Estimated Remaining Useful Life (in Years) 3 years  
Trade name    
Finite-Lived Intangible Assets [Line Items]    
Cost $ 576  
Accumulated Amortization (329)  
Net $ 247  
Weighted Average Useful Life (in Years) 2 years 8 months 12 days  
Weighted Average Estimated Remaining Useful Life (in Years) 1 year 4 months 24 days  
Patent licensing agreement    
Finite-Lived Intangible Assets [Line Items]    
Cost $ 496  
Accumulated Amortization (37)  
Net $ 459  
Weighted Average Useful Life (in Years) 15 years  
Weighted Average Estimated Remaining Useful Life (in Years) 13 years 10 months 24 days  
Favorable leases    
Finite-Lived Intangible Assets [Line Items]    
Cost $ 247  
Accumulated Amortization (117)  
Net $ 130  
Weighted Average Useful Life (in Years) 2 years 2 months 12 days  
Weighted Average Estimated Remaining Useful Life (in Years) 1 year 1 month 6 days  
XML 69 R52.htm IDEA: XBRL DOCUMENT v3.10.0.1
Goodwill and intangible assets - Summary of estimated future amortization expense of intangible assets with finite lives (Details) - USD ($)
$ in Thousands
Dec. 31, 2018
Dec. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]    
2019 $ 5,250  
2020 5,525  
2021 5,829  
2022 4,124  
2023 3,111  
Thereafter 6,630  
Net $ 30,469 $ 35,516
XML 70 R53.htm IDEA: XBRL DOCUMENT v3.10.0.1
Balance sheet components - Property and equipment (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Property and equipment      
Total property and equipment, gross $ 52,395 $ 49,871  
Accumulated depreciation and amortization (24,509) (19,530)  
Total property and equipment, net 27,886 30,341  
Depreciation 8,500 7,200 $ 6,600
Leasehold improvements      
Property and equipment      
Total property and equipment, gross 13,034 12,623  
Laboratory equipment      
Property and equipment      
Total property and equipment, gross 22,149 17,705  
Equipment under capital lease      
Property and equipment      
Total property and equipment, gross 7,129 11,446  
Computer equipment      
Property and equipment      
Total property and equipment, gross 4,723 4,023  
Software      
Property and equipment      
Total property and equipment, gross 2,594 2,520  
Furniture and fixtures      
Property and equipment      
Total property and equipment, gross 784 569  
Automobiles      
Property and equipment      
Total property and equipment, gross 20 20  
Construction-in-progress      
Property and equipment      
Total property and equipment, gross $ 1,962 $ 965  
XML 71 R54.htm IDEA: XBRL DOCUMENT v3.10.0.1
Balance sheet components - Accrued liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2018
Dec. 31, 2017
Balance Sheet Related Disclosures [Abstract]    
Accrued compensation and related expenses $ 7,917 $ 7,406
Deferred revenue 761 307
Liabilities associated with business combinations 6,460 9,497
Liability associated with co-development agreement 2,000 0
Other 9,425 5,532
Total accrued liabilities $ 26,563 $ 22,742
XML 72 R55.htm IDEA: XBRL DOCUMENT v3.10.0.1
Balance sheet components - Other long-term liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2018
Dec. 31, 2017
Balance Sheet Related Disclosures [Abstract]    
Lease incentive obligation, non-current $ 3,280 $ 3,831
Deferred rent, non-current 5,495 5,153
Liabilities associated with business combinations 0 3,779
Other non-current liabilities 181 677
Total other long-term liabilities $ 8,956 $ 13,440
XML 73 R56.htm IDEA: XBRL DOCUMENT v3.10.0.1
Fair value measurements - Financial instruments at fair value on a recurring basis (Details) - USD ($)
$ in Thousands
Dec. 31, 2018
Dec. 31, 2017
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents, restricted cash and marketable securities, amortized cost $ 121,133 $ 64,759
Cash equivalents, restricted cash and marketable securities, gross unrealized loss before tax (5) (171)
Cash equivalents, restricted cash and marketable securities, estimated fair value 121,128 64,588
Cash equivalents 101,395 592
Restricted cash 6,006 5,406
Marketable securities 13,727 58,590
Accrued liabilities 26,563 22,742
Recurring basis    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total financial assets 121,128 64,588
Total financial liabilities 4,998 3,779
Recurring basis | Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total financial assets 103,924 18,289
Recurring basis | Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total financial assets 17,204 46,299
Recurring basis | Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total financial liabilities 4,998 3,779
Money market funds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents, restricted cash and marketable securities, amortized cost 93,934 5,998
Money market funds | Recurring basis    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents, restricted cash and marketable securities, estimated fair value 93,934 5,998
Money market funds | Recurring basis | Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents, restricted cash and marketable securities, estimated fair value 93,934 5,998
Certificates of deposit    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents, restricted cash and marketable securities, amortized cost 300 300
Certificates of deposit | Recurring basis    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents, restricted cash and marketable securities, estimated fair value 300 300
Certificates of deposit | Recurring basis | Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents, restricted cash and marketable securities, estimated fair value 0 300
Certificates of deposit | Recurring basis | Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents, restricted cash and marketable securities, estimated fair value 300  
Commercial paper    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents, restricted cash and marketable securities, amortized cost 10,908  
Cash equivalents, restricted cash and marketable securities, gross unrealized loss before tax (1)  
Commercial paper | Recurring basis    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents, restricted cash and marketable securities, estimated fair value 10,907  
Commercial paper | Recurring basis | Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents, restricted cash and marketable securities, estimated fair value 0  
Commercial paper | Recurring basis | Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents, restricted cash and marketable securities, estimated fair value 10,907  
U.S. treasury notes    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents, restricted cash and marketable securities, amortized cost 9,990 12,010
Cash equivalents, restricted cash and marketable securities, gross unrealized loss before tax   (19)
U.S. treasury notes | Recurring basis    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents, restricted cash and marketable securities, estimated fair value 9,990 11,991
U.S. treasury notes | Recurring basis | Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents, restricted cash and marketable securities, estimated fair value 9,990 11,991
U.S. government agency securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents, restricted cash and marketable securities, amortized cost 6,001 46,451
Cash equivalents, restricted cash and marketable securities, gross unrealized loss before tax (4) (152)
U.S. government agency securities | Recurring basis    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents, restricted cash and marketable securities, estimated fair value 5,997 46,299
U.S. government agency securities | Recurring basis | Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents, restricted cash and marketable securities, estimated fair value 5,997 46,299
Contingent consideration    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Accrued liabilities 4,998 3,779
Contingent consideration | Recurring basis    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total financial liabilities 4,998 3,779
Contingent consideration | Recurring basis | Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total financial liabilities $ 4,998 $ 3,779
XML 74 R57.htm IDEA: XBRL DOCUMENT v3.10.0.1
Fair value measurements - Narrative (Details) - USD ($)
 12 Months Ended
Jan. 06, 2017
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Mar. 31, 2019
Mar. 31, 2018
Jan. 31, 2017
Fair Value, Option, Quantitative Disclosures [Line Items]              
Transfers of assets and liabilities between Level 1, Level 2 and Level 3   $ 0 $ 0        
Total fair value of investments with unrealized losses   13,400,000          
Available-for-sale securities gross realized gain (loss)   0 $ 0 $ 0      
AltaVoice              
Fair Value, Option, Quantitative Disclosures [Line Items]              
Contingently payable amount           $ 5,000,000.0  
Increase in fair value of contingent consideration $ 2,200,000            
AltaVoice | Common stock              
Fair Value, Option, Quantitative Disclosures [Line Items]              
Common stock issued, value           $ 5,000,000.0  
AltaVoice | Maximum | Common stock              
Fair Value, Option, Quantitative Disclosures [Line Items]              
Contingently payable amount   5,000,000.0          
AltaVoice | Maximum | New Contingent Milestone Based On Achieving Revenue Target During 2017 And 2018 | Scenario, forecast              
Fair Value, Option, Quantitative Disclosures [Line Items]              
Common stock issued, value         $ 5,000,000.0    
AltaVoice | Minimum | New Contingent Milestone Based On Achieving Revenue Target During 2017 And 2018 | Scenario, forecast              
Fair Value, Option, Quantitative Disclosures [Line Items]              
Contingent revenue threshold         $ 10,000,000    
Contingent consideration | AltaVoice | Level 3 | Recurring basis              
Fair Value, Option, Quantitative Disclosures [Line Items]              
Estimated fair value for contingent consideration             $ 2,200,000
Increase in fair value of contingent consideration   $ 2,800,000          
XML 75 R58.htm IDEA: XBRL DOCUMENT v3.10.0.1
Fair value measurements - Level 3 financial instruments measured at fair value on a recurring basis (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
AltaVoice | General and administrative    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Change in estimate of fair value $ 1,200 $ 1,600
AltaVoice | General and administrative | Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Change in estimate of fair value 1,219  
Contingent consideration | Recurring basis | Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
December 31, 2017 3,779  
December 31, 2018 $ 4,998 $ 3,779
XML 76 R59.htm IDEA: XBRL DOCUMENT v3.10.0.1
Fair value measurements - Carrying amount and the estimated fair value of the Company's outstanding debt (Details) - Recurring basis - Level 2
$ in Thousands
Dec. 31, 2017
USD ($)
Carrying Amount  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Debt $ 39,084
Fair Value  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Debt $ 40,526
XML 77 R60.htm IDEA: XBRL DOCUMENT v3.10.0.1
Investment in privately held company (Details)
$ in Millions
 12 Months Ended
Dec. 31, 2018
USD ($)
KEW  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]  
Loss on license agreement $ 2.9
XML 78 R61.htm IDEA: XBRL DOCUMENT v3.10.0.1
Commitments and contingencies - Operating leases narrative (Details) - USD ($)
$ in Thousands
Dec. 31, 2018
Sep. 30, 2015
Operating Leased Assets [Line Items]    
Total minimum lease payments $ 78,597  
Office Facility In San Francisco | New leases    
Operating Leased Assets [Line Items]    
Additional term of lease   10 years
Lease term   10 years
Security deposit   $ 4,600
Lease incentive in form of lease improvements   $ 5,200
Total minimum lease payments $ 57,800  
XML 79 R62.htm IDEA: XBRL DOCUMENT v3.10.0.1
Commitments and contingencies - Schedule of future minimum payments under operating leases (Details)
$ in Thousands
Dec. 31, 2018
USD ($)
Commitments and Contingencies Disclosure [Abstract]  
2019 $ 10,948
2020 10,860
2021 11,109
2022 11,067
2023 8,898
Thereafter 25,715
Future non-cancelable minimum operating lease payments 78,597
Less: minimum payments to be received from non-cancelable subleases (174)
Total future non-cancelable minimum operating lease payments, net $ 78,423
XML 80 R63.htm IDEA: XBRL DOCUMENT v3.10.0.1
Commitments and contingencies - Schedule of rent expense related to non-cancelable operating leases (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Commitments and Contingencies Disclosure [Abstract]      
Rent expense $ 9,720 $ 8,950 $ 8,901
Sublease income 227 398 257
Rent expense, net of sublease income $ 9,493 $ 8,552 $ 8,644
XML 81 R64.htm IDEA: XBRL DOCUMENT v3.10.0.1
Commitments and contingencies - Debt financing narrative (Details) - USD ($)
 1 Months Ended 3 Months Ended 12 Months Ended
Nov. 30, 2018
Mar. 31, 2017
Dec. 31, 2018
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Jan. 01, 2020
Mar. 31, 2018
Debt Instrument [Line Items]                
Debt extinguishment costs       $ 4,609,000 $ 0 $ 0    
Common stock, par value (in dollars per share)     $ 0.0001 $ 0.0001 $ 0.0001      
Common stock issued pursuant to Securities Purchase Agreement (see Note 9)       $ 5,353,000        
Note Purchase Agreement                
Debt Instrument [Line Items]                
Maximum borrowing capacity $ 200,000,000.0              
Debt instrument, term 7 years              
Debt instrument, interest rate, stated percentage     8.75% 8.75%        
Internal rate of return percentage       11.00%        
Debt instrument, average effective interest rate       10.60%        
Note Purchase Agreement | Payment made within 12 months after closing date                
Debt Instrument [Line Items]                
Term loans, fee percentage of funded draw       117.50%        
Note Purchase Agreement | Payment made within 24 months after closing date                
Debt Instrument [Line Items]                
Term loans, fee percentage of funded draw       132.50%        
Note Purchase Agreement | Payment made within 36 months after closing date                
Debt Instrument [Line Items]                
Term loans, fee percentage of funded draw       145.00%        
Note Purchase Agreement | Scenario, forecast                
Debt Instrument [Line Items]                
Percentage of net annual revenue receivable by purchasers in addition to interest, beginning on January 1, 2020             0.50%  
Maximum net annual revenue receivable by purchasers in addition to interest, beginning on January 1, 2020             $ 1,600,000  
Loan and Security Agreement | Initial term loan                
Debt Instrument [Line Items]                
Term loan, borrowing amount   $ 40,000,000.0            
Net proceeds from term loan   39,700,000            
Loan and Security Agreement | Second Term Loan                
Debt Instrument [Line Items]                
Term loan, borrowing amount               $ 20,000,000.0
Net proceeds from term loan   $ 19,800,000            
Loan and Security Agreement | Third Term Loan                
Debt Instrument [Line Items]                
Term loan, borrowing amount     $ 20,000,000.0 $ 20,000,000.0        
Loan and Security Agreement | Secured Debt                
Debt Instrument [Line Items]                
Term loan, line fee percentage on unused commitment amount     1.00% 1.00%        
Term loan, line fee on unused commitment amount     $ 200,000 $ 200,000        
Term loans, variable interest rate   7.73%            
Term loans, index interest rate, minimum   0.77%            
Term loans, frequency of periodic payment   monthly            
Term loans, floor interest rate   8.50%            
Term loans, fee percentage of funded draw   5.00%            
Term loans, facility fee percentage   0.50%            
Warrants issued to acquire shares, percentage of funded amount   3.00%            
Warrants issued to purchase shares of common stock (in shares)   116,845            
Warrants issued to purchase common stock exercise price (in dollars per share)   $ 10.27            
Fair value of warrant   $ 700,000            
Repayments of Long-term Debt $ 64,700,000     75,000,000.0        
Debt extinguishment costs     $ 5,300,000          
Debt issuance cost       700,000        
Interest expense       $ 6,700,000 $ 3,500,000 $ 300,000    
Loan and Security Agreement | Secured Debt | Minimum                
Debt Instrument [Line Items]                
Term loans, prepayment fee percentage of outstanding balance   1.00%            
Loan and Security Agreement | Secured Debt | Maximum                
Debt Instrument [Line Items]                
Term loans, prepayment fee percentage of outstanding balance   3.00%            
Loan and Security Agreement | Secured Debt | Second Term Loan                
Debt Instrument [Line Items]                
Warrants issued to purchase shares of common stock (in shares)   85,482            
Warrants issued to purchase common stock exercise price (in dollars per share)   $ 7.02            
Fair value of warrant   $ 400,000            
Warrants term   10 years            
Initial sale of notes | Note Purchase Agreement                
Debt Instrument [Line Items]                
Maximum borrowing capacity 75,000,000.0              
Proceeds from Notes Payable $ 10,300,000              
Common stock                
Debt Instrument [Line Items]                
Common stock issued during period (in shares)       17,103,000   8,433,000    
Common stock | Note Purchase Agreement                
Debt Instrument [Line Items]                
Common stock issued during period (in shares) 373,524              
Shares issued price per share (in dollars per share) $ 13.39              
Common stock issued pursuant to Securities Purchase Agreement (see Note 9) $ 5,000,000.0              
Fair value of common stock $ 5,400,000              
XML 82 R65.htm IDEA: XBRL DOCUMENT v3.10.0.1
Commitments and contingencies - Schedule of future payments under loan and security agreement (Details) - USD ($)
$ in Thousands
Dec. 31, 2018
Dec. 31, 2017
Future payments under the Loan Agreement    
2019 $ 6,654  
2020 8,297  
2021 8,279  
2022 8,279  
2023 8,279  
Thereafter 89,998  
Total remaining payments 129,786  
Less: amount representing debt discount (721)  
Less: amount representing interest (54,588)  
Total non-current debt obligation $ 74,477 $ 39,084
XML 83 R66.htm IDEA: XBRL DOCUMENT v3.10.0.1
Commitments and contingencies - Capital leases narrative (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Capital Leased Assets [Line Items]      
Lease term 3 years    
Interest expense $ 300 $ 200 $ 100
Total property and equipment, gross 52,395 49,871  
Accumulated depreciation and amortization 2,000 3,000  
Equipment under capital lease      
Capital Leased Assets [Line Items]      
Total property and equipment, gross $ 7,129 $ 11,446  
XML 84 R67.htm IDEA: XBRL DOCUMENT v3.10.0.1
Commitments and contingencies - Schedule of future minimum lease payments under capital leases (Details) - USD ($)
$ in Thousands
Dec. 31, 2018
Dec. 31, 2017
Future payments under the capital lease    
2019 $ 2,087  
2020 1,392  
2021 21  
Total capital lease obligations 3,500  
Less: amount representing interest (188)  
Present value of net minimum capital lease payments 3,312  
Less: current portion (1,937) $ (2,039)
Total non-current capital lease obligations $ 1,375 $ 3,373
XML 85 R68.htm IDEA: XBRL DOCUMENT v3.10.0.1
Commitments and contingencies - Schedule of future payments under noncancelable unconditional purchase commitments (Details) - Service agreements and laboratory supplies
$ in Thousands
Dec. 31, 2018
USD ($)
Long-term Purchase Commitment [Line Items]  
2019 $ 3,040
2020 3,040
2021 1,440
Total $ 7,520
XML 86 R69.htm IDEA: XBRL DOCUMENT v3.10.0.1
Commitments and contingencies - Other commitments narrative (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Other Commitments [Line Items]    
Registration payment arrangement term P12M  
Accrued liabilities $ 26,563 $ 22,742
Co Development Agreement    
Other Commitments [Line Items]    
Right of refusal fees related to acquisition agreement 3,000  
Payment of refusal fees related to the acquisition agreement 1,000  
Accrued liabilities $ 2,000  
XML 87 R70.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stockholders' Equity - Schedule of shares of common stock reserved for future issuance (Details) - shares
Dec. 31, 2018
Dec. 31, 2017
Class of Stock    
Common stock reserved for future issuance (in shares) 12,936,000 15,868,000
Convertible Preferred Stock    
Class of Stock    
Common stock reserved for future issuance (in shares) 3,459,000 3,459,000
Stock Payable Liabilities    
Class of Stock    
Common stock reserved for future issuance (in shares) 132,000 689,000
Payable as Contingent Consideration    
Class of Stock    
Common stock reserved for future issuance (in shares) 452,000 551,000
Shares of common stock subject to outstanding warrants    
Class of Stock    
Number of shares of common stock underlying warrants (in shares) 611,000 1,962,000
Shares of common stock subject to outstanding RSUs    
Class of Stock    
RSU awards issued and outstanding (in shares) 4,031,000 2,387,000
Stock incentive plans | Employee Stock Option    
Class of Stock    
Options issued and outstanding (in shares) 3,855,000 4,115,000
Shares available for grant under stock options plans (in shares) 118,000 2,397,000
2015 Employee Stock Purchase Plan    
Class of Stock    
Common stock reserved for future issuance (in shares) 277,577 308,000
XML 88 R71.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stockholders' Equity - Narrative (Details) - USD ($)
$ / shares in Units, $ in Thousands
 1 Months Ended 2 Months Ended 12 Months Ended
Aug. 31, 2018
Apr. 30, 2018
Aug. 31, 2017
Feb. 28, 2019
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Class of Stock [Line Items]              
Proceeds from issuance of common stock         $ 17,511 $ 74,619 $ 3,134
Common stock              
Class of Stock [Line Items]              
Common stock issued during period (in shares)         17,103,000   8,433,000
Common stock issued pursuant to exercise of warrants (in shares)         1,022,000 5,176,000  
Private placement              
Class of Stock [Line Items]              
Gross proceeds from private placement     $ 73,500        
Net proceeds from private placement     $ 68,900        
Preferred stock to common stock conversion ratio 100.00%            
Preferred stock liquidation preference per share (in dollars per share)     $ 0.001        
Private placement | Series A Convertible Preferred Stock              
Class of Stock [Line Items]              
Number of shares sold in private placement (in shares)     3,500,000        
Shares issued price per share (in dollars per share)     $ 8.50        
Private placement | Common stock              
Class of Stock [Line Items]              
Number of shares sold in private placement (in shares)     5,200,000        
Shares issued price per share (in dollars per share)     $ 8.50        
Underwritten public offering              
Class of Stock [Line Items]              
Proceeds from issuance of common stock   $ 57,500          
Net proceeds from issuance of common stock   $ 53,500          
Underwritten public offering | Common stock              
Class of Stock [Line Items]              
Number of shares sold in private placement (in shares)   12,800,000          
Shares issued price per share (in dollars per share)   $ 4.50          
2018 Sales Agreement | Cowen and Company, LLC              
Class of Stock [Line Items]              
Percentage of commission payable on gross proceeds 3.00%            
2018 Sales Agreement | Cowen and Company, LLC | Common stock              
Class of Stock [Line Items]              
Proceeds from issuance of common stock         $ 61,100    
Net proceeds from issuance of common stock         $ 58,900    
Common stock issued during period (in shares)         4,300,000    
Maximum | 2018 Sales Agreement | Cowen and Company, LLC              
Class of Stock [Line Items]              
Proceeds from issuance of common stock $ 75,000            
CombiMatrix              
Class of Stock [Line Items]              
Proceeds from warrant exercises         $ 6,500    
Common stock issued pursuant to exercise of warrants (in shares)         1,000,000.0    
Subsequent event | Series A Convertible Preferred Stock | Series A convertible preferred stock converted to common stock              
Class of Stock [Line Items]              
Shares converted (in shares)       1,100,000      
Subsequent event | Common stock | Series A convertible preferred stock converted to common stock              
Class of Stock [Line Items]              
Shares issued upon conversion (in shares)       1,100,000      
XML 89 R72.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stockholders' Equity - Schedule of outstanding warrants to purchase common stock (Details) - Common Stock
Dec. 31, 2018
$ / shares
shares
Class of Warrant or Right [Line Items]  
Number of shares of common stock underlying warrants (in shares) 610,875
CombiMatrix | Series F Warrants  
Class of Warrant or Right [Line Items]  
Exercise price per share (in dollars per share) | $ / shares $ 5.95
Number of shares of common stock underlying warrants (in shares) 408,548
Warrants issued to lender under Loan and Security Agreement  
Class of Warrant or Right [Line Items]  
Exercise price per share (in dollars per share) | $ / shares $ 10.27
Number of shares of common stock underlying warrants (in shares) 116,845
Warrants issued to lender under Loan and Security Agreement - 2018 Amendments  
Class of Warrant or Right [Line Items]  
Exercise price per share (in dollars per share) | $ / shares $ 7.02
Number of shares of common stock underlying warrants (in shares) 85,482
XML 90 R73.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stock incentive plans - Narrative (Details)
 1 Months Ended 12 Months Ended
Feb. 28, 2017
shares
Feb. 29, 2016
Jan. 31, 2015
Dec. 31, 2018
USD ($)
$ / shares
shares
Dec. 31, 2017
USD ($)
Employee
$ / shares
shares
Dec. 31, 2016
USD ($)
$ / shares
Stock incentive plan            
Stock-based compensation       $ 20,850,000 $ 19,221,000 $ 10,699,000
Additional shares reserved (in shares) | shares       12,936,000 15,868,000  
Number of employees affected by the stock option and RSU modifications | Employee         14  
Incremental compensation cost relating to stock option and RSU modifications           $ 300,000
Unrecognized stock-based compensation       $ 4,500,000    
Expected period to recognize on a straight-line basis       1 year 9 months 18 days    
Capitalized stock-based employee compensation       $ 0    
Shares of common stock subject to outstanding RSUs            
Stock incentive plan            
Weighted-average grant date fair value (in dollars per share) | $ / shares       $ 7.46 $ 10.03 $ 9.80
Share-based compensation arrangement by share-based payment award equity instruments other than options granted in period (in shares) | shares       3,282,000    
Unrecognized stock-based compensation       $ 22,600,000    
Expected period to recognize on a straight-line basis       2 years 1 month 6 days    
Shares of common stock subject to outstanding PRSUs            
Stock incentive plan            
Weighted-average grant date fair value (in dollars per share) | $ / shares           $ 6.50
Share-based compensation arrangement by share-based payment award equity instruments other than options granted in period (in shares) | shares       0 0  
Unrecognized stock-based compensation       $ 0    
Non-Employee Options            
Stock incentive plan            
Vested stock units awarded (in shares) | shares       0    
2015 Plan | Shares of common stock subject to outstanding PRSUs            
Stock incentive plan            
Vesting period   12 months        
Vested stock units awarded (in shares) | shares 352,045          
Stock-based compensation       $ 400,000 $ 1,900,000
Stock incentive plans            
Stock incentive plan            
Vesting period       4 years    
Share-based compensation arrangement by share-based payment award, award vesting rights, percentage       25.00%    
Share-based compensation arrangement by share-based payment award, vesting rights, equal monthly vesting percentage       2.08%    
Stock incentive plans | Shares of common stock subject to outstanding RSUs            
Stock incentive plan            
Vesting period       3 years    
Share-based compensation arrangement by share-based payment award equity instruments other than options granted in period (in shares) | shares       3,282,000    
Stock incentive plans | Shares of common stock subject to outstanding options            
Stock incentive plan            
Weighted-average grant date fair value (in dollars per share) | $ / shares       $ 4.87 $ 5.82 $ 6.18
Total grant date fair value of options to purchase common stock vested       $ 5,900,000 $ 6,900,000 $ 5,600,000
Exercised, aggregate intrinsic value       $ 1,700,000 $ 2,100,000 $ 1,400,000
Stock incentive plans | First anniversary | Shares of common stock subject to outstanding RSUs            
Stock incentive plan            
Share-based compensation arrangement by share-based payment award, award vesting rights, percentage       33.33%    
Stock incentive plans | Second anniversary | Shares of common stock subject to outstanding RSUs            
Stock incentive plan            
Share-based compensation arrangement by share-based payment award, award vesting rights, percentage       33.33%    
Stock incentive plans | Third anniversary | Shares of common stock subject to outstanding RSUs            
Stock incentive plan            
Share-based compensation arrangement by share-based payment award, award vesting rights, percentage       33.33%    
2015 Employee Stock Purchase Plan            
Stock incentive plan            
Weighted-average grant date fair value (in dollars per share) | $ / shares       $ 3.26 $ 2.51 $ 2.66
Stock-based compensation       $ 1,400,000 $ 1,100,000 $ 900,000
Purchase price of common stock of the lesser of fair market value on the purchase date or the last trading day preceding the offering date (as a percent)     85.00%      
Proceeds from stock plans       $ 600,000    
Additional shares reserved (in shares) | shares       277,577 308,000  
Minimum | 2010 Plan            
Stock incentive plan            
Employees holding voting rights of all classes of stock (as a percent)       10.00%    
Exercise price of options on common stock (as a percent)       110.00%    
Maximum | 2010 Plan            
Stock incentive plan            
Term of options granted       10 years    
XML 91 R74.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stock incentive plans - Schedule of activity under stock incentive plans (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Shares of common stock subject to outstanding RSUs    
Activity under the plan    
Units granted (in shares) (3,282)  
Units cancelled (in shares) 340  
Stock incentive plans | Shares of common stock subject to outstanding options    
Activity under the plan    
Shares available for grant, beginning balance (in shares) 2,397  
Stock options outstanding, beginning balance (in shares) 4,115  
Additional shares reserved (in shares) 754  
Options granted (in shares) 260  
Option cancelled (in shares) (169)  
Options exercised (in shares) (351)  
Shares available for grant, ending balance (in shares) 118 2,397
Stock options outstanding, ending balance (in shares) 3,855 4,115
Weighted- Average Exercise Price    
Balance at the beginning of the period (in dollars per share) $ 8.51  
Options granted (in dollars per share) 8.50  
Options cancelled (in dollars per share) 9.35  
Options exercised (in dollars per share) 7.73  
Balance at the end of the period (in dollars per share) $ 8.54 $ 8.51
Additional information    
Exercisable (in shares) 2,737  
Exercisable, weighted-average exercise price (in dollars per share) $ 8.27  
Weighted-average remaining contractual life 6 years 9 months 18 days 7 years 7 months 6 days
Exercisable, weighted-average remaining contractual life 6 years 4 months 24 days  
Aggregate intrinsic value $ 9,927 $ 5,128
Exercisable, aggregate intrinsic value $ 7,787  
Vested and expected to vest    
Number of options (in shares) 3,710  
Weighted-average exercise price (in dollars per share) $ 8.52  
Weighted-average remaining contractual life 6 years 9 months 18 days  
Aggregate intrinsic value $ 9,626  
Stock incentive plans | Shares of common stock subject to outstanding RSUs    
Activity under the plan    
Units granted (in shares) (3,282)  
Units cancelled (in shares) 340  
XML 92 R75.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stock incentive plans - Summary of RSU activity (Details) - Shares of common stock subject to outstanding RSUs - $ / shares
shares in Thousands
 12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Number of Shares      
Balance at the beginning of the period (in shares) 2,387    
Granted (in shares) 3,282    
Vested (in shares) (1,298)    
Cancelled (in shares) (340)    
Balance at the end of the period (in shares) 4,031 2,387  
Weighted-Average Grant Date Fair Value      
Balance at the beginning of the period (in dollars per share) $ 9.91    
Granted (in dollars per share) 7.46 $ 10.03 $ 9.80
Vested (in dollars per share) 8.84    
Canceled (in dollars per share) 8.84    
Balance at the end of the period (in dollars per share) $ 8.35 $ 9.91  
XML 93 R76.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stock incentive plans - Schedule of assumptions used in determination of fair value of options (Details)
 12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Non-Employee Options      
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]      
Expected volatility     76.92%
Non-Employee Options | Minimum      
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]      
Expected term (in years) 8 years 4 months 28 days 6 years 3 months
Expected volatility 69.90%  
Risk-free interest rate 1.83% 1.55%
Non-Employee Options | Maximum      
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]      
Expected term (in years) 8 years 9 months 29 days 10 years
Expected volatility 78.70% 0.00%
Risk-free interest rate 2.04% 2.37%
Employees and directors stock options | Employee Stock Option      
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]      
Expected term (in years) 6 years 6 years 10 days 6 years 10 days
Expected volatility 59.58% 72.64% 71.42%
Risk-free interest rate 2.80% 2.01% 1.37%
2015 Employee Stock Purchase Plan      
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]      
Expected term (in years) 15 days 15 days 15 days
Expected volatility 71.66% 52.50% 66.31%
Risk-free interest rate 2.09% 1.23% 0.50%
XML 94 R77.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stock incentive plans - Stock-based compensation expense (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Stock-based compensation      
Total stock-based compensation expense $ 20,850 $ 19,221 $ 10,699
Cost of revenue      
Stock-based compensation      
Total stock-based compensation expense 2,960 2,093 1,353
Research and development      
Stock-based compensation      
Total stock-based compensation expense 7,017 6,158 4,976
Selling and marketing      
Stock-based compensation      
Total stock-based compensation expense 4,887 3,956 1,709
General and administrative      
Stock-based compensation      
Total stock-based compensation expense $ 5,986 $ 7,014 $ 2,661
XML 95 R78.htm IDEA: XBRL DOCUMENT v3.10.0.1
Income Taxes - Narrative (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2018
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Income Tax Contingency [Line Items]          
Corporate tax rate   21.00% 34.00% 34.00%  
Provisional amount related to the remeasurement of certain deferred tax assets and liabilities $ 48,800   $ 48,800    
Increase in valuation allowance   $ 26,300 2,000 $ 33,400  
Net operating loss carryforwards change in ownership percentage minimum   50.00%      
Unrecognized tax benefits 16,375 $ 16,375 $ 10,561 $ 7,791 $ 11,429
Federal          
Income Tax Contingency [Line Items]          
Net operating loss carryforwards 318,700 $ 318,700      
Number of tax years open for examination   3 years      
California          
Income Tax Contingency [Line Items]          
Number of tax years open for examination   4 years      
Research and development | Federal          
Income Tax Contingency [Line Items]          
Tax credit carryforwards 9,000 $ 9,000      
Research and development | California          
Income Tax Contingency [Line Items]          
Tax credit carryforwards 7,400 7,400      
State          
Income Tax Contingency [Line Items]          
Net operating loss carryforwards 134,300 134,300      
Begins to expire 2030 | Federal          
Income Tax Contingency [Line Items]          
Net operating loss carryforwards 277,300 277,300      
No expiration date | Federal          
Income Tax Contingency [Line Items]          
Net operating loss carryforwards $ 41,400 $ 41,400      
XML 96 R79.htm IDEA: XBRL DOCUMENT v3.10.0.1
Income Taxes - Schedule of components of loss before income taxes by U.S. and foreign jurisdictions (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Income Tax Disclosure [Abstract]      
United States $ 132,194 $ 124,108 $ 99,793
Foreign (39) 1,128 463
Total $ 132,155 $ 125,236 $ 100,256
XML 97 R80.htm IDEA: XBRL DOCUMENT v3.10.0.1
Income Taxes - Schedule of components of the provision for income taxes (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Current:      
Foreign $ 62 $ 0 $ 0
Total current benefit for income taxes 62 0 0
Deferred      
Federal (2,862) (1,704) 0
State 0 (152) 0
Total deferred benefit for income taxes (2,862) (1,856) 0
Total income tax benefit $ (2,800) $ (1,856) $ 0
XML 98 R81.htm IDEA: XBRL DOCUMENT v3.10.0.1
Income Taxes - Schedule of reconciliation of the tax expense computed at the statutory federal rate and Company's tax expense (Details)
 12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Reconciliation of the tax expense computed at the statutory federal rate and Company's tax expense      
U.S. federal taxes at statutory rate 21.00% 34.00% 34.00%
State taxes (net of federal benefit) 5.20% 3.30% 1.40%
Stock-based compensation (0.70%) (1.10%) (1.70%)
Research and development credits (2.70%) 0.00% 0.00%
Non-deductible expenses (0.60%) 0.00% 0.20%
Foreign tax differential 0.00% (0.30%) (0.20%)
Other 0.00% 0.00% 1.10%
Change in valuation allowance (25.50%) (34.40%) (34.80%)
Change in deferred—Tax Reform 0.00% (39.00%) 0.00%
Change in valuation allowance—Tax Reform 0.00% 39.00% 0.00%
Total 2.10% 1.50% 0.00%
XML 99 R82.htm IDEA: XBRL DOCUMENT v3.10.0.1
Income Taxes - Schedule of net deferred tax assets (Details) - USD ($)
$ in Thousands
Dec. 31, 2018
Dec. 31, 2017
Deferred tax assets:    
Net operating loss carryforwards $ 76,972 $ 70,825
Tax credits 15 15
Revenue recognition differences 47,650 29,819
Accruals and other 7,262 5,544
Gross deferred tax assets 131,899 106,203
Valuation allowance (121,954) (95,687)
Total deferred tax assets 9,945 10,516
Deferred tax liabilities:    
Property and equipment (9,945) (10,516)
Total deferred tax liabilities (9,945) (10,516)
Net deferred tax assets $ 0 $ 0
XML 100 R83.htm IDEA: XBRL DOCUMENT v3.10.0.1
Income Taxes - Schedule of reconciliation of unrecognized tax benefits (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Income Tax Disclosure [Abstract]      
Unrecognized tax benefits, beginning of period $ 10,561 $ 7,791 $ 11,429
Gross increases—current period tax positions 5,686 2,552 782
Gross increases (decreases)—prior period tax positions 128 218 (4,420)
Unrecognized tax benefits, end of period $ 16,375 $ 10,561 $ 7,791
XML 101 R84.htm IDEA: XBRL DOCUMENT v3.10.0.1
Net loss per common share - Schedule of earnings per share, basic and diluted (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Dec. 31, 2017
Sep. 30, 2017
Jun. 30, 2017
Mar. 31, 2017
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Earnings Per Share [Abstract]                      
Net loss $ (29,841) $ (31,723) $ (31,671) $ (36,120) $ (40,493) $ (27,402) $ (28,557) $ (26,928) $ (129,355) $ (123,380) $ (100,256)
Shares used in computing net loss per share, basic and diluted (in shares)                 66,747 46,512 33,176
Net loss per share, basic and diluted (in dollars per share)                 $ (1.94) $ (2.65) $ (3.02)
XML 102 R85.htm IDEA: XBRL DOCUMENT v3.10.0.1
Net loss per common share - Schedule of antidilutive securities excluded from computation of earnings per share (Details) - shares
shares in Thousands
 12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Earnings Per Share [Line Items]      
Antidilutive securities excluded from computation of earnings per share (in shares) 12,019 11,982 5,968
Shares of common stock subject to outstanding options      
Earnings Per Share [Line Items]      
Antidilutive securities excluded from computation of earnings per share (in shares) 3,855 4,115 4,491
Shares of common stock subject to outstanding warrants      
Earnings Per Share [Line Items]      
Antidilutive securities excluded from computation of earnings per share (in shares) 611 1,962 0
Shares of common stock subject to outstanding RSUs      
Earnings Per Share [Line Items]      
Antidilutive securities excluded from computation of earnings per share (in shares) 4,031 2,387 892
Shares of common stock subject to outstanding PRSUs      
Earnings Per Share [Line Items]      
Antidilutive securities excluded from computation of earnings per share (in shares) 0 0 530
Shares of common stock pursuant to ESPP      
Earnings Per Share [Line Items]      
Antidilutive securities excluded from computation of earnings per share (in shares) 63 59 55
Shares of common stock underlying Series A convertible preferred stock      
Earnings Per Share [Line Items]      
Antidilutive securities excluded from computation of earnings per share (in shares) 3,459 3,459 0
XML 103 R86.htm IDEA: XBRL DOCUMENT v3.10.0.1
Geographic information - Schedule of revenue by country (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Dec. 31, 2017
Sep. 30, 2017
Jun. 30, 2017
Mar. 31, 2017
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Geographic information                      
Total revenue $ 45,356 $ 37,366 $ 37,306 $ 27,671 $ 25,399 $ 18,148 $ 14,336 $ 10,338 $ 147,699 $ 68,221 $ 25,048
United States                      
Geographic information                      
Total revenue                 138,239 62,446 20,758
Canada                      
Geographic information                      
Total revenue                 4,206 3,226 2,526
Rest of world                      
Geographic information                      
Total revenue                 $ 5,254 $ 2,549 $ 1,764
XML 104 R87.htm IDEA: XBRL DOCUMENT v3.10.0.1
Selected Quarterly Data (Unaudited) (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Dec. 31, 2017
Sep. 30, 2017
Jun. 30, 2017
Mar. 31, 2017
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Total revenue $ 45,356 $ 37,366 $ 37,306 $ 27,671 $ 25,399 $ 18,148 $ 14,336 $ 10,338 $ 147,699 $ 68,221 $ 25,048
Cost of revenue 21,141 20,441 20,447 18,076 17,049 13,274 10,490 9,329 80,105 50,142 27,878
Loss from operations (25,904) (30,110) (30,068) (36,475) (34,891) (30,976) (28,075) (27,337) (122,557) (121,279) (100,183)
Net loss $ (29,841) $ (31,723) $ (31,671) $ (36,120) $ (40,493) $ (27,402) $ (28,557) $ (26,928) $ (129,355) $ (123,380) $ (100,256)
Net loss per share, basic and diluted (in dollars per share) $ (0.40) $ (0.45) $ (0.47) $ (0.66) $ (0.78) $ (0.57) $ (0.66) $ (0.64) $ (1.94) $ (2.65) $ (3.02)
Debt extinguishment costs                 $ 4,609 $ 0 $ 0
Secured Debt | Loan and Security Agreement                      
Debt extinguishment costs $ 5,300                    
XML 105 R9999.htm IDEA: XBRL DOCUMENT v3.10.0.1
Label Element Value
Retained Earnings [Member]  
Cumulative Effect of New Accounting Principle in Period of Adoption us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption $ 11,241,000
EXCEL 106 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 107 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 108 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 110 FilingSummary.xml IDEA: XBRL DOCUMENT 3.10.0.1 html 401 478 1 false 118 0 false 7 false false R1.htm 0002000 - Document - Document and Entity Information Sheet http://www.invitae.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 1001000 - Statement - Consolidated Balance Sheets Sheet http://www.invitae.com/role/ConsolidatedBalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 1001501 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.invitae.com/role/ConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 1002000 - Statement - Consolidated Statements of Operations Sheet http://www.invitae.com/role/ConsolidatedStatementsOfOperations Consolidated Statements of Operations Statements 4 false false R5.htm 1003000 - Statement - Consolidated Statements of Comprehensive Loss Sheet http://www.invitae.com/role/ConsolidatedStatementsOfComprehensiveLoss Consolidated Statements of Comprehensive Loss Statements 5 false false R6.htm 1004000 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity Sheet http://www.invitae.com/role/ConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity Statements 6 false false R7.htm 1004501 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Parenthetical) Sheet http://www.invitae.com/role/ConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityParenthetical Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Parenthetical) Statements 7 false false R8.htm 1006000 - Statement - Consolidated Statements of Cash Flows Sheet http://www.invitae.com/role/ConsolidatedStatementsOfCashFlows Consolidated Statements of Cash Flows Statements 8 false false R9.htm 2101100 - Disclosure - Organization and description of business Sheet http://www.invitae.com/role/OrganizationAndDescriptionOfBusiness Organization and description of business Notes 9 false false R10.htm 2102100 - Disclosure - Summary of significant accounting policies Sheet http://www.invitae.com/role/SummaryOfSignificantAccountingPolicies Summary of significant accounting policies Notes 10 false false R11.htm 2103100 - Disclosure - Revenue, accounts receivable and deferred revenue Sheet http://www.invitae.com/role/RevenueAccountsReceivableAndDeferredRevenue Revenue, accounts receivable and deferred revenue Notes 11 false false R12.htm 2104100 - Disclosure - Business combinations Sheet http://www.invitae.com/role/BusinessCombinations Business combinations Notes 12 false false R13.htm 2105100 - Disclosure - Goodwill and intangible assets Sheet http://www.invitae.com/role/GoodwillAndIntangibleAssets Goodwill and intangible assets Notes 13 false false R14.htm 2106100 - Disclosure - Balance sheet components Sheet http://www.invitae.com/role/BalanceSheetComponents Balance sheet components Notes 14 false false R15.htm 2107100 - Disclosure - Fair value measurements Sheet http://www.invitae.com/role/FairValueMeasurements Fair value measurements Notes 15 false false R16.htm 2108100 - Disclosure - Investment in privately held company Investment in privately held company Sheet http://www.invitae.com/role/InvestmentInPrivatelyHeldCompanyInvestmentInPrivatelyHeldCompany Investment in privately held company Investment in privately held company Notes 16 false false R17.htm 2109100 - Disclosure - Commitments and contingencies Sheet http://www.invitae.com/role/CommitmentsAndContingencies Commitments and contingencies Notes 17 false false R18.htm 2110100 - Disclosure - Stockholders' Equity Sheet http://www.invitae.com/role/StockholdersEquity Stockholders' Equity Notes 18 false false R19.htm 2111100 - Disclosure - Stock incentive plans Sheet http://www.invitae.com/role/StockIncentivePlans Stock incentive plans Notes 19 false false R20.htm 2112100 - Disclosure - Income taxes Sheet http://www.invitae.com/role/IncomeTaxes Income taxes Notes 20 false false R21.htm 2113100 - Disclosure - Net loss per common share Sheet http://www.invitae.com/role/NetLossPerCommonShare Net loss per common share Notes 21 false false R22.htm 2114100 - Disclosure - Geographic information Sheet http://www.invitae.com/role/GeographicInformation Geographic information Notes 22 false false R23.htm 2115100 - Disclosure - Selected quarterly data (unaudited) Sheet http://www.invitae.com/role/SelectedQuarterlyDataUnaudited Selected quarterly data (unaudited) Notes 23 false false R24.htm 2202201 - Disclosure - Summary of significant accounting policies (Policies) Sheet http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of significant accounting policies (Policies) Policies 24 false false R25.htm 2302302 - Disclosure - Summary of significant accounting policies (Tables) Sheet http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of significant accounting policies (Tables) Tables http://www.invitae.com/role/SummaryOfSignificantAccountingPolicies 25 false false R26.htm 2303301 - Disclosure - Revenue, accounts receivable and deferred revenue (Tables) Sheet http://www.invitae.com/role/RevenueAccountsReceivableAndDeferredRevenueTables Revenue, accounts receivable and deferred revenue (Tables) Tables http://www.invitae.com/role/RevenueAccountsReceivableAndDeferredRevenue 26 false false R27.htm 2304301 - Disclosure - Business combinations (Tables) Sheet http://www.invitae.com/role/BusinessCombinationsTables Business combinations (Tables) Tables http://www.invitae.com/role/BusinessCombinations 27 false false R28.htm 2305301 - Disclosure - Goodwill and intangible assets (Tables) Sheet http://www.invitae.com/role/GoodwillAndIntangibleAssetsTables Goodwill and intangible assets (Tables) Tables http://www.invitae.com/role/GoodwillAndIntangibleAssets 28 false false R29.htm 2306301 - Disclosure - Balance sheet components (Tables) Sheet http://www.invitae.com/role/BalanceSheetComponentsTables Balance sheet components (Tables) Tables http://www.invitae.com/role/BalanceSheetComponents 29 false false R30.htm 2307301 - Disclosure - Fair value measurements (Tables) Sheet http://www.invitae.com/role/FairValueMeasurementsTables Fair value measurements (Tables) Tables http://www.invitae.com/role/FairValueMeasurements 30 false false R31.htm 2309301 - Disclosure - Commitments and contingencies (Tables) Sheet http://www.invitae.com/role/CommitmentsAndContingenciesTables Commitments and contingencies (Tables) Tables http://www.invitae.com/role/CommitmentsAndContingencies 31 false false R32.htm 2310301 - Disclosure - Stockholders' Equity (Tables) Sheet http://www.invitae.com/role/StockholdersEquityTables Stockholders' Equity (Tables) Tables http://www.invitae.com/role/StockholdersEquity 32 false false R33.htm 2311301 - Disclosure - Stock incentive plans (Tables) Sheet http://www.invitae.com/role/StockIncentivePlansTables Stock incentive plans (Tables) Tables http://www.invitae.com/role/StockIncentivePlans 33 false false R34.htm 2312301 - Disclosure - Income Taxes (Tables) Sheet http://www.invitae.com/role/IncomeTaxesTables Income Taxes (Tables) Tables 34 false false R35.htm 2313301 - Disclosure - Net loss per common share (Tables) Sheet http://www.invitae.com/role/NetLossPerCommonShareTables Net loss per common share (Tables) Tables http://www.invitae.com/role/NetLossPerCommonShare 35 false false R36.htm 2314301 - Disclosure - Geographic information (Tables) Sheet http://www.invitae.com/role/GeographicInformationTables Geographic information (Tables) Tables http://www.invitae.com/role/GeographicInformation 36 false false R37.htm 2315301 - Disclosure - Selected Quarterly Data (Unaudited) (Tables) Sheet http://www.invitae.com/role/SelectedQuarterlyDataUnauditedTables Selected Quarterly Data (Unaudited) (Tables) Tables 37 false false R38.htm 2401401 - Disclosure - Organization and description of business - Narrative (Details) Sheet http://www.invitae.com/role/OrganizationAndDescriptionOfBusinessNarrativeDetails Organization and description of business - Narrative (Details) Details 38 false false R39.htm 2402403 - Disclosure - Summary of significant accounting policies - Narrative (Details) Sheet http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails Summary of significant accounting policies - Narrative (Details) Details 39 false false R40.htm 2402404 - Disclosure - Summary of significant accounting policies - Schedule of significant customers, revenue as a percentage (Details) Sheet http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfSignificantCustomersRevenueAsPercentageDetails Summary of significant accounting policies - Schedule of significant customers, revenue as a percentage (Details) Details 40 false false R41.htm 2402405 - Disclosure - Summary of significant accounting policies - Schedule of cash, cash equivalents and restricted cash (Details) Sheet http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails Summary of significant accounting policies - Schedule of cash, cash equivalents and restricted cash (Details) Details 41 false false R42.htm 2402406 - Disclosure - Summary of significant accounting policies - Schedule of useful lives of property and equipment (Details) Sheet http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfUsefulLivesOfPropertyAndEquipmentDetails Summary of significant accounting policies - Schedule of useful lives of property and equipment (Details) Details 42 false false R43.htm 2403402 - Disclosure - Revenue, accounts receivable and deferred revenue - Narrative (Details) Sheet http://www.invitae.com/role/RevenueAccountsReceivableAndDeferredRevenueNarrativeDetails Revenue, accounts receivable and deferred revenue - Narrative (Details) Details http://www.invitae.com/role/RevenueAccountsReceivableAndDeferredRevenueTables 43 false false R44.htm 2403403 - Disclosure - Revenue, accounts receivable and deferred revenue - Schedule of impact of adoption of topic 606 on condensed statement of operations and balance sheet (Details) Sheet http://www.invitae.com/role/RevenueAccountsReceivableAndDeferredRevenueScheduleOfImpactOfAdoptionOfTopic606OnCondensedStatementOfOperationsAndBalanceSheetDetails Revenue, accounts receivable and deferred revenue - Schedule of impact of adoption of topic 606 on condensed statement of operations and balance sheet (Details) Details 44 false false R45.htm 2403404 - Disclosure - Revenue, accounts receivable and deferred revenue - Schedule of disaggregated revenue by payer category (Details) Sheet http://www.invitae.com/role/RevenueAccountsReceivableAndDeferredRevenueScheduleOfDisaggregatedRevenueByPayerCategoryDetails Revenue, accounts receivable and deferred revenue - Schedule of disaggregated revenue by payer category (Details) Details 45 false false R46.htm 2404402 - Disclosure - Business combinations - Narrative (Details) Sheet http://www.invitae.com/role/BusinessCombinationsNarrativeDetails Business combinations - Narrative (Details) Details 46 false false R47.htm 2404403 - Disclosure - Business combinations - Summary of fair values of assets acquired and liabilities assumed (Details) Sheet http://www.invitae.com/role/BusinessCombinationsSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetails Business combinations - Summary of fair values of assets acquired and liabilities assumed (Details) Details 47 false false R48.htm 2404404 - Disclosure - Business combinations - Schedule of economic benefits of intangible assets expected to be realized (Details) Sheet http://www.invitae.com/role/BusinessCombinationsScheduleOfEconomicBenefitsOfIntangibleAssetsExpectedToBeRealizedDetails Business combinations - Schedule of economic benefits of intangible assets expected to be realized (Details) Details 48 false false R49.htm 2405402 - Disclosure - Goodwill and intangible assets - Summary of goodwill (Details) Sheet http://www.invitae.com/role/GoodwillAndIntangibleAssetsSummaryOfGoodwillDetails Goodwill and intangible assets - Summary of goodwill (Details) Details 49 false false R50.htm 2405403 - Disclosure - Goodwill and intangible assets - Narrative (Details) Sheet http://www.invitae.com/role/GoodwillAndIntangibleAssetsNarrativeDetails Goodwill and intangible assets - Narrative (Details) Details 50 false false R51.htm 2405404 - Disclosure - Goodwill and intangible assets - Schedule of finite-lived intangible assets (Details) Sheet http://www.invitae.com/role/GoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails Goodwill and intangible assets - Schedule of finite-lived intangible assets (Details) Details 51 false false R52.htm 2405405 - Disclosure - Goodwill and intangible assets - Summary of estimated future amortization expense of intangible assets with finite lives (Details) Sheet http://www.invitae.com/role/GoodwillAndIntangibleAssetsSummaryOfEstimatedFutureAmortizationExpenseOfIntangibleAssetsWithFiniteLivesDetails Goodwill and intangible assets - Summary of estimated future amortization expense of intangible assets with finite lives (Details) Details 52 false false R53.htm 2406402 - Disclosure - Balance sheet components - Property and equipment (Details) Sheet http://www.invitae.com/role/BalanceSheetComponentsPropertyAndEquipmentDetails Balance sheet components - Property and equipment (Details) Details 53 false false R54.htm 2406403 - Disclosure - Balance sheet components - Accrued liabilities (Details) Sheet http://www.invitae.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails Balance sheet components - Accrued liabilities (Details) Details 54 false false R55.htm 2406404 - Disclosure - Balance sheet components - Other long-term liabilities (Details) Sheet http://www.invitae.com/role/BalanceSheetComponentsOtherLongTermLiabilitiesDetails Balance sheet components - Other long-term liabilities (Details) Details 55 false false R56.htm 2407402 - Disclosure - Fair value measurements - Financial instruments at fair value on a recurring basis (Details) Sheet http://www.invitae.com/role/FairValueMeasurementsFinancialInstrumentsAtFairValueOnRecurringBasisDetails Fair value measurements - Financial instruments at fair value on a recurring basis (Details) Details 56 false false R57.htm 2407403 - Disclosure - Fair value measurements - Narrative (Details) Sheet http://www.invitae.com/role/FairValueMeasurementsNarrativeDetails Fair value measurements - Narrative (Details) Details 57 false false R58.htm 2407404 - Disclosure - Fair value measurements - Level 3 financial instruments measured at fair value on a recurring basis (Details) Sheet http://www.invitae.com/role/FairValueMeasurementsLevel3FinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails Fair value measurements - Level 3 financial instruments measured at fair value on a recurring basis (Details) Details 58 false false R59.htm 2407405 - Disclosure - Fair value measurements - Carrying amount and the estimated fair value of the Company's outstanding debt (Details) Sheet http://www.invitae.com/role/FairValueMeasurementsCarryingAmountAndEstimatedFairValueOfCompanysOutstandingDebtDetails Fair value measurements - Carrying amount and the estimated fair value of the Company's outstanding debt (Details) Details 59 false false R60.htm 2408401 - Disclosure - Investment in privately held company (Details) Sheet http://www.invitae.com/role/InvestmentInPrivatelyHeldCompanyDetails Investment in privately held company (Details) Details http://www.invitae.com/role/InvestmentInPrivatelyHeldCompanyInvestmentInPrivatelyHeldCompany 60 false false R61.htm 2409402 - Disclosure - Commitments and contingencies - Operating leases narrative (Details) Sheet http://www.invitae.com/role/CommitmentsAndContingenciesOperatingLeasesNarrativeDetails Commitments and contingencies - Operating leases narrative (Details) Details 61 false false R62.htm 2409403 - Disclosure - Commitments and contingencies - Schedule of future minimum payments under operating leases (Details) Sheet http://www.invitae.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsUnderOperatingLeasesDetails Commitments and contingencies - Schedule of future minimum payments under operating leases (Details) Details 62 false false R63.htm 2409404 - Disclosure - Commitments and contingencies - Schedule of rent expense related to non-cancelable operating leases (Details) Sheet http://www.invitae.com/role/CommitmentsAndContingenciesScheduleOfRentExpenseRelatedToNonCancelableOperatingLeasesDetails Commitments and contingencies - Schedule of rent expense related to non-cancelable operating leases (Details) Details 63 false false R64.htm 2409405 - Disclosure - Commitments and contingencies - Debt financing narrative (Details) Sheet http://www.invitae.com/role/CommitmentsAndContingenciesDebtFinancingNarrativeDetails Commitments and contingencies - Debt financing narrative (Details) Details 64 false false R65.htm 2409406 - Disclosure - Commitments and contingencies - Schedule of future payments under loan and security agreement (Details) Sheet http://www.invitae.com/role/CommitmentsAndContingenciesScheduleOfFuturePaymentsUnderLoanAndSecurityAgreementDetails Commitments and contingencies - Schedule of future payments under loan and security agreement (Details) Details 65 false false R66.htm 2409407 - Disclosure - Commitments and contingencies - Capital leases narrative (Details) Sheet http://www.invitae.com/role/CommitmentsAndContingenciesCapitalLeasesNarrativeDetails Commitments and contingencies - Capital leases narrative (Details) Details 66 false false R67.htm 2409408 - Disclosure - Commitments and contingencies - Schedule of future minimum lease payments under capital leases (Details) Sheet http://www.invitae.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderCapitalLeasesDetails Commitments and contingencies - Schedule of future minimum lease payments under capital leases (Details) Details 67 false false R68.htm 2409409 - Disclosure - Commitments and contingencies - Schedule of future payments under noncancelable unconditional purchase commitments (Details) Sheet http://www.invitae.com/role/CommitmentsAndContingenciesScheduleOfFuturePaymentsUnderNoncancelableUnconditionalPurchaseCommitmentsDetails Commitments and contingencies - Schedule of future payments under noncancelable unconditional purchase commitments (Details) Details 68 false false R69.htm 2409410 - Disclosure - Commitments and contingencies - Other commitments narrative (Details) Sheet http://www.invitae.com/role/CommitmentsAndContingenciesOtherCommitmentsNarrativeDetails Commitments and contingencies - Other commitments narrative (Details) Details 69 false false R70.htm 2410402 - Disclosure - Stockholders' Equity - Schedule of shares of common stock reserved for future issuance (Details) Sheet http://www.invitae.com/role/StockholdersEquityScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetails Stockholders' Equity - Schedule of shares of common stock reserved for future issuance (Details) Details 70 false false R71.htm 2410403 - Disclosure - Stockholders' Equity - Narrative (Details) Sheet http://www.invitae.com/role/StockholdersEquityNarrativeDetails Stockholders' Equity - Narrative (Details) Details 71 false false R72.htm 2410404 - Disclosure - Stockholders' Equity - Schedule of outstanding warrants to purchase common stock (Details) Sheet http://www.invitae.com/role/StockholdersEquityScheduleOfOutstandingWarrantsToPurchaseCommonStockDetails Stockholders' Equity - Schedule of outstanding warrants to purchase common stock (Details) Details 72 false false R73.htm 2411402 - Disclosure - Stock incentive plans - Narrative (Details) Sheet http://www.invitae.com/role/StockIncentivePlansNarrativeDetails Stock incentive plans - Narrative (Details) Details 73 false false R74.htm 2411403 - Disclosure - Stock incentive plans - Schedule of activity under stock incentive plans (Details) Sheet http://www.invitae.com/role/StockIncentivePlansScheduleOfActivityUnderStockIncentivePlansDetails Stock incentive plans - Schedule of activity under stock incentive plans (Details) Details 74 false false R75.htm 2411404 - Disclosure - Stock incentive plans - Summary of RSU activity (Details) Sheet http://www.invitae.com/role/StockIncentivePlansSummaryOfRsuActivityDetails Stock incentive plans - Summary of RSU activity (Details) Details 75 false false R76.htm 2411405 - Disclosure - Stock incentive plans - Schedule of assumptions used in determination of fair value of options (Details) Sheet http://www.invitae.com/role/StockIncentivePlansScheduleOfAssumptionsUsedInDeterminationOfFairValueOfOptionsDetails Stock incentive plans - Schedule of assumptions used in determination of fair value of options (Details) Details 76 false false R77.htm 2411406 - Disclosure - Stock incentive plans - Stock-based compensation expense (Details) Sheet http://www.invitae.com/role/StockIncentivePlansStockBasedCompensationExpenseDetails Stock incentive plans - Stock-based compensation expense (Details) Details 77 false false R78.htm 2412402 - Disclosure - Income Taxes - Narrative (Details) Sheet http://www.invitae.com/role/IncomeTaxesNarrativeDetails Income Taxes - Narrative (Details) Details 78 false false R79.htm 2412403 - Disclosure - Income Taxes - Schedule of components of loss before income taxes by U.S. and foreign jurisdictions (Details) Sheet http://www.invitae.com/role/IncomeTaxesScheduleOfComponentsOfLossBeforeIncomeTaxesByUSAndForeignJurisdictionsDetails Income Taxes - Schedule of components of loss before income taxes by U.S. and foreign jurisdictions (Details) Details 79 false false R80.htm 2412404 - Disclosure - Income Taxes - Schedule of components of the provision for income taxes (Details) Sheet http://www.invitae.com/role/IncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetails Income Taxes - Schedule of components of the provision for income taxes (Details) Details 80 false false R81.htm 2412405 - Disclosure - Income Taxes - Schedule of reconciliation of the tax expense computed at the statutory federal rate and Company's tax expense (Details) Sheet http://www.invitae.com/role/IncomeTaxesScheduleOfReconciliationOfTaxExpenseComputedAtStatutoryFederalRateAndCompanysTaxExpenseDetails Income Taxes - Schedule of reconciliation of the tax expense computed at the statutory federal rate and Company's tax expense (Details) Details 81 false false R82.htm 2412406 - Disclosure - Income Taxes - Schedule of net deferred tax assets (Details) Sheet http://www.invitae.com/role/IncomeTaxesScheduleOfNetDeferredTaxAssetsDetails Income Taxes - Schedule of net deferred tax assets (Details) Details 82 false false R83.htm 2412407 - Disclosure - Income Taxes - Schedule of reconciliation of unrecognized tax benefits (Details) Sheet http://www.invitae.com/role/IncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetails Income Taxes - Schedule of reconciliation of unrecognized tax benefits (Details) Details 83 false false R84.htm 2413402 - Disclosure - Net loss per common share - Schedule of earnings per share, basic and diluted (Details) Sheet http://www.invitae.com/role/NetLossPerCommonShareScheduleOfEarningsPerShareBasicAndDilutedDetails Net loss per common share - Schedule of earnings per share, basic and diluted (Details) Details 84 false false R85.htm 2413403 - Disclosure - Net loss per common share - Schedule of antidilutive securities excluded from computation of earnings per share (Details) Sheet http://www.invitae.com/role/NetLossPerCommonShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails Net loss per common share - Schedule of antidilutive securities excluded from computation of earnings per share (Details) Details 85 false false R86.htm 2414402 - Disclosure - Geographic information - Schedule of revenue by country (Details) Sheet http://www.invitae.com/role/GeographicInformationScheduleOfRevenueByCountryDetails Geographic information - Schedule of revenue by country (Details) Details 86 false false R87.htm 2415402 - Disclosure - Selected Quarterly Data (Unaudited) (Details) Sheet http://www.invitae.com/role/SelectedQuarterlyDataUnauditedDetails Selected Quarterly Data (Unaudited) (Details) Details http://www.invitae.com/role/SelectedQuarterlyDataUnauditedTables 87 false false R9999.htm Uncategorized Items - nvta-10k.htm Sheet http://xbrl.sec.gov/role/uncategorizedFacts Uncategorized Items - nvta-10k.htm Cover 88 false false All Reports Book All Reports nvta-10k.htm nvta-20181231.xsd nvta-20181231_cal.xml nvta-20181231_def.xml nvta-20181231_lab.xml nvta-20181231_pre.xml nvta-exhibit1019.htm nvta-exhibit211.htm nvta-exhibit231.htm nvta-exhibit311.htm nvta-exhibit312.htm nvta-exhibit321.htm nvta-exhibit322.htm http://fasb.org/us-gaap/2018-01-31 http://xbrl.sec.gov/country/2017-01-31 http://fasb.org/srt/2018-01-31 http://xbrl.sec.gov/dei/2018-01-31 true true JSON 112 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "nvta-10k.htm": { "axisCustom": 0, "axisStandard": 44, "contextCount": 401, "dts": { "calculationLink": { "local": [ "nvta-20181231_cal.xml" ] }, "definitionLink": { "local": [ "nvta-20181231_def.xml" ], "remote": [ "http://xbrl.fasb.org/srt/2018/elts/srt-eedm1-def-2018-01-31.xml", "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-eedm-def-2018-01-31.xml" ] }, "inline": { "local": [ "nvta-10k.htm" ] }, "labelLink": { "local": [ "nvta-20181231_lab.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-doc-2018-01-31.xml", "https://xbrl.sec.gov/dei/2018/dei-doc-2018-01-31.xml" ] }, "presentationLink": { "local": [ "nvta-20181231_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-ref-2018-01-31.xml", "https://xbrl.sec.gov/dei/2018/dei-ref-2018-01-31.xml" ] }, "schema": { "local": [ "nvta-20181231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd", "http://xbrl.fasb.org/srt/2018/elts/srt-roles-2018-01-31.xsd", "http://xbrl.fasb.org/srt/2018/elts/srt-types-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-parts-codification-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-roles-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-types-2018-01-31.xsd", "http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd", "http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd", "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd", "https://xbrl.sec.gov/exch/2018/exch-2018-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" ] } }, "elementCount": 779, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2018-01-31": 60, "http://www.invitae.com/20181231": 5, "http://xbrl.sec.gov/dei/2018-01-31": 19, "total": 84 }, "keyCustom": 85, "keyStandard": 393, "memberCustom": 53, "memberStandard": 59, "nsprefix": "nvta", "nsuri": "http://www.invitae.com/20181231", "report": { "R1": { "firstAnchor": null, "groupType": "document", "isDefault": "true", "longName": "0002000 - Document - Document and Entity Information", "role": "http://www.invitae.com/role/DocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": null }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2102100 - Disclosure - Summary of significant accounting policies", "role": "http://www.invitae.com/role/SummaryOfSignificantAccountingPolicies", "shortName": "Summary of significant accounting policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2103100 - Disclosure - Revenue, accounts receivable and deferred revenue", "role": "http://www.invitae.com/role/RevenueAccountsReceivableAndDeferredRevenue", "shortName": "Revenue, accounts receivable and deferred revenue", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2104100 - Disclosure - Business combinations", "role": "http://www.invitae.com/role/BusinessCombinations", "shortName": "Business combinations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2105100 - Disclosure - Goodwill and intangible assets", "role": "http://www.invitae.com/role/GoodwillAndIntangibleAssets", "shortName": "Goodwill and intangible assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2106100 - Disclosure - Balance sheet components", "role": "http://www.invitae.com/role/BalanceSheetComponents", "shortName": "Balance sheet components", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2107100 - Disclosure - Fair value measurements", "role": "http://www.invitae.com/role/FairValueMeasurements", "shortName": "Fair value measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2108100 - Disclosure - Investment in privately held company Investment in privately held company", "role": "http://www.invitae.com/role/InvestmentInPrivatelyHeldCompanyInvestmentInPrivatelyHeldCompany", "shortName": "Investment in privately held company Investment in privately held company", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2109100 - Disclosure - Commitments and contingencies", "role": "http://www.invitae.com/role/CommitmentsAndContingencies", "shortName": "Commitments and contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2110100 - Disclosure - Stockholders' Equity", "role": "http://www.invitae.com/role/StockholdersEquity", "shortName": "Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2111100 - Disclosure - Stock incentive plans", "role": "http://www.invitae.com/role/StockIncentivePlans", "shortName": "Stock incentive plans", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001000 - Statement - Consolidated Balance Sheets", "role": "http://www.invitae.com/role/ConsolidatedBalanceSheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FI2018Q4", "decimals": "-3", "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2112100 - Disclosure - Income taxes", "role": "http://www.invitae.com/role/IncomeTaxes", "shortName": "Income taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2113100 - Disclosure - Net loss per common share", "role": "http://www.invitae.com/role/NetLossPerCommonShare", "shortName": "Net loss per common share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2114100 - Disclosure - Geographic information", "role": "http://www.invitae.com/role/GeographicInformation", "shortName": "Geographic information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:QuarterlyFinancialInformationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2115100 - Disclosure - Selected quarterly data (unaudited)", "role": "http://www.invitae.com/role/SelectedQuarterlyDataUnaudited", "shortName": "Selected quarterly data (unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:QuarterlyFinancialInformationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2202201 - Disclosure - Summary of significant accounting policies (Policies)", "role": "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of significant accounting policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2302302 - Disclosure - Summary of significant accounting policies (Tables)", "role": "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesTables", "shortName": "Summary of significant accounting policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfProspectiveAdoptionOfNewAccountingPronouncementsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2303301 - Disclosure - Revenue, accounts receivable and deferred revenue (Tables)", "role": "http://www.invitae.com/role/RevenueAccountsReceivableAndDeferredRevenueTables", "shortName": "Revenue, accounts receivable and deferred revenue (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfProspectiveAdoptionOfNewAccountingPronouncementsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q4YTD_us-gaap_BusinessAcquisitionAxis_nvta_AltaVoiceMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2304301 - Disclosure - Business combinations (Tables)", "role": "http://www.invitae.com/role/BusinessCombinationsTables", "shortName": "Business combinations (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q4YTD_us-gaap_BusinessAcquisitionAxis_nvta_AltaVoiceMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2305301 - Disclosure - Goodwill and intangible assets (Tables)", "role": "http://www.invitae.com/role/GoodwillAndIntangibleAssetsTables", "shortName": "Goodwill and intangible assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2306301 - Disclosure - Balance sheet components (Tables)", "role": "http://www.invitae.com/role/BalanceSheetComponentsTables", "shortName": "Balance sheet components (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "1001501 - Statement - Consolidated Balance Sheets (Parenthetical)", "role": "http://www.invitae.com/role/ConsolidatedBalanceSheetsParenthetical", "shortName": "Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2307301 - Disclosure - Fair value measurements (Tables)", "role": "http://www.invitae.com/role/FairValueMeasurementsTables", "shortName": "Fair value measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2309301 - Disclosure - Commitments and contingencies (Tables)", "role": "http://www.invitae.com/role/CommitmentsAndContingenciesTables", "shortName": "Commitments and contingencies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "nvta:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2310301 - Disclosure - Stockholders' Equity (Tables)", "role": "http://www.invitae.com/role/StockholdersEquityTables", "shortName": "Stockholders' Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "nvta:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2311301 - Disclosure - Stock incentive plans (Tables)", "role": "http://www.invitae.com/role/StockIncentivePlansTables", "shortName": "Stock incentive plans (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2312301 - Disclosure - Income Taxes (Tables)", "role": "http://www.invitae.com/role/IncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2313301 - Disclosure - Net loss per common share (Tables)", "role": "http://www.invitae.com/role/NetLossPerCommonShareTables", "shortName": "Net loss per common share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2314301 - Disclosure - Geographic information (Tables)", "role": "http://www.invitae.com/role/GeographicInformationTables", "shortName": "Geographic information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2315301 - Disclosure - Selected Quarterly Data (Unaudited) (Tables)", "role": "http://www.invitae.com/role/SelectedQuarterlyDataUnauditedTables", "shortName": "Selected Quarterly Data (Unaudited) (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "body", "html" ], "contextRef": "FI2018Q4", "decimals": "-4", "first": true, "lang": null, "name": "nvta:NumberOfGenes", "reportCount": 1, "unique": true, "unitRef": "gene", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401401 - Disclosure - Organization and description of business - Narrative (Details)", "role": "http://www.invitae.com/role/OrganizationAndDescriptionOfBusinessNarrativeDetails", "shortName": "Organization and description of business - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "body", "html" ], "contextRef": "FI2018Q4", "decimals": "-4", "first": true, "lang": null, "name": "nvta:NumberOfGenes", "reportCount": 1, "unique": true, "unitRef": "gene", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2018Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:InventoryNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402403 - Disclosure - Summary of significant accounting policies - Narrative (Details)", "role": "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails", "shortName": "Summary of significant accounting policies - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2018Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:InventoryNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002000 - Statement - Consolidated Statements of Operations", "role": "http://www.invitae.com/role/ConsolidatedStatementsOfOperations", "shortName": "Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FD2018Q4YTD", "decimals": "-3", "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q4YTD_srt_MajorCustomersAxis_nvta_CustomerMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402404 - Disclosure - Summary of significant accounting policies - Schedule of significant customers, revenue as a percentage (Details)", "role": "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfSignificantCustomersRevenueAsPercentageDetails", "shortName": "Summary of significant accounting policies - Schedule of significant customers, revenue as a percentage (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R41": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402405 - Disclosure - Summary of significant accounting policies - Schedule of cash, cash equivalents and restricted cash (Details)", "role": "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails", "shortName": "Summary of significant accounting policies - Schedule of cash, cash equivalents and restricted cash (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R42": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402406 - Disclosure - Summary of significant accounting policies - Schedule of useful lives of property and equipment (Details)", "role": "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfUsefulLivesOfPropertyAndEquipmentDetails", "shortName": "Summary of significant accounting policies - Schedule of useful lives of property and equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "I2018Q1Jan01", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403402 - Disclosure - Revenue, accounts receivable and deferred revenue - Narrative (Details)", "role": "http://www.invitae.com/role/RevenueAccountsReceivableAndDeferredRevenueNarrativeDetails", "shortName": "Revenue, accounts receivable and deferred revenue - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "I2018Q1Jan01", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q4QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403403 - Disclosure - Revenue, accounts receivable and deferred revenue - Schedule of impact of adoption of topic 606 on condensed statement of operations and balance sheet (Details)", "role": "http://www.invitae.com/role/RevenueAccountsReceivableAndDeferredRevenueScheduleOfImpactOfAdoptionOfTopic606OnCondensedStatementOfOperationsAndBalanceSheetDetails", "shortName": "Revenue, accounts receivable and deferred revenue - Schedule of impact of adoption of topic 606 on condensed statement of operations and balance sheet (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q4YTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member", "decimals": "-3", "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q4QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403404 - Disclosure - Revenue, accounts receivable and deferred revenue - Schedule of disaggregated revenue by payer category (Details)", "role": "http://www.invitae.com/role/RevenueAccountsReceivableAndDeferredRevenueScheduleOfDisaggregatedRevenueByPayerCategoryDetails", "shortName": "Revenue, accounts receivable and deferred revenue - Schedule of disaggregated revenue by payer category (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q4YTD_srt_MajorCustomersAxis_nvta_InstitutionsMember_srt_ProductOrServiceAxis_nvta_DiagnosticTestsMember", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404402 - Disclosure - Business combinations - Narrative (Details)", "role": "http://www.invitae.com/role/BusinessCombinationsNarrativeDetails", "shortName": "Business combinations - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "D2017Q1Jan06_us-gaap_BusinessAcquisitionAxis_nvta_AltaVoiceMember", "decimals": "-5", "lang": null, "name": "us-gaap:BusinessCombinationConsiderationTransferred1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404403 - Disclosure - Business combinations - Summary of fair values of assets acquired and liabilities assumed (Details)", "role": "http://www.invitae.com/role/BusinessCombinationsSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetails", "shortName": "Business combinations - Summary of fair values of assets acquired and liabilities assumed (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "I2017Q1Jan06_us-gaap_BusinessAcquisitionAxis_nvta_AltaVoiceMember", "decimals": "-3", "lang": null, "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404404 - Disclosure - Business combinations - Schedule of economic benefits of intangible assets expected to be realized (Details)", "role": "http://www.invitae.com/role/BusinessCombinationsScheduleOfEconomicBenefitsOfIntangibleAssetsExpectedToBeRealizedDetails", "shortName": "Business combinations - Schedule of economic benefits of intangible assets expected to be realized (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "I2017Q1Jan06_us-gaap_BusinessAcquisitionAxis_nvta_AltaVoiceMember", "decimals": "-3", "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2017Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405402 - Disclosure - Goodwill and intangible assets - Summary of goodwill (Details)", "role": "http://www.invitae.com/role/GoodwillAndIntangibleAssetsSummaryOfGoodwillDetails", "shortName": "Goodwill and intangible assets - Summary of goodwill (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R5": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FD2018Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003000 - Statement - Consolidated Statements of Comprehensive Loss", "role": "http://www.invitae.com/role/ConsolidatedStatementsOfComprehensiveLoss", "shortName": "Consolidated Statements of Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FD2018Q4YTD", "decimals": "-3", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:GoodwillPurchaseAccountingAdjustments", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405403 - Disclosure - Goodwill and intangible assets - Narrative (Details)", "role": "http://www.invitae.com/role/GoodwillAndIntangibleAssetsNarrativeDetails", "shortName": "Goodwill and intangible assets - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q4YTD", "decimals": "-5", "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405404 - Disclosure - Goodwill and intangible assets - Schedule of finite-lived intangible assets (Details)", "role": "http://www.invitae.com/role/GoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails", "shortName": "Goodwill and intangible assets - Schedule of finite-lived intangible assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2018Q4", "decimals": "-3", "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405405 - Disclosure - Goodwill and intangible assets - Summary of estimated future amortization expense of intangible assets with finite lives (Details)", "role": "http://www.invitae.com/role/GoodwillAndIntangibleAssetsSummaryOfEstimatedFutureAmortizationExpenseOfIntangibleAssetsWithFiniteLivesDetails", "shortName": "Goodwill and intangible assets - Summary of estimated future amortization expense of intangible assets with finite lives (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406402 - Disclosure - Balance sheet components - Property and equipment (Details)", "role": "http://www.invitae.com/role/BalanceSheetComponentsPropertyAndEquipmentDetails", "shortName": "Balance sheet components - Property and equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2018Q4", "decimals": "-3", "lang": null, "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406403 - Disclosure - Balance sheet components - Accrued liabilities (Details)", "role": "http://www.invitae.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails", "shortName": "Balance sheet components - Accrued liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "nvta:LeaseIncentivePayableNonCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406404 - Disclosure - Balance sheet components - Other long-term liabilities (Details)", "role": "http://www.invitae.com/role/BalanceSheetComponentsOtherLongTermLiabilitiesDetails", "shortName": "Balance sheet components - Other long-term liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "nvta:LeaseIncentivePayableNonCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "nvta:CashEquivalentsRestrictedCashAndMarketableSecuritiesAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407402 - Disclosure - Fair value measurements - Financial instruments at fair value on a recurring basis (Details)", "role": "http://www.invitae.com/role/FairValueMeasurementsFinancialInstrumentsAtFairValueOnRecurringBasisDetails", "shortName": "Fair value measurements - Financial instruments at fair value on a recurring basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "nvta:CashEquivalentsRestrictedCashAndMarketableSecuritiesAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2018Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407403 - Disclosure - Fair value measurements - Narrative (Details)", "role": "http://www.invitae.com/role/FairValueMeasurementsNarrativeDetails", "shortName": "Fair value measurements - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2018Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q4YTD_us-gaap_BusinessAcquisitionAxis_nvta_AltaVoiceMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407404 - Disclosure - Fair value measurements - Level 3 financial instruments measured at fair value on a recurring basis (Details)", "role": "http://www.invitae.com/role/FairValueMeasurementsLevel3FinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails", "shortName": "Fair value measurements - Level 3 financial instruments measured at fair value on a recurring basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q4YTD_us-gaap_BusinessAcquisitionAxis_nvta_AltaVoiceMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember", "decimals": "-3", "lang": null, "name": "us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "contextRef": "FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LongTermDebt", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407405 - Disclosure - Fair value measurements - Carrying amount and the estimated fair value of the Company's outstanding debt (Details)", "role": "http://www.invitae.com/role/FairValueMeasurementsCarryingAmountAndEstimatedFairValueOfCompanysOutstandingDebtDetails", "shortName": "Fair value measurements - Carrying amount and the estimated fair value of the Company's outstanding debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "contextRef": "FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LongTermDebt", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FI2015Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004000 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity", "role": "http://www.invitae.com/role/ConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity", "shortName": "Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember", "decimals": "-3", "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "body", "html" ], "contextRef": "FD2018Q4YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nvta_KEWIncMember", "decimals": "-5", "first": true, "lang": null, "name": "nvta:GainLossOnLicenseAgreement", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408401 - Disclosure - Investment in privately held company (Details)", "role": "http://www.invitae.com/role/InvestmentInPrivatelyHeldCompanyDetails", "shortName": "Investment in privately held company (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "body", "html" ], "contextRef": "FD2018Q4YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nvta_KEWIncMember", "decimals": "-5", "first": true, "lang": null, "name": "nvta:GainLossOnLicenseAgreement", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409402 - Disclosure - Commitments and contingencies - Operating leases narrative (Details)", "role": "http://www.invitae.com/role/CommitmentsAndContingenciesOperatingLeasesNarrativeDetails", "shortName": "Commitments and contingencies - Operating leases narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2015Q3_us-gaap_PropertyPlantAndEquipmentByTypeAxis_nvta_OfficeFacilityInSanFranciscoMember_us-gaap_TypeOfArrangementAxis_nvta_NewLeasesMember", "decimals": null, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseRenewalTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409403 - Disclosure - Commitments and contingencies - Schedule of future minimum payments under operating leases (Details)", "role": "http://www.invitae.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsUnderOperatingLeasesDetails", "shortName": "Commitments and contingencies - Schedule of future minimum payments under operating leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesRentExpenseMinimumRentals", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409404 - Disclosure - Commitments and contingencies - Schedule of rent expense related to non-cancelable operating leases (Details)", "role": "http://www.invitae.com/role/CommitmentsAndContingenciesScheduleOfRentExpenseRelatedToNonCancelableOperatingLeasesDetails", "shortName": "Commitments and contingencies - Schedule of rent expense related to non-cancelable operating leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesRentExpenseMinimumRentals", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FD2018Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PaymentsOfDebtExtinguishmentCosts", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409405 - Disclosure - Commitments and contingencies - Debt financing narrative (Details)", "role": "http://www.invitae.com/role/CommitmentsAndContingenciesDebtFinancingNarrativeDetails", "shortName": "Commitments and contingencies - Debt financing narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "I2018Q4Nov30_us-gaap_CreditFacilityAxis_nvta_NotePurchaseAgreementMember", "decimals": "-5", "lang": null, "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "nvta:LongTermDebtMaturitiesRepaymentsNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409406 - Disclosure - Commitments and contingencies - Schedule of future payments under loan and security agreement (Details)", "role": "http://www.invitae.com/role/CommitmentsAndContingenciesScheduleOfFuturePaymentsUnderLoanAndSecurityAgreementDetails", "shortName": "Commitments and contingencies - Schedule of future payments under loan and security agreement (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "nvta:LongTermDebtMaturitiesRepaymentsNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "nvta:CapitalLeasesTermOfContract", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409407 - Disclosure - Commitments and contingencies - Capital leases narrative (Details)", "role": "http://www.invitae.com/role/CommitmentsAndContingenciesCapitalLeasesNarrativeDetails", "shortName": "Commitments and contingencies - Capital leases narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "nvta:CapitalLeasesTermOfContract", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CapitalLeasesFutureMinimumPaymentsDueCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409408 - Disclosure - Commitments and contingencies - Schedule of future minimum lease payments under capital leases (Details)", "role": "http://www.invitae.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderCapitalLeasesDetails", "shortName": "Commitments and contingencies - Schedule of future minimum lease payments under capital leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CapitalLeasesFutureMinimumPaymentsDueCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2018Q4_us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_nvta_ServiceAgreementsAndLaboratorySuppliesMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RecordedUnconditionalPurchaseObligationDueWithinOneYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409409 - Disclosure - Commitments and contingencies - Schedule of future payments under noncancelable unconditional purchase commitments (Details)", "role": "http://www.invitae.com/role/CommitmentsAndContingenciesScheduleOfFuturePaymentsUnderNoncancelableUnconditionalPurchaseCommitmentsDetails", "shortName": "Commitments and contingencies - Schedule of future payments under noncancelable unconditional purchase commitments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2018Q4_us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_nvta_ServiceAgreementsAndLaboratorySuppliesMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RecordedUnconditionalPurchaseObligationDueWithinOneYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccruedLiabilitiesCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409410 - Disclosure - Commitments and contingencies - Other commitments narrative (Details)", "role": "http://www.invitae.com/role/CommitmentsAndContingenciesOtherCommitmentsNarrativeDetails", "shortName": "Commitments and contingencies - Other commitments narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2018Q4_us-gaap_TypeOfArrangementAxis_nvta_CoDevelopmentAgreementMember", "decimals": "-5", "lang": null, "name": "us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "1004501 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Parenthetical)", "role": "http://www.invitae.com/role/ConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityParenthetical", "shortName": "Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R70": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410402 - Disclosure - Stockholders' Equity - Schedule of shares of common stock reserved for future issuance (Details)", "role": "http://www.invitae.com/role/StockholdersEquityScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetails", "shortName": "Stockholders' Equity - Schedule of shares of common stock reserved for future issuance (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2018Q4_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember", "decimals": "-3", "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FD2018Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProceedsFromIssuanceOfCommonStock", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410403 - Disclosure - Stockholders' Equity - Narrative (Details)", "role": "http://www.invitae.com/role/StockholdersEquityNarrativeDetails", "shortName": "Stockholders' Equity - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "D2017Q3Aug01-Aug31_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember", "decimals": "-5", "lang": null, "name": "us-gaap:ProceedsFromIssuanceOfPrivatePlacement", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410404 - Disclosure - Stockholders' Equity - Schedule of outstanding warrants to purchase common stock (Details)", "role": "http://www.invitae.com/role/StockholdersEquityScheduleOfOutstandingWarrantsToPurchaseCommonStockDetails", "shortName": "Stockholders' Equity - Schedule of outstanding warrants to purchase common stock (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FD2018Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411402 - Disclosure - Stock incentive plans - Narrative (Details)", "role": "http://www.invitae.com/role/StockIncentivePlansNarrativeDetails", "shortName": "Stock incentive plans - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected", "reportCount": 1, "unique": true, "unitRef": "U_nvtaEmployee", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411403 - Disclosure - Stock incentive plans - Schedule of activity under stock incentive plans (Details)", "role": "http://www.invitae.com/role/StockIncentivePlansScheduleOfActivityUnderStockIncentivePlansDetails", "shortName": "Stock incentive plans - Schedule of activity under stock incentive plans (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_nvta_StockIncentivePlanMember", "decimals": "-3", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411404 - Disclosure - Stock incentive plans - Summary of RSU activity (Details)", "role": "http://www.invitae.com/role/StockIncentivePlansSummaryOfRsuActivityDetails", "shortName": "Stock incentive plans - Summary of RSU activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember", "decimals": "-3", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_TitleOfIndividualAxis_nvta_EmployeesAndDirectorsStockOptionsMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411405 - Disclosure - Stock incentive plans - Schedule of assumptions used in determination of fair value of options (Details)", "role": "http://www.invitae.com/role/StockIncentivePlansScheduleOfAssumptionsUsedInDeterminationOfFairValueOfOptionsDetails", "shortName": "Stock incentive plans - Schedule of assumptions used in determination of fair value of options (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_TitleOfIndividualAxis_nvta_EmployeesAndDirectorsStockOptionsMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411406 - Disclosure - Stock incentive plans - Stock-based compensation expense (Details)", "role": "http://www.invitae.com/role/StockIncentivePlansStockBasedCompensationExpenseDetails", "shortName": "Stock incentive plans - Stock-based compensation expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R78": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q4YTD", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412402 - Disclosure - Income Taxes - Narrative (Details)", "role": "http://www.invitae.com/role/IncomeTaxesNarrativeDetails", "shortName": "Income Taxes - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q4QTD", "decimals": "-5", "lang": null, "name": "nvta:TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateProvisionalIncomeTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R79": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412403 - Disclosure - Income Taxes - Schedule of components of loss before income taxes by U.S. and foreign jurisdictions (Details)", "role": "http://www.invitae.com/role/IncomeTaxesScheduleOfComponentsOfLossBeforeIncomeTaxesByUSAndForeignJurisdictionsDetails", "shortName": "Income Taxes - Schedule of components of loss before income taxes by U.S. and foreign jurisdictions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FD2018Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1006000 - Statement - Consolidated Statements of Cash Flows", "role": "http://www.invitae.com/role/ConsolidatedStatementsOfCashFlows", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FD2018Q4YTD", "decimals": "-3", "lang": null, "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R80": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CurrentForeignTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412404 - Disclosure - Income Taxes - Schedule of components of the provision for income taxes (Details)", "role": "http://www.invitae.com/role/IncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetails", "shortName": "Income Taxes - Schedule of components of the provision for income taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CurrentForeignTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R81": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q4YTD", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412405 - Disclosure - Income Taxes - Schedule of reconciliation of the tax expense computed at the statutory federal rate and Company's tax expense (Details)", "role": "http://www.invitae.com/role/IncomeTaxesScheduleOfReconciliationOfTaxExpenseComputedAtStatutoryFederalRateAndCompanysTaxExpenseDetails", "shortName": "Income Taxes - Schedule of reconciliation of the tax expense computed at the statutory federal rate and Company's tax expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q4YTD", "decimals": "3", "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R82": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412406 - Disclosure - Income Taxes - Schedule of net deferred tax assets (Details)", "role": "http://www.invitae.com/role/IncomeTaxesScheduleOfNetDeferredTaxAssetsDetails", "shortName": "Income Taxes - Schedule of net deferred tax assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R83": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2017Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412407 - Disclosure - Income Taxes - Schedule of reconciliation of unrecognized tax benefits (Details)", "role": "http://www.invitae.com/role/IncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetails", "shortName": "Income Taxes - Schedule of reconciliation of unrecognized tax benefits (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q4YTD", "decimals": "-3", "lang": null, "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R84": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q4QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413402 - Disclosure - Net loss per common share - Schedule of earnings per share, basic and diluted (Details)", "role": "http://www.invitae.com/role/NetLossPerCommonShareScheduleOfEarningsPerShareBasicAndDilutedDetails", "shortName": "Net loss per common share - Schedule of earnings per share, basic and diluted (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q4YTD", "decimals": "2", "lang": null, "name": "us-gaap:EarningsPerShareBasicAndDiluted", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R85": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "contextRef": "FD2018Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413403 - Disclosure - Net loss per common share - Schedule of antidilutive securities excluded from computation of earnings per share (Details)", "role": "http://www.invitae.com/role/NetLossPerCommonShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails", "shortName": "Net loss per common share - Schedule of antidilutive securities excluded from computation of earnings per share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "contextRef": "FD2018Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R86": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q4QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414402 - Disclosure - Geographic information - Schedule of revenue by country (Details)", "role": "http://www.invitae.com/role/GeographicInformationScheduleOfRevenueByCountryDetails", "shortName": "Geographic information - Schedule of revenue by country (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q4YTD_srt_StatementGeographicalAxis_country_US", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R87": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q4QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415402 - Disclosure - Selected Quarterly Data (Unaudited) (Details)", "role": "http://www.invitae.com/role/SelectedQuarterlyDataUnauditedDetails", "shortName": "Selected Quarterly Data (Unaudited) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q4QTD", "decimals": "-3", "lang": null, "name": "us-gaap:CostOfRevenue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101100 - Disclosure - Organization and description of business", "role": "http://www.invitae.com/role/OrganizationAndDescriptionOfBusiness", "shortName": "Organization and description of business", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9999": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "I2018Q1Jan01_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "", "isDefault": "false", "longName": "Uncategorized Items - nvta-10k.htm", "role": "http://xbrl.sec.gov/role/uncategorizedFacts", "shortName": "Uncategorized Items - nvta-10k.htm", "subGroupType": "", "uniqueAnchor": null } }, "segmentCount": 118, "tag": { "country_CA": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "CANADA", "terseLabel": "Canada" } } }, "localname": "CA", "nsuri": "http://xbrl.sec.gov/country/2017-01-31", "presentation": [ "http://www.invitae.com/role/GeographicInformationScheduleOfRevenueByCountryDetails" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "UNITED STATES", "terseLabel": "United States" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2017-01-31", "presentation": [ "http://www.invitae.com/role/GeographicInformationScheduleOfRevenueByCountryDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "If the value is true, then the document is an amendment to previously-filed/accepted document.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.invitae.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.invitae.com/role/DocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.invitae.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.invitae.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.invitae.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.invitae.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r459" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.invitae.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.invitae.com/role/DocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.invitae.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r459" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.invitae.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r460" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.invitae.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r459" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated), (5) Smaller Reporting Accelerated Filer or (6) Smaller Reporting Company and Large Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.invitae.com/role/DocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.", "label": "Entity Public Float", "terseLabel": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.invitae.com/role/DocumentAndEntityInformation" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r459" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.invitae.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r459" ], "lang": { "en-US": { "role": { "documentation": "Indicate if company meets the shell company criteria: a company with no or nominal operations, and with no or nominal assets or assets consisting solely of cash and cash equivalents.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.invitae.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r459" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a smaller reporting company with both a public float and revenues of less than $75 million.", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.invitae.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.invitae.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.invitae.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.invitae.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "nvta_AltaVoiceMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Alta Voice.", "label": "Alta Voice [Member]", "terseLabel": "AltaVoice" } } }, "localname": "AltaVoiceMember", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsNarrativeDetails", "http://www.invitae.com/role/BusinessCombinationsScheduleOfEconomicBenefitsOfIntangibleAssetsExpectedToBeRealizedDetails", "http://www.invitae.com/role/BusinessCombinationsSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetails", "http://www.invitae.com/role/BusinessCombinationsTables", "http://www.invitae.com/role/FairValueMeasurementsLevel3FinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails", "http://www.invitae.com/role/FairValueMeasurementsNarrativeDetails", "http://www.invitae.com/role/GoodwillAndIntangibleAssetsSummaryOfGoodwillDetails" ], "xbrltype": "domainItemType" }, "nvta_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesForSettlementOfConvertibleDebt": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Business acquisition equity interests issued or issuable number of shares for settlement of convertible debt.", "label": "Business Acquisition Equity Interests Issued Or Issuable Number Of Shares For Settlement Of Convertible Debt", "terseLabel": "Equity interests issued for settlement of convertible debt (in shares)" } } }, "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesForSettlementOfConvertibleDebt", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsNarrativeDetails" ], "xbrltype": "sharesItemType" }, "nvta_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssuedRelatedToHoldBack": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Business acquisition equity interests issued or issuable number of shares issued related to hold back.", "label": "Business Acquisition Equity Interests Issued Or Issuable Number Of Shares Issued Related To Hold Back", "terseLabel": "Common stock issued, related to hold back (in shares)" } } }, "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssuedRelatedToHoldBack", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsNarrativeDetails" ], "xbrltype": "sharesItemType" }, "nvta_BusinessAcquisitionNumberOfHoldBackSharesIssuedOrIssuableForPaymentOfBonus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Business acquisition number of hold back shares Issued or Issuable for payment of bonus.", "label": "Business Acquisition Number Of Hold Back Shares Issued Or Issuable For Payment Of Bonus", "terseLabel": "Issuance of common stock to settle bonuses (in shares)" } } }, "localname": "BusinessAcquisitionNumberOfHoldBackSharesIssuedOrIssuableForPaymentOfBonus", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsNarrativeDetails" ], "xbrltype": "sharesItemType" }, "nvta_BusinessCombinationAccruedLiabilitiesCurrent": { "auth_ref": [], "calculation": { "http://www.invitae.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Business combination accrued liabilities current.", "label": "Business Combination Accrued Liabilities Current", "terseLabel": "Liabilities associated with business combinations" } } }, "localname": "BusinessCombinationAccruedLiabilitiesCurrent", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "nvta_BusinessCombinationAccruedLiabilitiesNoncurrent": { "auth_ref": [], "calculation": { "http://www.invitae.com/role/BalanceSheetComponentsOtherLongTermLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Business combination accrued liabilities noncurrent.", "label": "Business Combination Accrued Liabilities Noncurrent", "terseLabel": "Liabilities associated with business combinations" } } }, "localname": "BusinessCombinationAccruedLiabilitiesNoncurrent", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/BalanceSheetComponentsOtherLongTermLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "nvta_BusinessCombinationCommonStockConversionRatio": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Business combination common stock conversion ratio.", "label": "Business Combination Common Stock Conversion Ratio", "terseLabel": "Business combination common stock conversion ratio" } } }, "localname": "BusinessCombinationCommonStockConversionRatio", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsNarrativeDetails" ], "xbrltype": "percentItemType" }, "nvta_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableForSettlementOfConvertibleDebt": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Business combination consideration transferred equity interests issued and issuable for settlement of convertible debt.", "label": "Business Combination Consideration Transferred Equity Interests Issued And Issuable For Settlement Of Convertible Debt", "terseLabel": "Equity interests issued for settlement of convertible debt" } } }, "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableForSettlementOfConvertibleDebt", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "nvta_BusinessCombinationContingentConsiderationActualRevenueTargetForPayout": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Business combination, contingent consideration, actual revenue target for payout.", "label": "Business Combination Contingent Consideration Actual Revenue Target For Payout", "terseLabel": "Contingent consideration, revenue target for payout" } } }, "localname": "BusinessCombinationContingentConsiderationActualRevenueTargetForPayout", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "nvta_BusinessCombinationContingentConsiderationAmountDeductedOnActualRevenueTarget": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Business combination, contingent consideration, amount deducted on actual revenue target", "label": "Business Combination Contingent Consideration Amount Deducted On Actual Revenue Target", "terseLabel": "Contingent consideration, amount deducted on revenue target" } } }, "localname": "BusinessCombinationContingentConsiderationAmountDeductedOnActualRevenueTarget", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "nvta_BusinessCombinationContingentConsiderationLiabilityRevenueThreshold": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Business combination contingent consideration liability revenue threshold.", "label": "Business Combination Contingent Consideration Liability Revenue Threshold", "terseLabel": "Contingent revenue threshold" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityRevenueThreshold", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "nvta_BusinessCombinationContingentConsiderationPercentageOfActualRevenueTarget": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Business combination, contingent consideration, percentage of actual revenue target.", "label": "Business Combination Contingent Consideration Percentage Of Actual Revenue Target", "terseLabel": "Contingent consideration, revenue target (as a percent)" } } }, "localname": "BusinessCombinationContingentConsiderationPercentageOfActualRevenueTarget", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsNarrativeDetails" ], "xbrltype": "percentItemType" }, "nvta_BusinessCombinationContingentConsiderationPossiblePayoutAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Business combination contingent consideration possible payout amount.", "label": "Business Combination Contingent Consideration Possible Payout Amount", "terseLabel": "Business combination possible payout amount" } } }, "localname": "BusinessCombinationContingentConsiderationPossiblePayoutAmount", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "nvta_BusinessCombinationHoldBackConsideration": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Business combination hold back consideration.", "label": "Business Combination Hold Back Consideration", "terseLabel": "Hold-back consideration amount" } } }, "localname": "BusinessCombinationHoldBackConsideration", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "nvta_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalentsAndRestrictedCash": { "auth_ref": [], "calculation": { "http://www.invitae.com/role/BusinessCombinationsSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 5.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Business combination recognized identifiable assets acquired and liabilities assumed cash and equivalents and restricted cash.", "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents And Restricted Cash", "terseLabel": "Cash and restricted cash" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalentsAndRestrictedCash", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "nvta_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedConvertiblePromissoryNotesPayable": { "auth_ref": [], "calculation": { "http://www.invitae.com/role/BusinessCombinationsSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 6.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Business combination recognized identifiable assets acquired and liabilities assumed convertible promissory notes payable.", "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Convertible Promissory Notes Payable", "negatedLabel": "Convertible promissory notes payable" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedConvertiblePromissoryNotesPayable", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "nvta_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses": { "auth_ref": [], "calculation": { "http://www.invitae.com/role/BusinessCombinationsSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Business combination recognized identifiable assets acquired and liabilities assumed current liabilities accrued expenses.", "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accrued Expenses", "negatedLabel": "Accrued expenses" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "nvta_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNotesPayable": { "auth_ref": [], "calculation": { "http://www.invitae.com/role/BusinessCombinationsSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 5.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Business combination recognized identifiable assets acquired and liabilities assumed notes payable.", "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Notes Payable", "negatedLabel": "Notes payable" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNotesPayable", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "nvta_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedProvisionalDeferredTaxLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Business combination recognized identifiable assets acquired and liabilities assumed provisional deferred tax liabilities.", "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Provisional Deferred Tax Liabilities", "verboseLabel": "Provisional deferred tax liability" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedProvisionalDeferredTaxLiabilities", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "nvta_BusinessCombinationRemainingHoldBackAmountPayableUponSettlementOfOutstandingClaims": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Business combination remaining hold back amount payable upon settlement of outstanding claims.", "label": "Business Combination Remaining Hold Back Amount Payable Upon Settlement Of Outstanding Claims", "terseLabel": "Remaining hold-back amount payable to settle outstanding claims" } } }, "localname": "BusinessCombinationRemainingHoldBackAmountPayableUponSettlementOfOutstandingClaims", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "nvta_BusinessCombinationRemainingHoldBackAmountPayabletoSettleBonuses": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Business Combination Remaining Hold Back Amount Payable to Settle Bonuses", "label": "Business Combination Remaining Hold Back Amount Payable to Settle Bonuses", "terseLabel": "Remaining hold back amount payable to settle bonuses" } } }, "localname": "BusinessCombinationRemainingHoldBackAmountPayabletoSettleBonuses", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "nvta_BusinessCombinationRemeasurementOfLiabilities": { "auth_ref": [], "calculation": { "http://www.invitae.com/role/ConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Business combination remeasurement of liabilities.", "label": "Business Combination Remeasurement Of Liabilities", "terseLabel": "Remeasurements of liabilities associated with business combinations" } } }, "localname": "BusinessCombinationRemeasurementOfLiabilities", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "nvta_BusinessCombinationSaleOfHoldBackStockForPaymentOfBonus": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Business combination sale of hold back stock for payment of bonus.", "label": "Business Combination Sale Of Hold Back Stock For Payment Of Bonus", "terseLabel": "Payment by issuance of common stock to settle bonuses" } } }, "localname": "BusinessCombinationSaleOfHoldBackStockForPaymentOfBonus", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "nvta_BusinessCombinationStepAcquisitionEquityInterestinAcquireeAccretionGainLossNet": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Accretion Gain (Loss), Net", "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Accretion Gain (Loss), Net", "terseLabel": "Accretion gains (losses)" } } }, "localname": "BusinessCombinationStepAcquisitionEquityInterestinAcquireeAccretionGainLossNet", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "nvta_CapitalExpendituresAndAdjustmentsIncurredButNotYetPaid": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Future cash outflow (inflow) associated with purchases of fixed assets that have occurred, including adjustments to the amount payable.", "label": "Capital Expenditures And Adjustments Incurred But Not Yet Paid", "terseLabel": "Purchases of property and equipment in accounts payable and accrued liabilities" } } }, "localname": "CapitalExpendituresAndAdjustmentsIncurredButNotYetPaid", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "nvta_CapitalLeasesTermOfContract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Term of the lessor's leasing arrangement in a capital leasing arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Capital Leases Term Of Contract", "terseLabel": "Lease term" } } }, "localname": "CapitalLeasesTermOfContract", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesCapitalLeasesNarrativeDetails" ], "xbrltype": "durationItemType" }, "nvta_CashEquivalentsRestrictedCashAndMarketableSecuritiesAmortizedCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Cash equivalents restricted cash and marketable securities amortized cost.", "label": "Cash Equivalents Restricted Cash And Marketable Securities Amortized Cost", "terseLabel": "Cash equivalents, restricted cash and marketable securities, amortized cost" } } }, "localname": "CashEquivalentsRestrictedCashAndMarketableSecuritiesAmortizedCost", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/FairValueMeasurementsFinancialInstrumentsAtFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "nvta_CashEquivalentsRestrictedCashAndMarketableSecuritiesAmortizedCostGrossUnrealizedLossBeforeTax": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Cash equivalents restricted cash and marketable securities amortized cost gross unrealized loss before tax.", "label": "Cash Equivalents Restricted Cash And Marketable Securities Amortized Cost Gross Unrealized Loss Before Tax", "negatedTerseLabel": "Cash equivalents, restricted cash and marketable securities, gross unrealized loss before tax" } } }, "localname": "CashEquivalentsRestrictedCashAndMarketableSecuritiesAmortizedCostGrossUnrealizedLossBeforeTax", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/FairValueMeasurementsFinancialInstrumentsAtFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "nvta_CashEquivalentsRestrictedCashAndMarketableSecuritiesFairValue": { "auth_ref": [], "calculation": { "http://www.invitae.com/role/FairValueMeasurementsFinancialInstrumentsAtFairValueOnRecurringBasisDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Cash equivalents restricted cash and marketable securities fair value.", "label": "Cash Equivalents Restricted Cash And Marketable Securities Fair Value", "totalLabel": "Cash equivalents, restricted cash and marketable securities, estimated fair value" } } }, "localname": "CashEquivalentsRestrictedCashAndMarketableSecuritiesFairValue", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/FairValueMeasurementsFinancialInstrumentsAtFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "nvta_ChangeInEstimateOfRevenueRecognitionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Change in estimate of revenue recognition.", "label": "Change In Estimate Of Revenue Recognition [Member]", "terseLabel": "Change in estimate of revenue recognition" } } }, "localname": "ChangeInEstimateOfRevenueRecognitionMember", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/RevenueAccountsReceivableAndDeferredRevenueNarrativeDetails" ], "xbrltype": "domainItemType" }, "nvta_CoDevelopmentAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Co-development agreement.", "label": "Co Development Agreement [Member]", "terseLabel": "Co Development Agreement" } } }, "localname": "CoDevelopmentAgreementMember", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesOtherCommitmentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "nvta_CollaborationAndGenomeNetworkMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Collaboration and genome network.", "label": "Collaboration And Genome Network [Member]", "terseLabel": "Other revenue" } } }, "localname": "CollaborationAndGenomeNetworkMember", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfOperations", "http://www.invitae.com/role/RevenueAccountsReceivableAndDeferredRevenueScheduleOfDisaggregatedRevenueByPayerCategoryDetails" ], "xbrltype": "domainItemType" }, "nvta_CombiMatrixCorporationMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "CombiMatrix Corporation.", "label": "Combi Matrix Corporation [Member]", "terseLabel": "CombiMatrix" } } }, "localname": "CombiMatrixCorporationMember", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsNarrativeDetails", "http://www.invitae.com/role/BusinessCombinationsScheduleOfEconomicBenefitsOfIntangibleAssetsExpectedToBeRealizedDetails", "http://www.invitae.com/role/BusinessCombinationsSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetails", "http://www.invitae.com/role/BusinessCombinationsTables", "http://www.invitae.com/role/GoodwillAndIntangibleAssetsNarrativeDetails", "http://www.invitae.com/role/GoodwillAndIntangibleAssetsSummaryOfGoodwillDetails", "http://www.invitae.com/role/StockholdersEquityNarrativeDetails", "http://www.invitae.com/role/StockholdersEquityScheduleOfOutstandingWarrantsToPurchaseCommonStockDetails" ], "xbrltype": "domainItemType" }, "nvta_CommonStockSalesAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Common stock sales agreement.", "label": "Common Stock Sales Agreement [Member]", "terseLabel": "2018 Sales Agreement" } } }, "localname": "CommonStockSalesAgreementMember", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "nvta_ContingentConsiderationMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Contingent consideration.", "label": "Contingent Consideration [Member]", "terseLabel": "Contingent consideration" } } }, "localname": "ContingentConsiderationMember", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/FairValueMeasurementsFinancialInstrumentsAtFairValueOnRecurringBasisDetails", "http://www.invitae.com/role/FairValueMeasurementsLevel3FinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails", "http://www.invitae.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "nvta_CostOfTestRevenueMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cost of test revenue.", "label": "Cost Of Test Revenue [Member]", "terseLabel": "Cost of revenue" } } }, "localname": "CostOfTestRevenueMember", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/StockIncentivePlansStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "nvta_CowenAndCompanyLimitedLiabilityCompanyMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cowen and company limited liability company.", "label": "Cowen And Company Limited Liability Company [Member]", "terseLabel": "Cowen and Company, LLC" } } }, "localname": "CowenAndCompanyLimitedLiabilityCompanyMember", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "nvta_CustomerMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the information pertaining to Customer A.", "label": "Customer [Member]", "terseLabel": "Medicare" } } }, "localname": "CustomerMember", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails", "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfSignificantCustomersRevenueAsPercentageDetails" ], "xbrltype": "domainItemType" }, "nvta_DebtInstrumentCommitmentFeePercentageOnUnusedBorrowingCapacity": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt instrument commitment fee percentage on unused borrowing capacity.", "label": "Debt Instrument Commitment Fee Percentage On Unused Borrowing Capacity", "terseLabel": "Term loan, line fee percentage on unused commitment amount" } } }, "localname": "DebtInstrumentCommitmentFeePercentageOnUnusedBorrowingCapacity", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesDebtFinancingNarrativeDetails" ], "xbrltype": "percentItemType" }, "nvta_DebtInstrumentFacilityFeePercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt instrument facility fee percentage.", "label": "Debt Instrument Facility Fee Percentage", "terseLabel": "Term loans, facility fee percentage" } } }, "localname": "DebtInstrumentFacilityFeePercentage", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesDebtFinancingNarrativeDetails" ], "xbrltype": "percentItemType" }, "nvta_DebtInstrumentFloorInterestRate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt instrument floor interest rate.", "label": "Debt Instrument Floor Interest Rate", "terseLabel": "Term loans, floor interest rate" } } }, "localname": "DebtInstrumentFloorInterestRate", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesDebtFinancingNarrativeDetails" ], "xbrltype": "percentItemType" }, "nvta_DebtInstrumentIndexInterestRateMinimum": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt instrument index interest rate minimum.", "label": "Debt Instrument Index Interest Rate Minimum", "terseLabel": "Term loans, index interest rate, minimum" } } }, "localname": "DebtInstrumentIndexInterestRateMinimum", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesDebtFinancingNarrativeDetails" ], "xbrltype": "percentItemType" }, "nvta_DeferredTaxAssetsRevenueRecognitionReserves": { "auth_ref": [], "calculation": { "http://www.invitae.com/role/IncomeTaxesScheduleOfNetDeferredTaxAssetsDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Deferred tax assets revenue recognition reserves.", "label": "Deferred Tax Assets Revenue Recognition Reserves", "terseLabel": "Revenue recognition differences" } } }, "localname": "DeferredTaxAssetsRevenueRecognitionReserves", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/IncomeTaxesScheduleOfNetDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "nvta_DeferredTaxAssetsTaxAccruedLiabilitiesAndOther": { "auth_ref": [], "calculation": { "http://www.invitae.com/role/IncomeTaxesScheduleOfNetDeferredTaxAssetsDetails": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accruals and not separately disclosed.", "label": "Deferred Tax Assets Tax Accrued Liabilities And Other", "terseLabel": "Accruals and other" } } }, "localname": "DeferredTaxAssetsTaxAccruedLiabilitiesAndOther", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/IncomeTaxesScheduleOfNetDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "nvta_DiagnosticTestsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Diagnostic tests.", "label": "Diagnostic Tests [Member]", "terseLabel": "Test revenue" } } }, "localname": "DiagnosticTestsMember", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfOperations", "http://www.invitae.com/role/RevenueAccountsReceivableAndDeferredRevenueNarrativeDetails", "http://www.invitae.com/role/RevenueAccountsReceivableAndDeferredRevenueScheduleOfDisaggregatedRevenueByPayerCategoryDetails", "http://www.invitae.com/role/RevenueAccountsReceivableAndDeferredRevenueScheduleOfImpactOfAdoptionOfTopic606OnCondensedStatementOfOperationsAndBalanceSheetDetails" ], "xbrltype": "domainItemType" }, "nvta_DocumentAndEntityInformationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Document and Entity Information", "label": "Document And Entity Information [Abstract]" } } }, "localname": "DocumentAndEntityInformationAbstract", "nsuri": "http://www.invitae.com/20181231", "xbrltype": "stringItemType" }, "nvta_EarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Earnings per share.", "label": "Earnings Per Share [Line Items]", "terseLabel": "Earnings Per Share [Line Items]" } } }, "localname": "EarningsPerShareLineItems", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/NetLossPerCommonShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "nvta_EarningsPerShareTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Earnings per share.", "label": "Earnings Per Share [Table]", "terseLabel": "Earnings Per Share [Table]" } } }, "localname": "EarningsPerShareTable", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/NetLossPerCommonShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "nvta_EmployeeStockPurchasePlan2015Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the information pertaining to the 2015 employee stock purchase plan.", "label": "Employee Stock Purchase Plan2015 [Member]", "terseLabel": "2015 Employee Stock Purchase Plan", "verboseLabel": "Shares of common stock pursuant to ESPP" } } }, "localname": "EmployeeStockPurchasePlan2015Member", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/NetLossPerCommonShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails", "http://www.invitae.com/role/StockIncentivePlansNarrativeDetails", "http://www.invitae.com/role/StockIncentivePlansScheduleOfAssumptionsUsedInDeterminationOfFairValueOfOptionsDetails", "http://www.invitae.com/role/StockIncentivePlansTables", "http://www.invitae.com/role/StockholdersEquityScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetails" ], "xbrltype": "domainItemType" }, "nvta_EmployeesAndDirectorsStockOptionsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Employees and Directors Stock Options [Member].", "label": "Employees And Directors Stock Options [Member]", "terseLabel": "Employees and directors stock options" } } }, "localname": "EmployeesAndDirectorsStockOptionsMember", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/StockIncentivePlansScheduleOfAssumptionsUsedInDeterminationOfFairValueOfOptionsDetails" ], "xbrltype": "domainItemType" }, "nvta_EstimatedFairValueForContingentConsideration": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Estimated fair value for contingent consideration.", "label": "Estimated Fair Value For Contingent Consideration", "verboseLabel": "Estimated fair value for contingent consideration" } } }, "localname": "EstimatedFairValueForContingentConsideration", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "nvta_ExpirationTaxYear2019Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Expiration, Tax Year 2019 [Member]", "label": "Expiration, Tax Year 2019 [Member]", "terseLabel": "Begins to expire 2030" } } }, "localname": "ExpirationTaxYear2019Member", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "nvta_ExpirationTaxYearUnknownMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Expiration, Tax Year Unknown [Member]", "label": "Expiration, Tax Year Unknown [Member]", "terseLabel": "No expiration date" } } }, "localname": "ExpirationTaxYearUnknownMember", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "nvta_FairValueAssetsAndLiabilitiesLevel1Level2AndLevel3TransfersAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value assets and liabilities level1 level2 and level3 transfers\u2019 amount.", "label": "Fair Value Assets And Liabilities Level1 Level2 And Level3 Transfers Amount", "terseLabel": "Transfers of assets and liabilities between Level 1, Level 2 and Level 3" } } }, "localname": "FairValueAssetsAndLiabilitiesLevel1Level2AndLevel3TransfersAmount", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "nvta_FavorableLeasesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Favorable leases.", "label": "Favorable Leases [Member]", "terseLabel": "Favorable leases" } } }, "localname": "FavorableLeasesMember", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/GoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "nvta_FirstAnniversaryOfGrantDateMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the information pertaining to first anniversary of grant date.", "label": "First Anniversary Of Grant Date [Member]", "terseLabel": "First anniversary" } } }, "localname": "FirstAnniversaryOfGrantDateMember", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/StockIncentivePlansNarrativeDetails" ], "xbrltype": "domainItemType" }, "nvta_FirstTermLoanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "First term loan.", "label": "First Term Loan [Member]", "terseLabel": "Initial term loan" } } }, "localname": "FirstTermLoanMember", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesDebtFinancingNarrativeDetails" ], "xbrltype": "domainItemType" }, "nvta_GainLossOnLicenseAgreement": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Gain (loss) on license agreement.", "label": "Gain Loss On License Agreement", "terseLabel": "Loss on license agreement" } } }, "localname": "GainLossOnLicenseAgreement", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/InvestmentInPrivatelyHeldCompanyDetails" ], "xbrltype": "monetaryItemType" }, "nvta_GoodStartGeneticsIncMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Good Start Genetics, Inc.", "label": "Good Start Genetics Inc [Member]", "terseLabel": "Good Start Genetics", "verboseLabel": "Good Start" } } }, "localname": "GoodStartGeneticsIncMember", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsNarrativeDetails", "http://www.invitae.com/role/BusinessCombinationsScheduleOfEconomicBenefitsOfIntangibleAssetsExpectedToBeRealizedDetails", "http://www.invitae.com/role/BusinessCombinationsSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetails", "http://www.invitae.com/role/BusinessCombinationsTables", "http://www.invitae.com/role/GoodwillAndIntangibleAssetsSummaryOfGoodwillDetails" ], "xbrltype": "domainItemType" }, "nvta_IncomeTaxExaminationNumberOfPeriodUnderExamination": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Income tax examination number of period under examination.", "label": "Income Tax Examination Number Of Period Under Examination", "terseLabel": "Number of tax years open for examination" } } }, "localname": "IncomeTaxExaminationNumberOfPeriodUnderExamination", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "durationItemType" }, "nvta_IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets": { "auth_ref": [], "calculation": { "http://www.invitae.com/role/ConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods and also includes other current operating assets not separately disclosed in the statement of cash flows.", "label": "Increase Decrease In Prepaid Expense And Other Current Assets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "nvta_InstitutionsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Institutions", "label": "Institutions [Member]", "terseLabel": "Institutions" } } }, "localname": "InstitutionsMember", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/RevenueAccountsReceivableAndDeferredRevenueScheduleOfDisaggregatedRevenueByPayerCategoryDetails" ], "xbrltype": "domainItemType" }, "nvta_InternalRateOfReturnPercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Internal rate of return percentage.", "label": "Internal Rate Of Return Percentage", "terseLabel": "Internal rate of return percentage" } } }, "localname": "InternalRateOfReturnPercentage", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesDebtFinancingNarrativeDetails" ], "xbrltype": "percentItemType" }, "nvta_KEWIncMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "KEW, Inc.", "label": "K E W Inc [Member]", "terseLabel": "KEW" } } }, "localname": "KEWIncMember", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/InvestmentInPrivatelyHeldCompanyDetails" ], "xbrltype": "domainItemType" }, "nvta_LeaseIncentivePayableNonCurrent": { "auth_ref": [], "calculation": { "http://www.invitae.com/role/BalanceSheetComponentsOtherLongTermLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "This item represents an incentive or inducement contractually stipulated between parties to a lease whereby the lessor has committed to provide the entity (lessee) with a cash payment as inducement to enter the lease. Used to reflect the current portion of the liabilities (due beyond one year or beyond the normal operating cycle if longer).", "label": "Lease Incentive Payable Non Current", "terseLabel": "Lease incentive obligation, non-current" } } }, "localname": "LeaseIncentivePayableNonCurrent", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/BalanceSheetComponentsOtherLongTermLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "nvta_LoanAndSecurityAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents information pertaining to loan and security agreement.", "label": "Loan And Security Agreement [Member]", "terseLabel": "Loan and Security Agreement" } } }, "localname": "LoanAndSecurityAgreementMember", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesDebtFinancingNarrativeDetails", "http://www.invitae.com/role/SelectedQuarterlyDataUnauditedDetails" ], "xbrltype": "domainItemType" }, "nvta_LongTermDebtMaturitiesRepaymentsInYearFifth": { "auth_ref": [], "calculation": { "http://www.invitae.com/role/CommitmentsAndContingenciesScheduleOfFuturePaymentsUnderLoanAndSecurityAgreementDetails": { "order": 5.0, "parentTag": "nvta_LongTermDebtMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Interest and principal amount of long-term debt, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long Term Debt Maturities Repayments In Year Fifth", "terseLabel": "2023" } } }, "localname": "LongTermDebtMaturitiesRepaymentsInYearFifth", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesScheduleOfFuturePaymentsUnderLoanAndSecurityAgreementDetails" ], "xbrltype": "monetaryItemType" }, "nvta_LongTermDebtMaturitiesRepaymentsInYearFour": { "auth_ref": [], "calculation": { "http://www.invitae.com/role/CommitmentsAndContingenciesScheduleOfFuturePaymentsUnderLoanAndSecurityAgreementDetails": { "order": 4.0, "parentTag": "nvta_LongTermDebtMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Interest and principal amount of long-term debt, Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long Term Debt Maturities Repayments In Year Four", "terseLabel": "2022" } } }, "localname": "LongTermDebtMaturitiesRepaymentsInYearFour", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesScheduleOfFuturePaymentsUnderLoanAndSecurityAgreementDetails" ], "xbrltype": "monetaryItemType" }, "nvta_LongTermDebtMaturitiesRepaymentsInYearThree": { "auth_ref": [], "calculation": { "http://www.invitae.com/role/CommitmentsAndContingenciesScheduleOfFuturePaymentsUnderLoanAndSecurityAgreementDetails": { "order": 3.0, "parentTag": "nvta_LongTermDebtMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Interest and principal amount of long-term debt, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long Term Debt Maturities Repayments In Year Three", "terseLabel": "2021" } } }, "localname": "LongTermDebtMaturitiesRepaymentsInYearThree", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesScheduleOfFuturePaymentsUnderLoanAndSecurityAgreementDetails" ], "xbrltype": "monetaryItemType" }, "nvta_LongTermDebtMaturitiesRepaymentsInYearTwo": { "auth_ref": [], "calculation": { "http://www.invitae.com/role/CommitmentsAndContingenciesScheduleOfFuturePaymentsUnderLoanAndSecurityAgreementDetails": { "order": 2.0, "parentTag": "nvta_LongTermDebtMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Interest and principal amount of long-term debt, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long Term Debt Maturities Repayments In Year Two", "terseLabel": "2020" } } }, "localname": "LongTermDebtMaturitiesRepaymentsInYearTwo", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesScheduleOfFuturePaymentsUnderLoanAndSecurityAgreementDetails" ], "xbrltype": "monetaryItemType" }, "nvta_LongTermDebtMaturitiesRepaymentsNextTwelveMonths": { "auth_ref": [], "calculation": { "http://www.invitae.com/role/CommitmentsAndContingenciesScheduleOfFuturePaymentsUnderLoanAndSecurityAgreementDetails": { "order": 1.0, "parentTag": "nvta_LongTermDebtMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Long term debt maturities repayments next twelve months.", "label": "Long Term Debt Maturities Repayments Next Twelve Months", "terseLabel": "2019" } } }, "localname": "LongTermDebtMaturitiesRepaymentsNextTwelveMonths", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesScheduleOfFuturePaymentsUnderLoanAndSecurityAgreementDetails" ], "xbrltype": "monetaryItemType" }, "nvta_LongTermDebtMaturitiesRepaymentsThereafter": { "auth_ref": [], "calculation": { "http://www.invitae.com/role/CommitmentsAndContingenciesScheduleOfFuturePaymentsUnderLoanAndSecurityAgreementDetails": { "order": 6.0, "parentTag": "nvta_LongTermDebtMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Interest and principal amount of long-term debt, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing after fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long Term Debt Maturities Repayments Thereafter", "terseLabel": "Thereafter" } } }, "localname": "LongTermDebtMaturitiesRepaymentsThereafter", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesScheduleOfFuturePaymentsUnderLoanAndSecurityAgreementDetails" ], "xbrltype": "monetaryItemType" }, "nvta_LongTermDebtMinimumPaymentsDue": { "auth_ref": [], "calculation": { "http://www.invitae.com/role/CommitmentsAndContingenciesScheduleOfFuturePaymentsUnderLoanAndSecurityAgreementDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of minimum payments owed for long-term debt, including principal and interest.", "label": "Long Term Debt Minimum Payments Due", "totalLabel": "Total remaining payments" } } }, "localname": "LongTermDebtMinimumPaymentsDue", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesScheduleOfFuturePaymentsUnderLoanAndSecurityAgreementDetails" ], "xbrltype": "monetaryItemType" }, "nvta_MaximumNetAnnualRevenueReceivableByLenderInAdditionToInterest": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Maximum net annual revenue receivable by lender in addition to interest.", "label": "Maximum Net Annual Revenue Receivable By Lender In Addition To Interest", "terseLabel": "Maximum net annual revenue receivable by purchasers in addition to interest, beginning on January 1, 2020" } } }, "localname": "MaximumNetAnnualRevenueReceivableByLenderInAdditionToInterest", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesDebtFinancingNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "nvta_MilestoneBasedOnCertainThresholdOfRevenueAchievedDuringTwoThousandSeventeenMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Milestone based on certain threshold of revenue achieved during two thousand seventeen.", "label": "Milestone Based On Certain Threshold Of Revenue Achieved During Two Thousand Seventeen [Member]", "terseLabel": "Milestone Based on Certain Threshold of Revenue Achieved During 2017 [Member]" } } }, "localname": "MilestoneBasedOnCertainThresholdOfRevenueAchievedDuringTwoThousandSeventeenMember", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsNarrativeDetails" ], "xbrltype": "domainItemType" }, "nvta_NetOperatingLossCarryforwardsChangeInOwnershipPercentageMinimum": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Net operating loss carryforwards change in ownership percentage minimum.", "label": "Net Operating Loss Carryforwards Change In Ownership Percentage Minimum", "terseLabel": "Net operating loss carryforwards change in ownership percentage minimum" } } }, "localname": "NetOperatingLossCarryforwardsChangeInOwnershipPercentageMinimum", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "percentItemType" }, "nvta_NetProceedsFromIssuanceOfCommonStock": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Net proceeds from issuance of common stock.", "label": "Net Proceeds From Issuance Of Common Stock", "terseLabel": "Net proceeds from issuance of common stock" } } }, "localname": "NetProceedsFromIssuanceOfCommonStock", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "nvta_NetProceedsFromIssuanceOfPrivatePlacement": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Net proceeds from issuance of private placement.", "label": "Net Proceeds From Issuance Of Private Placement", "terseLabel": "Net proceeds from private placement" } } }, "localname": "NetProceedsFromIssuanceOfPrivatePlacement", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "nvta_NewContingentMilestoneBasedOnAchievingRevenueTargetDuringTwoThousandSeventeenAndTwoThousandEighteenMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "New contingent milestone based on achieving revenue target during two thousand seventeen and two thousand eighteen.", "label": "New Contingent Milestone Based On Achieving Revenue Target During Two Thousand Seventeen And Two Thousand Eighteen [Member]", "terseLabel": "New Contingent Milestone Based On Achieving Revenue Target During 2017 And 2018" } } }, "localname": "NewContingentMilestoneBasedOnAchievingRevenueTargetDuringTwoThousandSeventeenAndTwoThousandEighteenMember", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsNarrativeDetails", "http://www.invitae.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "nvta_NewLeasesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information pertaining to new lease arrangements.", "label": "New Leases [Member]", "terseLabel": "New leases" } } }, "localname": "NewLeasesMember", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesOperatingLeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "nvta_NonEmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "An arrangement whereby a non-employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement.", "label": "Non Employee Stock Option [Member]", "terseLabel": "Non-Employee Options" } } }, "localname": "NonEmployeeStockOptionMember", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/StockIncentivePlansNarrativeDetails", "http://www.invitae.com/role/StockIncentivePlansScheduleOfAssumptionsUsedInDeterminationOfFairValueOfOptionsDetails", "http://www.invitae.com/role/StockIncentivePlansTables" ], "xbrltype": "domainItemType" }, "nvta_Noncashorpartnoncashamountsrelatedtocodevelopmentagreementinotherassetsandaccruedliabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Noncash or part noncash amounts related to co-development agreement in other assets and accrued liabilities", "label": "Noncash or part noncash amounts related to co-development agreement in other assets and accrued liabilities", "terseLabel": "Amounts related to co-development agreement in other assets and accrued liabilities" } } }, "localname": "Noncashorpartnoncashamountsrelatedtocodevelopmentagreementinotherassetsandaccruedliabilities", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "nvta_NotePurchaseAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Note purchase agreement.", "label": "Note Purchase Agreement [Member]", "terseLabel": "Note Purchase Agreement" } } }, "localname": "NotePurchaseAgreementMember", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesDebtFinancingNarrativeDetails" ], "xbrltype": "domainItemType" }, "nvta_NumberOfGenes": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of genes.", "label": "Number Of Genes", "terseLabel": "Number of genes" } } }, "localname": "NumberOfGenes", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/OrganizationAndDescriptionOfBusinessNarrativeDetails" ], "xbrltype": "integerItemType" }, "nvta_OfficeFacilityInSanFranciscoMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the information pertaining to office facility in San Francisco.", "label": "Office Facility In San Francisco [Member]", "terseLabel": "Office Facility In San Francisco" } } }, "localname": "OfficeFacilityInSanFranciscoMember", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesOperatingLeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "nvta_OmmdomIncMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Ommdom Inc.", "label": "Ommdom Inc [Member]", "terseLabel": "Ommdom, Inc.", "verboseLabel": "Ommdom" } } }, "localname": "OmmdomIncMember", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsNarrativeDetails", "http://www.invitae.com/role/BusinessCombinationsScheduleOfEconomicBenefitsOfIntangibleAssetsExpectedToBeRealizedDetails", "http://www.invitae.com/role/BusinessCombinationsSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetails", "http://www.invitae.com/role/BusinessCombinationsTables", "http://www.invitae.com/role/GoodwillAndIntangibleAssetsSummaryOfGoodwillDetails" ], "xbrltype": "domainItemType" }, "nvta_OperatingLeasesFutureMinimumPaymentsDueNet": { "auth_ref": [], "calculation": { "http://www.invitae.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsUnderOperatingLeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Operating Leases Future Minimum Payments Due, Net", "label": "Operating Leases Future Minimum Payments Due, Net", "terseLabel": "Future undiscounted non-cancelable minimum operating lease payments", "totalLabel": "Total future non-cancelable minimum operating lease payments, net" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueNet", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsUnderOperatingLeasesDetails", "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "nvta_OtherIncomeExpenseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other income expense.", "label": "Other Income Expense [Member]", "terseLabel": "Other (income) expense" } } }, "localname": "OtherIncomeExpenseMember", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsNarrativeDetails" ], "xbrltype": "domainItemType" }, "nvta_PatentLicensingAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Patent licensing agreement.", "label": "Patent Licensing Agreement [Member]", "terseLabel": "Patent licensing agreement" } } }, "localname": "PatentLicensingAgreementMember", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsScheduleOfEconomicBenefitsOfIntangibleAssetsExpectedToBeRealizedDetails", "http://www.invitae.com/role/BusinessCombinationsSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetails", "http://www.invitae.com/role/GoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "nvta_PatientDirectMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Patient direct.", "label": "Patient Direct [Member]", "terseLabel": "Patient - direct" } } }, "localname": "PatientDirectMember", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/RevenueAccountsReceivableAndDeferredRevenueScheduleOfDisaggregatedRevenueByPayerCategoryDetails" ], "xbrltype": "domainItemType" }, "nvta_PatientInsuranceMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Patient insurance.", "label": "Patient Insurance [Member]", "terseLabel": "Patient - insurance" } } }, "localname": "PatientInsuranceMember", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/RevenueAccountsReceivableAndDeferredRevenueScheduleOfDisaggregatedRevenueByPayerCategoryDetails" ], "xbrltype": "domainItemType" }, "nvta_PaymentOfTransactionCostsRelatingToAcquisitionRefusal": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Payment of transaction costs relating to acquisition refusal.", "label": "Payment Of Transaction Costs Relating To Acquisition Refusal", "terseLabel": "Payment of refusal fees related to the acquisition agreement" } } }, "localname": "PaymentOfTransactionCostsRelatingToAcquisitionRefusal", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesOtherCommitmentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "nvta_PercentageOfCommissionPayableOnGrossProceeds": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage of commission payable on gross proceeds.", "label": "Percentage Of Commission Payable On Gross Proceeds", "terseLabel": "Percentage of commission payable on gross proceeds" } } }, "localname": "PercentageOfCommissionPayableOnGrossProceeds", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "percentItemType" }, "nvta_PercentageOfNetAnnualRevenueReceivableByLenderInAdditionToInterest": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage of Net annual revenue receivable by lender in addition to interest.", "label": "Percentage Of Net Annual Revenue Receivable By Lender In Addition To Interest", "terseLabel": "Percentage of net annual revenue receivable by purchasers in addition to interest, beginning on January 1, 2020" } } }, "localname": "PercentageOfNetAnnualRevenueReceivableByLenderInAdditionToInterest", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesDebtFinancingNarrativeDetails" ], "xbrltype": "percentItemType" }, "nvta_PerformanceRestrictedStockUnitsRsusMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, when specified performance conditions are met.", "label": "Performance Restricted Stock Units Rsus [Member]", "terseLabel": "Shares of common stock subject to outstanding PRSUs" } } }, "localname": "PerformanceRestrictedStockUnitsRsusMember", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/NetLossPerCommonShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails", "http://www.invitae.com/role/StockIncentivePlansNarrativeDetails" ], "xbrltype": "domainItemType" }, "nvta_PeriodOfPaymentsToBeReceivedForGoodsOrService": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Period of payments to be received for goods or service.", "label": "Period Of Payments To Be Received For Goods Or Service", "terseLabel": "Period of payments to be received for goods or service" } } }, "localname": "PeriodOfPaymentsToBeReceivedForGoodsOrService", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/RevenueAccountsReceivableAndDeferredRevenueNarrativeDetails" ], "xbrltype": "durationItemType" }, "nvta_PreferredStockToCommonStockConversionRatio": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Preferred stock to common stock conversion ratio.", "label": "Preferred Stock To Common Stock Conversion Ratio", "terseLabel": "Preferred stock to common stock conversion ratio" } } }, "localname": "PreferredStockToCommonStockConversionRatio", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "percentItemType" }, "nvta_PrepaymentFeePercentageOfOutstandingBalance": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Prepayment fee percentage of outstanding balance.", "label": "Prepayment Fee Percentage Of Outstanding Balance", "terseLabel": "Term loans, prepayment fee percentage of outstanding balance" } } }, "localname": "PrepaymentFeePercentageOfOutstandingBalance", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesDebtFinancingNarrativeDetails" ], "xbrltype": "percentItemType" }, "nvta_ProceedsFromIssuanceOfPublicOfferingsOfCommonStockNetOfIssuanceCosts": { "auth_ref": [], "calculation": { "http://www.invitae.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Proceeds from issuance of public offerings of common stock net of issuance costs.", "label": "Proceeds From Issuance Of Public Offerings Of Common Stock Net Of Issuance Costs", "terseLabel": "Proceeds from public offering of common stock, net of issuance costs" } } }, "localname": "ProceedsFromIssuanceOfPublicOfferingsOfCommonStockNetOfIssuanceCosts", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "nvta_PropertyPlantAndEquipmentUsefulLivesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the tabular disclosure of useful lives of the property, plant and equipment.", "label": "Property Plant And Equipment Useful Lives [Table Text Block]", "terseLabel": "Schedule of useful lives of property and equipment" } } }, "localname": "PropertyPlantAndEquipmentUsefulLivesTableTextBlock", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "nvta_ResearchAndDevelopmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the information pertaining to research and development expenses included in the income statement.", "label": "Research And Development [Member]", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentMember", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/StockIncentivePlansStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "nvta_RestOfWorldMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the information pertaining to rest of the world.", "label": "Rest Of World [Member]", "terseLabel": "Rest of world" } } }, "localname": "RestOfWorldMember", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/GeographicInformationScheduleOfRevenueByCountryDetails" ], "xbrltype": "domainItemType" }, "nvta_RevenuePerformanceObligationSatisfiedAtPointInTimePeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Revenue performance obligation satisfied at point in time period.", "label": "Revenue Performance Obligation Satisfied At Point In Time Period", "terseLabel": "Performance obligations underlying contracts period" } } }, "localname": "RevenuePerformanceObligationSatisfiedAtPointInTimePeriod", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/RevenueAccountsReceivableAndDeferredRevenueNarrativeDetails" ], "xbrltype": "durationItemType" }, "nvta_SalesCommissionsAmortizationPeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sales commissions amortization period.", "label": "Sales Commissions Amortization Period", "terseLabel": "Sales commissions amortization period" } } }, "localname": "SalesCommissionsAmortizationPeriod", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/RevenueAccountsReceivableAndDeferredRevenueNarrativeDetails" ], "xbrltype": "durationItemType" }, "nvta_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of Common stock reserved for future issuance.", "label": "Schedule Of Common Stock Reserved For Future Issuance Table [Text Block]", "terseLabel": "Schedule of shares of common stock reserved for future issuance" } } }, "localname": "ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "nvta_ScheduleOfFuturePaymentsAndComponentsOfLongTermDebtTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of future payments of long-term debt, components of long-term debt and long-term debt less current maturities.", "label": "Schedule Of Future Payments And Components Of Long Term Debt Table [Text Block]", "terseLabel": "Schedule of future payments under loan and security agreement" } } }, "localname": "ScheduleOfFuturePaymentsAndComponentsOfLongTermDebtTableTextBlock", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "nvta_SecondAnniversaryOfGrantDateMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the information pertaining to second anniversary of grant date.", "label": "Second Anniversary Of Grant Date [Member]", "terseLabel": "Second anniversary" } } }, "localname": "SecondAnniversaryOfGrantDateMember", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/StockIncentivePlansNarrativeDetails" ], "xbrltype": "domainItemType" }, "nvta_SecondTermLoanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Second term loan.", "label": "Second Term Loan [Member]", "terseLabel": "Second Term Loan" } } }, "localname": "SecondTermLoanMember", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesDebtFinancingNarrativeDetails" ], "xbrltype": "domainItemType" }, "nvta_SeriesAConvertiblePreferredStockConvertedtoCommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Series A Convertible Preferred Stock Converted to Common Stock [Member]", "label": "Series A Convertible Preferred Stock Converted to Common Stock [Member]", "terseLabel": "Series A convertible preferred stock converted to common stock" } } }, "localname": "SeriesAConvertiblePreferredStockConvertedtoCommonStockMember", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "nvta_SeriesAConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Series A convertible preferred stock.", "label": "Series A Convertible Preferred Stock [Member]", "terseLabel": "Shares of common stock underlying Series A convertible preferred stock" } } }, "localname": "SeriesAConvertiblePreferredStockMember", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/NetLossPerCommonShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "nvta_SeriesDWarrantsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Series D warrants.", "label": "Series D Warrants [Member]", "terseLabel": "Series D Warrants" } } }, "localname": "SeriesDWarrantsMember", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsNarrativeDetails" ], "xbrltype": "domainItemType" }, "nvta_SeriesFWarrantsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Series F warrants.", "label": "Series F Warrants [Member]", "terseLabel": "Series F Warrants" } } }, "localname": "SeriesFWarrantsMember", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsNarrativeDetails", "http://www.invitae.com/role/StockholdersEquityScheduleOfOutstandingWarrantsToPurchaseCommonStockDetails" ], "xbrltype": "domainItemType" }, "nvta_ServiceAgreementsAndLaboratorySuppliesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Service agreements and laboratory supplies.", "label": "Service Agreements And Laboratory Supplies [Member]", "terseLabel": "Service agreements and laboratory supplies" } } }, "localname": "ServiceAgreementsAndLaboratorySuppliesMember", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesScheduleOfFuturePaymentsUnderNoncancelableUnconditionalPurchaseCommitmentsDetails" ], "xbrltype": "domainItemType" }, "nvta_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingRightsEqualMonthlyVestingPercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the monthly percentage of vesting of share-based compensation awards.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Vesting Rights Equal Monthly Vesting Percentage", "terseLabel": "Share-based compensation arrangement by share-based payment award, vesting rights, equal monthly vesting percentage" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingRightsEqualMonthlyVestingPercentage", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/StockIncentivePlansNarrativeDetails" ], "xbrltype": "percentItemType" }, "nvta_ShareBasedCompensationArrangementByShareBasedPaymentAwardVotingRightsOfCommonStockHoldingPercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the percentage of voting rights of all classes of stock held by the employees.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Voting Rights Of Common Stock Holding Percentage", "terseLabel": "Employees holding voting rights of all classes of stock (as a percent)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardVotingRightsOfCommonStockHoldingPercentage", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/StockIncentivePlansNarrativeDetails" ], "xbrltype": "percentItemType" }, "nvta_StockBasedEmployeeCompensationCapitalized": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Represents the information pertaining to capitalized stock based employee compensation.", "label": "Stock Based Employee Compensation Capitalized", "terseLabel": "Capitalized stock-based employee compensation" } } }, "localname": "StockBasedEmployeeCompensationCapitalized", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/StockIncentivePlansNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "nvta_StockIncentivePlan2010Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the information pertaining to the 2010 stock incentive plan, which provides for the granting of stock based awards to employees, directors, and consultants under terms and provisions established by the board of directors.", "label": "Stock Incentive Plan2010 [Member]", "terseLabel": "2010 Plan" } } }, "localname": "StockIncentivePlan2010Member", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/StockIncentivePlansNarrativeDetails" ], "xbrltype": "domainItemType" }, "nvta_StockIncentivePlan2015Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the information pertaining to the 2015 stock incentive plan.", "label": "Stock Incentive Plan2015 [Member]", "terseLabel": "2015 Plan" } } }, "localname": "StockIncentivePlan2015Member", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/StockIncentivePlansNarrativeDetails" ], "xbrltype": "domainItemType" }, "nvta_StockIncentivePlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the stock incentive plans of the entity, which includes the 2010 plan, the 2015 plan, employee stock purchase plan.", "label": "Stock Incentive Plan [Member]", "terseLabel": "Stock incentive plans" } } }, "localname": "StockIncentivePlanMember", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/StockIncentivePlansNarrativeDetails", "http://www.invitae.com/role/StockIncentivePlansScheduleOfActivityUnderStockIncentivePlansDetails", "http://www.invitae.com/role/StockholdersEquityScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetails" ], "xbrltype": "domainItemType" }, "nvta_StockIssuedDuringPeriodSharesAcquisitionRelatedTransactionBonus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock issued during period, shares, acquisition-related transaction bonus.", "label": "Stock Issued During Period Shares Acquisition Related Transaction Bonus", "terseLabel": "Common stock issued pursuant to acquisition-related transaction bonus (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesAcquisitionRelatedTransactionBonus", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "sharesItemType" }, "nvta_StockIssuedDuringPeriodSharesInConnectionWithPrivatePlacementNetOfOfferingCosts": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock issued during period shares in connection with private placement, net of offering costs.", "label": "Stock Issued During Period Shares In Connection With Private Placement Net Of Offering Costs", "terseLabel": "Common and convertible preferred stock issued in private placement, net of offering costs (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesInConnectionWithPrivatePlacementNetOfOfferingCosts", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "sharesItemType" }, "nvta_StockIssuedDuringPeriodSharesVestingOfCommonStockRelatedToEarlyExerciseOfOptions": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of share options exercised during the current period due to vesting of common stock related to early exercise of options.", "label": "Stock Issued During Period Shares Vesting Of Common Stock Related To Early Exercise Of Options", "terseLabel": "Vesting of common stock related to early exercise of options (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesVestingOfCommonStockRelatedToEarlyExerciseOfOptions", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "sharesItemType" }, "nvta_StockIssuedDuringPeriodSharesWarrantsExercised": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock issued during period shares warrants exercised.", "label": "Stock Issued During Period Shares Warrants Exercised", "terseLabel": "Common stock issued pursuant to exercises of warrants (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesWarrantsExercised", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "sharesItemType" }, "nvta_StockIssuedDuringPeriodValueInConnectionWithPrivatePlacementNetOfOfferingCosts": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Stock issued during period value in connection with private placement, net of offering costs.", "label": "Stock Issued During Period Value In Connection With Private Placement Net Of Offering Costs", "terseLabel": "Common and convertible preferred stock issued in private placement, net of offering costs" } } }, "localname": "StockIssuedDuringPeriodValueInConnectionWithPrivatePlacementNetOfOfferingCosts", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "nvta_StockIssuedDuringPeriodValueVestingOfCommonStockRelatedToEarlyExerciseOfOptions": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of stock issued as a result of the vesting of common stock related to early exercise of stock options.", "label": "Stock Issued During Period Value Vesting Of Common Stock Related To Early Exercise Of Options", "terseLabel": "Vesting of common stock related to early exercise of options" } } }, "localname": "StockIssuedDuringPeriodValueVestingOfCommonStockRelatedToEarlyExerciseOfOptions", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "nvta_StockIssuedDuringPeriodValueWarrantsExercised": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Stock issued during period value warrants exercised.", "label": "Stock Issued During Period Value Warrants Exercised", "terseLabel": "Common stock issued pursuant to exercises of warrants" } } }, "localname": "StockIssuedDuringPeriodValueWarrantsExercised", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "nvta_StockPayableLiabilitiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock payable liabilities.", "label": "Stock Payable Liabilities [Member]", "terseLabel": "Stock Payable Liabilities" } } }, "localname": "StockPayableLiabilitiesMember", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/StockholdersEquityScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetails" ], "xbrltype": "domainItemType" }, "nvta_SummaryOfSignificantAccountingPoliciesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Summary of significant accounting policies.", "label": "Summary Of Significant Accounting Policies [Line Items]", "terseLabel": "Summary Of Significant Accounting Policies [Line Items]" } } }, "localname": "SummaryOfSignificantAccountingPoliciesLineItems", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "nvta_SummaryOfSignificantAccountingPoliciesTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Summary of significant accounting policies.", "label": "Summary Of Significant Accounting Policies [Table]", "terseLabel": "Summary Of Significant Accounting Policies [Table]" } } }, "localname": "SummaryOfSignificantAccountingPoliciesTable", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "nvta_TaxCutsAndJobsActOf2017ChangeInDeferredTaxPercentage": { "auth_ref": [], "calculation": { "http://www.invitae.com/role/IncomeTaxesScheduleOfReconciliationOfTaxExpenseComputedAtStatutoryFederalRateAndCompanysTaxExpenseDetails": { "order": 9.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Tax cuts and jobs act of 2017, change in deferred tax percentage.", "label": "Tax Cuts And Jobs Act Of2017 Change In Deferred Tax Percentage", "terseLabel": "Change in deferred\u2014Tax Reform" } } }, "localname": "TaxCutsAndJobsActOf2017ChangeInDeferredTaxPercentage", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/IncomeTaxesScheduleOfReconciliationOfTaxExpenseComputedAtStatutoryFederalRateAndCompanysTaxExpenseDetails" ], "xbrltype": "percentItemType" }, "nvta_TaxCutsAndJobsActOf2017ChangeInValuationAllowance": { "auth_ref": [], "calculation": { "http://www.invitae.com/role/IncomeTaxesScheduleOfReconciliationOfTaxExpenseComputedAtStatutoryFederalRateAndCompanysTaxExpenseDetails": { "order": 10.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Tax cuts and jobs act of 2017, change in valuation allowance.", "label": "Tax Cuts And Jobs Act Of2017 Change In Valuation Allowance", "terseLabel": "Change in valuation allowance\u2014Tax Reform" } } }, "localname": "TaxCutsAndJobsActOf2017ChangeInValuationAllowance", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/IncomeTaxesScheduleOfReconciliationOfTaxExpenseComputedAtStatutoryFederalRateAndCompanysTaxExpenseDetails" ], "xbrltype": "percentItemType" }, "nvta_TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateProvisionalIncomeTaxExpenseBenefit": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Tax cuts and jobs act of 2017, incomplete accounting, change in tax rate, provisional income tax expense (benefit).", "label": "Tax Cuts And Jobs Act Of2017 Incomplete Accounting Change In Tax Rate Provisional Income Tax Expense Benefit", "terseLabel": "Provisional amount related to the remeasurement of certain deferred tax assets and liabilities" } } }, "localname": "TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateProvisionalIncomeTaxExpenseBenefit", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "nvta_ThirdAnniversaryOfGrantDateMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the information pertaining to third anniversary of grant date.", "label": "Third Anniversary Of Grant Date [Member]", "terseLabel": "Third anniversary" } } }, "localname": "ThirdAnniversaryOfGrantDateMember", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/StockIncentivePlansNarrativeDetails" ], "xbrltype": "domainItemType" }, "nvta_ThirdTermLoanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Third term loan.", "label": "Third Term Loan [Member]", "terseLabel": "Third Term Loan" } } }, "localname": "ThirdTermLoanMember", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesDebtFinancingNarrativeDetails" ], "xbrltype": "domainItemType" }, "nvta_TrailingAverageShareValue": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trailing average share value.", "label": "Trailing Average Share Value", "terseLabel": "Trailing average share value (in dollars per share)" } } }, "localname": "TrailingAverageShareValue", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsNarrativeDetails" ], "xbrltype": "perShareItemType" }, "nvta_TrancheOneMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tranche one.", "label": "Tranche One [Member]", "terseLabel": "Initial sale of notes" } } }, "localname": "TrancheOneMember", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesDebtFinancingNarrativeDetails" ], "xbrltype": "domainItemType" }, "nvta_UnderwrittenPublicOfferingMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Underwritten public offering.", "label": "Underwritten Public Offering [Member]", "terseLabel": "Underwritten public offering" } } }, "localname": "UnderwrittenPublicOfferingMember", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "nvta_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Unrecognized tax benefits increases decreases resulting from prior period tax positions.", "label": "Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions", "terseLabel": "Gross increases (decreases)\u2014prior period tax positions" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/IncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "nvta_WarrantsIssuedToAcquireSharesPercentageOfFundedAmount": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Warrants issued to acquire shares percentage of funded amount.", "label": "Warrants Issued To Acquire Shares Percentage Of Funded Amount", "terseLabel": "Warrants issued to acquire shares, percentage of funded amount" } } }, "localname": "WarrantsIssuedToAcquireSharesPercentageOfFundedAmount", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesDebtFinancingNarrativeDetails" ], "xbrltype": "percentItemType" }, "nvta_WarrantsIssuedToLenderUnderLoanAndSecurityAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Warrants issued to lender under loan and security agreement.", "label": "Warrants Issued To Lender Under Loan And Security Agreement [Member]", "terseLabel": "Warrants issued to lender under Loan and Security Agreement" } } }, "localname": "WarrantsIssuedToLenderUnderLoanAndSecurityAgreementMember", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/StockholdersEquityScheduleOfOutstandingWarrantsToPurchaseCommonStockDetails" ], "xbrltype": "domainItemType" }, "nvta_WarrantsIssuedToPurchaseCommonStock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Warrants issued to purchase common stock.", "label": "Warrants Issued To Purchase Common Stock", "terseLabel": "Warrants issued to purchase shares of common stock (in shares)" } } }, "localname": "WarrantsIssuedToPurchaseCommonStock", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesDebtFinancingNarrativeDetails" ], "xbrltype": "sharesItemType" }, "nvta_WarrantsTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Warrants term.", "label": "Warrants Term", "terseLabel": "Warrants term" } } }, "localname": "WarrantsTerm", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesDebtFinancingNarrativeDetails" ], "xbrltype": "durationItemType" }, "nvta_WarrantsissuedtolenderunderLoanandSecurityAgreement2018AmendmentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Warrants issued to lender under Loan and Security Agreement - 2018 Amendments [Member]", "label": "Warrants issued to lender under Loan and Security Agreement - 2018 Amendments [Member]", "terseLabel": "Warrants issued to lender under Loan and Security Agreement - 2018 Amendments" } } }, "localname": "WarrantsissuedtolenderunderLoanandSecurityAgreement2018AmendmentsMember", "nsuri": "http://www.invitae.com/20181231", "presentation": [ "http://www.invitae.com/role/StockholdersEquityScheduleOfOutstandingWarrantsToPurchaseCommonStockDetails" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r150", "r227", "r232" ], "lang": { "en-US": { "role": { "label": "Customer [Axis]", "terseLabel": "Customer" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.invitae.com/role/RevenueAccountsReceivableAndDeferredRevenueScheduleOfDisaggregatedRevenueByPayerCategoryDetails", "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails", "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfSignificantCustomersRevenueAsPercentageDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsNarrativeDetails", "http://www.invitae.com/role/CommitmentsAndContingenciesDebtFinancingNarrativeDetails", "http://www.invitae.com/role/FairValueMeasurementsNarrativeDetails", "http://www.invitae.com/role/GoodwillAndIntangibleAssetsNarrativeDetails", "http://www.invitae.com/role/RevenueAccountsReceivableAndDeferredRevenueNarrativeDetails", "http://www.invitae.com/role/StockIncentivePlansNarrativeDetails", "http://www.invitae.com/role/StockIncentivePlansScheduleOfAssumptionsUsedInDeterminationOfFairValueOfOptionsDetails", "http://www.invitae.com/role/StockholdersEquityNarrativeDetails", "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesDebtFinancingNarrativeDetails", "http://www.invitae.com/role/FairValueMeasurementsNarrativeDetails", "http://www.invitae.com/role/GoodwillAndIntangibleAssetsNarrativeDetails", "http://www.invitae.com/role/StockIncentivePlansNarrativeDetails", "http://www.invitae.com/role/StockIncentivePlansScheduleOfAssumptionsUsedInDeterminationOfFairValueOfOptionsDetails", "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Customer [Domain]", "terseLabel": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.invitae.com/role/RevenueAccountsReceivableAndDeferredRevenueScheduleOfDisaggregatedRevenueByPayerCategoryDetails", "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails", "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfSignificantCustomersRevenueAsPercentageDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r147", "r227", "r230", "r452" ], "lang": { "en-US": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfOperations", "http://www.invitae.com/role/RevenueAccountsReceivableAndDeferredRevenueNarrativeDetails", "http://www.invitae.com/role/RevenueAccountsReceivableAndDeferredRevenueScheduleOfDisaggregatedRevenueByPayerCategoryDetails", "http://www.invitae.com/role/RevenueAccountsReceivableAndDeferredRevenueScheduleOfImpactOfAdoptionOfTopic606OnCondensedStatementOfOperationsAndBalanceSheetDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfOperations", "http://www.invitae.com/role/RevenueAccountsReceivableAndDeferredRevenueNarrativeDetails", "http://www.invitae.com/role/RevenueAccountsReceivableAndDeferredRevenueScheduleOfDisaggregatedRevenueByPayerCategoryDetails", "http://www.invitae.com/role/RevenueAccountsReceivableAndDeferredRevenueScheduleOfImpactOfAdoptionOfTopic606OnCondensedStatementOfOperationsAndBalanceSheetDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Range [Axis]", "terseLabel": "Range" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsNarrativeDetails", "http://www.invitae.com/role/CommitmentsAndContingenciesDebtFinancingNarrativeDetails", "http://www.invitae.com/role/FairValueMeasurementsNarrativeDetails", "http://www.invitae.com/role/GoodwillAndIntangibleAssetsNarrativeDetails", "http://www.invitae.com/role/RevenueAccountsReceivableAndDeferredRevenueNarrativeDetails", "http://www.invitae.com/role/StockIncentivePlansNarrativeDetails", "http://www.invitae.com/role/StockIncentivePlansScheduleOfAssumptionsUsedInDeterminationOfFairValueOfOptionsDetails", "http://www.invitae.com/role/StockholdersEquityNarrativeDetails", "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Range [Domain]", "terseLabel": "Range" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsNarrativeDetails", "http://www.invitae.com/role/CommitmentsAndContingenciesDebtFinancingNarrativeDetails", "http://www.invitae.com/role/FairValueMeasurementsNarrativeDetails", "http://www.invitae.com/role/GoodwillAndIntangibleAssetsNarrativeDetails", "http://www.invitae.com/role/RevenueAccountsReceivableAndDeferredRevenueNarrativeDetails", "http://www.invitae.com/role/StockIncentivePlansNarrativeDetails", "http://www.invitae.com/role/StockIncentivePlansScheduleOfAssumptionsUsedInDeterminationOfFairValueOfOptionsDetails", "http://www.invitae.com/role/StockholdersEquityNarrativeDetails", "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.invitae.com/role/GeographicInformationScheduleOfRevenueByCountryDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r149", "r227", "r231", "r455", "r457" ], "lang": { "en-US": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.invitae.com/role/GeographicInformationScheduleOfRevenueByCountryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate201409Member": { "auth_ref": [ "r234" ], "lang": { "en-US": { "role": { "documentation": "Accounting Standards Update 2014-09 Revenue from Contracts with Customers (Topic 606).", "label": "Accounting Standards Update 2014-09 [Member]", "terseLabel": "Topic 606" } } }, "localname": "AccountingStandardsUpdate201409Member", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/RevenueAccountsReceivableAndDeferredRevenueNarrativeDetails", "http://www.invitae.com/role/RevenueAccountsReceivableAndDeferredRevenueScheduleOfImpactOfAdoptionOfTopic606OnCondensedStatementOfOperationsAndBalanceSheetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r35" ], "calculation": { "http://www.invitae.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]", "terseLabel": "Accounts receivable" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r20", "r228" ], "calculation": { "http://www.invitae.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.", "label": "Accounts Receivable, Net, Current", "terseLabel": "Accounts receivable" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedBalanceSheets", "http://www.invitae.com/role/RevenueAccountsReceivableAndDeferredRevenueScheduleOfImpactOfAdoptionOfTopic606OnCondensedStatementOfOperationsAndBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r38" ], "calculation": { "http://www.invitae.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.invitae.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued liabilities", "totalLabel": "Total accrued liabilities" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails", "http://www.invitae.com/role/CommitmentsAndContingenciesOtherCommitmentsNarrativeDetails", "http://www.invitae.com/role/ConsolidatedBalanceSheets", "http://www.invitae.com/role/FairValueMeasurementsFinancialInstrumentsAtFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r32", "r189" ], "calculation": { "http://www.invitae.com/role/BalanceSheetComponentsPropertyAndEquipmentDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Accumulated depreciation and amortization" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BalanceSheetComponentsPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r56", "r57", "r58" ], "calculation": { "http://www.invitae.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r55", "r58", "r59", "r345" ], "lang": { "en-US": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r21" ], "calculation": { "http://www.invitae.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForChangeInAccountingPrincipleAxis": { "auth_ref": [ "r120" ], "lang": { "en-US": { "role": { "documentation": "Information by type of change in accounting principle. Does not include error corrections.", "label": "Adjustments for Change in Accounting Principle [Axis]", "terseLabel": "Adjustments for Change in Accounting Principle [Axis]" } } }, "localname": "AdjustmentsForChangeInAccountingPrincipleAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/RevenueAccountsReceivableAndDeferredRevenueNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r120" ], "lang": { "en-US": { "role": { "documentation": "Information by new accounting pronouncement.", "label": "Adjustments for New Accounting Pronouncements [Axis]", "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/RevenueAccountsReceivableAndDeferredRevenueNarrativeDetails", "http://www.invitae.com/role/RevenueAccountsReceivableAndDeferredRevenueScheduleOfImpactOfAdoptionOfTopic606OnCondensedStatementOfOperationsAndBalanceSheetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r240", "r242", "r277", "r278" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.", "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts": { "auth_ref": [ "r201" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in additional paid in capital (APIC) resulting from issuance costs from a share-lending arrangement entered into, in contemplation of a convertible debt offering or other financing.", "label": "Adjustments to Additional Paid in Capital, Stock Issued, Own-share Lending Arrangement, Issuance Costs", "terseLabel": "Warrants issued pursuant to the 2017 Loan Agreement" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "auth_ref": [ "r104", "r163", "r164" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for advertising costs. For those costs that cannot be capitalized, discloses whether such costs are expensed as incurred or the first period in which the advertising takes place. For direct response advertising costs that are capitalized, describes those assets and the accounting policy used, including a description of the qualifying activity, the types of costs capitalized and the related amortization period. An entity also may disclose its accounting policy for cooperative advertising arrangements.", "label": "Advertising Costs, Policy [Policy Text Block]", "terseLabel": "Advertising" } } }, "localname": "AdvertisingCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_AdvertisingExpense": { "auth_ref": [ "r280" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.", "label": "Advertising Expense", "terseLabel": "Advertising expense" } } }, "localname": "AdvertisingExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r242", "r270", "r276" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.", "label": "Allocated Share-based Compensation Expense", "terseLabel": "Total stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockIncentivePlansStockBasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r94", "r174", "r180" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization expense" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/GoodwillAndIntangibleAssetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r124" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "verboseLabel": "Antidilutive securities excluded from computation of earnings per share (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/NetLossPerCommonShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r124" ], "lang": { "en-US": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/NetLossPerCommonShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r124" ], "lang": { "en-US": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/NetLossPerCommonShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This item is to be populated with the collective of (i) types (categories) of arrangements of the entity applicable to its revenue-generating activities or operations and non-arrangement transactions, including but not limited to, for instance, sales of product manufactured by the entity, if such comparison of arrangements as a component of all transactions is provided by the entity.", "label": "Arrangements and Non-arrangement Transactions [Domain]", "terseLabel": "Arrangements and Non-arrangement Transactions" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesOperatingLeasesNarrativeDetails", "http://www.invitae.com/role/CommitmentsAndContingenciesOtherCommitmentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AssetImpairmentCharges": { "auth_ref": [ "r94", "r186" ], "calculation": { "http://www.invitae.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.", "label": "Asset Impairment Charges", "terseLabel": "Impairment losses" } } }, "localname": "AssetImpairmentCharges", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfCashFlows", "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r146", "r422", "r441" ], "calculation": { "http://www.invitae.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r2", "r3", "r52" ], "calculation": { "http://www.invitae.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r353" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "terseLabel": "Total financial assets" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/FairValueMeasurementsFinancialInstrumentsAtFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsHeldUnderCapitalLeasesMember": { "auth_ref": [ "r393" ], "lang": { "en-US": { "role": { "documentation": "Long lived property, plant or equipment assets held by a lessee through a capital lease arrangement.", "label": "Assets Held under Capital Leases [Member]", "terseLabel": "Equipment under capital lease" } } }, "localname": "AssetsHeldUnderCapitalLeasesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BalanceSheetComponentsPropertyAndEquipmentDetails", "http://www.invitae.com/role/CommitmentsAndContingenciesCapitalLeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AutomobilesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Vehicles that are used primarily for transporting people.", "label": "Automobiles [Member]", "terseLabel": "Automobiles" } } }, "localname": "AutomobilesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BalanceSheetComponentsPropertyAndEquipmentDetails", "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfUsefulLivesOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This item represents the aggregate fair value of investments in debt and equity securities categorized neither as held-to-maturity nor trading securities that have been in a continuous unrealized loss position for less than twelve months.", "label": "Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value", "terseLabel": "Total fair value of investments with unrealized losses" } } }, "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r156", "r159" ], "calculation": { "http://www.invitae.com/role/FairValueMeasurementsFinancialInstrumentsAtFairValueOnRecurringBasisDetails": { "order": 3.0, "parentTag": "nvta_CashEquivalentsRestrictedCashAndMarketableSecuritiesFairValue", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale", "terseLabel": "Marketable securities" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/FairValueMeasurementsFinancialInstrumentsAtFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "auth_ref": [ "r158" ], "calculation": { "http://www.invitae.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.", "label": "Debt Securities, Available-for-sale, Current", "terseLabel": "Marketable securities" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": { "auth_ref": [ "r158" ], "calculation": { "http://www.invitae.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in net income (available-for-sale), classified as noncurrent.", "label": "Debt Securities, Available-for-sale, Noncurrent", "terseLabel": "Marketable securities, non-current" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "This item represents the difference between the gross realized gains and losses realized on the sale of debt or equity securities categorized neither as held-to-maturity nor trading securities. Additionally, this item would include any losses recognized for other than temporary impairments (OTTI) of the subject investments in debt and equity securities.", "label": "Available-for-sale Securities, Gross Realized Gain (Loss)", "terseLabel": "Available-for-sale securities gross realized gain (loss)" } } }, "localname": "AvailableForSaleSecuritiesGrossRealizedGainLossNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r243", "r274" ], "lang": { "en-US": { "role": { "documentation": "Information by award type pertaining to equity-based compensation.", "label": "Award Type [Axis]", "terseLabel": "Award Type" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsNarrativeDetails", "http://www.invitae.com/role/StockIncentivePlansNarrativeDetails", "http://www.invitae.com/role/StockIncentivePlansScheduleOfActivityUnderStockIncentivePlansDetails", "http://www.invitae.com/role/StockIncentivePlansScheduleOfAssumptionsUsedInDeterminationOfFairValueOfOptionsDetails", "http://www.invitae.com/role/StockIncentivePlansStockBasedCompensationExpenseDetails", "http://www.invitae.com/role/StockIncentivePlansSummaryOfRsuActivityDetails", "http://www.invitae.com/role/StockIncentivePlansTables", "http://www.invitae.com/role/StockholdersEquityScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetRelatedDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Balance Sheet Related Disclosures [Abstract]" } } }, "localname": "BalanceSheetRelatedDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsNarrativeDetails", "http://www.invitae.com/role/BusinessCombinationsScheduleOfEconomicBenefitsOfIntangibleAssetsExpectedToBeRealizedDetails", "http://www.invitae.com/role/BusinessCombinationsSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetails", "http://www.invitae.com/role/BusinessCombinationsTables", "http://www.invitae.com/role/FairValueMeasurementsLevel3FinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails", "http://www.invitae.com/role/FairValueMeasurementsNarrativeDetails", "http://www.invitae.com/role/GoodwillAndIntangibleAssetsNarrativeDetails", "http://www.invitae.com/role/GoodwillAndIntangibleAssetsSummaryOfGoodwillDetails", "http://www.invitae.com/role/StockholdersEquityNarrativeDetails", "http://www.invitae.com/role/StockholdersEquityScheduleOfOutstandingWarrantsToPurchaseCommonStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r321", "r322" ], "lang": { "en-US": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsNarrativeDetails", "http://www.invitae.com/role/BusinessCombinationsScheduleOfEconomicBenefitsOfIntangibleAssetsExpectedToBeRealizedDetails", "http://www.invitae.com/role/BusinessCombinationsSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetails", "http://www.invitae.com/role/BusinessCombinationsTables", "http://www.invitae.com/role/FairValueMeasurementsLevel3FinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails", "http://www.invitae.com/role/FairValueMeasurementsNarrativeDetails", "http://www.invitae.com/role/GoodwillAndIntangibleAssetsNarrativeDetails", "http://www.invitae.com/role/GoodwillAndIntangibleAssetsSummaryOfGoodwillDetails", "http://www.invitae.com/role/StockholdersEquityNarrativeDetails", "http://www.invitae.com/role/StockholdersEquityScheduleOfOutstandingWarrantsToPurchaseCommonStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.", "label": "Business Acquisition, Transaction Costs", "terseLabel": "Right of refusal fees related to acquisition agreement" } } }, "localname": "BusinessAcquisitionCostOfAcquiredEntityTransactionCosts", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesOtherCommitmentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned": { "auth_ref": [ "r338" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of equity interests (such as common shares, preferred shares, or partnership interest) issued or issuable to acquire the entity.", "label": "Business Acquisition, Equity Interest Issued or Issuable, Value Assigned", "terseLabel": "Common stock issued, value" } } }, "localname": "BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsNarrativeDetails", "http://www.invitae.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": { "auth_ref": [ "r338" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of equity interests issued or issuable to acquire entity.", "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares", "terseLabel": "Common stock issued (in shares)" } } }, "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsNarrativeDetails", "http://www.invitae.com/role/BusinessCombinationsScheduleOfEconomicBenefitsOfIntangibleAssetsExpectedToBeRealizedDetails", "http://www.invitae.com/role/BusinessCombinationsSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetails", "http://www.invitae.com/role/BusinessCombinationsTables" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "auth_ref": [ "r320" ], "lang": { "en-US": { "role": { "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.", "label": "Business Acquisition, Percentage of Voting Interests Acquired", "terseLabel": "Percentage of diluted interest acquired" } } }, "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r332", "r333", "r335" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "terseLabel": "Total purchase consideration" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": { "auth_ref": [ "r332", "r333" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.", "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable", "terseLabel": "Payment through issuance of shares company's common stock" } } }, "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": { "auth_ref": [ "r330", "r332", "r333", "r337" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.", "label": "Business Combination, Consideration Transferred, Liabilities Incurred", "terseLabel": "Purchase consideration, second payment discounted and recorded as liability" } } }, "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "auth_ref": [ "r93", "r340" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "terseLabel": "Change in fair value of contingent consideration", "verboseLabel": "Increase in fair value of contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsNarrativeDetails", "http://www.invitae.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r331", "r334", "r339" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "Business Combination, Contingent Consideration, Liability", "terseLabel": "Contingently payable amount" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsNarrativeDetails", "http://www.invitae.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r341" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]", "terseLabel": "Business combinations" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BusinessCombinations" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": { "auth_ref": [ "r324" ], "calculation": { "http://www.invitae.com/role/BusinessCombinationsSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of assets acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets", "totalLabel": "Total identifiable assets acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "auth_ref": [ "r324" ], "calculation": { "http://www.invitae.com/role/BusinessCombinationsSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents", "terseLabel": "Cash" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": { "auth_ref": [ "r324" ], "calculation": { "http://www.invitae.com/role/BusinessCombinationsSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets", "terseLabel": "Prepaid expense and other assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": { "auth_ref": [ "r324" ], "calculation": { "http://www.invitae.com/role/BusinessCombinationsSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables", "terseLabel": "Accounts receivable" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": { "auth_ref": [ "r324" ], "calculation": { "http://www.invitae.com/role/BusinessCombinationsSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable", "negatedLabel": "Accounts payable" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue": { "auth_ref": [ "r324" ], "calculation": { "http://www.invitae.com/role/BusinessCombinationsSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 4.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred revenue expected to be recognized as such within one year or the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue", "negatedLabel": "Deferred revenue" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": { "auth_ref": [ "r288", "r324" ], "calculation": { "http://www.invitae.com/role/BusinessCombinationsSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities", "negatedLabel": "Deferred tax liability", "terseLabel": "Deferred tax liability" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsNarrativeDetails", "http://www.invitae.com/role/BusinessCombinationsSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "auth_ref": [ "r323", "r324" ], "calculation": { "http://www.invitae.com/role/BusinessCombinationsSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 4.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles", "terseLabel": "Intangible Assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": { "auth_ref": [ "r324" ], "calculation": { "http://www.invitae.com/role/BusinessCombinationsSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities", "negatedTotalLabel": "Total liabilities assumed" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "auth_ref": [ "r323", "r324" ], "calculation": { "http://www.invitae.com/role/BusinessCombinationsSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net", "totalLabel": "Net identifiable assets acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther": { "auth_ref": [ "r324" ], "calculation": { "http://www.invitae.com/role/BusinessCombinationsSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 7.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other", "negatedLabel": "Other liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": { "auth_ref": [ "r324" ], "calculation": { "http://www.invitae.com/role/BusinessCombinationsSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 7.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets", "terseLabel": "Other assets - non current" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "auth_ref": [ "r323", "r324" ], "calculation": { "http://www.invitae.com/role/BusinessCombinationsSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 6.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment", "terseLabel": "Property and equipment" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": { "auth_ref": [ "r324" ], "calculation": { "http://www.invitae.com/role/BusinessCombinationsSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net", "totalLabel": "Net assets acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementLoss": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "In a business combination achieved in stages, this element represents the amount of loss recognized by the entity as a result of remeasuring to fair value the equity interest in the acquiree it held before the business combination.", "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Loss", "terseLabel": "Change in estimate of fair value" } } }, "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementLoss", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsNarrativeDetails", "http://www.invitae.com/role/FairValueMeasurementsLevel3FinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Business Combinations [Abstract]" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationsPolicy": { "auth_ref": [ "r104", "r318" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.", "label": "Business Combinations Policy [Policy Text Block]", "terseLabel": "Business combinations" } } }, "localname": "BusinessCombinationsPolicy", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member": { "auth_ref": [ "r233" ], "lang": { "en-US": { "role": { "documentation": "Calculated under guidance for revenue recognition in effect prior to change to new guidance for revenue from contract with customer when using transition method for cumulative effect in period including initial date of application.", "label": "Calculated under Revenue Guidance in Effect before Topic 606 [Member]", "terseLabel": "Without adoption of topic 606" } } }, "localname": "CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/RevenueAccountsReceivableAndDeferredRevenueScheduleOfImpactOfAdoptionOfTopic606OnCondensedStatementOfOperationsAndBalanceSheetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CaliforniaFranchiseTaxBoardMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Designated tax department of the government of the state of California.", "label": "California Franchise Tax Board [Member]", "terseLabel": "California" } } }, "localname": "CaliforniaFranchiseTaxBoardMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CapitalLeaseObligationsCurrent": { "auth_ref": [ "r12", "r391", "r394" ], "calculation": { "http://www.invitae.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderCapitalLeasesDetailsCalc2": { "order": 1.0, "parentTag": "us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments", "weight": 1.0 }, "http://www.invitae.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of capital lease obligation due within one year or the normal operating cycle, if longer.", "label": "Capital Lease Obligations, Current", "negatedLabel": "Less: current portion", "terseLabel": "Capital lease obligation, current portion" } } }, "localname": "CapitalLeaseObligationsCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderCapitalLeasesDetails", "http://www.invitae.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalLeaseObligationsIncurred": { "auth_ref": [ "r99", "r100" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase during the period in capital lease obligations due to entering into new capital leases.", "label": "Capital Lease Obligations Incurred", "terseLabel": "Equipment acquired through capital leases" } } }, "localname": "CapitalLeaseObligationsIncurred", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalLeaseObligationsNoncurrent": { "auth_ref": [ "r41", "r391", "r394" ], "calculation": { "http://www.invitae.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderCapitalLeasesDetailsCalc2": { "order": 2.0, "parentTag": "us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments", "weight": 1.0 }, "http://www.invitae.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal, through the balance sheet date and due to be paid more than one year (or one operating cycle, if longer) after the balance sheet date.", "label": "Capital Lease Obligations, Noncurrent", "terseLabel": "Capital lease obligation, net of current portion", "verboseLabel": "Total non-current capital lease obligations" } } }, "localname": "CapitalLeaseObligationsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderCapitalLeasesDetails", "http://www.invitae.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalLeasedAssetsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Capital Leased Assets [Line Items]", "terseLabel": "Capital Leased Assets [Line Items]" } } }, "localname": "CapitalLeasedAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesCapitalLeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CapitalLeasesFutureMinimumPaymentsDue": { "auth_ref": [ "r394" ], "calculation": { "http://www.invitae.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderCapitalLeasesDetails": { "order": 1.0, "parentTag": "us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of minimum lease payments for capital leases.", "label": "Capital Leases, Future Minimum Payments Due", "terseLabel": "Future undiscounted capital lease payments", "totalLabel": "Total capital lease obligations" } } }, "localname": "CapitalLeasesFutureMinimumPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderCapitalLeasesDetails", "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent": { "auth_ref": [ "r394" ], "calculation": { "http://www.invitae.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderCapitalLeasesDetails": { "order": 1.0, "parentTag": "us-gaap_CapitalLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of minimum lease payments for capital leases due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Capital Leases, Future Minimum Payments Due, Next Twelve Months", "terseLabel": "2019" } } }, "localname": "CapitalLeasesFutureMinimumPaymentsDueCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderCapitalLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears": { "auth_ref": [ "r394" ], "calculation": { "http://www.invitae.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderCapitalLeasesDetails": { "order": 3.0, "parentTag": "us-gaap_CapitalLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of minimum lease payments for capital leases due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Capital Leases, Future Minimum Payments Due in Three Years", "terseLabel": "2021" } } }, "localname": "CapitalLeasesFutureMinimumPaymentsDueInThreeYears", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderCapitalLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears": { "auth_ref": [ "r394" ], "calculation": { "http://www.invitae.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderCapitalLeasesDetails": { "order": 2.0, "parentTag": "us-gaap_CapitalLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of minimum lease payments for capital leases due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Capital Leases, Future Minimum Payments Due in Two Years", "terseLabel": "2020" } } }, "localname": "CapitalLeasesFutureMinimumPaymentsDueInTwoYears", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderCapitalLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments": { "auth_ref": [ "r394" ], "calculation": { "http://www.invitae.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderCapitalLeasesDetails": { "order": 2.0, "parentTag": "us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount necessary to reduce net minimum lease payments to present value for capital leases.", "label": "Capital Leases, Future Minimum Payments, Interest Included in Payments", "negatedLabel": "Less: amount representing interest" } } }, "localname": "CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderCapitalLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments": { "auth_ref": [ "r394" ], "calculation": { "http://www.invitae.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderCapitalLeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.invitae.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderCapitalLeasesDetailsCalc2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of minimum lease payments for capital leases net of executory costs, including amounts paid by the lessee to the lessor for insurance, maintenance and taxes.", "label": "Capital Leases, Future Minimum Payments, Present Value of Net Minimum Payments", "totalLabel": "Present value of net minimum capital lease payments" } } }, "localname": "CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderCapitalLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPaymentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Capital Leases, Future Minimum Payments, Present Value of Net Minimum Payments, Fiscal Year Maturity [Abstract]", "terseLabel": "Future payments under the capital lease" } } }, "localname": "CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderCapitalLeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CapitalLeasesIncomeStatementInterestExpense": { "auth_ref": [ "r392" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The financing charge for leasing arrangements meeting the criteria for capitalization.", "label": "Capital Leases, Income Statement, Interest Expense", "terseLabel": "Interest expense" } } }, "localname": "CapitalLeasesIncomeStatementInterestExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesCapitalLeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation": { "auth_ref": [ "r381", "r390" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The total charge for the use of long-lived depreciable assets subject to a lease meeting the criteria for capitalization.", "label": "Capital Leases, Lessee Balance Sheet, Assets by Major Class, Accumulated Depreciation", "terseLabel": "Accumulated depreciation and amortization" } } }, "localname": "CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesCapitalLeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "auth_ref": [ "r366", "r367" ], "lang": { "en-US": { "role": { "documentation": "Measured as reported on the statement of financial position (balance sheet).", "label": "Reported Value Measurement [Member]", "terseLabel": "Carrying Amount" } } }, "localname": "CarryingReportedAmountFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/FairValueMeasurementsCarryingAmountAndEstimatedFairValueOfCompanysOutstandingDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashAcquiredFromAcquisition": { "auth_ref": [ "r78" ], "calculation": { "http://www.invitae.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).", "label": "Cash Acquired from Acquisition", "terseLabel": "Acquisition of businesses, acquired cash" } } }, "localname": "CashAcquiredFromAcquisition", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r0", "r29", "r96" ], "calculation": { "http://www.invitae.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedBalanceSheets", "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "auth_ref": [ "r8", "r97", "r104", "r152", "r421" ], "lang": { "en-US": { "role": { "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.", "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash, cash equivalents, and restricted cash" } } }, "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r90", "r96", "r102" ], "calculation": { "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period", "totalLabel": "Total cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfCashFlows", "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r90", "r374" ], "calculation": { "http://www.invitae.com/role/ConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsAtCarryingValue": { "auth_ref": [ "r29" ], "calculation": { "http://www.invitae.com/role/FairValueMeasurementsFinancialInstrumentsAtFairValueOnRecurringBasisDetails": { "order": 1.0, "parentTag": "nvta_CashEquivalentsRestrictedCashAndMarketableSecuritiesFairValue", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash Equivalents, at Carrying Value", "terseLabel": "Cash equivalents" } } }, "localname": "CashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/FairValueMeasurementsFinancialInstrumentsAtFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "terseLabel": "Supplemental cash flow information of non-cash investing and financing activities:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_CertificatesOfDepositMember": { "auth_ref": [ "r434" ], "lang": { "en-US": { "role": { "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.", "label": "Certificates of Deposit [Member]", "terseLabel": "Certificates of deposit" } } }, "localname": "CertificatesOfDepositMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/FairValueMeasurementsFinancialInstrumentsAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ChangeInAccountingPrincipleMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A change from one generally accepted accounting principle to another generally accepted accounting principle when there are two or more generally accepted accounting principles that apply or when the accounting principle formerly used is no longer generally accepted. A change in the method of applying an accounting principle that is not treated as a change in accounting estimate also is considered a change in accounting principle.", "label": "Adjustments for Change in Accounting Principle [Domain]", "terseLabel": "Adjustments for Change in Accounting Principle [Domain]" } } }, "localname": "ChangeInAccountingPrincipleMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/RevenueAccountsReceivableAndDeferredRevenueNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsNarrativeDetails", "http://www.invitae.com/role/StockholdersEquityNarrativeDetails", "http://www.invitae.com/role/StockholdersEquityScheduleOfOutstandingWarrantsToPurchaseCommonStockDetails", "http://www.invitae.com/role/StockholdersEquityScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Class of Stock [Line Items]", "verboseLabel": "Class of Stock" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockholdersEquityNarrativeDetails", "http://www.invitae.com/role/StockholdersEquityScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r117", "r219", "r220", "r241" ], "lang": { "en-US": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]", "terseLabel": "Class of Warrant or Right" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockholdersEquityScheduleOfOutstandingWarrantsToPurchaseCommonStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [ "r108" ], "lang": { "en-US": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.", "label": "Class of Warrant or Right [Domain]", "terseLabel": "Class of Warrant or Right" } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockholdersEquityScheduleOfOutstandingWarrantsToPurchaseCommonStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r116" ], "lang": { "en-US": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Warrants issued to purchase common stock exercise price (in dollars per share)", "verboseLabel": "Exercise price per share (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesDebtFinancingNarrativeDetails", "http://www.invitae.com/role/StockholdersEquityScheduleOfOutstandingWarrantsToPurchaseCommonStockDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Warrant or Right [Line Items]", "terseLabel": "Class of Warrant or Right [Line Items]" } } }, "localname": "ClassOfWarrantOrRightLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockholdersEquityScheduleOfOutstandingWarrantsToPurchaseCommonStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [ "r117" ], "lang": { "en-US": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Class of Warrant or Right, Outstanding", "terseLabel": "Number of shares of common stock underlying warrants (in shares)" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockholdersEquityScheduleOfOutstandingWarrantsToPurchaseCommonStockDetails", "http://www.invitae.com/role/StockholdersEquityScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightTable": { "auth_ref": [ "r108", "r219", "r220", "r241" ], "lang": { "en-US": { "role": { "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Class of Warrant or Right [Table]", "terseLabel": "Class of Warrant or Right [Table]" } } }, "localname": "ClassOfWarrantOrRightTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockholdersEquityScheduleOfOutstandingWarrantsToPurchaseCommonStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "auth_ref": [ "r343" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.", "label": "Collaborative Arrangement Disclosure [Text Block]", "terseLabel": "Investment in privately held company" } } }, "localname": "CollaborativeArrangementDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/InvestmentInPrivatelyHeldCompanyInvestmentInPrivatelyHeldCompany" ], "xbrltype": "textBlockItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]", "terseLabel": "Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/InvestmentInPrivatelyHeldCompanyDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r198" ], "lang": { "en-US": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial paper" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/FairValueMeasurementsFinancialInstrumentsAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r43", "r196", "r429", "r448" ], "calculation": { "http://www.invitae.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Note 9)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r195", "r197" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r46" ], "lang": { "en-US": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Common stock reserved for future issuance (in shares)", "verboseLabel": "Additional shares reserved (in shares)" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockIncentivePlansNarrativeDetails", "http://www.invitae.com/role/StockholdersEquityScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock", "verboseLabel": "Common stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsNarrativeDetails", "http://www.invitae.com/role/CommitmentsAndContingenciesDebtFinancingNarrativeDetails", "http://www.invitae.com/role/ConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity", "http://www.invitae.com/role/FairValueMeasurementsNarrativeDetails", "http://www.invitae.com/role/StockholdersEquityNarrativeDetails", "http://www.invitae.com/role/StockholdersEquityScheduleOfOutstandingWarrantsToPurchaseCommonStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r19" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesDebtFinancingNarrativeDetails", "http://www.invitae.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r19" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r19" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r19", "r210" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r19" ], "calculation": { "http://www.invitae.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.0001 par value: 400,000 shares authorized; 75,481 and 53,597 shares issued and outstanding as of December 31, 2018 and 2017, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationRelatedCostsPolicyTextBlock": { "auth_ref": [ "r103", "r247" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.", "label": "Compensation Related Costs, Policy [Policy Text Block]", "terseLabel": "Stock-based compensation" } } }, "localname": "CompensationRelatedCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r61", "r63", "r64" ], "calculation": { "http://www.invitae.com/role/ConsolidatedStatementsOfComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for comprehensive income.", "label": "Comprehensive Income, Policy [Policy Text Block]", "terseLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]", "terseLabel": "Computer equipment" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BalanceSheetComponentsPropertyAndEquipmentDetails", "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfUsefulLivesOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r137", "r138", "r368", "r369" ], "lang": { "en-US": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails", "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfSignificantCustomersRevenueAsPercentageDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r137", "r138", "r368", "r369", "r453" ], "lang": { "en-US": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails", "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfSignificantCustomersRevenueAsPercentageDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r137", "r138", "r368", "r369", "r453" ], "lang": { "en-US": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails", "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfSignificantCustomersRevenueAsPercentageDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r133", "r438" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentrations of credit risk and other risks and uncertainties" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r137", "r138", "r368", "r369" ], "lang": { "en-US": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Concentration risk (as a percent)" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails", "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfSignificantCustomersRevenueAsPercentageDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r137", "r138", "r368", "r369" ], "lang": { "en-US": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails", "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfSignificantCustomersRevenueAsPercentageDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r104", "r344", "r349", "r350" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Principles of consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConsolidationVariableInterestEntityPolicy": { "auth_ref": [ "r104", "r346", "r347", "r348" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).", "label": "Consolidation, Variable Interest Entity, Policy [Policy Text Block]", "terseLabel": "Variable interest entity" } } }, "localname": "ConsolidationVariableInterestEntityPolicy", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress [Member]", "terseLabel": "Construction-in-progress" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BalanceSheetComponentsPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContingentConsiderationByTypeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of contingent consideration.", "label": "Contingent Consideration by Type [Axis]", "terseLabel": "Contingent Consideration by Type" } } }, "localname": "ContingentConsiderationByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsNarrativeDetails", "http://www.invitae.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ContingentConsiderationClassifiedAsEquityMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Contingent consideration in a business combination that is classified in shareholders' equity.", "label": "Contingent Consideration Classified as Equity [Member]", "terseLabel": "Payable as Contingent Consideration" } } }, "localname": "ContingentConsiderationClassifiedAsEquityMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockholdersEquityScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContingentConsiderationTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Description of contingent payment arrangement.", "label": "Contingent Consideration Type [Domain]", "terseLabel": "Contingent Consideration Type" } } }, "localname": "ContingentConsiderationTypeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsNarrativeDetails", "http://www.invitae.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r223", "r224", "r228" ], "calculation": { "http://www.invitae.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "terseLabel": "Deferred revenue" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r229" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Contract with Customer, Liability, Revenue Recognized", "terseLabel": "Revenue recognized" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/RevenueAccountsReceivableAndDeferredRevenueNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConversionOfStockByUniqueDescriptionAxis": { "auth_ref": [ "r99", "r100", "r101" ], "lang": { "en-US": { "role": { "documentation": "Information by description of stock conversions.", "label": "Stock Conversion Description [Axis]", "terseLabel": "Stock Conversion Description [Axis]" } } }, "localname": "ConversionOfStockByUniqueDescriptionAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConversionOfStockNameDomain": { "auth_ref": [ "r99", "r100", "r101" ], "lang": { "en-US": { "role": { "documentation": "The unique name of a noncash or part noncash stock conversion.", "label": "Conversion of Stock, Name [Domain]", "terseLabel": "Conversion of Stock, Name [Domain]" } } }, "localname": "ConversionOfStockNameDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConversionOfStockSharesConverted1": { "auth_ref": [ "r99", "r100", "r101" ], "lang": { "en-US": { "role": { "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of Stock, Shares Converted", "terseLabel": "Shares converted (in shares)" } } }, "localname": "ConversionOfStockSharesConverted1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.", "label": "Convertible Preferred Stock [Member]", "terseLabel": "Convertible Preferred Stock" } } }, "localname": "ConvertiblePreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockholdersEquityScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": { "auth_ref": [ "r17", "r18", "r211", "r214" ], "lang": { "en-US": { "role": { "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.", "label": "Convertible Preferred Stock, Shares Issued upon Conversion", "terseLabel": "Shares issued upon conversion (in shares)" } } }, "localname": "ConvertiblePreferredStockSharesIssuedUponConversion", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r72" ], "calculation": { "http://www.invitae.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "Cost of Revenue", "terseLabel": "Cost of revenue" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfOperations", "http://www.invitae.com/role/SelectedQuarterlyDataUnauditedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r71" ], "calculation": { "http://www.invitae.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total costs and operating expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesDebtFinancingNarrativeDetails", "http://www.invitae.com/role/SelectedQuarterlyDataUnauditedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesDebtFinancingNarrativeDetails", "http://www.invitae.com/role/SelectedQuarterlyDataUnauditedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.", "label": "Cumulative Effect of New Accounting Principle in Period of Adoption", "terseLabel": "Cumulative effect of accounting change" } } }, "localname": "CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity", "http://www.invitae.com/role/RevenueAccountsReceivableAndDeferredRevenueNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "auth_ref": [ "r115", "r311" ], "calculation": { "http://www.invitae.com/role/IncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Foreign Tax Expense (Benefit)", "terseLabel": "Foreign" } } }, "localname": "CurrentForeignTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/IncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "auth_ref": [ "r107", "r309", "r314" ], "calculation": { "http://www.invitae.com/role/IncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.", "label": "Current Income Tax Expense (Benefit)", "totalLabel": "Total current benefit for income taxes" } } }, "localname": "CurrentIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/IncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]", "terseLabel": "Current:" } } }, "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/IncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r136" ], "lang": { "en-US": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer concentration risk" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails", "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfSignificantCustomersRevenueAsPercentageDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerRelationshipsMember": { "auth_ref": [ "r328" ], "lang": { "en-US": { "role": { "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "label": "Customer Relationships [Member]", "terseLabel": "Customer relationships" } } }, "localname": "CustomerRelationshipsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsNarrativeDetails", "http://www.invitae.com/role/BusinessCombinationsScheduleOfEconomicBenefitsOfIntangibleAssetsExpectedToBeRealizedDetails", "http://www.invitae.com/role/BusinessCombinationsSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetails", "http://www.invitae.com/role/GoodwillAndIntangibleAssetsNarrativeDetails", "http://www.invitae.com/role/GoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails", "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtConversionConvertedInstrumentAmount1": { "auth_ref": [ "r99", "r101" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt Conversion, Converted Instrument, Amount", "terseLabel": "Warrants issued pursuant to 2017 Loan Agreement" } } }, "localname": "DebtConversionConvertedInstrumentAmount1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r12", "r13", "r14", "r423", "r425", "r440" ], "lang": { "en-US": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesDebtFinancingNarrativeDetails", "http://www.invitae.com/role/SelectedQuarterlyDataUnauditedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Term loans, variable interest rate" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesDebtFinancingNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r14", "r202", "r425", "r440" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-term Debt, Gross", "verboseLabel": "Term loan, borrowing amount" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesDebtFinancingNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFrequencyOfPeriodicPayment": { "auth_ref": [ "r41", "r435" ], "lang": { "en-US": { "role": { "documentation": "Description of the frequency of periodic payments (monthly, quarterly, annual).", "label": "Debt Instrument, Frequency of Periodic Payment", "terseLabel": "Term loans, frequency of periodic payment" } } }, "localname": "DebtInstrumentFrequencyOfPeriodicPayment", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesDebtFinancingNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentInterestRateDuringPeriod": { "auth_ref": [ "r40", "r377" ], "lang": { "en-US": { "role": { "documentation": "The average effective interest rate during the reporting period.", "label": "Debt Instrument, Interest Rate During Period", "terseLabel": "Debt instrument, average effective interest rate" } } }, "localname": "DebtInstrumentInterestRateDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesDebtFinancingNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r40" ], "lang": { "en-US": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Debt instrument, interest rate, stated percentage" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesDebtFinancingNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesDebtFinancingNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r41" ], "lang": { "en-US": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesDebtFinancingNarrativeDetails", "http://www.invitae.com/role/SelectedQuarterlyDataUnauditedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodAxis": { "auth_ref": [ "r436" ], "lang": { "en-US": { "role": { "documentation": "Information about timing of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period [Axis]", "terseLabel": "Debt Instrument, Redemption, Period [Axis]" } } }, "localname": "DebtInstrumentRedemptionPeriodAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesDebtFinancingNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodDomain": { "auth_ref": [ "r436" ], "lang": { "en-US": { "role": { "documentation": "Period as defined under terms of the debt agreement for debt redemption features.", "label": "Debt Instrument, Redemption, Period [Domain]", "terseLabel": "Debt Instrument, Redemption, Period [Domain]" } } }, "localname": "DebtInstrumentRedemptionPeriodDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesDebtFinancingNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodOneMember": { "auth_ref": [ "r436" ], "lang": { "en-US": { "role": { "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period One [Member]", "terseLabel": "Payment made within 12 months after closing date" } } }, "localname": "DebtInstrumentRedemptionPeriodOneMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesDebtFinancingNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodThreeMember": { "auth_ref": [ "r436" ], "lang": { "en-US": { "role": { "documentation": "Period three representing third most current period of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period Three [Member]", "terseLabel": "Payment made within 36 months after closing date" } } }, "localname": "DebtInstrumentRedemptionPeriodThreeMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesDebtFinancingNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": { "auth_ref": [ "r436" ], "lang": { "en-US": { "role": { "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period Two [Member]", "terseLabel": "Payment made within 24 months after closing date" } } }, "localname": "DebtInstrumentRedemptionPeriodTwoMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesDebtFinancingNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPricePercentage": { "auth_ref": [ "r436" ], "lang": { "en-US": { "role": { "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.", "label": "Debt Instrument, Redemption Price, Percentage", "terseLabel": "Term loans, fee percentage of funded draw" } } }, "localname": "DebtInstrumentRedemptionPricePercentage", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesDebtFinancingNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r41", "r112", "r211", "r215", "r216", "r217", "r376", "r377", "r379", "r437" ], "lang": { "en-US": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesDebtFinancingNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Term", "terseLabel": "Debt instrument, term" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesDebtFinancingNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r376", "r379" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Debt Instrument, Unamortized Discount", "negatedLabel": "Less: amount representing debt discount" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesScheduleOfFuturePaymentsUnderLoanAndSecurityAgreementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts": { "auth_ref": [ "r74" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Represents the charge against earnings during the period for commitment fees and debt issuance expenses.", "label": "Debt Related Commitment Fees and Debt Issuance Costs", "terseLabel": "Debt issuance cost" } } }, "localname": "DebtRelatedCommitmentFeesAndDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesDebtFinancingNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "auth_ref": [ "r107", "r310", "r314" ], "calculation": { "http://www.invitae.com/role/IncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Federal Income Tax Expense (Benefit)", "terseLabel": "Federal" } } }, "localname": "DeferredFederalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/IncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r94", "r107", "r310", "r314" ], "calculation": { "http://www.invitae.com/role/ConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.invitae.com/role/IncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "terseLabel": "Benefit from income taxes", "totalLabel": "Total deferred benefit for income taxes" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfCashFlows", "http://www.invitae.com/role/IncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]", "terseLabel": "Deferred" } } }, "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/IncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredIncomeTaxLiabilities": { "auth_ref": [ "r15", "r16", "r299", "r424", "r439" ], "calculation": { "http://www.invitae.com/role/IncomeTaxesScheduleOfNetDeferredTaxAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.", "label": "Deferred Tax Liabilities, Gross", "negatedTotalLabel": "Total deferred tax liabilities" } } }, "localname": "DeferredIncomeTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/IncomeTaxesScheduleOfNetDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRentCreditNoncurrent": { "auth_ref": [ "r44", "r383" ], "calculation": { "http://www.invitae.com/role/BalanceSheetComponentsOtherLongTermLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.", "label": "Deferred Rent Credit, Noncurrent", "terseLabel": "Deferred rent, non-current" } } }, "localname": "DeferredRentCreditNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BalanceSheetComponentsOtherLongTermLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "auth_ref": [ "r107", "r310", "r314" ], "calculation": { "http://www.invitae.com/role/IncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred State and Local Income Tax Expense (Benefit)", "terseLabel": "State" } } }, "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/IncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r300" ], "calculation": { "http://www.invitae.com/role/IncomeTaxesScheduleOfNetDeferredTaxAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Gross", "totalLabel": "Gross deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/IncomeTaxesScheduleOfNetDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r303" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "Deferred Tax Assets, Net", "terseLabel": "Net deferred tax assets" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/IncomeTaxesScheduleOfNetDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r301" ], "calculation": { "http://www.invitae.com/role/IncomeTaxesScheduleOfNetDeferredTaxAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Net of Valuation Allowance", "totalLabel": "Total deferred tax assets" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/IncomeTaxesScheduleOfNetDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Deferred Tax Assets, Net of Valuation Allowance [Abstract]", "terseLabel": "Deferred tax assets:" } } }, "localname": "DeferredTaxAssetsNetOfValuationAllowanceAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/IncomeTaxesScheduleOfNetDeferredTaxAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r282", "r307", "r308" ], "calculation": { "http://www.invitae.com/role/IncomeTaxesScheduleOfNetDeferredTaxAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards", "terseLabel": "Net operating loss carryforwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/IncomeTaxesScheduleOfNetDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": { "auth_ref": [ "r305", "r307", "r308" ], "calculation": { "http://www.invitae.com/role/IncomeTaxesScheduleOfNetDeferredTaxAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.", "label": "Deferred Tax Assets, Tax Credit Carryforwards", "terseLabel": "Tax credits" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwards", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/IncomeTaxesScheduleOfNetDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r302" ], "calculation": { "http://www.invitae.com/role/IncomeTaxesScheduleOfNetDeferredTaxAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedLabel": "Valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/IncomeTaxesScheduleOfNetDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Deferred Tax Liabilities, Gross [Abstract]", "terseLabel": "Deferred tax liabilities:" } } }, "localname": "DeferredTaxLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/IncomeTaxesScheduleOfNetDeferredTaxAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "auth_ref": [ "r283", "r307", "r308" ], "calculation": { "http://www.invitae.com/role/IncomeTaxesScheduleOfNetDeferredTaxAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.", "label": "Deferred Tax Liabilities, Property, Plant and Equipment", "negatedLabel": "Property and equipment" } } }, "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/IncomeTaxesScheduleOfNetDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r94", "r187" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BalanceSheetComponentsPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r94", "r144" ], "calculation": { "http://www.invitae.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DevelopedTechnologyRightsMember": { "auth_ref": [ "r329" ], "lang": { "en-US": { "role": { "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.", "label": "Developed Technology Rights [Member]", "terseLabel": "Developed technology" } } }, "localname": "DevelopedTechnologyRightsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsScheduleOfEconomicBenefitsOfIntangibleAssetsExpectedToBeRealizedDetails", "http://www.invitae.com/role/BusinessCombinationsSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetails", "http://www.invitae.com/role/GoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member": { "auth_ref": [ "r233" ], "lang": { "en-US": { "role": { "documentation": "Effect in current period from application of guidance for revenue from contract with customer compared with guidance for revenue recognition applicable prior to change when using transition method for cumulative effect in period including initial date of application.", "label": "Difference between Revenue Guidance in Effect before and after Topic 606 [Member]", "terseLabel": "Effect of adoption higher/lower" } } }, "localname": "DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/RevenueAccountsReceivableAndDeferredRevenueScheduleOfImpactOfAdoptionOfTopic606OnCondensedStatementOfOperationsAndBalanceSheetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/RevenueAccountsReceivableAndDeferredRevenueNarrativeDetails", "http://www.invitae.com/role/RevenueAccountsReceivableAndDeferredRevenueScheduleOfDisaggregatedRevenueByPayerCategoryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/RevenueAccountsReceivableAndDeferredRevenueNarrativeDetails", "http://www.invitae.com/role/RevenueAccountsReceivableAndDeferredRevenueScheduleOfDisaggregatedRevenueByPayerCategoryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r227" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Schedule of disaggregated revenue by payer category" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/RevenueAccountsReceivableAndDeferredRevenueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r221", "r279" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.", "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]", "terseLabel": "Stock incentive plans" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockIncentivePlans" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_DueToAffiliateCurrent": { "auth_ref": [ "r11", "r109", "r397", "r454" ], "calculation": { "http://www.invitae.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of payable due to an entity that is affiliated with the reporting entity by means of direct or indirect ownership. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Due to Affiliate, Current", "terseLabel": "Liability associated with co-development agreement" } } }, "localname": "DueToAffiliateCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r123" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Basic and Diluted", "terseLabel": "Net loss per share, basic and diluted (in dollars per share)" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/NetLossPerCommonShareScheduleOfEarningsPerShareBasicAndDilutedDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r104", "r124", "r125", "r126" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net loss per share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r127" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net loss per common share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/NetLossPerCommonShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r114", "r289", "r290" ], "calculation": { "http://www.invitae.com/role/IncomeTaxesScheduleOfReconciliationOfTaxExpenseComputedAtStatutoryFederalRateAndCompanysTaxExpenseDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-US": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "totalLabel": "Total" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/IncomeTaxesScheduleOfReconciliationOfTaxExpenseComputedAtStatutoryFederalRateAndCompanysTaxExpenseDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]", "terseLabel": "Reconciliation of the tax expense computed at the statutory federal rate and Company's tax expense" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/IncomeTaxesScheduleOfReconciliationOfTaxExpenseComputedAtStatutoryFederalRateAndCompanysTaxExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r289", "r290", "r313" ], "calculation": { "http://www.invitae.com/role/IncomeTaxesScheduleOfReconciliationOfTaxExpenseComputedAtStatutoryFederalRateAndCompanysTaxExpenseDetails": { "order": 1.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "terseLabel": "U.S. federal taxes at statutory rate", "verboseLabel": "Corporate tax rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/IncomeTaxesNarrativeDetails", "http://www.invitae.com/role/IncomeTaxesScheduleOfReconciliationOfTaxExpenseComputedAtStatutoryFederalRateAndCompanysTaxExpenseDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r289", "r290", "r313" ], "calculation": { "http://www.invitae.com/role/IncomeTaxesScheduleOfReconciliationOfTaxExpenseComputedAtStatutoryFederalRateAndCompanysTaxExpenseDetails": { "order": 8.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent", "terseLabel": "Change in valuation allowance" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/IncomeTaxesScheduleOfReconciliationOfTaxExpenseComputedAtStatutoryFederalRateAndCompanysTaxExpenseDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": { "auth_ref": [ "r289", "r290", "r313" ], "calculation": { "http://www.invitae.com/role/IncomeTaxesScheduleOfReconciliationOfTaxExpenseComputedAtStatutoryFederalRateAndCompanysTaxExpenseDetails": { "order": 6.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.", "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent", "terseLabel": "Foreign tax differential" } } }, "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/IncomeTaxesScheduleOfReconciliationOfTaxExpenseComputedAtStatutoryFederalRateAndCompanysTaxExpenseDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": { "auth_ref": [ "r289", "r290", "r313" ], "calculation": { "http://www.invitae.com/role/IncomeTaxesScheduleOfReconciliationOfTaxExpenseComputedAtStatutoryFederalRateAndCompanysTaxExpenseDetails": { "order": 5.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent", "terseLabel": "Non-deductible expenses" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/IncomeTaxesScheduleOfReconciliationOfTaxExpenseComputedAtStatutoryFederalRateAndCompanysTaxExpenseDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": { "auth_ref": [ "r289", "r290", "r313" ], "calculation": { "http://www.invitae.com/role/IncomeTaxesScheduleOfReconciliationOfTaxExpenseComputedAtStatutoryFederalRateAndCompanysTaxExpenseDetails": { "order": 3.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to equity-based compensation costs.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Compensation Cost, Percent", "terseLabel": "Stock-based compensation" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/IncomeTaxesScheduleOfReconciliationOfTaxExpenseComputedAtStatutoryFederalRateAndCompanysTaxExpenseDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": { "auth_ref": [ "r289", "r290", "r313" ], "calculation": { "http://www.invitae.com/role/IncomeTaxesScheduleOfReconciliationOfTaxExpenseComputedAtStatutoryFederalRateAndCompanysTaxExpenseDetails": { "order": 7.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.", "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent", "terseLabel": "Other" } } }, "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/IncomeTaxesScheduleOfReconciliationOfTaxExpenseComputedAtStatutoryFederalRateAndCompanysTaxExpenseDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r289", "r290", "r313" ], "calculation": { "http://www.invitae.com/role/IncomeTaxesScheduleOfReconciliationOfTaxExpenseComputedAtStatutoryFederalRateAndCompanysTaxExpenseDetails": { "order": 2.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent", "terseLabel": "State taxes (net of federal benefit)" } } }, "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/IncomeTaxesScheduleOfReconciliationOfTaxExpenseComputedAtStatutoryFederalRateAndCompanysTaxExpenseDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": { "auth_ref": [ "r289", "r290", "r313" ], "calculation": { "http://www.invitae.com/role/IncomeTaxesScheduleOfReconciliationOfTaxExpenseComputedAtStatutoryFederalRateAndCompanysTaxExpenseDetails": { "order": 4.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": -1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent", "terseLabel": "Research and development credits" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/IncomeTaxesScheduleOfReconciliationOfTaxExpenseComputedAtStatutoryFederalRateAndCompanysTaxExpenseDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r38" ], "calculation": { "http://www.invitae.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued compensation and related expenses" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]", "verboseLabel": "Stock-based compensation" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockIncentivePlansScheduleOfAssumptionsUsedInDeterminationOfFairValueOfOptionsDetails", "http://www.invitae.com/role/StockIncentivePlansStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r273" ], "lang": { "en-US": { "role": { "documentation": "Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition", "terseLabel": "Expected period to recognize on a straight-line basis" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockIncentivePlansNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r273" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Unrecognized cost of unvested options awarded to employees as compensation.", "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options", "terseLabel": "Unrecognized stock-based compensation" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockIncentivePlansNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "An arrangement whereby an employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Although there are variations, normally, after vesting, when an option is exercised, the employee-holder pays the strike value in cash to the issuing employer-entity and receives equity shares. The equity shares can be sold into the market for cash at the current market price without restriction. Options may be used to attract, retain and incentivize employees, in addition to their regular salary and other benefits.", "label": "Employee Stock Option [Member]", "terseLabel": "Shares of common stock subject to outstanding options", "verboseLabel": "Employee Stock Option" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsNarrativeDetails", "http://www.invitae.com/role/NetLossPerCommonShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails", "http://www.invitae.com/role/StockIncentivePlansNarrativeDetails", "http://www.invitae.com/role/StockIncentivePlansScheduleOfActivityUnderStockIncentivePlansDetails", "http://www.invitae.com/role/StockIncentivePlansScheduleOfAssumptionsUsedInDeterminationOfFairValueOfOptionsDetails", "http://www.invitae.com/role/StockIncentivePlansTables", "http://www.invitae.com/role/StockholdersEquityScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquipmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tangible personal property used to produce goods and services.", "label": "Equipment [Member]", "terseLabel": "Laboratory equipment" } } }, "localname": "EquipmentMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BalanceSheetComponentsPropertyAndEquipmentDetails", "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfUsefulLivesOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r210" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsNarrativeDetails", "http://www.invitae.com/role/CommitmentsAndContingenciesDebtFinancingNarrativeDetails", "http://www.invitae.com/role/ConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity", "http://www.invitae.com/role/StockholdersEquityNarrativeDetails", "http://www.invitae.com/role/StockholdersEquityScheduleOfOutstandingWarrantsToPurchaseCommonStockDetails", "http://www.invitae.com/role/StockholdersEquityScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityFairValueDisclosure": { "auth_ref": [ "r353" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of the entity's equity.", "label": "Equity, Fair Value Disclosure", "terseLabel": "Fair value of common stock" } } }, "localname": "EquityFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesDebtFinancingNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityInterestIssuedOrIssuableByTypeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of equity interests that are issued or issuable in a business combination.", "label": "Equity Interest Type [Axis]", "terseLabel": "Equity Interest Type" } } }, "localname": "EquityInterestIssuedOrIssuableByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsNarrativeDetails", "http://www.invitae.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquityInterestIssuedOrIssuableTypeDomain": { "auth_ref": [ "r338" ], "lang": { "en-US": { "role": { "documentation": "Name of equity interest issued or issuable to acquire an entity in a business combination.", "label": "Equity Interest Issued or Issuable, Type [Domain]", "terseLabel": "Equity Interest Issued or Issuable, Type" } } }, "localname": "EquityInterestIssuedOrIssuableTypeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsNarrativeDetails", "http://www.invitae.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "auth_ref": [ "r365" ], "lang": { "en-US": { "role": { "documentation": "Measured as an estimate of fair value.", "label": "Estimate of Fair Value Measurement [Member]", "terseLabel": "Fair Value" } } }, "localname": "EstimateOfFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/FairValueMeasurementsCarryingAmountAndEstimatedFairValueOfCompanysOutstandingDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/FairValueMeasurementsCarryingAmountAndEstimatedFairValueOfCompanysOutstandingDebtDetails", "http://www.invitae.com/role/FairValueMeasurementsFinancialInstrumentsAtFairValueOnRecurringBasisDetails", "http://www.invitae.com/role/FairValueMeasurementsLevel3FinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r352", "r353", "r354", "r355", "r358", "r359" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.", "label": "Fair Value Measurements, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/FairValueMeasurementsCarryingAmountAndEstimatedFairValueOfCompanysOutstandingDebtDetails", "http://www.invitae.com/role/FairValueMeasurementsFinancialInstrumentsAtFairValueOnRecurringBasisDetails", "http://www.invitae.com/role/FairValueMeasurementsLevel3FinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r236", "r237", "r239", "r354", "r402" ], "lang": { "en-US": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value, Hierarchy" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/FairValueMeasurementsCarryingAmountAndEstimatedFairValueOfCompanysOutstandingDebtDetails", "http://www.invitae.com/role/FairValueMeasurementsFinancialInstrumentsAtFairValueOnRecurringBasisDetails", "http://www.invitae.com/role/FairValueMeasurementsLevel3FinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails", "http://www.invitae.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementBasisAxis": { "auth_ref": [ "r353", "r360" ], "lang": { "en-US": { "role": { "documentation": "Information by measurement basis.", "label": "Measurement Basis [Axis]", "terseLabel": "Measurement Basis" } } }, "localname": "FairValueByMeasurementBasisAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/FairValueMeasurementsCarryingAmountAndEstimatedFairValueOfCompanysOutstandingDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r352" ], "lang": { "en-US": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/FairValueMeasurementsCarryingAmountAndEstimatedFairValueOfCompanysOutstandingDebtDetails", "http://www.invitae.com/role/FairValueMeasurementsFinancialInstrumentsAtFairValueOnRecurringBasisDetails", "http://www.invitae.com/role/FairValueMeasurementsLevel3FinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails", "http://www.invitae.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByShareholdersEquityClassDomain": { "auth_ref": [ "r357" ], "lang": { "en-US": { "role": { "documentation": "Classes of financial instruments classified in shareholders' equity.", "label": "Fair Value by Shareholders' Equity Class [Domain]", "terseLabel": "Fair Value by Shareholders' Equity Class" } } }, "localname": "FairValueByShareholdersEquityClassDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockholdersEquityScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueDisclosureItemAmountsDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.", "label": "Fair Value Measurement [Domain]", "terseLabel": "Fair Value Measurement" } } }, "localname": "FairValueDisclosureItemAmountsDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/FairValueMeasurementsCarryingAmountAndEstimatedFairValueOfCompanysOutstandingDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r362" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair value measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r236", "r237", "r239", "r354", "r403" ], "lang": { "en-US": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "verboseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/FairValueMeasurementsFinancialInstrumentsAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r236", "r237", "r239", "r354", "r404" ], "lang": { "en-US": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/FairValueMeasurementsCarryingAmountAndEstimatedFairValueOfCompanysOutstandingDebtDetails", "http://www.invitae.com/role/FairValueMeasurementsFinancialInstrumentsAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r236", "r237", "r239", "r354", "r405" ], "lang": { "en-US": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/FairValueMeasurementsFinancialInstrumentsAtFairValueOnRecurringBasisDetails", "http://www.invitae.com/role/FairValueMeasurementsLevel3FinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails", "http://www.invitae.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r352", "r353", "r354" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.", "label": "Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of Carrying amount and the estimated fair value of the Company's outstanding debt" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r356", "r359" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Schedule of Level 3 financial instruments measured at fair value on a recurring basis" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [ "r352", "r357" ], "lang": { "en-US": { "role": { "documentation": "Provides the general categories used to describe the frequency with which financial assets and liabilities (as defined) are measured at fair value (on a recurring or nonrecurring basis).", "label": "Fair Value, Measurement Frequency [Domain]", "terseLabel": "Fair Value, Measurement Frequency" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/FairValueMeasurementsCarryingAmountAndEstimatedFairValueOfCompanysOutstandingDebtDetails", "http://www.invitae.com/role/FairValueMeasurementsFinancialInstrumentsAtFairValueOnRecurringBasisDetails", "http://www.invitae.com/role/FairValueMeasurementsLevel3FinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails", "http://www.invitae.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r356" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "periodEndLabel": "December 31, 2018", "periodStartLabel": "December 31, 2017" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/FairValueMeasurementsLevel3FinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/FairValueMeasurementsCarryingAmountAndEstimatedFairValueOfCompanysOutstandingDebtDetails", "http://www.invitae.com/role/FairValueMeasurementsFinancialInstrumentsAtFairValueOnRecurringBasisDetails", "http://www.invitae.com/role/FairValueMeasurementsLevel3FinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails", "http://www.invitae.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r352", "r357" ], "lang": { "en-US": { "role": { "documentation": "This item represents a description of the frequency with which certain items are measured at fair value. Items measured at fair value on a recurring basis generally include those items for which measurement inputs are readily available and which are measured at fair value at successive reporting periods.", "label": "Fair Value, Measurements, Recurring [Member]", "terseLabel": "Recurring basis" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/FairValueMeasurementsCarryingAmountAndEstimatedFairValueOfCompanysOutstandingDebtDetails", "http://www.invitae.com/role/FairValueMeasurementsFinancialInstrumentsAtFairValueOnRecurringBasisDetails", "http://www.invitae.com/role/FairValueMeasurementsLevel3FinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails", "http://www.invitae.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r104", "r361", "r364" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair value of financial instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueOptionQuantitativeDisclosuresLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Option, Quantitative Disclosures [Line Items]", "terseLabel": "Fair Value, Option, Quantitative Disclosures [Line Items]" } } }, "localname": "FairValueOptionQuantitativeDisclosuresLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueOptionQuantitativeDisclosuresTable": { "auth_ref": [ "r370", "r371", "r372" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value under fair value option.", "label": "Fair Value Option, Disclosures [Table]", "terseLabel": "Fair Value Option, Disclosures [Table]" } } }, "localname": "FairValueOptionQuantitativeDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/FairValueMeasurementsFinancialInstrumentsAtFairValueOnRecurringBasisDetails", "http://www.invitae.com/role/FairValueMeasurementsLevel3FinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails", "http://www.invitae.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Useful Life", "terseLabel": "Intangible assets estimated useful lives", "verboseLabel": "Weighted Average Useful Life (in Years)" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsNarrativeDetails", "http://www.invitae.com/role/BusinessCombinationsScheduleOfEconomicBenefitsOfIntangibleAssetsExpectedToBeRealizedDetails", "http://www.invitae.com/role/GoodwillAndIntangibleAssetsNarrativeDetails", "http://www.invitae.com/role/GoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails", "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r179" ], "calculation": { "http://www.invitae.com/role/GoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedLabel": "Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/GoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "auth_ref": [], "calculation": { "http://www.invitae.com/role/GoodwillAndIntangibleAssetsSummaryOfEstimatedFutureAmortizationExpenseOfIntangibleAssetsWithFiniteLivesDetails": { "order": 6.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/GoodwillAndIntangibleAssetsSummaryOfEstimatedFutureAmortizationExpenseOfIntangibleAssetsWithFiniteLivesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r181" ], "calculation": { "http://www.invitae.com/role/GoodwillAndIntangibleAssetsSummaryOfEstimatedFutureAmortizationExpenseOfIntangibleAssetsWithFiniteLivesDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months", "terseLabel": "2019" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/GoodwillAndIntangibleAssetsSummaryOfEstimatedFutureAmortizationExpenseOfIntangibleAssetsWithFiniteLivesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r181" ], "calculation": { "http://www.invitae.com/role/GoodwillAndIntangibleAssetsSummaryOfEstimatedFutureAmortizationExpenseOfIntangibleAssetsWithFiniteLivesDetails": { "order": 5.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Five", "terseLabel": "2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/GoodwillAndIntangibleAssetsSummaryOfEstimatedFutureAmortizationExpenseOfIntangibleAssetsWithFiniteLivesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r181" ], "calculation": { "http://www.invitae.com/role/GoodwillAndIntangibleAssetsSummaryOfEstimatedFutureAmortizationExpenseOfIntangibleAssetsWithFiniteLivesDetails": { "order": 4.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Four", "terseLabel": "2022" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/GoodwillAndIntangibleAssetsSummaryOfEstimatedFutureAmortizationExpenseOfIntangibleAssetsWithFiniteLivesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r181" ], "calculation": { "http://www.invitae.com/role/GoodwillAndIntangibleAssetsSummaryOfEstimatedFutureAmortizationExpenseOfIntangibleAssetsWithFiniteLivesDetails": { "order": 3.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Three", "terseLabel": "2021" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/GoodwillAndIntangibleAssetsSummaryOfEstimatedFutureAmortizationExpenseOfIntangibleAssetsWithFiniteLivesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r181" ], "calculation": { "http://www.invitae.com/role/GoodwillAndIntangibleAssetsSummaryOfEstimatedFutureAmortizationExpenseOfIntangibleAssetsWithFiniteLivesDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Two", "terseLabel": "2020" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/GoodwillAndIntangibleAssetsSummaryOfEstimatedFutureAmortizationExpenseOfIntangibleAssetsWithFiniteLivesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r175", "r176", "r179", "r182", "r407" ], "lang": { "en-US": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsNarrativeDetails", "http://www.invitae.com/role/BusinessCombinationsScheduleOfEconomicBenefitsOfIntangibleAssetsExpectedToBeRealizedDetails", "http://www.invitae.com/role/BusinessCombinationsSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetails", "http://www.invitae.com/role/GoodwillAndIntangibleAssetsNarrativeDetails", "http://www.invitae.com/role/GoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails", "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r179", "r407" ], "calculation": { "http://www.invitae.com/role/GoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Gross Purchased Intangible Assets", "verboseLabel": "Cost" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsScheduleOfEconomicBenefitsOfIntangibleAssetsExpectedToBeRealizedDetails", "http://www.invitae.com/role/GoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/GoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r175", "r178" ], "lang": { "en-US": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsNarrativeDetails", "http://www.invitae.com/role/BusinessCombinationsScheduleOfEconomicBenefitsOfIntangibleAssetsExpectedToBeRealizedDetails", "http://www.invitae.com/role/BusinessCombinationsSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetails", "http://www.invitae.com/role/GoodwillAndIntangibleAssetsNarrativeDetails", "http://www.invitae.com/role/GoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails", "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r179" ], "calculation": { "http://www.invitae.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.invitae.com/role/GoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.invitae.com/role/GoodwillAndIntangibleAssetsSummaryOfEstimatedFutureAmortizationExpenseOfIntangibleAssetsWithFiniteLivesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "terseLabel": "Intangible assets, net", "totalLabel": "Net" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedBalanceSheets", "http://www.invitae.com/role/GoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails", "http://www.invitae.com/role/GoodwillAndIntangibleAssetsSummaryOfEstimatedFutureAmortizationExpenseOfIntangibleAssetsWithFiniteLivesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Assets, Remaining Amortization Period", "terseLabel": "Weighted Average Estimated Remaining Useful Life (in Years)" } } }, "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/GoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture and fixtures" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BalanceSheetComponentsPropertyAndEquipmentDetails", "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfUsefulLivesOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r94", "r205", "r206" ], "calculation": { "http://www.invitae.com/role/ConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain (Loss) on Extinguishment of Debt", "terseLabel": "Debt extinguishment costs" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r73" ], "calculation": { "http://www.invitae.com/role/ConsolidatedStatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r70" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsNarrativeDetails", "http://www.invitae.com/role/FairValueMeasurementsLevel3FinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails", "http://www.invitae.com/role/StockIncentivePlansStockBasedCompensationExpenseDetails", "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r165", "r167" ], "calculation": { "http://www.invitae.com/role/BusinessCombinationsSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 }, "http://www.invitae.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "December 31, 2018", "periodStartLabel": "December 31, 2017", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsNarrativeDetails", "http://www.invitae.com/role/BusinessCombinationsSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetails", "http://www.invitae.com/role/ConsolidatedBalanceSheets", "http://www.invitae.com/role/GoodwillAndIntangibleAssetsSummaryOfGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAcquiredDuringPeriod": { "auth_ref": [ "r168" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.", "label": "Goodwill, Acquired During Period", "terseLabel": "Goodwill acquired" } } }, "localname": "GoodwillAcquiredDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r183" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "Goodwill and intangible assets" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/GoodwillAndIntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": { "auth_ref": [ "r104", "r171" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.", "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]", "terseLabel": "Goodwill" } } }, "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": { "auth_ref": [ "r104", "r177" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.", "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]", "terseLabel": "Intangible assets" } } }, "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillImpairmentLoss": { "auth_ref": [ "r94", "r166", "r169", "r172" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Impairment Loss", "terseLabel": "Goodwill impairment loss" } } }, "localname": "GoodwillImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Goodwill [Line Items]", "terseLabel": "Goodwill [Line Items]" } } }, "localname": "GoodwillLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/GoodwillAndIntangibleAssetsNarrativeDetails", "http://www.invitae.com/role/GoodwillAndIntangibleAssetsSummaryOfGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GoodwillPurchaseAccountingAdjustments": { "auth_ref": [ "r170", "r319" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Purchase Accounting Adjustments", "terseLabel": "Goodwill adjustment" } } }, "localname": "GoodwillPurchaseAccountingAdjustments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsNarrativeDetails", "http://www.invitae.com/role/GoodwillAndIntangibleAssetsNarrativeDetails", "http://www.invitae.com/role/GoodwillAndIntangibleAssetsSummaryOfGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Goodwill [Roll Forward]", "terseLabel": "Goodwill [Roll Forward]" } } }, "localname": "GoodwillRollForward", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/GoodwillAndIntangibleAssetsSummaryOfGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": { "auth_ref": [ "r94", "r185" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.", "label": "Impairment of Long-Lived Assets to be Disposed of", "terseLabel": "Long-lived asset impairment losses" } } }, "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r104", "r184", "r192" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "terseLabel": "Long-lived assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "auth_ref": [ "r113" ], "calculation": { "http://www.invitae.com/role/IncomeTaxesScheduleOfComponentsOfLossBeforeIncomeTaxesByUSAndForeignJurisdictionsDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic", "negatedLabel": "United States" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/IncomeTaxesScheduleOfComponentsOfLossBeforeIncomeTaxesByUSAndForeignJurisdictionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r68", "r121", "r420", "r430", "r451" ], "calculation": { "http://www.invitae.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 }, "http://www.invitae.com/role/IncomeTaxesScheduleOfComponentsOfLossBeforeIncomeTaxesByUSAndForeignJurisdictionsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "negatedTotalLabel": "Total", "totalLabel": "Net loss before taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfOperations", "http://www.invitae.com/role/IncomeTaxesScheduleOfComponentsOfLossBeforeIncomeTaxesByUSAndForeignJurisdictionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "auth_ref": [ "r113" ], "calculation": { "http://www.invitae.com/role/IncomeTaxesScheduleOfComponentsOfLossBeforeIncomeTaxesByUSAndForeignJurisdictionsDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign", "negatedLabel": "Foreign" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/IncomeTaxesScheduleOfComponentsOfLossBeforeIncomeTaxesByUSAndForeignJurisdictionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) from continuing operations per each basic and diluted share of common stock or unit when the per share amount is the same for both basic and diluted shares.", "label": "Income (Loss) from Continuing Operations, Per Basic and Diluted Share", "terseLabel": "Net loss per share, basic and diluted (in dollars per share)" } } }, "localname": "IncomeLossFromContinuingOperationsPerBasicAndDilutedShare", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfOperations", "http://www.invitae.com/role/RevenueAccountsReceivableAndDeferredRevenueNarrativeDetails", "http://www.invitae.com/role/RevenueAccountsReceivableAndDeferredRevenueScheduleOfImpactOfAdoptionOfTopic606OnCondensedStatementOfOperationsAndBalanceSheetDetails", "http://www.invitae.com/role/SelectedQuarterlyDataUnauditedDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r191" ], "lang": { "en-US": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsNarrativeDetails", "http://www.invitae.com/role/FairValueMeasurementsLevel3FinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails", "http://www.invitae.com/role/StockIncentivePlansStockBasedCompensationExpenseDetails", "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsNarrativeDetails", "http://www.invitae.com/role/FairValueMeasurementsLevel3FinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails", "http://www.invitae.com/role/StockIncentivePlansStockBasedCompensationExpenseDetails", "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r292" ], "lang": { "en-US": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityNameAxis": { "auth_ref": [ "r292" ], "lang": { "en-US": { "role": { "documentation": "Information by name of taxing authority.", "label": "Income Tax Authority, Name [Axis]", "terseLabel": "Income Tax Authority, Name" } } }, "localname": "IncomeTaxAuthorityNameAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority, Name [Domain]", "terseLabel": "Income Tax Authority, Name [Domain]" } } }, "localname": "IncomeTaxAuthorityNameDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxContingencyLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Tax Contingency [Line Items]", "terseLabel": "Income Tax Contingency [Line Items]" } } }, "localname": "IncomeTaxContingencyLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxContingencyTable": { "auth_ref": [ "r293", "r296", "r298", "r312" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.", "label": "Income Tax Contingency [Table]", "terseLabel": "Income Tax Contingency [Table]" } } }, "localname": "IncomeTaxContingencyTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r317" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r107", "r145", "r315" ], "calculation": { "http://www.invitae.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 }, "http://www.invitae.com/role/IncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Income tax benefit", "totalLabel": "Total income tax benefit" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfOperations", "http://www.invitae.com/role/IncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r104", "r286", "r287", "r297", "r298", "r304", "r316", "r456" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r93" ], "calculation": { "http://www.invitae.com/role/ConsolidatedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r93" ], "calculation": { "http://www.invitae.com/role/ConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable", "negatedTerseLabel": "Decrease in accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsNarrativeDetails", "http://www.invitae.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "auth_ref": [ "r93" ], "calculation": { "http://www.invitae.com/role/ConsolidatedStatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.", "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities", "terseLabel": "Accrued expenses and other liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities, net of effects of business combination:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "auth_ref": [ "r93" ], "calculation": { "http://www.invitae.com/role/ConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in operating assets classified as other.", "label": "Increase (Decrease) in Other Operating Assets", "negatedLabel": "Other assets" } } }, "localname": "IncreaseDecreaseInOtherOperatingAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Deficit" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis": { "auth_ref": [ "r233" ], "lang": { "en-US": { "role": { "documentation": "Information about effect of transition method for cumulative effect in initial period of application.", "label": "Initial Application Period Cumulative Effect Transition [Axis]", "terseLabel": "Initial Application Period Cumulative Effect Transition [Axis]" } } }, "localname": "InitialApplicationPeriodCumulativeEffectTransitionAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/RevenueAccountsReceivableAndDeferredRevenueScheduleOfImpactOfAdoptionOfTopic606OnCondensedStatementOfOperationsAndBalanceSheetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Effect of transition method for cumulative effect in initial period of application.", "label": "Initial Application Period Cumulative Effect Transition [Domain]", "terseLabel": "Initial Application Period Cumulative Effect Transition [Domain]" } } }, "localname": "InitialApplicationPeriodCumulativeEffectTransitionDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/RevenueAccountsReceivableAndDeferredRevenueScheduleOfImpactOfAdoptionOfTopic606OnCondensedStatementOfOperationsAndBalanceSheetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r66", "r143", "r375", "r378", "r432" ], "calculation": { "http://www.invitae.com/role/ConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebt": { "auth_ref": [ "r74", "r204" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "Interest Expense, Debt", "terseLabel": "Interest expense" } } }, "localname": "InterestExpenseDebt", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesDebtFinancingNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r89", "r91", "r98" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Interest paid" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrentAndNoncurrent": { "auth_ref": [ "r428", "r449" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables.", "label": "Interest Payable", "negatedLabel": "Less: amount representing interest" } } }, "localname": "InterestPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesScheduleOfFuturePaymentsUnderLoanAndSecurityAgreementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InternalRevenueServiceIRSMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity.", "label": "Internal Revenue Service (IRS) [Member]", "terseLabel": "Federal" } } }, "localname": "InternalRevenueServiceIRSMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r1", "r49", "r160" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventory" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r7", "r50", "r104", "r128", "r161", "r162" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "terseLabel": "Inventory" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseIncentiveReceivable": { "auth_ref": [ "r384", "r385" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This item represents a receivable for an incentive or inducement contractually stipulated between parties to a lease whereby the lessor has committed to provide the entity (lessee) with a cash payment as inducement to enter the lease.", "label": "Lease Incentive Receivable", "terseLabel": "Lease incentive in form of lease improvements" } } }, "localname": "LeaseIncentiveReceivable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesOperatingLeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r188" ], "lang": { "en-US": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BalanceSheetComponentsPropertyAndEquipmentDetails", "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r395" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "auth_ref": [ "r396" ], "lang": { "en-US": { "role": { "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Renewal Term", "terseLabel": "Additional term of lease" } } }, "localname": "LesseeOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesOperatingLeasesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r396" ], "lang": { "en-US": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Lease term" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesOperatingLeasesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r37" ], "calculation": { "http://www.invitae.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r25", "r426", "r445" ], "calculation": { "http://www.invitae.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesAssumed1": { "auth_ref": [ "r99", "r100", "r101" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The fair value of liabilities assumed in noncash investing or financing activities.", "label": "Liabilities Assumed", "terseLabel": "Common stock issued to settle assumed liabilities" } } }, "localname": "LiabilitiesAssumed1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r39" ], "calculation": { "http://www.invitae.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r353" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure", "terseLabel": "Total financial liabilities" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/FairValueMeasurementsFinancialInstrumentsAtFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r36" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Maximum borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesDebtFinancingNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": { "auth_ref": [ "r36" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).", "label": "Line of Credit Facility, Remaining Borrowing Capacity", "terseLabel": "Term loan, line fee on unused commitment amount" } } }, "localname": "LineOfCreditFacilityRemainingBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesDebtFinancingNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r14", "r203", "r425", "r442" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "terseLabel": "Debt" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/FairValueMeasurementsCarryingAmountAndEstimatedFairValueOfCompanysOutstandingDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtByMaturityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Long-term Debt, Fiscal Year Maturity [Abstract]", "terseLabel": "Future payments under the Loan Agreement" } } }, "localname": "LongTermDebtByMaturityAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesScheduleOfFuturePaymentsUnderLoanAndSecurityAgreementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r41" ], "calculation": { "http://www.invitae.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Excluding Current Maturities", "terseLabel": "Total non-current debt obligation", "verboseLabel": "Debt" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesScheduleOfFuturePaymentsUnderLoanAndSecurityAgreementDetails", "http://www.invitae.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermPurchaseCommitmentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Long-term Purchase Commitment [Line Items]", "terseLabel": "Long-term Purchase Commitment [Line Items]" } } }, "localname": "LongTermPurchaseCommitmentLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesScheduleOfFuturePaymentsUnderNoncancelableUnconditionalPurchaseCommitmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermPurchaseCommitmentTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule setting forth key provisions of an arrangement under which the entity has agreed to purchase goods or services over a period of time greater than one year or the normal operating cycle, if longer, including the item for which expenditures will be made, minimum quantities, milestones, time period and committed amount.", "label": "Long-term Purchase Commitment [Table]", "terseLabel": "Long-term Purchase Commitment [Table]" } } }, "localname": "LongTermPurchaseCommitmentTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesScheduleOfFuturePaymentsUnderNoncancelableUnconditionalPurchaseCommitmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r41" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesDebtFinancingNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r41", "r200" ], "lang": { "en-US": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesDebtFinancingNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MarketableSecuritiesPolicy": { "auth_ref": [ "r433" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for investment classified as marketable security.", "label": "Marketable Securities, Policy [Policy Text Block]", "terseLabel": "Marketable securities" } } }, "localname": "MarketableSecuritiesPolicy", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r236" ], "lang": { "en-US": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "verboseLabel": "Money market funds" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/FairValueMeasurementsFinancialInstrumentsAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r90" ], "calculation": { "http://www.invitae.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r90" ], "calculation": { "http://www.invitae.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by (used in) investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r90", "r92", "r95" ], "calculation": { "http://www.invitae.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r60", "r62", "r69", "r95", "r125", "r431", "r450" ], "calculation": { "http://www.invitae.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.invitae.com/role/ConsolidatedStatementsOfComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.invitae.com/role/ConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfCashFlows", "http://www.invitae.com/role/ConsolidatedStatementsOfComprehensiveLoss", "http://www.invitae.com/role/ConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity", "http://www.invitae.com/role/ConsolidatedStatementsOfOperations", "http://www.invitae.com/role/NetLossPerCommonShareScheduleOfEarningsPerShareBasicAndDilutedDetails", "http://www.invitae.com/role/RevenueAccountsReceivableAndDeferredRevenueScheduleOfImpactOfAdoptionOfTopic606OnCondensedStatementOfOperationsAndBalanceSheetDetails", "http://www.invitae.com/role/SelectedQuarterlyDataUnauditedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent accounting pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1": { "auth_ref": [ "r99", "r100", "r101" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of payables that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Noncash or Part Noncash Acquisition, Payables Assumed", "terseLabel": "Consideration payable for acquisition of businesses" } } }, "localname": "NoncashOrPartNoncashAcquisitionPayablesAssumed1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncompeteAgreementsMember": { "auth_ref": [ "r327" ], "lang": { "en-US": { "role": { "documentation": "Agreement in which one party agrees not to pursue a similar trade in competition with another party.", "label": "Noncompete Agreements [Member]", "terseLabel": "Non-compete agreement" } } }, "localname": "NoncompeteAgreementsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsNarrativeDetails", "http://www.invitae.com/role/BusinessCombinationsScheduleOfEconomicBenefitsOfIntangibleAssetsExpectedToBeRealizedDetails", "http://www.invitae.com/role/BusinessCombinationsSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetails", "http://www.invitae.com/role/GoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/OrganizationAndDescriptionOfBusinessNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OffMarketFavorableLeaseMember": { "auth_ref": [ "r33" ], "lang": { "en-US": { "role": { "documentation": "Identifiable intangible asset established upon acquisition based on a favorable difference between the terms of an acquired lease and the current market terms for that lease.", "label": "Off-Market Favorable Lease [Member]", "terseLabel": "Favorable leases" } } }, "localname": "OffMarketFavorableLeaseMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsScheduleOfEconomicBenefitsOfIntangibleAssetsExpectedToBeRealizedDetails", "http://www.invitae.com/role/BusinessCombinationsSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OperatingCostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Operating Costs and Expenses [Abstract]", "terseLabel": "Costs and operating expenses:" } } }, "localname": "OperatingCostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [], "calculation": { "http://www.invitae.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "terseLabel": "Loss from operations", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfOperations", "http://www.invitae.com/role/RevenueAccountsReceivableAndDeferredRevenueNarrativeDetails", "http://www.invitae.com/role/SelectedQuarterlyDataUnauditedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasedAssetsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Operating Leased Assets [Line Items]", "terseLabel": "Operating Leased Assets [Line Items]" } } }, "localname": "OperatingLeasedAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesOperatingLeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": { "auth_ref": [ "r382", "r387" ], "calculation": { "http://www.invitae.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsUnderOperatingLeasesDetails": { "order": 1.0, "parentTag": "nvta_OperatingLeasesFutureMinimumPaymentsDueNet", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.", "label": "Operating Leases, Future Minimum Payments Due", "terseLabel": "Total minimum lease payments", "totalLabel": "Future non-cancelable minimum operating lease payments" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesOperatingLeasesNarrativeDetails", "http://www.invitae.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsUnderOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": { "auth_ref": [ "r382", "r387" ], "calculation": { "http://www.invitae.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsUnderOperatingLeasesDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments Due, Next Twelve Months", "terseLabel": "2019" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsUnderOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals": { "auth_ref": [ "r388" ], "calculation": { "http://www.invitae.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsUnderOperatingLeasesDetails": { "order": 2.0, "parentTag": "nvta_OperatingLeasesFutureMinimumPaymentsDueNet", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Contractually required future rental payments receivable on noncancelable subleasing arrangements.", "label": "Operating Leases, Future Minimum Payments Due, Future Minimum Sublease Rentals", "negatedTerseLabel": "Less: minimum payments to be received from non-cancelable subleases" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsUnderOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears": { "auth_ref": [ "r382", "r387" ], "calculation": { "http://www.invitae.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsUnderOperatingLeasesDetails": { "order": 5.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Five Years", "terseLabel": "2023" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInFiveYears", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsUnderOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": { "auth_ref": [ "r382", "r387" ], "calculation": { "http://www.invitae.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsUnderOperatingLeasesDetails": { "order": 4.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Four Years", "terseLabel": "2022" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsUnderOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": { "auth_ref": [ "r382", "r387" ], "calculation": { "http://www.invitae.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsUnderOperatingLeasesDetails": { "order": 3.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Three Years", "terseLabel": "2021" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsUnderOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": { "auth_ref": [ "r382", "r387" ], "calculation": { "http://www.invitae.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsUnderOperatingLeasesDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Two Years", "terseLabel": "2020" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsUnderOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter": { "auth_ref": [ "r382", "r387" ], "calculation": { "http://www.invitae.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsUnderOperatingLeasesDetails": { "order": 6.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due Thereafter", "terseLabel": "Thereafter" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueThereafter", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsUnderOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesRentExpenseMinimumRentals": { "auth_ref": [ "r380", "r382", "r386" ], "calculation": { "http://www.invitae.com/role/CommitmentsAndContingenciesScheduleOfRentExpenseRelatedToNonCancelableOperatingLeasesDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeasesRentExpenseNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This element represents the payments that the lessee is obligated to make or can be required to make in connection with a property under the terms of an agreement classified as an operating lease, excluding contingent rentals and a guarantee by the lessee of the lessor's debt and the lessee's obligation to pay (apart from the rental payments) executory costs such as insurance, maintenance, and taxes.", "label": "Operating Leases, Rent Expense, Minimum Rentals", "terseLabel": "Rent expense" } } }, "localname": "OperatingLeasesRentExpenseMinimumRentals", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesScheduleOfRentExpenseRelatedToNonCancelableOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesRentExpenseNet": { "auth_ref": [ "r386" ], "calculation": { "http://www.invitae.com/role/CommitmentsAndContingenciesScheduleOfRentExpenseRelatedToNonCancelableOperatingLeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.", "label": "Operating Leases, Rent Expense, Net", "totalLabel": "Rent expense, net of sublease income" } } }, "localname": "OperatingLeasesRentExpenseNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesScheduleOfRentExpenseRelatedToNonCancelableOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesRentExpenseSubleaseRentals1": { "auth_ref": [ "r382" ], "calculation": { "http://www.invitae.com/role/CommitmentsAndContingenciesScheduleOfRentExpenseRelatedToNonCancelableOperatingLeasesDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeasesRentExpenseNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The total amount of sublease rental income recognized during the period that reduces the entity's rent expense incurred under operating leases.", "label": "Operating Leases, Rent Expense, Sublease Rentals", "terseLabel": "Sublease income" } } }, "localname": "OperatingLeasesRentExpenseSubleaseRentals1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesScheduleOfRentExpenseRelatedToNonCancelableOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r305" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating Loss Carryforwards", "terseLabel": "Net operating loss carryforwards" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": { "auth_ref": [ "r119", "r122", "r142", "r351" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.", "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]", "terseLabel": "Organization and description of business" } } }, "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/OrganizationAndDescriptionOfBusiness" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r4", "r5", "r6", "r38" ], "calculation": { "http://www.invitae.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAccruedLiabilitiesNoncurrent": { "auth_ref": [ "r42" ], "calculation": { "http://www.invitae.com/role/BalanceSheetComponentsOtherLongTermLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Noncurrent", "terseLabel": "Other non-current liabilities" } } }, "localname": "OtherAccruedLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BalanceSheetComponentsOtherLongTermLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r34" ], "calculation": { "http://www.invitae.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCommitmentsAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of other commitment.", "label": "Other Commitments [Axis]", "terseLabel": "Other Commitments [Axis]" } } }, "localname": "OtherCommitmentsAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesOtherCommitmentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherCommitmentsDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other future obligation.", "label": "Other Commitments [Domain]", "terseLabel": "Other Commitments [Domain]" } } }, "localname": "OtherCommitmentsDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesOtherCommitmentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherCommitmentsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Other Commitments [Line Items]", "terseLabel": "Other Commitments [Line Items]" } } }, "localname": "OtherCommitmentsLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesOtherCommitmentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherCommitmentsTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about obligations resulting from other commitments.", "label": "Other Commitments [Table]", "terseLabel": "Other Commitments [Table]" } } }, "localname": "OtherCommitmentsTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesOtherCommitmentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax": { "auth_ref": [ "r54" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax, after reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.", "label": "Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, before Tax", "terseLabel": "Unrealized income (loss) on available-for-sale marketable securities, net of tax" } } }, "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": { "auth_ref": [ "r54" ], "calculation": { "http://www.invitae.com/role/ConsolidatedStatementsOfComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.", "label": "Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax", "terseLabel": "Unrealized income (loss) on available-for-sale marketable securities, net of tax" } } }, "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Other comprehensive income (loss):" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r42" ], "calculation": { "http://www.invitae.com/role/BalanceSheetComponentsOtherLongTermLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.invitae.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities", "totalLabel": "Total other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BalanceSheetComponentsOtherLongTermLiabilitiesDetails", "http://www.invitae.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncurrentLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of other noncurrent liabilities.", "label": "Other Noncurrent Liabilities [Table Text Block]", "terseLabel": "Schedule of other long-term liabilities" } } }, "localname": "OtherNoncurrentLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r75" ], "calculation": { "http://www.invitae.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other income (expense), net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherOperatingActivitiesCashFlowStatement": { "auth_ref": [], "calculation": { "http://www.invitae.com/role/ConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).", "label": "Other Operating Activities, Cash Flow Statement", "terseLabel": "Other" } } }, "localname": "OtherOperatingActivitiesCashFlowStatement", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "auth_ref": [ "r79", "r83", "r118" ], "calculation": { "http://www.invitae.com/role/ConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.", "label": "Payments for (Proceeds from) Other Investing Activities", "negatedTerseLabel": "Other" } } }, "localname": "PaymentsForProceedsFromOtherInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDebtExtinguishmentCosts": { "auth_ref": [ "r87" ], "calculation": { "http://www.invitae.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.", "label": "Payment for Debt Extinguishment or Debt Prepayment Cost", "negatedTerseLabel": "Payments for debt extinguishment costs", "terseLabel": "Debt extinguishment costs" } } }, "localname": "PaymentsOfDebtExtinguishmentCosts", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesDebtFinancingNarrativeDetails", "http://www.invitae.com/role/ConsolidatedStatementsOfCashFlows", "http://www.invitae.com/role/SelectedQuarterlyDataUnauditedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfLoanCosts": { "auth_ref": [ "r88" ], "calculation": { "http://www.invitae.com/role/ConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for loan origination associated cost which is usually collected through escrow.", "label": "Payments of Loan Costs", "negatedLabel": "Loan payments" } } }, "localname": "PaymentsOfLoanCosts", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r88" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Payments of Stock Issuance Costs", "terseLabel": "Offering costs" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireAvailableForSaleSecurities": { "auth_ref": [ "r80", "r157" ], "calculation": { "http://www.invitae.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to acquire debt and equity securities not classified as either held-to-maturity securities or trading securities which would be classified as available-for-sale securities and reported at fair value, with unrealized gains and losses excluded from earnings and reported in a separate component of shareholders' equity.", "label": "Payments to Acquire Available-for-sale Securities", "negatedLabel": "Purchases of marketable securities" } } }, "localname": "PaymentsToAcquireAvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r81", "r336" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Payments to Acquire Businesses, Gross", "terseLabel": "Cash consideration" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r82" ], "calculation": { "http://www.invitae.com/role/ConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r243", "r274" ], "lang": { "en-US": { "role": { "documentation": "Information by plan name pertaining to equity-based compensation arrangements.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockIncentivePlansNarrativeDetails", "http://www.invitae.com/role/StockIncentivePlansScheduleOfActivityUnderStockIncentivePlansDetails", "http://www.invitae.com/role/StockIncentivePlansScheduleOfAssumptionsUsedInDeterminationOfFairValueOfOptionsDetails", "http://www.invitae.com/role/StockIncentivePlansTables", "http://www.invitae.com/role/StockholdersEquityScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the equity-based compensation arrangement plan.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockIncentivePlansNarrativeDetails", "http://www.invitae.com/role/StockIncentivePlansScheduleOfActivityUnderStockIncentivePlansDetails", "http://www.invitae.com/role/StockIncentivePlansScheduleOfAssumptionsUsedInDeterminationOfFairValueOfOptionsDetails", "http://www.invitae.com/role/StockIncentivePlansTables", "http://www.invitae.com/role/StockholdersEquityScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "auth_ref": [ "r363" ], "lang": { "en-US": { "role": { "documentation": "Measured at fair value for financial reporting purposes.", "label": "Portion at Fair Value Measurement [Member]", "terseLabel": "Portion at Fair Value Measurement [Member]" } } }, "localname": "PortionAtFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/FairValueMeasurementsCarryingAmountAndEstimatedFairValueOfCompanysOutstandingDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockLiquidationPreference": { "auth_ref": [ "r18", "r106", "r110", "r211", "r212" ], "lang": { "en-US": { "role": { "documentation": "The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.", "label": "Preferred Stock, Liquidation Preference Per Share", "terseLabel": "Preferred stock liquidation preference per share (in dollars per share)" } } }, "localname": "PreferredStockLiquidationPreference", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]", "terseLabel": "Preferred Stock" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r18" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r18" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r18" ], "lang": { "en-US": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r18" ], "lang": { "en-US": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r18" ], "calculation": { "http://www.invitae.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, $0.0001 par value: 20,000 shares authorized; 3,459 shares issued and outstanding as of December 31, 2018 and 2017" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r2", "r27", "r28" ], "calculation": { "http://www.invitae.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrivatePlacementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.", "label": "Private Placement [Member]", "terseLabel": "Private placement" } } }, "localname": "PrivatePlacementMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": { "auth_ref": [ "r85" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.", "label": "Proceeds from Debt, Net of Issuance Costs", "verboseLabel": "Net proceeds from term loan" } } }, "localname": "ProceedsFromDebtNetOfIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesDebtFinancingNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r84" ], "calculation": { "http://www.invitae.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from issuance of common stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfCashFlows", "http://www.invitae.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": { "auth_ref": [ "r84" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.", "label": "Proceeds from Issuance of Private Placement", "terseLabel": "Gross proceeds from private placement" } } }, "localname": "ProceedsFromIssuanceOfPrivatePlacement", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLoanOriginations1": { "auth_ref": [ "r79" ], "calculation": { "http://www.invitae.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Cash inflow associated with loan origination (the process when securing a mortgage for a piece of real property) or lease origination.", "label": "Proceeds from Loan Originations", "terseLabel": "Net proceeds from issuance of debt" } } }, "localname": "ProceedsFromLoanOriginations1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": { "auth_ref": [ "r76", "r77", "r157" ], "calculation": { "http://www.invitae.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale", "terseLabel": "Proceeds from maturities of marketable securities" } } }, "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromNotesPayable": { "auth_ref": [ "r85" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.", "label": "Proceeds from Notes Payable", "terseLabel": "Proceeds from Notes Payable" } } }, "localname": "ProceedsFromNotesPayable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesDebtFinancingNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": { "auth_ref": [ "r76", "r77", "r157" ], "calculation": { "http://www.invitae.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Proceeds from Sale of Debt Securities, Available-for-sale", "terseLabel": "Proceeds from sales of marketable securities" } } }, "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockPlans": { "auth_ref": [ "r84" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow associated with the amount received from the stock plan during the period.", "label": "Proceeds from Stock Plans", "verboseLabel": "Proceeds from stock plans" } } }, "localname": "ProceedsFromStockPlans", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockIncentivePlansNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromWarrantExercises": { "auth_ref": [ "r84" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.", "label": "Proceeds from Warrant Exercises", "terseLabel": "Proceeds from warrant exercises" } } }, "localname": "ProceedsFromWarrantExercises", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductInformationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Product Information [Line Items]", "terseLabel": "Product Information [Line Items]" } } }, "localname": "ProductInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfSignificantCustomersRevenueAsPercentageDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r32", "r190" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Property, Plant and Equipment, Type [Axis]", "terseLabel": "Property, Plant and Equipment, Type" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BalanceSheetComponentsPropertyAndEquipmentDetails", "http://www.invitae.com/role/CommitmentsAndContingenciesCapitalLeasesNarrativeDetails", "http://www.invitae.com/role/CommitmentsAndContingenciesOperatingLeasesNarrativeDetails", "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails", "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfUsefulLivesOfPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r31", "r188" ], "calculation": { "http://www.invitae.com/role/BalanceSheetComponentsPropertyAndEquipmentDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Total property and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BalanceSheetComponentsPropertyAndEquipmentDetails", "http://www.invitae.com/role/CommitmentsAndContingenciesCapitalLeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property and equipment" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BalanceSheetComponentsPropertyAndEquipmentDetails", "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfUsefulLivesOfPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r9", "r10", "r190", "r447" ], "calculation": { "http://www.invitae.com/role/BalanceSheetComponentsPropertyAndEquipmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.invitae.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Total property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BalanceSheetComponentsPropertyAndEquipmentDetails", "http://www.invitae.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r30", "r104", "r190" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r9", "r190" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r9", "r188" ], "lang": { "en-US": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Property, Plant and Equipment, Type [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BalanceSheetComponentsPropertyAndEquipmentDetails", "http://www.invitae.com/role/CommitmentsAndContingenciesCapitalLeasesNarrativeDetails", "http://www.invitae.com/role/CommitmentsAndContingenciesOperatingLeasesNarrativeDetails", "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails", "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfUsefulLivesOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Useful lives", "verboseLabel": "Property and equipment, estimated useful lives" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails", "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfUsefulLivesOfPropertyAndEquipmentDetails" ], "xbrltype": "durationItemType" }, "us-gaap_QuarterlyFinancialInformationDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Quarterly Financial Information Disclosure [Abstract]" } } }, "localname": "QuarterlyFinancialInformationDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_QuarterlyFinancialInformationTextBlock": { "auth_ref": [ "r130" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.", "label": "Quarterly Financial Information [Text Block]", "terseLabel": "Selected quarterly data (unaudited)" } } }, "localname": "QuarterlyFinancialInformationTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/SelectedQuarterlyDataUnaudited" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReceivablesPolicyTextBlock": { "auth_ref": [ "r20", "r26", "r104", "r153", "r155", "r446" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for trade and other accounts receivable, and finance, loan and lease receivables, including those classified as held for investment and held for sale. This disclosure may include (1) the basis at which such receivables are carried in the entity's statements of financial position (2) how the level of the valuation allowance for receivables is determined (3) when impairments, charge-offs or recoveries are recognized for such receivables (4) the treatment of origination fees and costs, including the amortization method for net deferred fees or costs (5) the treatment of any premiums or discounts or unearned income (6) the entity's income recognition policies for such receivables, including those that are impaired, past due or placed on nonaccrual status and (7) the treatment of foreclosures or repossessions (8) the nature and amount of any guarantees to repurchase receivables.", "label": "Receivables, Policy [Policy Text Block]", "terseLabel": "Accounts receivable" } } }, "localname": "ReceivablesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RecordedUnconditionalPurchaseObligation": { "auth_ref": [ "r194" ], "calculation": { "http://www.invitae.com/role/CommitmentsAndContingenciesScheduleOfFuturePaymentsUnderNoncancelableUnconditionalPurchaseCommitmentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the recorded obligation to transfer funds in the future for fixed or minimum amounts or quantities of goods or services at fixed or minimum prices (for example, as in take-or-pay contracts or throughput contracts).", "label": "Recorded Unconditional Purchase Obligation", "totalLabel": "Total" } } }, "localname": "RecordedUnconditionalPurchaseObligation", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesScheduleOfFuturePaymentsUnderNoncancelableUnconditionalPurchaseCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis": { "auth_ref": [ "r193", "r194" ], "lang": { "en-US": { "role": { "documentation": "Pertinent information about recorded unconditional purchase arrangements to acquire goods or services, by category of goods or services.", "label": "Recorded Unconditional Purchase Obligation by Category of Item Purchased [Axis]", "terseLabel": "Recorded Unconditional Purchase Obligation by Category of Item Purchased [Axis]" } } }, "localname": "RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesScheduleOfFuturePaymentsUnderNoncancelableUnconditionalPurchaseCommitmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RecordedUnconditionalPurchaseObligationDueInSecondYear": { "auth_ref": [ "r194" ], "calculation": { "http://www.invitae.com/role/CommitmentsAndContingenciesScheduleOfFuturePaymentsUnderNoncancelableUnconditionalPurchaseCommitmentsDetails": { "order": 2.0, "parentTag": "us-gaap_RecordedUnconditionalPurchaseObligation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the recorded unconditional purchase obligation maturing in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Recorded Unconditional Purchase Obligation Due in Second Year", "terseLabel": "2020" } } }, "localname": "RecordedUnconditionalPurchaseObligationDueInSecondYear", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesScheduleOfFuturePaymentsUnderNoncancelableUnconditionalPurchaseCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RecordedUnconditionalPurchaseObligationDueInThirdYear": { "auth_ref": [ "r194" ], "calculation": { "http://www.invitae.com/role/CommitmentsAndContingenciesScheduleOfFuturePaymentsUnderNoncancelableUnconditionalPurchaseCommitmentsDetails": { "order": 3.0, "parentTag": "us-gaap_RecordedUnconditionalPurchaseObligation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the recorded unconditional purchase obligation maturing in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Recorded Unconditional Purchase Obligation Due in Third Year", "terseLabel": "2021" } } }, "localname": "RecordedUnconditionalPurchaseObligationDueInThirdYear", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesScheduleOfFuturePaymentsUnderNoncancelableUnconditionalPurchaseCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RecordedUnconditionalPurchaseObligationDueWithinOneYear": { "auth_ref": [ "r194" ], "calculation": { "http://www.invitae.com/role/CommitmentsAndContingenciesScheduleOfFuturePaymentsUnderNoncancelableUnconditionalPurchaseCommitmentsDetails": { "order": 1.0, "parentTag": "us-gaap_RecordedUnconditionalPurchaseObligation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the recorded unconditional purchase obligation maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Recorded Unconditional Purchase Obligation Due in Next Twelve Months", "terseLabel": "2019" } } }, "localname": "RecordedUnconditionalPurchaseObligationDueWithinOneYear", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesScheduleOfFuturePaymentsUnderNoncancelableUnconditionalPurchaseCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RecordedUnconditionalPurchaseObligationsTextBlock": { "auth_ref": [ "r193", "r194", "r199" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of unconditional purchase obligations that are recognized as a liability on the balance sheet, including the nature and term of the unconditional purchase obligations; the aggregate amount of payments for each of the five years following the date of the latest balance sheet; and the combined aggregate amount of maturities and sinking fund requirements for all long-term borrowings associated with suppliers' financing arrangements.", "label": "Recorded Unconditional Purchase Obligations [Table Text Block]", "terseLabel": "Schedule of future payments under noncancelable unconditional purchase commitments" } } }, "localname": "RecordedUnconditionalPurchaseObligationsTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RegistrationPaymentArrangementTerm": { "auth_ref": [ "r373" ], "lang": { "en-US": { "role": { "documentation": "Describes the term of the registration payment arrangement.", "label": "Registration Payment Arrangement, Term", "terseLabel": "Registration payment arrangement term" } } }, "localname": "RegistrationPaymentArrangementTerm", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesOtherCommitmentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r400" ], "lang": { "en-US": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/InvestmentInPrivatelyHeldCompanyDetails", "http://www.invitae.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r238", "r398", "r399", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419" ], "lang": { "en-US": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]", "terseLabel": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/InvestmentInPrivatelyHeldCompanyDetails", "http://www.invitae.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RepaymentsOfLongTermCapitalLeaseObligations": { "auth_ref": [ "r86" ], "calculation": { "http://www.invitae.com/role/ConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for the obligation for a lease meeting the criteria for capitalization (with maturities exceeding one year or beyond the operating cycle of the entity, if longer).", "label": "Repayments of Long-term Capital Lease Obligations", "negatedLabel": "Capital lease principal payments" } } }, "localname": "RepaymentsOfLongTermCapitalLeaseObligations", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r86" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments of Long-term Debt", "terseLabel": "Repayments of Long-term Debt" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesDebtFinancingNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r281", "r458" ], "calculation": { "http://www.invitae.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchMember": { "auth_ref": [ "r306" ], "lang": { "en-US": { "role": { "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.", "label": "Research Tax Credit Carryforward [Member]", "terseLabel": "Research and development" } } }, "localname": "ResearchMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCash": { "auth_ref": [ "r102", "r421", "r443" ], "calculation": { "http://www.invitae.com/role/FairValueMeasurementsFinancialInstrumentsAtFairValueOnRecurringBasisDetails": { "order": 2.0, "parentTag": "nvta_CashEquivalentsRestrictedCashAndMarketableSecuritiesFairValue", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCash", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/FairValueMeasurementsFinancialInstrumentsAtFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalents": { "auth_ref": [ "r8", "r96", "r102", "r421", "r443" ], "calculation": { "http://www.invitae.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash and Cash Equivalents", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedBalanceSheets", "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Shares of common stock subject to outstanding RSUs", "verboseLabel": "Restricted Stock Units (RSUs)" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsNarrativeDetails", "http://www.invitae.com/role/NetLossPerCommonShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails", "http://www.invitae.com/role/StockIncentivePlansNarrativeDetails", "http://www.invitae.com/role/StockIncentivePlansScheduleOfActivityUnderStockIncentivePlansDetails", "http://www.invitae.com/role/StockIncentivePlansSummaryOfRsuActivityDetails", "http://www.invitae.com/role/StockholdersEquityScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r22", "r218", "r444" ], "calculation": { "http://www.invitae.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedBalanceSheets", "http://www.invitae.com/role/RevenueAccountsReceivableAndDeferredRevenueScheduleOfImpactOfAdoptionOfTopic606OnCondensedStatementOfOperationsAndBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r225", "r226", "r227" ], "calculation": { "http://www.invitae.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Total revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfOperations", "http://www.invitae.com/role/GeographicInformationScheduleOfRevenueByCountryDetails", "http://www.invitae.com/role/RevenueAccountsReceivableAndDeferredRevenueNarrativeDetails", "http://www.invitae.com/role/RevenueAccountsReceivableAndDeferredRevenueScheduleOfDisaggregatedRevenueByPayerCategoryDetails", "http://www.invitae.com/role/RevenueAccountsReceivableAndDeferredRevenueScheduleOfImpactOfAdoptionOfTopic606OnCondensedStatementOfOperationsAndBalanceSheetDetails", "http://www.invitae.com/role/SelectedQuarterlyDataUnauditedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r105", "r235" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue recognition and cost of revenue" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r119", "r235" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Revenue, accounts receivable and deferred revenue" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/RevenueAccountsReceivableAndDeferredRevenue" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": { "auth_ref": [ "r148" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.", "label": "Revenue from External Customers by Geographic Areas [Table Text Block]", "terseLabel": "Schedule of revenue by country" } } }, "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/GeographicInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenue, Initial Application Period Cumulative Effect Transition [Line Items]", "terseLabel": "Revenue, Initial Application Period Cumulative Effect Transition [Line Items]" } } }, "localname": "RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/RevenueAccountsReceivableAndDeferredRevenueScheduleOfImpactOfAdoptionOfTopic606OnCondensedStatementOfOperationsAndBalanceSheetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information when using transition method for cumulative effect in initial period of application for revenue from contract with customer.", "label": "Revenue, Initial Application Period Cumulative Effect Transition [Table]", "terseLabel": "Revenue, Initial Application Period Cumulative Effect Transition [Table]" } } }, "localname": "RevenueInitialApplicationPeriodCumulativeEffectTransitionTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/RevenueAccountsReceivableAndDeferredRevenueScheduleOfImpactOfAdoptionOfTopic606OnCondensedStatementOfOperationsAndBalanceSheetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenue:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenues from External Customers and Long-Lived Assets [Line Items]", "terseLabel": "Geographic information" } } }, "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/GeographicInformationScheduleOfRevenueByCountryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale of Stock, Number of Shares Issued in Transaction", "terseLabel": "Number of shares sold in private placement (in shares)" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Sale of Stock, Price Per Share", "terseLabel": "Shares issued price per share (in dollars per share)" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Revenue from sale of goods and services rendered, in the normal course of business, after sales returns and allowances, and sales discounts, when it serves as a benchmark in a concentration of risk calculation.", "label": "Sales Revenue, Net [Member]", "terseLabel": "Revenue" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails", "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfSignificantCustomersRevenueAsPercentageDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScenarioForecastMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The reporting scenario used to indicate financial results forecast for a future period.", "label": "Scenario, Forecast [Member]", "terseLabel": "Scenario, forecast" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsNarrativeDetails", "http://www.invitae.com/role/CommitmentsAndContingenciesDebtFinancingNarrativeDetails", "http://www.invitae.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScenarioUnspecifiedDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Any scenario, that is, the particular reporting scenario is left unspecified. Scenarios distinguish among different kinds of business reporting facts, as for example actual versus budgeted figures.", "label": "Scenario, Unspecified [Domain]", "terseLabel": "Scenario, Unspecified" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsNarrativeDetails", "http://www.invitae.com/role/CommitmentsAndContingenciesDebtFinancingNarrativeDetails", "http://www.invitae.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of accrued liabilities" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r124" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of antidilutive securities excluded from computation of earnings per share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/NetLossPerCommonShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r321", "r322" ], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsNarrativeDetails", "http://www.invitae.com/role/BusinessCombinationsScheduleOfEconomicBenefitsOfIntangibleAssetsExpectedToBeRealizedDetails", "http://www.invitae.com/role/BusinessCombinationsSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetails", "http://www.invitae.com/role/BusinessCombinationsTables" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCapitalLeasedAsssetsTable": { "auth_ref": [ "r393" ], "lang": { "en-US": { "role": { "documentation": "Schedule of long-lived, depreciable assets that are subject to a lease meeting the criteria for capitalization and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Schedule of Capital Leased Assets [Table]", "terseLabel": "Schedule of Capital Leased Assets [Table]" } } }, "localname": "ScheduleOfCapitalLeasedAsssetsTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesCapitalLeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of cash and cash equivalents.", "label": "Schedule of Cash and Cash Equivalents [Table Text Block]", "terseLabel": "Schedule of cash, cash equivalents and restricted cash" } } }, "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r342" ], "lang": { "en-US": { "role": { "documentation": "Schedule of contractual arrangements that involve two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity. Additionally, the element may include all other transactions of the entity categorized collectively, if such comparison of collaborative arrangements as a component of all transactions of the entity is desired.", "label": "Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]", "terseLabel": "Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/InvestmentInPrivatelyHeldCompanyDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": { "auth_ref": [ "r269" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the amount of total share-based compensation cost, including the amounts attributable to each share-based compensation plan and any related tax benefits.", "label": "Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block]", "terseLabel": "Summary of stock based compensation expense related to stock options included in consolidated statements of operations" } } }, "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockIncentivePlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r311" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "terseLabel": "Schedule of components of the provision for income taxes" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r303" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Schedule of net deferred tax assets" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r125" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of earnings per share, basic and diluted" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/NetLossPerCommonShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r289" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Schedule of reconciliation of the tax expense computed at the statutory federal rate and Company's tax expense" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r242", "r269", "r276" ], "lang": { "en-US": { "role": { "documentation": "Schedule that sets forth the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.", "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]", "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockIncentivePlansScheduleOfAssumptionsUsedInDeterminationOfFairValueOfOptionsDetails", "http://www.invitae.com/role/StockIncentivePlansStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r352" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of Financial instruments at fair value on a recurring basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock": { "auth_ref": [ "r175" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of finite-lived intangible assets acquired as part of a business combination or through an asset purchase, by major class and in total, including the value of the asset acquired, any significant residual value (the expected value of the asset at the end of its useful life) and the weighted-average amortization period.", "label": "Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]", "terseLabel": "Schedule of economic benefits of intangible assets expected to be realized" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r175", "r178" ], "lang": { "en-US": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/GoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r175", "r178" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of finite-lived intangible assets" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/GoodwillAndIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock": { "auth_ref": [ "r394" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of future minimum lease payments as of the date of the latest balance sheet presented, in aggregate and for each of the five years succeeding fiscal years, with separate deductions from the total for the amount representing executor costs, including any profit thereon, included in the minimum lease payments and for the amount of the imputed interest necessary to reduce the net minimum lease payments to present value.", "label": "Schedule of Future Minimum Lease Payments for Capital Leases [Table Text Block]", "terseLabel": "Schedule of future minimum lease payments under capital leases" } } }, "localname": "ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": { "auth_ref": [ "r389" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.", "label": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]", "terseLabel": "Schedule of future minimum payments under operating leases" } } }, "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfGoodwillTable": { "auth_ref": [ "r171", "r173" ], "lang": { "en-US": { "role": { "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.", "label": "Schedule of Goodwill [Table]", "terseLabel": "Schedule of Goodwill [Table]" } } }, "localname": "ScheduleOfGoodwillTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/GoodwillAndIntangibleAssetsNarrativeDetails", "http://www.invitae.com/role/GoodwillAndIntangibleAssetsSummaryOfGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r171", "r173" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Goodwill [Table Text Block]", "terseLabel": "Summary of goodwill" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/GoodwillAndIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": { "auth_ref": [ "r113" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.", "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]", "terseLabel": "Schedule of components of loss before income taxes by U.S. and foreign jurisdictions" } } }, "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOperatingLeasedAssetsTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of long-lived, depreciable assets that are subject to a operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Schedule of Operating Leased Assets [Table]", "terseLabel": "Schedule of Operating Leased Assets [Table]" } } }, "localname": "ScheduleOfOperatingLeasedAssetsTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesOperatingLeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfProductInformationTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule detailing quantitative information concerning products or product lines by product or product line.", "label": "Schedule of Product Information [Table]", "terseLabel": "Schedule of Product Information [Table]" } } }, "localname": "ScheduleOfProductInformationTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfSignificantCustomersRevenueAsPercentageDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r32", "r190" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BalanceSheetComponentsPropertyAndEquipmentDetails", "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfUsefulLivesOfPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfProspectiveAdoptionOfNewAccountingPronouncementsTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the comparison between amounts disclosed under previous guidance and new guidance.", "label": "Schedule of Prospective Adoption of New Accounting Pronouncements [Table Text Block]", "terseLabel": "Schedule of impact of adoption of topic 606 on condensed consolidated statement of operations and balance sheet" } } }, "localname": "ScheduleOfProspectiveAdoptionOfNewAccountingPronouncementsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/RevenueAccountsReceivableAndDeferredRevenueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock": { "auth_ref": [ "r129" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.", "label": "Quarterly Financial Information [Table Text Block]", "terseLabel": "Schedule of selected quarterly data" } } }, "localname": "ScheduleOfQuarterlyFinancialInformationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/SelectedQuarterlyDataUnauditedTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "auth_ref": [ "r325" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "terseLabel": "Summary of fair values of assets acquired and liabilities assumed" } } }, "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRentExpenseTableTextBlock": { "auth_ref": [ "r386" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of rental expense from operating leases for each period for which an income statement is presented with separate amounts for minimum rentals, contingent rentals, and sublease rentals. Rental payments under leases with terms of a month or less that were not renewed need not be included.", "label": "Schedule of Rent Expense [Table Text Block]", "terseLabel": "Schedule of rent expense related to non-cancelable operating leases" } } }, "localname": "ScheduleOfRentExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": { "auth_ref": [ "r8", "r102", "r421", "r443" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.", "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]", "terseLabel": "Schedule of restrictions on cash and cash equivalents" } } }, "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.", "label": "Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]", "terseLabel": "Schedule significant customer, revenue as a percentage" } } }, "localname": "ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": { "auth_ref": [ "r65", "r67", "r149" ], "lang": { "en-US": { "role": { "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]", "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]" } } }, "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/GeographicInformationScheduleOfRevenueByCountryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": { "auth_ref": [ "r255", "r260", "r263" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure for share-based compensation plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Compensation, Activity [Table Text Block]", "terseLabel": "Schedule of activity under stock incentive plans" } } }, "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockIncentivePlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r243", "r274" ], "lang": { "en-US": { "role": { "documentation": "Components of an equity-based arrangement under which compensation is awarded to employees, typically comprised of compensation expense; changes in the quantity and fair value of the shares (or other type of equity) granted, exercised, forfeited, and issued and outstanding pertaining to that plan; and cash flow effects resulting from the equity-based payment arrangement. Component disclosures are by type of award and plan name.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockIncentivePlansNarrativeDetails", "http://www.invitae.com/role/StockIncentivePlansScheduleOfActivityUnderStockIncentivePlansDetails", "http://www.invitae.com/role/StockIncentivePlansSummaryOfRsuActivityDetails", "http://www.invitae.com/role/StockIncentivePlansTables" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "auth_ref": [ "r249" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.", "label": "Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block]", "terseLabel": "Summary of RSU activity" } } }, "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockIncentivePlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r265" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of assumptions used in determination of fair value of options" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockIncentivePlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r45", "r111", "r207", "r208", "r209", "r211", "r212", "r213", "r215", "r216", "r217", "r218" ], "lang": { "en-US": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockholdersEquityNarrativeDetails", "http://www.invitae.com/role/StockholdersEquityScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "auth_ref": [ "r108", "r219", "r220", "r241" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]", "terseLabel": "Schedule of outstanding warrants to purchase common stock" } } }, "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "auth_ref": [ "r178" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "terseLabel": "Summary of estimated future amortization expense of intangible assets with finite lives" } } }, "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/GoodwillAndIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SecuredDebtMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.", "label": "Secured Debt [Member]", "terseLabel": "Secured Debt" } } }, "localname": "SecuredDebtMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesDebtFinancingNarrativeDetails", "http://www.invitae.com/role/SelectedQuarterlyDataUnauditedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SecurityDeposit": { "auth_ref": [ "r51" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.", "label": "Security Deposit", "terseLabel": "Security deposit" } } }, "localname": "SecurityDeposit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesOperatingLeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r151" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Geographic information" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/GeographicInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentsGeographicalAreasAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Segments, Geographical Areas [Abstract]" } } }, "localname": "SegmentsGeographicalAreasAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_SellingAndMarketingExpense": { "auth_ref": [], "calculation": { "http://www.invitae.com/role/ConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.", "label": "Selling and Marketing Expense", "terseLabel": "Selling and marketing" } } }, "localname": "SellingAndMarketingExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingAndMarketingExpenseMember": { "auth_ref": [ "r70" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing selling and marketing expense.", "label": "Selling and Marketing Expense [Member]", "terseLabel": "Selling and marketing" } } }, "localname": "SellingAndMarketingExpenseMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockIncentivePlansStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesAPreferredStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Outstanding nonredeemable series A preferred stock or outstanding series A preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series A Preferred Stock [Member]", "terseLabel": "Series A Convertible Preferred Stock" } } }, "localname": "SeriesAPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesFPreferredStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Outstanding nonredeemable series F preferred stock or outstanding series F preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series F Preferred Stock [Member]", "terseLabel": "Series F Preferred Stock" } } }, "localname": "SeriesFPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r93" ], "calculation": { "http://www.invitae.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.", "label": "Share-based Compensation", "terseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfCashFlows", "http://www.invitae.com/role/StockIncentivePlansNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r244" ], "lang": { "en-US": { "role": { "documentation": "Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockIncentivePlansNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate": { "auth_ref": [ "r274" ], "lang": { "en-US": { "role": { "documentation": "Discount rate from fair value on purchase date that participants pay for shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Purchase Date", "terseLabel": "Purchase price of common stock of the lesser of fair market value on the purchase date or the last trading day preceding the offering date (as a percent)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockIncentivePlansNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r254" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Cancelled (in shares)", "terseLabel": "Units cancelled (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockIncentivePlansScheduleOfActivityUnderStockIncentivePlansDetails", "http://www.invitae.com/role/StockIncentivePlansSummaryOfRsuActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r259" ], "lang": { "en-US": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Canceled (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockIncentivePlansSummaryOfRsuActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r257" ], "lang": { "en-US": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "negatedLabel": "Units granted (in shares)", "terseLabel": "Share-based compensation arrangement by share-based payment award equity instruments other than options granted in period (in shares)", "verboseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockIncentivePlansNarrativeDetails", "http://www.invitae.com/role/StockIncentivePlansScheduleOfActivityUnderStockIncentivePlansDetails", "http://www.invitae.com/role/StockIncentivePlansSummaryOfRsuActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r256" ], "lang": { "en-US": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Balance at the end of the period (in shares)", "periodStartLabel": "Balance at the beginning of the period (in shares)", "terseLabel": "RSU awards issued and outstanding (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockIncentivePlansSummaryOfRsuActivityDetails", "http://www.invitae.com/role/StockholdersEquityScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Number of Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockIncentivePlansSummaryOfRsuActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r256" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Balance at the end of the period (in dollars per share)", "periodStartLabel": "Balance at the beginning of the period (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockIncentivePlansSummaryOfRsuActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted-Average Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockIncentivePlansSummaryOfRsuActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r258" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Vested (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockIncentivePlansSummaryOfRsuActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r258" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockIncentivePlansSummaryOfRsuActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r267" ], "lang": { "en-US": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockIncentivePlansScheduleOfAssumptionsUsedInDeterminationOfFairValueOfOptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r268" ], "lang": { "en-US": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockIncentivePlansScheduleOfAssumptionsUsedInDeterminationOfFairValueOfOptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Stock incentive plan" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockIncentivePlansNarrativeDetails", "http://www.invitae.com/role/StockIncentivePlansScheduleOfActivityUnderStockIncentivePlansDetails", "http://www.invitae.com/role/StockIncentivePlansSummaryOfRsuActivityDetails", "http://www.invitae.com/role/StockIncentivePlansTables" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of additional shares authorized for issuance under an established share-based compensation plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized", "terseLabel": "Additional shares reserved (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockIncentivePlansScheduleOfActivityUnderStockIncentivePlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r274" ], "lang": { "en-US": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "periodEndLabel": "Shares available for grant, ending balance (in shares)", "periodStartLabel": "Shares available for grant, beginning balance (in shares)", "terseLabel": "Shares available for grant under stock options plans (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockIncentivePlansScheduleOfActivityUnderStockIncentivePlansDetails", "http://www.invitae.com/role/StockholdersEquityScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]", "terseLabel": "Additional information" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockIncentivePlansScheduleOfActivityUnderStockIncentivePlansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r252" ], "lang": { "en-US": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "terseLabel": "Exercisable (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockIncentivePlansScheduleOfActivityUnderStockIncentivePlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r252" ], "lang": { "en-US": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Exercisable, weighted-average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockIncentivePlansScheduleOfActivityUnderStockIncentivePlansDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r262" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Exercised, aggregate intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockIncentivePlansNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r254" ], "lang": { "en-US": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Option cancelled (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockIncentivePlansScheduleOfActivityUnderStockIncentivePlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Options granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockIncentivePlansScheduleOfActivityUnderStockIncentivePlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r261" ], "lang": { "en-US": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-average grant date fair value (in dollars per share)", "verboseLabel": "Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockIncentivePlansNarrativeDetails", "http://www.invitae.com/role/StockIncentivePlansSummaryOfRsuActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r274" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Aggregate intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockIncentivePlansScheduleOfActivityUnderStockIncentivePlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r251", "r274" ], "lang": { "en-US": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Stock options outstanding, ending balance (in shares)", "periodStartLabel": "Stock options outstanding, beginning balance (in shares)", "terseLabel": "Options issued and outstanding (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockIncentivePlansScheduleOfActivityUnderStockIncentivePlansDetails", "http://www.invitae.com/role/StockholdersEquityScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Activity under the plan" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockIncentivePlansScheduleOfActivityUnderStockIncentivePlansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r250" ], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Balance at the end of the period (in dollars per share)", "periodStartLabel": "Balance at the beginning of the period (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockIncentivePlansScheduleOfActivityUnderStockIncentivePlansDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted- Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockIncentivePlansScheduleOfActivityUnderStockIncentivePlansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest [Abstract]", "terseLabel": "Vested and expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockIncentivePlansScheduleOfActivityUnderStockIncentivePlansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r263" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "terseLabel": "Aggregate intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockIncentivePlansScheduleOfActivityUnderStockIncentivePlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r264" ], "lang": { "en-US": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "terseLabel": "Number of options (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockIncentivePlansScheduleOfActivityUnderStockIncentivePlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r264" ], "lang": { "en-US": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "terseLabel": "Weighted-average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockIncentivePlansScheduleOfActivityUnderStockIncentivePlansDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost": { "auth_ref": [ "r272" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "An excess of the fair value of the modified award over the fair value of the award immediately before the modification.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Incremental Compensation Cost", "terseLabel": "Incremental compensation cost relating to stock option and RSU modifications" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockIncentivePlansNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected": { "auth_ref": [ "r271" ], "lang": { "en-US": { "role": { "documentation": "The number of employees affected by the modification of an equity-based compensation plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Number of Employees Affected", "terseLabel": "Number of employees affected by the stock option and RSU modifications" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockIncentivePlansNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r241", "r246" ], "lang": { "en-US": { "role": { "documentation": "Equity-based compensation award.", "label": "Equity Award [Domain]", "terseLabel": "Equity Award" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsNarrativeDetails", "http://www.invitae.com/role/StockIncentivePlansNarrativeDetails", "http://www.invitae.com/role/StockIncentivePlansScheduleOfActivityUnderStockIncentivePlansDetails", "http://www.invitae.com/role/StockIncentivePlansScheduleOfAssumptionsUsedInDeterminationOfFairValueOfOptionsDetails", "http://www.invitae.com/role/StockIncentivePlansStockBasedCompensationExpenseDetails", "http://www.invitae.com/role/StockIncentivePlansSummaryOfRsuActivityDetails", "http://www.invitae.com/role/StockIncentivePlansTables", "http://www.invitae.com/role/StockholdersEquityScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Options exercised (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockIncentivePlansScheduleOfActivityUnderStockIncentivePlansDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Options cancelled (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockIncentivePlansScheduleOfActivityUnderStockIncentivePlansDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Options granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockIncentivePlansScheduleOfActivityUnderStockIncentivePlansDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1": { "auth_ref": [ "r219", "r266" ], "lang": { "en-US": { "role": { "documentation": "Period an equity-based award is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Term", "terseLabel": "Expected term (in years)" } } }, "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockIncentivePlansScheduleOfAssumptionsUsedInDeterminationOfFairValueOfOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate": { "auth_ref": [ "r219", "r267" ], "lang": { "en-US": { "role": { "documentation": "The estimated measure of the percentage amount by which a share price is expected to fluctuate during the expected term of a nonvested share or option award issued to other than an employee.", "label": "Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Volatility Rate", "terseLabel": "Expected volatility" } } }, "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockIncentivePlansScheduleOfAssumptionsUsedInDeterminationOfFairValueOfOptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate": { "auth_ref": [ "r219", "r268" ], "lang": { "en-US": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing a nonvested share or option award issued to other than an employee.", "label": "Share-based Goods and Nonemployee Services Transaction, Valuation Method, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockIncentivePlansScheduleOfAssumptionsUsedInDeterminationOfFairValueOfOptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "auth_ref": [ "r244" ], "lang": { "en-US": { "role": { "documentation": "Percentage of vesting of share-based compensation awards.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage", "terseLabel": "Share-based compensation arrangement by share-based payment award, award vesting rights, percentage" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockIncentivePlansNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r245" ], "lang": { "en-US": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period", "terseLabel": "Term of options granted" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockIncentivePlansNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r266", "r275" ], "lang": { "en-US": { "role": { "documentation": "Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockIncentivePlansScheduleOfAssumptionsUsedInDeterminationOfFairValueOfOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r274" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Exercisable, aggregate intrinsic value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockIncentivePlansScheduleOfActivityUnderStockIncentivePlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r274" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Exercisable, weighted-average remaining contractual life" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockIncentivePlansScheduleOfActivityUnderStockIncentivePlansDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r264" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted-average remaining contractual life" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockIncentivePlansScheduleOfActivityUnderStockIncentivePlansDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r264" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted-average remaining contractual life" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockIncentivePlansScheduleOfActivityUnderStockIncentivePlansDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": { "auth_ref": [ "r248" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value", "terseLabel": "Total grant date fair value of options to purchase common stock vested" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockIncentivePlansNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of options vested.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares", "terseLabel": "Vested stock units awarded (in shares)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockIncentivePlansNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Purchase price of common stock expressed as a percentage of its fair value.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent", "terseLabel": "Exercise price of options on common stock (as a percent)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockIncentivePlansNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareholdersEquityClassAxis": { "auth_ref": [ "r357" ], "lang": { "en-US": { "role": { "documentation": "Information by class of financial instrument classified in shareholders' equity.", "label": "Shareholders' Equity Class [Axis]", "terseLabel": "Shareholders' Equity Class" } } }, "localname": "ShareholdersEquityClassAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockholdersEquityScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Shares Issued, Price Per Share", "terseLabel": "Shares issued price per share (in dollars per share)" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesDebtFinancingNarrativeDetails", "http://www.invitae.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance at the end of the period (in shares)", "periodStartLabel": "Balance at the beginning of the period (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r119" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of significant accounting policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/SummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.", "label": "Software and Software Development Costs [Member]", "terseLabel": "Software" } } }, "localname": "SoftwareAndSoftwareDevelopmentCostsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BalanceSheetComponentsPropertyAndEquipmentDetails", "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfUsefulLivesOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StateAndLocalJurisdictionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.", "label": "State and Local Jurisdiction [Member]", "terseLabel": "State" } } }, "localname": "StateAndLocalJurisdictionMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r17", "r18", "r19", "r210" ], "lang": { "en-US": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsNarrativeDetails", "http://www.invitae.com/role/StockholdersEquityNarrativeDetails", "http://www.invitae.com/role/StockholdersEquityScheduleOfOutstandingWarrantsToPurchaseCommonStockDetails", "http://www.invitae.com/role/StockholdersEquityScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r48", "r210" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsNarrativeDetails", "http://www.invitae.com/role/CommitmentsAndContingenciesDebtFinancingNarrativeDetails", "http://www.invitae.com/role/ConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity", "http://www.invitae.com/role/StockholdersEquityNarrativeDetails", "http://www.invitae.com/role/StockholdersEquityScheduleOfOutstandingWarrantsToPurchaseCommonStockDetails", "http://www.invitae.com/role/StockholdersEquityScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity", "http://www.invitae.com/role/ConsolidatedStatementsOfOperations", "http://www.invitae.com/role/SelectedQuarterlyDataUnauditedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementScenarioAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by scenario to be reported. Scenarios distinguish among different kinds of business reporting facts, as for example actual versus budgeted figures.", "label": "Scenario [Axis]", "terseLabel": "Scenario" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsNarrativeDetails", "http://www.invitae.com/role/CommitmentsAndContingenciesDebtFinancingNarrativeDetails", "http://www.invitae.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity", "http://www.invitae.com/role/ConsolidatedStatementsOfOperations", "http://www.invitae.com/role/SelectedQuarterlyDataUnauditedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssued1": { "auth_ref": [ "r99", "r100", "r101" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The fair value of stock issued in noncash financing activities.", "label": "Stock Issued", "terseLabel": "Common stock issued for acquisition of businesses" } } }, "localname": "StockIssued1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "auth_ref": [ "r18", "r19", "r218" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.", "label": "Stock Issued During Period, Shares, Acquisitions", "terseLabel": "Common stock issued pursuant to business combinations (in shares)", "verboseLabel": "Common stock issued pursuant to exercise of warrants (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesAcquisitions", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity", "http://www.invitae.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r47", "r210", "r211", "r218" ], "lang": { "en-US": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities", "terseLabel": "Common stock issued pursuant to debt financing (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r18", "r19", "r210", "r218" ], "lang": { "en-US": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Common stock issued pursuant to employee stock purchase plan (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r18", "r19", "r210", "r218" ], "lang": { "en-US": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Common stock issued in connection with initial public offering, net of offering costs (in shares)", "verboseLabel": "Common stock issued during period (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesDebtFinancingNarrativeDetails", "http://www.invitae.com/role/ConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity", "http://www.invitae.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.", "label": "Stock Issued During Period, Shares, Purchase of Assets", "terseLabel": "Common stock issued to settle assumed liabilities (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesPurchaseOfAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "auth_ref": [ "r210", "r218" ], "lang": { "en-US": { "role": { "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross", "terseLabel": "Common stock issued pursuant to vesting of restricted stock units (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r18", "r19", "r210", "r218", "r253" ], "lang": { "en-US": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedLabel": "Options exercised (in shares)", "terseLabel": "Options exercised (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity", "http://www.invitae.com/role/StockIncentivePlansScheduleOfActivityUnderStockIncentivePlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueAcquisitions": { "auth_ref": [ "r48", "r210", "r218" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of stock issued pursuant to acquisitions during the period.", "label": "Stock Issued During Period, Value, Acquisitions", "terseLabel": "Common stock issued pursuant to business combinations" } } }, "localname": "StockIssuedDuringPeriodValueAcquisitions", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r48", "r210", "r218" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Stock Issued During Period, Value, Conversion of Convertible Securities", "terseLabel": "Common stock issued pursuant to Securities Purchase Agreement (see Note 9)" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesDebtFinancingNarrativeDetails", "http://www.invitae.com/role/ConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "auth_ref": [ "r18", "r19", "r210", "r218" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.", "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "terseLabel": "Common stock issued pursuant to employee stock purchase plan" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r18", "r19", "r210", "r218" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Common stock issued in connection with initial public offering, net of offering costs" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.", "label": "Stock Issued During Period, Value, Purchase of Assets", "terseLabel": "Common stock issued to settle assumed liabilities" } } }, "localname": "StockIssuedDuringPeriodValuePurchaseOfAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "auth_ref": [ "r18", "r19", "r210", "r218" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.", "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross", "terseLabel": "Common stock issued pursuant to vesting of restricted stock units" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r48", "r210", "r218" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Common stock issued on exercise of stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options, after deduction of related income tax (expense) benefit.", "label": "Stock Issued, Value, Stock Options Exercised, Net of Tax Benefit (Expense)", "terseLabel": "Common stock issued on exercise of stock options, net" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r19", "r23", "r24", "r154" ], "calculation": { "http://www.invitae.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance at the end of the period", "periodStartLabel": "Balance at the beginning of the period", "terseLabel": "Stockholders' equity", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedBalanceSheets", "http://www.invitae.com/role/ConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity", "http://www.invitae.com/role/RevenueAccountsReceivableAndDeferredRevenueScheduleOfImpactOfAdoptionOfTopic606OnCondensedStatementOfOperationsAndBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity Note [Abstract]" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r222" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Stockholders\u2019 Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsNarrativeDetails", "http://www.invitae.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r401" ], "lang": { "en-US": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsNarrativeDetails", "http://www.invitae.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r401" ], "lang": { "en-US": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsNarrativeDetails", "http://www.invitae.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SummaryOfIncomeTaxContingenciesTextBlock": { "auth_ref": [ "r291", "r296", "r298" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.", "label": "Summary of Income Tax Contingencies [Table Text Block]", "terseLabel": "Schedule of reconciliation of gross unrecognized tax benefits" } } }, "localname": "SummaryOfIncomeTaxContingenciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "auth_ref": [ "r53" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "terseLabel": "Balance sheet components" } } }, "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BalanceSheetComponents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardAmount": { "auth_ref": [ "r305" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Tax Credit Carryforward, Amount", "terseLabel": "Tax credit carryforwards" } } }, "localname": "TaxCreditCarryforwardAmount", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxCreditCarryforwardAxis": { "auth_ref": [ "r306" ], "lang": { "en-US": { "role": { "documentation": "Information by specific tax credit related to an unused tax credit.", "label": "Tax Credit Carryforward [Axis]", "terseLabel": "Tax Credit Carryforward" } } }, "localname": "TaxCreditCarryforwardAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardNameDomain": { "auth_ref": [ "r306" ], "lang": { "en-US": { "role": { "documentation": "The name of the tax credit carryforward.", "label": "Tax Credit Carryforward, Name [Domain]", "terseLabel": "Tax Credit Carryforward, Name" } } }, "localname": "TaxCreditCarryforwardNameDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TaxPeriodAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information about the period subject to enacted tax laws.", "label": "Tax Period [Axis]", "terseLabel": "Tax Period [Axis]" } } }, "localname": "TaxPeriodAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TaxPeriodDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identified tax period.", "label": "Tax Period [Domain]", "terseLabel": "Tax Period [Domain]" } } }, "localname": "TaxPeriodDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TitleOfIndividualAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by title of individual or nature of relationship to individual or group of individuals.", "label": "Title of Individual [Axis]", "terseLabel": "Title of Individual" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockIncentivePlansScheduleOfAssumptionsUsedInDeterminationOfFairValueOfOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Title of individual, or nature of relationship to individual or group of individuals.", "label": "Relationship to Entity [Domain]", "terseLabel": "Relationship to Entity" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockIncentivePlansScheduleOfAssumptionsUsedInDeterminationOfFairValueOfOptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TradeNamesMember": { "auth_ref": [ "r326" ], "lang": { "en-US": { "role": { "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.", "label": "Trade Names [Member]", "terseLabel": "Trade name" } } }, "localname": "TradeNamesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsScheduleOfEconomicBenefitsOfIntangibleAssetsExpectedToBeRealizedDetails", "http://www.invitae.com/role/BusinessCombinationsSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetails", "http://www.invitae.com/role/GoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TransactionDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Agreement between buyer and seller for the exchange of financial instruments.", "label": "Transaction [Domain]", "terseLabel": "Transaction [Domain]" } } }, "localname": "TransactionDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TransactionTypeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of agreement between buyer and seller for the exchange of financial instruments.", "label": "Transaction Type [Axis]", "terseLabel": "Transaction Type [Axis]" } } }, "localname": "TransactionTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r406" ], "lang": { "en-US": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/FairValueMeasurementsFinancialInstrumentsAtFairValueOnRecurringBasisDetails", "http://www.invitae.com/role/FairValueMeasurementsLevel3FinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails", "http://www.invitae.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Adoption and early adoption of sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues Accounting Standards Updates to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.", "label": "Type of Adoption [Domain]", "terseLabel": "Type of Adoption [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/RevenueAccountsReceivableAndDeferredRevenueNarrativeDetails", "http://www.invitae.com/role/RevenueAccountsReceivableAndDeferredRevenueScheduleOfImpactOfAdoptionOfTopic606OnCondensedStatementOfOperationsAndBalanceSheetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r342" ], "lang": { "en-US": { "role": { "documentation": "Information by category of arrangement, including but not limited to collaborative arrangements and non-collaborative arrangements.", "label": "Type of Arrangement and Non-arrangement Transactions [Axis]", "terseLabel": "Type of Arrangement and Non-arrangement Transactions" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesOperatingLeasesNarrativeDetails", "http://www.invitae.com/role/CommitmentsAndContingenciesOtherCommitmentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "auth_ref": [ "r236", "r427" ], "lang": { "en-US": { "role": { "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).", "label": "US Government Agencies Debt Securities [Member]", "terseLabel": "U.S. government agency securities" } } }, "localname": "USGovernmentAgenciesDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/FairValueMeasurementsFinancialInstrumentsAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasurySecuritiesMember": { "auth_ref": [ "r236", "r239", "r427" ], "lang": { "en-US": { "role": { "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).", "label": "US Treasury Securities [Member]", "terseLabel": "U.S. treasury notes" } } }, "localname": "USTreasurySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/FairValueMeasurementsFinancialInstrumentsAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain": { "auth_ref": [ "r194" ], "lang": { "en-US": { "role": { "documentation": "General description of the goods or services to be purchased from the counterparty to the unconditional purchase arrangement.", "label": "Unconditional Purchase Obligation, Category of Goods or Services Acquired [Domain]", "terseLabel": "Unconditional Purchase Obligation, Category of Goods or Services Acquired [Domain]" } } }, "localname": "UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesScheduleOfFuturePaymentsUnderNoncancelableUnconditionalPurchaseCommitmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r284", "r294" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "periodEndLabel": "Unrecognized tax benefits, end of period", "periodStartLabel": "Unrecognized tax benefits, beginning of period", "terseLabel": "Unrecognized tax benefits" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/IncomeTaxesNarrativeDetails", "http://www.invitae.com/role/IncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "auth_ref": [ "r295" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.", "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions", "terseLabel": "Gross increases\u2014current period tax positions" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/IncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r131", "r132", "r134", "r135", "r139", "r140", "r141" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "auth_ref": [ "r285" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.", "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount", "terseLabel": "Increase in valuation allowance" } } }, "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_VestingAxis": { "auth_ref": [ "r274" ], "lang": { "en-US": { "role": { "documentation": "Information by vesting schedule for share-based compensation.", "label": "Vesting [Axis]", "terseLabel": "Vesting" } } }, "localname": "VestingAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockIncentivePlansNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VestingDomain": { "auth_ref": [ "r274" ], "lang": { "en-US": { "role": { "documentation": "Vesting schedule for share-based compensation.", "label": "Vesting [Domain]", "terseLabel": "Vesting" } } }, "localname": "VestingDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/StockIncentivePlansNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]", "terseLabel": "Shares of common stock subject to outstanding warrants" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/BusinessCombinationsNarrativeDetails", "http://www.invitae.com/role/NetLossPerCommonShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails", "http://www.invitae.com/role/StockholdersEquityScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsNotSettleableInCashFairValueDisclosure": { "auth_ref": [ "r353" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of warrants not settleable in cash classified as equity.", "label": "Warrants Not Settleable in Cash, Fair Value Disclosure", "terseLabel": "Fair value of warrant" } } }, "localname": "WarrantsNotSettleableInCashFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/CommitmentsAndContingenciesDebtFinancingNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted", "terseLabel": "Shares used in computing net loss per share, basic and diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.invitae.com/role/ConsolidatedStatementsOfOperations", "http://www.invitae.com/role/NetLossPerCommonShareScheduleOfEarningsPerShareBasicAndDilutedDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 7 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18726-107790" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(i))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19)(a)(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(d)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(d),(e))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(1)(i))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(i)(4))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(i))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690" }, "r119": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r122": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "http://asc.fasb.org/topic&trid=2122394" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r127": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=109236672&loc=d3e543-108305" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=109225645&loc=d3e1280-108306" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "270", "URI": "http://asc.fasb.org/topic&trid=2126967" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r142": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "a", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9054-108599" }, "r151": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "305", "URI": "http://asc.fasb.org/extlink&oid=6375392&loc=d3e26790-107797" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84173941&loc=d3e4975-111524" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=109979856&loc=d3e26610-111562" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=109979856&loc=d3e26853-111562" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=109979856&loc=d3e26626-111562" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=68049868&loc=d3e3927-108312" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=66092785&loc=d3e4492-108314" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=66092785&loc=d3e4556-108314" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=84159346&loc=d3e8275-108329" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=68054294&loc=d3e8384-108330" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13854-109267" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13854-109267" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r183": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2611-110228" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=77896938&loc=d3e25287-109308" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=77896938&loc=d3e25383-109308" }, "r195": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14326-108349" }, "r197": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "20A", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109126253&loc=SL6757427-112606" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6036836-161870" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=114001942&loc=d3e12317-112629" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=114001942&loc=d3e12355-112629" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=68057994&loc=d3e25284-112666" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r221": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/subtopic&trid=2208855" }, "r222": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=82913815&loc=SL49130532-203044" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=108792157&loc=SL49130690-203046-203046" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=108792157&loc=SL49130690-203046-203046" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=108792157&loc=SL49130690-203046-203046" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(i)(1)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048" }, "r235": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=112275985&loc=d3e4179-114921" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=79507207&loc=d3e4534-113899" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f(1))", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109196918&loc=d3e11149-113907" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109196918&loc=d3e11178-113907" }, "r279": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(b)", "Topic": "720", "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=115928272&loc=d3e28680-109314" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=115928272&loc=d3e28680-109314" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=SL37586934-109318" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e32123-109318" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e32247-109318" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e32280-109318" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e31917-109318" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6801-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "217", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109238393&loc=d3e36027-109320" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "05", "SubTopic": "30", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327" }, "r317": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)-(d)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=84229725&loc=d3e961-128460" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=108330185&loc=d3e2207-128464" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=84161108&loc=d3e4845-128472" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=84161108&loc=d3e4845-128472" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5263-128473" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5263-128473" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5333-128473" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5504-128473" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.15)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6405-128476" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=109124213&loc=d3e6578-128477" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=109124213&loc=d3e6613-128477" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911338&loc=d3e6819-128478" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(3)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(4)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479" }, "r341": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "http://asc.fasb.org/topic&trid=2303972" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r343": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "808", "URI": "http://asc.fasb.org/topic&trid=5833765" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "2AA", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "a", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108788376&loc=SL6759068-111685" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108788376&loc=d3e5728-111685" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108788376&loc=SL6759159-111685" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3A-02)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=27015204&loc=d3e355033-122828" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3A-03)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=27015204&loc=d3e355100-122828" }, "r351": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19190-110258" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "2C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=SL7498348-110258" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19279-110258" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=SL6742756-110258" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r362": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "820", "URI": "http://asc.fasb.org/topic&trid=2155941" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75026489&loc=d3e13220-108610" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=109250915&loc=d3e13279-108611" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=109250915&loc=d3e13433-108611" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=109250915&loc=d3e13467-108611" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=109250915&loc=d3e13476-108611" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=109250915&loc=d3e13531-108611" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=109250915&loc=d3e13537-108611" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14172-108612" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14210-108612" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14217-108612" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=99383193&loc=d3e16207-108621" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77910348&loc=d3e34039-112682" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(Note 2)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(Note 3)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902458&loc=d3e39927-112707" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902458&loc=d3e40010-112707" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902458&loc=d3e40019-112707" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41499-112717" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=84164758&loc=d3e45014-112735" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=84164758&loc=d3e45023-112735" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=84164758&loc=d3e45031-112735" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=84164817&loc=d3e45280-112737" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=84164817&loc=d3e45280-112737" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918666-209980" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6911-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=68078379&loc=d3e122625-111746" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6)(a)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62652-112803" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "405", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=50488274&loc=d3e64164-112818" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(c)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "e", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15)(b)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.26(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(5))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99384497&loc=SL65671331-158438" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=6488278&loc=d3e603758-122996" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "740", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r459": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r460": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6935-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8,17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r53": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "210", "URI": "http://asc.fasb.org/topic&trid=2122208" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e637-108580" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e681-108580" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669686-108580" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL34724394-108580" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e7018-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e557-108580" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-03(e))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868656-224227" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3151-108585" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3179-108585" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3179-108585" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3179-108585" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3367-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3044-108585" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4273-108586" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586" } }, "version": "2.0" } ZIP 113 0001501134-19-000022-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001501134-19-000022-xbrl.zip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�>C"T"<4(:.#1\ / (.]DE)O M6CCNM33&DI(EI5U)";7C="-!*8(PP(J<7!XIBI+"J(@TE!2@%[C>MB"EWI1$ M1$]"*IU%1FS7]V\R7'47O6(;W= FO=JDUQTY'&V-8!?XT ^]@. A C*$"KE MP93WA%$0KG?!?IK#K>>Z]AQ1(,)FNUHWGF6%EA7VR I9.Q! 1%#HYG*"-VW%P5$[LL*>PQ8**W4LD++"BTKM*RP/U8H8%L+1;@?D= +.?4A@0%T MW9H5,HX9VI<5]A@/<4F?U:*GQ@H'5@/5VXQ'<_$SX_B"Y&KN7*>9GN&0?1U2 MP=;'K&3?Y91RK1:,RB^>F<;WTTS/N3Z:>7%S>_U MO/)R>(T>[&?& MPM\F(19V;&4SENJOMZACSWBAQ4C(IA[:S%:#?>/63'/%WKS?ISG#PJ< M96?M1RHQV7_#9K#'\JWM5 ]]GC*;U$??G.S*7)"?9ME7?4;Z,E(@4HT$/!W)]=N:P6=7+,&EK M7@7%X89;.7NJ?!WMO*L"XIY4P&: ;(O9_[7(D@J=G]8$%=@F38.DIQCEBD;( M'=G8_).,?7Z3YI/75!516R;A^ACXPA?$A5BB$'$2\HKF ME?A=9%1KJ$8_E8,H5Q+I*Q@J83OPM3LO6#:L#P[6@R&9S9Y+']\[B M;I8]]ABEYSK72;(WFF[$TLX A0CZ@$5>X".)210$".-*B1541G*IR\P*BLYN M;U,S:C=*DE^37!?BQ5^33]EOV:)()IXA0@4+/]9-&>8/&Y#85VPEG=#P4]+ ?#V'*PM^5@->N(S<$9CJ$XPRP_-.#;-"- M(7(Q!AX-(/4\P6$UBMJ-?,GX^BAJI<-\NEXFX,_)K1+3"O['P0=V51K!P:91 MOV @ZOX.^9>Y4/OW0E[6(K#H#( WZJ5BA8\IE4K%T^E(6AE5IED\UY)3W6^: M)>5Z*'+RAQXIKY54[3.<)'^67]]-%\5AA2MIZ*;N,Q9Z>A?WE+D_BR:?L[[%:DU(L/JM-P"V,KZ%(TRY+W2!/V05;3ZC9 M4Z0JVT#W[#;HU,$"+6CU5VHC<672'Q0G:!O*@C#T$*4A9,03OB3 C5B%$X M$#VC<'W4&_A8X;Q&A*K.YS31 5RP==?AOAK6K.0L.]Z.P8XWOI_$#\YO%U\N MG$ W"_9HL\BZ>[4YR.[!BWV1)#5DB;S,W'[9[\ M[F^WZKN;Z<.NL.XX#8QPF!V>SMW6Y<:XZX4RY,P5P%?$3@)>]2F/ NKQ\!DZ MC_1:NW1^F@3.+];G'.Q)WZM^MO78LOFZU'96U9SUGC+O#JQV<;*R7//?F[Q^ MQ)TRI]]?*1GU^WLS=>)#/+V/'PK=Z>XFK_:R;Y?'5] 4SV %S3J6D&MS!\W M#2,L,/:1(-S''F)15,\X9YX/-0D]TYATX^WXT"A\V?%QC6>+Z<2YC7]/G(IU M-QKZ^UFF/C7M])5=FT[KO(,'I_3 B?*+[V;Y)H?ORIT(?#^JK>9J/DNS@.:5 MBO7?Y6DV3N^46: O;HR'>ZT@YLI>2//2[W*]F*H[E?F=S]5.C2AK,Q!*H_SJ M0O B[QP0Z3R7-,;,:1UK# ,)?$)CSS(J0MH$#!8<1G&HH O8VG\"4(I__\W.J/-TFQE6EUR3?JGRJ+FNY4&IEIK9L6N4;EX+A0YU8:3>\^C6/LWD;-:NR M2F/%U/*\BNC&8Z/A.<5-K-2^>GG5 [23!;(?"@7W6Z4ZJGW.QK^W/F1]Y1^+ MV3SM(_%K(WZWZ:8L#"- 0ADHQ.8>\6A$4)-N2A%;PN]_E'LM=)Y.,KF&>5@JR14B\DM)EDR05F"7 M,6BJ+(B\?EK\+J0) MV&2,+]%B:O"O2X<5%9HLH;N%LG!T+?DA:0B!-DW7XYY0Y")%Q +(6,@!""H: MXI1)^BP-_5JMUC=LXB^G6MK\8P^.NBF"AY8 3#XYDO&Y %7&SN,[43JC1\M.)$ M2]XE??SI=5JREB)IN8K._E.B3AFJ55')=9SFSK=XNG@-A&I=_J'G>2*B/*(8 M>=B'/J!UO@S / *K"%4CRR^S^9=D/I\F.L#[,?/CXB92._B[WD"0%II]+_)A M6K&[ITT4)\K2;YU]*+#T]ZP;8(G$411])W)2<,$0XXDV&%4T2ZA!RW M]-H_V7L?HLO#CL.2=S!UI8("*< 01IQEW,N6.0C4HD[#.AZZ=J1 MB[M>Z@CVD9+L O2.6ZU\=(Y -"+8*6""KDLA1=B+? 8I]B6LD8]!*4Y%-+Y= M]0JX6*\[[TNBRNFT1:E*0*Z6R#V7K'>CC%U=C:%%;T_>DWK Y!K.M048$D8" M,T^B0"=@A#K3O7:>A!)A\:CHU' Y$1G909;W2OGY,%GD][-\4B39N[]IM\)# M$N?%DR,D=V-0IM:B="^88*C!EM+G9T*NX^EBHE%AK AYFA1%5R#.OJ6%0M:] M:Z5Z+H]W?IE]*RM%-E5#J2O5IFNE:[4"ZITI)WGBDG<;2J">+''*G/BK>LA7 MD]O:QK=+']7B3E]Z6":/6UW5BR*):0"0#MEY5"@-U:MT5<7\Z9K]\UC:>.50 MWY T7N6,*\A@\!Q-&NK01UZ?>/^6# ('+ 70S7H47NUX>Z$=Z[N^6G.'-K?! ML.X2*RLB7FK&<%6#Z_!*!>D4X!/$A$N$B#B $"!/;_N%:A;=0\/WS:*@DLE MA,8WR:M>JZK! -#A^VKG,'%>H2DK\HEDWJE>46:E9F_9=^. MN_BAKLFL0X!:-=!965=*IIGDN-D==P1@H2/( J?/=9!2V<=:*[NLM++=L&3 ;CJ7',Q/UZGS>28;J3FL9&9Z833*LFV,YW59?L[\LVV4H2ZNX0]W.CVC2:4HVSJHZMW M1-H==>?.(DSWCR4">/[2Q[3L]4PDO'5F)60'R-*MLH?67#WI=8.T::'L]DEB M%"6%U1"5Q1!%K9XWY0P*YWXX+&YUNEG[0BKSBV!$.0: 265\U=Y8Y G!3ANW M+N]GO>(61F^+6W7"MT(NK:DC\BR.'3HE&+$VS(F42$4^A.I+SZ<"(K]J:*,L M_E#Z)\[#+K7DZ173R&,2^@TP3:&81B/L/H-I.^C+VW19(Z"7%A%J_:NA[(/,^/$ ^E4D(Y8Y3PNO++$P%=SG;JIK3_DLRE.XWS(R]/O5CNN7!;QE;J"RLV9^:) M*<.L-_S::(=W"H9<2EP9P1 A+V0\"'G$W0K!@I#ZRX5C56SH%'%KY^C!A7M8 M<[VR>8W;[6NF?C>.MT;:53XW[>O-9XNO59^1],^D4\^MSBW_FA1-'[66I55H MVJ#>:N;GDJ- 7:3^F3>(:_(_OR998H1M?-AB1R3:/!9,1<@8@\"G( *"<1ZP MRBJ7D;I\"6<-^F4*5]4B/UU_3I0HR ZLQ?;43;'_2L2T.HM&/5E;'&131=W-Z]+Q17:YIXOESX7CC!HP[@83A3-VN@:[W7LJ:U5TA(VI3WU^@2SO64&'N'%/??/ M&9X%]2QB:EC%:59T6/YXIEA^G;T?CV]2)0*:EB*U/)BJ?Z)'=V&M MY+EB 0F=%7_/4T3W0E; M"ZVR,C'3F19Y=:=:Q3Q/KQ9EA$0MZV8V58LHZC#\.+[3[<#*5'7=O[ZIB,^\659KK:O:X;N2B05OLTQE.UNNHK?6TZ296VE!35RBI(#=J; M\$21RW.'-UK+UGDVF;$*^JAC>31\5K]QJP$^5<[P065!9UR&ZWO8#[@,8! % M!* P:$H^98#%6JF#J8PIBV:ZS+^LG/XEN3<_/3+RH-<4;1Q=-E+5;"V&*8,CJ\4Q+Q2&0SNC,+PE-F'A,2 18QH M/Q8,FH;GBOK71LF52% B1^T3KFI"#IHAN#\Z[%OEB2^P.%@!BZET7\I>;MT# MA\4%U,:DI/2!\ AW,1=>0)EP8?>R>UW.H$'ZI-I3X4G(*$[A7@G^I/%/K+TU#A"MU1DU;!$A-Y]75 M7@M+3^P&[NMJA?+%>:(>F2I]L5,T=9O,;V83\U(]Y,!HE=/I;*PQN QI5%FN M==S"-&#H\KU*%M;>B6PV;^_ZH?1G+-5H/?6 92O6=&]*RBRG)M'AP(3D=ORV MT">N*R0%H?0% "Z%/J60(X9=*M82*$LN)$'&E=TZ*_-D=/;_ESN96E:4"$SDX;XS$BYX\]M M/%R/B[IE;9N9'"ODRK7[17U>E&!L2S$UADW3VBEE,NMSG5AA"C2J+K<&UU;# M+&7]F%3Y$%65_\2R3D-WK=U9(I_ ,D@9KY'91CH M-H*BCCH#90<\RX\VO@>^FT&72;8N\G1.LBID^ M7KF[F0-OL^1]=HQVX8\]AC ,>JM#*O-M"^<[TV=PMB@4ZA???VAH;TU3VBG- M?IVM]@ !M"S$ZM=J9^('L"*A].?N0C/-DJ;+<\[U->J19O"Z,TZFT^I7XP30 MGPM=]EA]?N2D+]/;I'!^2>Z=S[/;.%O=]'TZF=^H/]4)57/GQWK.Q5V1?*C_ M6/.)ZN4HC6ZNTUGTZS.=C=,=$U_]6JVF? 5'?_FAOFCU-_C,3^Y6MSWR6F/' M*VY?K;R$^P]+\$ K&D3W8OS;\#\WZ%/8DU_Y2\["E[//+DO:>-J-IWHPI4RHO_( MV6Q& ;6Q'Z[B\>]?<_6,B4;T6?[AW\;7U^!Z?!R(H7OM/XX6O2/]DP=5X95A M3FM(=>#]_Y\=-K\1XL\=PDY[->C0@^6V5?!$M#H^=@$./>9** .$O, 3A/I4 M=YN%W"5R>7!-5R?[N4Q]2).BK5[Z1>WG\CZ9?DM^-EF[CZ=W/J-LM^%P_'RE MZLBE&Z,7?<#[51 WS6Z43O?8'8_8X=NSK2/A3@AL$%IH@]#:99^#H$/2Z289 MR!!XB 8 46 81!Q/RCID,C(A?Q%=/@Q^Y\DSB_O9P#V 8Q(=:XJ->&!!ECWDXQ-!WF10,E<2'B>N%>!?BTZ4YAR0_ MMC%:VX?\&SA='@OYH;,5<9V^*XAX-/!U?S[F(Q8"3EQ249GO4Q_L0&71;)$? M#9$-G):.7L9A*^-6J:]3[4^8IRPZ+V!AY$$H<( @+*D/NA%M-@> M_>%(48R$X'W2X@8H#YPDMY048*C$:NK<\N0V3DW=<8U)0Y*?P_>BTH[W!D>! MSR7Q=7DI0DKNTJ#*E BH4H&]IPFZG"Q8Q\"#Q>%L1HC$B/'U(B+K-3T^1_'#PJL\DO MS132@U$Y)2/*7U.9W@C[T^ 0QZ1[*\"_KZ?=&HG=%L?NC0!8(7LK'M(1RWT<':3B'(]P%DQ"_7768E]""!:P,1.G;'*_ Y1D:$ M]1DCW@CA 9L=?S6YF,WW:[FHKU BTO.@G)7<\94:AK9O5-EQ.\WB3&><%J9T M[: 5#+3382P $@# MMI5J KI>* (1($BX\"'$;MW_R@O":*VSSW:@=8\9M >:Q3;>:L*?>]TJ@=- MD[A(BMT6>YBBR^X\F!L]/Z_;X.:;[H^X:%L?F>4[<4VJIDO2[,IT"IK&2H^, MY[/\P0Q3O2L+W2ZKLKABO3/FTC,+4XXT?[C3^NN^4XV>GW[IPM8! ACCE+K* M!!"2!S[$3,A:( */NTL!B J&/YGU:HO ]+"8:];RI+:S8MG.DRT M(W9-N>4RVK3&>MUY8FD.3#WTJKA)=NLK55DXY%5JE5]6P=GT1EDIXJSB6 :E MZF!6-,N7,6UC%6?$ /0Q!0'&KH^0'P5<-M7>+N.=*DX>$E_I" 3B"/H""(]C M4H]8 5RZS]8T;GS/4U6<*[6;JY0_WZ-,6N<,R<#S/28C!B51E@>L MFTAB%X<[D>''[/)^IC/J#U=]H&< M2T1#G_J.]LE:/42(];>MIDV_Z3 M;1EMZ=H#- 1A0!45$X("!%%8]U$G/ S%R^FZCN%_-'U2D\G'K/[EH&;ZL;U*GW5:Z M50=>K Z(EL[#* A8X&*?"3\*7$ZY\*K:5XD8?U8=^-2:4X=V1<.1P(?+1C]+ MD7\TSNOUHIL76O6V_,:6WVB^QU&GC[Q'! ,>X9[$ F(7>!A7[HU(^O[:%)PG M^-XK5.+ $7YDG+TMQ#GU0IR5]+2#5]YPC+I3%EC@8P1XH!0""'% ZG!U"!6I M/*O]?\S&L]ND&=^TDN+_3([J@%/M#UP=PW$[GPMI/VL010PRZ I$$8BJW,C( M1RQ:JX;>[^Q9?V>_;F,=2P4+)ZU@$(P# 16BNS2@D# /^'YU_(#0OH_?[>_X MUT-3MLK$5ID(KUX668VQ*R&R%!PI A$@;,E4"$ M, 1^I$Q=ZD(FUTK1ZHW\.HU-,XFPWLN/^:QXPCO55)<]>;/W-JJHA78!F4. 5N!IKM4.)/!!$-$12!A(S$3(:U+DS'D-KX]*7\%+[ M3Y/$*RN?XW_-PT.7/QTMZA0OK!2[X@'"96ZYS+ 7#/R[B7,G" M1-?'9;H:=Y+<9NEU.G[,W_JVBJ@L],3ZVW2N^7>I?@;)-+[7]:?JGVK]3CS6 MDSA-B>=].K_I5@/_^[]Q!-D/A7/UH&XH1MW?VJVKHTAU*:J9X3G+RX.97:LS M2?+"&$OJ#U.+G'PSU8;JF]FX]!*.M1)\DT[+^>/53?J"^FE.:J[7(J5(\F]E MVHM3+,8W6I>.Q^G\H2R4O8W_-.'M*E%&2?*[V5PGRBAMNZJ:70&6?O0BFZ;J MA)+)#\[-[%ZM+U_>I.XIJY?>;J^[N\Y@4G7)(J^GKZL'-Y_-A/7[HAQ$JKXI MKO4&RVK>/"U^UT)SI@6K M*3YY_\>6LT M[E8+Z]57^RZ/I##SY\O#JK=WE4Q3M>GB\V?OS+QT*JU1XT. 8P3XN-NG9-1M3U(L[NZ4 M.%)?FBX9ZGGO)THX36>E RW>=4QW;6%\KD:._Y:I&R:IQJAX6D^H[H0PG^WI MH'NBR\ +)96><#%P0TAI$+D($,)"S#H]'4CD,AY)X5'(*0X]KALU!Q'SPL"3 M!.!G47WC>]9Z.LA]VC5L\[I]5OO6[1I&CZI5/&^TLUE61@Q>HW/$$K_8( UZ0(XC:R2A.-/7-"N7 M%R_FL_J+,H''?&-[30PP[\FVFMC0:F*?3/?C3H2US29LLXEE7[1PVR:7-VE^TMP"CDB_"L2NJ#A\-K-$+'"H[,14( VEMFB(IE4/Y4/#8(&H MM:)"&KF2 <7RA">I%)0@[0;T/,@"S,BN_O9397IL1-'AF-XC.'7.E4BO$BC3 M[RCS']/,^9+_KL5OF%"'2J M@@2!@ D2N[OJ:+,]1\6=!"Z=##,@Y6#ZB"5?-JPD1->PA>G^K MKKQI$66D?[J_2<A6HGW5,6E'6Y:R##9]+RM@\(.OM8 X/!W,]8N0J23*3)%:/I:CYR' RXTL> MN,C,*E^'YY#.7'2/>@*'$?$B) FADH:>PCZ7"(!\7])5GB/'XWR13'YJ,]Z> M;0LQ P[8/:Y"7L;N"GY\5^Q4@SR!XT*HLKW& R.CX!&*XF)*U)S@V5 M:'(H58FTT%T,9_E\.1599S5?Y[-;9Y[>)F;NIO[W*M'UPXK4OLVFWXQ&W>2= M/7*>N1+E98*XR2;7&2\M9H>F__4=L#JP((^[[+B0^BY0\<9D$S(\"J;13RD(OE#I+(WXS9K!, M^A!<.#OFU7V9S\:_WZC')'FA"P3G#[_,YDF0%N.I25I_/I\N]*0?8C?R7 F% M"(72]DH\HNK?B';RZ0)/G1P,0BD] ,,@$DH$5Y5>D@0A?SY#;=-[UO+INMNJ MF+M3;N_)F6!;9L%NLY9]MK*2CK61.[^.:+E5YH-ZICK4ETO!SB2DP]?-O(P* MC*71S@\K]VEPYW.B$UZ3233+R_Y_'XMBH;6!S9/#L RE("ZG'H,A"PF1G-4@ M]GS>G1R&!.>EG33NT*"IVM5JK>%M0/R0ZM\S[7HT:FN1 M*B%Y;>JO2J0]4,;J+KK'5DAP1/FH/26;NAN335WQ3-8HV2T1=>\G;@Z-W::3 MR31Y]"[=5>#Y&E^NHYJ8;IK''7G:*C;X0"XF4'(1X_B*TPXLGT MBP-BQ/K1[):!=R $6K)I#YO4NPE)M$O\6LF^#S<*&LD:!]\EFF:Q8F>L8/OP MD$>20\9)C+^;%7/VAUO$29Q 3W<.@$A< MR-H9A#ZE$64HE A(&OH"> CX(8U"7^=TK:6 ?M&:M*>3"K2BG62%45 [;GKO MH;VD"C[)^SB?5##[U,))&4[&8?]L&,#DL38F.632_=_V[5I M&F>_J)5W4A_TM1\S39'IMT3_OA8Q*,V$'9-!.>VU(>M3&#G,_/"=MW,"@LIR MEI:S8-@I_45A1 @-0@]'@$*J+.RJ^1&/"'P3SL*.D+.0$81GS%EVLXL&J[I\ M_O*;H]L/37K47HXPN;SD%J33PH[RD,% 2)\$$?6"D'NTU$,BP)B_-H1U9VY1 MAB\^9L4\7Y@,2-.:XO(FSBH^\HOV !;S9+*'?O)9/2!/Q^HAAC?\IMA H2#? M+UL N,_!DX-5'4Y=0SA:ZNVTU0U\Z1$00N!B@&CDT4#6LMZ7P.U/UO= O9MU M@%>@7C3"O4Y1'[YX/G*7PYZ,%2Q !P@['7+.WZ4' )UV9JFK=!G#:#]$I?H%;[9YEI9=!5Q:NG]TG&+NS3WSX\3=H:W&=# MO:1- !+2]P."0\\3@5*)!06@F2P*?']]=M3+J9<-@7KA2+CKPTA/B7Y/K+_2 MDA@V-J]I0J[0I2K2**J"Q;L\N4YRW6ODD(-Z*N+R@.7$X$ M]BBIO.OJ4VA%TQ"//D):+VR]*:5('QUQIDYJI^\_ (%:>@;5N;]TAI MLC.7$5.7,A\3CBCT?8D9EG5=(J0 ^+>#RB[OXP8CBSA S MJU0KPA>PD\WF^JX/,: 7I5N/%IJ]O67#X7RN:@36+A,(+*9*8N\5W7<\'_S]Z;-R>.Y/G#;T51 M,1-/=X3MR?OHCIV(5"HUO]J8J:[MJIZ-_6M#!7*9:0P>!%7M??5/9DI" F&# M06 9M$>U;82DS/S>UR<4L.B[A@AKQ8^NTCO V4RTJTU=Q75WF\909C?\R!.ER+V\#GE@X$*'FB>KZ=,:;O)X%:?%UDR2Z^RZ[S_.E-,S[1 MTCS_:J[H:)ZMS!9U,[\]J0W2(\(SY.0BJBH0X,)1AD:(*@!"%&,4BH)Q>Z>J00;@["0I1U1JX4?2<0X:9-2Z@U B4 V&M]:%0L[OVJ(+BR8*# M3U;+IIG:5&S0$7&!;YK3=HXB+O*M"%0Y<]@58:P7LYU2C$A0$R.40!49BF*B M766H"&%.3!C#6#:*R5H1(Z]-,UT7)OG$@6F6E8 /GI*2!_O;'Z/['#SMN 12 M!4HAD!Q+C352H<0:1]300MHPQJ)&@4#TY=3-+YROD>]T2K^)4!40R-/3ZI.=2$6W.SJ%6S5H2,5V?]?TCGYW.B M3-PT\]GMG&@.[[(4].O"?919X6Z?>OUM6H(<5@9D:JVJ;_;U'<#A9+A6\SS? MC+[D;DU^=9Q6"](^[ ;X/(%]F,KO-WG[L[%JV3I8#%S"$_3 M[Q/[V+O1P\V.I)@C CWWV37]K_Y(/Z],0&RQ9=_ MI0/OXR7#?UE7<(GOF'YSQFJ.=9-DQ=.SA['5S5?NE;Z,)DD^9[8$RAF/?D_7 MCG2IE/*N:X\A5T%.VH?.TD$Z^I8&UC$>6<_6;GT.0FE?(!O=+\;S9)).%YF5 MW1X)\R$?4>!.HOJ&+WFOXQ:,S=,^U!S]<#/SW?QC]F,,. M%?=9YO[M?=+$+MKKE750!+_8'T;%=R?>-'37;(90>+HP?P?HK#+>L1XX:,Y/ M?O=\8.'@.(%8GZ;L_[V;E;=X2+ZFUU]F:?+[=7)K7^BG9/P]>A[D3M;,TAYMU&)OCY/N5^]O]=)AKHU7B@!T<8C^\;#G'BL MY!Y:L5>#3*N][]6J:E[?&*O]/(#PV*G=2CD;D'^0-I(0FSV\#OAFX : K24,>SMGSD/W,-"Y#JYT MN$>.S=5T@8585'=X19IG>4J[9X6.@EDR^=TQS[_L'E2W?I*P"A/%JBBGG]Q; MC<<>A'$T&#WX:'WU$B7)RJOK M_++K_#)OK/UX$T36>K1O7V*+TR^S&N#I7IM>9(:JY,\.43)9FT(!B (A MD0I""3DE.HZ001'A/(*QIK3! 'IIT!1DFTF[R:^MQN)UB8Q;2QY;O3[V4(B;"55YI?O\[2KX61>L1\D,0U:8%"K"@3/-:<4"XY"U$1PH=2;(!?."@? M)*S-]S##X 3)02]7?JMM>4Y2OQ0;WBKWHIMF"LUL.D]6J]-8O+1XQ]49Z+ MHP1%3V,>^UA;8O"#^Z*+8B#P\Z8]\!_!GW_, R%Z^CV=>,9J#-^Z_5K$[99]- MQRXK8]VEU+/L,Z; _&XV77Q=OF26?]\O)W$M0,M4T-+"+*)-DZF/..7ION.* M&%J)&&I"!5DD&;'&)]!:,UDH#(045PVCX>]\GL][3DPZ6OY.A[F-Y: M0>3X//AU8=F$0%KENWU*VL=K!I[R!^/%T$_F'#DD]GDP=F>5!^ES'KE/AH[3 M9NE@/GYT>4^7M7 8Y/\SG?U>2 _SQ^#.D5%>K6?W?KIQO?:%BL)A>Z=)^G4Z M'_D4Q+Q&4BO9YDT1U3Q,[$MVOB7C/)5<^93!U&K KTD18WJP+U&PO9<)UN=T M"UMF>X_I1]+:W-X(4ZF10$HI%AIF63DO!6-**QWA%:O!VM(NMV=%4\[%^3L7 MTPA^F?S-6;(ESS_#VF^-=2<%UM!F!\*E#I^K-VPP[Y\/-#(+?FGZ#9Z5T.!7Z44 )%)J0 M(RHBQ8G]N:@ AZ&*!#XP6-"3VAZ1C"/6J78\DK$RPFCS'/Y=WKEH/EV?RK", M;K3:>UCPVH?%O;44!D]1?\/.&-REP\4R5+8R"^3#=)X6D[&S8O!VYLK0PK'G MKV91&U92"BX-BC5#@D)%,"RKTF(:A]Q0:J9ZM M?MOZ'/@N2"V-/[CBSMDB??=750BSE3U:4N_V:M]*6Y MNW?=ZW^LO.G$2<[PJET ^,\%W9P<#Z\D7G_ILCOO=;LF@_'W# MJ7P>W5L#T 4*?IW>)XT)"]]'P_F=_='N4-&$NVW(SK/P MCS'5Z@7C?!J5T.)END:4&G157Q9:HI]B=B'G75K<062MV_[4+^34S1\/H[S6 M_8+/?:E-\;O+I(%T-AAEZ9/.T/%?P5?_O.;STUG@X[ 7S@#H(AG@P[)#\=,R MMKM2'?!;A5_PWT\C^.UN,#;'5-W>@MO!L;>OG2ZP<@?*Q,MHXDH$?/[31[FU M:WO]1S*?C?XH:^/CEH$/C[=;G;(X7HE,VFJM_& WTS.6:^CJ^OK[@V_OX/^1 MS 9W]M01[/KBNW3J>PVS?&JSCJP#_G2,@^WXD&\(:UVPL>8<<2FQ0J'],<2B MR/VS"(8*[P9Y61K>WOI=?KB,R\,MT_S#13::I%FF!O]>C++1:M=430OKJJ%Y MYPZ_6N=57+Y7.VFP[97S:,>Z>7HCFV6YK8*(M,M+IY@8?!FBLM6%=T.V(%$; MC!4!">-(2$,1Y$!HQ@K9@HS$3;Y.:$OO#1!7E+0ZI+AS8F0_ M4-^WXG[.I\$X];57>066_F-_AITZ0]2? MX9$ABE_/MWLS9A:O7#C#C 019!#@"!@1QX#7S"S2G(5Q!!=NXSTKRZF\75XT M_GGZ=Z_H?#3::3@U&18-+8]KI8+=<=(@N'&,__:!FWM)]59=*U&Y5IA++$/@ M&%\@@*&.8YSSO#90-9L+#W2MW@!['^(\0I_ .Y\$'JK!]"( =,PIDH!$%' : MAR%F,&8P5"P,07.*Y^MY?[FNGD]S3;THS<-D@WGH'E IZJ[Y@OP&M KSW;E( M>R\:+R9AATCE51*$K2-)F)"1C"D*(S?!QLD2$\74H%?R*KLC-@[Q,06](N*\ MI497\W/PA=P#NY?.Z)(,[-?7KZ]?WU'7MW,CSQFL]3+7MRMD_%Z^>->1X2$& M%=B>@,C]KS&8:()-''+-K-&)N:220&%:-CI?UPID$%P)WFJUYU8L^4N&C-^( MM5;>1E_.D&ZV8%B&>:MS=]T/ZG^P/;D#EW,VZ=#,J M'Q8SUW:]G/;H/EC.V?M'.ON:SNI3:3^E:>!&N 3D*GA7%F[F3RR !M_]N!P) MN?X64?46J6O[M8\?[C9P+[]E=K@LQJN:_<8"19I&F M F/,XSA2K&A<"+$!XMGY;X7N**.>.XPJW+NVN(VQ:L<;P>[',I?LD!USWB3$ M&-3PV05EQ)C(0$8$UXAQB!A@$-+80 -?-'"R=B0G.LB#,'!VGD]\N#IL05>1 M'>9$9I7LO-DT6:FNC_T_B7^3#$?$/I\3C)2BT!!)@"!,0@6H?8,PM"OX2U+[ MXI-JNVX2MS:&;;6S&L*;(-AOBEDTRIQ:6,SR&8 /Z23S.U,,\M/3;)YY2@Z3 MS,WU\WAYS\\RHT0A@@A@AA'+,0K&@I3'%L$(UV:9J4B0.*:4(V ,XB0RJ+@4 MQD!C]JPMLO4YC5EF!;+CQ"5P'9CCPSB99$^--ML5CW27USAD%6L3M[9._V^# MO/S%STSY>V(CUWAIYU=N?Z3?^XFS'L"J&9 ,IP]^9'=N)P&'0EHLX*-=P#H: M ?!_+0$%&,V'."<3#Z+J()C=_EQ_<2P3)%;\#/T N/3^ M83Q]3-/LJIAT/IUE)6)XYO&EK7U7""YOH+K/_',R#V[ML%2_C$?9786]&D[M MS=T3H_*&-_D8A::9NWSUJV#ZD*-EN^GI7XHW=V_J\,O7[4\'3S!VYN_)'>!+$#Z"Y7YH$JW2;<3V=I_I6CJ&T".&$I1?4Z8VE-7Z , MAPY-*Z(,ZL+BLMZZ7AV#6DFTNLQ33DU\]<9M^-@0>LJ=XS\]3FZ>=UX9FOK_ M\G578]6?5O8;X!!&DPUP".ZL/MAWKK5X>4NC)%KWN3O4=H>U[T*5L,'SPC;SW4Q6U)@*5!7W/)";SB9 MZV1J&W@O:R;?&FG6( 81BV/##((RBB*JP@@94]A9&B#3*,/9FS2K06>Y$_0B M2MP("O-22JR1UW66#GX:+F;?IU8!IY-W?W6HCRY0\;3-M]=AW.P0U5L!N7^V MK'"+N7>P:236JPW]OW>S\A8/5GE=?YFER>_7'J'ZIV3\/7G,G+]S-RO6LC5, MV6ZAY(;0:?\&*TYKC;A:\%C081X+?J''WKH-LU]=/!0:I@S /A%ZM9IX;E]_'9AV"7#V_N,O ME3=2SE"K#9O>I&X\(K9'/BJ LHO \?+M\[=;OJR/=%<>0W[-TO>A&WR?Q-I@ M5N+:%TXF$X=X9 TU*SVR'(FI",\DWY+1V,]XSG$R$P>(]B7].II,_(:LG4\> M_&5+C)OFAXC>V,,)'"4YHKQ:0N-4L$Z%X[5I5ZQC8GV=F7^;V]2!$033W.ER M 7[[V_>1M4V=#3D<;MBS9_>C,B4<3-R2?E9LU*MG[->KP*YC;K72? EKGJ_D M:AG:&LV7OSB$*FL^Y:Q>F-;./I[:UYAY9>B/,_7I1&?V++7YE;>_7:;%4^V: M+[CJKE8 7I8HK=$YRU=P75[RM#][$ZCBB.S3'J_6:._IC1LDV=V* [TG\,%Q MP@N_K!EZ7RW?S-P"@V_V[ *7PW? P-X$:@LJZ0DKCU16G@BM]#4&,QU2K 6- M.2^3#L90V<0%WM<+SEUAN])EL'N]!GM#;'L70VX7(^YVNI@=Q8H+/C\^N QV M2:;?\@5:WR4'>O!$NF[B6SZ9I-_MP=_Y3%\5"%F2MI7=YPJ23*7)Q[WE6.B^FNFZ7WRS[B?*;./G+P;CWWX.&<0=[\]S\K1P)Y?O?:9RO6S[91T^?73;]EKBA2*ER)%ASAB M"AD90Z9QR%1,"Y&B,65A,Q=V4I'BO[0$]ZG0B4KUZ07,;TY=VBW=PZ_\ MFZ7IZ\DC3RNKLF8Z<9'741ZJV"AQTL0J_ W"IHJ =(H?K)T7IU]F*^8[6S7? M2W'\T>_'BLE'BZ!W;N;D%PRFB_'0F3OVV'R QQL:A2RVFS-*O^6E$RXL^6#M MJ]M1ZJ%3/26X\?V6-'.S)@ONK;&[<,*_P:,>/O2/T7T.17I$CF4U)'AKY%*( M%4$($VKM9"Q)P;%08G5"(\ Q+/LO:(\.P&O[+Y)/,*[GOH_5YFYDX&RQWC&Q M8V2(/L/%7CF]^RM$ZZR;JZWL4 ZN4:ZOS+FJ-+ZR]O34,ZY3%ZY0E7I>RGJF] #N67F**KL#V(0\O+J%9E!;$TIGT M[F,>%_"*(3=B"_@R1V->1*XB'M\EF0]:+S.%]F^Y),V(3!MS . MW) C%<;E^.?'/659*V6TID2,@#240" ICCDOQ+]4(-RB!(A>#8OM?4Y36S38@T;8WSNLCSCZ??@AY&SYJ>+ MS%YMK027U'^8.R,BCY\%R?UT,2E"\IZ/?_SI^7K#%U+//F6U.^S316)\LG=/ M=XKGSR#/P5V"U@$TV[_CTQ_)UI_U2J_8E3;_MO+^/:#8DX!B>6C@%?'L5)G5 M?L5W<.6W?[M<"-E+9P'GW;PB]14AN]=\@ZH YL(YX#)A5?_;_Y8.KU]5#Z2S MY.MK:H%N@LM>"@OV;'>A;/>KK[IIJ)Z3OH.V?W*1QT4R?L6W^/OH-@U^R$,< MERD$+EP/JZ]?9^G7!KC]2=_AO>6$T20;#5[Q'?[INB+W&C]HCW?3V,1!FM[> MOHVY]V$R]HG39!YLS#BT!$^\_XYT>/94GGCCM$JO1IA&*E2&AX@@$P$52E:D M5R$S3+56R;-::K$,:L33F0\L;!A9Q6LCJS87X9FB;M4[J+F7>$ !WG/#+? R M4X>?S=2A*RS;A,AYDC"[.=+JI'S6,=7<"YA*P+ JLT]B9&)":&1"' ,**0)% M_080,8&-@V9:4XJ609@B$+*"D]$EV7H@ MH(6XH; 7K[UX/>W"NR.$-C=]"%"U:45"&!Y'E"%$);87D# JFSX0Q.V-GMDJ M@Y81T5I8\G,ZNTRUF36FSC/#Z,&O';)R]G$=Z!1W^WZ5:-[N% MQ5?E"NAH^+N:=%%VS]O_3V??TN&)1&DG! 6NS!(2AD8CZQF%4A%L"("XZ!S4 M#,5A^Q'LZ@2*6/9B?C>=V14\,XCLK46;.&WV%>TO+CKKUO2FTNGYVS'61PPQ M5DQT".6UPV?[5(1>; SU#8J4+1*E-B._ERAO3Z)TUK>[6!'1:IKES#(IG9!X MA%?S^ 2*M#&2@-@8;&6;X5D>FO^#V3-V7M])K1S0:"\(3GY,^T0O.B.^MDDO5$FO&!H<10S*.,12,<(P*BNU,->2MQZEV""^ M+B=4(6]PF_V"O>7RA@16O[YNAA'>^EHOJF"CQ <_^Y*-_2LR^_AU9UCSK"AR M1\]85+8EPQP;;;UB:U9:HS**?=8_MRV%Q,UV(6]_9=DB'48+!X";FX=Y17_- MD,M*"_&,'%]\FD[G<_&(+U9D]!4 KRT!MPA 6 L-,B1C(&(A#0$*1E(R4X8& MC;#>=>O.=2D8+]"UYC<<]U4 ER@2^X6?X<+[*H!SJ@+(@:WW;K9XN^X0K$%J M&TJI1A!0(A657,01+F>U$,0U;2U1:/Z]&,T?WT^R^6SAK89?'&#[Y[MDLK%2 ML#MPVZTX4E=(H#Z'>'9ASKWU70PO7D26SIOY MAU3ZOL&$R!8' &%2344"(9$ 2AQ1S2*!&.>H[('D'+;7 [G5 2B*<-+AF?H MI&\(.LN8R%G)CS[%?QX4V8++^/T(*"_S@^*AAB26NE7&+-(*2TP%SPFH0DAT(;&)C(\"L-7A# 3;Q!H M",)6)T5OH\]N3HR^@'!8+U8VB)7:%"F@*8TI1T8AH*C1$H0H%RN::Q6_"G#9 M6Y0G^$K05H'+>HGR%B5*JU&1ON]RJR2K38>"L08R"K4)J8[B4$&.EK%@K #K M#GC8J\FWP\="]?/R+U1(O<"-/!UN%\0,5<5@T@#%J:!" ,T$%B&)"OZ'AL>; MH71>';CK%>K#GP3N8C>B/>"NGHEZ3=^FIN>5IB>0&*A"@&4L(881U10OFT B MUE[9YQZ@6:^IV_=R7.251&UBN;^:5F^U'J2CL=6UIFT7EWMIG'49:T>7&FN_ MY$S+@3&'MU0,L)-:(;7>0FK_ H&4E# N9,0$H''134!CR%\^7GBWUD+'Q&<5 M"D-7'+>I4?8GR\YZF!J(=0PUK$,[3\(D5"4=C:C MIO6(6DT@7DQ$K57;NQ>$;T80OI8?1L;9U1$60;ZOJ6955U!,AD&Z1\/ MJ6L+"N93_^>C!?YZ'?"VUW>4JK9N* =1*0?"I12*A23B""-B- "\L"@!CV![ M]; %*_[3*70P4<+,,N)NY&VYQHU,NN-R2[NADLHP@LQ8*& M,1#__C)WXGWG=<-/$($__^Q7.YI8T37_B3C6.IAW/M^E M05(27S JJ2_XYL@O&+GA2./!8ISX*%D6S.WEP]'M;3I+70_REW3^/4TG_L\E MT$GPX(S98'KK_[JP+SL;/UH2MR]E:2R8%I$W%W)S%]PFHUGQM.(KCL>2R:,? M-L)_MF\PO;^?3HJO6T);N]'\+ID'W^T+V;>_MM^_MA>GCS>[;VI=@@F[I\?9 MY.^%BK].\G)/VT3E!36L-:@ M=9QPA#1V>&N2V?_D0:!0(Q2V7J'P+""\_S"RE!C;G=LD'M_X/'ARLSU_\,(3 MOSHVJ50Z%2$0*R.!LMXV,EIJIE39'@81;KW1]7!2X6^75.C-]HG!+SQQ+Y"/ M3"VR9H%A()B.B, (B#C$/#2%!19B:YMUCUK8VZ46=K-]&,-+J664*WWG]V5! M:I7EWL3S?([M5 +/R8-7X!Q'6'LO=99FSIVP5#-^O EV,#+J0^U/8$AP5C,D M8AE'!$NAK$TAC(A@6/ [BP RW>/WPX=)MHD40[9Z4!VS#$05;@-&81[#*#8Q M 3$*@5"P,")#I=IO)SN197"BLX?@!FR%">J>KA?59*5(:*% A(23 1#;S^)P MV??!S%O5]2^7]UI7W0E7=91Y@RFL]=BSWG-L@TV6[8?5TS;VA8>80?WY?GC6]P, M5H/'G H&5%(#J0Q59'4O+CL"D$(4OC&MNS?#'^P[T[;5;^="T_/I/!GGS',] M=&F %X:FBR+:XY,WJJ7PX@A3-Y#*4".51 A%I%!DAB,8'R>'7Y+WDHP[DI%_ M,DE'EV3.M@0498/* WMB8_M#IQU-AJJ@(M(2" : <3AU/*8Z9J!T-)' FT7> M:6CBE6/->]$$.QI-'-__9+A",92, 1H2$46:XY!( TR9Q!((LM9[XUY %J\< M5-Y35#1C42V1Q7'MMK?DEEYUPR_MFJ6R7I^PBW52UB6,M&B[H!KY=PX75JF\HX1)+P[6BF' 4:FH*%]ZZ M0AQWA$3>HA$#;YJ3=MLW8KH4O[OC9-/_.:_#7#=S:M6EC@K3V5KU M:<,,.MC*$7+M=?V_=[/R%@_)U_3ZRRQ-?K].;NT+_92,OR>/F7W07^YFQ5JV M5I"NK.C@5]ZGAO4"WF#Y'BO$M49]7OQ_MN_S*1VG7@Q=6^,0$40 ,XS0V"@8 MBSRRQ2F(8(1=X75QBW2HYB_^.ME"PFL%_&*M,^$XQOU:\\X39FI#X0WNTN%B MG!9@.@W5MRE([-63X\A(=K0$)BR6#;F$#Q_;-N> ]\%J55M#TXJS:P>]O[0 M[70\GGYWQ=6^+#W(%O?WR]9"5HI>3 M3[N9KA^\"I\N,JN^LBOK0 [2AWGPD%HA[,@L&";SY*_UMYHX2VF\PN<0Y)T[.6$Y?.3B4Y\Q<;_;]0_*WS?L[N?1 MO27##^GWX-?I?=+HM?H^&L[O[(]V.XK>]8$EYN0A2W\J?Z@+:M_<\6XY?F0Y M;(._>WHX2?X()O_\0//-9ZQ_AG;ZV? MH G(<^J]$"_;"G>Y_RU/8]M5C8?V^_E$"Q?%RL'@+K-+MY5\?II.\;.#)J3Y\:Z/KKA68!\W:QJ<9ZO8VX>;Z.9=M MS+D\R=EW9 CF&Y"7K#9 *"8AB+0DF$8L$L0( XLDGOT"!J\@+U]:6=>N*#VX MF%TV4S,7(TWWF9\).FJ8U>MM7WOXR4FE0ZVQ22L>A0@B&0K*#(,Q!F43*^%1 MBXB81RZF/Z$]A:_0]L[EMS ,Y +\\M,Q<#^]:*O8D;+OI3U9+^U;$$"M1G\Z M;67D=N]K>Z>G$0,_;)$# E9]M90*S(@4 DG,9<@IBXM,KVOJ"]N;8K;5_%BM M>.ZP^0&OD-PZ"J--"JLXY?7UXX^OS4+G;M_T0"8GM(@$KB0A9XQ QIAVP^H1 M"R-,6.F(0: W#W0]@21\Z[:2N!'-,LDC2,N.&U%OR%8:N&S9>'QF,9FM5A&I MO",8D@A* B",00P(C:@IP]XJ"^+I[#8=O0W#"),VP2C.Q?KIC9P^ MB-.FR<)J8DIA%"G&"441$% )P,KV,&Y(B] 4NXJIA14=O;URAK&=CIHKVRI[ MGD!9>T&!V$N0S,^S]$?4IK I*@R'D53628II&!D14J -C4T,.#_EY*?MI3_; M9]R?P"0B5P"WFJS>FSB[F(]2]"I_V).;!)ABFYQ\R>ET4D)4V'79X^UW^J[OXI]'<[N)@4YFZ)3(: MI$47=Y"/UE@.W'BPMER79H6\GP3_F=C3F#WF4MR]_%4=7"1(AM,'#_9K_^:7 M5C:H!YX]@H_ETES;>?"#N\P!DB#PL_GT\:/_$?[\XU7P_6XTN N^I ,K)0)+ MF'G7<;!XF.9MX(/Q-'/]>06VR?N/O]PL'Y4%#XDC^M&#)1M[3=$Y[AX0W">/ M3\PSL0;S,:>%RMH,0:8)C[ !.,0A($IJ'--RTA WAM_\7PF3D"*[,'RGNZR]Q-&@)P4EBE MFR>$7J/GQ5]3^/WYP'D"!>6,TRS+>X66J#GW?J>J43@K9%+0WY*&_&"_Z2P8 M)]D\F,\2QX'VCY;*9M;]\K^YZZ<.VR?_:)[>!&IO8FMY>,$@R>X"]Z:6NX;! MK:43RSR/L^EX; ]JN!CD0X#L:K.%ZYZ93RM6.OK8'XFJ#@L9 M9M-OHZ$5U:Z%.EE8F\3*M$&03*QV&5N)/9BE=ILS)[MS7S-(OB6CL6^:=5_Q M);)75D%\'4TF7A&LJ:9BIJP?E5$8$3DO6JOGZ]V&:Q'M$%LFQ?!0*WV.JI0P MKW$8#"&4H=-%AC,4&:V %HQ!#94@C9I\[:6BYPJ=/#@#)V^VM 9Q.K/"))[. MXH4+?[[/G.S8BL-[*.>]9 )UHQV)\RO*VT:)*BEW786X7O=9L4N>F$?%#N6H M;DL)NR?GGLQT]>=R[<(VUPN/8,-(7NN[K1Z5U7?Y MA]9ONJO,="=4+)U<+_]03LO[?I=.RO+]'#JF?/@L]3?*-G\O309.#3],9]YB M??!Y3?O"I?FPT2[9"NJ79$LKQUDGSBJQOV]\5J>TA'4SAND\G=U[L-X-<(9- MR,-Z:H(AYO=+ M+)O>%\\<6LMZD3G*_Y*.I]^M\^%V-=_MS U4?%A86AIE0;;X\J_">7'OZ2BL M7%L^DN)K.DEGR7CL2.3?BY$3&)EUN$>WUFNW5/JOQ?"KL^=S:FK@#OF;?O0_ M.(/?/S+GR,)0K=%Z/F7#PTC>!'5/PE*-)0_[36L(3NVC_R\'I4S_<%>D[DZ) MW8]9XFC@VM&#>X2]W$4'_4-<@*5&MV[_ZH?C2RC<#^Y.]O\&@W1LU^S\Q/Q& M[@M^U'S7R-"9$*O$9,G$'HV3>.ELGHPF&VBQ.HW\T-QI+SFQ?GEQLT&2?]=: M/>.%FR&SW"!WC?U>N;WNYG:5]E#\]?:3!WMPUW5JJM!"_5%L>H/EZ[WP\=8\ M.I%50JOT"D1Q;&)%&;*.,0R1D6$YJ\\:*G%[92=^#%YM/_(DRB^WRZ""\D&( M=%.U"2^F*"UMD=^\ 5-^=3^;!&Y-N;[4'$F7\1$/C)$4"PJ^/#8ILZ3C51(I M42-R,O!6NMM ^_.@(4YFZ3@/O^0^HR7)U7L=WWVD5<0%$RKL2<5A#"A!+()A MO)P:&TK97B7C.AF]K_:H?B=M=^C)D8^MN)--;*NS;1NJ[OY9(X%[D[;E$ M;TRAGS][\.7:[9S1Y.SVR3PW)PIMYX&2-]EB6 BF%5IY M;B%4!D):-P&SD67?7/7F3A/G MNL!1H*,/YW2[9_[X5H[WV]1)E_%H_GC8(8?I(+'VX8J*=Y+)6DG?[)Y9J^PN M'=MCF-B'>>/-FJ1S>T-K:WZQKU3%]:PE$*=?9JNQ<;_EPY%S%N;!7>)MP,=E ME/!N9"EDED^16_<\5HT.=XJ6U=.L(IYJ PH:<7>8?B_MD1PLO':1]TRJ&$KB ME,!X7&*/E^@_M2^XMW)2/9GY+^3K'>=O;Y]O2='2Y&#D\,JS_,+)R%G>N1F1 M6]3CU&&OLQ*?G(6K^."J<%ZGF=\=9,_MRHK6S+F^"_ MW>JR?*B;??*&][XNWOO+:/I@)?=],D@7/C&VY[O7CR=_<.$%^\^#[R/K+]9> MP_HECL_L2OV=ZH_RXX_L>5DJ]);]56!_=BYC< MN]R*>TAM#^K[/4N_VH>5KU_;G2+4L,ZN7ZS[=5\/=:Z^YO-2P.WHJA>\FV!8 M.G'+F^XI4;/1'WM^\]J*/4O!_LA6EK#T8KJME7ZU_'I].TL]D((UK9WU:\_I M?*W6AQ3R,GB=1@\)6L93D63T/ M#SC:*;;:?G'FQCQ/K^"], M?65+#BZ3/#[_+:\#9ZD546DCK#MTX<2E9!JNK-')*"<)]] ='1S1O2\,Q"ZC MO>OQB]H-,E<4E\<]JL#W]LG>C'#+#P+%"%!%L(FA 25[((I9;;)W&"D341$Q M$0%I*)8,\A)+DT0A?Y8-MSYG\V3OU3R"VX/",'S(=R%K1O^7^*>67*L86N[: MS>S;3&=Y-*NTSY9J.:\-*95LY_5./):"N*GIR:-[T7G&\ERBQS= MX00N<70V>_=TNTG^"/KABOPZ5(^W5GLUCY]Z6E:F@;5YD:T1#%MM(Z57NYJJAX!7LV&)A$&6E*) M)%!*A!I!7(YAM!] U!JL]++OJ^;>EH?ZV9[I$3'H/X_FS@5_/_$ABT4R;A:] M9FHRC$KWLNZ5EWY]+?M_G:6#GX:+F2- AR\.P).^8==HL\/2_.*94E1,:9UB MB'B$%>%***TT,V@Y&Q7%FTZ8\F"EEQ91(Q<90A&.% MI.$$ TSS\7PL$HBAS8-*3\64+:$7=X@I]QEJUW7;M5E&]\9,%/+0&(X$)@A! TG!?9[CO$N*K6XHJN^,T=H2):ZW\QDBLJ3$ RP@P)3"EO!R^)61\7!7J MSBVVQ_:^.+7+,%_1C6A.>CY ?_81GK-F5E(QJP@Y]$I740-@9 PBNM"X#(8P M[ *SGIFUBVY ;;=R-09*U^MKVZ\:?FKZ3-][GU5C!C3G2M5IT0'&,56]^8YRBK=T F\_4)/[X,_>RJSW?8T[[ZO*\^ M[ZO/.U=TW5>?]]7G??5Y7W/<5Y_WE-!7GY][]?D)+"W?E=[UE7=*5IQS&:6X M(="#2D#X!O64\2J4P6X075(&!+Y/HB_S[)IO=7(U<+8\?0)";8TU MY8UL-\/U']UL\;6EM[*OC)?7D.*+O+K.Z"CO3BA_PPZ$W@"!\&WZ$T6]]^MJYBEDW=__3!M M'9=IM[*('#:V/H'8Q=C<^/2US)7'^CILSN!QD(\V3+O+EL-UAYMA_4;U079K M50..O8'\>;5V(%BI';@)XF*TLP](%KO5#52U/;]83SB\E-3NKA!_'OPY>S_YZ(<>OQ09^CBXD8? 0^,;U,2//$Q*[LTN.YX^J\#" M0Q@#+9G=5!Z&1&H%9-'('H;,_M:]T^>=.GUT0YOUS ?JR ,$UZX$4 -$C@ * M':?S"")-=8B5+-A?2JG;*ZMMC0!8QPB M<_^;@I\CEPWSF$FO-E4F ;ZDY+ MN+@3:Q&.EF0$ #4A$L@@*A54D;6@25FCB2.PHQSI+D@PO&GVZ+:#ZG1L8<^K M#E-.,14QI\K^CS$FXB 410E]%$FT_R&U+Y/W/*2F+&[GD$X@DT7ED2JA"!"1 MYM*ZI8I&",.E4HZ VA$R[22B$Y=R0\L84(< MH5!IK&.(#59X.8L<(%2KY$=QC*D&6"L)9&A"AB)8$+:Q:D(]6\F_]3F[5O+O MY(NO3I6OP0%WLR1_A\WI2_+[DOR^)+]SE>@;2O*7,;>^+K^OP>WK\GM*V($2 M^KK\GA(.JLT;)M5Z:%07K:#]^.C]97'/3P4_B8J?(DHD=&'7&"#BADB' MM$BZJ! 0++HTT[WGIYZ?.LE/LN(GB(!@1@&.#"810" JT2Q#Z1 MNS2._77Y M:6=#\&W9>_MUV9QFJ2>=F$5!#:0@-)% - Y)* 7%R$US+K@"AE1U9*!LRPG> MPV;!;LCE]Y.8+X-Q8,4X/-2$QI);UE$R1C*DK&0<)EFX8_[UQ'/07Y%Q*+JA MK8Y@[1GG#3$.J@'(0>$2O$HS2"+.")+2%(R#>!@?=Z#JOB/,7Y%Q&+O!+QJ' M>B%QO!8:^5YY'T[+@KB&(A!RC)'442BI08I$I!A SI2),.9=&)/:'9,/W8!F M*5(_CKCGL\U\1FI8.9&11DC,E<94AD0)7=B(2JDPW!S">]W9X:_(9_ &X9[/ M>C[;D<]HQ6= 8*(XP23"Q@ @A#)Y+2S'D I\7$2X_<9^OR*?@1W3M;-U6M+3;!Y/9TTJJF@L4^/Q=."OKM?=KM\E"Q\=$6POL:4:1"&&2A,M M8X*!C&E45G<:$M5+;#F2$-H_AJ$+@P.$2!07+E@$(H6?+;'=^IS-);;+DMB\ M&M2RSWTRL[N?Y7TKFR:EKW>LK':L;HYF;Z^"W>7]#UD^>CGE]7VT^RYU-!F, M%XX>1ODP='MP/@WE"[*SN?V/9S57UCU]2&=)WE+^@[]ZNLCL:V<__K240PVI M=K+2[)VHZO)*LR$ZK#;[F8_V_-K9/*RS-<+'K!Z'\!7*QSM0+-[/;W^2)' G M&@JZ5A]ZH37C/57T]>,]5?0SWG>R.)QW[AR+6?HMM;[B*2:_/KEA^]%$._OP MI]8'*3ZW WLMU-/$B0*3'%>Y;B@E)C$6/#+"M>E+5,Y-"DT8QHWJJB(DE XW MQX-,'A#9GBU[/QE,[]-/I?_[]R+.5 4;'>W^/$(4?R3D/R3^F)# +-/2O2R[M)D':WJJW&H(QQAS7$42J0!1*((*FN M@&X,CME;UO$.R3H@FRG+7M;ULJZ7=>4V5+' !$HI)8(,,6H*-/BA&GS:MY:>6(.S[TZK]98FU_YT%YK MK-U9@^0,[(XS9T0CP>'3O CHA7198*F0A*'$HC$(HP-E*6VA$I%+^:S7MD=B17DF^=WOP6V/$2 MSNUOA[!NJ]O1#9XFE8J%&E@+F$=A)(6V9&Y_65J\ M0.E&@\(I+-[RFN(H+5?_HSS(XOXMLK80;1J^3Q)+9U7P.8?H+I;!6:6T&:!V M@Y#$@L942"K5$KD!A7'T*C;T"1D<7TG:IN[N&;QG\ XPN*A:GQQ3BU!0+608 M488CHHI(M,8$J$:[RBFL\A,R.+SB&YISSXG!SRCP_+=TDLZ2L3?.D^']:#+* MYJXEX]L3M5,[\O825'H<&L(8"0U# @H(J8)T"9U#*6T,S3BEH5X< MJV5SM7*H;?,ZO9*B566^A7 ZJ],O1W6?+6NC2H/+B(2 :: 9!C%4D-A?RUQR M&)+&,(Y3FNBG8FV7@6IB9_6LW;/VVV-M4I7_*DG"2'%** Q5&"MLM7@)FZJ@ M?I60^:E9&UTQMA7]\AQ8^Q+"ZY^GZD&W$ M;>450LG%#$ %35W-(8@*&,$1:8*<*HYF7YJ')MN2T[WVT( M17#%9*O9K#,3BB>:1-B\YW,3P'881+C#_"^B$$$$,,,(C8V"L2#E_*\(1MC! MIC\WE&[;U]G+&4[-]YWHUO(XN\5DE@ZF7R?VCT\,")RE8S_P;3ZU%W]+LWSX MVW3P>S#-9W1>!9/4SVJHT+HM']ZFH_EBEMI/'9#WGN^7RZ4_;1-,M8!_R&)A M3;3(FF8(F1B)D(BEM29AHR9G.1@TG7T;#=+-XNG#M%BXGU.:^4#-^BC)#]/Y M_Z161)6;68=U7Y-K[W,/^!FA1I="C3U?8UC MP9V?^^>6FDP>/44,YIFCA"71!/8XDL#%-QW37CL&#KXDV2@+G%UC/\HGFJ3# MZ\3^GGQ-@P*C MD<1'O_)X.BO^Y*Y[&D]Q(^*4F]+IACF+]1&=^?S.P\[\)OCM)=+@UT^_94'2 M%4'VVC((5X6_% DBN4(QH!J$Q+J,)7J-!BHRC7J"5Y1!RXR%O^OGQX=T)8_Q MJWVBI:YY<:O?+,UF]MBWYB]VE5\(W32+#GH!YNB)5 W1.I2AP9)KJ@PB&.K( MX(*>",2FD<3NB [C+:>%'[H!AY'^'7&)K,D.TL/%UG;)!:M O^6D R AN$( M8"XI#*VB+-RY$'(.NR^Q?+.2I4]/-I-!NI&ZLD6V372]_Q O91=H4J&57]^M M]Y:EDW=_G4RW>9,O/+:7&>,?<_V[_VSH':FDEG&WVHORV"#%((RU5!KBY6 & MZQZ55.+.XB>_[9XF2F)9.?OD863)P2UTC_10JX=TN)/;@@=J72_\X/B2A&M! /_OW:R\Q8/5J]=? M9FGR^W5R:U_HIV3\/7G,[(/^)I9/^-9! G+_0**.,:Q"*$B0I-(%"( &@-5#4%"*6"L MH60@.)>I:!MSYG(WZ-,VRF MDQ)+Q$5RK$#-[)&[=1?'_.4Q^.WFTXVGU-M\V<&_[-%GP]$@!QZQ/DA@?:8< M#&<##LESDNV%,F4?&W"'K>E12'H4DA8?UED$BCWU;(]"\@P*R5)C]5 D/;Q M#T724\4!5-%#D?14T184R8M@W-<_L J6]_UE9V(.\ZG;O),RR()HS)E MLC:YVG D.34\%E@(%CE@DMS%@Y*RN)'XSUWZOUM?-YY-[W7N/]H-^&6)IKGF M^J=9Z?P?W%23V7VR?WN^9A*C*RA;[1U^6S61?:%X+\\N3)YQB*I")J:-B#2. MJ$NR4288*4)6,%):-R;QMRO/7M8/LY,\0^0*@C;'__;R[(W+L\(\O4QYMJMM M_J;E&:[*G*Q-QJ2.M+%"(.:AB"B*"WG&.)6-2N!VY=G+6EEVD6=27O%+QDC: MV?M\&TYFD@$^7C_:T^=>D?,A!]\.Q?]XX8'&\^7E+:QW\_3^^S#=.(D MX6SJ1[V_=XG=-)N?+O5#F]WE_;R,/I;:B]1>I.XK4FO16"4T(<"0B$H&#(0T M8F$A4HU1J#&JX[0B]1C9)WJ%\/&&[/IO4B]/)%*J]X=+1 0#(54:&1B M#*P@+3JT8Q-+\T03XZE$:OM./ 3@"K4+0G9F(O5$4]T.G.'VTA"VM,GML-R^3:YODVOQ M8?MU1QVABJ#ODVN[:Z'OD^O[Y/H^N;XCJN^3ZZGB9%31=I_<($UO;X^M R]I< M>Z B1CE$*HXB8R#1$@!#C5 JLG]=CW\6RGDY,VPMXGG,0G>&+J'6[I),_\OE M0%D-^F \^" R&LFD?Y?FL[V+.LN4X M37?SB:E5=4]-!MC=^&K3N#J-_;1EF!9$M,HDAB$1W-I*)(RX@)R#D+ EX%B( M&\&44KD5FWNLH,HN'4#H2K0;8-EVTF]]?%;O3)TI/]VXS=]^&7-MJ&I&JS)AS9.4:DQ&(8BX@Q2S")02$H;#1[?O*7A4 IQR+>Q&F MSQE8.+UDZR5;+MD8J\TQ,+'"" !*(2*,<\UY,39;IKZF]T6 T'OF-VPYDH"E7@/*((1U' M(3!$J>7$?0V-K@$9A)9]XDB[#DLF"3!(HS+!I%&LV;- !EN?LQ'(( Y+91C*O!W30D\P;)9D+1D'X[>;3S=+!*!#6YC7?8_9DN\WI-J7[ M<1Q6'_,I&=6 D%C&$#/@YNWJHBI)AY0U)OSLXABK>=$?]ZD\F)6+=TG331;. M"JN'?=Y_B)=QGVOT?(H.WK22H=N5.MY,_#H7NG_N2Y-ZT?"4:,!H*1HB@PW1 M',64: @HDDJ80C0P2$!C!.!Q1$,CSW60:,"D%PV]:.A%PSZB@516@V**D@@" MP&"D2(P=*$8A&F2HXD8[[W%$0R-3U(N&TXJ&\QHLZ'OR"J_BATDZ=VF/TM:Z0E48)&A$-.2!1%)<,+"$VC]'@7AM_< YEF^_D' M>%<^IS>M-$6MG6Z7.H_WU^7GKK+?+B_R:D _P8QK#I6.1*Q13$(3JYP7(TAH M$YFC95[YYL>?%-\:+LM*+#"L9(LGC,!0\-FX2!RCT(E5$[&4( MOX 7=[" =^9%>-/*=+@WR8L7$C[_-)\.?K_^DF3IT!?PI)/,4]QK.[_=J-OF MH)KK$0'%@8$A4=!J6D@C8XJZ[8@@P<@^?/UAZDH,%O:R+^.T*(/\=)?,TM = MB*Z=AYYF.S6S;./V7:J^P0WOK-=[['+N/MQUX1R/R)+C+6^C$&H4(ATSZ_H2 M84H/EX!V.?[&MO5.?QPWL.;[G^,OD^-H,/49C&JF0$^M(4P%CJD)5VNY& MP;UL]X,Y_L46_6X:W#B0@D$8UX"+C&#$"H6,Z.B L$]@I;[\2.!P6LC])3V#-A MSX0G9$)1Z4050H- ! V,F7) )BR,GS"B?' MTUEJ[^9'M Q'E@QGZ60^>@KH]SQ=9E'K=3""R!@20ZE@0FO[?V%4<*[1&N[% MN<4>KUP1U?:Z[1+HWH'NHUA=9\FM;B^K6A-IK)314_#D4,N:BA@ !D[$ MF$>IHFC7]GTSC'DA(>=?YI:C>[?5\7.MOX'$2$IEF 91K$)("(3$Q9>5-D#$ M=*\:*;_3:OBO139W92JM]_OU0:@^"-4'H4INEJ#J'*10JA@B:$)I8DD,4026 M$&0,Z :*84O4>V[NN;D=;D:5;C8JTE ;$VEJ=!SA*%0E-X>2A(WIUBUQ M<[L]AQ?;BG IX61]ETR^IL%H$GQ+QL7L[<0-'D\F@WUF]767=;?YR;+6>P"A MT#&/0DI-2.U_#&-%4#D"2.[G)^<[_7Y2PO[9BU26I?/LG^7&JW+?3U:T3&_H M)?K,?3#KS3(IK5H"L2::A"&W.E9 "#@RM*S"8(:IO8;>',:D1PDX8W+VG?\] MDYX7D[):%Q^#%$8H5EJ$G $E%<$ED])([S6E\C F/4KPV3*IN$0FO9#H!:2BR(ZPTD$=60E+WX3&IQ#%[>P9A&+]?3LL-39+MH9?<<_78X>AM# M0UI+-0E(@09*&*$-9XA'97#:Y:"B8S#T#H8WZI5S'YC>(3#=BO5]2FB\D_)Y M#20"&X$B PD"D: 8T3B4LAR;A5@U ',7/C].G/ID3+[C<;\-7N^#8V^5.6NM M"Y)%A@H(F/64C<0@@K+PD,-8@XBWSIPO-JE/9TGW[->SWRG8K]:E()60(6%8 M@9 J+%FHHA) 2#/T_E>;7VKE@ZVELYP MNG!S.DI3Y[*0D1"H@3-$(C8N'HTC;9@T&DB(-$9Q9% <[SP07D\]4KW=B5\> MTIGG^V/#HJ!V2[$.)I$S@$?J0U^] -E-@-0Z+I#B(3.00Z50'2)I8+;+74JQ<@O0#I!OLODI+.U[1F/)NGU78YY#Q'X\^'[(]':Z_I_[V;E+1Z2K^GUEUF:_'Z= MW-H7^BD9?T\>,_N@O]S-BK4\]X+-%1W.],U-[M^@]AXKQ+5&?5XV?K;O\RD= MIUZ,7","!!1QC&,10D6$)I'P@1A.H3%0.<%4W"(=JOF+OXZWD/":P!!K,L7] M[C=P-+&*=?X3<1+E\/W+9>F'Q;U5OH.GG<=5;?!I<)<.%^/TE]M&\:.#)!LE M7T;CT7R49I^=5''[%(ZG@]_?;=AU!@42G.M(42XUB $1JMPVSB&^KLH_K*M, M>]64. MZ'6>WC],9\GL<3GS:)!F?J+^()G-'JW:^I[,AEDPOTOFP5>K+8/9*+-WF?JJ MD-&MU4"3>6!OX36EOZ-]2%G,YY^6^%T,DEEJ?[2*T 7RLN"'T<1>.EUD]EG9 MCS^5*K XMA>PX 8BVT@36WAEA]U<>8\5@PJL4;+[O?ZB$Z?]QRO$#T%N:7HM M%0S2\;CX]#_>@7?^=[L!@_+W#>3_>71O3^I#^CWX=7J?-.S2[Z/A_,[^:'>H M4-)6W8^3ARS]J?SAYW65_&X9_K.7N/W_CW?BW=/!P?P13/[YYW<-ZZ1X_#,? MX?V^=LR';0^ ;DQ#M!_G;$N7/.=H+(^8OWM^L2?-YS=6+EZV<'>Y_^U[SGE? MIN.A_;[RHBE*!ZDST_-MP?!JKR#X$5-1Q]^(G2@"OP)%-+=F/]_B2/OF#(?+ MS%?V5/$L5?"6$VFWM^!V\#8JR:*FE??3%AI"3]'0,3;D5>-7+X_Q/1WRB#)0J!T5N.=@6+K&;]# MC"\K- 6FI*)&,8R5"<.0"(CSIG\.8X8@;9?Q>3N,#ZX$:J5$XK49OV6WKK/& M@NO^>19#]W7LWDYP(P856I&&!,.8< M>69.]*_IMW2R2(-9.IA^M4?OB+&6-3^0,]\N Y** 36+"0XQEEAIB 35!=P M7[$*:;C:_M[@OF*#?ZWVUR'KSKZEQ].)A%\QVDJ_W6M;IQ?@EEX +[':&$8< M&60X#5$88AE!2*+2O)20*=(B+[6CS9"\$E"> R]=BJ>G!H/9PAZR+_B:/HT$ MLKMYN24'?(;FIZ@X-L8:4TD T$A$F/&(HJ+O/ ;":/P\Q[H?W'FD]7)#-1GZ MV>3'B\M>(=9F6'9O"NBLXNS]QHMD; *JYK1(1E)J:\H*$1(>QQ2CW*_D@ H= MHW89NQUM3*_L4BZ:L?>IMX59?VWF4O;;BBM?@5CN?NM8:2&&,)B%'$B M **AJ[?7$AOE6\-8#)& #5CY!@?[K3]>7!;#*R';-)R[65/1>ZAGSW2D*E(( ME6$Q)A@I;#2U!K T)F9Q\.%W M:>33C[W7VXN 746 J$0 XPA($!(=TC@$/(QSQ(8FY9$0#OZ7-(K)G@O M 7:7 &?F'ONI;KU[O*.E3FO1+8( )3%D1!DL(6. A;*PU%D8 ;:5S3^D\Z.I M=GDE2:M5$IVTTGO7^.P9#E5Z5834L7MPL0OO3__,*A8_SES3W_S1UW>D_UZ, M'ARZ^9&=XK?K^]):+8=FD6102LF%EL 8P $I?5\II'Q&1]>RO.4!?!PGD[F: M#$UY!MVWE]\PO,<^\:ZW+KEZ#G8P[3I($U M?S@'=\T /S,6;MMD?T.1K)KE_I9"VAUPR[=*C%K[$#/&,$B4UC1F(8X5DP6F M=NQ^?E)B+"<(U^3&V2CX=N/\,-!]HY;_8"LM@P??YT N'U!HOLO G= M%H+;9""OQI((+JB*'?H"Y)2@6')FM& \I#!B4#_G:>7YC)H,;#67>!2DA8WU M\)N0%CJ9][B .$@OHGH1Y464K";M:VNB(0@P%A)' &FM"7$B2G-!(H,;^'0O M%U%[6FJ]B-IL7AT?OJ6VN,VX'JW"4OPR68X?#Q"Z"AS%7'FP!#=NR4&@^B2- M T$-U&#NQI6[2X(?W"6.-!#PL.SV,_\;_/G'X'N2>1@&:[:-)O-I,$Z^!_?) M[Y915] 9!AY+-7.@#>YF[]THY$DR#LIY%GHZ3&\"75PUF@S&BZ&]97(_M3?R M7<'!:)[>9U=!$EB66.3,5D ]#*8S!R QSY$E_ ^WL^F]O=12E7V;V=>1>Y;_ MP'X%TS^[]TB"VW$R7_ZU/)AC2 $.JL(+*AG5@)!8QA S$.G(%(,3M0XI@[MA M1+F>^LG "H.\M'$>IY:)DO&G>3)?S*>SQY6+]X.O?/\AWAG LHE?^>C)Q#49^64M#,&@;))/T>C-.OHVR<%_ /%S-'PN[*6>JA1>QO#U:&3([\RS;XS2XL\S2<+<;S\F6L76(OV4#& M_L:.#[+@(9DMKR^VXZI\S8J1]?3>;O2C7_',74K;WC@#(] MK?T^I0/+1\ZL\OK/_)%K*[?P^U&6^0W,LH7E$2M?;V^#BLB"<#&V9&=W[L/T M)H!0!#^\^Z1"]].['[V2&0[M!N=2(GEX&%MM6$JAWVX^W>1RRGX]&\WSD\FL M\$@G7D)8:32?.>4YG-HWFTSGP5UB99V[U<0N),N/_)']P:S-,DL=SC3;)C.[8W< MZY=LE;]_M6S[S&!@[;UD-*D311W4J1)3-U;=^R_/AI[BOH_F=T&Q2P>(L%S( MYN3KK0][X4%"ZT_;I!:L=>,S$K$04TQC;K144$N62RVI56S8:THMJ]O_J_-2 M:T4V;<3JF@Q+L74[7S^Y&S7[U>MQ+049=[:\N\_UID7J];KDQG:650%)*Q3I?65%VX"RWG M?1M-%]FXHN";( \5-/_MN,C\7-O@.VN#6-ZS F*4W7FNO+6R;Z-*2;Y:N9#- M_4EL.MKA(BUW<#$IQ,C\,<@6,Q^NSU67]?/^;RDKLX5E]?S;-\'G%9VTZ06L M2'+BS#[5:L7CRH1:234E6" #H$/1BTRD&04H,BB$DB. 5JW[)N=2>L>?RD- ME*>M7826D><2Q*'@@(C0HPUR@_!JDP0X2,<0@,* M>=]#P/BFV<';DL:KN92/:3*STG3BK)L];]? D0OJ\&"G8M$Z^-0IJ=*=^=[/ M=1Y2'C<8/^[AM!Q/W>8(@0<21' P+X3/ ;>XE[:^S6SZAS?,Q\=6 MN9349 UB,1$0&JN("21$164P36$9-@3^2T%'_K?XXO\NK6^UF-]-K;/X^,'> M6/TQRFJ7Y#'-(J3Y*9U]&PW2][]^^D>:A]8.ETY0W#3;BUL23\?7$514YX:H MX2"*E-7*@ 1AE05[I,;;M8 D6CQW%;.S,5+4P>N/+7[_Y]60&?#D7_YULX, M8G(TRZIR^&OQO-O%?#'S[KC_(/?.KX*1Y=')XY7WW(M@L3_RS.U W8=_6,P> MIEF:K='Z C& MC8Z55SRTY77V)A]]8-]_VP5L_M?\\3":>9O4?O@_UEBS3Y>MG37B_'@BX;N] M2_ E_>I")U,7FAW-''L'S@-U(;/QL5FX5I-CH*ME=H#F@+DD-U)4(^L3&(PC M(<-&C_%;H8;?)K]/IM_;TQ$$'L_K\"'C24$)16[+2OP\BI(+_ZWVW7,TU1O0 MVPUHJT@MU;@(E@\X6GTZ]>T[!<+1ZUK3HCYN"U%$E-6UD&G&!8^T*%-Q1/.& M]-Z(5++123\NPVYXB?J=?BVVOS5^E4<+U9S "A>5MB8QX3AF%%OVY!"J$(F\ MOY3CD)JH,73EJ.>MD_'(WG(R2NRK3P9WH\Q='T[M(U[_Q/GQ!/0F&]X%SBL[ M?MEY]=B"&>_$?OG%C>+G*3D?5 >T^8M/:9HN*8B-=4?!#^_>_ZK?_1AD:EWVTC29Z?=_\* M//?.K+U+RYF)VY[N-S@]GBY;'LLUM?.I'D1"$JI(@@V EC5__48D (\Q!.D M0##KO7:+)(X\(GYQ9L1X/(7W+5WR1HKSX%8>-^*AJ3F3+0]']6%ZMV$MQK]1 M6 =W&",+BHPKW#[DS"0>2J^KS)G[),0@%[YC?-S,)[.*F?J8V>%ZLN+I\+MJ MRKI;&OV^;&GSC7F^A-GSZF#I$+Y^A FE#]$$5+8^4$EP'WZ.QM%H.CIZRM.* MACT'ICS5=BPNY_6&:P/%-A?I0?"J*^D&Z&D8)%4$,@6^B]*, P,'@S0/NP-' MX1VYMS583CT*^O^8P@/RU /X[F,<\S2')),^ KED43\/Q8(^?->6?0:-W.;#<'/F ^8)TURX APE8$0 M8%T ?G@&6Y7\-ENV!23ASZEA.R;-@_H?3X>#4AQ,Q],T7**DA0S:I4Q9_G6> M_KJX![6D7F3A,%E(^EW:HX.WP)07ALO_?4C*1TP 1M[> D+^^9:#Z?M@^!@\ MI?"B=P]),9>-B;MS,SH\UWR/U.$+&,%L''/$M4!]7"1]A_'@1*5ZE+"2 _6X@#2>[X5/W@K*ZO*H M2+I!G9BG83#S)_L MJ\2"O$ M2!H/T<.QL-8KJ#D:H34S*)5FN'F6_#_WDO54WRI-H*7.JNFXR);_[R)IJ\CT M/62TV[DF#%HED2@>\QS#URS'\2W%5W6?D<(U0;!"Y:)KXM?:J-%M4(QYYV.< M6X?UM*-Y!,KC Y,$7I5$/(]PB I][B!8ZTI,*[XLSB!PIBNT8>0TGJ&[DFFK MTQ2SXP?1G50CAII"OGCORD,$(<\4GJ*]6<]17Y&P=R7]^BS5H=6 N<^89=XO MT+VR!_)DZ)^91)DT@I5\2-N>AEXPP9?I",1._WDS=9Z^;Z8C((:GZ[N9)\WA M^@F8]'TP>U _L8=Q_\]7*[0=S30\<^P M /WR\PH2_AZ- ':^A(_2MW@4+!V:?HP&V0/\"2M4G.+LP\H'DS1\7_Y1-P3X MFMKE*R!&/W!_!!MRJ ME!"EFTK'GK+VX-+4C=UFCI?S3X\YG]_&PP'>Z^H*72[JOKUGJ[DZC=IR/8\#*@"]*(TV7IRLR]58!3Y=*#Z953%91[5] MGYJRI]FFZBF>@EZKO.>J[\B^M3\^:8W@D][330%/ IX$/%T*/,F$UCIJ:([B M,U4U3=IC-E?WA2FU&?:$]AYN7B4\>Z5WU,,-&BK">2%O4Q MR^S"LB .3DBY^?TL+C6N7*[U,?95NVQL[.33:D;*W^T $UX0)X M33%K1VX-1V4^+YQ,E[;6 EG6UYC/55E@M<$K[6#U[2J M; 6U+(,P57,('H@TJ4SM4OGT-;)MHO+:QX-'6UK31"4Z[E"#$@CHJO8:- MS/]\4ZBF$Z">Y!B*Z4D;,+6#\XU*RFH.DSUFR+JKVK9K>Z;BTE*CI=16Y\ZN M;6)[-US%_U]QYTZKU5*V7-^SJ5+_.U!(:P5TEYUI@O&?97Q**I%/?,T ?=OR M"7&IS0S5+3NX,M^R'.^DC-^(8M,B%9X[LF?9).7\WA1\[K\!WZXL.]12V?(9]#Q!XD7:,1]:SF^NXV%I3 M8DT^4S@>')3))/J;74I_,YG6BK&:3 -!#QQ>-+E"TZ\%/ DX$G 4YOAR627FW=Y MGNC4R<:PWU>4=)C >O>QX VO09.7D &3.PJMU3]@VYH2X(MJS8T4"!L/65,#;>KC;#HZ/@#R1TC"\,5**B]4;%F0X8Q5'A"?*,SU;=667<K^867)+V^RWW"OV(QJ]JOSX:"&ZVS/*<%O$W#_OO!-'D$89R& MXU=_PUZ,.6D\6TZE^+^#I6(#;*HN]GOJY<5)D6('1>/O:1;56PWF%866BNS& MR:;:2_-R;+YG*WZ3\P,6:4(YAIAUM6*1%K6 O_U+P">>:IY+3-GP74(M5;44 MFQ)#-WQ'\XBBRS:OH1)LHS[4 9-JAZL/_./\46$J7TG[U3GR@@0/TJ; #/+>JVPD4E$RM M49CC^)11&XOHV\34/4>SS(+"+$MQUU/8QOD_TGJ[&V%=6(&FNK:JR9^U4B:[ZVV7F]K+6E MM42-M6UGOGV--4F45Q,EDT1Y-5%(ZS"J$.75!%4T55[M)5*6&X\1EPZ3$_'% M^1?^V';7VQT??SX?FS'#"+5Z?-RR/U5"=:L0K1490 +1NHYH.JT03;%U MS_%U*INFX?D6U0V'%(BFF;+L[8IHNYT.VP[1Y!Z JT T@6@"T02BK48TN4(T M0]=\2V7,-JBG^!JU/5;D/WB^3/6E^AB;$*WY4V^4D!Y3FZSDU&U$:XMCLYD9 M\B!P*O'6<[R%WV@RY2D>R['0WG+$=-_CM >LT MG*><,7BLVY-Q5T*Q?_&71SAP((E">[#,KV)[\/U-,/^M#CEA;C\-M8:WZ1T MKTQF3>OIBMZ%LC>7Y#+L+'O5ZDLQ9BFN;FBFI;JNIF%Q&:]@+\>SU*6NAXVQ MUY+I< ![*5I/I9VH*B78JP/L9>BULJ2RK,G,9T0FGFLRX#-6L)?J6>92[>#& MV&M)CSV O62Y1_5.E"*]L-#&'KKEZ6SJCIG-K;",#5H=/F:*8E+3),33#)D2 MT[-5N^QG+!.R5*5U0^;JEO&,\NXZT+ 9SI M3>8K<[G5<5OL9>'DZZB33P#2 M$0!)K@!)UU75='V#:I[FJ(3HQ"CR9*G/9'GIN/'N@+0J'-$((+$KK;U!5@%( M I $(&T+2&H%2):N:(JE:J[.J&82F?IR6<>>FH[=@(:T*IK0""#)5Z1)?\?9 M ]*):B2L/"=>7KAXWF0Y@6_#@;>#5P:UYKGA\G\?DO(1D^ ^?'N;A,&?;X,[ M&-#[8/@8/*5XK. A*>:RL0Q$LZG_^Q2BN( 1U [CUHBK@3.;[+ SF_+N9S;; M=T;3@OES)TCT([P)^].\6H#WDQ<<&?#&"#Q,QQ=Y^4CGVN.;-C-M7Y%]7W<] MES+;D#VW7$&?:7[M^*9KN#*U3,WR&"RMIL@:*2ZE+MCLZX]O;GS/AN.;_7@T MBG'181Y2^(]I] /$#Q[DY(?';\-PC"?N^(+DY]=/=H9SFYD=LC#B#.?.K]W[ M#.=MV ^F*:\,$B5Y29\4=_TQG@X'\"N,*XO>EKPX?^1S\]G.W:JVK(210^%4 MWNHQ6]'DY9T0-0\[(,H:/WWY4D]L2\K+2<]S&I=RG-,3QSF;"0A?YA&M2S_. M*:AB%55<^G%.016KJ.*"CW,6B;;QW;QIFTYO_P M'*MVQE7^C!1/UC2H.]TJ MM2#7?KV[W#1KN4S,=TWBJ)@BJ#B^;?A&Z:\P%=M=.CQTH)O%&L$B9YL+$![X M&OMI]0/F*AAZH\DP?@K#&Z2I:TX[9>7"1A*L>L9I#G&VL\!QJX"I3='$R\(: M2BB=@8VJ*K8LJY:B$,-6-$ME3IDL8+I47NKG?BRPT3L'-DJ/4@$V FPN'6R8 M6H&-3XBIFI:L.QK3F$D=JVBR30%[R%)FTK' 1NL@V"C-MG X+[!IBU?O)4RL MQR!)@G%VJOHZ[0 5I0KO6K[LFK+I^*;MZ4Q1-<6SR^J\#K5/!BHO8"[]EF]] MDT"BT29AI+7:1]>5C//E[%K72=LS':::GNOX5*<*,:E,2G7!T4['V2]@FQR! MLVG/U,393<';+\C;M?/0ANW;U"0VLQFS"'-E1R_]#H:OF7Z'38$F>/N_PR0> M!.D#DI'!*/O0!<86$905ZOVWFU]?/'S2#O0PJA,%IDI M\'T(IV97.+X6BM0L7:::3677U65F6ZICT]*IZ3)CJ9%%!^P+P?&"XR^-XVLA M2I,2(EO [02[DQ++U RMX'C=IN;2X?@.F 8GX?@%&T&5F^Q4T6)3 &B_F]&- MR31)I\&86PC>S=>OPLF 2*)5]==]U? -PW0<#C9.B.C$41BR5R);JJG;9OE7%<:541:JV]T7:TX7XZO138=0]&9XYB^X3F^IC%0)>C,5^&PDU6H M.+71(3A>-AMJ59[WL?7F"JK)DY_2()ZBM5$>LK^P^A%,K>I' M,-DP'$.S78>:EN6JU"QC)$QQB:V?UM)HZ%@FZQ':J(]Q;P)J9VT'X:$42+$= M4M2BJ;;CZL0U%0^L% ?4!I5YI7]3AME4Q>K8_2UXO\$ MG!Q3PW44V] M9JN.RF3;(,1E!E6 YD"IU0UXP+N@=F/YYF=[ ?%%UB8'-_[A M'^=+'E/E2I+V; <4WH_ %/H63F(@K?&]&Z7]89Q.-_3WT1C3@ ^)KCA4<37# MD V];.5A4LIJ_7U\AS%5DTU'LWSFFF @&%YA%>BF[/EKV]AL?,]2?Y^/87R? M!),'6()HG#,A/.BY/CS;-I3:9AR'3&.A\\E:(FI3-ZEOX8\0IHRXZOW,PF0< M#)TIV-GPD-1^JO;"2L(@_8X)=8AL?BCR\OH^/1O9KG[-GUYTS>-EV M"]*6=(:3-@:B5'0&:F%*RTMV!I*?HX@1&+'#\$*[?5QZ9R!!%:NHXM([ PFJ M6$45^W4&.O]C7WCL#V3L319DX:DJ/KRLU^F9A?A?QW!,GZFW5:6Z$FI&95,S M$RPXIFNFX>D*=76FV7E81G-L17>63JO4K'\'WHTO^"W*'DH/0.YUA06QTA2L MX'#P/?CY?&)HFF2_<_I$?U3E.0B&/-VC,+I___6FYH.=IH/]0C6RT6/R24Z. MM-/#*D(Q N?,*ORL>S)3'5VV-2*;EFDZZ)[.<<'<=@;L6=BI3C .!L&!38_/,*4_YUVYJES$;,=PP39S;5O5B6?J MMI,7#M!G5M7J>\SD^K$]A7# MI[B,1<+Z!F>2912OV7$ME]0O^4G2W&CK^]^PVU>.D2Z+Z>K M/:8J1\O[WH& 6BNCN^R0$[CP'"X8M6HU/F$>:-@F\8A!?<>P56(5N #L2Y=. MLI]0[3X:+H &H!SOB*G !8$+9XH+F]"+0II,DZFJ MO* U<#1H=8J@3J> MI=JFK8")Y.'Y,=LHX@ ^D4WB'--.:@+"%+VGF:>MG]'*&-T%>"<%>@GT0O32 MM5KY!E M5N7,%-4R%-,D/K447_--XA5E5#7?-35VI CP4J&1O;U*:H\HIRTSTDKPVJJ: MR*ZDM.)=2\\\\&C^%B4>&JA;P0ZK6R'OSH86+X=0+MZ.-Y>'A',HEVE/JA\ MW?%AO S#GO?.G3 \F)P:V$C8B9X4#(?2,$9!%/W@1272,$NEQS )X>M^@$? MHKQ"Q=R!L*M5]77JQ%TOC,,4PW M:D5,B*78GF8S^)]C4L/Q9*UH72X3A3KKF7/C>Y:*F.3WPK;_HYR<- BR0'H] M'0<@FN"7-X<6RMEF4(?,Z5P+Y=ST'\+!=!A>WZTGK(TEV<"=C@;NG&K]."D5G.WW35W#["79MH!=4FVCIWO-9L-D7/- MU.105ZK"(Z9CR([*+$NVB>SI,C&U(NW'4A2?':GPB/$?]#^:B9SK/4UO-.VG M=8G5 F($Q)P?Q&A57K0L4T\W3J1DJRX.*FFG9CG$T+49N#F(T 3$" M8@3$M IB#%*=C] \1]>I9O@^TVW+4FQ'9@7$F+IO:D<[W=4,Q"AJ3U:[#3%M M:3O34'G%."]?L_\I5(&<.V#*2P'D>>!@[72_YAFNKSH:V&Y4EU5=5Q5'UQ1" M+-D@CK9TU +I^/JN0,-CNH*HT2-Z)ZIS"<86C'TBQE:K%&3/E155-F7+\15' M(\1GEH6,K9JJ9SF8X+XK8S?D@&&DIRBZ8&S!V(*QMV9LO6)LW2=$D4W/ (&M MV+:JHM1&QK9,7=-,NCMC-^3VX(S=9/!&,+9@[*XSME'UQM$,YA-#5UU'L1S9 M=&V9$<[8MD= 15\JP+>9L1MR-C#:H]U@[ M)5FSVTK+[C4 >@3S=0)Y:ER"7 M6(IC,,M3-=LV-57!DH Y\L@^_&]?Y-G%R;(5\I >T1JI12.01R"/0)X70AZU M*HZE:Z[F^9JO*,2CKH405*3XFI[K+T=LMD6>7;Q 6R(/I40@CT >@3QGC#QZ M#7D\P!K=QNB1[2F^Z3*O2,NS=!^^W1=Y=G%3;8,\3.V9I)'R[=U GFYETGP) M,VD(I+1G;9U_2:>39U8!*]JOJ4^C3;)7?WO-<(6G$Q$V$&&#%X1E2DC5T:L=V2? M^Y0IBDQMXGNZ;11G-E5JDJ6:J9L!H7%O$>WI3!: ( !! ,*Q $%3:KE&NDEM M:MB^KQBR[VD^*>M$,(_J2[E&FP&A<2>.V3.:23HZ*T"XD RETHE3U33N2;=! M&O5YQ>5!-)QF59W)$WMXZ/X>GLOSX1\@I\[ A[_MMK8=^[!\S[*6]--F46K9V]402C5Z[DV@E$ I@5(G1RFY\K,[ABP#0JF^HFFP MV43SJ%V60M-ES3XN2BV[X)I"J48RU05*"902*/52**56*$5L1;944R>.2JGN MN,Q068%2NF$:1[;XEOV"3:%4(_D$W4"I5K5?*7QK#'MOG1M"M7BN6Q>W[]B\ M+VFN8H^[/U>QQ]V?ZT7NL6AQV)VD#='BL-TZ=M>QNBWX?(&-HN9:'.HO1A^B MR]@Y$D^]Q:&@'4$[![4X% 0D".B0%H>KZ.="\BM%B\.3I**?04#K3,H0;(AG M*7)5)]/T36I@QP[')P8ANF?*M(AGR4SQC]2Z0V^LL#WIR7(C%9DV<6Q3&".Z M PF,N02,4:L^JCYQ"=68;^H*LTR'VHIOE!W(?$5;RC]L"F,:JK%/%<"8;K<' M$A@C,.8,,4:O,$9V;<9\GRB.8RFJ(\LN=SCM3E4&^JW#\U>E01>HS M&($Q+<,8L^JD:EK,=G5&+)524[,5U72M F,L:I"E#.6F,*:IS@-J3S;-3F-, MMXJSB3:'HN)!:X!0K95$K+I*89B*IYMR-1FV%S%]A59L_V=NR8UY@XR M>S)K$N%:JRP)QA:,W11C*]5)48W8ADN)#_\2U]%,WS-E9&R'F+JL*OKNC-V4 M#X;T%+/),PJ"LP5G=YZSM8JS#56V3(^HS&4ZL0S588;/.9OICJDY2RTV-G-V M4YX/NFXXWY M&ZC>(THGM/$+R7,1G0Z%(_=\';F;3G%K1*NB100[C)G$5YGG*2K\2:TB(FT; MGD[V:[ZQFQMCJ[J->D^6&RESTXWF&P)Z!/2<(_2P&O28S+8LV=)TE%GJ:+RC.C1T2750$] GK.&WJ4*G[MN;KL$-=V3=4UF2)[1-=S MK<7>WA9XC-#LT]482[@3T".@1T/-2T*-5T*/[ONZX1+5MW99UV53\ MLMNAZ=F>K.P+/4T7RI>5GF$V62C_S*&G6PDUHMMAEY"\=8!]+KAL5EUHB>,Y M"J6*XVBN9MJV:U._L$9=1R-LU]8E1W"!:3V3-9(9?5:M2P0@"$ X%2#HM 8( M.F.>X>F^JIN&:U'/++L=FA93U27WU&9 .()C2E6;](D+0!" ( !A#A#DRE_M M*>U/+R1+270[[ B.'R"G MSL")O^VVMAWYC5J?6UWS-969+F6.PPRFZ)Y7J((>TUWGF+TO5CF6FNIVV&3V M^9G[^P5*"90Z0Y0R2(52AN,9ID9-V_8(\0R+^+9<]AY9"C MK *E!$J=-TJQRL_.-.8HLBHS3[4U4]%]XI>!-X,8ZI);K5F4.EJWPV8<\P*E M!$H)E'HIE%(JE+(\E[BR;.NZY_H.(83)K/#UR;;&EJ*!S:+4T;H=ZB>IM'8> M*,6]AN^RX'88SK[G_]:&L=[OMT?H8#;*']TS)=["@FZW]LD / MK[9=<-S).0 E^3MWA8)F')V[RP!\_$Z3W7ENRPYB*4H!7T83A!LI&@_"20C_ MC+/A$^*$% ;]!ZRSE3V$TC^F09*%"=RY@0.^#X6/PE"(# M/23%7-8-\ AMRE:< !Z[$.8?'&X7> =K@9]A]6\"8 MJBX6Q-<\5U5M3R.VXYEY+I2N,LVB"D8FBT>$ RO;^79EJU$HNB<37S%MVS0] MUU545E;H5YG'=.,M6SN*C;?+9R9Z%K.H=WN[M$#86V!J\_*L =)3#B,]M1G2 M6\\ &V]7=B8>,#"&TP& Q7Z[GUM _VN3!:17U54LDS'-MXBB6BHSF*XSM!P>GWGAK>9]Q//L$RC] &_Q,HKJS(@\K[NOQ>/^-U)PD&4 MP=NC890]63^C=/;33=B?PJ_XZ,^\.\_L%_SJTSC-DBF^B=\T_I$%O_\2!V.P MM?B-^+3[) SQBOSV-5D7ZLRLTM9:4^K5;:+J%+;1NBG5*,F ON(H<<8/OO<(F MN_1M?BX%":RY8#(9PM+#:*Z6M/49NYBZX3'-,2V;8E,"U?(-4W%4JAG45W7B M"'9IF%VL,^ 7^"J)ASF,?TWB?@B2(4P;)?GF1^W]"(:%<$0I-^-4+HAFTYG, MIK.]!7M\=OT-9&T0 0 !1/WS7PS&R(?-$^CQ*^D'*4BE=-I_D,"V'J$C:1#> MP130CR1]FP[#W -&Y0"O)^8'JKX.WX!:-0!)C+*^T+Q 2DO>SS['2D! 7M>= MFK+2DT!RUW] 'U, \ (C ST7J!1>E<6@)?#!\M_JSJ4D_,3EMSZ&TET$* ,O3:>WH%'41CHW/)AH$O:Q(>6@EZ\*=BCH MH?-K%"2PN/ W+EC^='@?(CV\C:LW #_HUXKB :S=!#3%NRA?L-IBX,VS-W+M M)DWYA&!-\U]QDFG^%CYVO@OUN<,8@WY_.IH. QQ!KA:-1J#2]OD7L"3Q-(&] M'P?W7![UX/:BYP+_90(:63^:@.@)?\+(LN@'K,S=7=2'%WC&)Z0 85+#S"!1Q Y>&T_A 7)US4O"(B; MW@?6@UM_1 -8JS',,PF#-!XC1O6XFS.X36,,[. *P5MAV0JR1=*(;_] A?H' M;''A<-T\/,X+HS"[DJZW6@WI(8!]O W#\1P'C<(PJPVV-KH45),![%!Z)5F M14A;L)-/2"VUG=EF'>?)31J'R#; +K!,CT$ZQZRH/SQ)$3#F']/!/;\<7E?; M>EP(!ONYMF^!:L M.YK-V#K$]P)% 70!#2X0#!]?/MI',"@1 /IA/H2@_Q"%/W"9< 5A Y'?[V,8 M:@%HL(&P-!F\"YFV>#?,,-_>16G[LO+)Y@L;<_",DAD-Q+BN)9N$XT'Y9XZL M,!G09G*@!^1-)2L/+'SC@(Q/\P$H"^E$"B+Z>TZB#BS>':!OB7G7!>:]W@"* M;_BNY7=7:OLS=R]!YIN<,1%8T(>3PU.OF",']P$'TNTP#U *J>GN+L<3J0"8 ME0P^!*(;[KGEE7)]+*LI0K<](,YLIFVB31[[XN %_%E(:Q@S[M'BN"4DR-JV MYZH!\NCK8!NUZ>[-,\K(&S"FD)%++0+>-\[=,KE]R?FC8AJ C'X2W>;7?LK" M@@E,"Z'I1X$M,2@."9?$N5L&)S0,T@S&CVZO,KJ77_P XP?Y&.(2 6@'G.A0 M&((:Q16E@N:>;HO6+G+]/!-JN%]4_Y"6@A$DO'H+3P(2X.!,BZD*2E=H^J&1@2^'#\E2-PE/Z9L\T,N7&3881!W;._I-X&*$7%"^OR0=\ M*:X&#!15UUQ[K-L",^Q ?29"H56NQCH9N48"+R M A1CJ ^68W _CE-@BSSG#W2=7M[4P@+;="AQ$0#CG@5739[KN M3=A/PBQ(GE8]Z7.0@.T*GY2K@S=G7^FQL(8/N;V6WS/G,BI"_IW32\F)W"U49J!PC^Q8"D$[ MC)]R[>+3^ ?HU: G@K3G5MY8^A& 0CA-"W]G6G<)ES,#09C;A'>H3PZF?530 MQUP]+73<49#\&6:38=!?*2U;DX"I'9Z 64A^)ON^8NBF:^BZ:LJRH3JN@DV& M--MEKN[/2?Z69"V*$6Q!E9N]"8T/=(42\=7Z]EWZ].G3\ZJGK&@^=9AM&Y:I M*D0U557U9;BFZ>LN&>NXO=N)DPLU_Z2,:/ZA) MM#VY!&,T*R.\I:,_0AG)I3BZJ@K/2R7%\8IQOYPWORT)[]#/!&HD5U^RA3=4 M7M=^P(,X993<*[+?4!)6:UT&QE'N!J5/-_?]QS^?I)G?J1#T&&\>5,Z6+4+ MH&1@1)<[?\82+'NN"@Q -%43* (BN:N-NVR?PB ILNG:8(,_YZE.N;LJFSF; M<-5P-=#7B+/9\W4P4G/?D1:AH\]AF!5ZSTT6]_]\ "[C*E*<4\=7OK\WY?Y> M24X1_MM,KCR:G'"7Z;**B21;>8G@>5^#),OWX-/,'BOB6L_3ZC( %&8=Z(]1 MBIIH-DOI -I99!/TQ,*KZ]S2JB!A'HBI0MOC*L0P7R(P#Q) M:QO*7:.8)C :(1>AW30.\]N1 .TX2 9S+-^JA:@B.J %2'/V0?XU& E '"#J M.4O5(HF%Y_O/P,/*.J4/56/B)M!I^8C; MYD_SYFYR$N2+UZQP,)GR0GHQ[\M:;22>VB>!H-XPE.!8'$'?,-# M (]^3@EI.([B9#DNG=9R.4L>V,/[C^8GSYQ!5Q#WB?T9/M7=Q:5ABL,< '-R M%S,?'UK.:3HM,S3*L=^B%QIC!Q@302NTR)E8G!P&8?@9QDF<9KD[&^?P&-ZF M +[2X^/C590;PE? \_N] Y,T>+H/2/1@E$O9PI_/LZ!^\/6$A1\%?\1XTJ 4 MSLL[=07R!O-AHA\YAV7KAH,;AT;]4GY67'DN)'[-[)$%_RU, #&OG, ]"H-\ M JN'*!6RF$-C,$M5GC&)=#_3)GG*61[.X,'!:9KA*\HDL)F7HY[^@R!3D=PP M>+R2?BNP/0(BX>2".A-@!N# [3!^#.="6SPH-HM+YJ7+(RGC44C]\_'^>C"B$2U7;5M_)#*]G#OGK:309S MSWK2#=SF8VH+4%?D<[@ M!--TEY7;O"KI#%CFL1F32[)L\O[=NP64+O-I[SA E8/+3: 8TTS+%,$R:,'' M,YMU-=A6$)X, L4]SAL)1&/U8)83J*^9-U/HP!8\6,( M*YV I+T!>R2),:$@%])P.3!Y*'V^ ML_^0.X)9=\S[R?IPJ,N#J6PVNM*,"( M6X4SFED8'>8*#3$Y*2T\T(N_5P#B_9R$]:T!Y"VWP-8:>AH M\H3C]$@1Z!?P\#7@QTO7.O+>EG_-K5W=1[+D6EEUX9(9N^@F>IZC;G$ZK[%3^ M\5N8'PBJ&1%P"3=7NH\,A4%=+[U6V2I'V,I.0GV;Z<4?BA\>.$K[=;;E7(,C*M3\$&UJ3 ME:,WEI5#'850A =+HB4 M]@NBI6Q8S'WTP\(7#M%A6,4Q_ A/QNXK28XG&59C58LDE]&8Y&(N=3QB&:JI>ZKF,\MP M5)42W99-T_%E0TBN=H[@K/))_W.-ZTFW077R5)W /Y;N&XJKFXIA>[[L4V+/ MT]]A@GFARC=%_'V;AOVWL Y8,>]]7E/E24AP+L'5]DMP[^=#=!L5E?BJZ$Z5 M5G/3?P@'&-[8*,7W(JV"DHQFM#[%.!>:>?6WU\%.G3:.3QVO_N;&_6D>:,XS M78,T+Y!2)B[F"1)'H8,&:RGK["6(H"2]'9>\E8$I?O'[*(.78E>2%;"0OM\W M\>/;3&F.,!UF,'/SHLK[$S^L>EW]!%0MQ:4X\;18'\/@)_6JS-M//!$POCL. MA%TJZ;8R K.9="N)MC<-6UC!J7Q*+0\HYCD)@UDY""#K)Y[2B)4M2K.R*"TV M2YJ;Y:3/[,Z%PG!U&L?KJJS/M,8?F.&7\80Z(/4L/BZI'T=ZGQ7UMS),L$#] MI7*W)YV_YW6;*UBEZNO;-T#^@@0W ?)LLS(F-KZ7)A@3PW3+ M),&TF:*PW]P!VES;F!W*KDHD'57GI.P"E<[;UBF=BT2ZCY-P>1"UJY>6K>Y" MQ,_UQXUY O*\I5\L=6,MF!9&FU,1)3"/6ZQ2FF#SK6$P2?DKC'^JD>G\3_3YG\S:;YN)NNPDED^DY+3)3WY6;"#]A?#_ MCM(7<)TS9H_N2\\;R\\ZLHX_@B]33(;@6>Q\2:W;$.426[HOLVZCFH2=0_!Z/) MAW^=[Q/53M+94_]K#U20\)MB6JG8Z!RZ[NXQ_OK*3_@!7$WX6#^R!Y-PBRX!U5":6R\@XD%:6F M3)E*=4)D73?>#60FZX8Y"'\R>O60C78DXOFQOOI;?M;AZQ0&$:2A-&NHQ _B M#(H:@/\>C*=!\I3ODL;+".CYT6*X8A0_=_2L?H(C!149+4'>&[(\"3>,R@.> MI3]&HJ7S8E92F]\*5Q?5J[#(& SO]=J4T4))RP<,7%OZ%^?/SO-:6$YQ%&15 MH6FCK#-=6*?%.DC%$KRI3-.@JY#7'LX4@G@?_KX,L1"P+B7S9$ID1IC 3 M)+*ARZK>E$1&\3.K65,KN[%:,F,=34H/$\GUP^G'%LG2/M)8,M[.1#"?L'RP M "[,']\_1(-!./Y0((BZ4YXBKZ4>K6#DO3TB8JKG.-5.B6E9 MB&DAID\OIA69$NW=0)$56=6:$M.5/.:-#WF \T[Z'";W15VE;V%R-:[>VT)NPX=X' SB\@4WT]N\5G11%G)T&WW&RMX_YS)C3B*1K>D]%@FB MPB9N$YX(F_C2;6)%"%LA;%L@;-F1A>V!DM6>AN-EL=J3/F*?QYL,4Y\_AN,0 M&S"4/_%B07$6S@K*XA>UH@U.D/P(L6LD'^C7LAW3K$_D=0+2&D]R)=$/+'<% MXPK3+,_A^_3I4T_ZY2O.!I_Z;_DK2D,;A' 2IG!AP&L1;"O?62OD>_>,,S'5 M+DZU4UJ VM*]?!%:O3AQ;,B,F$QY-] 4 I]!'%/2A#RNE<-;#AW/"^0OL/.\ M,5$>-#4VR^29ESGB#UQ8MNU0WH5E>]F6 MK5PE8;5S'X5UV;PX(XJFFOB-3#3M74#5MRK1S=]I^%,>-.'-_1;R.7=*0Y,;2D/SP-JGRL5@>#%6%?&H'^POY=/'R24BHRY-0 MS_D_Y2;$TX)4[T$U:6D$JMF9B02EO1J")LK/.62G]IZ)@$ M=F#"TPK<>JG;23L(#66MW5)^Q0VAJH34G/"X*80'E5[[(#VD+_%5(8]DN?@) MI([@7IQ52[.-5. M"2AA-IVU@&K2"=A,UL6<("K\?,]D7,*(J^ MX#O,Q=I-.,GR//4&JJ*<#2"TAW$ZC G"\CI8;.UT_$J0:*?%EGQJL67QLES5 MV>EMQ9@LQ)@08]W!""'&#A9C6KOW\>Q)])S$6!/^PRW$F+^S];7..]@6L54V MLMFR^^P+]$0V#^^)O&Z E])8^.5'L'MKX^6GUJZ>@SW10>DD'92:$36;6N$< M57O@GT0'I3/LH-1-XA,=E(3>+DS+UE"IQ_/GD3/R;143VU:[NLA5<_ MU.P&0+2'D3J,$4*,'4BEE(CC:!DH:_%?HN8/"?QMA_AS_?4O)[ MDZV /L&,1N/\8!M*E4I@W8;9([9+7S@PC7F948:IEG /MO7!+P91$O9Y.<4= MCL8A97?[;-S9@$Q[>+'#,"-$X>&B\&6Z\?U%=!X08GA)##>1*PH"AA0'S'E% M_]W$Y_Y)H4)\"O%Y9O @Q.?AXO-ENN0)\2G$Y[+X;#)G]4L,*QQ6K6VO>11. M^CBS6.>^GMFX7%BR#R =QX,@&8!\#9-^E(;279Q(P2-\E4KW^ P0=7S1I)J\ M_C1&MD39MX?DWC\/5DAN(;G/#)F$Y#Y<WAU@X#D1#4APMJ0PCJSO)'^P3UK/FCJE.=\.:/5*=4Q^Z/ ME R:/-BT1E+_.@9AN49'5KR;P4??Z;)N2MP!,A M;]M#I<#GII"WG>6/]LG;]8:QT8"X]4:38?P4AN4AIBF,*$CW$H&&L%U;@5+M M8:@.8X60I8?+4DK:O9-G3Z3M$V@S U*3#47.#4B3L"8-R%]"E%^5^5=O+C8K ME)3O$I'X]@\$\]_L15E::V]@4W95(N3%H1DE" C)"$[:%29'51(NIB M):'*-*KEDE U-:-)21C#O?P,3MB?)BB<5DM%;+E9F$EZ*1$+47@#0JT/TN4_ M@^$P?)+L8/SG88*M<8=I-7C&A&03H"$D6WNH%-G\92H^_7,PFGP03M.+E*RJ MIJ@FH3H!"2O+[\8_LN MRE0J_ZX9352MV%:N?@Y@I!)5BU[6I4R]_GD7)P/) M"28@0H<]"6S*!HS%=14I>$]N/CPL*#M(>Y/%<] MZ6,<8TY0 !+N8S@.@4IF/UV/1H-X5'QPXM%M- JR)/HY]UX<3_VWS_$0YCT$ ML>A&P?TX3JLG;B^IUQ5]7&WX2L;;TMHM%U5B1KZ9P@Q0X<(7 1PQU3.>:LZL"W,<\#DM-P!2: -<$UIGL&S4!7-#94AY@CG8I+O<1W1ZPHM"J^S\#JW M>VK"Z[RU"--:JI (6_,DMJ8,QB93W@TTA7&3U M"^QYE=$J%:[E7IG(&X"LNU\EQGI=YO*L%HAS".!(18<,^'A>_#ATZ*(<-#AR#VPD'^C&@L M@6"+\>]'+'$\]_@5KS]B=G#->"S73]*WL1_?9<'M,)Q]7_J82^_PHL]Y&6SF M27I-[L:>@H62Q9,$_-^'I'S&!#;K[6T2!G^^#>Y@1.^#X6/PE,*;WCTDQ636 MC7 =?NXYYA6N=3&"+:AK"^JI73T'R030E<\B J@&?'G.JN(V' [B_@-YG^>7X(_@R M1;2,^-TS[2<1+1XIH;&L,#3%5X>1=:R&+*HK= M=2&UUC#7J6&J&@:!J2+KS1GFUW=@B$J_A!DP1VF-?PZ>))K'(,&2+/W*J_S' M/%+\ /KRD_1Q^@0/.HVARZ.DN?=8%]YCP?K">]P&*D6N-MJ]DV=/I.V53\Q4 M-,/ =&6FZ7IC\NESD/P99K D7-;\$MSB_.+D2;H)DQ]1/TPWU820V.RDSGP] MB)6.Y&ZE9 M)/WP+T'JF4WDY@;#%:(M+R,K+6;:/F>9.?%C.$MRG?#R1;_\XEQ)PF 2NJ@P MF%Z>2AF]HCOAOR#2-D,_HXV4]P$[@!LPM1,0PL4EF$$@=@NHE,D"L;N$V'(3 MB.W$XY27O;X#37P03D*>AU2X=/B)N:_3VV'4EZQ^/YZ.N3/+CY*10'7!,*U# M]0O!<47@^)F1Y=?X,4P08RT803(.GZ37?;@D /@?H',@IO"S(I@DF9-_G MV=RYBKO)(6? QT($K\\Y)6%SZ-+&K3 MS[ _YKN_NHCZ>!2K#H;AV\!4?>(IGB=)I<1[V!OO#Q..BK0QA*"50'-P$ MR6TP#M,"\Z]_8K%CJ\\U=48($PJXX+?6B8%+=*N 4&!"*'1(*#11J+ 2"GD) M(;A#" 4A%,Z%WX10.%0HL*M9_Y23GK3XO^*D1).]G%HY3U')O^@_A*.@V MP9[#I@IZO4P@=:Q?VKU[@C"W U(G&&+! NXZ^"4:_WD;I&&WR?<OW;LG"',[0/V:A'A*?3OS_YG>,.4HYK)7R%SVRHYCUB8K*^/_ MOO5_Y0QJHYO;I.YV!V&OGD><_!7*FA8@VBXM0,X&L?[208;^-!Y@P@]0%-!2 M<)_7@\.CSYASA&VH^O%H DR>ET6=# />FXIWB\PO[OA)YY8?'-IK3CXO\(KM MQ+ C=LX/Y>=_"^]*/?_/V[U>2!1 P><)?@O'3[!GE MZ_'M[P 1B@%(C]%P"&^3[J;).$H?L*5=7H/XQG.DZ00>FH3_F(9IUW'C_W:0 M[#Z-I:#?!Z6")R$A=G#RR97=@H9D]N9U%"T04G[%35D=(V_L /3P+1R&V+'Q M2WQ5G*13BFL4W32TO/-B?_X47D58T;@L=IT6=[,KRI^-B=52T2XQ2$)I@*S M*1''SXN5/E^[@S^!D_$XSI"4B[OQ=T8^\.K8_&_Z@3<@!FZ:Q&E8U 6OY<)2 M8W8J,.Q/DRB+X"+O9_\!16>9#4M-69%>XT7%\^L7%*]Y@R*WF@,,Z?D*X-$8 M9PGS@W$":4@\M9@/8O[-R>+ JO'(P,S]<)*5G!NBE@^?'H*,?TYFU<2E=!+V M^=Y@CX[:H%()H* ^KHYS^S\'HTD7S3TG'M]%:-G@\=@L"8.L$"EI+E'ND0K" M08X%8 (".7"R09X-@#^QMCSG6LX(P'"%F'B6''8Q#?%@P\(2T<5EI-J"A:;@ M%0?;]TX\B<*T9._@-OX15B(88:,J'E0T=$48"GX$T9";?06/IMA:_0&,4NR. MPX7C)'@:%=7> EC0((W'_(8),#&O.G07AL6ECPE*XID\A6>^EYR'*+Q;/M'< M6]V.@"J$2%5+YMU((WO8];YB[:0;(*0PZTDW<)N?X$C3?MS#!(((\'0NRBSL:[$532[#2 )%IY"6(C.Q!9"O< M:)^^>Y\!/E9MSPN2WHJ!\LXFE+S]NW0S'8V"Y&D;BMHH0%\%D M,H1E@IG33A9WB_^[6H[L !NIZMJV[MF[HBJH:JNGIJN]H MOFM[U*>>/ <,&Y?^4EIKO_P(-I+E\<>U E)N/GW\8GW_]9MWL_UZ+>JJVFET MU?HYSMQ\^\.TMVH1H'("4?Y+ZP31%BQ7U_B1O M,Y5;KUA(,R^KB>KR;?@0#._06L0'<7LUOX _.0FG:-'R!P;3["%.8&J#@T#R M[((YIGEE$)5H!F,:S,E0C]WX73&?C^UHS_^DJ"T+^QP_F%N+EYW[-#]]^<]/ MWRU/?LW[G1)M,@>FMZ]RKO3]_) /+XJ MMYQ&/0E-GRR9YM[Z5 *B@X#97&<:%S\<1?TLU[^ !Y/@8N'TJ1L3)!. M;_.1<=<]!AX?HA$::V C82@4XPE\Q'!3/T"K TVV'II<.-G\=S#Z!KGA5^8) M)'/]?U?&0N%2#'KF/1#@$;U\>%7*01EIA6MC_" -BOH4*0X,EG20=!2 MJ\38C?^,9QR(I0 2'9HO9,>_1]E0[/:E[#;:&'OY&T:P(\.P$Y;K"YOM+23Y M%FQN)SPR8FM?A&^WUMDZZ"F^ ,).XL<-P:Q&B?S($+65DU)ZO:8[V!M^IPMF M^>(U3,3 M+22KWX^GXPS#?:7E=)D$U2H0?'ECJ4,N,8&78G[G/3]A)G5B&X69)/:NG9S7 M13/I&ZBWH.3^=B7=]&$P%^TD[59TJ KV. ]!E(RPKEV>EVC'03+ #V7@)[W, M_6X55+V\,=.AR(] -3&_3LQ/V#2=V$9ATXB]:R?G==&F\9*H+UGWTRA(>M+G MBQ7\W3)G1))::Q!(F"H-KHH *S&_]=.SNNFK1)E22!]"9Z"/R^38(6-TIV];!7X"!NE41OETG%* MS.^,Y[>NRTV;>JNR%8TV_\>_O+N-!T]_^Y__\NXA&PW_]O\!4$L#!!0 ( M %"(7$X([V:C6AT -5) 0 1 ;G9T82TR,#$X,3(S,2YX?=NYO=X]O M3R\N=O[ZZY]^^9_=W7^>W%PZ9\*-9I2'SJFD)*2>\\3"J?/5H\$W9RS%S/DJ MY#?V2'9W=2-'_7@.O(^!.Z4SXI PE.PA"NFYD+,S.B:1'W[:B?CO$?'9F%$/ M4/ I=I&ID"H.B9S0\(K,:# G+OVT,PW#^<>]O:>GIS>,/[*0T#>NF.T=[A_\ M?'!X=+#C )4\^.@S_BU3^?E!^F^$G$#-_:,]+'X@ ;75N> \FI4W\$*Y%R[F M= \J[4(M*ID;MVMNE&OP&)+61" T+XRKITEXMZ<+TU59#<&,!R'A;DSPJ]L&'#Q_V5&E<-?#**@+8@[U_?KF\5:+>^?5/CJ-$SV9S(4.'%T0V)L&# M:AG(4)&ZNW^PB\1J9;D4+@F5:J;)+33:HWX8X%^["8@WT.^.L]A.D6N0*?8!/_:M>UV\=/N MP>%R6"3VHQL6MMTJL/BP1Z2+H@:QN>$N?9[[A)-0R,4Y_-T.,U_*#)3/"1!$ M\0.B>/!^"1059$XG.'VT1RG=:J5X=&"+;;%T_^7S1QLTTBVO=,,58M,/D_YH ME$]?+<>/;8 =O^O694#=-Q/QN.>*B(=R@9;IIS8FK:R=_6,W =(3F4A*\+YZ M8)-N&/^U-#X>98VV/JAJA#_Z6/<,,/KL3KNC$+=2OY9& KPQ&BA'XZB+4%+- MS._=!$0_3#AA;M!9.Y)6^N?2>A$P%\$==$'"ML$?NTGCG@B$<]E=+>)6ZE>- M6A#.1:@@X2?[<3YG?"ST%_B&L_9'.W7?T+&C_../9N*L]Z+WYE+,J0P9.%.I MJ$,!F$HZ_K2#(<&N=?W_[1+_#?C=MDJA@ZQ3H28I:.)&OB+B,D'20D"S_6DG M &[[U%#^W8GRZ+@K4="$<39@FGSRT)4F:$+]@9(SE[0K.= D@-"]E^(A@#NH MX# (+D^(CZ[Y[932\%2 6> -MAQL-+]S45EO*RPJ&ALN[,=)OKTZ^'!_ON# M_7UGUSEC@>N+()(4_C" G A.6X,ZI>]/( 6(:FRHU#7.# MN'6[[#@I;68^6I9W%L2QZ\J(>I>,/#"?H4:=T9 P?SD)54.M$]W;_?=O]X_: MB@Z*3#>.G_3C_&!Z^LO&BW843JF\%'QR1^5LQ0)N@MTHYK<=Q*PZ$ M[K;B+A7)M9X3%L?<^_Q[Q.:X\KH*4=?!;13S80 M?+J<, V(.KD=[;\_VC]H+;4 Z=@I,QO@!*^82!@3D. AH&GY_GU VI=R=.(!HA/OLO]987]ZHP M:-22HM-3H246(T>,'6IPL&D"](_:VS!$KE>T&>F' S1D+ M9VJY@7NG@H>,3RAW66NYU$&H]\D^E/AD*6AJ^+AI>%NY(!=.R1PDX%]2$M"^ M_EIO\/5F],/;_9\Z213+=7^.KSIT^$:[=C5R.:,/X3F8*OB#3U8O]GKPC6)_ MUU7LV)\SMAUNQ5XEE]&<(F/XY*7&>U,'C:(O1&U-HH][W([Y)N'CFFVJ_ 6D MW]1#D_@/NDWA\4*TFZJUE7^%=)*8^CP*@;M?H-=9-%,C]9HL5)M[[H$$TY/V MRI1CN>X;#Q5JEE&NCD?Y*4-6)N^&]6JL%ZTA%KE%$KD':2M2M6*-2//2T$X-+BE M;B19N#B>2$J[[^*^5.^-:O5^!6J54R1A2^ MI3!UY@;53-RY58?NXB^)) MM&=4HP5_*+QPKQ@/+J5T;^O U6M:IXV_9CCU^W\?2O;_ZF6^D?N /! ^\U"A MTTEO[854U;Y&. ?[^_ /+B#> M^TLX"R24#%&7,:V%8@87!-T A-:<@ SV6E MDP76(*IW:ARU%)7S0P;VIHZEF%O!:'Q*@NFY+Y[ZC*ER./4">]\PMA*8.+4A M5$>!W8IJC+F^DDYAFF>/]%($2XNL *]>=$?=1)>&[B#XK0B!Y?P13W?!3'XM MZ9A*B>7"_8;Q,_Y_*GR(&@),QP\72\NW4V?UPG_;4?AQUT[FY0G(89>GG%V<[J!7&:.+3]Z846@.K%?-C)/B1@-TA8 M]EXN/&X%D5VXN.!C(6<*JY9BJ@51(Z#]6$#QY6"IGSBP-#@G!6^#)!.G;W^A M!(-QI:MC[)]*>2)-/S.&W;F:4@;;H43HF4"\8GQS.\P@7U/@C9#$U* M7%U[LH0O@E$4XG51>#<>IO)U6P%\L>[K5_]^*LE3K- %E9BJ\7&(0D@-79CX M'&K12J7_HZ'%,H/>G\'R)@@Z'N8Z;N(28*F<398I\2]X$,I(+^R%B8SY#6XA M26#<"0E8Q[7E5?;8J$R%S,=J98I1<%B"@T/"C YQASC2HN(\("Y;M;%,O*2/ MU#\J$Z6IY;VL$JVD_T:5*NQ.5*N40L@YLDG4.=4RE;VMCG70L9[YM>U@-TIU$.IWDWXJV4VJDM,&[B/]1L5$DOF4N=TCKO*VM>[] M0=FY_@2.PS8RQBIE9'IK_9'RB)XL3O55C=V,74_@M=;OH.SP?[D8"QORJCOG M8>&8BR$_-]B&?SMR"TE4P-A/JU MCW=EQM% 4^%LX0*$K6"0"SW=P"X0ZYW!=R7.8+W@-MXGK&%^*KL1^Z.7P*-" MI96)NE-OC6I0B <;U2"3)ZDPV/41A9+*6SW)2LY>,9(L/*H\T^.9D"'[KT+< MI"06K[3YRL)I(O 5JM,+(-6H=855TF:M2RY%2:V/ZC1=DD(U3IXLO7Y'O9ZB ME=9!I=VJ:)4VV#JKU[,\Y$9E*3KN'91E8NMN!9T11S??O1%._9K&NS(/OEZ( M&^C)7W!@.+TCSZWEDFY1OXQQ6.*IZ]9.B,TWD\T]_? Z"/7+$("\[Q=K$STU=:#S&Y,,3"A$_354]6=S?@FTZAZ]LPO\>219XS%4Y*;TEN]KN M&]6B$([EU"+M=:?N=86_H$7@/"BV>HRGRGD1F,H-H$N#M0H MQ UW3'6,U(-NU*.2^#<0=ZI#8CI+*&FR LUX$7P:5:H0BM>HE,Q@:(T)ZI:- MNEV#*68%8%E@\77&&F$'G!NJIJ0DE2D-8*N=%=IPSY'[$X[7!4-5>_?Q"^A= M0T^-&E6XH;&31D6IWI5FQ!'+@VAG8SA2 *X,,T#=T\-2S MO*E\19)M[*9^D_7GTJ6;%B)O4VF#M $<;XS>K_5UE(+?3HFD+45VH M1&X 1\?K%=:6V^I1425^5*G; MKHK4/(W&5DNLY#JYXG40ZIWRHQ*GO%JB&^BAC^2$<+/QC\.%!JYDJQE #&@?=@0&^%EN%TSXVY7J#K ZZ#DH"KK5 W?C?/ MY&H?NRIU.KBA+H4@!','4#AZ:=K4:2GA+A#K1VN9>VY:_N@0 Q_7ITP'1M!F M/=VDA6]E6<;YGJ-WF1[J!W&9:]19UMO1W%X^B6L+/">3B:033-B+SVY MN1[2B>AZ/.2EL6C4I,+.:Q]-2CO?7AJY](&3.>+GN ;!KJGNM"G6*0;O#K4_H M+(M,NZO1!D:LM]17[[_^7T1D2*6_.",AN> &S/\?XZAH<@=9R*FE9;P++%NKTM83,@G'F"&>S M^=\SC&\#J=[@'909O#+Y;'Q(7L+KU.ZE"Q]9N%"/;)347%JLW;MJE'LA.*F2 M>V87U/1NGND(2IMLU2,O,WPL7H5KP7V )XB!053.S&/EHW'J4KR1KK9*A>G= M>:,*%1):6ZE0@H^#W,:,&2^-DCKMG+F.3YCJ6\72LL5/)P0 8DX$!/OID\/+ M:TX;Z(VJ44B?KU0-_+[[@/VI[ G;X4:G*9>)Q1[JO0DB.PR]H1%1GS<$NKT' /'0?E4\ MM+FW^A=YN$PT5 ^HWJ;M5SG%^9OSM[%0GM.)NYFZS?DK,@DO8Q3IUP4%5\V7 ME6W_'AN5H'QB*RI!VJM-WQ']9+# U^0RCQ5B IFRN5NER8I0)>KIMW6LM&Z M5OE(\:BWOB7G N(&W+-:G>+TZ;51>K0HJ1W7VGLN;UKM-^E>M4>%!E STG&T#.S((;C6N MA;#O SJ.?'4[JKKT"=@7+O#M*1C-<\R#?%E=:]U]HY85]T[Z:EFD<#+WK\+? M?<-/U-<)T.0!)G#BAI]V0HD'H% !^&-(_GWLA^0?@KGT"YT]4+GC<#*C MGW:*GYGO(TLM@" "B"R,L+??I(CFGW:>'Z3//K*0SG:<$'"%'@3GT>RC)V:$ M\0LH0!)V'%T1QB$3WIVJZ$4Z-WO'V2N@'J-J3]4=NS!N \4VO>YPP4.*'DJ M:U7 /*G6K #9JPB1M^MTC#T379[ZLE8?'7/4O[BO?1AI/ZB5\G6SD== M>D-]/$-R)_XF?.^$N-]6Q!37,Z@]Q M,/PY%;,'D\L"YA^0\2X9>6"^NC#B-)+XZG*> RW;]*=Q)CA,\G*1I]*'R+CF#WR])^);C;@_Q,L]?$@=3&@C:$> _H#1;5T%_;J-OCT MX$@YE%TDU/#NA;M]01%X]&&E-JL_)Q(OZEJ*&0L"(1=7(J0!#$*$\2+L;]'I M:YHQ^C-"1T7I AT\F6S]0IS]O3K=".Z_M)IOHD;';W40_RQYNB%5[R48W:;3 MU\5]7' &!\DZ!]H5,JIT/Q<\'0BGTF=/?<)F]2Q>%O(?AX^AT+2JY<<&Q>P& MYY7QB!+$MSYC9>J<_-7YN??! MN#'$>#^.I(H"&!IX:>M5;0R\'-3A,O"4S%E(?.4Z 1P8$AA*''O_B?1U\L&% M7OKV3J(0_(%_4; :+%YYJBNJ-*?-(O?TNL> MN>2V;& ( OI"Y#=@(F"9W'1NW@#&X"9(4;H\H*%&H4O3!M@' 3Z@0WS\E#P7 M"+[;RAC8T,D?B;GQ/0#+,"\-9&#,J5^MA4;8BDE6Y3Y FK MKS1$L@((3NY@.C!6+T]05?$027FB/'G4\9+-\%:X>"?2?,[3UZG- (DVZ>8Y MLO)?UY_QB'D9%S"ARVBFAL<,.(V_SBE-;7[R>UPW\4Z$E.()EYK(G+CJ"@=- MV-)0UIQSD\7_G+A*S3+8EY-:5758]/@"7V76@3P^L5I!2TFU=6]O9S&\X!Y] M3F/XA7$VBV;E]-347C]9N2>3B[ZM.24?)+1U:3*PN*":%JX80O\^T[V\: MQ52UJ[M$HC'XY7RR/[SW_QL43;Z J7VO]>AJKFDEXR"0Z7.):WH'Z[R&6X(\CFSL?9/,M M5P'HU6CT.7D4$E'5NTE9J5<5#D^+SYD,P&OA#(^+J".HO^$-9&<86&1):E%Q MH.3A3M^E(+R$H$+1^H>CW8 >\4OF8EI[G?7XF]@IJ>PCQ6@%35ZVG2BUAO5H.8'\:\)9H MTC5^/1N,JC<$L-R&4E@Q!@T,J.?%O MS%9D&,G4Z9 $^89::UIXJI3#_W[^6K EN6_KY_VE'@/V/F:=TG.Z8;W.U M5^,RX40+@]SL^2\J]NL::PU =()/T'/ E=DO)#09##=@S!8F>0H]_7,V#J<) M55V:#$VD72D7D>Q(N&[QRNG&@X>T&^&VR6NG_$ETI/NI[Z'T05!]19_#NR?J M/](O@H?3H"WQ)>U>+0_NP%>C9!S2UF,]T^)UT*TWUTQB=7 6E0_OLEJ#I>\+ M>49LKRB&\\GAW^2]T9/%)<7PXX(?>Y[:@[L3=L?1DK\LD->RE_6%^8 P=*G> MM1GQ4RI#<"'B(^9Q M^Q.V7PRSN+<"L S-O=5$0!04<&RD-*<\L/+P%X_9X1 MZ(-Y_)A/<(GBE$BY& OY1*07V.3'T1.G,IBR>1)$Y+:\EP>S[KUPH.!:"I=2 M+SB78F8O@\]<&9^BMDW=P1YOJ<3_6H(M"'$;RLTL8'5I,#2J*RW%%7U*-FKR MHUL/8BC+W+10/:0A $I]_LPFTZ(%^9X=#F]E%Z@O6WDO?AX@ZH)GMFOUUF6. MCOHZ [#T@N.-QD+.B0RY_H.H79Q ZBOH &WA):G@Q ;RC MB< M%[]X /"%^W@]"XMXH-MNZEG?-5AQO!($]S%!4!7&K;'6 M( EC4$$G*16H*2D:+ D7/(C0DM%2*HJEZ[<4\3EXE5^"KX;BS5\!9A?[RA[< MB=21\!LZ!J?73^CJUWAH@4K"C=1U;^H00X WEIB=I!%7!U5M.!8SH5N;=4?; M:7276]=:":3UG).H'L=4JF1DT*7D**Z**NXY [T.HEP0U:7! $:[:C :VQG] M3IP84:G7^#"))!C)6RH?8?Y(D=BIT0"2+ZZE.3"@)'$GFN\([M1B[6-8VGV" M[/FJ]&5 )]HBINCKT&3-IYQA^B64U%,I*G__CCZ')WYJ+;57RR5L6&C!K-S[PG-/!.)YS'1/ M5CBRAKJASO!<2IQ.1N.O0OI>@9)"P?JG%C/QI^;#$0RQB;F"*63!F%'O.+P6 M#!WA.S:C>EY)J.K=?@ 3CCHNGWA_]GX3?6-NALY6-8= 4?*47(N7>\LMS)(P MUFEK2OB@L;5>D#F<#L8=_AB-TWO<36NH)[;1+C6]4G MQE>4#9$(B4=D,]?ZIEU>4X#[!*G!FB=V*1BOCRG=R!\\H6=?\6U>GC]G7%4X M5#+.Z\@H%@Z2#(R5X[59=?Y+7Y8DY.(VFL]]EM^M[=AF_0ZA.CFLMMAQ>J,\ MT">\43@35?5DD50QD^$Q9JW\0]TV.;G!C75\0I[X*@'07YB"8M;]]^EJW5%_ M?RI%0F3&%<-+45?,T"Y=K9VAB)@BP>8/I*DU-V#BC80Q6SHT&-J"0;4Q0J*2 M4Q/Z'/Q^SOC4UQF@A2U#^%T+HH9\ 4 1X2:"UD],#GGU7IA.K=+!KGYY,+-+ MI!]E3':4,A<\+P]F[2\8UI)P@>_N<*HP_LK":3[-3RU.VG7+S$+GZL$.FU-F MBLZM+9@7/3\3Z2\^/\-$P0)_E 'ES#7BH&K'U-+@'V=+.PZU"H;#8[\>K_$)#RDKC$I<4YJ*@W0W6KU MTGSA&K#NS09W.5@[$C)7AG5KLOZ+Q&):[\CS::164_XN'L"#!%L.8 MK$I=0J*R1$\HIV,6-O!E57V\FJ6$NRF3K3:"VE0YA^!8&3D-KKQ2E1 MZ)6:(*%\M4 'YT#'[+/NOHX&3)*TU(,O2"?GG4>@#5[VZL"^C0>6:9LG0V<) M*^UO=_G-,@#6/X+RV-OS:"5GGMM57?O"C$439\$\ZN;;^M*:&M60*>:&PE=: M%%DM(B5:!*[=S\?PPU/;L.5*N3RX[Z>BO^PAIP*806?DUS_]/U!+ P04 M" !0B%Q._0\'X*4P )& ( %0 &YV=&$M,C Q.#$R,S%?8V%L+GAM;.U] M6W,C.7+NNW_%G/$S=G"_.+QV2"*U;D?/=+LO9^VG"ERE.DN1[2+9/=I??Q(D M)5$MB2RR+BSU[,:L6B*!1"+Q 3F;_OEG\B?\\T]Q MZF>AG%[]^>?/']'9QXLW;W[^]W_[IW_]/PC]]_F'MS^-9GYY$Z>+GRZJ:!S\_C3[_/R M7^;^.M[8MS-O%ZNVKQ>++__RRR_?OGW[T^^NFOQI5EW]0C%FO]S7>K%$_@O= M%4/Y(T0H8N1/O\_#SS]!#Z?S5=LU&KDK_ON3\M_8JC0QQORR^O:^Z+Q\KB"0 M);_\]Z]O/Z[ZB-UC(N+V?IUX6%[A--Z+KS M_[R[UN+V2_SSS_/RYLL$.OY+JYR=>5\M8WA;6E=.RD49YZ.XL.7D2);WDNNR M+^\6U[%Z.YM>?8K535L]JDFTRWZ]KV9?8K6X/9N&\?\NRR]Y6C?J4PV"7?;G MDW63>"3KC^NVQ.5R7D[C? ZMN'*Z6N?V<[>C3G=<_6:K"G[[&NL._P$TNN,Z M+ZUA.8GOTMC/IK.;TI_':4PE3*[T9@K+[54)@WHVG\?%?/S[E^AAN_HT.X=& M[:3\>PP-.MMRTQW*:'ES8ZO;=^G2EM7_M9-E! [7?)UYF*-5##!;M]8?^ [V M]T:R::?)[F12URTW QFRY ^0(EK-S/8HVJG?-X8;] MVM(4[J=]VX4W>(21A_^F%ZUV+M:=#OOW3O8K6W^L_71JTFY^QYF M+6OK^S:[6)-TYWU\V(LNEXME%7\MI^7-\F8E^??V=E7G\S0 L]M3JKD 6FEW MV-*YL!-/3R6B1XV?2DZ/N/QN5G<&H0,:[5TNCWA[.[-3J/ Q^F55@MUS5<5X M@!75<;.#EDW;4^OHMD\KI=]F4Y_-T4G6+#]/P9@(958U[>3]LO+7@/@MRAW# MJ@DO/4KQ WR=;:KI' A/[,JR M8O[EGO<)EJV';G4JIGVM0FT!:_T_EL4H8L MKFWO2PT^]U3LF+_WM@(97<=%Z>WD:&:?I=(^YQ\7\',UIN_2A9U?7TYFWPZ2 M\$X"'?,[N_E2Q6N85J _OYW-C^?[)4)=\S_]&JM%]OF\!XYC5>7O9_YO>1/* M_U[/)K# SK-7='%[?.>.:65(/3]Z0K7<9+P!-;R]]2FTP_'=X5UVT,.B MO[A],TVSZF;5U#Y>Z]1MA\M[O^&OL(>"DG)3YZAK9Z4.^;H L_\6ML^SF]ER M+9SYHKS) WI??+TLV>GM_-URD8\!\_%J]@#5U$RZ;K=#Z6Q\7';R9CI?5,NU MRK%XX'#Z(:OH%?!U;N=E756M@Z8ZE,';^#5.V'/L;4J%CB329L,=RN=0G]Q! M1#KDNYZN7:-J.SS^)+[<\F]/.ZOVCF/AZX-1Y#JO ];/I=R6B[B M6^#A2:'F_3NFF>[[?G<6_*"=K/Q.H+6 !O_W%>PW_I2G!^=_+1?7#WUI0T3= M<=.?)._*M"B.%TAVWJ>::V5= NWP^V8*O\9/]O?]G#U3M'4>#ET!:U1MG<>' MI62C]RM0]O(.=M-N3=-Y7 MLZ]E#KL%EK8*MR6$>N0[[.MO$] =MH!D;4I%SM$>\2 M?+W9*++0EXML2F4'SG(QJVXO8XB5G7R #6;E7E_;X ]5FHBA2T9ZE-_G:06? M7$US+!P4O0N>:U,R]9IHO<_U]K07*[3%#V@HJP.>-]/W5?D5 #"Y_8\XN<- M;3D?1*8?WO=]W[13=>FWTUM8UO)^]7X=2@0F[+6MXKXN[*S4(5\/D^ULNBA# M.5EF[6)SRE[&^?AW/UD&T*JKVUN91[D;MJ-M6&^FPW_76PAI5V^'Q775EIQLS+XLCSGU5?EF#XR[:=Q^S MA]#HC^M#C80F--OIU<9!=^9]=M#-8?..L-1FPRZSL];S-F7V=>8(4KWWX= ! M:H%T[WU\6(!&Y=Q>757Q*KM8[EVQ[^UM#G18OEN>C&;AJRG/YP-;Q\- ]7M.),N)=H5D[W+O=Z.=#3!=OKS M,4Y6%X;^:VFK1:PFMR.[L)^G=AE*^'0?\_5J]\%I340>1*0/ONN!Y! :+7&= M@UO YA5^YE\N4IG/!VZUQU HC.>MXP*#Q^6B]M51.PS)8_OU-%M M]-'K? 5OM;3//\_SL1&P$*N;S;VWK:M\>6T_Q%O;;:O=229_!'937%G]L+UM MGPTUZ/H!9+OKV]VQSX?Y\@Z)#;JTGUIG/:FY4.^KV")_!\5Y=AVS^93^44MS M+0I=]?[61SN0?FZZ(JLYV2 MOVMU(!LU?1H9;16[6,X7LQM8'^Z,_>R SCJ"O6H7[TU;/XVD0!]/R\DJTFD5 M3'!LHJ"NV^U3.C7WGB-HO=@+;R=^.5E9"6_A[TWQS'.3=&'KYN+OBP@&:.BP MP9IIN^XYR7S<<3*9^4>2WK2^RMN6[-RMLJPMY^C*VB^_Y!'X)4X6\[M/5F." M,-FD@?OGS/NSK)">]FU4;FW?9U#'":W<:[FZH']7EOW<+A2!4E$7%N"3)" M!22LA'-7/Z#*^D6.=KW;I.XZ<+L? M-G6J%\3%: 4U2*5D4**2(Z4L"%A3P3"7)ND&R*&O&#D=B6\_>)YN8_F3XID< M6(B,EK& M3[.SE%;!>7'_*O)L^8)X'&/0 @GJ%(J)4<1P M?>%AE3KK&$UL=\4B@,"XU!)A#9UU+C)DF#:(<,RU\5RKJ(]'B'C%"&E=< ]0 M^==?GC,;K@9^<2Z<>G)^M5#AG891%0DI'C:2G AJU',$Z MCK$@A GOC[$L7MCH5]EJ'LY([&TV3W-BF]U[^YYJ!1=T#/L1A>;.A3F_,&1\ M-B9G(W,VOL!GFAX_&?NQ#]H:H%EG,NMM"[\/>YDN+N#?-5@W^C$#NE@WNI7AB56_^MOESCY3I7V> & :*POS03AD M/".(8$Z\"L)@(X=N(G2THG0AO%,I@;7/!7I4 .]XRO$EBVW&?HN[,+VK6I&8 ML@%KC+R"$8D)=']OF$2@FCLBK?.^[Q7ZJMQ&N']'E5L5!:2II40M1* MBT20&CFK+5*&JQBH5BZ*H2N.[0WKK&/9];7PP]*SO%FN'.*C^*6*?GU/$WZ? MQ,TUE.TT#"_V<_4,RGVG">.ZUM]_AT[[,OG3>W.RZG\^8[>5&E>Z[;?.ND1VWEF;Y\N+\M M_R9DWT0J[;W [_JRE8KE:9]V*SH=M5A8;I(A*2*)8?VR3DLD+;'PPTN9&-=4 M\=/I2$?VNC_YOBA70C1/V;\0815&C%N-E ?A>LZL$QCT"9N&KH4- G.SH8U3 M7QI?FSU]G':N8_BOBQ0T.:ZX$TAH89"12D-/143:6JV]Y3A8^X/.@';0UB'R MCQZBUPC^'#Z[49PWT;4]382G#1?,B&2J=3RX 'A ;TB4; MA3B_D-J,E1B3L;CD9T:3EZ/(2XT9QS+EG+^T7 MV." M27(Z100DXPCKIQ&*G@'JK(Q(=:ZZ_;\W)%_I+DS](%[C1-GI5,^1#/U M:K8\VW:!G74^$H64M D9KB."OR,*GL6DN.2.-O ?JW],F&$,VFN<+%N?]#1% MMCXIO">@SG*P]AQ8>SB!MAN<#4@"(&P(0@;HV38>.K MV/YBD_AS3],]$<6$NM#FCYUP;)A@?ZW-%""5C ^ P ME_+RCW38TG1^#'[X7N-VL_6*4?]JV/.-%]X*)Q()*"3/$)>*(QNC1L*;&*+' MH/;6"J+[44Y3AKBQM#9TKW'2/%TX7GC9H7<=[3L^"FF\LTH[Y&2PV8N/D584 M(Q<-CXY+YW4#'>WUG;4,<2IU,8J#T-%^FRWB#JNET_8*KM@%NZ!8"3P2>#S2 MC(Q&8W4&6_DEQY=G?Z2#E<%I7@U&:A#(OIA-O\9JD0])W\/(E?/YK+KM&^Y[ MF2B8&HW9.99*#@F+F@7 %UA/$:<#( $KRI43.M?9$Q083Z/4=F Q1=6IU^/J: M0'<7>G9 _*Y( 7NA#=B9#>_&** :)8K&6&*LI3JX']2'U.F]IP8"[N'6[S-7 M.SN_\YM?52A7#\W.5Z\SK_)#Q^G33/)]M7IAOT#9R2I!59_7@7>P-(IN<0DC M G],KX;!TN9MN^G5D.2T6H&WOA\&5P]WNM=OA?Q:3LN;YJLWL!Z MA+Q3WXU^Q,PCQN]X?E_%.?R[>9H*5L;OOM^QSS0G7BAO=8R,(>]]S@*D8"DE M/B$BN'3WKE;]@J7(= P6<2Y@)Q*2(,I77X;]&QO(#R!3&.BH3!=U;LXB(9P%%:3"B(43,N3?< M-HB!' KL#A[W8Y!UO$@'!; WTT_?9O\3;=5LT7]$J4A!Q9S_!FGE&5)*P=QV M'B,AN$@T<.M9@\M-_=@@ X%9(ZD.#6G09FP+:_>T"MA"*",@>'LS7410/A9OIGZR#/F*4BNZ[[!+C_ M,##OD4 N))8C=2Y&Q)R9$368J3$?FTMAA!:7XA59H._5MPO M%I&P](Y@I!UGB.4,W8ERC(@SQAN!M==_!*.T7?CL6.+Z&:-3;,I;/:N5&7MO MW?V""8Q8SY.!Y3]$Q*W%8(2*$0XQ$A;'PV&O'Q>*3YF3Y3%X*-E%"7(WI9 M*_R\F_6E9B=VK#(U*10,!TPU8)0F!K:6Q1YAFC280$8(&K02KD&ZB6[WP<[& M^_MT_)W)LK>7'.KUH,:C7@<1*I)4E*G$D/)*(VV%1V!),T14(M%AAXD:?%K& M3D;_.(0=+]:! :V6)_9@6H7W8/VRY!$#<:.8<[%@K!F2)@08#X*3"4/7BP8$ MMT:2'1[BZGADCZ!6,!.59-(@GH)')HB$M,0P)B)@9404R36X(MW3(TB#0ET3 MV0X.=Y>S9=4:[.Z)%2ERS+V-2"4/TY)K@S3G"?%@<#1*2:('_\+JH%#71+3# M UWYM;VU[IY8 7(6Q%&." 7%@T?KD-<<(X4Q]3)(#8;UT*^.# MT#40[,-!] MNHY5M&FQ,SK]8%H%DUX2Z0CB.$1D<."(>2R0BI1R'PF1IH$)T<]-C0%!KI%D M!X:X1Y]_7+I)+IU?X;23%M:]7=2+[%9,D7$40HS(6TJ0RMFZ"1')1L<\U^U$ M?71Q CHPOTG+@AZ4#_61\_3MS.8'MSY&OZS*Q>W9%:BYS9Y#?.F%Z,V;VSDB MNY;7L$:M8LS&BIV?&0 !$>;L0H\QHYJ<7>KQ)>/CBV.\I77XMXLL+9#MA_AE MP\YO()Q/W^+D:_P5A'_]8C:30^D4R@DKL(<55W@'C"E 6^2P$ZNH7/)21=M MJ>[!&]K6&,[ZE>+1UU;W\?9FFK6K3]]FQT+DGD!Q>6&TP%J*\9D1%Y?C,Z+. MQA?G'!BBEQ=JL,EJ3H:+8T77-1BR=Z$A'#*)@HR9(&)\*;@6PIR/#<>CT<6Y M +V)&G8YV"0LIP;$$<+K&!+9]&^&B$RA&%THR14E6HV8.+_46F).SR\OC:%, M-;*,NW7'G!@01\BN:SR4:?%B#O0#2!3GP/\(JS'T@(N+LXOS$;[ 4I+<5S&6 M#8(DN_65G!H11PBO,TCL]&L<2*$PEV>C\[&Z #:P&)N1QF=87ER2\S'L@W+4 M(-M0MYZ,DP'B:-F]6C/PV'C7/FU!-LH13YQCQ;#1QABN1V,UA@G+J;P@HI&Q M.+3QRB%?^9WI2;YD_GGJ9]-0YL;MY/VR\M=V'K);/ASBV M'>ZQFA0*1SVQ@G 4LH$G F?(.*61YR%BGVPPL=9A^TGE &#^:[FX+J?OIBL_ M?'.Y?$^Q\$X2HB-%EDN.F*0&1)331J?5K1+I8<(.U:?0*29FIY)O7V[L^CUZ M,X7= ,JT!L%M@H4.V&MA'0J@.R%K+87?,$.:,+OGE[AE *SCC%D(Y7(!Y*0X"K!N 3MO$T!\\'Z2H8*OR;2'8AFG$]X M-JFD/X!NM8CATPQ4K8M[5:NU6/-.#B6WV'\^&KU6O<*S*)Q1 04+>Y9W6"#B M#47:1Z.==+"[U3I([+O/&Z/@X-/6%TD4/!)/DX)]7(8 C*RR[,.?*H64DG-6 M"S%T/:G%L=Y]EMJF&$]TJK_5A>\.?2*$X%EH[BUQD'B7/"**"P((L MC.2)VP![]F#/Z$^)J!8D>=(]IH=L<-/Y;%*&O&F=VTG>L3Y>QZTWS'K?G/8^ MH;9Y,LO HJ"P@.6 \X@"51CQJ!22RL 'GADB:AFC7?9B_RV41^6*H$SPGGAD M6(@(1Q\0=4$@Y4G*D4S&F0;/MO>S<1PS/+-VA=+?W=G5VZ'YG^WW0Q<7MJIN M80ZO[GON&/Q:]0M&$R?1&H2%ER@JDM];X X)+:U0)!"0P^L Q5$C^N0R:SD/4YJ$O,+HCS ?H$NA3->"SHUIAJ+9$0G,V M"0E]-!89;3RR##.%I=/>-O#T]N/H:!$K[8JJ+V"\K^(76]X]<@6+YBI=:UW- MI$;M G1S3+CU"%O/D8R!(B=80A;'X#&7039YP*F?FSOMP:0;B?6'EA=>HU=ML.)QL(HX]GKV& :(:,#.0U-D:V5 M2>AP8H5P(&2G THQYU+$H(M)*03"B3$C!0@_-5!1^MQ[FMG*?4BN+TQ=EE,0 MV-OR:TX1N+#3J_+^M8C=N]#NBJ"\N^ I]DAXD=.O1HF" FT--N$HK5&)-@E< MZ.>R9PM8:5U*?>%B."^I]'/+LH6Q;N7ADXY/41[4XUJ;Q+/EBQ <#D1S1"D6 MB%J"D7 XHF03]3XHHFR#^XO]/-_4PGBW)9R^!G_[J9]I^+B8^;]=SR8@\WE6 M?Q:W.W"PKVHAF28J<(R2 GTI6;#&N; ":0?_8V!T"5_K1:_.>UZODP4&%1#K M8%'"G"!N$U@'P6)0 IG@3G(#S_[<[:+,VA74"R.]WOSPM7-#@G0N1(D.X M!+T-EG.5I ?#D3BN2<2:OR88'#92+X_X\>+IVT.[>>^QOF_V<87"4P\=@5TA MX)00]4RAF))'*8DD6&08)/"* '#4P+W@FFTLJ1ZQ4"T?/;)8"P[/URDTIQ1V M.J*0RP<2-#J/6/($ M*4&LY3Q'40S^ +@U7;,M$?7J6-GJ?7WORK.5"NUMP6&5L74V]ZQ_\W?YW:-EVL5"7NI$X>^YE>W ^<*=DRK$$Y4 M26F=@_7P%>T7[;LDVA5>7T YR _WG,24% F CK27!KF\)EI") K"6$&M<+3) MH5SOVT;[L&A%9CT&$*4(:]M:"/NB69\I741+M;$FH!!!2:=96Z(DVG,8PMM44%.3Y%M!',96^W&6R[J]<6&&<%S8BR:"_WF0CG2:% M(G7!) 8_Z>#3O+<,DDZDUL9[C[NXO*Y_Y1?EU7QA(?2(%<0&[P+,_6B;D1Z:O[1P)7Z[3\L0OD[@:E&DXNYE5B_+O^S+M MU:E>.$(\ 9$A8:1#W+, W,C7X-.=@Z+;\B& M*EBI^_#S?(7"8.\\LPXE(022'"ODF./(@6EK-?"!.8!K #XS2=)'?/$AB;1%OI'6IBZ%&I?X'KJV7J:F&8'KNI4+T0R MTA/0!;5($1D#4\M'CY&GW@3%%8ZAP5YG?JB%JB.!'JU,:,S&YV>$B4LN#,;C[I%Z;NE=E\Z MSWH$BB! RIQ[Q +SR/D<.&D91C01)J4@R> F61#)#X&NSF5Z^JUN<]'OJ'UN M4[? EIE 8T12R("B#0)9J23B1!GN>+ Z-=CDR _EB>Y"FB=%T7>7 ^_6VH<< MTK6NYS!T1$)$3)S2(39)G4=^*-_V"83=XP'L0%3TB$B(W! 7O9X.BVGY7O]0<)M#,R MO5T#N'O <';F09!5?#GGV*[K ?6I%(1CDQS.@E8<9!' ?&*)(<443X9)9GF# M".#3ZGJ-Q_[[^P2=RK6_JR8S'V.87X(8,]/OTN[$=KN =B"I@C$?1)!TG7Q3 M*9H/2BE'2F-L";:)#3^)0E]@ZUZVIT#R9D>MPGL?,(7M@/B@D9.8HW%3-2' M*&XO$BEDT"91"GQ$4"V8=!0E;P/8?-Q'(K%,TK82;_$CZFUMBK5O@,$ZNKW\ MKBSQPVS8 RD5@D>L550H1$L0)UHC1; 'XUX$6*H9CO5>&]P;E/$#0:T[V9[8 M77)93NW4-W27/$.D@(E'5 1]%>OWNDG9& MYNASU>TY\V8^7^:K9^_2^Z6;E/X==+K*M^C>I:V[W:M[N'=%+V;SEX]9VZ!= M,"+92([HR)QKP80Z.Q-GG%%R-B9*R5&#$,>3WL5H/.RSTPKZ%);L0]>V>E+3 M2GVV;B&CU\[KB)P/!I0/T#N"AIE-/4T6YG,PPW_#I6. =2G,4X#H[.[;D$QMSX0@H0"JX?F' :!49@U6%..02*AB47)3ZKFMXZ@ M#J39/XHR]NOCYKYT0<$V"=Q[1!28*I3 ^NI)6E]JP40H)LFK]3UTAY0F\NLO M1\B7+7[7N3A?R-&Z S,'4"F,H=I@GL\J8+6-A.4#"^-1< D[Z9(3JL&V=5KG M0MM8ZE:N_>85>9368SO%TO;U^/[3>SQ-]E0CZ]:.6H5/$HO ##)8*D035LA* M)Y "FUUR33 VM9QGG3EY_J!)"5H;LU>:A6!7;K.7S^S.PO];SA>;]S3W38NV MFBA4DL%$FK/.T>5&WPV@Z[P=D(AGW+#F'Z-U2*_J?3<4NIZWWA/NQ%U%A.]830[&M9YJ9>@#3Z(^SRF M617O;_#&.5B2E85U"13'ZO8-#- JZ3G4A/$#_J[>3!>QBO-=9\@=MEKPH)T, MQ"!I1=9@;?;AY\<8"&8:NT!Q&'S>JP8(>AHK/2!)]Z8XW$5]UYJOSY0NA ?+ M1*B<3 >#56*41DP&^"&XJRR.R3'7ZPOX^U^ M(>%QT4)KRKQ/ 0EA$V)<1\2,73U4Q!A6--!Z+T^>-'"Y\7 ]27K=6$I]COV[ M]"%^C=,]NV^C(]FPS2,R/> M1#S]>1;G$=K*$1 C8'8R6\5;;42PTY>XHUY!2+[:'07R0D84E;;(1N40448; MJXF"3@_?,FP1#FV+JR]X?(RK/1#8_M56?XN+5<#+/FR\7*E@C%L8#(FXL3DA M0$@H61V052$2'8P2SK/:^.SV\LG[Q MUW)Q?;&<+T"EJL:_;P+H\DU\^"_L=EH>0:T@7F+N5P=XH+4+8D!MHTZ"@%S$ MA&&?AN^?;%L3[4>.O7K+P5R;/9;2_G5H=\6"DVAD@K4V!5X2$U"J_M!SF!-X;9%WU\NA77O]Z/KNY*%%=(Q[A02RCIDL?)();'Z'%WHK"8Y" M@K5@: ,G"^TM.J-5CV\;8NK^[&PT\\ML^V4%$:;0XO;-%&;-6F =GC%=VK): MO;?VZT-.VY>.E3IK[\)6U6U6+FYR^IPL@?FBO,G'7O?%UU$G=GH[?[=1,K9"=OIJ!Z+]>W:!71]R\ MV'=M96TUYL/DAU/D>^Y>NG+1B&B!Z4BH\_'E^/)\)+BF>GRNN%071A')]&AT MNI.][_IUMK@#W-Z'&W=6+**4(65-!!-*D)*<(BP$01P'[H5+08K!!M;T.>#/ MW!AN5:H].D6WY+/;"[I5L##$22Z21(E&C[11.5@=@^[J%5-8IJAU@U?"NS4; M3HB3QE+L"Q>[,WW4RHE1ET0!-CS#(EE$C+!@Z?N$/ [Y\$ $^-R;$ =[[_*$ M6.I0OMWKAL]J(&_S>0%[3@_9E I'ZR.=:4V_P4*_J/U/&0%=MOJ7.+NJ M[)?KTO>COC_;WD=_'<,RIR#:>/7.;R^R8EW==B_V9QGJ7NRS6?A63K([',Q^ M.[W*D7R/\^OVVVJ/0-_!Q0,08)F )?DM,/2DT/&F23N;YP[6?HN[G""[*Q:! MN> I]DAXH9%T4:*@A$38^B@M: ^4U$KATWNO_U+MCM':5[50EIN0E$0LO_\@ MG;5(JQ 0C<:JF()FF W5+.EB<&>=RZ\O17,'ZUMO%==\F?!P8H4W5!DG+:C@ MDJ)$. ;[S$@DHN=8*N;N[:4+.3J]EUZ<-$M%Z!> M;?=IXVU]E[ZOG$\4'T3TCYUG:#O/,X/X&XS'IV]Q\C7^.ILNKH_4?^1=JQOI#F%/>]JQ_XFV^O1MUAH, M-_0*JKTAB3G$%,ZA=C(A3HQ!TD1.I+36^0;/D/5SLC\8]!TOU &##IK?=51P M),4B*64DISH_"B$1C$*$.D5(=,.Z@;+NX M@[*%#E)0EP)*8/K I'3 *0X2.8,]MX8G(QL$/?7S\O"P<'><5(>)N[.TB%7K MX'M$M5'H]!MEI]./;(,6.SZ5T&IOG32-3SV\\?820NX=/R:OJ? MRZJ%6=$HL2(0S F'EG. M+6)<\FB"#XXU.(G\8]^7Z758NM?2]N[?JVR-E8/8IH=T>:.C&.KU MB]N'=W=WQ4(3&8/S L&2ZA AS"/E(T728QV"$(*1)J^]]KA$-!S1[X.DVQ9; M;XE"UHQOUIHCD/)2S<(Y)ZP$:S)%$1'1B2"P*/-YN=8\".W4\*'2YK ^CY@6 MQ=<79$:;E'N'+RY[:A916V-=HHCID.^,!8*2DS ##4LQ24:I&7S"D2Y6E_;E MUC=6+F/("1".A\QN H44.$JO$\HOPX)T(T&$RH24Y@:;I&F4@U]L6AWE%Q#4 MNAC[!M(JL^;9-+R%X6L ISID"H*MQ<9Z)+'CR 6M865G#GDM'$LXN80;'/;V MLQSU :J.A'DB*^:WN+CK&'PSC*CK)Z/XMK2NG.R[IK2K6B&\U5$QB@3/)P^" M*J1C9# @3 2;O-"L5I*>;GO\F.ECGOT\D%+!8\CW=PTP!4:V!]L;&:$B"L$; MAST)LLE+Q2?:2HX>^!>F?'?"['M#N9_CNX-(GRM><"4=D\HB8H-$T3&./"8. M"2.<$MQI:XI=57B^0A$, :T!B_S\84+&:X,\+->(A>1(",02VR#8KM\) ML+2YT/HA^MG5=/7&?,Z@6GU] M5FD]E$0A1" ):XNU0<8V*>D9LC(?MCJF$ DJ(!Z-B]HK;%,[ M=TRZO#W9O=[;BN1.Y.K)J^+4 ^A7]%8O-6V\5ODH>YDO?RZR\QUY/.!GB\V8WH_QH\('B^D@ZH4@@6B7,,(:M#-J.$:& M*XQ@DCAON8;5=?!F=5=PF0U!W'UM975Z][R+?:?SMPG9(E 6 B,,;$Z<-X9D M40H:A!=+>(&!T0XSY$ M+*-@JD%P5S\W0 >$T [D/22TKCR7#T]P-S61OB=78)R8DMIDF5!$O-0(1LLA MS@ 721-,>0.WLOJCH;$%^0X)?1?7=GH%!9KYIUMNJ<":&DZ]0S"&H(3GAU1 M,6=()=B&3%(XV 8OC>@_&F:[%?W1IVQ9!5ZN'JW[SYF;G_G%NP2%U#/@WL&P1Q1PC2H&IO3A0%:.&VP0OFYD> 69_"[0I( MM9:RXP@5/GDFC+5JMPQ?^ MOIH3FXCR'K+B;W'70[:/KW&M KV9OJ_*KP"8R>U_Q,G=26,?O=W-P;[O.V3M MM[C(P7&P&D);-[/IRO/8=WL/ #V#B1S*R3)/\8?'*-:O;L:PON"=SX\W^!W; M:@JS/I-;$>I^*/?P_SU#^9$)GQ^USGV*X43\=3[%WE57=KK)A[1ZPGONJ_++ M>HS.E_-R&N>G;K['%#R;R+ S[_-K$W-8="/,Z9S>*/.VUD V98;!Q3!E\S"K M1N7<7EU5\2KGV;Y_R^.]O064PT=7LSY>]#B*\S>P?F<%XBS,-GC\-/M2>HGE MN^E%]F=.YYM;7GGU?Y<>]!>@>FXG6;WX>!UC#\_['="_SM>3CW$2\U-(_[6T MU2)6D]N17=C/4[L,H!Z&DS7<_2#L;K][N2]F_F^@FV5WY=>8+QWUW%J/*]$S MK6_I(=G(*!>WGZ&YZIF2IV9O#@;3:D&9?Y[GRVC 3ZQNRNE&+]IZ+O3=NMAI M&,X?/3G&KA75UQ5'=XD./\R7=V-\$D;ZF-M;W1'[4 M^,-$V7HD]Z^9H_SVV>S]LO+7=A6*FC7D7/VT7*Z4]/DJS=,=0YN[!#DCX_IA MD3(S]PFM (O@@ %0 &YV=&$M,C Q.#$R,S%?9&5F+GAM;.R]6Y?;.)(N M^KY_19W:S]6%^Z77]-X+UQJ?Y7)ZVZ[N?9ZX:(F9UI12S*8HVSF__@"2J+PX M)5&\B;)KNJ=M9Q(@XHN/0$0@$/B/__WU=O[3YZQ8SO+%/WZ&?P,__Y0M)OET MMKCYQ\]_O/]%O3>O7OW\O__7__B/_^>77_ZO?O?Z)YM/5K?9HOS)%%E:9M.? MOLS*3S_]:YHM__SINLAO?_I77OPY^YS^\LNFT4_KO\QGBS__'O_G8[K,?OJZ MG/U].?F4W::O\TE:KM_]J2SO_O[KKU^^?/G;UX_%_&]Y4CT>?SLM=PT>/TQ_W?QR]^@W M77_!ZV>AE/+7]6]WCRYG+ST8.H6__M_?7[]?0_++;+$LT\4D^_E__8^??MH@ M5^3S[%UV_5/\\X]WKYYT,EM\GI5I]K=)?OMK_/VO.IW'YN\_95EI\MN[?!'4 MM0QC6'?UJ+F0U;<=B51S4[[E.MM MD=]E17FO%E/W[]7L+LX K62JT6&?\GQ(/\ZSAD-_VK:C4:Z6LT6V7(:W?)PM MUE/B\=$=:-/?J-ZD11'^]CFKJ_X3^NAOU'%JG:[FV=6UF^2+_'8VT=DBNYZ% MC^OZU2),MS>SH%2U7&;ETGV]RR9A9?N0Z_#2=#[[[VS:0MB.7]TC1JO;V[2X MO[KVZ:SX9SI?96&$FW&I2?A&BVP:OM9'\T_X73 %6F'3S2O[PZ3F/'&T93S MCZ4/V@__6-QT*%VM?GN7[BJLUFG\9^?:J]ES_Q)&*^O1[[L4L6;7O@$[>>RYTG@SP&5M[@^:$EPZ. MRY.QO<[316CP/INLBEFPYV^*+#O!.^CYM>?%YDV^F$0'8AYM@3\6P?R;SJ)Q MD,[?KHK)IZ#+1SWW#%B;L0R(XKOPZV@%+Y:AXWFZMH7#T,UNZ#U^@"W?W3M* M]8S1VAUT-=[%,I_/IA&NQ_YRC7$>:=CS^-ZF1<#H4U;.)NF\\6!?[*7[D;\O MP_^N=7IU;=+E)S_/OYR$\,$.>AYO?GM79)_"9Q4LGM?YLOFX]W74]_@7G[.B MC%[ZVS#BK"CB[_/)GW']B7]^RN=A@EW&.%9YWURX)F\9D^2-/ZB.7]DO)MLU MH$9\KGX/W8RXVIF)(=4PZ9?WKQ;7>7&[?M6QL=9IV\TH=Y&>W\,:&HR4VSJ; M$P<;]3@N$QRU^[!\JMM\M0%G6GA5CQB\SCYG<_S2 M\+9/37M"I,L7]XC/J5&4DSKI<=SU;.T:3;L9XV]9?E.D=Y]FDQ,F]8.->AS7 M8X_J<[989?K>Q'FLN*])@G:]]BA9/5;4:-K1&/-\^F4VGX<%XOE.TM$Q'F_: M^QA/G1L:=-6[#(]B+K/%K,Q>AS%\\U![^9J\IG_9J]V[!^MD'7<*5DNPX/][ M3?MM/.7;KJ9#N'8TV7O,M6<*^MVT,UX7RW"7[,/ MZ=?C(WOAT<['<.H,6*-IYV-\F'H>921=Q_"+SL+JECUZ5-__\3XHTH>?SFX6 M_^^JF"VGL\G:U3U=P%[>.Q Z;XO\\RSF5(8A/7JX*Q#J==^CK&^RX&9N@C/A M-RCR&&VB9A;K91C-IYDIV^I$>YZ\V%-9IV M,\:KXB9=;-V\"$>VG!2SNPTYJOS,8X,]I8_A1GVJD]"FSVZDV@;HU&02 W3+ ML'AG8:J-CETW!3930RQ[$*Q M;]/[F+U79C=Y[3#O0*\_(U:O@E$Q*<-B-LVW'^"'_&XV88!=+4R^F$8[_6%O M^/'6<.CU<9Y)GXCV-JV'&&E-1I[4R1#CKD>24_KH:-0QN25XCN$3"]/]V_!5'1_D_B:] MC>G4M>Z$+GH;\R.G8A)^."OOUQFQ+SS97*C&[QA"ZGAH:CVU+_]8QFVC,(2L MN-V>5'IT^"K.[:=$:_M]:W_(Q!\%ORE;>_UA>7N\-]1"]!.Z[4^V:MOGW7)5 M,;&%2,=[ZTV2FA/UL88=CN^D/,^^9[L#'%J\ MKB\L3OCD#[3K:'35U/=^=K.87<\F@2A;GR$PYVT^G]4Y=GM:+T.._.39HE6O M0TK6K6[.J:-'N[_I\E/\_\CWS^E\>[@G?*]E,8M^2OQ=IXIL]>KS8/3H,;-: MEOEMF!\J9S\&H*.-D-YTR_>V;S\/4L$>OU[-UYE.ZV2"IJ5=^G[OD.C47'L: M]+57BK285()L__I8EEW-J=FB_'4ZN_UU^\ROZ?S9Z9H]5:VJ0E6Q(A9=C_Y1 MRZX'%?X>SV7EBU^FV76ZFI<-A[BWGQX'G-^FLT7[\3[IIO/AKGO_Y3:[_9@5 M3=;K\N";@ M:OG+39K>_1HG^U^S>;FL?K*>_G\!<%M.\']N?YQ48XH1A_+QP(*\V:LRN]T- M;9Y^S.;_^#D,(ZG?./%<,H(0A\QQ+ @ 3!)#(#)<OT[('_=+A+),#<*02@\$1XYBG2% L$*N#HH/%!1%9.?\B*XC?_X M&58MM]/62:MN+'/9GT+S0; *8H4?K&?=%D[94\>\WE$^:H)IJMRYK6Z/TX[#D/:YY(=GFD.0]9UN5_8@3ZU>U= MD7_.ML>N'[M5+Y#D0*M$(DP 9@HP!KW1$ $G*SD=)&I(4XK&! M;XL6'B7 \<:)4A H#R35&#+$N<>(55*':18VY@2^1$YT#MA0--D>VBKJ3PY[ M6B28>2J@U]1101G#3H*=?,S"YH0@ETB(;E :B@7O\^OR2UK$]-+JKS;6;LG7 M0S?YLH;I4+N/!$*"+?3*>Q660TVLAY4QQBP3K#%3Z"4RI2_5E!P[SQNS@UTB.SH#:C"[8U7FM_G' MV;R.F?'\V41: "17#BK#H(: 6B&8U MOPDL/:[^0\V28%$'CYT+BR 5SI+@.556-0]_U8V9("Z1"1U"=?9HU6_%H[*H MIP2JU@T3HSGBP8F6 $-BI314F9VTVC4GQO!AB/8[+YUB-=@2,9FL;E?KXM4V MNRNRR:9B0OC[/-L>"'U<$&FOC(=6EHY>D4#@-6/44&B]UUQ*Y?4606&I;1X1 M'3[TT9YM9T+U[#/6F^P0UPXU2\)'A@'TPF/#F014:+F3E$E;:X]\)&&2'F>K MTY%ZX,1__/H,I##./WO*\G@I::[3W)*CUZ7U_;;#R=$#)J]4@UO?L;6LA#N: MMG*H66*E, C:P%NJ83"_'+$$44B)5,(34,NU[#MAY04!EOK^T;_J)Z[4ZRH1 MU#(D-6=A'F8$>ABWR=:H2 $9$P,:5 <36+I1[=[4E5[0&G4*R_O5QV7V[U5X MG?N\=5..I*WL:9%P#[FQ8*@P"@H#FN^$3)#:?V% ME?&(E;"G16(=MHARC(@+?R(CB$:5?*1-0NOIL91Q6@G= '=.8FPN1#Z^,AQM MFX!@OBOD/&#$2.2IUUQ5,L, P;BMAM::K,&,+O#Z,;@R2FMB?!0YE1K?'CV- M/TG4O$S_F<\FV5X#X:7'$D(U%D9H9:WTP@/"@=N.3C$LT/CL@@X1SSL#IK': MKFYO@]RO%I/#:GOV6,(1)W;_F9 M/>FV0Y2&3-V/]UV669$MRUCQ*)M>%>O*1\'?J'7BL&X7"<60>B(D@90ZXJ$1 MP2'=(@"Y;KX.GSX'C--+ZPG)<7"I5ERO;A>)UA9#1X70,=N)A(E2[[XFS[0: MMQ/7O:)/8E)K'']$1HW2U;L<(ITK?W17WJ_.\9.GSR9,A0G<$6*H-Q8@3*G% ME4Q!R!$&E+M7U[>G3UJ!--B.0E6Q_?TD6Z3%+#^V__S2\PDDD -+I+:.&Q>6 M=$9T)9LPQ@QHV8[38ND"ML$HL1WB'XOE73:97<^RZ?%]QGUM$N(TB4>^M2$> M*R4 A-76G&':CCR*W%)OWZ2Z=(O2]\F(41H08R'">0D0[\Z ?ON0?/N6K9;J8OH^_+[/L MR-Y,YR\*YA_W&@28 +)8:0:"'U\A!+AK[O;V9LYTJ/5\1- V)M^;[,L#),^E MV PV_&YWT5MQDY7[AZX6TT<_=K.;3\=).=@ $FV)U802K;AW'H;9PON=8BUH M7O.CMS2!GL@Z5L@;+K/+HGRTQ(9_/5]>PX^2=VF0=H^]_N3W"=+."49Y^%*T M=D8@ 2JWQG(.FMODIQ?_&)=-W@:FWE6[=Y)Y]D0B,5GA]WQP9U3H_7FIT%"I87W>S&&?=X_.4!]X3$(OTGDLKS2]#<@ORTV-EF-, M.*E]$DTKH*7W#&N-,$= 5N=,/+2&-F9&;R&:;IG1)UI#,<5']+-X>^'TU:(, M1O0LF$N;XM3Z_O?TO_+"S--@7AVV,4_H):$,D?"-@(!T0!5!;.T.!Z!:G+T[ MO4[C.&W._L < :D>QO\FO3V^3W9B3XDV0$BFO53A"[-86$.J.+P7',!QVZF] M:+X^NSI$]"^FC=+:O42"G8=8;_)H*MQE9:9NBJSF93C[&R5*.<0QL%(;K'FP MU!7:2JF XW)$T;3>]9CW!-I@>1_;F[#?9?--"<1/L[L:M:OWMTH4)@S9\#\* M*<4@BW)HG%5YJEV!/(?36:06= M9P):J'9? @2^^1E+^9T8S5W"-^PQN-U0:YYY>_9\PH$P5$J.I;;!CX3&L=UG MP('GXS9Y.]+;B\?;ND'J^V+#*,W2,9'@7+FD;0XT(D"%$DI3!YDR!A!HMQN> M"AHYK"]RRH'&QKHY>GKQ-$2&TO*_8JWL&G40GSR7,*<9(]0#39#@'%-0G=I1 ME*D6*4Z]68?=:K<-&D-I5GU)BVF-0R9/GDMP BIR"2GFIFF!"FDD4RV'S[ M'8+OQ*QK@]=@%O^GM-CD8T;&!^@V.XB1M#<;=U;?/SSS-KV//UL+]B#=8AJO M.*@5J.KC=0FQ'F--//,R_)AZGOLF59S"9E-EV;>7\$;2W?O?_CJ"EUL%W"$=-0:!3^E-(Z3%U5.E,Q MID7S'>S^#OB>5>5Y?^ .YF;?WLWS^RQ;C_CJ[F"-O*-M$N2 #\8,]D9*PI0. M?D9EC3))Q @CMZ,B4%? #A[<7<>WKZ[7XZX;V'W>)N%&.(CB);V.,\DPL%Y5 M,BI$FE\5!T^??L9I_G>%W6!AG$?#/'X&^)N'$RX#(MQZ:Y'CR@"F^/8$EN(. M8#=N,[P#;3T/['0%T?="@%$:LZ/0^YD6A*R894O_-G29%<76#CI>;F9_J\0K MC"P37,5D4HXDM+B"C O!1UASIHVRGL_WG0'3.&]Z.X1MT''_OO[^AQ-"@$;2 M4*^I<-HC3EEUM1SG1(_QZ')[%7:&1TO-V5,T]^SAQ'NG8GD*#K%B1F-L965U MF^< WITQ/W083E9@*!!V;A4[I)- &..0RQ- 9I M)"PQ8HN$D,ZUL-7[8D8OMU_VB-D(V?.T[.IR4W+]5X=5NR'7L+8GACGN' M)(V^$J;$=YI\J<#-ZUGZ<38/ M8I\\'1[L+1&> M_<]!39L4D_"R]R:ZN7QAY>V8=>4&B,7%4,H\LPUA#@0BOM"&5 MDT,6;;D 2U+KFD>C3#VI? ,^Z1W2(N2P/JW=8R3=S[4:$#B:P%WI-H'1, 84)LQ5_%$W(;07.DZ4X6I.@^3J,9CU@\ XONC$X\PF\RG^]=5VKKZZ/N9'G[Y[ MT/D($FJHP! 8;Z#T3EEG<)5:I; Q@R8)C8_&Y\:[RS7Z?9G=[?6]9[N;;-5D M4F3Q@=^"+EZ'=>+-209AB[NEP5VP);RT.ID1V^)<$K% MP\OT_/7_/ECF5VOYJ]GUX=V9NLT3[BFP1.DQ;' MJ"]K\Z$'L(:BR6]Y/OTRF\^W]-[>X?$V*V;Y(:_C4+/$QQTY)J2W,5IDB55@ M6R%0:2Q9B_,BE[55T"%(75I0_YG/ISJ=_/G$MCO!-GJQ?1*W,C")QQNPLXH" M#!"NY(&PS060EQW-[P*MUMIOM_>^+BN433_DE2S'R-+QZX)W#1E7%EF!C+78 M K&K4Z =ERV\NPL,YI\7W#/N@C_>H_AG'AW4G>35#'O:[G>-#A.AN!D"U_*P[[U\>:)IQPX2F"'!*,A'*$[#;7M92P MN6F#+BM&WC%0'>_<-4IQ]7GQ/BO+^=J;7P<^/V=%&=TWFWT\<9.OAP$D'#!D M$5'."D4)(U"@*K9@F&(M3DY?1EQ[U'"?S2QOQ]I^WIJ8>#4M(,)HX(QW#!M0 MN31&B#:'_"\P[#T*C#O==DGC0?;*:5@?I-IDGVT&JO/%ZJ4UMDUWB46*>JP$ MP3'F+PG#L J1&$]L<[D#PNIS**D;O!OC(_7S@_?%L\OIZ%T6T0LN9S7DS=9U&%\KWI\Q4+=^4&()-L"0H=LXIC#BG6N^^0^%:. ^7$0P? M!Z[#<:_,-^->?R%9=TQ[UF\P5;V6B % 33!-.0R6096!88,?UN+X_&7'V_M$ ML5L63?*;Q>R_L^FK::#X['J6[BX'J,)GP7%YE&P6?K>ZS:9OB_SS+%8<2>=V M6P#B0_KUT7,G4:ZO023$08B-P-RY\'5"@AFM]&D-9,UKM* +C-F/$?*A(G.O M%I,B2Y?!@=G\&5,I)O&37 8HLMGG(T?$ZS0/DA-! &3**F@HUA[NTH.L4K;% M9'A94?H>P!HZ)O]V54P^A:%O!QXF:P3L#[9/.**:QE+YPL?X M3C!><;7998%FS:/YZ#*C^5VBU6T\=U>K?A,#B1/?N_BKDV*R^SI))# 68*2Q MXMY "!%RVS,F&A$)FEOE^#)"^KU#UI@,'XHTK&>!A^'EZ4VV=D771VCW*7YO M@X1(0Z6%$D+O&"<@'@BI1JQ\BPI3^(*"YUW!<\:+B7)]1@&W3' M)040!]2ICF6^"/1:2<=)"U)>1IA\M% _$/P_?GV&73^_,2[>DSQ9 MI^[H[%V6SB-.-BO#U[U\*DCVM;$N:*V:I\7O.P7K?67'\6=EG^?S/-E-OW'SV6QMCBV/\P79?BJ MW"8:^8^?E]E-_,NY$N&.E-+>TR(8<-8IX &E*DR%2!"/:06* VK(*R#ZK:-= M6_O'<]P: '?&#,GJC,K1FLI'VR8>0L(HU,9Q PDEW%.VE9D3Y4=^U4UK3=9@ M1A=X_1A<.0]'CI3C'A]%.G*@U;Q,_YG/)MGATK[/'DL\D5)K2+47G& FE.1R M-SIT(:5;FR*>=P9,8[5=W=X&N5\M)H?5]NRQQ!I@@TR&$F8)1 Q;;JK124R; M7VHYI#?9A=K: =-8;3&0^KY,B_*WX+B5L\GRJ ;WMTA$X!>7Q"'M,69 0^0K M^UCX8-0TCPU^N]I69IHZA-0E%86#@+_P&& M, \Y][ :-P*^><1YR-2C+G3;(4KG/TL=W(_?T__*BW6!^2-^V0F])-!!3WPL MWH><@9+28)!4. C)ARQF/4Y?K3\P1T"JA_'7NC#RQ)X2BZE3!(BP(%KJPC=L M :_P %++CUAFZB98!>ND@:/7 M.NUOE 0S'1"@F,<6.2&,QM164G(&FU<_[,T'[4V/>4^@#46-J^OKW]/BSZST MZ>=@X@547L>$I*/L.-@NL=Q9Q.*98@ U0HA*"*H-!"3'>)'H4 3I$K>A./*A M2*=9E/WXI/'\T<008&CX/R,EUE S04#%>DD :[&-?NE,: E58X_Y;5K&BEBS M25QF%S>[>>JPSWRX5:*54\@89H64PF..E:C6UP"!;YY%W)O7W+>:NT=MJ,_= M9I^S>7Z733]DDT^+?)[?W+^;W7RJ83(<:9G( !O""FE%+2 *0D#=3EXLFY_K MZNV(S5"30;?(#<44LUJ6^6U6K(O5Q,#!I]G=<98<:)40R3'E5"#)XB7<8>(3 M5:1*4LY 8X;T=EAF*(9TA]H(W-ECI3Z.-4V$(MA03(5FU(<5TT*'MA(KSEI< M;7F>C-&F"3<=XW1^9G17\Q+'XIZ4"VA1L*>PLHQ7$6H%!&IQ*/T[84ACK,Z2 M@+FZO4V+^ZMKG\Z*=5KT\NJZ5L;I]Y=XR<*DKICD!G"I@+'82^NXQH9;I6K> M5_C])5Y:92"V<>43"#IG@L^#MZA RO&0*T+SQ,O:JFV;>'D:6C](XJ5QQ!&" MJ?7./>G&NMR9.SZIKA]6-P993;:^.CR'D3+U40&$K,%8)("J@P!:P:'2%L MT.S9KA*#:B-^*/'R-&"&3KS40*EX6IY) 9##U D#JM$)@9I'E,Z8>-E(;>V M&4?B)4?21;M&1,O&RFS,XS&DW@I$,=AS%QBH#"R MWAI.JW%S2T:XA=23;CM$Z?P!O;X2+P'E'G(J., 2.HJ)%I4+@[TW+0J$?">^ M6G]@CH!4/:?#D?"AC-NWZT7S+?/BFB'Z%]-&Z1E> M(L&^C\1+A,)B;Z@,AAU!T@7GBJK=Z@_D"+<]>]-C_<3+TT"[[,1+Y@$63E#C M)<%<&<"TJY%E8.\?GA(Y_QNX&ZXMG^=LBNTMGTUAM=[',PO-7Y:>L MV/SN'+0_-)X$6.44A5@8*ST)1B+$E>VI"6]Q7.4\]YF-[COH$/Q+_##>%L&# M+\V"=B#? A[WY]0(I0G!'$E) >>8$M@A3V"JGDA@/-QQ__0"1_\=T)%]HJ(,-_"" 4AZG%D)UMJ5#S(\WGN=UM M# 3O NA+)/=#%&LH2C]Z8^(Q8M@%OT@PKXV*]^KM5DGD;?/TYO-< S<&(C>' M]Q+I.^ADO)T4-/$:<@FHUY1#!KEW9HNJ\:A%=9GS7"42:J8%MM5NI4&\Q?WJY[D+;PPL[QKT[^,# MJ.YG>I=]SA8OWN1VEG$DP?3SVG.GN,)4NFS+E99%1D:Y,[EHX-(#./6QDCA[R M2YS.QWB)8D!<0&P1!MI0QHT%I-J3L(::%D2_C.W.T4(]BMGZ35YF!XSM7M^7 MA#4-"0:Q-TC&B]B9U%6PU%+?XD(6>!E[DV-"=Q1LW-RC7,9PS=L _6RYS(O[ MH2EZ=!")A\1[@P%U$A!%O('$5(G_?9$/E=80W)1X *YSP4!)ID862XBH* MY$B;BPOAC[LQ>#JN0_$TUI7Y,GNH7_D"P:I'$HF"-6XA$IPQ@AUT2-.=!+S- M3:27M?O6$)"13SV55,--0F$B(+??>,40,\Y0)I:H\;H<-;IY,!G^(C;". M\7W@[W!EH#\\R6K_+JHY ^@ABA.$=!9YI!$)DX8 JJI:4(?4_4A[SFK.Q"HM MJ /6&4N-E4Y)O$7%<-VB>ON0U9QKJ[9M->?3T$I_C&K.P%JI.=,>(.@@I5AJ M48'BR<,&PL57;R'*1B\R#H!%:76&%F-SJ%A ME=A5M=':B!^JYGP:,(W5UK":LX.Q6HM"SFC.K<9<>+4=G?4$-T_X/6,UYT9J M:P=,8[5U6LT9<\VH94IZQK2%+G".5V,FPC0_.W/&:LZ-E-D91HWUVGDU9RN5 M$4PX:S14F%B!O=SQ4?KFV]1GK.;<2+<=HC24^?3@@7P;5JH."!R,;Z_]D@_! MA=1A@'_6B@MT\J:$: T%8483JP''T'E4X>F@Q8.64^T@0-@^@' .6(>GZ8%2 M4#LQEV_#_/K@4S^**IY&U([>E5BF-572"( A 5XA2T&%J=#B,BR9+JEZ'F#[ MCF*'(=[.RMMM81J3AV]P<9,M)K.]8>SM:'IZJ4GOPK/S=>W3Y9NTB,O1Y^S< MUR0^'M5V?JH36#_4+!%(8P^M" X-X6&:8LPB8(P.RZJ57M7ZP/J>N)X+$"6H M'TO?VSJQ&!MC/':2DV G(NH%VT<>QWTT M/%JC=8(0IEH["@3@"C@H- 5;N8.?1,VX@^F=:K8N:UJC]^.P9Y3A];&3YCQD MV:SH_YG-IW\$0[)X8GL>K59\O'&B($82$!C<4808IH!"54EM9)NS$'WY4)WJ M,N\9L.;1Q,>O_I 5MV$%#A92D4Y>2AL[UB0Q&@(/!=-4 JU9&'TLU;\Q!)6G M+4X1]J7F3NW:CO$9ZN-_,N)7\7:6['V9EFL+.3CX69$MR^WQW)HNWI%>$J>1 MPEIK)#0GWGA$M*QP(+Y%S+FWD$HO_D]_D)W=R/BMR)>-O)EUPT0PPX1A3DK$ M(8EE(5TU_5EO\ @WG'HA2*9T%*#*=!@$FV?M/6;:M$O?D^K')9'6[ MF@?B3VUV5V23=9RP[E33_ V)08I90K VG"*N,2":5?@!IIIO0O2V]=7_-#08 MG&>,Y]KL8^EGBR!A^-%H0JMQ5*\6R[)8W:Z/^QV/JNYID2B!I%480Z6($%Y! M[A%@*'@U&G*D:QW$'$+&8P'4%YY.E ^TID "88%V !"/_48VI21PS5>&C@.F MK77SS?4W;;$8=6QT9_?$):Z\#Q_O7;Y8?[N'HZ('VR5&,!6+QFAI!5&(.QH6 MR"U A/D61SC[C8>V4O;S('N'" UE0CP;ZM%HU8O/)PH#)R F% /H$!=A54*5 M;-#@D5\.W)'>\OZ0^K[8,,IHY9A(<"9O(IAQ^>)]F4_^/'YMVO-G$^0,H\Y( M91URP67F0%:3IG:B1:WDW@)2+77SW+1OB]QK?1F4'M=\:H>^1"Z-,5S(10D9XE7<[U3R/GK<$I+'%%>O:OET5DT_I,JMI21]H MDFAEE(".Q%+C1$G##8+;45OOT) !DB'5V#$N0WVRK_/%39D5MY%V-8X&O/1X M(A! 7/E@Q"#"%(1.^LJ,"8XE;VYYGY[<<#:3K -@SJ7RH\ORRPT2Q[CW$#E/ MC#11"&,3.F5ATO.*%CD=8C#'NUA3OO%)'&>@L&7[Z8UE/<2\\FABM+ M,8*<6F0=#2L7J<;IF*$C/"[>I>8Z@*1YD/+3K*BIN1<>39S3#B/@.6&(8,FU M!]5NNB-6-C>8>LLY[E)Q[1$9S)^M3[)%6LSRNBEBCY]/#.56,0J"/$IP M#HR3E>'O FS-TT%.OZOB_*EA+9 9KH;(9HA_+)9WV61='N6H:;2W38(HTU(9 MX*P.DP@4CK@JEN\@DV+<5G)+O7US"K];E+Y/1HS27AX+$T&# 0(HH@153X'5[(\>:;5[W9VAUH:H_N6T'34/'+HGRD]/"OYPH/ M/TK>I8N;?7&P)[]/"&#&AR'R8+P(Q:0D$&S'[!V0S4.=IU_;,_C*W@:)WK6W M]_M\]D08-_6<0\\IMM8Y J3!U;BQQ'R5-J39Y+@+T(BPUHA-=4,.045?#3V(2L('5D+&Z.>=R-[KWI+OQ[7 MV^-G$L,T#"LU!T$"K1R&OLH9U( 0V#S1O?.H4R=Z:R'[>3);WV73[/8N8OLV M"V;6]*04]Y<:)Y0IB#0"1F*KI/4 *5U)+:5I'L X_;:WD:2\=P#3.,AQ8@KT MR\T3P+!GF# L/18TWA1:I88& -S8BWMUJ=J36-,*O1^)/Z.RX"Z%-F.DRZ&L M[A-[".!"JH'SF!BJF$'&/(#+A!_R>'ZC?.^V:CV),TUA&P=M/GS)6])FUT," M. 6 0RV0]1A:X9TBNV^2M[@";*!C H/2IBEL(Z%->%7;^>91'PD$4AG(I>14 M0^PTL\!7!34\&?3HP050IS%PYR&/28OB?K:X4;?Y:G'H)MM#S1)*L/8&(@<5 M Q)R'W-(MI*RX.^/?5%ZW7'UF%;P#$6$MT4^R;+IT@=PXO#?9.75]:OED<2*(=5P8C#5V*M9B5)+NH*0M:E4.M.2T)T7G(#7.W'E&SUWE M+I]E8=Z:A+^E-]G5XH_%:IE-=5X4^9= 7Y/>I9-9>;\OR:==KPF6<8*4A"J- M"0A3HJT2_37B/P1MH86E.D.'1&RR[-F!R=?WT:,&[+((;QEZ'6,TZ2L(' M)!4DS J&M(5!#;Z:8I&F>H27;'4]V?0*V'F,$YTN9\OW=T66!D_NGVFQOLG] M75IFL+:ALK^+=14 &4Q[[:2-AX8MI;!"0 K6W),^/4%M%$9+9U!UM$J]6DRS MKU65WCB.[692O=5H7^N$:D&,HA:$H0,#L/5N-V\*()NK_?3LA?.O.AVA=)[I MP1?9OU?98G)_=;UQOF:3M^G]IJ)BS>EA?Q>)"A,DDLYQAI1'88:$54ZU1D#C MYOEJIV__C&)ZZ RJCJ8'/\_SXC%UZ\T+WS1+M!.IKJ:!K:G[Q&NJ.16\U#1Q1EA& &72<^L$8\I7(5],B6N1IPS&KO">,&JL MZ;=%=K=98I[ZQ-=7JW)9IHMI]&PVA=3W:?R$+A(C(+!?TK ^/1ZB7\4B\GNCV,T[ M2P#W3!-J#,5>>Q;O!JGV";!2HD5L>_1QS,%0ZXP?516*1V59Z[+AA:8)$T9" M&)8R(!E"2$/(=BPGK,W!A&R^^5R^]OEH:A2H_Z2> M5\* )"&NE] 88JH=0*(I;9&L<3%AR2& &XI4 MU3C?Y.7[K"SG68R0O5J8=/G)I[/BG^E\E=G9,M[]L"H.^1ZG=91X["A0-GC6 ME&O!J2.V,K>(<:Y%9?6+"57VBECKY2<>ZSZVSL1G$HJ=110(3!211'+K2359 MAA62M' N+B/ZV *,<^Y@;=/AV^Y?[>LFL=)++(&"BG%F-1! 53$6@HUND0EZ M,<'&'O$Z3TQJSYRP_^%$8,HE81C'12XF H@'J8!LDT4S^DAD9ZB<(WDFEK]; MODWOCURVM:])HIR)U9=8++8'#:? V HL:K5J45;]8D*,'6$SE/;?58&28-G& M&C$?MC5B#FA_7Y,$8!V+(QIF 70;>["YU-%3JA4M@4?1A^%[ ND\Q@ MCW?1UG5$I@WVI0YUDF!E<)@:);+!OT%( J-/C39.UK--RT> MA43?9*5:+%;I_%WV.5NLLG?9))M]C@N;OG\=KSTM7BW4=+J&_T->C7[O7D;K MGN/E"-ICXD& U2CL(+.XPL!8T/R^1G09 BCF8.CUY@WZ_Y!7<$RHPL 998VPEO9*L><$B=#%!SEZ0&FQ+]6'3]VU:7!4; WN] M\Q+$6,MP: /U>.M$(*($@,Q#Q2PA\2:PRK1BA./F87!T,0'0[F$:;!I9DWA# M[BHS\!@I]K9)?. \(T):"X#E#G@+625C6&!;1$$N)B;:%3AG7D?6W#7YXG-6 MQ (C5]>;OY>S8#!O+UV<-5E>ZO6;&!#L8XQ!QMDQ@J)0@?D[$$4V0\$56)-,V-,,UWWO#%Q%R[ F=( M[^9=-H^KXY.CLTNU6%\F5O<@^TG])!HPCPDC%@/A"8 4@*J,#&<2-K^L#5]4 MQ+4OP(8B3^6AN:]WV6*9'=FZ>^'IA$JG8!## D,IA 1YOIL5H>'-+R'!HP^D M=@?+@[K_X]=GB(3A_;G^Q0L_W_;Q!)PO7[[\;;;X/"O3[&^3_/;7-3 /_(SD M#,M;W$C*%I.PK%W=944:__DZ2Y?!]XIY2>7L;_MP_ M,Y^.:ZJ6RZQ<[G1U@*2'&R8Q"YL+*1%7UA/M(##(<:>AXQS!>CD&/9F-DT_9 M=#6/QPQ>$N'#D:R*.LT3C;3U06"%@#8 41,8OI&>"09P\Z_U].4]G<_W?Z)= M*?&;VO.=8[3^=*.0T_+OT5#(IO_X.:[1.@MOEL8<<(F^YEMXH1QW7V## MM6AQB/QT0IU4&[9;)GR;Q-,Q< -F<[T\\EH7!-9HG3@!J!6."N(D5Y)S!D0E M-]?6C;M6;*>:K3;(J9?G5XGVZ\$5P M@((#O;]\9\V6B:2"44 ,C]O%*+A0&*M*!@SH" OK=:J9O$^TAIH>HN!7URH> M?+A9&T-'[(\7GT_B30E""B ,0QY+Y PT6]F$5;Y%0/R"+8XNH!J*!H]&&;W1 M-_DB??C)A_"W93J)JED>+=UZ8D\)<-!+'SX!"BDUQD,$<86'AEZ-V_9HJ>/\ M'-C]Q:E16B3CIE)']LB;[,LFIG78^'CV6&+C^1JCM=0$A6F80/J @B)VA/=A M]X9_WAE,@YU9S,)BFCU=8-]EB^Q+.C]R#.U(RT0ACCUQ5C*L!&8R2$^V\DH' M08NCQWW1HJ<86K= G9,8<;CKS=ZR"!_(B=QXVCAQ"@HE%%. A.<..60KJ1F MML4V2&_;80/2HQ56@V5M;';Z[VUVER]GA^CP[,DDT-MHKKV*%9^(-T$Z7LDC M%6N>]]G;#EA?X?56P PW%0297RUBSO+L\Z.D]8,3P,M-$F)Y<-YCH4?F7$P- M _>SL(T-MGWPE"0W'@V:ZG7Y6KHBKY6AVZLZM#E*C90T(#]XW3 M2AIGK *>P)VQI1C1S?V#W@X,],20?@ [Y\YY^2DK'OU^/%OGSP;VNLZN^;XV MB8"&.P 4QR(8=IQS@GW0MX5 4,-HK6SU8>0\MD/^XO,)U,!H2:1A!!@+D$=. M;.3C1##6O&!^UUOB[37T_(OL (]1;W]W$W"&,#C(TJ+@XEH@B!(,H?6$1+GS M'C6_\+;G+>Z6ZJT583X-F^\_&NB((Y@Q!(CP&A#(+:$5'EPA>XD1YMHZ;AD6 M;(;=7YRZH CS6*C44839Y#;[G,WS];:NNBFR]7@.AYL/M4DP-=!A;L(2;H4* M8Z90;7JY00*D]HX)*+RD7@74PH>R->BCG&+< M5D0[A1W1?BN$OC<>C'+E'X/ZSZ-VO5H&GWRY7!>&7ZXQCV=_@AFTJ10_=8MR M5MX_6A6/G?71C&.R&XM:[[&:V M+&-\,5]LHZ6/3*\C>]O'&R=&.,*%X58R8:TGEHNM728 QFR$=]1VSYC.86KL M6&S??G7]G)WK\X:SQ5 MI+!-U*N_3)8MS:HHLH/W ^YMDU#EA?!$ M(O'A*2G^S%K;?GJ@VY/V(5-Y/> MA4[GFWV[PYM;6U&&'?&3P3[;9AS3<)^,\W6>+D*#*F5B%]48[8#?Y(M)/,X^ MC][\'XM)OMA4]DOGCR_#J>ST,V^!5L63OQW:ZQJ;H35:)T@YYK1%G!'@J8(, M<>BT%YHK@"6KM3X.+?NQ#=(C+1,A!(N>%K44:@8P-X!O9):>.S::T\.=ZN]Y MHDNG&(UZ^_1=-HGZF;[XL5]]G,]NUJ:ROC=IF=WDQ?W5=<2V>F)Z).;91?>) M 32":PB0Q"))D#*N@IMRU^+"D'YCI)W1Z!L?9G!0AS)BCXCT(-!O>3Y=7A7O ML^+S;)(M*W__:!2NFQ=_1V6 +E(]+ 7SP^ M#<511I]_!/IV%&3:OGWG>41WX'7Z,2^B'N_?K^[NYK-CAZ=.Z2-QDBJ&"-.0 M>:TL_#1;7"VR_R]+#^7.-.PQ M4,>]M"V4<'&L!XA@I]N'3K.B28;O^$J XE, )XXSB MA,OPAZZP,8(V+W[3VY;,6 C6%,.1\:L]HQ+C(-5"24L8$P@*@AFHY$>>-M_G M[6WO9@0<.A&U4>SIO N_WA8DW1:I_9"_B29K%<(?T4;).N35ZZL7RWP^FT84 M=#J/$+S_E&7E.5[Y-HV[A)^R2"@V\ MQA@B3%20C6TE8EZXT1S2:Z.,;RXK:(' J/>5=I)M/K,X+^2+&DGR!]LEEA&% M%;!(6^B1Y<.P!G*['TVU*.![1>?3Z0+'Y3 M2G*G$'$VX$8KV:C%8-S[+1WI[<5+++I!ZOMBPRAW+<9$@O,H_ZDY=O0,Y4N/ M)P *8& %DOEC !:(%"MM%B+(7,!:OJV+37T32W@UJ ,I>Y'M[L=U?4WSR9: MZ/ ):(\ 4%2$19&;"B!AJ&F^D=1;I+5;1;=%9+"TX^DNII+.IJ\6VT32XR>D M#[5+# :*&:N85I(R;;50I)*5R1:GHGH+@W:K_2[1&3 !?76[6H>AJESLAUC MJT5PW+/CK*C;1^(PQ)!Q*0A#4!H%-),5!ERT*.'96Y"S8X;TA-1PX? RB)]- M75HL9HN;XR457FZ0 *XQ#'X3X)@@&(/$S%?2"0=&6'NK6QYT LM02@^\+&(D MVF:;/U\MOHW(O7[DQM ]9@%%C?$GRU*I=ENIB&Z>X0 YX_FP"D@/,:N>!K6V^=%+QRDV)- MVN8U7'MS*08C0$NL!IT"]ESNN_[=U=VZ$(W[FA63V3([M(*+2+?N(TMK>_)*"/95CA M'4;8"!PS.V&%C0"^^55;O7E-8YC*NL)S%--9AV0[TF&8[+5#T@F),5(0($(@ MKM#!##8WO-AWRK9N 1W#U.9N[^;Y?;:Q!JKLNWAM7L.I;6]_">?( R2,@P(S MH!4&RNVP@;CY#A'_3LG6*9ZCF-KV"M-X;MO?8T*%A)8;I@175H4_.>85/I:V M.# OOE.^=8SH&&:W-]F7]6^:&FJ[]HD([@^@$&#C#(IEA:2I4H-TO%VC,9OD M=\JF5OB-8K9J09YG'2104Q\^E3 Q$R*I$DC0RB[0+!@+S4."".\4\H@!+!#0PI$=XM30%A4Y+GZ78638#\7V?>D] M\7B5^IS.UB?] K;OTWFV+34XRY8/8.GL.B^R#^G7 [3N[!V)1LXAJ(5RT@(B M*$(6[@QP0EOD9E_\'L:Y0!Z*J&^R\D&@ V1[\EQB,6)*"R:]"6:/)U:IRF,S M&M(65V]=_%Y$&Z!Z<4W"-)LO%MFZ3G(L&_*VF'T.]L/;>3I9IRJ% 0?;X?HZ MB^WV%;[OX2T)1P9(;6E,@=>(:F99E1%KD(3-PR;P8K<8S@]S/WY)[QQL^IK$ MXV R6 R,)I8):!GG#^B -I=X7>S6PPAP'D-\^,4$A;5D8377V2(HO2KDT&7& MTLMO2"B2Q'B B ?60.(@ F"'7_BC.4^_URV+GB'N9Z)\+=)O#K:J1B[XHAB[J1QNP_4"=WBD-[%[F*< ==>+,!_K:_^*P\FP)W> M2>*L!\IRQHT25DLG*:C.J%@@;?. 'KK8C8O>4>QGUFE+D#V]),I8J(-H 3/L M, >8DXK[053;W+A"W^760SC0O-MU>?]Q%0@!$7C- M* !<<9NFII MMLSHYC5$T,7N'?2,X2AVV=O1Z-L^$J!4@)EA0)"4V 'E'C#@P2UNSJ.+#]3W M!>(8IJ-=YNZJVGQ&"0KT6E4WJM.?-#Z.@BPW> MCPKQP0H&;0I:S#YG[OHZFY17UV^R+VHRR5?K.K)OPV8L%_+N.U'<-["BLQ!Y86+/C MA"A(K%4.&Q_,'D:YP[I"BU#7O'(&NMAX_EF0?>!A7T7GNRBI?>;JY]N:]X_" M/!=7VUL[C1U#@E,+B42(QKLA,0KS$M50J5HYH#U+=F)M;^2-90!2#S2(?Q / MZ58BJ1UM'BSKO[9W;64=7U M9WO*>.][-)&68T4H,$ $.+%G(JR]&_$5%'C(XDMM*G?7UF+>*1X-#9!3-+M< M7U2^N=IN;UGF@\\GF#.#%.9 Z7AY2C#P!:ADTDB,M$AW>Q5]J^O.P/D^%'\> MA>^IQST2?7>T%V]GZ&36PUZ2RQAS@IO* &.0&4-QZ+"Q7K6(E&]+Y8T5^W+ M'.D1KL&.!59W^ZVW=,(,M\T]KC-O'&V; ,@DX8Y#"CD###NY6P&-=W*$%]UV M.)%T#<]@&VAAN/%6R#7%#^V)/7XNT<0Q(F$P%G]F$9<:)XKV-DJ AHQQ#ZAA$#G& M%-PML :B%LY#;]F-_?&A,YB&(D-P=@(6\S!@-;T-*HCRKS?KCS+B2,M$"\@L M-YQJ#@0%C'B/M_):#G#S7)W>LA3[HT6W6 UI)#R&X8B=\/C1()&14BGJI5$> M(PRDK=ANO6A1W*&W?,)^3846X SN)M0JS?#"TTEP?F)RMA) >R\@]):C2BXI M6L04>EL)^G %&@,R:)F8-_DB?SKBXU/^X8:)]%(!ZCTR2A+&'<&ZBKY92T!S M]Z"W&;]+]7>)S5!,>+4HLR);UG )GCV9<(TT48 ;ZZR"! 3/I]H"L6$R'.%E M6AWJNAT8PRFWFH>J&-9LL8IEW79I+YLR09OG/J1?LZ7[&E:ZH(C9(BWNUQ@% M1L<$@@#T?,WIC> 'B=+;6Q,FK1.* $NY\I2%Y5C!+ R#&RBJ\(R3DC=?F7I+S^Z<.&U! M&4KIS4J#0>XU=THX';PG (WEMG*@'.$M;BGI+?NY0P6W@6(\B]';K-#I1'%]4]D^@ KYIUF"#.*=>22VVL$-1R MB:KP@-,2M-@K[:TR28>L&@2TOM/:;3Y913ABL"9\%N7]JT4PJ6[3QR?'NL]/ M]^FL6)]&^3U+EZMBDYX^\.M,6A3W,7)]&P]F1?F7Y>PV9LSO'E^7@[Y+%_>/ MKW^TV+=[%PQ3%)CH?[."B M^F>DY/)UC?S[3M^3*$AA,+,4ML0%@UOH6*=) (4@A\#16FO0>/$\EO7?V3L2 M):ED1&G,))'&"1JPV^#(P@SF1G-@X$SLR<>!^Y#'%)H37M\_FA/7LNXYO5"S M9:(A04);1H-WK>(%(<*I"B0!9(OK!TXFYTF'&TJ04D!3RAP P6(PQC*L M=WA(,<(\XEZIU"]\0]&IBB)<7;>:DD[I)E$$"F< X]0[0JSC7&U=(^8)H\W+ M=O:6A=(KD7K$;G ;Z,E2[XOLWZML,;EOY*,]:9U(Q\*>[\-/:H#LXJUX:=WW#>G_K1'F.%,-6><6-\0)2PRJYI0+H$GVSAIK= MQYK.T?MQV'-!7MEX2#,>LBQWD_)1\Z=.\\0Y).(&+7?.L"WW6X$I+R,Y@[>S^^I^SK(CGC.Y?QU-&]0V> QTDSB(-M')0Q63V('7X M^W8+(1B K/DYKM/MY,NU>;H#^*QST;=B-%K"]O:30$&-M\H29C" $G,*?(4% M@!!>C"G4B<+K3%8=0_ECTVOLMM+X675F-KU:W*W*Y1H45-]>^K95 I&!03A$ MD 1>.>4%$)6<4*OFT:%!S:0.]+B/+:TQ&XH;K_/%S8>LN(TI2 ?(\/BQ1!B) MI61*<4"]441@PJJT"8C=H/7'3M3^6=-&6H#8=\[>RY_';)$N)K-T_FJQ+(MU M3M_RT:[,([S6 /V5P=:$3(12*IQA'@D##42!5IMKI@6U#H):ES>.%\_A,MB@ M 5A+I"6$-(#);3PVNL$12V1;7((YY@RVVNSI+8/M--S'G<'V[7QW+$CP$[,3A =RGI:7QE[G14/513C$9#K MEQ;.#V%@RY=_==2-Z_(U"=%6.BF)04@9KI0T#%5(6DC8R(,(;?F1CP[:O\C: M'-%QAB0NF:/GX>;O^2*[WU1[\JO%=']AY<,-$LH M(YHAHA5R"JA.=]*IR"W M>$B^U'--SZ/C7,^"ZB(:-KO+E[/R>";=_E:)1@XY2)T*(%'I M@0XN?24GPV:$67.C8$UWD Y&G?SV-E[-':_T"V;Q<=*\]'QB"0U6K2-$ >8D MUAI+4,EF1(M,[]YRX\9!EP[ '(HH?[S_4*S=G?N'VZ..LF5_H\0# "QCADMC M*6< 8*\K*3D"M:X8&K:JTR@HTQFBP_'FM_QS5BS6-M]-%N#(EC'<>Q*+ZG61 M$&! F%L)1Y!1BWB4O$( *](\XM5;]:B1<*H7?(\S;.^M%.L[/,-HXA5KL^FV M?L2Q^R@.-$HD\D(KP8.]1BPEG&I;?1L:V3&6>#HK,SI']#M*Z9:.,V["[&I< M,.@$@L/:?00X"5I-4'JAD3>.0A MR"XUVR [MQEZ/PY[QAD3'#EIQD.6KE.Z/0LP&DPT%EHHSUQ,2MU*[H4:/";*4W6K6H:W?W+]7L\_I?./E+^N:)^ M5$O@!1.V0Y4,2N8=]EV2===I A#6PL1;<0$2&(1_!+UL)'=A^,V]NO[7W,LB M8U/(AS+G-FB^4(GL@#&WMTTBI9<>!.N&4!?@%=(S4 MIX_-L:=IFH=LG)I=) 1Y#I$GU%+%E%70V0I(SW2+>T]ZN_)N'$3J">#!*#:9 M%*OL,7(FP+,^9[Z?4_O:)!*QN.-D%-0B_%<"H:MPGI?2-<\PZ>TBO)&0J"-$ MTW,41]D$=%_*0J[P^ZM42L<\G8ZZVVY4>?92B:0?L769LC.LY4OTOF:%<;C-T? #5 (:*8H)(:HQ#7 M*F"Y'7DT@<:77G$>Q=4_ 'H:HD/-4WJU#/;MHMM9D#69T@=>/P951VBOCHTA'1HB:E^D_\]ED_S6"+SV6J+ 8 M>@0D00H3*BR GFQ'YP&&(SPUT"'B>6? #/5%OUI,\MOL?9F6ZYC1ZZB/XS;# M@58)P]($ZPICHY75C$.\,[6\1:2YW7 QAR6;V@W=H7IF]AQ="PZV2YQAP&!$ M@ER4 ZF$4 ]?BL8C#[)THL5ZS&B%U_?-D5':"N.CQGDH\5NV"+[T/,R@:GH; M5!"\]3#HSYG[>A>0/'YO<:WV"B\X)*5S,@AMJ32$8D.PJ.;\@+G\/NI9 MU59XJ\I#S:#\L>DU=EMI_*PZ,YLZJTNSSO&EX6WQ! *CRD*$*CFM%,U/]HRD MGE5M/9Y0E^8TS,XYT_QK5G[Z8Y%_7&;%Y[C$;X0)ID"^F 0+81U(6[Y[E@F^ M,1[NCQU0[>5]B:'$!0M4 D*=HY@;*F"%K::L^>'H"ZEXTSK]_HS:&#KAPN2W M'V>+M1COR^SNT59U/.%;WK]:E%F1+ LA^7>I,5F%V(T!]^N[J)D_V>5 M+LHP_O70=A473CO:5J^GQ#%#)3((>(L=8A:XJE8D%@Z#6I;K.3&I?3SM>"^) M,A9Y;"PF4EFJ'?=Z6U\:&0Y;G+KNZP!:USK>M\9UCMT/:&P6XNI2\36/B9V&V5\G;_8?-\"<(BZTH!)+K:3@4.N=9@@: M^W4V;?G1YQ&<9M#^1=;FB(XS@G;)'.TH0[N'8V+!:P&QE)C5D&LML#*&/, ' M1IB]?1[%U3\F=AJBEW=,3#A+C-?.0&8TP(0)Z"KY6)!X0']_=(96-YA]'X=[ M++>Q'"_67D(%8Q*CWY8$0M92-W*3J+4F3S[ETPRO'X,KH[1(QD>1CLR,A@?! MN)98>< T\>$_Q*H@=34Z0,F@26Q='02KC?BA@V"G =/PBUX6Y:.O.?SK^9<< M?I2\2X/9LF?=?_+[Q!/,4;2?&5,,$2R-1[LQ$]0\2WJH0UT]K/)M$.I=JWN_ MU6=/)%X9J:W%FC"&N7;0L&HULMA53>K_I,9J4Q@B%DL+,48:H4Q(>Y4]G>2=+[ M%7^W.1?9N6W M?&TW,33LR]_%E[MBLYK%JXGPVW6>+]7RYLF/W?S;7?SI:=?*:!/(3$RRD@!Y MBFP %0I$JNLS+^23/N^3JZ0#2$EQ 9"/M=.]"#9FQTM$&U*\& C$-,6IT;C9]1289998'FX9H M@9DR4-'#0K(\];)!_3/Z+$GJC./O*%%)*F27(TA3Z?#W]S&VOKC^3VTZV2_/ M9H(RRJ$T#%C%$(+$'>*+O$<=FM$-IB#USZY?]/1N(+VU['H&$(=,>B4<\UIC MC>">>@RT9>U+;9_?KS Y=680"-]X@K, 0"E#A7 XF#(:6[;WN&+JE$W"\O<6KR1UG(N2JHFEJ;?\>4<($@X(*1P10$F$T+[A.698^?;7(*GD MSS?EXQGY\^=A-H$F-%!51:(#FH1CQ:!A"D-G"*CHYMRU+TEU?CO>E'6@GO"; M\H3JM_*=5EX1;W ,L>,2>L85K>A64/*+47:Z<[9%";QVZ/T^TI.Z+I.DT*0C M++W73>2 TV%<])+K15BX( JL$D78.F#GZWJ)IX%V5C"5&C MP;SZ?&81P@XRB[BW!A-"+:KT/^Z\:-]^YOS.[\GI+'T@-IHT[*?X=;GZGE_/ M;^?Y3>WI'U 9GTC@GB12","RF-(Y15U!DG1^U0UDQCZ(%31WC? M"9K6L5@GBW5M72]P^V\4?[/UQ#PFB-\7F^7Z%:;W\^*,$\T9 M1BYG',9(!5 M&KF8T";!C[2GJQVR^B$I56 B?9XO\OY(E-:: O9AYZI3"V M,& LK0+<'ZS+L)S!F"G\B0AN6HA/+]%_E(&TJSV9?P0.15(_Y*]MINU?ECDA M(-%,. ]C,JT5R)H*%29H>SD\/\GT8N2P)S#'$K%7JEP>"> ]E&<](6,MWI99 M3:'WU# O'9)*6\6J.T'!J6@O9.K.#^ .1&9F@C:L;>QX]5Y7X3950KP M_-LR?TT4^WEQ9IEG3,28.T\]=0A8)"JT@++MHQ//#SU+1! G ;;U/N=6Z_G] M;)W?'& )!_Z1-7-L0SOG'9E5P6PGE$,A!=*<<@"KRP()$6P?JWC^/7TB C,T MANEI6JHL8XKX]K['W,4_OEON+.^/MW7[->Q%.^LT@\SRH.E2;YP#S$JFO.25 M>T!*;-IO>N??VR0BPVESX'$%C%AO?GO]=:S*_'XV73[Z1UY\*V??[^;7[Y:W M17G_;(L>Z7.?K^_RF\TB_WB[5Z/T@XDL+!^F+K*_G\_*AZ7@PF?+Y6QA-JMU M<;\KW/F^6'Y['Z3_9N8"8R^1EUHH0)1@"N^!H (R,** G15Y M,1;_B_Y!;*F&-A.,G> ]G>'1Z_:3SV>$2(*(A\CSH%L($ZB2%4V,ND3;:/?$ MIV(XA-X&]Y,*M$B)Z5V8OQD&*737 ^Y%1PB&9YE1)UAF5$:MY(I9 M%E4AS*U3XHG L@XL&Z3&7?\L.QN"UCZ_JWP5C.Q_%T&'.UT%Z)<',Q9I0MP9 MPKP3A@<;'%5ZJU$="D;U?F':+Y-Z@6,L1]Q>-8R:8?2DE+/K;;?*2CMT/Z\7 MFYO85C!HAN&?FR^SG_5F[SEORZP3P!LIA')0,@6YX!'>@)/!'I $&]^.;LD- M#^O07J]7/4*#>[V*XN;O^6(16/)NN9XMO\W#]W8\F>2CR725K.;8Q)/UR[,9 M!]1RH B#%@,,)*1&Q?Z="B"!@L"EX**J9MW<]_1L1 81"=TA7-DG&:IC>H-TZ> MW1^F'5Z_AZPDY3M*5T1ZLG&W%]!_SM;E_*)<,XD5/*K->I'6_>=1_N@?#N[56:,"8" ,",0 R;(+46PFKOL M4D]T\):+K?C6@?:QU-CJ(/^T*:_O9JM<76]#9^(=^FMYZ^K_'83T+D]=6G<9'A& M."0!6>I<.,,DA_XM K-(-'*AV/WWFT$T]X M"*:.[3DQM?<-PGV:#,^4CAVQ/766&"F(Y<3&Q:L0C'&HLM&-Q= 10"<(:1X4 M5/>2C&JGK9)0(4LY%UP+2/9(F"#%8P8OGHP3ZI>M1T.'>L8KZ6BB"2X*E;20 M4ZB=L9 !R"7 %7@ P3'-PY;^M?[DH\O=X5DP3J^3#GVC$Y:Y"N RY(GS4GN* MC:KPL)C@-!U^@W*^X]5..T3_D;2DW)*7+&!OY>[0,@T0%HJ :!\"AS4ZX$FP M2[&ITU"SBK1)E&E5*I;6P@Y$V7.76D>2C-]#&$HTOY>PFCX37"\3+1S.N R;! MM+5$0&J5HX#QBB)$07L7W'"U54<2@XY0M0Z\_C1;!XE[/[^.JMCRVT$&3X=> MGQZ508.EADI[ YR6%!HN*Q"L [Q]FZWARIT.S.;^46O-<3_[4931TG^?SU8G M%O'QAS/A/#80>2VL4P9I 0BKO%2:^Q2KB([!WS[ 2L "W58,;V=R;H=FUD C M-&*60DDEULYS?7!B,C]J69;.XM'=-]LS7@E(B+J^WMQO%K'^Z=.+I78R<^1E MF?$T6/(*8 H("6IQ0/R "C6@O11-85(,*D7]()B 7)UN&'%Z8!:.2\V4-#J8 M45!K[[@S>VH]%2C!Z]VIY.5\M*:7C?ZB0A!0E&B)E EK0P+ A:Q<,YX(T#YB M: H;9$@Y:8W9]-*RNLHCLE')?K(A?LK+>7%SJB)URS=FA$&,*/-*2PTD\DZ+ MRHGCN4279? ,NO?T"..482B;^_M9^?#Q]K$._&:]*?.G1+F?WX.=E_\:;1/K M!CTB5!.M,FPYG ,=U3-3A\YT*XL#M?'>(\NX,D(Z)PD"._GQ##+?:&L?.BBF M:UDIGEL5IS)V&97'.0R+I0)8>R^)0Z# B MC% M+-'.$>PJ4*@5[5TS$Y7%:OX>L)!D?DIZ(].2K5XOU[%_%_/IXVN%KCV6( &^< M\DA13Z!!2.N*;NJ03S#?NT?$B]Z :YWR^O3;'OQ6*:@111Z9[$+ M,BN%I$!5LX-2)512>6"V=0.F-=NBYO%Y/2O7?^3+?#V_7M5R\/B(8#MKYJP1 MF))@SP:;%J.*<(:D:.]F&LP=.1 S>\.H-5][+RX6Q"]L) AYY#&'$@A!*WED M6./VR::#N1 'XFV/*(V=EGI5+!:^*/^>E:?:;;[R= :1CCU9+*428.6H$'+O M%?/<"S%J^9VV>61M;?'N>(S-YP;,S2R@V"DF B#"$(3\^$X6WED7L9B-::> P4P-HZCMD!/(\3#& =0@3ZQ&A"]_S05>W?Q9#- M_,OLYT@?2:9J_6%.AY:?UP]-7/4GQV5:QPXWRH*@ #I%I((81)70QIA7B29L MN/C:O.L<]T?'9-8@[R V#AM$!"3*4KVG$V @3"JN^YZX50R#2]*._$#>[C*S MQGW_[+G,,>>5TX!H0R@R4$&#]P! I$2RM>Q[8.G+,.@.N(P6 %_-L=;=^N+) MV! FF+G24J,)I)HQC&!%#[5*INV(;\F;8QSNA,GE\SI)1_HT+.[)S>-^?I^7 M^ZY&/_]//BO#(_*TE^?$D,PYHJ%#6!&'.990KU 9GV FO-K"6<0 V$LZ*25P0H:Q\K,W!9__[UJEX MFH[]M:?OL2&9\L)P0:TDCB.@H2*@.L.0$23QED!=V58K!9U0>HORD*1:EHH8 M3,/^;=/L;4_/Z]GB?V_*^>IF?GWR!J_AR P9*QG 4E,-O%=&,DWV]&*G])BE MPQKJ!-U9]S*XLE>(1C3+3)G?S-=F5I8/MSOO=[W+Y?4Q&:,FAK=SK#RUF#CA M):]H5!"TU_0'+IH_B/NE%XPFE8-&=9-J1F9" A=V4QA6$0H4$R>)J.B54IJT M]88>^-A$,CKC]?;E)$E](CWQF$8LKO)5L(BO[VH5B>HD(UC%Q MDAU0,DZW3_<:TC74#W]^:8O> 9CI[(=(^=DNA6I0AL*Q2H4+BA:G3BJ'-#-[ M*@FEH+U;X?SPK^3<"BU!FE846IB33]:.55YQ#X1 R"&"J >P\J$1:6CBMSI] ML+"15'1"ZRW+1Y(J0FIB,94XK/-R.5M+3/0)TUAB86:+>="AEO.9+V?+ MZ[OY*N*BBZ!3U==:K1N;!6H!$- XH&$@G%+*915@HS!KOU\,=E,UB&CT#=18 MPN%N;_/K&*QW0.5JMLZO\NMB>3U?S+=W<6KM\\"2V2*ZWS:!?0_/'CXA/CV\ M/;,.*J@LEI@;PY"UX3\5;F&]B83WGEXCTL;'LO65>"1]LUZIYOU MQ]OP$-_.Y?LB%@\]1.R:N]A<[-UR/\-/9?%C'H_\V>(P\WUI"ITO Q=?*[DT M^#>C$F$QB&Q" 3N#O=>'M:LM3/ ZOE\93 WAL7;'?\T6F]W"6BR*O\.^GMO\ M-B_+_"8>'S%ZNZ)4W4?23VR%Y[XJ$]Z'U4F=!P8ZCQ$$I+)R6=!AVR?N#):2 M-\R^-S!P8XG2Q^]YC&Q9?GM?K%9/_5JGW#K'!V62"^R%DHP)(!PU6J+J.I6% M?Q+,ZAM&/'J#:-K;P+KMX\2HH%D2Q[6-;= @EPHI3%U%)S>^O8=OL'I>PXA" M?QBUUGP^Y.OC EGM4Q__7N9E[+_P*2^O\^5Z]BW?M[8]IMQT?&U&L @3E90' MF\.: *>%E=X7$^C:&VF#E4 >0'\9%\2QMI.ORS*8 -^6\__9'HA[?>K4H7)D M1#!]$84!34>YX!83Y$QU'<+">=K>R<,O0TCZQ:?U%O)$0Y[=SY=;U>?#)@+Q M\7878?MU&6!]\MMCN\;Y;\JDTT$1EUP2PBR2P-F@0>UHC,ZL]AN%N P9& >W MH9--GR1C/E8J,\%**Y8Q-?;C;=S^=![VOOS)H_KAZ^=@W/GPT_FWY=/HJN&K M/M;.^&!"AND]>7B:B863Y*4-,M%,GKM_/MX^&M81O$VLL;T^^(+VOJ&K70Q= M?&"V?%@]#DF#A"/;[YB3&SXC^T>^2U-_M_Q4SG\$ABP>_E>^J'@R=>*T*1;A M+"EV6=RJ+*-JM$VJ#V*S[0#T^J^_A#^M9KL=XWV#/.L^/Y-A0*Q$!GN-H(($ MZ-@;G#ON((&.H$9AD0-%!#_9T#H3W+P0:U\?RS@S3! .%;!"0R##O^@>62!X M!T]#SXG@TXC3T?*O$^&?=,+YMOE@?O-I5JX?GA*J'Y[^IB;6J?E+@M6O1-#) M-*440J2)P$0>H/,=JN>/5E]V?"GZ)69N(+3'"YM\G&9M:,RO#V<6!W@,--IX MAQ&R$!)24:6]]FD'3 W!OA,2T@FSMR(1289(I2D(/?E,_C_W[]KJET^?R3#% MP41GUDH=ZX=ARD5UO .H1BT\WM#/T07(D9*&1?':&_'<0MB0- M[C?YY75S_Y^/W1M54CH[)D(;*<46] 5PK3@S6E0!I+$/X=2TLOU[7,?_9+!PND'$X(^@6KM$PSGW&U1WL=X_E?GL]JL3OMS&[\@$UH&:P%H M*!D$@@7J/*LHPM FV$.[=]8/BEAK&7AV_%3='#XM9LOP**VIGUH_-,-:.XV, M4#X<8]HAJ"FMJ# ")A@7/PS?^\>J-<<_YV7484VQ_)&7Z]@#XU.YCZ3;SNXT MTYN-SJ!6BB+)'+<>6( PD;)R:@$/VE_N#!;M/@S?!X%K6GNRL?E4FU#3R_LS M@I1UA$HN*&74">:8J+"3!"74BZEG1_"4, Y]"55S]_*+I3Y;S:_5\L9&&/*; MP0-57YW>T"&K'\MOL^7\?W:)F('6?'5=SK_OF%JUZYOVZPW;#O4PFWWYCWVZ M\^HJO\[G/R+^VZGM-MC],TE,(IF&3':^FGW[5N;?]KO!?G[O&\0*UPW-N-+0 M:($08!P@3R&UVA&#F= 6:-/HAF-4JNLB>4\-RZB.)4H\=5)0@P7Q6*,]M=*Y M47LFGXS)[8]MQ6#HC'D5N2K73P0G_.VET(0?95&SWV<><2QXH-9Z M"\/I";3C%:&&Z#$=XV?%M_;#O:([)"VUV>9L/&K0O'@BDUA(IH.93<)D(5'> M,UC-FPF;:%V^EMB_Y%PG#"Z'ATG=4XW+NO%8]N?L9TS7/LFT9\]D3J!8&P)3 M9A16$A))2#5WZ8U-QXAKC7K1#^U#\NU36=QLKM2F4H M%UA*YBRE%4V<2)3ND=F-1;_RNC=PW@;CDSMG$^!W3PY\.Y]]6Q:K]?SZ2[Y: MUUS1O?IP!KGS-/Q/2&>,$I!#?##YF!$)U:/O"?&B9TA&<\$_=E/W17FHLG:H M\O>IG"^OY]\7=<7ISWI/!L-:T$$-%6$-"!2./VSQ 0LKVD=4#]S?IM=S? SH MQA*C$[.NKS]<-S:#QG(5=%T-+:%08@.M/>RB5),TE8"!^?NR./% */X>$I24 M-G%I@M.3VE%-Q(63\WZVS@_;Z]6N5LS)D- SWY !CR2''AO)B!+4AQ/^0!,T M8LRJ 4TS#/OC4S$&9M-H,!_ROY\"5"S#'Z_WF9CG:# U[\F89E1X@0Q 2AN M)<>55\8"3MH'& _<<6<$#:9?Z,82HR_A:Q]OU4W1+/3\M<.^(HRSW3J"3/#RQ5\"4MK5SWTF(K:]GV914CQH-MCC:7D M'$LJJDL<2R$>,QJDH5#T'AH>J2XA*^]O'VT^QA>Q)^*72^ MB]/+8Y7=/XKB9G6X$CC&^;->DL4<'<8QOWO^?K.!+V^N,_+]_/97_/%?/WP MW.GS/_EKIU2[%V58$<$M"?\!%L-@"%@3[ *KM ZZF[#MU=G!4K2&DZDAD1LO M=W<[SUW>QZ_T[/)"P@J)-=/#/[' ]PEA:O&VC#AH#.5!H]-&6,)0$9B^V/$ZQD>+[7Z1?/:O+=[3Y=8MWQBL. M'YN)$H'GZK'X*E MD9P&'(1"OF(7(T-E&W!"@, (%B5S"4$ZF;55.XG$0K%70K)R4! M5!N$C260[6OL\EAM=TS??+=$J\9L.R?1ZCQTDDNTZAIRC@!"2B G')662,6, MV1?*Y@@J/V;D2'\7O8UY6A=R?AXZEQ%Y#)!$BI-8>A+Q !!%W%8T.8MQFK>X MW5G4* 2Y'3AO@_%)W=$FPN^>W.@]A)P[%Y1YG\59>5[.A9P]_J#F>,",$^X#]9JH 4) M[_9-"CA6Q+2OZ#1E;E\;1:LS-D-R.-:K^GC[;(HG3]NCSV<&&\ =Q9!8(;!2 MWK)J.6"";*+!W)*UN3<[NF4?K<,ZL%ZL_7/YMP$4B5T@*MJED1+T%XE'D1SZIEKW0'IRK8@-YLR1J@UXMR+IS.KL"%8 M8T>TD+'QD[$5T81WR5#I/O2(+] MT@;S90\/7Y(75N_NO\]BC%(5@_3Q]DOQ?7[- /NX##CYJ2PDNE&006+(U5V>=7MQ)@SF2/D8GV^HA]1! MMH^\5%(HEDP=PS&%X_5-:QR$W]P5G<4VJ'*> !O4 M=XEW'GZ7<9I>ZL:C1I4X[<-X&XY/S+R7 M[W0N\3SA4=-701T*\_A+O/$C&"]L\]]"J*;_0[H69 MX$QPI001PE/.C(.^TKAB=_OV C/PK='(9_^H**>! M5?L3YH_-_"8Z]]XM=\3H_+8H\\HY6%]:K?5+,PJ=U!A)A84/_[.6(%XF0\X%KICR:"=AQF7>9B\SM=_Y_GR)$E!;U:WZ[QL+(U]O#[C M# D%C0]:-264:4VLK)##M$.:V&!%%$:7RPEP'DM"IRD71[052!%,C$*6 TV" MNGY@A.L@A0] J8I" AVM)W*%9[K@%Y1JS ML%5!N?- ^GUBBQ GTG@G$41!CT,0'PKM*4LU:E]N:C#AF?XB?T" QQ*\#_FZ M42&.9\]E3%GBNGY*<^L$9DV%G M#AII6"T: \<(E%6L9S+"GZO"ZN_W-7+ )G5NZ_-_/U MPPFI^?7A#'NMD-/>> B]Y\Q+=5@;V'6HJCE8O;H)I:0S?@G%YV^]H,=BZ?=S M[#*5S_DBH)_?_/^;6;G.R\6#G:UG7Y>S8&.L'TMXCOW=J5,(#FD.[QND!/SZ M<$:@4!HB[)6FF %C(^I)UXA 0"VC=+F!J:L+F3_^8.9#0J:26XZ5=.%8)7LHG"1$C"@,9]U%M>7HRSOWKHB,%L_Q;**UH4*O/9Y9S)U& MG'+-"9-&AX/35Y112VS:%TA=6'62ZYW0>4O\3_*6:&JV3V1DY->;,BI/?QW/ M]#_Z;.:AIDPC$M1M9I7ADFU+4FQI8D%Q3L]+WXTU+T_[CH",%A\5)AC+292; M>)#5G-V_/AP./0 YE]):P6,W::$!V%/EE5"T-9L'#G?OZ>SNC,@T?([%$6KW M[V-#,D I,DY; 9WTA@'H&*\H1 R9M,_P+BP[R?W."+U%64CR/$]!!,YE_9$4 MM_?%;+G-]@K'3=1-OI7Y=EL[G>MV>E3F*048F1^%RC&8FOW=C9A X668HEX M$$Y,B IT5G1!BMK[Z08+=NB1Q=T!23Q0BD9S%$KCN46&*,"\VM."E>()!A[T MR-PN4/R>@4_<> 80!IY0J3 2&GI4880=;G_6#Q9GT*.XC 7;6*)5-2S]>!OU M:/HN_C >;:=VD=JQF3+!MJ*::P]T4) M%JY"&5-BVA= &2S8H$=1 MZ1N>H6,)3E^D#QX^$$,MPNH*X,Q_Y)\6L^6X'_LP*\MM%,GD$0-QMP@[2'YC MBOOO^7*U*[I[#H39Q8Q*;A3'@AG+B!+<5H0Z M;<:4JO,N9<9G==$=OY9:6G.>'_7EOG@B,\!(33U%D$C(PW2=IM6\J5.)!E>T MQ/XEYSIA<#D\3.I"95S6C<>R/P-\]YO[DTQ[]DS&P^E&':/>(P\(85I)M$/[8/R;?:SGF]/G\DX1P1*%HPY93G!&%-5:24@'!X)N:U[ MX5L'VD=S1@1#+%[@U<2B/'TLHX(#YR!3&A$$#=5>N(J2@$9[Y^7042B3*3P] MP#BV0-0&*3Q_,)-,0RH(0MP!J1RA$L"*FMAT/DUMJ!MCCG"W$R*7SN>D-*8I MV=M3R,FO?K/P##@=<')J3&:1D8%T[#&0+)QGVKG]WJ6A)SK!@@YM@2^&@:1? M5M(6K-R/R30!#F((/%$V7H=Z"E U;PH13T>=&IR5[2#ID97GLG$_7XBEPF'. ME@-E)0W"ATPU7P)L^XB^P6[YAV%A*SA:L\_=?U\4#WF^G<>G37E]%_2\9@NR MP=#,LAB(PA'TV/!HF'M;G3 P&!'M$WX'N]WO@ZG](S.6+O2O?!5O"FMLH"=/ M9=A@*00W#F--$." $G_89JAHKP4-7-!Q>A.H/8HC2T.M8OSLN;!DPMN 0N'( MP?E:JV6RZ AE*M9 M^?#Q]H^P.:WM;%W34;5V8&:IDEY$(H"DR."@[M.* A?(2L\&:LF!8D!8VBO/ M^76QO&G#V?J1&4"(42,L=L(810VA[@"-(JQ]8=3!;*(>6-L[+JUY^^5N7K9B M;>W C#L,.+$B3-Z"V-O!H$HI15:Z! .B>^!LW[",=<#N-,7PR;HZZD^?RSBG MP@+/C9)*$,8-X[BB14K:/I3B?,/IPM3J+CB.EN+>&IM'ZI8WC1W70WPN')&. M6P*5]DR1P!%/)-\CB[T%(&TUOZ64O(P12P?8?T2W/X23M%XN6&*GD=2KH'.4 M\QA4OO7#?0W<6EU]_EI;4^3DN(PP(X!VUB/KB<)80$/VM$J%58(&T[0L_R5= MM3]P6ZOFG_+RMBCO8P.?5^>SVM3T;&W\@LQ3CC5D1&L/M<1*LZ#\[J./#?'M MMYKATE-3$)=!41YK WIV#?"Q68N3HV,RQISS00.6U)JP.G18)]6%D!*"MK_B M'"X+-@5)ZAO8UIO.AV)YCD#4CLD@4H(KX0G65#&MK!:'Q 8$=*/JG"-GSJ8@ M$'T#V][YUS:WY5]%]*5?7LMEVBL M3V<>0 X81Q19#J6G6N/#GLQ)AXO!Z12E_I.-$N7&J,;D7_64__62\L.E>E * M\F>D[VFN,RD'^6CT606>*V"P[G]WGY MI.K\$,+]\AL99$A;@K!T'#+GC3"D\J9K9D&C5-O$],T$9;DC[,EX_4XJ;OO; MGQV%L$YZ>_I,Y@PRRCD.E%"(Q^IZN@J U(*J]@K(=/KQP (\#?+);[]/2=PI M6RVRIM.V#UHS#QI\.*$*K,$(F'&_8,LB[,/ MA^)&\EOVSI^SBG3F-Q\VD:_[B(3: C4]?RXCEG%'@4?$4XP<@$I5AZ&QRK0/ MP^)O2,X3XD#R*O6>U&WTT^K=WF[X=QX7>7ZC?N1E6,^'T"@_FY?_FBU.%E0= M>2:98)8AJS%%1B-H#*&@\M@:"EE[Q[5XJRLB6>9,NUC.END,(0J)M] YXK & M5$A59=T8S#I4*)*_C>B=B6'RV^FNM>)C$??5Q_5=7GZYFRU?74%#[*-G3B%C M@9$:$V:XEE9!IN4AM=-P(CHD+H/?1HPG9\MEZ= 5D8>#HM:--\ G,^BX!DI M;L,6%,QE!6$5]68T!!W:-[ZE2\7$V)#\"; GU_T,YO!\E1\6])=B/5N\6Z[+ M^7(UOQY:BV[R^8QI*C$A$&I!/& P8%X%R!DG68?HPS=[PY@62Y)?#':^VK9S MCA7&_YR5_\G7VVO6ZLXU&@M#+((&G\T0MOBFV-1EC(9SX?,8#PK&((B+<>HH9U^R@%P&$VU_VP3=[ MVY<62T;/#0HG65"N7T?B0['\L?7!;(E>;:W/E_1]*-;_)U]?Y=?%M^7\?_;Y M47O[M4F>T9#?SQ2'SB)N..#0!ZL84B_VV#OB0/N<)?@6K_I2Y,G%KX>]\[(H M]S^*SYWR78\[D4Q(3*#FTL=2O)RK("Q5W$W,>6U?R@6^Q1O)I)G3/M O+L\M M&15]SZ:[,WWB+(^&ZS5]00:#>61C-INS1!B I7#VL/B1[I"@\I9N#@<%]5%, M!NJD]VM[N<>B/.HZ_'"^?OBZ#%Q[YYQ1,B)#HKAV=O0X/WGFHK,8/WG MS@-[-F+_N?,]_"V:M%CA/)5 41HV>XC"@>[XGGPLF>U@DY\M:Q.54FLL *>: MM)P'XVA7/BV;=Q"FF G'MHXU HETC"-748,,2KQ(<3O&G.[BT0Z12^?S-/P] MITG+2.SMTY;IHQV$M5HB"KF2" I-)!3V0#;@IGV0^%C-61H#WJ@=Q'EPC+4J MV]4V91HQY 7EFH)"$.*J8H6;_R8O>\N[$#N@F,RUSP74" 2"J,(5F%A&>V% M#.N7X0I92#U-6SMH*25C5(IL!^P_HML?PDDJ/!80KC>DXA@,R 6+C=&T[X 3W" MO6N_\5Q6I=.V0M0GN,FDERB4F[3VQ)'DQKU:UNKG9RDB5GJ V MZ[NB/!*O,\)7,PZ$52HHG\8CXJ U"E0<9P#R]A>>Z:7))2;ZO3,G^47P:B6$ M/\IB-4@@SO&O9>'P9(Q)P'G88;"4.)A>%:[2="A7FU[*7F)"WQM3+D78 ]*W M^3PFG@U:%>;XUS($(?&"$D)U^#>@""IQV$2P:%\'([TTPC2%O3M31A/V[8WR M:K7);^RF/!3IW9U+3Q,#JF(')V7Y[)=EACD3C!KAC(!&."45JVP;+@QO[Q9, M+S=P(%$=&O/DM]T+K-#E% %66L)MP,(8CB"OG&M<,M<^SCZ]-,#$-NAA.77Y M:V5_&O*B36AVMVT(XD5FW8UY5-9Q,!ASB"G@ G=66.P2%KV($A96N?7&P]%R> M25UC#<.?-[9JIE\J&:(*84EHV%HM5HX:H [X4P@O,"&,>UO3B[AFC#YM34D+Y-96348/,8.Q$*\BV(5 M=QKUUVI=SJX'B1ML\MU,6F !$LP[[\,.!KVE%=8*8],^1#:],VEZWT*?K+@4 ML=\O[1@7.7BTX"_?RH04B(3]0WIE+2.6*,XJ3 5T'1I+)"?>_A2+\W!3++87 :^6)]48A7Z$<-IXW&(.<_#G1C467WYLL9A=0@1VCLRR44< + JL:.-AZV3P9/3W6: MWI_;+S,N7/C'3 MO.H4, $D%0UX9X9SD+NP]E39J$-*CE@D=YX3H32;'62M= M6?9V%LU$_N)N$\L<4L8+Y0$D&CH'L;"ZXI90MOUYDZP;^7(76(^,O!2+Y6Q0 MIG"1]3?)#"&G4)0ZXBVAC#/AJJ _8\*&^O:\T8,NQTMDZMLY$=6W;V7^;;;. M1W.YM9Y3YA2&A'I"*3(>6XHU/6@M!J/VC4_2L[LN_ASLAX>/ZVR*?D^KU>9^ M1^_754S@L_DZ[!7SY1:LC[=^-B^W1'V\W<,R=0>H1BW>U&*[,K8DO&SB%MN[ MK=XW: ?5\Y"4"KO%-QQW2(U:I?-DSZC)Y.IH ZGIN#![:\VD%%,J[/Q2 M0NT1L#"F9._)=\QT:* X6C.I283A5&.I\R =2VUMVW#( XT##EX[Y#WR'"D$ M*FHTHR;MUA'M&'.Z\U [1"Z=S]/P]YS&4B.Q]URV'FDL]:S(_J=->7T7]JPX ME? H/=UCJL'03$KLH<582 ,!H("$N5=46$83# !ORX9B4&3&6K9?YNMXF+T+ MAMJ/^5+[;HK.[FW[\4+AC2ZX?:\^#,-V666BP9UK'(*_%4 45]A0<&-O&>4AUY M7"DVOZ1>^L?:3EETU8UM8!70XJ;V1R A)#@L($=*^ M@-[Y5WH7K,MTP329&[4+:%/(/3-8.1[,%@>X=%+LES4%@ .DT]:&6DK)&/T* MVP'[C^CVAW"22M<%2^PTDMIOATU,-84^E@)R"C ,'1&FHI%Q/:K,3-@^"Y>#\/[I%O'@B8Y!+'\YD2B"#B .H&3S,FTB1ID+<$ON7G.N$P>7P M,"G-<%S6C<>R/P-\]YO[DTQ[]DPF+)&N0_7"MPZT)Y^&<8A# M?1*P>HC+'2JMHO:CF<;2*P*,]M(1;IR!UNU11DJ"!,VV9((/4V%*,IZM8];1 M*8+_5<1[D<5\_7 U6P^2T-#\ZQD5T@NH4#"JA*=@6PFVPCWL7NUSA@8S69-: M#$EQYR)7Q=5\]1]?YC$=(R_SU7K,-?':MS-!I1.QQIYPDF'C$>:/.Y$E[6]? M!\NB>Y,KH@?>C+\>_BB*FW@]_:%8YL^9LOH24%C-KB-MD=39SKNUOBMNSE*) M>OI,%I7,P$TB -56*6.M"^_,=@A=+>F(AWXL>%R'IK]:6WKV78.6B(9X(S#JVA MD-/J4,0Q_;:UG ]6".V-R'D/W)@BCSC^Z!>TXYI=KO)_$H7;RJ!F CH/@U)* M!!.*$8&DXE$X; K%O?YYW78M.,WW^_)KPG//3$J$P9[1[FR6#/OG0S_ MYQ4X HT:#Y3 C7]C42F&0G@L%?+(C&L#&4^.R[A$")$8]P*\L-Q:BRK\+&'6 MIAD[T"L7FTE&)[S>MHPD%9N0KFCT%$\8-[^/MU^B)9#_R)>;XS$FIQ[/M+;. M&\H9C84PF85*H6JV*A@TZ=U/]H1^T3LXK5EYE:_R,/@NIAJ%[R^*[Y&PT_P\ M-2;3"C&'(0L&H4,2.H$ K>8MJ&T?#3C8/=L 3.T1H='<0_EB$:N&+6_^G)7_ MR=?ASWM3N39PO&YHYK'1'"(F(:5..^49J38[&Z!(L"5POS(Q$%!CB<8?^3(O M9XLP;75S'Y@02]]%+TM3^6@T/C/<4.8U0A@( 80S2%?+PA'8P8L]V$7-,$(R M!%IIYWYJ*9V61",;-")MA1%$5[10!MI7+[G(.A9MSBH" O-(AIX4B&K!$DTU+VCE(R12=<.V']$MS^$D[2B+UAB)SJ$=^=,?O,Z MS7L]XM3IW.@%&::0$: ],(8)(0R'ICJHPL_ F,4D)[J.;7ME,0C 4]RP;N[O M9^5#P&FU4=?AQ['PR<07J]T;+0T1E/DH,Y9S2 #3R$ J-:$$N;U?AS 5]/@4 MKD_;;Y;-KTP[?B.CCF- (3"*4<()]UK9/8[$>CJF\_#D->F8(G/T9G1" I'C-P>NCU,;"0CK^66K'P\I?1'^$5Z]6[YCZ%#$@&A$:><(Y@S%]3D:>CZ% M#"!J$$7>>2\10!8%?;SB@+2F?7.E]-H3OY4UU(F#E[^& F-N\_G4R^B7663 M*A'T?.FU9X$-,1C*5'Q 6+O^&WLI*Z,O'R%].!42]:GV_/:3M;YX0]/'\N "*>%!1P1BZ7PBGOE*O(MZ5"3X6+2'AH+0-$;C&-IGHV#OE_& MF@9%.AS%"!NO 0XH(.[WU$!&2>+-C]LQY@AW.R%RZ7Q.,BQ_"O:>R]8CI;B> M=07]M"FO[\*6%*<2'J6G*W(U&)II3""'CD$DH &2H)A*OZ0>.A(E(+X[$'\ F-OTN"8F-6%\, VUHK_U LSQ&(VC&95")H MLMIHQ&PL]:FPI-6\ SZ7&#XWAD#T#>QHYUZ=8KNOF[157K_D/]#5BL9AUVCO?DXOQFIXF1T6_"F%^2F.3XZ%U:&+V9-N MJYUDN?V',FFX,=K$L''@&%",:+U'DQ"(VGO?T@M &D:41\-^?$E^BF^L,.F+ M\E>ZGVA;3RM4OLZE;9U*_1!5KA8"/^)\,J$;4+&:K5>!EG.'[ M!@$\KSZ? <(98$ '3@KN+0F[)$+><4^ A, U4K &/^>W;3P?M@2<$67S24;FG%GA$_:O'KDW$S'3EU_"CMB$C2P2V?-W^M\O_>A,^Y M'^%?#:[-CHS(), ^EAWAL: WPX(A+/>@&.OH)82\M&?T2^'I!:/1%*I?9UM_ M37!L3!9L'HAU[*YLA:)$RMC 94>CI1;2M*^I.G.N7A(ZX?0V92+)^Y]T1"$) M$:CO9O;:\QF5G!!B'&8:"06(MISM:?- BA2+[W7GTVG.MT)F+*[KS2KH3JN5 MN@YZ^VH'^FF%X,B(3#*(H7?,6J5(^,>81_J0]!?0G:H_A: ?C*:4@?C',J\_ M!&K'9BC QBC %GH<^]% P.!>(P<8:Y6V@M"9DPTDHP^\?@]925)Q2$]$>KK2 M-\7]7_,_9^MR_M,4Y?>BG-5?Z9\:DQG@)>!,84>1$=@AAVDU;^Y,@G>K/?*B M& :EE@M_5:Z?+/KPMY<+/OPHNXI^T2/JP+/?9QH22:B1& 8M!PC++%'[.4.' M8/N%>_ZUS62'?Q=$!N?BT57[XHF,6T(XL(%61A6E"FBEJWDS04&:QW5+[%]R MKA,&E\/#I([1<5DW'LO^G/V.M';M M2^7T?CRV1KWHA_:QM-TOY6RYFEU'.!NXRE]Y.H,*&XLY9=H8#(3C,!SH>[H0 M%*0U3\^_MYW<*NZ.SP1\K[5J?GDV\PYZ ,)2" N!0TV0=:*B*=8A3?,([85+ MQSG>"9NWP?>DCMTTV-V?I7I?++<[U>?9(E^I;\% NS_EQ6XR+ .**^8T4M)8 M(*VDA%>SQP*-F]G;S%[MP(%B,&#&6KU7^2(V"_XT*]GOZDYQ)N_ M).,LG'P04AL[:PN D0"@0L%BV-Z=02_O;!\,MBF$IW;O__7AC ;M56A,"'3, M4J4H$977AAA/$D_7'()])R2D$V9O12*25 ?2%(3>U(2_\Z5:;N,Y9\N']_/[ M6(#__7SVUWPQ7S_L?URG,S1_1Z80"Z>A@)Y39Q!FFK$#74"24>\SFBD079A3 MC /3F $1\YOYK'R(.M#^L&P0+??JF$ CE4Q1CBU 5D'F$3)[&BFR'0(CV.4I M"WVA-)HD/,XR9F9^O#W'3JP?G"E&7+"WC-4J8 <4]I!45!-%;=JZ0P_(84@EMU)SH+7 BH1CL,UD$JHT#N4J.BZELLM\EF M-;KDJ7&9\TQ2I165)!#IJ.."5[0&);K]92&_0'VR1Z3&DHH74ZW5"EY]/O-2 M8 4P4)93H!R&!QHPY;*Q#7'?OCVLA1.CTB]+6E(4RU,2 BF8?Z3VY9:1?"7 M9S-#!&>6":,<%Y$Q=\_'=$:;3U_F2:M3O]KP]GV')'L/164 J1 M)M:H U5A_20>7](#MU[N 'U!]%8$(.US?DJ^3[3U!R,U7ZE/X95Y6>X+2]4G M6!X?E2DBC32:0F*UAA0C"'Q5YD#C<36]9H=^%V:]W.][ V8\#6_Y(R]7N[(R MNW/OZW+^WYO>D, MW=L5E225C*0EI*>;AOWQMYO)>A[VQ^+:?";X@Y[$^>YKXBW>K=:;6(_V2>W.@UO ML^M>DR%%/7,$&1,.>6 9DNY0O8$-QG>+:^#0+^\F3\9Z-#D!1FG4/-(K)& 6H*9HE4"0K /6\M%X.5">Y7 M+@:!J;5&\B%?MV;\>2_(#!0&"^P LPPBRYP_I+.$PY*WKS(T6!W!]LLOG-MNK)[A=YD..3QT+MZ$Q*"1P6S BK"20>05_A&K"F MIK5\G!]A/=&9T#=&DSDO=FK/P6B")R2C=FQFE#2"!T.*2,JEM0##ZF+94-\A M!?_\2*E)Y*)OA,:5BE>,Z:=*\=?OL21[16"MG)SUM@P+X)#Q.&RFQ *IF-;1 M, ]0<4R=;)_@>?XE^X22,R1F$S@S&ANE1X9D#".JI? 2,\:TMQ;)*EO) .#: MGS/G7[!,[:3H LRT)ND3_>EL:_3)V(P#:2#51C )B0X6N5!5K)'5"' M!RMW]FW_^?DJ'CV?9@_QLOCC\H^R6*VJR1XU/,]X1Z85QH(+80@%6OFPK[%] M@A+$1,,.=V&)^R&'AFJ\X,L PTY?L9N8,1)HFAG(S&;O""S M1@,EO-+".B5U. JK<&5(J!4=]H@+<4P.@M,4JL*_8P>CY=K]#,(_7YV4C5/# M,B+">6>\\RQ:5A(97BE%,""+VVN+,'&/Y0#H)+%;/"D%W'K#>/J.3$G'):(4 M$00( \:Q*F0-$B95AP#^Q!V;0T/U*"YCM5A[C&'[N%FOUK/E3:!F+_2K+\6G M37E]-UOE3U2F1/JC[>?XL;R:?[M;OV_>*.W(P$Q*2KP@SEFF!)$N*/Y!(43* M1U9YPIH(]8@4US5,.SXHR*0F+)QDRD#+$"2 <[*C%%O(Y)@Q"TWZI75FV.M! MV-V1F27=-VV0'%X?3"1)%0_;F?*,41Y0WP/DI!\U??^L4-T^>'Y6"N]Y0%U6 MTF98<-@QXRG !@0:(;2HHLUZA](.R>V);XVR-]LA];:D(QKRI3>$]#Y&1\_:>GWMU>3O'QF22 M0R25XT(Q8PAU3LD#6E)TX/K #=,&./W[ FE206B:R?G:J(Q!I+#$"%E@PS(2 MR/I*X'W8)!/7 GK@7Q.)Z(35VY6-)'6"M$2BIXNGRI6SJ>?\^M-&8[&AA7H6[\PH"B=A]IAB[FGW'#@1$6Q83S!7FJ]\*^8 +S. MXC+?3G =L(ISVU03G+TRP?@2%?YP$_^R:B8\'5^?.>=T@!DX";"P7GO'086& M<+9],/W0EYO]B]*X4(YU)/77Y!(> M^BQ1%\LK0^FU5!1[0(UE2AYH!!T*%P_<^G#(VZV.((WLPVA=H$S%^&^#92S; MZ8@25#M;486U9FGK SUPJ[Y263N(WHH )'G()\'WGL[U74$27]FU3:J_O'@X MXTQ99 7W0% JF52&B2HB)$9VIW>2=X'[UVHNW?"8U-U!#:>*T5/AF88(L*H M4IH'I%E8I1)4ZQ+%&@47XG,<2&#:(S5ES.LN8/=91M!5OLK+'_F-+TJ_66_* MO,H;2B3N]7D$Z5=TSIL'#-GNG!8J0ON]:/&>5ZHIKF*6/N M1 U.@5 X\[RAEDE&C72R"NZ00&K3OO+*,'&N;3GUTG+K#9&DXUL_+6;+6 .O MQMA_^E@6=CGH*6:<2J681(0(ORF-&2F_93K#7G MGC^8"8&@=<(I" 0@S' F:$4-PBYQ6[X=8XYPMQ,BE\[G)$WV*=C;EX6^S7I: MQLS:^8]8NJO&ZW[L^/9<1BZ#BU'CAM2((62-%10OE+2*R)(8)0FLD+6>*;2UN=:2LEK9773 /8?T>T/X215U N6V&DD]9D2 M\/'[R7B4VC&9",J@=@Q:[(,F@AB%VE4T2L@2;$XP+:M?)N'U!.Q8PG.5K];E M_'J]+U3X-;!M=?7Y:ZT G1P7=$Y##$=,:!X6KU,"PGT*H\286)R>-IZ4$/4) M[NBQ4+UF_!N.L>4X$NNP- @0RBI:O>M0+G#@^.DA%/X^D;JL)&_-L-72(X&1 M(CH6YJ_B"<-_';9IJ^ ]\:U1MG<[I-Z6-"2IU:8D!-,P?W]C7ZM9/'LN@T8B MSB!60AKB %6LBB"5&%$\JI>]2ZI_8YX4_:$QJJG\+,9A>]K5'?S'1V688>Z9 M\,!!0)W0!JM]#(Y7YU\G7[OQ- M7Y%Q&7"%VCM!F*>".(VJG9,8BA-OT-D+;XM1H?L=A2A-C2)EV>GSSG=?./G] M?/;7?!$0SNNBLT\-RKAP%"MIB?1."FY-C$??SSQVLDQ/H>B?*;_<"_>$UFB! MML5R/5]^BYD'15@L 8VMMV:+Q?QVGM^H/3H-:DN=]::,.1&;<"0H_DAAB(3BP7L J>E*A#GU9SZ]0/+W^ MVA-*EY+*Q2 5!A%N'0IG;XR[P-4ZHES0U#72[MRJS^EJ!]%;$8 TME=/,I%V'?KF;+?<(?(BK=K7.;X:3WG/GD-&@9Q*N10!< M4$J9L;#:*1BUI'TFU2!YM*\<-^XCLTY1ZYW]7HLMPOL./IEH]MQV??Y^O98C?_ MHWF^)[7-,]^5Q;5,PHDE*6(.:\PLJ4QV!A1NOW&.W$JKK; -C=A;*"R@PZJ! MQF$DN)!$:J]QE?YC"*+M-Z21FVFUEI%^ 1J_GL#6.W>L,,!^*IV^N+F_GY4/ M ?#YM^7\=GX=8%+7U\5FZ_;]5"SFU_/IO_\A\B]FMK4OE'#L#JK1]]^?J(G0 MYC49XBR<9;$>KB!.4@T-,HA"2I0 WC5KD]4KA<=J(9S[BDQ22+SA7G/J!)12 M"@MWE'&BC1LS?NO5P@C#LJL8!;6DBR>88IN&NKLGNIJO_J,?=+Z\O@M8U%VY MU W-!!3.(@DU$#88,D$'5!5,5&O3_C@;J,C"<'+PJSNN3^1&=,Z^F'8UZ7K7 M?,W03*I@X6(879K44![^#VA%,95:IGU3TQ]#:R6E%]Q^!XE)\FHG74&9R)TT M6T03\$>^W.0?\OJ Y%>?SP '2#&$A")> 6H]EZBB#5#:/A5].%=[;^QZZ=/I M :#1Z@[LCM4PW>M\_B.>J+7\/S8D@\ :(QT,I"$1;$ZK'-E3R+QR[6];AO-+ M#R4"/6$TW1GQT* 6Q8E1&3-$(^^=H'#IT>F3%!I,">8TT]X,));ROM24-/VD>0CJ=>MN'> M2XGH%:664K$JUT\D(OSMI32$'V5_SOZK**OI'DM]>_W!#&('".*30&"9E0MX:>,"[ZPF+(U7@50X9.G+2'WV?0.2@!@@)@)3%SCMC] MY1RW$,OV%5\'2BB\1+@N]_9.%$CHRJ(7 MOG6@?;0Z%Q'+_/W\1W[S;KD.!,>$*;5:Y;'BX$Z):U!,YXRW9$BP@)\VBG+" M'6,L1KCN<'#&F^22DT>[JA@.Q 2$Z7'^C>H1G_FFS @EH0_P2J8,5)1A6UT< M.FV,25,7&Y3SS:6K1T3_D;2D-,9+%K!IKU2N\L76V[^ZFW\_7O"GP:C,V)AA M;"V!7&L+]=93L:=3$-^^&/%P%7^&XN21ZY7NJ(TE'9_*(F@,ZX=8:'FMEML, MQ^^[M+$& 1P-1F>0" B-T1A8$&@7$+$#W6$UMJ_>P"Y<.^H?O,F%IM'5?8/1 MF:;& $4MA\XKP@454NSI]L$H3+Q <:^<;2HUG='[?:0G28TF=:&91EC>Y[/5 MML3:N_OO9?%CUSF@5GLY,2JS AL/,92," 8H8IS+BDY,28+:2Z_<*X9":BR) M>+>\#BK6H;S2^\B@R(C3FLJ)49D)M &! U%0("21"W^NZ!1(MX\\YQ>NH?0' MVL3"47NJG!R7<8>TL5@#@B (YJ/#MC(@/< B\0ZTO7"QF61TPNMMRTB2.D=Z MHC&-2/R1+_-RM@AGJ[JY#RQ8K7>Y[^YGK*A2G]'2:'P6VX42$O9;J"3ST"@ M]"&EV8R:2MM0\^B)E\7P:$T6K?XIG-?A![-O.3PA(*>&94&]4H 9P74G&#F M,2,5I4QW2'7I72Y&R>0? +/QCI8?88)%^? A/U4,Z^ECF0300ZZ9-%9A2RTD M6E:4*&_';,&;$O<[8#3]E":P8M18&XYB%KW2 4J\ MIQQ*U2%MH??R9J-*QP#8C:9K%,7-W_/%(ACT)K<%=IH VDP.K-0B$ A@L:;0+XS%A[6 M@ >P_>U+[]7(1I62_J$;+=\^;G*/PFWN9N6W_-3V\?J +!RCFDC/B EJE#;! MHK.5>@V=\.WC1,^_EDM),'I!:S1U\S#/C[?OB^6W[7FXN];^4NCG=-&F[\BL$O^WO*OM;1N'P=_OU^B5DKX<0%$6<, !!]P?,+(UPQ7HEJ%I MNOW\DST[&=HFM679<;8/30/$,L2'M$R)Y$,P06.LO$P3BI:\[C&08-B"QZ1K MLIBY %QL0;EK6>7W"91N WYI,7EU<:U#Q2IJO"N/VI)2RG:'RU9$C?GQ%'O3 M9C$9J<5.-'X0N;:!H/T/]M8N/;MC"]Z'PT46W2'CZ\!0& .H!4OB<\>P"KWL M1"Y_E^MNVDKF "^[E.^?KVVKJ;2$79S.VV<;(^]0)Z"<\!7RM($G*00'?GP8 MC.(3PK#L)BUB7OQ.-C$3B^X@=-;";7OJRD6;_7_-7^/_/V\>VO[17^[^W>Z? M'N\_/FWOFM\N$^!>8=(_778L(.[8PG!_.B3-)^XMMKF].WQ\^NO+I]WCYTV' MREE.WP&C:G065-J[D[ QF3@I].F#"[*&.&.#,I7GD?6DG-?S/\?S.WAL#4T/ M<\8]5)J\;W:ATG1R.^_4DL5A;Q+\%M7=2RZ\PNAL;HS(=R*-&M>R0B3I+ -P M;7TY=. @*%R253&S<>)DM8_@3QN'UM5BCI,9LM!#$SI35/$8#-/6\=C+&3RL MO*5B$0V.H,K*0^O7M8Y5IK*LS2BN9 RS\:=1#(!,2!^L,R""!1MZ>85QBS(U M3^=/&ZR]D?QIXU"ZVA)1L#] I"H8[I!%3A!8B/'X&O8)@273%];K8$R!['I& M4H[F705+$BV"%SY:#5HHWDMLM;\]?R-3H6/YWO-P^QTLYE9\D)48RG4,I$QC M "V#8J!]\N&D099$<[J7C9.^!>;6;'4-:@PP#J!Y^7,FD+9R@8&1B]8"-\@U M\>.SX:/,SX*=B;1U/D>B"$!SJKD<;:=V@E%4&F25EL+(FER]_E20!6_6Z1A, M5= @_LX\:'X-M:_J[;X*;1<*\6:QM6(EE/&1/#$T8$A$Z#?+9&E9/OTI;*V# M,;[ UCH.BUNN2N&,%*%.@AIT7G*%7!TE51/>QW/621Z M/F_WK>_2)L3^G N[@@#RVTFZ?P^+([\SN%8>28F*R6""820U0U59AD(X\GI8 M0N,"X>0SM?]CHLH7;E$;Q*;9 T>( 2-GZ=UE.A2XP!DHIIC&"$$I0\;.CEM@Q62D$^BV8S.'SRT/M]K&=5^\I;,9KK&$L\/"8M M'!ZW:=;Q_GOS[7W>I_.#:N: T1GN#:D+9! VTO)+*QH$SN+[E[6SY8":K$J ME4/:A>\^W#\,L()7U]9D0?JHE4YR! S6"28[F;QQ)C^:-%MCV3F5/Q6?I71^ ME/E=C;^XLO;"R"J U];H$+AWSMBC/+'*3U8I7C6_A+ZGH;/<&=;GKX>G[>-P MK9\94?N@M.!61"?!66VMXZ*7+Z9_V=HO7AF_A/;+H+18R'CWZ>G;IGTO]5_# M]GG[L&NG3KO] /;'P?>H48(&,I95%:_ 2D 7^P.#QM_*MI3BU?%+6,I$0 5 ;G9T82TR M,#$X,3(S,5]L86(N>&UL[+W[C]PXEB;Z^_X5O#W W1H@W:7W8^[,+$B*ZO7" MY?2U7=V[* P"R@BE4UV1H2Q)D7;V7W])/>+EB$B2(B6Z<8&9+ML9&?S.=\CO M'+X.__U_?'M<@^>\JHMR\Q]_LO]L_0GDFV6Y*C9?_N-/OWYZ S_AMV__]#_^ M\[_]^__UYLW_1A_?@:1<;A_S30-PE6=-O@)?B^8!_&V5U[^#^ZI\!'\KJ]^+ MY^S-F^Z70/N'=;'Y_=_8_]QE=0Z^U<6_U_NWGG[]^ M_?KG;W?5^L]E]>5GQ[+_=?$3[&]OAH^]8?_TQG;>N/:?O]6K/P%JX:9N MV^9H9/CXM^\^_]5M/VW'U%=/'/[!,_;_(OC.\/>564JT]-5C7OLKM\ M36&TW_90Y??GOV)=54??P!B*&4-VP!CZEU>^N'EYRO_C3W7Q^+2F]/P\ K\$ MX.9[L+K0M22\EP%YC=73+U2,]S,=NKE:Q-]_I6+,7443;96W#.^^\J+F-?L4^_HG_H/LF^_(K]MX[VH'GQQ_JW)-ZM\U8KFT5># M8O4??Z)_6FSK-U^R[&F1%/5R7=;;*K^]Q^7C4[ZIV\#R,5\SZ+BLF_K30U;E M3.57'[(7%L-J>%5G2C..I>7/4%UB2-H^QY2R#I>.84G*.W^]TA*5KJ^V:0B)4U,J7//^4 M5\_%,F^1((;D$"M%F:3.H(?''&_#X@%GYF=;^6R*3%0U<"UKP]PHPX-C,' MI4EC5"SJO=TLR\>)LZ8>6)EXV M1XF3!B*5R5.'S0R!ZK"(2Y0@OT:+E*@M?#(EQ=!K0K5Y;K(%R\YN[S_G=?,Q M?\XWV_R7_/$NKQ8()23%?ACX@9/"(+$A=(:FH&5;//HTJ@'-LL1@L7E7U8'B M$Z-QC%W7H,G($I.>EJ?;>\ P@1X4^*V#Q;DH,8ZU5;]EVXZ#^=D[@B/D5\EY,RKNFI,*!5V%@&-_9C7.?W@ ]RL$MK6 MNGQB/6AH#SH!<>T ^S9Q8IM$CC6L!">1GWC<0CNJ%C$LY.?Z8/]&?MIM_S4,.BLU]63UV M"?537C4TU2HV7T!3@NI"OP7Y-[;VE=?T=Y?K[2I?T3_TW]6FZO60P8U5^6M, M7I)Z)>P;H/=J["A5]TO!/;E\37_ZA;;X2U;]GC?TSZ3K/'VSJ8M1:#M!;/L^ M002F@3>L/B043RJTO3:V,=T[91V^=C@]#@@%M[9&\\FY2S4EE8(;3@Q+,M**)B:EK4+&4]R'809D'4!P3 M%'O(28@?HB3"D8>&-OS LD6D3>R;-4M8"P8P-&*2)4@/GS3I8T9,@O:DS++W M>T3#%4&1H\L,X9#$7JKH,(*3M_.G7:J*]IAV>E^CE_UG^E.>+; ]NLWJ ^U@ M[[/'O-_%H;/+ 6>3?R(2E3B^"@)!J@P\B*A"=\< #7+$OEC6S0OH 4H.#>< MQ5V<\TG3/24FDX=.FFD76@>CUZ:IEX+3Z?#\_N -(VK.4+XK-OG; M)G^DP2Z(;)+:+DZ]*(A@X$5.W*-,[019B^>\NBMY8\C4Z$1$Z= 0_O6QIES^ MWI^Y7A[8(!9,)G<:7QPQV5N"RY@7CL:#@S$,[E[.7=KJXL[-\:^UF^R_, M@AI6=2=>8^$B[MKBBUKFS=!5U4:=+M?HX(Q7!5&V9O5+/CWD>=/?T-U?X-W? MRO40"4CJ.W'B14EL!PF*8C])/2K)ON]ZO!<<%;6F;V#V $&+<'='_@#C;'?B M^:B[,C05M#!V,;>7W3 :0P1.1-28.:%2[)[W,*9"5V M]48MI7Q:-CF;8G(VP.N*& X ;W:J]C*3IO'0=D76E+)NAK*I-:G4V$L%;K6@ M;5UL\KJFL[B[8M.M=G7)RQE]M4/D^%:8P@ 2E*:Q1Z UM.]XEL-]RT5IJYJ5 M[@ 1R.JZ7!;[FJ-WO1TLT1L,XH 3#$GUH4->DT;= ME OKG;->A,UP99[X+U@0N6'>2Q5V1$Z#D3=_11;, 5&CUVE;H[IUB: MG6SSSR6\OZ>-48$=VL(1IK'-AZ%C$81C'(76D-*'- ABD;Q:KH6)PLO+=\%E M6;XYO*R6?:GRG/^ZY4A:^7)K_8R*Q0V*AUWXVR&:*7<^2\N59'D_NKYCC/3#L$C'?(LJQ:JF]4WT'9(P0XJ.,!Z M<"1CMA,9@F1>&9>ZW&+&:-5F73E-YY9]:> JGK;L\^?\6X,H5;\O(F2YOFL3 MY"6)[5HV:2X,D-0Y*"7"OJ*W/#O+ZZF%G)#WT\1<=+424,'.M;0" K$ M=KL$O]IL">#E1TP$-% C+0.S7+[GOC8OR9A98B *_H(<2'' =1AK=QF1W6?[ M0/O,0U;GK%GJ/K^OE13';FHGKAO%V+8LW_)H8T.S2>!S'315UIAFT6!(#A[C M8D#!@!0PJ +G?I1P>UU>9J%53'"ND=FR+5&/6 FS @>IIF98"Y6 MVVS=)JR6Y<5IX),0P\2/7(Q)$/9MI8GG^B*YI%P+FJ-#"XJMP>UAB267DKSQ MY9CZ*1-3_C-LS3+W/,O+E(G;ARXR+)#XJ4^M*"?#BA<*QDG.B/;UBQ'A\A87.^PC52DL71+ M:M6$3(NIV'F29YH]"](F(G**'&"H_*FR[C5A5,JBT R^9F]3%%6^I+S7;49X M^]2B&(J\ITD:Q<0*/&S'"79L%PVKB6GD6EPZJ;1!S>*X@]F]P3( [:D6&Y67W?/"^W8[2;Y/D6VZ*?]RI7Z-=U13^ M%5Y>F\:KHM6@J;PRD\Y-Y]7R)5QK=-]@WY[K(]].@\!-";0"UR9>A-OV?,L* M0H0DJX8*MR,RO*3J?YXL57;@)(M_BK/(ESA/0]^H)=X.U4P/;ESDYTHN/)Y3 M,[)>!79F/^]904@Y#5)-HD#6.1F9\ MRN]>0 8VM)/N-HZ*&N1L@KO.5]V[E\N=&45'^OAR_)NX25KZ&?JIWQ9W!>T MT2?ZJ[2%K :K_+[8[!_4W%U>'IL%7_/3I=17B6\-R'?5V%&J[O5\0:6NFL5' MUH';U>K8CJS0B]G71P2%)+2=W7?'R.-Z+UGL&W6O_C(@?,(FR,3U2*"/!,&% M689!Q882->@@OZ1_.\TMCRP^,^3E&)EW>$MB+L?T <%AVXM"8(=QFD#+]^S M=D++1H&]^W8OYGKV2/0[#1RZO&QP#EX-1$@-7Q7;*/P#^&+4EN7%D$$LBOIT M&$M9S3.0?RDVQ>/VL?_^*/'BT$LQ=+S C]S \['5?[_MNE[".Y3%OE7S8.[! M\ ]G04Y>']#ZZ! ;TCT.-2L_7(/ZR/(+PUJ.G?D'MB3N#[W=) M (GOIW&$H]!UPCB&:/A^GT#$/;B%OE7WX.[ " QN,4XX!KG/_N7/N].7/].LJ/Z:K;8G48/N?5H[U ;IQ"S\(HC8D78H+MA/2 '1A;7-F/ 3!U'\KJ MP0#ZNX_@IV(#7O*LJO]5XKGFF=S(MTO_@WA0+ -4$**8>:"U#QP8> -V_8+9 M.,-KT%I<=25H&= _S(A?)A!Q[GUH$WPC%-6N/6A]Z3WK:X#_6K)#S*Q*],>L MR1=^%*>1S1Z <*/4MZ(D)NF W"8A$0YO,^.=*LX][V!)A+BY?2H0ZWX@=YH7 M]/;& F;M#/%/K_M>"X2&=!Z#(J(IC)P+C:9@FR]&?BSJW],JS]]N:&C(ZZ;% M'?DQB1!RXHC$@8M3QPWWL3WQA.XASH]6]P8XQ?3FOF('R'I4H+JF?*;Z=(8( MJ=V=QL1'9BE@IH+!UA\]/)[SW53!<52_^2<,C>/XT!D8%7A*/"S^I2Q7[.+1 M^W*3'Z_EUI^I%776'M!E4+/NP&;S4*Z.9[=L]\FR+2^R?)1 & 9V$@X0TP1R MG>Z8!=B/L^@YF:M$ YMA7I*/8:TA[>GT U/ 8 LX,.8&[,P!G3WSKV,J\@57 M3)K0Y::%GRE-OQAI)N=_XJ!R,B^T$B=!5IK@T LPBEW'QM& U2>6T*-8\R#\ M<=8<)_7;I*%&H\MFCSF&+",J](_^."39'_ZI I(L!WHBTRB/3!2BSL[07$)L M[*5!% :AG6#?#OUAAN8Z+M\]E3GQ_5A+?A/Z;9( I=UE%CPA*8&Q#)_'#, I19'L# @MKMHV M&IK5?>/AX$V[#NN;%NR9P=T]L,99Q46' SA3P'FX%\SLU-&N^3&[UTB\EH&I M]X09^JG#L(MOU2GFCE)W5=5MZ(H!Q0I,O&Q&2$1Z539KF;M?&7@WKV %B]H 8O)IE+V^71S+N+%A%.(\UD>.A#@\8IV MZO"&&>*IQ;)2?U]6)I_[]@]>%0N]!%*U#IS4(VF,4M_%<$"1N)[0$Z"JVYY5 M1F^.!K3X2X+*'3%:3;7[0*6B?D__3(\N"!(J)ZVC7&.\O(ZSCE]B%;#(*[-X M6S?E8UX=OO8P5.A. F0Y;@0]R_/9&XTNUHEL\!&J@.L8F) MY"@:^01Q*@;%Q&]'WA&LF:IF7Z'HBIRI(-8,Z5)B2:F^VXE)4I(_Y^ORB9WN M6CYLRG7YY>5C\>6A&5K%V',0;0#Y/IN=$]NVAH7.)$ZAT#KCV+8T2],.'FAV M^,2$:329?.(T)8]B K6G< \-=-AF4JE7N+JB5*I8-D.ME%E3ZNF+8JKUGAK- M+DTT.1Q*=@\-0B^D#3H!S=MLVTW] #G#^F*2V&(;(R.:T:Q5K.I_#VU?M5Q, MK,9PR*=3$]$G)E%[4&"/:B9QNDS0%5U2P*H9DJ3"D%)YCQ-\>;3*5CF;-P[- MA(C.$Q,/)UYD^PDDOA6$0S..S_=DGO27:Q:=%@_8""]JB9/$IR]:^1%3E8Z: M%LM,6G)*QA4%D>;-#-V0AW_Z$N*/J0-52$WA7+?%,7FR\[6>I;M+$; M(QNB%%L$Q;Z-PWA89TJ(%8;<3Q2-;$>S9]XK&,BGP8M&$C,J]672Y:XY]!.BZZ6?T625A!CP$I,J24GUW$A#P M-'LN*W9RY5V>U;M($9'4Q;:3HB@A$#LHLKR@;XB@,.6J2CSBZW7O<0Z@P+I% M)2 MDG1Q:+-^I@1W(G=K&Q8GO6SDL:.XX4 Z1U MI &EL@ZB[)C)NUT99XB($R6I3V@B'D=>$GJ),S0-HUAH 4])@_.>R^.JQZZ1 M;;ZI^.1$"VJU HZG/B?RCJ.0O5+:S9C=JS6)_QB(+%\*M.\O55G7BP3;.$). MD/AV[,)#2W7 MMSR/V#:5SQT0'UO)8I-_8;\T6L1D 7 -S;@;FH=8N4?H 3!PB$R9U$E3/UK\ MM'*N10Z%G3&U0EZ@5$XSQ_K'>!4=;2"_KJKA4H'2OL^;!0YC%, 8(P@M&Z&4 MA 3WC:9^Y/B+IFRR]6A-Y6E*:#*\0\5_.B-7EQ-R,3=:%%63IE8 K_$YM=91 M+'*Z)D*Q\1HF9 R_7HES-%Z;?JWS^^WZ77&?+QP+^AZ*'8BI.,:6%4;Q<#@Y M]2++4C5Y%6A2^P3V;SD[Z,@R"_KKV9<<=. 0]>6[/T_$B5[U; ]5M4TT:Q0 MVVX.V39%XO:T20F=!.NFRYV,2=RB)\V7@K3L8\[NB;$MZ(/LL'N6TEYX@>TZ M?I!"%",K=E*"HN'0I'MT8-.]J?">.I&Z*QW8BMH.M63!'^FAT9CB9 M>]2FC'OW'.(&'7!3E/8JN7)9IA)WF:['BJSDSTL5LLI=1:NA,L-.)-S>?VK* MY>\/Y9KR79,_MD7SLJO@A3P_=&#DP" ,H&>',&0ILDVCB!,X,>)^M55)8_I& M^PX?J]UTB/"_@P[C;*7ON)B[,I35,F_&P%5LTVF5)@V,"0_*K@I4Z,9^A*P4 MN:[MN![T8SL8&DDC(O;RF=A7:TY\]@-.K@*=($^"*J6>(EDYFJ=0W!$//.(B M1IAA*B((_I)BH(AH)U!,4[[C;I9":E?9X5&:4:P:)CSC;+FD M0PH8XI6EDZ;ZJD Q2; 3N3 ."70\DE A](>V_,2U1.1(KH6)94A,A21)XU,? M_7R-4YV9"HV=I>6*W(RCT0R9&6E#J;)CBI6W\0TQ0YQO@D13M98HIRPM-,]\C/ MD7)%3T9Q:(::P'12Q^SHHI2Q /Z)SLA /HA5A'WM" M-02%OUVSC'2 9#1$@B@^ ='+D9AZ'-(S5T7 4SJNZ(8\=6:(Q@C\IS7_1C+! M*Q=PM2K8YDNV_I 5J[<;G#T53;8>ZG2Y%@QP @,$8S] "8J@-[09Q$3H);IQ M+6F6D3TXP-"]>;L!/3XQ41E))Y_ 3,>DF-BJX2=46&U!!LAB0I MLJ74T04%I6I_^/JV><@K-CFK\@=6\^$Y?\M*?.5]^\2U73L(X\@+'#O&T$)! M/+0?1HE0QJ.N5=T2=G"KH44*CJ""#BOXZ5U9BYZF4<@\I\+-0KJ@VMWBMP V M357<;9NV9D%34MVKN*KOZ)$[7M:N29]RY@V10?5VG4JB)N9XY?%CWF3%)E^1 MK&(G:X::#5:(7!LY@16ZGF,[D 1!.C06";YV+]G$A,*7Y/?%LA!//_73W=LYYULP149T@2WWO7P):8J@E3IW6U_QU$E901[ M9BC)& ,N;:;+IV6U=>L6BVB%*+02F"< MQC&F3J=_2WH4%% D]*28ZK8U:\\ %_PT /Y74&Q.3NM*Y3O*G< G5W/R+Z9E M7-0/!Z499-!CGECO!!F](H:Z?&.&4FJSKIRFAXMF::=M+K!+/!C01CS7):QZ MM>,->P>QE=CAXJF]>T'#0-7PYFK"C8B,UU,\W$,79?2ORQQD#:"3<'"7?RDV M[;6E\K[]AZ?K%Y:4$XID[K3EFZFM9)4VJ&6(TQX+NT M;B07W)+S0+M%?;MMZB;;K.AP6U@.M$B*'!)X,$D3$D?A<+@A#I+0D5 \6A9UOEJ$@1@!7S3G\GJ,8,=Z!E2*Q%.7\N\M/C'$-W49]^YO$TC MDR-UMY/]\T"P%]H8D=A'EH_=-+2P/0"!3D2$+L-H:%ZS\@ZC>9#:,7F?!NY' MZ>Q4M$MDCF_N,L8UVW'/-W57F016%?UVG_&;)%F)M!@F]V M&ERSQ;XY*IN(,R\NQRK<:+0>*S&03Y#5<:DB$_Z8UTU5+)O^ED';N[M"T&D< MNS&=]Q/7<7'DVK%KVP.6R.)[ET@O@ADRXJ=M56\S*@--"9XI\'[.7NULZ#^^ MW13B%Z^U>&E\FCR-@Y2GRGO8?=;<*_<,=>VEV)5,FL=[RVBA5F6C0/*LBE$E M"?1E,&& B!.3*'9=!]J6XWFL(E8'Q@ULH<>.-$$P7; U)=XC?*8@^9[&7>KD M>UC6-5^_7^%7-LT>[S"C%5R9D2+IMBI.5:3P$'0M2'98;%?H^KX>!#,K>-X#[S_QU$,'3_1;U&7;(QPT M/MN>QC?*L^T!=J_5 W#PX9IG)D^V+Y(KF6R/=Y;14JW*1H%D6Q6C2I+MBV#J MA1_%=A+B $8A3"#];^B& YK$#P)EV?8(# :+M:9,>XS#%*3:$_E*?:Y]3;U- MRK4O$RR;;"MPF=$2KLY*D71;&:LJ\NWW^=?V)_4BZ MH\@."%&57_.W.(-$4^&E76J3+]L=KZ]%\P!8S?4B6U.)OEL7M*_>W^?,HANP MR=MBW\,_T%^L52YK"WAF?&*MQRG*$VD*L_N &;I[3)UDFBQ.O=&:*FN30!HL MRYB2M'??N(W\E*HS3; ]+_9AY$3^L#B"@M@5NDFEJ,D?43$U9;L"?E*0W.IQ MD?I7L-1'=/#?95?7^:[?1='M_4)#M8]X6 MF_A; M=LM#;:XZV.U" P-^=%)9Z(SR/.Z\KLC&>U*5;G=I+QB\?'L/CJI/]B:!SR5H MC=H=MV.?O#7?RZMRN67'!KL7GW]8;Q^9P3]T6]?N+@[TV516@XSMOV_7S7#= MZ5EFC'"VT\=O'>2?B?*S^GC>7&!>TTL#QMCXO*++:&0P MIC@F"&/L(9NX*+9X4(6YBO'.@\R@S,+\1G=3,Z53S/,\*NR/*,S9^9$ M0Z.CQV<:9CA<+M5XOV45S-JT@%FQ&Z;[.S6KKC>P=&.YK=J"F_TMZ]4V/SD= M*"P'FM(/:8\(YA_Z/6]N C*![1P9R%0>X*_P_O=MW;!Q6'\N+]1M;C&WEZ,. M[U!]S/_8%G71Y)_RZKE8YIU]'_-E^673?DN;;"TB+TH)=%(GL-S(L5!$O!UL M'_M(K$C\S& U)RIM/^BOH2T/KZOEW]B?<]%J\W.[EF\Q>G:<^M*4 ]-86#DI M@0_V)?!OCJX@'MK(SD?W5H+>S"'3.3!TZLKY>CUV9>W5%ON,DPY4A9'N^T%7WZ5!I#G"_;JH\6Q?_:/=:NP<'UNS! 5: )!L, M>4/!OJFI*> QJW[/N^)B]!,+)]H?)48M^L6?XI&+"^=JE/!3E\TJN/%S'Y9)0< MR:41-36/V+FB:'(LFJ%*DMA+%?U(T?$3FDGOCJO]K6@>/E3%<]:P\]?+MK0- M!7=[?]N?4,/L@-HB=+ 5H\1G[XHBQT=!$@R/;V$GMKE.1L^!:YK3@-F&+;QL MGO.J*=CP>]H]KWMZ3O"I,XG=<>EL&G6&>A9/CSR8,K.3%9]+84\Z[H]^,GM M;Q#860286+-=HL'#V' /*SJ4,K.GY3:*/AT.V'Y/J-\'>FX]?N:P+^^@UGD( M19QLF3,H&EUJ[@Z0=LMY3Z!H9W_\ 10)B*EKH2AQ+8R\)(CL) C#/43+2=2< M/]$ [$?-+72<3='A][%'4V9VN>J3*7.F&OJ*F58-LC M-G7:#AW]C]82_I*8ILDSCK*):X7]6[G17-U?UGM\B[@F.DX^6WBM]O]-FQ10 M+U(#0&\!^*FWX7(":,;+ .>9O[*T/+5OS5B4GMSJL6\+*&%]_'05+KM#(^WY MD>X<995MZJP->*C<;.D,.HIC MG]C=#QW9#$F.SB&8D05\V]28#,$"8.JSEE M>PO>[(Y$[VT =\P('5-/%3X<.]6)-/Y9N^$:?UAGAZU1*S0 5>LCT&9]*4[EG>,KY';T[_;>,/;+2'+QZ09+4 M@DD8A!A&"8I)[%MQ#R"QXF3T#47)9F<.N,,$K6:Y_=<>O:)=10D?C-P6UDN_ MXEW? 2S' VO:>5>T6:N7?TU[L4.OWU_CT[G%^AU%,CNH\CR;&[[&&L:[_SF6 MN_'SQ>\10)S8B )(:&@D;FBYH3<$1PHH4;1[*=ZNB<%)Q^Q/PB-C)WMZG:%Z M;JIM<%NC;S)@M7%TB2FH#)4VUNP!IM&??T:BQ[*O;'#J9X]<*S M;"=%@>6AR+<<9/LV&598DP"C6-4&F%"C,P>KNVU=;/*Z9I>G[XI-)E#,0SW_ MX[>PM%&O*C3M=JP.D9JS$76(2G*G24PC#R"7N4R4NA8T,;I0.$&"7* M3EL)-SR#B%+MI-":=0XR^@^/]%_61797K-LKP^J237$?C$\XM=*O/.G99)R?13VB%&J^A(TP32T)'\*4E%O\.00-^/(I0DD17%5H!"% \E M!(@=015B*MFR:6JJ*1T5]XB"E%2K,]2GI8:*ZWDN91-4:9\8+:]C;1-)5$\^!_3RCY'97''S7CB/H>#XD$8E2F*)H M6,(E* UMY;4IU4/4+-F[3:8M?0Y%*#9[E4_0? MP*EBTB]2D/+H:@(U[4U7<;DW#AQ8=P,&^UZYISA?-4IA)UV)*3/W"C."S]PD MR-2;U.T3WG"&MX_;==84SSFYO\^7S>W]^_PK7"[+[8:5A?Y H^RR>%KG;S== MK*71==5=VEK0B&KCQ L2-R8D20GR4CP "KU$Z#EJC3!TSR1VR$'>0F=I:K9# M#FA.0MTI%HET.H4OVACB#[&(YIO#QSLD+, TY]J8?.*'OVTX4*> MY2LA80+7F2'[4QA:3CXLU"V=X[;"1TT;9\7]=]4^]D4E%]!"T(\=E^ 48>BE MGA,,1QT)\4-E:^GCD,^W M^\(9!O811Z\-5CE"#1J D@:<&U1CN. >*.TPO=TV=9.URZN+T',\$B=AY/LQ ML6-LNW;2MY-&GN4(CQ/A%@P8)EP)C)XA_^EX&X67V@"(8+;+?W:9<+LYV,K&F706IX5S=5MFP6 M,4440MM/(8IM*PA\E(0X)&&2QGX2PM=N2TX+1E^R>HB_34OW%K05> ]M8,-S M9P78FP%^&PSYKXD?(5)!_I6Q/:USS="#B6T^?7AH!L9'ZP[*ZJ*^O3_$A_K; M(DE>+ZOBJ;?@8!&>_O*2IMZ?\V\-HO3_SDY:0L]*,/$@\KS0"7P'#9BM,!!Z MQ&A>I)I700Z-:R5JM4?.%&JXJ"/XUMV\SAT9;(SSJ[(@= -:VYAC#ZVC_SS< MQSHPL.T.A_NHO8W@-V8E:,TT)42I<)E,Z)JTJQ@>TJ;E@C?4S> A[H,XY>-C MT9T:HNU3U*SQ?,.:3HIZN2[K;97OPC!&:6K#"#I.&CBN&T>N[5F!$P<1C*V$ MNVJQVD8UGNS8XVR%Z @IV$.=+5T6(O+:X0TM#C%#*S39=GI$0R.#O&,YR>^: MMQO:1%ORY3-[/G$!TR!(?"NVHL1"Q+*\U$W[EFA3!(DDH3+?KSEU_+1\R%?; M=7M)XUVY^?*&?L;5P" Y\@F.8$(&@'D2A)%\]Y M=5=RG],5_GZ1T7((16KK?OJ@?T3&*X%=CC@SAL,(_&<"]!@FY((P_%;4"X>] M(T-PF 1Q$J+4L>E?AH92 H6JKTA\O>80?!(GQL18/K9D0JQRHL0B[ E'=+Y M\EXGSWF2?F8%9M%& 4X=&/:9(@MUPLM M9"=#PUD^Y+>;O&^#V&YDQRD."$JQ12"D\^&^ M#6Q9"5=:*??-FL7\[:9HV(&F.NL6-3=EPUN83I(I#N'62I*85/=0 ,4B(\WB M] B(L5::Y.1WH*O$7%OFEV?/C!GT& -.%_K'.%&X9$>301"$1->&JE$CQP7UC MC,T#\Q5;^.OS'902%-@XP<2U_2 *TC0(AW8\SX-"M^2%OUWWN9T.4'O(1/ J MNSA1? *BER,Q]3BDY_49FIX;>K,$(T1^$]OS(UD@FLAA]7\&>H! MG:X;(8AA9!//BTCHP1B'V+'[YI*4.%QG#48WHED\VII'WQ=$$EC!&,4@QUK/ M5.2)J&IX1O <(FE=7*T\65VVAD3W2C]GJQ9EIC.\7(ERQM%HQF)WC@32H7=:IRH M]%-1$H1I:CLD]7'DPBBV_'#7F$U/8P9ME,.$O& MM3,CH\@S8ZUOI W?52[>2#8Q MF?3<][CD=$>4.#'1T*"RHSB1*Z#D!7'6&C6I* YS=+S7;&8/).1:3*@7T3E"7YQQI5U1,(>-F*)I*@ZY6[5' E1JE&^XM M!6X:N%[@QJD;^9Y'\%!1@B(@/E:G=9P-FJ!VK\U<--*M0O$T,*U!\PRH1G:> M.&G=$^3]1U ^49.$M$^*+S7JMR\@X0>VCRR2NA[V88 =C/?:&T3IB%+H\FUJ MUL /V4M[P^E9!:9HLCB%@(+'Z&Q?(3CVQJF#J6IU!(=U@ M(H44(5^)1FKB78-*,J1FZN2>0WFEE/###Z&5,G:)J:4T MP,B)$^BZ-H1>%*70#E-G:"UTD%"Q(MDVIEU/!+\Q9*"%-FK]4(!$&973P]\H M3>.C;@+UVG'#K57B;)JH3!)67-4A65;D5 =G5?5",P[XR-Y*7?B>BU)L.\2& M@173!MG]KK[) !);[*6Q44V)C""I1\<^#R>\;\!=657E5Y9X92VX,1(DRJB, M#FFD4DR,3F_(_Z4JKSPM/H$*'3/#+462A)JH1[*F7!6E4?SP*M.'JESF^:I. MJ86L^?=YY!*+ 3F'L[R31]UTQ?5+0H':5 MHIC 4X\3,-^+WK%7R2Z?5DU,JYAB?3CBLE,MQG%Y#P:(H,4XK8J]SMD5+5-( MN!F*IM*@4EOG%+B<>:*FN_>MTSRGL\TENZ/V);_=_+K9UOD*#=D(SIZR9=&\ M+-R834!CSX?(]2PZY4R&NI?("5V'OW2(9AR:9XT'&=N:37KN\YR]V]/#!N4& M;%O@8+DS3"BAF\15US74-"^-FYONH0.*'>S!@]L-Z."#'7XP&&"0LP0NLQKD M-+E[KZWSBKWS#@;1Q8&VGS@M>T/&7I<=1^.9(#FE7T75^PS!^- M$+?WQU7G/^:/W1MO9T"X*(:V%R11X*#$AEZ4#E,:!_G(%RK_I[;I&:+JZ%"J MRPM\,Y 9'2"X?L((IU./DQ]8QM%B,0)>W$L\7U[:#Z. M@A&'1$>2N?HL2=#!9Z!J M@H_7Z)Y@-?HR?=PKTPH\8(9"JC?KZHJU,MXDUG?>;E;YM[?]F&=M_D+U^7'[ MN/!1Y&'H)Q9MR,*6FZ1DE^E&5LPEB"K;FU +"X;Q6 AOP&.'4WK"+T^T\"K, M)!R/6VUI(8(!8RM^X)?9&)9>.IF$:35+)&8%(%'KT?V+H)(%O)RBQ MAWU:ESA\MZR4-#2E"#)P,NL):A@53IOUDCDN7VZQ'>?+4W(IG2#KY51-9GRF MGZK-B+\C@2\5EN?.N!QXA"F7D]^Q_(R^*U85RX--PP7QTL1'KAVAV$.VY\?( M'<**2Q&-2'KEVYQ2[D\VWN_!_99.3U9@565?%5T0$V5<)N6=ANR1&>\>)&A1 MWAP<6#'D7M@Q>=SY[GCZ34QW%5C%>R-L%&LRR6Z_MW=T@F)!<)0$GN4'<1HF M) H"F [7=EW?(UQBJ*RQ*56P!W@BA_+)FAR[XLFO=F)')L #K\>'\Z;F53X1 MULZOHF3X?/]5G!"?(X,S*1[%HWF)\3ASKB3'"GCB"@8?JKQ?USP^0G=_NVWJ M)MNLV&F/;,V.K"]P9%M)B&BCH1O8+B+8'LYXN($7Q]Q!066C$P:'IQWL,]ER MN8<.[CKL NJFU T+GP\D&PQX^- M,P+L7(HW.@@V(.YH,:O4W#$%XM#?LJK*-DW-[D?EJ\\E7/ZQ+:K\TT-&N^AOAUIA&B#/Q]AW4Y0&H9?BH3*E"V%DH6^,WY%1WABTJ:G,,1I^;WBUC$VKFD PP^EZ"'##K,)T&L@PV@(1X1"&3S M>T8NI+TZ:*Z-F;'Q38JT2Y%.KP<,B'F:#2PGZ\TCXN 'VHT?LCIG5YW*S:>F M7/Z^""(XIQ[E,%[I(%VV@$'-$(.? MBDW_HW\=H:A2Q$M$--V)]ZM;;S.ZOKVO@=P6WTLOCPTY!L-5T6=MSM)NQ_6 M_4]K>^''%K*0XUF>Y<>I96$/#R4&/>3[0G>E]""8,:8<19*\-P0\,4O:P+(J MU^NL:I/$+LAPQAC-+N/;*9_?6V+1J,7+XGL/BBH$:%'=@ %UMW]^\)EZ]Z&) MZ^I(D7ME7UVOL\S89==L8SEE]Q>3[J&=]V7S*6^:=(EP\Z/APD1>O%.<=.:Q9I! L\,$QOD M7SOL8IJKFFL^L9V19LFZB 1CL&]@:T+FCQ@CW@:<55C,PKJJK)*V;( MJ2[CRDEZML0J"=N=7?@N21S?BEP/>K$7ATGJ#;FUEV*/_ZR2T+=.E:.R&HP2 MLVT^9@36*Y23(BE2GW7R(;',H)R7D>L)K+^H6C1@MKVV.B!DOT'+ &*XS\WW M)2P?4U'JE^P;NQOZ?>F5)$YC-[:@#8,P2) 567 X-N^Y& F]$*JT8,Z M4QEN?.$H>;+YDL/9>!93W7>7BD8-W)M8,NH2CU>R0BWN,",GU&,:1[$H1?S) M7?-IM3ER_3#V M=E,W566C?:-V3%A.MTR(BOURQ_)T=_;P0RQ3&<\>F;9KK$ M5.R[ZS=7<\@)KME&YHPQX.H]&0DN9)X$H!/;O/Z0O;!Y[0(2#-,H M"; =8AN'OH63X0:.GR#HBJB(=".:M>2X5'V+#/30Y$O_B['(IRN3$"BF+C+< M:2_L?\C-%:493:<9>C/>C"NE^T?PPJL]'X>CM_7M/7OGALD<$[Z%Y2+/BP@. M$LLFW0;$L/?@^Z%8(1[I1C1KSQX7FVD#-*Q?U,,//9-<8:(=\:.EG;%O5#5V&=/5.2DI0V'#H!?Z='%*F=*-"FA@KG1<'FHK%I) L?P MP/#/!_>,&.2)\Z;7"+R60"DCWPPM4VC/:4JEF"FY=:'#>C.?&OH_JX/KM2[$ M+DWM8B&:S8?3R+M]0JM]NX&I5L.WJS^6 =$%L%Z6NEUH1LC%TB1TD M[H *)Q;A+Q:@'XONU;6C"V6;O %9:P2H.BOH?PR! MSPX_Z T >PL >@&=#53NP6 %NV0SV&&8[T0*&YCE0\EZ!T^ LAZX4QTZ-?M*(&J;XS.Y@,T]$O6& MZE$T7HK2T_C&@ ]D:'EY/U>("RWW[VA0.CD_O;^8]YLJ\W!'!\G3AI'!"/H MN*[MNC[VAK71P(EBKD,H*MK1'%@'=-W[1C0%KUJ YT00ZE/VK6Z;L,1U2)[6_),6]Z7M+G[D6@EV$HR3H7$8!^&"RL5= MR:N)BAH5&:&'^+@'*CZL/--7IEEUH[-[@I"KL)F6DVJ#UEU6W6;SNW-?@JCQ;"(' ]&EAVD-@P2SXM11(;%Z< +7:%[ MIRK:TYRU'([/&_"4#55)E%2%4D$W7\(R-=-BVX$I1773G2'EYBZ]E*JJX$7Q4EB M64E(K#2Q@Z$].F$4.@(MWXIFB>M+5/?)1U?T;B=I2H1N!,%\\C8-MV*BUM/: M@;KI*];-I&,7^;F6O8WFU S-4F#':8ZFB!E>?2)_;-FC0&>*+&$_CBW:%DX\ MUW=PZD5XT,,01UCHKKM\*YKUZ;@6W&&I3C$5&D$CGPI-PZ"8"G68C*CF=I&> M*R(TGE(S1$B!':7JSB:^KOTQ7[.*4L^R?X1M3?(Q->Q%=+,OYP]#\,2J]H] M4+!'RIX)JT&V6777R@:T[:6RBH^8H86:;#NSY*V+05[-'!;: MR;>G?%/G[6U>/R;0IE^<6-CW;=MSTA .+=DX#$244>;[ISC+P?:9\@Z3F/I) M$<:G<;JYDCBIP6CJX=S,<'?_#"-7%&D,?V;HSB@+2G6]27!Q:OF0K[;K_/:^ MG6*BK&X%C37;GF&!K"SEE[R]98M>]I_I;]["KUFU^MQ6,0G=D,H:30H#Z&*" MP]"E+&*,*.S4I7\66LR:#)7NQ:_>$#:U;&&^N6,XP:$QX- :=JST\(/#9??6 M)/!;:]1_"2Z/3>=BSN4T([TKN/PVK6/U+-NI\L.U9;[)?6U&-)C![M-EQ)F8 MYSJ9W.U#;]A9N>(Y_T"'%NVCUB_YXUU>+1('QQ Y;NI:<> [-B*D;P_9J8>X MWA(:WXKFR,"0 9)X,SL.-:NB_.TA F*;7M\98<+#,# ;QTTSH"H@$.!4\>3 M<2EWYOAC_D1_VD:FYH&=C;POJ\VQIFQ_VI+='R+:>>&)?M\- M^/I0+!_ 4U4^%ZN\;HORL-_XPJJ9M_?/[OM?[,)>QF2E9M^;/SZMRY>FE7C>@$/3:NPH58^)L6'&[]M#GD5LU[92#R8> M#-+4MYRA/=]VPG%AAK<5_6'&5Q)FN%F3#3,Z"%,29GQE88:;P[%A1@>7TX09 M_VR8T:+BOH2*BQ)KJHH+V_&JBLLQ(ZGB?5NV&T.7MI>$%DQBG\8,!P]M>5;" M=5AT7 NZEX_.C 7.DI$CF9-2<0VDC5=P->K-R]LHY=; GQ+5/B?);6U@]D/V M;^P(2#<1H!]:;]E$8#=MZ*8).WGO_CHD__U7[U[*U2/VHD(OZ -CS'OR!;1@F */;S$B#% ->D+BVJFM7)H0E&56?5R^W]7]B2<9(U^; >Z,,X MC5B[5NP[V"66Y0^-$HJ$>W8WOBG-,M$"9*6F!H0"4Q4%/'+,]::E4$Q2.O8. MP+'2-"T\P/#)S/\4D"HP$9R67,WK>/>G?9G-$]O=(+"B!HV=W+W*U:59GCJ2 M#9CN*32FU-(115;W\6O M12@9"U10R;/P-RV+@DN '8%*PX$*7D46!J?E5W- J+_KT6HCPNML75SX4\>S M 3%!I36EGMXH$!4^/Q35]49#XEJAET20%:V.8.QAQQX:36+"=7E>45.:8T(+ M4#(D*."1(R),2Z%80.C84QH/%) J$ ZF)5?[-O])7U8;#%[EZE(L4$>R :% MH3&EEHXH^I)MW53%LLE7[<;4KYNBJ3]^^K5OTPMP9"&2I$Z2>M!U(QM[?9LQ M="'7,I&:EG1/#;J*'R=%"D"]O?M[OFS8X"JW3=UDFQ4;:Q2VX..2(VGF6X>> MCF&Q*+''U=6) BTR\!.C\5]?CQ&:7K^]PM65U6LU')NQFJW(EN\>PU7'$._; M9VU$I#:?;;O>UGWCJ1^ZR X\A%(;Q2Y$01STC4/LI5S7Z!0W:92N?> 7-M7, MD"2(8 *M-";LABY)+&]8?X6> M%6AJ6_O#XI:_\]RO>KJ^0\/ M$*66'5I!Z/A.$MIQZB/D[M+!T.,[2F\,6,TQ8PCZ-7CHH('G%CNH6O L_&4ZZR' 3@U1RB KDH_G/'$:HS M$W1VLIW%P\<&0&^KW MY)E O=&S% +R3[W0^'3WNSB<:#_EZ5[%B5P5C]#$8 M_>Q?/$=CD.,-6 \RBH[2T $J,4>^>QWYW2GR#_W%TK:._A'T'C,K;D4S.FAA M%Y((6:Z?[LXNH12&7(_@&@!3=W[TC>(HV 7=]IT)*F7]2A=[7_YH84PF(S* M/Y'YN/D>GGB>?@,&\_IW2,KC/.AF2(!FF,-K<=9K<_MY>XA!<_Z9B3BW%F"" M;[3'/?+MJ:C:#_=O;]J!@Q+/<6,2V@%)<82]X606"A)+?(EX$E2Z#];FU>-A M+&O/(>:77ZR=VT>:8Y16]TP>DO;6S/(0L3(OZ(@UTI[^P4.+O-VJ(LE(YK5O M*G;SO>[R=X?07A#L8$A(:,$(.F&8^BD:2GJAR(="Y1DF!:8Y? RU#)ZNRXL! M#M*\V:C;-Y/'CGYMM_?O;.%#D2]T[$2.<;E!061RTU7M3H[G7_L$,/40L1WD^0%.G:&L$/+CA*O&^[P(ISAWUJO3\E#%LF,5JP\^]]2K M6-:I6/L?\-RK6+\%C9_#NIZ*1T1@'Z#W(,T]'F?P@SU&@ M!*VAH+?T<";X@_:02<[QS--3E)SC&;3@Y#Q/[W=V=.>B"K4OVLQW?(>;=/7' M=]3[^X<^OJ.!#C7'=W3Y2?L20G?]IF8X\]7[+;N%TS]G5R^\) B);Z6.E_JN M0RP;PF&U R<0U5,=T!GE2,U+ M %/Y/^6L\";K^!S7M$8NZN9E&9%]==LO^%X_BVER8V(1YQD>5',21#8VZ N=;<1S:A>Z63=9'?""[Y$N1$^R2!_+$MFI>WNQ)@ M]6WSD%>?'[+-615=!#&!R/4"'*(X@7: XMV+JCCT(O&C,B: -GW/L*VYUKP< M5&JK0F& M"<%'O2MUS!]T]2:3 ^2CUV[0[4P/(W<3&7M@D1!:,[#"AN4=D.]"V MW0$NLBU[^MTI"9"ZK]^53;:^L&!W<"NO*??O0Q]=-7]N[9IC!TO&X5/N8FGV M]=P[68?+TP:_*4]]YTU:2&,G,$EB)W(\+R NHKB' MO;#$M_C*M1H!5'.DW)6:VI4B.YH4TK^S\]SKO*Z[HV[MI/*QM6686VZZTHW# M%[5SS[+J?B^K&]!465NV.A52H6JD*O>/[RA M]D-5+O-\5;.6NT)K= C7"Q>[&#GTRV$261%QW-BUAL9H8$>+Y[RZ*WG#I&0C M(LITB(<_Q/6X.G7IXAI[Q4+P04=9#OF"PP3DBX/5UG3HL'G>;FB MGB.)-$/WQAI1*NU<8EIS4,X19T\%G4UTI\L_YC2%?,Y7:5FEVV9;Y6_K>LO> MX5J@-""QEP;83E*4^FD X^%$26+A4%"&U+>O7:'@JGM:+EOWAQU U8.5/P"A MP0U\2C8O_V(B=UQ6MX?;7^PO!N[>HP!9CVUXJ:)?7GGJCM%M5NR%;Q_^2+(;9=7^0K8^_"9O@M.) M@+V)-_T>46_EM)%S$L=="9UF=1PS8J=AG)0F#W5#HF=_9+ZL^G]BG[,74>QZ M-@KC- HM$H:0)-90Q9"@&$9&A%$YZ-J/H3]UB[[];68Z/]T%6'9N+J-!MLI8 M68\W] MS0(6X$)R?&D;HW(%6?S>8*^(R:\^&W<[D=I/RP.A_DOA[UI]S!.)Q M'>N?/"*/)&>JT*S"AWQO'K =C+E@ %<&P^BB^+P,GHFOFEQ@ M0H%Z]4:56KNMX';F\B%?;=?Y[?TM[7KM-MF[G,&!=9TW]>?L;ITOD(.2%#L$ M.A;"EN/CU*&AD"";!%%@N8'0=J2*!C7'H $C.U&Q0PDZF*##"7YKD?Z7X&ZA M$K8Y=_NF)EHP^BC@6,\N&P=OUW;)5-)NQKQ K4FGNU3J^1*X]<+"[0O;[VK@ MIBV2]-1MC'VF7P2_%?7"2L+43>W0=M(D1'&*(?%)B%P<6"&*8J%R@"K:TZQ\ M \1N*[QI3TCL8-X !E/X5LQXCOD$;VIZQ?2.@UGP&\,XL=QQL';]-HTRSLT0 M.Z46?7_/1C%;HZ6.M9N4CW3*L2"1Y2<1\2./Q"&,PS"PHJ'E$"5"A\Y4M#>_ MU('?.JB"69X2LD=JGB:>-6C>:Q1/JWI[WF143X)UPU5/QB)>U9-FBVN1]?;^ MOECF:;8LUFWIRT_9)JVRS9)=LOXE9X>&%[$?!;[EX1#"T'>L*'5=.+3J6CY7 MV4A5;6E6NPXA&"""MQM 08(=2H'U/17$#0XH3AXQ=''V=K4NKH@IY-F Y5*4UI9[>*)89LR!T>W]P M*K;-PJ%M!5$<61$.G-2-'8)MW+<5)3 5.M,BUX+F>-#F7N7]T=EXEIZ]+S=O M#JOV?Z9_K+.EQ,T(26+Y\E[]G(K% QDZ9YGNGR7N2JH[CF@SDMN1-I0JNYZ8 M.!VT4M/,F?:F@\YTV)=ZB;2(G<8IE4/?]GV,4]NQW0$%LE.AJG:JV]8L:(=P M%2N9$2>HA8EO8Z3;FP]"Q(=?Y5$5-Z5Y MO71&A2$$+43!;:*QU/)ED1.R*KB$.H90+2GB=:JN9(2*.#8C 51E3*FE'XJI MUSM6ESP_;OIC3L-6MOZ<5X\+Z(1NZI$D#EP8N4%,%=3K-3.F$(0>*1[;EN[Y M\;Z&)/WM1[98U89N,'F#XII6M5\BZHENJ M:#9#N)194^KIC..EBS5W>X_+35/1R?&"0#N"$0R@Y5O8=E)('#0T'"2AT+%L M! (7281_&[-$C7 M :L.C^#E$%&B^%1))T=B$K2C)WF%'CWW.HYYN"(KLHR9H2'2Z$\O9HQB@3_- MH3KT=L.>="J>:5JUS(OG]LJ'EX1^Y"4VM -"7,N/+)@,S26Q(W3Q0KJ125*: M8@#&#BVQI=;=W P4CT]5^=PMJXIF/;*\\N8Z$U JFN$PRG:8P![4U"G->6JN M)C(CV31#>L:;\5W2HH07N<7NNJO._TNQ*1ZWCWV!Q#K9Y@N?2B F",:8X 1: MJ6?O]B)AX"&A8Q:JVM1]7JQ]/?ZQP]6KTU,/;\RR]PB29=:_I^%WU$)X?3,\ M)M*C'(K4UB"9^K%93O*XE\;'TV^&T"FWZNIBN2K6>&5P]R8Z>Y!N7=:T[1K> MU=TDT0IM%_NQ2SSBQ6%,W-1-,4T$B05=-_!X9R6CVM W%AFL[E5G< ,_#9 MFWA'ZAI+5P:=$G+-&&EJ3"DU=#[9.AN[QKLM,+A9O2NR.W;LO6![^1E#L[K= M?&33+_;X+6)%_]IK\)_S;PVBY/R^<..8V&Z"<(@=FXJ A2$9,*(D$=IVGQ:9 M[A68@ZH2:;%A%PAHVE)LJ&^W_?'$IGNC>/;IVU;,7'#+FJU9P+W4!'Q0T0\ M+TD2R_+]%*('4##NT"K6'@V++9XY@.+_%,9>;H%&9$M7DIN#1UFL\?.F+<'HOO MLS/4A/Y?FL1V[-L.1@,63"RA[6D]"":,4CBKJAVOM+)[^'G=%(\9 MJT5^&)WNVY^Q^I79YN6_UZ#<-G5#?X5]P2J_$]P.U^0^];%(C^>T!YL?*I*H M#A7B/OOQ8H&$C2/$7I917C7?+]6Q$TO[$KD?V>..K/9[W=3?/6=V@ HZR$I# MWX<)MIS80Q#'48OD,'+=>.Z;B.O=B-;4SSNM0;T-D)$=IEG J3YM3I9#&NG_(V M=/3FWYB4=B]R;)MNZ9;]C,Z FRWMTR_@/J>]-UL#:F?>SJ3W,^6#+Q!\WFTJ M5_-IK(E>%M/CG07@0)D9TI-UV/9=-99 SZ;5BKB^HNM3>].,&#"YU:?/F\W" M^KC8<@*A23NI^S1HW]&'%SZR( YB'X81F2V&P5"]Q:GP*,YIOSZ MYT]_W@4'&@GR]I#*/FZP>*$B*BAVTIB(,)]_=$4#ZK'>"+"SXO27=C'#A$ A MY +A(*''P28'"$T6?R^N%E[@H\7S+33T_A7:4 MTME0#\GQ[53!3$,1$.TKLTQ;NACPTR9OV 1CB QW^2:_+YI_51\*Y-VB+@9, MXA%=XM^YK3V-R. ??)[=YC!6]"]Q/E+M1[ORQY'Y\:9*Z+LB?E4*^_MRL\I7 M6_JQNW5.NH6,\^\RL_7E14@@G8&0!-, 9&,[C,(H&( Z;LQ5:'-&>%-LS_4; M/N*/'<_I-G7A8$:/Z0H21R:!WJ;C[;WCQY>I808'#S$/C0PIFKK#CQ-H=!$@ M$7ZT^D)E4*+_B*M\533UQ[S.Z3<_+)S(33&.(@=%!#K0C4-VXI# V TB/_&Q MZL C 4'[!D:'H\U65^P0>MF^Q066'4[U04;&#>H"B68/Z H6[ <=;E99L -N M<##XGN61@C_";3^.J(\Q4D*X1W.J>\:PL&R'>+Z#O=B+D>V.\*:]!E.0_H3?&5DC]Q(F^L.)\C6D,^SNV['T>@QYFI M*+<6Y%6E2*=EE1=?-D>?2 KZBQ4[.9RM:7)OIY%OA0$F"8J)%:5D2.XC+XI\ MU8(]&I!F\>[QM>=Y5@>XU*OW>->H4_))O:)+U0?7G7[NT!"#1?XU'XP4?&4N M_G'$7YW)$H% ,=\J@\)M\Y!7L(%L *=>O)5Z39VNS^4P79*_]^I@ M4?O9OCS8SBBPL\K@D"#@FY'10D MU7#9W-[3SAN>0=6/F.Q+OHB0$P1>$J5.'#O8"T(_WN'PL<]UB5Y?ZY.%D%4/ M[__^E\BQG?^GE:><5>X7>$-6#__70X49U(L%@W8GE.(%%#!@B &%##K,@_Z_ M/='_/?#9'2+P\N_LCI%['I@1OMSVU3C_SAR4+=N#RPS\#5A^-VK:U=&GG0EC MGPN6H>U, -7O @,>'M9K7SE59U87YL[$6A=AG/@DBM,80?;B#8K3'@1T;<(VF,=3).&!_H-/.O) M_(@VQCB!<#::0_6E/19Q@#S+"2/?3\(@)H'EV<,U/^B@P%TT[$F?,8N!4LT* MQ; =0OX1RWY%5PV-USD=LU2GG4Y=JW &+:F=XU!XM6R4(TQ>"!MGF'2="D'N MN)]4V3X]K=NW$;,URM9,=3\]Y'ES\*C+05'*,,3(MN+$\UV1L+(O)Y"%,,+#= CU^06J^ MAT<$>+PBE5K<8898ZC'M]%40??SQ"B8NU_2O)5/EYQQ6%H00',(\*8\_%)E3P_%,J/TYMG^N<#(M=@!S) X20SCT"&V-TBU8SM)Q)OM MC&Y(8XK38[L!A^A "V^V\H>O$G8MEU%&MAEC4:$]IUF+8J9XQ]W'_#G?;/.4 MFDJ^T3B^R=9X6S=TGEG5Z&6/IL5R\F):XCH8TE'OI'9(;(0]&R4](M=-O40D M==&)0W,J<_B.2]69 >Y>:!*SW3258!*CU1U\ FF*)\2DLT<-V)@% VZP \X< MLH<^*.K,[[*,8/J*YD[A/S/4>!)+R^E'AYB"_Z4L5U^+]1IN5F_IG'?SA5UI M[ ZXG4O?'!05,S16EW'E)#U;:@[Z,7\J MJZ;8?#G7,B2V15!,\^\T(3@)/"N-.PV'-HFAT.M6*MK3K9G[G*G8L,-($@7R ME- J-+F?C%&IZ3W8P3-#"#E(>WV*KX1R,R1/J47GI_D*V>(6M]UCZ>=KR$&V MQ5PT+RJI/EC M7C=5L6SR55NQ^-=-T=3P:U:M+J%T"'8]V[)M&Q,;A4D4^@-*-XG%D6 M\^WC8U:],"W_^.G7G9ZKU6SE_E(CYG.Z2E#E#T+N9<7?VP.ZAW9;BT!KTH\3 M#@2],B).Z/+_CQ% M%DO&%GT>F%,R.F?H&W!M-ANG]I3I?LS]W6]?>S^[00D MG9]@C##%ZE@DL&#@(=2#]#S;L<=&'(W0IIP][$&"+=.S]JXF_=+'8M/=:6&O MT&1%U=YR:7^E[#X^/C[I=*Y\>#+$KVJB4V],%X!N^IC4&W1S>*/LH!N8&)WD MG2(8G";POKFQ:0KC.4+39#X0CTRG+QRD9?4][OU9M9I="5MV5:4NQ-[VS77T M\H$.YQ-;(DA\/[1BQ\=^ )THM4)[L 6[L5!!;#,MF&YBU:V*??^LSN[EYBI? M9RQK;\K^LWV48RMIZ^VJ"XQT:-7ENEBUGV1O='84=4%QN/ B&Q=-L!]69V/O0=VWX"]Y==FDNTWMB>$& $&A>0)'*8%>",Y MNI@'&(E6+%T8(L/M?4IG49MED:T_E'71IB[#T5F;) Y*DB#RHQ0'812'MNTF MR$JAYX2^$_-*L(JV-"KF (^)W0X@&!#.=X"<@[9K^J.2=4/D0JE)IZ-;/5^\ M@_%#U5<;:F<2'[+JMFK1K-AL(O^0=^*RB&S?1LCQB!4B&WM^E"!W:!P[EM"Y M<45-:LZ.=RB[A/<&/&7#(L]/;!&(7;^I:E:K"]0,K^#;PZIXYY/!&2@7$\(] MVY\ZMBE&P!+&%F6[$I.S6@I=1CBM&/*1=T4.%;-OAB"J-JK4VF/'B&+;4@VW MS4-9%?_(5PL?>QC!*'%3#[J>XP:ANU-BG$2QO!@*-S6U"&8[:*T*MLI7CY(^ M<79E)$\KL2.EKL,&]N#FE+=3HKAE39IA$^5,WIBK,C:2HS'R];:NM[1!.G,C M$6TBM.DL+O*B!,;^T& $?7>L='$V,[5L%2TLM9+%RZB\7&D@4XU4=<#FEZD. MAZ!$";)JKCR)&L(A35+1 MRB=<4_$I)EH]E69,!J]0=$6L5!!KAE IL>2[2DVJV)$6J#ZOBP,[P79LV9@D MV,*8I&$\M&8%R3AQXFQC4F$:.^^3)E)2D#1P.%Z,;F:9[UW@1D2%!-DT5(%$ MK7A-?:18D5:>PVPL1*'MA:GO!W1^"6WD>XDS-)D$*1XE/R(-3:I!2J9VXWB5 M5"-=E*J0I-FF=-=8$A$G&7(-52@I4UZ3*7E^N-X^>K]]O,NKV_N_Y)N\7K"7 MPF&Q9*[.[^/O'"..5:>I+X6LTZU(%A1XN^,#@"K^$(LG-=7S03 M(Z8F/2>W]^ O>CD1>/U''S=R+_N<])NQC_4M M>P%8V'CMC;(H"R(\V/,R7^MJE[F5V:2P&J"!IL>F%XE-(%(M#)N'0R/5%/0= M48%/;]'G)/RZR,Y([#6=T64$7A;\J&SW-=.78EUA'"*K)9Z*Y%#Q1[,OUWBW MX>+OR[OG%](#CCGA**0L@9CYV!=ZV"4RIQ$+(BVM/3/]H,C[>=3^"_#W79;,KUI+=9CAI332^7 MU(YZJGK>A'T=L;[93E7%;L#@0-MLO0L+>O%D1/J(6,_5G,N0]-F\O?B>: Z6 MS1X2=XHV(!2H6/<8E8@P^;;7^]/N;3VJG/(,'48V&"HT3,.#Q% M01:2 5+, F*8(<\!D!D%OGZ"?'O UR"CC(%U3YOOV9S,IP$"/A$=P6 MHL_G6U#+JK4RM,RZ"FY_:\X_P'1:<-' NO/"E=O6?&)0K2Z\H&E!GVNE><%A M$RYM8G#IZL69P3F_^E,#[6]T"BQ=,0&Q!GE?YE\$G'U9/$]HQ#S":9HF) A" M2 0R*/=@,=Z"EC)L42G'6%KH"?KUF,-?N 7.K MV7WM%#F[GN%>D&QK,:RDV&[:;&EB[8%F&J*(^'[B,9K"5*PB0I@-YOTDT2I79O!3G M+]W:2[O>O*UV4-3C:S2!I@"?,MF=1%.Z9T;[&SA"L)FPN7]\=ZK)=$SM R%%*4L"S\,^PC#TL1^Q.$Q\2F%* Z9R MP=K5^+NU*:V.U_R>^+%<0^]WCBQV+5S^5#RH"@ MP4P0,*6(SOC#'4=N_? X@0(2E9H(F1,V+NBS<*6GWYHTO1)"-4,,U13K?]Q5 MW_Z7\+(+G\07SZ.F2PR\HBN3R;JNC$R'7UGJ-+HBD0EUJO/MN]VF^/Z?Q>/* MQQQ[PE!$HS"!/N*(AKV=(.-J=>?,/WT>F>A1@186$+ATA4*;-%6E<,F7D52H M4V5/+)Z1,*H6IH0M12Z,\;_0BVE,J C&$,Q\%O]BE4$_\Q*"(,_2C 1>C&@V M?#P,H=))KO:'.I:'8\0MP:AK@AXO;TN!,TH,%WNC;-@8]N<.7QCM1IQ3WH M"$PP\N+ 0QR3S",H2K+H:(H'H>HX-S;@>,CWN$ '#$AD!G&!.7UO:\$LS.G) M@A%I-D3B$A<7]&(R==>7CNDN5!:[DO868V?PU^*AJMOGJ?+ZFW!5-L^(()7Z R^ MJ.]$,41A6W@"98F,>J1BP@0[< M\*!45S,,:535#O<,&FF(+GGVQ.150D9%91J%2Q&7B5Z\$!D;K&B(S??/=;[K M2L1V)S*LI4/C26-5^+[?:H67$8PB@* M&0U1 ),8>>%Q6R6.$DTAT?KHF18U$I)I?*)'E?*2QA5+9BL:)8(L+FC.O!]? MSYC0M!1Q, /_?ZFV*Y^&$/&()MC/8I*B!*;#/1 4 MX519"_0^U;$,]&! AT9= #2I>7OLNV-%;]@K$F)CP#]Q^<)8-Z/E^L/<$'_/_,PY&0P!3OJXO#Q/QOP@$IC&A+A?_$O'& M?^ZJ/W>?BKRI=L6F+2%5KR"%0IHRAA%/_#0( R\<'I:%E/M*]9RF6YE'/B2Z M'_^0\," KRN+5NL*B3&;JH(R!Y%&PF+ H3V)N<#*J-1,97(IDC/9CQ?28X<9 MC8M@8^6A H+B ">I4#[NQR2.*3P:37T/:5X'FV)JIDMAKY6,5:F(YH1=55V: MC5@C<3+FU.*%,;W2QRIR];'PY=MN>;;*M^OD$RGG'*8 M>"'F..8<8??(\HM0A BTD70'2XDE5;UQ19"0O2NS8DY(SWT>5 MPX2CI0B%$?87NF#.@,XKV=.5>2[^IEFE&"/BQ3!@-,Y8D"8I\P=+)%//E6'Z M^8XEX?C\\_R%1XM,_ZVL-G5OZ\,WZPC'9@U?> MS4YC0U]$NI/@SA8EOD?].(Q$T\+,"V 8'>,6/V'*E\O,+H^<8L@AS3[4>A_'G.PS)>TAR6'0K?97THTZR E]B MYY7A8HW0963]G>Y&9;FCZ8V;?Q7EW==]L<'?BCJ_*X9*JJWILZT%DC=M&3U: M;F4=GA4*2(8]/TLABA#E)(APT(.)"0F4CEH=0W \I?=;:X>FV(!RUU'36C=T1E';?7,C38M9/5K&-@6MSSW*I8N\$P MR1(*&:0^CD)*PL$JYIG2TLJ6+<>*_(NR\&ZJ[3:OSWY14X,GDVX6<[KD>VKH M>77I?(,LC4C4E.9EB*$U;]Z(2Z>QI%]0[:>JVOQ9;K=M_9.5#U'B\3!(EA'L"1 )9V8%T_1LN XPSVKQ#,#Z\B^*Q24FDZ@F4W/PIR=/1M0Y MKE'VA)L1-9K*YC)4:+(7%VN(36%%576&-]9X_>]#V3U%8=098X R7GMH8DZ>F-G/PIJ@9A:; M"]2,B,U4,IEB([^LBX)6]WFY6S$Y#>K'FL'A^+Z:%=_OB MOEG%7BB"6(PBGP9>X*5^F.'>3@+31"GUG_FG.Q;BT]Z/A 1:3)I[9P:,J86, M;LG2DV ]GIP$A"_H& D S:E;1L W 7]EJQ.9Z<9'T8&^YDV!U^OJL)/7'?#F MOP_-7LY0S2HE).4>@6&$PP!3S\^R8+#M0^R9:,DTBW/I2W[$9*8N$WG54YSY M*#53H1LP( 0GB. ,XW64:90V!;6R0_NR%,R23Q=4S29CJDK'RUVY+]Z7WXK- M.Q%U[^[*+]L"-TVQ_ZTI;@]":6^+%8I])&0V9,S' 4,AABSI3:=A3)4*25LU MZ%CG3L! +I$UH&CVY7TN[U,<6I1@*QR8>6"J,#ERF%'U1N4 M^%[62_B?=GWTX?:9]6;%_( &6<@2'J1^ZA//PT/,DZ*$:NV/3S3E>"">HP/% M]X=BUVANB4^E4BW4F)%%O1CC"8'5+3A3M@[;O!(VSM.(>%DB>!FR9U;O& M,..%IV*X8#AVE]/T%I3EEE&3Q"4TBIY6GK>'TH7/_HH5D.!!B_YJMZVT.%:Z MC>6FU98AP,Z]O'B;RR6K^I*-Q2*SU181Y'XJUH>ZW)=%P[ZOMX=-L>&"MZQ] MYM-/*<_!GX B/^%)BK.,TXS"%,981,$]4(JI;Z;FL\&;4>CS,Y] = M5T#VUOYUU3%J>SD[F$X%\[6X[BRQR,8VGT#.W0$G?P![TL[9TW9^[87K8J88 M6PVD-/O,WAN6-C'-3\#%.>M*;:&\67+<+?U8;EFL1I+Q$T#U 2$,?\2SF) Y9XJ=IFE!_,$\R MIK1NMV[4=?S6004?;L$96/#J"-1YKV2?_'$]NRKOFJ'47X9RC4MTUZ+>[$[= MT 0B+FW.FB _-<%#CWCJ-3L-7B[=NG-![0(NX3EQJW+<)?7"MTS2L-MWEP%_ M+9L_R",I=NNO M8?[2N4Q$^8B!9]XB4T)@F./3R8#0G)M Z?)QMS?I/Z#!^0 M ,$1WUM/K!RQJQ8BSTJLWE0RA5,GT?);7(W$S-9H7D;D;,^=RE%WG*IE@]'^ M^4F*PR@+?(_)C=PP%O_OA8/9,"5:::0F&[NJEKWU"LL1OZ9JYI!:FVIVE;=M M;[&EI6>&1"]5STS=>5//)O&D?%*4;XOFU^);L3L4OQ3[_JF&%WL01Q F&''L MA93'Z; #(:R&L=9ACY$%Q\K5X]$\8S'C2O&8Q#E-FLMSB0?T@&Z S$3UYNLU M-\<3KQ$S=L(PBS;*4^<(.3"), M*&:H-Q=QS+1>91D;<7V7L<<%ZB,PS:N,QNQI'7.X)<[HD$-*S8#I2D)SB9RW M#SC,^5R&W$QWX_7#C:F\3-A@^BP^H%T&1ADBD'.6A9"F7I21-,"]19(BI)7@ M:(J=^9=B$MKDK21U'HUWD9Q0.'G))5$M9>]H8$AOVTB;UV6(D15/WMXL,F3' M6)*DO7XE%Z:R[&OH>5[H!3Q!)$#>8)$E3"ECB T[UY$D6QM#.H0::I,C+BUI MTS)V@DX2Y<5EEZ2[R:>K_Z.?_OJA[,-FW\Y@?,0W$<=F9@1E#E;&P-A/.G8F)^.ZYD+SN_2NZ M,9&FZ\K$5/"5E:ZB+@*_Y/?%A]LGIOIHR?=Y2"'C2>)%U.<8QV$\V&*)K[3) M/,W"7-&*WB)J(FMO2\0\A)DJA8V5DI)67*3A@F1,I^WZRF'!A\IF1]+)Z]I; MZ,.5#-$$L\!/4TC2)$T]+QYV@C*8I.H7WS4_U[%F_%QLRK7R@T(C8L8%PC4G MIK)@D(Q5DQ>=]*ON^#&['/YK\2!^*O-2@?W7 I2[VZJ^[Y9T#T6]%T-27A#? M5^!(*)ZP V2!V&;L_5CRI['<[Z\\7WQ]3QL(XBEG,6>PEB*4A M\3.8=1 2C[-4:?_:B6''HJ7SINZ];OYH-RVA$#I>LQ'T=.\OR+_UQXUNVN'_ MC@>.[T=2@3NE> '!KS/7]!\[FO)G?/GC8U'+O\CO"G\E9D7L(8_1Q" M1&@P&9&)%])T#,UZ_4.>IX(?\@;D(\]0:< MD%WY_L<913H70$R8748X;<>5MZZ F/.C*E+O=M^$@:I^_*78KU+/YWY,HC2C M.* A]1%)!Q.84ZT'/UH?[%B$CECTQ$:/&S5Q<4:+GI@<8;1O>N85CW,*1L3" MB*EEB(,9],I"3S&K?B*6[WE9R\#Z?=6(<"CP0\ZR%"+$600I.]Z%37PF%#,PIZ<9IS(F)TC@_1AK3LN6/.5E1$@F M$KD,29GJQ(5*)),X4969CW4ESXH>/V[E.FRW8?\^E _2YEE]!>HGB; !_8QG M @#+J!\,EKGGH]6WHOY2J:J.#8LZ ^D&-;@D2=Y2KZ=3< M7.N)UH!.K)6V[::/X)J=N.XP @ER7A538&U$TFQRO@Q]L^I1Y:Z':KZ#EA49 M3AJ;?1Q&<(SU8GG;YYM<**\>7.T\^'V?;6[ M:VM8=55@/E>DH&7S(**2S8?;%<5)%-,0[[:TU4EBW0K;A9=A6G-G:03I]4M:"EO8?9EI^35L"\%&*"* MWYEYLTF5PK&=*.O-L SI<^#7\STL1\PIQU\;L3+;ETVYNV-=4;E52)G',IRR MF. PR1!"29\0,($\Q%H7UPP^WK'DG2$R+*-GP)ABU.66+,V(ZXPG]@9/;H*M M%VR,!5KFU"U#::8X\#S FLJ%\O%]_E#N\VU[QZWAA_VA+GXN=^7]X?YC_MC> M=*,'L6[T,(SC"(?0$^;]U,.,#K:S+-4Z,K-CT;'"=+C 8;=;?$]H!O $]Z3U&,( $="1YH9N#?Q7BQFX M6"5^&>)FV:?G=P(<,*9TV_;#0R$O(HB@;=2T/)WT$I1"PK#O89X%$/J1?Q3@ M&/E*,95MFU>0P5VU^W&=BSZS;?/7W?>CM1J<,M)'ZVTQKI#7; 8]C3R"[%5R M3"3';SFXY5OC:NV5>#>[56N/?[6[M>KDO#+_N*)W 3=J77A5N>V4>H%XG[.V MJS^W:XMC_:OP!T+9HGY+PM2G&$.?8X2&'D>EU7G*,M8QK%J;&C+G#OE MZQ$.E24[C.!/ ?+T"O-:%>(4V1L)$6WSOXP@T;I7E=M>:W6(GE6&# */!CXF M,":)CQ,:4#289Q@II>FQ;M1QJ'C,GIZ_3 S=57TO;HNZ%@%D;9*/WA[W5O31 M#>T.!/)JE795"3372/TV^$N(I(%;>BIIRINJ3))#4^Z*ILFJ^R_EK@VWS^I] M>F&&0IYFD8\89[Z/8,H2L:Z'89:*4%AQ>$ZRX6Y(#K# .:ZK12EC)(T,.RO< M+F.HV7&E1R'G=^N. /(=\ [X\GO^%7LU5=VVB)GU7;0X].;3?$FZJ M[F@R.J*=SAIG&7KJSKWG97S<\JAT-("W^_R?5;D>ZGG$- A9Z@>0,A$LA6%; MW:,WP6"FI*E&'^SZ-L4 1V/K6)L;A?UXE[1HWIL02$ +Q21QFC8W&GOG+CDR MVR _<34UK<0SWR[M;YM2L(!-;&/HE84NH',H>G^_J>[?[=:]">:G.(08LHS$ M,25!G,CZ1:T)RE&@E,;!Z(,=*U\'YP8(0)<[KP5Z5 XC'3*C>>+8(I&=OJ2U%FA:@.S:\**RVWG, MCA/.EOSOCSG-9,(0&%.&4D8AAP0B$O8F69R%6ON8TEA3.:2>0N8T_1CBL7SF@L\*-_1O-KL:[N=N7_%)MW M&S'_E;?E\!RLA5.+[W:;]V7^I=P*9$4C?B8FRDV[D7EV.$N(GZ H(X@2+PY\ MQH\G2BD=_FW7/,O/>EO7BR/7DC?R[= M,3WIF:EE=0^"EM>HYN=$)U_ R9GAF2T^;]#N[YG#" M22-"0IQFB1?XR.,8TM ;<"8DT4KL.S^Z&2\@B%ZQJ^[+-?@BEDNWY;Z=IIV9I9=Z9:8@N;SU6=-WTFB),_+V>K!DB? MGER#.'-K0;.6I?91FK?F[@M+F[EF]__BW'6=EE#:C6^?X[QK$T8+>!_S1SE2 M?JEVV:&NQ=^M.$1A& >,!81Y/D->Y&59 ,,88H:@KU[';JHAQW-*"T],'#T^ M4'W9EGQ'''.OJY;OSWEN+;S:'=5M+25:C;R_/'O+M]A$T^_+AL&TS M@WXI]G\6Q0X\".F1JSP1'.7]\^(_OQ9U\>6Q+=>W%7HD/O&KF&;7U?U]N>\# M*5FMJ=P4[>](P_M'\(/\W:+X>_=,(@?KO/DZ/%66T_09*O$!XH^B[DT(H_^0 MB33;3Q9S[U;$:^V/^I$''JJZG:S$JK7:%>"QR&O) M0?]7\M=WLN#@]NP5]?IQ+;IC>0NVU>ZNJ/\^]?SCC6YSZ1#$5F];P$F(-5^+/2N.4I<%@DI,HUDIL/LF0 MXRF1GAZ4R22WVK.@'3+55D"S\:@W"QXI_+7-Q]D"NP$G:/,N0\9(&EE16.%V M&8L#.ZY4#OJ>1LC^RA(!K]?UH3C?_CJ#@#(_"C&BC"1!Y'DIBS,V0,@2HA[" MVS;L.J1_>BY1KJ M&?JJ7BC]0:R^ZE&[44I($# _30,$4Q]Y"42#W33RE0KLVK/F^DJ\!'@>2Y^/ M0;VXV@*S:L'UO*3J334=GZ_,+=<+L]^D:R36MD?U,@)NB_Y4KCJE@9Z];C"$ M&4)!G 4\0C&%B9]">A10GI#5OI(Y&-7'G)D9+04[(E+??93_!%3MN)-[9S\* M%;R?J&*&?&K(EWLJ371K.7IE)%332%V00DUTY#5ILL&-LB8]3:XG-R+ZK-9] MACWY-_FV6078\T5TQP+NAC/*8F^/ M5D6AN@:CFK+U+%WG3;>SV<.\.:;M[)'.+&2*_(W)FNTF6(C(67?KN>2YX6VZ M 'XZ?&G/%GO[_BKDF8=APK,T"6F,61C@> 0IEAI-]2!6>F M@_KL3E5"I\3:U<(CYPL3P^<4&LFA<3LL71#-'5.6Q(G<31=%F669)S 6L2B+ M,B'!$(E -$*#S2CB7&NQ.LF2X_7J>?QW W9%>TVT<:.'2L1.E4#;G-I5/8T4 M[:Z%[O4D[G8)7KJ<:?FBK&#Z#"D7HVS'XZ=]OF]OB1WS/D:,!IRA,(J#)(V) MG]&P.YP0 AG%H:]:"]'PX]V-IPX1.$*Z6C;3"]2,C*"I9"YC[$SVXGFU0BNL MO#5>FGHO*U)O#NO]A_I347\KUP7^7C:KE,8!1J&7>0F1RZQ(++9Z,]A/ J52 M8L8?[G@5TV-J7R?VL,1P$< 4G^>;DS:N+K/PI202 M%:_(R&36KJL?T^%7EGJ/MF(T>+?I#36TNL_+W2J(HPSB(/8P04'DT2!-O,$6 M@8G2:_AI%JZA'1TT??4P(5!90AQS9T%'WJ+-MI*\9&1<3B8PN!A-F>+#2V&9 MS(C2S51:YG>[JMF7Z\]%LV_ZM$5I(#Z3QCB,./)]ZL$@XH,A1#A4OG]J]O&. M=45"T2NY,H6J<1&9B24]!3GA 2T@D\1MAFQI7.QTSYK9]>D&YC12%G#/M]B4NSN954;\W^9S_GU% M4<1HPK,0>0SYF&9QD Q(*(^TKCJYL.]Z9=Y>5'=1#=6,;2TYNAK11HHU5B/U M!APQ@P$T$*@752[U-5K?%C\GC;0H?73CH5X]50ML:E^9RL1*7^Z9]O<=3NKN M^5&*8A;[H1]'7A2P]+C@SSA+]1XK3K;F6$%;7.U2YI0WI[])U6A&;Q:85=// M>4G54\O3W:D3LP.\J\5\;Q*F;GO/ZCD#'38- C M?A3%W NSR(K)T MSMP1UG4TZ3(_(X)D@=1EJ)$-1YYG4[?%C:H.R?I[=;X5!O'FOMR5(\Z*W2V M\'3&::LNQ(O7PVG&5/P&H)TN3*573ICG9 MU!.H)X&7IES9O*34_4W_,YWV(29K(TQ3CD:89Y ,O MI8- 4B[LZKSUU?YP+6TR34>U'MFIUM\,TB-/?3_(&6_Z6T)/-Y_GWQ4ZI^*- MC2$CUI:A*^;P7]D>FL"#]OE7]XCQ?=4T\MTB3-, )Q[A//%]3F,X6$H3>1/) M(%& QN<[U@^)H3N^[I5#.1'T)-(T#[,<\65Z?-4_6OY! OK[E8ZK3I2H'% 9 M$+@,"9GDP:5#*&,VM+)D_E+MJJ<6A[@GY2GV0LYAAE,4Q0P%9'A[1"GRM,ZA M)IIRO'3J;J^7_7CI0Y*_MWE(#/)D3F!447#F(U-3>UH>SY$=1:@'-[<.C3(U M)DEV*%Z(.EERYK4,FK8X4D\](L9WT1RWMV,""<)>G%%&L8^\$/O#\VN:<897 MN^).5I10DRG=3U<:2FDWE,Z!*(^H 9!9;DQMLM3TQPE+AGE9>GJNLC'SC(<1 M.3%E;!GZ88S^1=*5*2SH)2>28=-P5['<'80Z?3BN'$AQ6]5%]WN?\^]%P[[O MZUS06.[R^O'=OKAOLP'+6XY5NY\] %]%*64)1AX-8\S#R(]2[/>(&4P)TUEF M71.GX^7:+\4>;.62[4OK =A+\+K2=<565)7!OT8#ZDKJV:KQ=&6\]L7FT]>\+E:84)*$"?)12A)$@A#%0U(!YB51J#_Q MND#A>&H^+NT$4-!(1#?@B\397=3ND((?RAW8R#P-]=DO7IZ)YFXH6^N[.=K( MS>KM!@CL@!P;KH#"@!RU\\+MT +0> MZ&3G<]M4&FG[%M-D9OG\!*"#6&6(A4>S%LL2V4#5L1'?'EQ3T_U-8>^5J7"^ M%EE @L!Y_*SF[NN:X>L1TNM3^[_RNLYW^^9#_6MY]W7?G/!X49Q$$+$81C0) M$LP3B(]X4*R5-\P=BAGGUNJP;_9B+2L7NG_V@,&^ @_BWWZ55<3.IUS-EYKN M6DEQ_;&(!C*<547;7%RFW( !NE ;T($73";8SVB0R<>O+$0P]C#GPC[.DCC@ MOEH%%RN&' OSQ[KB @=_[/Z^F MCF-LC0B@%9*7H7%V7'GQ>,P:/ZI*]5LC1),U^_(^WQ?-"D89)E$%YO7?][UO564!'X4)AC")$M]&&>0'Z4V]*%6 MMFFG0%PKHP!U ];BOZ X8;MI-; ^>M#^@J8*.FT=19E<2L-HZJAL#=D [1?L MO%E.V,'(;RU&9R?P/R;$?2_E\_*IJ?9>93NXP?RK6A[J445EO M$";<@P@%GLSD2?GIJ> M,7="M1R-O,S9B ):('H9^F;#D[<.@Q@GWH MI5GF#X$O\I(TTLO\;6S&L3;A];HZR-/ ^@A1-^.W.8-JRC03>7K*= 9J.7IT MF:D1/;) [S+TR(8C+S)]6^)&_;',-Q&/5?7C3%#&LQ 3"C/*_("E9#"7 MA:E67EUC(XZUZ(A+]]V**6=J^C,+77KJO?E'1!5YAEG(5QD"4!"WW/9QP?10YF4"L&FF#& ML>X,R.2%M2,T/0V:PJ&:"LU$GYX.'9D[1[482;I,V8@H6>!Y&;)DPY'*>A_4 MK#9059L_RZU,%?YNMQ<]KQ2AF"QXN6^>?]_C\#T/A@Q&/ IYX&.6(<@&''Y MM13+OG7G =2 "N0M+,U"!/;95M.VZQ*M)WD#UG;[_HSP#M[-:W^U%#W4IGE$ M)MTUV3+4TZ%_SZLA.&;2@M8./QKL8\Q(%H?0"V"6QIBCXS$!8EZJE9?!GE7' MVCJ@L2:INJ1.EE*'?-J5T.'G?PGE?,JJF6(:MLSBE=+4+W6%G,2$(4(AS$B$!HMBF:Z5'&Z*'E;A^H&=+BNKUXC+(WHE0UNEZ%05CRI[/<\/17Z6,N\[_O'CZ*O[671FW\? MRK;PZ'/SD&0XI3X.4B_"/(->Z@\GI6'D4:8C2=:,.M:G 6<;4A0#2(."$O98 M5E.PJQ"L)V<#1!&.29!=B:P3Q4N)T529')$\ZXVQ#/VS[U;EN!-K'IK>/^1E M+>U]J&G9/%1-OOUP^[[:W;TOOQ6;\[7S"4H:>Y 3'WF,DXA"GGED6$2'01!H M54UV L!U1"?0_;B5\(SV"MUPKG@@>VVZ-0]KCW#ED_L!L'S(TK9!BWEQ>X4F M'(\=];ILLF6HK%L7GQ\1N^?3Z/G]/_.ZE-=ECI5'=OMRWY]CKUA,Q!H\\Q)A MC$4X2G%ZLI_YN@_6+%EUK+,#-E >*PNUZ":\RI]&LIK&7H=?/6%]]E[_R/2I M2%&+_%MD3E4HN5#L?^;;0_'AEI>[?+0^"P*Q']@1+PP8$?;'DR)CDC:L>A8("5(\$VBE"'1[8!3 MZ.41J)Y66N)932?GIUA/(UMV_SFP>X0(SC N1Q^5R!S11KN-L0Q=M.Q3Y;+[ MZKZ]^%;L#L60UEHFU/U7N?^:'9I]=5_4SZ/73":)8FF,O10%D1>'* L&$$D6 M:0FC9=..%;)'*Y]H5'>[LGVA+S?AUI6(<<2HKKN?Z[[;L,N^FEQ>D7@]W1PX M/V;TEU#!GP(K&,!>7R_UV!P13D?-L@P%=>7ABIE9\4L3VA1W+.=@3'-7\EC!;#GQWR6: MQC86IS*[#(V:[L:E%'?!+R75=.Z!#+%5M;=SD1T\F(+,H!B!1V3!'M( MK*Q)R&,_&JR'D*9Z6X!V;#I6I39)ZH]?\D:F8CF#K+L!:(E@U>V_^;G5W?P[ M(00]1-!B7(Z>*;(XNMMGMQV6H7;6O7JQT^>"-54MQ)MO1;TOFW)W]ZI5(;XQ M\L(XYEF889P&L3_D%HU\EF@]49EJR['VG<'3D[O)'*K)W)STZB]+#^NIWF0JU<1N3A;U-&Y UM;^_=35;EZ*PKW!VHBPV>)[&7IFS9O* M3:_44Z]?BC_[C&["]L>ZVE4R&?K96>YS&#[$$88^S:(P\(.$<88'$8U#Y&D] M%K%NW/FYJLQZ#?(C9O#P!+2>VMFG7DW^KLJZGAX*J."$%3P%NQQIU&5T1"N= M-]5,G5SS#5[^V-KL2Y\-E2O;9?HJ\5"*,0]YG(D_(TI2/Y#5S9@7 MX\S#2.O=W11#CF7SP^UM4F:%VV5HEQU7GK^$L\>/\L;=-F^$O;[J8E]TL2WHN<(I01''!&<^ MC:"/O#A&7@0QYP'UHU2O4(:Y&=>;)FDB[A[V6S2F,?IIC%"8ZR#(6, MX13V]EB:>%J5M,VM7$N5+*B1&HL3Q,@Z@=:T2");@A1)'+I*I,7J@H5(SP\5 M'3)@9I(,T>H^+W>K2*P2@S2 D'J4T2B!E/N]19[R2&LO?XJ=O[ 4J3(Y08P< MD&A-CCIL2Q"D#HFN)&ERNV!1TO5$19:,V'E+F';?]OFJM]/(!6*Q^5R]+W:" MM-_D?]Y7^0[O-GT!G$=\5Q?M1M?/Q?V7HA8JF3+N$Q;0(.9AG,4>2P8P610K M:99C"([E; .RA8YV%=@VV('A_:_$GW[/FK #XX.J F>ZQ8:U\(%-8Z>3![; MI0,-/E>@@PU^.[4+?K5=P.\=>L6ENNL&VE3K]OUC>X'TK]!03P!;&TC;82 U M0X/E@P__4)WQ)$GM/.;#?A:;1MLK$]Q,[7#=N6\N)ZM9^[;!C-GUU7W5]=3# M "9_!8SL=EA\L6FW9'MHC#$BIFV/I5Z04$XXB[T!6L+4$K;."FBYLRGX$4B/ MP,DE _EVWIX:L^V2FM)P[K71BE-F8^?-:3 W+ZE9W@^7TVEU^;[>?E6W4;[Y,8,:W-?J'>'J^VVX9>B&(_Y23%8<"],*,13CM[ MR(->X.ELXIE;F6L+KT6DMV\W@3JU7;MY6#/9<*&U8?"KJLFCX$%;UT5$< M80II$G,O"<,T2G$6]3LCR,]\M>=#$S[>L89TH ?3LIT-@0,^5)8WKNG2D\] M7K!DLN VI$MC^>R>-K/%\)&^/WMD4S>C7W7TTK)T&BL+6&1.=*"RUD,LW.-X M7^Z*=R(L;%9I&B*>(,9$])>@E"&2>(-1Q)%);&9JZGK7725&T(*T<>=5@]P) MMSO<\&KM@H<*I?-=\CB2I7O/0Y_E145]DYU1N>UARM$D!6/?BWI=-L7'NEP7 MQQ\V_4\;?\58&B0QX2Q+D,_"P$M8?%13Y-'5MZ+^4DV2MLD8=$;F.5SE 3H@ M! \2XND].OBAW(%-M=WF]=DK];\O8*2^Q:GN +;61@L>U_9\5!GNEAF=I (? M#OMFG^\VY>YN%?@012'&)!8R%(F%:>H-2U&(/#S]T8Z.,<>QS"\'&3'*F;<= MN.TH=&52A.F%ZR*1NZH"* Y3ZI:]T%,R;E\L=VE\7E?-2*VXIE/PR"%L1>2 M "$<<93%C&.8R#(#6D6@3#[?L:))#%W2^*H#5^UF?MG["BDC(V@*A]5D M(;;-.MPD'9#*V>JU9''@]P'EMVUW!K+&)C.O+MT,NR$1>6Y;O^U MJ%\Q*S7DET)@D[G8B[JL-N+O:UDWG!;=GT=@F"+L!R&' 864X"R@7M(#2[W8 MUZIP,P,1S.OP\(IN;:QMZC[_EY5:F5N!5 M_2G?%OW%R;)H\.:_#\U>3E8#^!5L,P#ZD4\H#+B?B?^-!GBA^-*6ZEL%Y5C[ M?]N))MR6_U-LGDH^D)7/!C]^O*WJ'QOA";C/ZS^*?5O[M3EZ=0-VG0[M\^_V M9@J[33M]OKA:JUJ?-3Z=M1Q^T<;B[X[^W(#\5G0J.<$L9U;1:0C#N<5)6R]_ MAG'CML8\XY#W"=GYCQ9QG*2ICP/!.Q=K&@\&/ALLIM2/5_MJGV\5#PPFV-&: M$XZ0U+>N[>?@5Z=0<>-_)O8T]_S58G6AL/M]77XY=!/IO@(?\WKLS?QO)U1WY =[8W_]S(2;_AA?ZB+G\M=>7^X'U(DTD.1'6K9P^23 MH3#)!(X8^31*DR0A'D-9$$51B%"HE83:LFG'@:X8!:EF<&J96L40]'JL:@:: M U#0(;T!'5;0@P7'-*P"KI2_[WOP^<]B*Y3QYVJW_WJMPQHE7E7.<>PVT#)$ MT95SETY_7'!H63K?[3[_6?U7D=?-"L4891#C+$OCA =Q!BD<<&2)IY5WVKYU MYP(*/2<"JD.P50UUQ*TC&;V1.@K*G1#1"K2H%RF@)U*G:ZA! _VE9-3$/S,E M-6;2OIB*/EET2#*>4LP@3Q*>4.HQQL-P0,)\JI44TH5]]X+JNQ)4#9)M2ZH; M?IV+JH2];%D]$FM%6/6;Z:\FK08>&HNK*9O6Y96+(=$!\5'F$YQ21A$+/>3! M@.$C$!Y@)^JJ;MZ]N$)'XJI!L65M=<.N:VF5J!>MK$=:;0BK?AO]Q735P$%3 M637ETKZJEM]Z>9<5H$,_8UDO15VTUTM6+$A3G 6< M(L(#'V-(L_B(@_HN]E4UK#O6U!,2)\JJ0[-5877$L%-=56B+:XKJ"=YT335H MGK^4I)KX9Z:HQDQ:%M0539B(COV(8R\D(40!R]!@'0=>J',]R99-QU>5^M&\ MJW8_KF7YQVU[H^:^']S5^R,$]?4@K-\9?:B"K>V4V?#59LSQH MG_S]I\.7MJ/^*C-U;9L5Y"GE+$D(CDG*DRP-O4Q@Y21B*:*8K7;%7;XO-I^M MAT>38"F-^;0;\R\\4![Z[XNF^8_C4!^&MKQ-]Z4 =;$N1)B[Z1X(/Y.'IO=' M\UKC+"UJ-01SWXISW!QZ]L/!#] [LD@Q'V-^NM!;:=>_U"1@QV.S"<(BVTKI M3!5A_5+L5RQ,_80RC.(X3F$ ,\I.\6;"H4K$9]NFXXCOL_PGX-8H[FL?*DU, M8:G.U"OCW!77"TAVZ<*KRFT/U1F3]_>;ZO[=;MUGWL0^A:'/&0T8BE":B&&/ M6>)AZ//03S%7RQ5G]-$ZX\LH!5P':.HP>>K5Q;%@Z/P2.KPI],I"XVMTW9^J M:O-IG]?[GPJA?N6Z.;-&Q#1%LR0($<=$+( "2'IK$4P33Z,73[#BO$-+;* % M-[%37W;R4O^V0,L"NKH-+RJ[G45O,2X-_EENM[]6VRVOZC_S>K/R(8GCD-(P M3+T LS!)4MA;BGF2:!TZF'R^XV.% 1+X78("/2K-;,5&O*DM85U3IK:# +_1E:VB\VTXVV>] 3#*CEF*G$=65#0 M F5NEB4 ZK OC'I-O[6'>@ ]GF&*(80(LYB3$*7]QR>01'$_U-ENHSG0W_I@ M_8$^8# >YLER>[S?+ZUVYNVL^%O4GF>3Y<_%]3X0# M?ZP8HV'*8Q9PEB:8(-^+NJ?JC"#NPU G-#:WXCA EOD89&Z+-IO]D I;(M2; MYB:PJ#;OS4.@WD0X8 ("%&A1@=\E+M "FSELODC0B*1,)W49&F/!C\IV=]-, MSUO>[O3I\/]?5X_MBG[3X!!?D0,'GK(FD5J+1&NIEY7X%I/RLX @A-" M,$"\HJZI438IC%YPI[=._$%YYI+E*HC#!E&1A)*]FQRD4 MWW4YT9F742]0KF)I]O&.->[5.$("TZG/:$CT%=%I&*$HHH2GB9>%)(MCX7K4=U:+=OTH3ZDT[%UH/_"YQS1P4.V1X)))>0KLN(_Q> M!!/5\D:=C2GIE_R^H-5]7NY6-(,!QR&#- @RG(89:I.%MF8)#;3R=$XV=IW) MX09(B#:F"!U>I^B\(TJMB'7')OB]P[<(T3[1I:V\!DPO63Y-W%'20&.>5(6L MKW/87][B/*0X"M,DCE@:4#\E8=S;\'&4:*F6WB>[WHM]O69J<_CRW\5Z+]\< M5:<2C\?ZJ7K:I4FEFE"Y8U%/E88BJ+]W2&;6GRB^*3'$ ?16_YFC?%1]%71-.%O=F $$9@EF >\HPPZ),P',QFB<\T MKB7;,*?U3GO_ !8_,+1$_ PN-+]OL;&NJUF4#B8N$(+:)ZJ#M2> M001'C* %^78PX(YCC=.,*W!M=KRATIVG'GBHD7%I'K%,Y0*F$ML>5>XZWH2C MZ/?EKGBW+^YEB6X89E[D1S&,4 !C0D)_,!8&B5()Q8DFKG D+<&!%MV4@U8- M%@W.IMT0./U\>G;N)AQ4N^%PJ8?51V]5#ZSUZ5F 0EMP8NS@VI23F0ZO\;V\ MPK1"$%.&PC1.PC *61*Q*!FPI0B&:BOJ>3$Y7W8_V2D_5;,%1>](ESMH?7)% MKB6*%\,2_%#V%\>;O\]ZH*W:MK,<73MH5#N'U.Q):V9/6_/EA'4#.D^6<$"B M2;Z[\VO-QEW&ANC,/ML]DS9B7+G$;=Y\Q;N-_(/]^U!^R[0K>9WE=RXV1 M?^;;0['BE*0X9)1X(88\0X12DB$?9DF,/$JUJJ7;L>@X\I?H0+[;@+7\HCCA MU*Q^:X==-=6>GU@]53YRVGYQ!O$&Y'LPH 0MS)G+WZHP-R*I=IE?AF1:]NEY M<5P'C*E*WJ]%LZ_+];[8O(YB%60HC% %Z&A-ESIW+4'_5CM6>6 M7B!Y^A?GF!(?(B_A./ $MB!"6>S!'E.8>2S6R0CN%HF6Y)EFC91J=_,BO&O' M;SU%$QTWDGHHN(SVT0\1;UZ)#U]3V>=_=S7!G43V&U&E^T9A< M#"N_@5]_+3:';?'A]M?B6[$[%(W<(&#?16RWR[?9H=E7]R+,$\C>5[N[]S*Q M.6Z:8M]TSZ:P3Q(H,UV1 /H)2CAD @H1LP]%,4NTTG4XAN+ZSD>/7N[M#?B[ MC;_! W!TH144Z<2/K1>@5<#:@V RRH[31OB[AO-CBNJOSAZ_E.M^VCY"". D"GD*> MD@3+7 ,1#GI;8>)'GHK 3[/@6+?/\:@I[T3"Q@5U/J[T=/(D@EKZ6 K M"IE2!J5I%I8I(N:$*8C(+%Q-$1$;[P'59.02%9=D9#)U"Y"1Z3Y4-CN3FHRT M68_JQ]5OGU84,9C$B,<\#!("4YSYY/C!&>4JFJ'Q<8X%XK==N6\OGPLY5CS4 MU>%B7 XOI&C/CX; M]2>/7QGB!G1<=SR; *Z,FUYOI&9X%=(TQA&-H!][@4Q#EIQ%$I'>2%7X..=7 M,7;Y)M<;HBHDJ U1R_YK;H?C7S#%EC$V=0!7QFVN\9!";B1_ MN/U756\W_6N-2,[0,&89BCA+LAB%'/9&H@S[4/D!A?Y'SW"K0&[@_2DA:5SU M-^!H?!C/0(_^?0'PX1:T:$Q>O1E0I/$*PBU59J\??BT>Q$^[@JY?"U#N;JOZ MOKNV^U#4>Q'TRFMC^ZH]MY6]3OY6V_.FOI)XP<8K CF1M@6\BI@ OK+2=72O M;VGMT+X_/LH((L%,%/F,AGY(?2*U?8##0U\I+'(.8K9]D?-QI'OKRU4#J!UM M+8)[7=4W.\AZK_!@SM$E,C..1R^7.6ZV99Q@N7?SQ66T67A5KG5_>_MS7O]1 M['G^K:KE\5A;I+6?$FC,*(Q(S )/&(0P3'U/YLIF'DIAJE=H;YHEQT)[Q 2, MRLM/(U%-1^?C3T\L!:X?.V#@Q&(+[4HIHT:)&E$\.P0O0]8L^?*\ZKI%AE0% MBI=RZ[=5Q'=B*;*[D]D4.FW\J:Z:9I5@%&1A$"8D"GF8I=1GL#>+XPAI/7:: M;,QU/"A!@"$]T0:<0/8QR+PC[2VZ1@:;-::7,=[LN5,YZI&FUQK;?"7D,=OF M37]])H$P2C'/0AJED;#(4@J]"&+.4R\EF5(R*AMV9KR0V"4]^O((6GA3+QH: M4*H6(LS%IEZ ,(%(QU?_7K"D=*_/G-ME:)453R[>R)O*CK)"R;?67ZNM(*N1 MU[SWGXL(\4BOXM@$.ZX5Z@S:WT 'KAM8FLHT MA4I%99J)14UENDC@50HDC) T)DP6J%V(,-GPY+DP66-'><&2EW7['IH\7C#> M7_V)4Z&,/N$L01$/$\0(C ;S(J+3VERQ9M3Y/DM9=RD#9!!@2\#L4:ZF9E=A M6T_:5(F^4ED!50;'5I"V&V$9(FC?K>\J:4[;K,KYX_MUE&9?RFW;6Z= M?@,I3E@8X)2B5):IC6D&O6 PR (U0;1@QG74UBZ!>G3@#)Y.+MUI/"IM[6KI)G)HFIKZ8I>);YJ2L%8V[O:R:*\+>5993=]##=)6!*R%&9IC+(HH21( MTV-@[: )=,T&%;>[50MQKTJXW(URB&9RPRM;H M@][K'$EJLCD2];IJEV4$O\Z\>YY)PBF+&K(ZFAZ>L@3RC/A)G$5IRN(0AVEO M51[XZ*5QG&C+L6R.U)K0ELMIG"K+XVQT:LNA>=4.5^*G67'"-LN+$3<[WKP4 M,XLL*8N7U,K^N.?]*9,Z8Y&/4!EWF K#9EB_:]I-G3&EE'V\6[C M;#C-U-0G,]H45&91.1"Y&::#\]%Q@(C6D>[1%YP MDHFVBUW3!F=8EC>\:Y,Q]#N7[:^(!9?\*_QG7F\^/,A?;#Z<"GK^_6X0-DT![E6VFV>E$0UKI%PA6;4 M.(Q>; L:'&'_^*6]#7CN#3ASYW@"U/]>[Q)H?;H!O5?BBY-?-Z#S[ H'X#8; MYJUC\ZMT@F5,#U?T_[4C^BNVA/-IJ=M*>+=K]G6[-=]\V'\MZL]?\UWOP2\R M@F_VQ:;''T(O0C%)!-@D#&5V 7^(V*.0(KT;EHM![7@:^_73;R"7P!<??Z+S8JZC>EBMG36H?[BLZ@[7FS- MKHY;SOFLVZ$22]96\?&WO-S*DSE>U3^)?[M?D0 E 4MB%B<\36,((QP?@P1. MR2R3[%20<]PP;D ^X *W50WN)+*N&'=?F+OJ5Y /XA\W5YAF)S>UXUEUSE:> M?1+MG&MW^;K>@I_TEM;#O\B$^48[N9@?;76-O_AT:(T&6[.?W791/Q&^OZ]V M[29KEC^4^WS;V?^U:(KZ6[$1YOEA?ZB+=V*%DXLF6[=@OB089DW4/B- KB#$/?3WA;M".$!+45G.(4!=C3 M*O1IS:CK^\0]NAO0XFOWM(\(IR8BF,JWXK+Y&E3KR>$TEAUG*1AG;6Q1:IOX M96BA?;/<1A'41P'61 Q#_LD"&EO)?(8Q3JRI_O9CM5- M_'95R\[TV%;U;)'IB9DV66J:Y9(G/6DZDZ&KW-Y]QL2(W)ARM@Q5,49?V>DY M>AK198#ZW\5V\YOTQ]6M MI^IV_V=>%V)I-WQ)BV_%MFI-9U6S'Z3.]U% ?8XYQR'S":+JX@;35?C4O&C1 VNWEH[?G,$$+E/.T4 'CY77XU& Q#@B#$ 8UH2!*4>AP.!N. \5@K M1YVY&<G:4^H&6%>2LB6!5J7(50V M''F>*\X6-\K[6H=]=5]]*;='.RGUO#3&S,=9Y!/?"RE+!CLDPEJ'?OJ?[EAX MS@!I[E'I\Z2X)>64(LT=J!.6:VTV/6=C;&_)F+EER,<$_,]WCB8RH9$_1SY. M6,M+"N]V'^OJ3G2FP604Q8G'XH1"/TP816G(AGWW6'RI=;U_DB'G6T8G;#^6 MNQ\?>G3::7,F4*FZ>S03B[I;2"=8H-R! =CULN5<9&ET-\D"N'G@_3%_!A?K-A%%Q7[$XB!!GA>EPP6"F,>)5HU+"^9FNLO4+A4, M=[AMD*HF5S/SJ2=:;UQ8>G^M1#MODS:B81897X:2V72H5[G$11F(4^Y9S$:8HYZ>$E-*3I:E?<22N* M^U)SP5(:O6DW>L\]4-^R.7D"-F>NM*,Y/_-!<[MKMG93W"5;5(.9;:Z=M=2Y M#S?@Z$7;:.=^W(!G(GWS5*5GWIRSU AC>WISM_,R)']^MY_O(%Z']\DQ\"_% M?B4FI\#S><*#+(Y2+TQ(>C09I52LZ67@.#$"5C&D%?\>,5F*?W>%K86]$J<3 M8U_;=%J-?'\9H7+>N%<@,8EZ==A=A@#:<44UXM7G1U6HSL5SA8G'49)%?LS$ MA\=^XL5'$QARJ+,TU_I@QPOQ61]3"B*=E MJ(,9],I"/YGPL'IS6._/'W6W#Q@C%J29YY.(A1DA?@##(&[M)G%*4J3UM'"Z M-=>W6<_JD/<0G^4\F/J8VHQC-5V9EUX]L9G*K/L'U*\1-G:7U1K9RU LB_Z, MO96VP)3&$NR9M=/!!Q8A$X*493#AR \RA$G06\Q\S].JFS3%COOCU)7D MSSZARLNO6;C47GV9T>AJ[76)H_&EUV1FEZ%45CQYN?"RQ(YV#?CN$:58[#TI MU9DWA[K8?-C]6JP/=5WN[L0O_%+MZN%;DC=ETZFGGWD!22%)?3^,.(QIQ"@, M_1 E89!"JJ5E\Z%RK'QGQ>0XYI6(;4K#C[Z68L<3\% <>PXS[ MD(8T1D'46T,925.M&<'0AFM]/\M).. "OTMDNOIMRJ&B&L] GZ:V&C#G1CM? MIV9,"2>2N1!=F^K%O@&@^BP]N M7O\1K>[S_U'L^6&W M.;X&CCR?,D0BB"B&%"+49!I/9J;8L=QF'@.31ZL;CIPFN]Z MI_"H)CMS4:BG/<_9ZW%=ZU'O98Y&5,@&L\N0(BN>/'_1:XT=G>I,12VCK8_Y M0U'WMB@*?6$*(>Q%+ T("5)OL)4EJ9X<&5EP+41'4.!!HM).26E"FJ+V..=+ M4W5.5+6 KI>,\B4M8T(SB<:%2,PT'UXI$#65$559^>W3Y[H];GC\) \7^O.' MUB#W/(]&41:G&0WC2-#"R6 PAI[6:]H)9AP+S&__^/0/L._!@5VUU\V&-(5! M-:&9B3P]M?GM$QA0@1.L*VG.989&A,<"K\9P M5^S6PB MONQ?F$=>YHFP"L70CT(*8VEV,!]@I'4GQ9K1.33J[@@5Y!+K(VB. M,'45RQ;7JOIU!9JUU>R$$0P@@42Y!'53XV]4ZRPWP5*4S[9;+W30"6]OJ>+N MVSZ76:/VY>ZNS<*[:TI!97M]<,AJ!WE"A[W0O^WW*])ND:SKBKE-1RKK'RNOBWP<9LK6W M9]*4Q5&<"88RQB!+D!^QP3*#7&M=;<.>8PD_PP6.P QO0D]A52U6G9M0S4/- MU[B\SA6[MWD:NVYGD>5E1*)6/;IT6=@:6]IR]IK=_JI'B,*(!BGA<>ASWPMP M&@Y7/4@4)8&1G$VPY_H"W?$!P0VP*6U3&-:4MIG(U9.V-WF]TNTW!=94A,X" MYPL3.AL>71(Z:VQ-$;KF^/IBV/F,A*AF 2)!0A+,(^:CH\;R!)L]AYMBT+'4 MG9Y$?9'O3:8+FSZCYLKFE$PKTO;DT=F5:M8H$*>I;L:\+U?>S%U2T+>)?!DL M3(]?_N]2+(GK]=?'][+@5QM&"A,L"7"44A1S(;-1G&2]\8S@*#13 MPKF7,/J0$@8QYQF-,84TH9 1/SAB0 '1>BMFU_)LVC=9^NP0/2'IT([_)3; P8;3KFTHL:(E!;9E\MWLX[)M6E?UCB45$, Y\B),DXI3& M\'B@G1$O2?0>54VQI#- C5Y6M6B ;ZA\)MQIZIQCTLQ7LQVP&] S>.U5[$N> M5"1L KL+$ZPIGER2I\GL3!$CV%MD$44H"FC**$P2+R,9'A(.R-H<>I6@)]AQ M'(]UPPA.%R)EWLR%R 5EMH0(+DB(H)$0Z;*[7"'2]D1!B,S8F2)$P?"VRT>( MH2"E#(8QPY GF=];I#R(_:E"I&IG%B$*I@N1,F_F0N2",EM"%"Q(B (C(=)E M=[E"I.V)@A"9L3-G(L_WQV2C* S#A&41AP*<@!?C8](FRGR]Q,3S(IOQ!*#S MI]VD.?-H.+7;@&HWEBBR]6M"&N29&UQ3)WJF:_\@.$:!!$,?(1"R/.XV X[J:>[RF=.,\$Q?$\)'&V5,L/#INS*P\&) D0V%&/9@$GO@FXCT@)L9*I%)Q?088 M6GL7^O78)P4TXC?+>QE)@5NY1_M-.N1XUM)H/T=!BINFFRT(.>VF+Z>E',NWS%]TZC9P=.K4;,JMZB%W=[)QM$++9BTBU$-= MK-*4I]S+8(A"EC"9XC1*!GN0A%K/,LRM.-[T_RSG6G![+/>2MT#UCHTG4*AV M!#P/>WIS5X?IYFPB B=<\Y['7J1GY&QU.J7+.">UX$=EN[/I"=#9B>IK1F/, M* UYE(9![/L!CD,ZE)A@/ R5\NQ9,C6S%&U/:/7T:"JC:J(T(YF:%TU.8M[= M'#E1>H9Y$P B, MLBCU,??")/("?#2:(:W[RQ--S7R;0K-PQ$0:U21L1@:G;0S<@'P/!G!O+/O= M%)4896I$J"Q1O RALN7,\WH3-CE2%:JGB\]5'/@P3=($0YPB>1DMQ=G1"(ZT MDF)J?K1C(?KUZ408U-H:LF74 ML8[\_-INKN9&D35^%?>-KD&MG@(]J_!P XZ8?[RMZA\;@7KFS21%SL;VEFS3 MO@PEL^_6\YTG-[PIJ]]Z71^*\QO^V:&N142V2F$DLR%EV">)^+_42\CPO(RG M*=-ZNF5NQ;&^]<"4MIW,3\6_Q_X"41^%K.8D'$.<:_];0""?-L8Q?\ M+I&"%NK,[P65*1P1.OO-L SA<^!7Y;H#:PKC^FNQ.6R+#[=9_E#*FUU%WA0; MW+3G;)]EO+.B09!E&0]8&HN@!L&0)\C+,I+RD,0TU:S'L(XG$0E3CY#(YS#.!G.8ATHEE28;<:Q0+28@_N&]U@7R":2- MJ]"L?$U0H 9(7.##+1B0S<6?UO7Z>7@TNSS?$BA"T_W7 FR+IJGJOS7BB[QI ML_W4M?C=KO94N0,Y6/?LO_(+-_(W_O9Q]U^[GW?T\^Y_BS\^_0W<5O5]+GXF M_@3%]_S^85O6W"CLMS? MS:/>O4&\\_CX M#185PV5;;;&\Z-F:9R/!M%WVC/3QO9CDBX+DHA^OBT]?BV+?!?CD\>?\OZLZ MV^9-@](0QB3P$(D&=%Z$/6/M=(C)_4'M M@ IL6EAE5U9>1BA]]H'V+R8(KLL6,Q#CA336-*'NG "]%Z!UXY@*\\LC:%T! MK2_BK\\:F9XU\A6UW+P15'5^AF9>X!PPA]=C\\-LK.N?F'VLJ^:A6._%.@QO MJ@=I\\/M+\6? DYUV.W%[J][3[VF<'>E'H,S_B?HH(91A3QD)Y MH,?\..9<[YKB;*!F/'LK[Q_Z-6_>.](NRZN'<@TB+Y)I>$6'WL@P06:SV375 MMMRTDM0,T42[8'XHZK8_=!E]O_0"U\BN9'J"Y[KE=8_Y%M3HYF>!9TX ?-;B MP@]P<@0\]:0_*P37NSYAJ1&4SA9G:N=E3$/SNWWQE')6WE4G(EHV^=U=+=,, MMGA^+;X5NT/QS'8LID J]YXN@Z,*(L1EPHW9[^3_:O=[MU7WTU" -&641I2CBD21#&239\OH\3I:1F M^I_J6"\$%HV+O7I\C&N"6RKTI. _ 0/_DE?,WBZD/)44C>O-SL@QN\\LX+37 M\*9>"#YWZ](-8"/7%W#EUPQW-;71-2^M35^QOC^^60D\1%.8!9Q 'TNE3;P! MHL\0U,JH-BLPQ\)J<6/KO?%SNED;6BT$7&P;Z\T8,S>OFVMO%IMB[.[;-5I\ M&0'O=5Q_?@ON>OPK!=D_B>!=5E_ZL'M?KN4E+'Q7%RV$E<=CR!F-LTA\%= , M,I\-UGQ,E7+H3+7A>)YHR^A5.[#M<(%\ *81@4YA4"%(GXD\/0&6H+H:A!_$ MGSUY>&;R-(+YF4@T"^U;,G^0)?O^_FI?G!KR7W;^T@+ ET+6 [8\**RVXGT ME@K'C/+D\>%:Y[\&Z.1FZLD*_]AF/.I6^ MC )B[)$PC)CGA6F4930*R!%%FFC%A;9MNSZD&FIM=3AU,RE8YEGQ .F*%.O) MY(!P,?JH2=W8F8ZC1EB&3CKS[D5^ IM29D(5UF=;S M&*T/=BQM$H-FY6TM6M1$RQDC>J(D8?PHTP6#45KZT#1P(-4J\Z)8RB.M47T]%3SQ,$Q]8IG$0\^E M7BL3[4*F77 \ASI+W$*=JR5K,T8=:BWHK,6*R\. M8@^%<1J&$4G\(((H'- P$E+'BJN$P;WF^LXU5XUL9ZIKG>?Y=%="7[SR2I!V MM5>KQ?ZRZJOGY73]-6#5G0)S,5Q6T LX091X?DA]S (!ZO^P]ZZ]D>/8ENA? M(3# G2K =:XD4J\SGRA*JIN#K'+>3%D3( MCPB3%"G1V8UY5%;9G5Q[;6KMS^KLKE,2QF^#$=AP_M#P[BJR^ M731V<11KSGRY(.@77JA=>+FHUB:\JEF>3WCI_\9XX:6_JU9X1=SU;H57R,CI MPBO.J1[AQ3=4H@Z(G#AV4)JXKNT2"WF.[Z7^@(@D8M>6Z,2A68*O[O)=GC%$ M.H58D'H=:JR/]3DDN?70^Q#F)T0K4VWZ/C)S4V^[FX?*=C/N\N1 P)]!Z\44 <37MK0.![@8]Q M@((@=7V/)'::#&!0Y J]<*@)@F;5E]8-B?OL=3F)3^,-\(^8MFMRC19%ER/W MC))K]I89"J[;R&K6+T"W8O?7(=@><5(WB-/$=FRY;7GZQS[22,H!-B&*3T_\2QZT<# M(#M($K'K$;3!T*SD?R^:NVK?O/Z"N.B]"?I\P2?4AKA!3*J/H,&>H3Z\#SO@ M!D4Y*/5U"QU<'9YX7^J^!5F>SRCV#,XS0[/G,/3%A0PS<:,"WOSWOF[:-QS2:O=[_@VOU^SFH**\_;2K2OK' M=?_" ZL+H2@.'(P@(MB)?2M"7GRH"\6)F/RK'5FSSH_ NHC0.&"(U[P%+!4 MI5RQ(_A4?CD?B,FY4OJU*+80DV>D68]'S-!@3;95<\QI,56]HK]]>8/[E'!( MZU,[L'S'@5Z, SH %7$\#!5!*%3]D!I =P,@_066"0^H)$O/.;6@);9>I&5&W\LA53Q6QR9EJS4ZD8(IU3*<. M $&'$#"(OUCA0HMA+N;.I51*F3=#P!3;]#R%TL"8]N;>CX>'!3&R'0M:, A( M[#L1B6(W.0!#D= J=08XQC?Y?I1]-'8.7_*IKV%N%)/F>3QH5MOO1X[78&=T MJAFJ/Z?!JEJ 9;D63(GKS_DZ+[ZR?N/?\X;L=SOVDF'B.P1B*XYIW(IL.X8N M'#J/X]#QA([F31I(=WFRQP9V!W!2J; DBT(9L'X"I1+?&AQQL5LLFPO08ULD MVWV5I;>3W&GDFJ%R:DQY/:55P0]_)MMD5/PV2;8K:2I=4PB=2N:;.+\IUD6S M\D(W@(X# ]N.H)5XR Z=86 8I% L4YT\G'Z5&A"!30=)-)^X _SYWIO<78V4Q.&=UF:)A*@UYD8HJYXM6S+TVU_L==M:74 MU"ZZO\>Q-1P_ZQPHF5I-"*8AN&V(["V+/#]B5U M"WN69Y.)[P0+C*3Y4VD?W?G:/KIS?WQT1_9=Q+E+CK0BGM M@@(W,^/2YLY'OU3R+]A:JC2LE/:J)P][O-M5;OS2=,7^J>ZH)RV M=>[HD?5YM#UC)'!]+TB(' 0(GB $UX^ M810\L#:=7#X5G)=7,>U[B])%&EC?).R,Y*DCVPRA4VC/\U-ABIF:*&ILU/ZP M$K3R:Y.M?L^_'935^>:RQ.N[ M(O_:/H7>MBQ<9;O;O(GW._J?KKY55W?5OL[*S1?VTR;/2UQN1O\Y*6[OV'_M M>]R($[A6:#FIZ\04OQTX*.S!IT$8T%G,.LV]0$UD?TAX!-CPRA^0]$-0ZLO+$R?"]0J,)@%#N:VL^/)CP:3 MWVY1-GK>;*KUGA7.6PW]$>?/$P.%YM'Z.(_N#_/HNIU'-,_(#O-HU\^CIIM' MFVX>-72R-,-DJ0_SB/W;DQ_EO>G_P9NK,%^T&8CM]/G'O-YY)8DQ='HLFPF9 M2DIE]")C9V#YH;^U#H5*:R06<6O0XIG71@ MP'JA7 A%*%J!;'RZ"T/$HXX3W(HXQ90O(HS9O:OI./AT-" MB4?HL,2QTA@FCA=;B=M7"V&00$OL#5G%8\_6?W)QZ(D88W[:(/%1]E"F^R %"_SQ7N?E89-?% MMF@*.G+^-=_:[?_OL)^P/\#VG.8-U2I\SXY'K7P4^9YCN3'T4HA@2.S4&T 1 M%_/O=^B'HEF-#W#:RSU;(]IRX?9HQN%JR=8 8%_T?W#:7^S^S/DJ[5SNX]B8 M,,MSLM+=OX+8[A2,\'=>L;M_.-U/6QO T=^=%6;Y36!CP"S_R17\1\<)3GQZ MV\Z/V\Z/[4\[/S:#,?_/_P@? MJR;;@INCSM H7Y1?\^&6T6]%#2$\.,=>/B+#R_P6)I/(I"VZ\["NUS#_/7K"@9U-_S9I4$ ;L&*$A2.W83 M& =.3 8@7N JBEK2PVL.2*]H5WT #6X9:G#0K%N*&_S$8M+I6QYF<\O4:#.+ M1Y0&DA8Q&""#7UMO?#SKC9E#PRE.I51_LH-,%_3I!G)KM2(N>64XVM=%2>6? M5/?71=DNPD]T; \KHL=5'+EVFKK$2\/$"7$48R\9 MH;=:+:SFF_ "&S 2,(9V3CI3:W9AS2I,DSCUPM#R$A2A* QCDO2PPB"*N>Y4 MF@W,;%I\[.L>L D4Z&=Q"\?6BFD>F2[3)U7Z*-+'DQVF>DY@<\4T#\IMKQP\ MN1YY6I?94Y/&;"S,JNYU4)?A-S:!Z__VA== M)>Q\,]RP1532\7>$_ +P=/X>.B):$Y99-_ZENT. MX]N.G:Z^YKOKBFLQI71<$8T80^0_#C"@'>]PLX3UW B/!S:J6BA6,#EB1Z[*ITSTY= M&RQXMZ-3M;L7F=RQ/WXHN^ZRRYNW5DSV*O8#&[DI21++BT,/IZ$_-*"%(20V M7R@S#;7V0/BA7._RK,Y!43YK]IH6"4TC4OF^D#E^U[F7!,9FTE]K#65SI3.5 MS9-WO TUR8=*MJ[FF45F+=&,845ZBVQ.K_'&6=;9MJYN2]8V<95]C_(RORF: M>D4L/R41"GW?2KPT<.F_$0(=UTO]-([\@^*6 MMS$XT&3?P74/[X+^Z;8HV8LP3+6Z <1BF33%?+%G#E[%8L43,BDD,&":5]!/ M$'-&@*=2:89@3K:B4CO!E C2D'#6G_-ZOV52F5+#^X?FNK*^X77PEB]C_Z]*8OYY1>0?;%E5J7 M>XT6=FU&\\4!O9QS;5Z\A2S.7X/XB4+;O0(PC"%$:8 1](,P]B'Q,1H )@[? M!O4"L.8-'^"GS8#^YSZ4/##@$P+)$J[DV"8QUXN* LHAGM3@8,LHM#!K0&N. M6&!9W+<"VS'F^EANO^;D+UK@*2B MVI67&XXZE^'U&EZ*C4[K^:W@K->(L<+]>O7^NL[_VM,0E; ;L@^WPH863*$5 M0M^F";\' \^!H9,F?@I3$B0K\=6[.J,Y4-LU0GP B8B*S-^O65)&D.174E*\\>F*;LK$5$64+2V:\@HE M9Q1E"H%FZ,DD"RIUTTE:2_I4*$WLU+)MY;C\^LD+$M6>G?E3-$M]B;5^ZZ&%=@(\?B9 LJ:282_$7 M8E=4_K_U3\KWB$"/='2'V? 3J6B@DG:AT+ 0_;)Q8IC?ZY[L;>^&XP5D_4^F MAPU^9D['$ WL&A%0=-A5Z9Z7XILAQ:;(=H\LOEW>M*&NK6Q@QPT][/HPMIP8 MVU[J.*0?SW5B\0T1N5%T;XJP"\VKFR[C%=\1D62.?U=$/VF".R-COA;K_GB5 ME3W=,_OJR-8 \E,?1)'&$_A1:&J8V& M@1%V8R'=F3ZP:(E,*#7JN5ZJYXA6N M3[OB:];DG[;9>KS^CVT1U8LZ(T$0FS1">J4942F>7T'%8RLRW7=$T>?EI M?[TMUI3:*(YH M5(&.;:7]B&$$W5!HM3MA'-W+W!8:P.SFP*_YKBG84V('H%*KWRFD&@O0V1E0#AD&]ZA'Z8H"#VA70%E@^H6K_;S M.J(%(WQ2+<_JV.83LD6(%E2U"1QKT35>SLZ(G'+:S5 \]695FJ?K1"UDE<:^ MN @3"!%RG(1XH>=%CF,%F(Z(W9B$$'M"!SJFC*.]P^;P'0Z5]0O X$FV9T^B M5%+C-+$I)FL3B)Q'U8XLB0B9!+>&:I>,)6_)E30[7+7"/CD<+:2>YHG]#_)- M4XVZ%_OL$3D!PB0-?)_^TTX\G""+XHG< *<0A@%W'5$KBKD6H^O18O3AL)KJ M^G/7@P&@J5BWU:%S5Z!JIM=5'!5*8[PDN<0]4RT 9.R@)XWK$O5-O9X2J'T: MXS&YNJANS_%54*>0>*JZ.HMC#*B\SF-G-?>4%UP";+.Z[J/YQZ+,/S3Y?;VR MD.]9GA59(0K\-$8D(LY0>K&M1&BS7VX$W6D_ S7JI6' 0(ML[C3U-7;.):B3 MV#0D-9UFP_.D5 $C,DU]>_95TG^YR^@\Z][$_%".FG16#G93+T$.(9%/K-AS MPN0 (?;]5+:];_+ FK^M#B#[N.H6(JBK[88]L/3PO,$&_$3_:_=+/\MW!$YW M!.T,RV& MBOGC;S:LUGF^J=E5N^U[PI2=RYOG[4@KW[4CGXU%0LN-$?2P.QP^Q"A,?;'F M0R5#:A;1[DK[AQ[KX?+K:0V*:KCF4\L%:!;3R4]/N!T@,J%\T=HX=TQT*"5%5N@2 ML6K.]/%FCC3;(\B^%X.A9,\:=;7PMBJ^J;;;;%V4J/.NI-*?,HM.A%C4E5(^/3!)731:^*K=-PH#-(0>IX7I7'LA,/5F<2R$J&EM?0@LTKI X.F>/$L3R^?=,[" MK)@^/NL::V$MM28^10]?*Y@%E6CO7J BY\JV0V&Y$ B^T M411X,,##*T)QY$"A-'#Z:-HK?Z>V=\6/62FDF+>L-R>[HD6]4[U;XTTE$]JV M1GP)=VS)<&V&CBFTAZM/2YZI:2U:XW%CY-@^BB*4II%E><1&#N[&M1T4Q5RW M^:H;;?;&K&GJII!FCAWSV1D64[?S75E<"J>+7!6]6+I(UM&&-9[)VCJPSL<( M]60:L ^NUAZNEBMYIOBZK7(ZO^CDN^V'HK.([2QEC]DU3<'+MI]_ +:*,(2! M'P0$N5:$4YI[>_V5\S9$DUS4ZVU5[W?Y5?Z]B;9LQ1W0Y7:<6H[GN;;EV:EMVXCXB9]8B"1A[(FD M'),&TIQR=-A DWT7S2^FT<>77\S&G%A^T9-&<8$C,/ G@P9:;#-?RG2.IC/2 MI81=,]1*C2F5AMDGIDD?J_+V*M_=Q_EU$SW^EC54&)M'?%TWNVS=K*(P=5/+ M=Y+0#D+D^;'#3O='D+C8MNQ4Z 7&B4-IUJ5TW[!OZB%[9.6+&NS9 R&@N&U=S'-FDHOGVK-R*R8;C%@OU!GW ,&[0*D=%YG6_!?>;8# TSPYP!T M9A$[S]H9&5-$MQE"ILJ82LN4%-A?&(_8CU?D]>=\^*)_ITIZ]2W??LU_J\KF MKEXE29IB"@%;8>A@QX5^$ X8(LOCZK31,[)FJ:/?0RA0Q%9/+,?NP:*=T'JD#3L;YI'[HT=V1X^4S"-- MYY'[%OG4/051ID[M*VACW("]!7VV57/,687QZ$/)TJ"K;]4J@JZ%HS2@,XK= MQ)I@U\?#X$F8J@M$_$-JCT".I5#_!*A4$'KTL*@AYGPHNTR;0EV&;(511@_I M6[VABTH: M@O[:%[MV+5E?M']%15>9.U#GZ\&'?1V[N\';BWQH.[;EARAQ MAN$] KFN\E<^J/[X:ZL/"7QTJHO RIG4&8,9V*4H5Q^'E5/_KQF)F[MB]^] M_-KDFAB*A>;G^PG&8F9)A&,)WA0&Y)1^YROB6;'OVA 'OIU:%K&A/92&'1@F M7*^"J!Y3?SAVE,<&/C*516/E/&H,Q@SK0GPK#\7*>9\I$N,3/QE:OHV+U3?4 M].;NW\'ZY?2;%JN%)O"["=5B5HE':@G65 ;JXJ:Y6WFI[5H6BJ/0%,2D*_H=Y=G-W3"KF+;P79L(1]Z&-FIZR5T M%=^/CM-8W3ZRP)B:P_$1B<(((4*I@IBLB4T-(7EQMA6&8TVL_XM%XY; ?P?C M4U-+-A9+3,YW$(IEK!*)Q-*LB0?BHBSN]_>?^H'C?;X*26RY$%NI!?V > &T M@^ PHI_:JZ9JLJUH\!4?1RC@'B#Q!USV/Z'?WWU&H=%O;N!>-B!($"D:3[GM1#VE)]HY'BA@:UYU&4QED:@]II M?(RYY:8+.31V* T4+TCC"@[R5)L6$"98[=F+^4=+$ M;-<4_\PW[* >FWY:_*_):F'IOS 4#=>%P? M7-A]<&-H_$J6U_5_#ADJS#X?'68F6"I&M)'A M".X"C."!^"U>M1R5>Y.N5[1,/=5F')A3:$^E:U**WDO0A;O^_B6RW^WH^+C< M_$X9Z?YE91,C]!0IHYI.W MV?B5O,V@KW;T\.:^N^!-;LZHF4IFS= SI1:]N-! -5LR]QJ,!B,D"+#EVV&( M? NZT$H<;Q@LL:'0*W*20^BNB+<+]+(J?^D!=?E8=;TM;ML5E?P%!B(\\NG4 M#!2*K\_'%Q9T54JF^?W<'57&E[NM@$NI)G)KACA-->+,K032G' O&HLZN[W= MY=UG=WGS.?^:E_O\BBGARHVL('!H]D9UC\ I3!R$D2@%T1ADJ1([?>>'!DXYUX9ST2FX+)1F4L^2\ Q+YU:#*L@U0YO4F/)\ M#:B.'UZ=PIO_WM=-6T%+JQVYHY,N_U#B=;OD9+?D=;71;8Z_%_7*=AT4!7$: M)*$5.!0/C&&/(?;B (H(E]J1-2O9"&Q;3.[@LGZD(V!P0 S^9)@%U4VQ)_CD M;CDGB.F?6OZU:*(0E6=$4H]+S%!-3;95 3X_Z6WY_G>_HTC?VL1?$ MD1TCUPXAL>-X&#=Q([$WS2>/9IA^QA7;8Q944 6<\ZGFO'3K5ZS)C]DL9_S=75;MG_ M)YP\E&&"R!WZ&-?,(*?BSP\H9:I03+M"%LQ#Q8?FOR^7ODXLDD4.([E^9:3NK8;1\.P5D1" M!556_L&6J[0RC* %J:;<*D#PI)*K'FZ5E5UY:)VS]GJ@2[S^*LZT&9FS.G/X MZK"R/''ES?T8G_(=7;7=MX]R'G9MO]#_O[XI\@UN/E5%V7PHKXK[O'O 9!4[ M#O:#)(01#$/?AZ$;H $+.Q[.G45K0Z!9^T: 1SO=_27^VT>VWJ43JKUZO.X/ MD@@D>_K\PI%K&^$2,']\+K7'7(-MBZ4?%CF.G7IJR-4:$D\B!R#^&Y8#K&2U58VD.>BW"T6.Y M-[7JMK4E[LO^>YK MLE(8.\NU#T]1>I1,X0L9R_(M%CY[ZRYOC@=ZK"D3M;D-'/44+6KC@ M<@>^+$V]0&19S@5R04;N*Y@:=818.A6 ]%!M0"S29%BE?9H*]OWTE::_%\T= MV==-=9_O/A;9=;$MFL>G.R3_S#_%\-_R:XC2(]3S-CDT&7<\UXAG1R*GMO[1"?U75;G[1*C[67K6N"#(/ L9"=N M[-J19T&?6'X2I4'DAZF?>$+/I$\=2[,\'L^B#0#!$:'<\9G)[/))Y)S$BFGB M-$ZU'NP[0=89T5-%LQDJI\R:$V?^U+#$JV-,*"ECFS]*]M9:VPJ3;0<(QPIZ M]$BR)K^M=H^7-VQ?>?B-3=N73BR7 2'("E'LA,C!)!F@N7Y"1,1N%D#:$\;. M!O#$B..G/-IDO'X$@R%L$1NIPSCP>Y1-8XYPIND$\CQ^UZ+4*[L^( M^JRN-4/YYS6Y6O!3$HLA;T Z GI:UJCQNKT/=M.=ZUBEO@ORR?WC8 M%GG=-^XGH8L]!WF1[:413MS0Q^XP?A X7$=4U8^JN[.FPPJR ]CV6MCM 2ZH M>[PBK2!*:>=IM%F*<<&6FY[L(TY @8(C4C! E3FHI99UD5:F>EJI*_!\/IRL3#(CW.=M[+,F_=8$MD-H<]V.H!N#9F6D MWTVHI4XO3K;2TKQ6GK55XREJ=@#H]_Q[ ZZ^Y=NO.?BM*IN[F>]"E>1X>M5= MVFMFJ*MV*^5JZQ-95:_"'\HO.?N=%DR4.';L$N03[/A!;'M^# @7W1M?:(K0+1ZS=7#L6[) M;5$;KK@'9A4)KKBGWI_>2M@X06YE&56LMBN2V&X4X#!&GA9XK53VFD*)*/EVJ15+?9E.IB"HE4I=L&BF2TV61F_MW)83\5LE)GR!K_,]R MWN2[7;ZYRK[CNLZ;^O>\N;SY6[;=MZ-B]@8YN[$$7]?MR985C*TP#*S42XGO M)VGLHSBQ"?2@E5HXMH7.VBD?7'-".> %3?8=9"WB_Q1]G5,UW7RRN"C38OIX M()EB!1W8"T#ALKZS V!P0 S^'##/?8.@(*5GA%.;=\Q04'WFO7C]4RN/TIIZ M^9#O,G9S^,>JKDFVVSW>5+MOV6Y3KUS;BP/;1CXD#O)1:ELV'A!$#@XFR>F$ M<34K:?L]#^C EL(#ZS&^B:HZA7!)09V):P5:>D *&%1 N'B?1T)/DRBBG@I< M8:APJK#L+HMY5/" M&M?Y@1=#O[SU_W/.+E3*ZQ5VB!VB&/J0+OVC%$(_M@XY:H1M[N,#*@?5K'O/ MKK5I5WR;XH;BS^G4$3DRH)3I\V*X*,F3U?#59UT&J$L1+G!88"GBYNU9%_KG#O+4$P,"[+P29[01;,!Y 2UF59HGYI10P_ZP7N_V^6:XF:C(V1&& MR^8NWZV([T/73FT'X2 F3A3:Q.\1V#9&_(?5%(^K.>"TR+)M=V*G8HBF2-Y$ MBF7"S'SL3H\T[1\[L&"$MCVS=KDP]U,BSGP^D LZ^)X]8 BN02/>JNO(<"(M-"]W&U>1$_DA M"9S C3Q(@M )?32,3-/Z:%6R-]+RC:3N2(S(]26%W9)54(UV$JI.F5_H@%A:JEYR)J-8$Q@V5L"D6O:5GD]F:TARV0@$AR((VC-P8 M$VQ1*0V&H5"<^)-R*)X!YNAQU9!!<7$GJ5BJ:5,@4:<[MI9OTQ)LQ>*FUE M M$C*!HZ5*D \)M1DO%(=>+60'&#L.@G$8IF'@8P\/@])58R)T!^/$H>9L,]T> M\9:L?H-:.F?&-[6"\F;7IA1"D_2*:R-TQUCLE@J ML(Y+/56Q*"JG'\IU=9\_Q;+"H15 S[4C*_+H&M=*;"<>AH08D4$[K\07H5+C M2:CEE9(UZ2@OE)-..7K%=%(?I3I2PF7$[S6..)1N$K5FR=HT4TYHF )^I,MD MHR'9'*V5-^1(IHDLR:)5.3K7FKM#:))5ZQ^G*7[?*(/;M"JON'O*R[G83= MCD[ ]CKCZ/'X*_T;L)@UPK.TKWG\4-*E=-M[5+?]&U=W67GYP/Z*^O>J_)K7 M-,'Y7&VW:=<]OTH\Y$782\(X]CS;\E+;\XB?I!@B+TB@T/V;AD'7+:5[=H$T MJZ&W1@EJJ&%<<4JR8:CU*7QKQ2_7[0M<8U/!R%;V<-?X]WI[06OP!>A,!B.; MN^9)T%"K06\V#1N#X?2/SV84^).1 7HV9BZ#SNOJ,\'*T#EG1NPSE9SJ7>B& M<9&Y4X!5#!.4QJF/'90DJ1U!*X0#_M"%WNJA?0/^2Y/M&F-",R=V$#GXH2U*W4_OS#B6OGCF5U57!* M_,M(JB@O\ZNIE.>6%])?Z5_1U!_*3^WWO;)"SPHB)T6^[]@^\@@.PQZ^[Z<1 M7'W-=]?5\LL;0=@B$CJV4*!)G>+)?TA]?$KU(O(HZ>T?71UE:9E-'"?Y;7EM M_%LK[$?XCDLCP MK.'%GG[RT+G3&?VC1-6GKEPDJDK.IA\]JLK2,EM4G>2WY:-J6NUN\N*)!3$. MD(?#-$H]:H#E)1X9+'!@Y)H26,61:X^MA!5MMELSPZN$IY>.L)I<;'B0/5C] MX\79%PY=)-3*3ZL?/=I.8&:V@#O5>\O'W.=52I*2U'9@&-D>"E/+@P'-%'K\ M48K"?KLD*1>/N:+(Q3=+!B-EMTIR=K_2OS=)S)T*/[J$2O.RV":)F.<,DL^_ MY\7M'?TG_IKOLMN\K6_&-&M/LV+'S@7GXSUU"\E?DO=FFN9-LP/I+#Q:T: &#"QC>]I"VX/T<[XWBQ==*R\\<4]=3HPZU@1MP M=J8N=G37L-FQ;%ZA91[_RV0?>MB;/T?1. O>4R:S2H, V@D.'6BE<918, Z# MP307IJF1+773S3*MVVY#9UNVJ]E_ZA:5QI1W5 MJG!/TW_G)^*4&9B4"/I;>R;R:@?8VU98%+'K^18)L(4#Z#C0/A36PQ F,_6? M:D(_:QNJ0.)@EDC+D:]#CS5/@W $=D^,:,\K=HJS87I4:^KN0LWY3-EZ=7;DI/$U"7<\\;9?[65 MG."<,* #5]V\?>>)Q7*\+=3#J]KSRRY@' Y20VY446J2YC2D:PLV/A%1.TN6SD(6FR"FIB C0O[5L@^1N;!D1[+: MR?JCYQUZ2)N[CUF'SY?/. 1*Y4Z4. B%ON>C$":I[T?.< XY2)W4Q.[GZ4:9 MTAC];LO2_T)[A[QSZ4?7>QV4F;AW*.9O7JWO[BO^6-5U2GU&JK(IRGU1WE[2 M3[^ULH[:=WL/]QKG=4S_4#?%>D4LST4HM7!*[,#R MM'/D7DQPF.4P_Z8D=" M=2+1?L3SC[(]F?>EH?]3P2LSM7J ;[FU./52:Z0.#?B)X?ZY>^WY"!T_W\*_ (,!\P:V"4R?B4=S^,^,,#*+I=7\7X=VT:;+"AIARI47$8P"-T0. M.QYI!Q A. #R(B3X**Q&(-HENP>B7:RYF=>FU4HI7T"JW_*4*4K=XU0KU*+. M>[[Q0Y/?LP4"I;RAW-.1;C^434X_LV85 MAEZ*(I@2WPY)%/N.X[@]XB2PXDCB/:(EX4J(O>QS1L:K""^I:F5&N2O?K0ZI M9V*Z4&GR#J^2M54+4MW?%TU;Q;C*KK?YRHXL$H4H)!ZR2&PYJ9,$B9_$MN6C MP/--+!_43)Y;IB7.F17=?I>6,8DZC MT0RMFVA#I7)B\>E+^;7)5J2*\Z_YMFK?=L2WN[RMJ/Z6MY=00)?8":1+9A_% M 48N>^TQ\2-(7#_UPB#DT9CIH^AN!*G "!PXH..3&04DGI>:>?D3DYM3U($_ M.VB<4JV PTVU;DO\;00WA,LGF 0X_64SXC0; /X'KX0S(UMAMIU>EM\T^Q5I M5D?5LO*LT(Y*]22:E@;B[T6]BITH\=W$#A$FCI^@P++=/B+$?NI,R@*Y!I@_ M"62P)N: ?-3)I8#*69N< 9XG;)8$D$$0R/^$.#0S_1,SX8WL3X(/656)J_NL M*%=6&*6)%]A!&KHIIDFGA>QNL';88(JN< XQO[)TP"9J"R^!B92D\8R MZG:,&?*JW%1!SU&K133?)NR,/BIDVPPI5&E0I6UF"FRV]B-=WCQ7T\\L@2K*VZMJ M),.?NQ1K%9(0ABF$T WC"/HA1CX>@-BIDW+OPNH97K, #E_FF9R3'9^;D'?J M= W'WN[R7A'3S<$AES=<#=95_;R)*X#]6B>,1@J((>7:, M/81BFQ#B.F$41);C(J&J\3R(-$?*P0CVX=^T9H#[SHYAX5"#?4GG,Z@&,\"V MM4/PLIMYW,>WQ##/?UKQKIG9IN?'[=?@''QR,'@)-_9;0#YLY']$!+DI[[E60Y* M@MBU$QJO$$S8WJ7E>G)Q07Z\&55_Q]*^O$,Y7B"55?G+NKWOK!4+5?(_P0>B MXCX/_?+2S?"!'J!!FGR2-B[%G4ZZ:7JJP**3:JF*+:Y*TG.1'G09E^TE*57) M_N7RYF-%$_M\=Q_GU\TS4#8,$]]V'->Q H\$&$,W&@0ZME.NNZUG@C)_WOPL M7]Y660FR<@/J?+W?L7O]9$I,,_B,H]QDEKLD%??RD"P?LF.*'QP-8+_!3&AK M^( 9 3I1_I-'E1?QG4!ERBP?RE6I**#]-MN!35&OMU7-?/G*]T?_TY9:\0O; MY0(;:L<%6!^=_.*G[4?Z[#]MV-_\P6Z@V+2[-=GV$_V6[BB$R^MM<=O=8G'$ M$>$4VTGB^XZ'L(Z^6])1H*U:'%3P!"P:T8 1W<847YO5LQY8N'YFAWQKM>]'/I9=) M7G5^$@^>1(XA:'RBWP']9WNK\.7-[WGS[.?XFO6EK9N5E<2NDT0IM#T'IS9I M&VP1@9X;N[9K"_6YS@A+LYZGKVHXZP![DKJ+B?2<7N-3;T,=)B;K3W/SB^?9 M_(#T O2V=.^;L$A-S7GEU]*B7M._[K_R; =^ZPHYC^#/P="9XX Z#YT)$ M, M S,BQQ*&5XM_@JIC3;S/25?X7"$GL=W(=PBK3OET3J2HC28" VN. M%W3 4'4P$*%5E=QK8E2+H ,*]H)J.,W0K[[EVZ_T-ZJRN9OY )H(IY,D6,(U M[T5D94P3EE%I_I0*Y8?RZEO%4HMZA4D0>I!0S;;C*/!8OZL]H' ]*%1"5SVV M=KET+ UR*4*N0L74Q*LVT61/$5/$;89KHEH>^9PJF!*>>4>:*6.=C&Q*LZA: M.>E,S#L"[./42X@4!B8\*[KJ^4%>^^M'UJZ>M1ST%"%:KGWJXU:N@ M#+/)&GK@5(&*BOOG?>FHA'V22BK+I%(M77DI)"F)D>-C0E#BA"XZE K2-,*K MAO]-"34C"FFFY+,03XNWH#H6[ W\@J=^M=R,OZ,OE=\FF:]3D#%U7^3PLL.' MN+LH.F!0]:M59T13'J$J0='M$[Y[+@!X,\%GJ-/S8--4] M3?4D,5;@P?>BT2I,%99N9?S.M_V^0A9T(M>*$?(\CT0VPS0 (Y%OJTW )L/1 MG)T-.[-?AYW9,F\.';1/D[:'M[1C,8_-M>6NU%E+;K6;)O]O$:]U!YW;J^\E M%*@S6/F.N2#7,F%AU PV[#IY5I1Z41)$)/3BP,4)].-A4,N-B7PJ+S'83,GZ M<"#JH=HQ>/*B+<.GN"#K(G*ZV(Z;4R] #VXY 7U)%*I&>:2%8F:4=\1JC:$8ZXL$E0;;2VR=C#)V_23,GP_'6P @Q&+GW^:SOP9 MW9[1K68(^YP&G[FY:!:N94)#W>R*-5WBDJR^8YAX(7+L*" T5'E!&GDT)\>);"Q0-?Y M>!;D]+LGM_*>;V7I3V M#_D1O;SV*_.*N-@OX1 Q=?_\C'\R\-_^8036*"GGY)53NU5[R3RQ5F[A&776 MPZ:X')\8_VE,<&"0."AR[9@X,())X@3V$!.2*.%ZK4#3T#.*,-/:BQ>*V\K M[N#/]N>R*JS&&:("/+L?Y#/K]Z"[/'1R2:Y2OYBFMFJ-.RFT&CCD>Q5FQR[D M;1X_T:G<4 !L\/9=^3_J_&:__5A\?7&U3)P$08 5PA\OC+LBZ1NU/S\]!Z6;OU;I]O/A;9=;%M[Z)^IK9NDE*-=:+4 M\4E"(5AVD@P _, 5NOE+X; SBE_68:5)R@&L;)UD.MNB-9)9B9:OC_0PP0CG MXC+(3R)75429)\R011V&G:R&*.:.5R8OZ7)D=^P^.3U\X/LA_VPR>0B.WX*1MT1HFL&.;16P?24JF.<3ZA7(1L,9EL(8X:WXS22%[^SBBD M8H8_JS:HT3UW!KN!NV _ENKK/K[+O_6M345[F-T5#*G;D=E^4M_W+?%4Y MOH$0^]!-+=?U$4E\FMZFE.$DCI+4CR 6VI73"$.S?O;(_U.P05@C[7R2:0CC M8B+:@P8=:D!A'Q[(^ZE'_O,%.(('1_3+7>HJ3?2Y9F3]WC-#?^=O7%S;)2"339&* L3Y(A7O^+\)J?#;F1R/S?T;+4"A/7<:,HC/O!$R<* MA%;'BH;4O4CNT,DI\%0VQ<1V1B(E=;5':%#:R<<=AU J(M\L351EU GY4\J9 MJ-)]:;(FQ^7F(^7Z)(0@=)+0\6V"V W3@6R&88 MY31/#:]BRC<[I9+ZU^)L.QM;I ;J( ^3'&JHU"%F::):TTXHHP;^%"W;5\3W M/!M;44)\'Z&4/#%W;2>G_\PB,?/NHFU8@](2'[!BS M*-=1I ;MFO>S$O^()U7^FC*-[^;._O\]VCZR-][;')GN\08)#O@ _%WUB MP7W< 3W@6KPC]PQ59[1(!<%FZ)$22TX>1)C*CK@NI459-#D[!TLSBH9.OX). M+US7^8O;( ++M8Z.O\:8%_0L[5LZ> MDAE@@ZS%+2MO"ETA*GO+>$%>#CN\O[2 P1$QZ" ;))+HNSR#:*((V\A,<)[&%4!1Z?C1 3&U? MZ/* 68'-EW[F=5/-RO(S&OZB>BS /^3;ZH9KLRY MR5=^['LQE2+/%^\E%^[HH\[HFU?UU4;9?_.=\7=V6Q3^I.FPHA.*F MR [Z@-<4V2[?L$W-X[%<^K/]_>'BW-&MCBL_1&X $T)\ CT2IRYQG,2/(/%C M['M$*#=<&*KF#YT(7U*[M.OXDKUWY#6Q]&\P#(PLNP!'V\#8N*$\,)C7=8^, MKCOH+;PXWJ<[LG)>X=?KL3,QPY"I8D:X,86,RLC/6>#>7[V(Z;\]O3E^Y9,8 M)A9R2!HZV(XL"WFX-R%R/"XE-@WSO &3.U[BU^-E M%R[QTW#9_OO1;,"?6AGI$9'[E$W#+C*;Y"YC/LRJ]6A6[8ZSJAC/JKZFFHVS ML-&-7NSG[:PZ/.;SQJL24^]LGME=K^1>1L\: VZ+-I::ZAU\]0N6(KJCTMUO MTK\EI\;0_V6]@FG@8FQ!/R2!GP8$^5$P0/<2)-1*8 1@S5D97J^K/5._W0'3 M@E4*::\N4*N8PZ%F5"SZ6RB&O:Z1L>^X<''"?7.5+Z;.GA^PB#&9$IVE##7^ M6CQ4?MKE#UFQZ3?]Z.^W=W%V/UM9,4ZP:\. Q&&*;!_;T!]L03XB1L3.219H M#J8]MD/#!Y/4[H)AF?8],RE<.M3.YG\C8^\PPY+1#.NN6<;G9]C["LCGG+Q$ MA%8RZ7[PD*V&H[EBN$*/+A'43S84K%P4X!0AQ\=!Z%LI@C&R!^R.C=%205P> ML?:@+?_:H5E$+1":Y_&J$:'XVD"V<*M-.GT(\76!5PHC&0 MJO+8$H'SV=L3?<#W@RC&5DC_#[*0"VFX)^A0\,:.T 5"RZ/5'# O1RM:\ LH MJW*X]7>YH"GIUOD#IGZ/&A$L7SS]\]Z7IZ_Z;:8(.6W._'C1<2(?&B.C"D\M M$16/QT3J50H=#R8X\0,OC0@.<>P?%K].&@N]<;041LT1\,4!L.4"GY#GY@]W MNIQF1) [<2CP'4>YD1$SQ3:9"?+C130I%C3&,7FO+!&]^C ;H32R_=!RT\CU M;<_VTX3T0$GJ>)[(A6$+P!.*6=)WC9WIEEPNB/$Z'%7(C?X^&64>-"/Z#I=;?\Z_YN4^ M7P51G$:IGV ?0S?TO2B.X& #- MC[Z':?3YC6GT#J/O,X\N%GUE9]:_0O25YF;6Z#O-@_/?H?%:^K#;YT.O;;TB MGA_'/O0@]*,0)C ,W*&B3.P@AGRAUT#@2<<,GBT_VCT9 MZHC1=DN&8M\M40,9\L:K[/OHARL*.K!AS)X>)*[GD]A"PXGEF+B$,_LR"/!\ MU0[V1-<@@8_+U3QD'3M_H4.G1TVJ;AQF"'LE@\;KG9JIB3)PV/U[I M8BHA&NL52GPU>Y'B]ZK)#]L9&+I.X-DP)4[H)PGTPF@XM12[J6LO5(\0PJ@] M"+9HQ';;%_;:S"4&]>XRIYK0.?^M/7*3G+]0A4#;)#"H&%".E<"D5?^8_#D6 M^%+._L'6\G(US[YW,XV]SLIWQ[#E: M;$02I&#V++5W,NLL,BA=6G-HD4E9U)N.FF7O1-EL^<'R+87$:-L[4>R[)?9. MCF?X1S]K3_>OP@#'""6$V"FRTB1R8SU']E*;%< MR!3RY_PQ4KD/30J*/T0[P?P]!#)SXL<+KT EL^K]Y""9VXD3N MX:_WDU#D_DSNOU1(Z<4OO!QPS/NA#Z.>^4*%"3+CTQ*'74V<&+,D40.JDY]> M:,/83]/$%DT@@6B&9&HRQAF2JB7RJ.F^TYI/S>JV&?.J"S!8 M=O'^4ZRWG*0^U5(V+;F!+1D3[ENZ+:X.]% MO4J\),5)9*&((-P'1QX(NHC]C=K5ASVI71HP)\,CZ#("++$)RSZ M"!(3$WYNM.C'$QK.:(8<76;HA"3V2L6$D=2#N+K/BG(5)P&.O#!V281L-_(\ MZ-C#*&Z,A6I$HG_WC)K0(9)5!5ZN!'5! TWRRO 60WJUH1N=1QT$23-,'T31 MGU((*1:X#A8EWQ^*7;N^HH/]5Y[MJ.O"W_+[ZWRW2A(4V8D#,4J@#T,[\J$[ M#!?AE.MQPLF#:%:-*+\MRAHT%;M.B"XA@4.S+X$S%I/X.R\@LU(GIB1'5!?M MJH4! PP9^+/#QBF]TRD4.%0R%Y5R1T F4,IW5..,^:<.5JA@S(!C$$K,J!3/ MI"D:_4?YC[+Z5O8CQBATG^]1'>' MHS99(W(4;BJ%,DJMCST%8MV#4Z+7@EQ.D6Q]G"I4;6YN)87["0G-W?5KF@>VY5_E 8PBKPX1CZR(RM(XF"(&([E>HG4'H'8 M$/-M$!QP217N9!D4W!K01Y[TO@ W;WHW!9XPP[,C($>E&5YE-4<#12J4)U% M"H:GV!%2'D%"3=4>43/>5!\I7GCUYPM-I'/6AD%YW/[O_:ZH-\6:Y5M]AN60 M./0L&$9N9*4I)J$7H7Y4F.#($9&AJ6-I5J,6GICJ3&:/3WSF)$Y,@UID75\: MPP;&X(3756JTZ VRSDB2*IK-4"9EUE1Z)J/P!BG9Y9NB(=EN]WA3[;YENVY# MUG,)"0/D0YRZ,41)D(;^,!ZV+:[=C^FCS+!IVB$#8VC"&Z>R'')OH 7LM"W"(G3T$$P2D@2> >5)$GDB^B5X%^M M69X&-.W"9)-_S;?5 ]LS$E,F4;KXA$@C4V*Z)$'ND'1*YK3=P2XQYF@3*U3*HS MA4C9*K46#J?7J8?LQH@]LH$CH6JU,+%F"(\*0]ZL6$MR,TV0AMY;G&(_M8+ M<1('.6YJV4-+ J)*]0Y/VF@Q41)V0Z:"*M3]$D#H>H4RI#]-*[%EQ)Z3=8I M45.XE$J*'WZMHM]VF6W[M]F_Y+NOQ3K_\/E+G[*%B17:CNLX#@Z)3_\O3(:C M BA)TU1,KJ:-I5FQTIS.F>ST%3%Z^.,5IOFH$]6F#AGHH8$>&_B)HOMYH47: M&W2=E2@U1)NB4HJL>2%4*EGBU2J2;0NZ^"^++-UEY?JNJ)E61E6VV_3CTA$M M*[!)8D4V'=QU73_LQW4Q](22J^FC:=:K(T QR5) (Y]HS&PFS.=N_+@2B> MM>$D@LW0+D6V<-P!(\L0KV8E-S?YNBF^YH?!/V=-SJ[0*M?%MFA/ON"F7SFQ MSJL]Y?WQR2^OXL3&-HYA"'U"/">.Z3\&9#1/#%9?\]UUQ:MM9/C];K:MT)&[NBW0>'W:#[MJJ]%35%GVP/*Y/M# M7M9YE)?Y3=&PNGT,+:9O#L5,8)I&AP0MBFW^H\J+HM2<:(T0@NR>60%V^9:] MZ<*NJ6CNGST,*'/1= M=BJ0'6W0RA M(C&D+A?L5=C#%"FZ*<)^F/=3Y*?KSN:?I[X2J],AK^0SYDP" T[/F\%#9=KG M*;:<^ENVW7<)V79;?02)5(64#ZZ_4+2CZ4FK-5\'[" ;P(L5B=0SSUEY@!8E+HM 9[DGPZ/\5DM0)PV@63_8*1S6@ M UL*#ZS'^,349J>,YJF@%,SU$N%(97R M^:;B@'"G@:[#WHV,+0MCVP^Q@Z&;#"/Z)!5J4Y\RCF9-:A>IHBG%;!(4N[_%;2 M#_VN>/B4TUE9-MEM_EM1%O?[^Q6"06 [H>N[?A@3&UJQ/6P:>$'J<#5;S0)D MX51K5#*K!B/ P\$*<-^9(5!!U>XYCIJY24X3TU'FKW.9W:@(?L /C@: W\SS MET!1VR2_R=6M%7UO4XO1$XD\56^>RS\&E)1G,[5:8/Z+K0[^*'>'9^E8,V)7 MA:Y7,79<.\$HO@O;SIWCOYHZ3LC7ZZ"I,H@7'H MAPAYL1-:29RD/0IV1H$_9]4PMNXTM47']G?91_:89[N:A=$24/$#^1&G0%ZC MPP$?"W(MEFT]:)@Z 0.^-RYOA):46\OA7%O:#0$JYL#_DLL@/XSZ%HU_* MPU?RT/EEW_IE]"M3\T9QMDZEBAIY-R [U&E=-<_L%8AEOQ7;O&ZJ,H^R.M]< MEJ3KQ+NB4ZF^J[:;RYO^K!U>WQ7T3YMXOZ,9[-6WZNJNVM=9N?G"?M[D^7#/ MI8W\-+)HCFHY,<219V&*U;5=%(:QY2=YO P2BF M ,.)UL$NT!G6]D?)/'BR@(\YHJG9[A4+ML\]>_F:9R]/>Y8:!0:KP,&L=^)K M@8AMML_E OK1]]?#5SVT,S?CKWK7^SX;?+_I?-]\8TW1O>_KP;RIT5XYTZ>2 M@>5<:D"NL*#QE1&?E4"F<=GE['H=#^Y[C^'82^6&4N CC,'3XP$]=A_+/0WNR@*C+4\<1AV=A3;#_I26L7RD-#?\2P5"> M-X&8-@M_UX4N&*'9*>-)?)!2!U_ M/<(#+3[0 @0_48CUS[-?YWJ:J3/%?S4,F[$%H,B6EW>_*F.(^[6@?%?D=?II MU_<H=CRCB:DYP.&DC! 5SWC0D^ M'#2%R//)SMP?Y D#)VN-9;W7#QW[/= M+BN;>A@H33!!R/)MB#T201B'T3"01Q!_=5;NKY]'A&(PP!)8+$CRQ;'"TD^5 ME-8<69)96TG2);"PTD^;W*KJ0-^W'MG4)=6KAIY:3TUCQ8#%U$0#*F4S1"S% MB_9U4>9U3:K[ZWX_CE1E76SR_AUN"J'NA-U>1U4UV18\T)_>L7.:ZS%.L410+=U\F>%B3(O)]P 3C'!>@"=( MP0CJO(FC"(=G,DDMKC CM=1C6C7#5-8FF,E?^Z)Y;"_WI8OW^D-=[_,-+C?L M#]GU-E\1/_'3Q G=P/;8Y>.Q3X;T. A21^A)ICEQ:9;;3]EC>X-2<[>K]K=W MH&"XZ"1DVXWU74;_EX#=29&5C_^S_=,]589:?%$^JR>52_6L3M2JY!>@LP4< MC &=->U-.H,]QNK]6XY0$PZ4N?O=10MUELL'$\7LB\8:O*;CUP4#]2J2R]T M9.BT^]+*9/?3E1>[D>M'H<6>D@\BA\ 4#> 2UX$R848S),T1AHR"1AM>J-C\ M5)1]=#F]9[*HE\1"B$$.DHP>(PM>A(@A0E2[0X"X ,>6_,Z494+&-.(YHL5, MGC4K4,QE](D8,2OG7'7PUZ-7=Y%U\R2.X76S/[PM'/L>F!=R>\GEH(0L4 ME^?R&4?QWD!W35]D@)'[GBXW.B,.CG[^\>07E*H(H M<4,O=6(/PL@.'.0/>4:(DY!KI3#U!/@YO3I/C!]=-4-7]J]&_/G"_!OT3H_TJOSWKH*],J/E MXKU:SE6OWML+Z^)\LV>]OY>O)2+Q=0XEH]"_Z9 M73S3NO_E!_QJ8C#?\O]MFA54 13Z\EWE!TH-EZP)*.=>=6F@JNOB>IMW98K^ MFEL[3#QL878]& IM-T2!GPZ(?!+R/^RF&8?F3. U>0$//="^5-AKBIZEHI1O MU*[V=;M%ZQ)_<%6'_JT;NN=WE9ZEO&Z7J8O5)T/UB:]LQ@7[*R0J6*5/<_:<5)KX5AZD3Q;?M \_UTY?7+F]._$\&,Q[ME4O< -H628D=I@F.$P*'6QHP)$3!^;GY,>LN MXAX>'[C)BEW[<&6[#W0JX31!BI0[05BSEIL&)HO;@JQPJ>#27I.M2'UI\H>3 M#;)%V?YHE[/W@WHM'IY6J7+%&]/K'S-['7IFM@$N@5J9',XU*CZ8>1;WL05 MDS9]=P_*K%)VBM(+PC1F'9HQBK%E M]4-&,/1FQ .LBT%8#V^4=-#FE=1S M))W12"74H_NPKZIAA(P% ^W;==A.9I M]2']="OL>6I?0'HYR37T-KU*BT"%9AJM9M9>)MKT1E5%!6-",63:!2.?\VW6 MY)NK:L"]PL3V?!P[<>"0.(:Q%<3^ #7Q0_Z7>9<"J/UPT(L;H-B1X!8E:*K1 MQRU\+]2R?A6(:O@Y?'.J-&[P9UIP^_TQH&KZAA=WX/W)<*O MR;-@8K3.1K,A[V9#<9@-Q>$&L6*8#4T75(5YQ?2_E14LY6V# MDHC%*'@MYUC6'Q,NHAP?FOY;Q?I0#LB']?1;]\)J9Y37F7N[TJOKZI^H %=7O^Z8]LQ/O*# MU'5LWT;0"7""T.&^JB@,;:[:H[+!="_JLOINRNL103RP$:RW5[ M<."([@*T^.85Q;?8.B-_RH@V0^C4F5-IFI"3C[9+7;^>5KLO>=-LVTWHMB_Z M:[YKV!'".+]N5K[E.;&#L@-GV)$F'O:X3ND9!EFSD"8G%LOL9LWZ M +L_AS$ !QN*?/*A[$4F@-SFT#OPO8+=I9-G 4\6V/#HV8[VCMVCM:S2-K(7 MQ.]VRDP^\F_ZU%%[.\!H"C6C*72J*L<.!Q_*/3YYG';_&RDK(G02!:P;YS(-L,_I%KM0SNTL4%&X8 M9I8;'-N#6]S#JT=#ZM!B-\$S$X^6S^TAA?61FGF*?CW'IL/N ^H?,AHB>/L5 M:2AU\% G4+A0Z@F# JTV$]\ZX:V>3]D2P1"M#V!&O4C'F/X2G0UCZ,#8LU$< M)99%TL@?]KZ)@XCX P4S8-(<0#]P1TUU2WUM[I-;UIO@.05+^./R?!1IGW03 MCQ?SBJ+O'%Z=MC(WP;L*5^''%?8H2C_Q\N@M8JV1>SK' HMKW5XT*+[/:?4; MB^9Y6)==('_.[[.B+,K; 5YW(1W%PE#]\4!3EM$B_G+?U$U6;NCODVU6W->A,&.4'U1$] M6+?PIRWCM/M5;NUMDDL5+,N/+CZF"_WC1;U)@-GTK, _,@N0]^#K::MYDWRN M<*&_>_)Y@]<^[SWS_=/*_5*.I M.HQ1MU!>^58:A8YG62XA'O;MD*#ANMO81S[7;7'S()DUC7A59Q07YQ4[2D>F MH--'\^0%U&>="2 RT&%W=EL4_\\V'#?U*BIN"8<$UC1Z'PVVX'+_607]&/ZC-IUWUM:CIWY!M MX[SK@[S*OH]^;X42VX8D@'Z2T S"1M!SAX>58V)[R>IKOKNNY"/V8L!%Y&=L M(__V^Q$BV/0809-]%WU%R4#NI&/_N_"VDD1AL!2,306=K<<+#MDQC/%K3;V] M8#QW!HL!-7G\R^]W]DS-0M[%+%):DCC,IF(\F[)N-@TW%+0G,K:CV93UL^GA M+26BOZRE7*'+44()T>*SQ=3L:7EBWDRUEHY5F=QWGW3W8'<_N6 M8DU-R8NO##X=&@7(LCT<8YNX,$KMPXW^,<:QMRKSV_;&&/Y#_TK&Y1*WL!.W M%Q"Y!6Z R"Y0SWJ03.!ZE&*7 :CA^WPR,S_'4FG( _\- #\N;NCOJ?X\]L4 M:[D9@(>V5^1<"^MFW!"@UJ1*XRR=>E, ZYAJ>^&Z)G$FR)_9CU:A16(+.A'$ M?DILVW:%UJ3=Y0G#:J[XGCAW.^HK6Q\ @_9\XM1CU_(.D%O@S<2] M@@5:?[=HUVU]Q H^+TO[U!/KL]"O]-3YF=FOY<3X*88$EA0*:#9S2:#"L#=/ M7ROBCBLJ7>TRFO"7MY@.E-WF;8O6W]CC2RL4$C>,[="VT\3SD<5>K!\&PVG$ MOPTI/X3F:#, UF'K.N$[%_G9>W*FVJ[S78U>,AWW<]$.I?A=O65_QREZ:%;M65G\[OL[W]Z*Y^Z.LKNM\UY9J M/I0/^[9T0]U$T;36L7_=[]BS65%6%_7A*?E.HHF+$@NFH87<)'&A3]S M@B) MPC2V(]=+5@_M6UM?FFS7\.G=,CA%).ZY22+%Z+P],@3M"T"%R!2WS3 MXIXS(6W9Z6!&%%N8@\JD#]2(6(4#&U&0KH<2XM'HZKA1C]6Q? +[6)704+VD MY+V!4CQ2#09)QZG@WUJESX\_M%;QK]O^U]:V\;.Y;M]_D5!=R+N>< SJ#( M8CTX PS 5S4"G(F#DTP/+AH#09'*L:9EE:\>/LG\^DO62[(MR\4JDD7[3 /= M[2B.N/;:Y-KDYB8YX+LM+]1/$6GD((>0U"-K:YD?W7J((YC@;S6<_[3,D4:" MUC)7PS*SO;I3OT3L<_M>RL".8,*#U.L8]*69_J"ACI]E?Y"]@J^VQ6+?-),E M$&-$4ZFWA& @PI2TS2 JIY&]Y7'(EUO6QP92\"%85J@TQO\@JGJ(I&V6]%2R M):B&,T0G!_&D(92V^1JFE"UO=;<:NVMUQL:7U'(,'1[(Y2CXI:%NH2^84IT/ M6W436-,2)Q%#$8T$HAD&2&HTYVU+*DK@C9G_<73)EW# M]+-#-$)"M0G35U&;Q(T3TJZC&=+2)Y:^(J=#>?%'40=;<$94Q[$Q8M>?KW:+ M=:GR"U^+'WLJ;?S[+ 21B%5* ((D#UDB$415XR%.!()C=^Z'-#E!F7#/U;UI M;OOM-$U JYY*GZT /D(,_J9 !A7*EW7;597#&>KT*A7&<.]'[M.T4:]7#(SG MK*_L-54(WW;[[7RQGV6(TCB"B9RW)A%"%&28B0RC*&09ICG4D3?-K[8L8S4: M/=W2):>?/EGD14^'FM/??VNA.!:;QSQ<$)6!A/DA'D/!ET8ZS1 Q8(?M5DZ[ MNK:2&-(\%2+&@D55!1G*HT]",MB&LWHRCI'>LO(P7ZW;-POGZ^*+VH2M2AG5 M$SW'/S5H9C!C/,WD/"=*0A(C0:,\%!D),> LQ+37%H"MMBU+T;_-MW\O]E79 MV*[#IBE(IMGN*543$JTG8@I/< 1T%730/]R4VP_J995.X1S+FAZ'EP3/DC<\ MD4);UCT52:LL]I7/S]OB?KY:BA_WQ697D,WR>G];;!\)^(S&,,0L3S)(&&W@5?16P$,GLP W>IC#](N:*))ROW00:,6E?8ZZ(A5Z"RD>8)3Q%,680C5 M^3X&FC8(32F?[B]QC[JO[)*+G2)&K DM,H1Z.6FA.N M+_NN*WN3Y8=X#,1^:1VIR4#_"5!Y7VSW/S_+#K*72J3>A[U7>[N?BOT,)7DH MY083A)(8122A,&J;1 1K9:Q'-61]RE-CJV)QT0*["C:%\R#\,DD7HZ\!;OT8 M.69,>19OC?%C.B_S2=+2#'#&RX54-V<"&>M5O&FH*834+'2H[_ ZR4N<#.4<")IPGO(T12"/ M,LA0TK1%>9C'.J-J6 N6!U.=CAN2-AA(6+^)A7VN].8.C[.64TT2SK)R06S& ML>B'QHRTH339KX8D(.6B*P9A'".2Y1R3A(=IW"ZZ:!2I2[IT,X^O?J63E./P M5./KE.CD&(VR,22Y.$5.\=5D8F]6_!CENJ#/I@\U;>X[CD\OU-HLJTM>U=N& M,M:JY,K^9U?VDN8P(W(2@@G-, 0H1AELFP\SH55P8JQ1R_.'TV=^5$IQ=X+T M'_]7!D'Z+U6:L>^S4.9)[ZQ"U)EG'0_Q,R\6:7E MSCI8$)]6_H%4Y9$1IC'%69YD@D>H:S"*M=9+(YJQ+'IMW>K)0U.:Y;YC*-06 M-)OL#9:PZ:M_7V:HGV0-I=4[D1ILR,NR-(Z;WBNLYA&8YI72=ON8H8AP@4-. MY>R/YA&MG@6O&F,9AU1K=VE8$Y8%J'O_J'E36W,5-I"VGJLR^XQIKM):LAI$ M4Q6#G.7ETD)N')%^R,Q8(YXN]$QPTE=>V/Q^I9(CZL6IZV_KU??ZT'+;:)I$ M80:3A!&&,TI"Q'&[S<,0I%ISG9%-V9[OU.B"=?446]GAN^KJSN[+K?K [8BZ M3-J%D66(;3]&F"EC2BL]/.0)ZYP+'MS99Z-X4^Z"\\3*"]]K<-$>]'X/-H#W] M0OE@IGI'\W+S_6NQO5.%4B>-42@X#D."<"SG#E$H9P]QVU@6"S![*+;?RMY9 MPF&-Z R[4SR]!Y["XS@VG67B4GP:1YT?PV:L$4_CE E.M&J.3B+C28,)B#+& M($(((!)!$HJTWK M'V/(A"'G"FU,<#-@Z3A+4\%Y"J,(R4A&XPQ$23=:01+F ]>,KWZOD\6BB47B MZPQIKPZ-DC-X63C9:K#?,K W27[HPB#D+R_\-*WOO>(K[^Y6>W7&2>V&LW*S M7VV^%YM%]<8=%QD(!4\QP;%(""2X30QS@G.FM=8;T8[M5=X16E4:LC@%%_SR MJ=P7 >[Y$+(16OO)ARM&]>3D*9F/<#E>'[],T*65L0%:_1 @(Y8\70T;8Z>O M0%THT&$920$#-"8,,P X%%T.3"1Y*'3T:40SEN7IRXM%@9IE,V.8["=)CDC4 M4Z134/^GK?LC^_UV]>U0GR/=E\'G^:35-(,* VP[8=0F3"D--X3M2^(JM\) MKEJNWS*#<88XBS %+ 2,0 @X:5NBE&L=U![R_9:%J8-4URU?!?\[_*T5.\HV.^U(YIGLC]6+'L_+JH MI\Q'[]TT@V=%:!Y>:D&2P$$G(:%Q$>0Y1F.86\:P9@O6T^ MW2]WL-XK-Q=$"X4OJE8:7Z$,5 (41U\K)*PO(0?3Y(6##X9]9*H[@0:.,^7!W6,_W17T[GFSV M?EO<%IN='%(?-XORKOBMW*FS[]]03LE/)ZO^X1UJ &&_RBX/YZ M%7RJRTHD9N?EU3J$7E _6Z[Q0QRM6?>\4MLBB[VE=;E""#TCH@,;,.V5':P G4#ZX?5)EC4R#0%+L*-IY9BXIUT@N/5&HL58\52(CK Q/]L]"@*.0 M8H'C' *,"4]8VC24IQ!$.N4( [[>257"@'/_CM+06NGGWF3Z,53&&/!JNEF3 M"U/7:BAJ4/7.L,9%(@)FD!.@/P/2Y ZJ*K> MWN0YSADG6KO]AIN>LD#)6%W2(,[[9Y0GHEL_W_QB]9(?SP/K<3FLT&F,4_S0 M2EO&]2^'&L]A_T73?%\H#-88$%YF@*:@#S*,]B"HR',=28MCB#9GLRH47I3C5+5>X*RA1_,._R:A8VN M?-5/*CUTDYZHJDVHRDNM"<&WG\$ORHI@M?DUZ P)CI9H.>.UMU0?.3CSJ"J5N)1^83Z:\VX-5F LN&DBWN;$_8)/X+7 MM!0\VU6=W!]] QLO[J6NKJH@*G]>%^H'LEF2.W7GS7]7G\]BFG,:4IRG+(1, MY%F$P[9ID6.MBA C#5H./*<8JT3A_ 2<7B@QPV^_T."<6CVI/X5W%70 *X)) M'X*M2'4?TBY(KU'._9!2LR:5%OMH/ZG;/.SG,WK8K3;%3JX=[KZM-E4SOQ=W MQ5QE<.O4T^EA?"00RP&/& >8$D(20$ # / \ZO5@G(5F+(V35R89'F^^[ M7:D<)^=;?ZSVM\&WQC159=S:UG.[RH9'+DODQ,[0$\H69W "-'B$-+B^"?K< M[&&=]66Y.*A_5H];3]E_!%+?"R?].]@^\L+C$?)/?0.7HJ,*1P VP4B?H#,A MR2++TP8FFX:5UGNH[GR\/A-8KQ2^SG^('_?%9E?08E/\CK.I4P'[^P_4](Z^P='%N:(9?7Z:%AJQY M-B,TR5+?]$3_4FONPVMW6PUQ=<#@C7 "*XS#, 9-Q;Z?[AJ$!5OLM==T2JC=]4]C:G*6<,CQ& M5Y\7=GW]Z:MT75 QVR=KBBFZ^HH9#3.4))RD2U#X 6E,^\$/Q3/@EWG;K2UP%Q?!91SQZVZP9T7]?^?[*0T)]JZ;9280I*& M*>)AE*AR]UR(I $ D42E(X$&F[5=EG4K_Z3N,7FT/UZ]#%SEWT_2&-WK!\7- M3;&H\X#G^HF7=1/4R?RCIZHMB"#7UJ8ORHG'56V?:1BJJWL_BQ>4%8+ MKO!#6FT85EKOQF/%M7UI[O=B4:P>U"6+LT2P'!&*$!$@PFF6\Q2U34<1BV:; MXKO:.Q@JK .:[#5H<3UH3]'UKUUI'T_<=J"F'IO/:=(:E2-8]G4\CC'IU9$X MFJ]>>Y?/V_V\+=2]%4VFC&R::T2:AV6KL#Y#',44Q"#/DEPN.6&8D'83%<8T M0?U&I$4 UL=G S(H:I3U3*>Y&:EYV:F> FGLGUGR18_=RPF=,&YFTP(./FZ" MUB4-YD"";B].:CQ"//&(QL[F])X9ML/Y];90^RK-_'/9S3^7AZV:>4K(,K)5 M;Y_)/\DYQZJL"FS5Y_,[I7MJ:7!Z'>)=N2E^5C?JJ-^;+Q_F4K2#FW(;?"_+ MI5Q);(-=L7U8+>18W-_.]\&WJB%5(%?>K1;!MSKEOZO^R^ MWI4*\?JPE-_P>"0_6]9LRKUL[7XN/RW6/X-E?6"OZ$S8G1XN6W3'5L;NX@[J M#"_MYMKM61[LZEHVL'0V2D?G*QYG4.K& >81S2EB&-"$Q3")6)LNAC *\=A) M]:!&K8?M.A[H1&;3M [.+UCCTVANX6D>]S+3KK(*9[C3RRB,(=_7USR;ORQFQN(XH3RG M L993C#-D[R=.T<\CKC._9P&F]52FO!%7XHJPW#!E^CHLG=2+7\N'DH=AKWN*0D3I*$HHR$B '!0$AX M"RZ'1*M4U1$DVS5<3Z[66K7PC5^M9=Q7HQ1X2C<95>?.D+=WM9:F#_2UW9:3 MO=9]:T;WBPEV.>_]M.K\9W-3"EG\O\-J6Y"'^6JMDCAYN?TR7Q=?BL5A6T>L M%,B0%::4QCGE88KB2- 6 <5YJ+91D*!<^3* UAFA(> M)MVY"\12J#6=-MZXY8ESB[>>-JO1:TQ$C;NAIY).Z0%-.7U$OH+6'H$]D="K M,PKK^B%K/48O::LMYW@BL-;,>_8^ME4>ATCMO\WW38-5[=C/[FF ^7J]NX1O M%HJ80LQY*E"4(Y30XWXDPF$.A^JO/41.1?FN,\.",EOTFKY<^^&P,1I^M. J M.+&A?E%%6>&]P _V04_5M^]C_T*! YLOQ =7C/=^_&J^NVW6!DN%K_IYMZK. M$@ 0T83)8 4@Y4D*1)BT%TBJ=Z'O"^NK4AXDB(+,QC1&/Y?QBF/&H!)#$4(_.NPQMVFW:] M;W!64YVB!3DR[SJ"]8%I5\MT&\NZMCCE-%,AO>H>*;U,NYNTZXLDZF1=QWO" M#T&T8=AK.5=3W.G*I9Q"GLX\JV*T,SMILRQ+4\PXS46<)*$0:23:@^ HI&G2 M:N97C86_80@#U/.KD_NWC'.MIY1.^1TGE^JD["^/UN>_-B6YYZH-IM',GG3V M$$[3CO%+/8U;]X*$VF'1?'W8#*8 X4C ".<)"7G$4I9W0HY$:J":=DBSKJII M[T^KB YM%=&YLB];55^O>Z"?L$Y$OIZF#JC>\K4VRTC]56]7^*&B-@P;7$>E MR=U([^R4L)VB>?*85?7/1Z)W0A3>S2/1^7NZ; \/RK'WOIF@M8S@=V]RSRX$\ZMO>54@V-X M%>)OY7QSO5U];Q]=!#-"DTPV2#.&0!QC1J(X:]L4,1UOX54RV2.>![CG.5)DJ<<<9[F[6'"..* CM@>'=ZHFPW11YMW2^V7 MUZSNU;W(78_=N?&\>S(,S=GSP@Z<*:;TAZ,2@+JED.<1!CB"&..49!D# #,J">3\J>+K\A+7LOATC/22 M&WW^?!.8 1:\*"E#V>@K(K]WA?6JKEHQ8V$F M $7R?V'.,J;>I6E+!Q+YGUQ/7$RV;%UTV@>;UM4E>O=RS;A8W1=]UY6!34XP>I6TC1(O"!U-ESAAP1:L:RTWY%M M[=?/D,B(>AB191$2(LVC"+1IHR2"H3!0ZS2DV2EJGW^==]/[ZT8I MM[Z'[NL.N9%=\-ZN\$,S;1@V>#=;DSN=@Y/JOZJ:_V&^+JK'U7;[[6HA)V+5 M&:G-\O$')[_YN7HKZ/DMLNK!( E>_%A4SZ#^+B=UHGK<=);S1$Z4,6 (Y Q1 MS)),RGX<@I!'- HC'=7U#+H#Y3[W>-1J4PGZ52WKQ='"ZO3.MK-_X-E/CPC6 M.$[J$6I[T855;J_BRXD%5\'1N/HO53]X^MFC?U ;'9RYB/PJZ$P/6ML#97Q0 M6^_^&*P[SUZ(>)YV,3^BIJ_DG#G_ZR-,=]%[IBZ1#&$*XC2" $412_)V*RI) MH52@3 + . 0TI<<52D8;/1&;GFEHNVCTU:0% M;DE+"O4JG5S8)TM.ECAL%Y4IETYJ\6K-#NOKO0J7@ZE^Z\N!EJ2?475"EH23[ MH3Z#T3][3&\,"SHK-*5?GZ1Q\L?C4?C-\LRF$5_M%NMR=]@6G<@E""5="@/[DX1+GIW"9[<#1ALLG@6,Y?674[<:2I5ZW:31-"O58_7*UE[*I[IT^D+BKY($'3M&X ,,# MYPR[\B(_*+#ULK \[*N5X2]R:2C__]=@OMN5BY4ZK!+\L=K?!O>GX^YF]4-^ M+G^E4/=KW\[WP>W\H0C*16WHE:KC:Y(_\Q.'[TOYRW(HWJFAV8[,L1=E#*/_ M3,!TX4P/+L.P;6'I;FAH!-MF!5-N[^?;_:;^0]T/=]MBK;KYOER4R^*A6)=5 M$)E_WQ95XF2U*=5UMG5GEU&D"2(G,62&$P)2$N4@QS#B% K$XA8OA5#T#LF3 MHK0A)6;!QFXY0BM?]JKDUB[_;8:N75\!C,>9GF(< *R),T9 R0.P[;Y'$"M MW7MCC5J>F_S'?+N=*\%1=W])W9"+'74'V%X)C]2"M+['@K1.U,NEFF.^7U)U M$M+U9@756YY'C%=!AS(XPKP*:J!N$ZU]V;N0<37N #]2K^;-*BUW7,VB3G7] MXL=* , L33.48LRB"(HXRF. NKK1#".0:E5NZGRQ9:5CIQ>7-FJG+@V;O_2V MIF:QIA:'_?3,&GUZFE5?WUOC<%Q5>4+ I=+)(3SY(2W#H#\M@AQN?^_;-^JI MWO7VLYSW-7\X>5;S:S6ZU;&ZE[W9A#$J-<5_T4Z,IW3 X]:*P=M5#)VBO@A9OT !V?#N''ID7 MQ,^66_S01VO6/;VLPRJ+?57VM^-BN&L)"9;#+!(129.,YI "UNDY +'6JG3( M]T\P+9-KSUVQWZN]ZQJE?K)S%*/]]- VF7J:=X)F&D4[0\<%U1I#GA_*-,J" MTEQ7TESJW/?%9EA_?!-P0U.30I.;%+7 MOIW^7F-74!FFSOI4ILD?CL8%?U/F!8U]K@\J6G'2I<7YM+W"CV Q-0E/$P8^ M^,1ZR/ITN/M6;*]OJK_=D8?Y:JTF\1+M7]2>QXRG&",:)3!&# .4$L9@"Y?@ M*-&_(V($&QIGRN]O7.6,T6!*Y\SZ98+)>6W C&6YB..4AB%#&!-(<RQJAJ@EN0[T/:7B+?S;Q-T]%O7,S&VV]OMC;($\XF:F2YK+*M M\W6CNX?];;E5MR?,TC#CA.099CE$ G!&PG9JF80@[55H[ -.VUF&#EDC4.HR MLF+[(!>F?43+/[=:SCPX]JCS]$-MG]IL/.D9S3S^:.,;"6*O.\OF%-U %WGC M@2),'JAH"41AA'&(0M4LQ" M[#*+/@2?Y>#6(*M3#I-$M#&^$J-N7E]J:H#ZVV<&<0 )1G,4(QE?\;QA"0K(NB M40;T7B&< F$OF1OS6F&-+5BH'-%Z/66 &N1 -P'*FN< M8S$\C>D*[R,\C6+ <'@:[XT!QTWX8;O:?*];JQ=NU5\VD,2/8KM82;@SE@C& M,,@$RP#+!,$D:?=;THREL6;T,0_ 47#9!44+:<)="&WZ^IW=,.T+3S3"HH$O MGP.QPZ7U":BZU&__\WCN;7>MS@Q_O9UOSDZB9X*@D&..4BZ[*F,I!"EJX>-$ M1(YFI:9A6U>3?]^L]GJ)%+_F*YJ$VYC$V/*Y)ZKE'2VFICMV_3:]0C;S.'5Z MN+4 8<$!S06.0H+3F,$X;BU(\Q@Z22M;P&TYW5QKI-YJ_HVIY#/.)Q'*X9Y_ M[UHY@AEGY.7 2=A((GNTW:3 =4OE--^]:XI M'3A; ES4AQO>;I&@ 1JT2(,*ZF2GDHVYW\UF]L2>GVZO^_HT2+:FO]"9IGN3U;EWW415 MTUWMW85=XP39B\MV?.E9X)[!F, (HSB'D$=$Q"PD'?H8 #[I,<11R)T<3J3- M\F.^K^X-.1Y(+&_JBT2J+ZY6)TO99^;;G?JH7JDXKCPSUB.\"N!&N\';B-KO M,E1/'Y][]Z0_55#NS\HTD5C3:\;"[TZKI/RB!2R$(4UB#CBAE(F0<-)6FFZ6U%7',>'1-U)^A7;R3R3L&, M;O2=S'O.(O"9JOF+9B1)E'.0QS#/>9@0'.&XW3C$ G&S>6O7X!W%XLTWEMPUO2MS0AMJYN]DS!MC1[3L=JN'YT%[!9D/R-2 M3!, 8(8$9Q1F7. PZXQ@##@-UV:A.PK6C\^K31ZL#;O?4:B>SO,3!NK.Z/<; MIK7\:C-(V^E@[R1$6R+'=("VZ4/?-I0ID7,*2D24)S%E60Q9%K7H*2+AA'6M MHW [J'9]LIE<;);CMI'_9S_028]X(UKJFI6)]@/UO.9*/8^7(/+5;K$N=VJQ MUA;?S3 />0BS)!=Y+A=C(.=QJ_@DBIC3-WK&(;6\=#FY*G6UN2FW=Y5Q;NMH M1KK23?6,.R].5S-STAE.C'RS-:T7768Q')KI*N\C"!KBPG#H,^DA5P&O"S$KO9"^+<5LYXYQF*<&MX)WD=L&F&_X7@TUA,3Q*#+!2P"IBDB,9/Y;W>6@OOJE)D/IQ^,]07G$<]9-_ D M#KZM?20S?G03-HWTI'<73,VP8B_$&O2:5N#]]CKZ;]JYVM^+N_E*'9!CY:9: MOA[FZZ_%]@[."*><9Z(^-)DB)C+0WG] 4D#TEX>>X7=U;T ;@[**05($)?!W ;^25?7OD1V*QW# M362?ND_XNM1^+Y%]@'\M1G:;O>U]1':K#!F.[/:].4%)YT<)>+79K19_G:\/ MQ0Q1&B498G&:)GF4B8QWEZA2 5 XT1U^FBAM%R-]_[ZM7O@(5BVNX$$!F^Q> M'UTONLEENW&@)XOESL+@KQ>[@I?9ZA<]Y:8:=V#O\"@$3LN#O8K;49Z98*'Z M&"^8Y0)RD>*+UJ"Y,E\O.N<'H-I%3G:\E;?K3DR7C M]/'-BJO)E\9A%1_,]('T):#8XU"'3\OF]MB)CN58L[/D\9) MNR[V,F ^28V^Q0,N?9WI/H8.[T_O.IB.H,5-5!WK-W_"Z\7"9 $)RS.2AP!1 M( 2(,DY;HS+"?5B(FC+%=66OAZ=K;'<67R*WLW[R%N+YNSJH,\[WDX9_(YWR MSS(I,$.6\ZF"01^[VH[5-NI"^104!*K, \HYBI,TR41[PSQCJ?CL;?Y$__^@_M)_)_E!;\ZS_\ M?U!+ P04 " !0B%Q.Q +"N1#I "[^0L %0 &YV=&$M,C Q.#$R,S%? M<')E+GAM;.R]6W?;2)(N^KY_19W:S]65]\NLZ;U77FN\E\ORL5W=^SQAT10D M88HBU+S(5O_ZDTD1U,4B"2(!$**J>Z9M2\A$QA M_V3+\?(ZGRY^,K-\M,C/?_I6+*Y^^N=Y/O_SIXM9>?W3/\O9G\7MZ)=?[AO] MM/K+I)C^^1_Q?[Z.YOE/W^?%?\S'5_GUZ'TY'BU6[[Y:+&[^X]=?OWW[]K?O M7V>3OY6SRU\1 /C73:NM3\1__5(]]DO\T2\0_8+AW[[/SW_^*4@XG:_>7>,E MU>/??WC^&UX]#:64OZY^NWET7KST8.@6_OI_?W__>27G+\5TOAA-Q_G/_^M_ M_/33/1RSG=DTZ*Z6VQ&.5_&Y?7O\;?_ZI'D]C\\U6>+TQY M?5-.@P[F80RKKJYF^<7??Y[>+D9!?"@@NA?^?^YNM;B[R?_^\[RXOID$P7]M M=61J/)XM\_/WQ>AK,2D613ZW^6)43!H.>6]W767?';=ED0U M.^U2KH^S\B:?+>[4]-S]:UG<.A/V[8TRN6\F.;S M>7C+UV*ZFN?VCVY'F^Y&]6$TFX6_W>9UU7] ']V-.DZMY\M)?G;AQN6TO"[& M.I_F%T7XN"[>3<-T>UD$I:KY/%_,W?>;?!R6JR^E#B\=38I_Y^<)PK;\Z@XQ M6EY?CV9W9Q=^5,S^,9HL\S#"^W&I6)ORW9&&/J_+A;7JU5N>F[*Z2(87\$(*_8/L4;3SL=H1C?AVEJ]=NY=&=AM1[%?[:NO9H]=R]AM+(>_;Y-$6MV MW;F,#VN17RZ6L_SW8EI<+Z]7R'\X^%SI,!/F-K M9] <\-+><7DRMO?E:!H:?,['RUD1[/G+69X?L#OH^+7'Q>9#.1W'#<0DV@)_ M3(/Y=UY$XV T^;B3T31H/ M]L5>VA_YYT7XWY5.SR[,:'[E)^6W@Q#>V4''XRVO;V;Y5?BL@L7SOIPW'_>V MCKH>__0VGRWB+OUC&'$^F\7?E^,_X_H3_[PJ)V&"G4<_UN*NN7!-WC(DR1M_ M4"V_LEM,UFM #?]<_1[:&7$5;HDNU3#I+^[>32_*V?7J5?O&6J=M.Z/<>'I^ M#VMH,%*NZP0G=C;J<%PF;-3NPO*IKLOE/3CS17$=%;IY_'Y:&DWOYF?+10S< MQ(!8W+/7M$RZ?F^'Z*R]$J/)N^E\,5O>FQR+AQ%./T7K?!;&I4?SHJZIUL&K M.L3@?7Z;3_!+PUL_==X1(FV^N$-\#O6B'-1)A^.N9VO7:-K.&'_+R\O9Z.:J M&!\PJ>]LU.&X'N^H;O/I,M=W)LYCL[N:)$CKM4/)ZK&B1M.6QEB6Y]^*R20L M$,\C27O'N+]IYV,\=&YHT%7G,CSRN1338I&_#V/XX:%T^9J\IGO9J^C=@W6R M\CL%JR58\/]>T7[M3_DQU/G/8G'U($L;$'4WFOZ0K)YI$8XM778N4\VYLFX' M[8SWW33\-?\R^KY_9"\\VOH8#IT!:S1M?8P/4\^CC*2+Z'[1>5C=\D>/ZKL_ M/@=%^O#3XG+Z?Y:S8GY>C%=;W<,%[.2]/:'S<5;>%C%1,@SIT<-M@5"O^PYE M_9"';>:]*"+HRT7<2D4'SG)1 MSNY\?I[/1I-/88%9N=?O]^ /35)@Z'(@/>+WQW06?G(YC=E+X=$JW:E-9.J] MHG69ZZUI6QNT-9Y@H:P"/.^F'V?%;2# Y.Z_\DG%@=HX']1-/V/?]_M4H>KV MWXZT85J+Z]7'^^2/L(6]&LWR?2+L;-3AN!X^-C5=%.?%9!FMBW6 O;"VLT;6>,9[/+T72]S8MPY//QK+BY)T>5G[EOL(?TT=^H#]TDI/39 MCE1K!YT:CZ.#;AX6[SQ,M7%C%X=S;^>MG]DG3(.N>I?A4 6UT'7O,CY,0+:8 MCRXO9_EE=+%L7+$?1WV^17Y:UW;P]O?Z(6+T+1L5X$1:S\W+] 7XI;XHQ M ^QL:LKI>;33'V+#CT/#H=?'>29=(MK5('O'O=Z*U+C#=N3YG$]61SS^W^5H MMLAGDSL[6HS^F(Z6YT7XZ;[!UVO=QTAK,O*@3OH8=SV2'-)'2Z..R2UAYQ@^ ML3#=?PQ?U?Y!;F_2V9@.7>L.Z**S,3_:5(S##XO%W2HC]H4GFPO5^!U]2!T/ M3:VF]OD?\Q@V"D/(9]?KDTJ/#E_%N?T0;VVW;^T.F?BCL&_*5[O^L+P]C@TE MB'Y M]W)5H5]/LV7%1,31-K?6V>2U)RH]S5L<7P'Y7EVG;/Y8_^-IN9:/70U MXH?)XE$.VS_C(&(:3?GX8$(Y735O+%KRJ[K'8.4:N4]SKL;P*9_GL]L\1K;N M@]GOPJ0:[>T6<$AX75=8'/#)[VC7TNBJJ>]S<3DM+HIQ(,IZSQ"8\[&<%'6. MW1[62Y\C/WBV2.JU3\G:U.:4_)>CNF]S_/]Z&O^['C-2^TFL]F39K'8E8S% MKB!;2?)2;RV/-,9^6AWL\PY;'F_X2HORW$U;AOCE;CL9^^?%:-8RYMLZ;GG\ M7\)TF;<[\A^[;'O,92Q5T.Z8?^BRO3$W(,;BQV'69,%-V%O$%2^Z0-Z''ZR? MC_VF5*^[?U_^?9%/S_/S586\ZHV3CFU_CI/YK M/EG,JY^LIOE? %S7 OR?ZQ]GCX>S/A1NB_EX4L;C'G/U-5A!H_&B&MXD8O/W MG\-0LL,ZR+CV&AGJN;52:"\IYL)PQZV7AD.#G@(PB;40R]D:\6X1^+R\"JPZB_CJV*RB=3$,IC=\J7L30U!SFH*^/7%.:"SV:%FR<<3G#:( M=LQYBH**A)6062TDM9X83RC%A!UOVG!A22CO\JJ2QB/=F.4L?@@[A-_;-N-2 M0J0"SXV"5!%AF(.5W)BB6G*?]@11FQEEM]@_S K=\BT6.HF"QY,\U0:\&OS= M?LK5:1XD)QP+PL.4BZE"QD!-UI(S%5!(8!U*8=VK)%H'B._GVH\[^OB3[(4" MCC^N*=M)=' ?&>0:4<"]8LII[R5Q"E1R(9)DX."W.7]UK8.^YC&[S+^4ZN)B M==8AWS]QO?A\9H0)'PA5' &GC32"@VJ.YN%+,@G\(F]NIFH#XK[HLRHU>LZ/+>1B!Y/KD0?N]9.K+EI,@0@KG!GA%ND8!A#[#YJKS0O>[F![GA2F)8&Z ?;\=5 M.S'O!'=;R"LHN5(41>THR<)Z8PA$ALO 4:.F(:QR:*L]!,/NRP>*VF5=K@K M!:-F%YED@:8*02@\$1XYBC2I4, *N+]V;+5Y\CS]HAL5]+4.;1VTOOL2!J*^ M%_,=_*O1.J,:". PATA#0SGT2/JUW-2'C>P)4Z]];I1=XW]TWL5QV_)Z5$R; M\.ZA=::!!41(CFA8ZIG5FC)0R2TUE2?,NU9I49=RC:'OBW(K]UH\9?;N^F96 MWN;KTNK77_/9#JKM:)5)A G 3 $6]A%&0P2/9DQ13ECG&.#F0,*:DSM6AX&G$VAT- ]G5U2* WFWF*NJ[*HL5CA MCU(55*'B3\ENVWH'L\NR=4Z\OUE5*YJSL[J M3U=;6F28>2J@U]1101G#3H*-?,S"%&8-W:'9);/:@;LO.GTN+Q;? F;Q(J_U M7VV\PZ9<#=V4\QKF5>T^,@@)MM K[U58Z36Q'E8&*[-,I"2(#SU?J4O*=:6 MODCHE[-IL;H58GKNB^_Q;_M9M[U11JDF""ELF:5:$ D\JJ3DV'G>:^;2Z="L M-<1[L\V6B_*Z_%I,ZIABSY_-I 5 @]'D%87B_O([1YT-SX_FZ8\/=)OBY]__CJMZTR[CZQT,HK,@B\9HP:"JWW MFDNIO%XC*"RU*=&E^G/DBV6$7C=QCZ2@H\^B'_)=M-W5+ O?*P;0"X\-9Q)0 MH>5&4B9MRG)]N)>WW]2O8\R@AT/>7R;^PP>S,_/^X;%,:>#C@7_(79"!0P'X M1A*%?,I!K:';>ATG!B7 ?+Q,P9?JW)U@4J"2VA&D+'= ,F69P:J*(ENK^!&+ MK&S?=M2HR+2_<48!-]J&?2WBR ,'+ '5CM9*DQ1O'KJYW38W:B?&- 2_MS#. MHXL.GN?1K^:#6L7 :G>24>>E9$A[Q(T+. #H7(4"%Q3_M>0TI6!G2NCU5,1# M@GT3(M;M(A,\+."(.L0!<F$P=6R@'2ZJ8B04 HXJ)XK6RL7N3]H&4=;[\>AUD &)' MC98>0>:!84)"7"$0Z'[2A>9:84;9 ^S'^M9WWW;PRK]]B9Q0FA"F"1)6.DE) MF'TA)5(*:W6M%:]K$[020(V#^3PO5@+HNT?_JG\DJEY7F:"6H; G9SP81 1Z M&'/BUZA 5J\V*EE_G^;^6 45WNXXT[SD,M:5%QCWD MQE*A@02,>2<0IY5\&**C1;BZCJ"VK?X?ZAZW ?<1Z;3WE-/6-AEF%DK!F#10 M$A^L<>O,6D:I!*YUJ/4542I5T_N9TPC7(W%G?T[M2\]GBDEFK#4\[/@M]@)Z MSRK9F$E*;'P=G#E4Q[M9TPC5OACSPM2[9_':TB*S#EM$.4;$A3^1$42C2CZ2 M=GIWZ,ZZWE:R=K _)K?B7V?Y_A5M;]L,!!M3(>@#7> MF 8U:)4"=N-Z7VJR&/VC+,;YUI7KI<ZFPO47&-:"0 <004MPPY)#=C%DBTF^VTTFP MHC6P&Q-DY7_Z?;28%=]-.;LI9RO-[*;(KC89@V%/:,+NT$"#< "#;6Q\C2Q+ MR7(8^O'4CDC2(MQ]%F58W+V;!@7D\T6\^#H_/YNM+L .UGJM^D9UN\@HAM03 M(0FDU!$/C0@[PC4"\5:*$YZ5>MLF=:2,8="QED.P;A>9UA9#1X70\2P4"9.V MWGR0GNE3SO)JGR4'T;"Q$GJL 7%=3C\ORO&?=:H_/'TV8RI\M(X00[VQ &%* M+:YD"D+VZD2\S6=?R^%0JXGF?RS_D(1W;P[IH+Q55:;/XWPZ"L#OBXR]]'P& M">3 $JEM+ $=5@1&="6;,.9H-QJ=TIK9!O+]Y:'>#_&/Z?PF'Q<717Z^/T2V MK4U&G":QM)TVQ&.E!("P"@X9INTI.Q(3E?Y#/+\=B/NFD2]G^7@TKQ$N>[%! M)@VRT"*GPX1K+(18BPHOHSP]Y8.I+:A\"XF2,.ZQ>L.BF%ZNRM],YT50V4J! MM7:,>]MF059#"%!.&"RY@41O\FH,X3K%@37T.D:]+7MM:^'(S*NU.=S;-N/2 M&F48LPKC8(4""F6%II4 G?*NL$5"U*-:8]@;.U%_CU5Q%N4TUZ-YV)=,33Y; MA-=_"8WFL9CJV<6G_#:?+G,5L I_.[?+61CXEV_EEZMR.1]-SS_'WR_R?(_G MM?47!=.$>PT"3 !9K#0#86M3(02X2]D)O%)B-J%/.2 =-6;QA_S; R3/I;@? M;/C=>O!?1K/+?+%]Z&IZ_NC'KKB\VL_NW@:0:4NL)I1H%6]JA&':\7ZC6 M2 M#B(,/;[9$>N'JKN&YL-\MGAD.H1_/3<;PH^R3Z,@[1:C],GO,Z2=$XSR\,EI M[8Q E2VN^40Z]LV+GAF8)TY^S8.N$]>R(3.'QQ$'*"X^6TG&$,*I>X MDY2=XCK<4''/U=X(P"X5__OH>W&]O-ZI^B?/9! H91$SSG&*@4),U/"=[1*N-&6BP1=(YRJR%!UT7.]MESC)IPJZ<\+!%=T09& S M:Q8^Q2[9:@3 M4ZL4J$>K1F W3PF-)0+N1^*^W^33^9[KS> M4G&T4RW'(\>ABBS;A[FO^28F+,Y&DU@3\/RZF!;QY&H\O+V/4@>USZ(A '38 MX#&L-<(< 5EE27MH#3WA?7J[%.L2]KXHY\-X%_G[,-KS=T&?T\LB+/'W%\+H MN]]'_UW.S&043(+=IM4!O624(1(^-A"0#J@BB*W=X !4THF8H=?][LW4ZDX? M ^#EP_@_C*[WQY$.["G3!@C)M)&JN*EQS<;V5IG"A"$;_D"GGV?,:!,%1*CJ6V8;L$C6.;+XF#XY7[Z#/_ M-4WI+Y[[2(/Y1PJ]\L,0C>%XI233^5J=LQBG7NW(]-W#,Q]'=_%G*\$> MI)N>QR+TM;P]7;PN(]9CK(EG7H;_(TH%H[Y"%LBD&@U#MST:4NRYV7I\K?3% M]T_Y?#$KQHO\?+7Z_Q'VH/-/G__8N\+N;)=QQ#04&H4_I;0.4U?53%*,:9$2 MLQF^:79<]I3=Z:FW'=CUS:2\R_/5B,]N=A8CV=LF0P[XL$1A;Z0D3&D";66F M,$E$KRZEM\W%MG3T.GEHN-".46\)IO%N/(B0JF1TAIWRA1>OA(6'::AW[^?* M 7QVL1IW7<_G\S89-\)!!"'!CC/),+!^(Z-").7B3#ATX[!_MVSK@,B'#KK46.*P.8XNOC&(H[@%.FML%S*EW5SWUQJ?CV-C'ELR*? M^X^5>NH5M=G1*O,*(\L$5S'%C2,)+:X@XT+P4S[SGZ+UY[-/:P@WSB]=#V'M M+]P>$M[^<$8(T$B:L!!3X>(]:921:J2,:JB8=<169!<^ )"RH@Q]&CEF ?VF&NB;:X^N7GIZ%#I\+O-[U<(:W*O3 M3:8)<,QAB*4Q2"-AB1$5$M*YI*W7P*G8#D/VWWS7%O@#I.'3ZH?S^_*':GI> MU3]LAZ7[WI+%.P.]0Y+&&0%38KFI#$@A@C%QPF;9L4GT '#:(( U(\ZM*SHHZ:U,*7DW]&*+ MQYE3VU1'8]=/_>]*C1?+T>1)12A?SCZ.[LKE2]N#GQWPVC@J^S,\N7AAY.D7WO"#3F#@JF4>6 M8:RA0(17VI#*R5,N]'),EK:KECXFTNMR.5W8_'P94[W.7OK,6IA/][\D@]YH MBJ'7AC-H"2;>5GM02:U+">$-_;C\4:?5UE73Q^Q:!L,D&"GWL_^]""U,J2_T MFD'IF (*$^2(A%02L0F>2&Z2#-&A'_8[ZCR:KHL!NF*KW6"1Q[OZEO%'[7A? M7^@X4X8#*SW2E@"B@U(\70=E@H%D>-)=\T,_F7)LCVNZ/H;GCWJ<=6FNXE_? MK5>/LXM]WH_#0V&MCR"CA@H,@?$&2N^4=097:9\*&W/2"8Q']H+UJ;@VS8_/ MB_QFJ\>DV-S/J<;C61X?^&U43-^'E>O#049SPELRQKVGL>P"%%9Y#!7?U%U0 MUB1=2C+X-(5>[)/^E'/$&7^GD.\V0GX*7_!HOIRM:\K-ZR37M/"6#'.$8Y%, M 0B!EKJ@T,KN4X0G%=R';SK"UK]RCE]6[8]Y?K&<4V#!2ROI;E8QXTL6N+ MMZM9YF.C?]\8O\> M8#^^V#Z+03I,XCDW[*RB .$*WD@3+M'\Z\X54NP)],H+4=F5OR]GG_/%8K)RYJP\\;?Y M;!$WW3;_>F! O8,!9!PP9!%1S@I%"2-0H,JU9)AB205XWE3$9M!Z.]H>*(W^ MW;PU,_'6:D"$T< 9[Q@VH-H_&B'2BDZ]W8#.()35:F1R%(_G5CNTU6GO^VS8 M^X'JS2QGRT7\\5H>AZ>-Y-1\6+9B([>E!F"33"2 M*';.*8PXIUIO/FCADG9J26&>U\;7H^FD/]XNROMQK[ZNO#V6/NLW6/!>2\0 MH"98[!P&.Z=*N;)AGYM40RDI>'2RG$S30+L,')>7T^+?^?F[\X!=<5&,-O<) M5<[6L!=\E.(:?K>\SL\_SLK;@%XY'4WL6K]?1M\?/7<07;L:1$8V>.BMUF@?)B2 ,F45-!1K#S?9A%8IFS0GUX\SR7O>3O/+59#P=4W- M'>+==SSIXW(VO@I#7P\\+"OJ_+^7\\7*1UTCV+2S?<81U31>N"1\=. %$QY7 M$5\+-$N)1*&D2-0K(ED72+<;-=A+> M0 @1":AL0U9>^_1W\LS:K"-E]]) M"B .J%,=2^<2Z+62CI,D=B=%=5X!H0>KIH>/XS]__4%#0=X_5[]Z\3?K?GX MO9C>%HM1_K=Q>7VOJQ>$GC^49W7C%V.=3_.+8C$_NWA^ ;#[?I./5]E\ M.O^4CR81*YLOPNPP?RI,_GV13\_S\Y^/\K'/U=?Y8C8:OQ1UK=,LZA8U= !PJBJEX37C;2'%M/=@<#!=7FE8!QP'8BL,!02 . WJ&"B MDA+*7LF:FL:6YP7RNU7 $3-G]UP+LZ5%L#.M4\ #2E68+)$@'M-*/@?4*5\8 MV!T7]J?#-L#^F-Q:GQW<>T',WK:9AS!\H5 ;QPTDE'!/V5IF3I0_9;XETZ & MK5+ ;KR)5)/%Z!]E,FM%T9NJKFP- MX<;Z/[N^/B^OWTW'N_7_[+',&F"#3(829@E$#%MNJM%)3&&"_E]AGEP;^D]# MN+'^HY_T\V(T6_P6=C&+8CS?2X7M+3(1B,HE<4A[C!G0$'FR'K/P80%.V6B_ M35:T!G9C@JQ,^-]'BUGQW92SF_(^77DW17:UR2@*:R9GX;_ $.8AYQY6XT; MIWBF7V&V6!LD:1'NXU>(",;[[Z/_+F>KJY3V;(P.Z"6##GKB8T5:Y R4E :C MK<)!2'[*-V#TMEGJ3A\#X.7#^!]NLVW&S9=ZRBRF3A$@PBIOJ0O3@ 6\P@-( M?TJ4_-%M31%ST_E--QO(IYD:O+L&BL@MA[K^[WP90(J+R/63I[:;:S M76:YLXC%0^( :H00E1"L995(IIVL^HMIK2N@+[)]F8W.\RC[_FGL^:.9(<#0 M\!\C)=90,T% ]?E( EA26/>--Y\?1(E:X*\;Y=!X3*:J9<_>VK M3"NGD#',"BF%QQPK49D. 0*?DGH\](UGUWQI'_Z^)B";W^:3\B8FTXZOIN6D MO+S[5%Q>U3"K]K3,9( -886THA80!2&@;B,OEBG'XH9>/ZZOZ:E=%?1%.;.< M+\KK?+8J]11WX%?%S7ZZ[6B5$-,L4YX1IQ7C2D.CG64 5CYG:8-5<,(FUS$S#IHJ8 !> MLWVEE/8US80BV%!,A6;4![O30H?6$BO.GE]Z?U(NBG:84-\1U@3PXU.LO9+2 M.-;.IEQ B\+V!BO+>!4J44"@I!(;?U&M%="/EO6[O+X>S>[.+ORHF*UR^>=G M%[52G4\OVU<)#X.I9 G!G(D@TV-'=?8< L]Q[4"N*>7[6N5@=A&TT\@Z)Q! M&&Y0H1R_A74JC2VIV;Z'*>#U9?L:1QPAF%KO/!?866EU)5_8V*;<'#YT@G7' MA9K9OH=A?QK9OI9#(AVPBAFE!:,02KF6&6E#3IEOR30X.-OW,+#[SO9506 H M,5<((BF@PA2P:G2$L+>6^-U0=;NR?0]#N.]L7PV4BD47F!0 .4R=,* :G1 H MQ;_X"C=&;>@_#>%A9/L&8\YSJAD4QC.(E(?(KL>, 8(I.>!#=P9VQ(K6P!Y. MMJ] '(6@:T?OMB6IL*> W9O@0@0:3E!ICPO5"OM/.5 M1!KYE.#LT'>;?5$J$?-A9?LRB!%2P6CP6 *I*&*";KX P$[YF&G7?&D?_A/( M]D5ARI6($\>X PAB9BL'KH(R*3/NU+)]FTY/[:K@]6;[8D<@-810ZBDPQ@C( M*T-2:>12SKV<6K9O4ZJU!_]KSO9E1%+%9%C^N531!/"R\CFK,*.G6/%#-[F. MF7'05 %]4ZV-4J!F-+\*OXC7PMV.)GNJIW?[XHQ+0@5VQG"#F;&>QCJ%:[0Y M,Z=\&+H=%G98,C9978TW)]U*$?[U*9\O9D4L$QM_O6VWT_,P,A[T[ !!QLM@ MQFL "*M6.4V92OD8AN[!:?5C> 7*>Y7KQG(657G_Y,.U(;VM'EM>GV$OJ%( M7C^;'&5S^Y_ M=XSO9]=X,F"54Q1B8:ST)&RU(*YV<)KPI.-?0W?CO:X/JD4MOL8O[..LO,EG MB[N/DU% Y'Y]OHG^T)Z^J*WOSR@1RA."N!*2 T^P);#"'D&54GEGZ)[)P7]! M;6GM-7XQJ_DAQLL?SR(]?2TOOCOC0EL%9/@O 83B,$<9LC&;%4JIV#%TQ^K@ MOY0V-/8:OY('-W=?W\:C-V8>(X9=V#L*YK51\?;;S;J-O$TY^''P9:U_?1%M MZ>DU?@>]+@_KV443KR&7@'I-.620>V?6J!J/D@K,U;_RM6)_N1A-_F)_FHI> M(_'7FZS'OUC?EKN^N[S?+?OV<60!<,44@&G_#:?OGASZE'&D06[UFO/G>(*4\F9MKH*)QM"95(U M\/K7]_[U,?6DP&%$)U^:(6;+O/+IO61]]3^(S#!N+<<,8ZXE=E@*6MFZ!@J; MDI4"Z\?I3^+3&+SV7N,B,\0;D /B F*+,-"&,FXL(%6$RQIJDKZ9^N'\D_AF M!JNU0:PA'\I%OF-CTNG[LK#2(L$@]@9)[AQF4E<^YK-%=+=]#- 7\WDYN^N;[7L'D7E(O#<84"/E?WT"?6CO-1I'#Q&<1[];Q79Z,I"V#R"30EE"G#'0$^"=II;JS7++TRY# MJA\I/XEO9]":>XW?3?\[B<>&:,RO)HX3Z@26GED,115FM6O@$A+^GJ-W\.'O*_$JO"FS -@A1,>2B(MLE!27#GS'$F[[1H>'@?_B_B) M"NJ+\+&;$0"O@0 M^KUIXN,I<9*IR2N4.$ZZ;:5I..VW(.@@ MI5AJ4BW 8W,>D4WO7(BC&PC9#"JT@MU)Z[(VK9-; MG.BTU5CS!]^$L$5)1:8S8SM4-O0?L-M;7K\H/# M0&VL\H:7'S@8RY%(EA%>E\C10&ZN\U?L.,->, M6J:D9TQ;Z )?>35F(DS*\;"DL_VOB@BMX=N8$ZU?<6"E,H()9XV&"A,KPD9_ MPV7I4V+N24?47Q4O6D3X-9=< ]!#%!V3TEGDD49$T[6DJ^+1I[78'',#TQ3S MOMCU@,V/SK_J^-/.N,@*L2_Y]X4. _RSEN>FE3=E1&LH"#.:6 TXALYOO!D. M6GS*=QNTP[.M7IYCZ*=_ON\H\KD1<_XQF! /T\8CK]IAC&_I79EE6E,EC0 8 M$N 5LA14F HMCK9)>/V%XO5%1'ALS5E^*"GE_ET7!PQ_+%C M3+:8CR?E?#G+:\1##NHG8Y1#"[3RA"$*(44"\W@'>##N'.*XUFU-1\2CSI1S M6$>9(\9IAJR"X3^&$8^U62/BC55)&5<#GT\ZHL[S"L]=ZN/(LX<9W10Q#![O M YE_&,WB7NHV/_95],>96L(^E @.%*:!'9IJ$5@"C-%AUZ@]XK46YJX-GL?Z MBO9<7-OJAUNWMLXLQL88CYWDA%J"J!>DDCWLS/EI.:L[XL56PZ0MW/LRL+?6 M&M-W7\) ]D1<:[3.E&0"2V"QIY91["UFKI(;,7VRT=<6F%!VC?;161;'O3?\ M6J-UAA"F6CL*!. *."@T!6NY34RD."V6M%!V#'9?%'L^J09I4HV'H6_Y6M%EV O0QYIL8%"^O M\\]!D:L[]=Y-@T+R^6)=1:7F]+.GE\QII+#6&@G-B3<>$2TK'(A/BEL/W6?= M*N&ZQ_[HQOMOLW+>:'>X:I@)9I@PS$F)."2Q%KRK5GCK#3ZQS)E.R-4JPD>9 MT][G 8I+R?Q?*_-@U['*W77G>^:OR$S2#%+ M"-:&4\0U!D2S"C_ 5$K,>NC73'0_%_:FER/[W6W^=>&+:9 R_.B-^]V-]AXJ MH1#R#&$L18RZ,B294!)86NM48#=X1"V]FX9A+E=;W#U^]A>>SI0/GP$%$@@+ MM . >.S7L@7A7,IR-D#O0$=Z_^%RWU2<>TM4J6RZN 0O[@(\-^5TA<1F19Q[8M#SX:ZUR_^XO.9 MPL )B G% #K$15@B424;-,=+M.O(G=2.GLOVD>W-G XS<3G]O"C'?^Z_0/SY MLQERAE%GI+(.N;#?Y$!6WY=V(NDNCX/9Y:D'Q_.8K%1X0RW3%JN/8+A'Y54WJF4&.[0G4)M+DK)R!Z'+Q]&U_N#M-N: M9%PPPU+\JDA9"88CPEKAJ[%S(I"(QKXH:3?19=H5S8XY\F8VF MXZO\;+KG^/3SYS('L8#2&^:T-\ I%=;0]?@, $G%^P<8 6U7]8E@]F:E!OR+ MA1^-XR&4NST6R(\/9Y!*Q1CD $AAE,*."5U)A3RIE0S^2J_0;M,"24;V.'S9 M:WV\]'@&O)+$D%->7E+TO),RC:#MS0D7U[\8*OBZW2[9 M^FP6["_-H+'&84B98-XS7LE$"$FJ]/RJZ'*HCI^[WA*1;6Q_Q*KI'Y>S\=5H MGM"0005SZLQX@P!:&3OEJ1PUZ/I]BP0X\5MVF@M(#ML5BSUTAYN4'F M&/<>(N>I$5@)"2C?2 ==6JG4@3,G3=M[J-,(WL:+CR]F\T7,*8Q[\=V+S@N/ M9@IA;$*G+'PR7O&P*Z>5!]HBK=\2"0[56]DJM(T)$,R>CP$O/9L9KBS% M"')JD74T3*"D&J=CAIYRM8 V*= "MLT]8%?%K"8%7G@T M5.%*1ZQ,L2$&F!'9IM+3T>P]4>3S.)^.PJ=5-T'D\?.9H=PJ1D&01PG.@7&R MLJ-=@"TER%__4J+7;VVV 6Y_I7#NA_C'='Z3CU=5?O9:G%O;9(@R+94!SNHP MAT'AB*M\S0XR*4[8WDA4^@]'O]N!N&\:^3*FT\YK.,I>;)!9'M!BP$"(*((4 M4>$W>"''4QSR@R=0NLJWD"@)XX8,FL\6C]@3_O6<.>%'V:?1]'*;6^3)[S," MF/%AB#PLOD(Q*0D$ZS%[!V2*UZS^I6"O=V5* ;-S FR=*YX]$<9-/>?0"A=7"'0:D#\TY?;IX!ACW#A&'IL:#Q4N J 2X MX$ZM.E";5#B(98W0'@;/=B4M'MA# !=2#9S'Q%#%##+F 5PF_(F=!&R7$@?Q MK2GDPZ#9!6MC14-/CI>5>WJT:PSZ<8CWOD91M"TM,B60 MM ICJ!01PBO(/:KDXTBGY&$FW7G]VO8 31$]#F/,:#:[*Z:7ZKI<3G=5G-C5 M+*,$:V\@EC+2E3#O9I>CT]SMJ[_[F!^G?2*0GIOCCU<5:.\_Q\ M[@,X]>GZUCG?CO)UG3-_4-O%Y'M;?<=3697XV_6.ZG.?GNIS-RF_A2S"CF]$X M0+XMQ2>MUPS+N-!+0I7&!(2EW599\QIQC%)2 @=O7#4G5__(]Y9O'# YNWB: MI_\ICT9G&'L=4C;K* L?GU20,"L8TA8&-?AJID>:ZA.[R;#M2:Y3L(]CJNG1 MO)A_#HH;G9]-_S&:%=%H_31:Y+"VV;:]B]4)>1FVU=I)&\^R6DIAA8 4+,5[ M]KI2V]HVX%K#O*5E]MWT//]>E4"-XUA'0.LMI]M:9U0+8A0-.RK>9 MO 60*?QY70DHK:ZA+<%]G G+S_)_+?/I^.[LXMZ=4HP_CN[B;VI/6-N[R%28 MLI%TCC.D/ IS-JQRRS4"&J>D4B;%+%\1X3K&O*4)RT_*"/,Z0CLQI3Y.,MO[E?/IUZ0B[/E8KX83<_C?O2^&OFTC]C%?/I8AY] MM?GYEW)]Y?+GJX#._/$0_3*6,]\:TFG>60:X9YI08RCVVK-X74859L5*B:1 MSU"33#NA5Q_PMT:TJJS(H[JK=6GU0M.,"2,A#*LTD PAI"%DF\^%L+0S3*^K MJEC+)$H'NR]C?'7-Q-G%6H"SV:?B\FKAO@?>%_-\9=QM?CE?_W:^R\W9J+\L MWCD%-"(@F '2 V"(J5(ZB*8T*6/P=56/2;?4^]! 7^RLQOFA7'S.%XM)'EVV M[Z9F-+_RHV+VC]%DF3]$QFT>*.5)(6"4Y"]_'YIS-8.,@W?=X]=VRF%_= MYQKNR3'>US;SS@>A.6(:0RL="AO1RK5&I;))7!K\\<$69J&6 3Z.P?,XC+VJ M5W7>(#"\JY,,*X/#E"R1#3M,A#2'M-IYA)4=IO@^T>"/#+9M(+6(=//XWB-? M_8=\H:;3Y6CR*;_-I\O\4S[.B]NX&.N[]_&*V=F[J3H/NX.@N"]E-?JM8;_D MGN.E)-ICXD& U2CL(+.XPL!8D'*1)3KU9/;>X6],P?4>LUWV)76:!4O3 640 M4E![;Y3BM"JC0L,JD'0P^H2SUWM'OC'G5N^;AL&%6??LXE.^6,ZF^Y-@=K?* MP@;%RV!WZE@[&F),'P[Q,B22"O&B)/_W*V!-J] >W_JRRUFP(._S3QM97H\[ MR(+I"2@2B@IN*$2*&58ARJ0 2=-1DA=]V,3J%.6^.+8*@]]'R!^/]C[3XD/^ M;?6KW:6@ZW20:1[D%=P3*C"P!EEC;"6]DBRE^"(ZV)/>QYV^;;.L$YQ[2VAX M2+GX.)J=S>ZW(ZLH8Q!C)<.N](7]K3.!B!( ,@\5LX3$^PHK8Y(1CE,B->@- MN-;;A[BW"6SU =Q_&%7>\SY";6V3^?"],"*DM0!8[H"WD%4R!K,@R<_U!KSM M;0%[Y-5OQ7M33L,Z,0]*/+NX__NB"-N+]76V19-%L5Z_F0%A-X$QH$))9 AB MDJWOB- !?%\LK#;&[OM-/IWG>Z+:+SR=4>D4#&)88"B% MD"#/-U,S-#SE+C+\5C+CV\/W@3?_^>L/T(8!_KGZU8N_6??S T#%]+98C/*_ MCY ?R!Z9'A;L&#C-I^.P4)_=Y+-1_.?[?#0/.^"8P+@H;H,DBU$QF3\= M:_Y]$7W"YS_WL]7=,N2'A4)]#9H00>.&I]=7!3CO,J-?S?] M/)KZ63#KPZ2^O2A[S9:9I()10 R/,6\4-@88JTH&#&BO16B'0I\F*BZ[A+VO MV2H*?G:AXIF?R]6MDWO6Q!>?S^+E3T(*( Q#'DOD##1KV815/LE9/G!*=;H* MMH%V7TQZ-,IHC7XHIZ.'GWP)?YL'(S3H=KZWP/^!/67!JO72AZ^(0DJ-\1!! M7.&AH4_Q+PU]0DLD2-DG\(U7PP_YM_NM_>ZE[]ECF8U'@8S64A,4/CP"Z0,* MBMB4 L5#IT5GBBQ;P[NO:>G%67GC-=LQ"^UNF,7"(EQ(B;BRGF@'09C?5U,Z MYP@FG<8:8,9PIZMXZ#[FF9*<2Q)\Y*AI7 M3(:OBJR_(QF$3ZIN,/!YJRTF/#]PW"KBQV18'.XJ7KW/:;R_<>84%$HHI@ % M)FR6E4.5/U RFQ1$&;K1WB//DD#O+?OE/NOASN8WY;S8Q:MG3V;A.S&::Z]B M*4#B39".5_)(Q5(RAH<>B.N(1&D(]SR9%4F'[X7&D M,ZV6W>#=VX[JV>R\9T%[Z?',1L\4=5 291!W1 !(UW.YY1ZE6$4#K,#3[GK6 M J#'HLK>%+67&V1 :N^8@,)+ZE5 +7Q>]]*MY$RJP#M\NARFX#UL:83HL?A2 M*Y:ZK4TFH.$. ,6QX-CS,(MBOY:1&D93J@$,,(S:[233%-6^F*.7\S#"^7QU MA\=\59 G'E,*-M[]I1[G+FQ%%W>/ENU]Y] :]I@%B+$4D'&LH.0""0=)M6A3 M38Z6M=T/ZQKPI#P&[GWQ\E-^641OQ^K"M'N7Y2.[@ML:QWBQKNU]=O/+IXS>W4DLYA>KB\HNO\D/N47R_EH M\@)YFG>622.Q]!AC*JW&7"K"524I3/,RO8(%LSF9>H.\-S?4>#Q;!D45HZ\Q MZ;S(YV8YBYCNLJ6A&-Z'3R7W0[VU&Q:P4U@B-@DFCL/4"044<,9A1 M2[6H=PM11W@\5LZ+$=F/]]Q95:U8E6U]]OLZ8+7VD@PX2Y'3'L-X7S8T*[-P MC22D,.EF@X%'Y3NBW/.B7L?256]EY?8*:)?Y_O7QD&ZR,(U#JCDRP$+/P\"\ M4!42/BCIE%E[!#X=3.G&JAH4:=]-OWPK_[]\--OE!SFPITP9(1DV 7EHM6#1 M&H$5'I3A%/_'T%-_7PMU&VMK:.P-[\S;XN^FK\PQSZ7@P;AFSC AC'WXHBGE M1_,;_\7@-O0U* ZG\C9C'AMO+$%<&4,GT\+UU& M/3\DCC96R?!H6L<+WZ"WS'AIE4,QQ458"YSSE%:X.&A/ MN?['T*C:5"F#(ZLOE[/6N+KI+ N[?JB5M,X21P$!"#NU0<7C?MWP;YJJ374R M/*86M^W-JIO.LH"]B\43#6?6V%C]!VT40"%,.4HU]"HE0V-J0YT,C*E?KO)9 M/KI8[#R-?G!?F<-2*H.])=$CH12RAF\PL3#%3DVZ+?BM\;2Q2@9&TW1R9E:X ML)) YA6@FB*"G2&5_ J#E$/+!U\NW'>H9DB4/% 1 R/BDY]_7GZ=K"N&!GVV ML-3OZCU#P7;W3@BMXMT5PD@*3$#2:^8D"59]+Y[RI\&;+P,K2=0Q=5M43^.# M9C6'^B%_R3-Z8 ^9HQ(*ZQ3AG$N$D;'N8)@VNU7VY0ZH %[+6D99N\'A? M3B_CF=EXT:.^^WVTN%?7?@!V-\S"=$@]X,@%0DO"N$6:KR6& /JC%:<:G.55 MFQK/B[JVB7_CE>GQ*-9C"&)^RF_6<\&'\&E_^99/;O/? PY7+YE+C?K)G/-> M!?$4D!(I1'' JI(O7FI[POQJ2_-E?_AWQJ]WT^B/^?*M;$JL30>9QA0H[448 M! \;9J=H=:Y;02>3[)ZAA]F.P:BFP'=-I1@W2213["(CU%, '=,<0P0!E\2A M2BIFDN(+0P^%'9%.#:#OF% QNI'&I]A#9ABPG$*L1-Q^ ,QK$!#6+J40A]# M#U<=CTX-D.^:3<7%XBJ13K&+C'E( 2!62T:%MEISXRNIN#2G7/K^B'QJ 'UG MA-H9!3JPA\Q"I* %A&.F"/24N3 !KV52/BGQ8^BQGV/0J3'R[;"I3JBF1JM, M&@LH5F'O&[8/A@D,A=B,G?N4DS1##\]TSII4M/N*P<3!OIL&L9=QH'],1]?E M;%'\.S^/OI)RN3/9=V_;S'#H,')4>.6PXH #3RN9(0,I!\.;QD]>+<>Z0KTO MIE4'(<,W$0NMKE..[^N$[S_54J-U!HT2 C@IJ$86A:_*6;V6.\S.-*5R4?W0 MR8FQK7W<^^+;8T!J4>SE!IDQ0BC H92$ TPQ<(A5TCF85(P/@K=E7+6*])## M;U&HT72<3^(W\\=T7$[/5T4L1Y./R]GX:C3/'Q<8?Y,Q.>VE1$)C2J#2$L<% MBCKMA>;2:R9KI55V.W'\J*I]%UKM:9D)(5@L&Q_/!VH6[$ #>"4S=RSEX.4 M*UUWQ(U.'W*QU%QYR_.#0]G0O6="5;$93F[.[N()5&K)\[W7"'2 M1O>9 33B9 B0Q"))D#*N0HYREW)R?8!L;8U'/]3+[ET5?9%XCT@/ OU6EN?S ML]GG?'9;C/-Y59=^[^4F[;P@\YQA; *9JKC*E@6Q)-[]!1@Y-0N&.B7<.4 M--;8J[9^^R8[*JY303?E+!+@[O/RYF82%JO=]W\=TD>\OU$Q1)B&S&OEJ.2* M5G()@9+V$L-C8M]D*/M12]\;V!]7I/!C=!9Q6,F- M)4N):@[P+HRN5OCVD1Z8%6J7^3^+Q54Q/9NNSE^E&Y[/>\Q4V.CCL-/'V&(A M D#QJJY[?*#$L%9IC-7RF-8(^[C#3#D%+#>%& M(2XL9-SB"AUJ])N9*?OD9X("ADC/+U?%K$UV;OK+@.)0 B>,,XH3+L,?NL+& MB*0J.@.\A6@HY&R*_\"XF<[&S,1Z_D))2Q@3" J"&:CD1SXI[I944OED^7<@ MXH.)E,1S>^[[33Z-1_@FJ].,Y8>X$:Q")7^5B1LOLL 4@R7&7",8ECN F6>& M6H\IQ9[I6G[77@[L/E+G.M_EX%.Y6[O(L )0"^RP!]1!0#FA;HT""5ORHUU# M-(1826V&[#YSVQ;X1SHO_FCXSPX&PT8$?-Y)1KT!"@EOI*"6*T>QXA4*5*J4 M0W0#-/J/3<%$^(]/PI?/?]=JEWF!N"'$,1,^-42@1(Q4LC+F^[U(=&"GOMNG MVN&(']F$6CDHWYH=I+1TS@*I-86$"\\<#QI"4@L-PN^.F"&RI>+Q_VCKC$AO"/0<,(.*$I=!A0PEV %(':$HRU*NWKM(9V1;N MS6/K6_(C5])?WY33^(^SB\>IH'OIU4['&<32<8@014 P(Y3"5%?H6NA3$IN& M?C:X6QH>13_]SXC;;^,.D_V3^R525_P#.L^P58AS(R41W$ "!?'5.@(Q5RE9 M3D,_HGS4Y;X['0TL4C"O0^2#^\JT\@HZQWG8@"FFPCZ/N0H3AI5,X&W24>C7 M3-6NM=#/=G@Z+R?%>0P3Z-$DQ@@^7^7YXGC;X,]!BE4R69@!BFD84!% +>&OL?NLTSXA!&GC@B-*""TR- \@)23 P0CI1*Y;;C?1J/L\?+C_:(>?3!S,1 M]C84(R:)9I@0#84T&XET4F&?H6]#V]5XV2+,?2TM]X.L3@W6YC]9APTLQ\! 11C%?RRZ=PJ?L'4LDPP^WV;4/ M=V_3T^VH6"4>!+O]T6Z5> ^.ZQ;HW[HU7U1KFP5;/PU<3Q/F0+VH0;4>S3!H5]I/! MC >*2,H@U!!47YFQ,,6G.G3/5LL4:P_EOOCT<9;?C(KSM=,WS,AGBZM\]@26 M';2JT3K3% %I/!-(&^*=HD;J2F[J9$J]H*%[F-IE5_M@'\6>KVO'9_&.9_MS20>9BO,C/ M7]YB[/1"[VZ:(2V)Q\IC:H0.",;[1"N)!34I,]+K,)22"=4RQ$/;\=6J&'5X M9YDQTE.!I,' 2@3K@EBK4*<%]TBG43 MOA63R0[B5(]D5FHFG$!.0V2M("1,P94$CB>=IQAZB>"6*-(0RMX2TQ_VD+46 MKQ>?SSQTFEG++><$>BR0(6PMF[; ]WMEXZND21NX]KN=W[N/#QL$"@&E1 EO MI6(6<%IM$#3&),6O6+^.[S$W\"T%X X$LK=*,\7H:S%9F5#QTKA%.?[SJIP$ M] (%*R?+;"] M409Y=%P0J:F6PH?EVF*RD1+3E'5LZ.'=]IFPG6IIL/<=:GM:Q+I&D.UI@\P0 MK*R3P.HP:6N/M?%B+9T1%AVMD&"_I&JL\RTQMB20>Z30;!E4\P,,NUGT?^$IP>,L0?)>/N)]3NAAEG& C$ MF%%&"JT L;+:EQJ"=,J:-W2G=@>L:A7LXYE1!YE/&=(XGH#V88>"!/8PIC-4 M4GEG4XY&)97R>9T42@;XR#-2+3_2WK99/,MEH*,28$>PL8S!RGEJ"3Q>KMLI MV.)MH]_;1-72[2P:.2O!*A$KS,,8A)F85M()ZE)RD@Y>\V[SV=?RI-C5"NB] M.L ?05+?"_YBHXQ!+(Q!A!!(%$8*.%X9CS8L""E))T-/=^N<6*W!?@3#JIY% ME7'NK.4(8Q*F7$T%Q&SSD4 &4DKZ##WIK4\/U($X]V91;3_GNC!/?J6HU\WWF[%Y[.$!7$&BPU- :A1"T MJI)+:YN2YC9T3WD;VO[QO$ BPGTN>^6T%FV>/YI)YX@+XRK+*^7JUK0JSU!+!$TRZ_RZ;RXS=]-Q^5U_KZ+XIEC(JSM]- MU]ZU7:Q[N45&(!*4&$T-,E0)[HRM3O@X!]TI5V/J@EVMH-S?P97%J)CFYVXT MFX9]Q/S1MV'SBV)<[++1]S?.A+12*QA]N8H:RK5VU8[$8YU4+'CHV=X=<*MU MP(^W!3QHZY(]AO1GB_#JH.:)0,\%"2/1.2/#.B MO*(8:2HU5@1Y2!\DQBJI4,_0\X3[]'FV ?X#W8Y0PNWC"M*K?%&,'ZRKDZSG M!IU%83?.!!7>,"XDAQ!;#7S0$*>HUA?1AY,G:.1LMI+H?+5=_)C//E\%+=7V M^VSK(!.00JT1<8!K: @55N,* 8.23CP.WQ74)D-V.H5:@O\X'L;52.=JN;@* M&OEW?EZ;=,\;9M2$W8 2%GNB,$&8<;P!TUB1L@ -WX?4&]D283\FR=[-Y\N# M"7;?*$,@;"Z#7!S&>VF(L-&;MI92J*1[[H;O,>J97(T@/R:QSI:+^6(T/0]; MR /9]:AEQ@30G$ G!?"&(F88L)6\S*!^KU(\<8HUQ_T(T90&]EF-UIFV8=,@ MG:4608>MU1:AM=R8>)62/C=\5U*'?&L?^R-P[@"S;$>K3 9A+'2<80$! (0@ MJRHY8QG0$TYBJH*;&;6=FRI#2[PUV8I\RLYJ#W[;K< MX#(_NXA5SORD_#:(6R@V@SG,6_E#LXR'E<((J#UUVE$EG)4662(A8)YS?,2K M%F/9W3#%+?W)ZQ669O+\+/U+X,&:^#2S@LR MY8$,QIRVG$/-H,=>H I!#5!*3/85>3D3F%4.0"U]K5M!N(>4F-WJWM9.%#6I!P:'SK%^F;#CV1LK(?^4I?^>SF_3V'_4L;[G\+R MO:I:_C#R+V5-$.MB!!,VPA<^/LD7S%E>JZNR]FB^/?JYSN(7Z=Y1K4/UJN6GAN PF9)8 DJ MR9V7IUPHYKA,*CM75F_977&3I$M4(&^] M]&OI((7DE$O-#(J*K:BG-V,B5BM\=WTS*F81/A/&?KGSX.++#3+G!%0Q.U=: M*8+Y#VST1*ZENJ+E[^-BND\ I7/SZ;N>\1D6BVX\Y*'8NT%WCB&=Q"S=A^9!H(P9A5G 5H+%4,( M51@03E(FSZ20[QL@:%=*ZHNH ;-9+)!F\_L_'Z&T/DE8P^-9OY.,:J0XX,0" MS.)9#.\<6Z. 2(#FA!-%C^S'[$Q)QZ/JCU>1'D32'YMGS!E/E"9$.8@E%][R M:@^(,#8I2:;UO9/RGI[3_#*&V/LC:!<,V4O"9"4TWHC_.):7+Q^M2IYNNQ"D M>6<9L81J2*$7S <;!@&F*O\JHIKU4]?C!.G6FTJ.N$P_-3SVW593KX,,2HNU MU\3(L+;$;&]L*FL:(0Q2PHSUE^<3)&2G:CC^ KR^IZ#1ZKMNFSD%"588^2 N M5,09!"K[& D!4BS#H3LIC[KP-L/_J)Q[=J5!-9%O0*M7D32UZTQ'WY^:KI01; MBON]5?=1W8F3W&-WIIW:V]Q6K\KV4QR[=?FKV#N0?TDG$8SVMPK:G7-JQ] M%#M=X:"E3PFX#]^-U#>7GI]G[DQ/_9VA+\=Y?C[W =HXX+.+W;>\[R+M@5UE M0A#@K&>8 \2YLH!MHA0D[$&/-K&>)E6[U\,K9=K9\ZC M?*N_WY\+W<'H':TR"+$.-IP@$&G+.'2 59E?A%AURGZP(_.T/:T$58.O!= K,'8FCT%LXES::SV+D /7+PUJPHH$Z YZR6![REM MOYR\;=NICH;G#VO%YY4A#HG$#F'IF0(6&V[\YLLEKM_B+F:V[B2)GQ',]B7GUAK/.-R^K-=YSS]"X\JDYE6MU)T:W'9??4?((G* M51)%<$O9IWSL7$B(\<;+0 00B-A5*.ENM?;,#PA>.&L])]X!K(F2T8&JDBLI M533GS.?80Z\^5VN[54OC/*O'YC_53$JUKJ]N/Z[_GDVOKVZCZE)K@0C/0Q6< M32N4ZE)3+@^G7;4Q=G#&8RLDA)"*Z-HC!G0565(/U6!EF'LUNIV1IQQ674,L M@CV(]DB2F@M]W#<37KG0S!!_? MEY/YU6)ZMSMVN(0UN?CBOJ T$_'%T\(02*DT"E-1R>JH[K6G^*_+PUR]]!WQ M;X]J/3V^=6A:KWUO\,1Z*KWQ+'I+EEC+_?Z]PQ;VTT=L)%%];RQL62O],S&] M._6YM[\Z .NQA!(C*2570A@(Y4XN9N.WO^+29_^L:ZJ/OGCV:;^GE9YU?A<- MPOTN(?)]2F*\BI[NW1:5(_P[8Y1@@'!0D_@W\D:8E&Q9K9NQ^+^<.B)-US9_ M&5YVIZ?QK2"ULDH4B!,J'8(U A,7G66,816[,8QZ[J4^U/IF7_3L3"]];JZG M_Z>=K>^36;$Y)AA!F5Y'*[/9K9W?//W!HRL_%M'^W+S,(K^>K5-A9??C^NMD M?E=\BA;+W=X61]=!^WV0X"V+4YN$T9GWAFAIF(BV@@((+-88]-OJI/.WI),E MTE%K[$V\/UV]#B'MR0#$(>4808*Q8;Z*51GW68U\SCXV\VVCZJ-[PGT MJ9-?F[\:.BL(=T1$8*0$4'/],%>*G'6'L\L!;?GKYCWZW"-D[WD:Z:U,Z?K; MM]D&J8WKT2-=KJ\GI6I?F4-6Y8[=&!$ MQKC7&@F^EJO=B4 M'GA4B+!Z(+U>?2A7_U%L[/RAI*5FHP5)E,04::LXPHPZB/8YB((;G3,[CST' MI'?^]:>GQIS<85$N(H2K^?:;R?VFI,NBF*5]F%5Y7=X4WXM9N3D6,+E;%)M9 M9#HO4Q;V9%-K:#*_F6SK:LQ.EQWO\C.#9 IRA3WT,G6X0XX86N&F4=;ADA%6 MQ!^&TB-28%\.04I4,&6$=[&,I-A^M4K[(!''=9),;>0_EA-5=XA@@? @Z@4* MQKTQ4%%0%8\3'J(<$SWVLWN#N0@=*:>W5:*40[AM)7N,@H\O"YP+PJ4T&"-' ML:>0[->[A"0PYY3(V M/#4:S# 7TMIF_Q>1J\3$:]]TWC\ZP[@J]+544XOXX MV\X<*:CH>@-%O0-.(P*E4?MD'($DS-G2&7L?\\$(V:V.^N+LXV)NIWGYRM6! MN.A>"^RPXDQHCS0T^W<10IHSYXY]\7LP[N7KX8%? S2J+N_CF%^+^7+Z_4F? MV2$;5F^;%Z1*&(^?;O?3LWI8UQDI6,%"6*(BIC_$QLEH9'(.2'6H2\*PS"V-?P^N+IKUK:0S< M/EPWZ6&YLA*^(HOMZV M]EY*5H/31^X**H;K$BHRCG0$(0U?)*6W60LKY2\Z/$FTOR!RW!_^P(<-F M67$:WY^/E58W*T(1MPD\L+E'*\? M^W35LLI?K)IFX-S?$OSN(;=")XM5SM-[KWY,CT6@1^\+EA&%%;!(6^BB64/" MNIVL7#*9TTKGS7#J3*T?(D\+^/;%I6>/:LO[R?18)=!7KP_268/B9"NY4X@X M&W&CE6S49C7L?C/.Q@_%G<_UTLCC#HMSE*CV;KY+<#M)G:/W!8.!8L8J MII5,/6VT4*22E4F7<_ID[#6!VJ51FS#W1JGKZ_7]>I,Y=FCUZ32]ZHX1'(88 M,BX%82CM8 /-9(4!%S;'8HT]OZIEJG4$>7]U5E91_.+&31;S5#/P),=>OR$ MKC&,80C@F""(E&/,5]()!RZYA5^[A&H%W]X#_O?QD=_%+VM%^?N+@[?*4!_# M6.&M]-1($T';2>4ER*FY,W;'J>W0OBFH_1VF?%X$XN4JV:=R-O/EXI_)XMCQ MHC-'"L(KS8%5TDMIXL/%[^P.CPB-Z*<5_< D:\".DUU$VT2]UR3A5[<8#J4* M/[DX^HZ.*!8E(A@[QIU I++J$N3MRA'.P[XU17R-NRZOU M:KF:S%-1FV.$>GYM $@!YS5RC"CKK9."5ZLADEF>TTOK[ GPLOF4"?T IQCL M.E7QWF8X_&LR6Q>;WUU]VQS<=#^*Q?5T>?0<[MEC!B.AC&5T8AQ$V D.)(:RP$<#GE'P? M^Q+)&(QK6XH9A8%MD;4G!HS3CW9(.B$Q1@H"1 C$%3J8P1P7=>Q'TD9A:-O2 MS!B,K;O_-BM_%EM'Y^-ZK>SXW_IS@C73:&$,T=%A+@*,37^$#3%9R(AQ[ MKL:0A.Y+8_VESNZK/GXI#R1J;F3^.P*].4A9S)<;QGPJMC5YBL_%XOOTNMCB M\ZFX+N_FFU$V[_[1[-MN/SH((KQ3R",&L$! "T?VB%.3U9X;_MX_&Z42WTK- M EWW47/QOD,]:SOXE,"1 5);FDZ[:40ULZPZ:F*0A#FK9O!7 MWSP;7E_=!(&=D[GIQP2/HS=D,3":6":@99P_H .0S6'SK[ZI-@*%C6'#XM6L MHJK,C2[FQ>UTM6DCL#Q>E*253P@426(\0,0#:R!Q,!)GCU_\)X?POS?CAM15 M-Z;[4=7@:G%F,8G1Y^:=U>5\W8XH.CWIEK7^AB#?_G(4C?- MB7D\1" (J\9(%I0@#2DT%5>AV5&Y]0F0[_ZKEC'RAA%:DP>'U^.$8!2$6:& M 4%28@>4>\" ,Y)UH/#W%E2WVAB#@:PR'J]NU:9!64,C^7R8$-7)!74I\9=X MA:""NJI?8:7.*CB#?N\(=:Z041C+?&Z^/DZPBE(AM+4"" F8YEI6&V NPI]% MSM^;1MUK9%2Y*P]R7OTS7R;QWA>;$^BN?N:V!-OU>N-O;XGIU=?NA^$== M7Z=^D>E5C^_[]?3;+(*]?>OC>WY3;M9UCY"_^: A&@QH+&$62^>L=YKXZABR MX\3F'*)!63M5;YO3O6ED#)[P0RO4)UT+'E)I&KK&)\<-"FA%)<+.>&T4\03M M*P4Z1WF6.Y*U[?2VV=NG4D;A+W? X)H#!Z(@L58Y;'STVQCE#NL*+4)=3ITL ME+4?=9$4[D8K;Z4F&V'020YU#&81Q"8&"J8ZENF\H#EGPO#9&U#;(EIN?G-Y M'FTV]&^C)!LGB#AIN:!4.B@-Q+""QPL"X M?RU6T^O)[*D0E]?2"G+&N>$6$(E3HR.M;.I$Y@"7U.E:F?_=R/]Q\G.GO?TL M6F<)YMAM040IE?+4MPYI#_4A[<15M-^3 M)YM[O;_VVTS]_4/5>-$/W!&8L]A'/Y%Q+"37,9RGSF 48Q\J&:>U5@T[-FUG M=JM#WE@&(/5 @_0/\9!6$FE'TZ) M^*/P<5'>K*]75XO=0;\#W><.71JB"X(5H< H;'#G@E< :*@P+T6>>Z>%DW5 M6+:*8@]\6";G;/N RX/MY(Y>'S!G!BG,@=($,V"Q%*"222,Q6#NY=IF1K]*7 MW,@&LW&FHIU.[N;1;YA>?RFB]W"PP^V/&I^%[,U\6R1HCU_-* A.=( F1 #&>5=UPANI<(Z,%FF&%Z MU-36[XO>65FP]DP4'Z$PY7SSI.E IUDO5]$0+MR/Z]EZDP2R7!;QS\WQJAT- M1@N6Q*!/>$,)< 2F)1DL*ERL9UDG><=GB)K3XG5^=0AU;^5DM@M3NX/"<1+> M':.L8[Q.WAL 9))PQR&%G &&G=P[>,8[^4NT=\M3"MF MLS0+SV_^G"S^JTBXU*@9[H/?I.SV&X83[]/C2*)&14BGJI5$>(PRDK5X;ZT56T<7S#S&5 MJ\GL$FB4B7+O\5RMDHFO7)UV@=,9526 ]EY Z"U'E5Q29*U G3_)]+F*V MQLCVQIA4/O1#.2^?/O'IV>SXC4%ZJ0#U'ADE">..8%UM"5A+0$X<-_;)K$T> MM0ER7Y1Z-X^ %\L:@=RS*P/72!,%N+'.*DA C%>KC64;S7..AUU_ZI);TLR+ MNY3&]29IDX=K?SRI;&.UDCJ=KU-U^WVVW+8V\?:Z+Y,?Q=+]B--XU.AT/EG\ MW& 47X[KM 9;;L*(2O"3:6V=?&I@TCJA"+"4*T]9]#44W.'LD-0Y=5[//T_[ M9B?/\6BHWS\V=$D['J!= 8[FM E]'>%8;XO,/E[Y96Y6#Z7CFV8_% M0D^6T^NTNCN=K5/V>CJ5DS6+'A@S*&VUH()$F+4@&E/"*Z0=$"RG(];8*Y3V M.D>V@W]?'/UW,;W[&I]1?8_/?U=\6*?TKZO;S2,_.AOV3*(C!&TV8$"<4ZXE ME]I8(:CE$E7K0TY+D)41,?8JIBW2LQ?T^SC18\OK]>:4Q/S&Q7=L]?/=/+J> M]Y/'-4O..,MS*#?YR*<Q RV6K*->;(QI2Q10IP6KV+KY:/_Y? M\5I)@(/7!JB\ E$.9AD5"!)/+-V)@5.-^ O,!.B#+'DP=\262N8O\4,.D.3Q M)<$@F(ZOD#C!2*,QX,2:ZJ%3-]L+W,SOEAL9Z'9,B8]5\00;_9L3W'AR;8CN M"-21U)AJA&)HQXSSE1B>XYP$QK%N8O1#DAR8.V*+BL]UDY[-SR:O50IY<4U0 MTDE+B#*(&(T\H4#KZK$%PCD=#\9:+;1;=N3 VQ$KS'J1\/#3Y?5D]A_%9''< MC!RZ/*"TZ,PQ(%YI S1APK"],#ZK#_A8*VUVRY66D.[6=]T^XZ?B6[E(F[<,=PZX2 0&4,S>-M6-9'X3) ;E3GGR^G\QF M>KV$FMXF!O%9W*<6'REL;?'E?: M +A;SOS8=*[;%"O?QFK'"?/B\A#C.*T<$5IJ@!3@5(IH&SF6S@"O;=9)YA$= MY.J%+;GH=COS?"UFLSI6Y?&% 7-*$6/464HP$IP NG>Q.!-9]!A1#81>)I[F MN'9$C$C7M+OW^>?]W^7L ">>7!.@I8AX9H6"AFM)!)+5"A!A2F;1X==.^ZK-K _7.2Z:-QQ@QA!PA?N]P6P=SVNS!7W-!M@V< M.Z7+OZ-Q^W_S\I_YYV*R+.?%S:;L^6L5FT[>$Y!%\0TP3A$OH,04 UIM:U+K M859WY%]SQ;9-O+M=BBOO[\MM!>LZ9<'KW1BP)APK(>.;XB'7G%NT%U#"K*/F M\-=O"P1ZP*5' E#E%?<>>;M_*0C)RC#[ ME==RFV/<\?;SPQ:%CS\YY/ JI], M%YN.5G]&EVR]V!:B;Y"PVDYV]_YI;(1N5J8'JE-A[-AM:?-%T^A7>F:D9B = MW)3;ZO^*0EROMU]_TGZ):.OXOX8\?2;CL;1U6]GT[^GLXV M'=EV*KVYFG]*7=H6VX)('\KYHOHVG918GFIKT=IG!"4C@D1IS"21Q@GJ**UP MA,1=2*7S=BEUR+[TK(R^3FSMY=,_'UFDS6,?:+11\\Z@(4%"IV1R192@& FG M*GD%D#DY"6]FINN/-(=HVXIR>B?CPQN<#K!MI\7#73[.N3U0"XV*?CYBE# A ML=5$["1WT&95LWTSM,PEQ6D?+!?WOACW,64,1B6N]C*\(LS![A(-1@F20!O# M5((PB!XOLHQ+5.% X_QT\7-R!C6>MY7K#/:^Z%)FBTL3"IXY4D J M>D"4,@= G&&,L0SK/1Y27')1[TXYV:T>^N)E%7]>W6;9Q7.&"8I X0Q@G'I' MB'6<*[Y#PA-&<[("QIH[T@LC.U3"L$&*7Q3_O2[FUS\;!2I/[@[2L3@+<"6L MY$!Q1JV E=S1T1[,'/Y:\4F.3GKGXFO/73]$.7QW4)XCQ;!->Y[&> &I897< M4N7M%8Z8BVTPX1#+6D-[2)8M]^_CR8FWSNW!.212&2'NG.64VBBXJ237.*M, MYYAYU@87:O L$^X!IM;]E_]G6BSBYW_]^3[UB*@_NQX9(#B+--#*P;3Q@J/4 M\>NM]#QZ&RPGQRK+N_L%)MCVU#*H]7LI1J/9]N X 0IJO%66,(,!E)A3X"LL M (0YI13'; ];(D@=D]@2]+W3\-W\VWJUW(""ZL^]+^\*$!D8A4,$2>"54UX M4/=.Z\R9H?W-7K6MOHY04$*I>0*6^(@DT)3O%L: MX!#$62F#NUF'-BY^!A] >WV]">_+^=V78G&?$EF.$/GQ94$8B:5D2G% O5%$ M8,(J22!V.8UQWLP&7K^4*%O3QF 95GXZG\ROIZGH( MM,-1(CM8!N< 256U*=594M5YRNC-P7MI;4ZMHKQ^1U#8$(Z!4\Y#9*GE!+.= M?,1H>:D!0W^\>,[,5O30%\\V!26B!A-2GXO%]^EUJAU_^]IDE^IY+E__U['XN^R8:L-0H^Q %[UE M7Q6+U?1V&A6?T+#%MW(Y79W.M#I\5]#((0>I4Q$D*CW0,:BJY&387%@:P2@8 MUYXZ>J-=>7]?+!(*'R??BL5IPKUV?;"$1M_&$:( RLCLO*81[BA M-@ZJM:"(ODCVU^NB' 4R[1(>!8#ZPT1"# @VG3"$634 M(IXDKQ# BN2LPF35 +IH/G:BF]/L/-!N:=LN+3[(*GZUG-[L6J8=Y-CIFX)$ M7F@E>/1/B:6$4VVK]THCVW/GU\MF5>O:N*!D9.DXXR8JU+CHP H"F:OD=LCG MS+4CC")&L.C7NDXN)QF9$LHLEMISFM;ZL9*T>JTU8Z+75921)"/794*#9.3S MT+ZD9&3/(HP&$XV%%LHSEU(C=I)[H2YU5ZT-+C1)1CX/[DM+1HXR.H$5DY9P M'S%F7)B=]$:KK.;%(UP[&=4$VYY:+CL9&6'NO;%*K%CD-\1X+@O6E;9.U M3)"L9.3SH!\R&1DV2D:&U:8,)5HI#)$2@GEK.=J'Z48#T6N!ECXVR#IB08UT MY&:(O]TT=\G]9CGG- 9L]_6.Z^:X?W[^,2Q;&M"*17.1+9;&I/E5_??Z^GWR6P;M2]7B^GUJKA)OXA/ MN,VL2;@\;+JH^U0&Z7_B->7RM>3P=@8.$!-B,6:<0.*B)CS'U8J!!1!<:MVJ M?ME3#JBRX4C[QZ)<+O^*Z$UFZ4?OXW>ZN"T7Q9?)C\X(?>Q#@[%::4$VB,GM,\IP5'?@95;LL^+NU0)^,MOSO>KU5[?ASWV;?)]/V@ "&MA"#46 M(('CA!K#SYWD+CY^SFK2^8YSN9K,?A.Y/77UY7=OT7SE0- 1'_K@/4%*+SV( M(0JA+L(KI&>BDA%IFD/)L?: &P<_VU9-;V>%'S ZCX/';PQ<.6NI9Y+B=&15 M<6JKW'3G*[\80E>@T8H9)J#R@ M@@&L]M(:DK/$-<(,M'$0L%65]$7 IR[%$<(]O3!P#)$44BBD)$FH2&7VTBB6 MDUR6U;?ND@F6I8+>W+OOD^DL>:2^7'R>/'9,GR;Y'O/V:@X1"/(<(D^HI8HI MJZ"S%9">Z:S&)%G=\"Z9A!TIIS=Z7E\OUL5CY$R$)Z)_C(^'[@D2L90R8!34 M(OZ10.AJ9\-+Z7)6X[.ZZETT 5O2QF!%9+9[8Z_EP%<8_F(E90B3!"/H+59. M.^.E0@08HZ4WUN!Z>UKCW2/LKZ2,T))R89&!0@#@4J\Z4>'(-+[4).LL2G56 M4N8\9;R]DC+04(T!!01#3AWR4A!4R27KX75+F\-$S M3CS#0$O(!4(60>0\V"'IA*:75K@WET]=EI0Y3Q5C.OII0)QI%!-44F,4XEI% M+'=/CH ;K"]<-R0:1NGUCWZ>IXV^C*->+V,4M%RJZ_]>3Y?3C9J/3\('[@A( M&V.$ 8Q(:0S6&A!9R4?XQ6;(#C8)MZ.'(7F6OEP4Q2]P0A!F!$6 ZX, MP4!Q^_!N271AF5S9FJ_!I!Q\&\^!:K::_*N<7A]NP_;:94%%>^H1D 0I3*BP M /HJP/( P\':\O:G_8;:*EL#M2\S\FY^7=X7GZ.>-NM7[Y,N3T]91^X*#$L3 M)W>,C596,P[Q?J;W%I&<:6O,"?B#35OMZ6)@SIV%YQAP&!$HER4 ZF$ M4 _OE\87%N&UHO5Z3&J$;U]<^J.8QZA@%E\K=7,_G4_3$N%J^KUP/[X5\^7I M]J.U[@\ *ZT@@\1H!B"2SC-7RE)#Q&E84(57):*2ZU;WR['#BC M.L9Y>/^NCG$LI]192D#:V&5P ZOQUE988F)RFCI>Z+&7EF;P ;0WY$3_[^GJ MZU_S\N]EL?B> -R^UE',.MG5R><%0XF+?KT$A#I' M,3=4P I;35G.\<2SK?JW8C$M;SZO)HO56SVD6)NJ-5R.OI7;=_J!*>__GLXW M8GQ>%=\>[:&FTW*KG^_FT506R]6[_9[JIXC+'IY4?*%&HD(+GQ((4(1@Q;U$ M1%J*,70[,VB1I2XG +S0=)K\-V(X_?V>0,ZR,4JD\C^8,N(,DQ0@6@59"'"3 M<[C@[#W[[03BYC>_IX_^53O8N:D/D\5V._ 2ST!9R##W!ADI)/>.4LQVI\.1 MH5;4RJ;K6-JK;TF/_]]Z,E]-5UM%/ A2^Y33Z5&",A9Y;"PF4EFJ'??:5EAP MF'6L=\PK$%FT.&0H6H?[[9U4TD9("RRC$#,'./44R$H^8_VE'HMK4_,USR*= MA_3OLTB'ST)@3A$76E")I592<*CU7C,$71IG<_G4Y5FD\U0QIK-(T;L$J<:1 MU9!K+; RACS !RXL1WL8I=<_BW2>-M[>623A+#%>.P.9T0 3)J"KY&-1XJ$6 M3_H,#CN<<]N!_3*.'EEN4]%5K+V$"J8T4[\K'8*LI6ZPV;$'JF73X.QS2.>! MW?#E R6"+B0%1HJ+ICAY+.0[BA@5DN5H^,2_SN MN6&)/PJ?)G%R/3 [/?E]\ 1SE#Q$QA1#!$OCT?Z9"R*X)61VEJL"6.8:P<=JWP[JZT;K'))A^1HJ+CG:F\$8)>*_W/R8WJ_ MOC^J^B?7!*.A5%YZQY5"BCDD;$5YA[@:+(&N#^6?J[ZR'1 [)..;]4/SS\"Q_3F?%3??V ,&D8TH2($^1C:!"@4BUE.^%?-1_[9:C6I%]WB$"X%!(9I;%@$#&!L*P\)B\MRW$:WTQSCP[G_H[T, XF MUO($Z@X1)*/,\NBR$RTP4P8JNG\7+1^NA$D/3&R?)6?1L+$2^O-$[^]3\FQY M_5\G#X"]N#8(RBB'TC!@58SL(''[O7;O45;'F,PV[H-3JXGF7[B<>7A?VE%K M!A"'3'HE'/-:8XW@3GH,M&4Y95*S#FI=R(3:B18N_&2U $ I0X5P./KC&ENV M6]+"U"E[R9%VVVS).V9]EA[>[C%K1P@2#@@I'!% 2830KCDG9ECYG.7$-\.W M=@EQQIGK\\ ?8/+MJ(08T1%-PK%BT#"%H3,$5')S[G+*Z61U;;N\:;2%S*-M@-X;H7:/^-=\^:VXGMY.BYN3 M\^7!>P+$1"$G8V3E!4.$*5LM76(N$+WD*#13Z<\IU!+$?=/(EXOB>K)_%G MO/KKP[KE$8/:T2<&#[U2&%L8,996 >[WBP9Q<@*#';E\FZ0?E[:&?QO^6$31 M/NW$_"/Z44G4#\6Q$C?G#Q:<$)!H)IR'Z4B:%VJ8EPY)I:UBU;:GX%3D$/0R\O[SV=J] M6AJ[O T>K4JYC>,NOY8/^#YW>EL8.H6BUC,I 7-$$RVE-;MCWU@*;7-.PE]& M8FJF#]R_C@:LT' \"ZX*!:9W\^(U3K&..Z P9J36CFY76XY?BYOUK+BZ/;>X]4/GD"]1 M.SH^WG\=W:EL\7-"Y*N#V&K##8*4$F"4J_!,10TN>(.S'9Z]V.,<3CN];XW6 M$.A%*?6GE=3K$+Z+CPO:4:X=(=9: &@TY=[8"EEB44[^Y%CKEG3*^Q$H:8ST M;YO?#]A0:K26+O[Q5D))(3*ZPL8XD)/:]&9JL@U%X*9:Z,,1_*,H[Q:3;U^G MU^_FM^7B_DE W[L+^+FXVWBB#T\UF:E%A+6&'WCRWJ P!-$J$"U!]+PU$M2# MA+[U"DJL:V4I="KWI^);N4BQQ -3:[EXI^\.RD$0>2'MXN?0_5ZZM0G,6,P8\-JE?2P&&=+ M<8T-L<2Y>EVGNPX0=QI9^DAM%X%?S"*<6HT1%$1XY/:(<9>5??_V+4EM.AV, WO029NA4VYM7[_'3WCPL,?1 MZP,ADB#B(?+<.2!,E$I6,C'J+K%N>4M*+MN']SS*+(OK_W57?O_?UUOO)+&& M5]\DTO!'I-G]./SU^16&//PR1-N,!">>>XJ%CH;;0+U_7F-S]AY'38=\!9:9 M6':O>Z..Z-ZH0*WDBEF&( >86Z?$(^:S+-V/=66O&]V?C67CW(1/Q7)U=?OO M&,.^$X83&R7'[A,RHK(JN8UT&:U?;K>#:U]+KF=[3 M^QJGLYH.&3"+*F,,.DLAM5"G=Z1"R-.L_):QVIF!W-F>5=4SF9,T*>,@A9NI M^7 ED?MQ/5O?I-['49KXY^;+Y,=I'I\S6K!. &^D$,I!R13D@B=;$5]Z@SVH MMYG^=DYY=4^?U_G:H4H&6UT<.+.DVR5$@8'5$76'K%22(P?);O58(HALK?+$ MG9N,%PS6/Q\DVLA3.Z,D8]1@,3(*:(0\Y YJ0Z"V.ZQB_'G1#<-:)-)AP]&Q M0GHQ(&5Y\\]T-HLF]EV\?WXWC0^\M;&#&9 CS_2PYU/#F)PU3O3-&3K%#8A''5MRWD !86VA-!; &)H01@V7=H\(XI?8/*QC MZI0]ZF-@Z_%ALEAL=KU M3F ^90[P YZR:]A> M&PNOO:;1HE*%J7%*6;Z3CVF6561G[,3*5GG-5MKG03PDA=IKI>T4L]@RPDQ" MTT;77^E*9LGX)>=29-/@[%;:YX'=>'=BM[-'T0 <-!9KJ1(U;%198N%85D=U<9J.QHJ[KG:&P'8I>+_ MC+;P?GU_5/5/K@D8>*(<,=1Q;QFE7.G*&@KGS"6N.C967]D.B)T28/+C- $> M7Q-2VAP$,2 5B $37P"*8/7L,J^QTUCCIE8(D %B7VYF-;F]KY$;^.+:P &U M'"C"H,4 PFI495,*,*408RQ5Z]L.Z#.!;=OPGQ<+ZZ_3I:%NMXD2*>\K9O_ MC.[O)@>D!HF.WA^DUM(#C2A3%"L+H#&XDATB-=CAJ&[WMAKH_@"+VD1W^ 69 MOY;%[3JBM8CQP,LZCPE>'UYY^S40=@#6UT19H)UVT#U@1(J)M4 A:X_SSWO3#).H< M45K]W)U3@P2JG;9*0H4LY5QP+2"ID(CJ9(6 M<@JU,Q8R +D$N,(!('B)BSU=LB5GV_0L38R D1UOFW)B5027(4^%A,+KHV9Q>TR=PV/4\=;W?;U#(-$!:*@!3$ (O=U=9IJ)^X,QA"DHVB:TC21. A! MY>I8Z2\Z1ZDONK6K@KXH]Z&B-8:^GUQ[,MBN(B27&$@&I58X"QBN) M$ 4Y2V!CWPOJBT^9F#=.^?XX6444WD^OB_DR;2549#Z>]'W\K@ -EAHJ[4VJ M'TJAX;("P3K W*7GNWQ"MJ.,$5#T>"/WXS>&Z(IJIJ31<1Z!6GO'G=E)ZZE M_293E*O)[/*)=S[LPY.LO:PP!!0E6B)EXDLF >!"5FO,G@B0DVUX]M+%KS+Y M-H9_>.(M/Q4IVDI!]2,C_;&(NKHYUENUX8B!,(@195YIJ8%$WFE1K4=[+K.: ML[WAE9).[6&+^A@Z$6U]?S]9_+RZ?6B/O%ZEW)I'@KD?WXKYLGB9"U7)'^H\17JKW0]34EW^*V??BSW*^^MHP M7*TQ< 0&8,L@O+];%T@&8#QM />TVL M!JF2O'(XHE2M.1"%?$[=P;$G#8R5M@WT,F+6QFO;96V\-A!G+77*082X! QJ MO4\0HTIGE449>T ^6M:>KY=QLE;=1HVV3MTGHP9D+2+>40JI 80ASGR5-A1? MM,DX"2ST7U& E]GF0-)6JS* B'_E>S^!4 M/!__L:QE5M?\F@N2" +'B",< XHXTH*QW6ZP)]3(6@>ANCY FUOI7C),@38* M"&FU$@2B*K/5$TTNLN94QV2H6>G^/.#[FGY:K'1/H<.(,$*UL$0[1ZJ%I(B7 M%3G9I&,G5K;*ZU:Z/POB(2G47J5[S[GG0 LJO/2 "^.J)#)/ 6"7W+DGFP9G M5[H_#^S&N>MJMIK\JYQ>'RZ3^=IE 1'@C5,>*>H)- AI7W1=65 MK2'<6/]7]_(\NX,D(Z)PD"E4R0^1Q+,_89$9YWF/YL-WS9YMYMIOO]5N$9J/4"1,U'MFQ?=EG3V M,@JM-?$8*("U=1RS/7@>7_*QVBZXU";88S1 &,487UF%$"+*<:\ID3L)!-(L M)X?X[&AI:X#X8C"+QWQ%FHC $2(+)M.*ZA ML?7JWO>VM5>U23]O>V_?7!U(I^)L&.,O:(AE&@*J*EFI89>\$],1*4YO\34$ MOZ\)HG[]B?/(5WNT( "CP@I%,,-<4LPXY3M<$%0@AY1OQ4OIBY1=*:5OLI;' M)#EXV.YL%K?Q,0$2C2'A3EEG 2%:,JXK)#WD.7M3EW5,()?> VBK#W_M72IH M&!_SQX">V?X9SO+#CMP5F+&> HFC:2$>>60DV$R&#D2=*U7KK>A-UCHVX]AM M07"BK0>(,0H!@QY"2"IIG;0Y9R[&[G>U0H*R,ZQ[?H,_3!9I*^1[,70:90=O MM!>4>F> 9H)+"R1#,&T$6NQ\='0'3)'5=S/0[)T9)],9GUT9K!-*,VFIT012S1BN MWAV?R@H/UN*@&W8TU.4A1C3"L'&Z20P4IMO\A?@ ZSS8Y*&H1)6SW[(CPK+35K)6OMT2%'$3[FB;VDZ-:K[YN JX3GL3K-P3M!=:: M64LX@>F@K145UQ&@+.>$S@CYTKY+T0JLPY'FI)-QZ):@O#!<4"N)XPAHJ BH M9EQD!.DUM:1'XC14\TG6-$*UMS7RJ*)"S6_>1RW._N]Z,5W>3*^/)LC6O#,@ M8R4#6&JJ@??*2*;)3E[LE!ZL=V9?+#I7[<_7J5N%M\<0QT2E3%=FLEC\O-WF M19P.A%^_)S!J4KU(CI6G%A,GO.25C J"'.=W[)LAG43(K< \*)5J]:T\<6<0 M$KAHS&%\$5&4F#A)1"6OE'*P-;D>:-4"">K0JC'8?9'K4]1>_*RO)V>YIQ>& MM+\-C+%>(H)U*K_-]B@9IR^Y<&9KBBY;1'@X]SI)?G9<5MT44+3>5+CH$G#J MI')(,[.3DE *OVL\HI[( 1"#A%$/8#56@:1 M)JLLZIMPM\]7>2T6-4*W/QY%I.>3V:?B>S%?%Y^+Q??I=?'NT^>3T]J).X-T M0$)$$4)*&A[_8%>MMA'G??N@RSO6GFW2?NC=$:0$0T+@8"$?!*:5<[F2F"K/!:C>_(5JU#7+O<]ZC M:?]]C<.S1^\+.M6;MLH"GY*EB500@TI6)E&.G[VMKA. M65'[A_\T616?BNMR?CV=3;=Z7/DB:G$R2\MHZZCSGT\N/L*W%D8/UD$%E<42 M'YS9!Z;JOJRV/^:S-9;S<]FY3_1:RGL3N?) M.4H9]Y6DZCZ)?L0\GSM4$-['UYPZ#PQT'B,(2#4SLA@9YE1->(M["/F6N&,- M],7)JV]%R@R9W[TOE\O'2YK'G-'#-P7)!?9"2<8$$(X:+5&U7\SBGTNN"M0- MSUK#>MB]SU,&[X6\^J?>83[Z_3;QV)QG;1W5_PYG4_OU_>'',#,80/!(CZHI)QR:4V$ MT\+*-T[54')69L;><: #'Z]?;?1EX/Z:+V*\=3>?_L]FKM_YG,?FRP-W!*L0 MA1%-1[G@%A/D3+7)QZ*KD+-LM?/HMX?LV/DC!>ETC'HDEX0PBR1P-GJ96QG3FGJ.Z1*_%)GZ44#/ M9R@?RAF8&%^7\U1]Z>HV&65=1(M*$Y&[]8 MKJ;7)[%H-&HP@%%"/%#>0 &8@)SP"JL8)?_-SX&!_*^-OY*NHF/M_=)N4AOJ7M4KKNIP8IF2<:>\.A M--KRM/F]P]D)8/M)%W_*^2_]=BP;"?$[TM@H/,?])DQ\NQ]/3Q?G(,:9U6$- MHP^O6.)'9(\%P!&'G/2^WMO448[2>I%>A@-[8*\QM 84S0<-P*D85'M *2>I MWKUE/KZ[SFKGN<99_43&G"R7PYGG24U]@=];&MU6H)T'4&<;O^:=@4FND%*I M3K4VPD3/0I(H+W6"86#=8$4YNR%;'\1XG8LM*:!GPM5/&ZEW8\!*$0(,!$Q) M'B=KZ"7=O-$8:*U9OT7!'SE3ET:W=O#OBVW5CG^[4W#&J(%*#@&(GBW !$EO M*1-@-_/8"&"M>F)O/4>IQ0FY/U7T3=E=BN#YAK+> %!+2/HPGH@'454:UDA M[I"^Z/:EO9#F %%;U4K?G'QRUK\Y,^L,$U)+ HDX-$0H1P2#A&PG%.0APEEG MZL=N*(?D9P>Z&86*".@,01A Z#!# ,/$.1VN%7<%^"GI+G;E]GE9P2.=8<* MV (I!?#,1U/GO.7$N@H59>%@M:D&M@2UR7)@8ND(_[X=G;T8C\BC8<'UO11>/4W1>/LZM7\6F;3YQD3Q6:%M^+UPAV M[A!!(0,EL:GXLB7:8QQGFSUJ6N4LCXW].%[G#.M8&>U1+'UQ?;U81SU-)W]/ M9_&IBG0@]FKU]7!U[/-&B<$LCS%(C#B($M8@+:'A.]D@5.22S^,-1+0V]3'8 MU/K'(CH%Y\RDFQN"$$@;Y"S& BLBO3*^>I.@%SIG:>'\DWK#K&3U/W$V@7XP M8KT$Y!R6O;P[:*2Y- ()JADV0B+)225WM-XY"_GU3^P-E>$['.FR-3$8 R-$ M9ZZA!"*,(0!#K*E51H'X>HE*L@A@SL&'\\_I_2IF[7S@!Z#4XRG^K 6Z5VX, M! JE$"+82NFEX(JI2MKH*+A+WI/L>#DN'^UAN?5Q47XK%JN?'V>3^2KZDNZ_ MU]-O]\71B@IGCA2BWX 4]5@S0)VC4$% *SP@(?U43AW!1)K%E5H4;$L'@^U\ M/Y+EG&WO1[<%)8' C$(--(M^ G 0V4K2Z+_F%)]O>C"KYT,J'5.N!=0'<]$> M/?*9WMK3.X.DG#& "$/4"@F@U)SM062XUK9?%\ML;Y)1[8 \V$;WTR*)5[DMZ M&Q/#/Y3)45S'R_Z>%3N?\O/7J#$]618;?S/^9'.E*8\6DFC_PP)W*FK,61/- M!C20"RY8A2K"\I)+!;^%MZ%3;8[I'=DG!"VKWFB9[\'+ 0,2V!N3]DZ%2[5. M);E=[:2QD3AU][5#HQY ! Y0I$A42.:8 LMK2(L M#($&O>9=_#;9'>AL3*S>U81X@E[+GQ0H$0XS0(&20CA+ M:<2VPM-SF),!,_8:UF^!_]VILG%2_9?7VTB]\J0/[04.I=8W&2L(C1@C-K4C MD-&98YS*O9S4T)R49_F;LJ]2MB]E=47*6B:VV4 !:V,L=4)ZJ9717&OI=Q(J M#%7.XAT$O_G8F(_9JAK6>7@-Q%8VU(-DF@#$!:66,QD# 0*K72J5TD=R"'O^ M+F._*6#CG/-;4--HDGP.-(2YO/0=(CBDT%*"$$-<6Z\\-!A1YKDWM%ZOW6YD M;:]=D@%1%DTDY\ Q+VC\SE0R6LW[R5#>68IOFQXPGU>3Q6H<23:U"5"S9=)Y M8/CX0/]U!(_,D0..%-<^$M0) MI!Q44'I<8>8PRSFO,_:,XU:H5 ZICK[FGM<;$ATHP]F NF>/&CS V"#H ;?. M6&,E2^LB.YR@RDF_>?CYMNU9%_Y2MEP)W-F?/'S:D#K54*";BR^TEP8;J M"BGN<%:MGK?L\N>3MG-=],_:%QN^*1O_X11H \*>-6)P0'LKI= 84Z0C0 "" M"A\!34Z!T+%7,>N6JUVJH3>:KN_O)XN?CV:(AS;@288ZO*PY1(C!&-,0QM#; M2B3C/$.1J1" (FM=;^R)MIT0L1O<^PE=OQ?;-+!W\X^+Z?=HXF<__T\QJPZ+ M#[W%=+6XF\RG_[,["#)?EK/IS99R\YN/CX2^NO73^23"O3U'6&P2VVJ$OJV, M']+!8*^%UUQ22SWS"J&-7E,=?J%JM;[H/LJ81?G+M!/ZO5"+1=K0WTHQO]DT M='W]UU_B5\LHXW;[-MK1FL%'.Q\6.#-,$!Y=7BLT!-%H0[I%E@#!658BR/A. MMO3,QB,!RR#JZVNJ_53,4J66PFN/TB@2 DNB::4 M0H@T$9C(/0H>Y 36(R3QD#0J>]+1$$RUY?UD.J_)R.W%P>((CX%&&^\P0A9" M0BJIM-<7ULRX"W4?850CC!MOQ_X_]^_H7OY9W/]]N*KVXVL"IMA9QZR5VB,K M,.7"5,\%U7"]"[O7_;F**=N!L"^CT()9C3%"\2[Z#</4[W^OBQR-1)&3A&A MM"+,&:V4T':[WJ415[Z6U>]W#GU8%:RSX'K&*,$P%L-Q[)%V@D@<$8FNR0X+ M8%%.AM ([5#/_*DYZ>7KI0^C]*%8)0/ZL5A$*W-?SC=E<0:S-&ZRF$_G=^EQ M-@]2IQ#E@5M"C*RH<4XC&NT_!58!M8FZK-,$:EVK3DT_4M9Y^P_>$YRS5'KN ML'=2J"@;8*Z2TT.44]IA[ E ^;I_?KJG)90'>W,?@@$U7TUOIK-ULDJ?B^OU M8K,[Z7YUX5SOP+24#FNJ#> :\6)P1KN9(3$F9QRFF^3 MDTWT_]R-;PGMOACU[TE:-EB=9-&3ZX+WU"I&I>#,26RC:T1Y)4O*B[W@%/K. MF).#<'_[]-$KGEZOBIL-O_^:I\*OG_\ZR9ZC]P4)))3&Q9< (\RY1]Y61APB M3G+JZ(T]M[TS-K6)>.,-KCB%WY:+^U0_Y]7G6:Z7QS?Z:P\0A);1PP4:2@:! M8%$ZSRJ),+0YN4=CSSEOG4.=0M^83$]FUH_KQ?77R;)(3?GBI?0XC6K<&K#6 M3B,CE(\SM'8(:DHK*8R .5/:V;GBWXO%W^7;IU#[L#[CA_ZMT=H%:*(LD,8=8(Y)BKL).EW1Z^W6; M/K6[@-I((R/8_7NQ?C=9;HH6 MV 1%<7-)NWM*DW3",GJ^&@F#M&?:[W3#E >U#F5W(V74T?:07M+4$=&>7!>T M5UXRJX#5E!A#@$=@)P_'C%YT"\%L'9?M(=O;XE\QO?N:6NE&4SNY*SZLDSMU M=;L!X&J]6JXF\YL(RK,W^-@J8:,! \':* "-1(01ZS5F"E?H:(US-NS&Z@YU MQKM>5-#;?L?QN>0,F_U<7F[BY"V,L"B595.,QA>SDE=YD^/HC'W-L77*M8OU M8"[,P#7-VG1,H 2<<8LLL()""X318IOLB152]1KE=2-E;3^Q25F=);>>$>T\W6-D]"57+\OGS>%R.AWJH/]*.IDAW'GT;>O# H'""ZF,\=98 M)!%7 E2H6I55'O;-NE/YS!Y(/7U,AX]/,:1WM5A>+Z;?MG+H]7(Z+Y:_2Z,< M/\(AI8-<0>J5EA P1K7EFR1M+ZGE:L#ZH0?E2Z9Y>77[6,9*V8\8$%%0U]=I M*2JR^6.\N6Z5IDX_-T3;H BPQI'HM1*.&$6ZPCN^Z8.=^._!QO5,V'*\:AV+ M;?R04G?2O##TXN;;L)5$8@8=2,4*&%5*0L'\5LF.&&8;12<']NRJY8\_BGEQ M<)_NR44A]3E5TL;H5Z:D4@*TA=73<>D'.P0Q9F-26Z-E2[#W%0I4S[CKK32_ M^USHE>_">P+1F@&#!#,$V F,P4Y6,P,"QFR>6GXKJ8?D]A\V;VV6IX=\U@\\SN\[=!SWRCFW]/5U_->KDJ[XM%C9FD MY@B!\ZB2&"PICZ G C$ MAIWQAFO:ATG'P2#.BYRW2$"P1A8#)5&7 NHA$U< MW:'@%!GLH&TWMJ)U;KS(C>T$]I$9A]$XI3T:"\DU0M03CA'00B-":)P8,!-: M$@EK!87=8&"GR\G=W:*XVTUR.XE.51H]=EN@&@B!/'524(,%\5BC2EKG?$Y) M^+=L%.IRH.P,ZH;.Z7*Q>D2H^-US,L4?A4^IQL>!L[5/?A\\XECP^.#66RBY M -KQZID-T8.=..R&'NVHK\P'LG/E'TQ5?G9%D%A(%N,I0^+#0J*\C[[S[KF9 MN)2*8 UU]5S3C3#K4M=_3GY,[]?W1[7]Y)K@!#):(DR943C&1D024CV[]&:P M#G6U^%PLOD^OC]GYURX-TGE-'$+.:4\1D4X0 ML9/$.@ER%L5'6'VR=9/? J8]L".5.-P]X/)@78*CUP"^%,O5B7.3KUX<('>>QO^$=,8H M 3G$NGI29L2%E.9K25MERW#V=L[DYC_7VU*>2U\NS-0G1EE%O/+]5#^*BF;V?K(K] M6_5IVQWY:*V;,T<(P"/)H<=&,J($]7$ZV,L$C;BP3B4MZKCL ^]AILH/Q3^/ M 2KG\<.>(KR3R[M"7>CK1>M@YT;_9K M+__G=*IKLKA9_O7M)EKB>#T!\B2G:MT?L%"<2Q7_4,L8TQ2+?<3D(;^0Q8)V MU/_<3G4 <%_D.F"XW]?HJ'/JUL"5AD8+A #C(-I_2.T^<@;:Y.Q,9/5E?4-3 M8,L8-W;;=Y_[J%K4U=^SZ?:I/L>_E[?3XD:M/I;3U%ODR_0^73HM7SNZF35> ML @I'J,?K+&4G&-)1;6*;RG$%[8;WI[ZR_[!;U[%:3(KENG$YG2YC(^T5/?E M8K5+*CQ.J]-W!H40],S[%)YHY33"A#\@)G**'[R=S9-, K4.25NYF\=61QL/ M&C##'D+%+1;:*"@\,#L7PT ):,[:_-M9<&C.R]XUT!M/7TFC>S^=_#V=35<_ MGR[E_<_16AOG#12P(H);@M-!+PQC*&Y-C,RMTCI&0,+F!)1OQ_MO@8]=HMX7 M!T]D=6Y/5\>W2RV71?QS\V7RHWF>\&NC!>*@,91'#U8;81VGE(OJW>34Y&PJ M917M?&-L[![ZOBBY/R-4JX#:*U<'2BER@,27BVNB.-1<@DHN %E.),%_(4KE M0]L791X>L.+_=+Z.#[Z3( 9"T25X5@GE2;?#5XC5>,RTV>:59*F@BB;1U> 2 MTPHC$K_-H)_XA>C7EP)&=FSHH>#)(V3WO]4_8V16+$S\T5VY^/GK'"WRW'J* M-(6:,<"U,T"S;4]G'CU[/&!]CRZ.%JGH(3HI":#:(&PL@8Q4TA)B+FQCL74. MG'.TZ#RHQYQ]C@!"2B G')662,6,D3M)$%3^PM*SVE'JJ>SS\S!]&]GG $FD M.$G%WA&/ %'$;263L_A""FSDJ[16]OEY8 Z9?>Y<=,*45PQ[!+0R7H*]W,3( M"S$/+6GK=/;Y>7 V3\M\:#&_J=7Q1S&/<^*'8O5/N3C1-:7&K8%I2IG#'@*C MH0?"&R8J*1#(*K8SHDVW#DC1/KC='F;\SW)1^5.'TBE?OS X+@#SA/L8Q459 MD/#.[:3 BIC!JEF^$;9$:!%W=/GG$HT[%P>N#P09P1S$D5@BLE+>L M>HDP0?9"(I9#Z8N2J/G%LO4C99+:T_NSI8A0W!&CNBA82I;9RMA"8\ M[ZS.B-)JNE-\'IZ7D&[,XI3H*#.86@(4!H# R@^.EB^K-^R(&-2)!]D1QK]. M>H% AC$'XA\-C:-.:\@K7+PB%U*$IWV:M)!>W?_;9*RS:ILLJO; M+^6WZ34#["I54KTIYLO4#G57*W5?XS1EW\YO]&263/_GKT6Q^G4VZP#7*0%= MQ[^Y(91$IV9W&%I)XE@M7[%3#-ZET[&3F?KV;3:]?I0=_3S'\$N;@[2G MMO/R!@["8(Z43R>/#/60.LALA9A0[,).3[3.H]>M53_*&/.6H,4V!A>>@%1. M&2$G$4>5)%Q?V@'5OM1^:M/P/-3?QJ9A?-\4E19[R &0T"I#0"63 O1"#%2^ M2FMM&IX'YI";AI[PY".JZ,49B2D6G(K].V'!A1P^;DE;IS<-SX.SO_3)1]Q[;47:A"9GZ9R 0R$X(K)8@0GG)F'/1NO]QKF@.V M 6TQ]K1:=2J;X2+WX/*7^\H F4&>BKA P)1'8HD!M.20Q2CGG'1 IK(K&&6C MMI94.BO]FMQ>I7D7UW_&X'^Q,P6_K:?7:;?@W6Q+C"Z^S1=%N=MPNH%;[9<& M"IW4&$F%A8__;RWENN02%&YD<4+[8'I:*M:59+H[+8@SCJR^*G2Q^J.CPT4)95H3*TO.89I5!31 ;Z)S3/<@H\[Z.O72 MEXYH*Y BF!B%+ >:1']N+PB7A=&0+?DM2K]*Y[CQ&=V;A.NE:T3G++0#[,?2 MTT+;N9Q>3TH+XD0:[R2"*'K-".)]OTIEJ48Y?:X&:%:[!%(#22_G":<>*R\IY$PR?<^W&#*.I#AH $#+8?OK[+'!#* "0F*1U Y: M!Q71>Q[IMV"Y,6AV):*.(Y\'N7]1^&N.I9Y9H3,2^J();#"KE1K:D^_LJAD^+^?)'!&Q$[GTAPY&=\(WP MOD1QZ3BSOX]9C(8^$1BCT$'FH23:.A6![FC)1>_=2%(-6\/64V/2CUAZ+E>L MC-I*XP./++T%M&G+&D7/JNCUG W0%J#9!L\[V+)^Z.XC>I37/_O M]601I7#[RTY6DS]GD_7U='7?E[OS]6T_'3^=3697T5MY-]M<&[))[I@NKV[G MR_6BJ+#.G?FFH+P!UF"A&.2*2B\)W16Q"JPTK53/VP-/JMB%:B\(S&*-H;$0 M<<&Q,I*5G0@%=I;U=K+Y(_JHB^@X;NQ+.U:B-;#,.Y!$_^:B[R+0_JR&E5I; M "ADS&N F) B2B 5IW9' MD1$\JS/6 #W6UN3]+ S.8')G"=Q1+M.5GUQM;GLXD0?X_.& !/#68RZYC59+ M.N$QV5'E)"%B7-"I*]*G:=2Y?.P''2=+3EYZ/%C,G4:<6*9>?YPM+0@ALU26BMX#->IT #L MJ/)**#JN#8R&EIEL/O:#CM2][.12G*>%< 000"< $9K82'>-$S=\H6.I=]P$\!H((?Y/&9W M%E3/EZO]H=&Q:/KA[6C!2O'>$GPO"R4Y/'V=50[<> 80!IY0J3 2&GI4\@@[G./U9"7W7A;N MNN)_5QC]-/FU2=3Z^"T%KN[?9'C7T^5-^F%:M8_9M9-C@S(JVF?-M0D[@[2]5P7EG(=/8(:@09,[@W=UN0!)N M326OL.V$WN/Y,>=G[Y[QOB TP!1#IXG=]!G0"-*2/U+CWC:+!YC^5!E*!_-W MVQ-,)Q8F%37$%3@.GOXL/MU.9OT9E'OQ?/QFYG<_BMER0]#G8E/&LS'2FX7_ MZV197)?VO()]R7MQ,'&IX48B(@7$0C/&[#:A%G".N*U48=,SQ_1#PBHF8.>\ M.2BD@>>4*FL DD0K(_<\HU;WUH^Z Q/4%=J>IV]W*+&>;-.'R6*Q*>_J.T]S MJ+8*,,YSA:@BT?/8Y_?K-?V0@\Z%%U*[N:VP*5 M[G?XG&9\Y%*0_>^#Q8Q*;A3'@AG+B!+NM(.9@3 M\N2)8("1FGJ*()&0Q^DZ3UKF#Y\)T=LG4#(O MC+*<8(QIN8YJ$*W=2$[&&Y%Y!M\Z.Q2(T4O*7#N1(_SPL4 %!\Y!IC0B"!JJ MO7 E)9$;.<>:60CHXGBI-P>A 4ETC:F36<6/'PR2:4@%02CM.RI'J 2PI(80 M.^:]F7I2/0"-6NRLG4C\?#*)L2@GR%*!RWA0B/N(EIS5,U.-M M@Y@X%P^[^4(L%8YSMAPH*VE$,3+E? FP.:>(0\^]:P<+M?A:&P?N[L?M_%=1 M;.;Q:;VXNHD.4C4346%HL"SEF7($/38\!>/>EHLGC Y\3MNY 3;5; (0S7.U M*T?SKV*9LF5.Q"X/G@K88"D$-PYC31#@@!*_MW54Y+B80[<=_8-BTI<)&L\@C&G/M6$V--,IOZETEWG@>5J,4TE*IM= MC3]GT]7R\Q]_GNR6=71<(,P(H)WUR'JB,!;0D!VM4F$U9L^^7^P\:T[0G)1J MNWZ?BL6FG&)V5;PXG^5Z>=P%K/R"X"G'&C*BM8=:8J59](FV%"D3@^P11PN# MP%VKXNK*)#[:YOU8[0[H@V,"8\[YZ!Y):DU4,QT5KCPL4$+0G .YH4@]+.]*CI@8Q.!^T6#M=$KZ>IOSK4\KWB0_1L2\>D;ZC^=12 MT*]W:4]3N49G$ 'KS;NWQ_3Q8.++MO0DJ?? M") A;0G"TG'(G#?"D/+H1C,+S)O0CPL$O" ])W/J11Z.05K\7 M#,9<*4^T@T@3RDRJM]SQEDJ;4THRP%O.^]:(GL770_S]<-[NO^O)[>_SV>KF M]M>]BK<6?U?^=.0BM HC9.(:BRUS',-R(U@;1W).CX;8F?'B0NZV)#GXI6*[ MP[Q,=!;7']9IHWFW77AR7[;ASP5B&7<4>$0\Q<@!J%2Y"!NK3$X^)G_3D6%) M;_#QQ([43<+B\MTN:/I/D0Q$<:U^%HMH"_;9C'XR7?PUN3UZM4'',PF"68:L MQA09C: QA(+R_,E0R'*.\,1;5-)X5-*)E/O5NK.5(R!$(?$6.D<']UV/+CZJ98?+F9S%Y4Q38L^YE3""P* M4F/"#-?2*LBTW!>)&TY$5E,&\*8/C=OT=N5[6:%%2>1^Z3JY/=O")P-T7 ,E M(+?1E@F(%(1EUK;1$&3=^OYV#MYRP)$MS\&O23MRW;_%XFJZ+/:6X7S@6DJ,2$0:D$\8##RO$SP-DZRK#3\MT/QUN*+%F0[>*U* M/8OGZ]DJW2#T^V3Q=[':9 :4:0(IH&I#FRI\-B!JE;42"40(BUYU9'<9OED* M\M*RAGCWZ@4J3O-B[*P%X&)^5137FYNSMNDO#V_P>*D5X(L#4D\)HU&D1ED! MA$-8XK)?F8WV("OL./N ^V>Q^#H?+TP;$4%7 'N0664F/Z9Q(=GN!7^.LE[\ M+*[]?.'7J_6B>+=G0N]F5XO-@,GMPS>E^T2Z4*(CGP\\ MLY5 M!$N9F9:Z;N0T*X-9Q^5OVM6E8.NGX";5WI!1TO=HNMM0+\WR8")MU1<$&,-! MFZK7G27" "R%LWO#@71615W62?9HH-JJ0.XAUND%G_?U[.HJ_G"Z^O7G+,K\ MA2??;@!]\<5!0"LHY(H2PYUUV""55G!J%4..ZDH.6$N1Y$7= (J%MMPS" V6 MQA*=MF-+/B(GLAS9@1]^=H7 UFX /4]VG1W6U+@#S KGJ02*TK@$0!1=!,=W ME&#);-;.Q,!1V , $::8B?Z 3MUXB72,(U=2@Z+"CAA7 M]:1Z_ ZP\]B9Y[XW<;>/M5JB9*,E@D(3"87=DPVXR:D[9AK%]1IP8:F6@#"DF"II\<;W=@'IJUAZCM@0UH18%\VNSY/*979VA88!$J7FK 4B]2:RE.YH)$YDF=>A M(Z]?S%3N['J>A+I"83LMUSVG$$!F0&H#Z0TG?,\]PKW+L8.#7^R'A,8FI308 M/Z#O]K"4>8!9G#T2"$HK-"8[KM'4&RL#VX-O8]:[(]NY_ :/^MW)^L?U:KF: MS%*WS\_SVUL_7Z1?MECS\_(' Q">6<@\0MI(K9'"N R *20ZZTAYZ-K1(38; M+O)I1)B#5Y7'_4?4S\GT-AFC2.VFK+8-93GQR6"YE$1'B5-B)"1<&8-*#BN) M69?J\F.32O#':K)878#2-(3?$PS$AUJ7,J#UZ876Z+\MI@O6]D ./RU M$!=UQI@$G$=3A:7$$I;!+),FJ['Y:-LY#TQ[&I/NI6A-Y/2W8IIJ+EMM6'7X M:P%!2+R@A% =_PTH@DKLK1$6.9UUJA?CRJW6S(KO*17M36]ZDV]G>K/)M5@N MU\6U72_V#=VW:^7#4I6R[\E1M3C[9<$P9V( *)P1T BG9,IBW'*%"\-S3D:J M5]B^B/K7 ?2V)39X^W^!70R=(L!*2[B-O#"&(\C+75$NF3ONV4@Q9 MZ)>O=KLE]+YI72^:]VP6P1'I+-3>20R4Y-2@?=I"NO8$92C?:+M"7YKJY4I] M\-HWP),?9ITW$$D@J>6488/V*.# J9R3G[-+;[>;UV[VMJSU+.;!*](@SGTP MX,)CY#4UQ!%KJ<9E19BPUF3E&)Q="_RF.WT+^ *5YLDU#66PN>D3F43RK@\'PO%>ER&OA>?%+G1:3VM"/HD:E?_SH7$%4(2T*C M);98.6J VO.?0MAI+O^EYS4TCOE^U/-,3 Q&)P^F 5>YO:@QO6QN%L$ !#2C M%EJ5;N\#J<-**0<)_-O-[I>AE;TAXF(T\X4CO;[4\\RI!,:PM]!3Y+T%3$DL M:1G(R!A.Y#BJKRB;:? ZVBXL+D91GUW0T9>:GC61P*5F,,9",0@R&@GK)!![ M:1B3D_[QBI*F!J^D;8)B,"HZFLA3JV@9M7+8,ZJ-H,B(LB)4:J)RKL\\^X*$ MR]Y8[5TQ>T'$I6CD?9+T?7.Z*LT46_UND!98@ 3SSOOHG$!O:6G]%,99YQJC M]5O[WV!M4J:7HC\[&Y%..EL__WOVK2"D0"2Z!M(K:QFQ1'%6\E1 EW4GYUCU MI%FPMG/'8&T17Z#:].0(5IQ!,-$MX411(KQ26B/)H"GY;X3.N0EH[-N<@U>Q M!@7?J>)]/4W]U[.]W<]%:K 3?V[FLXV$UI/;+\7B#IU2PFYG$U0,#ZQPVZB M$^,$+%,B%(= S1) M95^FKB%Q.>V/Q[Z7.4SE;!\$E^*R/C!3G5TG?_";@6B-F2"&UH27ORT> =LE'D"G"M/+'>*.1++D<+UDTYZIM" M#5#6E[) _;6],6UV[?[]L;GX]LL\_:B#S?P37PX44H,GR=:& $P"6/;"U M\3"GPF>T7F'_V_G-2O7"M:C+.I^J4P@ 2"H8\LH(YR1WT8B5CK9!2(_YLIG! M@+L;I4\4)Y (F&SD$LK"ZE)93-60''?HIPN9K:("(N M):H[FRE];&PV-\F D%,HH8YX2RCC3+@RY=V8:)G?#B/ZT>M+1,=XUFCU_?MB MTQVHLXW2VG,*3F%(J">4(N.QI5C3O1]E,,JYQ&*TL>G%K\S-@.%>8?NZRGNY M7-]M:?YSF7K6V")"Z&XZVWSGXS<_F2XVA'W\MF/-V^7>+[XX&&K+4+I"YL%+O_N38U<>39T+ MP!53*AIZ*:'V"%B8&KOL*'',Z)SRY:$CLF=H'+L,_#RI=(VOO M'?(>>8X4 B4UFM&5(]?!GX>.T^#X\!EX(\NKORT7ES=1(U(4XF/ MTN/W@E<8&J3$'EJ,A300 I(G'M)A65TS#G[=>4Y;Y7%75F1+]-5LKGO8@3R M6*Y>?#X 0*1GU'&C+!78&,?XCC9O"1[UA:*#6K>:$$]OT/O/='6S M<4!34'@S_?%E[F* N?IU\ S 7(* M;HTR/GNQ7*K9M9TNBJLHOD?MXZLMF">&A\@;+Z0#+$9 ,L8]$.O2@_ "@U<% MHZ8$_]*JVJPG<\\,5HY'O]L!+IT4.\M > Z1$;T9H0:ZP' M3&-2Z0KOC\*L[1IP<"4_.29@JBGTJ>V44X!AZ(@P)8V,ZTZ1][-8?)T/ZIBM M5=3,VY%1;8?QPWQV#K9.C@G4,*>!%6+?XMZ>6+?XH?$Z,.> D/OI]D# Z,$2F:0NGX^H T7[.4A,RYK2 M03B'.>)H'4('S=63)P*#7/KH:E "&40<0,W@?MY$CO'(,>FT>WG7PC]7?/-FF-@J ";_ MG@; PV<"=DPY2KT41G",N)1*EW.G3N6XO4-U31H!0 83.X^/LI;&]V615Y6H MJIDO!6R%ID0R8A47Z9(;S5G)3R!Q-[<-OV;/9AB"'7Q%P3YY\4&6XSZALZT* M@9,?#1I+KP@PVDM'N'$&6K?C,E(2C'D3K3? -I7AW[1T![/Y?"C,/T;P7_-T MA'0;(?-YLFHE-[_ZUP,5T@NHD#%8> HV#7]+OD=_(:>.9JB>TB"U:E!BODCU M^CQ=_NT71:HL*"(@5UTJUTO?#H)*)U+_0N$DP\8CS.]-FB4Y1^=9QYQOVM2E M7+O7I=_F\^N43O!A/BL>"V7Y)7)A.;E*M"52)]N]XM7-_/HL!Z^ASX046T9I M$@&HMDIQ!BTO.1ECUYQ]FJ'O]0Y/73J7YX5I1@VWK<'O!6"1UE*EF O1&EJ.V.-?2U@YZ AG@G..+2&0D[+91JGNM@, MA1EZ7[F1*$P#8NVK4CC]Z!G'DP&8+8NW4N"7"RXM=%(J*;'!-AI"8P"AACNO M,#)405E%85LRAJ,H!;;*2)KN3X)64@N88QB6_ 4ZJQ72T#=0NT)F)Z7 Y\FQ M*XKQ\=N7Y%T6/XO9^G"&V;''@];6>4,YHZDS)+-0*53.5D4G^?5!XUPQSAOG MI^]7L^O?)XN]B%?^\"P9/UG:<&AH\-II#Q"2DU&FG M/".E^;61%6.^:KY9<+7$\:XP]ELQ*Q:3VSAM=7TWG4U3[)(V)*H"K=+X8+BA MS&N$,! ""&>0+O7+$9BU#3WT(YMVT-8&VX==_JNE=%H2C6ST&K451A!=TD(9 MR,F#'/IJ.*RX+D5M_3V4X=$F@GH/,3&$\&$8D0@N>.GAU;GA,!G^Z'=EQH/RK#W*]K.O(\M M <7UR_3M'*AC;DFE%P1,(2- >V ,$T(8#DTIA?@S,.:&E;T!Z:FGTH:D^CH; M7M_=31:_(J^6:W45?YPZ"+T=";]X\,:D,B2*5#)*0?R?=0YL!4H()K92=GK; M1\+UG9/JQ\"9WPC4<0PH!$8Q2CCA7BM;\M%Z.N;MZ:X0>/#HMUO9#3OT=Y(" M!9$C'GA,T]UZ@"76.Y-SY,'0<]@"(H^'^>:)X"_>K!Y:.*6HPC&$E!A!2 MXJQ3)6>E I7RF"X4Y#4AUD6X?YY4NL+[YR*N,].4%;SQ%/^<35?+SW_\>7*S M_NBX #$GP!&%,3>(V=1GK5RTF+-RS CL%SOS]J0T& M\\M[<-HKN[D-(RSDD M@&F4;N30A!+D4,DU)5Q.:__+.3WHRX7H7'Z#1[W[[SH*_=TL*OIZP_B/JYMB M\>5F,MOU[_TPG_W<7(OU>7Y[Z^>+-*@-#:DUD6C9"-.*.6DM8Q P#QDKI2$< M'G-@V"66FU*C+H0\(I5K[\+P<^<0+$YW47JN$''.0XV!Q*4,),6=)M__V&S- M_K&:+%87H&XM8[Y[U:R%B,O7RM_B*U;+=[/MP4 O2OEX"@%(!H1&GG".8*J^ M5')W&A%_XK-N(CO;E1Q><^2QZV,6&"Y?';=WM?:JCH^G$ "B!E'DG?<2 611 M#+1+"4AK]]'&&Q?]<4J%[TIVR(*7I-6#UR5@Q<" M0Z5+[>3 *(O*>, M R,44 (CA.$^ I(2=]HQ^_&N\9LRMZ+,G>!D\'I[Y@;>,!?Q,^<8A .J*5WMM>#7DW6](7YHF/1>U[!M/E&X3=YN$ZXG^8UN"<"09F@138>LFU M8T0HP\H.#/$OPN=D2@V]\<6;*>@129=O!\83V"/M$"&2,TZB ^ M^;>-]]=N!UK#4D^URIML\;>RY*=%H-0 <0-1$8"S&7)1T=H;YT5!EF)7!ETK54BGR>NKAR7LE;K1"'R MP\<"$''1L( C8K$47G&O7$F))5E=[ 8(O!X0,&^,^5W#Z&3-\-/:P!C61W\> M8>,UP)$+B/L=-9!1TEN7\G:@5$^0!]!0BX.UN_KN>]DD-^?3>G%U$S&>IA(? MI<>;^U88&C0FD$/'(!+0 $E0:G:VHR)R**>KX8!Q<*X(YZUR==C-+X"D4L6( MWV#HH*:0&VEWM""@14XJ959:QU@7G1SN#V;7Y0+Z70BB10Q>.1'82F"P)*!T M3!''<&1>?$U4=='BXCQ!=-[1,IGY[3[)R?86!\<$285GT'BHB-3">.P!?$!C MIZTM!G'ZWBI0#O65S!1+;1_NPWQV#IQ.C@E2B>B[:*,1LZFCN\*2EO.._.DM MU7+$8&I:*(-9JGMNC"*1V722T9[KJ'Z($D!V7,-*Z)P 9(#7C??O7G8NLLZ M?HJUNZ:E&_9]*?Y=Z3B/OW,VC%]\82!>2.0<@%REBT:Y ;0T+%A#D&.;7T%O MDLK8.G>[N EA#07*+S7HVJYW36/\S"\%@IS!! ((H8F1!;>"EVL@CNMLS@[U M*Z@!:0O\[4JQ3ZUXR,<''MER?R6S6B[7=]N?92E%_0\%:;@QVJ2"'N 84(QH MO>,F(1#UYN&\/IWH3(C=J\1#_J8C63]?/*?[@7/YL/O]RU+:'.SJ7RELJJ$Y M'@MCWQ2AM&0*A MA28*$DD@0]A 1B%'WG&/?6HJ4>E&X-:#@T2"_F5N)\OE&3F!3T<%CC$Q&N*X MUFBFN9&OUU6?QW'5GF?L9_5K>#U1R0HAQF&DD%"#:NN1WAEFSI7Q<=34XFI7B-'K98SGETMU%5?KY70CKN/KU($10;+H6WO' MK%6*Q/\96)O[MJ96)/PJ?T[[O M@=7HT>^#3B$E-1+#N,@"89DE:C=GZ%"U;<:+3 7*7GMR^-BZ[ _:B2=/!&X) MX4<42%M]P;97=S1UJ[G)9D0Y3WN1*;-\.WKCS)+XO);#FY2H*HL$_VPM,! M*FPLYI1I8S 0CL.X;NWH0E!4VEUNXQQW^/:_.:[V@):3<<:S9X-WT ,0%2BJ M#X>:(.M$25/J>ST.R]&(5 \CI!8OVM*L," M4%PQIY&2Q@)I)26\G#T6:&QUS!G2F[?&U*Y,QJ[AQ*?)8O7K 2.6^M?#WYQ8 M=ZJ_)' 6S2Z$U&K#G0 8"0!*+E@,9RU!JS^X#3K]':Z^K7[\:G%K/H[@D(LFEH!/:?.(,PT8WNZ@"0CVSO-$>R\&Q9W>?PW MO9Y.%K_2XKRSQQ72#EX<$VFDDBG*L07(*L@\0F9'(T4VZQB0#3V-I:4LA"88 MW1F8[F>9BE\_?CLG\#H]."A&7(Q#C-4J\@XH["$IJ2:*VC%G2>5#X2FXFN9W M9UVH%M.?T7Q_NIU<'8_IC@\(%BH-*8 .:P41)PH]H(ZSWM:\+M#4H.R?-JYJ M@MFU':<_9Y'__T3NK8K9I_77V^G5QV]1#-/9]^/.TJEQ@7G./6(84LFMU!QH M+7?S9P@_O1_^XE,5FL='&VSN;%V+,MN >9N?FORZ^6Q37'+"43HV+CC/)%5: M44DBD8XZ+GA):_00"DP (I@H2PG M0#D,]K1A2\==*=*(T)_V\&F S5U!Z,'VZDE'Z-FSP1#!F67"*$>%LX0Q5^[L M1\WK-F?J<:NH#L"3*>9YL\SM?#';V-R*$?^A,0$K%HEA IG4J)T(!%"93"28 MA3GW^(FAVYXV%[%,1G=F?1Y,\^3J]?SA@"UW!$MO!:40:6*-VE,55;"W$[4N MEZ[ZHGYJ@7+YVYD)BBY_L52?2O%46[V.C J*2".-II!8'>-,C"#P.SJEQJ-V M@7*D_M3Z-,;A[KR?670;EMOJ_JT5_G,V_>^ZL,7R:C']4:$XH>HK D**,*2= M0$1);@13,AU42RZC09?&?PE=M5M?>@-R9T.U,5M.H+8^MZ>X7Q?5J M7B5RRWYG($@09;S@//X7.J8<28??F@KE,9:]599W!+$Z")CWP_L^?/;W%?JN MOOA\ (0SP( &,D:YWL;UP*#2'X# 9>T<@(&[7*VLC0UPN8]SWG5"^JZUTO+= M.)[ZC4!*>J9(\B8R%1@&9)NSPG+>3%9^*;1.P8V [-"9(HP3#CC@&D$6 6.O+&@D%8%;L./0VH@TC MJR$6=Y=(,+\JBNNECWQ)LY[,KJ)F/#W /II84.4%@5.H>2+62$ MP4S1,L,Y M1M6>9P!LZ#TYFP58*_RN[>I_*%:U$73>"X*!PF"!'6"60629\_O$^^A)\IQ& M"4-O.MD,@EKE=VT$/0XEOCR,(.X#F<])8H<@5/T-01"NE;+"2:RU1T20?=EW MND0B9ZM]@!4&#<*F-1YWM\X]).#]]+_KZ?5&A-M?%%$'CBYR)T<'*25P6# C MK":0> 1]R=?(:VI&G/?;] K7-+-[VQS=>H/[_1%X!&(GQP:CI!$QM)9$4BZM M!1B6A_*&^JQJW:QLEU-&<1$PZR\A &6NS2Y6= >F[M+$(YLV/IG=IUJ9G0\)M2++-IV]+][%/<4- MNT-M<+D/Y^@_Z2*+V>99B6(D,+]U &#F+M#^M+:I>OB.H*3C$E&*" *$ >-8F?\*"9,J*]_E[/WS MD5FK#$;?@ZW+NW?N$X ^KE?+U61V'2G:JG%U,UD6#US%L5[20P7P M,D9)T3Q@YJ&&+N$#*>^Q):):<^56T]QV4OFX^#S]?K,Z=4?/X4$1EYJPN(XJ M RU#D #.24DI9'+,"4A-8>#EE+=\9E]V';B/@:.DBD>#ISQCE#NB=[0ZZ4?= MAZ()!)Q5!GX>KR^K#-Q9AATSG@)L0*010HM*VJQWH[X+OAFA5RH#/X_-EU$& M3K&RWG"BD<:8&0<0@25-FH Q-U;*%/+)(O#S6-MQ#)HN9N7A0RW52* MF$4,,@R5HQ)O:8ZL%+RW&X,[0%8V#,Z^AO$\9M=>.QN_AE%@)Z2@C#C#*:1" M>PS+>2-"LHYG+Q D-85:^4[&\]C=^0YZ(\WG4NM@*+V6BF(/J+%,R3V-(*LI M[X64Q;6RRXX\LHH$HKG2]VP M?%^]$\Z!@4%*2KP@+D:N2A#IB!:@I)9XDF-0LBIL+W,Y:I39O4*K3*3;5*WL M?[G<_79YM#*RSON"#8L"1Z1>F# M3+9S ?E@:, 0$4:5TCQRFL6U1()R]4"I>\)K.PML"7GU6=YWQN0VY?-1''6 M=L?(/=(03R 4'3]OJ&6242.=+%,I))#:Y/2N&;ISW10*G@;JC7&[LW*/V\DL M=>(\L=/S\+$0323T%#-.I5),(D*$WU$"N1MU3E(C GY:X%&?MUVCY.1FSN,' M@Q (6B><@D P@QG@I;4(.S&O)%33ZH'H%&+G?7W;385(;-4+3G]F7IOG3A< M./1\,-I&LQDC20P-=D+'&9MROM+KG'NT!ECB7%=8\^9965OT[N['[?Q746Q[ M.>R*9=(TXJ/T. HJ# TV(E\JX-+U3SY&7\B3DB?(0S/FAIY-H*-Y%G>U@*A_ M)HOK+_&3)_R,1\\%8A%4G!HOO%8$(6ND*&FA7/:6?G.ACD8.5J4U)!8NH+>YV*Y6DRO5KON;W_.IJOEYS_^/ F_ MH^.B_V&(X8@)S:/J.R4@W)5T28R)Q6->LX>$QB:E=-E5O(9C;#E.Q#HL#0*$ MLI)6[[(:L@T]N[8-+[))9E]6&:]FV&KIDI@/&_#H]ZW[,9H5 M"=_S3G5V[2[?3R=?I[?3U;0XE95[;%#@PE&LI"72.RFX-2D/>3?S=*7CB!'3 MO'2?'0,UQ/;N^IS,5M,8Z,Y6\4_+:>3&1J8;7DR_38MKM>-.A2XH9[TI,"=2 M#WHC.3%,6(VEW&LHE"C'R1KZED-K,.Q&%I=9W.2$,]&-11)#+ 0'UHM= 9>D M"F5=>#GT;/)6-Q0R&7TIU4T,4F$0X=:AZ%"DDUIKF\[C M;X?+X\NWKE19#H^-##;=@&^,5PZQZ BW"OOF-(4I]M9=K1)ZG+RM,Z^)*[SJI0VEK0FV#R8C(M#AU;; M(\[E@WJ'[:W5.>D6YWXK&""P)T8(!*)>$@J-+8]66;KF\948OQH@.S?GHF71 M#![NVS#GW6RY6JPWA[D?5S?%XLO-9+;CP(>T@BQ7Q75[:G#N' *-YHIP+2+# M!:64&0O+58M12W)*/(8>&@]$/5H6V>#59DM565RF?DZFMVEI]?/%;^E IPTM M.?')H#%)/5BXX\)+R>,:K_C>,/FL^Y:'GA P$*5H5D+=A7#WUTM/?DQ7D]OM M_ \621X-ZLY\5TA&@<0U5%+$'-:865+ZH@PH_/INFJ^+VK99/X9:<1W5#QJ' MD>!"$JF]QF6YB2&(OHHKZ6OCJUGF]E,5OHE_QU?>+8TA& B G;(6:0>CCV7B M,F-]VBCRPZ<_(?;X4]8]C3+BK'\)K]S@ 8%PP1QQ&SZ9H[ M+Y#:\XCP,=]=T#!>NY9%)TO6^NYNLO@529E^GTV_3:_BQ-75U7R].:_^-+^= M7DU[7,">3Z7"XG5X4)#66F(U,QA@ S$WV(&- )Q20LE*#35;,AK'^%_)0E1Z M08B.-J**&TV\IA #HH0I.< 8&G/V=1.X>&H*VF#Z\VI$U!* M*2PL*=/&O5+]KBSO>2=L[S!;(O7 V":;?9XN_]:_=#&[NHEDG#2=AEL7TSN+KR6W:9OY9S-;%A^)T+=F+SP? M 5(,(:&(5X!:SV6Y)$0J:4Y7E,L#5%VY/W6'&^!T9[UTMC8[3O>JF/Y,YOHD MD X-"1!88Z2#D30DF-)6.;*CD'GEV_X2O,]WZVZ'Q6H3'L>% ! ?8B MQD<$E'2FEFJO:@&L(?Y3D*K-ZLX@M5ZNYG?%XMG,3^?2'Q\9F"!28,^QIAYP MX:2WY8JOH2R\7J ;3BWY["*OXH_#[YO_-%.=U# M)?LO/Q@@=H!PCN/$+>3&8,;9C@H#H-L+I-P*0631^_/9KB MP47MZ/,!0D\MRYTITWS]?:=?7E5T]

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

C<2&[>I!@DY=Y_).UHE<&B(?(H M1>HE&]!V&13JT$7MM&M<8SF_R%,5QUK.]1]NFGKS/[1&J'M=W B;^1 MHVAS DK ? L1Q9%.D$B*X+.4TYHQP419%2LB&L(3\Z/5UI]6EZF MQ63S",_ G =69@="UM_A;U?:%5?:K_MQI;TLI?&$010) G\.GDRHLE;"W5=C MK! #XZZTM#B#PYX0P9HR&2-WYL@GAK.L26IRI>D-2@F&+I_N9< H8GI Y_M" M$GIIQN\?#5-L?O?J!>5I5=K#ST9$-M:H=8/5P M4Q[=RSU)#U75?AW+7ZOR4UK9_7J9;GD:KQ\XZ73?T+YJ<7@":=C$Y$5U,'I9 M2H3>)Q%JSN&A)_K=B6_!!MRV!CFHLH1[0-Z@.S.9M%SH%DUI%1'!.K-X_!C1 M#8FWMG/N)H(U.19 PX5_A= '651_B15LBDNH36ZOXW>YF?&:?#@'&V1?L*UU MO5^G(JCN>(]KN-6IV$5=G=!"^X7*;2Y4;HS$4#8X;E#+!^-<+#3RAQG'37B5 M3>6I!9DK.U.6"PW/FJD/E+9$8LHC MA(1RS_\BQZ)I]NM8?.#Z7JX"WE6)"XHHNE)4T#MNF6GTK@PI:4JMIKB"9HP: M1$A WN]?Y<^(4I2FR):MBVUP>7PVVW=1:]L]$K4_B$N=&!^V!C=ZG9_=?DJ4 MV5;P='B*K.FK"B=F;4,D^FF.Y)FK,7FX1FNJ>$C-V^(;@3'C=U4>/\;17U%( M_V^OE/DW\K>]4N:7W X4W:ZT@AOC@Q!P^+:V ^M9$[[_P#V1[XN+/9+OEV5U M">O\X'59?A+*.6&"V-(3GLN#6GDZ9/P=\Z MU8P4G>R,FVF+'RB(6:K$7>WWO2W$>OIUIL)NOQ#KIM7^ ]>WM*RW)-58-04O M12.#*UFEN[6E:V2:)C$ND!J0"IK&R 'V1*]]_KQ/>LU44U.D]8.WG_.4RD:V M[Y"7=6@RE'Y()T<<2@5Q](>F5/NEA=]2%0;.((;2J/8(R%.,.J.LQ@ M2F-9,OCB+DOH8'5V\QLC[5QG"D>W>[YS+LCH+\V-;G8 >ODMM<62.NI@8'^(NGAS_XGW3- MN_%3>Z)H5JM]4C18ME6/QLMV%5#QT(%\&8%Q+$<*Q@%[0DPX5(Y5Q4J7/<"U M^/C0$G,.'6A/C"5,-Q#869I,F\EX-RA&PKG[.1KV&NOVFYCP )[\<#"='!Q- MQD.,A-K*J2!5H%)I.L+]&Y"/TF=Q5JY9QEE&)5'2:U=.+JO"DC545DA3#HX= M<0?U)3R[TN3%A[1I:*QV+P_1/_^Y1X<(H_-4Z+Z#/K;"49>DT\:/ M;'.S"JUNL\[:4Q/3]IHH:(K4RQ%K8,\(.ASX+-+_ MSV^'9=M1R$5 G9OPN'MGV#4G,Y.#'XX'&5/W1$#_W__;(P&U%<$O*=NQ*X9= MRN0PQ3>7]N>YY%.&FTZ C&7-")OZGFR[,6:/]IW2AEP;N>O4"/J(V!5I61:2 M=L8\1AI!'OAWL._-9]),COT0.2W9M=TN];PG'(G3Z72/ MI(CW\%U;P6FMM\]^6-3/S#J4DDE&@(1<3/Q.[NZ$5(7=F)K[S,*LK(=*+<,: MCV)XU$A3M]!70=A:E^?(@I8BL2HG4$#>T*:D2 O>O7/ID5->%K:+V>5Y1DR& M/M1#R%[8@-L3%3>;S?9(.%\S\]NNA#)L "B6M<<8,LJ0Z5&[#W&$^(F-HT=^ M;[^C)P?)L"%D1^;DCEJ.G&GQJ>^=V,<=@W\2//_XX&SP^G./C$HT!O?G[ MAQG)WU2/\5 MBF/FPOS7^Y)-F/*,"DG6^+.RN5:&A+E0@PO4AX /?!23AX.U#3(A<_#FPTY< M,*$JDC'NR?E/DF2/SO_+5V_>GX!<2 O1K?0 ]LFA&!G?+ 0T0M2'!!^>'!T= MHO/_X^3@=$(5*?.(7A]WI,JCVC4A? ^_A5)HL(OL Z_>?]E.\VQ&4#UX'2H. M9*S/2\,(]@:[M==-].]'3PZC!?:&ES9Y-W[.H7L.4^@4R 0 0DN1NXLR;QEP M;[^"K"BI_8[.L$PHHT'IY'MB(*Q1,NPT><*$W ,>Z+64Z$40]=-&70_ G,.Q)YZ MP\)3TX5U;DU UR$GZM)4W-FR$Y*QHS 6=;[ O'(%ED=*':;9D,#8WG[<&*-& MO6>E&RR])=I$;=,B6U4NLR*3UJJTKKI;OG%S&X%OV>4?;WQCD )0%A<5IEYE M0^+_B=8BYO P72WD/A.R@+*L,_Y&4[7-^;S-O7961'EY5K+N]&5-DGHPC"D! MU>7B*=428;MU/P3IQX=;&@M?P#6^ )/!:^(D&[^SO(E]ON<@DV(2$P5.V,][ ML;<']RUN=L_>6G0-MK8V2BPMR^=J?+"( MS]EKN&MRB"7->K%=I[.G*Y'+T;B+5W^-MVU6S=H%EM#,4B6*%+UE[4,E57>= MY;M).=ZUHQ^/U^;D?%;(28R6.'_/5]<*=(5#(!-!@,"2H-]SE[PC+GGE@H"1 MTAKK5NH5,(:O]>"!23EKM=G6"-HG=I8UMB5-!DL18'^_MUA$PJO9CH@^0:^, MM&Z72TD(:MOR >PCOXT: \V%8!.^7C>>.:.OU^BN6P)<[MY;QO&7WONQH(^* M ).,R<]50O2MI_[GT>[KVT-J%YXPH, M+7?LA,)%OUVG$P<2E<'%X>+4X>K4UUH>KHG.UKQ4[*FXWXN :RNS6MJ9#4;: MP^K.$32Y/>4'V\!AZ.,_8XUH-@,])BWUP$H\AV>#.KFQ1HR=VVWQ37/GTA// M2R \;-3;I,9%IQ))"+%M4VV.Z&A?JG-EHF7B;8YR=7;'%3IQ-$'"A#TK3EP& M[E/)^3)_)%FWD/#930WC=1NPQ;KO<#3SMD(]N0LAH#:#>)\X12:[-+( M^E+3=]Q\5%KW!/JR-$T9O6285X@"@P;A*GI!!>6@2A(_=!.Q%MJ1=KW^Y>-; M X.Z@$(WM=+\@4HAJ@UIF#CRG;;(T;%!ZK'EBEU=.&1^!$FR-]95%O1, ,%W M\2*ZDX6+V"OIPQ/ETDA\O&V$NJ0H%6>5L//4_=9E!R>3#?09STFB<_NIT>!> M_C4\"+QW_F"]_JL:6U@I:P"+E.6HRBQ/2/\[<%-B-+(MI+M@:>.6_G>SH$HT M*5.6I ).HPLFV5^S&3)@A40>]UI@UFS=6?1'9U MA6K?1H'SU->X#IXWY_M5S7G ^8_=@L\JLSS'96<@Y/%C2C0.%6A)MTV8M44B MTGYJGDQMR_#D]U;HW@;]C[X%_6^GZ"5PO3/*!)%B0T6PYGSJ=1?E97&65E1G M;1U@RK9)A;46VQKPB*2,@<"X/93OT9.UL03+&KDW@*.O.?CVAGLA"H9'%-^' MIEQ&;[$YX\_@GW/Q"&/XE*)#$.M^KQAF=I8I8Q<<:YWJI,5PD8H@[48RMT$NN$PEP?1, M./0TKJ,1FYH;,6*"/*VPS4^^\KT*6!8P"FNVI1A-'VY ;UU+OWMD)DB@I#*7 M&+M2&RO8B'/BA9A*O<.^-!FY;Z"P.U4ASSV&!6>./2/&. FKGA+.82ME\OP& M,?K! [==C+[KWLKH?WHFE']OI7MUQ%B%[#S- K )]EB257[Y#ED M-KP=OHF*&AA0EDDU./XWH]CW+!6\7,G!&M98+AX1=OI-6D[3P'HU["^1]Z$@ M4BKB^=RPEO7]B6$,W(0FQ;B:VO;"HHJ+3-LM?Q;>&A=&MQ0,/3%A1Z'C5P[Y M#0/0PSHZPKJ.&/\SP_\\CA7D%>MU/A&NRJG$E'G= MM>]@9D4:6@GN,#2 =:9MZ7!7D=UK4Y]R(';C(.&+ M9-Z=#P1M@"E,0Y>H6WQ!>=@&)3F%5>1\A0>(AJ]MCF,*-L!6Y*FQ;:VRP>5B M+LA@)+0(74]SXP1$& 0=.BH#216Y? /SG@(M9))P$,3:!_.^:AF4@X%(@C.W MMIGC@<0?M(UIF-J?1'4IV!ULJ8DZDIDF_:>5'FA4D*\2AU$D\;]P['Z'"1S= M7;PHX HSJTX$:UU@/)O;@^49>'^VR9F>:.\-L9P4^<(48_G491[_T27[**,$ MA+=+'WQ?#;?[AN;]$N4!0UKEEBRUSM7SS5;;V%:[AF_&P=/!J?$:]HL:U$9C MEW4U[JEV""2](ESLFVSCYF&34U/+3GDY)BZ0(%M/WHU0A*QH974#Y]FK$\(+ M!B-907!V+M'[33+TMW*WV&16O!UBLJ?;7;)JFKKYCK%Q>#M(EI^V M<(>*8$ M-["+U-LD+*+F=&ITEA9$12> 23)&TNI"PD046JCKH1#%GNC\]&O6^;ZSOH8E MR2GI;6Z"EV6>4Z^%R +PK(2/O)P24S/0A"#F+D[=B^$-:,A^IDSZ1"C&^"K3 M=58NL_3*T#./$#=O$&F47U93O%22W4'>*-JVBT0 M;T13,9[#O FT]=JFV":(UG"MKARP[\[::6Z8LM;E[G1,0EQDJ6E=:X@LD;S> M=F^GY5$#!-N^"GN3+:<>B'1Y#U.D$U5TF!XR9 #^R'F1O"ZM_@K54!A>H,FD M&@HB^F/B="QU3QE?,&;9BIF*:)-_!3.H<8L6H!W"[@+^&D[<[1!6Q=.6VP=D M?G 1UI:P"KWNU_?5OIE_S?;-"U,5Q+%B=>9.,Y@4J10#&4-I5DI G(A%2-%^ MYV6.Z5-?Z7B:)H[ 20EYJ5"X$2 EK5& M"B)07E6#(#6#"E!6Q 7AL'*&KX7HZ/@!O2?0M>K'R" MY*B!IB"EI'DY)H>JA/+/UIP8DU@?OFEIZ"AH:AT5<0YJLE? Q.!FP,HNEU:4 M*))D-Y&<6.QE[3_=Z_.+)YT.-_;Y%48(^Q;?[#H0F#/764C'T"6C4[-ZT"<.#LML'.[L'6*Q^?G3$3 MIIRJ7QF]A(NFP!ZRT7/4;0VO*#D+P?M CV<+*V)\YY4D)#"R?S\ZC \/#S5] M9LY@;\ZXP75">ZAG6!/Q[8#I? 95EJ?111%_HX=52REG9%QCK$:^B'E?JU?CBH@3J1T/;LEOR4@0W;JQ!$ M@(P$^_A:('/%#2G6&C+;+)I"^8S05;I&(A/E)H+^=^\;QH8##WBSBEALDOKD M'@1R?[KF7[3O%DS=V<=89"%<);?G]S:Y\^A;/'$D< 5*4J2C\C.(,O5!4SVX\Z>%J@*2@,R'\%HQPO:(2GY@:,7^8SYV?I M3].RH%J[Q3(O5VDJO_5/O#1GYM_GAOGP4%6A@2N9 :-7[ ME:I]]P%[/((R0^#_Z](4VM*"HZ,NH).0\6[HY/UA8 +1T9,X.CX\^A'-6,== MR7&EMY]!!2;1*??/CJ/7KT\Y70TW$SSM%"915Z7!O7I5S!Z&W4YF#.FBGA!HQW%T*. RJ,GC MX!T!Z89+W@]Y,UMZ10R>" M+[!8KC=%?H(R%UK*SBX(EL<_22J+<(DFPFBY&/M=NDVQ4&UI.;$.]F2$*;HE%L#YY'S\BE'J?NF+]EQ8*WT YM^ MR=M Q9M7S&X)=[O%;_"KX>HW'IXK7<"(!F+KO0[J)F]870E5@:2=K((_C V22I4S&J.D+;U[=T]^08?OJ:C^'S-HV>9[#(A*$X+HZG'FA,:H1LL.LTHLLO<2K)6EGC8\*%A)Z,$H9 MFS,8X;R*"RM(Y&CC(4KDV/0,'@*&"KN#R%TKJ8#)98@](@0BT"^P^M]"6+P& M8J*>N'-3%4W;.J,Z5'AY)6'/P!"PT4 ,,\^R)1QK?E@=A]"5/E!E3\YE_C6? MRVY_&NQ:8G.&[L+9,8C?OT']WA.EP*.X3$\XXSNH+[[4Q&4?.. V:"> XZ4+ M57H)QB%PF .:;<*_,0Y+X]0FYA\H$R-I!?Z\]X38M7W:)ECB-S?\[B^\C=1O M; OQX]Z%L1@L8RN(33HT/Q7[?=:J-$\O\*IFV =ODN0-AHK,:A@[1@K+]NQ< MZ_=[8>@!?E_\&>NZTJ)FU;@T*P[GC1 _=VLV2-@&S"KE5I=LFD2.VL64B:Y= M/HVVFM&$@XNT$:JNM="Z2ZS_8%>#_5;QC/UF=;3 U(&O])NVN_*(_KOV1!$O MOFY%'/"8XP&NGT6GSEB^94.)+?R ->AE5M5-9#']SS6K2!)MF6'\!@NH.O?(T?81^[%A@Y/(#TN%5<1[YK7,<$%<4B-:P58+)E MW3SPB'DTW8\AOVSV20CGO'506)'_& >)EK"*VIP']:0#D;X*97[-K7O&VIBE M"W;OA%MFO*?B>Y3'#_YKI*9=>1[Y"6BY_Q_VRL%8?2\E_-YC_L_H M8S!FA>$W&4IT*LC(SE!^@I&@P0_^-9GI4OP^YX1_EUK7ETL/48FWJ*G3R5@3 M'K8SE'C:H;?*@E5_6=DJ%.<=V$Z6""D%MR7'VD:_!<@@OT*.077@D09:JZ+W!J&HJ3*:S6T1,1^PC'>!B9/AI!IQ)@ORG[\ M%I9"2L/5HZ*W5**,;&DR=N1DGARX _(L97HK?)O5XUSDZ-29."CU4-C8(9\/ M^*U48DU<&.!L%(FI;&S:+@;BHV%/\8(P0Y-W/*(%[)*W% .?O6\8@/N'(J7- M"&2!&K0OD>1EK00.I1*<;3-N'L%!!N% Y: I+ &H2X>;6%EW[75I6;:HJAX! MZQ8(,X305%3/H/!P]P;_\=+*5L,^LA0,3:14Q1"M[M[I&PIF%#Y/=N_XAE:O MR_L(*3$"C@9[@EP-@UICW.S]51=+@M^JQAYTF%=R3^(?Q=<<_WA-B.>WG"7< M)M;Q=O- QI56$GE8@YJL$T@7DL N';3S)K2*S&)A8YQ M(55<4\98^!G!P>]U.31ZZMPU$I&]7T,3$$>+,LF0'HGRDI9W+Y9F"5YW@#6E M;=WZF/7LA;=;YKZM=0F; M95:_,"NHCL!ECVU*' L^NJ2*0$0]$206X?)Z,T1 M+PY0T3-P:'6\ES!%F;5I;F9848]-C.7-,RRL.K.&U"KB%HO!TE>DCJ6^B'K8 MRV9P53B\W8-V8#;08PGH0%^L"C\]>?NK0/WQOJ#0DG$0A83"$ S?0 B<4&X3 M"0&%I=Q'[0!ZK9@&DVE4IDPFJ[;V+BMXH*E@@YB91#J7.WD3A)L*UDSV0X1. M]BZ L'?!?OT55$YED=DYZ2/O2N7)WZ$HOZ*F#GFT([5K#2B!RL ^M\M$DK@P ML^'7.H)B@RM2*3AC!;07)R //#1%MTU>X0M"'D#%44MR"P"O8PBCQ MRSXZM!6L^$>LJ#TQ2I9?LU'R!T.S3A F05IMI]751=G #9 A<7DNG0'T)];8 M#?(_$;B-E0O3V+)4\;5)D"\BW,^X9PN70H'V;+*F;1A,LR R>^^2F#(MY4P$ MU'VT#-RJ2"I7P2/CA>'\".Q MF*U8(3(&Q33 C%(XI(1+.Z/;2]\^SG/HP77((OB6Y[QN/P'9;=J^@1II] W" MNK\^'H]IX0ZG#XY^&NMCLA_W[3^^YOOV55&W%6[JSHH))**,OE*69&#V([R< M_,Z%R0B01PK!SSKH']C?D@'9V!;#UMDYL7NJF 45RWZ;T" 46(W M:-"PD9SS@9 RS;2XR*JRH!KN'&LV%AE60\,5(&2%UJ5F(IUD%9PCQ- MD+8TCJ0C$WPG+['^-3>7>)BX Q];GUA-AZ. M[D&/#YA(._5N]:Q17>P<1+9R"2+LSU84B'+3!EZ>Q*5XYTJRMT@S4C09EA]4 M_6--;YJF+/T@^6E8>W^=IM=@ODO\S>/"F D7B$;]D((1)T!5,Q2:G5/)O(U* M#2TK1HCJE@*O!>@[MD@SBWR3NS(UO5I6J:0=>)U2I8FW-/5X7GV8)L;* MNN/?DR/9?,U'=ZGL9N4>>QK07 \'>/3E([==\D-Z4 MT5M,MW!#U/SF\"O,)?LE@G/,$B/\C.)"?I?*X"+@DN[#\;[U$S3X0-BDLI#Y MC[HURBA[-L%$H"BS-#-B] JX%RHFG?"9$/725-[#JE.7Z1K..N74&,NB46=FZ\C<7$Q'_RI#EF+?M#&DD ?:B0VD)9?Z^] MJ/%P!]V!POZX'R5'SC*5&:5LE""@1T/I/C-M^]AKMP5[HB4NOF8M\<%44P,N MWH.WG_-TI];O8,QIFVO7*]3U>"@Z5)]P'GHSVA,YO+R'M1Y;8KT;1%1:[YLV4)LQQZ^F%RJ)A'WGE&*8@#4\9BQJ7R':,A;2VBR?P4 M?,<$!!6A8GYX?S.#/WS+#-Z1.OCIX99'^,Z9MD_+(LDLR6_(F?_6=6S9XA#C M&?9[OR@UOU?3V6\_[.P3C9+ C?2GAY@2+XJ..!9NFME*TAI(X0DF&>8G] 0' M&$B)73)19D:]WI*>!7M.??%B"X%IPY8VG4^O[W!C1TPC0X/,4:\AH<4@3]MP MD8'8L .-R&-M#MQ9'/L<9F>H%-IHAR"/!(.1Z+UG%0UQHFOGE4$F+"C<[U:$ MYN?]N*7-/;RE[Y"-9Q -]D(MLVTOZ)'G6^B\9P(BQ,'6JEN^OSGA)R9D+]JV MC -M-0DF$? 4X4HADF[59*UX[VRR!T\;$.5OD$\)8!D3%>#_/U[8II.OV:A M?U.Z%(^(Q#9R_H:(:+HJD?H1UCXU+9,(")IGZFOBGR.2<>*N73:]&T2XU >R M?P)3TX:IA#5QJM@'GW)<,N0!#$C:):]) 0+*;)XA"$ 3=A+N:%;*JTF!16*] MHW("/<;^U;JN]S->Z-@8W948,#!60AW<:7>$S*E/GW4]&B9F66+IPK]84NY> M?^R;K9!B!YMR*=G@NJV%&,.KPMIHM73T&<&"_<8A2^8+I(CP7 &2H Q>*TT M4&,"Q4\@=TG#4D/(1KW/'4"'F_Y36(:>SZ_-) M-J"DM3:F^A+)L8]S77']ALL4UA_KQMRPH1E2CK5%4[5VR7H,U"H(YH2NEDG-?$YY">?8TK 5UU;B.8D[2S40^;B7 M]M#L:[>'X,+SM9FUC][*5;B-@23D+I;XAZPAIO0/D4X61#NN9OW3)3K6-5<- MN1V;/LB%#Q\W1_6?%>+-YKS9?CUZL)[/VCN;-'\<1]E[I?_\L9_5- M5=>>N"?)UWP<[=GCEAY;^28O;(?5P),=0!UR@U?I8Y,%$7-/?)E"=&T&$J^" MSEFGLK7@SC*"K-.N-L0^@(G+,L^X=G1JZJRVEY%-MR:8I$7+A?6_IN)\[$%.M"JHZ2\+,ZDW)J/*RY44IE+:BG [@]7$)K: MU3UYEG)WV;VV/@&'*O9)@G6:?4H3[S,3#4W(2\KJS!1>T9.QU:]%4;:%V.1K MOL.J#+?2=HQNJXL4[!IMRB1Q20H_R@/FZR9T;[,A/W[+AMQ.G=0U13CV_&1J M786F9L_+8.(^A%W.-'1N!B78P:W-%'QV^Z"!6+E+01QHIQ(B[[M0Y[WC1+NX M/AZ$/*,*0VQ Q]W>7'M,5(03[.B.3I/3@[6]O[%,8N'WZJ3"23*3Z$=F(J4N MQ%;S:OGU> U782&B'/;4\G:&J:Z_%/;$6$B_9F.A0\D5[8Q>SC?:P\Y:C4=4 MQ9WK@A&,$5<%T?E[S2)42M6!I;%, C)2CH$HYTJ7=>8TQSW M]4S%PPUXE*EE73LQZO74K0#SMBB@CF22:Z4L#$.S3.D7YH92?(\8,@LR*, M8X"4/\ ]40EG7[=*V!6MV/J+OL-#\^4O]_)+7.Y][JJ[UT=;3'Q/#O3YUWR@ M.V1\.VJ(M?YP^X1]7_AD\[IN3]5WQ?'NG>R L_!+'.LM)KPGQSK[FH\U;#16 MNE8N^+FCD[T9&VB\1@-TFB5(*!KC:"E\>MXUS:^) M$'_5O>7?E-$'BP7:"A+J\B*:.++D1T,Y(P%.L5CB-][\_<.+/9&8K[H-.M>7 M:JILJQ3FVR+R&@ .=03JI,R'"8GWX4(?HA'N>_VBT2GQ@:6G< ?@!.$S3"GA M4)^QOP(<_P\"!"X*(3=#M[-YFCR,3O(\B/74X5-CRUKLZ',\@)B;@]"=]GA< M!DO4'_9K^P?8^27^01/&S+!M5WSC\=I%"2[,@679#QWT5;=\[S V:./W/TRR ME>&%YV$NSQKJKNZ316D7]/$FZG">W>E@7$5@TUEPLN0;UW2_ZYXUPJUZE-9> MD2V3R#!\&]U.R8Y:!*TT6?5FL"<"_U6WUCXA(@+#4?K768V)\&T+>/H][#M2 M9BD?YI3_KCG[[JRUV%;GE45.;D A7=_F5KC[PG5? "$_?0.$?.L*=S<>UD>/ MQNL%EB9L>73[,#RO "FH?N#2&Z$A8O,';Q\9#X;1?$:QN[*DCXX.S+]Z;.SI MWM6$OX)_+PI7X\-T/D4#!D3;;!4=V(L-^[JKA=4?ZPC!S@AF4,40("Z3%W#= M_GE)+3.J18[U<@(_H-@^=14H*\0>Q]EO#F.UE>4$Z1CX8!7I9XX/]3,^:UQL M*>*S6M^9L_O 4'^V[F<<*Y,/L.?! R.P!L\0JQR8)I)^!N6?E\P#.\M-MB"> M5$8H9BD1L"X=:6IB%@;KPAR/5AS!F:;K(\_@:J#H0QP\W0-0,CDC82$1878>"#_WPEI5Z:C+Y0@^LNU1T' V3IMW@;/3V8W?PRFA"' MGVMX@39QUG#\WI8O3M/F4G'R(B9Z#+"K"XIUIJ),G67DB!!IF_R14E_N,=WO MK^RW090K^1T7L2A.U<+826 (H%O!SD^X&PR28YQSUQK:Q-C5[\JQE&\K.2\= M+*+")Q93ZPN,^<-Q[WC8T?7K;_%_6THN(/(CUQC$+0?4*B#XJ4#@-O6$<\:QNK]4:3 M4"C@N,X4"*Z87R\H<[>!TBL>Q*&6HNAV9K;D(AB5C MM%2&M/Y*:I/]>G,1!/L[6UDF@PUP7CW9&*X=(R*7C:I ^9-AT=BWQA]K(_94 MLYC5JFT;,60\HA-<3I3_E>W#RKU)N<^H:B#1/T[]K*SR<;J'54_M^!S6-I\9 M;Q>CM89$#I^,:"VN"AK45U8\M3J^TI:U!">44@.)S>.:V"-P@G:8S8:_7 MK,&1=52F)^(598(++9IR-1?]'BQC&Q"*''0M MM5K+V2<#=ECOT\.5\),=Z>G]T*!?-:7#._0KD[;:+M.)_#KD-C*Y4%4BK0YI M4/8+N8B2+EGEKW$.Y]WTC'^Z'5STQM]&@R1V)+.4?;%\2Z!F79*+B)&US%JR MN%*PJJJ7O65::3JAPN4C=:\(9"%G/-.F/:1 G-[NQP)6W R0@P+W?2-B)>ZE M"Y'68FA"0D3364VO_A>LY0+Y"ZBR'L$@*Z7U6QJ\9L%-JRY4QP=N%](8E3J* ML0%8(A^N!TZ#"(WW.;+,B;*P;YQB53 =%\K'B ';C](XB_7>)D:?;G8)?&6) MT1TL+]7%W_4VM"/^GKWWCLL^JM4U.GG(-1=!MA;P^- M9"7Q4#0$1I+FL#TT74%RXH,UV"?WJJ*C>K,9NI$ON$.57LA#UPCAHV8A4V;O MX7'T)\AH8UL86&;(@26H,Q @4^5*LRBQ7 T=9EP;SK>($=743:;=D)#+;V1K]]^O"FG*>F%?,U^S<5UD8+?JILN M2BV!D08.X:EY>2D^*/U1>X]ZV:A967.NSTM+E=S?$"&>;QYR-9#+PR\)NL1_551E0 V6>]K)TO#S@OE=G'M15'Z8' M3^)@-GHX#ZT:7P53T./@B /1/$8]%/K4T?5!1B &@3EZIJRP>8!1A15'!\>3 M-<_TQ![6'[.1\.<#&_A'3A2UK6F$$QOZ(QI"HF]B@;+*TS%*8_S'RRH-Y=AL M#[HDFQ/Q9L/'2+(97@ 2IEVGX<-'I_QHPAQ7\SSCP,RR1+W'O3;EM^GG# 5W MS5Q'C]+$IOZ&%U:+R@<.+.92V=68:3_R=<>Z+]L<(.NJ-?\ZZB5B!L:/&9'' MD['7HV#@V['6"#,=DMU/_(495J_^."2,9GQE06C8F]X75/RD[5G=(M9=C<1G M.8KXB'EUR')@3NZZXW73,.0!&&(K!/, 49F'1+%)_8?I5+.Q#-WGD <8:;_]_>M?^TD63KG^_^%:W57@DDA[&-@9"L M1G+ 9%DE! 5F1Z/1:%6VV[@W[6[??D!\__JM\ZA'/VP,;4/WQ"/M*H#=78]3 MI\[S^\H6NL5#Q ')I8C =.:?Z*O*: R22*-P:?0NGK]"V[8PHT%14!#;S-B2 M911DA,:@QRNLCB*A8JU=DKV'J8O"%T:4=2PU^>44A([L46BXI4P!%&PC)JTE MNT!%0BYCJFK2#X2B]ET&:"O?8BY8@C2#=AHAJZDW3)#SF"FR(#-G^08V!6CX MAT8VW4RAJ.-<6B4:[!:@AH.=(\?@_U(O84? O!*OM R0M6>W$VI!Y2H5[7!, MR.[+!2KDK7,7B?DT;D"D @Z\Z?XIJ9Q#"&,$"03?0]T6=#N#NIBZOBHI20.+ MG<5BE5#U.59]9I'S4S%HTYYH>SD)D16^0JTB:[KU:A M_V*]8J38!F.# M( G+A%5&L$8505D=IBJHSEXOG"KZZ9:BUINB:CM*!)$NX3(1A+=3 F&) MU$S*'X<9A\R$0!,Q1=[4"F>()Y *1*C MPDT^<&[@Q]QJ62>,FN!() P)#[9!S$)0GC@*T*EW,>@UEW_61#U/+.VVUW-E M,7"Q[M='C <4$5,/C45 7HG"R=AI7I!8<2V[TT#^[$5F?;X%X8/OCF&SI 6) MY7+9]Z&Q-0>A3[$$#%F?HXBQ]^<1=1V2CUE63GI08)RV:O=TAH@:%CG#4&+T M>]G365('N]5JM'%%##-DTU$P;+8$2N4!^.8BHXDBA=U/LCB3(DBD;-:'<.'& MH4N*+D&X\0#BI:,16K884%EV@FSU,T52$=HEVRK&\-@"OTTUPR7QYQBCKK&E MCQ[1#:WUE8,]1L1X)T59]YTNN+H60H&!R ^8#10L1"$PB6 ME$N\3!2BFGSD>:"&6=1)*RQ@.=V07?D^LH@21[J%)FM/>XE=-I-M= A"]HSD MTLD/.7>IYU.:>Q*)=)SZR//GQ5DV:** 6%%TW=F;[)?[3_NE-1 9DY';-A=J M9. 4/7".RXR/\@PK!GG@7(#R)271!"G(35D7N^N(=*%597VG505L3#>PU2)< MUA@,MTJV+[B5R]^C1\75./DM%)PJMFHO"*J,7YKWG1_K'EC/MW[B^"RSWW*4 M<1B4[0TY3U. X#+UO\N$^*4K8/,1 A4!0*_KA8KFJDF_2M51\\G"GKB5AD7= M(*5A5CK;&,NZ2NI8P3O0=:PE]:I*5)_Z*J.KZ%:W2&\\U1>Z, 5_#=@(O&.Y M?*BD"@TO6>'Y*1GB<;8XF!:!5M)B\I1:^3_I6,H\G=Y'JODL9VNQ;!.0+ @V MX$ 1N6%DW@Y 8[ 6W6W(A63<'(AF,&8VW3 )U=&N"%3,J>' %J*"_L@H@CN);>0VYD: MAMD@"QU;0@= A2/LSL6T/1BEI8=BV!!5,VS;F*!7I=LJHK'/WIQJDLG6Z*(M M5X+>P-:YSI&&/F)4HQ4'S!N#"CN N M5JBA//#DTXLN+?"_C6CQ;+3:9RBL4#VFK'�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